<SEC-DOCUMENT>0001558370-22-003208.txt : 20220310
<SEC-HEADER>0001558370-22-003208.hdr.sgml : 20220310
<ACCEPTANCE-DATETIME>20220310063845
ACCESSION NUMBER:		0001558370-22-003208
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		112
CONFORMED PERIOD OF REPORT:	20211231
FILED AS OF DATE:		20220310
DATE AS OF CHANGE:		20220310

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Immuneering Corp
		CENTRAL INDEX KEY:			0001790340
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-40675
		FILM NUMBER:		22727336

	BUSINESS ADDRESS:	
		STREET 1:		245 MAIN STREET, SECOND FLOOR
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02142
		BUSINESS PHONE:		617-500-8080

	MAIL ADDRESS:	
		STREET 1:		245 MAIN STREET, SECOND FLOOR
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02142
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>imrx-20211231x10k.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='UTF-8'?>

      <!-- iXBRL document created with: Toppan Merrill Bridge iXBRL 9.6.8042.36810 -->
      <!-- Based on: iXBRL 1.1 -->
      <!-- Created on: 3/10/2022 12:29:20 AM -->
      <!-- iXBRL Library version: 1.0.8042.36816 -->
      <!-- iXBRL Service Job ID: e06d5665-9be4-4d0a-ba9a-2ca33b6058e1 -->

  <html xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns="http://www.w3.org/1999/xhtml" xmlns:imrx="http://immuneering.com/20211231" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:xbrldi="http://xbrl.org/2006/xbrldi"><head><meta content="text/html" http-equiv="content-type" /><title></title></head><body><div style="margin-top:30pt;"></div><div style="display:none;"><ix:header><ix:hidden><ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" xs:nil="true" contextRef="As_Of_12_31_2021_TBpjtOXgEkKQahJJAv0aWg" name="us-gaap:CommitmentsAndContingencies" id="Hidden_OhL8gcvAuECVVyj9LyojJg"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" xs:nil="true" contextRef="As_Of_12_31_2020_OUSLyqWONEO8ccGPC6rBdg" name="us-gaap:CommitmentsAndContingencies" id="Hidden_J5Pumsw9HUmipxi7ENxUPQ"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" xs:nil="true" contextRef="As_Of_12_31_2021_TBpjtOXgEkKQahJJAv0aWg" name="us-gaap:PreferredStockValue" id="Hidden_p0qpzbFkjUmIXyLPEuHubA"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" xs:nil="true" contextRef="As_Of_12_31_2020_OUSLyqWONEO8ccGPC6rBdg" name="us-gaap:PreferredStockValue" id="Hidden_k_f9J9mo9EKzdMWk3hhDaQ"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" xs:nil="true" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_4sABCVevMkafGdslrmVHRg" name="us-gaap:CommonStockValue" id="Hidden_Ji_C-gw4jEO9BLC9_O7x-g"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" xs:nil="true" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_B1xkq5tyC0Czi0WWYygW9Q" name="us-gaap:CommonStockValue" id="Hidden_opmngYKGQ0qph4W2tUy_MA"></ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_USD_shares_0VraXufKhkCSOUw2U_zvgQ" sign="-" contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ" decimals="2" name="us-gaap:EarningsPerShareDiluted" id="Hidden_vIExmlqSA0il2FwIIjljsA">2.46</ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_USD_shares_0VraXufKhkCSOUw2U_zvgQ" sign="-" contextRef="Duration_1_1_2020_To_12_31_2020_J_O9OcmviUi8EDFgokrY1Q" decimals="2" name="us-gaap:EarningsPerShareDiluted" id="Hidden_xSYZT51g4Ui4zgZUNzyrYw">3.44</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ" contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" id="Hidden_xxMTkP-lV0-EgjeSauJGCQ">13612677</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ" contextRef="Duration_1_1_2020_To_12_31_2020_J_O9OcmviUi8EDFgokrY1Q" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" id="Hidden_LgjYDMLh-0OSLo7VEn1Dag">4950129</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ" contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" id="Hidden_ZBQ4Vc7h-U2qlaqOgmKYLA">13612677</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ" contextRef="Duration_1_1_2020_To_12_31_2020_J_O9OcmviUi8EDFgokrY1Q" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" id="Hidden_EOmO9C6eMEyMPTXbq4Turg">4950129</ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_USD_shares_0VraXufKhkCSOUw2U_zvgQ" sign="-" contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ" decimals="2" name="us-gaap:EarningsPerShareDiluted" id="Hidden_wHopsXwjskSWOmAaEI9k1w">2.46</ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_USD_shares_0VraXufKhkCSOUw2U_zvgQ" sign="-" contextRef="Duration_1_1_2020_To_12_31_2020_J_O9OcmviUi8EDFgokrY1Q" decimals="2" name="us-gaap:EarningsPerShareDiluted" id="Hidden_--dUy7H6lkGzBYeWkeucsA">3.44</ix:nonFraction><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ" name="dei:EntityCentralIndexKey" id="Tc_OJuW22KhmUKXUGTPs5ImOw_2_1">0001790340</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ" name="dei:CurrentFiscalYearEndDate" id="Tc_j6iy_Nic5ECtbyOu55MOWw_3_1">--12-31</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ" name="dei:DocumentFiscalYearFocus" id="Tc_sMnNb6kjcES09Q__KWApSQ_4_1">2021</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ" name="dei:DocumentFiscalPeriodFocus" id="Tc_t4DUm_EdPEywovp7vgv7-Q_5_1">FY</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ" name="dei:AmendmentFlag" id="Tc_LK4BPxeyG02cde1R1KUlhw_6_1">false</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ" name="dei:EntityRegistrantName" id="Hidden_fgCtgpgTukmrynqB0FP_2Q">Immuneering Corp</ix:nonNumeric><ix:nonFraction unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_imrx_SeriesBConvertiblePreferredStockMember_-Ckh5K8N7U-_9nyMHjiJxQ" decimals="INF" name="us-gaap:TemporaryEquitySharesIssued" id="Hidden_wF_0nJs4AUW7wStGe8GcEw">3619292</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_imrx_SeriesBConvertiblePreferredStockMember_lxbE9uvMQU-NU7BxZ_aTNg" decimals="INF" name="us-gaap:TemporaryEquitySharesOutstanding" id="Hidden_xHMzK-FTbUiWCV2uN0nvTQ">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_imrx_SeriesConvertiblePreferredStockMember_DzBbn1vSGECYmtSe-hivlw" decimals="INF" name="us-gaap:TemporaryEquitySharesOutstanding" id="Hidden_zcaSLU112UGCpUs8KvFQ0g">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_IvXJ6RHxqkyGTfDbgXwHsw" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" id="Hidden_hQaWYsqo90Sb_sJvpMwkJA">4950129</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_Mo7QF875vUy5d2OcEbQ2fA" decimals="INF" name="us-gaap:CommonStockSharesIssued" id="Hidden_gM7yvl_Iukyupu2DzdISow">26320199</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_B1xkq5tyC0Czi0WWYygW9Q" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" id="Hidden_mnf3gfljw0OxVAZJj6gZiA">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_B1xkq5tyC0Czi0WWYygW9Q" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" id="Hidden_APJYaMAFZ06Y2loH3L6lNQ">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_4sABCVevMkafGdslrmVHRg" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" id="Hidden_l9rZoBbeYUGiLVsuqepJnw">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="As_Of_10_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_imrx_OfficeLeaseInSanDiegoCalifornia2020Member_fOyKDK4i2USSpVi4_ouoxw" decimals="0" name="us-gaap:OperatingLeaseLiability" id="Hidden_XdPatEybTkShRMLsu6QibA">637863</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_imrx_SeriesConvertiblePreferredStockMember_LQiWJpT45k-D9eZ63E0DAw" decimals="INF" name="us-gaap:TemporaryEquitySharesIssued" id="Hidden_2vNVcAnmu0eNuJvoPM638Q">2495933</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ" decimals="0" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet" id="Hidden_tlcK7EHhSU-TZzE4mXesaw">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_Mo7QF875vUy5d2OcEbQ2fA" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" id="Hidden_lP6rYH5NMkSWKz0be_vdHw">26320199</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_IvXJ6RHxqkyGTfDbgXwHsw" decimals="INF" name="us-gaap:CommonStockSharesIssued" id="Hidden_hTzGFl4AukOhSIQvrJVGbw">4950129</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ" contextRef="As_Of_12_31_2020_OUSLyqWONEO8ccGPC6rBdg" decimals="INF" name="us-gaap:PreferredStockSharesIssued" id="Hidden_xAjxILI03ki2sJwBPGEg8w">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ" contextRef="As_Of_12_31_2021_TBpjtOXgEkKQahJJAv0aWg" decimals="INF" name="us-gaap:PreferredStockSharesIssued" id="Hidden_EJkC4Tf1N0ygjQLvvTdsyA">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="As_Of_6_30_2021_20XVqP3RqUOqbOiTPzCGHQ" decimals="-6" name="dei:EntityPublicFloat" id="Hidden_NIPTNUHQak-BWzbjyzG2cw">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_4sABCVevMkafGdslrmVHRg" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" id="Hidden_lih2VwcAz0CbONCF8ELgIQ">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="As_Of_12_31_2021_us-gaap_BusinessAcquisitionAxis_imrx_BioArkiveIncMember__OkMddmPKES0gb3KLXJAbw" decimals="0" name="us-gaap:OperatingLeaseLiability" id="Hidden_CeuFDcEWwUiE1feAvMT7Lw">4824700</ix:nonFraction></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="imrx-20211231.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="As_Of_8_3_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_boKn2a2ouUyMVqODG0-nIw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001790340</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-08-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_5_31_2021_us-gaap_StatementClassOfStockAxis_imrx_SeriesBConvertiblePreferredStockTrancheTwoMember_-1LYWcxnHk6UK-Jcbi7Lpw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001790340</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">imrx:SeriesBConvertiblePreferredStockTrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2021_us-gaap_StatementClassOfStockAxis_imrx_SeriesBConvertiblePreferredStockTrancheTwoMember_h-jV1278D0iiS0qgsgtv3A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001790340</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">imrx:SeriesBConvertiblePreferredStockTrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_imrx_SeriesBConvertiblePreferredStocksTrancheOneMember_bShZaSXyFkGkXYNwg6aJxA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001790340</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">imrx:SeriesBConvertiblePreferredStocksTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_20_2019_us-gaap_StatementClassOfStockAxis_imrx_SeriesConvertiblePreferredStockMember_CgdZd9wu3UC4tGQyNK6KPA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001790340</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">imrx:SeriesConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_31_2020_us-gaap_StatementClassOfStockAxis_imrx_SeriesConvertiblePreferredStockMember_Tref9-4zckC3A4JsB3VTMA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001790340</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">imrx:SeriesConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_imrx_SeriesConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_S2X3YlpbP0KTx8Hppox5ig"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001790340</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">imrx:SeriesConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_imrx_SeriesBConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_QCBVyWaLKkO0RDEZzs9qkw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001790340</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">imrx:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_LnfVME6pk0eWF42mjJCPCQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001790340</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_StatementClassOfStockAxis_imrx_SeriesConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_gIVkAxfsP0yONnc4vwzOSw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001790340</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">imrx:SeriesConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_QXRL0wO1MkWoDTBf_1Gh7w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001790340</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember_8yiTbINkMkqUQTRVdOLgQw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001790340</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember_CoisecZ1RkWQ4NibnKtk2g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001790340</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_MxWqlzAiY0eQbIPd0DtYAA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001790340</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_8_3_2021_To_8_3_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_nbYOiYQZAUed9mAOrNTolQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001790340</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-03</xbrli:startDate><xbrli:endDate>2021-08-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_8_3_2021_To_8_3_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_G9SnpifyxEmaJU1UE794ew"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001790340</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-03</xbrli:startDate><xbrli:endDate>2021-08-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_imrx_SeriesConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_IX7LGz4dkECxr-BxWs_jAw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001790340</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">imrx:SeriesConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_23_2021_To_7_23_2021_He5Glc1OZUuR4Os2aqbeew"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001790340</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-23</xbrli:startDate><xbrli:endDate>2021-07-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_ovzfxk9860SdXNv_qQhcsg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001790340</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_dPK7_g2dsk-p4OLSSYVc-g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001790340</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_bsF1orxDUUG1aHLclUMt2g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001790340</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_VV_zTjXofUy1ORoRFXwUxw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001790340</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_bPrhx3BPa0qPRD7gVwy7FA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001790340</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_h6gPSE4xM0ayt1JfJR8qkA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001790340</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_9W3qoLMgdUiyVG8R6gDuuQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001790340</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_5hpgxWyzr0iIgVEP8sXbRw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001790340</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_EWjFOikEMEGNPdcpkhlgHw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001790340</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_jy9qZmEtiE6UB1aH8SvR-w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001790340</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_7_23_2021_To_7_23_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_PlanNameAxis_imrx_TwoThousandTwentyOneIncentiveAwardPlanMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember__dnvok_t1k-ok2gZh6_g4Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001790340</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">imrx:TwoThousandTwentyOneIncentiveAwardPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-23</xbrli:startDate><xbrli:endDate>2021-07-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_23_2021_To_7_23_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_PlanNameAxis_imrx_TwoThousandTwentyOneEmployeeStockPurchasePlanMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_EGe_9LAr1062vI9kah96gg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001790340</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">imrx:TwoThousandTwentyOneEmployeeStockPurchasePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-23</xbrli:startDate><xbrli:endDate>2021-07-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_imrx_TwoThousandTwentyOneEmployeeStockPurchasePlanMember_ZkFEiJ1N4E69ZN1lBj-gpw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001790340</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">imrx:TwoThousandTwentyOneEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MinimumMember_kkvfHzsY3kuLg_xs_U9vtw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001790340</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_SGUutfcD1kqmyGRE2MRtsg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001790340</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_srt_RangeAxis_srt_MinimumMember_Ozt2OiOHCkmkib6hyeBSlQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001790340</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_srt_RangeAxis_srt_MaximumMember_a5iqF3xs7Uao9VNTsL_jaw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001790340</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_imrx_BioArkiveIncMember_TX8VFVwjvkmlDFzOu0fzHw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001790340</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">imrx:BioArkiveIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_imrx_BioArkiveIncMember_sa3-bf410kC_Z3vN1a5IFw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001790340</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">imrx:BioArkiveIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdsAndLeaseholdImprovementsMember_avFoqBKbtEy-F0FmYKH8ng"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001790340</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdsAndLeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdsAndLeaseholdImprovementsMember_SvHfzMjnikSnHY-nhQSILg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001790340</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdsAndLeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_HoHJdekunkWYrj04U5neCw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001790340</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_twFlKCzRuEusunTslMr32A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001790340</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_imrx_LabEquipmentMember_GI3DHb_K8EizCH_U5WinCA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001790340</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">imrx:LabEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_bZau0xYq2Eux-_CkfhyDgw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001790340</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_XLMYvLxYDEmGm0OC6_nT-A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001790340</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember__c5PFKa--kCuxwpGGlOIrg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001790340</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_imrx_LabEquipmentMember_WQeNLQggXkGO-8Q1oHgFeQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001790340</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">imrx:LabEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_ZN2vm0JtIkGqEGwjZuOpmA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001790340</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_ISSEkI2XdEmI7m0_HrAVEw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001790340</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_StatementClassOfStockAxis_imrx_SeriesConvertiblePreferredStockMember_ArKyrrqRQE6HOj-7SNUhxw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001790340</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">imrx:SeriesConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_imrx_SeriesBConvertiblePreferredStockMember_-C13Ii99_069N31zQd1hmQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001790340</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">imrx:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementClassOfStockAxis_imrx_SeriesConvertiblePreferredStockMember_hF8oI6VuEUaTinProxudjw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001790340</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">imrx:SeriesConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementClassOfStockAxis_imrx_SeriesBConvertiblePreferredStockMember_b0zil8ikRUOsnQGwGFI2sw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001790340</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">imrx:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_8_3_2021_To_8_3_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_7enA8yNRQkat6QV_1FoEOw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001790340</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-03</xbrli:startDate><xbrli:endDate>2021-08-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_srt_RangeAxis_srt_MinimumMember_0vGLrM36lEegdT0dgFrRAQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001790340</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2021_To_5_31_2021_us-gaap_StatementClassOfStockAxis_imrx_SeriesBConvertiblePreferredStockTrancheTwoMember_3Z1Gf_8wlESSr2qfBuPkyQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001790340</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">imrx:SeriesBConvertiblePreferredStockTrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_12_1_2020_To_12_31_2020_us-gaap_StatementClassOfStockAxis_imrx_SeriesBConvertiblePreferredStocksTrancheOneMember_CqCA_MA7zUSGLHpsb-XgQQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001790340</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">imrx:SeriesBConvertiblePreferredStocksTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_1_31_2020_us-gaap_StatementClassOfStockAxis_imrx_SeriesConvertiblePreferredStockMember_YK2LK50_8US_qyrO8ejjbA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001790340</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">imrx:SeriesConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementClassOfStockAxis_imrx_SeriesConvertiblePreferredStockMember_gEfHGMh_TEuDzZN3KX78bg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001790340</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">imrx:SeriesConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_TI6BHD47C0iaSPM1OYc68Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001790340</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_E6Pqm-5XGEGHnxL47x05BA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001790340</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_6VOCtAPe5UC8u2hi-12dxg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001790340</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_5VXgVFJHWUybWtDAZklDIQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001790340</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_ZzxD3WXn2kaEmrcG06sDqg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001790340</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_10_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_imrx_OfficeLeaseInSanDiegoCalifornia2020Member_fOyKDK4i2USSpVi4_ouoxw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001790340</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">imrx:OfficeLeaseInSanDiegoCalifornia2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_imrx_StorageSpaceInSomervilleMassachusettsMember_kCYYiCYXakieYFKlIrPRQg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001790340</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">imrx:StorageSpaceInSomervilleMassachusettsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_imrx_OfficeSpaceInCambridgeMassachusettsNewYorkMember_Qma-pjDe6kSAepAJusrqDA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001790340</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">imrx:OfficeSpaceInCambridgeMassachusettsNewYorkMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_imrx_OfficeLeaseInSanDiegoCalifornia2020Member_1elFJvUqZUChk73Bzb2TRg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001790340</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">imrx:OfficeLeaseInSanDiegoCalifornia2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_PlanNameAxis_imrx_StockIncentivePlan2015Member_yJ3Soj1ueEaHyYoF06Bg_g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001790340</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">imrx:StockIncentivePlan2015Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_BalanceSheetLocationAxis_us-gaap_AccountsPayableAndAccruedLiabilitiesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_imrx_BioArkiveIncMember_Fdx8Pw88t0GYE-WWz9kZLQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001790340</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsPayableAndAccruedLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">imrx:BioArkiveIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2017_To_12_31_2017_us-gaap_BusinessAcquisitionAxis_imrx_BioArkiveIncMember_eCOuV4siy0CntVgmBRHjJw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001790340</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">imrx:BioArkiveIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_9_20_2019_To_9_20_2019_us-gaap_StatementClassOfStockAxis_imrx_SeriesConvertiblePreferredStockMember_lHzkW0d_2keHgOLQonVBGg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001790340</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">imrx:SeriesConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-09-20</xbrli:startDate><xbrli:endDate>2019-09-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_8_3_2021_atfZ3VjOmEGor-TZ8PR3vw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001790340</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-08-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_MajorCustomersAxis_imrx_CustomerTwoMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_Otularec102-GYy-rhKAFA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001790340</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">imrx:CustomerTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_MajorCustomersAxis_imrx_CustomerOneMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_oWqze6TNHUeol6NT43Q40A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001790340</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">imrx:CustomerOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_MajorCustomersAxis_imrx_CustomerOneMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_P-jE_XQSn0Kh-0-xrDlmZQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001790340</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">imrx:CustomerOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_MajorCustomersAxis_imrx_CustomerFiveMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_gk7zsuubm020Nb-hEXSapw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001790340</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">imrx:CustomerFiveMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_srt_MajorCustomersAxis_imrx_CustomerTwoMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_aTYR5oNrDkmFoJWCgdwsfQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001790340</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">imrx:CustomerTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_srt_MajorCustomersAxis_imrx_CustomerTwoMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_lmfLr2N_xUWRAFF-XxH5Jg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001790340</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">imrx:CustomerTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_srt_MajorCustomersAxis_imrx_CustomerThreeMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_8wa3w0Ph8ke11E8Tb0NuUA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001790340</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">imrx:CustomerThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_srt_MajorCustomersAxis_imrx_CustomerOneMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_cn0C_B-BXUyAAsOsAChyRA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001790340</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">imrx:CustomerOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_srt_MajorCustomersAxis_imrx_CustomerOneMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_0Q_fVsZyC0qSpcRATuE8jw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001790340</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">imrx:CustomerOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_srt_MajorCustomersAxis_imrx_CustomerFourMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_wyidH8d1zk-PDM7YDj9tdg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001790340</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">imrx:CustomerFourMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_srt_MajorCustomersAxis_imrx_CustomerFourMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_FbdxXK1INke9vC8EPGq7hQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001790340</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">imrx:CustomerFourMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_srt_MajorCustomersAxis_imrx_CustomerFiveMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_DPXYIsD2zUO9cvTMSKl0VA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001790340</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">imrx:CustomerFiveMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_8_3_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_d6wIH2lUEkOg0doA4WJViw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001790340</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-08-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_4sABCVevMkafGdslrmVHRg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001790340</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_Mo7QF875vUy5d2OcEbQ2fA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001790340</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_8_3_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_ncRRUXx0q0atI42UV2_87w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001790340</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-08-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_B1xkq5tyC0Czi0WWYygW9Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001790340</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_IvXJ6RHxqkyGTfDbgXwHsw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001790340</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_PlanNameAxis_imrx_StockIncentivePlan2015Member_hVx7NwJaA026vu03npu7HA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001790340</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">imrx:StockIncentivePlan2015Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_EmployeeStockOptionMember_rlnPrQOdyEaM-QEeHvlTjQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001790340</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_PlanNameAxis_imrx_TwoThousandTwentyOneIncentiveAwardPlanMember_LI5PlJ73VUKxQRLedBtGOQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001790340</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">imrx:TwoThousandTwentyOneIncentiveAwardPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_7_23_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_PlanNameAxis_imrx_TwoThousandTwentyOneIncentiveAwardPlanMember_MwQmN40XTUqTS51FC7b-vQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001790340</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">imrx:TwoThousandTwentyOneIncentiveAwardPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_7_23_2021_us-gaap_PlanNameAxis_imrx_TwoThousandTwentyOneEmployeeStockPurchasePlanMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_oj9jqMIrFkaE72Eovxv2mw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001790340</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">imrx:TwoThousandTwentyOneEmployeeStockPurchasePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_WarrantMember_7wU2uI3NZ0SsDzZ_Fr8ZyQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001790340</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_EmployeeStockOptionMember_me35404Y-kWEl2teCnSUVg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001790340</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_imrx_SeriesConvertiblePreferredStockMember_LQiWJpT45k-D9eZ63E0DAw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001790340</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">imrx:SeriesConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_g3mjqkDWB0-f2XKJf0YL-A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001790340</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_FairValueByAssetClassAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_tGSOwi1HF0iLCEdWOlktoQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001790340</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_FairValueByAssetClassAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_N9UIc66mekClPPydSVC05g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001790340</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_l3XprlCXTkaFiHyKLJ8O2Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001790340</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_7uvXNSojR0qxLk1Ubdsmfg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001790340</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_VHW5LVIB6Ee8uLYurHx4cw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001790340</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_imrx_SeriesConvertiblePreferredStockMember_zQGWKL5kWkOEqyx46cK5mg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001790340</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">imrx:SeriesConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_imrx_SeriesBConvertiblePreferredStockMember_HJNQLItNRU-hYpDpxqiSoQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001790340</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">imrx:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_ZzhQndqazkWQw1a8tNpx5w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001790340</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_q0lSZG3emUWjV7QOWezTNQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001790340</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_dQH6PYSm8ke4t8B5Xp8bAw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001790340</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_imrx_StockIncentivePlan2015Member_1tvXqAKRfEm4AKlfifgVpg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001790340</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">imrx:StockIncentivePlan2015Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_PenqHZkD4kiUSIeznQQKKw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001790340</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_hOzxdtEG0UaD56zlDOhRBw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001790340</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_hRS8KqtkvEKMap0WY0snUg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001790340</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_PlanNameAxis_imrx_StockIncentivePlan2015Member_za8LgT3DyUmYmEzDhCQL2Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001790340</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">imrx:StockIncentivePlan2015Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_QLhYrVZJX02K66IZYiKorA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001790340</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_srt_MajorCustomersAxis_imrx_CustomerOneMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_BcRwAfOKVEeK4vZFJJoMnw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001790340</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">imrx:CustomerOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_srt_MajorCustomersAxis_imrx_CustomerTwoMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_HSU6DmbswUiywLkXXqH83Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001790340</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">imrx:CustomerTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_srt_MajorCustomersAxis_imrx_CustomerOneMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_7bxZ7DlQSkOfAj7fvd-5pw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001790340</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">imrx:CustomerOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_srt_MajorCustomersAxis_imrx_CustomerFourMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_Aa9AiVV9H0q60bn77lAIvQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001790340</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">imrx:CustomerFourMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_srt_MajorCustomersAxis_imrx_CustomerFiveMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_odT76IUTqEO-M3mGDrx6QQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001790340</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">imrx:CustomerFiveMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_12_31_2019_Q2tKCguYn0Sp3Siw9cnC0w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001790340</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_6_1_2021_To_6_30_2021_xjkMHQi3F0anA1B9rBC7Fg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001790340</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_imrx_SeriesBConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_8mJv2jJa6UumRofouB70lA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001790340</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">imrx:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementClassOfStockAxis_imrx_SeriesConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_JPabAp5qAEmR2gD7LN_b7A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001790340</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">imrx:SeriesConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementClassOfStockAxis_imrx_SeriesBConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_39QT10BRPUmkcB-ZGBN9mQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001790340</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">imrx:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_uitXKHVUDEugKPJ0WrK0pw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001790340</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_StatementClassOfStockAxis_imrx_SeriesConvertiblePreferredStockMember_DFd25cydBkuiug-BF6zGWQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001790340</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">imrx:SeriesConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2019_us-gaap_StatementClassOfStockAxis_imrx_SeriesConvertiblePreferredStockMember_O1RMY__04UyGW5MdXmEk9Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001790340</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">imrx:SeriesConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_StatementClassOfStockAxis_imrx_SeriesConvertiblePreferredStockMember_ncQIkgAZqEWsymLXhsJ6yg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001790340</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">imrx:SeriesConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_imrx_SeriesConvertiblePreferredStockMember_DzBbn1vSGECYmtSe-hivlw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001790340</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">imrx:SeriesConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementClassOfStockAxis_imrx_SeriesBConvertiblePreferredStockMember_TDIXNGLBjEmH6HPuewiRjg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001790340</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">imrx:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_27_2020_To_3_27_2020_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember_5FkHeRTRFUWenXHcqclDDQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001790340</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-03-27</xbrli:startDate><xbrli:endDate>2020-03-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_27_2020_To_3_27_2020_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember_SFNqtQEhiUilg2XoqHi-NA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001790340</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-03-27</xbrli:startDate><xbrli:endDate>2020-03-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_E-RNnZgaG06hPQcsgQNOlA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001790340</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_GoNlf5JQWEKfwIjieg6jCA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001790340</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_12_31_2019_To_12_31_2019_us-gaap_StatementClassOfStockAxis_imrx_SeriesConvertiblePreferredStockMember___WeTNXDqEKrDBAIVc3wUA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001790340</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">imrx:SeriesConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-31</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_imrx_SeriesBConvertiblePreferredStockMember_lxbE9uvMQU-NU7BxZ_aTNg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001790340</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">imrx:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_7_23_2021_To_7_23_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_PlanNameAxis_imrx_TwoThousandTwentyOneIncentiveAwardPlanMember_BLWmGGSlg0221-_bauHKMg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001790340</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">imrx:TwoThousandTwentyOneIncentiveAwardPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-23</xbrli:startDate><xbrli:endDate>2021-07-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_23_2021_To_7_23_2021_us-gaap_PlanNameAxis_imrx_TwoThousandTwentyOneEmployeeStockPurchasePlanMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_wllzZzefAkGrL1ozzU9u1Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001790340</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">imrx:TwoThousandTwentyOneEmployeeStockPurchasePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-23</xbrli:startDate><xbrli:endDate>2021-07-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_8_3_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_kxYscz4Wf02VzWLhksRRxw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001790340</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-08-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_6Dv2gap2qUy2S6CUjLz70A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001790340</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_Vps21bPl-0ucIcde4LcmUQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001790340</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_J2SvXNqcwUW3WhIW-fbZTA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001790340</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_XcWBVd3ItkaUL02nw_Pu2g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001790340</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_imrx_SeriesBConvertiblePreferredStockMember_-Ckh5K8N7U-_9nyMHjiJxQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001790340</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">imrx:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_BusinessAcquisitionAxis_imrx_BioArkiveIncMember__OkMddmPKES0gb3KLXJAbw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001790340</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">imrx:BioArkiveIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasurySecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_TueSJDcFvk-6KVBcFb4yWg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001790340</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_FairValueByAssetClassAxis_us-gaap_CommercialPaperMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_sHUMvfiqDEWTLNwGi2V19w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001790340</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_FairValueByAssetClassAxis_imrx_GovernmentSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_rv952rznEk2GkuC-bXIEgw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001790340</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">imrx:GovernmentSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasurySecuritiesMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_GndZSZIX5kONkZeJ-uwZvA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001790340</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_XD-w4rYEvkOhxL7DPVZDYA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001790340</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_DcZ3E7WdG0qTM9kwKkYCCA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001790340</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_FairValueByAssetClassAxis_us-gaap_CommercialPaperMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_0brBfUV_8k-73Ah2xvo5vA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001790340</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_FairValueByAssetClassAxis_imrx_GovernmentSecuritiesMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_hYwzM8-hekGhWFHX6of5Fg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001790340</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">imrx:GovernmentSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_NZFKYXEtB0ypESwMFRZYaA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001790340</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_ypcv1cNyLUqWUpUVKo2bMg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001790340</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_imrx_GovernmentSecuritiesMember__6KtOh0dNkKDNENoMm1rTg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001790340</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">imrx:GovernmentSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember_CWayHsb0d0ChYaEcAr7tvw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001790340</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_J_O9OcmviUi8EDFgokrY1Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001790340</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_12_22_2021_To_12_22_2021_us-gaap_BusinessAcquisitionAxis_imrx_BioArkiveIncMember_jaVHRkxuBESGO6YkECH_Bw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001790340</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">imrx:BioArkiveIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-12-22</xbrli:startDate><xbrli:endDate>2021-12-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_22_2021_us-gaap_BusinessAcquisitionAxis_imrx_BioArkiveIncMember_eZfDAI7yG0yVohELE3M0sA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001790340</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">imrx:BioArkiveIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_BusinessAcquisitionAxis_imrx_BioArkiveIncMember_us-gaap_LeaseContractualTermAxis_imrx_LeaseTerminationOnMarch312024Member_Foc4ig67vEu40iyOKMsf_Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001790340</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">imrx:BioArkiveIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">imrx:LeaseTerminationOnMarch312024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_BusinessAcquisitionAxis_imrx_BioArkiveIncMember_us-gaap_LeaseContractualTermAxis_imrx_LeaseTerminationOnDecember312022Member_dRAvJgmyQ02SlSKbOR13YQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001790340</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">imrx:BioArkiveIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">imrx:LeaseTerminationOnDecember312022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_BusinessAcquisitionAxis_imrx_BioArkiveIncMember_us-gaap_LeaseContractualTermAxis_imrx_LeaseTerminationOnApril302032Member_dW7b99b4G0eqpEl5CucuWA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001790340</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">imrx:BioArkiveIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">imrx:LeaseTerminationOnApril302032Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_TBpjtOXgEkKQahJJAv0aWg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001790340</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_OUSLyqWONEO8ccGPC6rBdg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001790340</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_3_2022_p8E7gto4PE--fHqym2mFLg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001790340</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-03-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2021_20XVqP3RqUOqbOiTPzCGHQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001790340</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_3_2022_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_weiDmNWAfEO5BLuMYcU-IQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001790340</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_3_2022_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_OPmYWjUA4Uatqa9PkXwy4Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001790340</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001790340</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="Unit_Standard_segment_tQmfuIJwOkyVlCDJy8sORg"><xbrli:measure>imrx:segment</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_sqft_pKK1i40-n0WN8q6DXkNohQ"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_pure_iothMaWWqUCV2N7d1PVg4w"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_D_qWJwQorwfUaf88ueMyElMA"><xbrli:measure>imrx:D</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_agreement_qexq1bbkzU-JqgEPv8PRCQ"><xbrli:measure>imrx:agreement</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_tranche_5kfv1Y9uXkefgNW7HJS6Rw"><xbrli:measure>imrx:tranche</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_Vote_y6IkSxDgD0SxcVMkCx6yHg"><xbrli:measure>imrx:Vote</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Divide_USD_shares_0VraXufKhkCSOUw2U_zvgQ"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit></ix:resources></ix:header></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:7.2pt;min-height:20.15pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:10.35pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;border-bottom:1.0pt solid #000000;border-top:3.0pt solid #000000;margin:0pt;"> <span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><a id="_38bc11c0_3aed_4a40_b361_0fd0b72f7fa0"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:14pt;font-weight:bold;">UNITED STATES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:14pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 5pt 0pt;"><b style="font-weight:bold;">Washington, D.C. 20549</b></p><div style="font-family:'Times New Roman','Times','serif';font-size:9.0pt;margin-bottom:5pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1px;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:14pt;text-align:center;margin:0pt 0pt 5pt 0pt;"><b style="font-weight:bold;">FORM&#160;</b><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ" name="dei:DocumentType" id="Narr_2y4duOtGC0C97t5PWjNzDA"><b style="font-weight:bold;">10-K</b></ix:nonNumeric></p><div style="font-family:'Times New Roman','Times','serif';font-size:9.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1px;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0pt 43.2pt;"><b style="font-weight:bold;">(Mark&#160;One)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ" name="dei:DocumentAnnualReport" id="Narr_nhVNZsQuAUKFaFF7BoupJw"><b style="font-family:'Segoe UI Symbol';font-size:9pt;font-style:normal;font-weight:bold;">&#9746;</b></ix:nonNumeric></span><b style="font-size:9pt;font-weight:bold;">ANNUAL&#160;REPORT&#160;PURSUANT&#160;TO&#160;SECTION&#160;13&#160;OR&#160;15(d)&#160;OF&#160;THE&#160;SECURITIES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 5pt 0pt;"><b style="font-weight:bold;">EXCHANGE&#160;ACT OF 1934</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><b style="font-size:7pt;font-weight:bold;">For the fiscal year ended </b><ix:nonNumeric format="ixt:datemonthdayyearen" contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ" name="dei:DocumentPeriodEndDate" id="Narr_cC81JmeMX0qb3XZrthpnAA"><b style="font-size:7pt;font-weight:bold;">December 31, 2021</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 5pt 0pt;"><b style="font-weight:bold;">or</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ" name="dei:DocumentTransitionReport" id="Narr_Ed8UHnH9GEK7b7UjJSnCYw"><b style="font-family:'Segoe UI Symbol';font-size:9pt;font-style:normal;font-weight:bold;">&#9744;</b></ix:nonNumeric></span><b style="font-size:9pt;font-weight:bold;">TRANSITION REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 5pt 0pt;"><b style="font-weight:bold;">EXCHANGE&#160;ACT OF 1934</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">For the transition period from </b><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</b><b style="font-weight:bold;">&#160; to</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:7pt;font-weight:bold;">Commission File Number: </b><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ" name="dei:EntityFileNumber" id="Narr_GZme4wgFREO9ke6_pVu52Q"><b style="font-size:7pt;font-weight:bold;">001-40675</b></ix:nonNumeric></p><div style="font-family:'Times New Roman','Times','serif';font-size:9.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1px;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:20pt;text-align:center;margin:0pt 0pt 5pt 0pt;"><span style="-sec-ix-hidden:Hidden_fgCtgpgTukmrynqB0FP_2Q;"><b style="font-family:'Times New Roman','Times','serif';font-size:20pt;font-style:normal;font-weight:bold;">Immuneering Corporation</b></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Exact name of registrant as specified in its charter)</b></p><div style="font-family:'Times New Roman','Times','serif';font-size:9.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1px;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p><a id="_1baf8d78_16b5_4ec6_85cb_475c14449c49"></a><a id="Tc_QVS-cEoXWk6WgYDIium39Q_2_0"></a><a id="Tc_y7Ggl3hC3U2eU2x8SZ7UWw_2_1"></a><a id="Tc_3R6fa04akke1zomI3kOTNw_4_0"></a><a id="Tc_EUIV67jMcUiosKSbGuGraw_5_0"></a><a id="Tc_2bXgUZf3rUeG38E4U4D0DA_6_0"></a><a id="Tc_T8ri6rG5T0uKYuALUsyo1A_6_1"></a><a id="Tc_aajIRoxdVkuLtrCajlTI8A_7_0"></a><a id="Tc_-x8NXl3_FUSLUUJKSD2v2Q_7_1"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric format="ixt-sec:stateprovnameen" contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ" name="dei:EntityIncorporationStateCountryCode" id="Tc__hz45fiExUu7P-VUyMxKDQ_1_0"><b style="font-size:7pt;font-weight:bold;">Delaware</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ" name="dei:EntityTaxIdentificationNumber" id="Tc_UYp6ali34UW1ODYE8EeffQ_1_1"><span style="font-size:7pt;">26-1976972</span></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(State or other&#160;jurisdiction of incorporation or organization)</b></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(I.R.S. Employer Identification Number)</b></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ" name="dei:EntityAddressAddressLine1" id="Narr_rDLdcRWTuE6OXoMffCBnmg"><b style="font-size:7pt;font-weight:bold;">245 Main St</b></ix:nonNumeric><b style="font-size:7pt;font-weight:bold;">.</b></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ" name="dei:EntityAddressAddressLine2" id="Narr_Me1MS0r_KUGWS1xZdFR2oA"><b style="font-size:7pt;font-weight:bold;">Second Floor</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ" name="dei:EntityAddressCityOrTown" id="Narr_7QdLv-Wq_UqHaWqCt1N5hQ"><b style="font-size:7pt;font-weight:bold;">Cambridge</b></ix:nonNumeric><b style="font-size:7pt;font-weight:bold;">, </b><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ" name="dei:EntityAddressStateOrProvince" id="Narr_y_AyTNHgP0G3OPy0FWh5fw"><b style="font-size:7pt;font-weight:bold;">MA</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ" name="dei:EntityAddressPostalZipCode" id="Narr_MxFx42XTxU2AFhVMORy4xQ"><b style="font-size:7pt;font-weight:bold;">02142</b></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Address of Principal Executive Offices)</b></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Zip Code)</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:7pt;font-weight:bold;">(</b><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ" name="dei:CityAreaCode" id="Narr_PBpZpNKtekarR1KNdcLxfw"><b style="font-size:7pt;font-weight:bold;">617</b></ix:nonNumeric><b style="font-size:7pt;font-weight:bold;">) </b><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ" name="dei:LocalPhoneNumber" id="Narr_1zH5TmbT-kSVALW3Vd71Pg"><b style="font-size:7pt;font-weight:bold;">500-8080</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Registrant&#8217;s telephone number)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">N/A</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Former name, former address and former fiscal year, if changed since last report)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><div style="font-family:'Times New Roman','Times','serif';font-size:7.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1px;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">Securities registered pursuant to Section&#160;12(b)&#160;of the Act:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p><a id="_2ede325f_17ac_4af7_8686_293bfccd9d62"></a><a id="Tc_7cLPnK2G5EOBoC617fd9Iw_1_0"></a><a id="Tc_yXaN0zY1yUyxnv3XgVRxVg_1_2"></a><a id="Tc_2oxlfLrsbU64lmew7J8a4g_1_4"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.071777344%;width:100.14%;"><tr style="height:1pt;"><td style="vertical-align:top;width:35.12%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:3.53%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:23.17%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:3.53%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:34.61%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:35.12%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Title of Each Class</b></p></td><td style="vertical-align:top;width:3.53%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:top;width:23.17%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Trading symbol</b></p></td><td style="vertical-align:top;width:3.53%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:top;width:34.61%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Name of Exchange on which registered</b></p></td></tr><tr><td style="vertical-align:top;width:35.12%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ" name="dei:Security12bTitle" id="Tc_Cy1uyUvOAE6jae--cca_LQ_2_0"><b style="font-size:7pt;font-weight:bold;">Class A common Stock, par value $0.001 per share</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:3.53%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:23.17%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ" name="dei:TradingSymbol" id="Tc_tJ_E766uG0a-LhSJl9Jung_2_2"><b style="font-size:7pt;font-weight:bold;">IMRX</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:3.53%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:34.61%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric format="ixt-sec:exchnameen" contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ" name="dei:SecurityExchangeName" id="Tc_HV9SkY2VRkOW6Odm9fGu9w_2_4"><b style="font-size:7pt;font-weight:bold;">The Nasdaq Global Market</b></ix:nonNumeric></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 5pt 0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 5pt 0pt;"><span style="font-size:7pt;white-space:pre-wrap;">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.   Yes&#160;&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:7pt;">&#9744;</span><span style="font-size:7pt;">&#160;&#160;&#160;&#160;</span><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ" name="dei:EntityWellKnownSeasonedIssuer" id="Narr_TpDVNSNBOkGEtVQnhTNgqQ"><span style="font-size:7pt;">No</span></ix:nonNumeric><span style="font-size:7pt;">&#160;&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:7pt;">&#9746;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 5pt 0pt;"><span style="font-size:7pt;">Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes&#160;&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:7pt;">&#9744;</span><span style="font-size:7pt;">&#160;&#160;&#160;&#160;</span><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ" name="dei:EntityVoluntaryFilers" id="Narr_nrwFOWDlv0uAr0fbfJ72iQ"><span style="font-size:7pt;">No</span></ix:nonNumeric><span style="font-size:7pt;">&#160;&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:7pt;">&#9746;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 5pt 0pt;"><span style="font-size:7pt;">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d)&#160;of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days. &#160;&#160;</span><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ" name="dei:EntityCurrentReportingStatus" id="Narr_XlxA4alyTEWGcH4hw8lbCg"><span style="font-size:7pt;">Yes</span></ix:nonNumeric><span style="font-size:7pt;">&#160;&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:7pt;">&#9746;</span><span style="font-size:7pt;">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:7pt;">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 5pt 0pt;"><span style="font-size:7pt;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation&#160;S-T (&#167;232.405 of this chapter) during the preceding 12&#160;months (or for such shorter period that the registrant was required to submit such files). &#160;&#160;</span><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ" name="dei:EntityInteractiveDataCurrent" id="Narr_T21sPV326EyxPuQ0X6OrNA"><span style="font-size:7pt;">Yes</span></ix:nonNumeric><span style="font-size:7pt;">&#160;&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:7pt;">&#9746;</span><span style="font-size:7pt;">&#160;&#160;&#160;&#160;No&#160;&#160; </span><span style="font-family:'Segoe UI Symbol';font-size:7pt;">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule&#160;12b-2 of the Exchange Act.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p><a id="_721cdc48_0a55_47e8_8a80_8d62b5816ff4"></a><a id="Tc_AyCjHVvf9EWdSk5e4B8Ezw_0_0"></a><a id="Tc_xMjd85Nxc0uOgXU7JnBX5g_0_1"></a><a id="Tc_U8Hw96udJUGFP-snwXlDWg_0_2"></a><a id="Tc_B4MleobtU0GTWDanrh9u9g_0_3"></a><a id="Tc_sPbJFlPBw0G-bAEV7FF6dQ_2_1"></a><a id="Tc_sN5ma1SnGk-llEBFSkTxvQ_2_2"></a><a id="Tc_qb93op_nzUGvwvrTuWGiww_2_4"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:16.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">Large&#160;accelerated&#160;filer</p></td><td style="vertical-align:bottom;width:23.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></p></td><td style="vertical-align:bottom;width:20.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">Accelerated&#160;filer</p></td><td style="vertical-align:top;width:15.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></p></td><td style="vertical-align:top;width:20.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:3.65pt;"><td style="vertical-align:bottom;width:16.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:23.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:20.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:20.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:4.05pt;"><td style="vertical-align:bottom;width:16.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:entityfilercategoryen" contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ" name="dei:EntityFilerCategory" id="Tc_m8-H8smZQkCx-0uRiDlL_A_2_0"><span style="font-size:7pt;">Non-accelerated filer</span></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:23.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><span style="font-family:'Segoe UI Symbol';">&#9746;</span></p></td><td style="vertical-align:bottom;width:20.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">Smaller&#160;reporting&#160;company</p></td><td style="vertical-align:top;width:15.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ" name="dei:EntitySmallBusiness" id="Tc_OOUmGj_FMEKSvOfEqNijTA_2_3"><span style="font-family:'Segoe UI Symbol';font-size:7pt;">&#9746;</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:20.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">Emerging&#160;growth&#160;company</p></td><td style="vertical-align:bottom;width:3.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ" name="dei:EntityEmergingGrowthCompany" id="Tc_rxEBAH2wEk-uiAbzwkyZXQ_2_5"><span style="font-family:'Segoe UI Symbol';font-size:7pt;">&#9746;</span></ix:nonNumeric></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 5pt 0pt;"><span style="font-size:7pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a)&#160;of the Exchange Act. </span><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ" name="dei:EntityExTransitionPeriod" id="Narr_t4eMEeVoYUOYUm_fGIHxsw"><span style="font-family:'Segoe UI Symbol';font-size:7pt;">&#9744;</span></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 5pt 0pt;"><span style="font-size:7pt;">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.&#160;&#160;</span><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ" name="dei:IcfrAuditorAttestationFlag" id="Narr_PVdroTc080ite5R-7I_oMA"><span style="font-family:'Segoe UI Symbol';font-size:7pt;">&#9744;</span></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 5pt 0pt;"><span style="font-size:7pt;">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Exchange Act). &#160;&#160;Yes&#160;&#160;</span><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ" name="dei:EntityShellCompany" id="Narr_KReOYEtve0CL8w7X6gMbvA"><span style="font-family:'Segoe UI Symbol';font-size:7pt;">&#9744;</span></ix:nonNumeric><span style="font-size:7pt;">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:7pt;">&#9746;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 5pt 0pt;"><span style="font-size:7pt;">As of June 30, 2021, the last day of the registrant&#8217;s most recently completed second fiscal quarter, the registrant&#8217;s Class A common stock was </span><span style="font-size:7pt;"><ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" format="ixt-sec:numwordsen" scale="0" contextRef="As_Of_6_30_2021_20XVqP3RqUOqbOiTPzCGHQ" decimals="0" name="dei:EntityPublicFloat" id="Narr_s0tITiBaAEypnba4bEd7jQ">no</ix:nonFraction></span><span style="font-size:7pt;">t publicly traded. The registrant&#39;s Class A common stock, began trading on the Nasdaq Global Market on July 30, 2021. As of March 3, 2022, the aggregate market value of the registrant&#8217;s voting and non-voting common stock held by non-affiliates of the registrant was approximately </span><span style="-sec-ix-hidden:Hidden_NIPTNUHQak-BWzbjyzG2cw;"><span style="font-family:'Times New Roman','Times','serif';font-size:7pt;font-style:normal;font-weight:normal;">$</span></span><span style="font-size:7pt;"><ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" format="ixt:numdotdecimal" scale="6" contextRef="As_Of_3_3_2022_p8E7gto4PE--fHqym2mFLg" decimals="-5" name="dei:EntityPublicFloat" id="Narr_0NtWfCKK80mO7TsXawl4WA">136.9</ix:nonFraction></span><span style="font-size:7pt;"> million (based upon the closing sale price of the Class A common stock on that date on the Nasdaq Global Market).</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 5pt 0pt;"><span style="white-space:pre-wrap;">As of March 3, 2022,  the registrant had </span><ix:nonFraction unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ" format="ixt:numdotdecimal" scale="0" contextRef="As_Of_3_3_2022_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_OPmYWjUA4Uatqa9PkXwy4Q" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" id="Narr_ZdP-Q77zekqnfYt-EJZS8A">26,377,299</ix:nonFraction> shares of Class A common stock, $0.001 par value per share, issued and outstanding and <ix:nonFraction unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ" format="ixt:numdotdecimal" scale="0" contextRef="As_Of_3_3_2022_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_weiDmNWAfEO5BLuMYcU-IQ" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" id="Narr_TWO-MWv1gEKVlN08SMK_ew">0</ix:nonFraction> shares of Class B common stock, $0.001 par value per share, issued and outstanding.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 5pt 0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:3pt 0pt 0pt 0pt;"><b style="font-weight:bold;">DOCUMENTS INCORPORATED BY REFERENCE</b></p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ" name="dei:DocumentsIncorporatedByReferenceTextBlock" id="Tb_yn2GtPRkw0-5sFGYk_xC0w" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:3pt 0pt 0pt 0pt;">Portions of the registrant&#8217;s Definitive Proxy Statement relating to the registrant&#8217;s 2022 Annual Meeting of Stockholders to be filed with the Securities and Exchange Commission within 120 days of the end of the registrant&#8217;s fiscal year ended December&#160;31, 2021 are incorporated by reference into Part III of this Annual Report on Form 10-K to the extent stated herein.</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 5pt 0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;border-bottom:3.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt 0pt 6pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_0ec32005_d89b_4e5f_bf2b_88333c3bc1ba"></a><a id="TOC"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">TABLE OF CONTENTS</b></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:8.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:3.88%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Page</b></p></th></tr><tr><td style="vertical-align:top;white-space:nowrap;width:8.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#PARTI_778188"><span style="font-style:normal;font-weight:normal;">PART&#160;I</span></a></p></td><td style="vertical-align:top;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:83%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:8.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:8.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item_01"><span style="font-style:normal;font-weight:normal;">Item&#160;1.</span></a></p></td><td style="vertical-align:top;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item_01"><span style="font-style:normal;font-weight:normal;">Business</span></a></p></td><td style="vertical-align:top;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">7</p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:8.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:8.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item_1A"><span style="font-style:normal;font-weight:normal;">Item&#160;1A.</span></a></p></td><td style="vertical-align:top;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item_1A"><span style="font-style:normal;font-weight:normal;">Risk Factors</span></a></p></td><td style="vertical-align:top;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">55</p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:8.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:8.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item1BUnresolvedStaffComments_541968"><span style="font-style:normal;font-weight:normal;">Item&#160;1B.</span></a></p></td><td style="vertical-align:top;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item1BUnresolvedStaffComments_541968"><span style="font-style:normal;font-weight:normal;">Unresolved Staff Comments</span></a></p></td><td style="vertical-align:top;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">116</p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:8.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:8.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item_02"><span style="font-style:normal;font-weight:normal;">Item&#160;2.</span></a></p></td><td style="vertical-align:top;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item_02"><span style="font-style:normal;font-weight:normal;">Properties</span></a></p></td><td style="vertical-align:top;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">116</p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:8.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:8.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item_03"><span style="font-style:normal;font-weight:normal;">Item&#160;3.</span></a></p></td><td style="vertical-align:top;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item_03"><span style="font-style:normal;font-weight:normal;">Legal Proceedings</span></a></p></td><td style="vertical-align:top;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">116</p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:8.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:8.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item_04"><span style="font-style:normal;font-weight:normal;">Item&#160;4.</span></a></p></td><td style="vertical-align:top;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item_04"><span style="font-style:normal;font-weight:normal;">Mine Safety Disclosures</span></a></p></td><td style="vertical-align:top;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">116</p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:8.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:8.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Part_II"><span style="font-style:normal;font-weight:normal;">PART&#160;II</span></a></p></td><td style="vertical-align:top;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:8.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:8.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item_05"><span style="font-style:normal;font-weight:normal;">Item&#160;5.</span></a></p></td><td style="vertical-align:top;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item_05"><span style="font-style:normal;font-weight:normal;">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</span></a></p></td><td style="vertical-align:top;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">116</p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:8.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:8.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item_6"><span style="font-style:normal;font-weight:normal;">Item&#160;6.</span></a></p></td><td style="vertical-align:top;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item_6"><span style="font-style:normal;font-weight:normal;">[Reserved]</span></a></p></td><td style="vertical-align:top;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">117</p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:8.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:8.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item_07"><span style="font-style:normal;font-weight:normal;">Item&#160;7.</span></a></p></td><td style="vertical-align:top;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item_07"><span style="font-style:normal;font-weight:normal;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></p></td><td style="vertical-align:top;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">117</p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:8.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:8.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item_07A"><span style="font-style:normal;font-weight:normal;">Item&#160;7A.</span></a></p></td><td style="vertical-align:top;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item_07A"><span style="font-style:normal;font-weight:normal;">Quantitative and Qualitative Disclosures about Market Risk</span></a></p></td><td style="vertical-align:top;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">129</p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:8.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:8.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item_08"><span style="font-style:normal;font-weight:normal;">Item&#160;8.</span></a></p></td><td style="vertical-align:top;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item_08"><span style="font-style:normal;font-weight:normal;">Financial Statements and Supplementary Data</span></a></p></td><td style="vertical-align:top;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">130</p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:8.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:8.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item_09"><span style="font-style:normal;font-weight:normal;">Item&#160;9.</span></a></p></td><td style="vertical-align:top;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item_09"><span style="font-style:normal;font-weight:normal;">Changes in and Disagreements With Accountants on Accounting and Financial Disclosure</span></a></p></td><td style="vertical-align:top;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">157</p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:8.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:8.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item_09A"><span style="font-style:normal;font-weight:normal;">Item&#160;9A.</span></a></p></td><td style="vertical-align:top;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item_09A"><span style="font-style:normal;font-weight:normal;">Controls and Procedures</span></a></p></td><td style="vertical-align:top;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">157</p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:8.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:8.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item_09B"><span style="font-style:normal;font-weight:normal;">Item&#160;9B.</span></a></p></td><td style="vertical-align:top;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item_09B"><span style="font-style:normal;font-weight:normal;">Other Information</span></a></p></td><td style="vertical-align:top;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">157</p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:8.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:8.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#_Item_9C._Disclosure"><span style="font-style:normal;font-weight:normal;">Item&#160;9C.</span></a></p></td><td style="vertical-align:top;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;"><a href="#_Item_9C._Disclosure"><span style="font-style:normal;font-weight:normal;">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</span></a></p></td><td style="vertical-align:top;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">157</p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:8.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:8.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#PARTIII_197185"><span style="font-style:normal;font-weight:normal;">PART&#160;III</span></a></p></td><td style="vertical-align:top;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:83%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:8.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:8.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item_10"><span style="font-style:normal;font-weight:normal;">Item&#160;10.</span></a></p></td><td style="vertical-align:top;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item_10"><span style="font-style:normal;font-weight:normal;">Directors, Executive Officers and Corporate Governance</span></a></p></td><td style="vertical-align:top;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">158</p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:8.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:8.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item11"><span style="font-style:normal;font-weight:normal;">Item&#160;11.</span></a></p></td><td style="vertical-align:top;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item11"><span style="font-style:normal;font-weight:normal;">Executive Compensation</span></a></p></td><td style="vertical-align:top;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">158</p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:8.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:8.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item_12"><span style="font-style:normal;font-weight:normal;">Item&#160;12.</span></a></p></td><td style="vertical-align:top;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item_12"><span style="font-style:normal;font-weight:normal;">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</span></a></p></td><td style="vertical-align:top;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">158</p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:8.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:8.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#item13"><span style="font-style:normal;font-weight:normal;">Item&#160;13.</span></a></p></td><td style="vertical-align:top;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#item13"><span style="font-style:normal;font-weight:normal;">Certain Relationships and Related Transactions, and Director Independence</span></a></p></td><td style="vertical-align:top;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">158</p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:8.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:8.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item_14"><span style="font-style:normal;font-weight:normal;">Item&#160;14.</span></a></p></td><td style="vertical-align:top;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item_14"><span style="font-style:normal;font-weight:normal;">Principal Accounting Fees and Services</span></a></p></td><td style="vertical-align:top;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">158</p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:8.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:8.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#PARTIV_696219"><span style="font-style:normal;font-weight:normal;">PART&#160;IV</span></a></p></td><td style="vertical-align:top;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:8.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:8.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item_15"><span style="font-style:normal;font-weight:normal;">Item&#160;15.</span></a></p></td><td style="vertical-align:top;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item_15"><span style="font-style:normal;font-weight:normal;">Exhibits, Financial Statement Schedules</span></a></p></td><td style="vertical-align:top;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">158</p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:8.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:8.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item_16"><span style="font-style:normal;font-weight:normal;">Item&#160;16.</span></a></p></td><td style="vertical-align:top;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item_16"><span style="font-style:normal;font-weight:normal;">Form 10-K Summary</span></a></p></td><td style="vertical-align:top;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">160</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">2</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_d5b7f453_8145_4d95_aac4_d24a57c73f8c"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">FORWARD-LOOKING STATEMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">This Annual Report on Form&#160;10-K contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section&#160;27A of the Securities Act of 1933, as amended, or the Securities Act, and Section&#160;21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act. In some cases, you can identify forward-looking statements by terms such as &#8220;may,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;expect,&#8221; &#8220;plan,&#8221; &#8220;anticipate,&#8221; &#8220;could,&#8221; &#8220;intend,&#8221; &#8220;target,&#8221; &#8220;project,&#8221; &#8220;contemplate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;predict,&#8221; &#8220;potential&#8221; or &#8220;continue&#8221; or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words. All statements other than statements of historical fact contained in this Annual Report on Form 10-K, including without limitation statements regarding our plans to develop, manufacture and commercialize our product candidates, the timing or outcome of our ongoing or planned clinical trials for IMM-1-104, any of our other pipeline product candidates and any future product candidates, the clinical utility of our product candidates, the filing with, and approval by, regulatory authorities of our product candidates, the sufficiency of funds to operate the business of the Company, the ongoing impact of the pandemic related to COVID-19 and its variants on our business and operations, including manufacturing, research and development, clinical trials and employees, our cash needs and availability including our revenue streams, and the plans and objectives of management for future operations, are forward-looking statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The forward-looking statements in this Annual Report on Form 10-K are only predictions and are based largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition and results of operations. These forward-looking statements speak only as of the date of this Annual Report on Form 10-K and are subject to a number of known and unknown risks, uncertainties and other important factors that could cause actual results to differ materially from those projected in the forward-looking statements, including, but not limited to, those described in the sections of this Annual Report on Form 10-K entitled &#8220;Risk Factors&#8221; and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221;. These risks and uncertainties include, but are not limited to:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt 0pt 6pt 0pt;">&#9679;</td><td style="padding:0pt 0pt 6pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our limited operating history;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt 0pt 6pt 0pt;">&#9679;</td><td style="padding:0pt 0pt 6pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our history of operating losses;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt 0pt 6pt 0pt;">&#9679;</td><td style="padding:0pt 0pt 6pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">risks related to the pandemic related to COVID-19 and its variants;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt 0pt 6pt 0pt;">&#9679;</td><td style="padding:0pt 0pt 6pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to raise the substantial additional capital that will be required to finance our operations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt 0pt 6pt 0pt;">&#9679;</td><td style="padding:0pt 0pt 6pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the difficulty of obtaining regulatory approval for any of our current or future product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt 0pt 6pt 0pt;">&#9679;</td><td style="padding:0pt 0pt 6pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to file INDs (as defined below) or IND amendments or comparable documents in foreign jurisdictions in order to commence clinical trials on the timelines we expect;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt 0pt 6pt 0pt;">&#9679;</td><td style="padding:0pt 0pt 6pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our limited experience in designing clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt 0pt 6pt 0pt;">&#9679;</td><td style="padding:0pt 0pt 6pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the risk of substantial delays in completing, if at all, the development and commercialization of our current or future product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt 0pt 6pt 0pt;">&#9679;</td><td style="padding:0pt 0pt 6pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">risks related to adverse events, toxicities or other undesirable side effects caused by our current or future product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt 0pt 6pt 0pt;">&#9679;</td><td style="padding:0pt 0pt 6pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the risk of delays or difficulties in the enrollment and/or maintenance of patients in clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt 0pt 6pt 0pt;">&#9679;</td><td style="padding:0pt 0pt 6pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our substantial reliance on the successful development of our current and future product candidates, as well as our platform, including our proprietary technologies such as DCT and Fluency;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt 0pt 6pt 0pt;">&#9679;</td><td style="padding:0pt 0pt 6pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">risks related to competition in our industry;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt 0pt 6pt 0pt;">&#9679;</td><td style="padding:0pt 0pt 6pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the market opportunity for our product candidates, if approved;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt 0pt 6pt 0pt;">&#9679;</td><td style="padding:0pt 0pt 6pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">risks related to manufacturing; </span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">3</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt 0pt 6pt 0pt;">&#9679;</td><td style="padding:0pt 0pt 6pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">risks related to our reliance on third parties;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt 0pt 6pt 0pt;">&#9679;</td><td style="padding:0pt 0pt 6pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">risks related to our intellectual property; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">other important risk factors that could affect the outcome of the events set forth in these statements and that could affect our operating results and financial condition are described in the &#8220;Risk Factors&#8221; section of this Annual Report on Form 10-K.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified and some of which are beyond our control, you should not rely on these forward-looking statements as predictions of future events. Moreover, we operate in an evolving environment. New risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict all risk factors and uncertainties. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Unless otherwise stated or the context requires otherwise, references to &#8220;Immuneering,&#8221; the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; and &#8220;our,&#8221; refer to Immuneering Corporation and its subsidiaries.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">4</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_02f7d939_515f_40af_8dfa_23320bb0b682"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">Risk Factors Summary</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We are subject to numerous risks and uncertainties, including those further described below in Part I Item IA. &#8220;Risk Factors&#8221; in this Annual Report on Form 10-K, that represent challenges that we face in connection with the successful implementation of our strategy and the growth of our business. In particular, the following are principal factors that may offset our competitive strengths or have a negative effect on our business strategy, which could materially adversely affect our business, financial conditions, results of operations, future growth prospects, or cause a decline in the price of our common stock:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We have a limited operating history, have not completed any clinical trials and have no products approved for commercial sale, which may make it difficult for you to evaluate our current business and predict our future success and viability.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We have incurred significant net losses for the past several&#160;years and we expect to continue to incur significant net losses for the foreseeable future and may never attain profitability.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We will require substantial additional capital to finance our operations. If we are unable to raise such capital when needed, or on acceptable terms, we may be forced to delay, reduce and/or eliminate one or more of our research and drug development programs or future commercialization efforts.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The regulatory approval processes of the FDA and other comparable foreign regulatory authorities are lengthy, time consuming and inherently unpredictable. If we are ultimately unable to obtain regulatory approval for our product candidates, or to obtain regulatory approval to treat the indications we seek to treat with our product candidates, we will be unable to generate product revenue or the level of planned product revenue and our business will be substantially harmed.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We may encounter substantial delays in completing, or ultimately be unable to complete, the development and commercialization of our product candidates.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The outcome of preclinical studies and early clinical trials may not be predictive of the success of later clinical trials, and the results of our clinical trials may not satisfy the requirements of the FDA or other comparable foreign regulatory authorities.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Our current or future product candidates may cause adverse events, toxicities or other undesirable side effects when used alone or in combination with other approved products or investigational new drugs that may result in a safety profile that could inhibit regulatory approval, prevent market acceptance, limit their commercial potential or result in significant negative consequences.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We are early in our development efforts. Our business is substantially dependent on the successful development of our current and future product candidates. If we are unable to advance our current or future product candidates through clinical trials, obtain marketing approval to treat the indications we seek to treat with our product candidates, and ultimately commercialize any product candidates we develop, or experience significant delays in doing so, our business will be materially harmed.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We are substantially dependent on our platform, including our proprietary technologies such as DCT and Fluency, which are supported by our information technology systems. Any failure of these or other elements of our platform will materially harm our business.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Our long-term prospects depend in part upon discovering, developing and commercializing product candidates, which may fail in development or suffer delays that adversely affect their commercial viability.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Our approach to the discovery and development of product candidates is unproven, and we may not be successful in our efforts to use and expand our DCT platform to build a pipeline of product candidates with commercial value.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We have never commercialized a product candidate before and may lack the necessary expertise, personnel and resources to successfully commercialize any products on our own or together with suitable collaborators.</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">5</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We face significant competition, and if our competitors develop and market technologies or products more rapidly than we do or that are more effective, safer or less expensive than the product candidates we develop, our commercial opportunities could be negatively impacted.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The COVID-19 pandemic and potential future pandemics could continue to adversely impact our business, including our anticipated clinical trials and their timelines, supply chain and business development activities.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We substantially rely, and expect to continue to rely, on third parties, including independent clinical investigators and contract research organizations, or CROs, to conduct certain aspects of our preclinical studies, and in the future, our clinical trials. If these third parties do not successfully carry out their contractual duties, comply with applicable regulatory requirements or meet expected deadlines, we may not be able to obtain regulatory approval for or commercialize our product candidates and our business could be substantially harmed.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We contract with third parties for the manufacturing of our product candidates for preclinical studies, and expect to continue to do so for clinical trials and ultimately, for commercialization of any approved product candidate. This reliance on third parties increases the risk that we will not have sufficient quantities of our product candidates or drugs or such quantities at an acceptable cost, which could delay, prevent or impair our development or commercialization efforts.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The manufacture of drugs is complex and our third-party manufacturers may encounter difficulties in production. If any of our third-party manufacturers encounter such difficulties, our ability to provide adequate supply of our product candidates for clinical trials or our products for patients, if approved, could be delayed or prevented.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">If we are unable to obtain and maintain patent and other intellectual property protection for our product candidates and technologies or if the scope of the intellectual property protection obtained is not sufficiently broad, our competitors could develop and commercialize products and technology similar or identical to ours, and our ability to successfully commercialize our products and technology may be impaired, and we may not be able to compete effectively in our market.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">6</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_a0cd3b68_763b_474e_8416_966a5e5fd251"></a><a id="PARTI_778188"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">PART I</b></p><a id="Item_01"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item 1. Business</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We aim to improve patient outcomes by advancing a unique pipeline of oncology and neuroscience product candidates developed using our translational bioinformatics platform. We have more than a decade of experience applying translational bioinformatics to generate insights into drug mechanism of action and patient treatment response. Building on this experience, our disease-agnostic discovery platform enables us to create product candidates based on 1) biological insights that are both counterintuitive and deeply rooted in data, and 2) novel chemistry. Our lead product candidate IMM-1-104 is designed to be a highly selective dual-MEK inhibitor that further disrupts KSR to modulate the signaling dynamics of the MAPK pathway.&#160; Specifically, it is designed to use deep cyclic inhibition to deprive tumor cells of the sustained proliferative signaling required for rapid growth, while providing a cadenced, moderate level of signaling sufficient to spare healthy cells.&#160; IMM-1-104 is being developed to treat advanced solid tumors in patients harboring RAS mutant tumors, guided by our proprietary, human-aligned 3D tumor modeling platform combined with translational bioinformatics and expertise in translational planning. In addition to IMM-1-104, we have six other oncology programs in the discovery stage that are designed to target either the MAPK or mTOR pathway, and two neuroscience programs in the discovery stage. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We plan to submit an Investigational New Drug application (an &#8220;IND&#8221;) to the Food and Drug Administration (&#8220;FDA&#8221;) for IMM-1-104 in the third quarter of 2022. In addition, we anticipate filing an IND for IMM-6-415, our MEK-io candidate, in 2023, and plan to file an additional IND for another oncology program in 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Overview</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our platform is enabled by our ability to efficiently analyze high-throughput molecular-level biochemical assays, including transcriptomics, genomics and/or proteomics, collectively referred to as Omics data. These different types of biochemical assays each provide us with unique information about the molecular mechanisms of disease biology and drug response. Since our inception, we have partnered with industry- leading pharmaceutical and biotechnology companies to perform a variety of analyses that utilize our expertise in translational bioinformatics. Examples publicly disclosed by our partners include our analyses of ibrutinib, ipilimumab, daratumumab, glatiramer acetate and pridopidine.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In early 2018, we began applying our proprietary platform and approach to internally develop our wholly owned pipeline of orally administered small molecule drug programs. Our approach played a critical role in determining the most important characteristics for and creation of IMM-1-104. Specifically, our platform enables us to:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">leverage insights from human data to identify disease transcriptional profiles we aim to counteract;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">identify novel biology, specifically evaluating new ways to drug an existing target by utilizing our proprietary Disease Cancelling Technology, or DCT, and analyze mechanisms of existing drugs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">generate novel chemistry that overcomes MAPK-feedback loops to achieve optimal signaling dynamics; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">profile IMM-1-104 in a large number of 3D models using our own translational planning to identify the types of cancer most likely to be sensitive to the product candidate.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our current oncology programs target mutations of the RAS/RAF/MEK/ERK, or MAPK, and the PI3K/AKT/mTOR, or mTOR, pathways. The MAPK and mTOR signaling pathways run parallel to each other, and in over half of all cancers, one or both of these pathways are inappropriately activated (as depicted below). Existing drugs targeting these pathways are limited by toxicity, resistance and/or are narrowly focused on subpopulations with specific mutations. The MAPK and mTOR pathways function to drive cell proliferation, differentiation, survival and a variety of other cellular functions that are critical for the formation of tumors.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">7</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:193.68pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">Fundamental Cancer Signaling Cellular Pathways: MAPK and mTOR</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><img src="imrx-20211231x10k006.jpg" alt="Graphic" style="display:inline-block;height:193.68pt;width:336.24pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Each of the programs in our oncology pipeline is designed to cause cyclical disruption of abnormal activation of the MAPK and mTOR signaling pathways while limiting drug-related toxicity. Traditional drug approaches have been designed to sustain pathway inhibition, which can cause on-target drug-related toxicity and limit clinical durability as a result of drug holidays or treatment discontinuation. Based on insights derived from our translational bioinformatics platform, our differentiated approach is to design drugs with short half-lives that provide enhanced mechanistic control of the target of interest and break tumor addiction, which is the tumor&#8217;s ability to indefinitely self-replicate, metastasize and evade the host&#8217;s immune system, among other capabilities, through deep cyclic disruption of these pathways (i.e., signaling dynamics). By cyclically disrupting these core oncogenic signaling pathways in cancer cells, we believe we can create novel therapeutics that maximize therapeutic activity in broad patient populations while providing an improved tolerability profile (as depicted below). We believe we are pioneers in this unique approach of leveraging signaling dynamics against tumor addiction.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">Signaling Dynamics: Traditional Sustained Inhibition Versus Our Cyclic Approach</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><img src="imrx-20211231x10k007.jpg" alt="Graphical user interface, diagram&#10;&#10;Description automatically generated with medium confidence" style="display:inline-block;height:161pt;width:432.5pt;" /></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">8</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:244.75pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our Wholly Owned Pipeline</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our oncology programs target clinically validated pathways, but we seek to improve patient outcomes across a wide range of addressable solid tumor types through our differentiated programs. In addition to our oncology pipeline, we are also leveraging our platform to build a neuroscience pipeline initially focusing on Alzheimer&#8217;s disease, or AD. Our current pipeline of product candidates and discovery programs is depicted below. &#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><img src="imrx-20211231x10k008.jpg" alt="Chart, funnel chart&#10;&#10;Description automatically generated" style="display:inline-block;height:244.75pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:485.3pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Dual-MEK Program</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our dual mitogen-activated protein kinase kinase, or MEK, product candidate, IMM-1-104, is designed to be a highly selective inhibitor of mitogen-activated protein kinase kinase kinase, or ERK, activation (i.e., phosphorylation), prevent MAPK pathway reactivation and have a short plasma half-life that reduces sustained pathway inhibition (as depicted below). Unlike MEK inhibitors approved by the U.S. Food and Drug Administration, or the FDA, IMM-1-104 is designed to prevent RAF-mediated activation of MEK by engagement of the RAF activation loop on MEK, such as CRAF-bypass, and further disrupt the kinase suppressor of RAS 1 and 2, or KSR. Additionally, with a short plasma half-life, IMM-1-104 can achieve deep cyclic inhibition of the MAPK pathway. We believe this innovative method of pathway inhibition normalizes cancer cell signaling dynamics and prevents further damage to normal healthy cells. Collectively, we believe these qualities differentiate IMM-1-104 from known MEK inhibitors by potentially enabling IMM-1-104 to avoid drug resistance while improving tolerability.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">9</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:204.6pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">Dual-MEK Inhibition Prevents Activation of MEK and Downstream Activation of ERK</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><img src="imrx-20211231x10k009.jpg" alt="Graphic" style="display:inline-block;height:204.6pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:431.4pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In preclinical studies, we observed that IMM-1-104 inhibited MEK and ERK across a wide range of human and murine solid tumor models, including those with activating mutations in KRAS, NRAS, HRAS and BRAF. In addition, in head-to-head preclinical studies, we evaluated IMM-1-104 in murine-based KRAS, NRAS, and BRAF mutant solid tumor models representing lung, colon, pancreas and skin cancer, and observed tumor stasis or regression with insignificant body weight loss, or BWL, when compared to certain current FDA- approved MEK and BRAF inhibitors. Given the data observed in these preclinical studies, we believe that IMM-1-104 has the potential to deliver clinical benefit as monotherapy and, in the future, may potentially be administered in select drug combinations for patients with RAS and/or RAF mutant solid tumors who currently have limited treatment options.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">IMM-1-104 is currently undergoing Investigational New Drug, or IND, enabling studies. We plan to submit an IND for IMM-1-104 to the FDA in the third quarter of 2022. We intend to enroll our first patient in our first-in-human Phase 1 clinical trial of IMM-1-104 in the fourth quarter of 2022 for the treatment of advanced solid tumors in patients harboring RAS mutant tumors, if our IND for IMM-1-104 is accepted.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">MEK-Immuno-Oncology </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our MEK-immuno-oncology, or MEK-io, program is focused on developing innovative allosteric MEK inhibitors to be administered in combination with select immune modulators (e.g., checkpoint inhibitors) for the treatment of &#8220;cold&#8221; solid tumors, which are immunologically inaccessible. Our investigational MEK-io program inhibitors were designed to target MEK in a way that disrupts the MAPK pathway at ERK and to also reduce baseline MEK activation. We designed these inhibitors with unique pharmacokinetic, or PK, and pharmacodynamic, or PD, profiles that may enhance cycle inhibition time of MEK and ERK to optimize the patient&#8217;s immune response and promote maximal antitumor responses when administered in combination with select immune modulators. We recently selected a development candidate, IMM-6-415, for the MEK-io program, and initiated IND-enabling studies in the first quarter of 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We observed an initial <i style="font-style:italic;">in vivo </i>proof-of-concept for our MEK-io program, from a related analogue compound to IMM-6-415, in a widely utilized syngeneic murine model. We evaluated this analogue compound as monotherapy and in combination with a checkpoint inhibitor and compared to vehicle to observe tumor growth inhibition in tumor-bearing BALB/C mice. Neither treatment alone altered tumor growth as compared to vehicle. However, when we administered our analogue MEK-io program inhibitor in combination with the checkpoint inhibitor, we observed greater than 50% tumor growth inhibition after two weeks of dosing as compared to vehicle treated mice.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">10</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">IMM-6-415 may enhance responses to checkpoint inhibitors in tumors that have been responsive to these class of agents. We observed single agent activity in the Colon-26 syngenetic colorectal tumor model and are evaluating IMM-6-415 as monotherapy or in combination with checkpoint inhibitors in CT26 and MC-38 syngeneic models. We plan to submit &#160;an IND for IMM-6-415 to the FDA in 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Additional Oncology Discovery Research Programs</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We are leveraging our platform to continue expanding our oncology pipeline by targeting the MAPK and mTOR pathways in novel ways. We have five additional programs in various stages of drug discovery focused on targeting these pathways through novel pharmacological approaches. We expect to file an IND for at least one of these programs in 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Neuroscience Programs</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">AD is the most common form of dementia and one in three adults over the age of 65 succumb to AD-related dementia or another form of dementia. We believe there are specific subgroups of AD that can be stratified through gene expression and brain pathology. To identify AD subgroups, we have leveraged our platform to employ a patient-centric, data-driven approach. AD is a neurodegenerative disorder of uncertain cause and pathogenesis characterized by memory impairment and further cognitive decline that can ultimately affect the patient&#8217;s behavior, speech, visuospatial orientation and motor system. AD is a complex multifactorial disease driven by genetic and environmental causes that affects older adults and is one of the leading sources of morbidity and mortality in the aging population. The estimated total healthcare costs for the treatment of AD were approximately $305 billion in 2020, with the cost expected to increase to more than $1 trillion by 2050.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our neuroscience programs are in the early stages of drug discovery, and we are evaluating undisclosed targets to pursue a unique approach to treating AD. Our focus is to slow the progression of AD by developing targeted therapies for distinct biological mechanisms that we have identified in specific AD subgroups. Our platform and expertise in neurology and neuroscience have allowed us to determine biological differences in AD patients to help develop novel product candidates that may potentially address the significant unmet needs of this underserved patient population.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our Team</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We were founded in 2008 by our Chief Executive Officer and President, Benjamin J. Zeskind, Ph.D., and the Chairman of our board of directors, Robert J. Carpenter, with the goal of leveraging translational bioinformatics to generate insights into the mechanisms that cause certain patients to respond to specific medicines across multiple therapeutic areas. Our multi-disciplinary team brings together experts across translational bioinformatics, preclinical and clinical development in both oncology and neuroscience and includes individuals with extensive experience at some of the leading pharmaceutical companies, including Johnson &amp; Johnson, AstraZeneca, Merck and Incyte.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our History</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our company is built on more than a decade of experience in translational bioinformatics. Since our founding in 2008, we have utilized this experience to generate insights into the mechanisms that cause certain patients to respond to specific medicines across therapeutic areas by analyzing Omics data. Our computational biology services business has helped us to better understand how translational bioinformatics can contribute to each stage of drug development, from early drug discovery to clinical development and through commercialization. However, we recognized the limitations of applying translational bioinformatics in isolation to specific stages of the drug development process and realized that bioinformatics could be even more helpful if applied continuously throughout the drug development process. Over time, we have developed a proprietary technology platform to facilitate that process and, in early 2018, we began applying the extensive insights from and capabilities of our platform and approach to create a wholly owned pipeline of drug programs, initially focusing on oncology.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">11</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our Strategy</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our mission is to develop novel therapies by utilizing our disease-agnostic platform to address areas of high unmet medical need, initially in cancer and neurologic diseases. Our platform allows us to leverage human biological data to generate insights that are not constrained by the inherent limitations of conventional approaches or prevailing scientific views. We are developing novel product candidates that aim to optimize both safety and efficacy for diseases with suboptimal treatment options. To achieve our mission, we are executing a near-term strategy with the following key elements:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Advance IMM-1-104 into Clinical Development</span><b style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">. </b><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We believe that IMM-1-104 has the potential to treat broad populations of solid tumor patients, specifically those with inappropriate activation of the MAPK pathway. IMM-1-104 has been specifically designed to overcome MAPK-feedback loops and, combined with its intentionally short half-life, could have the potential to provide broader therapeutic activity and an improved tolerability profile relative to known MEK inhibitors. We believe IMM-1-104 has the potential to target patients with a wide spectrum of mutations in KRAS and NRAS, as well as other mutations that activate the MAPK pathway. IMM-1-104 is currently in IND-enabling studies, and we expect to submit an IND in the third quarter of 2022.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Advance IMM-</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">6-415 through IND-Enabling studies. </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We recently commenced IND-enabling studies for IMM-6-415 and plan to submit an IND in 2023. IMM-6-415 is a dual-MEK inhibitor that has drug-like properties optimized for immune modulation, and may enhance and/or expand clinical responses to checkpoint inhibitors in tumors that have proved historically challenging to immune modulating therapies. In addition, we may target patient populations with RAS and RAF mutations who have observed low rates of clinical responses to checkpoint inhibitors.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Progress Our Pipeline of Additional MAPK and mTOR Pathway Programs to IND-Enabling Studies</span><b style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">. </b><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Other key programs in our oncology pipeline also leverage our knowledge of the MAPK and mTOR pathways, translational bioinformatics and signaling dynamics. For example, we are advancing programs which modulate the formation of RAS dimers to kill RAS-driven tumors while sparing healthy cells. We are also applying our platform to other relevant pathways and have initiated a program targeting PI3K&#945; in the mTOR pathway. We intend to develop other programs for the mTOR pathway, as well as other oncogenic pathways. We anticipate submitting an IND for at least one of these programs in 2024.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Utilize Our Platform to Advance Our Neuroscience Programs. </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">In addition to our extensive oncology pipeline, we have built a neuroscience pipeline initially focused on AD, which leverages key components of our platform. We have identified subgroups of AD with distinct molecular drivers and have identified unique undisclosed targets for these specific subgroups. Currently, we are developing investigational small molecules to inhibit these undisclosed targets, which we intend to continue advancing towards IND-enabling studies.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Continue to Grow and Advance Our Platform</span><b style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">. </b><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We have built a biopharmaceutical company that fully integrates bioinformatics across all aspects of drug discovery and development. We currently utilize our bioinformatics platform for our drug discovery efforts in oncology and neuroscience, and as we advance our product candidates into and through the clinic, we plan to utilize data and insights from our bioinformatics platform to not only guide future clinical development but to also provide key learnings back to our earlier stage programs. Lastly, we continue to iterate on our existing technology and processes, and develop new technologies for our platform, all aimed at creating the most efficient process for the development of product candidates that we believe have the potential to optimize both safety and efficacy in broad patient populations with high unmet medical needs.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our Bioinformatics Approach</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Leveraging our history in translational bioinformatics, we have built a biopharmaceutical company that incorporates our expertise into every step of our process to discover and develop novel product candidates. Our goal is to meaningfully improve patient outcomes as compared to drugs developed through traditional drug discovery approaches. Our integrated approach has already yielded programs that have exhibited preclinical tumor growth inhibition against a broad range of clinically challenging solid tumors, which are advancing towards the clinic. Our Dual-MEK and MEK-io drug programs are currently in IND-enabling studies, while the rest of our programs are in earlier stage preclinical studies. We have </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">12</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:264pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">expanded our team of experts, including drug discovery and clinical development experts, to develop a pipeline of product candidates by leveraging our translational bioinformatics expertise (as depicted below).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">Our Bioinformatics Expertise Leveraged Through All Stages of Drug Discovery and Development </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;"><img src="imrx-20211231x10k010.jpg" alt="Diagram&#10;&#10;Description automatically generated" style="display:inline-block;height:263.45pt;left:0%;padding-bottom:0.55pt;position:relative;top:0pt;width:485.3pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Cancer Overview</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Cancer is the second most common cause of death worldwide with approximately 10 million deaths annually and an incidence of approximately 19.3 million new cases in 2020. Cancer is defined as a collection of diseases in which abnormal cells divide uncontrollably and can invade nearby tissues. The uncontrollable division of abnormal cells typically results in a malignant tumor (i.e., cancerous) or benign tumor (i.e., non-cancerous). There are two main categories of cancer: hematologic (i.e., blood) cancers and solid tumor cancers. Hematologic cancers are cancers of the blood cells, and include leukemia, lymphoma and multiple myeloma. Solid tumor cancers are cancers of any of the body&#8217;s other organs or tissue, including the pancreas, skin, lung and colon. Core tumor capabilities seen in cancer patients include the ability to indefinitely self-replicate, develop new blood vessels (i.e., angiogenesis), evade cell death (i.e., apoptosis), sustain self-sufficient growth, invade other tissues (i.e., metastasis), alter signaling pathways, evade immune system responses and modify metabolism. Tumor survival is dependent on certain of these capabilities (i.e., tumor addiction).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">MAPK and mTOR Pathways</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In all cells, signaling pathways govern how cells regulate themselves as well as direct activities in relation to other cells in the body. Two of the most commonly altered signaling pathways in cancer are the MAPK and mTOR pathways. MAPK and mTOR are both oncogenic signaling pathways that run parallel to each other. RAS is a family of related oncogenes found upstream in each pathway that codes for four highly related protein isoforms, HRAS, NRAS, KRAS4A and KRAS4B. In over half of all cancers, one or both of these pathways are inappropriately activated, often through mutations in the key members of the pathway, including RAS, RAF and PI3K&#945;. When RAS is switched &#8220;on&#8221; through the activation of the membrane-bound receptor tyrosine kinase, or RTK, the MAPK and mTOR pathways function to drive cell proliferation, differentiation, survival and a variety of other cellular functions that are critical for the formation of tumors. In addition, the membrane-bound RTKs can separately activate the mTOR pathway without the assistance of RAS.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">13</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:207.36pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Through widespread adaptation of molecular profiling, we now recognize that up to one in two cancer patients harbor tumors which are inappropriately activated through the MAPK pathway, and an additional one in three display alterations that impact the mTOR pathway. Many of these patients display tumors with activation mutations in RAS or RAF, which lie upstream of MEK and ERK. Because inappropriate activation of the MAPK and/or mTOR pathways supports many of the core tumor capabilities described above, efforts to create new therapeutics to target these pathways has been a high priority in cancer drug research. However, therapeutics that target the MAPK and mTOR pathways have not lived up to the expectations of effectively disrupting these pathways with high patient tolerability. Nearly all targeted therapeutics against the MAPK and mTOR pathways have been designed for sustained pathway suppression, which has resulted in on-target drug-related toxicity that limits clinical durability and potential drug-drug combinations. Furthermore, sustained irreversible covalent inhibition of these pathways may lead to treatment resistance, as highlighted in a recently published study in the New England Journal of Medicine. The study focused on patients treated with adagrasib, an irreversible covalent inhibitor of KRAS<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">G12C</sup>, and reported that 45% of patients (17 patients out of 38) in the study receiving adagrasib monotherapy developed resistance. Of these patients, many resistance mechanisms were observed involving non-G12C variations in KRAS, variations in NRAS or BRAF, or other resistance mechanisms related to the MAPK and mTOR pathways. A second study published in Nature (November 10, 2021) evaluated 43 patients treated with sotorasib, an irreversible covalent inhibitor of KRAS<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">G12C</sup>, and reported 27 patients with multiple treatment-emergent resistance alterations. Of these, 15 patients reported resistance mechanisms involving RAS/RAF mutations. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Developing novel therapeutics to effectively and safely target these pathways may provide clinical benefit in large patient populations with significant unmet needs. In addition, although these two pathways represent two of the most active areas in cancer drug discovery and development, targeted therapeutics that more effectively and safely normalize, but not ablate, ERK and mTOR signaling may uncouple drug activity and tolerability, while optimizing both. Our oncology pipeline is designed to non-chronically disrupt molecular pathways that enable tumor addiction while limiting drug-related toxicity of normal healthy cells that also rely, to a lesser degree, on these pathways.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">Our Programs Target Aggressive Solid Tumors That Display High RAS/RAF Mutations</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;"><img src="imrx-20211231x10k011.jpg" alt="Graphic" style="display:inline-block;height:207.36pt;width:480.24pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our Differentiated Approach to Tackling Some the Most Challenging Cancers</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">We are leveraging our platform to target the MAPK and/or mTOR pathway. Our differentiated approach is to design drugs with short half-lives that provide enhanced mechanistic control of the target of interest and break tumor addiction through deep cyclic disruption of these pathways (i.e., signaling dynamics). We believe we are pioneers in this approach of leveraging signaling dynamics against tumor addiction, and our insights derived from our translational bioinformatics platform supports our belief that this approach may result in novel therapies targeting these pathways. Traditional drug approaches have been designed to sustain pathway inhibition, which leads to on-target drug-related toxicity and becomes </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">14</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:251.1pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">limiting for clinical durability as a result of drug holidays or treatment discontinuation. The mutational activation and/or overexpression of the signaling components that activate the MAPK pathway are well-known, and MEK has been previously validated as a therapeutic target. We believe our programs, as compared to FDA-approved treatments targeting the MAPK pathway, have the potential to be differentiated by their unique target engagement and PK and PD profiles. For example, our lead product candidate, IMM-1-104, is designed to inhibit ERK, prevent MAPK- pathway reactivation and have a short plasma half-life that reduces sustained pathway inhibition compared to other drugs targeting the same mechanistic pathway. By cyclically disrupting these core oncogenic signaling pathways in cancer cells, we believe we can create novel therapeutics in oncology that maximize therapeutic activity in broad patient populations while providing an improved tolerability profile as compared to other FDA-approved treatments for cancers caused by MAPK pathway activation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our Oncology Pipeline</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our current development programs in oncology are focused on providing treatments for patients with solid tumors caused by mutations of the MAPK and mTOR pathways. Our Dual-MEK product candidate, IMM-1-104, and our MEK-io product candidate, IMM-6-415 are currently being evaluated in IND-enabling studies and are complemented by multiple earlier- stage programs that also target the MAPK and mTOR pathways. The following table summarizes our oncology pipeline:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><img src="imrx-20211231x10k012.jpg" alt="Chart, funnel chart&#10;&#10;Description automatically generated" style="display:inline-block;height:251.1pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:485.3pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Overview of Our Lead Program: Dual-MEK</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 12pt 0pt;">Background of MEK Inhibitors</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Activating mutations of RAS and/or RAF in the MAPK pathway are observed in approximately 30% of all cancer patients, and inappropriate activation of this pathway is observed in up to 50% of all tumors and represents one of the most highly utilized signaling pathways in oncologic drug discovery. In aggressive solid tumors of the pancreas, skin, lungs and colon, mutations in RAS and/or RAF are even more common. For example, approximately 40% of lung cancers and approximately 90% of pancreatic cancers are due to RAS and/or RAF mutations. To date, FDA-approved MEK inhibitors have been ineffective at treating RAS mutant tumors when compared to BRAF mutant tumors because of a well-known mechanism of resistance, CRAF- mediated MEK activation, or the CRAF-bypass. In addition, a well-known limitation of current FDA- approved MEK inhibitors are their high rates of serious drug-related adverse events, most often in over 50% of &#160;treated patients, which results in drug intolerability. &#160;The longer half-life of &#160;these drugs (e.g., up to 2 to 4 days), or </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">15</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:205.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">moderate half-life (e.g., 3 to 6 hours) with increased dosing frequency, contributes to high rates of adverse events because these drugs systemically circulate for an extended period of time destroying healthy normal cells, which also rely on the pathway for survival. Our goal in developing IMM-1-104 is to address these shortcomings to potentially provide patients with better outcomes, improved tolerability, durability and expand drug-drug combination opportunities (as depicted below).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">IMM-1-104: Designed to be a Highly Differentiated Dual-MEK Inhibitor</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><img src="imrx-20211231x10k013.jpg" alt="Diagram&#10;&#10;Description automatically generated" style="display:inline-block;height:205.05pt;left:0%;padding-bottom:0.45pt;position:relative;top:0pt;width:468pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our Solution: IMM-1-104</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We have leveraged our platform to develop our lead product candidate, IMM-1-104, which is designed to be a highly selective dual-MEK inhibitor that promotes additional scaffold-related disruption of KSR. We are developing IMM-1-104 to treat patients with cancer, including pancreatic, melanoma, colorectal and non-small cell lung cancer, or NSCLC, caused by mutations of RAS and/or RAF. In order to overcome MAPK-feedback and CRAF-mediated MEK activation, a well-known limitation of current FDA-approved MEK inhibitors, we developed IMM-1-104 to allosterically inhibit MEK by targeting the site lying adjacent to the binding pocket of adenosine triphosphate, or ATP, which results in downstream inhibition of ERK. In addition, unlike FDA-approved MEK inhibitors, IMM-1-104 is designed to prevent RAF-mediated activation of MEK by unique engagement of MEK that further disrupts KSR. We believe the bypass of these drug resistance mechanisms will provide for better patient outcomes by enhancing therapeutic activity throughout the course of treatment. By reducing steady state drug trough levels, we also designed IMM-1-104 to limit or reduce high rates of serious drug-related adverse events that are observed in current FDA-approved MEK inhibitors (e.g., ranging from 45% to 69%), most often given in combination with a RAF inhibitor, which contribute to discontinuation rates of up to 10% to 15%.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">With a goal of improving the tolerability profile of our MEK inhibitor, we designed IMM-1-104 to have a short plasma half-life, resulting in a near-zero steady state drug trough concentration that enables deep cyclic inhibition of the MAPK pathway. We believe this method of drug cadence-driven pathway inhibition has the potential to normalize cancer cell signaling dynamics and prevent further damage to normal healthy cells. Collectively, we believe these qualities may differentiate IMM-1-104 from known MEK inhibitors by potentially allowing IMM-1-104 to avoid drug resistance while improving tolerability due to its dual allosteric inhibition of MEK, KSR disruption and short plasma half-life.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">16</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Preclinical Studies Overview: IMM-1-104</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In multiple preclinical studies, we observed that IMM-1-104 inhibited activated MEK (i.e., pMEK) and activated ERK (i.e., pERK) across a wide range of murine and humanized 3D solid tumor models, including those with activating mutations in KRAS, NRAS, HRAS and BRAF. In addition, in head-to-head preclinical studies, we evaluated IMM-1-104 in murine-based KRAS, NRAS, and BRAF mutant solid tumor models representing lung (i.e., A549), colon (i.e., Colon-26), pancreas (i.e., MIA PaCa-2) and skin cancer (i.e., A375 and SK-MEL-2), and observed tumor stasis or regression with insignificant BWL when compared to current FDA-approved MEK inhibitors, including selumetinib, binimetinib, encorafenib and AMG-510 (now known as sotorasib). Given the data observed in our previously conducted preclinical studies, we believe that IMM-1-104 has the potential to deliver clinical benefit as monotherapy and, in the future, may potentially be administered in select drug combinations for patients with RAS and/or RAF mutant solid tumors who currently have limited treatment options.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 12pt 0pt;">Preclinical Studies: Maximum Tolerated Dose and Therapeutic Effect<span style="display:inline-block;width:73.03pt;"></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In our early maximum tolerated dose, or MTD, studies, we observed that oral administration of IMM-1-104 twice a day of up to 150 mg/kg/dose was well-tolerated in mice. In other preclinical studies, we observed that the maximum therapeutic effect of IMM-1-104 was reached when administered orally twice a day between 100 and 150 mg/kg/dose. These dosing studies provided the basis of IMM-1-104&#8217;s dosing schedule in subsequent preclinical studies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 12pt 0pt;">Preclinical Studies: Pharmacogenomics</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In a pharmacogenomics study utilizing a colorectal KRAS<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">G12D</sup> tumor model in BALB/c mice, we evaluated downstream ERK inhibition of the MAPK pathway after IMM-1-104 treatment. We orally administered vehicle, selumetinib and IMM-1-104 twice a day at 100 mg/kg/dose, then harvested the tumors after 18 days of chronic treatment at 2 and 12 hours following the last drug dose to evaluate RNAseq changes. The tumors were collected across distinct BALB/c mice and RNAseq changes were evaluated using statistical analysis software. Consistent with IMM-1-104&#8217;s designed short plasma half-life, we observed deep, cyclic inhibition of most of the top genes in the ERK transcriptome, as noted by the differences of the dark and light blue bars, which we believe may improve tolerability by allowing healthy normal cells to regenerate before the next dose is administered. For example, <i style="font-style:italic;">Erg1 </i>and <i style="font-style:italic;">Spry4 </i>were both downregulated over 16-fold at 2 hours after receiving the first dose on day 18 of the study, and at 12 hours after the first dose, which was prior to the second dose, both genes were approaching their baseline state when compared to vehicle treated tumors (as depicted below). In contrast to IMM-1-104, we did not observe deep cyclic inhibition by selumetinib, but rather observed sustained MAPK pathway suppression versus vehicle groups between the two timepoints on day 18 (as depicted below). The top 20 genes were a subset of a 52-gene signature for ERK signaling.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">17</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:219.05pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">Head-to-Head Comparison of IMM-1-104 Against Selumetinib Using a Colon-26 Syngeneic Tumor Model: Deep Cyclic Inhibition of the ERK Transcriptome</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><img src="imrx-20211231x10k014.jpg" alt="Graphic" style="display:inline-block;height:219.05pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:485.3pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">* Adjusted p-value &lt; 0.05, for each treatment versus vehicle (n = 3-4 independent tumors per group) </i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 12pt 0pt;">Preclinical Studies: Resistance to CRAF-bypass</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We evaluated IMM-1-104 head-to-head against four FDA-approved MEK inhibitors for CRAF-bypass resistance in a KRAS mutant NSCLC tumor model. We exposed the tumor cells with 100 nM of each drug for 2 hours and evaluated MEK and ERK activation levels. We observed that IMM-1-104 was able to reduce overall activity of the MAPK pathway at ERK and pathway reactivation at MEK through a decrease in MEK and ERK activation, resulting in CRAF-bypass resistance. In contrast, we observed that all four FDA- approved MEK inhibitors displayed an increase in activated MEK, resulting in CRAF-bypass (as depicted below).</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">18</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:220.9pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">Head-to-Head Comparison of IMM-1-104 against Four FDA-Approved MEK Inhibitors Using a A549 Xenograft Tumor Model: Prevented Downstream Activation of ERK (&#8595; pERK) and Inhibited Activation of MEK (&#8595; pMEK)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><img src="imrx-20211231x10k015.jpg" alt="Graphic" style="display:inline-block;height:220.9pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:485.3pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 12pt 0pt;">Preclinical Studies: Tumor Regression and Body Weight Loss</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We evaluated IMM-1-104 head-to-head against binimetinib and selumetinib in an aggressive murine colorectal tumor model (i.e., Colon-26), which expresses mutant KRAS<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">G12D</sup>. We observed that IMM-1-104 demonstrated greater tumor growth inhibition, where notably 5 of 8 mice experienced tumor regression during the first 10 days of dosing, as well as greater tolerability, evidenced by changes in BWL. In addition, we observed that IMM-1-104 had overall better durability of antitumor response as compared to the two FDA- approved MEK inhibitors, as demonstrated by significantly lower tumor volume, or TV, progression. This study demonstrated that IMM-1-104 as compared to binimetinib and selumetinib provided greater tumor inhibition, lower BWL and lower TV progression (as depicted below).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">19</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:281.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">Head-to-Head Comparison of IMM-1-104 Against Binimetinib and Selumetinib Using a Colon-26 Syngeneic Tumor Model: Body Weight Loss and Tumor Volume</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><img src="imrx-20211231x10k016.jpg" alt="Graphical user interface&#10;&#10;Description automatically generated" style="display:inline-block;height:281.15pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:485.3pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">After observing the results of the Colon-26 tumor study, we completed two follow-up <i style="font-style:italic;">in vivo </i>studies, where we evaluated IMM-1-104 head-to-head against binimetinib or encorafenib, a BRAF inhibitor, as monotherapy plus the combination of binimetinib with encorafenib in BALB/c mice tumor models with RAS and RAF mutations. It should be noted that when encorafenib is used to treat KRAS mutant tumors that are wild type for BRAF, it can paradoxically activate the MAPK pathway and antagonize the effects of binimetinib. In addition, the drug doses and schedules used for binimetinib and encorafenib in these studies were consistent with what was provided in their NDAs to the FDA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We evaluated IMM-1-104 head-to-head against binimetinib monotherapy and in combination with encorafenib in the KRAS<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">G12S</sup> human NSCLC tumor model (i.e., A549). When comparing IMM-1-104 to binimetinib monotherapy, we observed that IMM-1-104 had greater tumor growth inhibition (as depicted below). The observations of IMM-1-104 head-to-head against binimetinib alone and in combination with encorafenib, which was not considered relevant for a KRAS mutant, RAF wild-type tumor model, has been included in the figure below for comparison purposes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">20</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:263.2pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">Head-to-Head Comparison of IMM-1-104 Against Binimetinib +/- Encorafenib Using a A549 Xenograft Tumor Model: Tumor Volume </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><img src="imrx-20211231x10k017.jpg" alt="Chart&#10;&#10;Description automatically generated" style="display:inline-block;height:263.2pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:485.3pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We also evaluated IMM-1-104 head-to-head against binimetinib and encorafenib monotherapy and the combination of binimetinib with encorafenib in a BRAF<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">V600E</sup> human melanoma tumor model. It should be noted that the administered combination of binimetinib and encorafenib for BRAF mutant melanoma, such as BRAF<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">V600E/K</sup>, is an FDA-approved combination. As expected, when comparing IMM-1-104 alone to binimetinib in combination with encorafenib, we observed that the combination therapy had greater tumor growth inhibition (as depicted below). However, when we compared IMM-1-104 to binimetinib monotherapy, we observed that IMM-1-104 had greater tumor growth inhibition (as depicted below). We believe the greater single agent MEK inhibitor activity provides an opportunity to expand IMM-1-104 into drug-drug combinations with other MAPK pathway inhibitors, such as encorafenib, to treat RAF mutant cancers, such as BRAF<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">V600E/K</sup>, among other MAPK pathway mutations.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">21</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:260.05pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">Head-to-Head Comparison of IMM-1-104 Against Binimetinib +/- Encorafenib Using a A375 Xenograft Tumor Model: Tumor Volume </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><img src="imrx-20211231x10k018.jpg" alt="Chart&#10;&#10;Description automatically generated" style="display:inline-block;height:260.05pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:485.3pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In a further <i style="font-style:italic;">in vivo </i>study based on humanized 3D tumor model data, we evaluated IMM-1-104 head-to-head against AMG-510 (sotorasib) and gemcitabine alone, and IMM-1-104 in combination with AMG-510, for 21 days in the KRAS<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">G12C </sup>mutant tumor model (i.e., MIA PaCa-2). In a previous study conducted by a third-party, AMG-510 demonstrated sensitivity to this pancreatic tumor model. Comparing IMM-1-104 alone, against AMG-510 and in combination with AMG-510, we observed tumor regressions with insignificant BWL (i.e., within 3% of baseline), which we believe indicates activity, durability and tolerability of IMM-1-104 against a KRAS<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">G12C </sup>mutant pancreatic cancer model (as depicted below).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">22</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:237.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">Head-to-Head Comparison of IMM-1-104 +/- AMG-510 (sotorasib) and Gemcitabine Using a MIA PaCa-2 Xenograft Tumor Model: Tumor Volume</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><img src="imrx-20211231x10k019.jpg" alt="Graphical user interface, chart&#10;&#10;Description automatically generated" style="display:inline-block;height:237.4pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:485.3pt;" /></p><a id="_Hlk93063732"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In an <i style="font-style:italic;">in vivo </i>study based on humanized 3D tumor model data, we evaluated IMM-1-104 monotherapy as compared to binimetinib for 21 days in the NRAS<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">Q61R</sup> mutant tumor model (i.e., SK-MEL-2). We observed better tumor growth inhibition relative to binimetinib (as depicted below). </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">23</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:285pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">Head-to-Head Comparison of IMM-1-104 Against Binimetinib Using a SK-MEL-2 Xenograft Tumor Model: Tumor Volume</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><img src="imrx-20211231x10k020.jpg" alt="Chart, line chart&#10;&#10;Description automatically generated" style="display:inline-block;height:284.55pt;left:0%;padding-bottom:0.45pt;position:relative;top:0pt;width:485.3pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In a further <i style="font-style:italic;">in vivo </i>study based on humanized 3D tumor model data, we evaluated IMM-1-104 monotherapy as compared to vehicle for 21 days in the NRAS<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">Q61R</sup> mutant tumor model (i.e., SK-MEL-2). We observed midcycle tumor regressions in mice treated with IMM-1-104, which we believe indicates activity and durability of IMM-1-104 against an NRAS<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">Q61R</sup> mutant melanoma cancer model (as depicted below).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">24</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:330.2pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">Evaluation of IMM-1-104 as Compared to Vehicle Using a SK-MEL-2 Xenograft Tumor Model: Tumor Volume</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><img src="imrx-20211231x10k021.jpg" alt="Chart, line chart&#10;&#10;Description automatically generated" style="display:inline-block;height:330.2pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:345.85pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 12pt 0pt;">Preclinical Studies: 3D Tumor Growth Models</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">3D tumor growth models mimic the tumor microenvironment, or TME, more closely than 2D models, and we believe the 3D model more accurately reflects human tumor biology and complexity when evaluating pharmacological data of MAPK pathway inhibition <i style="font-style:italic;">in vivo</i>. &#160;We have established and evaluated over 60 humanized 3D tumor models that display mutations in the RAS isoforms, amongst other altered MAPK pathway targets, including BRAF, CRAF, NF1 and ERK, to evaluate their sensitivities to IMM-1-104. In general, we observed that tumor models with KRAS or NRAS mutations and certain molecular profiles were most sensitive to IMM-1-104, followed closely by tumor models with BRAF mutations. For example, the IC<sub style="font-size:7.5pt;vertical-align:sub;">50</sub> of IMM-1-104 ranged from 68.7 nM in NRAS<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">Q61K</sup> to 214.7 nM in NRAS<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">G12D</sup>, whereas the IC<sub style="font-size:7.5pt;vertical-align:sub;">50</sub> of IMM-1-104 ranged from 814.7 nM to greater than 10,000 nM in BRAF<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">V600E </sup>and certain RAS mutants, respectively. More specifically, our 3D tumor modeling data suggested that KRAS mutant pancreatic cancer and NRAS mutant melanoma may be particularly sensitive to single agent IMM-1-104.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">To further examine the translational opportunity in KRAS mutant pancreatic cancer and NRAS mutant melanoma, we evaluated several of these cancer mutations utilizing real-world data through a pan-cancer registry, the Genomics Evidence Neoplasia Information Exchange, or GENIE. The total number of patients in the analysis are depicted below in blue and the percentage of patients with a known mutation in KRAS or NRAS are shown as a percentage of the total patients (depicted below in black). Biomarker sensitive profiles (depicted below in green) and biomarker resistant profiles (depicted below in red) are projected subsets of patients with mutated KRAS or NRAS that may be sensitive or resistant to IMM-1-104. We observed that the overwhelming majority of pancreatic cancers associated with KRAS mutations (i.e., 92%) and melanoma associated with NRAS mutations (i.e., 73%) are found to harbor a biomarker profile that may be sensitive to IMM-1-104 (as depicted below).</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">25</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:259.53pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">Translational Profiling for KRAS Mutant Pancreatic Cancer and NRAS Mutant Melanoma Utilizing a Pan-Cancer Registry, GENIE</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><img src="imrx-20211231x10k022.jpg" alt="Chart&#10;&#10;Description automatically generated with low confidence" style="display:inline-block;height:259.43pt;left:0%;padding-bottom:0.1pt;position:relative;top:0pt;width:476.89pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;"><img src="imrx-20211231x10k023.jpg" alt="A picture containing diagram&#10;&#10;Description automatically generated" style="display:inline-block;height:250.28pt;left:0%;padding-bottom:0.25pt;position:relative;top:0pt;width:479.23pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Clinical Development Overview: IMM-1-104</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">IMM-1-104 is currently undergoing IND-enabling studies. We plan to submit an IND for IMM-1-104 to the FDA in the third quarter of 2022. We continue to expand our preclinical pharmacology models, including research to further understand sensitivity and resistance biomarkers related to IMM-1-104. We have conducted 28-day good laboratory </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">26</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">practices, or GLP, orally dosed safety and toxicology studies in rats and dogs prior to initiating our Phase 1 clinical trial of IMM-1-104. We intend to enroll the first patient in our first-in-human Phase 1 clinical trial of IMM-1-104 in the fourth quarter of 2022 for the treatment of advanced solid tumors in patients harboring RAS mutant tumors if our IND for IMM-1-104 is accepted. The Phase 1 clinical trial of IMM-1-104 is being designed to primarily evaluate its safety and tolerability, and to also identify dose-limiting toxicities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our clinical development plan for IMM-1-104 will initially focus on indications selected by our translational data. Additional indications will be based on future preclinical studies and clinical trial outcomes. Our goal is to further expand the development of IMM-1-104 in indications, including a broad range of RAS and/or RAF mutant tumors. In addition, we plan to evaluate IMM-1-104 in combination with FDA-approved MAPK and adjacent pathway inhibitors to treat certain cancers in the future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">MEK-io Program</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We are developing innovative investigational allosteric MEK inhibitors to be administered in combination with select immune modulators (e.g., checkpoint inhibitors) for the treatment of &#8220;cold&#8221; solid tumors. Our investigational MEK-io program inhibitors are designed to target MEK in a way that disrupts the MAPK pathway at ERK and to also reduce baseline MEK activation. We are designing these inhibitors with unique PK and PD profiles that may enhance cycle inhibition time of MEK and ERK to optimize the patient&#8217;s immune response and promote maximal antitumor responses when administered in combination with select immune modulators. KRAS mutant tumors impact approximately 15% of patients globally and include cold or &#8220;non-inflamed&#8221; tumors. Cold tumors are immunologically inaccessible, meaning the patient&#8217;s immune system cannot provide an appropriate antitumor response because the lack of T-cell infiltration in the tumor, which is required for the immune system (i.e., T-cells) to find, target and attack the tumor. Checkpoint inhibitors work by helping to reactivate and enhance the patient&#8217;s immune system by allowing T-cells to better provide an appropriate antitumor response. If a cold tumor were to become &#8220;hot&#8221; or &#8220;inflamed,&#8221; this would create an inflammatory process enabling T-cells to infiltrate the tumor and allow them to recognize and attack the tumor (i.e., an antitumor response). We believe our investigational MEK-io program inhibitors have the potential to turn a cold tumor hot, and when administered in combination with a checkpoint inhibitor, could provide an innovative approach to treat patients with cold solid tumors by providing MEK/ERK inhibition and optimizing antitumor response, which would not typically be seen in these patients.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We observed an initial <i style="font-style:italic;">in vivo </i>proof-of-concept for our MEK-io program, with a related analogue to our MEK-io product candidate IMM-6-415, in a widely utilized syngeneic murine model. We evaluated it as monotherapy and in combination with a checkpoint inhibitor as compared to vehicle to observe tumor growth inhibition in tumor-bearing BALB/C mice. Neither treatment alone altered tumor growth as compared to vehicle. However, when we administered in combination with the checkpoint inhibitor, we observed greater than 50% tumor growth inhibition (TGI) after two weeks of dosing as compared to vehicle treated mice.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our MEK-io product candidate, IMM-6-415, is currently in IND-enabling studies. IMM-6-415 may enhance responses to checkpoint inhibitors in tumors that have been poorly responsive to these class of agents. We observed dose-dependent, tumor growth inhibition by IMM-6-415 in a syngeneic Colon-26 animal model following oral administration of the drug to identify maximum tolerated dose in a once per day, or QD, &#160;schedule (TGI after 8 days at 175 mg/kg = 46%) or twice per day, or BID, schedule (TGI after 8 days at 150 mg/kg = 74%). Current preclinical studies are evaluating IMM-6-415 as monotherapy or in combination with checkpoint inhibitors in CT26 and MC-38 syngeneic models. We plan to submit an IND for IMM-6-415 to the FDA in 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Trifecta-MEK Program</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">We are developing novel product candidates that are designed to uniquely engage MEK and inhibit the upstream activation events of MEK and the downstream activation events of ERK in MEK itself, for the treatment of solid tumors. We believe the inhibition of upstream and downstream activation events of MEK and ERK bypass MAPK pathway reactivation events (i.e., drug resistance). Our investigational Trifecta- MEK program inhibitors are designed to be differentiated from IMM-1-104 and IMM-6-415 due to their potential mechanism of target engagement, novel allosteric inhibition of MEK and KSR disruption, along with a unique PK approach. The potential dosing intervals, potency and mechanisms of target engagement of our investigational Trifecta-MEK program inhibitors may broaden the application of these inhibitors to </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">27</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:354.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">metabolically diverse RAS and RAF mutant tumors. We are designing our investigational Trifecta-MEK program inhibitors to be administered as monotherapy to provide potentially better alternatives to combination therapies inhibiting MEK and RAF in BRAF mutant tumors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We have evaluated one of our investigational Trifecta-MEK program inhibitors head-to-head against binimetinib and encorafenib in a cell-based potency study to observe comparisons in the reduction of activated MEK and ERK in KRAS<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">G12S</sup> and BRAF<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">V600E</sup> mutant tumor models. &#160;In the KRAS mutant tumor model, our investigational Trifecta-MEK program inhibitor provided greater inhibition of activated MEK and ERK as compared to binimetinib and encorafenib (as depicted below). In the BRAF mutant tumor model, our investigational Trifecta-MEK program inhibitor displayed greater inhibition of activated MEK and ERK as compared to binimetinib, and greater activated ERK inhibition as compared to encorafenib (as depicted below). Our Trifecta-MEK program is currently in the drug discovery stage of development.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">Head-to-Head Comparison of One of Our Investigational Trifecta-MEK Program Inhibitors Against Encorafenib and Binimetinib Using A549 and A375 Xenograft Tumor Models</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><img src="imrx-20211231x10k024.jpg" alt="Graphic" style="display:inline-block;height:353.52pt;left:0%;padding-bottom:0.5pt;position:relative;top:0pt;width:462.24pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">KRAS4B Program</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">We are developing investigational mutation agnostic KRAS4B inhibitors that are designed to bind to a unique, undisclosed site on KRAS4B for the treatment of solid tumors. We believe our investigational KRAS4B inhibitors have the potential to disrupt RAS nanocluster biology and prevent MAPK signaling in patients with KRAS mutant tumors, which represent approximately 15% of all cancer patients. Although drugs in this class have begun targeting RAS mutations, such as </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">28</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">KRAS<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">G12C</sup>, we believe a majority of KRAS mutations, which we are designing our KRAS4B inhibitors to target, will remain unaddressed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In an <i style="font-style:italic;">in vitro </i>tumor model, we observed a half maximal tumor inhibitor concentration, or IC<sub style="font-size:7.5pt;vertical-align:sub;">50</sub>, of 1 &#956;M for one of our investigational KRAS4B inhibitors. A low IC<sub style="font-size:7.5pt;vertical-align:sub;">50</sub> value means that a drug is effective at low concentrations and may provide lower systemic toxicity when administered to the patient because of the low concentration required to generate therapeutic activity. Based on this tumor model, we believe our investigational KRAS inhibitors may achieve KRAS4B inhibition when administered at low concentrations, providing a potentially improved tolerability profile as compared to other FDA-approved MAPK pathway inhibitors. Our KRAS4B program is currently in the drug discovery stage of development.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">RAS Induction Program</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We are developing investigational RAS inducers that are designed to hyperactivate the MAPK pathway to potentially induce tumor cell death. Our RAS inducers are designed to be agnostic to known activating mutations of any oncogene of the MAPK pathway, providing the potential clinical opportunity to effectively treat any patient with an activated MAPK pathway, which represents over 50% of all cancer patients globally. A study by Leung et al (Mol Can Res 2019) supports this novel pharmacological approach by demonstrating that the hyperactivation of the MAPK pathway in tumor cells that express mutant RAS or RAF are intolerant to further increases in activity at the level of ERK and induce tumor cell death. This approach was further validated by clinical observations of secondary tumor reductions in some patients when targeted agents that inhibit the MAPK pathway were discontinued.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In an <i style="font-style:italic;">in vitro </i>KRAS mutant tumor model, we observed cell-based induction of the MAPK pathway at activated ERK of 844% when administering 30 &#956;M of one of our RAS inducers. Additional <i style="font-style:italic;">in vivo </i>modeling is required to validate this pharmacologic strategy, but we believe that, if successful, short pulsatile target induction will be critical. Our RAS induction, or RASi, program is currently in the drug discovery stage of development.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Covalent-MEK Program</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We are developing investigational irreversible allosteric inhibitors of MEK by attacking one of three critical amino acids lying adjacent to the binding pocket. We believe the covalent, or irreversible inhibition, fully disrupts MEK enzymatic activity completely avoiding any potential drug resistance from MAPK pathway reactivation events. Covalent-MEK&#8217;s novel pharmacological approach provides scaled attenuation of the MAPK pathway disruption that is anchored to the half-life of MEK itself, which has been reported to be approximately 12 to 14 hours.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our Covalent-MEK program is in the drug discovery stage of development and builds on our dynamic portfolio of novel and mechanistically distinct MEK inhibitors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">PI3K-alpha Program</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We are developing investigational allosteric PI3K&#945; inhibitors designed to target PI3K&#945; agnostically in common mutations and further disrupt upstream activation events of the mTOR pathway. Similar to IMM- 1-104, we intend to design our PI3K&#945; inhibitors with a short plasma half-life to potentially normalize tumor signaling dynamics while retaining healthy normal cells. While still in the early drug discovery stage of development, we envision our PI3K-alpha program will be able to address significant unmet clinical needs in certain subsets of cancer, as well as reaching a broader patient population in combination with one or more of our MEK or RAS drug programs, where the mTOR pathway may synergistically work in tandem with MAPK pathway inhibition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our Neuroscience Programs</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">In addition to our extensive oncology pipeline, we are also leveraging our platform to build a neuroscience pipeline initially focusing on AD. Our neuroscience programs are in the early stages of drug discovery, and we are evaluating undisclosed targets to pursue a unique approach to treating AD. We believe by treating AD- related neuroinflammation, rather than treating amyloid beta protein, or &#946;-amyloid, and hyperphosphorylated tau deposition in the brain, we may be able to slow the progression of AD. We believe our platform and expertise in neurology and neuroscience has allowed us to determine </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">29</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">biological differences in AD patients to help develop novel product candidates that have the potential to address the significant unmet needs of this underserved patient population.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Alzheimer&#8217;s Disease Overview</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">AD is a neurodegenerative disorder of uncertain cause and pathogenesis and is the most common form of dementia. AD is characterized by memory impairment and further cognitive decline that can ultimately affect the patient&#8217;s behavior, speech, visuospatial orientation and motor system. AD is a complex multifactorial disease driven by genetic and environmental causes that affects older adults and is one of the leading sources of morbidity and mortality in the aging population. Established risk factors for AD include age, family history of dementia, rare dominantly inherited mutations in genes that impact &#946;-amyloid in the brain (as described below) and apolipoprotein E epsilon 4 allele (as described below). The disease is most often categorized into three different groups: early-onset AD, late-onset AD and familial AD. Late-onset AD, also referred to as sporadic AD, is the most common form of the disease representing approximately 90% of the patients, and is classified in patients who present with symptoms at older ages (i.e., &#8805; 65 years), while early-onset AD is classified in patients who present with symptoms at younger ages (i.e., &lt; 65 years). Familial AD is an inherited form of AD (i.e., genetic) and patients with early-onset AD most often have some inherited form of the disease. In contrast, sporadic AD most often involves common and rare genetic risk factors, as well as environmental factors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Available data supports a worldwide prevalence of AD of approximately 35 million people, or approximately 6 million people in the United States. The prevalence of AD is known to increase exponentially with age, essentially doubling every 5 years after the age of 65. Diagnosis of AD is typically only considered after symptoms manifest and while the diagnosis of AD can be based on clinical criteria or detection of certain biomarkers, such as &#946;-amyloid and tau, a postmortem histopathologic examination is required to confirm the diagnosis. Recent emerging evidence supports that neurological changes may occur years before patients start to experience early clinical manifestations of AD, which is most often memory impairment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Limitations of Current Targeted Therapies for Alzheimer&#8217;s Disease</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Since 2003, only two new treatments for AD have been approved by the FDA, representing a significant unmet medical need. Despite clinical trials of numerous agents over a wide range of mechanisms, there are currently only six FDA-approved treatments for AD, and none of these treatments has been shown to do anything more than briefly and modestly improve AD symptoms, ultimately failing to prevent or slow disease progression. Patients may develop AD irrespective of &#946; amyloid deposition. Without a disease-modifying treatment that targets the underlying cause of AD, many AD patients require daily supportive care from their families or other caregivers.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Pathogenesis of Alzheimer&#8217;s Disease</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">While the pathogenesis of AD remains unclear, the genetic basis for early-onset and familial AD is understood most clearly. Most AD patients appear to have an overproduction and/or decreased clearance of &#946;-amyloid, which is neurotoxic. This explanation of AD is otherwise known as the &#8220;amyloid hypothesis.&#8221; &#946;-amyloid is produced by the cleavage of a protein translated from the amyloid precursor protein gene, or <i style="font-style:italic;">APP</i>, and cleaved by &#945;-secretase, &#946;-secretase, and &#947;-secretase. Presenilin is a sub-component of &#947;-secretase and is partially responsible for cleaving <i style="font-style:italic;">APP</i>. Mutations in presenilin 1 gene, or <i style="font-style:italic;">PSEN1</i>, or presenilin 2, or <i style="font-style:italic;">PSEN2</i>, and <i style="font-style:italic;">APP </i>result in overproduction of &#946;-amyloid and are known to cause familial AD in greater than 95% of patients. In addition, the pathogenesis of AD is believed to involve a second protein, tau.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Tau plays a role in stabilizing the biological mechanisms required for facilitating neuronal activity and communication. In patients suffering from AD, observations have shown that tau accumulates and causes neurotoxicity as a result of its hyperphosphorylation. In addition, transmission of pathologic forms of tau between neurons has been proposed to account for the spread of AD in the brain.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">There are several other important and potentially overlapping pathways that are considered to be involved in AD. For example, the strongest association of sporadic AD involves human apolipoprotein E gene, or <i style="font-style:italic;">APOE</i>. <i style="font-style:italic;">APOE </i>is involved in multiple cellular processes, including cholesterol transport and immune regulation, amongst others. <i style="font-style:italic;">APOE </i>is known to </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">30</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:186.48pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">have three alleles, including epsilon 4, or <i style="font-style:italic;">APOE4</i>. Carriers of one <i style="font-style:italic;">APOE4 </i>are two to three times more likely to develop AD as compared to noncarriers, and those with two <i style="font-style:italic;">APOE4 </i>are at approximately 8 to 12 times more likely to develop AD. Despite <i style="font-style:italic;">APOE4</i>&#8217;s strong link to sporadic AD, some carriers of <i style="font-style:italic;">APOE4 </i>never develop any cognitive decline. Unlike familial and early-onset AD, the genetic basis for sporadic AD is complex and poorly understood, and often involves environmental factors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Pathology of Alzheimer&#8217;s Disease</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The hallmark neuropathologic changes of AD are diffuse and neuritic plaques, marked by extracellular &#946;-amyloid deposition and neurofibrillary tangles, comprised of the intracellular accumulation of hyperphosphorylated tau (as depicted below). The pathology of AD is characterized by the widespread death of neurons in the brain and follows a destructive trajectory starting at the hippocampus, which is responsible for learning and memory. As AD progresses, the pathology gradually spreads to other important regions of the brain further causing cognitive decline. Among AD patients, the levels of brain atrophy vary and the underlying cause of this is unknown.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">Healthy Brain Compared to an AD Patient&#8217;s Brain with &#946;-Amyloid and Tau Deposition</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><img src="imrx-20211231x10k025.jpg" alt="Graphic" style="display:inline-block;height:186.48pt;width:437.04pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Heterogeneity Among Alzheimer&#8217;s Disease Patients</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">A growing body of evidence suggests that AD is a heterogeneous group of diseases, which may partially explain the lack of consistent clinical data, including clinical trials. The cardinal symptoms of AD are cognitive impairment, including memory impairment, loss of executive function, impaired judgement and problem solving, behavioral and psychological problems, and visuospatial impairment. While nearly all AD patients struggle with cognitive decline, there is no prescribed pattern or progression of symptoms. For example, some AD patients have significant &#946;-amyloid and hyperphosphorylated tau deposition, but experience little or no cognitive impairment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The pattern of memory impairment in patients suffering from AD is distinctive. Memory of events occurring at a particular time and place is often profoundly affected in these patients. These memory deficits develop insidiously and progress slowly over time, evolving to include deficits of semantic memory (i.e., general knowledge accumulated throughout life) and immediate recall. Impairments of procedural memory (i.e., how to perform certain actions and skills) appear only in the late stages of AD. In addition, behavioral and psychologic symptoms become more common in the middle to late course of the disease. These can begin with relatively subtle symptoms including apathy, social disengagement and irritability. However, emergence of behavioral disturbances such as agitation, aggression, wandering and psychosis are seen as well. Approximately 11% of AD patients suffer from some form of psychosis and at least 75% of AD patients deal with agitation, aggression and wandering. Although the signs and symptoms of AD are understood, the underlying cause of the disease, including progression of certain aspects of the disease, still remain unknown and provide an opportunity </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">31</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:141.12pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">for the development of disease-modifying treatments that would address significant unmet needs in the underserved AD patient population.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our Approach to Alzheimer&#8217;s Disease</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We believe there are specific subgroups of AD that can be stratified through gene expression and brain pathology. To identify AD subgroups, we have leveraged our platform to employ a patient-centric, data-driven approach through:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Patient Data</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">. Categorizing and quality controlling postmortem patient data available from multiple public repositories.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Patient Stratification</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">. Using a combination of different types of data, such as brain pathology and gene expression, to stratify patients into certain groups.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Our Expertise</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">. Leveraging our computational biology expertise to develop machine learning algorithms to detect patterns across biological data and find subgroups based on distinct patterns.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our approach to stratify AD patients based off specific subgroups and discover therapies that may benefit these patients is depicted in the image below.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">AD Patient Subgroup Stratification and Application of Our Drug Discovery Platform</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><img src="imrx-20211231x10k026.jpg" alt="Graphic" style="display:inline-block;height:141.12pt;width:431.28pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We believe our platform and expertise in neurology and neuroscience has allowed us to determine biological differences in AD patients to help develop novel product candidates that have the potential to address the significant unmet needs of this underserved patient population. Through postmortem patient data, we have determined multiple subgroups of AD with varying degrees of neuropathology and cognitive deficiencies, differences in brain gene expression irrespective of &#946;-amyloid or tau deposition, and inclusion or lack of high levels of gene expression resulting in neuroinflammation of the brain. We categorize the subgroup of patients with high levels of gene expression resulting in neuroinflammation of the brain as &#8220;Type I AD.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Through our next-generation approach for AD drug discovery (as depicted above), we have been able to develop a streamlined strategy for identifying novel product candidates by utilizing the following elements of our platform:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Novel Biology</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">. Leveraging DCT to identify robust novel targets using gene expression signatures from each AD subgroup. Characterizing mechanisms of action in central nervous system, or CNS, cell types for target assessment.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Novel Chemistry</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">. Employing our Fluency technology to accelerate the identification of small molecules that selectively bind to a target of interest.</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">32</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:120.6pt;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Proprietary Translational Planning. </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Utilizing the AD subgroup data that we have generated to select ideal preclinical models to improve clinical translation, including AD subgroup-specific induced pluripotent stem cell, or iPSC, lines, and defined existing and novel biomarkers specific to these patients.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">By leveraging our data-driven discoveries, we believe we have a unique advantage to develop a targeted strategy for patient selection and to increase response rates by treating the underlying biology of the AD subgroups.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our Neuroscience Pipeline</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our current neuroscience programs are dedicated to providing treatments for patients classified in a specific AD subgroup for which there are significant unmet needs and underserved patient populations. Our neuroscience programs are currently in the early stages of drug discovery and we are focused on advancing these programs into lead optimization. The following table summarizes our neuroscience pipeline:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><img src="imrx-20211231x10k027.jpg" alt="Table&#10;&#10;Description automatically generated" style="display:inline-block;height:120.6pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:485.3pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our Neuroscience Programs&#8212;Rationale for Treating Neuroinflammation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We believe treating neuroinflammation in Type I AD patients will slow the progression of the disease. Previous academic studies have shown that neuroinflammation is a possible cause of AD pathology. In addition, other studies have determined that neuroinflammation is an early AD event that precedes &#946;-amyloid and/or tau deposition in AD patients, and is necessary for AD patients to progress from mild cognitive symptoms to more severe cognitive impairment leading to diagnosis of AD. In a meta-analysis review of peripheral inflammatory markers in AD, an academic group reviewed 175 studies that enrolled over 26,000 patients and observed that AD patients have elevated inflammatory markers, including IL-1&#946; and IL-6. In another study, IL-1&#946; was associated with a faster rate of decline on executive functioning in older adults and IL-6 was associated with a faster decline of verbal memory. These observations are in agreement with our studies that identified subgroups of AD patients with elevated levels of neuroinflammatory gene expression. Collectively, through our own research and publicly available literature, we believe that treating neuroinflammation earlier in Type I AD patients may be able to slow the progression of the disease in these patients.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our Solution: IMM-ALL-01</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We are developing investigational small molecule inhibitors against an undisclosed target, or AO.01, for our IMM-ALL-01 program, which is currently in early stages of discovery. We believe that inhibition of AO.01 will decrease AD-related neuroinflammation by reducing the activation of microglia. Microglia are innate immune cells that have been observed to significantly increase AD-related neuroinflammation. Our preclinical studies in cultured microglia have demonstrated that 50 &#956;M treatment with our AO.01 inhibitors decrease the release of IL-6 (as depicted in figure B below), an inflammatory marker that drives AD-related neuroinflammation, while promoting anti-inflammatory IL-10 expression (as depicted in figure A below).</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">33</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:202.52pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">In Vitro </span>Observation of AO.01 Inhibitors Decreasing the Release of IL-6 and Promoting IL-10 Expression</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><img src="imrx-20211231x10k028.jpg" alt="Graphic" style="display:inline-block;height:202.32pt;left:0%;padding-bottom:0.2pt;position:relative;top:0pt;width:431.28pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">DCT revealed AO.01 as a target involved in AD-related neuroinflammatory mechanisms dysregulated in the brains of Type I AD patients. Through our bioinformatics analysis of independent study data, we observed that gene expression of AO.01 is significantly increased in activated microglia. In our <i style="font-style:italic;">in vitro </i>studies, knockdown of AO.01 gene expression suppressed the neuroinflammatory behavior of primary microglia. Our RNAseq analysis of our internal microglia experiment confirmed reduced expression of neuroinflammatory pathway genes after AO.01 knockdown. Based on these studies, we observed that knockdown of AO.01 directly correlates with a decrease in neuroinflammatory markers. We further observed that knockdown of AO.01 gene expression decreased neuronal hyperphosphorylated tau deposition in a tau cell model. We believe this suggests that AO.01 inhibition may block multiple independent AD-related neuroinflammatory pathways by inhibiting and/or suppressing the release of neuroinflammatory markers, including IL-6, and decreasing tau deposition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We plan to improve the <i style="font-style:italic;">in vitro </i>potency of our AO.01 inhibitors by focusing on a resolved catalytic pocket of AO.01 to further reduce the proinflammatory activity of microglia. While our preliminary studies demonstrate high cell permeability for our current AO.01 inhibitors, we plan to focus on optimizing blood brain barrier penetrance during lead optimization to provide desirable activity in the brain. Our goal is to increase translatability by exploring the effect of our AO.01 inhibitors on inflammation in human microglia derived from acquired iPSC lines of Type I AD patients.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our Solution: IMM-ALL-03</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We are developing investigational small molecule inhibitors against an undisclosed target, or AO.03, for our IMM-ALL-03 program, which is currently in the early stages of discovery. We leveraged Fluency to identify and rank initial hits against the AO.03 protein and screened a subset of hits with drug-like properties through a cell-free assay. The screening assays confirmed several Fluency hits from different chemical classes to AO.03, and subsequent modification of our AO.03 hits significantly improved inhibition of AO.03&#8217;s activity (as depicted in figure A below). Our preclinical studies in activated microglia have demonstrated that 10 and 50 &#956;M treatment with our AO.03 inhibitors decrease the release of IL-6 (as depicted in figure B below). In addition, in our preliminary studies, we have observed high cell permeability for our current AO.03 inhibitors. We plan to optimize blood brain barrier penetrance during lead optimization to provide desirable activity in the brain.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">34</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:196.56pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">Fluency Platform Identifies Small Molecules Designed to Inhibit AO.03 and In Vitro Observation of AO.03 Inhibitors Decreasing the Release of IL-6</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><img src="imrx-20211231x10k029.jpg" alt="Graphic" style="display:inline-block;height:196.56pt;width:437.04pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 12pt 0pt;">Biological Relevance of AO.03</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Through our platform, we have discovered that AO.03 is a target that is involved in aberrant inflammatory pathways in Type I AD pathogenesis, and that reduced AO.03 gene expression corrects the expression of genes related to Type I AD biology. In our <i style="font-style:italic;">in vitro </i>studies, we observed that stimulation of microglia into a proinflammatory state triggered significant increases in AO.03 gene expression, whereas reduction of AO.03 gene expression had a causative effect in converting microglial behavior from a proinflammatory state to an anti-inflammatory state. Similar to AO.01, we also observed that lower AO.03 gene expression blocked neuronal tau deposition in a tau cell model, including phosphorylation of tau at a protein site called Threonine 181, or p181 (as depicted below). Based upon literature, there is strong evidence that p181 phosphorylation occurs early in AD progression and is positively correlated to the age of onset, suggesting early prevention of p181 phosphorylation may significantly delay AD symptoms. While <i style="font-style:italic;">in vitro </i>analysis of stimulated microglia after AO.03 and AO.01 knockdown revealed non-identical, overlapping changes in cytokine release, RNAseq analyses have revealed that the targeted pathways of AO.03 and AO.01 are different. Concretely, reduction of AO.01 gene expression reduced expression of signaling genes for oxidation phosphorylation and the pentose phosphate pathway, whereas reduction of AO.03 gene caused a reduction of genes widely known to be involved in neuroinflammatory pathways in AD, including the IL-6 and toll-like receptor signaling pathways (as depicted below). We believe this represents unique opportunities for regulating several neuroinflammatory pathways in Type I AD patients.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">35</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:240pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">The Biological Effect of Reducing AO.03 Gene Expression on Inflammation and Tau Deposition, and Pathway Analysis of AO.01 versus AO.03</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><img src="imrx-20211231x10k030.jpg" alt="A picture containing bar chart&#10;&#10;Description automatically generated" style="display:inline-block;height:239.25pt;left:0%;padding-bottom:0.75pt;position:relative;top:0pt;width:485.3pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our Platform</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Consistent with our approach of weaving bioinformatics and computational biology into every stage of the drug development process, we have developed a proprietary disease-agnostic platform that allows us to leverage human biological data to generate insights that are not constrained by the inherent limitations of conventional approaches or prevailing scientific views. We are developing novel product candidates that aim to optimize both safety and efficacy for diseases with high unmet medical needs and suboptimal treatment options. Key elements of our platform include:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Insights from Human Data.</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> Compare distinct groups of individuals who differ in a certain aspect of disease or response to a particular therapy, or identify new patient subsets.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Novel Biology.</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> Identify novel targets and new ways to drug existing targets using DCT and/or our insights into mechanisms of response.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Novel Chemistry.</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> Rapidly identify small molecules that selectively bind to a target of interest using our proprietary Fluency technology, and/or engineer PK to achieve optimal signaling dynamics.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Proprietary Translational Planning.</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> Use humanized preclinical models and bioinformatics to prioritize indications and identify sensitive subpopulations.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Underlying each of these elements is our rigorous quality control and ability to analyze complex biological datasets. We are one of the few biopharmaceutical companies that has been involved in defining best practices for robustly analyzing bioinformatics data, as evidenced by co-authorship on journal articles together with regulators as well as writing invited reviews to educate the scientific community on this topic. This attention to rigorous quality control pervades all of our analyses, and we believe this enables us to extract meaningful information from a variety of databases of human data, including GENIE and The Cancer Genome Atlas Program, or TCGA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Our platform is not limited to a single aspect or pathology; rather, it is disease-agnostic, which we believe enables us to identify, develop and evaluate product candidates across multiple disease areas simultaneously, with our initial focus in </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">36</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">oncology and neuroscience. While we currently have an emphasis on transcriptomic data, our platform is not limited to a single data type and thus we believe it will be able to evolve as new datasets emerge. Our platform enabled the initiation, discovery and development of our lead product candidate, IMM-1-104, and has led us to identify additional product candidates with novel compositions of matter by leveraging our platform and drug discovery process. Moreover, our platform has been applied extensively in successful partnerships with large pharmaceutical and biotechnology companies, and through our internal drug discovery and development.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Insights from Human Data</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our analyses often begin by comparing existing transcriptomic data from two groups of patients (e.g. from those whose tumors have metastasized versus those whose tumors have not) to help elucidate the biological mechanisms underlying a particular aspect of disease which we seek to counteract. As another example, we may analyze existing data from patients with differences in response to an existing therapy, in order to better understand what is happening in responders versus non-responders. We may also analyze existing data from patients with a disease to identify novel subsets of patients. Our platform has enabled us to conduct multiple projects that involve stratifying patients into novel subsets. We associate transcriptomic profiles with each subset, which can then be directly inputted into DCT to identify novel targets specific to a given patient subset.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Novel Biology</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 12pt 0pt;">Disease Cancelling Technology</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We have developed DCT to identify targets that reverse a disease signal across multiple relevant genes with the potential to yield product candidates with differentiated mechanisms that are less likely to be discovered by traditional drug discovery methods. Additional biologic context is derived from quantifying the extent to which different time points, concentrations and perturbations (e.g., inhibition and overexpression) may cancel a disease signal more effectively than existing drug targets. DCT ranks target perturbations by the extent to which they generate signals that counteract disease-associated gene expression changes observed in patient data. Thus, we believe DCT enables hypothesis-free, data-driven identification of novel targets and new ways to drug existing targets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">DCT leverages gene expression data derived from human patient samples to identify targets that may rescue abnormal gene expression and restore pathway homeostasis. In addition, DCT identifies biology relevant to attenuating a disease by quantifying the similarity of genome-wide signatures of specific aspects of the disease to signatures of target induced gene expression changes using a mathematical similarity metric. Uniquely, DCT quantifies the per-gene contribution to overall disease amplification or cancellation. An example of a typical analysis begins by running DCT to identify an unwanted, disease-specific gene expression pattern. The ideal input to DCT is focused on a specific aspect of a disease, such as tumors that have metastasized versus those that have not, rather than comparing diseased versus healthy states. DCT identifies target candidates by screening a disease differential expression signature and comparing it to thousands of target gene expression signatures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">DCT is able to rapidly compare disease state signatures against vast numbers of target signatures. DCT ranks signatures resulting from the modulation of specific targets by the extent to which they oppose disease signatures (as depicted below). Unlike some algorithms or artificial intelligence, or AI, approaches, the results originating from DCT are designed to be interpretable from a computational and biological perspective. This platform uses gene expression from patient datasets and does not rely on literature. Together with the target, DCT provides a specific list of testable genes associated with the target of interest, relevant drug concentrations and temporal dynamic information driving the result. Thus, we believe DCT can identify new targets and readily detect dynamic relevant biology relating to modulating a target in a better way.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">A summary workflow for DCT&#8217;s novel target identification can be described as follows:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Carefully curated and quality controlled human transcriptomic data representing a specific aspect of disease, or Input 1, is input and vectorized for processing (as depicted below).</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">37</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:405pt;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">A carefully curated and quality controlled library of gene expression signals associated with perturbing specific targets at specific time points and concentrations, or Input 2, is input and vectorized for processing (as depicted below). This library can potentially include clustered regularly interspaced short palindromic repeats, or CRISPR, RNA interference, tool compounds, screening library compounds and existing drugs.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The strength of disease signal cancellation is measured between Input 1 and every target signature in Input 2.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">Disease Cancelling Technology Summary Workflow for Target Identification</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><img src="imrx-20211231x10k031.jpg" alt="Graphic" style="display:inline-block;height:405pt;width:393.6pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">A second filtration step selects target candidates for which multiple biological pathways are restored in the proper direction compared to the disease signal. DCT includes a method to compute a per pathway contribution to disease canceling in terms of percent contribution to overall disease reversal for cases when a specific pathway is particularly relevant. DCT is designed to have many capabilities in addition to identifying novel targets or novel ways to drug existing targets. To enable rapid translation to experimental validation, DCT can suggest ideal concentrations, temporal dynamics and marker genes to monitor. DCT is also capable of predicting target combinations for a given disease or an ideal target for combination with an existing therapy. For expanded utility, DCT has a graphical user interface that enables our biologists to interact with, sort, modify, query and run results along with producing visualizations of results.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">38</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:177pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We believe DCT has several advantages over other target identification technologies. The platform uses patient data as a starting point, rather than artificial 2D <i style="font-style:italic;">in vitro </i>models. For example, our neuroscience program uses gene expression data from AD patient subsets as an input to DCT. We have presented data at American Association for Cancer Research and other conferences demonstrating how cell lines fail to capture the heterogeneity of patient tumors, and our discovery team&#8217;s experience in the 3D tumor modeling field has also highlighted the limitations of 2D <i style="font-style:italic;">in vitro </i>data. Moreover, working closely with several FDA-approved drugs, we have found that transcriptomic data was most frequently and dynamically linked to drug activity. Thus, our core insights are derived from transcriptomic data (RNA), while some of our competitor&#8217;s platforms may focus on sequencing data (DNA), imaging data from phenotypic screens and/or literature. DCT is focused on identifying novel targets or novel ways to modulate existing targets, with the goal of generating novel therapeutics with improved clinical activity. We have not in-licensed external drugs and we do not focus on &#8220;drug repurposing&#8221; activities. Our pipeline is composed of programs with potentially novel pharmacological effects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 12pt 0pt;">Biological Mechanisms of Response</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We also identify novel biology by applying translational bioinformatics to analyze the biological mechanisms of response of existing therapies. This may include comparing the transcriptional profiles induced by a drug at different timepoints in order to highlight biological feedback loops that we then seek to counteract.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Novel Chemistry</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 12pt 0pt;">Fluency</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We developed Fluency, an easy-to-use AI-based tool, to allow for the rapid screening of large compound libraries for potential binders to a protein target of interest. Fluency can be run with any compound library, including libraries containing millions of compounds. It identifies the most attractive drug candidates within a library by making ranked predictions of binding affinity for all compounds. It also makes predictions about the target binding location for all compounds, which allows us to filter the library for drug candidates that are the most likely to affect a specific region of interest on the desired target. Fluency accelerates our drug development process by allowing us to go from millions of potential compounds down to what Fluency selects as the best hundred drug candidates within a single work day. This allows us to quickly advance only those select candidates to medicinal chemistry and experimental validation (as depicted below), increasing our capital efficiency. Knowledge of the 3D structure of the protein target of interest is not required, which expands the applicability of Fluency to include targets with poorly defined or non-existent 3D structures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">Fluency Accelerates Our Drug Discovery</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><img src="imrx-20211231x10k032.jpg" alt="Graphic" style="display:inline-block;height:177pt;width:384pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">To illustrate both the ease of use, as well as the power of Fluency to identify promising drug candidates, we constructed a test screen of Tukysa&#174; (tucatinib), a recently FDA-approved drug for the treatment of advanced breast cancer in combination with trastuzumab and capecitabine. Tukysa&#174; is a tyrosine kinase inhibitor of human epidermal growth factor </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">39</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:135.6pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">receptor 2, or HER2 (also referred to as ERBB2). We created a test compound library by placing Tukysa&#174; in a diverse chemical library of 17.8 million drug-like molecules and evaluated whether or not Fluency could identify it as a promising drug candidate against ERBB2 (depicted in the first panel below). The binding models within Fluency were trained against millions of carefully quality controlled, publicly available binding affinity measurements for compounds against thousands of proteins. However, because Fluency did not see Tukysa&#174; or other molecules highly similar to Tukysa&#174; during training, it did not know whether or not it was a promising candidate before the test screen was run. In our test screens, we input the protein of interest into Fluency, then select a library to screen, and optionally enter the region of interest within the protein (depicted in the second panel below). In the test screen for Tukysa&#174;, we screened the test library against all amino acids within ERBB2.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">Fluency Test Screen Input Example</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><img src="imrx-20211231x10k033.jpg" alt="Graphic" style="display:inline-block;height:135.6pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:412.2pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Fluency rapidly screened approximately 17.8 million compounds in less than 7 hours and identified Tukysa&#174; as the best binder to ERBB2 along with a number of other potential candidates (as depicted below). Fluency&#8217;s location prediction for this compound points towards the kinase domain of ERBB2 which contains the binding site. Referring back to our drug discovery flow chart depicted above, Tukysa&#174; would have been amongst the hundreds of compounds to go on to medicinal chemistry and experimental validation if we were searching for general ERBB2 binders or if we were searching for potential binders specific to the kinase domain.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">Fluency Test Screen Output Example</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><img src="imrx-20211231x10k034.jpg" alt="Graphic" style="display:inline-block;height:123.6pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:413.4pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Fluency has been used to screen for potential drug candidates within our early-stage oncology and neuroscience programs. We have a dedicated team of AI experts who continue to evolve Fluency and are embedded in our end-to-end preclinical drug development processes. We continue to seek new ways to apply our AI expertise to develop novel product candidates and potentially improve the lives of patients.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">40</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 12pt 0pt;">Signaling Dynamics (PK-Driven)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Transcriptomic data has proven critical to these analyses because it provides an understanding of the extent to which specific genes are expressed at any given time, capturing temporal changes in pathway activation. Signaling networks differ between cell types, and we leverage this to modulate targets in such a way that certain cell types will be more impacted than others. Our platform enables us to assess the signaling dynamics of product candidates, which we believe allows us to optimize the chemistry of our product candidate programs to achieve broad therapeutic activity against diseased cells while sparing healthy normal cells. Modulation of these signaling networks impacts cell fate decisions in many cell types, including cancerous cells. Our computational biology expertise enables us to analyze transcriptomic data that closely reflects spatiotemporal dynamics of biological signaling networks.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Proprietary Translational Planning</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Humanized Models</i><span style="font-style:italic;font-weight:bold;">. </span>In oncology, we are deeply experienced in advanced, humanized 3D-based tumor growth models, which based on peer reviewed research by members of our team and others, more accurately predict drug response in animal models, and we believe in patients, compared to standard models. Unlike <i style="font-style:italic;">in vitro </i>approaches, the 3D tumor growth models reflect the complexity of tumor biology given their alignment with the TME. Thus, we believe our deep expertise in 3D tumor models enables us to more accurately stratify patients likely to benefit from our potential product candidates. In neuroscience, we similarly seek to use human iPSC based models that more faithfully represent the biology of a heterogeneous patient population than more traditional cell lines.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Prioritize Indications and Identify Sensitive Subpopulations</i><span style="font-style:italic;font-weight:bold;">. </span>We are able to leverage bioinformatics to analyze genomic data from large patient databases to identify specific indications where the majority of patients have characteristics that align with our more reflective humanized models, and identify biological mechanisms and biomarkers that enable us to identify subpopulations that are more likely to be sensitive based on their similarity to our translational approaches.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our Platform and its Role in the IMM-1-104 Program</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our platform played a key role in creating the most important characteristics of our lead product candidate, IMM-1-104. In the early stages of the program, insights from human data were used to identify transcriptional profiles we aimed to counteract. DCT and our analysis of mechanisms of existing drugs led us to identify what we believe to be novel biology, specifically new ways to drug an existing target, to highlight the goal of counteracting a biologic feedback loop. Novel chemistry was generated to counteract the feedback loop, and the PK was tuned to generate optimal signaling dynamics (deep but cyclic interruptions of the pathway) as confirmed for translational profiling. Our proprietary translational planning has involved profiling IMM-1-104 in a large number of 3D models to identify the types of cancer (and biomarkers of subsets when needed) that we believe will have the highest probability of success in the clinic. Together, these insights enabled us to demonstrate in an <i style="font-style:italic;">in vitro </i>model that a drug with feedback loop resistance combined with a short half-life was able to move toward <i style="font-style:italic;">in vivo </i>improvements in key efficacy metrics and tolerability through modulation of tumor cell signaling dynamics.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Early in the program, we utilized human data to generate translational profiles specific to cancer patients experiencing cachexia, which causes extreme weight loss and muscle wasting. DCT was then utilized to identify targets and intervention time points, otherwise known as biological perturbations, that could counteract cachexia. Among the highest ranked perturbations were multiple MEK, inhibitors, but only the gene expression profiles induced by these MEK inhibitors at early time points (i.e., at 3 and 6 hours) were ranked highly for cancelling the disease-associated signals according to our technology. In contrast, the gene expression signals induced by MEK inhibitors at a later time point (i.e., at 24 hours) amplified or mimicked the transcriptomic signatures associated with diseases. These findings pointed to the importance of a feedback loop in the MAPK pathway called the CRAF-bypass, which may lead to resistance of MEK inhibition, and highlighted the critical importance of designing IMM-1-104 to potentially counteract the CRAF-bypass.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">We next applied our platform&#8217;s ability to characterize mechanisms of response by generating transcriptomic (RNA sequencing) data evaluating the impact of a recently approved MEK inhibitor, selumetinib, relative to vehicle in KRAS<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">G12D</sup> tumor-bearing BALB/c mice, which are inbred, albino and immunodeficient mice ordinarily used in research models for cancer therapy. The BALB/c mice were orally administered 100 mg/kg of selumetinib twice a day for 18 days. Notably, </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">41</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">when we examined a set of genes known to be downstream of ERK and activated by the MAPK pathway, we saw reduced downregulation of the pathway following selumetinib treatment. There was very little difference between the degree of MAPK pathway downregulation at the 2 hour time point and the 12 hour time point, demonstrating that the inhibition achieved by a typical MEK inhibitor with a non-zero drug trough was both static and limiting in a chronic setting. This focused us on the need to develop IMM-1-104 with novel chemistry, specifically a short half-life to achieve deep cyclic inhibition. Through the medicinal chemistry process, we were able to conduct similar analyses to assess the impact of varying PK profiles on signaling dynamics, and when we conducted the same analysis with IMM-1-104 in the model referenced above, we observed much stronger downregulation at the 2 hour time point followed by a return to baseline at the 12 hour time point. These observed results confirm that we achieved the desired signaling dynamics of cycles of deep inhibition and release of the MAPK pathway.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We are utilizing our platform&#8217;s proprietary translational planning capabilities by evaluating IMM-1-104 in a large panel of 3D tumor models, and then applying our ability to robustly analyze challenging datasets to assess genomic data from publicly available cancer patient databases to prioritize indications for IMM-1-104 and identify biomarkers of response, when needed. We believe this analysis will enable us to identify substantial translational opportunities for additional indications.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our Platform and Our Early-Stage Oncology Pipeline</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We utilize Fluency, the novel chemistry element of our platform, to rapidly identify small molecule hits for a targeted region of a protein for many of the earlier stage programs in our oncology pipeline. Fluency is being utilized to accelerate the advancement of our RAS and PI3K-alpha programs. In addition, these earlier stage programs also utilize our platform&#8217;s ability to generate novel biology by characterizing mechanisms of response to address these targets in new ways. In the case of our RAS modulators, this involves targeting the process of RAS dimerization. Finally, we are also leveraging novel chemistry in the form of PK changes with the goal of achieving optimal signaling dynamics and deep cyclic inhibition to maximize therapeutic activity in broad populations while improving tolerability. We plan to evaluate each of our programs in humanized 3D models and leverage bioinformatics to prioritize indications and identify sensitive patient subgroups.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our Platform and Our Neuroscience Programs</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our neuroscience programs began with our platform&#8217;s ability to identify insights from human data, specifically by methodically analyzing challenging datasets by assessing the robustness of various publicly available AD datasets. Given the lack of disease-modifying therapies and AD patient heterogeneity, robust analysis of data is a motivating factor to drive our success in this space. We applied our platform&#8217;s capability to stratify patients into previously undiscovered subsets, identifying new subpopulations of AD patients with strikingly different molecular biology and distinct gene expression profiles. We then applied our platform&#8217;s ability to identify novel biology by leveraging DCT to identify and rank novel targets for specific subsets of AD patients. Two of these undisclosed AD targets, AO.01 and AO.03, have been identified <i style="font-style:italic;">in vitro </i>and have gone on to become the focus of our two lead neuroscience programs, IMM-ALL-01 and IMM-ALL-03, respectively. Once those targets had been identified and experimentally confirmed, we utilized Fluency to rapidly identify small molecules that are designed to selectively bind to the targets, and such selective binding has since been observed <i style="font-style:italic;">in vitro</i>. We also leveraged our platform&#8217;s capabilities for characterizing mechanisms of response to assess the biological impact of those hits, and we are preparing for proprietary translational planning by using iPSC models to confirm the differences in response we expect to see in specific AD patient subgroups.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Competition</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The pharmaceutical and biotechnology industries are characterized by rapid advancement of novel technologies, significant competition and a strong defense of intellectual property rights. While we believe that our proprietary platform and scientific expertise provides us with competitive advantages, we face competition from multiple sources, including larger and better-funded pharmaceutical and biotechnology companies, academic institutions, governmental agencies and public and private research institutions. Any product candidates that we successfully develop and commercialize will compete with currently approved therapies and new therapies that may become available in the future. Key factors that would affect our ability to effectively compete with other therapeutics include safety, efficacy, ease of administration, pricing, brand recognition and availability of reimbursement and coverage by third party payors.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">42</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our Oncology and Neuroscience Programs</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The current FDA-approved treatment options that target MAPK pathway cancers are either MEK inhibitors limited by their high rates of serious drug-related adverse events that result in drug intolerability and drug resistance through MAPK-feedback loops, or KRAS inhibitors limited to patients with specific KRAS mutations. We expect that our oncology programs targeting the MAPK pathway may compete with current FDA-approved therapies or clinical programs targeting KRAS mutant tumors that are being advanced by certain pharmaceutical and biotechnology companies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">There are currently only five FDA-approved treatments for AD, and these treatments are widely considered to only briefly and modestly improve AD symptoms, ultimately failing to prevent or slow disease progression.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We expect that our neuroscience programs that are initially focused on treating neuroinflammation in AD may compete with products or programs being advanced by certain pharmaceutical and biotechnology companies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Intellectual Property</p><a id="_Hlk96423688"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our ability to obtain and maintain intellectual property protection for our products and technology is fundamental to the long-term success of our business. We rely on a combination of intellectual property protection strategies, including patents, trademarks, copyrights, trade secrets, license agreements, confidentiality policies and procedures, non-disclosure agreements, invention assignment agreements and technical measures designed to protect the intellectual property and confidential information and data used in our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">As of March 3, 2022, we have: one issued U.S. patent; two pending U.S. patent applications; one U.S. provisional application; and one Patent Cooperation Treaty, or PCT, application that has not entered national stage. These patents and patent applications relate to subject matter, including: our lead product candidate, IMM-1-104, our MEK-io candidate, IMM-6-415, our DCT, and Fluency. Excluding any possible patent term adjustments or extensions and assuming payment of all appropriate maintenance, renewal, annuity or other governmental fees, as applicable; our owned issued U.S. patent and any patents that may issue from our owned pending U.S. patent applications are expected to expire in February, 2039; and any patents that may issue from our owned pending foreign patent applications or PCT applications are expected to expire in January, 2041.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">With respect to IMM-1-104, as of March 3, 2022, we have one pending U.S. provisional application and one pending PCT application. The pending U.S. provisional application is directed to, among other things, combination claims with respect to IMM-1-104. This U.S. provisional application would need to be converted to a non-provisional application by January 6, 2023. Any patent that may issue, based upon this provisional U.S. application is expected to expire in January, 2043, excluding any possible patent term adjustments or extensions and assuming payment of all appropriate maintenance, renewal, annuity or other governmental fees, as applicable.The pending PCT application has not yet entered the national stage; its pending claims are directed to compounds, pharmaceutical compositions, and methods of use. Any patent that may issue, based upon this pending PCT application related to IMM-1-104, is expected to expire in January, 2041, excluding any possible patent term adjustments or extensions and assuming payment of all appropriate maintenance, renewal, annuity or other governmental fees, as applicable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">With respect to IMM-6-415, as of March 3, 2022, we have one pending provisional U.S. application; this application would need to be converted to a non-provisional application by January 6, 2023. &#160;Any patent that may issue, based upon this provisional U.S. application related to IMM-6-415, is expected to expire in January, 2043, excluding any possible patent term adjustments or extensions and assuming payment of all appropriate maintenance, renewal, annuity or other governmental fees, as applicable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">With respect to our DCT, as of March 3, 2022, we have one issued U.S. patent and one pending U.S. patent application. The issued claims of this U.S. patent and the pending claims of this U.S. patent application are directed to methods (processes) and systems. Our issued U.S. patent related to our DCT and any patent that may issue from our pending patent application related to our DCT are expected to expire in February, 2039, excluding any possible patent term adjustments or extensions and assuming payment of all appropriate maintenance, renewal, annuity or other governmental fees, as applicable.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">43</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">With respect to Fluency, as of March 3, 2022, we have one pending U.S. patent application. The pending claims of this U.S. patent application are directed to methods (processes) and systems. Any patent that may issue from our pending patent application related to Fluency is expected to expire in February, 2039, excluding any possible patent term adjustments or extensions and assuming payment of all appropriate maintenance, renewal, annuity or other governmental fees, as applicable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The term of individual patents depends upon the legal term for patents in the countries in which they are granted. In most countries, including the United States, the patent term is 20 years from the earliest claimed filing date of a non-provisional patent application in the applicable country. In the United States, a patent&#8217;s term may, in certain cases, be lengthened by patent term adjustment, which compensates a patentee for administrative delays by the USPTO in examining and granting a patent, or may be shortened if a patent is terminally disclaimed over a commonly owned patent or a patent naming a common inventor and having an earlier expiration date. We cannot be sure that our pending patent applications that we have filed or may file in the future will result in issued patents, and we can give no assurance that any patents that have issued or might issue in the future will protect our current or future products, will provide us with any competitive advantage, and will not be challenged, invalidated, or circumvented.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In the United States, the patent term of a patent that claims an FDA-approved drug or biologic may also be eligible for patent term extension, which permits patent term restoration as compensation for the patent term lost during FDA regulatory review process. The Hatch-Waxman Act permits a patent term extension of up to five years beyond the expiration of the patent. The length of the patent term extension is related to the length of time that the drug or biologic is under regulatory review. Patent term extension cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval and only one patent applicable to an approved drug or biologic may be extended. Similar provisions are available in the EU and certain other foreign jurisdictions to extend the term of a patent that covers an approved drug or biologic. In the future, if any drug candidates that we may develop receive FDA approval, we expect to apply for patent term extensions where applicable on patents covering those drugs. We plan to seek patent term extensions to any of our future issued patents in any jurisdiction where these are available. However, there is no guarantee that the applicable authorities, including the FDA in the United States, will agree with our assessment of whether these extensions should be granted, and if granted, the length of these extensions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We intend to pursue additional intellectual property protection to the extent we believe it would be beneficial and cost-effective. Our ability to stop third parties from making, using or commercializing any of our patented inventions will depend in part on our success in obtaining, defending and enforcing patent claims that cover our technology, inventions, and improvements. With respect to our intellectual property, we cannot provide any assurance that any of our current or future patent applications will result in the issuance of patents in any particular jurisdiction, or that any of our current or future issued patents will effectively protect any of our products or technology from infringement or prevent others from commercializing infringing products or technology.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In addition to our reliance on patent protection for our inventions, products, and technologies, we also seek to protect our brand through the procurement of trademark rights. As of March 3, 2022, we have certain trademark registrations and pending applications for trademark registration, for the marks DISEASE CANCELLING and IMMUNEERING in the United States and/or certain foreign jurisdictions. Furthermore, we rely on trade secrets, know-how, unpatented technology and other proprietary information, to strengthen our competitive position. We have determined that certain technologies, including some of our software, are better protected as trade secrets. To mitigate the possibility of trade secret misappropriation, we enter into non-disclosure and confidentiality agreements with parties who have access to our trade secrets, such as our employees, consultants, advisors and other third parties. We also enter into invention assignment agreements with our employees and consultants that obligate them to assign to us any inventions they have developed while working for us. We generally control access to our proprietary and confidential information through the use of internal and external controls that are subject to periodic review. Although we take steps to protect our proprietary information and trade secrets, third parties may independently develop substantially equivalent proprietary information and techniques or otherwise gain access to our trade secrets or disclose our technology. As a result, we may not be able to meaningfully protect our trade secrets. For further discussion of the risks relating to intellectual property, see the section titled &#8220;Risk Factors&#8212;Risks Related to Our Intellectual Property.&#8221;</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">44</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Government Regulation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Among others, the FDA, U.S. Department of Health and Human Services Office of Inspector General, the Centers for Medicare and Medicaid Services and comparable regulatory authorities in state and local jurisdictions and in other countries impose substantial and burdensome requirements upon companies involved in the preclinical and clinical development, manufacture, marketing and distribution of drugs such as those we are developing. These agencies and other federal, state and local entities regulate, among other things, the research and development, testing, manufacture, quality control, safety, effectiveness, labeling, packaging, storage, record keeping, approval, sales, commercialization, marketing, advertising and promotion, distribution, post-approval monitoring and reporting, sampling and export and import of our product candidates. Any drug candidates that we develop must be approved by the FDA before they may be legally marketed in the United States and by the appropriate foreign regulatory agency before they may be legally marketed in those foreign countries. Generally, our activities in other countries will be subject to regulation that is similar in nature and scope as that imposed in the United States, although there can be important differences. Additionally, some significant aspects of regulation in the European Union, or EU, are addressed in a centralized way, but country-specific regulation remains essential in many respects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">U.S. Drug Development Process</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In the United States, the FDA regulates drugs under the federal Food, Drug, and Cosmetic Act, or the FDCA, and its implementing regulations. The process required by the FDA before a drug may be marketed in the United States generally involves the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">completion of preclinical laboratory tests, animal studies and formulation studies in accordance with FDA&#8217;s good laboratory practice requirements and other applicable regulations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">submission to the FDA of an IND which must become effective before human clinical trials may begin;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">approval by an independent institutional review board, or IRB, or ethics committee at each clinical site before each trial may be initiated;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">performance of adequate and well-controlled human clinical trials in accordance with good clinical practice, or GCP, requirements to establish the safety and efficacy of the proposed drug for its intended use;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">submission to the FDA of a New Drug Application, or NDA, after completion of all pivotal trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">payment of user fees associated with an NDA;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a determination by the FDA within 60 days of its receipt of an NDA to file the NDA for review;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">satisfactory completion of an FDA advisory committee review, if applicable;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">satisfactory completion of an FDA inspection of the manufacturing facility or facilities at which the drug is produced to assess compliance with current good manufacturing practice, or cGMP, requirements to assure that the facilities, methods and controls are adequate to preserve the drug&#8217;s identity, strength, quality and purity, and of selected clinical investigation sites to assess compliance with GCPs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">potential FDA audit of the preclinical and/or clinical trial sites that generated the data in support of the NDA; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">FDA review and approval of the NDA to permit commercial marketing of the product for particular indications for use in the United States.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Prior to beginning the first clinical trial with a product candidate in the United States, we must submit an IND to the FDA. An IND is a request for authorization from the FDA to administer an investigational new drug product to humans. The </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">45</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">central focus of an IND submission is on the general investigational plan and the protocol(s) for clinical studies. Some preclinical testing may continue even after the IND is submitted. The IND also includes results of animal and in vitro studies assessing the toxicology, PK, pharmacology, and PD characteristics of the product; chemistry, manufacturing, and controls information; and any available human data or literature to support the use of the investigational product. An IND must become effective before human clinical trials may begin. The IND automatically becomes effective 30 days after receipt by the FDA, unless the FDA, within the 30-day time period, raises safety concerns or questions about the proposed clinical trial. In such a case, the IND may be placed on clinical hold and the IND sponsor and the FDA must resolve any outstanding concerns or questions before the clinical trial can begin. Submission of an IND therefore may or may not result in FDA authorization to begin a clinical trial.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Clinical trials involve the administration of the investigational product to human subjects under the supervision of qualified investigators in accordance with GCPs, which include the requirement that all research subjects provide their informed consent for their participation in any clinical study. Clinical trials are conducted under protocols detailing, among other things, the objectives of the study, the parameters to be used in monitoring safety and the effectiveness criteria to be evaluated. A separate submission to the existing IND must be made for each successive clinical trial conducted during product development and for any subsequent protocol amendments. Furthermore, an independent IRB for each site proposing to conduct the clinical trial must review and approve the plan for any clinical trial and its informed consent form before the clinical trial begins at that site and must monitor the study until completed. An IRB is charged with protecting the welfare and rights of trial participants and considers such items as whether the risks to individuals participating in the clinical trials are minimized and are reasonable in relation to anticipated benefits. The IRB also approves the informed consent form that must be provided to each clinical trial subject or his or her legal representative and must monitor the clinical trial until completed. Regulatory authorities, the IRB or the sponsor may suspend a clinical trial at any time on various grounds, including a finding that the subjects are being exposed to an unacceptable health risk or that the trial is unlikely to meet its stated objectives. Some studies also include oversight by an independent group of qualified experts organized by the clinical study sponsor, known as a data safety monitoring board, which provides authorization for whether or not a study may move forward at designated check points based on access to certain data from the study and may halt the clinical trial if it determines that there is an unacceptable safety risk for subjects or other grounds, such as no demonstration of efficacy. There are also requirements governing the reporting, under certain timelines, of ongoing clinical studies and clinical study results to public registries, specifically the clinicaltrials.gov website managed by the National Institutes of Health.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Human clinical trials are typically conducted in three sequential phases that may overlap or be combined:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Phase 1: The product candidate is initially introduced into healthy human subjects or patients with the target disease or condition. These studies are designed to test the safety, dosage tolerance, absorption, metabolism and distribution of the investigational product in humans, the side effects associated with increasing doses, and, if possible, to gain early evidence on effectiveness. In the case of some products for severe or life-threatening diseases, such as cancer, especially when the product may be too inherently toxic to ethically administer to healthy volunteers, the initial human testing is often conducted in patients.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Phase 2: The product candidate is administered to a limited patient population with a specified disease or condition to evaluate the preliminary efficacy, optimal dosages, dose tolerance and dosing schedule and to identify possible adverse side effects and safety risks.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Phase 3: The product candidate is administered to an expanded patient population to further evaluate dosage, to provide statistically significant evidence of clinical efficacy and to further test for safety, generally at multiple geographically dispersed clinical trial sites. These clinical trials are intended to establish the overall risk/benefit ratio of the investigational product and to provide an adequate basis for product approval. </span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Post-approval trials, sometimes referred to as Phase 4 studies, may be conducted after initial marketing approval. These trials are used to gain additional experience from the treatment of patients in the approved indication. In certain instances, such as with accelerated approval drugs, the FDA may mandate the performance of Phase 4 trials as a condition of approval of an NDA.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">46</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The FDA or the sponsor may suspend a clinical trial at any time on various grounds, including a finding that the research subjects or patients are being exposed to an unacceptable health risk. Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution if the clinical trial is not being conducted in accordance with the IRB&#8217;s requirements or if the drug has been associated with unexpected serious harm to patients. In addition, some clinical trials are overseen by an independent group of qualified experts organized by the sponsor, known as a data safety monitoring board or committee. Depending on its charter, this group may determine whether a trial may move forward at designated check points based on access to certain data from the trial.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">A sponsor may choose, but is not required, to conduct a foreign clinical study under an IND. When a foreign clinical study is conducted under an IND, all IND requirements must be met unless waived. When the foreign clinical study is not conducted under an IND, the sponsor must ensure that the study complies with certain FDA regulatory requirements in order to use the study as support for an IND or application for marketing approval. Specifically, the FDA has promulgated regulations governing the acceptance of foreign clinical trials not conducted under an IND, establishing that such studies will be accepted as support for an IND or application for marketing approval if the study was conducted in accordance with GCP, including review and approval by an independent ethics committee, or IEC, and use of proper procedures for obtaining informed consent from subjects, and the FDA is able to validate the data from the study through an on-site inspection if the FDA deems such inspection necessary. The GCP requirements encompass both ethical and data integrity standards for clinical studies. The FDA&#8217;s regulations are intended to help ensure the protection of human subjects enrolled in non-IND foreign clinical trials, as well as the quality and integrity of the resulting data. They further help ensure that non-IND foreign studies are conducted in a manner comparable to that required for IND studies. If a marketing application is based solely on foreign clinical data, the FDA requires that the foreign data be applicable to the U.S. population and U.S. medical practice; the studies must have been performed by clinical investigators of recognized competence; and the FDA must be able to validate the data through an on-site inspection or other appropriate means, if the FDA deems such an inspection to be necessary.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">During the development of a new drug, sponsors are given opportunities to meet with the FDA at certain points. These points are generally prior to submission of an IND, at the end of Phase 2, and before an NDA is submitted. Meetings at other times may be requested. These meetings can provide an opportunity for the sponsor to share information about the data gathered to date, for the FDA to provide advice, and for the sponsor to obtain the FDA&#8217;s feedback on the next phase of development. Sponsors typically use the meetings at the end of the Phase 2 trial to discuss Phase 2 clinical results and present plans for the pivotal Phase 3 clinical trials that they believe will support approval of the new drug.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Concurrent with clinical trials, companies usually complete additional animal studies and must also develop additional information about the chemistry and physical characteristics of the drug and finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the product candidate and, among other things, the manufacturer must develop methods for testing the identity, strength, quality and purity of the final drug. In addition, appropriate packaging must be selected and tested, and stability studies must be conducted to demonstrate that the product candidate does not undergo unacceptable deterioration over its shelf life.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">While the IND is active and before approval, progress reports summarizing the results of the clinical trials and nonclinical studies performed since the last progress report must be submitted at least annually to the FDA, and written IND safety reports must be submitted to the FDA and investigators for serious and unexpected suspected adverse events, findings from other studies suggesting a significant risk to humans exposed to the same or similar drugs, findings from animal or <i style="font-style:italic;">in vitro </i>testing suggesting a significant risk to humans, and any clinically important increased incidence of a serious suspected adverse reaction compared to that listed in the protocol or investigator brochure.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">U.S. Review and Approval Process</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Assuming successful completion of all required testing in accordance with all applicable regulatory requirements, the results of product development, preclinical and other non-clinical studies and clinical trials, along with descriptions of the manufacturing process, analytical tests conducted on the chemistry of the drug, proposed labeling and other relevant information are submitted to the FDA as part of an NDA requesting approval to market the product. Data may come from company-sponsored clinical trials intended to test the safety and effectiveness of a use of a product, or from a number of </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">47</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">alternative sources, including studies initiated by investigators. To support marketing approval, the data submitted must be sufficient in quality and quantity to establish the safety and effectiveness of the investigational drug product to the satisfaction of the FDA. The submission of an NDA is subject to the payment of substantial user fees; a waiver of such fees may be obtained under certain limited circumstances. Additionally, no user fees are assessed on NDAs for products designated as orphan drugs, unless the product application also includes a non-orphan indication.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The FDA reviews an NDA to determine, among other things, whether a product is safe and effective for its intended use and whether its manufacturing is cGMP-compliant to assure and preserve the product&#8217;s identity, strength, quality and purity. Under the Prescription Drug User Fee Act, or PDUFA, guidelines that are currently in effect, the FDA has a goal of ten months from the date of &#8220;filing&#8221; of a standard NDA for a new molecular entity to review and act on the submission. This review typically takes twelve months from the date the NDA is submitted to the FDA because the FDA has approximately two months to make a &#8220;filing&#8221; decision after it the application is submitted. The FDA conducts a preliminary review of all &#160;NDAs &#160;within the first &#160;60 days after submission, before accepting them for filing, to determine whether they are sufficiently complete to permit substantive review. The FDA may request additional information rather than accept an NDA for filing. In this event, the NDA must be resubmitted with the additional information. The resubmitted application also is subject to review before the FDA accepts it for filing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The FDA may refer an application for a novel drug to an advisory committee. An advisory committee is a panel of independent experts, including clinicians and other scientific experts, that reviews, evaluates and provides a recommendation as to whether the application should be approved and under what conditions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Before approving an NDA, the FDA will typically inspect the facility or facilities where the product is manufactured. The FDA will not approve an application unless it determines that the manufacturing processes and facilities are in compliance with cGMP and adequate to assure consistent production of the product within required specifications. Additionally, before approving an NDA, the FDA will typically inspect one or more clinical sites to assure compliance with GCPs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">After the FDA evaluates an NDA, it will issue an approval letter or a Complete Response Letter. An approval letter authorizes commercial marketing of the drug with prescribing information for specific indications. A Complete Response Letter indicates that the review cycle of the application is complete, and the application will not be approved in its present form. A Complete Response Letter usually describes the specific deficiencies in the NDA identified by the FDA and may require additional clinical data, such as an additional clinical trial or other significant and time-consuming requirements related to clinical trials, nonclinical studies or manufacturing. If a Complete Response Letter is issued, the sponsor must resubmit the NDA, addressing all of the deficiencies identified in the letter, or withdraw the application. Even if such data and information are submitted, the FDA may decide that the NDA does not satisfy the criteria for approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">If regulatory approval of a product is granted, such approval will be granted for particular indications and may contain limitations on the indicated uses for which such product may be marketed. For example, the FDA may approve the NDA with a Risk Evaluation and Mitigation Strategy, or REMS, to ensure the benefits of the product outweigh its risks. A REMS is a safety strategy to manage a known or potential serious risk associated with a medicine and to enable patients to have continued access to such medicines by managing their safe use, and could include medication guides, physician communication plans, or elements to assure safe use, such as restricted distribution methods, patient registries, and other risk minimization tools. The FDA also may condition approval on, among other things, changes to proposed labeling or the development of adequate controls and specifications. Once approved, the FDA may withdraw the product approval if compliance with pre- and post-marketing requirements is not maintained or if problems occur after the product reaches the marketplace. The FDA may also require one or more Phase 4 post-market studies and surveillance to further assess and monitor the product&#8217;s safety and effectiveness after commercialization, and may limit further marketing of the product based on the results of these post-marketing studies. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Pediatric Research Equity Act, or PREA, requires a sponsor to conduct pediatric clinical trials for most drugs, for a new active ingredient, new indication, new dosage form, new dosing regimen, or new route of administration. Under PREA, original NDAs and supplements must contain a pediatric assessment unless the sponsor has received a deferral or waiver. The required assessment must evaluate the safety and effectiveness of the product for the claimed indications in all relevant pediatric subpopulations and support dosing and administration for each pediatric subpopulation for which the </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">48</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">product is safe and effective. The sponsor or the FDA may request a deferral of pediatric clinical trials for some or all of the pediatric subpopulations. A deferral may be granted for several reasons, including a finding that the drug is ready for approval for use in adults before pediatric clinical trials are complete or that additional safety or effectiveness data needs to be collected before the pediatric clinical trials begin.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Orphan Drug Designation and Exclusivity</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Under the Orphan Drug Act, the FDA may grant orphan designation to a drug intended to treat a rare &#160;disease or condition, which is a disease or condition that affects fewer than 200,000 individuals in the United States or, if it affects more than 200,000 individuals in the United States, there is no reasonable expectation that the cost of developing and making a drug product available in the United States for this type of disease or condition will be recovered from sales of the product. Orphan designation must be requested before submitting an NDA. After the FDA grants orphan designation, the identity of the therapeutic agent and its potential orphan use are disclosed publicly by the FDA. Orphan designation does not convey any advantage in or shorten the duration of the regulatory review and approval process.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">If a product that has orphan designation subsequently receives the first FDA approval for the disease or condition for which it has such designation, the product is entitled to orphan product exclusivity, which means that the FDA may not approve any other applications to market the same drug for the same indication for seven years, except in limited circumstances, such as a showing of clinical superiority to the product with orphan exclusivity (i.e., greater safety, greater efficacy, or a major contribution to patient care) or inability to manufacture the product in sufficient quantities. The designation of such drug also entitles a party to financial incentives such as opportunities for grant funding towards clinical trial costs, tax advantages and user-fee waivers. Competitors, however, may receive approval of different products for the indication for which the orphan product has exclusivity or obtain approval for the same product but for a different indication for which the orphan product has exclusivity. If an orphan designated product receives marketing approval for an indication broader than what is designated, it may not be entitled to orphan exclusivity. In addition, exclusive marketing rights in the United States may be lost if the FDA later determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantities of the product to meet the needs of patients with the rare disease or condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Expedited Development and Review Programs</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The FDA has a number of programs intended to expedite the development or review of products that meet certain criteria. Sponsors may request that FDA allow the use of one or more of these programs. For example, product candidates are eligible for fast track designation if they are intended to treat a serious or life- threatening disease or condition and demonstrate the potential to address unmet medical needs for the disease or condition. Fast track designation applies to the combination of the product candidate and the specific indication for which it is being studied. The sponsor of a fast track product candidate has opportunities for more frequent interactions with the review team during product development, and the FDA may consider for review sections of the NDA on a rolling basis before the complete application is submitted, if the sponsor provides a schedule for the submission of the sections of the NDA, the FDA agrees to accept sections of the NDA and determines that the schedule is acceptable, and the sponsor pays any required user fees upon submission of the first section of the NDA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">A product candidate intended to treat a serious or life-threatening disease or condition may also be eligible for breakthrough therapy designation to expedite its development and review. A product candidate can receive breakthrough therapy designation if preliminary clinical evidence indicates that the product candidate, alone or in combination with one or more other drugs or biologics, may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. The designation includes all of the fast track program features, as well as more intensive FDA interaction and guidance beginning as early as Phase 1 and an organizational commitment to expedite the development and review of the product candidate, including involvement of senior managers.</p><a id="_Hlk96525842"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Any product candidate submitted to the FDA for approval, including a product candidate with a fast track designation or breakthrough therapy designation, may also be eligible for other types of FDA programs intended to expedite development and review, such as priority review and accelerated approval. An NDA for a product candidate is eligible for priority </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">49</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">review if it has the potential to provide significant improvement in treatment, diagnosis or prevention of a serious disease or condition compared to marketed products. The FDA will attempt to direct additional resources to the evaluation of an application for a new drug designated for priority review in an effort to facilitate the review. The FDA endeavors to review applications with priority review designations within six months of the filing date as compared to ten months for review of new molecular entity NDAs under its current PDUFA review goals.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">In addition, a product candidate may be eligible for accelerated approval. Drug products intended to treat serious or life-threatening diseases or conditions may be eligible for accelerated approval upon a determination that the product candidate has an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit, or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality, that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity, or prevalence of the condition and the availability or lack of alternative treatments. As a condition of approval, the FDA may require that a sponsor of a drug receiving accelerated approval perform adequate and well-controlled post-marketing clinical trials. The FDA may withdraw accelerated approval if, among other things, the confirmatory study fails to verify clinical benefit; the applicant fails to perform required confirmatory studies with due diligence; postmarketing use demonstrates that postmarketing restrictions are inadequate to assure safe use; the applicant fails to adhere to agreed-upon postmarketing restrictions; promotional materials are false or misleading; or, other evidence demonstrates that the product is not shown to be safe or effective under its conditions of use. In addition, the FDA currently requires pre-approval of promotional materials as a condition for accelerated approval, which could adversely impact the timing of the commercial launch of the product. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Fast track designation, breakthrough therapy designation, priority review and accelerated approval do not change the standards for approval but may expedite the development or approval process. Even if a product candidate qualifies for one or more of these programs, the FDA may later decide that the product no longer meets the conditions for qualification or decide that the time period for FDA review or approval will not be shortened.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Post-approval Requirements</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Drug products manufactured or distributed pursuant to FDA approvals are subject to pervasive and continuing regulation by the FDA, including, among other things, requirements relating to record-keeping, reporting of adverse experiences, periodic reporting, product sampling and distribution, and advertising and promotion of the product. After approval, most changes to the approved product, such as adding new indications or other labeling claims, are subject to prior FDA review and approval. There also are continuing, annual program fees for any marketed products. Drug manufacturers and their subcontractors are required to register their &#160;establishments &#160;with &#160;the &#160;FDA &#160;and &#160;certain &#160;state &#160;agencies, &#160;and &#160;are &#160;subject &#160;to &#160;periodic &#160;unannounced inspections by the FDA and certain state agencies for compliance with cGMP, which impose certain procedural and documentation requirements upon us and our third-party manufacturers. Changes to the manufacturing process are strictly regulated, and, depending on the significance of the change, may require prior FDA approval before being implemented. FDA regulations also require investigation and correction of any deviations from cGMP and impose reporting requirements. Accordingly, manufacturers must continue to expend time, money and effort in the area of production and quality control to maintain compliance with cGMP and other aspects of regulatory compliance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The &#160;FDA &#160;may &#160;withdraw &#160;approval &#160;if &#160;compliance &#160;with &#160;regulatory &#160;requirements &#160;and &#160;standards &#160;is &#160;not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information; imposition of post-market studies or clinical studies to assess new safety risks; or imposition of distribution restrictions or other restrictions under a REMS program. Other potential consequences include, among other things:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">restrictions on the marketing or manufacturing of the product, complete withdrawal of the product from the market or product recalls;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">fines, warning letters, or untitled letters;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">clinical holds on clinical studies;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">50</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">refusal &#160;of &#160;the &#160;FDA to &#160;approve &#160;pending &#160;applications &#160;or supplements &#160;to approved &#160;applications, &#160;or suspension or revocation of product approvals;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">product seizure or detention, or refusal to permit the import or export of products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">consent &#160;decrees, &#160;corporate &#160;integrity &#160;agreements, &#160;debarment &#160;or &#160;exclusion &#160;from &#160;federal &#160;healthcare programs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">mandated &#160;modification &#160;of &#160;promotional &#160;materials &#160;and &#160;labeling &#160;and &#160;the &#160;issuance &#160;of &#160;corrective information;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the issuance of safety alerts, Dear Healthcare Provider letters, press releases and other communications containing warnings or other safety information about the product; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">injunctions or the imposition of civil or criminal penalties.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The FDA closely regulates the marketing, labeling, advertising and promotion of drug products. A company can make only those claims relating to safety and efficacy that are approved by the FDA and in accordance with the provisions of the approved label. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses. Failure to comply with these requirements can result in, among other things, adverse publicity, warning letters, corrective advertising and potential civil and criminal penalties. Physicians may prescribe, in their independent professional medical judgment, legally available products for uses that are not described in the product&#8217;s labeling and that differ from those tested by us and approved by the FDA. Physicians may believe that such off-label uses are the best treatment for many patients in varied circumstances. The FDA does not regulate the behavior of physicians in their choice of treatments. The FDA does, however, restrict manufacturer&#8217;s communications on the subject of off-label use of their products. However, companies may share truthful and not misleading information that is otherwise consistent with a product&#8217;s FDA-approved labelling.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Marketing Exclusivity</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Market exclusivity provisions authorized under the FDCA can delay the submission or the approval of certain marketing applications. The FDCA provides a five-year period of non-patent data exclusivity within the United States to the first applicant to obtain approval of an NDA for a new chemical entity. A drug is a new chemical entity if the FDA has not previously approved any other new drug containing the same active moiety, which is the molecule or ion responsible for the action of the drug substance. During the exclusivity period, the FDA may not approve or even accept for review an abbreviated new drug application, or ANDAm or an NDA submitted under Section 505(b)(2), or (505(b)(2) NDA), submitted by another company for another drug based on the same active moiety, regardless of whether the drug is intended for the same indication as the original innovative drug or for another indication, where the applicant does not own or have a legal right of reference to all the data required for approval. However, an application may be submitted after four years if it contains a certification of patent invalidity or non-infringement to one of the patents listed with the FDA by the innovator NDA holder.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The FDCA alternatively provides three years of marketing exclusivity for an NDA, or supplement to an existing NDA if new clinical investigations, other than bioavailability studies, that were conducted or sponsored by the applicant are deemed by the FDA to be essential to the approval of the application, for example new indications, dosages or strengths of an existing drug. This three-year exclusivity covers only the modification for which the drug received approval on the basis of the new clinical investigations and does not prohibit the FDA from approving ANDAs or 505(b)(2) NDAs for drugs containing the active agent for the original indication or condition of use. Five-year and three-year exclusivity will not delay the submission or approval of a full NDA. However, an applicant submitting a full NDA would be required to conduct or obtain a right of reference to any preclinical studies and adequate and well-controlled clinical trials necessary to demonstrate safety and effectiveness.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Pediatric exclusivity is another type of marketing exclusivity available in the United States. Pediatric exclusivity &#160;provides &#160;for &#160;an &#160;additional &#160;six &#160;months &#160;of &#160;marketing &#160;exclusivity &#160;attached &#160;to &#160;another &#160;period &#160;of exclusivity if a sponsor conducts </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">51</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">clinical trials in children in response to a written request from the FDA. The issuance of a written request does not require the sponsor to undertake the described clinical trials. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Other Healthcare Laws </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Pharmaceutical companies like us are subject to additional healthcare regulation and enforcement by the federal government and by authorities in the states and foreign jurisdictions in which they conduct their business. &#160;Such regulation may constrain the financial arrangements and relationships through which we research, develop, and ultimately, sell, market and distribute any products for which we obtain marketing approval. Such laws include, without limitation, federal and state anti-kickback, fraud and abuse, and false claims laws, such as the federal Anti-Kickback Statute and the federal Civil False Claims Act, as well as federal and state data privacy and security laws and regulations, and transparency laws and regulations addressing drug pricing and payments and other transfers of value made by pharmaceutical manufacturers to physicians and other healthcare providers, such as the federal Physician Payment Sunshine Act. Violations of any of such laws or any other governmental regulations that apply may result in significant penalties, including, without limitation, administrative, civil and criminal penalties, damages, fines, disgorgement, the curtailment or restructuring of operations, integrity oversight and reporting obligations to resolve allegations of noncompliance, exclusion from participation in federal and state healthcare programs, such as Medicare and Medicaid, and imprisonment. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Coverage and Reimbursement </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Sales of any pharmaceutical product depend, in part, on the extent to which such product will be covered by third-party payors, such as federal, state, and foreign government healthcare programs, commercial insurance and managed healthcare organizations, and the level of reimbursement for such product by third-party payors. Decisions regarding the extent of coverage and amount of reimbursement to be provided are made on a plan-by-plan basis. These third-party payors are increasingly reducing coverage and reimbursement for medical products, drugs and services. In addition, the U.S. government, state legislatures and foreign governments have continued implementing cost-containment programs, including price controls, restrictions on coverage and reimbursement and requirements for substitution of generic products. Adoption of price controls and cost-containment measures, and adoption of more restrictive policies in jurisdictions with existing controls and measures, could further limit sales of any product. Decreases in third-party reimbursement for any product or a decision by a third-party payor not to cover a product could reduce physician usage and patient demand for the product and also have a material adverse effect on sales. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Moreover, as a condition of participating in, and having products covered under, certain federal healthcare programs, such as Medicare and Medicaid, we may become subject to federal laws and regulations that require pharmaceutical manufacturers to calculate and report certain price reporting metrics to the government, such as Medicaid Average Manufacturer Price, or AMP, and Best Price, Medicare Average Sales Price, the 340B Ceiling Price, and Non-Federal Average Manufacturer Price reported to the Department of Veteran Affairs, and with respect to Medicaid, pay statutory rebates on utilization of manufacturers&#8217; products by Medicaid beneficiaries. &#160;Compliance with such laws and regulations will require significant resources and may have a material adverse effect on our revenues. &#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Healthcare Reform </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">In the United States, in March 2010, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, each as amended, collectively known as the ACA, was enacted, which substantially changed the way healthcare is financed by both governmental and private insurers, and significantly affected the pharmaceutical industry. The ACA contained a number of provisions, including those governing enrollment in federal healthcare programs, reimbursement adjustments and changes to fraud and abuse laws. For example, the ACA: </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p><div style="padding-left:0.25pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:4%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:3.99%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#8226;</p></td><td style="vertical-align:top;width:0.99%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:90.99%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">increased the minimum level of Medicaid rebates payable by manufacturers of brand name drugs from 15.1% to 23.1% of the average manufacturer price; </p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><div style="padding-left:0.25pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:4%;margin:0pt;padding:0.25pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"></div></div></td><td style="vertical-align:top;width:3.99%;margin:0pt;padding:0.25pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:0.99%;margin:0pt;padding:0.25pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:90.99%;margin:0pt;padding:0.25pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:middle;width:4%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:3.99%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#8226;</p></td><td style="vertical-align:top;width:0.99%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:90.99%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">required collection of rebates for drugs paid by Medicaid managed care organizations;</p></td></tr></table></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">52</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="padding-left:0.25pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:4%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.99%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#8226;</p></td><td style="vertical-align:top;width:0.99%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:90.99%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">expanded beneficiary eligibility criteria for Medicaid programs by, among other things, allowing states to offer Medicaid coverage to certain individuals with income at or below 138% of the federal poverty level, thereby potentially increasing manufacturers&#8217; Medicaid rebate liability;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:4%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.99%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#8226;</p></td><td style="vertical-align:top;width:0.99%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:90.99%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">expanded the types of entities eligible for the 340B Drug Pricing Program;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:4%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:3.99%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#8226;</p></td><td style="vertical-align:top;width:0.99%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:90.99%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">required manufacturers to participate in a coverage gap discount program, under which they must agree to offer 70&#160;percent point-of-sale discounts off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the manufacturer&#8217;s outpatient drugs to be covered under Medicare Part D; </p></td></tr><tr><td style="vertical-align:middle;width:4%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:3.99%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#8226;</p></td><td style="vertical-align:top;width:0.99%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:90.99%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">imposed a non-deductible annual fee on pharmaceutical manufacturers or importers who sell &#8220;branded prescription drugs&#8221; and biologic agents apportioned among these entities according to their market share in certain federal government programs;</p></td></tr><tr><td style="vertical-align:middle;width:4%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.99%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#8226;</p></td><td style="vertical-align:top;width:0.99%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:90.99%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">established the Center for Medicare and Medicaid Innovation within the Centers for Medicare and Medicaid Services (&#8220;CMS&#8221;) to test innovative payment and service delivery models to lower Medicare and Medicaid spending, potentially including prescription drug spending;</p></td></tr><tr><td style="vertical-align:middle;width:4%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.99%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#8226;</p></td><td style="vertical-align:top;width:0.99%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:90.99%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">created the Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research; and</p></td></tr><tr><td style="vertical-align:middle;width:4%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.99%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#8226;</p></td><td style="vertical-align:top;width:0.99%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:90.99%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">required annual reporting of certain information regarding drug samples that manufacturers and distributors provide to licensed practitioners.</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Since its enactment, there have been executive, judicial and Congressional challenges to certain aspects of the ACA. &#160;On June 17, 2021, the U.S. Supreme Court dismissed the most recent judicial challenge to the ACA brought by several states without specifically ruling on the constitutionality of the ACA. Prior to the Supreme Court&#8217;s decision, President Biden issued an executive order initiating a special enrollment period from February 15, 2021 through August 15, 2021 for purposes of obtaining health insurance coverage through the ACA marketplace. &#160;The executive order also instructed certain governmental agencies to review and reconsider their existing policies and rules that limit access to healthcare. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Other legislative changes have been proposed and adopted since the ACA was enacted, including aggregate reductions of Medicare payments to providers of 2% per fiscal year, which went into effect on April 1, 2013 and, due to subsequent legislative amendments to the statute, will stay in effect through 2030, with the exception of a temporary suspension from May&#160;1, 2020 through March&#160;31, 2022 unless additional action is taken by Congress. &#160;In addition, the American Taxpayer Relief Act of 2021, effective January 1, 2024, would eliminate the statutory cap on rebate amounts owed by drug manufacturers under the Medicaid Drug Rebate Program, or MDRP, which is currently capped at 100% of the AMP for a covered outpatient drug. In the future, there may be additional challenges and/or amendments to the ACA. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Moreover, there has been heightened governmental scrutiny recently over the manner in which manufacturers set prices for their marketed products, which have resulted in several recent Congressional inquiries and proposed and enacted legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for pharmaceutical products. At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. It also possible that governmental action will be taken in response to the COVID-19 pandemic. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">We expect that additional state and federal healthcare reform measures will be adopted in the future, any of which could impact the amounts that federal and state governments and other third-party payors will pay for healthcare products and services.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">53</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Data Privacy and Security </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Numerous state, federal and foreign laws, regulations and standards govern the collection, use, access to, confidentiality and security of health-related and other personal information, and could apply now or in the future to our operations or the operations of our partners. In the United States, numerous federal and state laws and regulations, including data breach notification laws, health information privacy and security laws and consumer protection laws and regulations govern the collection, use, disclosure, and protection of health-related and other personal information. In addition, certain foreign laws govern the privacy and security of personal data, including health-related data. For example, the GDPR imposes strict requirements for processing the personal data of individuals within the European Economic Area, or the EEA. Companies that must comply with the GDPR face increased compliance obligations and risk, including more robust regulatory enforcement of data protection requirements and potential fines for noncompliance of up to &#8364;20 million or 4% of the annual global revenues of the noncompliant company, whichever is greater. Further, from January 1, 2021, companies have had to comply with the GDPR and also the UK GDPR, which, together with the amended UK Data Protection Act 2018, retains the GDPR in UK national law. The UK GDPR mirrors the fines under the GDPR, <i style="font-style:italic;">i.e.</i>, fines up to the greater of &#8364;20 million (&#163;17.5 million) or 4% of global turnover. Privacy and security laws, regulations, and other obligations are constantly evolving, may conflict with each other to complicate compliance efforts, and can result in investigations, proceedings, or actions that lead to significant civil and/or criminal penalties and restrictions on data processing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Human Capital</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">As of December 31, 2021 we had 64 full-time employees, 54 of whom are dedicated to research and development. 31 of our employees hold doctorate degrees (i.e., Ph.D. or M.D.). None of our employees are represented by labor unions or covered by collective bargaining agreements. We consider our relationship with our employees to be good.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">We believe that our future success largely depends upon our continued ability to attract and retain highly skilled employees. We provide our employees with competitive salaries and bonuses, opportunities for equity ownership, development programs that enable continued learning and growth and a robust employment package that promotes well-being across all aspects of their lives, including health care, retirement planning and paid time off.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">We believe that much of our success is rooted in the diversity of our teams and our commitment to inclusion. We value diversity at all levels and focus on extending our diversity and inclusion initiatives across our entire workforce.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:8pt 0pt 0pt 0pt;"><span style="color:#333333;font-style:italic;font-weight:bold;">Our Corporate Information</span></p><a id="_cp_text_1_149"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-top:6pt;background:#ffffff;margin:0pt;"><span style="color:#333333;">We were incorporated under the laws of the state of Delaware in February 2008. Our principal executive offices are located at 245 Main Street, Second Floor, Cambridge, MA 02142 and our telephone number is (617) 500-8080. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-top:6pt;background:#ffffff;margin:0pt;"><span style="color:#333333;">Our corporate website address is&#160;</span><i style="color:#333333;font-style:italic;">www.immuneering.com</i><span style="color:#333333;">. The information contained in, or accessible through, our website is not incorporated by reference into this Annual&#160;Report&#160;and you should not consider information on our website to be a part of this Annual Report. We have included our website address in this Annual Report solely as an inactive textual reference.</span></p><a id="_cp_text_1_150"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-top:18pt;background:#ffffff;margin:0pt;"><span style="color:#333333;font-style:italic;font-weight:bold;">Where you can find more information</span></p><a id="_cp_text_1_151"></a><a id="_cp_field_47_152"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-top:6pt;background:#ffffff;margin:0pt;"><span style="color:#333333;">We are subject to the information requirements of the Securities Exchange Act of 1934, as amended. The SEC maintains an internet site that contains reports, proxy and information statements, and other information regarding issuers that file electronically, such as ourselves</span><span style="color:#333333;">, with the SEC at&#160;</span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">http://www.sec.gov</span><span style="color:#333333;">.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">54</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_7c04b233_cfbf_4b9e_bd6f_717a355c2772"></a><a id="Item_1A"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Item&#160;1A. Risk Factors</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><i style="font-style:italic;">Our future operating results could differ materially from the results described in this Annual Report on Form 10-K due to the risks and uncertainties described below. You should consider carefully the following information about risks below in evaluating our business. If any of the following risks actually occur, our business, financial conditions, results of operations and future growth prospects would likely be materially and adversely affected.&#160;Additional risks and uncertainties not presently known to us or that we currently deem immaterial also may impair our business operations.&#160;In these circumstances, the market price of our Class A common stock would likely decline. In addition, we cannot assure investors that our assumptions and expectations will prove to be correct. Important factors could cause our actual results to differ materially from those indicated or implied by forward-looking statements. See &#8220;Forward Looking Statements&#8221; for a discussion of some of the forward-looking statements that are qualified by these risk factors. Factors that could cause or contribute to such differences include those factors discussed below.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><b style="font-weight:bold;">Risks Related to Our Financial Condition and Capital Requirements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;">We have a limited operating history in developing pharmaceutical products, have not completed any clinical trials and have no products approved for commercial sale, which may make it difficult for you to evaluate our current business and predict our future success and viability.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;">Pharmaceutical product development is a highly speculative undertaking and involves a substantial degree of risk. We are a biopharmaceutical company with a limited operating history in developing pharmaceutical products which makes it difficult to evaluate our business and prospects in future product development. We have no products approved for commercial sale and have not generated any revenue from product sales. To date, we have devoted substantially all of our resources and efforts to providing computational biology services to pharmaceutical and biotechnology companies, organizing and staffing our company, business planning, executing partnerships, raising capital, discovering, identifying and developing potential product candidates, securing related intellectual property rights and undertaking research and preclinical studies of our product candidates, including the anticipated Phase&#160;1 clinical trial of IMM-1-104 for the treatment of advanced solid tumors in patients harboring RAS mutant tumors. We have not yet demonstrated our ability to successfully initiate any clinical trials, obtain marketing approvals, manufacture a commercial-scale product or arrange for a third party to do so on our behalf, or conduct sales and marketing activities necessary for successful product commercialization. As a result, it may be more difficult for you to accurately predict our future success or viability to develop new pharmaceutical products than it could be if we had a longer operating history.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">In addition, we may encounter unforeseen expenses, difficulties, complications, delays and other known and unknown factors and risks frequently experienced by biopharmaceutical companies developing products in rapidly evolving fields. We also may need to transition from a company with a research focus to a company capable of supporting commercial activities. If we do not adequately address these risks and difficulties or successfully make such a transition, our business will suffer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;">We have incurred significant net losses for the past several&#160;years and we expect to continue to incur significant net losses for the foreseeable future and may never obtain profitability.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">We have incurred net losses in each reporting period for the past several&#160;years, have not generated any revenue from product sales to date and have financed our operations principally through our computational biology services to pharmaceutical and biotechnology companies, the issuance of convertible debt and the sale of our convertible preferred stock and Class&#160;A common stock. We have incurred net losses of approximately $33.5 million and $17&#160;million for the&#160;years ended December&#160;31, 2021 and 2020 respectively. As of December 31, 2021, we had an accumulated deficit of approximately $59.3&#160;million. Our losses have resulted principally from expenses incurred in research and development of our product candidates, from management and administrative costs and other expenses that we have incurred while building our business infrastructure. Our lead product candidate, IMM-1-104, is undergoing IND-enabling studies and we expect to submit an IND to the FDA in the third quarter of 2022. Subject to the FDA&#8217;s allowing us to proceed with clinical studies under an IND, we intend to enroll the first patient in a Phase&#160;1 clinical trial of IMM-1-104 in the fourth quarter of 2022 for the treatment of advanced solid tumors in patients harboring RAS mutant tumors, if our IND for IMM-1-104 is </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">55</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">accepted. Our other product candidates are in earlier stages of drug development. As a result, we expect that it will be several&#160;years, if ever, before we have a commercialized product and generate revenue from product sales. Even if we succeed in receiving marketing approval for and commercializing one or more of our product candidates, we expect that we will continue to incur substantial research and development and other expenses as we discover, develop and market additional potential product candidates. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">We expect to continue to incur significant losses for the foreseeable future, and we expect these losses to increase substantially if and as we:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">&#8226; advance the development of our lead product candidate, IMM-1-104, and our other product candidates, including IMM-6-415, through preclinical and clinical development, and, if approved by the FDA or other comparable foreign regulatory authorities, commercialization;</p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;">&#8226; incur manufacturing costs for our product candidates;</p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;">&#8226; seek regulatory approvals for any of our product candidates that successfully complete clinical trials;</p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;">&#8226; increase our research and development activities to identify and develop new product candidates;</p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;">&#8226; hire additional personnel;</p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;">&#8226; expand our operational, financial and management systems;</p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;">&#8226; invest in measures to protect and expand our intellectual property;</p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">&#8226; establish a sales, marketing, medical affairs and distribution infrastructure to commercialize any product candidates for which we may obtain marketing approval and intend to commercialize;</p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;">&#8226; expand our manufacturing and develop our commercialization efforts; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;">&#8226; operate as a public company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;">The net losses we incur may fluctuate significantly from quarter to quarter such that a period-to-period comparison of our results of operations may not be a good indication of our future performance. The size of our future net losses will depend, in part, on the rate of future growth of our expenses and our ability to generate revenue. Our prior losses and expected future losses have had and will continue to have an adverse effect on our working capital and our ability to achieve and maintain profitability.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;">We will require substantial additional capital to finance our operations. If we are unable to raise such capital when needed, or on acceptable terms, we may be forced to delay, reduce and/or eliminate one or more of our research and drug development programs or future commercialization efforts.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">Developing pharmaceutical products, including conducting preclinical studies and clinical trials, is a very time-consuming, expensive and uncertain process that takes&#160;years to complete. Our operations have consumed substantial amounts of cash since inception, and we expect our expenses to increase in connection with our ongoing activities, particularly as we initiate and conduct clinical trials of, and seek marketing approval for our current and any future product candidates. Even if one or more of the product candidates that we develop is approved for commercial sale, we anticipate incurring significant costs associated with commercializing any approved product candidate. Our expenses could increase beyond expectations if we are required by the FDA or other comparable foreign regulatory authorities to perform clinical trials or preclinical studies in addition to those that we currently anticipate. Other unanticipated costs may also arise. In addition, if we obtain marketing approval for any of our product candidates, we expect to incur significant commercialization expenses related </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">56</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">to drug sales, marketing, manufacturing and distribution. Because the design and outcome of our anticipated clinical trials are highly uncertain, we cannot reasonably estimate the actual amounts necessary to successfully complete the development and commercialization of any product candidate we develop. We also expect to incur additional costs associated with operating as a public company. Accordingly, it is likely that we will need to obtain substantial additional funding in order to maintain our continuing operations in the future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">As of December 31, 2021, we had approximately $150.2&#160;million in cash and cash equivalents and marketable securities. Based on our current business plans, we believe that our existing cash and cash equivalents and marketable securities will be sufficient to fund our operating expenses and capital expenditures requirements into the third quarter of 2024. Our estimate as to how long we expect our existing cash and cash equivalents and marketable securities to be able to continue to fund our operating expenses and capital expenditures requirements is based on assumptions that may prove to be wrong, and we could use our available capital resources sooner than we currently expect. Changing circumstances, some of which may be beyond our control, could cause us to consume capital significantly faster than we currently anticipate, and we may need to seek additional funds sooner than planned.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">Our future funding requirements will depend on many factors, including, but not limited to:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;">&#8226; the initiation, progress, timeline, cost and results of our clinical trials for our product candidates;</p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">&#8226; the initiation, progress, timeline, cost and results of additional research and preclinical studies related to pipeline development and other research programs we initiate in the future;</p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">&#8226; the cost and timing of manufacturing activities as we advance our product candidates through preclinical and clinical development, and commercialization;</p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;">&#8226; the potential expansion of our current development programs to seek new indications;</p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;">&#8226; the negative impact of the COVID-19 pandemic or future pandemics on our business;</p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">&#8226; the outcome, timing and cost of meeting regulatory requirements established by the FDA and other comparable foreign regulatory authorities;</p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">&#8226; the cost of filing, prosecuting, defending and enforcing patent claims and other intellectual property rights, in-licensed or otherwise;</p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;">&#8226; the effect of competing technological and market developments;</p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;">&#8226; the payment of licensing fees, potential royalty payments and potential milestone payments;</p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;">&#8226; the cost of general operating expenses;</p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;">&#8226; the cost and timing of completion of commercial-scale manufacturing activities;</p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">&#8226; the cost of establishing sales, marketing, and distribution capabilities for any product candidates for which we may receive regulatory approval in regions where we choose to commercialize our products on our own; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;">&#8226; the cost of operating as a public company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;">Advancing the development of our product candidates will require a significant amount of capital. Our existing cash and cash equivalents will not be sufficient to fund all of the activities that are necessary to complete the development of our product candidates.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">57</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;">We will be required to obtain further funding through public or private equity offerings, debt financings, collaborations and licensing arrangements or other sources, which may dilute our stockholders or restrict our operating activities. We do not have any committed external source of funds. Adequate additional financing may not be available to us on acceptable terms, or at all. Additionally, the impact of the pandemic related to COVID-19 and its variants on the capital markets may affect the availability, amount and type of financing available to us in the future. Our failure to raise capital as and when needed or on acceptable terms would have a negative impact on our financial condition and our ability to pursue our business strategy, and we may have to delay, reduce the scope of, suspend or eliminate one or more of our research-stage programs, clinical trials or future commercialization efforts.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Raising additional capital may cause dilution to our existing stockholders, restrict our operations or require us to relinquish rights to our product candidates on unfavorable terms to us.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;">We may seek additional capital through a variety of means, including through public or private equity offering, debt financings or other sources, including up-front payments and milestone payments from strategic collaborations. To the extent that we raise additional capital through the sale of equity or convertible debt or equity securities, your ownership interest will be diluted, and the terms may include liquidation or other preferences that adversely affect your rights as a stockholder. Such financing may result in dilution to stockholders, imposition of debt covenants, increased fixed payment obligations or other restrictions that may affect our business. If we raise additional funds through up-front payments or milestone payments pursuant to strategic collaborations with third parties, we may have to relinquish valuable rights to our product candidates, or grant licenses on terms that are not favorable to us. In addition, we may seek additional capital due to favorable market conditions or strategic considerations even if we believe we have sufficient funds for our current or future operating plans.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Our ability to use our net operating losses and other tax attributes may be limited.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;">As of December&#160;31, 2021, we had approximately $56.5&#160;million of federal and $51.3&#160;million of state net operating loss carryforwards, or NOLs, available to offset future taxable income. Under Sections&#160;382 and 383 of the U.S. Internal Revenue Code of 1986, as amended, or the Code, a corporation that undergoes an &#8220;ownership change,&#8221; generally defined as a greater than 50% change by value in its equity ownership over a three-year period is subject to limitations on its ability to utilize its pre-change NOLs and other tax attributes such as research tax credits to offset future taxable income. We have not performed an analysis to determine whether our past issuances of stock and other changes in our stock ownership may have resulted in other ownership changes. If it is determined that we have in the past experienced other ownership changes, or if we undergo one or more ownership changes as a result of future transactions in our stock, which may be outside our control, then our ability to utilize NOLs and other pre-change tax attributes could be further limited by Sections&#160;382 and 383 of the Code, and certain of our NOLs and other pre-change tax attributes may expire unused. As a result, if or when we earn net taxable income, our ability to use our pre-change NOLs or other tax attributes to offset such taxable income or otherwise reduce any liability for income taxes may be subject to limitations, which could adversely affect our future cash flows.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><b style="font-weight:bold;">Risks Related to Development, Regulatory Approval and Commercialization</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;">The regulatory approval processes of the FDA and other comparable foreign regulatory authorities are lengthy, time consuming and inherently unpredictable. If we are ultimately unable to obtain regulatory approval for our product candidates, or to obtain regulatory approval to treat the indications we seek to treat with our product candidates, we will be unable to generate product revenue or the level of planned product revenue and our business will be substantially harmed.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;">We are not permitted to commercialize, market, promote or sell any product candidate in the United States without obtaining marketing approval from the FDA. Foreign regulatory authorities impose similar requirements. The time required to obtain approval by the FDA and other comparable foreign regulatory authorities is unpredictable, typically takes many&#160;years following the commencement of clinical trials and depends upon numerous factors, including the type, complexity and novelty of the product candidates involved. In addition, approval policies, regulations or the type and amount of clinical data necessary to gain approval may change during the course of a product candidate&#8217;s clinical </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">58</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;">development and may vary among jurisdictions, which may cause delays in the approval or the decision not to approve an application. Regulatory authorities have substantial discretion in the approval process and may refuse to accept any application or may decide that our data are insufficient for approval and require additional preclinical, clinical or other data. Even if we eventually complete clinical testing and receive approval of any regulatory filing for our product candidates, the FDA and other comparable foreign regulatory authorities may approve our product candidates for a more limited indication or a narrower patient population than we originally requested. We have not submitted for, or obtained, regulatory approval for any product candidate, and it is possible that none of our existing product candidates or any product candidates we may seek to develop in the future will ever obtain regulatory approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;">Applications for our product candidates could fail to receive regulatory approval for many reasons, including the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">&#8226;the FDA or other comparable foreign regulatory authorities may disagree with the design, implementation or results of our clinical trials;</p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">&#8226; the FDA or other comparable foreign regulatory authorities may determine that our product candidates are not safe and effective, only moderately effective or have undesirable or unintended side effects, toxicities or other characteristics that preclude our obtaining marketing approval or prevent or limit commercial use;</p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">&#8226; the population studied in the clinical trial may not be sufficiently broad or representative to assure efficacy and safety in the full population for which we seek approval;</p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">&#8226; the FDA or other comparable foreign regulatory authorities may disagree with our interpretation of data from preclinical studies or clinical trials;</p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">&#8226; the data collected from clinical trials of our product candidates may not be sufficient to support the submission of a New Drug Application, or NDA, or other submission or to obtain regulatory approval in the United States or elsewhere;</p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">&#8226; we may be unable to demonstrate to the FDA or other comparable foreign regulatory authorities that a product candidate&#8217;s risk-benefit ratio for its proposed indication is acceptable;</p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">&#8226; the FDA or other comparable foreign regulatory authorities may fail to approve the manufacturing processes, test procedures and specifications or facilities of third-party manufacturers with which we contract for clinical and commercial supplies; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">&#8226; the approval policies or regulations of the FDA or other comparable foreign regulatory authorities may significantly change in a manner rendering our clinical data insufficient for approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;">This lengthy approval process, as well as the unpredictability of the results of clinical trials, may result in our failing to obtain regulatory approval to market any of our product candidates, which would significantly harm our business, results of operations and prospects. In addition, the FDA or comparable foreign regulatory authorities may change their policies, adopt additional regulations or revise existing regulations or take other actions, which may prevent or delay approval of our future product candidates under development on a timely basis. Such policy or regulatory changes could impose additional requirements upon us that could delay our ability to obtain approvals, increase the costs of compliance or restrict our ability to maintain any marketing authorizations we may have obtained.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;">In addition, even if we obtain approval of our product candidates, regulatory authorities may approve any of our product candidates for fewer or more limited indications than we request, may impose significant limitations in the form of narrow indications, warnings, or a Risk Evaluation and Mitigation Strategy, or REMS. Regulatory authorities may not approve the price we intend to charge for products we may develop, may grant approval contingent on the performance of costly post-marketing clinical trials, or may approve a product candidate with a label that does not include the labeling claims necessary or desirable for the successful commercialization of that product candidate. Any of the foregoing scenarios could seriously harm our business.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">59</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;">We may not be able to submit INDs or IND amendments or comparable documents in foreign jurisdictions to commence additional clinical trials on the timelines we expect, and even if we are able to, the FDA may not permit us to proceed.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;">While we plan to submit INDs or comparable documents for our potential product candidates, we may not be able to submit such INDs or comparable documents on the timeline we expect. For example, due to supply chain constraints and the impact of follow-on effects due to such constraints, we have had to move our planned submission of the IND for IMM-1-104 to the FDA from the first quarter of 2022 to the third quarter of 2022. We may also experience manufacturing delays or other delays with IND-enabling studies. Moreover, we cannot be sure that submission of an IND or comparable document will result in the FDA or other comparable foreign regulatory authorities allowing further clinical trials to begin, or that, once begun, issues will not arise that suspend or terminate clinical trials. Additionally, even if such regulatory authorities agree with the design and implementation of the clinical trials set forth in an IND, we cannot guarantee that such regulatory authorities will not change their requirements in the future. These considerations also apply to new clinical trials we may submit as amendments to existing INDs or to a new IND. Any failure to file INDs on the timelines we expect or to obtain regulatory approvals for our trials may prevent us from completing our clinical trials or commercializing our products on a timely basis, if at all.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Our company has limited experience in designing clinical trials and may experience delays or unexpected difficulties in obtaining regulatory approval for our current and future product candidates.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;">We have limited experience in designing clinical trials and may be unable to design and execute a clinical trial to support marketing approval. We cannot be certain that our planned clinical trials or any future clinical trials will be successful. It is possible that the FDA may refuse to accept any or all of our planned NDAs for substantive review or may conclude after review of our data that our application is insufficient to obtain regulatory approval for any product candidates. If the FDA does not approve any of our planned NDAs, it may require that we conduct additional costly clinical trials, preclinical studies or manufacturing validation studies before it will reconsider our applications. Depending on the extent of these or any other FDA-required studies, approval of any NDA or other application that we submit may be significantly delayed, possibly for several&#160;years, or may require us to expend more resources than we have available. Any failure or delay in obtaining regulatory approvals would prevent us from commercializing our product candidates, generating revenues and achieving and sustaining profitability. It is also possible that additional studies, if performed and completed, may not be considered sufficient by the FDA to approve any NDA or other application that we submit. If any of these outcomes occur, we may be forced to abandon the development of our product candidates, which would materially adversely affect our business and could potentially cause us to cease operations. We face similar risks for our applications in foreign jurisdictions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;">We may encounter substantial delays in completing, or ultimately be unable to complete, the development and commercialization of our product candidates.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;">Before obtaining marketing approval from the FDA or other comparable foreign regulatory authorities for the sale of our product candidates, we must complete preclinical development and extensive clinical trials to demonstrate the safety and efficacy of our product candidates. Clinical testing is expensive, difficult to design and implement, can take many&#160;years to complete and its ultimate outcome is uncertain. A failure of one or more clinical trials can occur at any stage of the process. The outcome of preclinical studies and early-stage clinical trials may not be predictive of the success of later clinical trials. Moreover, preclinical and clinical data are often susceptible to varying interpretations and analyses, and many companies that have believed their product candidates performed satisfactorily in preclinical studies and clinical trials have nonetheless failed to obtain marketing approval of their drugs. The outcome of preclinical studies and early-stage clinical trials may not be predictive of the success of later clinical trials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">In addition, we are substantially dependent on preclinical, clinical and quality data generated by CROs and other third parties for regulatory submissions for our product candidates. While we have or will have agreements governing these third parties&#8217; services, we have limited influence over their actual performance. If these third parties do not make data available to us, or, if applicable, make regulatory submissions in a timely manner, in each case pursuant to our agreements with them, our development programs may be significantly delayed, and we may need to conduct additional studies or collect additional data independently. In either case, our development costs would increase, perhaps substantially.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">60</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">We do not know whether our future clinical trials will begin on time or enroll patients on time, or whether our future clinical trials will be completed on schedule or at all. Clinical trials can be delayed for a variety of reasons, including delays related to:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">&#8226; the FDA or comparable foreign regulatory authorities disagreeing as to the design or implementation of our clinical studies;</p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">&#8226; obtaining regulatory authorizations to commence a trial or reaching a consensus with regulatory authorities on trial design;</p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">&#8226; any failure or delay in reaching an agreement with CROs and clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites;</p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;">&#8226; obtaining approval from one or more institutional review boards, or IRBs;</p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;min-height:10.0pt;text-align:center;margin:0pt;"><i style="font-style:italic;">&#160;</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">&#8226;IRBs refusing to approve, suspending or terminating the trial at an investigational site, precluding enrollment of additional subjects, or withdrawing their approval of the trial;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">&#8226;delays in enrollment due to travel or quarantine policies, or other factors related to COVID-19 and its variants, other pandemics or other events outside our control;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;">&#8226;changes to clinical trial protocol;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;">&#8226;clinical sites deviating from trial protocol or dropping out of a trial;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">&#8226;manufacturing sufficient quantities of product candidates or obtaining sufficient quantities of combination therapies for use in clinical trials;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">&#8226;subjects failing to enroll or remain in our trial at the rate we expect, or failing to return for post-treatment follow-up;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">&#8226;subjects choosing an alternative treatment for the indication for which we are developing our product candidates, or participating in competing clinical trials;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;">&#8226;lack of adequate funding to continue the clinical trial;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;">&#8226;subjects experiencing severe or unexpected drug-related adverse effects;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">&#8226;occurrence of serious adverse events in trials of the same class of agents conducted by other companies;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">&#8226;selection of clinical end points that require prolonged periods of clinical observation or analysis of the resulting data;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">&#8226;a facility manufacturing our product candidates or any of their components being ordered by the FDA or comparable foreign regulatory authorities to temporarily or permanently shut down due to violations of current good manufacturing practice, or cGMP, regulations or other applicable requirements, or infections or cross-contaminations of product candidates in the manufacturing process;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;">&#8226;any changes to our manufacturing process that may be necessary or desired;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">61</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">&#8226;third-party clinical investigators losing the licenses or permits necessary to perform our clinical trials, not performing our clinical trials on our anticipated schedule or consistent with the clinical trial protocol, good clinical practices, or GCP, or other regulatory requirements;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;">&#8226;third-party contractors not performing data collection or analysis in a timely or accurate manner; or</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">&#8226;third-party contractors becoming debarred or suspended or otherwise penalized by the FDA or other government or regulatory authorities for violations of regulatory requirements, in which case we may need to find a substitute contractor, and we may not be able to use some or all of the data produced by such contractors in support of our marketing applications.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;">For instance, due to supply chain constraints and the impact of follow-on effects due to such constraints, we have had to move our previously announced planned enrollment of the first patient in our first-in-human Phase 1 clinical trial of IMM-1-104 for the treatment of advanced solid tumors in patients harboring RAS mutant tumors in the fourth quarter of 2022 from the first half of 2022 as previously expected, assuming our IND for IMM-1-104 is accepted. &#160;In addition, the ongoing pandemic related to COVID-19 and its variants and the measures taken by the governmental authorities could disrupt the supply chain and the manufacture or shipment of drug substances and finished drug products for our product candidates for use in our research and clinical trials, delay, limit or prevent our employees and CROs from continuing research and development activities, impede the ability of patients to enroll or continue in clinical trials, or impede testing, monitoring, data collection and analysis or other related activities, any of which could delay our clinical trials and increase our development costs, and have a material adverse effect on our business, financial condition and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;">We could also encounter delays if a clinical trial is suspended or terminated by us, by the IRBs of the institutions in which such trials are being conducted, by a Data Safety Monitoring Board for such trial or by the FDA or comparable foreign regulatory authorities. Such authorities may impose such a suspension or termination due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, inspection of the clinical trial operations or trial site by the FDA or comparable foreign regulatory authorities resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from using a drug, changes in governmental regulations or administrative actions or lack of adequate funding to continue the clinical trial. In addition, changes in regulatory requirements and policies may occur, and we may need to amend clinical trial protocols to comply with these changes. Amendments may require us to resubmit our clinical trial protocols to IRBs for reexamination, which may impact the costs, timing or successful completion of a clinical trial.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;">Further, conducting clinical trials in foreign countries, as we may do for our product candidates, presents additional risks that may delay completion of our clinical trials. These risks include the failure of enrolled patients in foreign countries to adhere to clinical protocol as a result of differences in healthcare services or cultural customs, managing additional administrative burdens associated with foreign regulatory schemes, as well as political and economic risks relevant to such foreign countries.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;">Additionally, if the results of our clinical trials are inconclusive or if there are safety concerns or serious adverse events associated with our product candidates, we may:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;">&#8226; be delayed in obtaining marketing approval, if at all;</p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;">&#8226; obtain approval for indications or patient populations that are not as broad as intended or desired;</p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">&#8226; obtain approval with labeling that includes significant use or distribution restrictions or safety warnings</p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;">&#8226; be subject to additional post-marketing testing requirements;</p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">&#8226; be required to perform additional clinical trials to support approval or be subject to additional post-marketing testing requirements;</p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">62</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">&#8226; have regulatory authorities withdraw, or suspend, their approval of the drug or impose restrictions on its distribution in the form of a modified REMS;</p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;">&#8226; be subject to the addition of labeling statements, such as warnings or contraindications;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;">&#8226; be sued; or</p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;">&#8226; experience damage to our reputation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">Our development costs will also increase if we experience delays in testing or obtaining marketing approvals. We do not know whether any of our preclinical studies or clinical trials will begin as planned, need to be restructured or be completed on schedule, if at all. Any delay in, or termination of, our clinical trials will delay the submission of an NDA to the FDA or similar applications with comparable foreign regulatory authorities and, ultimately, our ability to commercialize our product candidates, if approved, and generate product revenue. Even if our clinical trials are completed as planned, we cannot be certain that their results will support our claims for differentiation or the effectiveness or safety of our product candidate. The FDA has substantial discretion in the review and approval process and may disagree that our data support the claims we propose.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">Moreover, principal investigators for our clinical trials may serve as scientific advisors or consultants to us from time to time and receive compensation in connection with such services. Under certain circumstances, we may be required to report some of these relationships to the FDA or comparable foreign regulatory authorities. The FDA or comparable foreign regulatory authorities may conclude that a financial relationship between us and a principal investigator has created a conflict of interest or otherwise affected interpretation of the study. The FDA or comparable foreign regulatory authorities may therefore question the integrity of the data generated at the applicable clinical trial site and the utility of the clinical trial itself may be jeopardized. This could result in a delay in approval, or rejection, of our marketing applications by the FDA or comparable foreign regulatory authorities, as the case may be, and may ultimately lead to the denial of marketing approval of one or more of our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">If we experience delays in the completion of, or termination of, any clinical trial of our product candidates, the commercial prospects of our product candidates will be harmed, and our ability to generate product revenues from any of these product candidates will be delayed. Moreover, any delays in completing our clinical trials will increase our costs, slow down our product candidate development and approval process and jeopardize our ability to commence product sales and generate revenues.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">In addition, many of the factors that cause, or lead to, termination or suspension of, or a delay in the commencement or completion of, clinical trials may also ultimately lead to the denial of regulatory approval of a product candidate. Any delays to our clinical trials that occur as a result could shorten any period during which we may have the exclusive right to commercialize our product candidates and our competitors may be able to bring products to market before we do, and the commercial viability of our product candidates could be significantly reduced. Any of these occurrences may harm our business, financial condition and prospects significantly.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;">The outcome of preclinical studies and early clinical trials may not be predictive of the success of later clinical trials, and the results of our clinical trials may not satisfy the requirements of the FDA or other comparable foreign regulatory authorities.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;">Before obtaining regulatory approvals for the commercial sale of any of our product candidates, we will be required to demonstrate with substantial evidence through well-controlled clinical trials that our product candidates are safe and effective for their intended uses. Clinical testing is expensive and can take many&#160;years to complete, and its outcome is inherently uncertain. Failure can occur at any time during the clinical trial process. Success in preclinical studies and early-stage clinical trials does not mean that future clinical trials will be successful. We do not know whether any of our product candidates will perform in current or future clinical trials as they have performed in preclinical studies. Product candidates in later-stage clinical trials may fail to demonstrate sufficient safety and efficacy to the satisfaction of the FDA or other </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">63</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;">comparable foreign regulatory authorities despite having progressed through preclinical studies and early-stage clinical trials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;">In some instances, there can be significant variability in safety and efficacy results between different clinical trials of the same product candidate due to numerous factors, including changes in trial protocols, differences in size and type of the patient populations, differences in and adherence to the dosing regimen and other trial protocols and the rate of dropout among clinical trial participants. Patients treated with our product candidates may also be undergoing surgical, radiation and chemotherapy treatments and may be using other approved products or investigational new drugs, which can cause side effects or adverse events that are unrelated to our product candidate. As a result, assessments of efficacy can vary widely for a particular patient, and from patient to patient and site to site within a clinical trial. This subjectivity can increase the uncertainty of, and adversely impact, our clinical trial outcomes. We do not know whether any clinical trials we may conduct will demonstrate consistent or adequate efficacy and safety sufficient to obtain marketing approval to market our product candidates. Most product candidates that begin clinical trials are never approved by regulatory authorities for commercialization.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;">We have limited experience in designing clinical trials and may be unable to design and execute a clinical trial to support marketing approval. We cannot be certain that our planned clinical trials or any other future clinical trials will be successful. Additionally, any safety concerns observed in any one of our clinical trials in our targeted indications could limit the prospects for regulatory approval of our product candidates in those and other indications, which could seriously harm our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;">Moreover, preclinical and clinical data are often susceptible to varying interpretations and analyses and many companies that believed their product candidates performed satisfactorily in preclinical studies and clinical trials nonetheless failed to obtain FDA or comparable foreign regulatory authority approval. We cannot guarantee that the FDA or comparable foreign regulatory authorities will interpret trial results as we do, and more trials could be required before we are able to submit applications seeking approval of our product candidates. To the extent that the results of the trials are not satisfactory to the FDA or comparable foreign regulatory authorities for support of a marketing application, we may be required to expend significant resources, which may not be available to us, to conduct additional trials in support of potential approval of our product candidates. Even if regulatory approval is secured for any of our product candidates, the terms of such approval may limit the scope and use of our product candidate, which may also limit its commercial potential. Furthermore, the approval policies or regulations of the FDA or comparable foreign regulatory authorities may significantly change in a manner rendering our clinical data insufficient for approval, which may lead to the FDA or comparable foreign regulatory authorities delaying, limiting or denying approval of our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Interim, &#8220;top-line&#8221; and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;">From time to time, we may publicly disclose interim, preliminary or top-line data from our preclinical studies and clinical trials, which is based on a preliminary analysis of then-available data, and the results and related findings and conclusions are subject to change following a more comprehensive review of the data related to the particular study or trial. We also make assumptions, estimations, calculations and conclusions as part of our analyses of data, and we may not have received or had the opportunity to fully and carefully evaluate all data. Top-line and preliminary data also remain subject to audit and verification procedures that may result in the final data being materially different from the top-line or preliminary data we previously published. As a result, top-line and preliminary data should be viewed with caution until the final data are available.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;">From time to time, we may also disclose interim data from our preclinical studies and clinical trials. Interim data from clinical trials that we may complete are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available or as patients from our clinical trials continue other treatments for their disease. Adverse differences between top-line, preliminary or interim data and final data could significantly harm our business prospects. Further, disclosure of interim data by us or by our competitors could result in volatility in the trading price of our Class&#160;A common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">64</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;">Further, others, including regulatory agencies, may not accept or agree with our assumptions, estimates, calculations, conclusions or analyses or may interpret or weigh the importance of data differently, which could impact the value of the particular program, the approvability or commercialization of the particular product candidate or product and our company in general. In addition, the information we choose to publicly disclose regarding a particular study or clinical trial is based on what is typically extensive information, and you or others may not agree with what we determine is material or otherwise appropriate information to include in our disclosure. If the interim, top-line, or preliminary data that we report differ from actual results, or if others, including regulatory authorities, disagree with the conclusions reached, our ability to obtain approval for, and commercialize, our product candidates may be harmed, which could harm our business, results of operations, prospects or financial condition. Moreover, such disclosure could adversely affect the trading price of our Class&#160;A common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Our current or future product candidates may cause adverse events, toxicities or other undesirable side effects when used alone or in combination with other approved products or investigational new drugs that may result in a safety profile that could inhibit regulatory approval, prevent market acceptance, limit their commercial potential or result in significant negative consequences.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;">As is the case with pharmaceuticals generally, it is likely that there may be side effects and adverse events associated with the use of our product candidates. Results of our preclinical studies and clinical trials could reveal a high and unacceptable severity and prevalence of side effects or unexpected characteristics. Undesirable side effects caused by our product candidates could cause us or regulatory authorities to interrupt, delay or halt clinical trials and could result in a more restrictive label or the delay or denial of regulatory approval by the FDA or comparable foreign regulatory authorities. The drug-related side effects could affect patient recruitment or the ability of enrolled patients to complete the trial or result in potential product liability claims. Any of these occurrences may harm our business, financial condition and prospects significantly.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;">If our product candidates are associated with undesirable side effects or have unexpected characteristics in preclinical studies or clinical trials when used alone or in combination with approved or other investigational products we may need to interrupt, delay or abandon their development or limit development to more narrow uses or subpopulations in which the undesirable side effects or other characteristics are less prevalent, less severe or more acceptable from a risk-benefit perspective. Treatment-related side effects could also affect patient recruitment or the ability of enrolled subjects to complete the trial, or result in potential product liability claims. Any of these occurrences may prevent us from achieving or maintaining market acceptance of the affected product candidate and may harm our business, financial condition and prospects significantly.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;">Patients in our clinical trials may in the future suffer significant adverse events or other side effects not observed in our preclinical studies or previous clinical trials. Some of our product candidates may be used as chronic therapies or be used in pediatric populations, for which safety concerns may be particularly scrutinized by regulatory agencies. In addition, if our product candidates are used in combination with other therapies, our product candidates may exacerbate adverse events associated with the therapy. Patients treated with our product candidates may also be undergoing surgical, radiation and chemotherapy treatments, which can cause side effects or adverse events that are unrelated to our product candidate, but may still impact the success of our clinical trials. The inclusion of critically ill patients in our clinical trials may result in deaths or other adverse medical events due to other therapies or medications that such patients may be using or due to the gravity of such patients&#8217; illnesses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;">If significant adverse events or other side effects are observed in any of our future clinical trials, we may have difficulty recruiting patients to the clinical trials, patients may drop out of our trials, or we may be required to abandon the trials or our development efforts of that product candidate altogether. We, the FDA, other comparable regulatory authorities or an IRB may suspend clinical trials of a product candidate at any time for various reasons, including a belief that subjects in such trials are being exposed to unacceptable health risks or adverse side effects. Some potential therapeutics developed in the biotechnology industry that initially showed therapeutic promise in early-stage trials have later been found to cause side effects that prevented their further development. Even if the side effects do not preclude the product candidate from obtaining or maintaining marketing approval, undesirable side effects may inhibit market acceptance due to its tolerability versus other therapies. Any of these developments could materially harm our business, financial condition and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">65</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;">Additionally, if any of our product candidates receives regulatory approval, and we or others later identify undesirable side effects caused by such product, a number of potentially significant negative consequences could result. For example, the FDA could require us to adopt a REMS to ensure that the benefits of treatment with such product candidate outweigh the risks for each potential patient, which may include, among other things, a communication plan to health care practitioners, patient education, extensive patient monitoring or distribution systems and processes that are highly controlled, restrictive and costlier than what is typical for the industry. We or our collaborators may also be required to adopt a REMS or engage in similar actions, such as patient education, certification of health care professionals or specific monitoring, if we or others later identify undesirable side effects caused by any product that we develop alone or with collaborators. Other potentially significant negative consequences include that:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">&#8226; we may be forced to suspend marketing of that product, or be forced to or decide to remove the product form the marketplace;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">&#8226; regulatory authorities may withdraw or change their approvals of that product in one or more countries;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">&#8226; regulatory authorities may require additional warnings on the label or limit access of that product to selective </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">specialized centers with additional safety reporting and with requirements that patients be geographically close to these centers for all or part of their treatment;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">&#8226; we may be required to create a medication guide outlining the risks of the product for patients, or to conduct post-marketing studies;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;">&#8226; we may be required to change the way the product is administered;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">&#8226; we could be subject to fines, injunctions, or the imposition of criminal or civil penalties, or to be sued and held liable for harm caused to subjects or patients; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;">&#8226; the product may become less competitive, and our reputation may suffer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;">Any of these events could diminish the usage or otherwise limit the commercial success of our product candidates and prevent us from achieving or maintaining market acceptance of the affected product candidate, if approved by applicable regulatory authorities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;">If we experience delays or difficulties in the enrollment and/or maintenance of patients in clinical trials, our clinical development activities could be delayed or otherwise adversely affected.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;">Patient enrollment is a significant factor in the timing of clinical trials, and the timing of our clinical trials depends, in part, on the speed at which we can recruit patients to participate in our trials, as well as completion of required follow-up periods. We may not be able to initiate or continue clinical trials for our product candidates if we are unable to locate and enroll a sufficient number of eligible patients to participate in these trials to such trial&#8217;s conclusion as required by the FDA or other comparable foreign regulatory authorities. Additionally, our clinical trials will compete with other clinical trials for product candidates that focusing on the same therapeutic targets (e.g., evaluating patients harboring RAS mutant tumors) as our current and potential future product candidates, which may further limit enrollment of eligible patients or may result in slower enrollment than we anticipate. The eligibility criteria of our clinical trials, once established, may further limit the pool of available trial participants.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;">Patient enrollment may also be affected if our competitors have ongoing clinical trials for product candidates that are under development for the same indications as our product candidates, and patients who would otherwise be eligible for our clinical trials instead enroll in clinical trials of our competitors&#8217; product candidates. Patient enrollment for any of our clinical trials may be affected by other factors, including:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;">&#8226; size and nature of the patient population;</p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">66</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;">&#8226; severity of the disease under investigation;</p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;">&#8226; availability and efficacy of approved drugs for the disease under investigation;</p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;">&#8226; patient eligibility criteria for the trial in question as defined in the protocol;</p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;">&#8226; perceived risks and benefits of the product candidate under study;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">&#8226; clinicians&#8217; and patients&#8217; perceptions as to the potential advantages of the product candidate being studied in relation to other available therapies, including any new products that may be approved for the indications we are investigating;</p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;">&#8226; efforts to facilitate timely enrollment in clinical trials;</p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;">&#8226; patient referral practices of physicians;</p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;">&#8226; the ability to monitor patients adequately during and after treatment;</p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;">&#8226; proximity and availability of clinical trial sites for prospective patients;</p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;">&#8226; continued enrollment of prospective patients by clinical trial sites;</p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">&#8226; the risk that patients enrolled in clinical trials will drop out of the trials before completion or, because they may be late-stage cancer patients, will not survive the full terms of the clinical trials; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">&#8226; delays or difficulties in enrollment and completion of studies due to the pandemic related to COVID-19 and its variants or any future pandemic.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">Our inability to enroll a sufficient number of patients for our clinical trials would result in significant delays or may require us to abandon one or more clinical trials altogether. Enrollment delays in our clinical trials may result in increased development costs for our product candidates and jeopardize our ability to obtain marketing approval for the sale of our product candidates. Furthermore, even if we are able to enroll a sufficient number of patients for our clinical trials, we may have difficulty maintaining enrollment of such patients in our clinical trials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Even if approved, our product candidates may not achieve adequate market acceptance among physicians, patients, healthcare payors and others in the medical community necessary for commercial success.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">Even if our product candidates receive regulatory approval, they may not gain adequate market acceptance among physicians, patients, healthcare payors and others in the medical community. The degree of market acceptance of any of our approved product candidates will depend on a number of factors, including:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;">&#8226; the efficacy and safety profile as demonstrated in clinical trials compared to alternative treatments;</p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;">&#8226; the timing of market introduction of the product candidate as well as competitive products;</p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;">&#8226; the clinical indications for which the product candidate is approved;</p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">&#8226; restrictions on the use of our product candidates, such as boxed warnings or contraindications in labeling, or a REMS, if any, which may not be required of alternative treatments and competitor products;</p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;">&#8226; the potential and perceived advantages of product candidates over alternative treatments;</p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">67</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;">&#8226; the cost of treatment in relation to alternative treatments;</p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">&#8226; the availability of coverage and adequate reimbursement, as well as pricing, by third-party payors, including government authorities;</p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;">&#8226; the availability of the approved product candidate for use as a combination therapy;</p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;">&#8226; relative convenience and ease of administration;</p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">&#8226; the willingness of the target patient population to try new therapies and of physicians to prescribe these therapies;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;">&#8226; the effectiveness of sales and marketing efforts;</p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">&#8226; unfavorable publicity relating to our products or product candidates or similar approved products or product candidates in development by third parties; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;">&#8226; the approval of other new therapies for the same indications. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;">If any of our product candidates is approved but does not achieve an adequate level of acceptance by physicians, hospitals, healthcare payors and patients, we may not generate or derive sufficient revenue from that product candidate and our financial results could be negatively impacted.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;">We may be unable to obtain U.S. or foreign regulatory approvals and, as a result, may be unable to commercialize our product candidates.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;">Our product candidates are subject to extensive governmental regulations relating to, among other things, research, testing, development, manufacturing, safety, efficacy, approval, recordkeeping, reporting, labeling, storage, packaging, advertising and promotion, pricing, marketing and distribution of drugs. Rigorous preclinical testing and clinical trials and an extensive regulatory approval process must be successfully completed in the United States and in many foreign jurisdictions before a new drug can be marketed. Satisfaction of these and other regulatory requirements is costly, time consuming, uncertain and subject to unanticipated delays. We cannot provide any assurance that any product candidate we may develop will progress through required clinical testing and obtain the regulatory approvals necessary for us to begin selling them.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;">We have not conducted, managed or completed large-scale or pivotal clinical trials nor managed the regulatory approval process with the FDA or any other regulatory authority. The time required to obtain approvals from the FDA and other regulatory authorities is unpredictable, and requires successful completion of extensive clinical trials which typically takes many&#160;years, depending upon the type, complexity and novelty of the product candidate. The standards that the FDA and its foreign counterparts use when evaluating clinical trial data can and often changes during drug development, which makes it difficult to predict with any certainty how they will be applied. We may also encounter unexpected delays or increased costs due to new government regulations, including future legislation or administrative action, or changes in FDA policy during the period of drug development, clinical trials and FDA regulatory review.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;">Any delay or failure in seeking or obtaining required approvals would have a material and adverse effect on our ability to generate revenue from the particular product candidate for which we are developing and seeking approval. Furthermore, any regulatory approval to market a drug may be subject to significant limitations on the approved uses or indications for which we may market the drug or the labeling or other restrictions. In addition, the FDA has the authority to require a REMS as part of approving a NDA, or after approval, which may impose further requirements or restrictions on the distribution or use of an approved drug. These requirements or restrictions might include limiting prescribing to certain physicians or medical centers that have undergone specialized training, limiting treatment to patients who meet certain safe-use criteria and requiring treated patients to enroll in a registry. These limitations and restrictions may significantly limit the size of the market for the drug and affect reimbursement by third-party payors.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">68</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;">We are also subject to numerous foreign regulatory requirements governing, among other things, the conduct of clinical trials, manufacturing and marketing authorization, pricing and third-party reimbursement. The foreign regulatory approval process varies among countries, and generally includes all of the risks associated with FDA approval described above as well as risks attributable to the satisfaction of local regulations in foreign jurisdictions. Moreover, the time required to obtain approval may differ from that required to obtain FDA approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;min-height:10.0pt;text-align:center;margin:0pt;"><i style="font-style:italic;">&#160;</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.5pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Our approach to the discovery and development of product candidates is unproven, and we may not be successful in our efforts to use and expand our DCT platform to build a pipeline of product candidates with commercial value.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.5pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.5pt;text-align:justify;margin:0pt;">A key element of our strategy is to use and expand our DCT platform to build a pipeline of product candidates and progress these product candidates through clinical development for the treatment of various cancers. Although our research and development efforts to date have resulted in our discovery and preclinical development of IMM-1-104, it and other product candidates may not be safe or effective for the indications for which we study them in clinical trials, and we may not be able to develop any other product candidates. Our DCT platform is evolving and may not reach a state at which building a pipeline of product candidates is possible.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.5pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.5pt;text-align:justify;margin:0pt;">We have not commenced clinical trials for any product candidates developed with our DCT platform. The scientific research that forms the basis of our efforts to develop product candidates with our platforms is still ongoing. Further, the scientific evidence to support the feasibility of developing therapeutic treatments based on our DCT platform is both preliminary and limited. As a result, we are exposed to a number of unforeseen risks and it is difficult to predict the types of challenges and risks that we may encounter during development of our product candidates. For example, we have not tested any of the product candidates being developed using our DCT platform in humans, and our current data is limited to animal models and preclinical cell lines, the results of which may not translate into humans. As a result, it is possible that safety events or concerns could negatively affect the development of our product candidates, including adversely affecting patient enrollment among the patient populations that we intend to treat.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.5pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.5pt;text-align:justify;margin:0pt;">Given the novelty of our technologies, we intend to work closely with the FDA and comparable foreign regulatory authorities to perform the requisite scientific analyses and evaluation of our methods to obtain regulatory approval for our product candidates; however, due to a lack of comparable experiences, the regulatory pathway with the FDA and comparable regulatory authorities may be more complex and time-consuming relative to other more well-known therapeutics. Even if we obtain human data to support our product candidates, the FDA or comparable foreign regulatory agencies may lack experience in evaluating the safety and efficacy of our product candidates developed using our platforms, which could result in a longer than expected regulatory review process, increase our expected development costs, and delay or prevent commercialization of our product candidates. The validation process takes time and resources, may require independent third-party analyses, and may not be accepted or approved by the FDA and comparable foreign regulatory authorities. We cannot be certain that our approach will lead to the development of approvable or marketable products, alone or in combination with other therapies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.5pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.5pt;text-align:justify;margin:0pt;">Additionally, a key element of our strategy is to use and expand our platforms to build a pipeline of product candidates and progress those product candidates through clinical development for the treatment of a variety of different types of diseases. Although our research and development efforts to date have been focused on identifying a pipeline of product candidates directed at various disease types, we may not be able to develop product candidates that are safe and effective. Even if we are successful in building our pipeline, the potential product candidates that we identify may not be suitable for clinical development, including as a result of being shown to have harmful side effects or other characteristics that indicate that they are unlikely to be approvable or marketable products that will receive marketing approval and achieve market acceptance. If we do not continue to successfully develop, get approval for and begin to commercialize any product candidates, we will face difficulty in obtaining product revenue in future periods, which could result in significant harm to our financial position and adversely affect our share price.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.5pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">69</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.5pt;text-align:justify;margin:0pt;">Even if we are successful in building our pipeline of product candidates, the potential product candidates that we identify may not be suitable for clinical development or generate acceptable clinical data, including as a result of being shown to have unacceptable toxicity or other characteristics that indicate that they are unlikely to be products that will receive marketing approval from the FDA or other regulatory authorities or achieve market acceptance. If we do not successfully develop and commercialize product candidates, we will not be able to generate product revenue in the future, which likely would result in significant harm to our financial position and adversely affect our stock price.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;">We may develop our current and future product candidates in combination with other therapies, which exposes us to additional risks.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">We may also develop certain product candidates as biologic/drug combination products. Additional time may be required to obtain regulatory approval for our product candidates if they are combination products. Our product candidates that may be biologic/drug combination products will require coordination within the FDA and other comparable foreign regulatory authorities for review of their biologic and drug components. Although the FDA and other comparable foreign regulatory authorities have systems in place for the review and approval of combination products, we may experience delays in the development and commercialization of our product candidates that may be combination products due to regulatory timing constraints and uncertainties in the product development and approval process.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">In addition, even if any product candidate we develop were to receive marketing approval or be commercialized for use in combination with other existing therapies, we would continue to be subject to the risks that the FDA or comparable foreign regulatory authorities outside of the United States could revoke approval of the therapy used in combination with our product or that safety, efficacy, manufacturing or supply issues could arise with any of those existing therapies. If the therapies we use in combination with our product candidates are replaced as the standard of care for the indications we choose for any of our product candidates, the FDA or comparable foreign regulatory authorities may require us to conduct additional clinical trials. The occurrence of any of these risks could result in our own products, if approved, being removed from the market or being less successful commercially.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">We also may choose to evaluate our current product candidates or any other future product candidates in combination with one or more cancer therapies that have not yet been approved for marketing by the FDA or comparable foreign regulatory authorities. We will not be able to market and sell our product candidates we develop in combination with an unapproved cancer therapy for a combination indication if that unapproved therapy does not ultimately obtain marketing approval either alone or in combination with our product. In addition, unapproved cancer therapies face the same risks described with respect to our product candidates currently in development and clinical trials, including the potential for serious adverse effects, delay in their clinical trials and lack of FDA approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">If the FDA or comparable foreign regulatory authorities do not approve these other drugs or revoke their approval of, or if safety, efficacy, quality, manufacturing or supply issues arise with, the drugs we choose to evaluate in combination with our product candidate we develop, we may be unable to obtain approval of or market such combination therapy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;">If we successfully develop our product candidates, we may seek approval from the FDA through the use of accelerated approval pathways. If we are unable to obtain such approval, we may be required to conduct additional preclinical studies or clinical trials beyond those that we initially contemplate, which could increase the expense of obtaining, and delay the receipt of, necessary marketing approvals. Even if we receive accelerated approval from the FDA, if our confirmatory trials do not verify clinical benefit, or if we do not comply with rigorous post-marketing requirements, the FDA may seek to withdraw accelerated approval.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">We may in the future seek an accelerated approval for one or more of our product candidates. Under the accelerated approval program, the FDA may grant accelerated approval to a product candidate designed to treat a serious or life-threatening condition that provides meaningful therapeutic benefit over available therapies upon a determination that the product candidate has an effect on a surrogate endpoint or intermediate clinical endpoint that is reasonably likely to predict clinical benefit. The FDA considers a clinical benefit to be a positive therapeutic effect that is clinically meaningful in the context of a given disease, such as irreversible morbidity or mortality. For the purposes of accelerated approval, a surrogate </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">70</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">endpoint is a marker, such as a laboratory measurement, radiographic image, physical sign, or other measure that is thought to predict clinical benefit, but is not itself a measure of clinical benefit. An intermediate clinical endpoint is a clinical endpoint that can be measured earlier than an effect on irreversible morbidity or mortality that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit. The accelerated approval pathway may be used in cases in which the advantage of a new drug over available therapy may not be a direct therapeutic advantage, but is a clinically important improvement from a patient and public health perspective. If granted, accelerated approval is usually contingent on the sponsor&#8217;s agreement to conduct, in a diligent manner, additional post-approval confirmatory studies to verify and describe the drug&#8217;s clinical benefit. If such post-approval studies fail to confirm the drug&#8217;s clinical benefit, the FDA may withdraw its approval of the drug.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">Prior to seeking accelerated approval for any of our product candidates, we intend to seek feedback from the FDA and will otherwise evaluate our ability to seek and receive accelerated approval. There can be no assurance that after our evaluation of the feedback and other factors we will decide to pursue or submit an NDA for accelerated approval or any other form of expedited development, review or approval. Similarly, there can be no assurance that after subsequent FDA feedback we will continue to pursue or apply for accelerated approval or any other form of expedited development, review or approval, even if we initially decide to do so. Furthermore, if we decide to submit an application for accelerated approval or receive an expedited regulatory designation (e.g., breakthrough therapy designation) for our product candidates, there can be no assurance that such submission or application will be accepted or that any expedited development, review or approval will be granted on a timely basis, or at all. The FDA or other comparable foreign regulatory authorities could also require us to conduct further studies prior to considering our application or granting approval of any type. A failure to obtain accelerated approval or any other form of expedited development, review or approval for our product candidate would result in a longer time period to commercialization of such product candidate, could increase the cost of development of such product candidate and could harm our competitive position in the marketplace.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;">We may expend our limited resources to pursue a particular product candidate or indication and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">Because we have limited financial and managerial resources, we focus on research programs, therapeutic platforms and product candidates that we identify for specific indications. As a result, we may forego or delay pursuit of opportunities with other therapeutic platforms or product candidates or for other indications that later prove to have greater commercial potential or a greater likelihood of success than our product candidates. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. Our spending on current and future research and development programs, therapeutic platforms and product candidates for specific indications may not yield any commercially viable products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><b style="font-weight:bold;">Risks Related to Our Business</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;">We are early in our development efforts. Our business is substantially dependent on the successful development of our current and future product candidates. If we are unable to advance our current or future product candidates through clinical trials, obtain marketing approval to treat the indications we seek to treat with our product candidates, and ultimately commercialize any product candidates we develop, or experience significant delays in doing so, our business will be materially harmed.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">We are early in our development efforts and we have not yet completed our IND-enabling studies for our lead product candidate, IMM-1-104. Our other product candidates are in earlier stages of drug development. We have invested substantially all of our efforts and financial resources in the identification of targets and preclinical development of small molecules targeting the MAPK and mTOR pathways in cancer therapy and small molecules targeting central nervous system disorders, including AD.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">The success of our business, including our ability to finance our company and generate revenue from products in the future, which we do not expect will occur for several&#160;years, if ever, will depend heavily on the successful development and eventual commercialization of the product candidates we develop, which may never occur. Our current product candidates, </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">71</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">and any future product candidates we develop, will require additional preclinical and clinical development, management of clinical, preclinical and manufacturing activities, marketing approval in the United States and other markets, demonstrating effectiveness to pricing and reimbursement authorities, obtaining sufficient manufacturing supply for both clinical development and commercial production, building of a commercial organization, and substantial investment and significant marketing efforts before we generate any revenues from product sales.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;">The success of our current and future product candidates will depend on several factors, including the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;">&#8226; the successful and timely completion of additional preclinical studies;</p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">&#8226; the successful initiation, patient enrollment and completion of our anticipated clinical trials on a timely basis, including any delays arising out of the pandemic related to COVID-19 and its variants or any future pandemic;</p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">&#8226; maintaining and establishing relationships with CROs and clinical sites for clinical development, both in the United States and internationally;</p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;">&#8226; the frequency and severity of adverse events in the clinical trials;</p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">&#8226; the efficacy, safety and tolerability profiles that are satisfactory to the FDA or any comparable foreign regulatory authority for marketing approval;</p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;">&#8226; the timely receipt of marketing approvals from applicable regulatory authorities;</p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">&#8226;the extent of any required post-marketing approval commitments to applicable regulatory authorities;</p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">&#8226; the maintenance of existing or the establishment of new supply arrangements with third-party drug product suppliers and manufacturers for clinical development;</p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">&#8226; the maintenance of existing, or the establishment of new, scaled production arrangements with third-party manufacturers to obtain finished products that are appropriate for commercial sale of our product candidates, if approved;</p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">&#8226; obtaining and maintaining patent protection, trade secret protection and regulatory exclusivity, both in the United States and internationally;</p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;">&#8226; the protection of our rights in our intellectual property portfolio;</p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;">&#8226; the successful launch of commercial sales following any marketing approval;</p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;">&#8226; a continued acceptable safety profile following any marketing approval;</p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;">&#8226; commercial acceptance by patients, the medical community and third-party payors; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;">&#8226; our ability to compete with other therapies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;">We do not have complete control over many of these factors, including certain aspects of clinical development and the regulatory submission process, potential threats to our intellectual property rights and the manufacturing, marketing, distribution and sales efforts of any future collaborator. If we are not successful with respect to one or more of these factors in a timely manner or at all, we could experience significant delays or an inability to successfully commercialize the product candidates we develop, which would materially harm our business. If we do not receive marketing approvals for IMM-1-104, or any other product candidate we develop, we may not be able to continue our operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">72</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;">We are substantially dependent on our platform, including our proprietary technologies such as DCT and Fluency, which are supported by our information technology systems. Any failure of these or other elements of our platform will materially harm our business.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;">We are substantially dependent on our platform, including our proprietary technologies such as DCT and Fluency, which are supported by our information technology systems, for significant elements of our drug discovery process, bioinformatics and computational biology software systems, database of information relating to our product candidates and their role in the targeted disease process, amongst others. Although we invest substantially in the backup/restore, high-availability architecture, monitoring and reporting, documentation and preventive security controls of our systems and proprietary technologies, these elements of our platform are still vulnerable to damage from a variety of sources, including telecommunications or network failures, malicious or inadvertent human acts, and natural disasters. Our information technology systems and proprietary technologies are potentially also vulnerable to physical or electronic break-ins, employee errors, computer viruses and similar disruptive problems. Despite the precautionary measures we have taken to prevent unanticipated problems that could affect our information technology systems and proprietary technologies, failures or significant downtime of these systems could prevent us from conducting research and development activities for our current and future product candidates, and ultimately delay our drug discovery process. Any failure of our information technology systems and proprietary technologies will materially harm our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Our long-term prospects depend in part upon discovering, developing and commercializing product candidates, which may fail in development or suffer delays that adversely affect their commercial viability.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;">Our future results of operations are dependent on our ability to successfully discover, develop, obtain regulatory approval for and commercialize product candidates beyond those we currently have in preclinical studies and early stage development. A product candidate can unexpectedly fail at any stage of preclinical and clinical development. The historical failure rate for product candidates is high due to risks relating to safety, efficacy, clinical execution, changing standards of medical care and other unpredictable variables. The results from preclinical studies or early clinical trials of a product candidate may not be predictive of the results that will be obtained in later stage clinical trials of the product candidate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;">The success of the product candidates we have or may develop will depend on many factors, including the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;">&#8226; the success of our research methodology in identifying potential indications or product candidates;</p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;">&#8226; generating sufficient data to support the initiation or continuation of clinical trials;</p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;">&#8226; obtaining regulatory permission to initiate clinical trials;</p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;">&#8226; contracting with the necessary parties to conduct clinical trials;</p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;">&#8226; successful enrollment of patients in, and the completion of, clinical trials on a timely basis;</p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;">&#8226; the timely manufacture of sufficient quantities of the product candidate for use in clinical trials;</p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;">&#8226; adverse events in the clinical trials; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">&#8226; any potential interruptions or delays resulting from factors related to the pandemic related to COVID-19 and its variants or any future pandemic.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;">Even if we successfully advance any other product candidates into clinical development, their success will be subject to all of the clinical, regulatory and commercial risks described elsewhere in this &#8220;Risk Factors&#8221; section. Accordingly, we cannot assure you that we will ever be able to discover, develop, obtain regulatory approval of, commercialize or generate significant revenue from our other product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">73</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;">We have never commercialized a product candidate before and may lack the necessary expertise, personnel and resources to successfully commercialize any products on our own or together with suitable collaborators.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;">We have never commercialized a product candidate, and we currently have no sales force, marketing or distribution capabilities. We will have to develop our own sales, marketing and supply organization or outsource these activities to a third party to commercialize our products. If we decide to license our product candidate to others, we may need to rely on the marketing assistance and guidance of those collaborators.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;">Factors that may affect our ability to commercialize our product candidates on our own include recruiting and retaining adequate numbers of effective sales and marketing personnel, obtaining access to or persuading adequate numbers of physicians to prescribe our product candidates and other unforeseen costs associated with creating an independent sales and marketing organization. Developing a sales and marketing organization will be expensive and time-consuming and could delay the launch of our product candidates. We may not be able to build an effective sales and marketing organization. If we are unable to build our own distribution and marketing capabilities or to find suitable partners for the commercialization of our product candidates, we may not generate revenues from them or be able to reach or sustain profitability.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;">We face significant competition, and if our competitors develop and market technologies or products more rapidly than we do or that are more effective, safer or less expensive than the product candidates we develop, our commercial opportunities will be negatively impacted.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;">The pharmaceutical and biotechnology industries are characterized by rapidly advancing technologies, intense competition and a strong emphasis on proprietary and novel products and product candidates. Our<b style="font-weight:bold;">&#160;</b>competitors have developed, are developing or may develop products, product candidates and processes competitive with our product candidates. Any product candidates that we successfully develop and commercialize will compete with existing therapies and new therapies that may become available in the future. We believe that a significant number of products are currently under development, and may become commercially available in the future, for the treatment of conditions for which we may attempt to develop product candidates. In addition, our products may need to compete with off-label drugs used by physicians to treat the indications for which we seek approval. This may make it difficult for us to replace existing therapies with our products. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;">In particular, there is intense competition in the fields of oncology we are pursuing. We have competitors both in the United States and internationally, including major multinational biopharmaceutical companies, established biotechnology companies, specialty biopharmaceutical companies, emerging and start-up companies, universities and other research institutions. For example, our product candidates and programs for oncology and neuroscience will compete with products or programs being advanced by certain pharmaceutical and biotechnology companies. We also compete with these organizations to recruit management, scientists and clinical development personnel, which could negatively affect our level of expertise and our ability to execute our business plan. We will also face competition in establishing clinical trial sites, enrolling subjects for clinical trials and in identifying and in-licensing new product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;">We have chosen to initially address well-validated biochemical targets, and therefore expect to face competition from existing products and products in development for each of our product candidates. There are a large number of companies developing or marketing treatments for cancer, including many major pharmaceutical and biotechnology companies. Many of these current and potential competitors have significantly greater financial, manufacturing, marketing, drug development, technical and human resources and commercial expertise than we do. Large pharmaceutical and biotechnology companies, in particular, have extensive experience in clinical testing, obtaining regulatory approvals, recruiting patients and manufacturing biotechnology products. These companies also have significantly greater research and marketing capabilities and experience than we do and may also have products that have been approved or are in late stages of development, and collaborative arrangements in our target markets with leading companies and research institutions. Established pharmaceutical and biotechnology companies may also invest heavily to accelerate discovery and development of novel compounds or to in-license novel compounds that could make the product candidates that we develop obsolete. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies, as well as in acquiring technologies complementary to, or necessary for, our programs. As a result of all of these factors, our competitors may succeed in obtaining approval from </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">74</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;">the FDA or other comparable foreign regulatory authorities or in discovering, developing and commercializing products in our field before we do.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">Our commercial opportunities could be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective, have fewer or less severe effects, are more convenient, have a broader label, are marketed more effectively, are reimbursed or are less expensive than any products that we may develop. Our competitors also may obtain marketing approval from the FDA or other comparable foreign regulatory authorities for their products more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the market. Even if the product candidates we develop achieve marketing approval, they may be priced at a significant premium over competitive products if any have been approved by then, resulting in reduced competitiveness. Technological advances or products developed by our competitors may render our technologies or product candidates obsolete, less competitive or not economical. If we are unable to compete effectively, our opportunity to generate revenue from the sale of our products we may develop, if approved, could be adversely affected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;">If the market opportunity for any product candidate that we develop is smaller than we believe, our revenue may be adversely affected and our business may suffer.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">We intend to initially focus our product candidate development on treatments for various oncology indications. Our projections of addressable patient populations that may benefit from treatment with our product candidates are based on our estimates. These estimates, which have been derived from a variety of sources, including scientific literature, surveys of clinics, patient foundations and market research, may prove to be incorrect. Further, new studies may change the estimated incidence or prevalence of these cancers. Additionally, the potentially addressable patient population for our product candidates may not ultimately be amenable to treatment with our product candidates. Our market opportunity may also be limited by future competitor treatments that enter the market. If any of our estimates prove to be inaccurate, the market opportunity for any product candidate that we develop could be significantly diminished and have an adverse material impact on our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;">We have never obtained marketing approval for a product candidate and we may be unable to obtain, or may be delayed in obtaining, marketing approval for any product candidate.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;">We have never obtained marketing approval for a product candidate. It is possible that the FDA may refuse to accept for substantive review any NDAs that we submit for our product candidates or may conclude after review of our data that our applications are insufficient to obtain marketing approval of our product candidates. We believe our approach of treating conditions or diseases through neuroregeneration is novel and, as a result, the process for, and the outcome of, FDA approval is especially uncertain. If the FDA does not accept or approve our NDAs for our product candidates, it may require that we conduct additional clinical, preclinical, or manufacturing validation studies and submit that data before it will reconsider our applications. Depending on the extent of these or any other FDA-required studies, approval of any NDA that we submit may be delayed or may require us to expend more resources than we have available. It is also possible that additional studies, if performed and completed, may not be considered sufficient by the FDA to approve our NDAs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;">Any delay in obtaining, or an inability to obtain, marketing approvals would prevent us from commercializing our product candidates, generating revenues, and achieving and sustaining profitability. If any of these outcomes occur, we may be forced to abandon our development efforts for our product candidates, which could significantly harm our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;">The COVID-19 pandemic and potential future pandemics could continue to adversely impact our business, including our anticipated clinical trials, supply chain and business development activities.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;">In December&#160;2019, SARS-CoV-2, a novel strain of coronavirus, was first reported in Wuhan, China and has since become a global pandemic. The President of the United States declared the COVID-19 pandemic a national emergency and many states and municipalities in the United States have announced aggressive actions to reduce the spread of the disease, including limiting non-essential gatherings of people, ceasing all non-essential travel, ordering certain businesses and government agencies to cease non-essential operations at physical locations and issuing &#8220;shelter-in-place&#8221; orders which direct individuals to shelter at their places of residence (subject to limited exceptions). We may experience limitations on </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">75</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;">employee resources in the future, including because of sickness of employees or their families. The effects of government actions and our own policies and those of third parties to reduce the spread of COVID-19 and its variants may negatively impact productivity and slow down or delay our future clinical trials, preclinical studies and research and development activities, and may cause disruptions to our supply chain and impair our ability to execute our business development strategy. In the event that government authorities were to enhance current restrictions, our employees who currently are not telecommuting may no longer be able to access our facilities, and our operations may be further limited or curtailed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;">As COVID-19 and its variants continues to spread, we may experience ongoing disruptions that could severely impact our business, preclinical studies and clinical trials, including:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">&#8226; interruption or delays in our operations, which may impact our ability to conduct and produce preclinical results required for submission of an IND;</p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;">&#8226; delays in receiving approval from local regulatory authorities to initiate our planned clinical trials;</p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;">&#8226; delays or difficulties in enrolling patients in our clinical trials;</p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">&#8226; delays or difficulties in clinical site initiation, including difficulties in recruiting clinical site investigators and clinical site staff;</p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">&#8226; delays in clinical sites receiving the supplies and materials needed to conduct our clinical trials, including interruption in global shipping that may affect the transport of clinical trial materials;<b style="font-weight:bold;">&#160;</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">&#8226; changes in local regulations as part of a response to the pandemic related to COVID-19 and its variants which may require us to change the ways in which our clinical trials are conducted, which may result in unexpected costs, or to discontinue such clinical trials altogether;</p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">&#8226; diversion of healthcare resources away from the conduct of clinical trials, including the diversion of hospitals serving as our clinical trial sites and hospital staff supporting the conduct of our clinical trials;</p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">&#8226; interruption of key clinical trial activities, such as clinical trial site monitoring, due to limitations on travel imposed or recommended by federal or state governments, employers and others, or interruption of clinical trial subject visits and study procedures, the occurrence of which could affect the integrity of clinical trial data;</p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">&#8226; interruption or delays in the operations of the FDA or other regulatory authorities, which may impact review and approval timelines;</p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">&#8226; risk that participants enrolled in our clinical trials will contract COVID-19 while the clinical trial is ongoing, which could impact the results of the clinical trial, including by increasing the number of observed adverse events; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;">&#8226; refusal of the FDA to accept data from clinical trials in affected geographies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;">These and other disruptions in our operations and the global economy could negatively impact our business, results of operations and financial condition. &#160; For example, due to supply chain constraints and the impact of follow-on effects due to such constraints, we had to move the timing of our recently announced plans to submit an IND for IMM-1-104 to the FDA, which are now expected to be in the third quarter of 2022, as well as the timing of our enrollment of the first patient in our first-in-human Phase 1 clinical trial of IMM-1-104 for the treatment of advanced solid tumors in patients harboring RAS mutant tumors in the fourth quarter of 2022, assuming our IND for IMM-1-104 is accepted. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;">Our future clinical trials may be affected by the pandemic related to COVID-19 and its variants or any future pandemic. For example, some clinical trial sites have slowed down or stopped further enrollment of new patients in clinical trials, denied access to site monitors and otherwise curtailed certain operations. Similarly, our ability to recruit and retain </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">76</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;">principal investigators and site staff who, as healthcare providers, may have heightened exposure to COVID-19 and its variants, may be adversely impacted. Our planned clinical trials may also be impacted by interruptions or delays in the operations of the FDA and comparable foreign regulatory agencies. We and our CROs will act in accordance with the guidance issued by the FDA in our future clinical trials to ensure the monitoring and safety of patients and minimize risks to trial integrity during the pandemic related to COVID-19 and its variants. This may have unforeseen effects on the enrollment, progress and completion of these trials and the findings. These events could delay our clinical trials, increase the cost of completing our clinical trials and negatively impact the integrity, reliability or robustness of the data from our clinical trials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;">In addition, quarantines, shelter-in-place and similar government orders, or the perception that such orders, shutdowns or other restrictions on the conduct of business operations could occur, related to COVID-19 and its variants or other infectious diseases could impact personnel at third-party manufacturing facilities upon which we may rely in the future, or the availability or cost of materials, which could disrupt the supply chain for our product candidates. To the extent our future suppliers and service providers are unable to comply with their obligations under our future agreements with them or they are otherwise unable to deliver or are delayed in delivering goods and services to us due to the pandemic related to COVID-19 and its variants, our future ability to continue meeting clinical supply demand for our product candidates or otherwise advancing development of our product candidates may become impaired.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;">The spread of COVID-19 and its variants and actions taken to reduce its spread may also materially affect us economically. While the potential economic impact brought by, and the duration of, the pandemic related to COVID-19 and its variants may be difficult to assess or predict, there could be a significant disruption of global financial markets, reducing our ability to access capital, which could in the future negatively affect our liquidity and financial position. In addition, the trading prices for other biopharmaceutical companies have been highly volatile as a result of the pandemic related to COVID-19 and its variants. As a result, we may face difficulties raising capital through sales of our Class&#160;A common stock or such sales may be on unfavorable terms. COVID-19 and its variants and actions taken to reduce their spread continue to rapidly evolve. The extent to which COVID-19 and its variants may impede the development of our product candidates, reduce the productivity of our employees, disrupt our supply chains, delay our clinical trials, reduce our access to capital or limit our business development activities, will depend on future developments, which are highly uncertain and cannot be predicted with confidence. To the extent the pandemic related to COVID-19 and its variants adversely affects our business and financial results, it may<b style="font-weight:bold;">&#160;</b>also have the effect of heightening many of the other risks described in this &#8220;Risk Factors&#8221; section, such as those relating to the timing and results of our clinical trials and our financing needs</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;">We may fail to adequately meet the requirements under our computational biology service contracts to pharmaceutical and biotechnology companies, which may harm our reputation, possibly resulting in related losses.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;">Over a decade ago, we began to offer computational biology services to pharmaceutical and biotechnology companies. We have deprioritized this business and plan to gradually wind down our computational biology services to pharmaceutical and biotechnology companies in the future. However, we are currently servicing several companies and in doing so, we must:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;">&#8226; accurately assess and meet the customer&#8217;s needs;</p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">&#8226; ensure our computational biology services meet industry standards and practices for performance of similar services;</p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;">&#8226; retain the proper personnel to fulfill these service contracts; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;">&#8226; compete effectively with other computational biology service providers performing similar services.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;">If we fail to adequately meet the requirements under our computational biology service contracts to our typical high standards, our reputation, growth opportunities and prospects could be adversely affected, possibly resulting in related losses. In addition, as is typical for contracts of this nature, there are inherent legal risks and potential liabilities associated with our work under each of our past, present and future contracts.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">77</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><b style="font-weight:bold;">Risks Relating to Our Dependence on Third Parties</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;">We substantially rely, and expect to continue to rely, on third parties, including independent clinical investigators and CROs, to conduct certain aspects of our preclinical studies, and in the future, our clinical trials. If these third parties do not successfully carry out their contractual duties, comply with applicable regulatory requirements or meet expected deadlines, we may not be able to obtain regulatory approval for or commercialize our product candidates and our business could be substantially harmed.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">We substantially rely, and expect to continue to rely, on third parties, including independent clinical investigators and third-party CROs, to conduct certain aspects of our preclinical studies and to monitor and manage data for our ongoing preclinical programs. We rely on these parties for execution of our preclinical studies and clinical trials, and control only certain aspects of their activities. Nevertheless, we are responsible for ensuring that each of our studies and trials is conducted in accordance with the applicable protocol, legal, regulatory and scientific standards, and our reliance on these third parties does not relieve us of our regulatory responsibilities. We, our third-party contractors and CROs are required to comply with GCP requirements, which are regulations and guidelines enforced by the FDA and comparable foreign regulatory authorities for all of our products candidates in clinical development. Regulatory authorities enforce these GCPs through periodic inspections of trial sponsors, principal investigators and trial sites. If we or any of these third parties or our CROs fail to comply with applicable GCPs, the clinical data generated in our clinical trials may be deemed unreliable and the FDA or comparable foreign regulatory authorities may require us to perform additional clinical trials before approving our marketing applications. We cannot assure you that upon inspection by a given regulatory authority, such regulatory authority will determine that any of our clinical trials comply with GCP regulations. In addition, our clinical trials must be conducted with product produced under cGMP regulations. Our failure to comply with these regulations may require us to repeat clinical trials, which would delay the regulatory approval process. Moreover, our business may be adversely affected if any of these third parties violates federal or state fraud and abuse or false claims laws and regulations or healthcare privacy and security laws.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">Further, there is no guarantee that any such CROs, investigators or other third parties on which we rely will devote adequate time and resources to our development activities or perform as contractually required. These risks are heightened as a result of the efforts of government agencies and the CROs themselves to limit the spread of COVID-19 and its variants, including quarantines and shelter-in-place orders. These third parties may also have relationships with other commercial entities, including our competitors, for whom they may also be conducting clinical trials or other product development activities, which could affect their performance on our behalf. If independent investigators or CROs fail to devote sufficient resources to the development of our product candidates, or if CROs do not successfully carry out their contractual duties or obligations or meet expected deadlines, if they need to be replaced or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical protocols, regulatory requirements or for other reasons, our clinical trials may be extended, delayed or terminated and we may not be able to obtain regulatory approval for or successfully commercialize our product candidates. As a result, our results of operations and the commercial prospects for our product candidates would be harmed, our costs could increase and our ability to generate revenues could be delayed or precluded entirely.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;">Our CROs have the right to terminate their agreements with us in the event of an uncured material breach. In addition, some of our CROs have an ability to terminate their respective agreements with us if it can be reasonably demonstrated that the safety of the subjects participating in our clinical trials warrants such termination, if we make a general assignment for the benefit of our creditors or if we are liquidated.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;">If any of our relationships with these third-party CROs terminate, we may not be able to enter into arrangements with alternative CROs or to do so on commercially reasonable terms. Switching or adding additional CROs involves additional cost and requires management time and focus. In addition, there is a natural transition period when a new CRO commences work. As a result, delays occur, which can materially impact our ability to meet our desired clinical development timelines. Additionally, CROs may lack the capacity to absorb higher workloads or take on additional capacity to support our needs. Though we carefully manage our relationships with our CROs, there can be no assurance that we will not encounter similar challenges or delays in the future or that these delays or challenges will not have a material adverse impact on our business, financial condition and prospects.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">78</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;">We rely on, and in the future may rely on, third-party datasets and collaborations with third parties to inform patient selection, drug target identification and other bioinformatic and computational biology analyses for our existing product candidates and any future product candidates and for the supply of biomarker companion diagnostics.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;">We are using bioinformatics, including data analytics, biostatistics and computational biology, throughout our drug discovery and development process, including to identify new target and biomarker opportunities. As part of this approach, we interrogate public and proprietary datasets, including, but not limited to, human tumor genetic information and specific cancer-target dependency networks. We rely on these datasets and data analytics for multiple analyses, including identifying or validating some of our biomarker-target relationships and access to these databases may not continue to be available publicly or through a proprietary subscription on acceptable terms. Our past, present and future use of such datasets could also create potential liabilities for us if the data provided to us contains inherent errors, inaccuracies or artifacts, or if we improperly analyze, handle, store or utilize the data.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;">Many of our product candidates also rely on the availability and use of commercially available tumor diagnostics panels or data on the prevalence of our target patient population to inform the patient selection and drug target identification for our product candidates. In cases where such biomarker diagnostic is not already commercially available, we expect to establish strategic collaborations for the clinical supply and development of companion diagnostics. If these diagnostics are not able to be developed, or if commercial tumor profiling panels are not able to be updated to include additional tumor-associated genes, or if clinical oncologists do not incorporate molecular or genetic sequencing into their clinical practice, we may not be successful in developing our existing product candidates or any future product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;">If we decide to establish new collaborations in the future, but are not able to establish those collaborations on commercially reasonable terms, we may have to alter our development and commercialization plans.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;">Our drug development programs and the potential commercialization of our product candidates will require substantial additional cash to fund expenses. We may seek to selectively form collaborations to expand our capabilities, potentially accelerate research and development activities and provide for commercialization activities by third parties. Any of these relationships may require us to incur non-recurring and other charges, increase our near and long-term expenditures, issue securities that dilute our existing stockholders, or disrupt our management and business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;">We may face significant competition in seeking appropriate collaborators and the related negotiation process is time-consuming and complex. Whether we reach a definitive agreement for a collaboration will depend, among other things, upon our assessment of the collaborator&#8217;s resources and expertise, the terms and conditions of the proposed collaboration and the proposed collaborator&#8217;s evaluation of a number of factors. Those factors may include the design or results of clinical trials, the likelihood of approval by the FDA or comparable foreign regulatory authorities, the potential market for the subject product candidate, the costs and complexities of manufacturing and delivering such product candidate to patients, the potential of competing drugs, the existence of uncertainty with respect to our ownership of intellectual property and industry and market conditions generally. The potential collaborator may also consider alternative product candidates or technologies for similar indications that may be available to collaborate on and whether such collaboration could be more attractive than the one with us for our product candidate. Further, we may not be successful in our efforts to establish a collaboration or other alternative arrangements for future product candidates because they may be deemed to be at too early of a stage of development for collaborative effort and third parties may not view them as having the requisite potential to demonstrate safety and efficacy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;">In addition, there have been a significant number of recent business combinations among large biopharmaceutical companies that have resulted in a reduced number of potential future collaborators. Even if we are successful in entering into a collaboration, the terms and conditions of that collaboration may restrict us from entering into future agreements on certain terms with potential collaborators.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;">If and when we seek to enter into collaborations, we may not be able to negotiate collaborations on a timely basis, on acceptable terms, or at all. If we are unable to do so, we may have to curtail the development of a product candidate, reduce or delay its development program or one or more of our other development programs, delay its potential commercialization or reduce the scope of any sales or marketing activities, or increase our expenditures and undertake development or </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">79</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;">commercialization activities at our own expense. If we elect to increase our expenditures to fund development or commercialization activities on our own, we may need to obtain additional capital, which may not be available to us on acceptable terms or at all. If we do not have sufficient funds, we may not be able to further develop our product candidates or bring them to market and generate product revenue.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;">We may enter into collaborations in the future with third parties for the development and commercialization of product candidates. If those collaborations are not successful, we may not be able to capitalize on the market potential of these product candidates.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;">We may seek third-party collaborators in the future for the development and commercialization of one or more of our product candidates. Our likely collaborators for any future collaboration arrangements include large and mid-size pharmaceutical companies, regional and national pharmaceutical companies and biotechnology companies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;">We will likely have limited control over the amount and timing of resources that our collaborators dedicate to the development or commercialization of our product candidates. Our ability to generate revenues from these arrangements will depend on our collaborators&#8217; abilities and efforts to successfully perform the functions assigned to them in these arrangements. Collaborations involving our product candidates could pose numerous risks to us, including the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">&#8226; collaborators have significant discretion in determining the efforts and resources that they will apply to these collaborations and may not perform their obligations as expected;</p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">&#8226; collaborators may deemphasize or not pursue development and commercialization of our product candidates or may elect not to continue or renew development or commercialization programs based on clinical trial results, changes in the collaborators&#8217; strategic focus, including as a result of a sale or disposition of a business unit or development function, or available funding or external factors such as an acquisition that diverts resources or creates competing priorities;</p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">&#8226; collaborators may delay clinical trials, provide insufficient funding for a clinical trial program, stop a clinical trial or abandon a product candidate, repeat or conduct new clinical trials or require a new formulation of a product candidate for clinical testing;</p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">&#8226; collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with our product candidates if the collaborators believe that competitive products are more likely to be successfully developed or can be commercialized under terms that are more economically attractive than ours;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">&#8226; a collaborator with marketing and distribution rights to multiple products may not commit sufficient resources to the marketing and distribution of our product relative to other products;</p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">&#8226; collaborators may not properly obtain, maintain, defend or enforce our intellectual property rights or may use our proprietary information and intellectual property in such a way as to invite litigation or other intellectual property related proceedings that could jeopardize or invalidate our proprietary information and intellectual property or expose us to potential litigation or other intellectual property related proceedings;</p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">&#8226; disputes may arise between the collaborators and us that result in the delay or termination of the research, development or commercialization of our product candidates or that result in costly litigation or arbitration that diverts management attention and resources;</p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">&#8226; collaborations may be terminated and, if terminated, may result in a need for additional capital to pursue further development or commercialization of the applicable product candidates;</p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">&#8226; collaboration agreements may not lead to development or commercialization of product candidates in the most efficient manner or at all; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">80</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">&#8226; if a collaborator of ours were to be involved in a business combination, the continued pursuit and emphasis on our drug development or commercialization program could be delayed, diminished or terminated.</p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Our employees, independent contractors, consultants, commercial collaborators, principal investigators, CROs, suppliers and vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;">We are exposed to the risk that our employees, independent contractors, consultants, commercial collaborators, principal investigators, CROs, suppliers and vendors may engage in misconduct or other improper activities. Misconduct by these parties could include failures to comply with FDA regulations, provide accurate information to the FDA, comply with federal and state health care fraud and abuse and compliance laws and regulations, accurately report financial information or data or disclose unauthorized activities to us. In particular, sales, marketing and business arrangements in the health care industry are subject to extensive laws and regulations intended to prevent fraud, submission of false claims, misconduct, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting/rebating, marketing and promotion, consulting, sales commission, customer incentive programs and other business arrangements. Misconduct by these parties could also involve the improper use of information obtained in the course of clinical trials, which could result in regulatory sanctions and serious harm to our reputation. It is not always possible to identify and deter misconduct by these parties, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with these laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of significant penalties, including civil, criminal and administrative penalties, damages, fines, disgorgement, individual imprisonment, exclusion from participation in government funded healthcare programs, such as Medicare and Medicaid, integrity oversight and reporting obligations, contractual damages, reputational harm, diminished profits and future earnings and the curtailment or restructuring of our operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><b style="font-weight:bold;">Risks Related to Manufacturing</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;">The manufacture of drugs is complex and our third-party manufacturers may encounter difficulties in production. If any of our third-party manufacturers encounter such difficulties, our ability to provide adequate supply of our product candidates for clinical trials or our products for patients, if approved, could be delayed or prevented.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;">Manufacturing drugs, especially in large quantities, is complex and may require the use of innovative technologies. Each lot of an approved drug product must undergo thorough testing for identity, strength, quality, purity and potency. Manufacturing drugs requires facilities specifically designed for and validated for this purpose, and sophisticated quality assurance and quality control procedures are necessary. Slight deviations anywhere in the manufacturing process, including filling, labeling, packaging, storage and shipping and quality control and testing, may result in lot failures, product recalls or spoilage. When changes are made to the manufacturing process, we may be required to provide preclinical and clinical data showing the comparable identity, strength, quality, purity or potency of the products before and after such changes. If microbial, viral or other contaminations are discovered at the facilities of our manufacturer, such facilities may need to be closed for an extended period of time to investigate and remedy the contamination, which could delay clinical trials and adversely harm our business. The use of biologically derived ingredients can also lead to allegations of harm, including infections or allergic reactions, or closure of product facilities due to possible contamination. If our manufacturers are unable to produce sufficient quantities for clinical trials or for commercialization as a result of these challenges, or otherwise, our development and commercialization efforts would be impaired, which would have an adverse effect on our business, financial condition, results of operations and growth prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">81</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;">We contract with third parties for the manufacture of our product candidates for preclinical studies, and expect to continue to do so for clinical trials and ultimately, for commercialization of any approved product candidate. This reliance on third parties increases the risk that we will not have sufficient quantities of our product candidates or drugs or such quantities at an acceptable cost, which could delay, prevent or impair our development or commercialization efforts.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">We do not currently have the infrastructure or internal capability to manufacture supplies of our product candidates for use in development and commercialization. We rely, and expect to continue to rely, on third-party manufacturers for the production of our product candidates for preclinical studies and clinical trials under the guidance of members of our organization. We do not have long-term supply agreements. Furthermore, the raw materials for our product candidates may be sourced, in some cases, from a single-source supplier. If we were to experience an unexpected loss of supply of any of our product candidates or any of our future product candidates for any reason, whether as a result of manufacturing, supply or storage issues or otherwise, we could experience delays, disruptions, suspensions or terminations of, or be required to restart or repeat, any pending or ongoing clinical trials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">We expect to continue to rely on third-party manufacturers for the commercial supply of any of our product candidates for which we obtain marketing approval. We may be unable to maintain or establish required agreements with third-party manufacturers or to do so on acceptable terms. Even if we are able to establish agreements with third-party manufacturers, reliance on third-party manufacturers entails additional risks, including:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">&#8226; the failure of the third party to manufacture our product candidates according to our schedule, or at all, including if our third-party contractors give greater priority to the supply of other products over our product candidates or otherwise do not satisfactorily perform according to the terms of the agreements between us and them;</p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">&#8226; the reduction or termination of production or deliveries by suppliers, or the raising of prices or renegotiation of terms;</p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">&#8226; the termination or nonrenewal of arrangements or agreements by our third-party contractors at a time that is costly or inconvenient for us;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;">&#8226; the breach by the third-party contractors of our agreements with them;</p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;">&#8226; the failure of third-party contractors to comply with applicable regulatory requirements;</p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;">&#8226; the failure of the third party to manufacture our product candidates according to our specifications;</p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">&#8226; the mislabeling of clinical supplies, potentially resulting in the wrong dose amounts being supplied or active drug or placebo not being properly identified;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt 0pt 6pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt 0pt 6pt 0pt;">&#8226; clinical supplies not being delivered to clinical sites on time, leading to clinical trial interruptions, or of drug supplies not being distributed to commercial vendors in a timely manner, resulting in lost sales; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;">&#8226; the misappropriation of our proprietary information, including our trade secrets and know-how.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;">We do not have complete control over all aspects of the manufacturing process of, and are dependent on, our contract manufacturing partners for compliance with cGMP regulations for manufacturing both active drug substances and finished drug products. Third-party manufacturers may not be able to comply with cGMP regulations or similar regulatory requirements outside of the United States. If our contract manufacturers cannot successfully manufacture material that conforms to our specifications and the strict regulatory requirements of the FDA or others, they will not be able to secure and/or maintain marketing approval for their manufacturing facilities. In addition, we do not have control over the ability of our contract manufacturers to maintain adequate quality control, quality assurance and qualified personnel. If the FDA or a comparable foreign regulatory authority does not approve these facilities for the manufacture of our product candidates or if it withdraws any such approval in the future, we may need to find alternative manufacturing facilities, which would </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">82</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;">significantly impact our ability to develop, obtain marketing approval for or market our product candidates, if approved. Our failure, or the failure of our third-party manufacturers, to comply with applicable regulations could result in sanctions being imposed on us, including fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, license revocation, seizures or recalls of product candidates or drugs, operating restrictions and criminal prosecutions, any of which could significantly and adversely affect supplies of our product candidates or drugs and harm our business and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;">In the event that any of our manufacturers fails to comply with such requirements or to perform its obligations to us in relation to quality, timing or otherwise, or if our supply of components or other materials becomes limited or interrupted for other reasons, including due to the impact of the pandemic related to COVID-19 and its variants, we may be forced to manufacture the materials ourselves, for which we currently do not have the capabilities or resources, or enter into an agreement with another third-party, which we may not be able to do on commercially reasonable terms, if at all. In particular, any replacement of our manufacturers could require significant effort and expertise because there may be a limited number of qualified replacements. In some cases, the technical skills or technology required to manufacture our product candidates may be unique or proprietary to the original manufacturer and we may have difficulty transferring such skills or technology to another third-party and a feasible alternative may not exist. In addition, certain of our product candidates and our own proprietary methods have never been produced or implemented outside of our company, and we may therefore experience delays to our development programs if and when we attempt to establish new third-party manufacturing arrangements for these product candidates or methods. These factors would increase our reliance on such manufacturer or require us to obtain a license from such manufacturer in order to have another third-party manufacture our product candidates. If we are required to or voluntarily change manufacturers for any reason, we will be required to verify that the new manufacturer maintains facilities and procedures that comply with quality standards and with all applicable regulations and guidelines and that the product produced is equivalent to that produced in a prior facility. The delays associated with the verification of a new manufacturer and equivalent product could negatively affect our ability to develop product candidates in a timely manner or within budget.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;">Our or a third-party&#8217;s failure to execute on our manufacturing requirements, do so on commercially reasonable terms and timelines and comply with cGMP requirements could adversely affect our business in a number of ways, including:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;">&#8226; inability to meet our product specifications and quality requirements consistently;</p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;">&#8226; inability to initiate or continue clinical trials of our product candidates under development;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">&#8226; delays in submitting regulatory applications, or receiving marketing approvals, for our product candidates, if at all;</p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;">&#8226; inability to commercialize any product candidates that receive marketing approval on a timely basis;</p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;"><span style="font-size:10pt;">&#8226; </span><span style="white-space:pre-wrap;">  </span><span style="font-size:10pt;">loss of the cooperation of future collaborators;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">&#8226; subjecting third-party manufacturing facilities or our manufacturing facilities to additional inspections by regulatory authorities;<b style="font-weight:bold;">&#160;</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;">&#8226; requirements to cease development or to recall batches of our product candidates;</p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">&#8226; in the event of approval to market and commercialize our product candidates, an inability to meet commercial demands for our product or any other future product candidates; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;">&#8226; our future profit margins.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">83</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Changes in methods of product candidate manufacturing or formulation may result in additional costs or delay.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">As product candidates progress through preclinical and clinical trials to marketing approval and commercialization, it is common that various aspects of the development program, such as manufacturing methods and formulation, are altered along the way in an effort to optimize yield and manufacturing batch size, minimize costs and achieve consistent quality and results. Such changes carry the risk that they will not achieve these intended objectives. Any of these changes could cause our product candidates to perform differently and affect the results of planned clinical trials or other future clinical trials conducted with the altered materials. This could delay completion of clinical trials, require the conduct of bridging clinical trials or the repetition of one or more clinical trials, increase clinical trial costs, delay approval of our product candidates and jeopardize our ability to commercialize our product candidates, if approved, and generate revenue.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><b style="font-weight:bold;">Risks Related to Legal and Regulatory Compliance Matters</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Our relationships with healthcare professionals, clinical investigators, CROs and third party payors in connection with our current and future business activities may be subject to federal and state healthcare fraud and abuse laws, false claims laws, transparency laws, and government price reporting, which could expose us to, among other things, criminal sanctions, civil penalties, contractual damages, exclusion from governmental healthcare programs, reputational harm, administrative burdens and diminished profits and future earnings.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">Healthcare providers and third-party payors play a primary role in the recommendation and prescription of any product candidates for which we obtain marketing approval. Our current and future arrangements with healthcare professionals, clinical investigators, CROs, third-party payors and customers may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations that may constrain the business or financial arrangements and relationships through which we market, sell and distribute our products for which we obtain marketing approval. Restrictions under applicable federal and state healthcare laws and regulations include, among others, the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">&#8226; the federal Anti-Kickback Statute, which prohibits, among other things, persons and entities from knowingly and willfully soliciting, offering, receiving or providing remuneration, directly or indirectly, in cash or in kind, to induce or reward, or in return for, either the referral of an individual for, or the purchase, order or recommendation of, any good or service, for which payment may be made under a federal healthcare program such as Medicare and Medicaid. The term &#8220;remuneration&#8221; has been broadly interpreted to include anything of value. A person or entity does not need to have actual knowledge of the federal Anti-Kickback Statute or specific intent to violate it in order to have committed a violation;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">&#8226; the federal false claims laws, including the civil False Claims Act, which can be enforced by private citizens through civil whistleblower or qui tam actions, and civil monetary penalties laws, prohibit individuals or entities from, among other things, knowingly presenting, or causing to be presented, to the federal government, claims for payment that are false or fraudulent or making a false statement to avoid, decrease or conceal an obligation to pay money to the federal government, with potential liability including mandatory treble damages and significant per claim penalties per false claim or statement. In addition, the government may assert that a claim including items or services resulting from a violation of the U.S. federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the civil False Claims Act;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">&#8226; the federal Criminal Statute on False Statements Relating to Healthcare Matters, which makes it a crime to knowingly and willfully falsify, conceal, or cover up a material fact, make any materially false, fictitious, or fraudulent statements or representations, or make or use any materially false writing or document knowing the same to contain any materially false, fictitious, or fraudulent statement or entry in connection with the delivery of or payment for healthcare benefits, items, or services;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">&#8226; the federal Civil Monetary Penalties Law, which authorizes the imposition of substantial civil monetary penalties against an entity, such as a pharmaceutical manufacturer, that engages in activities including, among others (1)&#160;knowingly presenting, or causing to be presented, a claim for services not provided as claimed or that is otherwise false or fraudulent in any way; (2)&#160;arranging for or contracting with an individual or entity that is excluded from participation in federal </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">84</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">healthcare programs to provide items or services reimbursable by a federal healthcare program; (3)&#160;violations of the federal Anti-Kickback Statute; or (4)&#160;failing to report and return a known overpayment;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">&#8226; the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, prohibits, among other things, executing or attempting to execute a scheme to defraud any healthcare benefit program or making false statements relating to healthcare matters. Similar to the federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">&#8226; the federal Physician Payments Sunshine Act requires applicable manufacturers of covered drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program, with specific exceptions, to annually report to the Centers for Medicare and Medicaid Services, or CMS, information regarding payments and other transfers of value to physicians (as defined by statute), certain other healthcare providers starting in 2022 and teaching hospitals, as well as information regarding ownership and investment interests held by physicians and their immediate family members. The information reported is publicly available on a searchable website, with disclosure required annually;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">&#8226; analogous state and foreign laws and regulations, such as state anti-kickback and false claims laws, may apply to sales or marketing arrangements and claims involving healthcare items or services reimbursed by non-governmental third-party payors, including private insurers; some state laws require biotechnology companies to comply with the biotechnology industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government and may require drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">&#8226; some state laws require biotechnology companies to report information to state agencies and/or commercial purchasers on the pricing of certain drug products that exceed a certain level as identified in the relevant statute. Some of these laws and regulations contain ambiguous requirements that government officials have not yet clarified. Given the lack of clarity in the laws and their implementation, our reporting actions could be subject to the penalty provisions of the pertinent federal and state laws and regulations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;<span style="font-size:10pt;">Efforts to ensure that our current and future business arrangements with third parties will comply with applicable healthcare laws and regulations will involve on-going substantial costs. It is possible that governmental authorities will conclude that our business practices, including our arrangements with physicians, some of whom have ownership interests in us, may not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant penalties, including civil, criminal and administrative penalties, damages, fines, disgorgement, individual imprisonment, exclusion from participation in government funded healthcare programs, such as Medicare and Medicaid, integrity oversight and reporting obligations, contractual damages, reputational harm, diminished profits and future earnings and the curtailment or restructuring of our operations. Defending against any such actions can be costly, time-consuming and may require significant financial and personnel resources. Therefore, even if we are successful in defending against any such actions that may be brought against us, our business may be impaired. Further, if any of the physicians or other healthcare providers or entities with whom we expect to do business is found to be not in compliance with applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Actual or perceived failures to comply with applicable data protection, privacy and security laws, regulations, standards and other requirements could adversely affect our business, results of operations, and financial condition.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;">The global data protection landscape is rapidly evolving, and we are or may become subject to numerous state, federal and foreign laws, requirements and regulations governing the collection, use, disclosure, retention, and security of personal information, such as information that we may collect in connection with clinical trials in the U.S. and abroad. Implementation standards and enforcement practices are likely to remain uncertain for the foreseeable future, and we cannot yet determine the impact future laws, regulations, standards, or perception of their requirements may have on our business. This evolution may create uncertainty in our business, affect our ability to operate in certain jurisdictions or to </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">85</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;">collect, store, transfer use and share personal information, necessitate the acceptance of more onerous obligations in our contracts, result in liability or impose additional costs on us. The cost of compliance with these laws, regulations and standards is high and is likely to increase in the future. Any failure or perceived failure by us to comply with federal, state or foreign laws or regulations, our internal policies and procedures or our contracts governing our processing of personal information could result in negative publicity, government investigations and enforcement actions, claims by third parties and damage to our reputation, any of which could have a material adverse effect on our business, results of operation, and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;">As our operations and business grow, we may become subject to or affected by new or additional data protection laws and regulations and face increased scrutiny or attention from regulatory authorities. For instance, in the U.S., most healthcare providers, including research institutions from which we may obtain patient health information, are subject to privacy and security regulations promulgated under HIPAA, as amended. We are not currently acting as a covered entity or business associate under HIPAA and thus are not subject to its requirements. However, any person may be prosecuted under HIPAA&#8217;s criminal provisions either directly or under aiding-and-abetting or conspiracy principles. Consequently, depending on the facts and circumstances, we could face substantial criminal penalties if we knowingly receive individually identifiable health information from a HIPAA-covered healthcare provider or research institution that has not satisfied HIPAA&#8217;s requirements for disclosure of individually identifiable health information. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;">We are also or may become subject to rapidly evolving data protection laws, rules and regulations in foreign jurisdictions. For example, the European Union General Data Protection Regulation, or the GDPR, governs certain collection and other processing activities involving personal data about individuals in the EEA. Among other things, the GDPR imposes requirements regarding the security of personal data, the rights of data subjects to access and delete personal data, requires having lawful bases on which personal data can be processed, includes requirements relating to the consent of individuals to whom the personal data relates, requires detailed notices for clinical trial participants and investigators and regulates transfers of personal data from the EEA to third countries that have not been found to provide adequate protection to such personal data, including the United States. In addition, the GDPR imposes substantial fines for breaches and violations (up to the greater of &#8364;20 million or 4% of our annual global revenue). The GDPR also confers a private right of action on data subjects and consumer associations to lodge complaints with supervisory authorities, seek judicial remedies and obtain compensation for damages resulting from violations of the GDPR. Further, from January 1, 2021, companies have to comply with the GDPR and also the UK GDPR, which, together with the amended UK Data Protection Act 2018, retains the GDPR in UK national law. The UK GDPR mirrors the fines under the GDPR, e.g. fines up to the greater of &#8364;20 million (&#163;17.5 million) or 4% of global turnover. The European Commission has adopted an adequacy decision in favor of the UK, enabling data transfers from EU member states to the UK without additional safeguards. However, the UK adequacy decision will automatically expire in June 2025 unless the European Commission re-assesses and renews/extends that decision, and remains under review by the Commission during this period. The relationship between the UK and the EU in relation to certain aspects of data protection law remains unclear, and it is unclear how UK data protection laws and regulations will develop in the medium to longer term, and how data transfers to and from the UK will be regulated in the long term. These changes may lead to additional costs and increase our overall risk exposure. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;">If we or third-party contract manufacturing organizations, or CMOs, CROs or other contractors or consultants fail to comply with applicable federal, state or local regulatory requirements, we could be subject to a range of regulatory actions that could affect our or our contractors&#8217; ability to develop and commercialize our product candidates and could harm or prevent sales of any affected products that we are able to commercialize, or could substantially increase the costs and expenses of developing, commercializing and marketing our products. Any threatened or actual government enforcement action could also generate adverse publicity and require that we devote substantial resources that could otherwise be used in other aspects of our business. Increasing use of social media could give rise to liability, breaches of data security or reputational damage.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">86</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Our business entails a significant risk of product liability and if we are unable to obtain sufficient insurance coverage such inability could have an adverse effect on our business and financial condition.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;">Our business exposes us to significant product liability risks inherent in the development, testing, manufacturing and marketing of therapeutic treatments. Product liability claims could delay or prevent completion of our development programs. If we succeed in marketing products, such claims could result in an FDA or other regulatory authority investigation of the safety and effectiveness of our products, our manufacturing processes and facilities or our marketing programs. FDA or other regulatory authority investigations could potentially lead to a recall of our products or more serious enforcement action, limitations on the approved indications for which they may be used or suspension or withdrawal of approvals. Regardless of the merits or eventual outcome, liability claims may also result in decreased demand for our products, injury to our reputation, costs to defend the related litigation, a diversion of management&#8217;s time and our resources and substantial monetary awards to trial participants or patients. We currently have insurance that we believe is appropriate for our stage of development and may need to obtain higher levels prior to marketing any of our product candidates, if approved. Any insurance we have or may obtain may not provide sufficient coverage against potential liabilities. Furthermore, clinical trial and product liability insurance is becoming increasingly expensive. As a result, we may be unable to obtain sufficient insurance at a reasonable cost to protect us against losses caused by product liability claims that could have an adverse effect on our business and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Any product candidates we develop may become subject to unfavorable third-party coverage and reimbursement practices, as well as pricing regulations.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;">The availability and extent of coverage and adequate reimbursement by third-party payors, including government health administration authorities, private health coverage insurers, managed care organizations and other third-party payors is essential for most patients to be able to afford expensive treatments. Sales of any of our product candidates that receive marketing approval will depend substantially, both in the United States and internationally, on the extent to which the costs of our product candidates will be covered and reimbursed by third-party payors. If reimbursement is not available, or is available only to limited levels, we may not be able to successfully commercialize our product candidates. Even if coverage is provided, the approved reimbursement amount may not be high enough to allow us to establish or maintain pricing sufficient to realize an adequate return on our investment. Coverage and reimbursement may impact the demand for, or the price of, any product candidate for which we obtain marketing approval. If coverage and reimbursement are not available or reimbursement is available only to limited levels, we may not successfully commercialize any product candidate for which we obtain marketing approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;">There is significant uncertainty related to third-party payor coverage and reimbursement of newly approved products. In the United States, no uniform policy of coverage and reimbursement for products exists among third-party payors and coverage and reimbursement levels for products can differ significantly from payor to payor. The Medicare and Medicaid programs increasingly are used as models for how private payors and other governmental payors develop their coverage and reimbursement policies for drugs and biologics. However, one third-party payor&#8217;s determination to provide coverage for a product candidate does not assure that other payors will also provide coverage for the product candidate. As a result, the coverage determination process is often time-consuming and costly. This process will require us to provide scientific and clinical support for the use of our products to each third-party payor separately, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;">Increasingly, third-party payors are requiring that drug companies provide them with predetermined discounts from list prices and are challenging the prices charged for medical products. Further, such payors are increasingly challenging the price, examining the medical necessity and reviewing the cost effectiveness of medical product candidates. There may be especially significant delays in obtaining coverage and reimbursement for newly approved drugs. Third-party payors may limit coverage to specific product candidates on an approved list, known as a formulary, which might not include all FDA-approved drugs for a particular indication. We may need to conduct expensive pharmacoeconomic studies to demonstrate the medical necessity and cost effectiveness of our products. Nonetheless, our product candidates may not be considered medically necessary or cost effective. We cannot be sure that coverage and reimbursement will be available for any product that we commercialize and, if reimbursement is available, what the level of reimbursement will be.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">87</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;">Outside the United States, international operations are generally subject to extensive governmental price controls and other market regulations, and we believe the increasing emphasis on cost containment initiatives in Europe, Canada and other countries has and will continue to put pressure on the pricing and usage of therapeutics such as our product candidates. In many countries, particularly the countries of the European Union, medical product prices are subject to varying price control mechanisms as part of national health systems. In these countries, pricing negotiations with governmental authorities can take considerable time after a product receives marketing approval. To obtain reimbursement or pricing approval in some countries, we may be required to conduct a clinical trial that compares the cost-effectiveness of our product candidate to other available therapies. In general, product prices under such systems are substantially lower than in the United States. Other countries allow companies to fix their own prices for products, but monitor and control company profits. Additional foreign price controls or other changes in pricing regulation could restrict the amount that we are able to charge for our product candidates. Accordingly, in markets outside the United States, the reimbursement for our products may be reduced compared with the United States and may be insufficient to generate commercially reasonable revenue and profits.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;">If we are unable to establish or sustain coverage and adequate reimbursement for any future product candidates from third-party payors, the adoption of those products and sales revenue will be adversely affected, which, in turn, could adversely affect the ability to market or sell those product candidates, if approved. Coverage policies and third-party payor reimbursement rates may change at any time. Even if favorable coverage and reimbursement status is attained for one or more products for which we receive regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in the future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;">If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on our business.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;">We are subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. Our operations in the future may involve the use of hazardous and flammable materials, including chemicals and biological materials. Our operations in the future may also produce hazardous waste products. In the future, we may generally contract with third parties for the disposal of these materials and wastes. We cannot eliminate the risk of contamination or injury from these materials. In the event of contamination or injury resulting from our use of hazardous materials, we could be held liable for any resulting damages, and any liability could exceed our resources. We also could incur significant costs associated with civil or criminal fines and penalties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;">Although we will maintain workers&#8217; compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees resulting from the potential use of hazardous materials in the future, this insurance may not provide adequate coverage against potential liabilities. We do not maintain insurance for environmental liability or toxic tort claims that may be asserted against us in connection with our storage or disposal of hazardous and flammable materials, including chemicals and biological materials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;">In addition, we may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations. These current or future laws and regulations may impair our research, development or commercialization efforts. Failure to comply with these laws and regulations also may result in substantial fines, penalties or other sanctions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;">The FDA or other comparable foreign regulatory authorities may not accept data from trials conducted in locations outside of their jurisdiction.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;">We may choose to conduct international clinical trials in the future. The acceptance of study data from clinical trials conducted outside the U.S. or another jurisdiction by the FDA or comparable foreign regulatory authority may be subject to certain conditions or may not be accepted at all. In cases where data from foreign clinical trials are intended to serve as the sole basis for marketing approval in the U.S., the FDA will generally not approve the application on the basis of foreign data alone unless (i) the data are applicable to the U.S. population and U.S. medical practice; (ii) the trials were performed by clinical investigators of recognized competence and pursuant to GCP regulations; and (iii) the data may be considered valid without the need for an on-site inspection by the FDA, or if the FDA considers such inspection to be necessary, the FDA is able to validate the data through an on-site inspection or other appropriate means. In addition, even where the </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">88</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;">foreign study data are not intended to serve as the sole basis for approval, the FDA will not accept the data as support for an application for marketing approval unless the study is well-designed and well-conducted in accordance with GCP requirements and the FDA is able to validate the data from the study through an onsite inspection if deemed necessary. &#160;Many foreign regulatory authorities have similar approval requirements. In addition, such foreign trials would be subject to the applicable local laws of the foreign jurisdictions where the trials are conducted. There can be no assurance that the FDA or any comparable foreign regulatory authority will accept data from trials conducted outside of the U.S. or the applicable jurisdiction. If the FDA or any comparable foreign regulatory authority does not accept such data, it would result in the need for additional trials, which could be costly and time-consuming, and which may result in current or future product candidates that we may develop not receiving approval for commercialization in the applicable jurisdiction. If the FDA or any other comparable foreign regulatory authority does not accept such data, it would result in the need for additional trials, which would be costly and time-consuming and delay aspects of our business plan, and which may result in our product candidates not receiving approval for commercialization in the applicable jurisdiction.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Obtaining and maintaining regulatory approval of our product candidates in one jurisdiction does not mean that we will be successful in obtaining regulatory approval of our product candidates in other jurisdictions.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;">Obtaining and maintaining regulatory approval of our product candidates in one jurisdiction does not guarantee that we will be able to obtain or maintain regulatory approval in any other jurisdiction. For example, even if the FDA grants marketing approval of a product candidate, comparable regulatory authorities in foreign jurisdictions must also approve the manufacturing, marketing and promotion and reimbursement of the product candidate in those countries. However, a failure or delay in obtaining regulatory approval in one jurisdiction may have a negative effect on the regulatory approval process in others. Approval procedures vary among jurisdictions and can involve requirements and administrative review periods different from those in the United States, including additional preclinical studies or clinical trials as clinical trials conducted in one jurisdiction may not be accepted by regulatory authorities in other jurisdictions. In many jurisdictions outside the United States, a product candidate must be approved for reimbursement before it can be approved for sale in that jurisdiction. In some cases, the price that we intend to charge for our products is also subject to approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;">Obtaining foreign regulatory approvals and establishing and maintaining compliance with foreign regulatory requirements could result in significant delays, difficulties and costs for us and could delay or prevent the introduction of our products in certain countries. If we or any future collaborator fail to comply with the regulatory requirements in international markets or fail to receive applicable marketing approvals, our target market will be reduced and our ability to realize the full market potential of our product candidates will be harmed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Even if our product candidates receive regulatory approval, they will be subject to significant post-marketing regulatory requirements and oversight.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;">Any regulatory approvals that we may receive for our product candidates will require the submission of reports to regulatory authorities and surveillance to monitor the safety and efficacy of the product candidate, may contain significant limitations related to use restrictions for specified age groups, warnings, precautions or contraindications, and may include burdensome post-approval study or risk management requirements. For example, the FDA may require a REMS in order to approve our product candidates, which could entail requirements for a medication guide, physician training and communication plans or additional elements to ensure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. In addition, if the FDA or foreign regulatory authorities approve our product candidates, the manufacturing processes, labeling, packaging, distribution, adverse event reporting, storage, advertising, promotion, import, export and recordkeeping for our product candidates will be subject to extensive and ongoing regulatory requirements. These requirements include submissions of safety and other post-marketing information and reports, registration, as well as on-going compliance with cGMPs and GCP for any clinical trials that we conduct post-approval. In addition, manufacturers of drug products and their facilities are subject to continual review and periodic, unannounced inspections by the FDA and other regulatory authorities for compliance with cGMP regulations and standards. If we or a regulatory agency discover previously unknown problems with a product, such as adverse events of unanticipated severity or frequency, or problems with the facilities where the product is manufactured, a regulatory agency may impose restrictions on that product, the manufacturing facility or us, including requiring recall or withdrawal of the product from </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">89</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;">the market or suspension of manufacturing. In addition, failure to comply with FDA and other comparable foreign regulatory authority requirements may subject our company to administrative or judicially imposed sanctions, including:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;">&#8226; delays in or the rejection of product approvals;</p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">&#8226; restrictions on our ability to conduct clinical trials, including full or partial clinical holds on ongoing or planned trials;</p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;">&#8226; restrictions on the products, manufacturers or manufacturing process;</p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;">&#8226; warning or untitled letters;</p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;">&#8226; civil and criminal penalties;</p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;">&#8226; injunctions;</p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;">&#8226; suspension or withdrawal of regulatory approvals;</p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;">&#8226; product seizures, detentions or import bans;</p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;">&#8226; voluntary or mandatory product recalls and publicity requirements;</p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;">&#8226; total or partial suspension of production; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;">&#8226; imposition of restrictions on operations, including costly new manufacturing requirements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">The occurrence of any event or penalty described above may inhibit our ability to commercialize our product candidates and generate revenue and could require us to expend significant time and resources in response and could generate negative publicity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">The FDA&#8217;s and other regulatory authorities&#8217; policies may change, and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our product candidates. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained, and we may not achieve or sustain profitability.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">We also cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative or executive action, either in the United States or abroad. We currently have a limited set of compliance policies and personnel, and intend to develop our compliance infrastructure in the future, as our clinical development programs progress. Developing a compliance infrastructure is costly and time-consuming, and even a well-designed and implemented compliance program cannot necessarily prevent all violations of relevant laws. Any government investigation of alleged violations of law could require us to expend significant time and resources in response and could generate negative publicity. Any failure to comply with ongoing regulatory requirements may significantly and adversely affect our ability to commercialize and generate revenue from our product candidates, if approved. If regulatory sanctions are applied or if regulatory approval is withdrawn, the value of our company and our operating results will be adversely affected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;">The FDA and other regulatory agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">If any of our product candidates are approved and we are found to have improperly promoted off-label uses of those products, we may become subject to significant liability. The FDA and other regulatory agencies strictly regulate the promotional claims that may be made about prescription products, such as our product candidates, if approved. In </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">90</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="font-size:10pt;">particular, a product may not be promoted for uses that are not approved by the FDA or such other regulatory agencies as reflected in the product&#8217;s approved labeling. If we receive marketing approval for a product candidate, physicians may nevertheless prescribe it to their patients in a manner that is inconsistent with the approved label. If we are found to have promoted such off-label uses, we may become subject to significant liability. The U.S. federal government has levied large civil and criminal fines against companies for alleged improper promotion of off-label use and has enjoined several companies from engaging in off-label promotion. The government has also required companies to enter into consent decrees or imposed permanent injunctions under which specified promotional conduct is changed or curtailed. If we cannot</span><span style="font-family:'Calibri','Helvetica','sans-serif';"> </span><span style="font-size:10pt;">successfully manage the promotion of our product candidates, if approved, we could become subject to significant liability, which would materially adversely affect our business and financial condition.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Disruptions at the FDA, the SEC and other government agencies caused by funding shortages or global health concerns could hinder their ability to hire and retain key leadership and other personnel, prevent new products and services from being developed or commercialized in a timely manner or otherwise prevent those agencies from performing normal business functions on which the operation of our business may rely, which could negatively impact our business.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;">The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel and accept the payment of user fees, and statutory, regulatory, and policy changes. Average review times at the FDA have fluctuated in recent&#160;years as a result. In addition, government funding of the Securities and Exchange Commission, or the SEC, and other government agencies on which our operations may rely, including those that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;">Disruptions at the FDA and other agencies may also slow the time necessary for new drugs to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. For example, in recent&#160;years, the U.S. government shut down several times and certain regulatory agencies, such as the FDA and the SEC, had to furlough critical employees and stop critical activities. If a prolonged government shutdown occurs, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business. Further, as a public company, future government shutdowns could impact our ability to further access the public markets and obtain necessary capital in order to properly capitalize and continue our operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;">Separately, in response to the COVID-19 pandemic, in March 2020, the FDA announced its intention to postpone most inspections of foreign manufacturing facilities, and on March 18, 2020, the FDA temporarily postponed routine surveillance inspections of domestic manufacturing facilities. Subsequently, in July 2020, the FDA resumed certain on-site inspections of domestic manufacturing facilities subject to a risk-based prioritization system. The FDA utilized this risk-based assessment system to assist in determining when and where it was safest to conduct prioritized domestic inspections. Additionally, on April 15, 2021, the FDA issued a guidance document in which the FDA described its plans to conduct voluntary remote interactive evaluations of certain drug manufacturing facilities and clinical research sites, among other facilities. According to the guidance, the FDA may request such remote interactive evaluations where the FDA determines that &#160;remote evaluation would be appropriate based on mission needs and travel limitations. In May 2021, the FDA outlined a detailed plan to move toward a more consistent state of inspectional operations, and in July 2021, the FDA resumed standard inspectional operations of domestic facilities and was continuing to maintain this level of operation as of September 2021. More recently, the FDA has continued to monitor and implement changes to its inspectional activities to ensure the safety of its employees and those of the firms it regulates as it adapts to the evolving COVID-19 pandemic Regulatory authorities outside the United States may adopt similar restrictions or other policy measures in response to the pandemic related to COVID-19 and its variants. If a prolonged government shutdown occurs, or if global health concerns continue to prevent the FDA or other regulatory authorities from conducting their regular inspections, reviews, or other regulatory activities, it could significantly impact the ability of the FDA or other regulatory authorities to timely review and process our regulatory submissions, which could have a material adverse effect on our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;">We may face difficulties from changes to current regulations and future legislation.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;">Existing regulatory policies may change and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our product candidates. We cannot predict the likelihood, nature or extent of government </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">91</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;">regulation that may arise from future legislation or administrative action, either in the United States or abroad. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained and we may not achieve or sustain profitability.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;">For example, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, collectively referred to as the ACA, was passed, which substantially changed the way healthcare is financed by both the government and private insurers, and significantly impacts the U.S. pharmaceutical industry. The ACA, among other things, subjected biologic products to potential competition by lower-cost biosimilars; increased the minimum level of Medicaid rebates payable by manufacturers of brand name drugs from 15.1% to 23.1% of the average manufacturer price; required collection of rebates for drugs paid by Medicaid managed care organizations; imposed a non-deductible annual fee on pharmaceutical manufacturers or importers who sell certain &#8220;branded prescription drugs&#8221; to specified federal government programs; implemented a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted, or injected; expanded eligibility criteria for Medicaid programs; required reporting of certain financial arrangements between manufacturers of biologics, physicians and teaching hospitals under the federal Physician Payments Sunshine Act; expanded the types of entities eligible for the 340B Drug Pricing Program; created a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research; and established a Center for Medicare &amp; Medicaid Innovation at CMS to test innovative payment and service delivery models to lower Medicare and Medicaid spending, potentially including prescription drug spending.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;">Since its enactment, there have been judicial, executive and Congressional challenges to certain aspects of the ACA. On June 17, 2021, the U.S. Supreme Court dismissed the most recent judicial challenge to the ACA brought by several states without specifically ruling on the constitutionality of the ACA. Prior to the Supreme Court&#8217;s decision, President Biden issued an executive order initiating a special enrollment period from February 15, 2021 through August 15, 2021 for purposes of obtaining health insurance coverage through the ACA marketplace. &#160;The executive order also instructed certain governmental agencies to review and reconsider their existing policies and rules that limit access to healthcare</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">In addition, other legislative changes have been proposed and adopted in the United States since the ACA was enacted. These changes included aggregate reductions to Medicare payments to providers of 2% per fiscal year, effective April&#160;1, 2013, which, due to subsequent legislative amendments, will stay in effect through 2030, with the exception of a temporary suspension from May&#160;1, 2020 through March&#160;31, 2022 due to the coronavirus pandemic, unless additional congressional action is taken. In January&#160;2013, the American Taxpayer Relief Act of 2012 was signed into law, which, among other things, reduced Medicare payments to several providers, and increased the statute of limitations period for the government to recover overpayments to providers from three to five&#160;years. These new laws may result in additional reductions in Medicare and other healthcare funding, which could have a material adverse effect on customers for our drugs, if approved, and accordingly, our financial operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">Moreover, there has been heightened governmental scrutiny recently over the manner in which drug manufacturers set prices for their marketed products, which has resulted in several Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drug products. At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;">We expect that other healthcare reform measures that may be adopted in the future may result in more rigorous coverage criteria and in additional downward pressure on the price that we receive for any approved product. Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability or commercialize our product candidates. Further, it is possible that additional governmental action is taken in response to the pandemic related to COVID-19 and its variants.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">92</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><b style="font-weight:bold;">Risks Related to Our Intellectual Property</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;">If we are unable to obtain and maintain patent and other intellectual property protection for our product candidates and technologies or if the scope of the intellectual property protection obtained is not sufficiently broad, our competitors could develop and commercialize products and technology similar or identical to ours, and our ability to successfully commercialize our products and technology may be impaired, and we may not be able to compete effectively in our market.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">We rely upon a combination of patents, trademarks, trade secret protection and confidentiality agreements to protect the intellectual property related to our products and technologies and to prevent third parties from copying and surpassing our achievements, thus eroding our competitive position in our market. Our commercial success depends in part on our ability to obtain and maintain patent, trade secret or other intellectual property protection for our product candidates, proprietary technologies and their uses as well as our ability to operate without infringing the proprietary rights of others. If we are unable to protect our intellectual property rights or if our intellectual property rights are inadequate for our technology or our product candidates, our competitive position could be harmed. We generally seek to protect our proprietary position by filing patent applications in the United States and, in some cases, abroad related to our product candidates, technology platforms and their uses that are important to our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">As of March 3, 2022, we owned one issued patent and pending patent applications, in the United States only, related to our platform technologies, as well as pending patent applications related to our product candidates. We currently do not have any issued patents related to our product candidates. Further, patent prosecution with respect to our pending patent applications related to our product candidates is in the early stages and, as such, no patent examiner has yet scrutinized the merits of such pending patent applications. Our patent applications cannot be enforced against third parties practicing the technology claimed in such applications unless, and until, patents issue from such applications, and then only to the extent the issued claims cover the technology and such third parties practice the technology in countries where such patents have issued. With respect to our issued patent and patent applications related to our platform technology, we filed those applications only in the U.S., so it is possible that a competitor may practice outside the U.S. the aspects of our platform technology disclosed in those patent applications. We maintain other aspects of our platform technology as trade secrets, which were not disclosed in those patent applications. There can be no assurance that any of our current and future issued patents and patent applications, if any, owned by us or our future in-licensed patent applications will result in patents being issued or that issued patents will afford sufficient protection against competitors with similar technology, nor can there be any assurance that the patents if issued will not be infringed, designed around, invalidated or rendered unenforceable by third parties, or would effectively prevent others from commercializing competitive products or technologies. Composition of matter patents for biological and pharmaceutical product candidates often provide a strong form of intellectual property protection for those types of products, as such patents may provide protection without regard to any method of use. We cannot be certain that the claims in our pending patent applications related to composition of matter of our product candidates will be considered patentable by the United States Patent and Trademark Office, or USPTO, or by patent offices in foreign countries, or that the claims in any of our issued patents will be considered valid and enforceable by courts in the United States or foreign countries. Method of use patents protect the use of a product for the specified method. This type of patent does not prevent a competitor from making and marketing a product that is identical to our product for an indication that is outside the scope of the patented method. The patent position of biopharmaceutical companies generally is highly uncertain, involves complex legal and factual questions, and has been the subject of much litigation in recent&#160;years. As a result, the existence, issuance, scope, validity, enforceability and commercial value of our patent rights are highly uncertain.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;">Although we may obtain licenses to issued patents in the United States and foreign countries in the future, we cannot be certain that the claims in future in-licensed U.S. pending patent applications, if any, corresponding international patent applications and patent applications in certain foreign countries will be considered patentable by the USPTO, courts in the United States or by the patent offices and courts in foreign countries, nor can we be certain that the claims in future in-licensed issued patents will not be found invalid or unenforceable if challenged.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">93</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;">The patent application process is subject to numerous risks and uncertainties, and there can be no assurance that we or our licensors or any of our potential future collaborators will be successful in protecting our product candidates by obtaining and defending patents. These risks and uncertainties include the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">&#8226; the USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other provisions during the patent process, the noncompliance with which can result in abandonment or lapse of a patent or patent application, and partial or complete loss of patent rights in the relevant jurisdiction;</p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;">&#8226; patent applications may not result in any patents being issued;</p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">&#8226; patents may be challenged, invalidated, modified, revoked, circumvented, found to be unenforceable or otherwise </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">may not provide any competitive advantage;</p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">&#8226; our competitors, many of whom have substantially greater resources than we or our potential licensors do and many of whom have made significant investments in competing technologies, may seek or may have already obtained patents that will limit, interfere with or block our ability to make, use and sell our product candidates;</p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">&#8226; there may be significant pressure on the U.S. government and international governmental bodies to limit the scope of patent protection both inside and outside the United States for disease treatments that prove successful, as a matter of public policy regarding worldwide health concerns; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">&#8226; countries other than the United States may have patent laws less favorable to patentees than the patent law typically applied by U.S. courts, allowing foreign competitors a better opportunity to create, develop and market competing products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;">The patent prosecution process is also expensive and time-consuming, and we may not be able to file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner or in all jurisdictions where protection may be commercially advantageous. In addition, we may decide to abandon national and regional patent applications before they are granted. The examination of each national or regional patent application is an independent proceeding. As a result, patent applications in the same family may issue as patents in some jurisdictions, such as in the United States, but may issue as patents with claims of different scope or may be refused in other jurisdictions. It is also quite common that depending on the country, the scope of patent protection may vary for the same product or technology. For example, certain jurisdictions do not allow for patent protection with respect to method of treatment. Moreover, the scope of claims in a patent application can be significantly reduced before any claims in a patent are issued, and claim scope can be reinterpreted after issuance. Even if our current or future patent applications issue as patents, they may not issue in a form that will provide us with any meaningful protection, prevent competitors or other third parties from competing with us, or otherwise provide us with any competitive advantage. Consequently, we do not know whether our product candidates will be protectable or remain protected by valid and enforceable patents. Our competitors or other third parties may be able to circumvent our patents by developing similar or alternative technologies or products in a non-infringing manner, which could materially adversely affect our business, financial condition, results of operations and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">It is also possible that we may not identify patentable aspects of our research and development output before it is too late to obtain patent protection. Publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until 18&#160;months after filing, or in some cases not at all. Therefore, we cannot be certain that we were the first to make the inventions claimed in our patents or pending patent applications, or that we were the first to file for patent protection of such inventions. In addition, the USPTO might require that the term of a patent issuing from a pending patent application to be disclaimed and limited to the term of another patent that is commonly owned or names a common inventor. Moreover, in some circumstances, we may not have the right to control the preparation, filing and prosecution of patent applications, or to maintain the patents, directed to technology that we license, including those from our licensors, if any, and from third parties. We also may require the cooperation of our potential future licensors in order to enforce the licensed patent rights, and such </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">94</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">cooperation may not be provided. Therefore, these patents and applications may not be prosecuted and enforced in a manner consistent with the best interests of our business. We cannot be certain that patent prosecution and maintenance activities by our potential future licensors have been or will be conducted in compliance with applicable laws and regulations, which may affect the validity and enforceability of such patents or any patents that may issue from such applications. If they fail to do so, this could cause us to lose rights in any applicable intellectual property that we may in-license, and as a result our ability to develop and commercialize products or product candidates may be adversely affected and we may be unable to prevent competitors from making, using and selling competing products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">Even if our current or future patent applications issue as patents, they may not issue in a form that will provide us with any meaningful protection, prevent competitors from competing with us or otherwise provide us with any competitive advantage. Our competitors may be able to circumvent our owned or potential future in-licensed patents by developing similar or alternative technologies or products in a non-infringing manner. The issuance of a patent is not conclusive as to its scope, validity or enforceability, and our owned and any future in-licensed patents may be challenged in the courts or patent offices in the United States and abroad. We may be subject to a third party pre-issuance submission of prior art to the USPTO, or become involved in opposition, derivation, revocation, reexamination, post-grant review, or PGR, and inter partes review, or IPR, or other similar proceedings in the USPTO or foreign patent offices challenging our patent rights. The outcome following legal assertions of invalidity and unenforceability is unpredictable. With respect to validity of our patents, for example, we cannot be certain that there is no invalidating prior art, of which we and the patent examiner were unaware during prosecution. There is no assurance that all potentially relevant prior art relating to our patents and patent applications has been found. There is also no assurance that there is no prior art of which we are aware, but which we do not believe affects the validity or enforceability of a claim in our patents and patent applications, which may, nonetheless, ultimately be found to affect the validity or enforceability of a claim. An adverse determination in any such submission, proceeding or litigation could reduce the scope of, or invalidate or render unenforceable, our patent rights, allow third parties to commercialize our product candidates and compete directly with us, without payment to us. Such loss of patent rights, loss of exclusivity or our patent claims being narrowed, invalidated or held unenforceable could limit our ability to stop others from using or commercializing similar or identical technology and products, or limit the duration of the patent protection of our product candidates. Such proceedings also may result in substantial cost and require significant time from our scientists and management, even if the eventual outcome is favorable to us. In addition, if the breadth or strength of protection provided by our patents and patent applications is threatened, regardless of the outcome, it could dissuade companies from collaborating with us to license, develop or commercialize current or future product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">In addition, although we enter into non-disclosure and confidentiality agreements with parties who have access to patentable or trade secret aspects of our technology platforms and research and development output, such as our employees, outside scientific collaborators, CROs, third-party manufacturers, consultants, advisors, licensors, and other third parties, any of these parties may breach such agreements and disclose such aspects or output before a patent application is filed, thereby jeopardizing our ability to seek patent protection or maintain the trade secret status of our technology platforms or research and development output.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">As referenced above, we have filed patent applications directed to our platform technologies that involve certain of our proprietary software modules. Moreover, while software and other of our proprietary works may be protected under copyright law, we have chosen not to register any copyrights in these works, and instead, rely on the above-referenced patent applications for protection of certain modules and trade secret protection for other of our software modules. In order to bring a copyright infringement lawsuit in the United States, the copyright must be registered. Accordingly, the remedies and damages available to us for unauthorized use of our software may be limited.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;">If we fail to comply with our obligations in future agreements under which we may license intellectual property rights from licensors and third parties or otherwise experience disruptions to our business relationships with future licensors, we could lose license rights that may in the future be important to our business.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">In the future, we may enter into license agreements under which we are granted rights to intellectual property that may be important to our business. We expect that any future license agreements where we in-license intellectual property would impose on us various development, regulatory and/or commercial diligence obligations, payment of milestones and/or </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">95</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">royalties and other obligations. If we fail to comply with our obligations under these agreements (including as a result of COVID-19 and its variants impacting our operations), or we use the licensed intellectual property in an unauthorized manner or are subject to bankruptcy-related proceedings, the licensors may have the right to materially modify the terms of the licenses, such as by rendering currently exclusive licenses non-exclusive, or terminate the licenses, in which event we would not be able to market products covered by the licenses. We may also in the future enter into license agreements with third parties under which we are a sublicensee. If our sublicensor fails to comply with its obligations under its upstream license agreement with its licensor, the licensor may have the right to terminate the upstream license, which may terminate our sublicense. If this were to occur, we would no longer have rights to the applicable intellectual property unless we are able to secure our own direct license with the owner of the relevant rights, which we may not be able to do on reasonable terms, or at all, which may impact our ability to continue to develop and commercialize our product candidates incorporating the relevant intellectual property.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">We may need to obtain licenses from third parties to advance our research or allow commercialization of our product candidates or platform, and we cannot provide any assurances that third-party patents do not exist that might be enforced against our product candidates or platform in the absence of such a license. For example, our programs may involve additional product candidates that may require the use of additional proprietary rights held by third parties. Our product candidates may also require specific formulations to work effectively and efficiently. These formulations may be covered by intellectual property rights held by others. We may be unable to acquire or in-license any relevant third-party intellectual property rights that we identify as necessary or important to our business operations. We may fail to obtain any of these licenses on commercially reasonable terms, if at all. We may need to cease use of the compositions or methods covered by such third-party intellectual property rights, and may need to seek to develop alternative approaches that do not infringe such intellectual property rights which may entail additional costs and development delays, even if we were able to develop such alternatives, which may not be feasible. Even if we are able to obtain a license, it may be non-exclusive, thereby giving our competitors access to the same technologies licensed to us. The licensing and acquisition of third-party intellectual property rights is a competitive practice, and companies that may be more established, or have greater resources than we do, may also be pursuing strategies to license or acquire third-party intellectual property rights that we may consider necessary or attractive for commercializing our product candidates. More established companies may have a competitive advantage over us due to their larger size and cash resources or greater clinical development and commercialization capabilities. There can be no assurance that we will be able to successfully complete such negotiations and ultimately acquire the rights to the intellectual property surrounding the additional product candidates that we may seek to acquire.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;">In addition, disputes may arise between us and any future licensors regarding intellectual property subject to a license agreement, including:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">&#8226; the scope of rights granted and obligations imposed under the license agreement and other interpretation-related issues;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">&#8226; whether and the extent to which our technology and processes infringe intellectual property of the licensor that is not subject to the licensing agreement;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;">&#8226; our right to sublicense patents and other rights to third parties;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">&#8226; our diligence obligations with respect to the use of the licensed technology in relation to our development and commercialization of our product candidates, and what activities satisfy those diligence obligations;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">&#8226; the amounts, if any, we owe to a potential licensor in respect of sublicense fees or income or in respect of backup product;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;">&#8226; our right to transfer or assign the license; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">&#8226; the ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our licensors and its affiliates and sublicensees and by us and our partners and sublicensees.</p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">96</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;">If disputes over intellectual property that we have licensed prevent or impair our ability to maintain our future licensing arrangements on acceptable terms, we may not be able to successfully develop and commercialize the affected product candidates, which would have a material adverse effect on our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;">In addition, certain of our agreements may limit or delay our ability to consummate certain transactions, may impact the value of those transactions, or may limit our ability to pursue certain activities. For example, we may in the future enter into license agreements that are not assignable or transferable, or that require the licensor&#8217;s express consent in order for an assignment or transfer to take place.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;">The patent protection and patent prosecution for some of our product candidates may be dependent on our future licensors and third parties.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;">We or our future potential licensors may fail to identify patentable aspects of inventions made in the course of development and commercialization activities before it is too late to obtain patent protection on them. Therefore, we may miss potential opportunities to strengthen our patent position. It is possible that defects as to form in the preparation or filing of our potential future in-licensed patents or patent applications may exist, or may arise in the future, for example with respect to proper priority claims, inventorship, claim scope, or requests for patent term adjustments. If we or our future potential licensors fail to establish, maintain or protect such patents and other intellectual property rights, such rights may be reduced or eliminated. If our future potential licensors are not fully cooperative or disagree with us as to the prosecution, maintenance or enforcement of any patent rights, such patent rights could be compromised. If there are material defects in the form, preparation, prosecution, or enforcement of our future potential in-licensed patents or patent applications, such patents may be invalid and/or unenforceable, and such applications may never result in valid, enforceable patents. Any of these outcomes could impair our ability to prevent competition from third parties, which may have an adverse impact on our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;">As a future potential licensee of third parties, we would rely on third parties to file and prosecute patent applications and maintain patents and otherwise protect the licensed intellectual property under some of our future license agreements. We would not have primary control over these activities for certain of our patents or patent applications and other intellectual property rights. We cannot be certain that such activities by third parties have been or will be conducted in compliance with applicable laws and regulations or will result in valid and enforceable patents or other intellectual property rights. Future potential licensors may have the right to control enforcement of our future potential licensed patents or defense of any claims asserting the invalidity of these patents and even if we are permitted to pursue such enforcement or defense, we will require the cooperation of our future licensors. We cannot be certain that our future licensors will allocate sufficient resources or prioritize their or our enforcement of such patents or defense of such claims to protect our interests in the licensed patents. Even if we are not a party to these legal actions, an adverse outcome could harm our business because it might prevent us from continuing to license intellectual property that we may<b style="font-weight:bold;">&#160; </b>need to operate our business. If any of our future potential licensors or future collaborators fail to appropriately prosecute and maintain patent protection for patents directed to any of our product candidates, our ability to develop and commercialize those product candidates may be adversely affected and we may not be able to prevent competitors from making, using and selling competing products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;">In addition, even where we have the right to control patent prosecution of patents and patent applications we have acquired or licensed from third parties in the future, we may still be adversely affected or prejudiced by actions or inactions of our potential licensors and their counsel that took place prior to us assuming control over patent prosecution.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;">Technology we may acquire or license from various third parties in the future may be subject to retained rights. Our future licensors may retain certain rights under their agreements with us, including the right to use the underlying technology for use in fields other than the fields licensed to us or for use in noncommercial academic and research use, to publish general scientific findings from research related to the technology, and to make customary scientific and scholarly disclosures of information relating to the technology. It may be difficult to monitor whether our future licensors may limit their use of the technology to these uses, and we could incur substantial expenses to enforce our rights to our licensed technology in the event of misuse.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">97</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Our commercial success depends significantly on our ability to operate without infringing the patents and other proprietary rights of third parties. Claims by third parties that we infringe or misappropriate their proprietary rights may result in liability for damages or prevent or delay our developmental and commercialization efforts.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;">Our commercial success depends in part on avoiding infringement or misappropriation of the patents and other proprietary rights of third parties. However, our research, development and commercialization activities may be subject to claims that we infringe or otherwise violate patents or other intellectual property rights owned or controlled by third parties. Because the intellectual property landscape in the industry in which we participate is rapidly evolving and interdisciplinary, it is difficult to conclusively assess our ability to freely make, use, and sell our products without infringing third party rights. Other entities may have or obtain patents or proprietary rights that could limit our ability to make, use, sell, offer for sale or import our product candidates and products that may be approved in the future, or impair our competitive position. There is a substantial amount of litigation, both within and outside the United States, involving patent and other intellectual property rights in the biopharmaceutical industry, including patent infringement lawsuits, oppositions, reexaminations, IPR proceedings and PGR proceedings before the USPTO and/or foreign patent offices. Numerous third-party U.S. and foreign issued patents and pending patent applications exist in the fields in which we are developing product candidates. There may be third-party patents or patent applications with claims to materials, formulations, methods of manufacture or methods for treatment related to the use or manufacture of our product candidates, as well as related to our platform.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;">As the biopharmaceutical industry expands and more patents are issued, the risk increases that our product candidates or platform may be subject to claims of infringement of the patent rights of third parties. Because patent applications are maintained as confidential for a certain period of time, until the relevant application is published we may be unaware of third-party patents that may be infringed by commercialization of any of our product candidates, and we cannot be certain that others have not filed patent applications for a product candidate or technology covered by our pending patent applications, or that we were the first to file a patent application related to a product candidate or technology. Our competitors may have filed, and may in the future file, patent applications covering our products or technology similar to ours. Any such patent application may have priority over our patent applications or patents, which could require us to obtain rights to issued patents relating to such technologies. Moreover, because patent applications can take many&#160;years to issue, there may be currently pending patent applications that may later result in issued patents that our product candidates may infringe.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;">In addition, identification of third-party patent rights that may be relevant to our product candidates or platform is difficult because patent searching is imperfect due to differences in terminology among patents, incomplete databases and the difficulty in assessing the meaning of patent claims. We cannot guarantee that any of our patent searches or analyses, including the identification of relevant patents, the scope of patent claims or the expiration of relevant patents, are complete or thorough, nor can we be certain that we have identified each and every third-party patent and pending application in the United States and abroad that is relevant to or necessary for the commercialization of our product candidates in any jurisdiction. The scope of a patent claim is determined by an interpretation of the law, the written disclosure in a patent and the patent&#8217;s prosecution history. Our interpretation of the relevance or the scope of a patent or a pending application may be incorrect. For example, we may incorrectly determine that our products are not covered by a third-party patent or may incorrectly predict whether a third-party&#8217;s pending application will issue with claims of relevant scope. Our determination of the expiration date of any patent in the United States or abroad that we consider relevant may be incorrect. Our failure to identify and correctly interpret relevant patents may negatively impact our ability to develop and market our products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">Further, third parties may obtain patents in the future and claim that use of our technologies infringes upon these patents. Any claims of patent infringement asserted by third parties would be time-consuming and could:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;">&#8226; result in costly litigation that may cause negative publicity;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;">&#8226; divert the time and attention of our technical personnel and management;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;">&#8226; cause development delays;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">98</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">&#8226; prevent us from commercializing any of our product candidates until the asserted patent expires or is held finally invalid or unenforceable or not infringed in a court of law;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;">&#8226; require us to develop non-infringing technology, which may not be possible on a cost-effective basis;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;">&#8226; subject us to significant liability to third parties; or</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">&#8226; require us to enter into royalty or licensing agreements, that may not be available on commercially reasonable terms, or at all, or that might be non-exclusive, which could result in our competitors gaining access to the same technology.</p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">Although no third party has asserted a claim of patent infringement against us as of the date of this Annual Report on Form 10-K, others may hold proprietary rights that could prevent our product candidates from being marketed. Any patent-related legal action against us claiming damages and seeking to enjoin activities relating to our product candidates or processes could subject us to potential liability for damages, including treble damages if we were determined to willfully infringe, and require us to obtain a license to manufacture or develop our product candidates. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of management and employee resources from our business. We cannot predict whether we would prevail in any such actions or that any license required under any of these patents would be made available on commercially acceptable terms, if at all. Moreover, even if we or our future strategic partners were able to obtain a license, the rights may be non-exclusive, which could result in our competitors gaining access to the same intellectual property. In addition, we cannot be certain that we could redesign our product candidates or processes to avoid infringement, if necessary. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">Accordingly, an adverse determination in a judicial or administrative proceeding, or the failure to obtain necessary licenses, could prevent us from developing and commercializing our product candidates, which could harm our business, financial condition and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">Parties making claims against us may be able to sustain the costs of complex patent or trade secret litigation more effectively than we can because they have substantially greater resources. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation or administrative proceedings, there is a risk that some of our confidential information could be compromised by disclosure. In addition, any uncertainties resulting from the initiation and continuation of any litigation could have a material adverse effect on our ability to raise additional funds or otherwise have a material adverse effect on our business, results of operations, financial condition and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">Moreover, if our product candidates or platform are found to infringe the intellectual property rights of third parties, these third parties may assert infringement claims against our future licensees and other parties with whom we have business relationships, and we may be required to indemnify those parties for any damages they suffer as a result of these claims. The claims may require us to initiate or defend protracted and costly litigation on behalf of such licensees and other parties regardless of the merits of these claims. If any of these claims succeed, we may be forced to pay damages on behalf of those parties or may be required to obtain licenses for the products they use.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;">We may be involved in lawsuits to protect or enforce our patents or the patents of our future licensors, which could be expensive, time-consuming and unsuccessful. Further, our future in-licensed issued patents could be found invalid or unenforceable if challenged in court.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;">Competitors may infringe or otherwise violate our, or our future licensors&#8217;, patents, trademarks or other intellectual property. To prevent infringement or other violations, we and/or our future licensors may be required to file claims, which can be expensive and time-consuming. Further, our future licensors may need to file such claims, but elect not to file them. In addition, in a patent infringement proceeding, a court may decide that a patent we own or license is not valid, is unenforceable and/or is not infringed. If we or any of our future licensors or potential future collaborators were to initiate legal proceedings against a third party to enforce a patent directed at one of our product candidates, the defendant could counterclaim that our patent is invalid and/or unenforceable in whole or in part. In patent litigation, defendant counterclaims alleging invalidity and/or unenforceability are commonplace. Grounds for a validity challenge include an </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">99</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;">alleged failure to meet any of several statutory requirements, including lack of novelty or written description, non-patentable subject matter (laws of nature, natural phenomena, or abstract idea), obviousness or non-enablement. Grounds for an unenforceability assertion could include an allegation that someone connected with prosecution of the patent intentionally withheld material information from the USPTO or the applicable foreign counterpart, or made a misleading statement, during prosecution. A litigant or the USPTO itself could challenge our patents on this basis even if we believe that we have conducted our patent prosecution in accordance with the duty of candor to the USPTO and in good faith. The outcome following such a challenge is unpredictable. With respect to challenges to the validity of our patents, there might be invalidating prior art, of which we and the patent examiner were unaware during prosecution.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;">If a defendant were to prevail on a legal assertion of invalidity and/or unenforceability, we would lose at least part, and perhaps all, of the patent protection on such product candidate. In addition, if the breadth or strength of protection provided by our patents and patent applications or those of our future licensors is threatened, it could dissuade companies from collaborating with us to license, develop or commercialize current or future product candidates. Such a loss of patent protection would have a material adverse impact on our business. Even if a defendant does not prevail on a legal assertion of invalidity and/or unenforceability, our patent claims may be construed in a manner that would limit our ability to enforce such claims against the defendant and others.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;">Even if resolved in our favor, litigation or other legal proceedings relating to our intellectual property rights, particularly those in a foreign jurisdiction, may cause us to incur significant expenses, and could distract our technical and management personnel from their normal responsibilities. Such litigation or proceedings could substantially increase our operating losses and reduce the resources available for development activities or any future sales, marketing or distribution activities. Enforcing our intellectual property rights against third parties may also cause such third parties to file other counterclaims against us, which could be costly to defend, particularly in a foreign jurisdiction, and could require us to pay substantial damages, cease the sale of certain products or enter into a license agreement and pay royalties (which may not be possible on commercially reasonable terms or at all). We may not have sufficient financial or other resources to conduct such litigation or proceedings adequately. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could compromise our ability to compete in the marketplace.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation or other legal proceedings relating to our intellectual property rights, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation or other proceedings.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Intellectual property litigation may lead to unfavorable publicity that harms our reputation and causes the market price of our common shares to decline.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;">During the course of any intellectual property litigation, there could be public announcements of the initiation of the litigation as well as results of hearings, rulings on motions, and other interim proceedings in the litigation. If securities analysts or investors regard these announcements as negative, the perceived value of our existing products, programs or intellectual property could be diminished. Accordingly, the market price of shares of our Class&#160;A common stock may decline. Such announcements could also harm our reputation or the market for our future products, which could have a material adverse effect on our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Derivation or interference proceedings may be necessary to determine priority of inventions, and an unfavorable outcome may require us to cease using the related technology or to attempt to license rights from the prevailing party.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;">Derivation or interference proceedings provoked by third parties or brought by us or our future licensors, or declared by the USPTO or similar proceedings in foreign patent offices may be necessary to determine the priority of inventions with respect to our or our potential future licensors&#8217; patents or patent applications. An unfavorable outcome could require us to cease using the related technology or to attempt to license rights to it from the prevailing party. Our business could be harmed if the prevailing party does not offer us a license on commercially reasonable terms. Our or our licensors&#8217; defense of such proceedings may fail and, even if successful, may result in substantial costs and distract our management and other employees. In addition, the uncertainties associated with such proceedings could have a material adverse effect on our </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">100</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;">ability to raise the funds necessary to continue our clinical trials, continue our research programs, license necessary technology from third parties or enter into development or manufacturing partnerships that would help us bring our product candidates to market.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Patent reform legislation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;">In 2011, the Leahy-Smith America Invents Act, or the Leahy-Smith Act, was signed into law. The Leahy-Smith Act includes a number of significant changes to U.S. patent law. These include provisions that affect the way patent applications are prosecuted and may also affect patent litigation. In particular, under the Leahy-Smith Act, the United States transitioned in March&#160;2013 to a &#8220;first inventor to file&#8221; system in which, assuming that other requirements of patentability are met, the first inventor to file a patent application will be entitled to the patent regardless of whether a third party was first to invent the claimed invention. A third party that files a patent application in the USPTO after March&#160;2013 but before us could therefore be awarded a patent covering an invention of ours even if we had made the invention before it was made by such third party. This requires us to be cognizant of the time from invention to filing of a patent application. Furthermore, our ability to obtain and maintain valid and enforceable patents depends on whether the differences between our technology and the prior art allow our technology to be patentable over the prior art. Since patent applications in the United States and most other countries are confidential for a period of time after filing or until issuance, we cannot be certain that we were the first to either (1)&#160;file any patent application related to our product candidates or (2)&#160;invent any of the inventions claimed in our patents or patent applications. Even where we have a valid and enforceable patent, we may not be able to exclude others from practicing the claimed invention where the other party can show that they used the invention in commerce before our filing date or the other party benefits from a compulsory license.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;">The Leahy-Smith Act also includes a number of significant changes that (i)&#160;affect the way patent applications are prosecuted, (ii)&#160;redefine prior art, and (iii) provide more efficient and cost-effective avenues for competitors to challenge the validity of patents. These include allowing third-party submission of prior art to the USPTO during patent prosecution and additional procedures to attack the validity of a patent by USPTO administered post-grant proceedings, including PGR, IPR, and derivation proceedings. An adverse determination in any such submission or proceeding could reduce the scope or enforceability of, or invalidate, our patent rights, which could adversely affect our competitive position.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;">Because of a lower evidentiary standard in USPTO proceedings compared to the evidentiary standard in United States federal courts necessary to invalidate a patent claim, a third party could potentially provide evidence in a USPTO proceeding sufficient for the USPTO to hold a claim invalid even though the same evidence would have been insufficient to invalidate the claim if presented in a district court action. Accordingly, a third party may attempt to use the USPTO procedures to invalidate our patent claims that would not have been invalidated if first challenged by the third party as a defendant in a district court action. Thus, the Leahy-Smith Act and its implementation increase the uncertainties and costs surrounding the prosecution of our or our future licensors&#8217; patent applications and the enforcement or defense of our issued patents, all of which could have a material adverse effect on our business, financial condition, results of operations and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Changes in U.S. patent law, or laws in other countries, could diminish the value of patents in general, thereby impairing our ability to protect our product candidates.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;">As is the case with other biopharmaceutical companies, our success is heavily dependent on intellectual property, particularly patents. Obtaining and enforcing patents in the biopharmaceutical industry involves a high degree of technological and legal complexity. Therefore, obtaining and enforcing biopharmaceutical patents is costly, time-consuming and inherently uncertain. Changes in either the patent laws or in the interpretations of patent laws in the United States and other countries may diminish the value of our intellectual property and may increase the uncertainties and costs surrounding the prosecution of patent applications and the enforcement or defense of issued patents. Further, the laws of foreign countries may not protect our rights to the same extent as the laws of the United States. We cannot predict the breadth of claims that may be allowed or enforced in our patents or in third-party patents.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;">In addition, Congress or other foreign legislative bodies may pass patent reform legislation that is unfavorable to us. For example, the U.S. Supreme Court has ruled on several patent cases in recent&#160;years, either narrowing the scope of patent </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">101</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;">protection available in certain circumstances or weakening the rights of patent owners in certain situations. In addition to increasing uncertainty with regard to our or our future licensors&#8217; ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents, once obtained. Depending on decisions by the U.S. Congress, the U.S. federal courts, the USPTO, or similar authorities in foreign jurisdictions, the laws and regulations governing patents could change in unpredictable ways that would weaken our or our licensors&#8217; ability to obtain new patents or to enforce our existing patents and patents we might obtain in the future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;">We or our future licensors may be subject to claims challenging the inventorship or ownership of our or our future in-licensed patents and other intellectual property.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;">We may also be subject to claims that former employees or other third parties have an ownership interest in our patents or other intellectual property. The failure to name the proper inventors on a patent application can result in the patents issuing thereon being unenforceable. Inventorship disputes may arise from conflicting views regarding the contributions of different individuals named as inventors, the effects of foreign laws where foreign nationals are involved in the development of the subject matter of the patent, conflicting obligations of third parties involved in developing our product candidates or as a result of questions regarding co-ownership of potential joint inventions. Litigation may be necessary to defend against these and other claims challenging inventorship or ownership. If we or our future licensors fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights. Such an outcome could have a material adverse effect on our business. Even if we or our future licensors are successful in defending against such claims, litigation could result in substantial costs and distraction to management and other employees.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;">Our future licensors may have relied on third-party consultants or collaborators or on funds from third parties, such as the U.S. government, such that our future licensors are not the sole and exclusive owners of any patents we may in-license. If other third parties have ownership rights or other rights to our in-licensed patents, they may be able to license such patents to our competitors, and our competitors could market competing products and technology. This could have a material adverse effect on our competitive position, business, financial conditions, results of operations, and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;">In addition, while it is our policy to require our employees and contractors who may be involved in the conception or development of intellectual property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with each party who, in fact, conceives or develops intellectual property that we regard as our own. The assignment of intellectual property rights may not be self-executing, or the assignment agreements may be breached, and we may be forced to bring claims against third parties, or defend claims that they may bring against us, to determine the ownership of what we regard as our intellectual property. Such claims could have a material adverse effect on our business, financial condition, results of operations, and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Patent terms may be inadequate to protect our competitive position on our product candidates for an adequate amount of time.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;">Patents have a limited lifespan. In the United States, if all maintenance fees are timely paid, the natural expiration of a patent is generally 20&#160;years from its earliest U.S. non-provisional filing date. Various extensions may be available, but the term of a patent, and the protection it affords, is limited. Even if patents directed to our product candidates are obtained, once the patent term has expired, we may be open to competition from competitive products. Given the amount of time required for the development, testing and regulatory review of product candidates, patents directed to our product candidates might expire before or shortly after such candidates are commercialized. As a result, our patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;">Depending upon the timing, duration and specifics of FDA marketing approval of our product candidates, one or more of our U.S. patents may be eligible for limited patent term restoration under the Drug Price Competition and Patent Term Restoration Act of 1984, or the Hatch-Waxman Amendments. The Hatch-Waxman Amendments permit a patent restoration term of up to five&#160;years as compensation for patent term lost during product development and the FDA regulatory review process. A maximum of one patent may be extended per FDA-approved product as compensation for the patent term lost during the FDA regulatory review process. A patent term extension cannot extend the remaining term of a patent beyond a total of 14&#160;years from the date of product approval and only those claims covering such approved drug product, a method for using it or a method for manufacturing it may be extended. Patent term extension may also be </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">102</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;">available in certain foreign countries upon regulatory approval of our product candidates. However, we or our licensors may not be granted an extension because of, for example, failing to apply within applicable deadlines, failing to apply prior to expiration of relevant patents or otherwise failing to satisfy applicable requirements. Moreover, the applicable time period or the scope of patent protection afforded could be less than we request. If we or our licensors are unable to obtain patent term extension or restoration or the term of any such extension is less than we request, our competitors may obtain approval of competing products following our patent expiration, and our revenue could be reduced, possibly materially. Further, if this occurs, our competitors may take advantage of our investment in development and trials by referencing our clinical and preclinical data and launch their product earlier than might otherwise be the case.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;">We may not be able to protect our intellectual property rights throughout the world.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">Although we have pending patent applications in the United States and we seek to file patent applications in certain other countries, filing, prosecuting and defending patents in all countries throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the United States can be less extensive than those in the United States. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the United States. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the United States or from selling or importing products made using our inventions in and into the United States or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and, further, may export otherwise infringing products to territories where we or our licensors have patent protection but enforcement is not as strong as that in the United States. These products may compete with our product candidates, and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of many foreign countries do not favor the enforcement of patents and other intellectual property protection, which could make it difficult for us to stop the infringement of our or our licensors&#8217; patents or marketing of competing products in violation of our proprietary rights. Proceedings to enforce our or our potential future licensors&#8217; patent rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our or our potential future licensors&#8217; patents at risk of being invalidated or interpreted narrowly and our or our potential future licensors&#8217; patent applications at risk of not issuing and could provoke third parties to assert claims against us. We or our licensors may not prevail in any lawsuits that we or our potential future licensors initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our or our potential future licensors&#8217; efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or in-license.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">Many countries have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. In addition, many countries limit the enforceability of patents against government agencies or</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;">government contractors. In these countries, the patent owner may have limited remedies, which could materially diminish the value of such patent. If we or our licensors are forced to grant a license to third parties with respect to any patents relevant to our business, our competitive position may be impaired, and our business, financial condition, results of operations and prospects may be adversely affected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Obtaining and maintaining our patent protection depends on compliance with various procedural, documentary, fee payment and other requirements imposed by regulations and governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;">Periodic maintenance fees, renewal fees, annuity fees and various other governmental fees on patents and/or applications will be due to the USPTO and various foreign patent offices at various points over the lifetime of our patents and/or applications. We have systems in place to remind us to pay these fees, and we rely on third parties to pay these fees when due. Additionally, the USPTO and various foreign patent offices require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. We employ reputable law firms and other professionals to help us comply, and in many cases, an inadvertent lapse can be cured by payment of a late fee or by other means in accordance with rules applicable to the particular jurisdiction. While an inadvertent lapse, </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">103</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;">including due to the effect of the pandemic related to COVID-19 and its variants, our patent maintenance vendors or law firms, can in many cases be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. Non-compliance events that could result in abandonment or lapse of a patent or patent application include, but are not limited to, failure to respond to official actions within prescribed time limits, non-payment of fees and failure to properly legalize and submit formal documents. If we fail to maintain the patents and patent applications relating to our product candidates, our competitive position would be adversely affected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;">If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;">In addition to seeking patent protection for some of our technology and product candidates, we rely on the protection of our trade secrets, including unpatented know-how, technology and other proprietary information to maintain our competitive position, especially with respect to our technology platform. Any disclosure, either intentional or unintentional, by our employees or third-party consultants and vendors that we engage to perform research, clinical trials or manufacturing activities, or misappropriation by third parties (such as through a cybersecurity breach) of our trade secrets or proprietary information could enable competitors to duplicate or surpass our technological achievements, thus eroding our competitive position in our market. Because we expect to rely on third parties in the development and manufacture of our product candidates, we must, at times, share trade secrets with them. Our reliance on third parties may require us to share our trade secrets, which increases the possibility that a competitor will discover them or that our trade secrets will be misappropriated or disclosed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;">Although we have taken steps to protect our trade secrets and unpatented know-how, including entering into non-disclosure and confidentiality agreements with third parties who are given access to them, such as our corporate collaborators, outside scientific collaborators, contract research organizations, contract manufacturers, consultants, advisors and other third parties. With our consultants, contractors and outside scientific collaborators, these agreements typically include invention assignment obligations. We cannot guarantee that we have entered into such agreements with each party that may have or has had access to our trade secrets or proprietary technology and processes. Further, we cannot provide any assurances that all such agreements have been duly executed or that competitors will not otherwise gain access to our trade secrets or independently develop substantially equivalent information and techniques. In addition, any of these parties may breach the agreements and disclose our proprietary information, including our trade secrets, and we may not be able to obtain adequate remedies for such breaches. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time-consuming, and the outcome is unpredictable. In addition, some courts inside and outside the United States are less willing or unwilling to protect trade secrets. We may need to share our proprietary information, including trade secrets, with future business partners, collaborators, contractors and others located in countries at heightened risk of theft of trade secrets, including through direct intrusion by private parties or foreign actors, and those affiliated with or controlled by state actors.<b style="font-weight:bold;">&#160;</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;">Moreover, third parties may still obtain this information or may come upon this or similar information independently, and we would have no right to prevent them from using that technology or information to compete with us. If any of these events occurs or if we otherwise lose protection for our trade secrets, the value of this information may be greatly reduced and our competitive position would be harmed. If we or our licensors do not apply for patent protection prior to such publication or if we cannot otherwise maintain the confidentiality of our proprietary technology and other confidential information, then our ability to obtain patent protection or to protect our trade secret information may be jeopardized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;">We also seek to preserve the integrity and confidentiality of our data and trade secrets by maintaining physical security of our premises and physical and electronic security of our information technology systems. While we have confidence in these individuals, organizations and systems, agreements or security measures may be breached, and we may not have adequate remedies for any breach.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">104</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;">We may be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information or alleged trade secrets of third parties or competitors or are in breach of non-competition or non-solicitation agreements with our competitors or their former employers.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;">As is common in the pharmaceutical and biotechnology industries, we employ individuals and engage the services of consultants who previously worked for other biotechnology or pharmaceutical companies, including our competitors or potential competitors. Although no claims against us are currently pending, we may be subject to claims that we have wrongfully hired an employee from a competitor or that we or our employees have wrongfully used or disclosed alleged confidential information, trade secrets or other proprietary information of their former employers, or that our consultants have used or disclosed trade secrets or other proprietary information of their former or current clients. Litigation may be necessary to defend against these claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel, which could adversely affect our business. Even if we are successful in defending against these claims, litigation could result in substantial costs and be a distraction to our management team and other employees.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;">If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">We use and will continue to use registered and/or unregistered trademarks or trade names to brand and market ourselves and our products. Our trademarks or trade names may be challenged, infringed, circumvented or declared generic or determined to be infringing on other marks. We may not be able to protect our rights to these trademarks and trade names, which we need to build name recognition among potential partners or customers in our markets of interest. At times, competitors may adopt trade names or trademarks similar to ours, thereby impeding our ability to build brand identity and possibly leading to market confusion. In addition, there could be potential trade name or trademark infringement claims brought by owners of other trademarks or trademarks that incorporate variations of our registered or unregistered trademarks or trade names. Over the long term, if we are unable to establish name recognition based on our trademarks and trade names, then we may not be able to compete effectively and our business may be adversely affected. We may license our trademarks and trade names to third parties, such as distributors. Though these license agreements may provide guidelines for how our trademarks and trade names may be used, a breach of these agreements or misuse of our trademarks and tradenames by our licensees may jeopardize our rights in or diminish the goodwill associated with our trademarks and trade names.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">Moreover, any name we have proposed to use with our product candidate in the United States must be approved by the FDA, regardless of whether we have registered it, or applied to register it, as a trademark. Similar requirements exist in Europe. The FDA typically conducts a review of proposed product names, including an evaluation of potential for confusion with other product names. If the FDA (or an equivalent administrative body in a foreign jurisdiction) objects to any of our proposed proprietary product names, it may be required to expend significant additional resources in an effort to identify a suitable substitute name that would qualify under applicable trademark laws, not infringe the existing rights of third parties and be acceptable to the FDA. Furthermore, in many countries, owning and maintaining a trademark registration may not provide an adequate defense against a subsequent infringement claim asserted by the owner of a senior trademark.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;">We use third-party open source software, which could negatively affect our ability to offer our solutions and subject us to litigation or other actions.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;">We use open source software licensed to us by third-party authors under &#8220;open source&#8221; licenses in our platform and solutions and expect to continue to use such open source software in the future. Use and distribution of open source software may entail greater risks than use of third-party commercial software, as open source licensors generally do not provide support, warranties, indemnification or other contractual protections regarding infringement claims or the quality of the code. To the extent that our platform depends upon the successful operation of open source software, any undetected errors or defects in this open source software could prevent the deployment or impair the functionality of our platform, delay introductions of new solutions, result in a failure of our platform, and injure our reputation. For example, undetected errors or defects in open source software could render it vulnerable to breaches or security attacks, and, as a result, possibly </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">105</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;">make our systems more vulnerable to data breaches. In addition, the public availability of such software may make it easier for others to compromise our platform.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;">Further, there are uncertainties regarding the proper interpretation of and compliance with open source licenses, and there is a risk that such licenses could be construed in a manner that imposes unanticipated conditions or restrictions on our ability to use such open source software, and consequently to provide or distribute our platform and solutions. Some open source licenses contain express requirements that we make available source code for modifications or derivative works we create based upon the type of open source software we use, or grant other licenses to our intellectual property. If we combine our proprietary software with open source software in a certain manner, we could, under certain open source licenses, be required to release the source code of our proprietary software to the public. This would allow our competitors to create similar offerings with lower development effort and time and ultimately could result in a loss of our competitive advantages. Alternatively, to avoid the public release of the affected portions of our source code, we could be required to expend substantial time and resources to re-engineer some or all of our software.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;">Despite our efforts to monitor our use of open source software to avoid subjecting our platform to conditions we do not intend, there is a risk that open source licenses could be construed in a way that could impose unanticipated conditions or restrictions on our ability to provide or distribute our platform. Additionally, we may from time to time face claims from third parties claiming ownership of, or seeking to enforce the terms of, an open source license, including by demanding release of source code for the open source software, derivative works or our proprietary source code that was developed using, or that is distributed with, such open source software. These claims could also result in litigation and could require us to make our proprietary software source code freely available, devote additional research and development resources to re-engineer our platform, seek costly licenses from third parties, pay monetary damages to the owner of the copyright in the relevant open source software or otherwise incur additional costs and expenses, any of which could result in reputational harm and would have a negative effect on our business and results of operations. In addition, if the license terms for the open source software we utilize change, we may be forced to re-engineer our platform, incur additional costs to comply with the changed license terms or replace the affected open source software. Although we have implemented policies to regulate the use and incorporation of open source software into our platform and solutions, we cannot be certain that that such policies will be effective and that we have not incorporated open source software in our platform and solutions in a manner that is inconsistent with such policies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Intellectual property rights do not necessarily address all potential threats to our competitive advantage.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;">The degree of future protection afforded by intellectual property rights is uncertain because intellectual property rights have limitations, and may not adequately protect our business or permit us to maintain our competitive advantage. For example:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">&#8226; others may be able to develop products that are similar to our product candidates but that are not covered by the claims of the patents that we may own or license;</p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">&#8226; we or our potential future licensors might not have been the first to make the inventions covered by the issued patents or patent application that we may own or license;</p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="font-size:10pt;">&#8226; we or our potential future licensors might not have been the first to file patent applications covering certain of our inventions;</span><i style="font-style:italic;">&#160;</i><b style="font-size:10pt;font-weight:bold;">&#160;</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">&#8226; others may independently develop similar or alternative technologies or duplicate any of our technologies without </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">infringing our intellectual property rights;</p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">&#8226; it is possible that our or our future licensors&#8217; pending patent applications will not lead to issued patents;</p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">&#8226; future issued patents that we own or license may be held invalid or unenforceable, as a result of legal challenges by our competitors;</p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">106</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">&#8226; our competitors might conduct research and development activities in countries where we do not have patent rights and then use the information learned from such activities to develop competitive products for sale in our major commercial markets;</p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;">&#8226; we may not develop additional proprietary technologies that are patentable; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;">&#8226; the patents of others may have an adverse effect on our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">Should any of these events occur, it could significantly harm our business, results of operations and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><b style="font-weight:bold;">Risks Related to Employee Matters and Managing our Growth</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;">If we are unable to establish sales or marketing capabilities or enter into agreements with third parties to sell or market our product candidates, we may not be able to successfully sell or market our product candidates that obtain regulatory approval.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">We currently do not have and have never had a marketing or sales team. In order to commercialize any product candidates, if approved, we must build marketing, sales, distribution, managerial and other non-technical capabilities or make arrangements with third parties to perform these services for each of the territories in which we may have approval to sell or market our product candidates. We may not be successful in accomplishing these required tasks.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">Establishing an internal sales or marketing team with technical expertise and supporting distribution capabilities to commercialize our product candidates will be expensive and time-consuming, and will require significant attention of our executive officers to manage. Any failure or delay in the development of our internal sales, marketing and distribution capabilities could adversely impact the commercialization of any of our product candidates that we obtain approval to market, if we do not have arrangements in place with third parties to provide such services on our behalf. Alternatively, if we choose to collaborate, either globally or on a territory-by-territory basis, with third parties that have direct sales forces and established distribution systems, either to augment our own sales force and distribution systems or in lieu of our own sales force and distribution systems, we will be required to negotiate and enter into arrangements with such third parties relating to the proposed collaboration. If we are unable to enter into such arrangements when needed, on acceptable terms, or at all, we may not be able to successfully commercialize any of our product candidates that receive regulatory approval or any such commercialization may experience delays or limitations. If we are unable to successfully commercialize our approved product candidates, either on our own or through collaborations with one or more third parties, our future product revenue will suffer and we may incur significant additional losses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Our success is highly dependent on our ability to attract and retain highly skilled executive officers and employees.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">To succeed, we must recruit, retain, manage and motivate qualified clinical, scientific, technical and management personnel, and we face significant competition for experienced personnel. We are highly dependent on the principal members of our management and scientific and medical staff. If we do not succeed in attracting and retaining qualified personnel, particularly at the management level, it could adversely affect our ability to execute our business plan and harm our results of operations. In particular, the loss of one or more of our executive officers could be detrimental to us if we cannot recruit suitable replacements in a timely manner. The competition for qualified personnel in the biotechnology field is intense and as a result, we may be unable to continue to attract and retain qualified personnel necessary, including bioinformatics and computational biologist specialists, for the future success of our business. We could in the future have difficulty attracting experienced personnel to our company and may be required to expend significant financial resources in our employee recruitment and retention efforts.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;">Many of the other biotechnology companies that we compete against for qualified personnel have greater financial and other resources, different risk profiles and a longer history in the industry than we do. They also may provide a wide range of opportunities and better prospects for career advancement. Some of these characteristics may be more appealing to high-quality candidates than what we have to offer. If we are unable to continue to attract and retain high-quality personnel, </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">107</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;">the rate and success at which we can discover, develop and commercialize our product candidates will be limited and the potential for successfully growing our business will be harmed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;">In order to successfully implement our plans and strategies, we will need to grow the size of our organization, and we may experience difficulties in managing this growth.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;">As of December 31, 2021, we had 64 full-time employees, including 54 employees engaged in research and development. In order to successfully implement our development and commercialization plans and strategies, including operating as a public company, we expect to need additional managerial, operational, sales, marketing, financial and other personnel. Future growth would impose significant added responsibilities on members of management, including:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;">&#8226; identifying, recruiting, integrating, maintaining and motivating additional employees;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">&#8226; managing our internal development efforts effectively, including the clinical, FDA and other comparable foreign regulatory agencies&#8217; review process of IMM-1-104, IMM-6-415, and any other product candidate we develop, while complying with any contractual obligations to contractors and other third parties we may have; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;">&#8226; improving our operational, financial and management controls, reporting systems and procedures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;">Our future financial performance and our ability to successfully develop and, if approved, commercialize IMM-1-104 and any other product candidate will depend, in part, on our ability to effectively manage any future growth, and our management may also have to divert a disproportionate amount of its attention away from day-to-day activities in order to devote a substantial amount of time to managing these growth activities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;">We currently rely, and for the foreseeable future will continue to rely, in substantial part on certain independent organizations, advisors and consultants to provide certain services, including key aspects of clinical development and manufacturing. We cannot assure you that the services of independent organizations, advisors and consultants will continue to be available to us on a timely basis when needed, or that we can find qualified replacements. In addition, if we are unable to effectively manage our outsourced activities or if the quality or accuracy of the services provided by third party service providers is compromised for any reason, our clinical trials may be extended, delayed or terminated, and we may not be able to obtain marketing approval of any current or future product candidates or otherwise advance our business. We cannot assure you that we will be able to manage our existing third party service providers or find other competent outside contractors and consultants on economically reasonable terms, or at all.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;">If we are not able to effectively expand our organization by hiring new employees and/or engaging additional third party service providers, we may not be able to successfully implement the tasks necessary to further develop and commercialize IMM-1-104, IMM-6-415 and any other current or future product candidates and, accordingly, may not achieve our research, development and commercialization goals.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><b style="font-weight:bold;">Risks Related to Ownership of Our Class&#160;A Common Stock</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;">We may be unable to maintain an active, liquid and orderly trading market for our Class A common stock and, as a result, it may be difficult for you to sell your shares of our Class A common stock.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;">The market value of our Class A common stock may decrease from time to time, and you may not be able to resell your shares of our Class A common stock at or above the price you purchased them. The lack of an active market may impair your ability to sell your shares at the time you wish to sell them or at a price that you consider reasonable. The lack of an active market may also reduce the fair market value of your shares. Furthermore, an inactive market may also impair our ability to raise capital by selling shares of our Class A common stock and may impair our ability to enter into strategic collaborations or acquire companies, technologies or other assets by using our shares of Class A common stock as consideration.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">108</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;">The price of our stock may be volatile, and you could lose all or part of your investment.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">The trading price of our Class&#160;A common stock is likely to be highly volatile and subject to wide fluctuations in response to various factors, some of which we cannot control. The stock market in general, and pharmaceutical and biotechnology companies in particular, have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of these companies. The trading prices for common stock of other pharmaceutical and biotechnology companies have also been highly volatile as a result of the pandemic related to COVID-19 and its variants.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">Broad market and industry factors may negatively affect the market price of our Class&#160;A common stock, regardless of our actual operating performance. In addition to the factors discussed in this &#8220;Risk Factors&#8221; section and elsewhere in this Annual Report on Form 10-K, these factors include:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">&#8226; the timing and results of preclinical studies and clinical trials of our product candidates or those of our competitors;</p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">&#8226; the success of competitive products or announcements by potential competitors of their product development efforts;</p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;">&#8226; regulatory actions with respect to our products or our competitors&#8217; products;</p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;">&#8226; actual or anticipated changes in our growth rate relative to our competitors;</p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;">&#8226; regulatory or legal developments in the United States and other countries;</p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;">&#8226; developments or disputes concerning patent applications, issued patents or other proprietary rights;</p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;">&#8226; the recruitment or departure of key personnel;</p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">&#8226; announcements by us or our competitors of significant acquisitions, strategic collaborations, joint ventures, collaborations or capital commitments;</p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">&#8226; actual or anticipated changes in estimates as to financial results, development timelines or recommendations by securities analysts;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;">&#8226; fluctuations in the valuation of companies perceived by investors to be comparable to us;</p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;">&#8226; market conditions in the pharmaceutical and biotechnology sector;</p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;">&#8226; changes in the structure of healthcare payment systems;</p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;">&#8226; share price and volume fluctuations attributable to inconsistent trading volume levels of our shares;</p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;">&#8226; announcement or expectation of additional financing efforts;</p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;">&#8226; sales of our Class&#160;A common stock by us, our insiders or our other stockholders;</p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;">&#8226; expiration of market stand-off or lock-up agreements;</p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">&#8226; the ongoing and future impact of the pandemic related to COVID-19 and its variants, or any future pandemics, and actions taken to slow their spread; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">109</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;">&#8226; general economic, industry and market conditions, including the effects of recession or slow economic growth in the U.S. and abroad, interest rates, fuel prices, international currency fluctuations, corruption, political instability, acts of war, including the Russian Federation&#8217;s invasion of Ukraine in February 2022, acts of terrorism, and the ongoing COVID-19 pandemic or other public health crises.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">The realization of any of the above risks or any of a broad range of other risks, including those described in this &#8220;Risk Factors&#8221; section, could have a dramatic and adverse impact on the market price of our Class&#160;A common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;">If securities or industry analysts do not publish research or reports, or if they publish adverse or misleading research or reports, regarding us, our business or our market, our stock price and trading volume could decline.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;">The trading market for our Class&#160;A common stock will be influenced by the research and reports that securities or industry analysts publish about us, our business or our market. If any of the analysts who cover us issue adverse or misleading research or reports regarding us, our business model, our intellectual property, our stock performance or our market, or if our results of operations fail to meet the expectations of analysts, our stock price would likely decline. If one or more of these analysts cease coverage of us or fail to publish reports on us regularly, we could lose visibility in the financial markets, which in turn could cause our stock price or trading volume to decline.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Our principal stockholders and management own a significant&#160;percentage of our stock and will be able to exert significant control over matters subject to stockholder approval.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">As of December 31, 2021, our executive officers, directors, holders of 5% or more of our capital stock and their respective affiliates beneficially owned approximately 60.4% of our voting stock and these stockholders will be able to influence us through this ownership position. These stockholders may be able to determine all matters requiring stockholder approval. For example, these stockholders may be able to control elections of directors, amendments of our organizational documents or approval of any merger, sale of assets or other major corporate transaction. This may prevent or discourage unsolicited acquisition proposals or offers for our Class&#160;A common stock that you may feel are in your best interest as one of our stockholders. The interests of this group of stockholders may not always coincide with your interests or the interests of other stockholders and they may act in a manner that advances their best interests and not necessarily those of other stockholders, including seeking a premium value for their Class&#160;A common stock, and might affect the prevailing market price for our Class&#160;A common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Sales of a substantial number of shares of our Class&#160;A common stock in the public market could cause our stock price to fall.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;">Sales of a substantial number of shares of our Class A and/or Class B common stock, or the perception that these sales might occur, could depress the market price of our Class A common stock and could impair our ability to raise capital through the sale of additional equity securities. The shares of Class A common stock that were sold in the initial public offering of our Class A common stock are freely transferable without restrictions or further registration under the Securities Act of 1933, as amended, or the Securities Act, except for any shares acquired by our affiliates, as defined in Rule 144 under the Securities Act. The remaining shares of our Class A common stock that are outstanding are either unrestricted or restricted as a result of securities laws. In addition, there are shares of Class A common stock that are either subject to outstanding options or reserved for future issuance under our existing equity incentive plans and may become eligible for future sale subject to vesting, and Rule 144 and Rule 701 under the Securities Act. If these additional shares of Class A common stock are sold, or if it is perceived that they will be sold, in the public market, the trading price of our Class A common stock could decline.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;">As of December 31, 2021, the holders of approximately 11,939,281 shares, or approximately 45.4% of our outstanding shares of our common stock have rights, subject to some conditions, to require us to file registration statements covering the sale of their shares or to include their shares in registration statements that we may file for ourselves or our other stockholders. Once we register the offer and sale of shares for the holders of registration rights, these shares will be able to be sold in the public market upon issuance, subject to the lock-up agreements described above.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">110</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;">In addition, in the future, we may issue additional shares of Class&#160;A common stock, or other equity or debt securities convertible into Class&#160;A common stock, in connection with a financing, acquisition, employee arrangement or otherwise. Any such issuance could result in substantial dilution to our existing stockholders and could cause the price of our Class&#160;A common stock to decline.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;">We do not currently intend to pay dividends on our Class&#160;A common stock and, consequently, your ability to achieve a return on your investment will depend on appreciation of the value of our Class&#160;A common stock.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;">We have never declared or paid any cash dividends on our equity securities. We currently anticipate that we will retain future earnings for the development, operation and expansion of our business and do not anticipate declaring or paying any cash dividends for the foreseeable future. Any return to stockholders will therefore be limited to any appreciation in the value of our Class&#160;A common stock, which is not certain.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Provisions in our certificate of incorporation and bylaws and Delaware law might discourage, delay or prevent a change in control of our company or changes in our management and, therefore, depress the market price of our Class&#160;A common stock.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;">Our certificate of incorporation and bylaws contain provisions that could depress the market price of our Class&#160;A common stock by acting to discourage, delay or prevent a change in control of our company or changes in our management that the stockholders of our company may deem advantageous. These provisions, among other things:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;">&#8226; establish a classified board of directors so that not all members of our board are elected at one time;</p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">&#8226; permit only the board of directors to establish the number of directors and fill vacancies on the board;</p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">&#8226; provide that directors may only be removed &#8220;for cause&#8221; and only with the approval of two-thirds of our stockholders;</p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">&#8226; authorize the issuance of &#8220;blank check&#8221; preferred stock that our board could use to implement a stockholder rights plan (also known as a &#8220;poison pill&#8221;);</p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;">&#8226; eliminate the ability of our stockholders to call special meetings of stockholders;</p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">&#8226; prohibit stockholder action by written consent, which requires all stockholder actions to be taken at a meeting of our stockholders;</p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;">&#8226; prohibit cumulative voting;</p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;">&#8226; authorize our board of directors to amend the bylaws;</p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">&#8226; establish advance notice requirements for nominations for election to our board or for proposing matters that can be acted upon by stockholders at annual stockholder meetings; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;">&#8226; require a super-majority vote of stockholders to amend some provisions described above.</p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;">In addition, Section&#160;203 of the General Corporation Law of the State of Delaware, or the DGCL, prohibits a publicly-held Delaware corporation from engaging in a business combination with an interested stockholder, generally a person which together with its affiliates owns, or within the last three&#160;years has owned, 15% of our voting stock, for a period of three&#160;years after the date of the transaction in which the person became an interested stockholder, unless the business combination is approved in a prescribed manner.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">111</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;">Any provision of our certificate of incorporation, bylaws or Delaware law that has the effect of delaying or preventing a change in control could limit the opportunity for our stockholders to receive a premium for their shares of our capital stock and could also affect the price that some investors are willing to pay for our Class&#160;A common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Our amended and restated certificate of incorporation and amended and restated bylaws provides for an exclusive forum in the Court of Chancery of the State of Delaware for certain disputes between us and our stockholders, which could limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">Our amended and restated certificate of incorporation and amended and restated bylaws provide that the Court of Chancery of the State of Delaware (or, in the event that the Court of Chancery does not have jurisdiction, the federal district court for the District of Delaware or other state courts of the State of Delaware) is the exclusive forum for any derivative action or proceeding brought on our behalf, any action asserting a claim of breach of fiduciary duty, any action asserting a claim against us arising pursuant to the DGCL, our amended and restated certificate of incorporation or our amended and restated bylaws, or any action asserting a claim against us that is governed by the internal affairs doctrine; provided that, the exclusive forum provision will not apply to suits brought to enforce any liability or duty created by the Exchange Act or any other claim for which the federal courts have exclusive jurisdiction; and provided further that, if and only if the Court of Chancery of the State of Delaware dismisses any such action for lack of subject matter jurisdiction, such action may be brought in another state or federal court sitting in the State of Delaware. Our amended and restated certificate of incorporation and amended and restated bylaws also provide that the federal district courts of the United States of America is the exclusive forum for the resolution of any complaint asserting a cause or causes of action against any defendant arising under the Securities Act. Such provision is intended to benefit and may be enforced by us, our officers and directors, employees and agents, including the underwriters and any other professional or entity who has prepared or certified any part of this Annual Report on Form 10-K. Nothing in our amended and restated certificate of incorporation or amended and restated bylaws preclude stockholders that assert claims under the Exchange Act from bringing such claims in state or federal court, subject to applicable law.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;">We believe these provisions may benefit us by providing increased consistency in the application of Delaware law and federal securities laws by chancellors and judges, as applicable, particularly experienced in resolving corporate disputes, efficient administration of cases on a more expedited schedule relative to other forums and protection against the burdens of multi-forum litigation. This choice of forum provision may limit a stockholder&#8217;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or any of our directors, officers, other employees or stockholders, which may discourage lawsuits with respect to such claims or make such lawsuits more costly for stockholders, although our stockholders will not be deemed to have waived our compliance with federal securities laws and the rules and regulations thereunder. Furthermore, the enforceability of similar choice of forum provisions in other companies&#8217; certificates of incorporation has been challenged in legal proceedings, and it is possible that a court could find these types of provisions to be inapplicable or unenforceable. While the Delaware courts have determined that such choice of forum provisions are facially valid, a stockholder may nevertheless seek to bring a claim in a venue other than those designated in the exclusive-forum provisions, and there can be no assurance that such provisions will be enforced by a court in those other jurisdictions. If a court were to find the choice of forum provision that will be contained in our amended and restated certificate of incorporation and amended and restated bylaws to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action in other jurisdictions, which could adversely affect our business and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">112</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><b style="font-weight:bold;">General Risks</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Our internal computer systems, or those of any of our CROs, manufacturers, other contractors, consultants, collaborators or potential future collaborators, may fail or suffer security or data privacy breaches or other unauthorized or improper access to, use of, or destruction of our proprietary or confidential data, employee data, or personal data, which could result in additional costs, loss of revenue, significant liabilities, harm to our brand and material disruption of our operations.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;">Despite the implementation of security measures, our internal computer systems and those of our current and any future CROs and other contractors, consultants, collaborators and third-party service providers, are vulnerable to damage from computer viruses, cybersecurity threats, unauthorized access, natural disasters, terrorism, war and telecommunication and electrical failure. If such an event were to occur and cause interruptions in our operations or result in the unauthorized acquisition of or access to health-related or other personal information (violating certain privacy laws such), it could result in a material disruption of our drug discovery and development programs and our business operations, whether due to a loss of our trade secrets or other similar disruptions. Some of the federal, state and foreign government requirements include obligations of companies to notify individuals of security breaches involving particular personally identifiable information, which could result from breaches experienced by us or by our vendors, contractors, or organizations with which we have formed strategic relationships. Notifications and follow-up actions related to a security breach could impact our reputation, cause us to incur significant costs, including legal expenses and remediation costs. For example, the loss of clinical trial data from completed or future clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the lost data. We also rely on third parties to manufacture our product candidates, and similar events relating to their computer systems could also have a material adverse effect on our business. To the extent that any disruption or security breach were to result in a loss of, or damage to, our data, or inappropriate disclosure of confidential or proprietary information, we could be exposed to litigation and governmental investigations, the further development and commercialization of our product candidates could be delayed, and we could be subject to significant fines or penalties for any noncompliance with certain state, federal and/or international privacy and security laws.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;">Our insurance policies may not be adequate to compensate us for the potential losses arising from any such disruption, failure or security breach. In addition, such insurance may not be available to us in the future on economically reasonable terms, or at all. Further, our insurance may not cover all claims made against us and could have high deductibles in any event, and defending a suit, regardless of its merit, could be costly and divert management attention.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Our operations are vulnerable to interruption by fire, severe weather conditions, power loss, telecommunications failure, terrorist activity, future pandemics and other events beyond our control, which could harm our business.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;">Our facilities are located in regions which experience severe weather from time to time. We have not undertaken a systematic analysis of the potential consequences to our business and financial results from a major tornado, flood, fire, earthquake, power loss, terrorist activity, future pandemics or other disasters and do not have a recovery plan for such disasters. In addition, we do not carry sufficient insurance to compensate us for actual losses from interruption of our business that may occur, and any losses or damages incurred by us could harm our business. The occurrence of any of these business disruptions could seriously harm our operations and financial condition and increase our costs and expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;">We are an &#8220;emerging growth company,&#8221; and we cannot be certain if the reduced reporting requirements applicable to emerging growth companies will make our Class&#160;A common stock less attractive to investors.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">We are an &#8220;emerging growth company,&#8221; as defined in the JOBS Act. For as long as we continue to be an emerging growth company, we intend to take advantage of exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies, including:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">&#8226; being permitted to provide only two&#160;years of audited financial statements, in addition to any required unaudited &#160;financial statements, with correspondingly reduced &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; disclosure in this Annual Report on Form 10-K;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">113</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">&#8226; not being required to comply with the auditor attestation requirements of Section&#160;404 of the Sarbanes-Oxley Act;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">&#8226; not being required to comply with any requirement that may be adopted by the Public Company Accounting Oversight Board regarding the communication of critical audit matters in the auditor&#8217;s report on financial statements;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">&#8226; reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">&#8226; exemptions from the requirements of holding nonbinding advisory stockholder votes on executive compensation and stockholder approval of any golden parachute payments not previously approved.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">We cannot predict if investors will find our Class&#160;A common stock less attractive because we may rely on these exemptions. If some investors find our Class&#160;A common stock less attractive as a result, there may be a less active trading market for our Class&#160;A common stock and our stock price may be more volatile.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">We will remain an emerging growth company until the earliest to occur of: (1)&#160;the last day of the fiscal year in which we have more than $1.07&#160;billion in annual revenue; (2)&#160;the date we qualify as a &#8220;large accelerated filer,&#8221; with at least $700&#160;million of equity securities held by non-affiliates; (3)&#160;the date on which we have issued more than $1.0&#160;billion in non-convertible debt securities during the prior three-year period; and (4)&#160;the last day of the fiscal year ending after the fifth anniversary of our initial public offering.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">Under the JOBS Act, emerging growth companies can also delay adopting new or revised accounting standards until such time as those standards apply to private companies. We intend to take advantage of the extended transition period for adopting new or revised accounting standards under the JOBS Act as an emerging growth company. As a result of this election, our financial statements may not be comparable to companies that comply with public company effective dates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;">The requirements of being a public company may strain our resources, result in more litigation and divert management&#8217;s attention.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">As a public company, we are subject to the reporting requirements of the Exchange Act, the Sarbanes-Oxley Act, the Dodd-Frank Wall Street Reform and Consumer Protection Act, or the Dodd-Frank Act, the listing requirements of Nasdaq and other applicable securities rules and regulations. Complying with these rules and regulations has increased and will increase our legal and financial compliance costs, make some activities more difficult, time consuming or costly and increase demand on our systems and resources. The Exchange Act requires, among other things, that we file annual, quarterly and current reports with respect to our business and results of operations. The Sarbanes-Oxley Act requires, among other things, that we maintain effective disclosure controls and procedures and internal control over financial reporting. We are required to disclose changes made in our internal control and procedures on a quarterly basis. In order to maintain and, if required, improve our disclosure controls and procedures and internal control over financial reporting to meet this standard, significant resources and management oversight may be required. As a result, management&#8217;s attention may be diverted from other business concerns, which could adversely affect our business and results of operations. We may also need to hire additional employees or engage outside consultants to comply with these requirements, which will increase our costs and expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;">In addition, changing laws, regulations and standards relating to corporate governance and public disclosure are creating uncertainty for public companies, increasing legal and financial compliance costs and making some activities more time consuming. These laws, regulations and standards are subject to varying interpretations, in many cases due to their lack of specificity and, as a result, their application in practice may evolve over time as new guidance is provided by regulatory and governing bodies. This could result in continuing uncertainty regarding compliance matters and higher costs necessitated by ongoing revisions to disclosure and governance practices. We intend to invest resources to comply with evolving laws, regulations and standards, and this investment may result in increased general and administrative expenses and a diversion of management&#8217;s time and attention from revenue-generating activities to compliance activities. If our efforts to comply with new laws, regulations and standards differ from the activities intended by regulatory or governing </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">114</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;">bodies due to ambiguities related to their application and practice, regulatory authorities may initiate legal proceedings against us and our business may be adversely affected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;">These new rules and regulations may make it more expensive for us to obtain director and officer liability insurance and, in the future, we may be required to accept reduced coverage or incur substantially higher costs to obtain coverage. These factors could also make it more difficult for us to attract and retain qualified members of our board of directors, particularly to serve on our audit committee and compensation committee, and qualified executive officers.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;">By disclosing information in this Annual Report on Form 10-K and in future filings required of a public company, our business and financial condition will become more visible, which we believe may result in threatened or actual litigation, including by competitors and other third parties. If those claims are successful, our business could be seriously harmed. Even if the claims do not result in litigation or are resolved in our favor, the time and resources needed to resolve them could divert our management&#8217;s resources and seriously harm our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;">If we fail to maintain an effective system of internal control over financial reporting, we may not be able to accurately report our financial results or prevent fraud. As a result, stockholders could lose confidence in our financial and other public reporting, which would harm our business and the trading price of our Class&#160;A common stock.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;">Effective internal controls over financial reporting are necessary for us to provide reliable financial reports and, together with adequate disclosure controls and procedures, are designed to prevent fraud. Any failure to implement required new or improved controls, or difficulties encountered in their implementation could cause us to fail to meet our reporting obligations. In addition, any testing by us conducted in connection with Section&#160;404, or any subsequent testing by our independent registered public accounting firm, may reveal deficiencies in our internal controls over financial reporting that are deemed to be material weaknesses or that may require prospective or retroactive changes to our financial statements or identify other areas for further attention or improvement. Inferior internal controls could also cause investors to lose confidence in our reported financial information, which could have a negative effect on the trading price of our stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;">We will be required to disclose changes made in our internal controls and procedures on a quarterly basis and our management will be required to assess the effectiveness of these controls annually. However, for as long as we are an emerging growth company, our independent registered public accounting firm will not be required to attest to the effectiveness of our internal controls over financial reporting pursuant to Section&#160;404. An independent assessment of the effectiveness of our internal controls over financial reporting could detect problems that our management&#8217;s assessment might not. Undetected material weaknesses in our internal controls over financial reporting could lead to restatements of our financial statements and require us to incur the expense of remediation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;">We may be subject to securities litigation, which is expensive and could divert management attention.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">The market price of our Class&#160;A common stock may be volatile and, in the past, companies that have experienced volatility in the market price of their stock have been subject to securities class action litigation. We may be the target of this type of litigation in the future. Securities litigation against us could result in substantial costs and divert our management&#8217;s attention from other business concerns, which could seriously harm our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">New tax legislation may impact our results of operations and financial condition.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The U.S. government may enact significant changes to the taxation of business entities including, among others, an increase in the corporate income tax rate, an increase in the tax rate applicable to the global intangible low-taxed income and elimination of certain exemptions, and the imposition of minimum taxes or surtaxes on certain types of income. The likelihood of these changes being enacted or implemented is unclear. We are currently unable to predict whether such changes will occur. If such changes are enacted or implemented, we are currently unable to predict the ultimate impact on our business.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">115</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"> &#160; &#160; &#160; &#160; <span style="visibility:hidden;">&#8203;</span></p><a id="_7e979625_0764_4010_992f_c2908cbda40d"></a><a id="Item1BUnresolvedStaffComments_541968"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item 1B. Unresolved Staff Comments</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">None</p><a id="_f528b521_7c75_4227_9a39_ae9f649ed762"></a><a id="Item_02"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item 2. Properties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-size:9.5pt;">Our principal office is located at 245 Main Street, Second Floor Cambridge, Massachusetts 02142, where we lease</span><span style="font-size:10pt;"> approximately 586 square feet of office space under a service agreement that can be terminated by either party upon 30 days written notice</span><span style="font-size:9.5pt;">. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We also lease the following properties in San Diego, California: (i) approximately 3,657 square feet of office space; under a lease that terminates on October 1, 2023 and is currently being subleased to a third-party through the remainder of the term of the lease; (ii) approximately 38,613 square feet of office and laboratory space under a lease that terminates on April 30, 2032; (iii) approximately 6,100 square feet of office and laboratory space under a lease that terminates on December 31, 2022 and currently being subleased to a third-party through the remainder of the term of the lease; and (iv) 4,760 square feet of office and laboratory space under a lease that terminates on March 31, 2024. &#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Additionally, we lease approximately 190 square feet of office space in New York, New York under a service agreement that currently runs through March 31, 2022 and automatically renews unless we provide 30 days advance notice to terminate; and approximately 66 square feet of office space in San Francisco, California under an agreement that can be terminated by either party upon 60 days&#8217; notice</p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-size:9.5pt;">We believe that our facilities are sufficient to meet our current needs and that suitable additional space will be available as and when needed.</span></p><a id="_75403698_d3fa_4ff6_8c06_07d03c343d3b"></a><a id="Item_03"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;3. Legal Proceedings</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">From time to time we may be involved in claims and proceedings arising in the course of our business. The outcome of any such claims or proceedings, regardless of the merits, is inherently uncertain. We are not currently party to any material legal proceedings</p><a id="_26a32b19_1693_43a6_b5e2_af09619b7413"></a><a id="Item_04"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;4. Mine Safety Disclosures</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Not applicable</p><a id="_5406b0af_a3fa_4119_97dc_be950375b0e0"></a><a id="Part_II"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">PART II &#8212; OTHER INFORMATION</p><a id="Item_05"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Item 5. &#160;Market For The Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Market Information for Common Stock</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our common stock trades under the symbol &#8220;IMRX&#8221; on the Nasdaq Global Market. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Holders of Our Common Stock</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As of March 3, 2022, there were approximately 83 registered holders of record of our common stock. The actual number of holders of our common stock is greater than this number of record holders and includes stockholders who are beneficial owners, but whose shares are held in &#8220;street name&#8221; by brokers or held by other &#8220;nominees&#8221;. The number of holders of record also does not include stockholders whose shares may be held in trust by other entities.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">116</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Dividend Policy</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We have never declared or paid any cash dividends on our common shares. We currently anticipate that we will retain all available funds and future earnings for the development, operation and expansion of our business and do not anticipate declaring or paying any cash dividends for the foreseeable future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Securities Authorized for Issuance Under Equity Compensation Plans</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">See Item 12, Part III of this Form 10-K.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Unregistered Sales of Equity Securities</p><a id="_Hlk96353815"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">In December 2021, we acquired BioArkive, Inc. (&#8220;BioArkive&#8221;) and in exchange issued to BioArkive and its shareholders 379,635 shares of Immuneering&#8217;s Class A common stock, which was calculated using a value of $8.75 million divided by the average of the daily volume weighted average prices of the Class A common stock on the Nasdaq Stock Exchange for the 30-trading day period ending on and including the trading day immediately prior to the closing.&#160;</span><span style="white-space:pre-wrap;background:#ffffff;">These shares were offered and sold in a private placement exempt from registration under Section 4(a)(2) of the Securities Act.  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Issuer Purchases of Equity Securities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">We did not purchase any of our registered equity securities during the quarterly period ended December 31, 2021.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Securities Authorized for Issuance Under Equity Compensation Plans</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Information about our equity compensation plans will be included in our definitive proxy statement to be filed with the SEC with respect to our 2022 Annual Meeting of Stockholders and is incorporated herein by reference.</p><a id="_60ce005e_6657_434b_b3af_d0251b16cfeb"></a><a id="Item_06"></a><a id="Item_6"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;6. [Reserved]</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_efe8da57_1924_45f6_bc98_c31e08fba837"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item 7.</p><a id="Item_07"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;font-weight:normal;">The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our consolidated financial statements and related notes appearing in Part&#160;II,&#160;Item 8 of this Annual Report on Form&#160;10-K. Some of the information contained in this discussion and analysis or set forth elsewhere in this Annual Report on Form&#160;10-K, including information with respect to our plans and strategy for our business, includes forward-looking statements that involve risks and uncertainties. As a result of many factors, including those factors set forth in Part I, Item IA. &#8216;&#8216;Risk Factors&#8217;&#8217; of this Annual Report on Form&#160;10-K, our actual results could differ materially from the results described in, or implied by, the forward-looking statements contained in the following discussion and analysis.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Overview</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">We aim to improve patient outcomes by advancing a unique pipeline of oncology and neuroscience product candidates developed using our translational bioinformatics platform. We have more than a decade of experience applying translational bioinformatics to generate insights into drug mechanism of action and patient treatment response. Building on this experience, our disease-agnostic discovery platform enables us to create product candidates based on 1) biological insights that are both counterintuitive and deeply rooted in data, and 2) novel chemistry. Our lead product candidate IMM-1-104 is designed to be a highly selective dual-MEK inhibitor that further disrupts KSR to modulate the signaling dynamics of the MAPK pathway.&#160; Specifically, it is designed to drive deep cyclic inhibition that deprives tumor cells of the sustained proliferative signaling required for rapid growth, while providing a cadenced, moderate level of signaling sufficient to </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">117</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">spare healthy cells.&#160; IMM-1-104 is being developed to treat advanced solid tumors in patients harboring RAS mutations, and is translationally guided by our proprietary, human-aligned 3D tumor modeling platform combined with patient-aligned bioinformatics. In addition to IMM-1-104, we have six other oncology programs in the discovery stage that are designed to target components of the MAPK or mTOR pathway, as well as two discovery stage neuroscience programs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We plan to submit an Investigational New Drug application, or IND, for IMM-1-104 to the U.S. Food and Drug Administration, or the FDA, in the third quarter of 2022. In addition, we plan to submit an IND for IMM-6-415 to the FDA in 2023. &#160;We anticipate filing at least one additional IND for our other oncology programs in 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">For the period from inception through 2017, we devoted substantially all of our efforts to business planning, service revenue generation, developing tools to aid in drug discovery, and recruiting management and technical staff. Since 2018, we have also focused significant effort on our own internal research and development programs. We have financed our operations through service revenues, the issuance of convertible debt and the sale of convertible preferred stock and common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">On December&#160;22, 2021, the Company completed the acquisition of all outstanding shares of capital stock of BioArkive, Inc., a California corporation (&#8220;BioArkive&#8221;) for a market value of $8.75 million.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">BioArkive is a San Diego based contract research organization that has previously provided preclinical research services and biosample storage to the Company and other biotechnology companies. BioArkive is in the process of being fully integrated into the Company to exclusively support the Company&#39;s internal preclinical research activities for its oncology pipeline.&#160;In connection with the acquisition,&#160;the Company has assumed the obligations under BioArkive&#8217;s three lease agreements. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">The purchase price was paid by Immuneering through the issuance of an aggregate of 379,635 shares of Immuneering&#8217;s Class&#160;A common stock. The number of shares of common stock issued was calculated using a value based on the average of the daily volume weighted average prices of the common stock on the Nasdaq Stock Exchange for the 30-trading day period ending on and including the trading day immediately prior to the closing date.</span> The sellers of BioArkive are restricted from selling these shares for a 6 month period from the date of the acquisition. As such, we estimated that there was an approximate 10% discount for the lack of marketability of the shares. The fair value of the purchase price in the acquisition has been preliminarily estimated to be $7.88 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our operations have been financed primarily by service revenues and aggregate net proceeds of approximately $81.4 million from the issuance of convertible notes payable, convertible preferred stock (Series A and B) including gross proceeds of approximately $24.8 million from the issuance of shares in the second tranche of Series&#160;B Preferred in April&#160;and May&#160;2021, common stock, exercise of stock options. On August&#160;3, 2021, we completed our IPO pursuant to which we issued and sold 8,625,000 shares of Class A common stock, inclusive of 1,125,000 shares sold by us pursuant to the full exercise of the underwriters&#8217; option to purchase additional shares. We received aggregate net proceeds of approximately $120.3 million from the IPO, after deducting underwriting discounts and commissions, but before deducting offering costs payable by us, which were $2.1 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Since inception, we have had significant annual operating losses. Our net loss was approximately $33.5 million, for the year ended December 31, 2021 and $17.0 million for the&#160;year ended December&#160;31, 2020. As of December&#160;31, 2021, we had an accumulated deficit of approximately $59.3 million and approximately $150.2 million in cash and cash equivalents and marketable securities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Cash used to fund operating expenses is impacted by the timing of when we pay these expenses, as reflected in the change in our accounts payable and accrued expenses. We expect to continue to incur net losses for the foreseeable future, and we expect our research and development expenses, general and administrative expenses, and capital expenditures will continue to increase. In particular, we expect our expenses to increase as we continue our development of, and seek regulatory approvals for, our internally developed product candidates as well as add operational, financial and management informational systems and personnel to support our product development. In addition, if and when we seek and obtain regulatory approval to commercialize any product candidate, we will also incur increased expenses in connection with commercialization and marketing of any such product. Our net losses may fluctuate significantly from quarter-to-quarter </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">118</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">and&#160;year-to-year, depending on the timing of our clinical trials and our expenditures on other research and development activities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Based upon our current business plans, we believe that our existing cash and cash equivalents and marketable securities will be sufficient to fund our development activities and other operations into the third quarter of 2024. We have based this estimate on assumptions that may prove to be wrong, and we could exhaust our available capital resources sooner than we expect. To finance our operations beyond that point we will need to raise additional capital, which cannot be assured.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We have not had any internally developed products approved for sale. We do not expect to generate any product sales unless and until we successfully complete development and obtain regulatory approval for one or more of our internally developed product candidates. If we obtain regulatory approval for any of our internally developed product candidates, we expect to incur significant commercialization expenses related to product sales, marketing, manufacturing and distribution. As a result, until such time, if ever, that we can generate substantial product revenue, we expect to finance our cash needs through service revenue, equity offerings, debt financings or other capital sources, including collaborations, licenses or similar arrangements. However, we may be unable to raise additional funds or enter into such other arrangements when needed or on favorable terms, if at all. Any failure to raise capital as and when needed could have a negative impact on our financial condition and on our ability to pursue our business plans and strategies, including our research and development activities. If we are unable to raise capital, we will need to delay, reduce or terminate planned activities to reduce costs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In March&#160;2020, the World Health Organization declared the COVID-19 outbreak a pandemic. In particular, the ongoing pandemic related to COVID-19 and its variants has resulted in federal, state and local governments and private entities mandating various restrictions, including travel restrictions, access restrictions, restrictions on public gatherings, and stay at home orders. The effect of these orders, government imposed quarantines and measures we have taken, such as implementing work-at-home policies, may negatively impact productivity, disrupt our business and/or could adversely affect our development plans and results. We cannot presently predict the scope and severity of any potential business shutdowns or disruptions, but if we or any of the third parties with whom we engage, including personnel at third-party manufacturing facilities and other third parties with whom we conduct business, were to experience shutdowns or other business disruptions, our ability to conduct our business in the manner and on the timeline presently planned could be materially and adversely impacted. It is unknown how long these conditions will last and what the complete effect will be on us. While to date we have been able to continue to execute our overall business plan, some of our business activities have been slowed and taken longer to complete, particularly with respect to our process for recruiting new employees, and we continue to adjust to the challenges of operating in a largely remote setting with our employees. Overall, we recognize the challenges the pandemic may pose to our business, will continue to closely monitor events as they develop and plan for alternative and mitigating measures that we can implement if needed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Components of Our Results of Operations</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Revenue</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our revenue is generated by providing computational biology professional services to pharmaceutical and biotechnology companies. We charge an agreed upon rate per hour based on the aggregate level of personnel assigned to work on the project or a fixed fee for a defined scope of work. Our contracts specify the period of time over which these professional services will be provided. We recognize revenue over time by measuring the progress toward complete satisfaction of the performance obligation using a single method of measuring progress, which depicts the performance in transferring control of the associated services to the customer. We use input methods to measure the progress toward the complete satisfaction of performance obligations and evaluate the measure of progress each reporting period and, if necessary, adjust the measure of performance and related revenue recognition. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenue and net loss in the period of adjustment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We expect revenue to continue to decrease as we have deprioritized new services work in order to focus on developing our wholly owned pipeline. We expect that, by the end of 2022, revenue associated with this computational biology professional services business will be eliminated.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">119</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We are in the process of discontinuing biosample storage, which was acquired through the BioArkive transaction, to external parties and expect it to complete in the second half of 2022. The revenue earned associated with this is immaterial to the financial statements and is expected to continue decrease until these external services are discontinued.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Cost of Revenue</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our cost of revenue expenses consists primarily of costs related to providing professional services to our customers. These costs include salaries, bonuses, benefits, and stock-based compensation expense, depreciation, facilities, and other outside services. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Operating Expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our operating expenses consist of (i)&#160;research and development expenses and (ii)&#160;general and administrative expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Research and Development </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Research and development expenses account for a significant portion of our operating expenses. Our research and development expenses consist primarily of direct and indirect costs incurred in connection with the development of our research platform, product candidates, discovery efforts and preclinical studies related to our program pipeline.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">Our direct costs include:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">expenses incurred under agreements with CROs and other vendors that conduct our preclinical activities on our behalf; including laboratory expenses related to the execution of preclinical studies on our behalf;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">expenses associated with the manufacturing of our product candidates and preclinical material, including fees paid to contract manufacturers; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">consulting fees and expenses related to preparation of initiation of clinical trials</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">Our indirect costs include:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">personnel-related expenses, consisting of employee salaries, bonuses, benefits and stock-based compensation expense and recruiting costs for personnel engaged in research and development activities; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">facility and equipment related expenses, consisting of indirect and allocated expenses for rent, depreciation, maintenance of facilities, insurance, and other supplies.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We expense research and development costs as incurred. Our direct research and development expenses are not currently tracked on a program-by-program basis, but we anticipate tracking costs on a program-by-program basis at the time IMM-1-104 enters clinical trials, which we expect to occur in the fourth quarter of 2022, assuming our IND application is accepted. We use our personnel and infrastructure resources across multiple research and development programs directed toward identifying and developing product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Due to the inherently unpredictable nature and numerous risks and uncertainties associated with product development and the current stage of development of our product candidates and programs, we cannot reasonably estimate or know the nature, timing and estimated costs necessary to complete the remainder of the development of our product candidates or programs. We are also unable to predict if, when, or to what extent we will obtain approval and generate revenues from the commercialization and sale of any of our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The duration, costs and timing of preclinical studies and clinical trials and development of our product candidates will depend on a variety of factors, such as:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">successful completion of preclinical studies and initiation of clinical trials for future product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">successful enrollment and completion of clinical trials for our current product candidates;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">120</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">data from our clinical programs that support an acceptable risk-benefit profile of our product candidates in the intended patient populations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">acceptance by the FDA or other applicable regulatory agencies of IND applications, clinical trial applications and/or other regulatory filings for our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">expansion and maintenance of a workforce of experienced scientists and others to continue to develop our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">successful application for and receipt of marketing approvals from applicable regulatory authorities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">obtainment and maintenance of intellectual property protection and regulatory exclusivity for our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">making of arrangements with contract manufacturing organizations for, or establishment of, commercial manufacturing capabilities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">establishment of sales, marketing and distribution capabilities and successful launch of commercial sales of our product candidates, if and when approved, whether alone or in collaboration with others;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">acceptance of our product candidates, if and when approved, by patients, the medical community and third-party payors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">effective competition with other therapies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">obtainment and maintenance of coverage, adequate pricing and adequate reimbursement from third-party payors, including government payors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">maintenance, enforcement, defense and protection of our rights in our intellectual property portfolio;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">avoidance of infringement, misappropriation or other violations with respect to others</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8217;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> intellectual property or proprietary rights; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">maintenance of a continued acceptable safety profile of our products following receipt of any marketing approvals.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">A change in the outcome of any of these variables with respect to the development of any of our product candidates could significantly change the costs and timing associated with the development of that product candidate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The process of conducting the necessary preclinical and clinical research to obtain regulatory approval is costly and time-consuming. The actual probability of success for our product candidates may be affected by a variety of factors. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We may never succeed in achieving regulatory approval for any of our product candidates. Further, a number of factors, including those outside of our control, could adversely impact the timing and duration of our product candidates&#8217; development, which could increase our research and development expense. We may obtain unexpected results from our preclinical studies and clinical trials. We may elect to discontinue, delay or modify clinical trials of some product candidates or focus on others. A change in the outcome of any of these factors could mean a significant change in the costs and timing associated with the development of our current and future preclinical and clinical product candidates. For example, if the FDA or another regulatory authority were to require us to conduct clinical trials beyond those that we currently anticipate will be required for the completion of clinical development, or if we experience significant delays in execution of or enrollment in any of our preclinical studies or clinical trials, we could be required to expend significant additional financial resources and time on the completion of preclinical and clinical development.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We expect that our research and development expenses will substantially increase for the foreseeable future as we continue to implement our business strategy, which includes advancing our product candidates through clinical development, expanding our research and development efforts, including hiring additional personnel to support our research and development efforts, and seeking regulatory approvals for our product candidates that successfully complete clinical trials. In addition, product candidates in later stages of clinical development generally incur higher development costs than those in earlier stages of clinical development, primarily due to the increased size and duration of later-stage clinical trials. As a result, we expect our research and development expenses to increase as our product candidates advance into later stages of clinical development. As of the date of this Annual Report on Form 10-K, we cannot reasonably determine or accurately project total program-specific expenses through commercialization. There are numerous factors associated with the successful commercialization of any of our product candidates, including future trial design and various regulatory requirements, many of which cannot be determined with accuracy at this time based on our stage of development.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">121</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">General and Administrative</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our general and administrative expenses consist primarily of personnel-related expenses, including employee salaries, bonuses, benefits, stock-based compensation, and recruiting costs for personnel in executive, finance, and other administrative functions. Other significant general and administrative expenses include legal fees relating to intellectual property and corporate matters, professional fees for accounting, tax and consulting services, insurance costs, travel expenses and facility related expenses not otherwise included in research and development expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We expect our general and administrative expenses will substantially increase for the foreseeable future as we continue to increase our general and administrative headcount to support our continued research and development activities and, if any product candidates receive marketing approval, commercialization activities, as well as to support our operations generally. As we expand our operations, we also expect to incur increased expenses associated with operating as a public company, including costs related to accounting, audit, legal, regulatory, and tax-related services associated with maintaining compliance with exchange listing and rules&#160;and regulations of the SEC, Sarbanes-Oxley Act, director and officer insurance costs, and investor and public relations costs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-bottom:12pt;margin:0pt;">Other Income (Expense)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"><i style="font-style:italic;">Interest income</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;">Interest income consists of interest earned on our cash and cash equivalents balances and our marketable securities. The primary objective of our investment policy is capital preservation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"><i style="font-style:italic;">Other expense</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;">Other expense consists of the amortization of premiums or accretion of discounts related to our marketable securities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><a id="_Hlk96353998"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"><i style="font-style:italic;">Income tax benefit</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;">Income tax benefit is due to a release of a valuation reserve during 2021 as a result of the business combination.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">122</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Results of Operations</p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-size:9.5pt;font-weight:bold;">Comparison of the Years Ended December&#160;31, 2021 and 2020</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The following table summarizes our results of operations for the periods indicated:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:58.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:58.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:20.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:16.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Change</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">%&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="13" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:58.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="10" style="vertical-align:bottom;white-space:nowrap;width:37.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in thousands, except percentages)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Revenue</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 2,080</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 2,311</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (231)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (10.0)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:58.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Cost of revenue</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 1,153</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 1,280</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (127)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (9.9)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:58.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Gross profit</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 927</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 1,031</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (104)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (10.1)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:58.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Operating expenses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 26,541</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 15,004</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 11,537</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 76.9</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:58.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 8,272</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 3,110</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 5,162</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 166.0</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:58.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total operating expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 34,813</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 18,114</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 16,699</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 92.2</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:58.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Loss from operations</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (33,886)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (17,083)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (16,803)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 98.4</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Other income (expense)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Interest income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 170</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 43</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 127</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 295.3</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:58.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (127)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (127)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">N/M</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:58.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Loss before income taxes</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (33,843)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (17,040)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (16,803)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 98.6</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Income tax benefit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 307</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 307</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">N/M</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:58.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Net loss</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (33,536)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (17,040)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">N/M &#8211; Not meaningful</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Revenue</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The following table summarizes the revenue recognized for the periods indicated:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:58.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:58.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:18.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:17.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Change</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">%&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="13" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:58.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:40.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in thousands, except percentages)</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Revenue</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 2,080</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 2,311</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (231)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (10.0)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Revenue decreased by approximately $0.2 million, or 10% to approximately $2.1 million for the year ended December&#160;31, 2021 compared to approximately $2.3 million for the year ended December 31, 2020. The decrease in revenue was due to approximately $0.3 million related to customer agreements that were completed in 2020, offset by a $0.1 million increase in new customers in the year ended December 31, 2021. <span style="font-size:12pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">123</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Cost of Revenue</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The following table summarizes the components of cost of revenue expenses for the periods indicated:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:58.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:58.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:18.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:17.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Change</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">%&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="13" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:58.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:39.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in thousands, except percentages)</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Employee related costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 934</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,087</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (153)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (14.1)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:58.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Stock-based compensation expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 103</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 108</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (5)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (4.6)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:58.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outside contract research services</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 6</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (6)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (100.0)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:58.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Facilities and other allocated expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 108</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 74</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 34</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 45.9</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:58.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Depreciation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 8</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.33%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 5</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 3</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 60.0</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:top;width:58.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total cost of revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,153</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.33%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,280</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (127)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (9.9)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Cost of revenue decreased by approximately $0.1 million, or 9.9%, to approximately $1.2 million for the year ended December 31, 2021 compared to approximately $1.3 million for the year ended December 31, 2020. The decrease was primarily due to decreased employee-related costs of approximately $0.2 million offset by an increase in facilities and other allocated expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Research and Development</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The following table summarizes the components of our research and development expenses for the periods indicated:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:58.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:58.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:18.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:17.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Change</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:7.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">%</b></p></td><td style="vertical-align:bottom;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="13" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:58.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="10" style="vertical-align:bottom;white-space:nowrap;width:37.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in thousands, except percentages)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Employee related costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">8,001 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 5,505</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">2,496 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 45.3</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:58.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Stock-based compensation expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">769 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 503</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">266 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 52.9</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:58.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outside contract research services</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">17,307 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 8,646</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">8,661 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 100.2</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:58.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Facilities and other allocated expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">434 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 330</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">104 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 31.5</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:58.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Depreciation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">30 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 20</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">10 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 50.0</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:58.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">26,541 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 15,004</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">11,537 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 76.9</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Research and development expenses increased by approximately $11.5 million, or 76.9%, to approximately $26.5 million for the year ended December 31, 2021 compared to approximately $15.0 million for the year ended December 31, 2020. The increase of approximately $11.5 million was primarily due to approximately $8.7 million of outside contract research services for our preclinical candidates resulting from an increased number of discovery programs and increased spending on later stage preclinical efforts. The increase also includes approximately $2.5 million of additional employee-related costs, primarily due to an increase in headcount, approximately $0.3 million increase for stock-based compensation expense and $0.1 million increase for facilities and other allocated expenses.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">124</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">General and Administrative</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The following table summarizes the components of our general and administrative expenses for the periods indicated:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:58.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:58.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:18.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:17.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Change</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">%&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="13" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:58.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:39.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in thousands, except percentages)</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Employee related costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 4,506</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,426</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 3,080</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 216.0</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:58.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Stock-based compensation expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 931</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 476</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 455</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 95.6</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:58.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Professional fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,803</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 836</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 967</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 115.7</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:58.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Public relations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 262</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 289</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (27)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (9.3)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:58.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outside consultants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 75</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 18</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 57</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 316.7</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:58.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Facilities and other allocated expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 125</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 38</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 87</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 228.9</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:58.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 570</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.33%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 27</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 543</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 2,011.1</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:58.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total general and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 8,272</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.33%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 3,110</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 5,162</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 166.0</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">General and administrative expenses increased by approximately $5.2 million, or 166.0%, to approximately $8.3 million for the year ended December 31, 2021 compared to approximately $3.1 million for the year ended December 31, 2020. The increase of approximately $5.2 million was primarily due to increased employee-related costs of approximately $3.1 million as a result of increased headcount, increased professional fees incurred for accounting, auditing, legal, public relations and tax services of approximately $1.0 million, increased facilities expenses of approximately $0.1 million, approximately $0.5 million increase in stock-based compensation expense and $0.5 million increase in other, which is primarily related to franchise tax expense.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Other Income (expense)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Interest income increased by approximately $0.1 million due to the interest earned on our cash and cash equivalents and marketable securities balances due to the higher balances as a result of the IPO proceeds.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Other expense increased by $0.1 million as a result of the amortization of premiums related to our marketable securities. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Liquidity and Capital Resources</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Sources of Liquidity</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Since our inception, we have financed our operations through service revenues, the issuance of convertible notes payable, convertible preferred stock, common stock, and the exercise of stock options. As of December 31, 2021, we had an accumulated deficit of $59.3 million and $150.2 million in cash and cash equivalents and marketable securities. Cash and cash equivalents are comprised of deposits at major financial banking institutions and highly liquid investments with an original maturity of three&#160;months or less at the date of purchase. &#160;Our primary use of cash is to fund operating expenses, which consist primarily of research and development expenditures, and to a lesser extent, general and administrative expenditures. Cash used to fund operating expenses is impacted by the timing of when we pay these expenses, reflected in the change in our outstanding accounts payable and accrued expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Since our inception, we have incurred significant operating losses. We have not yet commercialized any of our product candidates, and we do not expect to generate revenue from sales of any product candidates for the next several&#160;years, if at all. To date, our operations have been financed primarily by service revenues and aggregate net proceeds of approximately $81.4 million from the issuance of convertible notes payable, convertible preferred stock including gross proceeds of approximately $24.8 million from the issuance of shares in the second tranche of Series&#160;B Preferred in April&#160;and May&#160;2021, common stock, the exercise of stock options. In August 2021, we completed our IPO pursuant to which we issued and sold 8,625,000 shares of Class A common stock, inclusive of 1,150,000 shares sold by us pursuant to the full exercise of the underwriters&#8217; option to purchase additional shares. We received aggregate net proceeds of approximately </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">125</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">$120.3 million from the IPO, after deducting underwriting discounts and commissions, but before deducting offering costs payable by us, which were $2.1 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As of December 31, 2021, we have contractual obligations related to various leases of $0.7 million for 2022, $0.9 million for 2023, $0.9 million for 2024, $0.9 million for 2025, $0.8 million for 2026 and $4.5 million for the periods thereafter.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We have no off-balance sheet arrangements that have a material current effect or that are reasonably likely to have a material future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures, or capital resources.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Cash Flows</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The following table summarizes our sources and uses of cash for the periods indicated:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:73.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="7" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net cash (used in) provided by:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (30,851)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (14,621)</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Investing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (75,616)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (53)</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Financing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 144,265</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 37,982</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net increase in cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 37,798</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 23,308</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Net Cash Used in Operating Activities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">During the year ended December 31, 2021, operating activities used approximately $30.9 million of cash, primarily resulting from our net loss of approximately $33.5 million, deferred tax benefit of $0.3 million, and cash provided by changes in our operating assets and liabilities of approximately $0.9 million, partially offset by stock-based compensation expense of approximately $1.8 million, net amortization of premium (accretion of discount) on marketable securities of $0.1 million, and $0.2 million right of use amortization and depreciation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">During the year ended December&#160;31, 2020, operating activities used approximately $14.6&#160;million of cash, primarily resulting from our net loss of approximately $17.0&#160;million, partially offset by stock-based compensation expense of approximately $1.1&#160;million and cash provided by changes in our operating assets and liabilities of approximately $1.3&#160;million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Net Cash Used in Investing Activities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">During the year ended December 31, 2021 and 2020, investing activities used approximately $75.6 million, and approximately $0.1 million respectively. For the year 2021, cash used from investing was primarily related to purchases of marketable securities of approximately $75.6 million, approximately $0.1 million for the purchases of property and equipment, and cash acquired in business combination of approximately $0.1 million. &#160;For 2020 cash used in investing was a result of purchases of property and equipment of approximately $0.1 million. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Net Cash Provided by Financing Activities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">During the year ended December 31, 2021, net cash provided by financing activities was approximately $144.3 million, consisting primarily of approximately $24.8 million in net proceeds received from the issuance of Series&#160;B preferred stock, approximately $118.2 million from the net proceeds from our initial public offering, approximately $0.9 million in net proceeds from the exercise of warrants and approximately $0.4 million from the exercise of stock options.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">During the year ended December&#160;31, 2020, net cash provided by financing activities was approximately $38.0&#160;million, consisting primarily of approximately $37.0&#160;million in net proceeds received from the issuance of Series&#160;B preferred stock and approximately $1.0&#160;million in net proceeds from the issuance of Series&#160;A preferred stock.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">126</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Future Funding Requirements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We expect that our expenses will increase substantially in connection with our ongoing activities, particularly as we advance the preclinical activities and clinical trials for our product candidates in development. The timing and amount of our operating and capital expenditures will depend largely on:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the impacts of the pandemic related to COVID-19 and its variants and potential future pandemics;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs and results of our potential future clinical trials for our other product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the scope, progress, results and costs of discovery research, preclinical development, laboratory testing and clinical trials for our other product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs, timing and outcome of regulatory review of our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to enter into contract manufacturing arrangements for supply of active pharmaceutical ingredient, or API, and manufacture of our product candidates and the terms of such arrangements;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the payment or receipt of milestones and receipt of other collaboration-based revenues, if any;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs and timing of any future commercialization activities, including product manufacturing, sales, marketing and distribution, for any of our product candidates for which we may receive marketing approval;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the amount and timing of revenue, if any, received from commercial sales of our product candidates for which we receive marketing approval;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs and timing of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property and proprietary rights and defending any intellectual property related claims;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the extent to which we acquire or in-license other products, product candidates, technologies or data referencing rights;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to establish and maintain strategic collaborations, licensing or other arrangements and the financial terms of such arrangements;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to access the private and public capital markets or to obtain financing at commercially reasonable rate;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the ability to receive additional non-dilutive funding, including grants from organizations and foundations; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs of operating as a public company.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We believe that our existing cash, cash equivalents and marketable securities, will enable us to fund our operating expenses and capital expenditure requirements into the third quarter of 2024. We have based this estimate on assumptions that may prove to be wrong, and we could utilize our available capital resources sooner than we expect.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Critical Accounting Policies and Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our consolidated financial statements are prepared in accordance with generally accepted accounting principles in the United States, or GAAP. The preparation of our consolidated financial statements and related disclosures requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenue, costs and expenses and the disclosure of contingent assets and liabilities in our financial statements. We base our estimates on historical experience, known trends and events and various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. We evaluate our estimates and assumptions on an ongoing basis. Our actual results may differ from these estimates under different assumptions or conditions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">While our significant accounting policies are described in more detail in Note 2 to our consolidated financial statements appearing at the end of this Annual Report on Form 10-K, we believe that the following accounting policies are those most critical to the judgments and estimates used in the preparation of our financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Research and Development Costs</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">We incur substantial expenses associated with manufacturing and clinical trials. Accounting for clinical trials relating to activities performed by contract research organizations, or CROs, and other external vendors requires management to </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">127</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">exercise significant estimates in regard to the timing and accounting for these expenses. We estimate costs of research and development activities conducted by service providers, which include the conduct of sponsored research, preclinical studies and contract manufacturing activities. The diverse nature of services being provided under CROs and other arrangements, the different compensation arrangements that exist for each type of service and the lack of timely information related to certain clinical activities complicates the estimation of accruals for services rendered by CROs and other vendors in connection with clinical trials. Because payments of research and development activities do not always line up with the provision of such services, the balance sheet may reflect either an accrued or prepaid position. In estimating the duration of a clinical study, we evaluate the start-up, treatment and wrap up periods, compensation arrangements and services rendered attributable to each clinical trial and fluctuations are regularly tested against payment plans and trial completion assumptions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We estimate these costs based on factors such as estimates of the work completed and budget provided and in accordance with agreements established with our collaboration partners and third-party service providers. We make significant judgments and estimates in determining the accrued liabilities and prepaid expense balances in each reporting period. As actual costs become known, we adjust our accrued liabilities or prepaid expenses. We have not experienced any material differences between accrued costs and actual costs incurred since our inception.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our expenses related to clinical trials will be based on estimates of patient enrollment and related expenses at clinical investigator sites as well as estimates for the services received and efforts expended pursuant to contracts with multiple research institutions and CROs that may be used to conduct and manage clinical trials on our behalf. We will accrue expenses related to clinical trials based on contracted amounts applied to the level of patient enrollment and activity. If timelines or contracts are modified based upon changes in the clinical trial protocol or scope of work to be performed, we will modify our estimates of accrued expenses accordingly on a prospective basis.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Stock-Based Compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We measure stock-based awards granted to employees, non-employees and directors based on their fair value on the date of the grant using the Black-Scholes option-pricing model for options or the difference between the purchase price per share of the award, if any, and the fair value of our common stock for restricted common stock awards. Compensation expense for those awards is recognized over the requisite service period, which is generally the vesting period of the award for employees and directors and the period during which services are performed for non-employees. We use the straight-line method to record the expense of awards with service-based vesting conditions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Black-Scholes option-pricing model uses as inputs the fair value of our common stock and assumptions we make for the volatility of our common stock, the expected term of our stock options, the risk-free interest rate for a period that approximates the expected term of our stock options, and our expected dividend yield.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Off-balance Sheet Arrangements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">During the periods presented, we did not have, nor do we currently have, any off-balance sheet arrangements as defined in the rules&#160;and regulations of <span style="display:inline-block;width:4.36pt;"></span>the SEC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Recently Issued Accounting Pronouncements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">A description of recently issued accounting pronouncements that may potentially impact our financial position, results of operations or cash flows is disclosed in Note 2 to our consolidated financial statements appearing at the end of this Annual Report on Form 10-K.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Emerging Growth Company Status</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">As an emerging growth company, or EGC, under the Jumpstart Our Business Startups Act of 2012, or JOBS Act, we may delay the adoption of certain accounting standards until such time as those standards apply to private companies. Other exemptions and reduced reporting requirements under the JOBS Act for EGCs include presentation of only two&#160;years of audited consolidated financial statements, an exemption from the requirement to provide an auditor&#8217;s report on internal </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">128</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">controls over financial reporting pursuant to Section&#160;404(b)&#160;of the Sarbanes-Oxley Act, an exemption from any requirement that may be adopted by the Public Company Accounting Oversight Board, and less extensive disclosure about our executive compensation arrangements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In addition, the JOBS Act provides that an EGC can take advantage of an extended transition period for complying with new or revised accounting standards. This provision allows an EGC to delay the adoption of some accounting standards until those standards would otherwise apply to private companies. We have elected to use this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date we (i)&#160;are no longer an emerging growth company or (ii)&#160;affirmatively and irrevocably opt out of the extended transition period provided in the JOBS Act. As a result, our &#160;consolidated financial statements may not be comparable to companies that comply with new or revised accounting pronouncements as of public company effective dates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We may remain classified as an EGC until the end of the fiscal&#160;year following the fifth anniversary of our IPO, although if the market value of our common stock that is held by non-affiliates exceeds $700 million as of June&#160;30 of any&#160;year before that time, or if we have annual gross revenues of $1.07 billion or more in any fiscal&#160;year, we would cease to be an EGC as of December&#160;31 of the applicable&#160;year. We also would cease to be an EGC if we issue more than $1.0 billion of non-convertible debt over a three-year period.</p><a id="_622cbe5c_26a4_4c51_80ad_8c656cd0ee61"></a><a id="Item_07A"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;7A. Quantitative and Qualitative Disclosures about Market Risk</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As a smaller reporting company, as defined by Rule 12b-2 of the Securities Exchange Act of 1934, as amended, we are not required to provide this information.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">129</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_101e0d7c_a035_4752_bd54_469652bf774f"></a><a id="Item_08"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item 8. Financial Statements and Supplementary Data</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Immuneering Corporation</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Index to Consolidated Financial Statements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:90.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:9.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:90.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.11%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Page(s)</b></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:90.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ReportofIndependentRegisteredPublic"><span style="font-style:normal;font-weight:normal;">Report of Independent Registered Public Accounting Firm</span></a><span style="white-space:pre-wrap;">  (PCAOB ID: </span><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ" name="dei:AuditorFirmId" id="Narr_xsV1-nvWcUmLGGhr35kEtA">49</ix:nonNumeric>)</p></td><td style="vertical-align:top;width:9.11%;background:#cceeff;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">131</p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:90.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Balance_Sheets"><span style="font-style:normal;font-weight:normal;">Consolidated Balance Sheets</span></a></p></td><td style="vertical-align:top;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">132</p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:90.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Operations"><span style="font-style:normal;font-weight:normal;">Consolidated Statements of Operations and Comprehensive Loss</span></a></p></td><td style="vertical-align:top;width:9.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">133</p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:90.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Equity"><span style="font-style:normal;font-weight:normal;">Consolidated Statements of Convertible Preferred Stock and Stockholders&#8217; Equity (Deficit)</span></a></p></td><td style="vertical-align:top;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">134</p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:90.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Cash_Flows"><span style="font-style:normal;font-weight:normal;">Consolidated Statements of Cash Flows</span></a></p></td><td style="vertical-align:top;width:9.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">135</p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:90.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Notes"><span style="font-style:normal;font-weight:normal;">Notes to Consolidated Financial Statements</span></a></p></td><td style="vertical-align:top;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">136</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">130</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_6cd1d417_17ae_4b1d_9b44_1b8558e9c33e"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:10.0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="concept126"></a><a id="concept125"></a><a id="ReportofIndependentRegisteredPublic"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.0pt;text-align:center;background:#ffffff;margin:0pt;"><b style="font-weight:bold;">Report of Independent Registered Public Accounting Firm</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.0pt;background:#ffffff;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.0pt;background:#ffffff;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.0pt;background:#ffffff;margin:0pt;">To the Stockholders and the Board of Directors of Immuneering Corporation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.0pt;background:#ffffff;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.0pt;background:#ffffff;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.0pt;background:#ffffff;margin:0pt;"><b style="font-weight:bold;">Opinion on the Financial Statements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.0pt;background:#ffffff;margin:0pt;">We have audited the accompanying consolidated balance sheets of Immuneering Corporation and its subsidiaries (the Company) as of December 31, 2021 and 2020, and the related consolidated statements of operations and comprehensive loss, convertible preferred stock and stockholders&#8217; equity (deficit) and cash flows for the years then ended, and the related notes to the consolidated financial statements (collectively, the financial statements). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2021 and 2020, and the results of its operations and its cash flows for the years then ended, in conformity with accounting principles generally accepted in the United States of America.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.0pt;background:#ffffff;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.0pt;background:#ffffff;margin:0pt;"><b style="font-weight:bold;">Basis for Opinion</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.0pt;background:#ffffff;margin:0pt;">These financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits. We are a public accounting firm registered with the&#160;Public Company Accounting Oversight Board (United States) (PCAOB)&#160;and are required to be independent with respect to the Company in accordance with U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.0pt;background:#ffffff;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.0pt;background:#ffffff;margin:0pt;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.0pt;background:#ffffff;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.0pt;background:#ffffff;margin:0pt;">Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.0pt;background:#ffffff;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.0pt;background:#ffffff;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;min-height:10.0pt;background:#ffffff;margin:0pt;"><span style="font-size:10pt;">/s/ </span><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ" name="dei:AuditorName" id="Narr_tGDmj-Iym0682hfrgFKbTw"><span style="font-size:10pt;">RSM US LLP</span></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.0pt;background:#ffffff;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.0pt;background:#ffffff;margin:0pt;">We have served as the Company&#39;s auditor since 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.0pt;background:#ffffff;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;min-height:10.0pt;background:#ffffff;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ" name="dei:AuditorLocation" id="Narr_UwhcT2byQ0-wu3gkD8iOLQ"><span style="font-size:10pt;">Boston, Massachusetts</span></ix:nonNumeric><span style="font-size:10pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.0pt;background:#ffffff;margin:0pt;">March 10, 2022</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;min-height:10.0pt;text-align:center;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">131</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_ee75d3f6_73e7_4b1d_a9a6_7a8a13422091"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">PART I &#8211; FINANCIAL INFORMATION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Item 1. Financial Statements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">IMMUNEERING CORPORATION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="Balance_Sheets"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">CONSOLIDATED BALANCE SHEETS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><a id="_c6d0d112_ca12_4029_ae77_e9a43746b771"></a><a id="Tc_b944xNFRRUuBtV9Ppc4H8Q_1_2"></a><a id="Tc_jhCWk_S_xk21-Plj-WmN1A_1_5"></a><a id="Tc__DEj1RQVBkiKlF677oHfkQ_3_0"></a><a id="Tc_NlVQUYMoU0iGl0H5N9WSOQ_4_0"></a><a id="Tc_gT4CFLXCZUifKTp1jTPXYg_5_0"></a><a id="Tc__BSCWpWzE0eg52qkzWRIqg_5_2"></a><a id="Tc_JaBq1U-v-ECVukN0lvtsKg_5_5"></a><a id="Tc_AgRRX8HUgky8UBCPpHsZiA_6_0"></a><a id="Tc_fcrN9Fouo02PwKFjqrVfNg_6_6"></a><a id="Tc_qpem8QZaHEGu0ml8i-7D2Q_7_0"></a><a id="Tc_acKgJ9G6G0-2dfSQ20jfrA_8_0"></a><a id="Tc_j0rtZX3A1UKTuC5UrX7c8g_9_0"></a><a id="Tc_MEZO-9pILkyTzflWEbDqYw_11_0"></a><a id="Tc_MEUyM9p2d0ytASusu295LQ_11_6"></a><a id="Tc_UM6bb_udCUeQAr-em13eDQ_12_0"></a><a id="Tc_BA6hqBx1A0-Y4uF_PbheOg_13_0"></a><a id="Tc_-cYNPSw9i0ui3sUcJPQZ5A_13_6"></a><a id="Tc_4da1_VR8zkGjNd6HzmNB-w_14_0"></a><a id="Tc_uZhGGtc05k61CWVwl8PpGw_14_6"></a><a id="Tc_glsaglvNtU-hpvKVWWm-4Q_15_0"></a><a id="Tc_Dzqez16mlEGCKXyGEDAYqQ_16_0"></a><a id="Tc_PbBmkkW1VUirY5L56EZPXw_17_0"></a><a id="Tc_Sr-0lIxS1kalRY5jThFviA_17_2"></a><a id="Tc_2swXhkQH8UGpYUZ0RL-Tig_17_5"></a><a id="Tc_rJJy6ZAV1EeVbmroIXL6nQ_19_0"></a><a id="Tc_PA4zsqqpj0ipJNFYo0fWQg_20_0"></a><a id="Tc_0PDpv8cqrEiaGKUYYKS2ig_21_0"></a><a id="Tc_5Qx-QW8erUSLqr5tNv9QIw_21_2"></a><a id="Tc_z_zcEGQ3-kqbhpOTqA1gvA_21_5"></a><a id="Tc_zLdLER_m6Eaq9PULw4IC6w_22_0"></a><a id="Tc_luuylokhqEKPVB_Sc0sVZw_23_0"></a><a id="Tc_1YwApZ2Gb0u7fO2JDMPaSg_24_0"></a><a id="Tc_dBm6t-MkeUiA4UtImBp-Dw_26_0"></a><a id="Tc_4rpyAXENs0GV37nqYATspA_27_0"></a><a id="Tc_Gal8lUyklkG9hRWZFygFsw_28_0"></a><a id="Tc_qC7U_T_AZUW3gAogTb7o9A_29_0"></a><a id="Tc_Ia3eppSzLUO9vrbZyLOLqQ_30_0"></a><a id="Tc_4bpu9FmJ6U6eQGLmUBZZ7w_31_0"></a><a id="Tc_zoATaDr0H0enTaYXN17-oA_31_3"></a><a id="Tc_fhKPfJb-A0G6WbpQeS1y2g_32_0"></a><a id="Tc_LGb20HPsDUmKgUG1-P9F2w_32_3"></a><a id="Tc_TRZ4vOgZmUO3E3K1HFMEdg_33_0"></a><a id="Tc_lIW4PmCmdkSWf6_8AV_M4A_33_3"></a><a id="Tc_xLlOwJ5NIUWBTQ8nGEvW-w_34_0"></a><a id="Tc_SHepDn6bdUSkAf3LssCFhA_35_0"></a><a id="_6f7a5043_bc82_4f9d_b72a_bb23155c5602"></a><a id="_6f7a5043_bc82_4f9d_b72a_bb23155c5602_2"></a><a id="_6f7a5043_bc82_4f9d_b72a_bb23155c5602_3"></a><a id="Tc_CODRs4GsgkySzJEEoe3_6A_36_0"></a><a id="Tc_gb7UpYIqWkKqvkYRBc-SMA_37_0"></a><a id="Tc_CXVhpQmWhEG5rBTvjKG1dg_38_0"></a><a id="Tc_MUHsbHmiNk2yARRONeCABg_39_0"></a><a id="Tc_eutNq-eHn0-z0I54-QuO-g_39_6"></a><a id="Tc_BHG1fIawTEOsnA8EmslYjQ_40_0"></a><a id="Tc_uGAlxMgugkaU9sNZSx-lRA_41_0"></a><a id="Tc_Q2IJXBbSQEOv1bjGXbbcIw_42_0"></a><a id="Tc_Iwc1OeTQbEiTJKqKJkfvZQ_42_2"></a><a id="Tc_Z-ZV435bhEWEg31UhN_ApA_42_5"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:69.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:69.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2020</b></p></td></tr><tr><td style="vertical-align:top;width:69.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:69.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><b style="font-weight:bold;">Assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:top;width:69.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">Current assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:top;width:69.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="As_Of_12_31_2021_TBpjtOXgEkKQahJJAv0aWg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" id="Tc_Q-6GlEjgkEi-S2GsUzGcxw_5_3">74,888,145</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="As_Of_12_31_2020_OUSLyqWONEO8ccGPC6rBdg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" id="Tc_wa_KapMYvUqWJgg2UiYZuw_5_6">37,090,151</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:69.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">Marketable securities, current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="As_Of_12_31_2021_TBpjtOXgEkKQahJJAv0aWg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:MarketableSecuritiesCurrent" scale="0" id="Tc_IwFixIMC-0qe9awCxCha0A_6_3">74,311,203</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:69.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">Accounts receivable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="As_Of_12_31_2021_TBpjtOXgEkKQahJJAv0aWg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="0" id="Tc_QW6v4UUUCEuW5RZsZ2BeWQ_7_3">246,040</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="As_Of_12_31_2020_OUSLyqWONEO8ccGPC6rBdg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="0" id="Tc_qZYyybmKCU2gY5tmVP10Sw_7_6">500,110</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:69.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">Prepaids and other current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="As_Of_12_31_2021_TBpjtOXgEkKQahJJAv0aWg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="0" id="Tc_ZyQik3--T0KfhriocBezPA_8_3">2,888,608</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="As_Of_12_31_2020_OUSLyqWONEO8ccGPC6rBdg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="0" id="Tc_BEX_4WsGuk2ag8UpnSPrTA_8_6">140,958</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:69.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">Total current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="As_Of_12_31_2021_TBpjtOXgEkKQahJJAv0aWg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="0" id="Tc__7hMqetkikiN6G3FhpxKXg_9_3">152,333,996</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="As_Of_12_31_2020_OUSLyqWONEO8ccGPC6rBdg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="0" id="Tc_kk7xSNAv8EmkZP8Lkbm5ng_9_6">37,731,219</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:69.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:69.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">Marketable securities, non-current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="As_Of_12_31_2021_TBpjtOXgEkKQahJJAv0aWg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:MarketableSecuritiesNoncurrent" scale="0" id="Tc_6pbUVNQb9k23NDnDjgnivQ_11_3">996,560</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:69.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">Property and equipment, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="As_Of_12_31_2021_TBpjtOXgEkKQahJJAv0aWg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" id="Tc_V-xS8PsXZku6XgECrepA2Q_12_3">807,223</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="As_Of_12_31_2020_OUSLyqWONEO8ccGPC6rBdg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" id="Tc_vodyQGjYZU-riaunSgearw_12_6">64,363</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:69.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">Goodwill</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="As_Of_12_31_2021_TBpjtOXgEkKQahJJAv0aWg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="0" id="Tc_OTmA1WVNZE2PKzNUqLkBmA_13_3">6,701,726</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:69.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">Intangible asset</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="As_Of_12_31_2021_TBpjtOXgEkKQahJJAv0aWg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="0" id="Tc_-ko1-DaLZE6uWBmssv-Mtw_14_3">439,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:69.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">Right-of-use assets, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="As_Of_12_31_2021_TBpjtOXgEkKQahJJAv0aWg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="0" id="Tc_AquINwWVckOdcSEtr5wBww_15_3">5,324,198</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="As_Of_12_31_2020_OUSLyqWONEO8ccGPC6rBdg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="0" id="Tc_96hE3lsqcUapDgN8AyJKWw_15_6">613,103</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:69.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">Other assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="As_Of_12_31_2021_TBpjtOXgEkKQahJJAv0aWg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="0" id="Tc_h0cUbr53CEKI53ndVIitkA_16_3">102,129</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="As_Of_12_31_2020_OUSLyqWONEO8ccGPC6rBdg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="0" id="Tc_QOmP-DAecEqi1c4mBji_1w_16_6">14,333</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:69.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><b style="font-weight:bold;">Total assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.98%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="As_Of_12_31_2021_TBpjtOXgEkKQahJJAv0aWg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="0" id="Tc_vFfiOUx9jke0XhO8t2twIw_17_3">166,704,832</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="As_Of_12_31_2020_OUSLyqWONEO8ccGPC6rBdg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="0" id="Tc_eYXVXUbFSk6BxL3szpbbqQ_17_6">38,423,018</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:top;width:69.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:69.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><b style="font-weight:bold;">Liabilities, convertible preferred stock and stockholders&#39; equity (deficit)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:top;width:69.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">Current liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:top;width:69.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">Accounts payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="As_Of_12_31_2021_TBpjtOXgEkKQahJJAv0aWg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="0" id="Tc_1CPnnIwapkKRuLJ0028GvQ_21_3">1,394,340</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="As_Of_12_31_2020_OUSLyqWONEO8ccGPC6rBdg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="0" id="Tc_j3akNlw_z0a9Z2lHTS86MQ_21_6">1,480,537</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:69.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">Accrued expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="As_Of_12_31_2021_TBpjtOXgEkKQahJJAv0aWg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="0" id="Tc_4gdnCtALzE2dhFqjMWfDTw_22_3">3,965,447</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="As_Of_12_31_2020_OUSLyqWONEO8ccGPC6rBdg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="0" id="Tc_C9dVE6pYyEK4WhWQKMMM-A_22_6">698,992</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:69.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">Lease liabilities, current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="As_Of_12_31_2021_TBpjtOXgEkKQahJJAv0aWg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="0" id="Tc_-CIO1WYpSE6YERZfmincxw_23_3">274,039</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="As_Of_12_31_2020_OUSLyqWONEO8ccGPC6rBdg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="0" id="Tc_OHaXMkWoQ0q0FhZ50sTZsA_23_6">76,322</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:69.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">Total current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="As_Of_12_31_2021_TBpjtOXgEkKQahJJAv0aWg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="0" id="Tc_D15yOK4PakKcNUklvNIazg_24_3">5,633,826</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="As_Of_12_31_2020_OUSLyqWONEO8ccGPC6rBdg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="0" id="Tc_Ns4SOBCLvU-Uc4fRdXZ1KA_24_6">2,255,851</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:69.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:69.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">Long-term liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:top;width:69.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">Lease liabilities, non-current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="As_Of_12_31_2021_TBpjtOXgEkKQahJJAv0aWg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="0" id="Tc_ia-6R1OSR0-x6sivg6vMRQ_27_3">5,090,897</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="As_Of_12_31_2020_OUSLyqWONEO8ccGPC6rBdg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="0" id="Tc_HNd5-udbiUOe3wSUw0wltA_27_6">544,767</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:69.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">Total liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="As_Of_12_31_2021_TBpjtOXgEkKQahJJAv0aWg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="0" id="Tc_64Be6xs0EUOA-ITIzbCAgw_28_3">10,724,723</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="As_Of_12_31_2020_OUSLyqWONEO8ccGPC6rBdg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="0" id="Tc_5DBTHV_zJkCMwAmjTwL3Xw_28_6">2,800,618</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:69.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">Commitments and contingencies (Note 13)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:top;width:69.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">Convertible preferred stock:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:top;width:69.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;">Series B preferred stock, </span><span style="font-size:7pt;">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_0VraXufKhkCSOUw2U_zvgQ" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_imrx_SeriesBConvertiblePreferredStockMember_-Ckh5K8N7U-_9nyMHjiJxQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityParOrStatedValuePerShare" scale="0" id="Narr_npAndejvG0O0zI_L5uqgKA"><ix:nonFraction unitRef="Unit_Divide_USD_shares_0VraXufKhkCSOUw2U_zvgQ" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_imrx_SeriesBConvertiblePreferredStockMember_lxbE9uvMQU-NU7BxZ_aTNg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityParOrStatedValuePerShare" scale="0" id="Narr_Bj_ffFbLLEKke04VDfYZMw">0.001</ix:nonFraction></ix:nonFraction></span><span style="font-size:7pt;"> par value, </span><span style="font-size:7pt;"><ix:nonFraction unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_imrx_SeriesBConvertiblePreferredStockMember_lxbE9uvMQU-NU7BxZ_aTNg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesAuthorized" scale="0" id="Narr__GvOhS9jeEe44h_wBu83kw">0</ix:nonFraction></span><span style="font-size:7pt;"> and </span><span style="font-size:7pt;"><ix:nonFraction unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_imrx_SeriesBConvertiblePreferredStockMember_-Ckh5K8N7U-_9nyMHjiJxQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesAuthorized" scale="0" id="Narr_5Bxji6PW4EyhAIBSADRleQ">6,032,183</ix:nonFraction></span><span style="font-size:7pt;"> shares authorized at December 31, 2021 and December 31, 2020, </span><span style="font-size:7pt;"><ix:nonFraction unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_imrx_SeriesBConvertiblePreferredStockMember_lxbE9uvMQU-NU7BxZ_aTNg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesIssued" scale="0" id="Narr_0NXTg5Ec-kGDadl3VHS9VA">0</ix:nonFraction></span><span style="font-size:7pt;"> and </span><span style="font-size:7pt;"><ix:nonFraction unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_imrx_SeriesBConvertiblePreferredStockMember_-Ckh5K8N7U-_9nyMHjiJxQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesOutstanding" scale="0" id="Narr__IeATAVZeE6UVjpfa_VDHg">3,619,292</ix:nonFraction></span><span style="font-size:7pt;"> shares </span><span style="-sec-ix-hidden:Hidden_wF_0nJs4AUW7wStGe8GcEw;"><span style="font-family:'Times New Roman','Times','serif';font-size:7pt;font-style:normal;font-weight:normal;">issued</span></span><span style="font-size:7pt;"> and </span><span style="-sec-ix-hidden:Hidden_xHMzK-FTbUiWCV2uN0nvTQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:7pt;font-style:normal;font-weight:normal;">outstanding</span></span><span style="font-size:7pt;"> at December&#160;31,&#160;2021 and December&#160;31,&#160;2020</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_imrx_SeriesBConvertiblePreferredStockMember_-Ckh5K8N7U-_9nyMHjiJxQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="0" id="Tc_nc2KMoiTL0OIFsmcjGbFIA_31_6">36,983,910</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:69.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;">Series A preferred stock, </span><span style="font-size:7pt;">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_0VraXufKhkCSOUw2U_zvgQ" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_imrx_SeriesConvertiblePreferredStockMember_LQiWJpT45k-D9eZ63E0DAw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityParOrStatedValuePerShare" scale="0" id="Narr_gScqLLScl0OGdgho-Dneug"><ix:nonFraction unitRef="Unit_Divide_USD_shares_0VraXufKhkCSOUw2U_zvgQ" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_imrx_SeriesConvertiblePreferredStockMember_DzBbn1vSGECYmtSe-hivlw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityParOrStatedValuePerShare" scale="0" id="Narr_5Uz8ZFYaMEy9EPNZ8NVupA">0.001</ix:nonFraction></ix:nonFraction></span><span style="font-size:7pt;"> par value, </span><span style="font-size:7pt;"><ix:nonFraction unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_imrx_SeriesConvertiblePreferredStockMember_DzBbn1vSGECYmtSe-hivlw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesAuthorized" scale="0" id="Narr_-5PJmzMjoU2MxMCCHSRIAQ">0</ix:nonFraction></span><span style="font-size:7pt;"> and </span><span style="font-size:7pt;"><ix:nonFraction unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_imrx_SeriesConvertiblePreferredStockMember_LQiWJpT45k-D9eZ63E0DAw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesAuthorized" scale="0" id="Narr_v6LDdX67NEqaWwwLzZFZRA">2,495,933</ix:nonFraction></span><span style="font-size:7pt;"> shares authorized at December 31, 2021 and December 31, 2020, </span><span style="font-size:7pt;"><ix:nonFraction unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_imrx_SeriesConvertiblePreferredStockMember_DzBbn1vSGECYmtSe-hivlw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesIssued" scale="0" id="Narr_s6Ah7bUeaEitAMgXZMI4Ww">0</ix:nonFraction></span><span style="font-size:7pt;"> and </span><span style="font-size:7pt;"><ix:nonFraction unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_imrx_SeriesConvertiblePreferredStockMember_LQiWJpT45k-D9eZ63E0DAw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesOutstanding" scale="0" id="Narr_oCe9tzdXd0S9FTiOF6xmbw">2,495,933</ix:nonFraction></span><span style="font-size:7pt;"> shares </span><span style="-sec-ix-hidden:Hidden_2vNVcAnmu0eNuJvoPM638Q;"><span style="font-family:'Times New Roman','Times','serif';font-size:7pt;font-style:normal;font-weight:normal;">issued</span></span><span style="font-size:7pt;"> and </span><span style="-sec-ix-hidden:Hidden_zcaSLU112UGCpUs8KvFQ0g;"><span style="font-family:'Times New Roman','Times','serif';font-size:7pt;font-style:normal;font-weight:normal;">outstanding</span></span><span style="font-size:7pt;"> at December&#160;31,&#160;2021 and December&#160;31,&#160;2020</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_imrx_SeriesConvertiblePreferredStockMember_LQiWJpT45k-D9eZ63E0DAw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="0" id="Tc_ivzRCH0wyUSZcXuZXyoQpw_32_6">21,119,940</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:69.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">Total convertible preferred stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="As_Of_12_31_2020_OUSLyqWONEO8ccGPC6rBdg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="0" id="Tc_XaB3Jnb1OEqqkuMJpCikCw_33_6">58,103,850</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:69.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">Stockholders&#8217; deficit:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:top;width:69.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">Preferred stock, $<ix:nonFraction unitRef="Unit_Divide_USD_shares_0VraXufKhkCSOUw2U_zvgQ" contextRef="As_Of_12_31_2020_OUSLyqWONEO8ccGPC6rBdg" decimals="3" format="ixt:numdotdecimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="Narr_5arq0xRZwE2X2pWxG71FFw"><ix:nonFraction unitRef="Unit_Divide_USD_shares_0VraXufKhkCSOUw2U_zvgQ" contextRef="As_Of_12_31_2021_TBpjtOXgEkKQahJJAv0aWg" decimals="3" format="ixt:numdotdecimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="Narr_hoY3GObMFkqgHlXFHdJtBg">0.001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ" contextRef="As_Of_12_31_2021_TBpjtOXgEkKQahJJAv0aWg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="Narr_SV-QibJ--U6qgC2dphmvzA">10,000,000</ix:nonFraction> and <ix:nonFraction unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ" contextRef="As_Of_12_31_2020_OUSLyqWONEO8ccGPC6rBdg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="Narr_PUVP-FVOhk-AZ6c0wGAo5g">0</ix:nonFraction> shares authorized at December 31, 2021 and December 31, 2020, respectively; <ix:nonFraction unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ" contextRef="As_Of_12_31_2020_OUSLyqWONEO8ccGPC6rBdg" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="Narr_ufa5sxDVO0KrCUw6iSVGEA"><ix:nonFraction unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ" contextRef="As_Of_12_31_2021_TBpjtOXgEkKQahJJAv0aWg" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="Narr_GthL0GLlMEGBDowbhjTG6g">No</ix:nonFraction></ix:nonFraction> shares issued or outstanding</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_p0qpzbFkjUmIXyLPEuHubA;"><span style="font-family:'Times New Roman','Times','serif';font-size:7pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_k_f9J9mo9EKzdMWk3hhDaQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:7pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td></tr><tr><td style="vertical-align:top;width:69.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;">Class A common stock, </span><span style="font-size:7pt;">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_0VraXufKhkCSOUw2U_zvgQ" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_IvXJ6RHxqkyGTfDbgXwHsw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_PePS-eWi1Uy1GgqZGkB7fw"><ix:nonFraction unitRef="Unit_Divide_USD_shares_0VraXufKhkCSOUw2U_zvgQ" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_Mo7QF875vUy5d2OcEbQ2fA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_HmUHmM-MPUiKVOG4AX3qGA">0.001</ix:nonFraction></ix:nonFraction></span><span style="font-size:7pt;"> par value, </span><span style="font-size:7pt;"><ix:nonFraction unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_Mo7QF875vUy5d2OcEbQ2fA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_F1rRceMfS0CecfwWGMGu_A">200,000,000</ix:nonFraction></span><span style="font-size:7pt;"> and </span><span style="font-size:7pt;"><ix:nonFraction unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_IvXJ6RHxqkyGTfDbgXwHsw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_D5sSwSjilk6FNqA8j0M69Q">22,026,200</ix:nonFraction></span><span style="font-size:7pt;"> shares authorized at </span><span style="-sec-ix-hidden:Hidden_hQaWYsqo90Sb_sJvpMwkJA;"><span style="font-family:'Times New Roman','Times','serif';font-size:7pt;font-style:normal;font-weight:normal;">December 31, 2021</span></span><span style="font-size:7pt;"> and </span><span style="-sec-ix-hidden:Hidden_gM7yvl_Iukyupu2DzdISow;"><span style="font-family:'Times New Roman','Times','serif';font-size:7pt;font-style:normal;font-weight:normal;">December 31, 2020</span></span><span style="font-size:7pt;"> respectively; </span><span style="font-size:7pt;"><ix:nonFraction unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_Mo7QF875vUy5d2OcEbQ2fA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="Narr_bEgfXr6xfUCBg24S95lSNg">26,320,199</ix:nonFraction></span><span style="font-size:7pt;"> and </span><span style="font-size:7pt;"><ix:nonFraction unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_IvXJ6RHxqkyGTfDbgXwHsw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="Narr_Gs5ktAjOLEeWV4F9UvwzAw">4,950,129</ix:nonFraction></span><span style="font-size:7pt;"> shares issued and outstanding at December&#160;31,&#160;2021 and December&#160;31,&#160;2020</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_Mo7QF875vUy5d2OcEbQ2fA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CommonStockValue" scale="0" id="Tc_PLt3dHxXvUaABcWVa9jHaA_36_3">26,320</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_IvXJ6RHxqkyGTfDbgXwHsw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CommonStockValue" scale="0" id="Tc_B2uzVg2dIUm04T3eAkmQdw_36_6">4,950</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:69.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;">Class B common stock, </span><span style="font-size:7pt;">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_0VraXufKhkCSOUw2U_zvgQ" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_B1xkq5tyC0Czi0WWYygW9Q" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_EHJ0frEiO0qE50u2QmPvUw"><ix:nonFraction unitRef="Unit_Divide_USD_shares_0VraXufKhkCSOUw2U_zvgQ" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_4sABCVevMkafGdslrmVHRg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_3O50ZHr5pEmDzOHPHti7Ng">0.001</ix:nonFraction></ix:nonFraction></span><span style="font-size:7pt;"> par value, </span><span style="font-size:7pt;"><ix:nonFraction unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_4sABCVevMkafGdslrmVHRg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_-Qr7oBQ_MUaP0VbcAitVUQ">20,000,000</ix:nonFraction></span><span style="font-size:7pt;"> and </span><span style="font-size:7pt;"><ix:nonFraction unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_B1xkq5tyC0Czi0WWYygW9Q" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_Q_9_ozpWOk6sm72fYs45rg">6,032,183</ix:nonFraction></span><span style="font-size:7pt;"> shares authorized at </span><span style="-sec-ix-hidden:Hidden_lih2VwcAz0CbONCF8ELgIQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:7pt;font-style:normal;font-weight:normal;">December 31, 2021</span></span><span style="font-size:7pt;"> and </span><span style="-sec-ix-hidden:Hidden_mnf3gfljw0OxVAZJj6gZiA;"><span style="font-family:'Times New Roman','Times','serif';font-size:7pt;font-style:normal;font-weight:normal;">December 31, 2020</span></span><span style="font-size:7pt;"> respectively; </span><span style="font-size:7pt;"><ix:nonFraction unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_B1xkq5tyC0Czi0WWYygW9Q" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="Narr_oXOFWBhns06va6fmVTHSgA"><ix:nonFraction unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_4sABCVevMkafGdslrmVHRg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="Narr_GUeW-UFCx0my0U6j9N6C7Q">0</ix:nonFraction></ix:nonFraction></span><span style="font-size:7pt;"> shares issued and outstanding at December&#160;31,&#160;2021 and December&#160;31,&#160;2020</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_Ji_C-gw4jEO9BLC9_O7x-g;"><span style="font-family:'Times New Roman','Times','serif';font-size:7pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_opmngYKGQ0qph4W2tUy_MA;"><span style="font-family:'Times New Roman','Times','serif';font-size:7pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td></tr><tr><td style="vertical-align:top;width:69.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">Additional paid-in capital</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="As_Of_12_31_2021_TBpjtOXgEkKQahJJAv0aWg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="0" id="Tc_DHxigKfvJkKBaWvFS-Omsg_38_3">215,276,186</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="As_Of_12_31_2020_OUSLyqWONEO8ccGPC6rBdg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="0" id="Tc_aqXSVBTTUE-J29V4tpHamw_38_6">3,251,240</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:69.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">Accumulated other comprehensive loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="As_Of_12_31_2021_TBpjtOXgEkKQahJJAv0aWg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" sign="-" scale="0" id="Tc_ZyAWJ65MC0ebYjcW48i8Ew_39_3">49,009</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:69.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">Accumulated deficit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="As_Of_12_31_2021_TBpjtOXgEkKQahJJAv0aWg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" sign="-" scale="0" id="Tc_OPaHfW8EpES35dobDTS8hg_40_3">59,273,388</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="As_Of_12_31_2020_OUSLyqWONEO8ccGPC6rBdg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" sign="-" scale="0" id="Tc_gBIzErnHUECR2uleoBXraQ_40_6">25,737,640</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:69.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">Total stockholders&#39; equity (deficit)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="As_Of_12_31_2021_TBpjtOXgEkKQahJJAv0aWg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_vqNKiPPLpUudBPni0hetLg_41_3">155,980,109</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="As_Of_12_31_2020_OUSLyqWONEO8ccGPC6rBdg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="0" id="Tc_hwTeFV3NP02ak4QT1_xy0Q_41_6">22,481,450</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:69.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><b style="font-weight:bold;">Total liabilities, convertible preferred stock and stockholders&#39; equity (deficit)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.98%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="As_Of_12_31_2021_TBpjtOXgEkKQahJJAv0aWg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="0" id="Tc_FyjOYBIJgkGLXtUtmhGxtA_42_3">166,704,832</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="As_Of_12_31_2020_OUSLyqWONEO8ccGPC6rBdg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="0" id="Tc_oc_kxb4V7UOdtIL7qKnt9w_42_6">38,423,018</ix:nonFraction></b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">The accompanying notes are an integral part of these consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">132</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_cec0eca7_f4b2_445a_921f_6b1eee313a36"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">IMMUNEERING CORPORATION</b></p><a id="Operations"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">FOR THE YEARS ENDED DECEMBER 31, 2021 AND 2020</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_6215d9bb_d956_4059_ba57_772f3b0cfc0f"></a><a id="Tc_rbDGYAN1lUWvp8INVYVUkg_1_2"></a><a id="Tc_JpBG6-6-00KsFBh4VlQnxQ_2_2"></a><a id="Tc_G5t1FhmbnUqmyqu7ZkD6jA_2_5"></a><a id="Tc_qpiUcKnTf0qR7fp31q6FxA_4_0"></a><a id="Tc_coP2ArgN30CfAs0nHurhMA_4_2"></a><a id="Tc_KfZ2GcKM20CQ69s_1cHieA_4_5"></a><a id="Tc_6ujAuWjWAUG5Nic7KDLJsg_5_0"></a><a id="Tc_TA6pWbG29kelD9j2CDzn4w_7_0"></a><a id="Tc_hJKjHhOUQUebUV7s6uKshg_9_0"></a><a id="Tc_JQxUTtNl4UWbslsmxD65-g_10_0"></a><a id="Tc_SUlqfjn_pkC500UIDzJHLQ_11_0"></a><a id="Tc_nOzHwIm3FUevIa7uNA-_vw_12_0"></a><a id="Tc_lx3Lxnk3iUyVp7mMT-dlnQ_13_0"></a><a id="Tc_ijoyiAzfpU-_3Kjk1FsgBA_15_0"></a><a id="Tc_qo8lT7hw_UuW6p1GQE8i4Q_16_0"></a><a id="Tc_22Hwp1B7lUaW9HGJzSdKvw_17_0"></a><a id="Tc_xxGjcG91iUOPkjhTnGlK-w_17_6"></a><a id="Tc_INWTr_XNfU2y_4Re6cIrpA_18_0"></a><a id="Tc_O1zTIUfSak-hlauikGQixg_19_0"></a><a id="Tc_mxycVyGSdUSoOmUR-Y6vMg_19_6"></a><a id="Tc_OsAhJd6Taku9i_ZAIX-4Hg_20_0"></a><a id="Tc_GUUV5ytQrUSzU7gKBdT1vA_20_2"></a><a id="Tc_nviyYcPBYUGxousppdk-1w_20_5"></a><a id="Tc_q8BqoDsGzEiIh85_wX8KEA_22_0"></a><a id="Tc_bNWIeGVW2kaXFQGAeuvNQg_23_0"></a><a id="Tc_9TjI3BvlF0yoyMjJ9TGbRg_25_0"></a><a id="Tc_ncIUnx2-oUSHAo8bUqxuVw_26_0"></a><a id="Tc_N3zkSBd-8kaKrbhtjnJo9Q_26_6"></a><a id="Tc_w-T9QWUuTUylC6_doJTfDg_27_0"></a><a id="Tc_GLZFXZ3FBESnWt6oj8ItJw_27_2"></a><a id="Tc_HLlrxuBmcEKYYNvDZOvlAQ_27_5"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:69.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:69.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:69.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Revenue</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="0" id="Tc_lOM4Xif49E6lfROE5BLXvQ_4_3">2,079,961</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="Duration_1_1_2020_To_12_31_2020_J_O9OcmviUi8EDFgokrY1Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="0" id="Tc_KnHr-Hm59UCXWDeKmDB47w_4_6">2,311,535</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Cost of revenue</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CostOfRevenue" scale="0" id="Tc_cIfsWnIQAUSk8kbJU-2qfQ_5_3">1,153,073</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="Duration_1_1_2020_To_12_31_2020_J_O9OcmviUi8EDFgokrY1Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CostOfRevenue" scale="0" id="Tc_jiwNvhs1hkScNW-W2h2iGQ_5_6">1,280,325</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Gross profit</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:GrossProfit" scale="0" id="Tc_HeI0abhgVEeEAF4VZMtihA_7_3">926,888</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="Duration_1_1_2020_To_12_31_2020_J_O9OcmviUi8EDFgokrY1Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:GrossProfit" scale="0" id="Tc_kWe_DU9c2UC11Bi9TwoBQA_7_6">1,031,210</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Operating expenses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" id="Tc_uaOH4RLS30WklGJ1CxP4pA_10_3">26,540,959</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="Duration_1_1_2020_To_12_31_2020_J_O9OcmviUi8EDFgokrY1Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" id="Tc_qvVpd4MxCkyjCYi8WzWMdw_10_6">15,003,786</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" id="Tc_psVtn6Wzc0ahLiXae3NFuQ_11_3">8,271,998</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="Duration_1_1_2020_To_12_31_2020_J_O9OcmviUi8EDFgokrY1Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" id="Tc_cemfq8W3Z0uHeNyjQTi7Qw_11_6">3,109,978</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total operating expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="0" id="Tc_c2dCHNHu50e9eoqYpNnofA_12_3">34,812,957</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="Duration_1_1_2020_To_12_31_2020_J_O9OcmviUi8EDFgokrY1Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="0" id="Tc_bIyQBL6orUma2uQQl1llaQ_12_6">18,113,764</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Loss from operations</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="0" id="Tc_Jg6uTdoRSEmR-WFUWogmPA_13_3">33,886,069</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="Duration_1_1_2020_To_12_31_2020_J_O9OcmviUi8EDFgokrY1Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="0" id="Tc_E6kbV38QyUyqhCDJWKG1gQ_13_6">17,082,554</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:69.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Other income (expense)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Interest income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InvestmentIncomeInterest" scale="0" id="Tc_tGBQVSaxDU2jzRh9grMOBg_16_3">169,899</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="Duration_1_1_2020_To_12_31_2020_J_O9OcmviUi8EDFgokrY1Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InvestmentIncomeInterest" scale="0" id="Tc_P54kGOYBFkGsMoYmp8Btmw_16_6">42,656</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncomeExpense" sign="-" scale="0" id="Tc_YCL_669GQUqv0hVPKVk-KQ_17_3">127,063</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Loss before income taxes</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" sign="-" scale="0" id="Tc_-_KfbSsiL0-QTvnrlNx7RA_18_3">33,843,233</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="Duration_1_1_2020_To_12_31_2020_J_O9OcmviUi8EDFgokrY1Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" sign="-" scale="0" id="Tc_7qeBGOLlckOpl49uOg-7iQ_18_6">17,039,898</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Income tax benefit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" sign="-" scale="0" id="Tc_hF1ljQIK-U6QAKMQF5_mRQ_19_3">307,485</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Net loss</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_GbWKC8hCZUaxWnn5_lF-rQ_20_3">33,535,748</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="Duration_1_1_2020_To_12_31_2020_J_O9OcmviUi8EDFgokrY1Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_i__OR-W07kiFfjvUb3PaAA_20_6">17,039,898</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net loss per share attributable to common stockholders, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_0VraXufKhkCSOUw2U_zvgQ" contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_XDnwGwSChESzmhiHJsWGKQ_22_3">2.46</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_0VraXufKhkCSOUw2U_zvgQ" contextRef="Duration_1_1_2020_To_12_31_2020_J_O9OcmviUi8EDFgokrY1Q" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_XuKF3dS0v0apc6bLwXJwXg_22_6">3.44</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted-average common shares outstanding, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ" contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_Z-zJvwx0HESCMkHa5pbFrg_23_3">13,612,677</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ" contextRef="Duration_1_1_2020_To_12_31_2020_J_O9OcmviUi8EDFgokrY1Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_lCAkyx54CkqZdG0mtfR_3Q_23_6">4,950,129</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other comprehensive loss:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Unrealized losses from marketable securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:MarketableSecuritiesUnrealizedGainLoss" sign="-" scale="0" id="Tc_yzJUzOHUKkO5ISkwH992VA_26_3">49,009</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:69.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Comprehensive Loss</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" sign="-" scale="0" id="Tc_-pGfnfaCjk2zakWZZp8nrg_27_3">33,584,757</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="Duration_1_1_2020_To_12_31_2020_J_O9OcmviUi8EDFgokrY1Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" sign="-" scale="0" id="Tc_rBgJbDRa6UGiwfuizsiv0g_27_6">17,039,898</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">The accompanying notes are an integral part of these consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">133</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:4.55%;padding-right:4.55%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_1c4b8b26_0f35_4ed7_9678_e2a53f474daf"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">IMMUNEERING CORPORATION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:4pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><a id="Equity"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS&#8217; EQUITY</b><b style="font-weight:bold;"> (DEFICIT)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">FOR THE YEAR ENDED DECEMBER 31, 2021 AND 2020</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_b1ee5549_29bc_4614_9d50_e7d5d84c600e"></a><a id="Tc__JR1yrZqkUqfiP7oqzFXWA_1_2"></a><a id="Tc_DOTyTkk_Rk6U4cf27V42KQ_1_17"></a><a id="Tc_IyxnZMZLIkaYQL3NHlPv9w_2_13"></a><a id="Tc_UgU7Uq2-10WyMGOHzueg-g_2_28"></a><a id="Tc_Sa2u5ysgVECesSi3FMuv9g_2_31"></a><a id="Tc_-ZnyKasArUWwnEpPqe7nVQ_2_37"></a><a id="Tc_d5q-Hg92WU-Jxs9ZEpBHRA_3_2"></a><a id="Tc_yugPZeEUkEWQeeDKoAnfkQ_3_7"></a><a id="Tc_SVjyZhLfW0y-gGi65OPSYw_3_13"></a><a id="Tc_hS7R-C-CMkyRbL2Uglz_tA_3_17"></a><a id="Tc_g01XuI12tkSrEjSFQCr6kQ_3_23"></a><a id="Tc_Sm2OqEdWC0OOdQT5zFM2Mg_3_28"></a><a id="Tc_LunRCrEj30ePJbttwCtgUw_3_31"></a><a id="Tc_dSrbQxbyLkqVZ9WNDLl9EA_3_34"></a><a id="Tc_CZiQ-THXt0SbfwbFDDva8Q_3_37"></a><a id="Tc_HJSjfH4DnkS77B03b4Z9rw_4_2"></a><a id="Tc_TvrE47xeWEOQCuhWSk-xEQ_4_4"></a><a id="Tc_E_w0X6kH-E2WOpk2JrRv6Q_4_7"></a><a id="Tc_0nxnsqIkj0WnUceX9vjmzw_4_10"></a><a id="Tc_N-s3-i2uJkGZc4aAATJg5Q_4_13"></a><a id="Tc_Hedo4CEKkkiY5tGUQl0gSQ_4_17"></a><a id="Tc_SXoyhtSHa0-PwRHlezmwCw_4_20"></a><a id="Tc_h28EJqKnxEiYk6jlGWMrwQ_4_23"></a><a id="Tc_vbpGRGmJoUWzgQrrQlReiA_4_25"></a><a id="Tc_WnNBIeuWUk6PVr7cH2tjMA_4_28"></a><a id="Tc_oKKAYqZB2Em0hb-KD0G4-A_4_31"></a><a id="Tc_Qnk6sdNKFUCO29vdwA-M_w_4_34"></a><a id="Tc_ZP5h7bafMEe62s3M_CZ-DA_4_37"></a><a id="Tc_mT4-qN7NA0WoYJC9YSVIPA_6_0"></a><a id="Tc_-V_1NUZm5UaVJ6GUXkyGVg_6_2"></a><a id="Tc_hwzChK5nYUuqFs4Qsdbosw_6_4"></a><a id="Tc_Pjo-xSCZYUSdTvDkg3nulw_6_5"></a><a id="Tc_Twry2IYyFUyY6yrbK9UyQQ_6_10"></a><a id="Tc_sSpYVG7ndE2TX-43i5l1rg_6_13"></a><a id="Tc_sPD2EomK6EOIV6jv-gPzNw_6_20"></a><a id="Tc_PoF7xZ3vkUmawsBGI6tumw_6_23"></a><a id="Tc_GcVstZrjY0q2Lud_Dcouow_6_25"></a><a id="Tc_19DlL_ROGUibR3dHEpJewg_6_26"></a><a id="Tc_a16wPUD8b0-vWQz8pIFtQg_6_28"></a><a id="Tc_z5nYd7DuCESCn5Bq9BMa3g_6_31"></a><a id="Tc_BHEq3jLXDE2bfKIsZuS3Ow_6_32"></a><a id="Tc_llbKt2OctkOY_y75Otsi-w_6_34"></a><a id="Tc_q2nEJba0MkCr5BubBHsDnQ_6_37"></a><a id="Tc_VcSZ7rXWp0e6NE8kGlBsEA_8_0"></a><a id="Tc_aJFgfRzGNEChQFF1m7vhfw_8_2"></a><a id="Tc_ILaJWacrdk6aZsfF8YTjlw_8_5"></a><a id="Tc_c06EWRyTFUiFfEx614qLjQ_8_18"></a><a id="Tc_6zhkd725T0K5YRkUmjyciA_8_21"></a><a id="Tc_-YzvyE8W7EegympH12dodw_8_23"></a><a id="Tc_C8J3vsLhekGUj4pCO0u5NA_8_26"></a><a id="Tc_0oSY-g2KIE-pYQQ7GUeRtw_8_29"></a><a id="Tc_PQVvh0ta0kWKyYR-rcataw_8_32"></a><a id="Tc_Sg6d3-1LAEWB6le83MmNYQ_8_35"></a><a id="Tc_WHSRUsc3o0WVstJpyYKj7g_8_38"></a><a id="Tc_bWHojc0Bm0qKHugTru-eyw_10_0"></a><a id="Tc_13sp1IoiE0muXv7bNUdwag_10_8"></a><a id="Tc_hKTaWrqUgkKSoXRGYTMd6Q_10_11"></a><a id="Tc_S1RmwTXTWUGaWYbsrxYBhg_10_18"></a><a id="Tc_Wt9TTzrZ6U-6vw9PyipEFg_10_21"></a><a id="Tc_FL4MOERrq02DSBfWiHjaFw_10_23"></a><a id="Tc_kHjAbMMtlEGVrEIV1DOF2g_10_26"></a><a id="Tc_d49f-brc30ipuokBMwW5CQ_10_29"></a><a id="Tc_YgcLZICxfkOuiIGmCleVxg_10_32"></a><a id="Tc_fVg26Z2-HkK1rc9jexQl0g_10_35"></a><a id="Tc_aYzVRy2ku0uCxEVB31kl4Q_10_38"></a><a id="Tc_IKekvOwKykCsgINqfmtBBw_12_0"></a><a id="Tc_V2BFTqpB90O_KtDIkDADtw_12_2"></a><a id="Tc_d-5PtsHugEOBoKfbf0XOjw_12_5"></a><a id="Tc_eXrDCGoVvUqvdPZBhnmc8w_12_8"></a><a id="Tc_T2hUT3NK4EezRlclJemmHA_12_11"></a><a id="Tc_ZGgQr5uxxUehRGEwAr-khg_12_14"></a><a id="Tc_uYoLx8rtfki1d0LEPgcmAg_12_18"></a><a id="Tc_RkutvqyMr02CeCDz6Yr9HA_12_21"></a><a id="Tc_v9UOqpJ4CEGRU1d7RP94-g_12_23"></a><a id="Tc_NJZMRyvmpEy8xwnrBBWvWg_12_26"></a><a id="Tc_TcZ01V-bB0ew_i_YS3FZmg_12_32"></a><a id="Tc_D9OhnB-Nd0WoV_77SAvJcQ_12_35"></a><a id="Tc_I-LcBXa1SEukon61ZmUcXQ_14_0"></a><a id="Tc_By55wFYCm0ewUlBfnu7peA_14_2"></a><a id="Tc_lr7wA9RgPkGeczCv_4ggyg_14_5"></a><a id="Tc_YuUguebV0ke_tup_7owzbQ_14_8"></a><a id="Tc_4yU1YrR1ZkWSqXHOrOYRjw_14_11"></a><a id="Tc_m1d1bcRdtk69NYucRsXaaA_14_14"></a><a id="Tc_BARF2lWSz0KQGSj34OdT9g_14_18"></a><a id="Tc_HGmqpLIVDEGpaiX3AFHWEA_14_21"></a><a id="Tc_fuAoiNiim0KlHnqGH60_CQ_14_23"></a><a id="Tc_nTP6lMkYJ02FxBjsbgy4lA_14_26"></a><a id="Tc_b3NKNF_FnEiBpFeuwBhsng_14_29"></a><a id="Tc_eZUvDKzeL06JseEfSj1tVw_14_32"></a><a id="Tc__m12uXiEHUOkINiXbY0IYg_16_0"></a><a id="Tc_wHYYzyxCvU6RjoY4f-vv5Q_16_4"></a><a id="Tc_A1_F8tlP5EWgftTogPGnrw_16_10"></a><a id="Tc_qLcShmLdTUy5MubaLU87Gg_16_13"></a><a id="Tc_lb6fFUJCHUGpfoBf8X_qUg_16_20"></a><a id="Tc_27IyvT3YQUe4PbkLNeHoEA_16_23"></a><a id="Tc_LDzItWd6QUy7WSLCDnE13w_16_25"></a><a id="Tc__ltbHbGjRkGOrvNGVlCG8w_16_26"></a><a id="Tc_sqz9m9SEj0-IjkuEJI_vVw_16_28"></a><a id="Tc_N7PHFSuEPEykCipxl1CEjg_16_31"></a><a id="Tc__bye_md1gEud_Zky6cTS2w_16_32"></a><a id="Tc_Dii1nSy77kWXjjOBtnFrrA_16_34"></a><a id="Tc_u8q_gmoR9kibxGkPWMO61A_16_37"></a><a id="Tc_oDjJRCBG-EKMgaUuqg79VA_18_0"></a><a id="Tc_8sz8EvEsa0KoB6CC-Dx_5g_18_8"></a><a id="Tc_0TKT3c34FE2du-C8kQsc0A_18_11"></a><a id="Tc_bdt2ESh--0iTmpEMWT6ehg_18_18"></a><a id="Tc_hk3kBoZz3k2jZFpB6KKmwQ_18_21"></a><a id="Tc_ZQrjrZ2MCEusW-y7DVzrsQ_18_23"></a><a id="Tc_sFsu72ZHLke6iWKJV1Uh_w_18_26"></a><a id="Tc_1wX51g-Dt0qo_YMOn_oUpg_18_29"></a><a id="Tc_Zk20yz-AG0S_kVCftZi6_Q_18_32"></a><a id="Tc_cQk84waJp024GsI8I39HkQ_18_35"></a><a id="Tc_FBjZGH6wjUidXgGxucCRCg_18_38"></a><a id="Tc_EoJ2YNEf3UeMi2rmL1z2xg_20_0"></a><a id="Tc_RQ01sU99W0yRjqqThOVOlA_20_2"></a><a id="Tc_ceEyQMjCQUmVcwT4lTvuJA_20_5"></a><a id="Tc_qK2N7gFDxUqJj3LBKyJxFg_20_8"></a><a id="Tc_lU-xJop1AUWiNxi-wDxDZg_20_11"></a><a id="Tc_oykn1iDx_Uy1bXE5fVXnYQ_20_14"></a><a id="Tc_DAt6CGbro0qyerrBCSqFrg_20_23"></a><a id="Tc_H7Ddz2lLEkirCQW2BIixtQ_20_26"></a><a id="Tc_11PjqT608k-whnPXilHFPQ_20_32"></a><a id="Tc__15_5rnTFUaRHceQfek78w_20_35"></a><a id="Tc_r1p6F1Xa3kyqcdqKoJYa0g_22_0"></a><a id="Tc_5yO7Bp4W3UWJvF0CEiO6Ng_22_2"></a><a id="Tc_jXCV03HG00ykJH7CBkdylg_22_5"></a><a id="Tc_8Rgqa2Dze0W1hk8quk2GWA_22_8"></a><a id="Tc_2wwviggmYkmYKzGVHJiUqA_22_11"></a><a id="Tc_7_FmLbAqrUucEZj77yI37A_22_14"></a><a id="Tc_nlvrAqC3iEGFQJyT0HcXbA_22_23"></a><a id="Tc_ldPouzhRxEyBPBdqpnZ05w_22_26"></a><a id="Tc_ZpsMzU5b_USJ6GkBJ0aLdw_22_32"></a><a id="Tc_h5OBkb3XpketMAimzWoSMQ_22_35"></a><a id="Tc_2_t6Z3o0HU6EECKaGUcbDA_24_0"></a><a id="Tc_QCaMr7ntXEefqr3Yq1PVqg_24_23"></a><a id="Tc_LhyqgNk1eUm9wfRkdBtn6A_24_26"></a><a id="Tc_3l_6O7sC4ESCMlK0uF1RKw_24_32"></a><a id="Tc_f0IA5K_tXUu-I64U49VecQ_24_35"></a><a id="Tc_5IeEM5Rp9U20bxpsI2GdOg_26_0"></a><a id="Tc_cTA6xMTapk-690rYSZdfCw_26_2"></a><a id="Tc_5BHp-lRDhEqeq5J4zVloYw_26_5"></a><a id="Tc_UUEiHXyVOEiEPYXBqp-6wQ_26_8"></a><a id="Tc_QrYy1g8b6EamOoPtZNQTbQ_26_11"></a><a id="Tc_rElHawpGs0m2HRN_NASOMA_26_14"></a><a id="Tc_oxM_JdosiUayFNeUk-dp5Q_26_23"></a><a id="Tc_eR8EzwAjBU2BVMRgAvCbvA_26_26"></a><a id="Tc_YhWDJkq8Q0uZckIIs6PgGQ_26_32"></a><a id="Tc_jp3UCdDAoUSdmvG1mR-0gg_26_35"></a><a id="Tc_VzI8jy0CTEO_Rt7VBAwu2w_28_0"></a><a id="Tc_6w99_So3zkqZs_Gx2Z16MQ_28_2"></a><a id="Tc_8NU8UQi_vE-XdD-0QxWr8A_28_5"></a><a id="Tc_fOcLPFFGN0e-1QXA4xXhrA_28_8"></a><a id="Tc_PYFRwbCYO0-VH7RLZGz1Cw_28_11"></a><a id="Tc_1PpwdWIp_UOVstlCv97jaQ_28_14"></a><a id="Tc_dzEISYHHLUW0PpbGXc7fvA_28_23"></a><a id="Tc_2MLD6clELUqfzp3sI34KbA_28_26"></a><a id="Tc_tbZj__a4xE-mw97kw_BbQg_28_32"></a><a id="Tc_AT67gNhQHEeqZxu6wqNz6w_28_35"></a><a id="Tc_0ZaznU2ik0yKdJ3fhKDDkg_30_0"></a><a id="Tc_N_RmM3WOEE268HleflNyxw_30_2"></a><a id="Tc_PKKk2ShziEO_zk0Q_wkRog_30_5"></a><a id="Tc_MQHHALonNECX1VWBkE2b2A_30_8"></a><a id="Tc_6ykCZ-NViEeaT0Te2lNlDA_30_11"></a><a id="Tc_NPQ38MJh1Uy6VQvKRtV9gA_30_14"></a><a id="Tc_3f-o-lcdjkypQMi23Kd41g_30_18"></a><a id="Tc_kVl_-RbRbkmfi0fQyWDFNw_30_21"></a><a id="Tc_HjZIo3eNokebuOg_62ix3Q_30_23"></a><a id="Tc_zOZr1hcya0efuBy7y7lS7A_30_26"></a><a id="Tc_f7oSgLMkQUuu2BGwnVCXBw_30_32"></a><a id="Tc_o69iLVaj_E-4GvOc1nAuyg_30_35"></a><a id="Tc_eFRnxmrfvESYMfg-4lgcQA_32_0"></a><a id="Tc_T8OjEqCi9kmOOWOxPXPDSw_32_2"></a><a id="Tc_IPiSrkY0Nka25zIikePtEw_32_5"></a><a id="Tc_U97XAj54A02XhzEaRfJU1Q_32_8"></a><a id="Tc_OM62GvBjvkKkYcVDYcEJsw_32_11"></a><a id="Tc_EXMZooo4G0iNpVTMh5nHmA_32_14"></a><a id="Tc_7g7W4X12F0G2rAznbYCTxQ_32_18"></a><a id="Tc_MhM_O-EdJ0GAwIrcq1ktpA_32_21"></a><a id="Tc_usAWMrY-00ejEenRq3HzPA_32_23"></a><a id="Tc_Ts9QJnOv70KtLHchzMJh6A_32_26"></a><a id="Tc__Fd05OyhwkWZXUZD2kgaQg_32_29"></a><a id="Tc_zjYW4knSlEumCmvAderxEg_32_32"></a><a id="Tc_H8SpWJ9hUU-w44g8ZADXvA_34_0"></a><a id="Tc_qH8-YyUfLEqqOgGXnLcxIg_34_2"></a><a id="Tc_XldOJz6x80qbURt5SDMbDg_34_5"></a><a id="Tc_ro8uNu2UL0iXtHnIYRW7mg_34_8"></a><a id="Tc_AFSqBVqcGk2SuP9EBVYDmQ_34_11"></a><a id="Tc_wkG6idT9dEeY-KRkCGRm1w_34_14"></a><a id="Tc_XrCzlhv1oEiJgDZCsbcXcQ_34_18"></a><a id="Tc_GxyMjoUX80inpjrAQ-uRLw_34_21"></a><a id="Tc_wzP2O9BM3UuaBZTMUgehcA_34_23"></a><a id="Tc_1-Vm68v5-UmxlblvTYPlTw_34_26"></a><a id="Tc_LznKmqYXbEWIy8KPBtTKtQ_34_29"></a><a id="Tc_8aADsRnL30-vC8Zq0JTkZw_34_35"></a><a id="Tc_CgCKS2E-xUusyo_2rEsJ2w_36_0"></a><a id="Tc_IkBUzFhe5kKuUuPb_mSfWg_36_2"></a><a id="Tc_jwI_BKLf2kWBNXfKqb9APg_36_4"></a><a id="Tc_iqq-0eGiz0-JJR3Zdg3SFA_36_5"></a><a id="Tc_NpLSt1Y6NUCrOJvXFAKNdA_36_8"></a><a id="Tc_qFfO-_YZEEG6ah3X02XwyA_36_10"></a><a id="Tc_Rn6uLBaYdUuXzNCYHGyI3Q_36_11"></a><a id="Tc_Bo01D2RmVk6z4YyFDFHcxA_36_13"></a><a id="Tc_Gf3vMJ6Jt0a417kLqp1-ZQ_36_14"></a><a id="Tc_-nlQF8cfsEG5X-CrssXOZg_36_20"></a><a id="Tc_a1ubgalCPkaVLC6UwMHmRw_36_23"></a><a id="Tc_wKsZpEbfn0CIgG8_67k7Mg_36_25"></a><a id="Tc_0oEJHjYfAUy_mBR48zaViw_36_26"></a><a id="Tc_yTibeCqiR0uTxbiAaQGnrw_36_28"></a><a id="Tc_ha4xUDL7Sk2v9PK1_uQXTA_36_31"></a><a id="Tc_YhIIC6f7BU20xdaHeiVdtg_36_34"></a><a id="Tc_q_6boSK5Bk6ce1NhkpJlEA_36_37"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:20.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:20.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="13" style="vertical-align:bottom;white-space:nowrap;width:28.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Convertible Preferred Stock</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="22" style="vertical-align:bottom;white-space:nowrap;width:49.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Stockholders&#39; Equity (Deficit)</b></p></td></tr><tr><td style="vertical-align:top;width:20.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:5.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:5.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Additional</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Accumulated other</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:top;width:20.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:10.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Series B</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:10.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Series A</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:5.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Convertible</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:11.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Class A Common Stock</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:8.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Class B Common Stock</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:5.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Paid-In</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">comprehensive</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:5.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Accumulated</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Stockholders&#39;</b></p></td></tr><tr><td style="vertical-align:top;width:20.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:5.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:4.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:5.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:5.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Preferred&#160;Stock</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:5.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:5.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Par&#160;Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:4.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Par&#160;Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:5.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Capital</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">loss</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:5.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Deficit</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Equity (Deficit)</b></p></td></tr><tr><td style="vertical-align:top;width:20.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:20.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;"><b style="font-weight:bold;">Balance at December&#160;31,&#160;2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ" contextRef="As_Of_12_31_2019_us-gaap_StatementClassOfStockAxis_imrx_SeriesConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_gIVkAxfsP0yONnc4vwzOSw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesOutstanding" scale="0" id="Tc_YWU36xVKS0aWsyL245An6g_6_8">1,966,043</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="As_Of_12_31_2019_us-gaap_StatementClassOfStockAxis_imrx_SeriesConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_gIVkAxfsP0yONnc4vwzOSw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="0" id="Tc_qTQutgFoyUOShiSmPzI8pA_6_11">16,611,832</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_QXRL0wO1MkWoDTBf_1Gh7w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="0" id="Tc_hDM6TZzcaEW8JDhiAVAunw_6_14">16,611,832</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ" contextRef="As_Of_12_31_2019_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_jy9qZmEtiE6UB1aH8SvR-w" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_2oKJU_GtGkaFYMIta0Nd5Q_6_18">4,950,129</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="As_Of_12_31_2019_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_jy9qZmEtiE6UB1aH8SvR-w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_eyDOpshuYkaNFOz0zudagA_6_21">4,950</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_9W3qoLMgdUiyVG8R6gDuuQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_1FvdGBfJ3EC0NsW5hoUdBg_6_29">2,164,471</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_h6gPSE4xM0ayt1JfJR8qkA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="0" id="Tc_DeEdpzzyjEyWe4C4bDB3CQ_6_35">8,697,742</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="As_Of_12_31_2019_g3mjqkDWB0-f2XKJf0YL-A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="0" id="Tc_41iM5kc_JU6vMa58hghgpQ_6_38">6,528,321</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:20.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:20.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">Issuance of Series A convertible preferred stock, net of issuance costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementClassOfStockAxis_imrx_SeriesConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_JPabAp5qAEmR2gD7LN_b7A" decimals="INF" format="ixt:numdotdecimal" name="imrx:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" scale="0" id="Tc_XPTVIsyYdEuAqbGWOep40g_8_8">529,890</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementClassOfStockAxis_imrx_SeriesConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_JPabAp5qAEmR2gD7LN_b7A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues" scale="0" id="Tc_PnQEywtXgkOPXfKZyFTmtA_8_11">4,508,108</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_uitXKHVUDEugKPJ0WrK0pw" decimals="0" format="ixt:numdotdecimal" name="imrx:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" scale="0" id="Tc_xuH0DJUFcUGn1JxuCjlbXA_8_14">4,508,108</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:20.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:20.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">Issuance of Series B convertible preferred stock, net of issuance costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementClassOfStockAxis_imrx_SeriesBConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_39QT10BRPUmkcB-ZGBN9mQ" decimals="INF" format="ixt:numdotdecimal" name="imrx:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" scale="0" id="Tc__m3FuXPhoUipf1mI0JDEcw_10_2">3,619,292</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementClassOfStockAxis_imrx_SeriesBConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_39QT10BRPUmkcB-ZGBN9mQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues" scale="0" id="Tc_Ue_dT9TviEuH8G2eKr71bA_10_5">36,983,910</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_uitXKHVUDEugKPJ0WrK0pw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues" scale="0" id="Tc_X4HtJZ7pY0mMw6ImVE-cTQ_10_14">36,983,910</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:20.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:20.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">Stock-based compensation expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_QLhYrVZJX02K66IZYiKorA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" id="Tc_5dbY7-gnF0OuLcUdPZsvGQ_12_29">1,086,769</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="Duration_1_1_2020_To_12_31_2020_J_O9OcmviUi8EDFgokrY1Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" id="Tc_UPk5DtkJwkm_ahR2M7UwCw_12_38">1,086,769</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:20.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:20.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_ZzxD3WXn2kaEmrcG06sDqg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_wyxfxoVAGUuBVQwLuMyyFA_14_35">17,039,898</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="Duration_1_1_2020_To_12_31_2020_J_O9OcmviUi8EDFgokrY1Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_hrLZ2-4_UUqtLpeg5EnS8g_14_38">17,039,898</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:20.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:20.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;"><b style="font-weight:bold;">Balance at December&#160;31,&#160;2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.09%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_imrx_SeriesBConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_QCBVyWaLKkO0RDEZzs9qkw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesOutstanding" scale="0" id="Tc_SJzPRQ0gEUuDNb6sQjbPZg_16_2">3,619,292</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_imrx_SeriesBConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_QCBVyWaLKkO0RDEZzs9qkw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="0" id="Tc_1VgNgMLh1k2--B_IN1HUXg_16_5">36,983,910</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.09%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_imrx_SeriesConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_S2X3YlpbP0KTx8Hppox5ig" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesOutstanding" scale="0" id="Tc_2Fx_ReqqfUeN9mcjoJjNVA_16_8">2,495,933</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_imrx_SeriesConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_S2X3YlpbP0KTx8Hppox5ig" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="0" id="Tc_LycaEba_AECnlivaTQe1Gg_16_11">21,119,940</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.73%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_LnfVME6pk0eWF42mjJCPCQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="0" id="Tc_Queayp7no0edY0fpJ1Hkxg_16_14">58,103,850</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.06%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_EWjFOikEMEGNPdcpkhlgHw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_AJj_Fs-qekyhVCq9yC33Fg_16_18">4,950,129</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_EWjFOikEMEGNPdcpkhlgHw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_xC0Oh4OUpUuVYaO3DRtacQ_16_21">4,950</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.06%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_bPrhx3BPa0qPRD7gVwy7FA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_FO52rH1ABkmUlGR976AKzg_16_29">3,251,240</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_VV_zTjXofUy1ORoRFXwUxw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="0" id="Tc_2cAjvraEHEqNaGS9rsA1yw_16_35">25,737,640</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="As_Of_12_31_2020_OUSLyqWONEO8ccGPC6rBdg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="0" id="Tc_kHp949J4-0qlxUEptMNOzA_16_38">22,481,450</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:20.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:20.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">Issuance of Series B convertible preferred stock, net of issuance costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_imrx_SeriesBConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_8mJv2jJa6UumRofouB70lA" decimals="INF" format="ixt:numdotdecimal" name="imrx:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" scale="0" id="Tc_7rgoZ7s0TkqOj_ZqhIAjlA_18_2">2,412,853</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_imrx_SeriesBConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_8mJv2jJa6UumRofouB70lA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues" scale="0" id="Tc_s0qcLgagEEmwAVF_I6cxEQ_18_5">24,788,851</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_MxWqlzAiY0eQbIPd0DtYAA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues" scale="0" id="Tc_YrINbTkMlki8GZNa4qSpxQ_18_14">24,788,851</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:20.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:20.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">Issuance of common stock upon exercise of stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_GoNlf5JQWEKfwIjieg6jCA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Tc_ssPvqQsWE0qeF4vyN3AJug_20_18">117,846</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_GoNlf5JQWEKfwIjieg6jCA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="0" id="Tc_VNP7m9Z3pkyXN_Gmk8PH8A_20_21">118</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_E-RNnZgaG06hPQcsgQNOlA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="0" id="Tc_HWIM0kyzBkuAqplpgta1xQ_20_29">354,316</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="0" id="Tc_l9xkoaIx5U-ZhQKct3vYSg_20_38">354,434</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:20.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:20.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">Issuance of common stock upon exercise of warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_GoNlf5JQWEKfwIjieg6jCA" decimals="INF" format="ixt:numdotdecimal" name="imrx:StockIssuedDuringPeriodSharesWarrantsExercised" scale="0" id="Tc_ElVVzRVCl0uSay0edpU7-g_22_18">308,308</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_GoNlf5JQWEKfwIjieg6jCA" decimals="0" format="ixt:numdotdecimal" name="imrx:StockIssuedDuringPeriodValueWarrantsExercised" scale="0" id="Tc_uYVo-Pk6U0K1PR_mPNxpNw_22_21">308</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_E-RNnZgaG06hPQcsgQNOlA" decimals="0" format="ixt:numdotdecimal" name="imrx:StockIssuedDuringPeriodValueWarrantsExercised" scale="0" id="Tc_zpnvYY5doEK9aeYEKWW5pw_22_29">926,817</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ" decimals="0" format="ixt:numdotdecimal" name="imrx:StockIssuedDuringPeriodValueWarrantsExercised" scale="0" id="Tc_7qDns1GqTk6s4zruHO6qkg_22_38">927,125</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:20.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:20.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">Conversion of Preferred Stock into common stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_imrx_SeriesBConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_8mJv2jJa6UumRofouB70lA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" sign="-" scale="0" id="Tc_hGme46Jge0yfcTL1Nh88MQ_24_2">6,032,145</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_imrx_SeriesBConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_8mJv2jJa6UumRofouB70lA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" sign="-" scale="0" id="Tc_UD-D-fMhuEKgTk0GAaaeuQ_24_5">61,772,761</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_imrx_SeriesConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_IX7LGz4dkECxr-BxWs_jAw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" sign="-" scale="0" id="Tc_7f2ae949q0WRpzsUWb7vjQ_24_8">2,495,933</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_imrx_SeriesConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_IX7LGz4dkECxr-BxWs_jAw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" sign="-" scale="0" id="Tc_TQBYTM1zbU2fWqW5q1X5NQ_24_11">21,119,940</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_MxWqlzAiY0eQbIPd0DtYAA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" sign="-" scale="0" id="Tc_EKog_ZCr5ECv3MXWt-zIMQ_24_14">82,892,701</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_GoNlf5JQWEKfwIjieg6jCA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="0" id="Tc_NM91b91K1EqqraV3-xYCUw_24_18">11,939,281</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_GoNlf5JQWEKfwIjieg6jCA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="0" id="Tc_TMcRiPyGtkWUqETRaRDigA_24_21">11,939</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_E-RNnZgaG06hPQcsgQNOlA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="0" id="Tc_fXkgZtzRCkS5mdt0UB2MxQ_24_29">82,880,762</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="0" id="Tc_9Phk6-g5cUeLATkhy0_arQ_24_38">82,892,701</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:20.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:20.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;"><span style="white-space:pre-wrap;">Issuance of common stock upon initial public offering, net of issuance costs  (</span>$<ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ" decimals="-3" format="ixt:numdotdecimal" name="imrx:StockIssuanceCosts" scale="3" id="Narr_vRj86CTMfkiQudd0wxruTQ">2,124,317</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_GoNlf5JQWEKfwIjieg6jCA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Tc_t49sCRFsNECdwmpdEy89AA_26_18">8,625,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_GoNlf5JQWEKfwIjieg6jCA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" id="Tc__QFG7F3tf0m-cVnhsQH26g_26_21">8,625</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_E-RNnZgaG06hPQcsgQNOlA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" id="Tc_8BPmEqtyRUm6AsKi4baX4Q_26_29">118,185,808</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" id="Tc_oZ8YPwfvK0e1Jt-i_G-3lg_26_38">118,194,433</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:20.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:20.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">Issuance of common stock for acquisition</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_GoNlf5JQWEKfwIjieg6jCA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesAcquisitions" scale="0" id="Tc_HzlFuZwpIkKeOZPFVDFz3w_28_18">379,635</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_GoNlf5JQWEKfwIjieg6jCA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" scale="0" id="Tc_--IjP0t3XUqEuw9EavGsZw_28_21">380</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_E-RNnZgaG06hPQcsgQNOlA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" scale="0" id="Tc_IfyVFRG1FEucVoCsV4Bwgg_28_29">7,874,620</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" scale="0" id="Tc_9G-DQ6dhV0ycWpgoNdkSHQ_28_38">7,875,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:20.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:20.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">Stock-based compensation expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_E-RNnZgaG06hPQcsgQNOlA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" id="Tc_cYEAF7-DUUiyXbAj7Ddy-Q_30_29">1,802,623</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" id="Tc_luOM3f7yZUG2C5IPK9Cj1A_30_38">1,802,623</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:20.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:20.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_5VXgVFJHWUybWtDAZklDIQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_f_W1rtGY9USH0LkByi-ADA_32_35">33,535,748</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_m9ioWoAeTECWRtt-43x7oA_32_38">33,535,748</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:20.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:20.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">Other comprehensive loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_TI6BHD47C0iaSPM1OYc68Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" sign="-" scale="0" id="Tc_Uh1LO-xx8UyIG_M9oW8zmA_34_32">49,009</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" sign="-" scale="0" id="Tc_heRCodgOkUqUU033Dfe7qQ_34_38">49,009</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:20.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:20.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;"><b style="font-weight:bold;">Balance at December&#160;31,&#160;2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.09%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.09%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.73%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.06%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_5hpgxWyzr0iIgVEP8sXbRw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_0lQbOnbn00mgxDzNoZFJwg_36_18">26,320,199</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_5hpgxWyzr0iIgVEP8sXbRw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_sydh2X-a102Gw2JTa6bAwA_36_21">26,320</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.06%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_dPK7_g2dsk-p4OLSSYVc-g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_rxEgfmA4iE-aBYXaxCWZ0A_36_29">215,276,186</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_bsF1orxDUUG1aHLclUMt2g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="0" id="Tc_sZdzMh2NpUGI_W3zg8OnGg_36_32">49,009</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_ovzfxk9860SdXNv_qQhcsg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="0" id="Tc_J_oQyQIcmE6ISeJflBgNqw_36_35">59,273,388</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="As_Of_12_31_2021_TBpjtOXgEkKQahJJAv0aWg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_QO_IPgUFiE6EXjXqCK94og_36_38">155,980,109</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">The accompanying notes are an integral part of these consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">134</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:90.91%;border:0;margin:30pt 4.55% 30pt 4.55%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_b37865ee_26bd_4c5b_9d2d_1932a14168d3"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">IMMUNEERING CORPORATION</b></p><a id="Cash_Flows"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> CONSOLIDATED STATEMENTS OF CASH FLOWS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">FOR THE YEAR ENDED DECEMBER 31, 2021 and 2020</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_a2fe9fa4_a961_42df_a635_aab666d6cccf"></a><a id="Tc_x7fbhKIq2UaN4xUDCWWK3g_1_2"></a><a id="Tc_C0tKTgrfGkmPNAls-IZerA_1_5"></a><a id="Tc_d5kboxVqgkOO2fgStUTBiA_3_0"></a><a id="Tc_u7g2HVkhKUa4eTDwsPWOUA_4_0"></a><a id="Tc_5bDe5s4SC0K0wrFsKtbTbA_4_2"></a><a id="Tc_9mlydS7KwkaBQmzPC6zXnw_4_5"></a><a id="Tc_7wwei6J1n0OA7qqEvpOIQQ_5_0"></a><a id="Tc_obXp2TCJOUGHoMA26y2GTw_6_0"></a><a id="Tc_4qQXqPd8u0aQjURLew25Ag_7_0"></a><a id="Tc_2mJllPJlOEySyINqfdiPoQ_8_0"></a><a id="Tc_utOuVHgfr0-HHrfCoem5yw_9_0"></a><a id="Tc_Jq9SXpj40UKK1Td_x-FodQ_9_6"></a><a id="Tc_9C-lbVBUOUyo7ckMHh7Kig_10_0"></a><a id="Tc_12sp5PDQo0im141q4H3dnA_10_6"></a><a id="Tc_o_5AMELag06omagEl7t00g_11_0"></a><a id="Tc_Q2Oym7WaREmytbqdyyif1Q_12_0"></a><a id="Tc_wkyVvdZWUUqycG8x5goLSg_13_0"></a><a id="Tc_LKOK2EqsHESVTprs8xfTMA_14_0"></a><a id="Tc_pQdSHkQhQEihply5wka41w_15_0"></a><a id="Tc_u0Qkt15HSEKgbKSjrIHQEg_15_3"></a><a id="Tc_B2Z58MnI1Ea4-9Xf1KzRAw_16_0"></a><a id="Tc_5TPdnqHWqEmfyBojT-g1Rg_17_0"></a><a id="Tc_k7FD_7QCVEetiNywDFNv4A_18_0"></a><a id="Tc_HbK-CkQsikqpuBUJ3sHqNg_19_0"></a><a id="Tc_tNhqtUzxFk6c9maxN9ScdQ_20_0"></a><a id="Tc_aCnigp1m5U65KyK8X2ClIA_21_0"></a><a id="Tc_sCeKPYdyY0W5qMHYL5g3JQ_22_0"></a><a id="Tc_0PbmAUekzkmU9IGBo3OMnw_23_0"></a><a id="Tc_UylLqtM5Sk-gYw0Olb2ESw_23_6"></a><a id="Tc_nasM-fvU8UieoWBmaaXvyw_24_0"></a><a id="Tc_vsWxOX3Qr0ikq64Ud_sdFA_24_6"></a><a id="Tc_2_fkdMKHpUG8K4_gFiYkUA_25_0"></a><a id="Tc_K4ZvwS1190GkM6VjzCCUZg_26_0"></a><a id="Tc_Tx89aZGNlUmGAYbKC9UmDA_27_0"></a><a id="Tc_Nada_ZSsAUuEBMZ-xDsTlg_27_3"></a><a id="Tc_rjA3D_wkPEOXFic8uQ_A4g_28_0"></a><a id="Tc_gcacLF8tDE-c4Yn_mm4NPg_29_0"></a><a id="Tc_GsQB4CYOsUqTjnQbhcOvgw_29_6"></a><a id="Tc_h2xuMz5GIkSDln-pcoxlxA_30_0"></a><a id="Tc_6L05ZD4d2kOiGGgnsW4BAQ_30_6"></a><a id="Tc_wWw2C8i_jEeLeYhzLTa_Bg_31_0"></a><a id="Tc_IseBuXDZ-k6Zd5dkW0Rd9w_31_6"></a><a id="Tc_cwh4eikPXUCMdag4Vyv6sQ_32_0"></a><a id="Tc_UnSdMm2-WEGy-FGQ7vpTaw_32_6"></a><a id="Tc_HV2crXlRX0aENQY6CxvdLQ_33_0"></a><a id="Tc_c_YWLvpt9U2xl88CeAfa1g_34_0"></a><a id="Tc_fy92Ri60xECuvNysuD0v3w_35_0"></a><a id="Tc_UCsYjmozOk641Q9rx1p6tQ_36_0"></a><a id="Tc_Bwd75J7brUKsg0QdDKHT9Q_36_2"></a><a id="Tc_39VsYLKaNE2vcVPEtJiDfA_36_5"></a><a id="Tc_f2FpjhWNZkCzEcYCQig1rw_37_0"></a><a id="Tc_AjA3quiPpUm0a69qbSqh3A_38_0"></a><a id="Tc_NSCfy7MKw06t8Y8sSlAYIQ_38_2"></a><a id="Tc_a0Srkolvs0OJTHKouybnSg_38_5"></a><a id="Tc_nDTsPw-k-kucFkcRHK2D-Q_38_6"></a><a id="Tc_10zTjAd9yUGlHV8GVadf8Q_39_0"></a><a id="Tc_6HCb_wg5rkC-PPu138CgBg_39_6"></a><a id="Tc_2VrU4Pc2f0Of-GnG6p0CSw_40_0"></a><a id="Tc_t1rn9GorokKR62edneU3SA_40_6"></a><a id="Tc_TRK0AlzVOE-kGMOJbEB1Yw_41_0"></a><a id="Tc_0jZoggEtAUWrYpKgeRhYcw_41_3"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:70.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Cash flows from operating activities:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:70.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_EDzg1bdky0OAekCIxqKNYw_4_3">33,535,748</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="Duration_1_1_2020_To_12_31_2020_J_O9OcmviUi8EDFgokrY1Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_x-OeXePhZEC2w1qp1iQV4w_4_6">17,039,898</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:70.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Adjustment to reconcile to net loss to net cash used in operating activities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:70.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Depreciation expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="0" id="Tc_CvqwyHS82EajbRPBldP2ew_6_3">45,467</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="Duration_1_1_2020_To_12_31_2020_J_O9OcmviUi8EDFgokrY1Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="0" id="Tc_jbluDu53KkqepM0iEDCdow_6_6">24,328</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Right-of-use asset amortization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" scale="0" id="Tc_6hyWZXSB-kq5SGIRdHpDmA_7_3">113,605</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="Duration_1_1_2020_To_12_31_2020_J_O9OcmviUi8EDFgokrY1Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" scale="0" id="Tc_W_xXMMZWXkuFD1d1JNZVuA_7_6">54,977</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Stock based compensation expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="0" id="Tc_UcBdTgeSCkGEmY-VoL_56w_8_3">1,802,623</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="Duration_1_1_2020_To_12_31_2020_J_O9OcmviUi8EDFgokrY1Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="0" id="Tc_rv5OSpO2i0uQvqfC_LsECw_8_6">1,086,769</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:70.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net amortization of premium (accretion of discount) on marketable securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium" sign="-" scale="0" id="Tc_ZeVolLeYREGmpbDXCZocLA_9_3">130,240</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:70.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Deferred tax benefit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxExpenseBenefit" sign="-" scale="0" id="Tc_7uipiNRmQ0eZY1iTT8QWcg_10_3">307,485</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:70.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Change in assets and liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:70.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(Increase) decrease in:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:70.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">    Accounts receivable</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" sign="-" scale="0" id="Tc_xEsb3Qm4-UOObEFKPNxrNQ_13_3">279,713</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="Duration_1_1_2020_To_12_31_2020_J_O9OcmviUi8EDFgokrY1Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="0" id="Tc_Ay2fdurPk0ioTXTeE5Cilw_13_6">290,170</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:70.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">    Prepaid expenses and other current assets</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="0" id="Tc_hzA0KLj4PkWVtgieC0n8Qg_14_3">2,408,986</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="Duration_1_1_2020_To_12_31_2020_J_O9OcmviUi8EDFgokrY1Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="0" id="Tc_Hl91OLBm4kSlSCYB68KMwA_14_6">69,740</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:70.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">   Other assets</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="Duration_1_1_2020_To_12_31_2020_J_O9OcmviUi8EDFgokrY1Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="0" id="Tc_mC9jDEAi5US9KaRqvSSmIQ_15_6">14,333</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:70.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Increase (decrease) in:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:70.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">   Accounts payable</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" sign="-" scale="0" id="Tc_KPrsrvjnTk26hlPl1e_OGQ_17_3">130,398</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="Duration_1_1_2020_To_12_31_2020_J_O9OcmviUi8EDFgokrY1Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="0" id="Tc_kOOJ_FQkXUWZBBLdfXmKRg_17_6">1,185,589</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">   Accrued expenses</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="0" id="Tc_kP-TQmtf6E-u68ddEegigg_18_3">3,240,940</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="Duration_1_1_2020_To_12_31_2020_J_O9OcmviUi8EDFgokrY1Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="0" id="Tc_2Df-buhgX0-T6Hm-BeBlqg_18_6">488,644</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">   Lease liability</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" sign="-" scale="0" id="Tc_r_bLYmp-L0-UNJlT3OLEvg_19_3">80,853</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="Duration_1_1_2020_To_12_31_2020_J_O9OcmviUi8EDFgokrY1Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" sign="-" scale="0" id="Tc_bEhCvH1jY0mhZebZl6H2YQ_19_6">46,991</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:70.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net cash used in operating activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" sign="-" scale="0" id="Tc_3kWKBKU8eEe3dgend7NLbA_20_3">30,850,882</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="Duration_1_1_2020_To_12_31_2020_J_O9OcmviUi8EDFgokrY1Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" sign="-" scale="0" id="Tc_9t_1zKNbI0GRGpTBf2CkZA_20_6">14,620,825</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:70.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Cash flows from investing activities:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:70.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Purchases of property and equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="0" id="Tc_I-CWsuzUDESJdjriYAQXTQ_22_3">60,786</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="Duration_1_1_2020_To_12_31_2020_J_O9OcmviUi8EDFgokrY1Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="0" id="Tc_bw1BgKcE-0milYHNYeiBOg_22_6">53,415</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:70.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Purchases of marketable securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireMarketableSecurities" scale="0" id="Tc_iq06kW5kXUWlak8V5X0Q0w_23_3">75,625,529</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:70.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash acquired in business combination</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashAcquiredInExcessOfPaymentsToAcquireBusiness" scale="0" id="Tc_Ht1hWIj6eUWRxhbp4ATHkw_24_3">70,348</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:70.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net cash used in investing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" sign="-" scale="0" id="Tc_LAijq2Qm70OdvFA-U8LXJQ_25_3">75,615,967</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="Duration_1_1_2020_To_12_31_2020_J_O9OcmviUi8EDFgokrY1Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" sign="-" scale="0" id="Tc_oImnbqHvoEybRfMZd9y8Aw_25_6">53,415</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:70.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Cash flows from financing activities:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:70.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Proceeds from the issuance of Series A preferred stock, net of issuance costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementClassOfStockAxis_imrx_SeriesConvertiblePreferredStockMember_hF8oI6VuEUaTinProxudjw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock" scale="0" id="Tc_TjP7HxCPtEytZlLcfB9VEA_27_6">998,306</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Proceeds from the issuance of Series B preferred stock, net of issuance costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_imrx_SeriesBConvertiblePreferredStockMember_-C13Ii99_069N31zQd1hmQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock" scale="0" id="Tc_5ecJwhq7vEymlhyOqcaHJw_28_3">24,788,851</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementClassOfStockAxis_imrx_SeriesBConvertiblePreferredStockMember_b0zil8ikRUOsnQGwGFI2sw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock" scale="0" id="Tc_lpsfp0Y_dUW3DTwxF3fXlQ_28_6">36,983,910</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Proceeds from initial public offering of common stock, net of commissions and underwriting</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="0" id="Tc_hIEF6Vsw40GIEn2DZGv2Gw_29_3">120,318,750</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:70.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Payment of initial public offering costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="0" id="Tc_R4aPmc-OO02X87h99R8ODQ_30_3">2,124,317</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:70.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Proceeds from exercise of stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="0" id="Tc_zHfks0juuk2l3XkjhntvaQ_31_3">354,434</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:70.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Proceeds from exercise of warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromWarrantExercises" scale="0" id="Tc_2VVJcCl93UyxYpGPt5kB9g_32_3">927,125</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:70.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net cash provided by financing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="0" id="Tc_ljo3yNeJYUGlTlfRE_P5uQ_33_3">144,264,843</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="Duration_1_1_2020_To_12_31_2020_J_O9OcmviUi8EDFgokrY1Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="0" id="Tc_wOSTrclr80SFM_5LYfvoLQ_33_6">37,982,216</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Net increase in cash and cash equivalents</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="0" id="Tc_9zzKDYMN-0CfCjiLmE_R0w_34_3">37,797,994</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="Duration_1_1_2020_To_12_31_2020_J_O9OcmviUi8EDFgokrY1Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="0" id="Tc_2538VChCGE6jU2ffPc2XFQ_34_6">23,307,976</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Cash and cash equivalents at beginning of period</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="As_Of_12_31_2020_OUSLyqWONEO8ccGPC6rBdg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" id="Tc_Uf4ilmZ8K0utMht9_0jguw_35_3">37,090,151</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="As_Of_12_31_2019_g3mjqkDWB0-f2XKJf0YL-A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" id="Tc_X44SF6Z7fUOcEWmhH6vf-w_35_6">13,782,175</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Cash and cash equivalents at end of period</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="As_Of_12_31_2021_TBpjtOXgEkKQahJJAv0aWg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" id="Tc_o0x_uP3ML0efsrwi0RcQyA_36_3">74,888,145</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="As_Of_12_31_2020_OUSLyqWONEO8ccGPC6rBdg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" id="Tc_96PXifPhWUajhMteLikEVw_36_6">37,090,151</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Supplemental disclosures of noncash investing and financing information:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:70.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Conversion of convertible Series A and B preferred stock into common stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssued1" scale="0" id="Tc_1xT5YWLhokWVvvAoFTxPiw_38_3">82,892,701</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:70.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Business combination non cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationAcquisitionRelatedCosts" scale="0" id="Tc_T0ytlyyl2U6KR2bzzR3vQw_39_3">7,804,652</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:70.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Class A common stock issued for business combination</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ" contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ConversionOfStockSharesIssued1" scale="0" id="Tc_r_UhI3F-U0CVXwsm7O8I1Q_40_3">7,875,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:70.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Reclassification of liability for Series A preferred stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.75%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="Duration_1_1_2020_To_12_31_2020_J_O9OcmviUi8EDFgokrY1Q" decimals="0" format="ixt:numdotdecimal" name="imrx:ReclassificationOfLiabilityOfPreferredStock" scale="0" id="Tc_OY0BmCrB80i6oE-JWn1qBg_41_6">3,509,802</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">The accompanying notes are an integral part of these consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">135</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_d84475d8_ba49_45ce_9602_9b5205791e6a"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">IMMUNEERING CORPORATION</b></p><a id="Notes"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="Tb_JWMXGq4bKE29Fx9wviYNBQ" continuedAt="Tb_JWMXGq4bKE29Fx9wviYNBQ_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Note&#160;1&#160;&#8211; Organization and Nature of Business</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Immuneering Corporation, a Delaware corporation, (&#8220;Immuneering&#8221; or the &#8220;Company&#8221;) was incorporated in 2008. The Company aims to improve patient outcomes by advancing a unique pipeline of oncology and neuroscience product candidates developed using the Company&#8217;s translational bioinformatics platform. The Company has more than a decade of experience applying translational bioinformatics to generate insights into drug mechanism of action and patient treatment response. Building on this experience, the Company&#8217;s disease-agnostic discovery platform enables the Company to create product candidates based on 1) biological insights that are both counterintuitive and deeply rooted in data, and 2) novel chemistry.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On October&#160;30, 2019, Immuneering formed a wholly owned subsidiary, Immuneering Securities Corporation (&#8220;ISC&#8221;), a Massachusetts securities corporation, for the sole purpose of buying, selling and holding securities on the Company&#8217;s behalf. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On December 22, 2021, <span style="background:#ffffff;">the Company acquired all outstanding shares of capital stock of BioArkive, Inc. (&#8220;BioArkive&#8221;), a California corporation, which as a result became a wholly owned subsidiary. &#160;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Immuneering, ISC and BioArkive are collectively referred to as &#8220;the Company&#8221; throughout these &#160;consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company is subject to a number of inherent risks associated with any biotechnology company that has substantial expenditures for research and development. These risks include, but are not limited to, the need to obtain adequate additional funding, possible failure of clinical trials or other events demonstrating lack of clinical safety or efficacy of its product candidates, dependence on key personnel, reliance on third-party service providers for manufacturing drug product and conducting clinical trials, the ability to successfully secure its proprietary technology, and risks related to the regulatory approval and commercialization of a product candidate. There can be no assurance that the Company&#8217;s research and development program will be successful. In addition, the Company operates in an environment of rapid technological change and is largely dependent on the services of its employees, advisors, and consultants.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On August 3, 2021, the Company completed its initial public offering (&#8220;IPO&#8221;) pursuant to which it issued and sold <ix:nonFraction unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ" contextRef="Duration_8_3_2021_To_8_3_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_nbYOiYQZAUed9mAOrNTolQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_5GaAZJ-Ds0SM3o11INV8mQ">8,625,000</ix:nonFraction> shares of its Class A common stock, inclusive of <ix:nonFraction unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ" contextRef="Duration_8_3_2021_To_8_3_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_G9SnpifyxEmaJU1UE794ew" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_yWLzTY6-TEmNGoFLyI7hAQ">1,125,000</ix:nonFraction> shares of its Class A common stock sold pursuant to the full exercise of the underwriters&#8217; option to purchase additional shares. The aggregate net proceeds received by the Company from the IPO were $<ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="Duration_8_3_2021_To_8_3_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_7enA8yNRQkat6QV_1FoEOw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="0" id="Narr_WlmIWJhEdEmj_MBEQUp2OQ">120,318,750</ix:nonFraction>, after deducting underwriting discounts and commissions, but before deducting offering costs payable by the Company, which were $<ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="As_Of_8_3_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_kxYscz4Wf02VzWLhksRRxw" decimals="0" format="ixt:numdotdecimal" name="imrx:OfferingCostPayable" scale="0" id="Narr_048q5eCg_U6gsMnEc0MhqA">2,124,317</ix:nonFraction>. Upon the closing of the IPO, all <ix:nonFraction unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ" contextRef="As_Of_8_3_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_kxYscz4Wf02VzWLhksRRxw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesOutstanding" scale="0" id="Narr_zpUsu3C1NU-QubfONpalhg">8,528,078</ix:nonFraction> shares of the Company&#8217;s convertible preferred stock then outstanding automatically converted into <ix:nonFraction unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ" contextRef="As_Of_8_3_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_boKn2a2ouUyMVqODG0-nIw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesOutstanding" scale="0" id="Narr_cPaTqMe8S0mZNoJAAeiBFA">11,939,281</ix:nonFraction> shares of Class A common stock. Upon the conversion of the convertible preferred stock, the Company reclassified the carrying value of the convertible preferred stock to common stock (at par value) and additional&#160;paid-in&#160;capital (see Note 8). </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">To date, the Company has funded its operations through service revenues, and with proceeds from the sale of its capital stock and convertible notes and, most recently, with proceeds from the IPO. The Company has incurred recurring losses over the past several&#160;years and as of December&#160;31, 2021, the Company had an accumulated deficit of $<ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="As_Of_12_31_2021_TBpjtOXgEkKQahJJAv0aWg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" sign="-" scale="0" id="Narr_Q4p5YkiFxEWAgczNQFP7rQ">59,273,388</ix:nonFraction>. The Company expects to continue to generate operating losses for the foreseeable future. The future viability of the Company is dependent on its ability to raise additional capital to finance its operations. The Company&#8217;s inability to raise capital as and when needed could have a negative impact on its financial condition and ability to pursue its business strategies. There can be no assurances that additional funding will be available on terms acceptable to the Company, or at all. If the Company is unable to raise additional funds when needed, it may be required to delay, reduce the scope of, or eliminate development programs, which may adversely affect its business and operations. Management considers that there are no conditions or events, in the aggregate, that raise substantial doubt about the entity&#8217;s ability to continue as a going concern and estimates that its cash and cash equivalents will be sufficient to fund its operating expenses and capital expenditure requirements for at least 12&#160;months from the issuance date of the consolidated financial statements. The full extent to which coronavirus (&#8220;COVID-19&#8221;) pandemic will directly or indirectly impact the Company&#8217;s business, results of operations and financial </p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">136</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_JWMXGq4bKE29Fx9wviYNBQ_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">condition, including expenses and research and development costs, will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning COVID-19 and its variants and the actions taken to contain or treat COVID-19 and its variants, as well as the economic impact on local, regional, national and international markets. The Company has considered potential impacts arising from the pandemic related to COVID-19 and its variants and is not presently aware of any events or circumstances that would require the Company to update its estimates, judgements or revise the carrying values of its assets or liabilities.</p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><a id="_1fba1559_e6fc_4931_82c0_3d7744fdaf23"></a><a id="_6f1c6136_62e1_4878_8be0_1b579a6d2081"></a><a id="_02bbde80_6ab8_4bf2_bc00_72d8d0b659b0"></a><a id="_b3ba233f_4f0c_42c1_870c_547b53ec4e5f"></a><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="Tb_hTOft3WF_0avV4xSFcC6Vg" continuedAt="Tb_hTOft3WF_0avV4xSFcC6Vg_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Note&#160;2 - Summary of Significant Accounting Policies</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="Tb_p6IXcqzObE-kel0ai_bhDA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Basis of Presentation</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The consolidated financial statements have been prepared in accordance with accounting standards set by the Financial Accounting Standards Board (&#8220;FASB&#8221;). The FASB sets generally accepted accounting principles (&#8220;GAAP&#8221;) to ensure the consolidated financial statements are consistently reported. References to GAAP issued by the FASB in these footnotes are to the FASB Accounting Standards Codifications (&#8220;ASC&#8221;). The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ" name="us-gaap:StockholdersEquityPolicyTextBlock" id="Tb_gl5ZFufieUeqyxPG-c1OvA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Stock Split</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;">On July 23, 2021, the Company approved a </span><span style="font-weight:normal;"><ix:nonFraction unitRef="Unit_Standard_pure_iothMaWWqUCV2N7d1PVg4w" contextRef="Duration_7_23_2021_To_7_23_2021_He5Glc1OZUuR4Os2aqbeew" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" scale="0" id="Narr_PmJfsXGaNESUU25MtnMKFQ">one</ix:nonFraction></span><span style="font-weight:normal;white-space:pre-wrap;">-for-1.4 stock split which was consummated in connection with the Company&#8217;s IPO.  All information in the accompanying financial statements and notes thereto regarding share amounts of common stock, price per share of common stock and the conversion factor for Series A and Series B Preferred Stock into common stock have been adjusted to reflect the application of the stock split on a retroactive basis.</span></p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ" name="us-gaap:UseOfEstimates" id="Tb_Sd-K4-ZPt0CVgXq3I3C_2g" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Use of Estimates&#160;</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses during the reporting periods. These estimates and assumptions are based on current facts, historical experience and various other factors believe to be reasonable under the circumstances, the results of which form the basis for making judgements about the carrying values of assets, liabilities and the recording of expenses that are not readily apparent from other sources. Significant estimates reflected in these &#160;consolidated financial statements included but are not limited to, the research and development expenses, determination of fair value of stock-based awards, the valuation of common stock prior to the IPO, business combination, and the right-to-use assets and operating lease liability. Actual results may differ materially and adversely from these estimates.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="Tb_UDrXh7IE9USCA2zcYGg4BQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Segments</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker (&#8220;CODM&#8221;) in making decisions regarding resource allocation and assessing performance. The Company&#8217;s chief executive officer is the CODM, and he uses consolidated financial information in determining how to allocate resources and assess performance. The Company has determined that it operates in <ix:nonFraction unitRef="Unit_Standard_segment_tQmfuIJwOkyVlCDJy8sORg" contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:NumberOfOperatingSegments" scale="0" id="Narr_p62sbgIC6EKASVlEcPi1Dg">one</ix:nonFraction> segment.</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="display:inline-block;visibility:hidden;width:0pt;">&#8203;</span><br /><span style="font-size:13.5pt;visibility:hidden;background:#ffffff;">&#8203;</span><span style="font-size:13.5pt;visibility:hidden;background:#ffffff;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:13.5pt;visibility:hidden;background:#ffffff;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:13.5pt;visibility:hidden;background:#ffffff;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:13.5pt;visibility:hidden;background:#ffffff;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:13.5pt;visibility:hidden;background:#ffffff;">&#8203;</span></p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">137</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_3163b973_6b8a_4e86_8f5d_d40841574317"></a><ix:continuation id="Tb_hTOft3WF_0avV4xSFcC6Vg_cont1" continuedAt="Tb_hTOft3WF_0avV4xSFcC6Vg_cont2"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ" name="us-gaap:BusinessCombinationsPolicy" id="Tb_23eSFnAsH0uL4kFQf4_LxQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;background:#ffffff;">Business Combination</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:13.5pt;font-weight:bold;visibility:hidden;background:#ffffff;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="background:#ffffff;">Results of operations of acquired companies are included in the Company&#8217;s results of operations as of the respective acquisition dates. Acquired businesses are accounted for using the acquisition method of accounting, which requires that assets acquired and liabilities assumed be recorded at fair value, with limited exceptions. Any excess of the purchase price over the fair value of the net assets acquired is recorded as goodwill. Transaction costs and costs to restructure the acquired Company are expensed as incurred. The operating results of the acquired business are reflected in the consolidated financial statements after the date of acquisition. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:13.5pt;visibility:hidden;background:#ffffff;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">If the acquired net assets do not constitute a business under the acquisition method of accounting, the transaction is accounted for as an asset acquisition and no goodwill is recognized.&#160;Refer to Note 6, Business Combination for more information.</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="Tb_p-J-ljxBHkuEPSs1K3HKCA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Cash and Cash </b><b style="font-weight:bold;">Equivalents</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">Cash and cash equivalents are comprised of deposits at major financial banking institutions and highly liquid investments with an original maturity of three&#160;months or less at the date of purchase. Cash is maintained at Federal Deposit Insurance Company (&#8220;FDIC&#8221;) insured financial institutions. At times, the Company has maintained cash in excess of FDIC limits, however it has not experienced any losses with respect to its cash balances. The Company regularly monitors the financial condition of the institutions in which it has depository accounts and believes the risk of loss is minimal.</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ" name="us-gaap:MarketableSecuritiesPolicy" id="Tb_pzuaLW5-GkKDJUtWdfLcYQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Marketable Securities </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our marketable securities are classified as available-for-sale pursuant to ASC 320,<span style="background:#ffffff;"> Investments &#8211; Debt and Equity Securities</span> and are recorded at fair value. Unrealized gains/(losses) are included as a component of accumulated other comprehensive loss in the &#160;consolidated balance sheets and statements of convertible preferred stock and stockholders&#8217; equity (deficit) and a component of total comprehensive loss in the consolidated statements of comprehensive loss, until realized. The Company assesses its available-for-sale marketable securities for impairment on a quarterly basis. There were no impairments of the Company&#8217;s available-for-sale marketable securities measured and carried at fair value during the year ended December 31, 2021. &#160;Realized gains and losses are included in other expense on a specific-identification basis.&#160;There were&#160;no&#160;realized gains or losses on marketable securities for the year ended December 31, 2021.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" id="Tb_qfjCoFJAT0a0exarFjEsEg" continuedAt="Tb_qfjCoFJAT0a0exarFjEsEg_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Fair Value Measurements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We record cash equivalents and marketable securities at fair value. ASC 820,&#160;Fair Value Measurements and Disclosures, establishes a fair value hierarchy for those instruments measured at fair value that distinguishes between assumptions based on market data (observable inputs) and our own assumptions (unobservable inputs). The hierarchy consists of three levels:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Level 1</i>&#160;&#8211; Unadjusted quoted prices in active markets for identical assets or liabilities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Level 2</i>&#160;&#8211; Quoted prices for similar assets and liabilities in active markets, quoted prices in markets that are not active, or inputs which are observable, directly or indirectly, for substantially the full term of the asset or liability.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Level 3</i>&#160;&#8211; Unobservable inputs that reflect our own assumptions about the assumptions market participants would use in pricing the asset or liability in which there is little, if any, market activity for the asset or liability at the measurement date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Our financial assets, which include cash equivalents and marketable securities, have been initially valued at the transaction price, and subsequently revalued at the end of each reporting period, utilizing third-party pricing services or other observable market data. The pricing services utilize industry standard valuation models, including both income and market based approaches, and observable market inputs to determine value. After completing our validation procedures, we did not adjust or override any fair value measurements provided by the pricing services as of December&#160;31, 2021. Fair value </p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">138</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_7c9e3222_0149_49e0_84d8_7c91c4fbdfdc"></a><a id="_03cf44f7_280d_4c16_89fe_5ea02a00b153"></a><a id="_5cccf264_e96b_4b2f_b57b_5b58b91398cd"></a><a id="_f5b3c1ed_9ca5_49c5_834c_cd5ff38b9e49"></a><a id="_3b07df01_b608_452d_aac3_85cbde01cf28"></a><a id="_620959dd_8bf4_4c95_965f_bbe42f02b14a"></a><a id="_0ac89e96_f8dd_48d1_9b49_a4864e07cbb9"></a><a id="_1272d708_f939_41fd_8c86_d9ffbfda82d1"></a><a id="_eb542205_7ecf_4d7d_95fb_bbb56c601903"></a><a id="_ddbce2c2_e07c_468b_aea9_fd5c60fd8a4f"></a><a id="_7302c8d5_cd84_49a3_a88b_80decde0cfdc"></a><a id="_ab68f49e_3f80_4148_b09a_03b5f4432a30"></a><a id="_799efe78_eda4_47c5_af3f_bde1ffa10379"></a><a id="_ede071a7_0e8e_4dc6_b804_5aa42b04eefe"></a><a id="Tc_qw8To8ICnkSbJPa5EegYsQ_1_2"></a><a id="Tc_xUFXJAOgeEaCete_v3hIJg_1_7"></a><a id="_bbf94a6d_9a99_4b80_a99c_1a3870bdf47b"></a><a id="Tc_S26Con9q1U-u8YavcYfGqA_2_2"></a><a id="Tc_XJ8HQ8_kqEun_hr8dyFzFw_2_5"></a><a id="Tc_fuuYDWdavkiJ4XeKUD8sUw_2_7"></a><a id="Tc_Un-J4LwX_0uuuKQXFyl3dg_2_10"></a><a id="_2c7dbc39_fe6a_4e93_a709_97e4590e2db8"></a><a id="_379241ec_21d4_463b_8729_b993ec7c5a69"></a><a id="_d690f1d3_f551_4ade_94e6_e5bb89bdf575"></a><a id="Tc_sNU9yykVSUCYM0l-TDTHqA_3_0"></a><a id="Tc_BqbKKkau9kiU8qR6b5IkkA_3_2"></a><a id="Tc_VXx2x5oAmUqDlHfkJ9J-QA_3_6"></a><a id="Tc_6v6byig94EusLlE_BzzvsQ_3_7"></a><a id="Tc_NpiKZdqL8UmxqJtLH1e7cQ_3_11"></a><a id="_26529289_f94e_4da1_a8af_d26938c38633"></a><a id="_607c51e7_9c83_419a_880b_be9a208357b4"></a><a id="_5600a2f0_5571_4957_8544_d0068ed55402"></a><a id="Tc_C9l-xFzcMUqBXPxQwXdOyQ_4_0"></a><a id="Tc_t48XiP6TAUu_2sF8eH7mFg_4_8"></a><a id="Tc_WsTYPVYkG0WnoZIxsvDCQg_4_10"></a><a id="_4413b29f_4ed2_44c1_8758_1744fdac8a30"></a><a id="_7bc9b98e_370b_4f4f_a129_4af123715695"></a><a id="_30b8126a_04b0_4aaf_8af8_3f1456932f92"></a><a id="Tc_359AOh22dECUD2C9S0pi5g_5_0"></a><a id="Tc_ZHn1uAjVp0-w_YnGDVnmZA_5_8"></a><a id="Tc_oodj0L42QEmVEtLg_cmEjw_5_10"></a><a id="_497155b9_1fd4_451a_ab50_09afec13a412"></a><a id="_8e10d361_c77c_4a79_8c48_55ae35e75aac"></a><a id="_9f5fb8dd_6018_4322_8306_edf9db26a4d5"></a><a id="_d086b31b_6e57_4c8c_bc98_38c420100934"></a><a id="_8ba11340_1cef_4327_8e5b_17d1cd0de008"></a><a id="_f79723c0_b59b_4de7_b21b_3c8fa8402635"></a><a id="_4e5b5e59_c613_400c_8a95_28265f9bc9d2"></a><a id="_6e04885f_36ec_4053_8ca8_385f90be4412"></a><a id="_6e9123b4_779f_4f37_8416_af6296427d25"></a><a id="_5715bbfd_bfd9_4bff_8f33_f95aa15fcbe7"></a><a id="_1bd0c656_21d7_4fa7_80a1_b0dfda621316"></a><a id="_5d549e94_4c84_4684_ba57_af5bf0241bf8"></a><a id="_e6fdd9f2_9a0c_4dd0_8649_061408f5ecfc"></a><a id="_7c28f124_e8eb_4c14_8d35_40bd0648903f"></a><a id="Tc_8Opd_GvRyU6tARhcXsjFtQ_1_2"></a><a id="Tc_zU5xds65AEeBF5kLWnAWWg_1_7"></a><a id="_69d326cb_8f92_4b00_8799_31a8266e56a7"></a><a id="Tc_CMx2ZTTZjkKnR80JTgRIpA_2_2"></a><a id="Tc_VjrbyP35iEG4Ldz3qjCx9A_2_5"></a><a id="Tc_8z6gAtlyGU--JluJsDSmbg_2_7"></a><a id="Tc_mcxjMqlB7Ea7TKkNm5zZqA_2_10"></a><a id="_b20391fe_f758_45c9_8224_2e194775152e"></a><a id="_db1bac42_96dc_4934_90d4_550db79e650a"></a><a id="_d3096ff1_57b1_49a7_9f58_c47088c24767"></a><a id="_711835a0_99f4_431b_abc7_debb15f364a0"></a><a id="_303e994c_8eea_4978_ae0a_54e09468de6e"></a><a id="Tc_Vr-qCjsCi0SLc_A2KhXAGQ_3_0"></a><a id="Tc_4IGoJepicUq4L6XeliTYQg_3_2"></a><a id="Tc_1HKrb_5GLkKXy1iP61IRLw_3_6"></a><a id="Tc_tTZyfivMvEWLizibz_K0ow_3_7"></a><a id="Tc_Rehi_wNnfkuqwECoA5lkxQ_3_11"></a><a id="_7626eb4e_5a8a_4507_ba45_d2af7156be75"></a><a id="_10156901_ad48_4261_9e08_fc7517dc51b9"></a><a id="_47dc1440_3b12_407a_ac8c_2ec7b2e13c14"></a><a id="_39a0f4e4_eafd_4493_a750_9426a2dd5a5f"></a><a id="_83c44589_12fe_410a_b553_1dd51dae767c"></a><a id="Tc_ZeMZe95DLUycbP19pn5VLQ_4_0"></a><a id="_0868a0ef_a4c4_476e_997f_c0c77eb6ee7f"></a><a id="_5f11cab8_9209_4c3c_8ccd_18e1b5ca6eaf"></a><a id="_38f982d6_9b83_4bdd_aa0d_04e2002f84b1"></a><a id="Tc_0tUVT3ezX0GUyZsJfOj1Ww_5_0"></a><a id="Tc_LP23MX4qGkudZbsXgxUqZA_5_8"></a><a id="Tc_M_JY35qXl0mM1WaEok4oZA_5_10"></a><a id="_16bf77ed_b029_4d0e_bfca_7edb50792e79"></a><a id="_5238a81e_e89f_4161_b8f4_11d50561b8e6"></a><a id="_67598d9b_2653_4641_b6b2_5d8aa6b6d72d"></a><a id="_3f3af5bf_67f0_47b0_aaca_2cac2f7a45d2"></a><a id="_efbcf40b_35c7_46ba_aadc_a4804b8c30d2"></a><a id="Tc_YFt1bV72V0iYgbNHeDnLbA_6_0"></a><a id="_01e43265_6b69_4825_affd_aec30fa116df"></a><a id="_79a09022_f7c6_42a6_abc9_326fb932d8c7"></a><a id="_d6f60685_d400_4c75_91e9_b1eba67d6448"></a><a id="Tc_Ro4cQDhi_k6-WDjKCgun2Q_7_0"></a><a id="Tc_X64vFVVhEkyOIbHuwPDqZw_7_3"></a><a id="Tc_Kqzo0zrvmkCtpj1UPkhfZA_7_5"></a><a id="_02c535fc_4d58_42a0_bb8f_ea949d4c6821"></a><ix:continuation id="Tb_hTOft3WF_0avV4xSFcC6Vg_cont2" continuedAt="Tb_hTOft3WF_0avV4xSFcC6Vg_cont3"><ix:continuation id="Tb_qfjCoFJAT0a0exarFjEsEg_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">information for these assets, including their classification in the fair value hierarchy is included in Note 4 &#160;Fair Value Measurements<b style="font-weight:bold;">.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:13.5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">There have been no changes to the valuation methods during the year ended December&#160;31, 2021. We evaluate transfers between levels at the end of each reporting period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:13.5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The carrying amounts reflected in the consolidated balance sheets for cash, accounts receivable, accounts payable and accrued expenses approximate their respective fair values because of the short-term maturity of those financial instruments.</p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ" name="us-gaap:TradeAndOtherAccountsReceivableUnbilledReceivablesPolicy" id="Tb_l6wuEhXZbkmaY4eEI6B_iw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Accounts Receivable</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">Accounts receivable are stated at the amount management expects to collect from outstanding balances. An allowance for doubtful accounts is estimated for those accounts receivable considered to be uncollectible based upon historical experience and management&#8217;s evaluation of outstanding accounts receivable. Bad debts are written off against the allowance when identified. At December&#160;31, 2021 and 2020 there was <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="As_Of_12_31_2020_OUSLyqWONEO8ccGPC6rBdg" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables" scale="0" id="Narr_2X2alUC46EefC-_t2__dtw"><ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="As_Of_12_31_2021_TBpjtOXgEkKQahJJAv0aWg" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables" scale="0" id="Narr_4kKmyV1Vvkmn0bEreSldnA">no</ix:nonFraction></ix:nonFraction> allowance for doubtful accounts.</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ" name="us-gaap:ConcentrationRiskCreditRisk" id="Tb_PALbY50xuE-uwxFaUqcMuQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Concentration of Credit Risk</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">Financial instruments that potentially subject the Company to significant concentration of credit risk consist primarily of accounts receivable and revenue. To manage accounts receivable credit risk, the Company continuously evaluates the creditworthiness of its customers and the need for an allowance for potential credit losses. The Company has not experienced any losses in such accounts.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">The following customers comprised 10% or more of the Company&#8217;s total accounts receivable or revenues as of or for the period ended December&#160;31, 2021 (customers with an asterisk are less than 10%): </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ" name="us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" id="Tb_8aSQ6mI_4U6GgswXOYISnw" escape="true"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:47.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:47.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:22.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="color:#231f20;font-weight:bold;">Year Ended December&#160;31,&#160;2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:23.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="color:#231f20;font-weight:bold;">As&#160;of&#160;December&#160;31,&#160;2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:47.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Revenue</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">%&#160;of&#160;Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Accounts&#160;Receivable</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">%&#160;of&#160;Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:47.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Customer #1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="Duration_1_1_2021_To_12_31_2021_srt_MajorCustomersAxis_imrx_CustomerOneMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_oWqze6TNHUeol6NT43Q40A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" id="Tc_KCTWMhSB80uV2jk9di6jew_3_3">745,030</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_iothMaWWqUCV2N7d1PVg4w" contextRef="Duration_1_1_2021_To_12_31_2021_srt_MajorCustomersAxis_imrx_CustomerOneMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_oWqze6TNHUeol6NT43Q40A" decimals="3" format="ixt:numdotdecimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="Tc_TFKO0ofFakq2s9fmb0nBRw_3_5">35.8</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="As_Of_12_31_2021_srt_MajorCustomersAxis_imrx_CustomerOneMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_BcRwAfOKVEeK4vZFJJoMnw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="0" id="Tc_sDUlw8oYXkmb4_DM4UB--w_3_8">235,500</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_iothMaWWqUCV2N7d1PVg4w" contextRef="Duration_1_1_2021_To_12_31_2021_srt_MajorCustomersAxis_imrx_CustomerOneMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_P-jE_XQSn0Kh-0-xrDlmZQ" decimals="3" format="ixt:numdotdecimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="Tc_N0ar_kiSTEKvPI2vG3ba3Q_3_10">95.7</ix:nonFraction>%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:47.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Customer #2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="Duration_1_1_2021_To_12_31_2021_srt_MajorCustomersAxis_imrx_CustomerTwoMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_Otularec102-GYy-rhKAFA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" id="Tc_mw0f3v4PcEC_QKuUTNZuYA_4_3">380,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_iothMaWWqUCV2N7d1PVg4w" contextRef="Duration_1_1_2021_To_12_31_2021_srt_MajorCustomersAxis_imrx_CustomerTwoMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_Otularec102-GYy-rhKAFA" decimals="3" format="ixt:numdotdecimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="Tc_-RXWAxFCV0WnMV84QLSqPA_4_5">18.3</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:47.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Customer #5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="Duration_1_1_2021_To_12_31_2021_srt_MajorCustomersAxis_imrx_CustomerFiveMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_gk7zsuubm020Nb-hEXSapw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" id="Tc_1e5yZjmwPEmx813yJYyZTw_5_3">353,050</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_iothMaWWqUCV2N7d1PVg4w" contextRef="Duration_1_1_2021_To_12_31_2021_srt_MajorCustomersAxis_imrx_CustomerFiveMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_gk7zsuubm020Nb-hEXSapw" decimals="3" format="ixt:numdotdecimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="Tc_w945rKWcSUeOkeO2tg1TLw_5_5">17.0</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:47.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:47.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:22.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="color:#231f20;font-weight:bold;">Year Ended December&#160;31,&#160;2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:23.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="color:#231f20;font-weight:bold;">As&#160;of&#160;December&#160;31,&#160;2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:47.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Revenue</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">%&#160;of&#160;Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Accounts&#160;Receivable</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">%&#160;of&#160;Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:47.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Customer #1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="Duration_1_1_2020_To_12_31_2020_srt_MajorCustomersAxis_imrx_CustomerOneMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_cn0C_B-BXUyAAsOsAChyRA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" id="Tc_UHpyBUJvSki5roS5CniJWA_3_3">676,710</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_iothMaWWqUCV2N7d1PVg4w" contextRef="Duration_1_1_2020_To_12_31_2020_srt_MajorCustomersAxis_imrx_CustomerOneMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_cn0C_B-BXUyAAsOsAChyRA" decimals="3" format="ixt:numdotdecimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="Tc_fz-IScsKykuM0ZjhoJsjrg_3_5">29.3</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="As_Of_12_31_2020_srt_MajorCustomersAxis_imrx_CustomerOneMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_7bxZ7DlQSkOfAj7fvd-5pw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="0" id="Tc_PzEIf0qKXEWhD2xN4gHsmA_3_8">214,345</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_iothMaWWqUCV2N7d1PVg4w" contextRef="Duration_1_1_2020_To_12_31_2020_srt_MajorCustomersAxis_imrx_CustomerOneMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_0Q_fVsZyC0qSpcRATuE8jw" decimals="3" format="ixt:numdotdecimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="Tc_Zz03ft7k80qoJwaJ24PC5A_3_10">42.9</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:47.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Customer #2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="Duration_1_1_2020_To_12_31_2020_srt_MajorCustomersAxis_imrx_CustomerTwoMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_aTYR5oNrDkmFoJWCgdwsfQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" id="Tc_VIqK7CEXGkGhU4QB6JoRzw_4_3">570,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_iothMaWWqUCV2N7d1PVg4w" contextRef="Duration_1_1_2020_To_12_31_2020_srt_MajorCustomersAxis_imrx_CustomerTwoMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_aTYR5oNrDkmFoJWCgdwsfQ" decimals="3" format="ixt:numdotdecimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="Tc_2bq1Aowxm0mqF53u8kYV8g_4_5">24.7</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="As_Of_12_31_2020_srt_MajorCustomersAxis_imrx_CustomerTwoMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_HSU6DmbswUiywLkXXqH83Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="0" id="Tc_5I55O0jfwkaizvHqmFoFpQ_4_8">71,250</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_iothMaWWqUCV2N7d1PVg4w" contextRef="Duration_1_1_2020_To_12_31_2020_srt_MajorCustomersAxis_imrx_CustomerTwoMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_lmfLr2N_xUWRAFF-XxH5Jg" decimals="3" format="ixt:numdotdecimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="Tc_cFCXtoNJgEWy-D-mlFBYVw_4_10">14.2</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:47.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Customer #3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="Duration_1_1_2020_To_12_31_2020_srt_MajorCustomersAxis_imrx_CustomerThreeMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_8wa3w0Ph8ke11E8Tb0NuUA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" id="Tc_zFrdrvXa2U2YsWX8cu4CJg_5_3">306,900</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_iothMaWWqUCV2N7d1PVg4w" contextRef="Duration_1_1_2020_To_12_31_2020_srt_MajorCustomersAxis_imrx_CustomerThreeMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_8wa3w0Ph8ke11E8Tb0NuUA" decimals="3" format="ixt:numdotdecimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="Tc_FwczFv7t7EWLAGy6BcLDNw_5_5">13.3</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:47.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Customer #4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="Duration_1_1_2020_To_12_31_2020_srt_MajorCustomersAxis_imrx_CustomerFourMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_wyidH8d1zk-PDM7YDj9tdg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" id="Tc_6wZ8yCAuzkenHiiRW-flHw_6_3">250,880</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_iothMaWWqUCV2N7d1PVg4w" contextRef="Duration_1_1_2020_To_12_31_2020_srt_MajorCustomersAxis_imrx_CustomerFourMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_wyidH8d1zk-PDM7YDj9tdg" decimals="3" format="ixt:numdotdecimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="Tc_9jm9dSYKykGLxKpSfdjupA_6_5">10.9</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="As_Of_12_31_2020_srt_MajorCustomersAxis_imrx_CustomerFourMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_Aa9AiVV9H0q60bn77lAIvQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="0" id="Tc_HPtu1UZ5sUydP6SIQMVLDQ_6_8">63,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_iothMaWWqUCV2N7d1PVg4w" contextRef="Duration_1_1_2020_To_12_31_2020_srt_MajorCustomersAxis_imrx_CustomerFourMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_FbdxXK1INke9vC8EPGq7hQ" decimals="3" format="ixt:numdotdecimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="Tc_KtArs1VQKUmNEzDqDKY7_Q_6_10">12.6</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:47.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Customer #5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="As_Of_12_31_2020_srt_MajorCustomersAxis_imrx_CustomerFiveMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_odT76IUTqEO-M3mGDrx6QQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="0" id="Tc_Kx8uzkxIBEetkWk7nH_iDg_7_8">91,975</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_iothMaWWqUCV2N7d1PVg4w" contextRef="Duration_1_1_2020_To_12_31_2020_srt_MajorCustomersAxis_imrx_CustomerFiveMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_DPXYIsD2zUO9cvTMSKl0VA" decimals="3" format="ixt:numdotdecimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="Tc_ZUlSZD3T60q9-QPK6sRLKw_7_10">18.4</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table></ix:nonNumeric></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="Tb_WGX7SA3Ci0Ky2K_BFhonkw" continuedAt="Tb_WGX7SA3Ci0Ky2K_BFhonkw_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Property and Equipment</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">Property and equipment are recorded at cost, net of accumulated depreciation. Expenditures for major replacements and improvements are capitalized, while expenditures for general repairs and maintenance are expensed as incurred. Upon retirements or disposition of property and equipment, the related cost and accumulated depreciation are removed from the consolidated balance sheet and any resulting gain or loss is recorded in the consolidated statement of operations. Depreciation is calculated using the straight-line method once assets are placed in service. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">139</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_14a95296_903c_4a57_918c_7f3d39d521d3"></a><a id="_38d7b608_74af_49f0_8827_7a2196c917fb"></a><a id="_866070ad_cc61_4475_bc91_d26fbafc1cdd"></a><a id="_ee41c671_9679_494a_bcb4_e67e514113c2"></a><a id="Tc_qVTF438FOkOpfI-S341pNQ_1_2"></a><a id="_bad3d951_ae45_4747_8d7b_332ddabacf03"></a><a id="Tc_L2e6e0GQIk6nnuCuCcVoiw_2_0"></a><a id="Tc_cxEqv-k4gU2mHz_N5CoVFQ_2_2"></a><a id="_e3cf0d87_2835_4f08_8dbb_572974904d83"></a><a id="Tc_6CUQVWzo1U6eOHAG7Nb6xA_3_0"></a><a id="_c4d0b910_fdf0_46cd_9e03_9d69e79a45e1"></a><a id="Tc_GH6aCzTuUkWsKo-jZpaqQg_4_0"></a><a id="_72e2c9b1_9c6d_482b_8e96_3a83b3a671de"></a><a id="Tc_Ow9wKPm3F0ehiE8hwn6eIA_5_0"></a><a id="_65b13cfd_0e44_4208_a29a_11ed66f21d1a"></a><a id="_351eafc9_225b_4cdb_a361_d38ce7bf0a41"></a><a id="Tc_UIpkgZVmxEGQcYDp7Yccrw_6_0"></a><a id="Tc_CAsd5tXjOUqgmeJlf7luXA_6_2"></a><ix:continuation id="Tb_hTOft3WF_0avV4xSFcC6Vg_cont3" continuedAt="Tb_hTOft3WF_0avV4xSFcC6Vg_cont4"><ix:continuation id="Tb_WGX7SA3Ci0Ky2K_BFhonkw_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ" name="imrx:ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock" id="Tb_GUeYSca55ku0in2IYbkyjQ" escape="true"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:86.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:86.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Estimated</b></p></td></tr><tr><td style="vertical-align:bottom;width:86.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Asset Class</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Useful&#160;Lives</b></p></td></tr><tr><td style="vertical-align:bottom;width:86.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Computer equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_twFlKCzRuEusunTslMr32A" format="ixt-sec:durwordsen" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="Tc_zN4P5LDYlUeUaBwv-vy6jQ_3_2">3 years</ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:86.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Furniture and fixtures</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_HoHJdekunkWYrj04U5neCw" format="ixt-sec:durwordsen" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="Tc_LZ68bYyneUigxvfI2twI-Q_4_2">5 years</ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:86.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Lab equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_imrx_LabEquipmentMember_GI3DHb_K8EizCH_U5WinCA" format="ixt-sec:durwordsen" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="Tc_8mM6_PG2I0uE_kdgeggltA_5_2">7 years</ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:86.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Leasehold improvements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdsAndLeaseholdImprovementsMember_avFoqBKbtEy-F0FmYKH8ng" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="Narr_OCZyeeHwhkGC2tvUByryJQ">1</ix:nonNumeric>-<ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdsAndLeaseholdImprovementsMember_SvHfzMjnikSnHY-nhQSILg" format="ixt-sec:durwordsen" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="Narr_v1f6SoKJeEylMn31Iqja6g">10 years</ix:nonNumeric></p></td></tr></table></ix:nonNumeric></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" id="Tb_JmTSj41w-kW7Pzbd_M5Cuw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Impairment of Long-lived Assets</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">Periodically, the Company evaluates its long-lived assets, which consist primarily of property and equipment, for impairment whenever events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted net cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the asset exceeds the fair value of the asset. To date, <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" scale="0" id="Narr_p_sl-F64wEiMa8A0jWhKvA">no</ix:nonFraction> impairments have occurred.</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ" name="us-gaap:LesseeLeasesPolicyTextBlock" id="Tb_uNRVy_A2ikOumn9MJ1kv5A" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Leases</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">In February&#160;2016 the FASB issued Accounting Standards Update (&#8220;ASU&#8221;) No. 2016-02, Leases (Topic 842) (&#8220;ASC 842&#8221;), a standard issued to increase transparency and comparability among organizations related to their leasing activities. This standard established a right-of-use model that requires the recognition of right-of-use assets and lease liabilities for most leases as well as provides disclosure with respect to certain qualitative and quantitative information related to a company&#8217;s leasing arrangements to meet the objective of allowing users of financial statements to assess the amount, timing and uncertainty of cash flows arising from leases.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">The Company adopted the leasing standard using the modified retrospective transition approach as of January&#160;1, 2020, with <ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ" format="ixt:booleantrue" name="us-gaap:LeasePracticalExpedientsPackage" id="Narr_mi7QqDUS0kmvOTH0FmbnLg">no</ix:nonNumeric> restatement of prior periods or cumulative adjustment to retained earnings. Upon adoption, the Company elected the package of transition practical expedients, which allowed the Company to carry forward prior conclusions related to whether any expired or existing contracts are or contain leases, the lease classification for any expired or existing leases, and initial direct costs for existing leases. The Company also made an accounting policy election to not recognize leases with an initial term of 12&#160;months or less within its consolidated balance sheets, and to recognize those lease payments on a straight-line basis in its consolidated statements of operations over the lease term. The adoption of the leasing standard did not have an impact on the consolidated statement of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">The Company determines if an arrangement is a lease at contract inception. Right-of-use assets represent the Company&#8217;s right to use an underlying asset for the lease term and lease liabilities represent its obligation to make lease payments arising from the lease. Right-of-use assets and lease liabilities are recognized at the commencement date of the lease based upon the present value of future lease payments over the expected lease term. When determining the lease term, the Company includes options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. As most of the Company&#8217;s leases do not provide an implicit interest rate, the Company uses its incremental borrowing rate, which is based on rates that would be incurred to borrow on a collateralized basis over a term equal to the lease payments in a similar economic environment, in determining the present value of lease payments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">The Company has elected not to separate lease and non-lease components as a single lease component. The Company&#8217;s lease are reflected in right-of-use assets and lease liabilities (current and non-current) in the consolidated balance sheets.</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="Tb_JLwTjSfZbkWwAQlObBzRLA" continuedAt="Tb_JLwTjSfZbkWwAQlObBzRLA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Revenue Recognition</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="font-weight:bold;letter-spacing:-0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">In accordance with ASC 606, revenue is recognized when a customer obtains control of promised goods and services. The core principle of the standard is to recognize revenue to depict the transfer of promised goods or services to customers in </p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">140</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_446ed883_5de1_4b63_b398_eab3410688dd"></a><ix:continuation id="Tb_hTOft3WF_0avV4xSFcC6Vg_cont4" continuedAt="Tb_hTOft3WF_0avV4xSFcC6Vg_cont5"><ix:continuation id="Tb_JLwTjSfZbkWwAQlObBzRLA_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods or services. To achieve that core principle, the Company applies the following five-step model:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt 0pt 0pt 18pt;">&#8226; Identify the contract with a customer</p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt 0pt 0pt 18pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt 0pt 0pt 18pt;">&#8226; Identify the performance obligations in the contract</p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt 0pt 0pt 18pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt 0pt 0pt 18pt;">&#8226; Determine the transaction price</p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt 0pt 0pt 18pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt 0pt 0pt 18pt;">&#8226; Allocate the transaction price to the performance obligations in the contract</p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt 0pt 0pt 18pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt 0pt 0pt 18pt;">&#8226; Recognize revenue when or as performance obligations are satisfied</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">The Company&#8217;s contracts generally consist of the promise to provide computational biology professional services to pharmaceutical and biotechnology companies, which the Company has concluded constitutes one performance obligation that is delivered over time. The transaction price is the amount of consideration to which the Company expects to be entitled in exchange for transferring the services to the customer. The Company&#8217;s contracts provide for either agreed upon rates per hour based on the level of the professional working on the project or a fixed fee for a defined scope of work. The Company recognizes revenue over time by measuring the progress toward complete satisfaction of the performance obligation using a single method of measuring progress, which depicts the performance in transferring control of the associated services to the customer. The Company uses input methods to measure the progress toward the complete satisfaction of performance obligations and evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenue and net loss in the period of adjustment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">The Company&#8217;s contract terms do not allow for a right of return or refund and do not contain significant financing components. Receivables associated with the contract will generally be collected within thirty to sixty days, in accordance with the underlying payment terms.</p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ" name="us-gaap:IncomeTaxPolicyTextBlock" id="Tb_vxXoQUco2k-_928sTKgAIA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Income Taxes</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">The Company provides for income taxes in accordance with ASC Topic 740, Income Taxes. Deferred tax assets and liabilities are determined based on the difference between the financial reporting and tax bases of assets and liabilities using enacted tax rates and laws in effect in the&#160;years in which the differences are expected to reverse. A valuation allowance is provided if, based upon the weighted available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;">The Company accounts for uncertainty in income taxes recognized in the consolidated financial statements by applying a two-step process to determine the amount of tax benefit to be recognized. First, the tax position must be evaluated to determine the likelihood that it will be sustained upon external examination by the taxing authorities. If the tax position is deemed more likely than not to be sustained, the tax position is then assessed to determine the amount of benefit to recognize in the consolidated financial statements. The amount of the benefit that may be recognized is the largest amount that has a greater than 50% likelihood of being realized upon ultimate settlement. The provision for income taxes includes the effects of any resulting tax reserves (i.e., unrecognized tax benefits) that are considered appropriate as well as the related net interest. <span style="color:#222222;background:#ffffff;">As of December 31, 2021 and 2020, the Company had uncertain tax positions of </span><span style="color:#222222;background:#ffffff;">$<ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TaxAdjustmentsSettlementsAndUnusualProvisions" scale="0" id="Narr_Dd05obD2nECqnNBGu8xDPw">380,902</ix:nonFraction></span><span style="color:#222222;background:#ffffff;"> and </span><span style="color:#222222;background:#ffffff;">$<ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="Duration_1_1_2020_To_12_31_2020_J_O9OcmviUi8EDFgokrY1Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TaxAdjustmentsSettlementsAndUnusualProvisions" scale="0" id="Narr_nezOacZvGUGtbvIu4q3cqQ">174,950</ix:nonFraction></span><span style="color:#222222;background:#ffffff;">.&#160;&#160; The Company has classified the unrecognized tax benefits as reductions of its tax credit carryforwards.</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ" name="us-gaap:InProcessResearchAndDevelopmentPolicy" id="Tb_nKbWMT5SxkGFkhOP5ssIBg" continuedAt="Tb_nKbWMT5SxkGFkhOP5ssIBg_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Research and Development</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;">Research and development costs are expensed as incurred. Research and development costs consist of expenses incurred in performing research and development activities, including salaries and benefits, materials and supplies, preclinical expenses, stock-based compensation expense, depreciation of equipment, contract services, and other outside expenses. The Company also incurs costs to develop software programs for internal use in identifying potential human drug targets which may then lead to the development of human drug candidates. To date the software programs have primarily been used for internal research and development activities and the costs incurred have been expensed as research and development.</p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">141</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_hTOft3WF_0avV4xSFcC6Vg_cont5" continuedAt="Tb_hTOft3WF_0avV4xSFcC6Vg_cont6"><ix:continuation id="Tb_nKbWMT5SxkGFkhOP5ssIBg_cont1"></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ" name="imrx:ResearchAndManufacturingContractCostsAndAccrualsPolicyTextBlock" id="Tb_uzGmrtyGikKkcssomoxS7g" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Research and Manufacturing Contract Costs and Accruals</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company has entered into various research, development and manufacturing contracts with research institutions and other companies in the United States. These agreements are generally cancelable, and related costs are recorded as research and development expenses as incurred. The Company records accruals for estimated ongoing research, development and manufacturing costs. When billing terms under these contracts do not coincide with the timing of when the work is performed, the Company is required to make estimates of outstanding obligations to those third parties as of period end. Any accrual estimates are based on a number of factors, including the Company&#8217;s knowledge of the progress towards completion of the research, development and manufacturing activities, invoicing to date under the contracts, communication from the research institutions and other companies of any actual costs incurred during the period that have not yet been invoiced and the costs included in the contracts. Significant judgments and estimates may be made in determining the accrued balances at the end of any reporting period. Actual results could differ from the estimates made by the Company. The historical accrual estimates made by the Company have not been materially different from the actual costs.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ" name="imrx:PatentCostsPolicyPolicyTextBlock" id="Tb_r2PQ_z5aEUG6dG3Qx9XgEg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="color:#231f20;font-weight:bold;">Patent </b><b style="font-weight:bold;">Costs</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">All patent-related costs incurred in connection with filing and prosecuting patent applications are expensed as incurred due to the uncertainty about the recovery of the expenditure. Amounts incurred are classified as general and administrative expenses.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock" id="Tb_AgRBo_Q500OCW41sBj55hA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="color:#231f20;font-weight:bold;">Com</b><b style="font-weight:bold;background:#ffffff;">prehensive Loss</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Comprehensive loss includes net loss as well as other changes in stockholders&#8217; equity (deficit) that result from transactions and economic events other than those with stockholders. </p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ" name="us-gaap:DeferredChargesPolicyTextBlock" id="Tb_hPKsQCRnz0uaPFFJjynqOg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;background:#ffffff;">Deferred Offering Costs</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">The Company capitalizes certain legal, professional accounting and other third-party fees that are directly associated with&#160;in-process&#160;equity financings as deferred offering costs until such financings are consummated. After consummation of an equity financing, these costs are recorded as a reduction of the proceeds from the offering, either as a reduction of the carrying value of the preferred stock or in stockholder&#8217;s equity (deficit) as a reduction of additional&#160;paid-in&#160;capital generated as a result of the offering. Should the&#160;in-process&#160;equity financing be abandoned, the deferred offering costs would be expensed immediately as a charge to operating expenses in the statements of operations and comprehensive loss. There were&#160;</span><span style="background:#ffffff;"><ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="As_Of_12_31_2020_OUSLyqWONEO8ccGPC6rBdg" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:DeferredOfferingCosts" scale="0" id="Narr_sFvo3gLVx0SbfRQ6lbwT6g"><ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="As_Of_12_31_2021_TBpjtOXgEkKQahJJAv0aWg" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:DeferredOfferingCosts" scale="0" id="Narr_MiY-w1vtu0SJaNUjSsG4WQ">no</ix:nonFraction></ix:nonFraction></span><span style="background:#ffffff;">&#160;deferred offering costs as of December&#160;31,2021 or December 31, 2020.</span></p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ" name="us-gaap:EarningsPerSharePolicyTextBlock" id="Tb_zuJHu9NFYkubUnNPJN8oSg" continuedAt="Tb_zuJHu9NFYkubUnNPJN8oSg_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="color:#231f20;font-weight:bold;">Net Income (Loss) per Share</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Prior to the closing of the IPO, the Company followed the two-class method when computing net income (loss) per share, as the Company had issued shares that meet the definition of participating securities. The two-class method determines net income (loss) per share for each class of common and participating securities according to dividends declared or accumulated and participation rights in undistributed earnings. The two-class method requires income available to common stockholders for the period to be allocated between common and participating securities based upon their respective rights to receive dividends as if all income for the period had been distributed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Basic net income (loss) per share attributable to common stockholders is computed by dividing the net income (loss) attributable to common stockholders by the weighted average number of common shares outstanding for the period. Diluted net income (loss) attributable to common stockholders is computed by adjusting net income (loss) attributable to common stockholders to reallocate undistributed earnings based on the potential impact of dilutive securities. Diluted net income (loss) per share attributable to common stockholders is computed by dividing the diluted net income (loss) attributable to common stockholders by the weighted average number of common shares outstanding for the period, including potential dilutive common shares assuming the dilutive effect of common stock equivalents.</p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">142</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_hTOft3WF_0avV4xSFcC6Vg_cont6" continuedAt="Tb_hTOft3WF_0avV4xSFcC6Vg_cont7"><ix:continuation id="Tb_zuJHu9NFYkubUnNPJN8oSg_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s convertible preferred stock contractually entitled the holders of such shares to participate in dividends but does not contractually require the holders of such shares to participate in losses of the Company. Accordingly, in periods in which the Company reports a net loss, such losses are not allocated to such participating securities. In periods in which the Company reports a net loss attributable to common stockholders, diluted net loss per share attributable to common stockholders is the same as basic net loss per share attributable to common stockholders, since dilutive common shares are not assumed to have been issued if their effect is anti-dilutive.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Subsequent to the closing of its IPO, the Company only has one class of shares outstanding and basic net income (loss) per common share is computed by dividing the net income (loss) by the weighted average number of shares of common stock outstanding for the period. Diluted net income (loss) per common share is computed by dividing net income (loss) by the weighted average number of shares of common stock outstanding for the period, including potential dilutive common shares assuming the dilutive effect of outstanding stock awards. For periods in which the Company reports a net loss, diluted net loss per common share is the same as basic net loss per common share, since dilutive common shares are not assumed to have been issued if their effect is anti-dilutive. The Company reported a net loss attributable to common stockholders for each of the years ended December&#160;31, 2021 and 2020.</p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="Tb_arr5kK9U3UuLzciLoZqF0Q" continuedAt="Tb_arr5kK9U3UuLzciLoZqF0Q_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Stock-based Compensation</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="font-weight:bold;letter-spacing:-0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company issues stock-based awards to employees and nonemployees in the form of stock options. The Company accounts for stock-based awards in accordance with ASC 718, Compensation&#8201;&#8212;&#8201;Stock Compensation (&#8220;ASC 718&#8221;), which requires all stock-based payments to employees and nonemployees, including grants of employee stock options and modifications to existing stock options, to be recognized in the consolidated statement of operations based on their fair values.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The fair value of options is estimated on the grant date using the Black-Scholes option-pricing model (&#8220;Black-Scholes&#8221;). Black-Scholes requires the Company to make assumptions and judgments about the variables used in the calculation including the expected term of its stock option, the volatility of the Company&#8217;s common stock, and an assumed risk-free interest rate. The Company uses the simplified calculation of expected life and volatility is based on an average of the historical volatility of a group of publicly traded companies in a similar industry that the Company believes would be considered a peer group had it been a publicly held company for the duration of the expected life of the award. The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of grant for periods corresponding with the expected life of the option. Forfeitures are recognized as they occur. <ix:nonFraction unitRef="Unit_Standard_pure_iothMaWWqUCV2N7d1PVg4w" contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ" decimals="2" format="ixt-sec:numwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="Narr_wlhUXsaOO0CNF56o0Wjh7g">No</ix:nonFraction> dividend yield was assumed as the Company does not pay, and does not expect to pay, dividends on its common stock. The assumptions underlying these valuations represent management&#8217;s best estimates, which involve inherent uncertainties and the application of management&#8217;s judgement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In accordance with ASU No. 2018-07, Compensation-Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting, compensation expense for stock-based awards granted to nonemployees is recognized over the period during which services are rendered by such nonemployees. The new standard largely aligns the accounting for share-based payment awards issued to employees and nonemployees by expanding the scope of ASC 718 to apply to nonemployee share-based transactions, as long as the transaction is not effectively a form of financing. There was no adjustment to the financial statements upon adoption of this standard as of January&#160;1, 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As there had been no public market for the Company&#8217;s common stock prior to the IPO, the estimated fair value of its common stock has been determined by its board of directors as of the date of each option grant, with input from management, considering the Company&#8217;s most recently available third-party valuations of common stock and its board of directors&#8217; assessment of additional objective and subjective factors that it believed were relevant and which may have changed from the date of the most recent valuation through the date of the grant. These third-party valuations were performed in accordance with the guidance outlined in the American Institute of Certified Public Accountants&#8217; Accounting and Valuation Guide, Valuation of Privately-Held-Company Equity Securities Issued as Compensation. Each valuation methodology includes estimates and assumptions that require the Company&#8217;s judgment. These estimates and assumptions include a number of objective and subjective factors, including external market conditions, the prices at which the Company sold shares of preferred stock, the superior rights and preferences of securities senior to the Company&#8217;s common stock at the time of, and the likelihood of, achieving a liquidity event, such as an initial public offering or sale.</p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">143</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_3c5bc143_1eda_41c9_aa69_398ab7db08b8"></a><ix:continuation id="Tb_hTOft3WF_0avV4xSFcC6Vg_cont7" continuedAt="Tb_hTOft3WF_0avV4xSFcC6Vg_cont8"><ix:continuation id="Tb_arr5kK9U3UuLzciLoZqF0Q_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The assumptions underlying these valuations represent management&#8217;s best estimates, which involve inherent uncertainties and the application of management&#8217;s judgment. As a result, if the Company had used different assumptions or estimates, the fair value of its common stock and its stock-based compensation expense could be materially different.</p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ" name="us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy" id="Tb_Yn-2NJdTZE-pQCV4FHppGA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Goodwill</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Goodwill represents the excess of the fair value of the acquiree over the recognized bases of the net identifiable assets acquired and includes the future economic benefits from other assets that could not be individually identified and separately recognized. Goodwill is not amortized, but instead is periodically reviewed for impairment and an impairment charge is recorded in the periods in which the recorded carrying value of goodwill exceeds its fair value.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">On a quarterly basis, the Company performs a review of its business to determine if events or changes in circumstances have occurred which could have a material adverse effect on the fair value of the Company and its goodwill. If such events or changes in circumstances were deemed to have occurred, the Company would perform an impairment test of goodwill as of the end of the quarter and record any noted impairment loss.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">The goodwill test is performed at least annually, or more frequently if events or changes in circumstances indicate that the asset might be impaired. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">The Company performs its annual impairment test during the fourth quarter of each fiscal year. There were </span><span style="background:#ffffff;"><ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:GoodwillImpairmentLoss" scale="0" id="Narr_S70y5nkZHEmi0No3oPDK3g">no</ix:nonFraction></span><span style="background:#ffffff;"> impairments in 2021.</span><span style="background:#ffffff;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Intangible Assets</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Intangible assets are recognized at fair value, as an asset apart from goodwill if the asset (i) arises from contractual or other legal rights, or (ii) is separable. Intangible assets, principally representing technology acquired, are capitalized and amortized on the straight-line method over their expected useful lives.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company reviews the recoverability of its long-lived assets (including amortizable intangible assets), other than goodwill, when events or changes in circumstances occur that indicate that the carrying value of the asset may not be recoverable. </p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="Tb_eGXEccogmEmeCL-nBH4m2w" continuedAt="Tb_eGXEccogmEmeCL-nBH4m2w_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Recently Issued Accounting Pronouncements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies and adopted by the Company as of the specified effective date. The Company is an &#8220;emerging growth company&#8221; as defined in the Jumpstart Our Business Startups Act of 2012, as amended (&#8220;JOBS Act&#8221;). The Jobs Act provides that an emerging growth company can take advantage of an extended transition period for complying with new or revised accounting standards. Thus, an emerging growth company can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. The Company elected to avail itself of this extended transition period and, as a result, we will not be required to adopt new or revised accounting standards on the relevant dates on which adoption of such standards is required for other public companies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In 2016, the FASB issued ASU 2016-13, Financial Instruments&#160;&#8211; Credit Losses (Topic 326): Measurement of Credit Losses on Financial Statements. The new standard, as amended, requires that expected credit losses relating to financial assets measured on an amortized cost basis and available-for-sale debt securities be recorded through an allowance for credit losses. It also limits the amount of credit losses to be recognized for available-for-sale debt securities to the amount by which carrying value exceeds fair value and also requires the reversal of previously recognized credit losses if fair value increases. The targeted transition relief standard allows filers an option to irrevocably elect the fair value option of ASC 825-10, Financial Instruments-Overall, applied on an instrument-by-instrument basis for eligible instruments.&#160;ASU No.&#160;2016-13, Financial Instruments&#160;- Credit Losses (Topic 326) will become effective for the Company on January&#160;1, 2023. The Company is currently assessing the impact of the adoption of this guidance on its consolidated financial statements.</p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">144</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_hTOft3WF_0avV4xSFcC6Vg_cont8"><ix:continuation id="Tb_eGXEccogmEmeCL-nBH4m2w_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In December&#160;2019, the FASB issued ASU No.&#160;2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes, which simplifies the accounting for income taxes by removing certain exceptions to the general principles in the existing guidance for income taxes and making other minor improvements. The amendments are effective for annual reporting periods beginning after December&#160;15, 2020 with early adoption permitted. The adoption of this standard did not have a material impact to the financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In January 2017, the FASB issued ASU No. ASU 2017-04, &#160;Intangibles&#8212;Goodwill and Other (Topic 350<i style="font-style:italic;">)</i>, which eliminates Step 2 from the goodwill impairment test. Step 2 measures a goodwill impairment loss by comparing the implied fair value of a reporting unit&#8217;s goodwill with the carrying amount of that goodwill. Instead, entities will record an impairment charge based on the excess of a reporting unit&#8217;s carrying amount over its fair value (i.e., measure the charge based on today&#8217;s Step 1). This update is effective for annual and interim impairment tests performed in periods beginning after December 15, 2022. Early adoption of the standard is permitted. The Company is currently evaluating the new guidance and assessing the potential impact on its consolidated financial statements. &#160;</p></ix:continuation></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><a id="Tc_A2BKQWzfdUy8rUeJu2BqOQ_1_2"></a><a id="Tc_FtzqUPaZhUWhcJrRjgqyVw_2_2"></a><a id="Tc_T8kruQQ470u7DUQuAu20ww_2_5"></a><a id="Tc_E1c5tXj_lkWNQRyS83qB3Q_2_8"></a><a id="Tc_fDJFr3rAu0iot1801m3iKA_2_11"></a><a id="Tc_Hka01VLVK0-TT_6rqBoHFA_3_0"></a><a id="Tc_B2rcw1Cb0UC77T-gh9OqNQ_4_0"></a><a id="Tc_1D4IJEtlsEOcKzfctTzNcA_5_0"></a><a id="Tc_AKYKY70Im0-XKa2BT23fow_5_2"></a><a id="Tc_KatBrQGj10GUqQqbnfA1jw_5_5"></a><a id="Tc_pZ2qA86SwEC3-8CupLSBSg_5_6"></a><a id="Tc___5Q-W7p9EW3-r546dNW3w_5_8"></a><a id="Tc_t_GsjHQDv0qYE2w2xtmwag_5_11"></a><a id="Tc_jdbeE_Mp-kmRuIng3-2B8Q_6_0"></a><a id="Tc_b0dyxRX87UmhUmmlUHsi4w_6_6"></a><a id="Tc__yIc8c5_VES2e3tYOLJP3Q_7_0"></a><a id="Tc_rqFtN7ye7EKmXw-D5GJGQg_8_0"></a><a id="Tc_3oz5KRolf0WRs3ooU7NCUA_10_0"></a><a id="Tc_prfpszuVqE-qwzyM4SNRWw_11_0"></a><a id="Tc_qczdnYtXX0aD4zlC9Zw8PQ_11_6"></a><a id="Tc_Nc_gi97oDkiKgn4yDkimJQ_12_0"></a><a id="Tc_siFOnaJ760iDiaa00gwweQ_12_3"></a><a id="Tc_Lw7dRKj8UU6b_KXDmTcJ4A_12_6"></a><a id="Tc_xt8o9dbWlEWAXUH-YCz8OQ_12_9"></a><a id="Tc_Azu2Kr1V0EqWwo5_bP0JYQ_12_12"></a><a id="Tc_MykxfLCF9UG4AzCVyfyr5g_13_0"></a><a id="Tc_bAO8d8FhqEuIOnCv7xEbzQ_13_6"></a><a id="Tc_Y_P3PF9Xm0W2XsWu1vJLQg_14_0"></a><a id="Tc_scQqpdt1Wkii5ZJdSsSbYA_14_2"></a><a id="Tc_jfcPKRjOG06wzc1hPfSKfQ_14_5"></a><a id="Tc_yS4KZrFHOEmXeUUEHXpduA_14_8"></a><a id="Tc_o95Zlc-VsUWdjsA6iUT6fw_14_11"></a><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ" name="us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" id="Tb_Zwu3RFwsukKGldUFY5H8Cg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Note 3 &#8211; Marketable Securities </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Marketable securities as of December 31, 2021 consisted of the following:</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ" name="us-gaap:MarketableSecuritiesTextBlock" id="Tb_ggXUIA_E20WmNSctDckHIg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:29.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:11.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:12.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:12.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:14.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:29.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:67.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, 2021</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:29.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:middle;width:13.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amortized Cost</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:middle;width:14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Unrealized Gains</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:middle;width:14.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Unrealized Losses</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:middle;width:16.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair Value</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:29.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Assets:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:11.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:12.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:12.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:14.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:29.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;">             Current:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:29.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">U.S. Treasuries</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_ypcv1cNyLUqWUpUVKo2bMg" decimals="0" format="ixt:numdotdecimal" name="imrx:MarketableSecuritiesAmortizedCostBasisCurrent" scale="0" id="Tc_Pvy4To_yw0Gt2HpZL0ykHA_5_3">42,147,385</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_ypcv1cNyLUqWUpUVKo2bMg" decimals="0" format="ixt:numdotdecimal" name="imrx:MarketableSecuritiesAccumulatedUnrealizedLossesCurrent" scale="0" id="Tc_6xANhtIaakuXj_LiiwEBMw_5_9">28,575</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_ypcv1cNyLUqWUpUVKo2bMg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:MarketableSecuritiesCurrent" scale="0" id="Tc_6SFBVV_oXEqG3OwsTlsYyg_5_12">42,118,810</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:29.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">Government securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_imrx_GovernmentSecuritiesMember__6KtOh0dNkKDNENoMm1rTg" decimals="0" format="ixt:numdotdecimal" name="imrx:MarketableSecuritiesAmortizedCostBasisCurrent" scale="0" id="Tc_5-H4qKIxxki4uPOAGOh4Bw_6_3">19,218,057</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_imrx_GovernmentSecuritiesMember__6KtOh0dNkKDNENoMm1rTg" decimals="0" format="ixt:numdotdecimal" name="imrx:MarketableSecuritiesAccumulatedUnrealizedLossesCurrent" scale="0" id="Tc_L8RGWxUOu0ahGn9GG_VJkQ_6_9">13,689</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_imrx_GovernmentSecuritiesMember__6KtOh0dNkKDNENoMm1rTg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:MarketableSecuritiesCurrent" scale="0" id="Tc_AlVxUrNppUufV2TzmIDFlw_6_12">19,204,368</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:29.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">Commercial Paper</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember_CWayHsb0d0ChYaEcAr7tvw" decimals="0" format="ixt:numdotdecimal" name="imrx:MarketableSecuritiesAmortizedCostBasisCurrent" scale="0" id="Tc_lOrl0c7nDUKk7Nar-WYeJg_7_3">12,992,165</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember_CWayHsb0d0ChYaEcAr7tvw" decimals="0" format="ixt:numdotdecimal" name="imrx:MarketableSecuritiesAccumulatedUnrealizedGainsCurrent" scale="0" id="Tc_6GYqmETaEU6S3dNV0R0gWA_7_6">57</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember_CWayHsb0d0ChYaEcAr7tvw" decimals="0" format="ixt:numdotdecimal" name="imrx:MarketableSecuritiesAccumulatedUnrealizedLossesCurrent" scale="0" id="Tc_kT_HJr7_50ym6iqnWjILDQ_7_9">4,197</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember_CWayHsb0d0ChYaEcAr7tvw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:MarketableSecuritiesCurrent" scale="0" id="Tc_IsL13cfMZUecnORFk32AeA_7_12">12,988,025</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:29.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;">Total Current</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="As_Of_12_31_2021_TBpjtOXgEkKQahJJAv0aWg" decimals="0" format="ixt:numdotdecimal" name="imrx:MarketableSecuritiesAmortizedCostBasisCurrent" scale="0" id="Tc_sm9ip-9kvEmvdJtiinTasw_8_3">74,357,607</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="As_Of_12_31_2021_TBpjtOXgEkKQahJJAv0aWg" decimals="0" format="ixt:numdotdecimal" name="imrx:MarketableSecuritiesAccumulatedUnrealizedGainsCurrent" scale="0" id="Tc_K6pocdW_TEaKaIg7ZBsAOQ_8_6">57</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="As_Of_12_31_2021_TBpjtOXgEkKQahJJAv0aWg" decimals="0" format="ixt:numdotdecimal" name="imrx:MarketableSecuritiesAccumulatedUnrealizedLossesCurrent" scale="0" id="Tc_ao49vdkkAEWZzrxx0gYLKg_8_9">46,461</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="As_Of_12_31_2021_TBpjtOXgEkKQahJJAv0aWg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:MarketableSecuritiesCurrent" scale="0" id="Tc_LZIDGXeEHEm1d5xEoj7Acw_8_12">74,311,203</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:29.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:29.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;">           Non-current:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:29.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">U.S. Treasuries</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_ypcv1cNyLUqWUpUVKo2bMg" decimals="0" format="ixt:numdotdecimal" name="imrx:MarketableSecuritiesAmortizedCostBasisNonCurrent" scale="0" id="Tc_Z-1oN3YPukCq3WZJGEFdHw_11_3">999,186</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_ypcv1cNyLUqWUpUVKo2bMg" decimals="0" format="ixt:numdotdecimal" name="imrx:MarketableSecuritiesAccumulatedUnrealizedLossesNonCurrent" scale="0" id="Tc_GSAApjh7-Uu4MsF1jhH4ZA_11_9">2,626</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_ypcv1cNyLUqWUpUVKo2bMg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:MarketableSecuritiesNoncurrent" scale="0" id="Tc_UQiOn--KrUa2RCFRbBsn1w_11_12">996,560</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:29.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">Government securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> -</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:29.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;">Total Non-current</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="As_Of_12_31_2021_TBpjtOXgEkKQahJJAv0aWg" decimals="0" format="ixt:numdotdecimal" name="imrx:MarketableSecuritiesAmortizedCostBasisNonCurrent" scale="0" id="Tc_nMEqo830PESQDGXftJ8I2A_13_3">999,186</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="As_Of_12_31_2021_TBpjtOXgEkKQahJJAv0aWg" decimals="0" format="ixt:numdotdecimal" name="imrx:MarketableSecuritiesAccumulatedUnrealizedLossesNonCurrent" scale="0" id="Tc_cNI6bh8siUuBzaqPxcSCwg_13_9">2,626</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="As_Of_12_31_2021_TBpjtOXgEkKQahJJAv0aWg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:MarketableSecuritiesNoncurrent" scale="0" id="Tc_2oaDnF_AHEeSUfY4xDQeww_13_12">996,560</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:29.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;">Total marketable securities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="As_Of_12_31_2021_TBpjtOXgEkKQahJJAv0aWg" decimals="0" format="ixt:numdotdecimal" name="imrx:MarketableSecuritiesAmortizedCostBasis" scale="0" id="Tc_MADVwPbx0UevtRhULYFSiA_14_3">75,356,793</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="As_Of_12_31_2021_TBpjtOXgEkKQahJJAv0aWg" decimals="0" format="ixt:numdotdecimal" name="imrx:MarketableSecuritiesAccumulatedUnrealizedGains" scale="0" id="Tc_6P6ExhQeWE2XRuyKZxXapQ_14_6">57</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="As_Of_12_31_2021_TBpjtOXgEkKQahJJAv0aWg" decimals="0" format="ixt:numdotdecimal" name="imrx:MarketableSecuritiesAccumulatedUnrealizedLosses" scale="0" id="Tc_IUxZ1oeKp0edjdy6xoP2_w_14_9">49,087</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="As_Of_12_31_2021_TBpjtOXgEkKQahJJAv0aWg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:MarketableSecurities" scale="0" id="Tc_K9AibAPlj0eTLm2uNBvoYg_14_12">75,307,763</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">There were <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="As_Of_12_31_2020_OUSLyqWONEO8ccGPC6rBdg" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:MarketableSecurities" scale="0" id="Narr_LhUIPQrX4Eq0-v9reMijQA">no</ix:nonFraction> marketable securities as of December 31, 2020. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">There were <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:ImpairmentOfInvestments" scale="0" id="Narr_SOSyg0jydkGF-1tQ2UuTlQ">no</ix:nonFraction> impairments of the Company&#8217;s available-for-sale marketable securities measured and carried at fair value during the year ended December 31, 2021.  Realized gains and losses are included in other expense on a specific-identification basis.&#160;There were&#160;<ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:MarketableSecuritiesRealizedGainLoss" scale="0" id="Narr_rf1qFu5Fl06VZjo6CdosNw">no</ix:nonFraction>&#160;realized gains or losses on marketable securities for the year ended December 31, 2021.</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">145</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_HACjADvvukWp7bM8nQwnBw_1_3"></a><a id="Tc_QD7ZV-ZybE60DRk-rZ7LAg_1_6"></a><a id="Tc_A82y-0sW2kWo00uZLrGNVA_1_9"></a><a id="Tc_8M2zkEUcTkOhYVjR4p9iIw_1_12"></a><a id="Tc_ys3LrfiRVUinDCNniYW3sQ_2_0"></a><a id="Tc_rRx6wbZoRk6sfrMlfKZ8lQ_3_0"></a><a id="Tc_tE0TA7cWfE-gQBYAvCLRBQ_4_0"></a><a id="Tc_5XEmHKplrkKHmBv-L-rbhg_4_2"></a><a id="Tc_ciNQZ48-S0-b4Oiv2lo4Cg_4_5"></a><a id="Tc_vUZNR2BB3Um87483So1SBQ_4_6"></a><a id="Tc_5CU3OEc8Ak-kwx-LUuXQPg_4_8"></a><a id="Tc_dwhFLflOEkSCd97dm2Yipw_4_9"></a><a id="Tc_qP4KEDY4BEe0gB6S1dOJ4A_4_11"></a><a id="Tc_lT0Mqwisx0W28KFpWuT9qA_5_0"></a><a id="Tc_A7UKkgwQokaIz1cV7ClzUg_5_3"></a><a id="Tc_z_DY8Tkl-UujTutWqTz9Tw_5_9"></a><a id="Tc_n6aHkKCtvUyvjW-I9WQpLg_6_0"></a><a id="Tc_DSvlF3J4y0arkROemDVC-g_6_9"></a><a id="Tc_ZhdxXbfg-U6S0Ndo0j_p-A_8_0"></a><a id="Tc_71neC3HxOUq3EhMO2SV-ng_9_0"></a><a id="Tc_HcgU0KWa_0S5T6-e-wja6Q_9_2"></a><a id="Tc_N_8wy24VMUa_DT3yijOzZQ_9_5"></a><a id="Tc_rEZjL4_0tky1c2Mb5srnug_9_6"></a><a id="Tc_4PbQB_8ugkuI4d6ejq6qrg_9_8"></a><a id="Tc_TTsp_qDiik2PwDLo58GyLQ_9_9"></a><a id="Tc_MafnDfT1WU6nW-JDsZGDjQ_9_11"></a><a id="Tc_xV2KOXOJ2kas-TDpg4CMJA_10_0"></a><a id="Tc_-B8NSt4MlUCUhWYuuH_JKA_10_3"></a><a id="Tc_9eVZxxHNOUSnbocwaQTEhg_10_9"></a><a id="Tc_OtW0aSNhpEuBJ7jYVBHPjQ_11_0"></a><a id="Tc_WhpfZwNZIEqY27IFEC_nDg_11_3"></a><a id="Tc_m_BRkWmUIkq3K2NWtFBjqA_11_9"></a><a id="Tc_KmaOGhgTmESqjw8RA8hhyA_12_0"></a><a id="Tc__2J7tPSf-U6efdq_tfB4vA_12_9"></a><a id="Tc_zmwfwokdvU2faAp8zm02Tg_13_0"></a><a id="Tc_HMYgbR3VM0Gznxe9zHFkKA_13_2"></a><a id="Tc_rP-qoJRdR0eLrkzbdP9x7A_13_5"></a><a id="Tc_zGe0kIkqjUqvjkO3XAup5w_13_8"></a><a id="Tc_tvuj99SpkkWlKHnxsDh82g_13_9"></a><a id="Tc_bdl4EhBbXkie7_yaavvniw_13_11"></a><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ" name="us-gaap:FairValueDisclosuresTextBlock" id="Tb_MSI1na2ypUyKfSGalbsVtg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Note 4 &#8211; Fair Value Measurements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The following table summarizes our cash equivalents and marketable securities measured at fair value on a recurring basis as of December 31, 2021:</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ" name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock" id="Tb_w9LWMx5x8kOu-CS09RI5qQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:39.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:39.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Level 1</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Level 2</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Level 3</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:39.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:39.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:39.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">       Money market</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="As_Of_12_31_2021_us-gaap_FairValueByAssetClassAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_tGSOwi1HF0iLCEdWOlktoQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="0" id="Tc_TsxWBqq0-kmA5n4YUccwdw_4_3">33,961,344</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="As_Of_12_31_2021_us-gaap_FairValueByAssetClassAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_N9UIc66mekClPPydSVC05g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="0" id="Tc_L8LyZf-THU-qbR2UPkgYhQ_4_12">33,961,344</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:39.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">       Commercial paper</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="As_Of_12_31_2021_us-gaap_FairValueByAssetClassAxis_us-gaap_CommercialPaperMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_sHUMvfiqDEWTLNwGi2V19w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="0" id="Tc_uOHxDlVN5kmp1Jea29yU1A_5_6">2,000,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="As_Of_12_31_2021_us-gaap_FairValueByAssetClassAxis_us-gaap_CommercialPaperMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_0brBfUV_8k-73Ah2xvo5vA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="0" id="Tc_tYnEiuBdMUeUEtyk1HnfXA_5_12">2,000,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:39.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">        Total cash equivalents</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="As_Of_12_31_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_DcZ3E7WdG0qTM9kwKkYCCA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="0" id="Tc_l_ZG4V8pe0euw8hZhHhuwA_6_3">33,961,344</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="As_Of_12_31_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_XD-w4rYEvkOhxL7DPVZDYA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="0" id="Tc_OeqQ6EJ2pkKtsoOYtnhxjA_6_6">2,000,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="As_Of_12_31_2021_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_NZFKYXEtB0ypESwMFRZYaA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="0" id="Tc_45VVUaBxFUiKQkLAAtqt8g_6_12">35,961,344</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:39.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:39.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Marketable securities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:39.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">      U.S. Treasuries</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="As_Of_12_31_2021_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasurySecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_TueSJDcFvk-6KVBcFb4yWg" decimals="0" format="ixt:numdotdecimal" name="imrx:MarketableSecuritiesFairValueDisclosure" scale="0" id="Tc_TOLlfWM7CESNclC2ZrK_pg_9_3">43,115,370</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="As_Of_12_31_2021_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasurySecuritiesMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_GndZSZIX5kONkZeJ-uwZvA" decimals="0" format="ixt:numdotdecimal" name="imrx:MarketableSecuritiesFairValueDisclosure" scale="0" id="Tc_R6H0l-g_EkiEBKahjOKOhw_9_12">43,115,370</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:39.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">      Government securities</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="As_Of_12_31_2021_us-gaap_FairValueByAssetClassAxis_imrx_GovernmentSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_rv952rznEk2GkuC-bXIEgw" decimals="0" format="ixt:numdotdecimal" name="imrx:MarketableSecuritiesFairValueDisclosure" scale="0" id="Tc_HD57mL5rG0qQTuDjCGwZWA_10_6">19,204,368</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="As_Of_12_31_2021_us-gaap_FairValueByAssetClassAxis_imrx_GovernmentSecuritiesMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_hYwzM8-hekGhWFHX6of5Fg" decimals="0" format="ixt:numdotdecimal" name="imrx:MarketableSecuritiesFairValueDisclosure" scale="0" id="Tc_H4ED9AepXk2mHwcPfsjSfQ_10_12">19,204,368</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:39.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">      Commercial paper</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="As_Of_12_31_2021_us-gaap_FairValueByAssetClassAxis_us-gaap_CommercialPaperMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_sHUMvfiqDEWTLNwGi2V19w" decimals="0" format="ixt:numdotdecimal" name="imrx:MarketableSecuritiesFairValueDisclosure" scale="0" id="Tc_FU5ngA-nDUqfueOHyTJB2Q_11_6">12,988,025</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="As_Of_12_31_2021_us-gaap_FairValueByAssetClassAxis_us-gaap_CommercialPaperMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_0brBfUV_8k-73Ah2xvo5vA" decimals="0" format="ixt:numdotdecimal" name="imrx:MarketableSecuritiesFairValueDisclosure" scale="0" id="Tc_9nIRyU75iEGpC31ecCtegg_11_12">12,988,025</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:39.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">        Total marketable securities</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="As_Of_12_31_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_DcZ3E7WdG0qTM9kwKkYCCA" decimals="0" format="ixt:numdotdecimal" name="imrx:MarketableSecuritiesFairValueDisclosure" scale="0" id="Tc_T7vFDc4gjUCSTVvHsw_GFA_12_3">43,115,370</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="As_Of_12_31_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_XD-w4rYEvkOhxL7DPVZDYA" decimals="0" format="ixt:numdotdecimal" name="imrx:MarketableSecuritiesFairValueDisclosure" scale="0" id="Tc_PMr8pBebek6NKElwW0Q3Fg_12_6">32,192,393</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="As_Of_12_31_2021_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_NZFKYXEtB0ypESwMFRZYaA" decimals="0" format="ixt:numdotdecimal" name="imrx:MarketableSecuritiesFairValueDisclosure" scale="0" id="Tc_Pe-B2xAdKECYPovvGu5_6w_12_12">75,307,763</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:39.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total cash equivalents and marketable securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.04%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="As_Of_12_31_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_DcZ3E7WdG0qTM9kwKkYCCA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="0" id="Tc_gEgVg57JEU6HINm9WUmkcA_13_3">77,076,714</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="As_Of_12_31_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_XD-w4rYEvkOhxL7DPVZDYA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="0" id="Tc_kmPfUV2VTEG7BcnYRdofuw_13_6">34,192,393</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.43%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="As_Of_12_31_2021_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_NZFKYXEtB0ypESwMFRZYaA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="0" id="Tc_l1H6cW2F50SLNwtjwkKIMg_13_12">111,269,107</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">There were no transfers between Level 1 and Level 2 and we had no&#160;financial assets or <span style="-sec-ix-hidden:Hidden_tlcK7EHhSU-TZzE4mXesaw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">liabilities</span></span> that were classified as Level 3 at any point during the year ended December 31, 2021. There were <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="As_Of_12_31_2020_OUSLyqWONEO8ccGPC6rBdg" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:MarketableSecurities" scale="0" id="Narr_QcuXiEylUUu8Gt2Swlqt3g">no</ix:nonFraction> marketable securities as of December 31, 2020. </p></ix:nonNumeric><a id="Tc_VKfEZzhy50-j5bUmU_PvMg_1_2"></a><a id="Tc_iRiAwuOJWEeqzq3aBzFpKg_1_5"></a><a id="Tc_P3lyen6HjUSkdqOUnqTLAA_2_2"></a><a id="Tc_kw0MIIHxfkWtonssaMndmw_2_5"></a><a id="Tc_o8AX_r8-U0Wu4Zwx3oha5Q_4_0"></a><a id="Tc__mQu0j_bVU-hQh29v_PuKg_4_2"></a><a id="Tc_8opKDZrYCUic6v-I6EFvrg_4_5"></a><a id="Tc_XItQi8huXUWaRZLIsSKv5w_5_0"></a><a id="Tc_uc9ZZwNJ4Ea7ryXM2B1PQQ_6_0"></a><a id="Tc_dst1A3sHQ0SOXLVOEGdyDg_6_6"></a><a id="Tc_8uvZyLHwe025up2vfJu-rA_7_0"></a><a id="Tc_z8dEtlvZQU-a7GOIcd5i6Q_7_6"></a><a id="Tc_j0HZQQsLdUCUaHvzaDr2Mw_8_0"></a><a id="Tc_m5aPxUiLmUaZOhMfMz8Z2A_9_0"></a><a id="Tc_CZrIS0FBSEq3tfjODItglA_10_0"></a><a id="Tc_993Dg17Whk-o98NA7-Uwew_10_2"></a><a id="Tc_IIyohEmUT0G8YlKjUjPO5g_10_5"></a><a id="Narr_Lnsr27GCSEy-nqUbNXLYnw"></a><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="Tb_BaK3T6QdzkyNNVUp2xK1WA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Note&#160;5&#160;&#8211; Property and Equipment, net</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Property and equipment, net consisted of the following:</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="Tb_cgr4MvVR0ECBEnteqpDFjA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Computer equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember__c5PFKa--kCuxwpGGlOIrg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" id="Tc_Aob7Wdf2AkqwlJm4D6qntA_4_3">281,666</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_ISSEkI2XdEmI7m0_HrAVEw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" id="Tc_AuT47o8ry0SkYVU8yimLFQ_4_6">174,317</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Furniture and fixtures</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_XLMYvLxYDEmGm0OC6_nT-A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" id="Tc_V2WZo12HUEeHfT3fEMreQw_5_3">84,477</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_ZN2vm0JtIkGqEGwjZuOpmA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" id="Tc__ERoMRqLwE2rB6g1V8Bg7Q_5_6">18,798</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Lab equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_imrx_LabEquipmentMember_WQeNLQggXkGO-8Q1oHgFeQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" id="Tc_mzDb5Xjlt0eDKvtUGiIfPw_6_3">463,182</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">-</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Leasehold improvements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_bZau0xYq2Eux-_CkfhyDgw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" id="Tc_-8_vnp0MtEmoaR-99G2D2Q_7_3">152,117</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">-</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="As_Of_12_31_2021_TBpjtOXgEkKQahJJAv0aWg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" id="Tc_Pa9GB8fBpEWVXKKdMsJcrQ_8_3">981,442</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="As_Of_12_31_2020_OUSLyqWONEO8ccGPC6rBdg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" id="Tc_fmppGZFR802QAyp-DalOsQ_8_6">193,115</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accumulated depreciation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="As_Of_12_31_2021_TBpjtOXgEkKQahJJAv0aWg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="0" id="Tc_DIl5le-kP0ermw9CeKN1Bg_9_3">174,219</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="As_Of_12_31_2020_OUSLyqWONEO8ccGPC6rBdg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="0" id="Tc_ad7Pkh0pHk6aJfoOZRF_nQ_9_6">128,752</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Property and equipment, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="As_Of_12_31_2021_TBpjtOXgEkKQahJJAv0aWg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" id="Tc_wMjCwnPmEEugL5gpVEhKPA_10_3">807,223</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="As_Of_12_31_2020_OUSLyqWONEO8ccGPC6rBdg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" id="Tc_afMPc58gf0GT1VzLJTP5Vg_10_6">64,363</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Depreciation expense totaled $<ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="0" id="Narr_4AZd3gyM5UqPdJuSNaL8tA">45,467</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="Duration_1_1_2020_To_12_31_2020_J_O9OcmviUi8EDFgokrY1Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="0" id="Narr_Ru6dyTgxvUyHpfwNbVa6XA">24,328</ix:nonFraction> for the year ended December 31, 2021 and 2020, respectively. </p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ" name="us-gaap:BusinessCombinationDisclosureTextBlock" id="Tb_LWV6DgjBPUe7ZaejeCXT6g" continuedAt="Tb_LWV6DgjBPUe7ZaejeCXT6g_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Note&#160;6&#160;&#8211; Business Combination</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;background:#ffffff;">BioArkive Acquisition</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">On December&#160;22, 2021, the Company completed the acquisition of all outstanding shares of capital stock of BioArkive, Inc., a California corporation (&#8220;BioArkive&#8221;), for a market value of </span><span style="background:#ffffff;">$<ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="As_Of_12_22_2021_us-gaap_BusinessAcquisitionAxis_imrx_BioArkiveIncMember_eZfDAI7yG0yVohELE3M0sA" decimals="4" format="ixt:numdotdecimal" name="imrx:BusinessCombinationPurchasePrice" scale="6" id="Narr_dE1BMsXCjE64P-mEy3tkGQ">8.75</ix:nonFraction></span><span style="background:#ffffff;"> million.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">BioArkive is a San Diego based contract research organization that has previously provided preclinical research services and biosample storage to the Company and other biotechnology companies. BioArkive is in the process of being fully integrated into the Company to exclusively support the Company&#39;s internal preclinical research activities for its oncology pipeline.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">In connection with the acquisition,&#160;the Company has assumed the obligations under BioArkive&#8217;s </span><span style="background:#ffffff;"><ix:nonFraction unitRef="Unit_Standard_agreement_qexq1bbkzU-JqgEPv8PRCQ" contextRef="As_Of_12_22_2021_us-gaap_BusinessAcquisitionAxis_imrx_BioArkiveIncMember_eZfDAI7yG0yVohELE3M0sA" decimals="INF" format="ixt-sec:numwordsen" name="imrx:NumberOfLeasesObligationsAssumed" scale="0" id="Narr_iJHn-IbgkUK8L5vlO11W8A">three</ix:nonFraction></span><span style="background:#ffffff;"> lease agreements.</span></p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">146</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_g053n5XobkmtlNVhKQngbQ_1_2"></a><a id="Tc_UFdKmuGZWUKoOYQ8t79DXA_1_5"></a><a id="Tc_FugayN1CCUyi8Cu95SA_hg_2_0"></a><a id="Tc_EF0JOnj6ikygthKBRqQ-Eg_2_2"></a><a id="Tc_4jBA9YkdnEuR_iaruunaTQ_3_0"></a><a id="Tc_g1r47mbpf0SLDwbn-OY03A_4_0"></a><a id="Tc_LC_7ts4zhk2ZpBjfsnHwsQ_5_0"></a><a id="Tc_zbpg9m4WBkaQtptRAfiU1g_6_0"></a><a id="Tc_9F1mji0y802sOQgAUn3HwQ_7_0"></a><a id="Tc_5bmNBT2bQ0WzCz4VndEyAA_8_0"></a><a id="Tc_n6sjVAXYv0mSzsJeypQE3Q_9_0"></a><a id="Tc_LUEvZTu1tU-numzG4w5kCw_11_0"></a><a id="Tc_dR4N3Z5ljEClE_o0G4WoZQ_13_0"></a><a id="Tc_i4i4zwlz8kKmav7-aI-A6w_14_0"></a><a id="Tc_1mL8HFkUp0GDTgKZI59cUw_15_0"></a><a id="Tc_eAWrx9azpk-jczVg-mKEDw_16_0"></a><a id="Tc_bm203DlUwUm9NMDMl8J66g_16_2"></a><ix:continuation id="Tb_LWV6DgjBPUe7ZaejeCXT6g_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">The purchase price was paid by Immuneering through the issuance of an aggregate of </span><span style="background:#ffffff;"><ix:nonFraction unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ" contextRef="Duration_12_22_2021_To_12_22_2021_us-gaap_BusinessAcquisitionAxis_imrx_BioArkiveIncMember_jaVHRkxuBESGO6YkECH_Bw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesAcquisitions" scale="0" id="Narr_GwuF8RDgJ0mYQYAzvoH1fg">379,635</ix:nonFraction></span><span style="background:#ffffff;"> shares of Immuneering&#8217;s Class&#160;A common stock. The number of shares of common stock issued was calculated using a value based on the average of the daily volume weighted average prices of the common stock on the Nasdaq Stock Exchange for the </span><span style="background:#ffffff;"><ix:nonFraction unitRef="Unit_Standard_D_qWJwQorwfUaf88ueMyElMA" contextRef="Duration_12_22_2021_To_12_22_2021_us-gaap_BusinessAcquisitionAxis_imrx_BioArkiveIncMember_jaVHRkxuBESGO6YkECH_Bw" decimals="INF" format="ixt:numdotdecimal" name="imrx:BusinessCombinationSharesIssuedSharePriceThresholdTradingDays" scale="0" id="Narr_DAOqxSamwESkllsXV27uiQ">30</ix:nonFraction></span><span style="background:#ffffff;">-trading day period ending on and including the trading day immediately prior to the closing date.</span> The sellers of BioArkive are restricted from selling these shares for a <ix:nonNumeric contextRef="Duration_12_22_2021_To_12_22_2021_us-gaap_BusinessAcquisitionAxis_imrx_BioArkiveIncMember_jaVHRkxuBESGO6YkECH_Bw" format="ixt-sec:durwordsen" name="imrx:BusinessCombinationSharesIssuedLockInPeriod" id="Narr_LHVdJj0yMUW8i7YMyspEVw">6 month</ix:nonNumeric> period from the date of the acquisition. As such, we estimated that there was an approximate <ix:nonFraction unitRef="Unit_Standard_pure_iothMaWWqUCV2N7d1PVg4w" contextRef="Duration_12_22_2021_To_12_22_2021_us-gaap_BusinessAcquisitionAxis_imrx_BioArkiveIncMember_jaVHRkxuBESGO6YkECH_Bw" decimals="2" format="ixt:numdotdecimal" name="imrx:BusinessCombinationSharesIssuedDiscountDueToMarketabilityPercentage" scale="-2" id="Narr_peMFNFsB2kSQ5hufG3llpw">10</ix:nonFraction>% discount for the lack of marketability of the shares. The fair value of the purchase price in the acquisition has been preliminarily estimated to be $<ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="Duration_12_22_2021_To_12_22_2021_us-gaap_BusinessAcquisitionAxis_imrx_BioArkiveIncMember_jaVHRkxuBESGO6YkECH_Bw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationConsiderationTransferred1" scale="0" id="Narr_gr2cy1ETgUSWXV6j0C8nlA">7,875,000</ix:nonFraction>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">Prior to the acquistion, Brett Hall, Chief Scientific Officer of Immuneering and the Founder and Chairman of the board of directors of BioArkive, held the majority of the outstanding shares of BioArkive capital stock.</span> &#160;BioArkive provided contract services to the Company. <span style="background:#ffffff;">Research and development expenses in the consolidated statement of operations include the cost of services provided by BioArkive to the Company which amounted to </span><span style="background:#ffffff;">$<ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_imrx_BioArkiveIncMember_TX8VFVwjvkmlDFzOu0fzHw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" scale="0" id="Narr_qISp4tD4gkqYMJlj0Fjz4A">4,548,780</ix:nonFraction></span><span style="background:#ffffff;"> in 2021 through date of the acquisition and </span><span style="background:#ffffff;">$<ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_imrx_BioArkiveIncMember_sa3-bf410kC_Z3vN1a5IFw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" scale="0" id="Narr_t3UNa9c7IEyQG8gX12SeVA">2,744,051</ix:nonFraction></span><span style="background:#ffffff;"> in 2020. As of December&#160;31, 2020, </span><span style="background:#ffffff;">$<ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="As_Of_12_31_2020_us-gaap_BalanceSheetLocationAxis_us-gaap_AccountsPayableAndAccruedLiabilitiesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_imrx_BioArkiveIncMember_Fdx8Pw88t0GYE-WWz9kZLQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DueToRelatedPartiesCurrent" scale="0" id="Narr_hdCnI4ozEka9hP3drSsGcw">279,153</ix:nonFraction></span><span style="background:#ffffff;"> was owed to BioArkive and is included in accounts payable or accrued contract research expenses in the consolidated balance sheets. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;">Assets Acquired and Liabilities Assumed at Fair Value</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The BioArkive Acquisition has been accounted for using the acquisition method of accounting. This method requires that assets acquired and liabilities assumed in a business combination to be recognized at their fair values as of the acquisition date. As of December&#160;31, 2021, certain amounts relating to working capital have not been finalized. The finalization of these matters could result in changes to goodwill.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;">Intangible Assets</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The estimated fair value of the intangible assets was determined using the relief from royalty approach.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;">Goodwill</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Goodwill is the excess of the consideration transferred over the net assets recognized and represents the expected cost savings of the combined company and assembled workforce. One of the key factors that contributes to the recognition of goodwill, and a driver for the Company&#39;s acquisition of BioArkive, is the planned investment in the internal preclinical research activities for our oncology pipeline.&#160;Goodwill recognized as a result of this acquisition is non-deductible for income tax purposes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Pro forma results are not presented for this acquisition as they are not material to the consolidated results of the Company&#8217;s operations.</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ" name="us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" id="Tb_tlzzUtZpakixSuMzNJzyGw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:99.4%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:52.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:22.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:52.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';">&#160;&#160;&#160;&#160;</span></p></td><td colspan="2" style="vertical-align:bottom;width:23.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Preliminary Valuation</b></p></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;width:19.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted Average Life</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:52.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash</p></td><td style="vertical-align:bottom;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="As_Of_12_22_2021_us-gaap_BusinessAcquisitionAxis_imrx_BioArkiveIncMember_eZfDAI7yG0yVohELE3M0sA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" scale="0" id="Tc_2fzGbORspEqCjrUfktRS2A_2_3">70,348</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:52.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other currents assets</p></td><td style="vertical-align:bottom;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="As_Of_12_22_2021_us-gaap_BusinessAcquisitionAxis_imrx_BioArkiveIncMember_eZfDAI7yG0yVohELE3M0sA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" scale="0" id="Tc_hEsvXETcnkym9Li719u_tw_3_3">225,790</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:52.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other long term assets</p></td><td style="vertical-align:bottom;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="As_Of_12_22_2021_us-gaap_BusinessAcquisitionAxis_imrx_BioArkiveIncMember_eZfDAI7yG0yVohELE3M0sA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" scale="0" id="Tc_XhH979z6CE6IXcF5NwUmEQ_4_3">87,796</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:52.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Property, plant and equipment, net</p></td><td style="vertical-align:bottom;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="As_Of_12_22_2021_us-gaap_BusinessAcquisitionAxis_imrx_BioArkiveIncMember_eZfDAI7yG0yVohELE3M0sA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" scale="0" id="Tc_Q0LklAO9Y0SHrjgnzhZcTQ_5_3">727,539</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:52.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Right of use assets</p></td><td style="vertical-align:bottom;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="As_Of_12_22_2021_us-gaap_BusinessAcquisitionAxis_imrx_BioArkiveIncMember_eZfDAI7yG0yVohELE3M0sA" decimals="0" format="ixt:numdotdecimal" name="imrx:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets" scale="0" id="Tc_Z8hi34EDW0aPWyJEFYEuew_6_3">4,824,700</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:52.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Intangible asset</p></td><td style="vertical-align:bottom;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:52.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">   Technology</span></p></td><td style="vertical-align:bottom;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="As_Of_12_22_2021_us-gaap_BusinessAcquisitionAxis_imrx_BioArkiveIncMember_eZfDAI7yG0yVohELE3M0sA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" scale="0" id="Tc_H7OcizgiK0icjTorjuiTDA_8_3">439,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_12_22_2021_To_12_22_2021_us-gaap_BusinessAcquisitionAxis_imrx_BioArkiveIncMember_jaVHRkxuBESGO6YkECH_Bw" format="ixt-sec:durwordsen" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" id="Tc_qPDY_jewwk-IvLrzAAkrQg_8_6">15 years</ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:52.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Goodwill</p></td><td style="vertical-align:bottom;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="As_Of_12_22_2021_us-gaap_BusinessAcquisitionAxis_imrx_BioArkiveIncMember_eZfDAI7yG0yVohELE3M0sA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="0" id="Tc_XPJYLYWmdUKMo1MZ3p22Cg_9_3">6,701,726</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:52.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:52.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total assets acquired</b></p></td><td style="vertical-align:bottom;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="As_Of_12_22_2021_us-gaap_BusinessAcquisitionAxis_imrx_BioArkiveIncMember_eZfDAI7yG0yVohELE3M0sA" decimals="0" format="ixt:numdotdecimal" name="imrx:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIncludingGoodwill" scale="0" id="Tc_lWDGZXYxR0udGD-MEGlpDw_11_3">13,076,899</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:52.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:52.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accounts payable, accrued expenses and other liabilities</p></td><td style="vertical-align:bottom;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="As_Of_12_22_2021_us-gaap_BusinessAcquisitionAxis_imrx_BioArkiveIncMember_eZfDAI7yG0yVohELE3M0sA" decimals="0" format="ixt:numdotdecimal" name="imrx:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAccruedExpensesAndOtherLiabilities" scale="0" id="Tc_BdQkTQ_jNke3q7BFD8tbmQ_13_3">69,714</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:52.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Deferred tax liabilities</p></td><td style="vertical-align:bottom;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="As_Of_12_22_2021_us-gaap_BusinessAcquisitionAxis_imrx_BioArkiveIncMember_eZfDAI7yG0yVohELE3M0sA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" scale="0" id="Tc_idAS0zhfQkmPtwwLpsno2Q_14_3">307,485</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:52.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Lease liabilities</p></td><td style="vertical-align:bottom;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="As_Of_12_22_2021_us-gaap_BusinessAcquisitionAxis_imrx_BioArkiveIncMember_eZfDAI7yG0yVohELE3M0sA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation" scale="0" id="Tc_mJOAvbELqEiwYr2cI7SPvQ_15_3">4,824,700</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:52.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Net assets acquired</b></p></td><td style="vertical-align:bottom;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.26%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="As_Of_12_22_2021_us-gaap_BusinessAcquisitionAxis_imrx_BioArkiveIncMember_eZfDAI7yG0yVohELE3M0sA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" scale="0" id="Tc_Z4sKPb21U0C3L3v8Tud-Gg_16_3">7,875,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">147</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_-my4keK9JEuQFsP8rlGdGA_1_2"></a><a id="Tc_APzV2edck0a2TynEI9JULg_1_5"></a><a id="Tc_jvFKEQ0J_km6fODTTt1o2w_2_2"></a><a id="Tc_3xv1sHBcu0SM-trx2y-yZw_2_5"></a><a id="Tc_nuj08lQ7i0GmMgTfXCeuFw_4_0"></a><a id="Tc_8ujIt6V42kmzHJHLXNEfdw_4_2"></a><a id="Tc_Nxi_3-rjo0u2kFg_-0xJjg_4_5"></a><a id="Tc_BvTKGhMPwEaSYOz10VAZ_Q_5_0"></a><a id="Tc_d_wjAvaNV0qD34Gl7qlz3w_6_0"></a><a id="Tc__8hkDO-LVE-783pxJn6Tzg_7_0"></a><a id="Tc__szjZaRqYUKHGxrGkS12vA_7_6"></a><a id="Tc_i9H-wvka-EefK6U457APxA_8_0"></a><a id="Tc_H-tFp-8bqEKm0weGoijkxg_8_2"></a><a id="Tc_tXHVuTzYZ0u8C-Z82XjnrQ_8_5"></a><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ" name="imrx:AccruedLiabilitiesDisclosureTextBlock" id="Tb_0Z6Mqss9c0a_9Yz5bl1lwA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Note&#160;7&#160;&#8211; Accrued Expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Accrued expenses consisted of the following:</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="Tb_4ERb0B2gpUSdKuwmatk1PQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued professional services</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="As_Of_12_31_2021_TBpjtOXgEkKQahJJAv0aWg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccruedProfessionalFeesCurrentAndNoncurrent" scale="0" id="Tc_cFaxT2SnREqJHIkdMLfqkg_4_3">250,977</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="As_Of_12_31_2020_OUSLyqWONEO8ccGPC6rBdg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccruedProfessionalFeesCurrentAndNoncurrent" scale="0" id="Tc_hKoliSTHZ0iCSUL2WpsCyA_4_6">269,302</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued employee expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="As_Of_12_31_2021_TBpjtOXgEkKQahJJAv0aWg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccruedEmployeeBenefitsCurrentAndNoncurrent" scale="0" id="Tc_vcJqntuHAECY7jb0BGVSfw_5_3">2,917,282</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="As_Of_12_31_2020_OUSLyqWONEO8ccGPC6rBdg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccruedEmployeeBenefitsCurrentAndNoncurrent" scale="0" id="Tc_Zp8qP2t5kECZerJwbakk3Q_5_6">163,668</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued contract research expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="As_Of_12_31_2021_TBpjtOXgEkKQahJJAv0aWg" decimals="0" format="ixt:numdotdecimal" name="imrx:AccruedContractResearchExpensesCurrent" scale="0" id="Tc_xGvsKxR6jUinT9FlOqO4mA_6_3">585,416</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="As_Of_12_31_2020_OUSLyqWONEO8ccGPC6rBdg" decimals="0" format="ixt:numdotdecimal" name="imrx:AccruedContractResearchExpensesCurrent" scale="0" id="Tc_gpKFe7LZW0aECFoAG-PQHg_6_6">266,022</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="As_Of_12_31_2021_TBpjtOXgEkKQahJJAv0aWg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherAccruedLiabilitiesCurrentAndNoncurrent" scale="0" id="Tc_q5Nj140K_0KtjFCGbEBoBQ_7_3">211,772</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:73.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="As_Of_12_31_2021_TBpjtOXgEkKQahJJAv0aWg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="0" id="Tc_Osb3WLIf4ECmaqveQz_Lzw_8_3">3,965,447</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="As_Of_12_31_2020_OUSLyqWONEO8ccGPC6rBdg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="0" id="Tc_OKXom-kEt0OcNyPktBIk1w_8_6">698,992</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ" name="imrx:TemporaryEquityDisclosureTextBlock" id="Tb_MXA5JjSgL0uR3SggiUskfw" continuedAt="Tb_MXA5JjSgL0uR3SggiUskfw_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Note&#160;8&#160;&#8211; Convertible Preferred Stock</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Series&#160;A Preferred Stock</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In September&#160;2019, the Company authorized the sale and issuance of up to <ix:nonFraction unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ" contextRef="As_Of_9_30_2019_us-gaap_StatementClassOfStockAxis_imrx_SeriesConvertiblePreferredStockMember_O1RMY__04UyGW5MdXmEk9Q" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesAuthorized" scale="0" id="Narr_oTUjqcnusUS3Vq_QTcyypw">1,987,979</ix:nonFraction> shares of Series&#160;A Preferred Stock, $<ix:nonFraction unitRef="Unit_Divide_USD_shares_0VraXufKhkCSOUw2U_zvgQ" contextRef="As_Of_9_30_2019_us-gaap_StatementClassOfStockAxis_imrx_SeriesConvertiblePreferredStockMember_O1RMY__04UyGW5MdXmEk9Q" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityParOrStatedValuePerShare" scale="0" id="Narr_tyFYzZtVYkmQf6ZBdfhnuw">0.001</ix:nonFraction> par value per share, at an original issuance price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_0VraXufKhkCSOUw2U_zvgQ" contextRef="As_Of_9_30_2019_us-gaap_StatementClassOfStockAxis_imrx_SeriesConvertiblePreferredStockMember_O1RMY__04UyGW5MdXmEk9Q" decimals="4" format="ixt:numdotdecimal" name="imrx:TemporaryEquityIssuancePrice" scale="0" id="Narr_Ya9Ir_tBAU2BphNVO-yZrw">8.5514</ix:nonFraction> per share. In January&#160;2020, the number of shares authorized for the Series&#160;A Preferred Stock was increased to <ix:nonFraction unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ" contextRef="As_Of_1_31_2020_us-gaap_StatementClassOfStockAxis_imrx_SeriesConvertiblePreferredStockMember_Tref9-4zckC3A4JsB3VTMA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesAuthorized" scale="0" id="Narr_cToBHJPWmUqzijq0GonoEA">2,495,933</ix:nonFraction> shares. The Series&#160;A Preferred Stock financing was structured to be issued in rolling closes during 2019 and 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On September&#160;20, 2019, the Company issued an additional <ix:nonFraction unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ" contextRef="As_Of_9_20_2019_us-gaap_StatementClassOfStockAxis_imrx_SeriesConvertiblePreferredStockMember_CgdZd9wu3UC4tGQyNK6KPA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesIssued" scale="0" id="Narr_ScQNL3C-zEa4jjn87oqLTQ">1,122,458</ix:nonFraction> shares of Series&#160;A Preferred Stock for gross cash proceeds of $<ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="Duration_9_20_2019_To_9_20_2019_us-gaap_StatementClassOfStockAxis_imrx_SeriesConvertiblePreferredStockMember_lHzkW0d_2keHgOLQonVBGg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock" scale="0" id="Narr_JieNrEQUsUSYD-S1SlMj2w">9,598,847</ix:nonFraction> and issued <ix:nonFraction unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ" contextRef="Duration_9_20_2019_To_9_20_2019_us-gaap_StatementClassOfStockAxis_imrx_SeriesConvertiblePreferredStockMember_lHzkW0d_2keHgOLQonVBGg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" scale="0" id="Narr_vFVAWrow2EiV1FwffE8FlA">785,706</ix:nonFraction> shares of Series&#160;A Preferred Stock in conjunction with the conversion of the outstanding amount of the Convertible Notes. In 2019, the Company incurred issuance costs of $<ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementClassOfStockAxis_imrx_SeriesConvertiblePreferredStockMember_gEfHGMh_TEuDzZN3KX78bg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="0" id="Narr_1CFpSKefWEGZSAGxQqX5Mg">200,587</ix:nonFraction> in connection with this offering.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company received funds for issuance of an additional <ix:nonFraction unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ" contextRef="As_Of_12_31_2019_us-gaap_StatementClassOfStockAxis_imrx_SeriesConvertiblePreferredStockMember_ncQIkgAZqEWsymLXhsJ6yg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesIssued" scale="0" id="Narr_3aiNvCHuZk-GqOG68_NWqA">468,315</ix:nonFraction> shares of Series&#160;A Preferred Stock for gross cash proceeds of $<ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="Duration_12_31_2019_To_12_31_2019_us-gaap_StatementClassOfStockAxis_imrx_SeriesConvertiblePreferredStockMember___WeTNXDqEKrDBAIVc3wUA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock" scale="0" id="Narr_KnV0dn3WdEaZXeESK7oCZQ">4,004,975</ix:nonFraction> through December&#160;31, 2019. Of these shares, <ix:nonFraction unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ" contextRef="As_Of_12_31_2019_us-gaap_StatementClassOfStockAxis_imrx_SeriesConvertiblePreferredStockMember_ncQIkgAZqEWsymLXhsJ6yg" decimals="INF" format="ixt:numdotdecimal" name="imrx:TemporaryEquityNumberOfSharesExcessOfAuthorized" scale="0" id="Narr_XG6zgi1Y1EGnHlaSJeRbMQ">410,436</ix:nonFraction> shares of Series&#160;A Preferred Stock for gross cash proceeds of $<ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="Duration_12_31_2019_To_12_31_2019_us-gaap_StatementClassOfStockAxis_imrx_SeriesConvertiblePreferredStockMember___WeTNXDqEKrDBAIVc3wUA" decimals="0" format="ixt:numdotdecimal" name="imrx:ProceedsFromIssuanceOfConvertiblePreferredStockExcessOfAuthorizedAmount" scale="0" id="Narr_BkOV1Me0skmr-ZF26EIfLQ">3,509,802</ix:nonFraction> exceeded the authorized amount allowed by the articles of incorporation, resulting in a liability of $<ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="As_Of_12_31_2019_us-gaap_StatementClassOfStockAxis_imrx_SeriesConvertiblePreferredStockMember_ncQIkgAZqEWsymLXhsJ6yg" decimals="0" format="ixt:numdotdecimal" name="imrx:TemporaryEquityDueToExcessAuthorizedAmount" scale="0" id="Narr_wckDTQ7srk2ZDjDIAYSa3w">3,509,802</ix:nonFraction> and a total of <ix:nonFraction unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ" contextRef="As_Of_12_31_2019_us-gaap_StatementClassOfStockAxis_imrx_SeriesConvertiblePreferredStockMember_ncQIkgAZqEWsymLXhsJ6yg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesOutstanding" scale="0" id="Narr_cHHoQIRdn0Os2jt3JNFVIw">1,966,043</ix:nonFraction> shares of Series&#160;A Preferred Stock outstanding at December&#160;31, 2019. In January&#160;2020, the shares that were previously classified as a liability as of December&#160;31, 2019 were reclassified to temporary equity upon the approved increase to authorized shares of Series&#160;A Preferred Stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In January&#160;2020, the Company issued <ix:nonFraction unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ" contextRef="As_Of_1_31_2020_us-gaap_StatementClassOfStockAxis_imrx_SeriesConvertiblePreferredStockMember_Tref9-4zckC3A4JsB3VTMA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesIssued" scale="0" id="Narr_PZGt50kiCky3Tus0QsmnXQ">119,454</ix:nonFraction> additional shares of Series&#160;A Preferred Stock for gross cash proceeds of $<ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="Duration_1_1_2020_To_1_31_2020_us-gaap_StatementClassOfStockAxis_imrx_SeriesConvertiblePreferredStockMember_YK2LK50_8US_qyrO8ejjbA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock" scale="0" id="Narr_fv7ZOeBKE0q8Jpdd5jA-Cg">1,021,413</ix:nonFraction>. The Company incurred issuance costs of $<ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="Duration_1_1_2020_To_1_31_2020_us-gaap_StatementClassOfStockAxis_imrx_SeriesConvertiblePreferredStockMember_YK2LK50_8US_qyrO8ejjbA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="0" id="Narr_97KzF151NU6QJnEGuORzhg">23,610</ix:nonFraction> in connection with the financing in January&#160;2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Series&#160;B Preferred Stock</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In December&#160;2020, the Company authorized the sale and issuance of up to <ix:nonFraction unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_imrx_SeriesBConvertiblePreferredStockMember_-Ckh5K8N7U-_9nyMHjiJxQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesAuthorized" scale="0" id="Narr_OKdDxg7cwU6c2pGPLT6gfQ">6,032,183</ix:nonFraction> shares of Series&#160;B Preferred Stock, $<ix:nonFraction unitRef="Unit_Divide_USD_shares_0VraXufKhkCSOUw2U_zvgQ" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_imrx_SeriesBConvertiblePreferredStockMember_-Ckh5K8N7U-_9nyMHjiJxQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityParOrStatedValuePerShare" scale="0" id="Narr_wW1HF5ba3k-exztpr5Riug">0.001</ix:nonFraction> par value per share, at an original issuance price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_0VraXufKhkCSOUw2U_zvgQ" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_imrx_SeriesBConvertiblePreferredStockMember_-Ckh5K8N7U-_9nyMHjiJxQ" decimals="4" format="ixt:numdotdecimal" name="imrx:TemporaryEquityIssuancePrice" scale="0" id="Narr_uQgd3pfr00mXuaZcfkl_0g">10.2782</ix:nonFraction> per share. The Series&#160;B Preferred Stock financing was structured to close in <ix:nonFraction unitRef="Unit_Standard_tranche_5kfv1Y9uXkefgNW7HJS6Rw" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_imrx_SeriesBConvertiblePreferredStockMember_-Ckh5K8N7U-_9nyMHjiJxQ" decimals="INF" format="ixt-sec:numwordsen" name="imrx:NumberOfTranches" scale="0" id="Narr_CqrhZcjDrEadDcDZNtcwcg">two</ix:nonFraction> tranches. The first tranche closed in December&#160;2020 and the Company issued <ix:nonFraction unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_imrx_SeriesBConvertiblePreferredStocksTrancheOneMember_bShZaSXyFkGkXYNwg6aJxA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesIssued" scale="0" id="Narr_d0Ij0IbIo0KqjZyMOBkfAw">3,619,292</ix:nonFraction> shares of Series&#160;B Preferred Stock for gross cash proceeds of $<ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="Duration_12_1_2020_To_12_31_2020_us-gaap_StatementClassOfStockAxis_imrx_SeriesBConvertiblePreferredStocksTrancheOneMember_CqCA_MA7zUSGLHpsb-XgQQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock" scale="0" id="Narr_QNGGbLtaJU61s7fYYKddLg">37,199,929</ix:nonFraction>. The Company incurred issuance costs of $<ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="Duration_12_1_2020_To_12_31_2020_us-gaap_StatementClassOfStockAxis_imrx_SeriesBConvertiblePreferredStocksTrancheOneMember_CqCA_MA7zUSGLHpsb-XgQQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="0" id="Narr_sDLz0YuW20-Jq4LUWrtDiA">216,019</ix:nonFraction> in connection with the financing in December&#160;2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company determined the right of the investors to purchase <ix:nonFraction unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ" contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementClassOfStockAxis_imrx_SeriesBConvertiblePreferredStockMember_TDIXNGLBjEmH6HPuewiRjg" decimals="INF" format="ixt:numdotdecimal" name="imrx:TemporaryEquityContingentlyIssuableShares" scale="0" id="Narr_qZxAUXwd-UqU9687QdovkQ">2,412,853</ix:nonFraction> shares of Series&#160;B Preferred Stock in the second tranche does not meet the definition of a freestanding financial instrument as it is not separable from the Series&#160;B Preferred Stock issued in the first tranche. The issuance of the second tranche is subject to the Company meeting certain development milestones or at the election of the holders of at least a majority of the then outstanding shares of Series&#160;B Preferred Stock which must include one specific shareholder (the &#8220;Requisite Holders&#8221;). Each holder of Series&#160;B Preferred Stock may elect to purchase their requisite shares of the second tranche at any time. As of March 31, 2021, the Company had not met these development milestones nor did the Requisite Holders elect to purchase the second tranche prior to meeting these milestones and therefore <ix:nonFraction unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ" contextRef="As_Of_3_31_2021_us-gaap_StatementClassOfStockAxis_imrx_SeriesBConvertiblePreferredStockTrancheTwoMember_h-jV1278D0iiS0qgsgtv3A" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:TemporaryEquitySharesIssued" scale="0" id="Narr_9InkLRnVk0mQsh3cQbygVA">no</ix:nonFraction> shares of the second tranche were issued.</p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">148</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_MXA5JjSgL0uR3SggiUskfw_cont1" continuedAt="Tb_MXA5JjSgL0uR3SggiUskfw_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In April&#160;and May&#160;2021, all <ix:nonFraction unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ" contextRef="As_Of_5_31_2021_us-gaap_StatementClassOfStockAxis_imrx_SeriesBConvertiblePreferredStockTrancheTwoMember_-1LYWcxnHk6UK-Jcbi7Lpw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesIssued" scale="0" id="Narr_s43SZKB_qU2ITCMJpRk-Dg">2,412,853</ix:nonFraction> shares of the second tranche of Series&#160;B Preferred Stock were issued based on the voluntary election of substantially all of the holders of Series&#160;B Preferred Stock. The Company received gross proceeds of $<ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="Duration_4_1_2021_To_5_31_2021_us-gaap_StatementClassOfStockAxis_imrx_SeriesBConvertiblePreferredStockTrancheTwoMember_3Z1Gf_8wlESSr2qfBuPkyQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock" scale="0" id="Narr_xulpin2iIkWzGLWCldpZeQ">24,799,786</ix:nonFraction>. The Company incurred issuance costs of $<ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="Duration_4_1_2021_To_5_31_2021_us-gaap_StatementClassOfStockAxis_imrx_SeriesBConvertiblePreferredStockTrancheTwoMember_3Z1Gf_8wlESSr2qfBuPkyQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="0" id="Narr_Z9N6mgUIckOPu3JjwX0M8Q">10,935</ix:nonFraction> in connection with the second tranche of Series&#160;B Preferred Stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The rights and preferences of the Series&#160;A Preferred Stock and Series&#160;B Preferred Stock (&#8220;Preferred Stock&#8221;) were as described below:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;">Conversion</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Each share of Preferred Stock may be converted at any time, at the option of the holder, into shares of Class&#160;A common stock, subject to the applicable conversion rate as determined by dividing the original issue price by the conversion price. The conversion price for the Series&#160;A Preferred Stock and Series&#160;B Preferred Stock (as may be adjusted for certain customary dilutive events) is $<ix:nonFraction unitRef="Unit_Divide_USD_shares_0VraXufKhkCSOUw2U_zvgQ" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_imrx_SeriesConvertiblePreferredStockMember_DzBbn1vSGECYmtSe-hivlw" decimals="4" format="ixt:numdotdecimal" name="imrx:TemporaryEquityConversionPrice" scale="0" id="Narr_6frQH9eRp0ChrrOnKH_mIQ">6.1081</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Divide_USD_shares_0VraXufKhkCSOUw2U_zvgQ" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_imrx_SeriesBConvertiblePreferredStockMember_lxbE9uvMQU-NU7BxZ_aTNg" decimals="4" format="ixt:numdotdecimal" name="imrx:TemporaryEquityConversionPrice" scale="0" id="Narr_cRu_vz9JX0W90e93LuYAGw">7.3416</ix:nonFraction>, respectively. The Preferred Stock automatically convert into shares of Class&#160;A common stock at the then effective conversion rate upon the closing of a public offering of the Company&#8217;s securities with gross proceeds to the Company of at least $<ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_StatementClassOfStockAxis_imrx_SeriesConvertiblePreferredStockMember_ArKyrrqRQE6HOj-7SNUhxw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock" scale="0" id="Narr_AIxPy5DgcUGF1cAJNs-BGw">75,000,000</ix:nonFraction> and a share price of at least $<ix:nonFraction unitRef="Unit_Divide_USD_shares_0VraXufKhkCSOUw2U_zvgQ" contextRef="As_Of_12_31_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_StatementClassOfStockAxis_imrx_SeriesConvertiblePreferredStockMember_DFd25cydBkuiug-BF6zGWQ" decimals="4" format="ixt:numdotdecimal" name="imrx:TemporaryEquityIssuancePrice" scale="0" id="Narr_t2WbOJUFaEaBtQSxrIaosQ">7.3416</ix:nonFraction> or at the election of the holders of the Requisite Holders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Holders of Series&#160;B Preferred Stock that would beneficially own at least <ix:nonFraction unitRef="Unit_Standard_pure_iothMaWWqUCV2N7d1PVg4w" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_imrx_SeriesBConvertiblePreferredStockMember_lxbE9uvMQU-NU7BxZ_aTNg" decimals="3" format="ixt:numdotdecimal" name="imrx:PercentageOfEquitySecuritiesOwnedToGetConvertedStock" scale="-2" id="Narr_J7V3cwptb0-ASRGEvxFo9g">9.9</ix:nonFraction>% of any then outstanding class of equity securities may elect to receive a portion of their converted Series&#160;B Preferred Stock as Class&#160;B common stock upon conversion.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Upon the closing of the IPO on August&#160;3, 2021, all <ix:nonFraction unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ" contextRef="As_Of_8_3_2021_atfZ3VjOmEGor-TZ8PR3vw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesOutstanding" scale="0" id="Narr_VMxtbiPPGUm8dbY2_f2_dQ">8,528,078</ix:nonFraction> shares of the Company&#8217;s convertible preferred stock then outstanding automatically converted into <ix:nonFraction unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ" contextRef="As_Of_8_3_2021_atfZ3VjOmEGor-TZ8PR3vw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion" scale="0" id="Narr_8J31G5NFykmDK-TIi7Lydg">11,939,281</ix:nonFraction> shares of Class A common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;">Dividends</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Preferred Stockholders are entitled to receive per annum dividends of <ix:nonFraction unitRef="Unit_Standard_pure_iothMaWWqUCV2N7d1PVg4w" contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:PreferredStockDividendRatePercentage" scale="-2" id="Narr_r-Zx0ZE0D0WdeW9zPtqjoA">7</ix:nonFraction>% of the original issue price share, payable only when, as and if declared by the Board of Directors. The right to receive these dividends is not cumulative, and therefore, if not declared in any&#160;year, the right to receive such dividends shall terminate and not carry forward into the next&#160;year. As of December&#160;31, 2021 and December&#160;31, 2020, <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="Duration_1_1_2020_To_12_31_2020_J_O9OcmviUi8EDFgokrY1Q" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:DividendsPreferredStock" scale="0" id="Narr_pEnD3V8PrUGdH5lPqPpxTA"><ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:DividendsPreferredStock" scale="0" id="Narr_hMaqAR7SukmQ3mgGPJlIOQ">no</ix:nonFraction></ix:nonFraction> dividends had been declared.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;">Voting Rights</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Preferred Stock and common stock vote together as one class on an as converted basis. Common stock voting rights on certain matters are subject to the powers, preferences, and rights of the Preferred Stock. Preferred Stockholders are entitled to vote on all matters and shall have the number of votes equal to the number of shares of common stock into which the shares of Preferred Stock held by such holder are then convertible. As long as <ix:nonFraction unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ" contextRef="As_Of_12_31_2021_srt_RangeAxis_srt_MinimumMember_0vGLrM36lEegdT0dgFrRAQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="Narr_YYe_Lm4Ie0eYr0wTDAJrcw">2,132,029</ix:nonFraction> shares of Preferred Stock are outstanding, certain actions such as mergers, acquisition, liquidation, dissolution, wind up of business, and deemed liquidation events, must be approved by the holders of at least a majority of the then-outstanding shares of Preferred Stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;">Liquidation Preference</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Upon liquidation, dissolution, or winding up of business, holders of Preferred Stock are entitled to receive a liquidation preference in priority to holders of common stock at the original respective Preferred Stock issue price for such series. If assets available for distribution are insufficient to satisfy the liquidation payment to holders of Preferred Stock in full, assets available for distribution will be allocated among holders of Preferred Stock on a pari passu basis at an amount per share equal to the greater of the respective original Preferred Stock issue price for such series plus any declared but unpaid dividends or such amount had all shares been converted to common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">When holders of Preferred Stock are satisfied in full, any excess assets available for distribution will be allocated ratably among common stock holders based on their pro rata shareholdings. Upon a deemed liquidation event, as defined in the articles of incorporation, holders have the option to redeem their shares at the liquidation payment amounts summarized above.</p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">149</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_MXA5JjSgL0uR3SggiUskfw_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;">Redemption</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Other than described above, the shares of Preferred Stock are not redeemable.</p></ix:continuation><a id="Tc_lO68TesG6EikYlz8FfeVLQ_1_2"></a><a id="Tc_kI3KTLL8eEK60aL3_kFx5Q_1_4"></a><a id="Tc_Z3xOtO3cakahKYJdv7K5Sw_2_2"></a><a id="Tc_VhI9h1aTV0aMznIwxiGR5g_2_4"></a><a id="Tc_zs1O45_S70GiXIjvnJ-3wg_4_0"></a><a id="Tc_McmTV-nt9Uaka5HpmhgPYw_4_2"></a><a id="Tc_gNOWF66LzECmgi9e6o82uQ_5_0"></a><a id="Tc_LRYIP2nA6UaF5LlGOC0JBQ_5_2"></a><a id="Tc_IxikNJ_-W0CUTBP_5_ijQA_6_0"></a><a id="Tc_XAFuKCsIpEiIgE-4ve6rNw_6_2"></a><a id="Tc_g9KvABopEkS9jt7sB7MdVw_7_0"></a><a id="_a4c50b49_edc3_44d5_a4f8_fafa79f13289"></a><a id="_a4c50b49_edc3_44d5_a4f8_fafa79f13289_2"></a><a id="_a4c50b49_edc3_44d5_a4f8_fafa79f13289_3"></a><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="Tb_gD66OqR_JE6T7wUdrIyDJw" continuedAt="Tb_gD66OqR_JE6T7wUdrIyDJw_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Note&#160;9&#160;- Common Stock</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company had <ix:nonFraction unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_Mo7QF875vUy5d2OcEbQ2fA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_mDUSY89wqkSHNTXy5n450A">200,000,000</ix:nonFraction> authorized shares of Class&#160;A common stock, $<ix:nonFraction unitRef="Unit_Divide_USD_shares_0VraXufKhkCSOUw2U_zvgQ" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_Mo7QF875vUy5d2OcEbQ2fA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_BVax2mmfl0ClUFLBIrrE-Q">0.001</ix:nonFraction> par value per share as of December 31, 2021 and <ix:nonFraction unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_IvXJ6RHxqkyGTfDbgXwHsw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_UOh0-7nFIEuYMZNiQ190VQ">22,026,200</ix:nonFraction> authorized shares of Class A common stock, $<ix:nonFraction unitRef="Unit_Divide_USD_shares_0VraXufKhkCSOUw2U_zvgQ" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_IvXJ6RHxqkyGTfDbgXwHsw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_pE-jOVxcT0mYn5UR5QMljg">0.001</ix:nonFraction> par value per share as of December 31, 2020, respectively, of which <ix:nonFraction unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_Mo7QF875vUy5d2OcEbQ2fA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="Narr_oRHS3JIWwUGosfH3ZOjrBA">26,320,199</ix:nonFraction> and <ix:nonFraction unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_IvXJ6RHxqkyGTfDbgXwHsw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="Narr_LRRFnxtvgkOiCUePHqN22w">4,950,129</ix:nonFraction> were <span style="-sec-ix-hidden:Hidden_hTzGFl4AukOhSIQvrJVGbw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">issued</span></span> and <span style="-sec-ix-hidden:Hidden_lP6rYH5NMkSWKz0be_vdHw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">outstanding</span></span>, respectively. The holders of Class&#160;A common stock are entitled <ix:nonFraction unitRef="Unit_Standard_Vote_y6IkSxDgD0SxcVMkCx6yHg" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_XcWBVd3ItkaUL02nw_Pu2g" decimals="INF" format="ixt-sec:numwordsen" name="imrx:NumberOfVotesPerShare" scale="0" id="Narr_iyZqWU5Sgk-Jcgf_xnhq9g"><ix:nonFraction unitRef="Unit_Standard_Vote_y6IkSxDgD0SxcVMkCx6yHg" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_Vps21bPl-0ucIcde4LcmUQ" decimals="INF" format="ixt-sec:numwordsen" name="imrx:NumberOfVotesPerShare" scale="0" id="Narr_HWZ9DdpXnUKfhzYnF4oekQ">one</ix:nonFraction></ix:nonFraction> vote for each share of common stock. Dividends may be paid when, and if declared by the Board of Directors, subject to the limitations, powers and preferences granted to the Preferred Stockholders and on a proportionate basis with holders of Class&#160;B common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As of December 31, 2021 and December&#160;31, 2020, the following number of shares of Class&#160;A common stock have been reserved:</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ" name="us-gaap:ScheduleOfStockByClassTextBlock" id="Tb_YWccSn3JBkO18Y9nBRkh7A" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:75.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:75.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Conversion of Series A Preferred</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_imrx_SeriesConvertiblePreferredStockMember_LQiWJpT45k-D9eZ63E0DAw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="Tc_nL5zehwOwEiM-nkiIXZ9RQ_4_4">3,494,306</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:75.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Conversion of Series B Preferred</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_imrx_SeriesBConvertiblePreferredStockMember_-Ckh5K8N7U-_9nyMHjiJxQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="Tc_qaxzwLUpU0O18byIBvJeGw_5_4">5,066,995</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:75.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exercise of common stock warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_WarrantMember_7wU2uI3NZ0SsDzZ_Fr8ZyQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="Tc_uf7TYpePmEqF5MV8rv652A_6_4">308,308</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:75.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exercise of common stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_EmployeeStockOptionMember_rlnPrQOdyEaM-QEeHvlTjQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="Tc_g62oUPejC0ypxAlhJtf2CQ_7_2">2,859,544</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_EmployeeStockOptionMember_me35404Y-kWEl2teCnSUVg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="Tc_Cqm7XMA3XEeS9bQhZRE_lw_7_4">1,801,263</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:75.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ" contextRef="As_Of_12_31_2021_TBpjtOXgEkKQahJJAv0aWg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="Tc_H3CYPQoQvUaLedWdR-q-Yg_8_2">2,859,544</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ" contextRef="As_Of_12_31_2020_OUSLyqWONEO8ccGPC6rBdg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="Tc_o0NF76Rv6U2fHvdSrsD3eA_8_4">10,670,872</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company had <ix:nonFraction unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_4sABCVevMkafGdslrmVHRg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_QFJaMceefkWum5nD5uD0Cg">20,000,000</ix:nonFraction> authorized shares of Class&#160;B common stock, $<ix:nonFraction unitRef="Unit_Divide_USD_shares_0VraXufKhkCSOUw2U_zvgQ" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_4sABCVevMkafGdslrmVHRg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_TPmmgHI0LEurwU6NCrwBMw">0.001</ix:nonFraction> par value per share as of December 31, 2021 and <ix:nonFraction unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_B1xkq5tyC0Czi0WWYygW9Q" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_jehBzIxa70WsAdebHIwAzQ">6,032,183</ix:nonFraction> authorized shares of Class&#160;B common stock, $<ix:nonFraction unitRef="Unit_Divide_USD_shares_0VraXufKhkCSOUw2U_zvgQ" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_B1xkq5tyC0Czi0WWYygW9Q" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_Zd_afTw4UkSexQdLQH08Jw">0.001</ix:nonFraction> par value per share as of December 31, 2020, of which <ix:nonFraction unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_B1xkq5tyC0Czi0WWYygW9Q" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:CommonStockSharesIssued" scale="0" id="Narr_2kNa6knqbUSmAaZqMcRROA"><ix:nonFraction unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_4sABCVevMkafGdslrmVHRg" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:CommonStockSharesIssued" scale="0" id="Narr_dRf97eZHkUCXqXD8Nuz09g">no</ix:nonFraction></ix:nonFraction> shares have been issued nor are outstanding. The holders of Class&#160;B common stock have <ix:nonFraction unitRef="Unit_Standard_Vote_y6IkSxDgD0SxcVMkCx6yHg" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_J2SvXNqcwUW3WhIW-fbZTA" decimals="INF" format="ixt-sec:numwordsen" name="imrx:NumberOfVotesPerShare" scale="0" id="Narr_SP0Gi_O5gUSbAJSK-7XUyA"><ix:nonFraction unitRef="Unit_Standard_Vote_y6IkSxDgD0SxcVMkCx6yHg" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_6Dv2gap2qUy2S6CUjLz70A" decimals="INF" format="ixt-sec:numwordsen" name="imrx:NumberOfVotesPerShare" scale="0" id="Narr_-HscR83Hq0CPpA_TYh6CHw">no</ix:nonFraction></ix:nonFraction> voting rights. Dividends may be paid when, and if, declared by the Board of Directors, subject to the limitations, powers and preferences granted to the preferred stockholders and on a proportionate basis with holders of Class&#160;A common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Common Stock Warrants</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">During 2019, the Company issued warrants to purchase an aggregate of <ix:nonFraction unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ" contextRef="As_Of_12_31_2019_g3mjqkDWB0-f2XKJf0YL-A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Narr_ijiGBSYv3ES7L9bXzDBVDA">308,308</ix:nonFraction> shares of Class A common stock at an exercise price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_0VraXufKhkCSOUw2U_zvgQ" contextRef="As_Of_12_31_2019_g3mjqkDWB0-f2XKJf0YL-A" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_QYk6JZNrkU2ssifOB-YmvQ">3.01</ix:nonFraction> per share to several advisors, including <ix:nonFraction unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ" contextRef="Duration_1_1_2019_To_12_31_2019_Q2tKCguYn0Sp3Siw9cnC0w" decimals="INF" format="ixt:numdotdecimal" name="imrx:WarrantsIssuedInLieuOfCashPayment" scale="0" id="Narr_dbYofG9uTU6idUjHD7SSqA">200,984</ix:nonFraction> shares to entities related to members of the Board of Directors of the Company, in lieu of cash payments. These warrants vested immediately upon issuance, became exercisable on January&#160;9, 2021 and have a <ix:nonNumeric contextRef="As_Of_12_31_2019_g3mjqkDWB0-f2XKJf0YL-A" format="ixt-sec:durwordsen" name="us-gaap:WarrantsAndRightsOutstandingTerm" id="Narr_hlP80C8Yfki336TbPU1k4g">10-year</ix:nonNumeric> term set to expire on January&#160;9, 2030. The Company evaluated the terms of these warrants and determined that equity classification was appropriate. As of December&#160;31, 2020, <ix:nonFraction unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ" contextRef="Duration_1_1_2020_To_12_31_2020_J_O9OcmviUi8EDFgokrY1Q" decimals="INF" format="ixt-sec:numwordsen" name="imrx:WarrantsExercised" scale="0" id="Narr_j4Obend910SlNftTkMb1xw">no</ix:nonFraction> warrants had been exercised. During June&#160;2021, all warrant holders exercised their warrants to purchase an aggregate of <ix:nonFraction unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ" contextRef="Duration_6_1_2021_To_6_30_2021_xjkMHQi3F0anA1B9rBC7Fg" decimals="INF" format="ixt:numdotdecimal" name="imrx:WarrantsExercised" scale="0" id="Narr_lMufSJ14-0WUqXhT0v9zgQ">308,308</ix:nonFraction> shares of common stock. As of December 31, 2021, there were <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="As_Of_12_31_2021_TBpjtOXgEkKQahJJAv0aWg" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:WarrantsAndRightsOutstanding" scale="0" id="Narr_H1_WcZCnUkybh7BnTmSrvQ">no</ix:nonFraction> warrants outstanding.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Initial Public Offering</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On August 3, 2021, the Company completed its initial public offering pursuant to which it issued and sold <ix:nonFraction unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ" contextRef="Duration_8_3_2021_To_8_3_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_nbYOiYQZAUed9mAOrNTolQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_FCyK4kv4mEiSVtKoUC5ecw">8,625,000</ix:nonFraction> shares of its Class A common stock, inclusive of <ix:nonFraction unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ" contextRef="Duration_8_3_2021_To_8_3_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_G9SnpifyxEmaJU1UE794ew" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_sRhC1mgED02G0CaHfcsPmQ">1,125,000</ix:nonFraction> shares of its Class A common stock sold pursuant to the full exercise of the underwriters&#8217; option to purchase additional shares. The aggregate net proceeds received by the Company from the IPO were $<ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="Duration_8_3_2021_To_8_3_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_7enA8yNRQkat6QV_1FoEOw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" scale="0" id="Narr_D8WKO_QXr0aYF0i_a0BOaw">120,318,750</ix:nonFraction>, after deducting underwriting discounts and commissions, but before deducting offering costs payable by the Company, which were $<ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="As_Of_8_3_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_kxYscz4Wf02VzWLhksRRxw" decimals="0" format="ixt:numdotdecimal" name="imrx:OfferingCostPayable" scale="0" id="Narr_7c91BLQovkGDHN-ZMCVDcQ">2,124,317</ix:nonFraction>. Upon the closing of the IPO, all <ix:nonFraction unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ" contextRef="As_Of_8_3_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_kxYscz4Wf02VzWLhksRRxw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesOutstanding" scale="0" id="Narr_oVsQelsATke12Dg8ml-ecw">8,528,078</ix:nonFraction> shares of the Company&#8217;s convertible preferred stock then outstanding automatically converted into <ix:nonFraction unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ" contextRef="As_Of_8_3_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_boKn2a2ouUyMVqODG0-nIw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesOutstanding" scale="0" id="Narr_02NKWp_V70qHuu9P_HFzqw">11,939,281</ix:nonFraction> shares of Class A common stock. Upon the conversion of the convertible preferred stock, the Company reclassified the carrying value of the convertible preferred stock to common stock (at par value) and additional&#160;paid-in&#160;capital. &#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On August 3, 2021 in connection with the closing of the IPO, the Company filed a restated certificate of incorporation, which amended and restated the Company&#8217;s certificate of incorporation to, among other things: (i)&#160;increase the number of </p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">150</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_gD66OqR_JE6T7wUdrIyDJw_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">authorized shares of common stock to <ix:nonFraction unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ" contextRef="As_Of_8_3_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_d6wIH2lUEkOg0doA4WJViw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_DC6kCzQ490OnU3vDTRPZmw">200,000,000</ix:nonFraction> shares of Class&#160;A common stock, <ix:nonFraction unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ" contextRef="As_Of_8_3_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_ncRRUXx0q0atI42UV2_87w" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_M0BGRtkXNECwAT0PUy7iPw">20,000,000</ix:nonFraction> shares of Class&#160;B common stock, par value $<ix:nonFraction unitRef="Unit_Divide_USD_shares_0VraXufKhkCSOUw2U_zvgQ" contextRef="As_Of_8_3_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_ncRRUXx0q0atI42UV2_87w" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_lKwM3oW5-0O2P8DfRQx97g">0.001</ix:nonFraction> per share, and (ii) authorize <ix:nonFraction unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ" contextRef="As_Of_8_3_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_kxYscz4Wf02VzWLhksRRxw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="Narr_yrWRN_6L506X-AZZ3N3gGA">10,000,000</ix:nonFraction> shares of Preferred Stock; and (iii)&#160;authorize the Board of Directors to establish the rights, preferences and restrictions on any unissued series of Preferred Stock.</p></ix:continuation><a id="Tc_wmT4ASxOu0at3yB2KgF4Aw_1_2"></a><a id="Tc_KtymKgY7EEeYf6QVbMaJcw_2_2"></a><a id="Tc_yeNKcvgSjkmNrP--Mdub4A_2_5"></a><a id="Tc_oK_Js5UszUmo4kpXah-qew_4_0"></a><a id="Tc_pe1abOQbKU-60W_AaJiAXg_5_0"></a><a id="Tc_WMYQDWiA0EKxTBnJoO80Ew_5_2"></a><a id="Tc_JOUOQgjcKkaDrL9kntLJkQ_5_5"></a><a id="Tc_2gOSvIJVj02nNp5xMdgz5A_6_0"></a><a id="Tc_OYIAI4Z11kSg13kT_CEHfQ_7_0"></a><a id="Tc_kZSiA7NTcECLv4o6-ipoIQ_8_0"></a><a id="Tc_eTvkoNKvME6x6NL9meJ0CA_1_2"></a><a id="Tc_oijcugA89kiTzxdhfUnkBA_1_4"></a><a id="Tc_FQjFlQwmskGJfC4GG_-aeA_3_0"></a><a id="Tc_z-qgt5IodkK5RbEa2ywG2g_3_2"></a><a id="Tc_md9Yboaoj0WNbTRhh1Xe1g_4_0"></a><a id="Tc_kNjM2X9znkq1Zv-sW9rIqg_4_2"></a><a id="Tc_3JfJD5t42EabcC939t754w_5_0"></a><a id="Tc_67WBSkVUTk-aOFQW94uqxQ_5_2"></a><a id="Tc_hyL3yCK8UUWncSBJt7-w9g_6_0"></a><a id="Tc_ozrUgcSJpkeWqwmY3h3Qsw_7_0"></a><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ" name="us-gaap:EarningsPerShareTextBlock" id="Tb_tgil1DKdxEGxXeSl2uqTmQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Note&#160;10&#160;- Net Loss Per Share Attributable to Common Stockholders</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Basic and diluted net loss per share attributable to common stockholders was calculated at December&#160;31, 2021 and 2020 as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="Tb_cXC2FtZ11U61Rj0LcJSlIA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:70.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:70.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Numerator:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:70.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_vEa2UYbCG0iHOC-7ZuPz2g_5_3">33,535,748</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="Duration_1_1_2020_To_12_31_2020_J_O9OcmviUi8EDFgokrY1Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_mwIJ8EatmEu0-sZfC3pioQ_5_6">17,039,898</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Denominator - basic and diluted:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted-average common shares outstanding, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ" contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_vFfrFtDtqkGq8nhH9yHxJw_7_3">13,612,677</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ" contextRef="Duration_1_1_2020_To_12_31_2020_J_O9OcmviUi8EDFgokrY1Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_Ntg6zMboekyI-2KJDbn65A_7_6">4,950,129</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net loss per share - basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_wHopsXwjskSWOmAaEI9k1w;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_0VraXufKhkCSOUw2U_zvgQ" contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_rL_1XQWPPEm8kDIDIIogaw_8_3">2.46</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_--dUy7H6lkGzBYeWkeucsA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_0VraXufKhkCSOUw2U_zvgQ" contextRef="Duration_1_1_2020_To_12_31_2020_J_O9OcmviUi8EDFgokrY1Q" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_1ZbuUcK99E61Bapi-HovZQ_8_6">3.44</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The following table sets forth the potentially dilutive securities that have been excluded from the calculation of diluted net loss per share because to include them would be anti-dilutive (in common stock equivalent shares) at December&#160;31, 2021 and 2020:</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="Tb_50lBPwS8WUWDzj7WvoPQbg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:75.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:75.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Series A Preferred</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_imrx_SeriesConvertiblePreferredStockMember_zQGWKL5kWkOEqyx46cK5mg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_me0Vn8txck-NPeViV24Nag_3_4">3,494,306</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:75.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Series B Preferred</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_imrx_SeriesBConvertiblePreferredStockMember_HJNQLItNRU-hYpDpxqiSoQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_qdOZyppG10iX93e-nxAZeQ_4_4">5,066,995</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:75.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Warrants to purchase common stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_7uvXNSojR0qxLk1Ubdsmfg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_VyV7aCn1Ok-tXo8UGmyqjA_5_4">308,308</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:75.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Options to purchase common stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_l3XprlCXTkaFiHyKLJ8O2Q" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_gvaNjYE0f02dYX7aVLBBgw_6_2">2,859,544</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_VHW5LVIB6Ee8uLYurHx4cw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_HugvgD80ME-V49wCdmuAjA_6_4">1,801,263</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:75.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total shares of common stock equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ" contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_GI2YGlxDgU2DmkVmOYXI2g_7_2">2,859,544</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ" contextRef="Duration_1_1_2020_To_12_31_2020_J_O9OcmviUi8EDFgokrY1Q" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_SE4WcYdV40yE_qMr-zKBWQ_7_4">10,670,872</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="Tb_n9dAAcSV402eglza2cJpoA" continuedAt="Tb_n9dAAcSV402eglza2cJpoA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Note&#160;11&#160;&#8211; Stock-Based Compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">During 2015, the Company established the Long Term Incentive Plan (&#8220;Incentive Plan&#8221;), under which incentive stock options, nonqualified stock options, restricted stock or other awards may be awarded to employees, directors or consultants of the Company. The options typically vest over a <ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_imrx_StockIncentivePlan2015Member_1tvXqAKRfEm4AKlfifgVpg" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_Q9CYCGn-_Ue1khNcofBnmg">four-year</ix:nonNumeric> period. As of December&#160;31, 2021, the maximum number of shares available for issuance under the Incentive Plan was <ix:nonFraction unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ" contextRef="As_Of_12_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_PlanNameAxis_imrx_StockIncentivePlan2015Member_hVx7NwJaA026vu03npu7HA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="Narr_XaAWN8sQ50ijajss6YtvOQ">2,825,173</ix:nonFraction> shares. Upon the effectiveness of the Company&#8217;s 2021 Incentive Award Plan, the Company ceased granting awards under the Incentive Plan. However, the Incentive Plan continues to goven awards outstanding thereunder.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On July 23, 2021, the Company&#8217;s Board of Directors adopted, and on July 23, 2021 its stockholders approved, the 2021 Incentive Award Plan (the &#8220;2021 Plan&#8221;), which became effective on July 29, 2021. The 2021 Plan provides for the grant of incentive stock options, stock appreciation rights, restricted stock awards, restricted stock units, and other stock-based awards. The number of shares reserved for issuance under the 2021 Plan was initially equal to <ix:nonFraction unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ" contextRef="As_Of_7_23_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_PlanNameAxis_imrx_TwoThousandTwentyOneIncentiveAwardPlanMember_MwQmN40XTUqTS51FC7b-vQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="Narr_Iw4PPwzGiUeItdNX6sijUQ">2,590,000</ix:nonFraction> plus an annual increase on the first day of each calendar year, beginning on January 1, 2022 and ending on and including January 1, 2031, equal to the lesser of (i) <ix:nonFraction unitRef="Unit_Standard_pure_iothMaWWqUCV2N7d1PVg4w" contextRef="Duration_7_23_2021_To_7_23_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_PlanNameAxis_imrx_TwoThousandTwentyOneIncentiveAwardPlanMember_BLWmGGSlg0221-_bauHKMg" decimals="3" format="ixt:numdotdecimal" name="imrx:PercentageOfAggregateNumberOfSharesOutstanding" scale="-2" id="Narr_pPQvHrDDeke3kfvZAXIpEQ">4</ix:nonFraction>% of the aggregate number of shares of Class A common stock outstanding on the final day of the immediately preceding calendar year and (ii) such smaller number of shares of Class A common stock as determined by the Board of Directors. No more than <ix:nonFraction unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ" contextRef="Duration_7_23_2021_To_7_23_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_PlanNameAxis_imrx_TwoThousandTwentyOneIncentiveAwardPlanMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember__dnvok_t1k-ok2gZh6_g4Q" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Narr_RyozMgYFqkO7nfX27O01Fw">15,350,000</ix:nonFraction> shares of Class A common stock may be issued under the 2021 Plan upon the exercise of incentive stock options. Shares issued under the 2021 Plan may be authorized but unissued shares, shares purchased on the open market or treasury shares. If an award under the 2021 Plan expires, lapses or is terminated, exchanged for or settled in cash, surrendered, repurchased, cancelled without having been fully exercised/settled or forfeited, any unused shares subject to the award will, as applicable, become or again be available for new grants under the 2021 Plan. In addition, shares subject to stock options issued under the Incentive Plan may become available for issuance under the 2021 Plan to the extent such stock options are canceled, forfeited, exchanged, settled in cash or </p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">151</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_Iz44rIbm0kekd-Bz1CdBUw_1_2"></a><a id="Tc_AagXs1R0-0C_6Tfkg5lfHg_2_2"></a><a id="Tc_w4ccZmz9O0KyqydUht6fcw_2_4"></a><a id="Tc_j-DZxWsHz02mkdanj7L9VA_4_0"></a><a id="Tc_1ahZsqKGM0C01J35qMJYMA_4_2"></a><a id="Tc_eBBZBGmt10yOKChGw6XqdA_4_4"></a><a id="Tc_C3EUr_OtUEC0FFtU8cz6Rw_5_0"></a><a id="Tc_f95RmLtht0ez8kk7Dh3ubg_5_2"></a><a id="Tc_AtbrPGRphUGw58YvFLzvmA_5_4"></a><a id="Tc_6FXxZFEVKUur40cQNGG_OQ_6_0"></a><a id="Tc_PyXyJ23K0UCTeBZwQFgnxw_7_0"></a><a id="Tc_XgmhXZaH4UeLsQ4t_a6wAg_7_2"></a><a id="Tc_AeY7g25pAUCpARcJC_1a8w_7_4"></a><a id="Tc_Qr2fYz7Cp0yyAsJs_9QSkg_1_7"></a><a id="Tc_38Jv6xRKsUOvYyRXFZVfRA_2_4"></a><a id="Tc_eFOYzsrXOUCaEVWv4pFDJw_2_7"></a><a id="Tc_jrAiLrpRBkikTizDuipq-Q_3_4"></a><a id="Tc_DmHwJvt-M0eYGm23Ve8vjQ_3_7"></a><a id="Tc_RtDt7WPT0k6QVPeOJMbp3A_4_2"></a><a id="Tc_Pr7eN0MumUmfX8FwrxczCQ_4_4"></a><a id="Tc_RneaWDYjNU6ATLhdnmAFzg_4_7"></a><a id="Tc_IZMNRPBIQkCe3D2Pxqnu0Q_4_9"></a><a id="Tc_pX59W8vgtE2FTBomJldvrw_5_2"></a><a id="Tc_wVqMZmxEzkGINLSUmgHiEQ_5_4"></a><a id="Tc_zBj80myOgkerW3G33pmtJw_5_7"></a><a id="Tc_5sJUf9ivZ0GzMkMQ1g3low_5_9"></a><a id="Tc_X9R1yrwNPUavSgbmDuQDlQ_7_0"></a><a id="Tc_MBSvKn-21UOgIXVZCuKrng_7_4"></a><a id="Tc_bq2CuJDvMki_7yWdq6P9NQ_8_0"></a><a id="Tc_mQE3KhlrREOnBW5RAeT73w_9_0"></a><a id="Tc_oGvZTJNeBkeIcEw2K5kHTQ_10_0"></a><a id="Tc_iY3viw-z1UKc0yv1kGKHXw_11_0"></a><a id="Tc_194jpOdL50-tDqXe5TmD9w_11_4"></a><a id="Tc_ahuw-hBZSk-Dks7tNKQWuQ_11_9"></a><a id="Tc_6I180ApyB0GvsIMwLLiNNw_13_0"></a><a id="Tc_O29gtqynDEGILBG29YYiZA_13_4"></a><a id="Tc_BCEtYxywHkWxMfNVdQKgDg_13_9"></a><a id="Tc_ptCx-brA2UC5swNuq9hdeQ_14_0"></a><a id="Tc_G8cqb0vhcECVhVwiOlFkrw_14_4"></a><a id="Tc_ceRCAesfF0uLGrpYVmlE9Q_14_9"></a><ix:continuation id="Tb_n9dAAcSV402eglza2cJpoA_cont1" continuedAt="Tb_n9dAAcSV402eglza2cJpoA_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">otherwise terminated. As of December 31, 2021, there were <ix:nonFraction unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ" contextRef="As_Of_12_31_2021_us-gaap_PlanNameAxis_imrx_TwoThousandTwentyOneIncentiveAwardPlanMember_LI5PlJ73VUKxQRLedBtGOQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="Narr_gi6I9W2kgEGFaSs5yX3cdg">2,298,432</ix:nonFraction> shares available for future issuance under the 2021 Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On July 23, 2021, the Company&#8217;s Board of Directors adopted, and on July 23, 2021 its stockholders approved, the 2021 Employee Stock Purchase Plan (the &#8220;2021 ESPP&#8221;), which became effective on July 29, 2021. A total of <ix:nonFraction unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ" contextRef="As_Of_7_23_2021_us-gaap_PlanNameAxis_imrx_TwoThousandTwentyOneEmployeeStockPurchasePlanMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_oj9jqMIrFkaE72Eovxv2mw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="Narr_xVlLCK-kSECwvE2Zmn0z5A">250,000</ix:nonFraction> shares of Class A common stock were initially reserved for issuance under this plan. The number of shares of Class A common stock that may be issued under the 2021 ESPP will automatically increase on the first day of each calendar year, beginning on January 1, 2022 and ending on and including January 1, 2031, equal to the lesser of (i) <ix:nonFraction unitRef="Unit_Standard_pure_iothMaWWqUCV2N7d1PVg4w" contextRef="Duration_7_23_2021_To_7_23_2021_us-gaap_PlanNameAxis_imrx_TwoThousandTwentyOneEmployeeStockPurchasePlanMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_wllzZzefAkGrL1ozzU9u1Q" decimals="3" format="ixt:numdotdecimal" name="imrx:PercentageOfAggregateNumberOfSharesOutstanding" scale="-2" id="Narr_890k-J3fbUqAObnkPENVoQ">1</ix:nonFraction>% of the shares of Class A common stock outstanding on the final day of the immediately preceding calendar year and (ii) such smaller number of shares of Class A common stock as determined by the board of directors, provided that not more than <ix:nonFraction unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ" contextRef="Duration_7_23_2021_To_7_23_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_PlanNameAxis_imrx_TwoThousandTwentyOneEmployeeStockPurchasePlanMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_EGe_9LAr1062vI9kah96gg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Narr_gje2sbhoz0WhazVObcTyhg">3,340,000</ix:nonFraction> shares of Class A common stock may be issued under the 2021 ESPP. As of December 31, 2021, <ix:nonFraction unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_imrx_TwoThousandTwentyOneEmployeeStockPurchasePlanMember_ZkFEiJ1N4E69ZN1lBj-gpw" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Narr_Y9dLDBAjDEWrfsdLbCSqfw">no</ix:nonFraction> shares had been issued under the 2021 ESPP.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">During the year ended December 31, 2021 and 2020, the Company recognized stock-based compensation expense of $<ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_imrx_StockIncentivePlan2015Member_1tvXqAKRfEm4AKlfifgVpg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" id="Narr_8eRqszd9b0KVnekEC1jUPQ">1,802,623</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_PlanNameAxis_imrx_StockIncentivePlan2015Member_za8LgT3DyUmYmEzDhCQL2Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" id="Narr_eTsrw5x490m40NT62UlYqg">1,086,769</ix:nonFraction>, respectively. As of December&#160;31, 2021, compensation expense remaining to be recognized for outstanding stock options was $<ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="As_Of_12_31_2021_us-gaap_PlanNameAxis_imrx_StockIncentivePlan2015Member_yJ3Soj1ueEaHyYoF06Bg_g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" scale="0" id="Narr_MA9CbALDSUus9xiY2_Y4bw">8,403,600</ix:nonFraction> and to be recognized over a weighted-average period of <ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_imrx_StockIncentivePlan2015Member_1tvXqAKRfEm4AKlfifgVpg" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="Narr_rmSLgy60aUeefsqkLHeGVg">2.93</ix:nonNumeric> years.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The fair value of options granted is calculated on the grant date using the Black-Scholes option valuation model. <span style="background:#ffffff;">The Company historically has been a private company and lacks company-specific historical and implied volatility information. Therefore, it estimates its expected stock volatility based on the historical volatility of a publicly traded set of peer public companies and expects to continue to do so until such time as it has adequate historical data regarding the volatility of its own traded stock price.</span> For the year ended December 31, 2021, the Company granted <ix:nonFraction unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ" contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Narr_GS0mDX2tQUabU0pozQbQgA">1,452,462</ix:nonFraction> shares of stock options at a weighted-average grant date fair value of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_0VraXufKhkCSOUw2U_zvgQ" contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Narr_q0465y2YxES35wuIFkLSYQ">6.29</ix:nonFraction>. For the year ended December 31, 2020, the Company granted <ix:nonFraction unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ" contextRef="Duration_1_1_2020_To_12_31_2020_J_O9OcmviUi8EDFgokrY1Q" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Narr_SZ8W6ws73kK5zeJ-V9pibg">343,169</ix:nonFraction> shares at a weighted-average grant date fair value of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_0VraXufKhkCSOUw2U_zvgQ" contextRef="Duration_1_1_2020_To_12_31_2020_J_O9OcmviUi8EDFgokrY1Q" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Narr_t7w9T75aSEeYJU0XtWfRag">3.06</ix:nonFraction>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company used the following assumptions in its application of the Black-Scholes option pricing model for grants during the year ended December 31, 2021 and 2020:</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="Tb_nMJn_AThAkyewJOXzDo39g" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:67.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:67.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:30.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted-average risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_iothMaWWqUCV2N7d1PVg4w" contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MinimumMember_kkvfHzsY3kuLg_xs_U9vtw" decimals="5" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="Narr_P1ZPKhg5fkunmC3AayUt5Q">0.89</ix:nonFraction>% - 1.71%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_iothMaWWqUCV2N7d1PVg4w" contextRef="Duration_1_1_2020_To_12_31_2020_J_O9OcmviUi8EDFgokrY1Q" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="Narr_dYHU94fr5EGUrhQb55SMtg">0.36</ix:nonFraction>% - <ix:nonFraction unitRef="Unit_Standard_pure_iothMaWWqUCV2N7d1PVg4w" contextRef="Duration_1_1_2020_To_12_31_2020_J_O9OcmviUi8EDFgokrY1Q" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="Narr_8d9-MvuTuEKpupIC-RaDTg">1.45</ix:nonFraction>%</p></td></tr><tr><td style="vertical-align:bottom;width:67.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected term (in years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MinimumMember_kkvfHzsY3kuLg_xs_U9vtw" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Narr_5ZZn181rDUqrIk0FoyAX1A">5.83</ix:nonNumeric> - <ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_SGUutfcD1kqmyGRE2MRtsg" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Narr_dxoRgZrMME6XtPIWYOIx9Q">10 years</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_srt_RangeAxis_srt_MinimumMember_Ozt2OiOHCkmkib6hyeBSlQ" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Narr_GyslcB2IXk-v3NwkpcABWQ">5.92</ix:nonNumeric> - <ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_srt_RangeAxis_srt_MaximumMember_a5iqF3xs7Uao9VNTsL_jaw" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Narr_Oc4kN62S2UaDRot3x4ie_g">10 years</ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:67.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_iothMaWWqUCV2N7d1PVg4w" contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="Tc_yFcA1mAnQ06m19qWFi7D8A_6_2">0</ix:nonFraction>%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_iothMaWWqUCV2N7d1PVg4w" contextRef="Duration_1_1_2020_To_12_31_2020_J_O9OcmviUi8EDFgokrY1Q" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="Tc_jo6HNgj1t0qG6k8tnRhfcQ_6_4">0</ix:nonFraction>%</p></td></tr><tr><td style="vertical-align:bottom;width:67.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_iothMaWWqUCV2N7d1PVg4w" contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="Narr_2_K_vHC98EOadIcMRZ1zLA">66.76</ix:nonFraction>% - <ix:nonFraction unitRef="Unit_Standard_pure_iothMaWWqUCV2N7d1PVg4w" contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="Narr_VRx-fowJgUW7Xlw0jWrpoA">80.99</ix:nonFraction>%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_iothMaWWqUCV2N7d1PVg4w" contextRef="Duration_1_1_2020_To_12_31_2020_J_O9OcmviUi8EDFgokrY1Q" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="Narr_e8SFcwEfFUGNm-Jx6d23bA">67.30</ix:nonFraction>% - <ix:nonFraction unitRef="Unit_Standard_pure_iothMaWWqUCV2N7d1PVg4w" contextRef="Duration_1_1_2020_To_12_31_2020_J_O9OcmviUi8EDFgokrY1Q" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="Narr_LmnEKdIYG0idLKUd_qNWfg">80.85</ix:nonFraction>%</p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The following table summarizes the stock option activity during the year ended December 31, 2021 under the Plan:</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="Tb_cTl0SAeqsUqYz_D20erJ_w" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:51.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:51.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted-</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Remaining</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exercise Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Contractual</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Aggregate</b></p></td></tr><tr><td style="vertical-align:bottom;width:51.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;">    </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Options</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;">    </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">per Share</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Term (in Years)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;">    </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;"> Intrinsic Value</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:51.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding at of December&#160;31,&#160;2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ" contextRef="As_Of_12_31_2020_OUSLyqWONEO8ccGPC6rBdg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_i3j-TSyuh0mAqit6T9Ihmg_7_2">1,801,263</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_0VraXufKhkCSOUw2U_zvgQ" contextRef="As_Of_12_31_2020_OUSLyqWONEO8ccGPC6rBdg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_VLa9X3kLkECiQZDyAbGrvg_7_5">3.01</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:51.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ" contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Tc_r4JlOrdSZUKqpTs0K8BELQ_8_2">1,452,462</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_0VraXufKhkCSOUw2U_zvgQ" contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_9S1tNs6EcEeBgK2VD3rFIQ_8_5">10.07</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:51.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ" contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Tc_VnFw6thqHUyOTIL3aalF3g_9_2">117,847</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_0VraXufKhkCSOUw2U_zvgQ" contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_oXOGCvsSkkSR68esl_Y2HQ_9_5">3.01</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:51.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cancelled</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ" contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ" decimals="INF" format="ixt:numdotdecimal" name="imrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRepurchased" scale="0" id="Tc_XBCibDxOAESIRKJwZKaUmQ_10_2">276,334</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_0VraXufKhkCSOUw2U_zvgQ" contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ" decimals="2" format="ixt:numdotdecimal" name="imrx:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsRepurchasedInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_p1Kqp6v9vECrY6UxCqiFyw_10_5">3.58</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:51.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding at December&#160;31,&#160;2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ" contextRef="As_Of_12_31_2021_TBpjtOXgEkKQahJJAv0aWg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_YUwHObjiH0mNj_y5lr31cg_11_2">2,859,544</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_0VraXufKhkCSOUw2U_zvgQ" contextRef="As_Of_12_31_2021_TBpjtOXgEkKQahJJAv0aWg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_Psx5UZlzmEekSnwEnPNPVw_11_5">6.55</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="Tc_RpXQ-XoZqku3WX6BIUyBFQ_11_7"> 8.30</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="As_Of_12_31_2021_TBpjtOXgEkKQahJJAv0aWg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="0" id="Tc_KDUlUNy4K0q4E9eAP18bkA_11_10">27,615,466</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Vested and exercisable at December&#160;31,&#160;2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ" contextRef="As_Of_12_31_2021_TBpjtOXgEkKQahJJAv0aWg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" scale="0" id="Tc_ErXq2IumwEWpKm467yujNA_13_2">1,102,543</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_0VraXufKhkCSOUw2U_zvgQ" contextRef="As_Of_12_31_2021_TBpjtOXgEkKQahJJAv0aWg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" scale="0" id="Tc_S-qEIqFTekSEEL9ZHe1hiw_13_5">3.01</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" id="Tc_LBjM4i0dL0SLUNpHQWOH4w_13_7"> 7.14</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="As_Of_12_31_2021_TBpjtOXgEkKQahJJAv0aWg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" scale="0" id="Tc_Flp9buQKFE-jC6SSGYX0cw_13_10">14,507,723</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:51.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Vested and expected to vest at December&#160;31,&#160;2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ" contextRef="As_Of_12_31_2021_TBpjtOXgEkKQahJJAv0aWg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" scale="0" id="Tc_6519J5YGXEWBDXcY4SCPEQ_14_2">2,859,544</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_0VraXufKhkCSOUw2U_zvgQ" contextRef="As_Of_12_31_2021_TBpjtOXgEkKQahJJAv0aWg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_cVAo0Zhhl0CRLJ_El7e2nQ_14_5">6.55</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" id="Tc_wgrkTONkYE6o_Y9dnpdCeg_14_7"> 8.30</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="As_Of_12_31_2021_TBpjtOXgEkKQahJJAv0aWg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" scale="0" id="Tc_kFozl7F120e9myOMgYurPA_14_10">27,615,466</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">152</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_-JsNLrKLoUOTyhuz3hHwdw_1_2"></a><a id="Tc_YKxbowJDikSGWPNGK4YKaA_2_2"></a><a id="Tc_q2rw6est-0ekMSH9PMonbQ_2_5"></a><a id="Tc_oF1zNUEZykO4JhJMTfc48w_4_0"></a><a id="Tc_w-24Szg2kUqxINq7ELVSJQ_4_2"></a><a id="Tc_kwp5Ts9g_kmaEA1AqtJTWw_4_5"></a><a id="Tc_3PGluRnY_EqM0_sJE2UL5Q_5_0"></a><a id="Tc_csrM6NrQVk6HFKhkRYelFw_6_0"></a><a id="Tc_vrP-me_M8UeOpgRjLPyl9A_7_0"></a><a id="Tc_Rfyk02xz1UmDPWyjPzWf0w_7_2"></a><a id="Tc__gtsZyk5iES3bopNjB9uHQ_7_5"></a><ix:continuation id="Tb_n9dAAcSV402eglza2cJpoA_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">For the year &#160;ended December 31, 2021 and 2020, the Company recognized share-based compensation expense recognized on the accompanying &#160;consolidated statements of operations as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ" name="us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" id="Tb_I5yio1JZ70Gm_7Fj4ubVQA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cost of revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_dQH6PYSm8ke4t8B5Xp8bAw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" id="Tc_I60qW5QMNUGixi7R-zStUA_4_3">103,329</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_hRS8KqtkvEKMap0WY0snUg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" id="Tc_sX4L2archkqK9_lVF36j_g_4_6">108,027</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_ZzhQndqazkWQw1a8tNpx5w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" id="Tc_iaDaHPG270KFcSmYP5bRxQ_5_3">768,679</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_PenqHZkD4kiUSIeznQQKKw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" id="Tc_3F41n7M_zUKDoqDZM2fUhg_5_6">503,111</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_q0lSZG3emUWjV7QOWezTNQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" id="Tc_Eh4BXVwBVU6MSk5mqL2ObQ_6_3">930,615</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_hOzxdtEG0UaD56zlDOhRBw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" id="Tc_fBJNsbAUe0-769E8RVEjUQ_6_6">475,631</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" id="Tc_uXkzbNeShUWb3W6D6k7fYA_7_3">1,802,623</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="Duration_1_1_2020_To_12_31_2020_J_O9OcmviUi8EDFgokrY1Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" id="Tc_ErFhfWmVvEO0O4BpP5kQ8Q_7_6">1,086,769</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><a id="Tc_xBMFNtMVPk6DfsrmVaC2yA_1_2"></a><a id="Tc_Z37wqZV4106pN7f0n5UIaw_1_4"></a><a id="Tc_6R3mnxm-NUSaGgqQ-_5X0w_2_0"></a><a id="Tc_DdY-VxpIX0GAww2tBPu1Fg_2_3"></a><a id="Tc_-HkY-Jy_YUKYJiYhH88d7g_2_5"></a><a id="Tc_M1AAUtSw6keaN-ac1LK4CA_3_0"></a><a id="Tc_Vaeg8oueEUqZjmuiweEYKQ_3_3"></a><a id="Tc_O-XGajZ8gkqEooaQOwTOQw_3_5"></a><a id="Tc_VNlLYdloY0CSo4tT_21jGw_4_0"></a><a id="Tc_cm0nvzjhyEKgtGIui4azbA_4_3"></a><a id="Tc_FVzRM_I0pESoFMqDMFYugw_4_5"></a><a id="Tc_fZwegcIZ6kCfuI84gEw3dQ_5_0"></a><a id="Tc_OfNxeMf8bkqA7rwK_FxacQ_5_3"></a><a id="Tc_eVgaMNacv06ISRBkfWEL1g_5_5"></a><a id="Tc_8pCnFYklOEecvbsWnulMeQ_6_0"></a><a id="Tc_utayrj-hSES5XiIoBbtI0w_6_3"></a><a id="Tc_2gDqgeznpUKMFc-WfBKjtQ_6_5"></a><a id="Tc_elW5EMs8iEeyBN5LvxjZkg_7_0"></a><a id="Tc_DFzkhvvPNkme-SUXNLRqWQ_7_3"></a><a id="Tc_nA11ulBl2EircHDzh0NpTw_7_5"></a><a id="Tc_MvOS0A-rwk-1V3OVbaNdDg_8_0"></a><a id="Tc_jX7FRyNuj0OXL_Z5M7hzJw_8_3"></a><a id="Tc_zROAa9xPxE-ecstgTFsOvA_8_5"></a><a id="Tc_Y7E4AXZDyUOITkyRHuIWSA_9_0"></a><a id="Tc_DX_T3PivKUSZBW55pWlTig_9_3"></a><a id="Tc_jvNBKz---UGCB0q6ph0egg_9_5"></a><a id="Tc_tAkd18DLEEuU2IXcBixOvw_10_0"></a><a id="Tc_xb5SyM4d-USyvuqZ5_N9rQ_10_3"></a><a id="Tc_oxJmO1PD20KBQxONvWRTdQ_10_5"></a><a id="Tc_ePbHRXXeikOhrsqcx2buXg_1_2"></a><a id="Tc_2qOGNzEYAkugW4GOSTQVnA_1_5"></a><a id="Tc_BauJKCEEo0Gw5I8RXZNR_w_2_0"></a><a id="Tc_WTNeIKR5lkyWXWJhbiv4Vg_3_0"></a><a id="Tc_1eoYgbgwgkeQ6tqtLd-NYg_3_2"></a><a id="Tc_wPsqUwzhIkSmjEPsD_lhdA_3_5"></a><a id="Tc_R14YIqlu4E-TzNsOl6InfA_4_0"></a><a id="Tc_c2efCWxAZkW7dT0d27tNzQ_4_6"></a><a id="Tc_dPJ6tqi7kkSwHISdPQ6p9g_5_0"></a><a id="Tc_-em1WLr-mkaekAtVxa8_tA_6_0"></a><a id="Tc_NL_97u6Nxku2zFgy7qahXA_7_0"></a><a id="Tc__fz9SoYImku0RjrHT9nZNA_8_0"></a><a id="Tc_EBNCgCQgS0-3R78cpqev3Q_9_0"></a><a id="Tc_ubIKSuU4XkC-hSZFg-i64w_10_0"></a><a id="Tc_8s9ACpjKSUulDyXcspgk2g_11_0"></a><a id="Tc_JQSGBWrLUkKY36lErqyb_g_12_0"></a><a id="Tc_oKijccc7B0i4vdGmsNoPkw_13_0"></a><a id="Tc_uArtdue2SU6Dc0T3Q8IUIw_14_0"></a><a id="Tc_JqtDQ6ApJ0GTr-2zMnkCOg_14_2"></a><a id="Tc_BEjc6k3CnECInczAQQU8Tw_14_3"></a><a id="Tc_RWJtUwMwe0yHx4-xtBKygw_14_5"></a><a id="Tc_4UM1D-KzKkiGTVtGMYr3SQ_14_6"></a><a id="_Hlk96586226"></a><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ" name="us-gaap:IncomeTaxDisclosureTextBlock" id="Tb_XPZTzxDBc0SNIlfVKquasQ" continuedAt="Tb_XPZTzxDBc0SNIlfVKquasQ_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Note&#160;12&#160;&#8211; Income Taxes</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">A reconciliation of the effect of applying the federal statutory rate to the net loss and the effective income tax rate are as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="Tb_05x_REImOUOSa96LHVT8vA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:74.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Statutory federal income tax rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_iothMaWWqUCV2N7d1PVg4w" contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="Tc_XPKrRFk5hES5IiGvCUXCeA_2_2">21.0</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_iothMaWWqUCV2N7d1PVg4w" contextRef="Duration_1_1_2020_To_12_31_2020_J_O9OcmviUi8EDFgokrY1Q" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="Tc_3bWM-GiApUWowC8XrIIz-A_2_4">21.0</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:74.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">State tax, net of federal benefit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_iothMaWWqUCV2N7d1PVg4w" contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="Tc_bGK97fNR7kGjjpZRxIYI2A_3_2">5.5</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_iothMaWWqUCV2N7d1PVg4w" contextRef="Duration_1_1_2020_To_12_31_2020_J_O9OcmviUi8EDFgokrY1Q" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="Tc_bGVxqDX6TUOHzEVEW8kSiA_3_4">6.3</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:74.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Permanent differences</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_iothMaWWqUCV2N7d1PVg4w" contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense" sign="-" scale="-2" id="Tc_LdNaHxCA3UK3dr71KFXIfg_4_2">0.6</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_iothMaWWqUCV2N7d1PVg4w" contextRef="Duration_1_1_2020_To_12_31_2020_J_O9OcmviUi8EDFgokrY1Q" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense" sign="-" scale="-2" id="Tc_xdPOgas6xUWneiMbqanJdw_4_4">1.5</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:74.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Federal research and development credits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_iothMaWWqUCV2N7d1PVg4w" contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" scale="-2" id="Tc_T1ighhEvQ020MYC_bgbpAA_5_2">5.6</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_iothMaWWqUCV2N7d1PVg4w" contextRef="Duration_1_1_2020_To_12_31_2020_J_O9OcmviUi8EDFgokrY1Q" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" scale="-2" id="Tc_HJ_0U5mMgkuPPO-1nHHahA_5_4">4.5</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:74.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">State research and development credits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_iothMaWWqUCV2N7d1PVg4w" contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ" decimals="3" format="ixt:numdotdecimal" name="imrx:EffectiveIncomeTaxRateReconciliationTaxCreditStateResearchAndDevelopmentPercent" scale="-2" id="Tc_0myw2Ly6pEiCiMy-wkqeNA_6_2">0.4</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_iothMaWWqUCV2N7d1PVg4w" contextRef="Duration_1_1_2020_To_12_31_2020_J_O9OcmviUi8EDFgokrY1Q" decimals="3" format="ixt:numdotdecimal" name="imrx:EffectiveIncomeTaxRateReconciliationTaxCreditStateResearchAndDevelopmentPercent" scale="-2" id="Tc_1GnhjE-gaE2MghOEvVDtAw_6_4">0.6</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:74.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Uncertain tax positions</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_iothMaWWqUCV2N7d1PVg4w" contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ" decimals="3" format="ixt:numdotdecimal" name="imrx:EffectiveIncomeTaxRateReconciliationUncertainTaxPositions" sign="-" scale="-2" id="Tc_JXEoZ4XBqEiGMse5WaYoWg_7_2">0.6</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_iothMaWWqUCV2N7d1PVg4w" contextRef="Duration_1_1_2020_To_12_31_2020_J_O9OcmviUi8EDFgokrY1Q" decimals="3" format="ixt:numdotdecimal" name="imrx:EffectiveIncomeTaxRateReconciliationUncertainTaxPositions" sign="-" scale="-2" id="Tc__pNVdtY6qkixjBFMey_ylA_7_4">1.0</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:74.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other differences</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_iothMaWWqUCV2N7d1PVg4w" contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="Tc_ScopayW6vkyWKXExlPFYag_8_2">0.7</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_iothMaWWqUCV2N7d1PVg4w" contextRef="Duration_1_1_2020_To_12_31_2020_J_O9OcmviUi8EDFgokrY1Q" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" sign="-" scale="-2" id="Tc_tCtf-lDS8UKQUaI6ZpP6wg_8_4">2.6</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:74.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Change in valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_iothMaWWqUCV2N7d1PVg4w" contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" sign="-" scale="-2" id="Tc_s40FLSmVrUKL-ipJmMyhxA_9_2">31.1</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_iothMaWWqUCV2N7d1PVg4w" contextRef="Duration_1_1_2020_To_12_31_2020_J_O9OcmviUi8EDFgokrY1Q" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" sign="-" scale="-2" id="Tc_5RoxT3CvrESLCDOE8FTRJQ_9_4">27.3</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:74.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Effective income tax rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_iothMaWWqUCV2N7d1PVg4w" contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="Tc_amiC1-2NPkyNZxTqYDQCbg_10_2">0.9</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_iothMaWWqUCV2N7d1PVg4w" contextRef="Duration_1_1_2020_To_12_31_2020_J_O9OcmviUi8EDFgokrY1Q" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="Tc_s9XIFNjpKUSsEo8cUje4pQ_10_4">0.0</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:12pt 0pt 12pt 0pt;">As of December 31, 2021 and 2020, the components and tax effects of each type of item that gave rise to the net deferred tax assets were as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="Tb_l6T3AxJQbkC6oIzQP1zsAQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Deferred tax assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:73.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Stock-based compensation expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="As_Of_12_31_2021_TBpjtOXgEkKQahJJAv0aWg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="0" id="Tc_prP2mnaq10W2xdruo2FoHg_3_3">373,602</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="As_Of_12_31_2020_OUSLyqWONEO8ccGPC6rBdg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="0" id="Tc_35OnE3OSlkGIscp0zyQ5ng_3_6">73,984</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Unrealized losses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="As_Of_12_31_2021_TBpjtOXgEkKQahJJAv0aWg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsUnrealizedCurrencyLosses" scale="0" id="Tc_Ak_2j8tpsEeHPzJeY9jpKg_4_3">12,990</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:73.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">R&amp;D credit carryforward</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="As_Of_12_31_2021_TBpjtOXgEkKQahJJAv0aWg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" scale="0" id="Tc_ZAs2VDkQXUaqvLCbc0XbsQ_5_3">3,346,097</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="As_Of_12_31_2020_OUSLyqWONEO8ccGPC6rBdg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" scale="0" id="Tc_ipi0bVLvFkqZ2wDBGbqUTg_5_6">1,574,596</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">NOL carryforward</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="As_Of_12_31_2021_TBpjtOXgEkKQahJJAv0aWg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="0" id="Tc_gBk241our0aTniJaRWubjg_6_3">14,699,524</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="As_Of_12_31_2020_OUSLyqWONEO8ccGPC6rBdg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="0" id="Tc_wafbK02RY0KhH2Dpok_xFw_6_6">5,525,123</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Gross deferred tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="As_Of_12_31_2021_TBpjtOXgEkKQahJJAv0aWg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsGross" scale="0" id="Tc_RboWd1vaiU6D6nVqiZzDzg_7_3">18,432,213</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="As_Of_12_31_2020_OUSLyqWONEO8ccGPC6rBdg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsGross" scale="0" id="Tc_I_BfRhqx8kmeyntyLMZ9AQ_7_6">7,173,703</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="As_Of_12_31_2021_TBpjtOXgEkKQahJJAv0aWg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="0" id="Tc_mGSZrVKrhUW1vbDUAbxOxQ_8_3">17,677,899</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="As_Of_12_31_2020_OUSLyqWONEO8ccGPC6rBdg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="0" id="Tc_yILfZhJ9GUyNHWPhviWNBQ_8_6">7,127,448</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:73.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net deferred tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="As_Of_12_31_2021_TBpjtOXgEkKQahJJAv0aWg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsNet" scale="0" id="Tc_mJEgYLyFMEmlQqp_8THRIw_9_3">754,314</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="As_Of_12_31_2020_OUSLyqWONEO8ccGPC6rBdg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsNet" scale="0" id="Tc_8e3xrq_qiE-j0hNiKh4o0w_9_6">46,255</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net deferred tax liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:73.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Prepaid expenses deducted for tax</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="As_Of_12_31_2021_TBpjtOXgEkKQahJJAv0aWg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxLiabilitiesPrepaidExpenses" scale="0" id="Tc_D1rYRTiigUebk0v5q8N6Aw_11_3">425,755</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="As_Of_12_31_2020_OUSLyqWONEO8ccGPC6rBdg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxLiabilitiesPrepaidExpenses" scale="0" id="Tc_ueE3DR8A-U6y9wNC8D_XhQ_11_6">28,671</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:73.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Tax depreciation in excess of book</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="As_Of_12_31_2021_TBpjtOXgEkKQahJJAv0aWg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" scale="0" id="Tc_Nu5Ft6NmUEyi2UHCSKQeCQ_12_3">328,559</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="As_Of_12_31_2020_OUSLyqWONEO8ccGPC6rBdg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" scale="0" id="Tc_wqQa9c6Ga0Cu7V7VvgfjBw_12_6">17,584</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:73.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total deferred tax liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="As_Of_12_31_2021_TBpjtOXgEkKQahJJAv0aWg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxLiabilities" scale="0" id="Tc_DBKPqMFIgUCaQ0Ugj2rZ0w_13_3">754,314</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="As_Of_12_31_2020_OUSLyqWONEO8ccGPC6rBdg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxLiabilities" scale="0" id="Tc_82xmEeloOUyY0iJIZsQt4A_13_6">46,255</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:73.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net deferred taxes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Federal net operating losses (&#8220;NOL&#8221;) generated in tax years ended after December 31, 2017 are limited to 80% of taxable income, only carried forward and carried forward indefinitely under the Internal Revenue Code (&#8220;IRC&#8221;). The Company recorded a deferred tax liability of $<ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="Duration_1_1_2017_To_12_31_2017_us-gaap_BusinessAcquisitionAxis_imrx_BioArkiveIncMember_eCOuV4siy0CntVgmBRHjJw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxesBusinessCombinationValuationAllowanceAvailableToReduceIncomeTaxExpense" scale="0" id="Narr_Lyi38PyplUSQlo2kJefKVw">304,485</ix:nonFraction> on the acquisition of BioArkive. It had pre-existing deferred tax assets for which there was a fuill valuation allowance. As a result of the taxable temporary differences recognized in the business combination, the Company released $<ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="Duration_1_1_2017_To_12_31_2017_us-gaap_BusinessAcquisitionAxis_imrx_BioArkiveIncMember_eCOuV4siy0CntVgmBRHjJw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" scale="0" id="Narr_Q8wznx410UiFsBWO3Gi8nA">304,485</ix:nonFraction><span style="white-space:pre-wrap;"> of its valuation allowance and recognized the income tax benefit in the income statement at the acquisition date in accordance with ASC 740  There was no income tax expense or benefit in 2020. The Company has provided a valuation allowance for the full amount of the net deferred tax assets as, based on all available evidence, it is considered more likely than not that all the recorded deferred tax assets will not be realized in a future period. At December 31, 2021, the Company has federal and state NOLs of </span>$<ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="As_Of_12_31_2021_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_6VOCtAPe5UC8u2hi-12dxg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="0" id="Narr_TfwTAp4Te0iciw6O6Z3DfQ">56,544,731</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="As_Of_12_31_2021_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_E6Pqm-5XGEGHnxL47x05BA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="0" id="Narr_x6OPyy7M10S6-J24jjVR0w">51,310,112</ix:nonFraction>, </p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">153</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_NGLHlVwfBk-zpA0CCx9viA_1_2"></a><a id="Tc_GoYFOnWzlUK9JiWvdnxVWg_1_5"></a><a id="Tc_X1d7KJYI60qfu5bvNBzNzw_2_0"></a><a id="Tc_etcfbicp-UO2mc_pRg3gQg_2_2"></a><a id="Tc_cu0ryVCHdUKw2w4SdijcVQ_2_5"></a><a id="Tc_9hE0BJQjx0qkOWZKpxUycQ_3_0"></a><a id="Tc_B-F-UpqCPkKxkpPTG0_JSA_4_0"></a><a id="Tc_Heh5W0ABb0SDVUhBQBmyjw_4_2"></a><a id="Tc__VUUoXaHdkqY5klPUmhk6w_4_5"></a><ix:continuation id="Tb_XPZTzxDBc0SNIlfVKquasQ_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">respectively all generated after the tax year ended December 31, 2017. At December 31, 2021, the Company has federal and state research and development credit carryforwards, $<ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="As_Of_12_31_2021_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember_CoisecZ1RkWQ4NibnKtk2g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TaxCreditCarryforwardAmount" scale="0" id="Narr_wnijpU7vI0OxFoWYYbE92g">3,034,827</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="As_Of_12_31_2021_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember_8yiTbINkMkqUQTRVdOLgQw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TaxCreditCarryforwardAmount" scale="0" id="Narr_hVeATFJYmUaKzSsffDRBKw">394,013</ix:nonFraction>, respectively, that start to expire beginning in 2025.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'TimesNewRomanPSMT';visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:9.95pt;background:#ffffff;margin:0pt 8.55pt 0pt 0pt;">As the Company has not yet achieved profitable operations, management believes the tax benefits as of December 31, 2021 did not satisfy the realization criteria set forth in ASC Topic 740, Income Taxes and, therefore, has recorded a full valuation allowance for the entire deferred tax asset. The valuation allowance increased in 2021 by $<ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" scale="0" id="Narr_LFGB7dA8ckKVGVXDxGOn-g">10,550,451</ix:nonFraction> due to the increase in the deferred tax assets by the same amount, primarily due to NOL and research and development credit carryforwards. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:9.95pt;background:#ffffff;margin:0pt 8.55pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:9.95pt;text-align:justify;background:#ffffff;margin:0pt 8.55pt 0pt 0pt;">Utilization of the U.S. net operating loss carryforwards and research and development tax credit carryforwards may be subject to a substantial annual limitation under Section 382 of the Internal Revenue Code of 1986, and corresponding provisions of state law, due to ownership changes that have occurred previously or that could occur in the future. These ownership changes may limit the amount of carryforwards that can be utilized annually to offset future taxable income. In general, an ownership change, as defined by Section 382, results from transactions increasing the ownership of certain stockholders or public groups in the stock of a corporation by more than 50% over a three-year period. The Company has not conducted a study to assess whether a change of control has occurred or whether there have been multiple changes of control since inception due to the significant complexity and cost associated with such a study. If the Company has experienced a change of control, as defined by Section 382, at any time since inception, utilization of the net operating loss carryforwards or research and development tax credit carryforwards would be subject to an annual limitation under Section 382, which is determined by first multiplying the value of the Company&#8217;s stock at the time of the ownership change by the applicable long-term tax-exempt rate, and then could be subject to additional adjustments, as required. Any limitation may result in expiration of a portion of the net operating loss carryforwards or research and development tax credit carryforwards before utilization. Further, until a study is completed by the Company and any limitation is known, some amounts are being presented as an uncertain tax position.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:9.95pt;text-align:justify;background:#ffffff;margin:0pt 8.55pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">As of December 31, 2021 and 2020, the Company had uncertain tax positions of $<ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="As_Of_12_31_2021_TBpjtOXgEkKQahJJAv0aWg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefits" scale="0" id="Narr_jVdzBlFGuEuPnV5xzCKg3g">380,902</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="As_Of_12_31_2020_OUSLyqWONEO8ccGPC6rBdg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefits" scale="0" id="Narr_ZzJAw4T5YkKhl8Aze-1TiQ">174,950</ix:nonFraction> which have been classified as reductions of its tax carrforwards. The Company has elected to recognize interest and penalties related to income tax matters as a component of income tax expense, of which <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="As_Of_12_31_2020_OUSLyqWONEO8ccGPC6rBdg" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" scale="0" id="Narr_Vp3FFp_Fy0aQCz3bF0uKpg"><ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="As_Of_12_31_2021_TBpjtOXgEkKQahJJAv0aWg" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" scale="0" id="Narr_0Ffc-4ueHkO5n2H0Pmu4oQ">no</ix:nonFraction></ix:nonFraction> interest or penalties were recorded for the years ended December 31, 2021 and 2020. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">As of December 31, 2021 and 2020, unrecognized tax benefits were as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ" name="us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" id="Tb_bTvsnDyQTUexYY_7J1-7Tg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:9.95pt;text-align:justify;background:#ffffff;margin:0pt 8.55pt 0pt 0pt;"><span style="font-family:'TimesNewRomanPSMT';font-weight:bold;margin-right:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:70.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:70.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:70.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Beginning balance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="As_Of_12_31_2020_OUSLyqWONEO8ccGPC6rBdg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefits" scale="0" id="Tc_sxbMn3JNsUSe04o5kcaKMQ_2_3">174,950</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="As_Of_12_31_2019_g3mjqkDWB0-f2XKJf0YL-A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefits" scale="0" id="Tc_W8SNqhY8eEea1DO98-6-Rg_2_6">96,952</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:70.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Increase due to current year tax position</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="0" id="Tc_QFvAdBCBk0qpNxG3rx8IHw_3_3">205,952</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="Duration_1_1_2020_To_12_31_2020_J_O9OcmviUi8EDFgokrY1Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="0" id="Tc_knVwJpXYv0O8QetYyC7cEQ_3_6">77,998</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:70.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Ending balance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="As_Of_12_31_2021_TBpjtOXgEkKQahJJAv0aWg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefits" scale="0" id="Tc_iQajE8Gk-UiVcnLxoC4SrQ_4_3">380,902</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="As_Of_12_31_2020_OUSLyqWONEO8ccGPC6rBdg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefits" scale="0" id="Tc_gQJA0Ar-jUCkvurkOs3qzQ_4_6">174,950</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:9.95pt;text-align:justify;background:#ffffff;margin:0pt 8.55pt 0pt 0pt;"><span style="font-family:'TimesNewRomanPSMT';font-weight:bold;margin-right:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The Company files tax returns in the United States including California, New York, Pennsylvania, Massachusetts and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Texas. All tax years from 2017 to 2021 remain open to examination by the major taxing jurisdictions to which the Company is subject, as carryforward attributes generated in years past may still be adjusted upon examination by the Internal Revenue Service (&#8220;IRS&#8221;) or other authorities if they have or will be used in a future period. The Company is not currently under examination by the IRS or any other jurisdictions for any tax years.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'TimesNewRomanPSMT';visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On March 27, 2020, the Coronavirus Aid, Relief, and Economic Security Act (the &#8220;CARES Act&#8221;) was enacted in response to the COVID-19 pandemic. The CARES Act, among other things, permits NOL carryovers and carrybacks to offset 100% of taxable income for taxable years beginning before 2021. In addition, the CARES Act allows NOLs incurred in 2019, 2020, and 2021 to be carried back to each of the five preceding taxable years to generate a refund of previously paid income taxes. The enactment of the CARES Act resulted in increased federal and state research and development carryforwards from 2013 through 2018 of $<ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="Duration_3_27_2020_To_3_27_2020_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember_5FkHeRTRFUWenXHcqclDDQ" decimals="0" format="ixt:numdotdecimal" name="imrx:TaxCreditCarryforwardIncreaseDecreaseCaresAct" scale="0" id="Narr_e9P9jtR-g0GFTiUkP_zuZQ">93,437</ix:nonFraction> and decreased federal NOL of $<ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="Duration_3_27_2020_To_3_27_2020_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember_SFNqtQEhiUilg2XoqHi-NA" decimals="0" format="ixt:numdotdecimal" name="imrx:TaxCreditCarryforwardIncreaseDecreaseCaresAct" scale="0" id="Narr_Qn4ANYhwDkK6BMdtn2r0PQ">759,794</ix:nonFraction> from 2018.</p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">154</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_g25LlZq5wke1SHSVReRURQ_1_2"></a><a id="Tc_phsXRyMeqU6hIViZyCw7yw_2_0"></a><a id="Tc_PxBOvcoJ5keh2jVQMuzRSQ_2_2"></a><a id="Tc_KESLSyKLtkOV2xKK9v7HsA_3_0"></a><a id="Tc_zxZeM2IXlEeaKrh2f9rN7Q_4_0"></a><a id="Tc_iB2EgzbyZE-1OZusUe6Ihw_5_0"></a><a id="Tc_X2eqUfJlrEOaWGZBd_LAcg_6_0"></a><a id="Tc_rNkdU87xHUWuJPbVpe0KDQ_7_0"></a><a id="Tc_3da2kdNGbUOIIfV6yusebQ_8_0"></a><a id="Tc_LHzjsR4pF0GMcilRxB3O8w_9_0"></a><a id="Tc_1_RUf0BrMUmRZoLXrSULhg_10_0"></a><a id="Tc_spJ3nh-3P0mhjQR6PWCQOg_10_2"></a><a id="Tc_y6fvKYzYz0O8SEJKVDx81A_11_0"></a><a id="Tc_Vew-qSuasUW-pSGepJ89PQ_12_0"></a><a id="Tc_OWCWjrvRy0usLJdWoyQQVA_13_0"></a><a id="Tc_2y3p2LaUK027qMiOR9VgKg_13_2"></a><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="Tb_88m9YkHyT0Oz-YgkGlARXg" continuedAt="Tb_88m9YkHyT0Oz-YgkGlARXg_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Note&#160;13&#160;&#8211; Commitments and Contingencies</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;">Operating Leases</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company leases office space in Cambridge, Massachusetts, New York, New York and as of July&#160;2021, San Francisco, California, pursuant to short-term arrangements. The Cambridge and San Francisco leases are on a&#160;month-to-month basis, requiring one&#160;month&#8217;s notice before termination. The New York lease is renewable on a quarterly basis and the last renewal extended the lease term until March&#160;31, 2022. These lease agreements include payments for lease and non-lease components and the Company has elected to not separate such components and these payments were recognized as rent expense.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As of December 31, 2021, total future minimum lease payments for its short-term leases in Cambridge, Massachusetts, New York, New York and San Francisco, California was $<ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_imrx_OfficeSpaceInCambridgeMassachusettsNewYorkMember_Qma-pjDe6kSAepAJusrqDA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="0" id="Narr_p23O0BE1iUOtkLbOSgSrSA"><ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_imrx_OfficeSpaceInCambridgeMassachusettsNewYorkMember_Qma-pjDe6kSAepAJusrqDA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="0" id="Narr_fTG9kG4Rm0eH3eEBHeE35g">30,840</ix:nonFraction></ix:nonFraction> due in 2022. The Company leases storage space for its electronic data equipment in Somerville, Massachusetts. This lease is renewable on an annual basis effective every March&#160;1st. Prior to December 31, 2021, the Company renewed the lease through March&#160;31, 2022. As of December 31, 2021, total future minimum lease payments for this lease were $<ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_imrx_StorageSpaceInSomervilleMassachusettsMember_kCYYiCYXakieYFKlIrPRQg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="0" id="Narr_gT-jQnpLHEykAdsQUZ9BXg">3,569</ix:nonFraction> due in 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In October&#160;2020, the Company entered into an office lease in San Diego, California with a lease term of <ix:nonNumeric contextRef="As_Of_10_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_imrx_OfficeLeaseInSanDiegoCalifornia2020Member_fOyKDK4i2USSpVi4_ouoxw" format="ixt-sec:durwordsen" name="us-gaap:LesseeOperatingLeaseTermOfContract" id="Narr_wEghFj16m0OZfD_WzM-h0g">67 months</ix:nonNumeric>. At the lease commencement date, a right-to-use asset and <span style="-sec-ix-hidden:Hidden_XdPatEybTkShRMLsu6QibA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">lease liability</span></span> was recognized by the Company for $<ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="As_Of_10_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_imrx_OfficeLeaseInSanDiegoCalifornia2020Member_fOyKDK4i2USSpVi4_ouoxw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="0" id="Narr_NwlLnXduskSbIur3W9E1_Q">637,863</ix:nonFraction>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As part of the BioArkive acquisition, the Company assumed the obligations of <ix:nonFraction unitRef="Unit_Standard_pure_iothMaWWqUCV2N7d1PVg4w" contextRef="As_Of_12_31_2021_us-gaap_BusinessAcquisitionAxis_imrx_BioArkiveIncMember__OkMddmPKES0gb3KLXJAbw" decimals="0" format="ixt-sec:numwordsen" name="imrx:NumberOfLeasesObligationsAssumed" scale="0" id="Narr_i1F4xqNJ60Op1V_EeVScEw">three</ix:nonFraction> leases in San Diego, California, one is for <ix:nonFraction unitRef="Unit_Standard_sqft_pKK1i40-n0WN8q6DXkNohQ" contextRef="As_Of_12_31_2021_us-gaap_BusinessAcquisitionAxis_imrx_BioArkiveIncMember_us-gaap_LeaseContractualTermAxis_imrx_LeaseTerminationOnApril302032Member_dW7b99b4G0eqpEl5CucuWA" decimals="INF" format="ixt:numdotdecimal" name="imrx:AreaOfPropertyUnderLease" scale="0" id="Narr_RS2xxMtiTEWudvbzx6NtGQ">38,613</ix:nonFraction> square feet of office and laboratory space, under a lease that terminates on April 30, 2032, a second is a <ix:nonFraction unitRef="Unit_Standard_sqft_pKK1i40-n0WN8q6DXkNohQ" contextRef="As_Of_12_31_2021_us-gaap_BusinessAcquisitionAxis_imrx_BioArkiveIncMember_us-gaap_LeaseContractualTermAxis_imrx_LeaseTerminationOnDecember312022Member_dRAvJgmyQ02SlSKbOR13YQ" decimals="INF" format="ixt:numdotdecimal" name="imrx:AreaOfPropertyUnderLease" scale="0" id="Narr_2FYnqWIo_06vZ0Rv3-llLw">6,100</ix:nonFraction> square feet of office and laboratory space under a lease that terminates on December 31, 2022, and third is a lease for <ix:nonFraction unitRef="Unit_Standard_sqft_pKK1i40-n0WN8q6DXkNohQ" contextRef="As_Of_12_31_2021_us-gaap_BusinessAcquisitionAxis_imrx_BioArkiveIncMember_us-gaap_LeaseContractualTermAxis_imrx_LeaseTerminationOnMarch312024Member_Foc4ig67vEu40iyOKMsf_Q" decimals="INF" format="ixt:numdotdecimal" name="imrx:AreaOfPropertyUnderLease" scale="0" id="Narr_RSjgM-kJKkWDFMKTUpINIg">4,760</ix:nonFraction> square feet of office and laboratory space under a lease that terminates on March 31, 2024. &#160;As a result, we recorded right-to-use assets and <span style="-sec-ix-hidden:Hidden_CeuFDcEWwUiE1feAvMT7Lw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">lease liabilities</span></span> of $<ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="As_Of_12_31_2021_us-gaap_BusinessAcquisitionAxis_imrx_BioArkiveIncMember__OkMddmPKES0gb3KLXJAbw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="0" id="Narr_JmDtiUueDEOL6UAQ0YOI8w">4,824,700</ix:nonFraction> on the acquisition date of December 22, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-size:9.5pt;">Future minimum lease payments for operating leases with initial or remaining terms in excess of one year at December&#160;31, 2021 were as follows</span></p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="Tb_pgE3yVXIqkOJKKpiB54Hyg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amount</b></p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_imrx_OfficeLeaseInSanDiegoCalifornia2020Member_1elFJvUqZUChk73Bzb2TRg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="0" id="Tc_f2XpdHmqjUWq7RwCbGPIhg_2_3">659,990</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_imrx_OfficeLeaseInSanDiegoCalifornia2020Member_1elFJvUqZUChk73Bzb2TRg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="0" id="Tc_E0kYZB2kaUGiKXE9YhdVMg_3_3">880,121</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_imrx_OfficeLeaseInSanDiegoCalifornia2020Member_1elFJvUqZUChk73Bzb2TRg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="0" id="Tc_9tlr6R7r4EqhC_WKfnpfUQ_4_3">894,044</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_imrx_OfficeLeaseInSanDiegoCalifornia2020Member_1elFJvUqZUChk73Bzb2TRg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" scale="0" id="Tc_8mZhuc_ykEuajdcQDsSppw_5_3">906,839</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_imrx_OfficeLeaseInSanDiegoCalifornia2020Member_1elFJvUqZUChk73Bzb2TRg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" scale="0" id="Tc_M0eyLCb8Y0mv0W0FUTNqXg_6_3">819,210</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Thereafter</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_imrx_OfficeLeaseInSanDiegoCalifornia2020Member_1elFJvUqZUChk73Bzb2TRg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" scale="0" id="Tc_1v-qnUAJKEaNArqcFy9Z-w_7_3">4,467,246</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total future lease payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_imrx_OfficeLeaseInSanDiegoCalifornia2020Member_1elFJvUqZUChk73Bzb2TRg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="0" id="Tc_G_7RNOv04UulSWY_dDlZgQ_8_3">8,627,450</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Less: Imputed interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_imrx_OfficeLeaseInSanDiegoCalifornia2020Member_1elFJvUqZUChk73Bzb2TRg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="0" id="Tc_DFlbirDb9UGSCHh_Rtn-dg_9_3">3,262,514</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_imrx_OfficeLeaseInSanDiegoCalifornia2020Member_1elFJvUqZUChk73Bzb2TRg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="0" id="Tc_AfW5VAGILEazatPe3s5lsQ_10_3">5,364,936</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Current portion lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_imrx_OfficeLeaseInSanDiegoCalifornia2020Member_1elFJvUqZUChk73Bzb2TRg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="0" id="Tc_ADQaU76vpUKFaxzBoq9Z2w_11_3">274,039</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Lease liabilities, noncurrent</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_imrx_OfficeLeaseInSanDiegoCalifornia2020Member_1elFJvUqZUChk73Bzb2TRg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="0" id="Tc_UIe-4C6nzEK2bE5w-ZI33g_12_3">5,090,897</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_imrx_OfficeLeaseInSanDiegoCalifornia2020Member_1elFJvUqZUChk73Bzb2TRg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="0" id="Tc_iYuVdqY0WUyJWA-tHFpbtQ_13_3">5,364,936</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">155</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc__QAHvEGHK0-lWiBW_liTbQ_1_2"></a><a id="Tc_m6QUZPqoEUeBOyj_1JKT6w_1_5"></a><a id="Tc_gG1y4Y9sF0mf5TkvOubScA_2_2"></a><a id="Tc_MdyizdkD_U-8jD6KACnUjA_2_5"></a><a id="Tc_EujG4wEqgE6QP3yZbGaAoQ_3_0"></a><a id="Tc_y4eNbXnSbkqMcNqarsT60g_4_0"></a><a id="Tc_PZjqjoLDw0egoQogeUP3cQ_4_2"></a><a id="Tc_3c-mCU_ldE-fJtWy3bLC-g_4_5"></a><a id="Tc_C_EIDojMVkGrtrxIWm30ig_5_0"></a><a id="Tc_lSfkRLC4YEKTQnpC6rWqjw_6_0"></a><a id="Tc_7rKCiYaZKkWQLjfTSwtA9w_6_3"></a><a id="Tc_6W3PyFrhL02Ahytxy9XDtA_7_0"></a><a id="Tc_CPwJnLTYbkK_hoqXTf77EQ_7_2"></a><a id="Tc_psCiwi7SG0aLM6K6WUznlw_7_5"></a><a id="Tc_4oblYeTtKUayhU5LWcXvOw_8_0"></a><a id="Tc_rQlrMh5fU0GvuMH2SqUiEg_9_0"></a><a id="Tc_XSP7HfeUo0uXgMEZAIIi7A_9_2"></a><a id="Tc_hRcSWSOwDka8TovpdSLYLw_9_5"></a><a id="Tc_FJxrCnd1R0WH4S9XRW0RXw_10_0"></a><a id="Tc_N7GjXMxoSESsVtrxEDIW-g_11_2"></a><a id="Tc_KWJCsv9pH0iaeI4XaKBktg_11_5"></a><a id="Tc_N7Hfole3HUOS4FpeoCSqGg_12_0"></a><a id="Tc_6Pku6JR1sk2SJX3zWrFaMw_12_3"></a><a id="Tc_5X5BB1ylhUaGnhsEmoM92Q_12_6"></a><a id="Tc_7nWe71A9aEeqo9_dBR5xag_13_0"></a><ix:continuation id="Tb_88m9YkHyT0Oz-YgkGlARXg_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Quantitative information regarding the Company&#8217;s leases for the year ended December 31, 2021 and 2020 is as follows: </p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ" name="us-gaap:LeaseCostTableTextBlock" id="Tb_LC4J9-4Btk-X80nIiraQxQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Lease costs:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Operating lease cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseCost" scale="0" id="Tc_JIdEyicJhEi8-Kl49FCUjA_4_3">160,872</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="Duration_1_1_2020_To_12_31_2020_J_O9OcmviUi8EDFgokrY1Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseCost" scale="0" id="Tc_t3EGMJq1U02CK2GU-a6J5g_4_6">66,652</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Short-term lease cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShortTermLeaseCost" scale="0" id="Tc_NBzIQcSDf0WDky9mjEgZeg_5_3">258,357</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="Duration_1_1_2020_To_12_31_2020_J_O9OcmviUi8EDFgokrY1Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShortTermLeaseCost" scale="0" id="Tc_-dWbDS1hW0Omq628nQlIGw_5_6">252,796</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Variable lease cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="Duration_1_1_2020_To_12_31_2020_J_O9OcmviUi8EDFgokrY1Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:VariableLeaseCost" scale="0" id="Tc_FqebeqLbk0S3wJeBaiYmTg_6_6">14,700</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total lease costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LeaseCost" scale="0" id="Tc_GpitQWsm9EuRoKtENIR4sA_7_3">419,229</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="Duration_1_1_2020_To_12_31_2020_J_O9OcmviUi8EDFgokrY1Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LeaseCost" scale="0" id="Tc_Z2joknlwOUOx_BzrvD2VoA_7_6">334,148</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash paid for amounts included in the measurement of lease liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:73.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Operating cash flows from operating leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasePayments" scale="0" id="Tc_MgzXwkBvd02EDHOIJNqfrw_9_3">111,527</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="Duration_1_1_2020_To_12_31_2020_J_O9OcmviUi8EDFgokrY1Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasePayments" scale="0" id="Tc_FLafa5X5eUyTLwd4138oGQ_9_6">58,666</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Operating cash flows from short-term leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShortTermLeasePayments" scale="0" id="Tc_88pTjSGRokKjLb32_DNftA_10_3">236,700</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="Duration_1_1_2020_To_12_31_2020_J_O9OcmviUi8EDFgokrY1Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShortTermLeasePayments" scale="0" id="Tc_AvyNaCToDUagX151bPuBfg_10_6">252,796</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ" decimals="0" format="ixt:numdotdecimal" name="imrx:LeasePayments" scale="0" id="Tc_3zSyEbtO1EK3Gtt04L8Fbw_11_3">348,227</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow" contextRef="Duration_1_1_2020_To_12_31_2020_J_O9OcmviUi8EDFgokrY1Q" decimals="0" format="ixt:numdotdecimal" name="imrx:LeasePayments" scale="0" id="Tc_c_6CyXgcSEqSSRBmIDarZg_11_6">311,462</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted-average remaining lease term - operating leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="As_Of_12_31_2021_TBpjtOXgEkKQahJJAv0aWg" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="Narr_jvYRNY5DHkqsWIoNbDSfFA">9.62</ix:nonNumeric> years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="As_Of_12_31_2020_OUSLyqWONEO8ccGPC6rBdg" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="Narr_7dioStN-tE-042StHmRLPw">5.33</ix:nonNumeric> years</p></td></tr><tr><td style="vertical-align:bottom;width:73.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted-average discount rate - operating leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_iothMaWWqUCV2N7d1PVg4w" contextRef="As_Of_12_31_2021_TBpjtOXgEkKQahJJAv0aWg" decimals="3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="Tc_wACpKkMlikaSR2htRi9lfw_13_3">9.7</ix:nonFraction>%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_iothMaWWqUCV2N7d1PVg4w" contextRef="As_Of_12_31_2020_OUSLyqWONEO8ccGPC6rBdg" decimals="3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="Tc_fi_hNk1qNUiM1ZlYfwoWpg_13_6">6.0</ix:nonFraction>%</p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As the Company&#8217;s leases typically do not provide an implicit rate, the Company uses an estimate of its incremental borrowing rate based on the information available at the lease commencement date in determining the present value of lease payments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;">Litigation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">From time to time, the Company may have certain contingent liabilities that arise in the ordinary course of its business activities and may be exposed to litigation in connection with its products and operations. The Company&#8217;s policy is to assess the likelihood of any adverse judgments or outcomes related to legal matters, as well as ranges of probable losses. When it is probable that future expenditures will be made and can be reasonably estimated the Company will accrue a liability for such matters. Significant judgement is required to determine both probability and estimated amount. The Company is not aware of any material legal matters.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;">Clinical Research Contracts</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company may enter into contracts in the normal course of business with clinical research organizations for clinical trials, with contract manufacturing organizations for clinical supplies, and with other vendors for preclinical studies, supplies and other services for our operating purposes. These contracts generally provide for termination with a 30-day notice.</p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">156</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_5ca00e35_a085_444c_ba6b_ae32a7d43fb8"></a><a id="Item_09"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:45pt;text-indent:-45pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item 9. Changes in and Disagreements</b><b style="font-weight:bold;"> With Accountants on Accounting and Financial Disclosure</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">None.</p><a id="_8f774e19_678e_449a_b5d8_ee5a0d71a62e"></a><a id="Item_09A"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;9A. Controls and Procedures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Evaluation of Disclosure Controls and Procedures</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our management, with the participation of our President and Chief Executive Officer and our Chief Financial Officer (our principal executive officer and principal financial and accounting officer, respectively), evaluated the effectiveness of our disclosure controls and procedures as of December&#160;31, 2021. The term &#8220;disclosure controls and procedures,&#8221; as defined in Rules&#160;13a-15(e)&#160;and 15d-15(e)&#160;under the Exchange Act, means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s rules&#160;and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company&#8217;s management, including its principal executive and principal financial officers, as appropriate to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on the evaluation of our disclosure controls and procedures as of December&#160;31, 2021, our President and Chief Executive Officer and our Chief Financial Officer concluded that, as of such date, our disclosure controls and procedures were effective at the reasonable assurance level. As permitted by related SEC staff interpretive guidance for newly acquired businesses, the internal control over financial reporting of BioArkive, Inc. was excluded from the evaluation of the effectiveness of our disclosure controls and procedures as of December 31, 2021. BioArkive, Inc., which we acquired in December 2021, represented less than 1% of our consolidated total assets, as of December 31, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Management&#8217;s Annual Report on Internal Control over Financial Reporting</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">This Annual Report on Form 10-K does not include a report of management&#8217;s assessment regarding our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) or an attestation report of our independent registered accounting firm due to a transition period established by rules of the SEC for newly public companies. Additionally, our independent registered accounting firm will not be required to opine on the effectiveness of our internal control over financial reporting pursuant to Section 404 for so long as we remain an &#8220;emerging growth company&#8221; as defined in the JOBS Act.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Changes in Internal Control over Financial Reporting</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">There were no changes in our internal control over financial reporting (as defined in Rules&#160;13a-15(f)&#160;and 15d-15(f)&#160;under the Exchange Act) that occurred during fourth quarter of 2021 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. As noted above, we acquired BioArkive, Inc. in December 2021, We are in the process of reviewing the internal control structure of BioArkive, Inc. and, if necessary, will make appropriate changes as we continue to integrate BioArkive, Inc. into our overall internal control over financial reporting process.</p><a id="_58570f65_c6da_491f_a78c_df6f1ce55b7b"></a><a id="Item_09B"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;9B. Other Information</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">None.</p><a id="_faf7c2ca_afad_47bd_9e2b_d835ab7c7aa0"></a><a id="_Item_9C._Disclosure"></a><a id="Item9CDisclosureRegardingForeignJurisdic"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Not applicable. </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">157</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><a id="_3a6bb5a0_5107_4c3a_87ee_f893ab91ff2e"></a><a id="PARTIII_197185"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">PART III</b></p><a id="Item_10"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item 10. </b><b style="font-weight:bold;">Directors, Executive Officers and Corporate Governance</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The information required by this Item 10 will be included in our Definitive Proxy Statement to be filed with the SEC with respect to our 2022 Annual Meeting of Stockholders and is incorporated herein by reference.</p><a id="_02a264bc_d4d9_410b_93cb_52cc306e6339"></a><a id="_Hlk92692797"></a><a id="Item11"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item 11</b><b style="font-weight:bold;">. Executive Compensation</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The information required by this Item 11 will be included in our Definitive Proxy Statement to be filed with the SEC with respect to our 2022 Annual Meeting of Stockholders and is incorporated herein by reference.</p><a id="_3bdeb1fa_f0d7_4e72_9952_3b7b41c82905"></a><a id="Item_12"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The information required by this Item 12, including information regarding securities authorized for issuance under equity compensation plans pursuant to Item5(a), Part II of Form 10-K, will be included in our Definitive Proxy Statement to be filed with the SEC with respect to our 2022 Annual Meeting of Stockholders and is incorporated herein by reference.</p><a id="_00a304d4_8601_4b85_a8fa_3a54edcefc23"></a><a id="ss_012"></a><a id="item13"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item 13.</b><b style="font-weight:bold;"> Certain Relationships and Related Transactions, and Director Independence.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The information required by this Item 13 will be included in our Definitive Proxy Statement to be filed with the SEC with respect to our 2022 Annual Meeting of Stockholders and is incorporated herein by reference.</p><a id="_f6262377_1c06_41cf_b627_9fb4a0b0f8e6"></a><a id="Item_14"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item 14. Principal Accountant Fees and Services</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The information required by this Item 14 will be included in our Definitive Proxy Statement to be filed with the SEC with respect to our 2022 Annual Meeting of Stockholders and is incorporated herein by reference.</p><a id="_1d97ad4e_8987_4ca9_b375_be1bb4bd9523"></a><a id="PARTIV_696219"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">PART IV</p><a id="Item_15"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item 15. Exhibits and Financial Statement Schedules</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(a)&#160;1. Financial Statements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">For a list of the financial statements included herein, see Index to Consolidated Financial Statements in this Annual Report on Form&#160;10-K, incorporated into this Item by reference.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">2. Financial Statement Schedules</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Financial statement schedules have been omitted because they are either not required or not applicable or the information is included in the consolidated financial statements or the notes thereto.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">3. Exhibits</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">See the Exhibit&#160;Index in Item&#160;15(b) below.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">158</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_57f88bbd_4b9f_429e_b845_d73603fe0547"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(b)</b> <b style="font-weight:bold;">EXHIBIT INDEX</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:9.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">op</p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:45.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:6.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:10.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:6.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:11.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:10.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></div></div></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:9.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:45.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th colspan="4" style="font-weight:normal;text-align:left;vertical-align:bottom;width:35.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Incorporated&#160;by&#160;Reference</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:10.03%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Filed/</b></p></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:9.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">Exhibit Number</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:45.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit&#160;Description</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:6.88%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Form</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:10.22%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">File&#160;No.</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:6.94%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:11.66%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Filing</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Date</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Furnished</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Herewith</b></p></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:top;width:9.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:45.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:6.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:10.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:6.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:11.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th></tr><tr><td style="vertical-align:top;width:9.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">2.1</p></td><td style="vertical-align:top;width:45.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9pt;" href="https://www.sec.gov/Archives/edgar/data/1790340/000110465921152368/tm2136034d1_ex2-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Share Purchase Agreement by and among Immuneering Corporation, BioArkive, Inc. and BioArkive&#8217;s shareholders, dated as of December 22, 2021</span></a></p></td><td style="vertical-align:top;width:6.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:top;width:10.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">001-40675</p></td><td style="vertical-align:top;width:6.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">2.1</p></td><td style="vertical-align:top;width:11.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">12/22/2021</p></td><td style="vertical-align:top;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">3.1</p></td><td style="vertical-align:top;width:45.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9pt;" href="https://www.sec.gov/Archives/edgar/data/1790340/000155837021012336/imrx-20210630xex3d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amended and Restated Certificate of Incorporation of Immuneering Corporation</span></a></p></td><td style="vertical-align:top;width:6.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">10-Q</p></td><td style="vertical-align:top;width:10.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">001-40675</p></td><td style="vertical-align:top;width:6.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">3.1</p></td><td style="vertical-align:top;width:11.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">09/09/2021</p></td><td style="vertical-align:top;width:10.03%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:9.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">3.2</p></td><td style="vertical-align:top;width:45.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9pt;" href="https://www.sec.gov/Archives/edgar/data/1790340/000155837021012336/imrx-20210630xex3d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amended and Restated Bylaws of Immuneering Corporation</span></a></p></td><td style="vertical-align:top;width:6.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">10-Q</p></td><td style="vertical-align:top;width:10.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">001-40675</p></td><td style="vertical-align:top;width:6.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">3.2</p></td><td style="vertical-align:top;width:11.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">09/09/2021</p></td><td style="vertical-align:top;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">4.1</p></td><td style="vertical-align:top;width:45.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9pt;" href="https://www.sec.gov/Archives/edgar/data/0001790340/000110465921095557/tm2115679d11_ex4-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Specimen Stock Certificate</span></a></p></td><td style="vertical-align:top;width:6.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">S-1/A</p></td><td style="vertical-align:top;width:10.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">333-257791</p></td><td style="vertical-align:top;width:6.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">4.1</p></td><td style="vertical-align:top;width:11.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">07/26/2021</p></td><td style="vertical-align:top;width:10.03%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:9.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">4.2</p></td><td style="vertical-align:top;width:45.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9pt;" href="https://www.sec.gov/Archives/edgar/data/1790340/000110465921090635/tm2115679d7_ex10-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amended and Restated Investors&#8217; Rights Agreement, dated December 21, 2020, by and among the Registrant and the other parties thereto.</span></a></p></td><td style="vertical-align:top;width:6.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">S-1/A</p></td><td style="vertical-align:top;width:10.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">333-257791</p></td><td style="vertical-align:top;width:6.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">4.2</p></td><td style="vertical-align:top;width:11.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">07/26/2021</p></td><td style="vertical-align:top;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">4.3</p></td><td style="vertical-align:top;width:45.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9pt;" href="imrx-20211231xex4d3.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Description of Securities</span></a></p></td><td style="vertical-align:top;width:6.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:11.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">*</p></td></tr><tr><td style="vertical-align:top;width:9.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">10.1&#8224;</p></td><td style="vertical-align:top;width:45.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9pt;" href="https://www.sec.gov/Archives/edgar/data/1790340/000110465921095557/tm2115679d11_ex10-5.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Employment </span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Agreement, dated July 23, 2021, by and between Biren Amin and Immuneering Corporation</span></a></p></td><td style="vertical-align:top;width:6.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">S-1/A</p></td><td style="vertical-align:top;width:10.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">333-257791</p></td><td style="vertical-align:top;width:6.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">10.5</p></td><td style="vertical-align:top;width:11.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">07/26/2021</p></td><td style="vertical-align:top;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">10.2&#8224;</p></td><td style="vertical-align:top;width:45.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9pt;" href="https://www.sec.gov/Archives/edgar/data/1790340/000110465921095557/tm2115679d11_ex10-6.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">E</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">mployment</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;"> </span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Agreement, dated July 23, 2021, by and between Brett Hall, Ph.D. and Immuneering Corporation</span></a></p></td><td style="vertical-align:top;width:6.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">S-1/A</p></td><td style="vertical-align:top;width:10.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">333-257791</p></td><td style="vertical-align:top;width:6.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">10.6</p></td><td style="vertical-align:top;width:11.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">07/26/2021</p></td><td style="vertical-align:top;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">10.3&#8224;</p></td><td style="vertical-align:top;width:45.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9pt;" href="https://www.sec.gov/Archives/edgar/data/1790340/000110465921095557/tm2115679d11_ex10-7.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">E</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">mployment</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;"> </span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Agreement, dated July 23, 2021, by and between Scott Barrett, M.D. and Immuneering Corporation</span></a></p></td><td style="vertical-align:top;width:6.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">S-1/A</p></td><td style="vertical-align:top;width:10.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">333-257791</p></td><td style="vertical-align:top;width:6.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">10.7</p></td><td style="vertical-align:top;width:11.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">07/26/2021</p></td><td style="vertical-align:top;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">10.4&#8224;</p></td><td style="vertical-align:top;width:45.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9pt;" href="https://www.sec.gov/Archives/edgar/data/1790340/000110465921095557/tm2115679d11_ex10-8.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">E</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">mployment</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;"> </span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Agreement, dated July 23, 2021, by and between Benjamin J. Zeskind, Ph.D. and Immuneering Corporation</span></a></p></td><td style="vertical-align:top;width:6.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">S-1/A</p></td><td style="vertical-align:top;width:10.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">333-257791</p></td><td style="vertical-align:top;width:6.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">10.8</p></td><td style="vertical-align:top;width:11.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">07/26/2021</p></td><td style="vertical-align:top;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">10.5&#8224;</p></td><td style="vertical-align:top;width:45.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9pt;" href="https://www.sec.gov/Archives/edgar/data/1790340/000110465921095557/tm2115679d11_ex10-9.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">E</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">mployment Agreement, dated July 23, 2021, by and between Michael D. Bookman and Immuneering Corporation</span></a></p></td><td style="vertical-align:top;width:6.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">S-1/A</p></td><td style="vertical-align:top;width:10.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">333-257791</p></td><td style="vertical-align:top;width:6.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">10.9</p></td><td style="vertical-align:top;width:11.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">07/26/2021</p></td><td style="vertical-align:top;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">10.6&#8224;</p></td><td style="vertical-align:top;width:45.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9pt;" href="https://www.sec.gov/Archives/edgar/data/1790340/000110465921090635/tm2115679d7_ex10-4.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Immuneering Corporation 2008 Stock Incentive Plan and form of option agreement thereunder.</span></a></p></td><td style="vertical-align:top;width:6.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">S-1</p></td><td style="vertical-align:top;width:10.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">333-257791</p></td><td style="vertical-align:top;width:6.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">10.4</p></td><td style="vertical-align:top;width:11.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">07/09/2021</p></td><td style="vertical-align:top;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">10.7&#8224;</p></td><td style="vertical-align:top;width:45.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9pt;" href="https://www.sec.gov/Archives/edgar/data/1790340/000110465921090635/tm2115679d7_ex10-5.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Immuneering Corporation Long Term Incentive Plan and form of option agreement thereunder.</span></a></p></td><td style="vertical-align:top;width:6.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">S-1</p></td><td style="vertical-align:top;width:10.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">333-257791</p></td><td style="vertical-align:top;width:6.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">10.5</p></td><td style="vertical-align:top;width:11.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">07/09/2021</p></td><td style="vertical-align:top;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">10.8&#8224;</p></td><td style="vertical-align:top;width:45.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9pt;" href="https://www.sec.gov/Archives/edgar/data/1790340/000110465921095557/tm2115679d11_ex10-10.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Immuneering Corporation 2021 Incentive Award Plan and forms of award agreements thereunder.</span></a></p></td><td style="vertical-align:top;width:6.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">S-1/A</p></td><td style="vertical-align:top;width:10.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">333-257791</p></td><td style="vertical-align:top;width:6.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">10.10</p></td><td style="vertical-align:top;width:11.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">07/26/2021</p></td><td style="vertical-align:top;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">10.9&#8224;</p></td><td style="vertical-align:top;width:45.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9pt;" href="https://www.sec.gov/Archives/edgar/data/1790340/000110465921095557/tm2115679d11_ex10-11.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Immuneering Corporation 2021 Employee Stock Purchase Plan.</span></a></p></td><td style="vertical-align:top;width:6.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">S-1/A</p></td><td style="vertical-align:top;width:10.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">333-257791</p></td><td style="vertical-align:top;width:6.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">10.11</p></td><td style="vertical-align:top;width:11.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">07/26/2021</p></td><td style="vertical-align:top;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">10.10&#8224;</p></td><td style="vertical-align:top;width:45.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9pt;" href="https://www.sec.gov/Archives/edgar/data/1790340/000110465921095557/tm2115679d11_ex10-12.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Indemnification Agreement by and among the Registrant and its directors and officers.</span></a></p></td><td style="vertical-align:top;width:6.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">S-1/A</p></td><td style="vertical-align:top;width:10.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">333-257791</p></td><td style="vertical-align:top;width:6.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">10.12</p></td><td style="vertical-align:top;width:11.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">07/26/2021</p></td><td style="vertical-align:top;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">10.11&#8224;</p></td><td style="vertical-align:top;width:45.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9pt;" href="https://www.sec.gov/Archives/edgar/data/1790340/000110465921095557/tm2115679d11_ex10-13.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Immuneering Corporation Non-Employee Director Compensation Program.</span></a></p></td><td style="vertical-align:top;width:6.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">S-1/A</p></td><td style="vertical-align:top;width:10.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">333-257791</p></td><td style="vertical-align:top;width:6.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">10.13</p></td><td style="vertical-align:top;width:11.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">07/26/2021</p></td><td style="vertical-align:top;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">10.12</p></td><td style="vertical-align:top;width:45.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9pt;" href="https://www.sec.gov/Archives/edgar/data/1790340/000110465921090635/tm2115679d7_ex10-3.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Advisory Agreement, dated September 17, 2019, by and between PEF LLC and the Registrant.</span></a></p></td><td style="vertical-align:top;width:6.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">S-1</p></td><td style="vertical-align:top;width:10.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">333-257791</p></td><td style="vertical-align:top;width:6.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">10.3</p></td><td style="vertical-align:top;width:11.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">07/09/2021</p></td><td style="vertical-align:top;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">10.13</p></td><td style="vertical-align:top;width:45.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9pt;" href="https://www.sec.gov/Archives/edgar/data/1790340/000110465921090635/tm2115679d7_ex10-2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Master Services Agreement, dated August 5, 2019, by and between Bioarkive LLC and the Registrant.</span></a></p></td><td style="vertical-align:top;width:6.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">S-1</p></td><td style="vertical-align:top;width:10.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">333-257791</p></td><td style="vertical-align:top;width:6.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">10.2</p></td><td style="vertical-align:top;width:11.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">07/09/2021</p></td><td style="vertical-align:top;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">10.14</p></td><td style="vertical-align:top;width:45.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9pt;" href="https://www.sec.gov/Archives/edgar/data/1790340/000110465921152368/tm2136034d1_ex10-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Lease Agreement, by and between BioArkive, Inc. and Thornmint 13, LLC, dated as of July 22, 2021</span></a></p></td><td style="vertical-align:top;width:6.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:top;width:10.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">001-40675</p></td><td style="vertical-align:top;width:6.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">10.1</p></td><td style="vertical-align:top;width:11.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">12/22/2021</p></td><td style="vertical-align:top;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">21.1</p></td><td style="vertical-align:top;width:45.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9pt;" href="imrx-20211231xex21d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Subsidiaries of Immuneering Corporation</span></a></p></td><td style="vertical-align:top;width:6.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:11.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">*</p></td></tr><tr><td style="vertical-align:top;width:9.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">23.1</p></td><td style="vertical-align:top;width:45.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9pt;" href="imrx-20211231xex23d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Consent of RSM US, LLP, Independent Registered Pubic Accounting Firm</span></a></p></td><td style="vertical-align:top;width:6.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:11.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">*</p></td></tr><tr><td style="vertical-align:top;width:9.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">31.1</p></td><td style="vertical-align:top;width:45.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9pt;" href="imrx-20211231xex31d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certification of Chief Executive Officer pursuant to Rule 13a-14(a)/15d-14(a).</span></a></p></td><td style="vertical-align:top;width:6.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:11.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">*</p></td></tr><tr><td style="vertical-align:top;width:9.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">31.2</p></td><td style="vertical-align:top;width:45.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9pt;" href="imrx-20211231xex31d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certification of Chief Financial Officer pursuant to Rule 13a-14(a)/15d-14(a).</span></a></p></td><td style="vertical-align:top;width:6.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:11.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">*</p></td></tr><tr><td style="vertical-align:top;width:9.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">32.1</p></td><td style="vertical-align:top;width:45.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9pt;" href="imrx-20211231xex32d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350.</span></a></p></td><td style="vertical-align:top;width:6.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:11.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">**</p></td></tr><tr><td style="vertical-align:top;width:9.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">32.2</p></td><td style="vertical-align:top;width:45.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9pt;" href="imrx-20211231xex32d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350.</span></a></p></td><td style="vertical-align:top;width:6.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:11.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">**</p></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">159</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:9.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">op</p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:45.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:6.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:10.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:6.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:11.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:10.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></div></div></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:9.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:45.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th colspan="4" style="font-weight:normal;text-align:left;vertical-align:bottom;width:35.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Incorporated&#160;by&#160;Reference</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:10.03%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Filed/</b></p></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:9.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">Exhibit Number</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:45.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit&#160;Description</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:6.88%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Form</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:10.22%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">File&#160;No.</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:6.94%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:11.66%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Filing</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Date</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Furnished</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Herewith</b></p></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:top;width:9.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:45.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:6.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:10.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:6.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:11.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th></tr><tr><td style="vertical-align:top;width:9.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">101.INS</p></td><td style="vertical-align:top;width:45.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Inline XBRL Instance Document &#8211; the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.</p></td><td style="vertical-align:top;width:6.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:11.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">*</p></td></tr><tr><td style="vertical-align:top;width:9.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">101.SCH</p></td><td style="vertical-align:top;width:45.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Inline XBRL Taxonomy Extension Schema Document.</p></td><td style="vertical-align:top;width:6.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:11.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">*</p></td></tr><tr><td style="vertical-align:top;width:9.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">101.CAL</p></td><td style="vertical-align:top;width:45.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Inline XBRL Taxonomy Extension Calculation Linkbase Document.</p></td><td style="vertical-align:top;width:6.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:11.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">*</p></td></tr><tr><td style="vertical-align:top;width:9.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">101.DEF</p></td><td style="vertical-align:top;width:45.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Inline XBRL Taxonomy Extension Definition Linkbase Document.</p></td><td style="vertical-align:top;width:6.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:11.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">*</p></td></tr><tr><td style="vertical-align:top;width:9.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">101.LAB</p></td><td style="vertical-align:top;width:45.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Inline XBRL Taxonomy Extension Label Linkbase Document.</p></td><td style="vertical-align:top;width:6.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:11.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">*</p></td></tr><tr><td style="vertical-align:top;width:9.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">101.PRE</p></td><td style="vertical-align:top;width:45.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Inline XBRL Taxonomy Extension Presentation Linkbase Document.</p></td><td style="vertical-align:top;width:6.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:11.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">*</p></td></tr><tr><td style="vertical-align:top;width:9.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">104</p></td><td style="vertical-align:top;width:45.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)</p></td><td style="vertical-align:top;width:6.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:11.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">*</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">*</span></span> &#160;Filed herewith.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">**</span></span> &#160;Furnished herewith.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8224;</span></span> &#160;Indicates a management contract or compensatory plan or arrangement.</p><a id="_7b302a0f_e361_4ead_9867_67a5fb7dd97d"></a><a id="Item_16"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item 16. Form 10-K Summary</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">None.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">160</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_5d13d83f_3bed_489f_bc05_6e89f947efb6"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">SIGNATURES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, duly authorized.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:43.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:6.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:49.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:43.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:56.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">IMMUNEERING CORPORATION</b></p></td></tr><tr style="height:12pt;"><td style="vertical-align:middle;width:43.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 0pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:6.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:49.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:43.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: March 10, 2022</p></td><td style="vertical-align:top;width:6.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:top;width:49.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Benjamin J. Zeskind</p></td></tr><tr><td style="vertical-align:top;width:43.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="vertical-align:bottom;width:49.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Benjamin J. Zeskind, Ph.D.</p></td></tr><tr><td style="vertical-align:top;width:43.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:bottom;width:49.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Co-Founder, President, Chief Executive Officer and Director (Principal Executive Officer)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:43.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49.57%;margin:0pt;padding:0pt;"></td></tr><tr style="height:12pt;"><td style="vertical-align:middle;width:43.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:6.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:49.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:12pt;"><td style="vertical-align:middle;width:43.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:12pt;"><td style="vertical-align:middle;width:43.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:12pt;"><td style="vertical-align:middle;width:43.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:6.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:49.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">POWER OF ATTORNEY</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Each person whose individual signature appears below hereby authorizes and appoints Benjamin J. Zeskind, and Biren Amin and each of them, with full power of substitution and resubstitution and full power to act without the other, as his or her true and lawful attorney-in-fact and agent to act in his or her name, place and stead and to execute in the name and on behalf of each person, individually and in each capacity stated below, and to file any and all amendments to this annual report on Form 10-K and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing, ratifying and confirming all that said attorneys-in-fact and agents or any of them or their or his substitute or substitutes may lawfully do or cause to be done by virtue thereof.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this Report has been signed below by the following persons on behalf of the Registrant in the capacities and on the dates indicated.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">161</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:32.91%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:2.21%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:44.6%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:2.78%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:17.48%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:32.91%;border-bottom:1px solid #000000;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Name</b></p></td><td style="vertical-align:bottom;width:2.21%;border-bottom:1px solid transparent;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"></td><td style="vertical-align:bottom;width:44.6%;border-bottom:1px solid #000000;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Title</b></p></td><td style="vertical-align:bottom;width:2.78%;border-bottom:1px solid transparent;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"></td><td style="vertical-align:bottom;width:17.48%;border-bottom:1px solid #000000;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Date</b></p></td></tr><tr><td style="vertical-align:bottom;width:32.91%;border-top:1px solid #000000;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"></td><td style="vertical-align:bottom;width:2.21%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"></td><td style="vertical-align:bottom;width:44.6%;border-top:1px solid #000000;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"></td><td style="vertical-align:bottom;width:2.78%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"></td><td style="vertical-align:bottom;width:17.48%;border-top:1px solid #000000;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"></td></tr><tr><td style="vertical-align:bottom;width:32.91%;border-bottom:1px solid #000000;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Benjamin J. Zeskind</p></td><td style="vertical-align:bottom;width:2.21%;border-bottom:1px solid transparent;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"></td><td style="vertical-align:bottom;width:44.6%;border-bottom:1px solid transparent;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">President, Chief Executive Officer and Director (Principal Executive Officer)</p></td><td style="vertical-align:bottom;width:2.78%;border-bottom:1px solid transparent;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"></td><td style="vertical-align:bottom;width:17.48%;border-bottom:1px solid transparent;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">March 10, 2022</p></td></tr><tr><td style="vertical-align:bottom;width:32.91%;border-top:1px solid #000000;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Benjamin J. Zeskind, Ph.D.</b></p></td><td style="vertical-align:bottom;width:2.21%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"></td><td style="vertical-align:bottom;width:44.6%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"></td><td style="vertical-align:bottom;width:2.78%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"></td><td style="vertical-align:bottom;width:17.48%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"></td></tr><tr><td style="vertical-align:bottom;width:32.91%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"></td><td style="vertical-align:bottom;width:2.21%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"></td><td style="vertical-align:bottom;width:44.6%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"></td><td style="vertical-align:bottom;width:2.78%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"></td><td style="vertical-align:bottom;width:17.48%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"></td></tr><tr><td style="vertical-align:bottom;width:32.91%;border-bottom:1px solid #000000;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Biren Amin</p></td><td style="vertical-align:bottom;width:2.21%;border-bottom:1px solid transparent;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"></td><td style="vertical-align:bottom;width:44.6%;border-bottom:1px solid transparent;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Financial Officer (Principal Financial and Accounting Officer)</p></td><td style="vertical-align:bottom;width:2.78%;border-bottom:1px solid transparent;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"></td><td style="vertical-align:bottom;width:17.48%;border-bottom:1px solid transparent;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">March 10, 2022</p></td></tr><tr><td style="vertical-align:bottom;width:32.91%;border-top:1px solid #000000;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Biren Amin</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.21%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"></td><td style="vertical-align:bottom;width:44.6%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"></td><td style="vertical-align:bottom;width:2.78%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"></td><td style="vertical-align:bottom;width:17.48%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"></td></tr><tr><td style="vertical-align:bottom;width:32.91%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"></td><td style="vertical-align:bottom;width:2.21%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"></td><td style="vertical-align:bottom;width:44.6%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"></td><td style="vertical-align:bottom;width:2.78%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"></td><td style="vertical-align:bottom;width:17.48%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"></td></tr><tr><td style="vertical-align:bottom;width:32.91%;border-bottom:1px solid #000000;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Ann E. Berman</p></td><td style="vertical-align:bottom;width:2.21%;border-bottom:1px solid transparent;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"></td><td style="vertical-align:bottom;width:44.6%;border-bottom:1px solid transparent;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Director</p></td><td style="vertical-align:bottom;width:2.78%;border-bottom:1px solid transparent;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"></td><td style="vertical-align:bottom;width:17.48%;border-bottom:1px solid transparent;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">March 10, 2022</p></td></tr><tr><td style="vertical-align:bottom;width:32.91%;border-top:1px solid #000000;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Ann E. Berman</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.21%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"></td><td style="vertical-align:bottom;width:44.6%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"></td><td style="vertical-align:bottom;width:2.78%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"></td><td style="vertical-align:bottom;width:17.48%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"></td></tr><tr><td style="vertical-align:bottom;width:32.91%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"></td><td style="vertical-align:bottom;width:2.21%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"></td><td style="vertical-align:bottom;width:44.6%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"></td><td style="vertical-align:bottom;width:2.78%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"></td><td style="vertical-align:bottom;width:17.48%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"></td></tr><tr><td style="vertical-align:bottom;width:32.91%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Robert J. Carpenter</p></td><td style="vertical-align:bottom;width:2.21%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"></td><td style="vertical-align:bottom;width:44.6%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Director</p></td><td style="vertical-align:bottom;width:2.78%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"></td><td style="vertical-align:bottom;width:17.48%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">March 10, 2022</p></td></tr><tr><td style="vertical-align:bottom;width:32.91%;border-top:1px solid #000000;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Robert J. Carpenter</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.21%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"></td><td style="vertical-align:bottom;width:44.6%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"></td><td style="vertical-align:bottom;width:2.78%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"></td><td style="vertical-align:bottom;width:17.48%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"></td></tr><tr><td style="vertical-align:bottom;width:32.91%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"></td><td style="vertical-align:bottom;width:2.21%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"></td><td style="vertical-align:bottom;width:44.6%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"></td><td style="vertical-align:bottom;width:2.78%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"></td><td style="vertical-align:bottom;width:17.48%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"></td></tr><tr><td style="vertical-align:bottom;width:32.91%;border-bottom:1px solid #000000;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Peter Feinberg</p></td><td style="vertical-align:bottom;width:2.21%;border-bottom:1px solid transparent;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"></td><td style="vertical-align:bottom;width:44.6%;border-bottom:1px solid transparent;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Director</p></td><td style="vertical-align:bottom;width:2.78%;border-bottom:1px solid transparent;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"></td><td style="vertical-align:bottom;width:17.48%;border-bottom:1px solid transparent;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">March 10, 2022</p></td></tr><tr><td style="vertical-align:bottom;width:32.91%;border-top:1px solid #000000;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Peter Feinberg</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.21%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"></td><td style="vertical-align:bottom;width:44.6%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"></td><td style="vertical-align:bottom;width:2.78%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"></td><td style="vertical-align:bottom;width:17.48%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"></td></tr><tr><td style="vertical-align:bottom;width:32.91%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"></td><td style="vertical-align:bottom;width:2.21%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"></td><td style="vertical-align:bottom;width:44.6%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"></td><td style="vertical-align:bottom;width:2.78%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"></td><td style="vertical-align:bottom;width:17.48%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"></td></tr><tr><td style="vertical-align:bottom;width:32.91%;border-bottom:1px solid #000000;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Diana F. Hausman, MD</p></td><td style="vertical-align:bottom;width:2.21%;border-bottom:1px solid transparent;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"></td><td style="vertical-align:bottom;width:44.6%;border-bottom:1px solid transparent;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Director</p></td><td style="vertical-align:bottom;width:2.78%;border-bottom:1px solid transparent;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"></td><td style="vertical-align:bottom;width:17.48%;border-bottom:1px solid transparent;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">March 10, 2022</p></td></tr><tr><td style="vertical-align:bottom;width:32.91%;border-top:1px solid #000000;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Diana F. Hausman, MD</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.21%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"></td><td style="vertical-align:bottom;width:44.6%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"></td><td style="vertical-align:bottom;width:2.78%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"></td><td style="vertical-align:bottom;width:17.48%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"></td></tr><tr><td style="vertical-align:bottom;width:32.91%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"></td><td style="vertical-align:bottom;width:2.21%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"></td><td style="vertical-align:bottom;width:44.6%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"></td><td style="vertical-align:bottom;width:2.78%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"></td><td style="vertical-align:bottom;width:17.48%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"></td></tr><tr><td style="vertical-align:bottom;width:32.91%;border-bottom:1px solid #000000;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Laurie B. Keating</p></td><td style="vertical-align:bottom;width:2.21%;border-bottom:1px solid transparent;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"></td><td style="vertical-align:bottom;width:44.6%;border-bottom:1px solid transparent;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Director</p></td><td style="vertical-align:bottom;width:2.78%;border-bottom:1px solid transparent;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"></td><td style="vertical-align:bottom;width:17.48%;border-bottom:1px solid transparent;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">March 10, 2022</p></td></tr><tr><td style="vertical-align:bottom;width:32.91%;border-top:1px solid #000000;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">Laurie B. Keating</b></p></td><td style="vertical-align:bottom;width:2.21%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"></td><td style="vertical-align:bottom;width:44.6%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"></td><td style="vertical-align:bottom;width:2.78%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"></td><td style="vertical-align:bottom;width:17.48%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">162</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:avoid;width:79.3%;border:0;"></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.3
<SEQUENCE>2
<FILENAME>imrx-20211231xex4d3.htm
<DESCRIPTION>EX-4.3
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.11.0.85--><!--Created on: 3/10/2022 12:30:12 AM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Exhibit 4.3</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">DESCRIPTION OF THE REGISTRANT&#8217;S SECURITIES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">REGISTERED PURSUANT TO SECTION 12 OF THE</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">SECURITIES EXCHANGE ACT OF 1934, AS AMENDED</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Immuneering Corporation had one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;). References herein to &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our&#8221; and the &#8220;Company&#8221; refer to Immuneering Corporation and not to any of its subsidiaries.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following description of our securities and certain provisions of our Amended and Restated Certificate of Incorporation (&#8220;Certificate of Incorporation&#8221;) and Amended and Restated Bylaws (&#8220;Bylaws&#8221;) are summaries and are qualified in their entirety by reference to the full text of our Certificate of Incorporation and our Bylaws, each of which has been publicly filed with the Securities and Exchange Commission (the &#8220;SEC&#8221;). &#160;We encourage you to read our Certificate of Incorporation and our Bylaws and the applicable provisions of the Delaware General Corporation Law (the &#8220;DGCL&#8221;) for additional information.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-style:italic;font-weight:bold;">Authorized Capital Stock</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our authorized capital stock consists of 200,000,000 shares of Class A common stock, $0.001 par value per share, 20,000,000 shares of Class B common stock, $0.001 par value per share, and 10,000,000 shares of preferred stock, $0.001 par value per share.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-style:italic;font-weight:bold;">Common Stock</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Class A Common Stock</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The holders of our Class A common stock are entitled to one vote for each share held on all matters submitted to a vote of the stockholders. The holders of our Class A common stock do not have any cumulative voting rights. Holders of our Class A common stock are entitled to receive ratably any dividends declared by our board of directors out of funds legally available for that purpose, subject to any preferential dividend rights of any outstanding preferred stock. Our Class A common stock has no preemptive rights, conversion rights or other subscription rights or redemption or sinking fund provisions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In the event of our liquidation, dissolution or winding up, holders of our Class A common stock will be entitled to share ratably in all assets remaining after payment of all debts and other liabilities and any liquidation preference of any outstanding preferred stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Upon our dissolution or liquidation, after payment in full of all amounts required to be paid to creditors and to the holders of preferred stock having liquidation preferences, if any, the holders of shares of our Class A common stock will be entitled to receive pro rata our remaining assets available for distribution to stockholders after the payment of all of our debts and other liabilities, subject to the prior rights of any preferred stock then outstanding.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Class B Common Stock</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Class B common stock is identical to our Class A common stock in all respects, except that the holders of our Class B common stock are not be entitled to vote on shareholder matters except as required by law. In addition, holders of our Class B common stock do not have the right to convert each share of Class B common stock into one share of Class A common stock at the holder&#8217;s election, unless, as a result of such conversion, the holder and its affiliates would own more than 9.9% of the combined voting power of our outstanding share capital, and subject to certain additional restrictions as more particularly described in our Certificate of Incorporation. Shares of Class B common stock, once converted to shares of Class A common stock, may not be converted back into shares of Class B common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-style:italic;font-weight:bold;">Preferred Stock</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our board of directors has the authority, without further action by our stockholders, to issue up to 10,000,000 shares of preferred stock in one or more series and to fix the rights, preferences, privileges and restrictions thereof. These rights, preferences and privileges could include dividend rights, conversion rights, voting rights, terms of redemption, liquidation preferences, sinking fund terms and the number of shares constituting, or the designation of, such series, any or all of which may be greater than the rights of Class A common stock. The issuance of our preferred stock could adversely affect the voting power of holders of Class A common stock and the likelihood that such holders will receive payments upon our liquidation. In addition, the issuance of preferred stock could have the effect of delaying, deferring or preventing a change in control of our company or other corporate action.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-style:italic;font-weight:bold;">Choice of Forum</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our Certificate of Incorporation and Bylaws provide that, unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware will be the exclusive forum for the following types of actions or proceedings under Delaware statutory or common law: (i) any derivative action or proceeding brought on our behalf; (ii) any action asserting a claim of breach of fiduciary duty owed by any of our directors, officers or stockholders to us or to our stockholders; (iii) any action asserting a claim against us arising pursuant to the DGCL, our Certificate of Incorporation or our Bylaws (as either may be amended from time to time); and (iv) any action asserting a claim against us that is governed by the internal affairs doctrine. As a result, any action brought by any of our stockholders with regard to any of these matters will need to be filed in the Court of Chancery of the State of Delaware and cannot be filed in any other jurisdiction; provided that, the exclusive forum provision will not apply to suits brought to enforce any liability or duty created by the Exchange Act or any other claim for which the federal courts have exclusive jurisdiction; and provided further that, if and only if the Court of Chancery of the State of Delaware dismisses any such action for lack of subject matter jurisdiction, such action may be brought in another state or federal court sitting in the State of Delaware. Our Certificate of Incorporation and Bylaws will also provide that the federal district courts of the United States of America will be the exclusive forum for the resolution of any complaint asserting a cause or causes of action against us or any defendant arising under the Securities Act. Nothing in our Certificate of Incorporation and Bylaws preclude stockholders that assert claims under the Exchange Act from bringing such claims in state or federal court, subject to applicable law.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If any action the subject matter of which is within the scope described above is filed in a court other than a court located within the State of Delaware, or a Foreign Action, in the name of any stockholder, such stockholder shall be deemed to have consented to the personal jurisdiction of the state and federal courts located within the State of Delaware in connection with any action brought in any such court to enforce the applicable provisions of our Certificate of Incorporation and Bylaws and having service of process made upon such stockholder in any such action by service upon such stockholder&#8217;s counsel in the Foreign Action as agent for such stockholder. Although our Certificate of Incorporation and Bylaws will contain the choice of forum provision described above, it is possible that a court could find that such a provision is inapplicable for a particular claim or action or that such provision is unenforceable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">This choice of forum provision may limit a stockholder&#8217;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or any of our directors, officers, other employees or stockholders, which may discourage lawsuits with respect to such claims or make such lawsuits more costly for stockholders, although our stockholders will not be deemed to have waived our compliance with federal securities laws and the rules and regulations thereunder.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-style:italic;font-weight:bold;">Dividends</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Declaration and payment of any dividend will be subject to the discretion of our board of directors. The time and amount of dividends will be dependent upon our business prospects, results of operations, financial condition, cash requirements and availability, debt repayment obligations, capital expenditure needs, contractual restrictions, covenants in the agreements governing our current and future indebtedness, industry trends, the provisions of Delaware law affecting the payment of distributions to stockholders and any other factors our board of directors may consider relevant. We currently intend to retain all available funds and any future earnings to fund the development and growth of our business and to repay indebtedness, and therefore do not anticipate declaring or paying any cash dividends on our common stock in the foreseeable future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-style:italic;font-weight:bold;">Anti-Takeover Provisions</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our Certificate of Incorporation and Bylaws contain provisions that may delay, defer or discourage another party from acquiring control of us. We expect that these provisions, which are summarized below, will discourage coercive takeover practices or inadequate takeover bids. These provisions are also designed to encourage persons seeking to acquire control of us to first negotiate with our board of directors, which we believe may result in an improvement of the terms of any such acquisition in favor of our stockholders. However, they also give our board of directors the power to discourage acquisitions that some stockholders may favor.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Authorized but Unissued Shares</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The authorized but unissued shares of our common stock and our preferred stock are available for future issuance without stockholder approval, subject to any limitations imposed by the listing standards of the Nasdaq Global Market. These additional shares may be used for a variety of corporate finance transactions, acquisitions and employee benefit plans. The existence of authorized but unissued and unreserved common stock and preferred stock could make it more difficult or discourage an attempt to obtain control of us by means of a proxy contest, tender offer, merger or otherwise.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Classified Board of Directors</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our Certificate of Incorporation provides that our board of directors is divided into three classes, with the classes as nearly equal in number as possible and each class serving three-year staggered terms. In all other cases and at any other time, directors may only be removed from our board of directors for cause by the affirmative vote of a majority of the shares entitled to vote. These provisions may have the effect of deferring, delaying or discouraging hostile takeovers, or changes in control of us or our management.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Stockholder Action; Special Meeting of Stockholders</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our Certificate of Incorporation provides that our stockholders are not able to take action by written consent for any matter and may only take action at annual or special meetings. As a result, a holder controlling a majority of our capital stock would not be able to amend our Bylaws or remove directors without holding a meeting of our stockholders called in accordance with our Bylaws, unless previously approved by our board of directors. Our Certificate of Incorporation further provides that special meetings of our stockholders may be called only by the chairman of our board of directors, our chief executive officer, our president or another officer selected by a majority of our board of directors, thus limiting the ability of a stockholder to call a special meeting. These provisions might delay the ability of our stockholders to force consideration of a proposal or for stockholders controlling a majority of our capital stock to take any action, including the removal of directors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Advance Notice Requirements for Stockholder Proposals and Director Nominations</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, our Bylaws establishes an advance notice procedure for stockholder proposals to be brought before an annual meeting of stockholders, including proposed nominations of candidates for election to our board of directors. In order for any matter to be &#8220;properly brought&#8221; before a meeting, a stockholder has to comply with advance notice and duration of ownership requirements and provide us with certain information. Stockholders at an annual meeting may only consider proposals or nominations specified in the notice of meeting or brought before the meeting by or at the direction of our board of directors or by a qualified stockholder of record on the record date for the meeting, who is entitled to vote at the meeting and who has delivered timely written notice in proper form to our secretary of the stockholder&#8217;s intention to bring such business before the meeting. These provisions could have the effect of delaying stockholder actions that are favored by the holders of a majority of our outstanding voting securities until the next stockholder meeting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Amendment of Certificate of Incorporation or Bylaws</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The DGCL provides generally that the affirmative vote of the holders of a majority in voting power of the shares entitled to vote is required to amend a corporation&#8217;s certificate of incorporation, unless a corporation&#8217;s</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">certificate of incorporation requires a greater percentage. Our Bylaws may be amended or repealed by a majority vote of our board of directors or by the affirmative vote of the holders a majority of the votes which all our stockholders would be eligible to cast in an election of directors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Section 203 of the DGCL</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We are subject to Section 203 of the DGCL, which prohibits persons deemed &#8220;interested stockholders&#8221; from engaging in a &#8220;business combination&#8221; with a publicly held Delaware corporation for three years following the date these persons become interested stockholders unless the business combination is, or the transaction in which the person became an interested stockholder was, approved in a prescribed manner or another prescribed exception applies. Generally, an &#8220;interested stockholder&#8221; is a person who, together with affiliates and associates, owns, or within three years prior to the determination of interested stockholder status did own, 15% or more of a corporation&#8217;s voting stock. Generally, a &#8220;business combination&#8221; includes a merger, asset or stock sale, or other transaction resulting in a financial benefit to the interested stockholder. The existence of this provision may have an anti-takeover effect with respect to transactions not approved in advance by the board of directors, such as discouraging takeover attempts that might result in a premium over the market price of our common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-style:italic;font-weight:bold;">Limitations on Liability and Indemnification of Officers and Directors</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our Bylaws provide indemnification for our directors and officers to the fullest extent permitted by the DGCL, along with the right to have expenses incurred in defending proceedings paid in advance of their final disposition. We entered into indemnification agreements with each of our directors and executive officers that may, in some cases, be broader than the specific indemnification and advancement provisions contained under our Bylaws and provided under Delaware law. In addition, as permitted by Delaware law, our Certificate of Incorporation includes provisions that eliminate the personal liability of our directors for monetary damages resulting from breaches of certain fiduciary duties as a director. The effect of this provision is to restrict our rights and the rights of our stockholders to recover monetary damages against a director for breach of fiduciary duties as a director.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers or persons controlling our company pursuant to the foregoing provisions, we have been informed that, in the opinion of the SEC, such indemnification is against public policy as expressed in the Securities Act, and is, therefore, unenforceable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-style:italic;font-weight:bold;">Dissenters&#8217; Rights of Appraisal and Payment</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under the DGCL, with certain exceptions, our stockholders have appraisal rights in connection with a merger or consolidation of Immuneering Corporation. Pursuant to the DGCL, stockholders who properly demand and perfect appraisal rights in connection with such mergers or consolidations will have the right to receive payment of the fair value of their shares as determined by the Delaware Court of Chancery, subject to certain limitations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-style:italic;font-weight:bold;">Stockholders&#8217; Derivative Actions</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under the DGCL, any of our stockholders may bring an action in our name to procure a judgment in our favor, also known as a derivative action, in certain circumstances. Among other things, either the stockholder bringing any such action must be a holder of our shares at the time of the transaction to which the action relates or such stockholder&#8217;s stock must have thereafter devolved by operation of law, and such stockholder must continuously hold shares through the resolution of such action.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-style:italic;font-weight:bold;">Transfer Agent and Registrar</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The transfer agent and registrar for our Class A common stock is American Stock Transfer and Trust Company, LLC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-style:italic;font-weight:bold;">Trading Symbol and Market</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our Class A common stock is listed on the Nasdaq Global Market under the symbol &#8220;IMRX.&#8221;</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>3
<FILENAME>imrx-20211231xex21d1.htm
<DESCRIPTION>EX-21.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.11.0.85--><!--Created on: 3/10/2022 12:30:14 AM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-size:11pt;font-weight:bold;">Exhibit&#160;21.1</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:11pt;font-weight:bold;">Subsidiaries of Immuneering Corporation</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">Immuneering Securities Corporation</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">BioArkive, Inc.</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>4
<FILENAME>imrx-20211231xex23d1.htm
<DESCRIPTION>EX-23.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.11.0.85--><!--Created on: 3/10/2022 12:30:16 AM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Exhibit 23.1</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Consent of Independent Registered Public Accounting Firm</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">We consent to the incorporation by reference in the Registration Statement (No. 333-258416) on Form S-8 of Immuneering Corporation of our report dated March 10, 2022, relating to the consolidated financial statements of Immuneering Corporation and subsidiaries, appearing in this Annual Report on Form 10-K of Immuneering Corporation for the year ended December 31, 2021.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">/s/ RSM US LLP</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Boston, Massachusetts</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">March 10, 2022</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>5
<FILENAME>imrx-20211231xex31d1.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.11.0.85--><!--Created on: 3/10/2022 12:30:19 AM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><b style="font-weight:bold;">Exhibit 31.1 </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:12pt 0pt 0pt 0pt;"><b style="font-weight:bold;">CERTIFICATION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:12pt 0pt 0pt 0pt;">I, Benjamin J. Zeskind, certify that: </p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:6pt;"><font style="font-size:10pt;">1.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:6pt;"><font style="font-size:10pt;">I have reviewed this Annual Report on Form 10-K of Immuneering Corporation; </font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:6pt;"><font style="font-size:10pt;">2.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:6pt;"><font style="font-size:10pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; </font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:6pt;"><font style="font-size:10pt;">3.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:6pt;"><font style="font-size:10pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; </font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:6pt;"><font style="font-size:10pt;">4.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:6pt;"><font style="font-size:10pt;">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have: </font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:6pt;"><font style="font-size:10pt;">(a)</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:6pt;"><font style="font-size:10pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; </font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:6pt;"><font style="font-size:10pt;">(b)</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:6pt;"><font style="font-size:10pt;">Omitted; </font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:6pt;"><font style="font-size:10pt;">(c)</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:6pt;"><font style="font-size:10pt;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and </font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:6pt;"><font style="font-size:10pt;">(d)</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:6pt;"><font style="font-size:10pt;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and </font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:6pt;"><font style="font-size:10pt;">5.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:6pt;"><font style="font-size:10pt;">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions): </font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:6pt;"><font style="font-size:10pt;">(a)</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:6pt;"><font style="font-size:10pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and </font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:6pt;"><font style="font-size:10pt;">(b)</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:6pt;"><font style="font-size:10pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting. </font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:12pt 0pt 0pt 0pt;">Date: March 10, 2022</p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:top;width:51.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:5.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:42.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:51.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td colspan="2" style="vertical-align:top;width:48.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:51.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">By:</p></td><td style="vertical-align:top;width:42.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="white-space:pre-wrap;"> /s/ Benjamin J. Zeskind</font></p></td></tr><tr><td style="vertical-align:top;width:51.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Name:</p></td><td style="vertical-align:top;width:42.42%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Benjamin J. Zeskind, Ph.D</p></td></tr><tr><td style="vertical-align:top;width:51.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Title:</p></td><td style="vertical-align:top;width:42.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Co-Founder, President, Chief Executive Officer and Director (Principal Executive Officer)</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-size:10pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:10.29%;margin-right:10.29%;margin-top:30pt;page-break-after:avoid;width:79.41%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>6
<FILENAME>imrx-20211231xex31d2.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.11.0.85--><!--Created on: 3/10/2022 12:30:22 AM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><b style="font-weight:bold;">Exhibit 31.2 </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:12pt 0pt 0pt 0pt;"><b style="font-weight:bold;">CERTIFICATION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:12pt 0pt 0pt 0pt;">I, Biren Amin, certify that: </p><div style="margin-top:6pt;"></div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">1.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">I have reviewed this Annual Report on Form 10-K of Immuneering Corporation; </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">2.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">3.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">4.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have: </font></td></tr></table><div style="margin-top:6pt;"></div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(a)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(b)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Omitted; </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(c)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(d)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">5.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions): </font></td></tr></table><div style="margin-top:6pt;"></div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(a)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(b)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting. </font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:12pt 0pt 0pt 0pt;">Date: March 10, 2022</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:top;width:51.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="line-height:1;">J.</font></p></div></div></td><td style="vertical-align:top;width:5.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:42.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:51.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td colspan="2" style="vertical-align:top;width:48.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:51.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">By:</p></td><td style="vertical-align:top;width:42.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">/s/ Biren Amin</p></td></tr><tr><td style="vertical-align:top;width:51.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Name:</p></td><td style="vertical-align:top;width:42.41%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Biren Amin</p></td></tr><tr><td style="vertical-align:top;width:51.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Title:</p></td><td style="vertical-align:bottom;width:42.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Chief Financial Officer and Treasurer</p></td></tr><tr><td style="vertical-align:top;width:51.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-size:10pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:42.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">(Principal Financial Officer and Principal Accounting Officer)</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:10.29%;margin-right:10.29%;margin-top:30pt;page-break-after:avoid;width:79.41%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>7
<FILENAME>imrx-20211231xex32d1.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.11.0.85--><!--Created on: 3/10/2022 12:30:24 AM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;line-height:1.19;margin:13.5pt 0pt 0pt 0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><b style="font-weight:bold;">Exhibit 32.1 </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:6pt 0pt 0pt 0pt;"><b style="font-weight:bold;">CERTIFICATION PURSUANT TO</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:6pt 0pt 0pt 0pt;"><b style="font-weight:bold;">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:6pt 0pt 0pt 0pt;"><b style="font-weight:bold;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:12pt 0pt 0pt 0pt;">In connection with the Annual Report on Form 10-K, for the fiscal period ended December 31, 2021 of Immuneering Corporation (the &#8220;Company&#8221;), as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, the undersigned, certify, pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, to the best of my knowledge, that:</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:6pt;"><font style="font-size:10pt;">(1)</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:6pt;"><font style="font-size:10pt;">The Report fully complies with the requirements of Section&#160;13(a) or Section&#160;15(d) of the Securities Exchange Act of 1934; and </font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:6pt;"><font style="font-size:10pt;">(2)</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:6pt;"><font style="font-size:10pt;">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. </font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:12pt 0pt 0pt 0pt;">Date: March 10, 2022 </p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:6.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:43.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:6.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:43.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:6.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">By:</p></td><td style="vertical-align:top;width:43.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">/s/ Benjamin J. Zeskind</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:6.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Name:</p></td><td style="vertical-align:top;width:43.51%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Benjamin J. Zeskind, Ph.D.</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:6.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Title:</p></td><td style="vertical-align:top;width:43.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Co-Founder, President, Chief Executive Officer and Director (Principal Executive Officer)</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:10.29%;margin-right:10.29%;margin-top:30pt;page-break-after:avoid;width:79.41%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>8
<FILENAME>imrx-20211231xex32d2.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.11.0.85--><!--Created on: 3/10/2022 12:30:27 AM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;line-height:1.19;margin:13.5pt 0pt 0pt 0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><b style="font-weight:bold;">Exhibit 32.2 </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:6pt 0pt 0pt 0pt;"><b style="font-weight:bold;">CERTIFICATION PURSUANT TO</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:6pt 0pt 0pt 0pt;"><b style="font-weight:bold;">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:6pt 0pt 0pt 0pt;"><b style="font-weight:bold;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:12pt 0pt 0pt 0pt;">In connection with the Annual Report on Form 10-K, for the fiscal period ended December 31, 2021 of Immuneering Corporation (the &#8220;Company&#8221;), as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, the undersigned, certify, pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, to the best of my knowledge, that:</p><div style="margin-top:6pt;"></div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(1)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">The Report fully complies with the requirements of Section&#160;13(a) or Section&#160;15(d) of the Securities Exchange Act of 1934; and </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(2)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. </font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:12pt 0pt 0pt 0pt;">Date: March 10, 2022 </p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="line-height:1;">J. </font></p></div></div></td><td style="vertical-align:top;width:6.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:43.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:6.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:43.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:6.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">By:</p></td><td style="vertical-align:top;width:43.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">/s/ Biren Amin</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:6.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Name:</p></td><td style="vertical-align:top;width:43.51%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Biren Amin</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:6.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Title:</p></td><td style="vertical-align:bottom;width:43.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Chief Financial Officer and Treasurer</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:6.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-size:10pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:43.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">(Principal Financial Officer and Principal Accounting Officer)</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:10.29%;margin-right:10.29%;margin-top:30pt;page-break-after:avoid;width:79.41%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>imrx-20211231x10k006.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 imrx-20211231x10k006.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %Q H$# 2(  A$! Q$!_\0
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M2]A_/MU[4?:US]T\#/0]/RZ^U52F">1U[G_Z_P"7I2A"2"6()XQN''Z]?4T
M6?M0SC:,].IZ_ET]Z!=J<$*<'/7(Z=>U5=IP""AXSP1C'KU^[[4H0@#DY!_B
M8'^OY4 6?M0_N_S[].U'VL<_+T.._7\NGO5781CD$YZ C/\ /KZ^M&P[3\R]
M,\GC^?W?:@"U]K7!.. ,]^GY4?:A_=]^_?IVJL4.XC/!X)R,C]>OI1L)(Y'Y
MC/7Z_GZT 6?M(X&T9Z=3U_*D^V*5#!3@\]#G'Y=?:JP4C:<KC&>HQ]>O3VH\
ML@8W=#CE@3_/K[T 6C= #)7OCC)Z].U'VH9QM]N_7\JJ["2<$=<C:0,\]N?S
M]:4KU^9.@//3^?3T% %G[6N<;3TW=#T_+K[4?:1G&W]3^':JPC8G&6'&/O#/
M\_O>](4Y'S+T]1S^O3UH M?:ERHQR>!U[=>U'VM<9V\=>_3\NOM541DX.[&/
M<8_GT]/2D*';COG& PSG'KG[WO0!;^U+EAMY4X/7KV[4?:AGI_/MU[56*'!.
MX=,]>/Y]/6C803\R]!Z?X_EZ4 6!>*1D*<8W=#T_+K[4OVH=-HSTZGK^73WJ
MJ(S@?,V>G+#/\_O>]&P\8*D=>" /Y_=]J +0NU(R!U..<CZ]J#=J 20< 9X!
MZ?EU]JK%,9^8<'^(C_'\J3822,G\&&<_GU]30!:-UCC:,].IZ_ET]Z/M:]<<
M=>_0=>U567J=R?=SSC'\_N^U+L.[&?;.1Q]>>OIZ4 6?M2\<>_?\.U'VL9 V
M\YQWZ_ET]ZK!#\O(S]1G^?7UI A(Y8# R,$8/Z_=]J +7VL<_+P/KT'7M2&[
M4$@J>,= 3UZ=O_U56V'+#<.O<C/\^OIZ4>668\D#V8=O3G\_6@"U]I'3:,].
MIZ_ET]Z3[8N?NGINZ'I^77VJL5/7<G3/.,8_/[OM2B,\<D'H<L,_SZ^] %G[
M4.Z_S_#M_P#JH%T".%YSCG/7\NGO578>Q!Y_A('?Z_GZT;,(?F7'!RQX_GT]
M!0!:^UK@G;QU[YQ^77VH^UKDC'(X/7OT[55V'Y@.O3@C/3Z_>]Z7RS@G<.>>
MO'7Z]/7UH L_:AD#;UZ=?\*3[8I4, <$9Z'./RZ^U5@IR#E<>Q&/Y]/2@QD8
M&<\XY(S_ #^][T 6C=J.".<X[]>W:C[4.P[XYS^/:JI0G//&<\$8_GT]?6E*
M8S\RXR/O$?X_E0!8-XH!)4X SP#T_+K[4OVK!QM'YGK^55?+))&3SQPPSG\_
MO>]!0Y'S)TSV_P >GJ* +7VI2P 7D].O;KV__74D4PESQC&#^%4@AR.<<]R.
M_P"/Y>E6+-=N_D'H.#_/WH LT444 4[SF1.O'3]>GO4&.".,8(Z\?_J]:FO!
ME^G5<=2,_P"'UJ _>(VG).0>>W?V^G>@  XQA<;0.O\ GCTI1GY3SG/XYQ_Z
M%[4@Z@\XQGOW_P ].U X51@YQMQN)YQTS_[-0 B@!  %Q@CY3QC_  ]:4C(.
M1W'WC[]_Z4<G!Y/);.".G?'].](.#T((.>YX)_7^E #AD'C/7/'7I_Z%ZBF[
M?9/N$=>,?_$^]!4X*XST7&XC\,_U[TH;<<@GGYN5(Z<9_P#K=Z %.<CKV_G_
M )QZT@'*^N2??O\ KZTA!!'R] ?XCW_Q_2A><#GLO4]O?^O>@ VGR\8'W<8!
MXQ_\3[]:4CYFZ=0>O/'K[^E(20 W/7=GGTZX_P#9:7'!X[>I[G_//:@!<'/?
MO_GZ^M-(_P!F/[F.6XQ_\3[TN"21CL!U/;_/7O0&S\P)QC=]T^G7'_LM #L'
M=W]><9Z?SIJC&,8ZG[I]3S_]?TI#QC(/3;P2>N./_K]J7!/;/..XZ'_/UH "
M,H00N, ?,>,?_$^AI2.6/.<YXZYQ_.DS@G&1_'G!/'K]?]FAQ\C#&>,8W'\L
M_P!>U  ._P!#].O^<^E(!P, ?= Z\?\ ZO2E'WB-I^;IU[?R_K0.-K<_WN_?
MV_IVH .>,]=V>>N<?^A>U &!P!WZ'CK_ "]::,[=N#D#:1DGMTS_ .S4X]3Q
MGG.>1T_ST[T (R_,V0AR%^\??O[>E.Y!)&<YSQC/3^?M33PQZC'/0GK_ #^G
M:E8$#&.<!<;B.<=,_P!: # R.%^Z1P>W^'K2@'(_#K]?\X]:0'<<\\\\@CIW
MQV^G>D^[@D' ZXR>I_7/Z4 *,]ASNSD=<X_]"]J0@[3P.01UXQ_\3[TN#MQ]
M%QD_EG^M-.>3@]=V<GL.N/\ V7OUH <1\SGCDCOS[9_IZTH!R.O7\?\ ]?K2
M$=< ]/?N?\_2D[XP>0%')Z^GM]>]  J_*  F-I'!XQ_\3[TK#/4?Q _-QT_K
MZ4'/!Y_O=#Z=<?TIN<<$$$''&3U/KW^O:@!RCCCCYB?E/US^/K2$95@0I&T#
MD\8_^)]Z7!Z8R<@=2.G^>O>C/)QD9^;.">W7_P"QH 7!W,>>N??\??THQ\Z=
M.,]^>?3^M(1SC';'4]^V?Z]J!\Q'!ZX[\X_P]>] "8X [8QUXQ_\3Z&E;GL/
MOYY/.<?^A>@I.ZM@]=W?TZX_I2\G<N#QP>O?MG^O:@ QCI[]/K_G-!')X7[H
M')_G[>E!&2>,\^I'0_Y^M YPPR!][H?SQ_3M0 O.<\YSGG&<X_\ 0O:D48"X
M"C&?NGW_ ,YI,8 &#TVX#$\^F?\ V:E!+ 'D\YY!'3_/XT *,\?AUZ=?Y>GK
M28.<X_BSQUSC_P!"]J3.W#%3@'<>IZ^W?/IVI2I (QV"XW'TZ9_K0 $'!X'W
M2.O&/\/6EQR/H._O_+TI#RV.>>0>>V.?;Z=Z.ZG!QUZGN?\ /TH <,Y4\YY/
MOT_G3 /D  7&TC@\8_\ B?4TH& HVG)&W&3^6?ZT'/J3R3GD=.^/Z=Z !AG.
M0/O#[QQW[^_I2\[N_7/'7I_/U%- P2,$$?4]3^O]*4J3D;>P7[Q'X9_KWH 3
M ST3[A'7M_\ $^]..=PZ_P"?Z^E-#9.1NZ%L[3Z8SC^GXTK#)'!X!'WCW_G]
M>U  !\R'C.2??\/?UH(^0CCICKQC_P")]^M ^8# /7;CD9Q[_P!>])G"EN>N
M[//IUQZ_[- #B#EN!G(/7GM^OI2\Y[]_Y_YS2$'!&.V,9/?W_KVHP<GY3R/4
M]C_GZT ,51M PF-@'!XQ_P#$^].P>#SUSSUSC_T+VI!T#<]-V=I].N/Z4<K@
M8(XV_>)Z]L_^S=J !1@#&.IQM/OV_K2LN4(.W& /F/&/\/0T$$YZGGW'0_Y^
MM /)X8$?/G!/'K_];M0 ISN)P>N>,9SC_P!"]NE)@XZ#H>_'_P"KUI&!Y&,_
M+MQN(_#/_LU*.6QS\W3.>W\OIWH 7' Z8P._'_ZO2D(Z''.[//7./_0O:C.-
MIP?4]>^>W].U(!E2N#P-I&3Z=,_^S4 4->N)K+PYJES VR:&TFDC8 -M8*2"
M 1R,CG-><KXDUJ#3-.U,>+;+4;BX>$/I0MXA(<GE3M^88/L/Z'TC6K.74M$U
M*RB*B2YMY(D+E@,E2,G .,9Z=ZY1/ TUA9Z1=Z2+.VUS3U02OAA%< C#AB%R
M2>><9'Y8:)=Q_C>?Q%I.S4-/UXP6\MQ%"MM]CC;86&"VXY)/&<8[U7U;6=3\
M(7VAQ:KK8N[:8W)N9!:I'O144J@ S_%GD8)SBM[Q5H=WKVE6UK;F&.5+B*1O
M,D;;A<D@$#GZXYINN>'I-9\0Z#J'[AK6P>:25)0VYB0NTA<8X*YP<=* :9#X
M0U#5->CFUN[NHUL;AMMK91A2(E5L9=@,[N.!G'].H' R.N[/R]<\_P#CWJ*Y
MG0_#]YH&OZBUO)"-%NF\U( S;X9#P=HQ@@_7CCTYZ8J?+*[<YP,9(_#/]>]#
M&A-OR,./NXY/&/\ XGWZTXCEC@=1WY_'W]*;D#>V#_>XR>W7'_LM.YYZ]/?N
M?\_2D,.<@G/<^_\ ^OUIJKB-0,8VXX/&/_B??K2C[P 4Y/R]3V_SU[T=@>3S
MNSR.W7'_ ++0 ./F/ ^\#\QY_P#U^E*!CIZ_P_YZ^M-)QQR#G'<]??\ KVI6
M!YXR21W(Z?Y_&@!"/E(POW0.3QC_ .)]Z=@[CUZY_'W]_04F<G.&'\8.#TQU
M_P#L:3&#C';;]X]^WO\ 7M0 H'*\#OT/OV_K5FR&-_T 'Z]/;TJL/FQUY..X
MZ'_/UJS8Y_>9[X/?G.>?;Z=J +=%%% %*\SOZKPN>1G\_4>U0Y.YAGH0#Q]/
MU]/2K%VS!U"LPX['^7O4.]^?F['^+C_]7K0 WD$<^OZ?U]?6D!S&"&7[F[H<
M?EZ>U.WN?X^P_B_SQZ4H=\#YGS]>>G\Z &X(XR?O8YY/_P"OT-(#D @YR3]T
M8Z'M_7UIP=]H^?UZ-D?_ *O6E,CX/S$<]SC_ #[4 1LV$)++]T'E<C\O3VI^
M"'QD^G7V_G[TH=P?O,?H>?\ ]?M2;WR/F'W?[Q_SCWH :Q/'*]#_  ^G^>?6
M@9"J<C& >G'_ .KT':GEG!!W,?;/^?P]:-[_ "_,>OKS_P#K]: &'/ W8^;'
M3GIZ^OO2\X//J>!QP?Y>OK2[W"YW9R/[W _^M[TI=\M\_<?Q<_\ Z_3UH 8#
M\S<C[H/(_P \>@[4O.[&6]/?I_/WIP=Q_$Q_'_//K2%W_O#[O][_ #Q[T -!
MR1AEY4GA3_G'M1D],GJ/O#/4_P"<>E2;W!'S-^)Y_P#UTT,_]_N>C9[_ .<^
ME "#G."?O8XX/3^?O2$_NV.5^[G)''Y>GM3][[3\V.!U;C_]7O07?YOF;\^?
M_P!= # ?F;GT[>O^>/2E&>/F[D>__P"OU/>G!W_O=,]_\_CZ4@9SCY^P_BX_
M_5Z4 ,!S&"&7[N>!QCZ?W?;K2MP2,X^8#D9//]?3TIYD?'WF'/KST_G[4@=^
M?G)^C<?_ *O6@!""6/)Y.../\GU]::S84DLN-@/*Y'Y>GM3V=]S?..W5CZ_R
M]/6G;W!^\Y_GT_G[4 ,Y#8R>N/\ /O[T#DJ,CDGH,=#_ )SZTXN^1\^..S?Y
MX]:4.^1\QZCJ?\_AZT 1Y(CR2,8!R1Q^7I[4A.6(W '<!TYZ>OK[U)O?!^9N
MO8\__K]J0N^#\QZ?WN/_ -7O0 ASD\\<_H?\Y]:3.3]X<*#]W_/'H*>6?<WS
M]QQN_G_3UH#N,#<Q_'_//K0 WG(&3UQSUZ?S]^E(#D AASG[HQT/\O7UIP=\
M#Y^W9N/_ -7O2F1_[Q'(ZG'^3Z4 ,R=IR>X/S#/?^7IZ4HSR 3][''7./Y^_
M2E5GQ]\]3]UO\\^M+O?!Y[=VX_\ U>] #">,Y'W2>G'_ .KU%*,Y'/H>GKZ_
MT]*=N?).YCSZ_P _?THWOE1N]?XN?\^OI0 S/S*-PSNQTYZ>OK[TI)VYSZGI
MQ_\ J]J4,_'SD_CQ_P#J]Z5G?^\1\WKS_P#K]J &,<$\CJ.H]?\ /'I2X.<9
M/7'^??WIP=P?O$_C_G\:0N^?OCH/XOY^WO0 P'@'<OW-V0IQ_P#J]J=R#@D\
M'^+G_/MZ4X._]Y_7D\]/Y^U =\#Y^YZ-_G\: &CJHR/O$<#GC^OKZTTGY"Q(
M^Z#R./R]/;K4H=_[Q[=3_GCTIN]^N]NO8\__ *_;I0 TYRW/0@=.>?Z^A[4O
M4J,COV]#_G/K3R[C//0>O'_ZO6DW/D?.>W?C_P#5Z4 ,!^53N'W<]./_ -7M
M0<C SSNQSUZ?S]ZDWOQ\S?GS_P#KIH=]H^?MV;C_ /5[T -!)Z-U)^Z,=#_G
M/K03C/*_=!Y7C_\ 5[5PR>)/&%_-K<M@-$6TTV[F@_TGS5=@AXZ'&<8].:TF
M\83GP%%KZQ 74\86& MD-,QV >_/./2G85SJ!G=C+>G7V_G[TA/*_,O*D]/\
M\>OK61X8URXUK2VDNECBOK>22WN8D) 1U/;))VXP<]>:Y_PYXQ\0:]J$<L=O
MITE@TS)-;QS$75LN<!G#$ _@.:+!<[C) '/'!Z<?_J]/2DZG&>=VWIST_G[U
MGZIJ5W#>6>GV.PW=T68/(25B1<;F('4\@;>.3U%11:CJ-IJD-AJ+02BZ5C!<
M0*T:Y4 E&4LQQC)#9['@5/,KFRI2<;_/Y(UB3M;GL3TX_P#U>H[TF>3R.@[>
MI_SCTK!T6^U_5M+MM0-]81K,-QC%HY(YQC/F]?3BGV%]KFIO>O#>64$<%W+;
MHDEH[L0C8R2)1SZ\<4N:Y3H.+:<EIOO_ )&X,Y );TYZ]/Y^]-!R =R_=)X&
M!_\ J]J5&EV+OE4MM&2K$ G_ .)].]/WOQ\S=>YY_P#U^U48#&.T$DXP1U&>
M_P#G'I2C)S@GKCC@_P#Z_>E#O_?/_ 3[]OZT%WVGYAT'5CC_ /5[T ,=L G<
MOW,\KQ_^KVIW.3SR,<=__P!?IZ4XN^3\SGZ'GI_/VZ4%WQ]XCCU_SQZT -&<
MJ,]R.G/']?7UI,_(#D?=SP./R]/;K3][\?.3T_BX_P#U>E!=^/G/7UYZ?S]J
M &$X9AD<,!TYY]_7T/:JE[JECI[8NKN.-B>$W?,>>R]?KQS5;Q1JMYI'AJ]O
MK1=\\:J$4Y(Y=5X]>#^=8^E_9);-+NUD\[S@&:=CN>0XZL>N?;M4RERJYI3I
M\[M<UU\1Z<X)5KD@#&?L$^,_]\]/:G0^(]*FD"?;/*8\ 7"-$3_WV!D^]4Z1
MT61"CJ'4\%6&0:S]KY&[PRZ,Z!3NQA@<D_=&.A_SGUI"2(BQ88P#DKD?EZ>@
MKB[7Q =(O8].LR9H+B[@AB4L2D0+8EP<]%RF!T!;\*[<.^"=[=>QY_\ U^HK
M9;7.5JSL-&?GYYW8P.O3^?O2YZ\]CVXX/\O7UI=[[3\W;^]Q_P#J]Z4N^3\Q
MX[9_G_2@0P-T.X= >!_GCT':CGY<G&6QR.>GKZ^_2G[WX^8C\>?_ -?K2!WV
M#Y\\=FX__5[]: &GID'CD\#CC^GKZTK' ))'4=1GO_G'I3F=\GYCU[MS_P#K
M]*-SY^\W7& ?\\^M #>3D GKCCKT_G[TF3D991\A/W?I^GM3B[[3\P' ZL<?
M_J]Z4,X/WF/.>O\ /WH :,Y'/IU]S_G'I5BQ_P"6O.<''3^?J?>H-[G WD=>
MA]^W]:LVC,=^XYX&.<^O3VH LT444 4[P9D ]1CKUZ_E]:KX^\>?7.#V[X_I
MWJKK=WJD%VJ66E0W<31Y+O=>5@\\$;3D<#OW_&LXZGX@RW_%/6__ (,1D\9_
MYY]>P_PYI70[,VQV.3P,]#WZ_P#ZNU*!\H'/3&,GICIG^M8G]I>(!S_8%L<9
M_P"8CUXS_P \^^<?AVI#J7B!4P/#]JV 1@:@,'I_TSZ'T]J+KN'*^QM#Y@"2
M2>6SM(Y]<?T[TI&T9Y&#Z$]3^O\ 2L0ZGX@!/_%/P'!)S_:(YZ#_ )Y]?3V%
M*-2U_P#Z %L.3TU''\6./W?<<_3WXHNNX<K[&T1P1@GMC)'X9_KWH).>I^[N
M^Z>OK_\ 6K$.HZ^5Q_PC]J<@#!U#(ZX_YY].^/Z\4HU/Q 6&?#\ SCDZD/IG
M_5]1C/T-%UW#E?8VBHR.O ]3WZ_Y[4 8VCGGCOV[9[?7O6(-1U]]I/A^U7C'
M.H#C/_;/VY]<TJZEK^!_Q(+8<+Q_:'3J?^>?0=/Q[T77<.5]C9.< Y.?O9P>
MN.N/_9:7&"PYX.,8)Z]>>_U[5A_VEX@./^*>M^N>=1&?N]?]7USQG^G-+_:7
MB @_\4_;C@\?VB/3./\ 5]^GU]N:+KN'*^QN;<D@@XZ=3SC_ #U[TF2.=Q^[
MN^X>OKC^E8IU'7QN/]@6IXQ_R$.N.?\ GG[X'TI#J?B ,<>'X#C/34ASCO\
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MCX@P/^*?M1\N,?V@/3./]7TSQCU]N:4ZGX@4$C0+=L'/_(1&3QG_ )Y_@/\
M#FE==PY7V-L#!!Y&#GOW_P ].U-QP1SC[N.1QCIG_P!FK$_M+Q O(\/6YP2>
M-0'/T_=]3_3M2G4=?"D?V!:G@C_D(<'';_5].^/:BZ[AROL;9Y#')]<X/YX_
MIWI<<@\],]^YY_SVKG+OQ#J5D)6NM,TZ!$7>S2ZJJ84,!N),?N,$_P ^*I#Q
MNSQ0S"'13'*S+$XUN,AR&PP4[>2,@G'8^O%%T%F=@%Z#!Z;<9/3TS_6FY)4,
M2>?FS@CGUQ_3O6*FI:\P7_B06H& /^0B,=<=H^@ZX_KQ2C4=?.W.@VPY'+:C
MG'O_ *OJ/7W[T77<.5]CCIOAP=3C\0W-W;F#49=1EEL9O,WAD)RH*@D8)/.1
MD?I6C<Z'J_B)-!LKVPETBTM%,EP;2>-=LJ#$8CP3M Y.<=\=16^NI^("!GP]
M;KGD_P#$Q'&>?^>?Y^N:!J7B @?\4];#('!U <<$X/[OH.GU]N:?,NXN1]C,
MT+P_J'AWQ-=+;SW5YIU[;"5[J[<.Z3KD#<."P(/3Z>E8DGAS7M0\16-W+H%I
MIM]!=![C5+2[Q',@+9 CSNRV1R>>QP#QU%WKVL6-NT]QHMND8P,_VCDDD<
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MCX@P<>'[4_+C']H#TSC_ %?3/&/7VYI3J?B ;C_PCT!],:B.< '_ )Y_@/\
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M110 4444 %%%% !5NR_Y:?A_6JE6[+_EI^']:N'Q$3^$MT445N<Y1O/]</\
M=JO5B\_UP_W:KUSRW.F'PH****DH**** "BBB@ HHHH **** "BBB@ HHHH
M**** *.LMLT2^;<%Q YR5W <'MWJ]5+5V*Z/>,KNA$+D-&N6''4#(R:NU;^!
M?/\ 0A?&_E^H4445!84444 %%>;VOBWQ?<>%V\1^1H7V% 6:,^:LA ;:<<XS
M^/\ A71Z[XCN;30K"XTVV234-1:-;:"7)'S#<<X()P,_CBK<&0IIJYTM%<GJ
M'BV6/X>'Q'91Q&X"1YCD!*JY=4<$ @\$GO2^'-9UG4]0"76H>&KBW$99TTZ9
MWE7TX)P!GK2Y7:X<ZO8ZNBBN>UO4I/.:UAWJJD!V"GDGL,?S[=ZJG3=25D4W
M8W1/"SA5E0L21@,,Y'6I*X57D!&!)G) QN'(]\\8]?XJW=.UD_99?M =FC3>
M&$;?,.G3''/;K6U3#.*O'4E3N;;ND>-[JN3@9.,GTH21)%W1NKKTRIR*XVZN
M[B[FWR;]V=H5=P ]@1Q_P/MTI+6\N+6021E^Y(VM@X]L\8]/XNHJOJCMOJ+G
M.UHJ."9;B!)5SAQD9&*DKD:MH:!1112 **** "BBB@ HHJO?7L&GVDES<-MC
M0>HR3Z#WII-NR L45Q)\>MYV!9)Y>[^_SC/\ZM:[XI5=)MWT]R'N0?F[H!U'
MUK;ZM4NDUN!U+31(VUY$5O0L :?7C+2N[,69F8YR2>M=1X2URXCODL)W:2"7
MA-QSL/M[5K4PCC&Z=P.^HHHKC **YWQAK5_HEA8OIJ6SW%U>QVH^TAB@W!N?
ME(/4"LEO%.O:9>:EI^KP::UW#ILE];O:%RGR _*X8YYQVQ^O%*+:N0YI.QW%
M%<-J'BGQ#%X>LM5MK338K=K$7-Q<74A5&<C/E1J&W;CVSUSBIIO'/V/5;<7\
M26MC)I"W[JP)E61FP$'(!],8SGTI\C#G1V=%8OAN^U;4[%K[4[:"UCG(:U@0
M'S%C[%R3@D\< #'XX$VN^(M(\-67VO5[Z*UA)PN_DN?10.2?I4VUL4GI<U**
MY#P_\1-%UZ&6[%S;65F&*0F[N$227'5MF?E7TSR?05H'QQX6WE%U_3W<=5CG
M#G\AFBS"Z-N2=(617W9<X&U"WYX''XTV*[@F*A)5+-G"G@G'7@\UA#QKI<PS
M96^IWQ#;2+;3Y3@_4J!^.:KW&L>(;RXM19Z MF#(0LFI7"C)VMQMCW$<9.<C
MICO51BGH0Y6U.KK)U7Q+I6CR+!=70:[?_5VD*F69_HBY/XXQ5 Z!K.H?\A?Q
M%,L1ZV^F1_9E/U?+/^3"M32M!TK1$9=.L88"_+N!EW/JS'EOQ-3H7J9++XB\
M0':V[0=./7#![R4?496+\-S?2MG2](L-%M/LVGVZPQD[F(R6=N[,QY8GU/-7
MJ*+A8****0PHHHH **** "BBB@ HHHH **** "BBB@ JW9?\M/P_K52K=E_R
MT_#^M7#XB)_"6Z***W.<HWG^N'^[5>K%Y_KA_NU7KGEN=,/A04445)04444
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MN:W*IZLI?1[Q0DCDPN L1PQXZ X/-7*N4G**OY_H1&*C)V\@HHHK,T"BBB@
MHHHH **** "BBFR2)#&TDCJB*,LS'  ]S0 ZL/7/#%GKNHZ9>7 &^QEWXQ]]
M>NT_B ?S]:MIKVDR7'V=-1MC+DKM\P<D=OK6CG(R*JTH[Z":3T8454O=4L-.
M ^V7<,&>@=P">O;\#2V>I66H*3:744V.H1@2/J/QHY96O;09:HHHJ0"BBB@
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M8_F# ]CCK['\J@*E,!@0P# @\$84_P"?Y4*CRG9&I9V4!0.I)Q^OZUM96MT
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MIWQVJ[5+6&VZ+>MN1<0.=SIN4<=Q@Y'MBKM6_@7S_0A?&_E^H4445!84444
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MJWD:@H(COHF^0!3-;[CNXR3M9<]^!CK5JSC:Y#NI7L7:*;&'$:B1E9P!N*C
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MT_#^M7#XB)_"6Z***W.<HWG^N'^[5>HM8,WVM/+N)(QL'"A3W/J#6=_I6?\
MC^G^]G&V/IZ?=Z?K7+.:4FCKA"3BF:U%96;GC_39NN?NI^7W:1?M0QF^G;&>
MJQ\_^.U'/$OV<C6HK)_TKC_3Y^F/NQ_G]VES<X_X_IONXSMCZ^OW>OZ4^>(>
MSD:M%9/^E<_Z?/R,?=CX]_NT-]J.[%].,XQA8^/_ !VCGB'LY&M1643<G/\
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MT"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M^UGKQBE9CNBQ15:TU*QU#?\ 8KVWN=F-_DRJ^W/3.#QT/Y59H:L-.^P4444
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MG6@HI-F516K_ &-_TW_\<_\ KT?V-_TW_P#'/_KU'L*G8OV]/N95%:O]C?\
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M_'/_ *]']C?]-_\ QS_Z]'L*G8/;T^YE45J_V-_TW_\ '/\ Z]']C?\ 3?\
M\<_^O1["IV#V]/N95%:O]C?]-_\ QS_Z]']C?]-__'/_ *]'L*G8/;T^YE45
MJ_V-_P!-_P#QS_Z]']C?]-__ !S_ .O1["IV#V]/N95%:O\ 8W_3?_QS_P"O
M1_8W_3?_ ,<_^O1["IV#V]/N95%:O]C?]-__ !S_ .O1_8W_ $W_ /'/_KT>
MPJ=@]O3[F516K_8W_3?_ ,<_^O1_8W_3?_QS_P"O1["IV#V]/N95%:O]C?\
M3?\ \<_^O1_8W_3?_P <_P#KT>PJ=@]O3[F56KHW_+?_ (#_ %H_L;_IO_XY
M_P#7JU9V?V3?^\W[L=L8Q5TJ4XS3:,ZM6$H-)EJBBBNPX@HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
5HH **** "BBB@ HHHH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>imrx-20211231x10k007.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 imrx-20211231x10k007.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %" V$# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH @N[RWL+<SW4RQ1;@NYO4G 'U)(JO?ZU8:;*L=S*X<KO(CA>38
MO]YMH.U>#R<#@U4\3Z?'>Z46^QK<7$4D9B/E[W3YUR5XR.!V]*J:]?"/4)+)
M;:ZA6> ">]@TZ6=F3+ 1J40C(RQRW3=P#GC.4FG8Z*5*,[;O?]/4WI[RWMK3
M[5+*!!\OS@$CD@#I[D5/6)K=H)?"S6MK#*R8B5(U5@P4.O;J,#\16;=Z'%'>
M7%I:V30V,DUI(R6Z%$+;VWGCV"[OUIN3YK>A,*<91NW;^E_F=;13(88K>%(8
M(TCBC4*B(H"J!T  Z"GU9B%%%% !1110 4444 (2%!)( '))[51;6M/738M0
M%QOMIL")HT9S(3T"JH+,>#T':K5Q;07<#07,,<T+8W1R*&4]^0:YB&9]'\*:
M2#IDKW*-LC'V.27[,<-\Y5%+ 8R.,9W8R <U$I-,VITU->=_\SI+.^M]0MQ/
M;.7CR5.5*LI'4%2 01Z$9IUI=0WUI%=6[[X95#(V",CZ'FJ.A)"NGM)$UR[R
MRM)+)<6[P,[GJ=C $#H!QT'>L'2M%%GI^D3QV#17C6[QW+B,AR/+.%<]>H&
M>G:E*37W#5*+<E>UG_F=E169H&GPZ=HMK%'#Y<C1(TI8?.S[0"6)Y)XQSZ5I
MUH]#&22=D%%%% @HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@"N]];)?Q6+3*+J5&D2+N54@$_3+#\ZJQZ_ILNH"Q2=C,7:-6,+B-G&
M<JLA&QF&#E0<\'TJG/IL<?C;3[Z"R52]K<+/<)%C)S%M#,!UP#C/H:H6=Y#J
M6LPPRVE[9P6UP[6]L-,G1&<;AYCRE @!R2 #WR22<"U&Z7]=0>B.G>ZACNH;
M9WQ-,&:-<'D+C//3N*FK"UC3(M3US3$NK,7-HL4_F+(FZ/D)@,.A[\'T]JSM
M$T8-J%L]Y:2;+2%T@653M3$[[, \9"A=I[ \=:22T_KN)NQUU%%%2,**** "
MBBB@ J*YNK>RMWN+J:.&%!EI)&"J/Q-2T4 8Z^([272+34;>*>=;QMMM"B@2
M2GDX&X@#A2>2.!S5S3=2CU*W>1(I87C<Q2PR@!XW'53@D="#P2.:Q0NLZ5X8
ML[:SL)9;HR%91"T1:)"6)8;W52>@'/&<X.,5IZ%#Y.FE38W=H[.S.MV\;RR,
M>KL49AS]>,8P!BJ:5FT+L&G:_IFJ*HM[N'SS%YK6[2+YJ+ZLH)(%7+:]M;U6
M:UN89PA 8Q2!MI(!&<>Q!^AKG;/1;J#3="B^RJDEKYOG %?EW1N/7G+$=*V=
M!L?[-\/Z=9&%86@MHT9%QA6"C/3WS0TM?Z[BN[V_KH:%%%%24%%%% !1110
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M<I*))1EK*:--JN5'S.H&< 9&<YSQQQM4 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 44R6:."-I)75$49+,< "N*U/XE6$,C0Z5;R:A(O!=.(P
M?]X]?PIQBY.R0I245=L[BBO)YO'OB2=LQBRME_NA2Y_6FQ^.?$T;9:>SE']U
MHL?RKH^J5M^4P^MT?YCUJBO/K#XF!6"ZOISPKWGMSO0?4=17<6&H6FJ6B75E
M<1SP/T=&R*PE"4':2L;1G&:O%W+-%%%24%%%% !1110 4444 %%%% !1110
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MO^1ROO\ KQ;_ -#2OH:E7IJG/D70$[ZA117/WMC:7WB^*.\M8+A%L&8+-&'
M/F#GFL>MAR=E?^M['045R=A+<M=BRL+UHK$W<R1NJASY:HIPA;(P&+ =1U':
MDMM4N[2T+90K/]HC@18U4>>)F"C@#J#_ ..D]S2N2IG6T5RDVIZLEU<[!<,+
M.5(CS;K%(,*27+,&!.3C;@=.M:VA27=S:R7-U=&7?+(B($50BK(P'09)P/\
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M -"-=^7_ ,1^A$SUO]G[_CQUW_KI#_)Z]FKQG]G[_CQUW_KI#_)Z]FKGQ/\
M%D..P4445@4-9T4X9E!]S7 :)_R!;/\ ZY"M[Q5X?BU2.._CM([B\M%.V)U#
M"9#U3GOW!]?8FLFS>"2TB:V55A*_(JKM"CTQVQZ5T45NSCQ3>B-+PO(BWFK[
MG4?OH^I_Z9BNGK@$T2T\1:N86M8'A@*F\F,8+'NL0;KD]3Z#ZBN^ "@   #@
M =JRJ+WC>BVX(6BBBH-0KY?^,/\ R4S4_P#<A_\ 1:U]05\O_&'_ )*9J?\
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M2?\ H3U[K7A7QC_Y'&W_ .O)/_0GK*M_#9Z>5_[W'Y_DS+^&/_)1-+_[;?\
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MC=ERBJVG6TEII\$$TSSS*O[R1CDLQY)^F2<#L*LURE+8****!A1110 4444
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M[!J-C#>6SAX95W*?Z?7M7D)&1@U:T#Q+)X3EFADADN+"8%HXU/*2>@]CW_\
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MZ"O,_BS<P7?Q&U&:VFCFB98@'C8,IQ&H."/>O1P#O5OY'J4ZZJPOU-_X#?\
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MR]<5Y;XQC2+Q).D:[5"I@?\  17JU>5^-?\ D9[C_=3_ -!%=N6_QOD;8/\
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M0,,2<$@G*_3CFMK3T-OJ5[;++,\2K&ZB61G*D[LX+$G' XH TJ*** "BBB@
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M_P BQ??[J_\ H0I/"G_( B_WF_G2^+/^18OO]U?_ $(5G'^,O7]3Q/\ E_\
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M755%;6Z6MM'!&,)&N!4M%K:(C'8J6*KRK2Z_ET(+C_767_7S'_.O;:\1N/\
M7V7_ %]1_P Z]DU"^33[7S65I'8A(XE^](YZ**WI['1E^TB5KF%;I+4O^^="
MX4#/RC R?3K4M4--L6MEDN+E@][<$-,XZ#T5?]D=OS[U?K0]$**** "BBB@
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MP WXW2'U8]:]/,IQ4%&VK.G%22A9[LW/"J;[_4YS_>6,'Z9S_2NHKG_!Z?\
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M_P!#5=_]^3_\71_PIN7_ *&J[_[\G_XNC0+OL<G176?\*;E_Z&J[_P"_)_\
MBZ/^%-R_]#5=_P#?D_\ Q=&@7?8Y.BNL_P"%-R_]#5=_]^3_ /%T?\*;E_Z&
MJ[_[\G_XNC0+OL<G176?\*;E_P"AJN_^_)_^+H_X4W+_ -#5=_\ ?D__ !=&
M@7?8Y.BNL_X4W+_T-5W_ -^3_P#%T?\ "FY?^AJN_P#OR?\ XNC0+OL<G176
M?\*;E_Z&J[_[\G_XNC_A3<O_ $-5W_WY/_Q=&@7?8Y.BNL_X4W+_ -#5=_\
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MO+RZ _Y:7<QD;_ZP]A6E4&@4444 %%%% !1110 4444 %%%% !1110 4444
M(0#2XQ110 4444 %%%% !1110 4444 %%%% "$A022 !R2:X^6U_M-;J2U/V
M]F>5,Q78*@D@QL1NQM RI'?T-=/J<$ESI5W!$,R20NBC..2"!65 VJPW\MPN
MCJ%>&.+:+E.-I;G_ ,>'Y4+<'L;PX _I61XLX\(:P?\ ISE_]!-;%5M1LHM2
MTVZL9BPBN(FB<J<$!ACC\Z!-75CQ[3?#.D:QHMK-=#RYPS;GC<*7 8\'_.:Z
M]%M([=;=/)$*KL"9& /3%4C\(X,\:[=8_P"N*4G_  J.'_H.W7_?E*S5**;:
MZG/*6+G3A3G*ZCLKO3T[&</!^B+K$=_&P14;>;<,/++=CCL/;I71.]O(N':)
MAUP2#6=_PJ.'_H.W7_?E*/\ A4</_0=NO^_*4HT8Q^$O$5L;B>7VTN;E5E=_
M\ T_.B_YZI_WT*/.B_YZI_WT*S/^%1P_]!VZ_P"_*4?\*CA_Z#MU_P!^4JN0
MYO8U>R^__@&GYT7_ #U3_OH4>=%_SU3_ +Z%9G_"HX?^@[=?]^4H_P"%1P_]
M!VZ_[\I1R![&KV7W_P# -/SHO^>J?]]"CSHO^>J?]]"LS_A4</\ T';K_ORE
M'_"HX?\ H.W7_?E*.0/8U>R^_P#X!HM) Z,C/&588(+#D5%:QV=E;K;VWEQQ
M+T4-5/\ X5'#_P!!VZ_[\I1_PJ.'_H.W7_?E*.0/8U>R^_\ X ^STO2;"\FN
M[6&&.>;[[!OY#.!^%6[A;6[MY()S')%(-K*6X(JC_P *CA_Z#MU_WY2C_A4<
M/_0=NO\ ORE)4TE9&L_K4Y*<G=JVMW?3;[B[#'9P6B6L7E+ B; F[(VXQBH-
M,L-.T>V-O9;(XV<N<ODDG_(J'_A4</\ T';K_ORE'_"HX?\ H.W7_?E*/9H5
ML3:2OI+5ZO7U[E[;:?:/M&(?.V[?,XW8],U+YT7_ #U3_OH5F?\ "HX?^@[=
M?]^4H_X5'#_T';K_ +\I3Y#/V-7LOO\ ^ :?G1?\]4_[Z%'G1?\ /5/^^A69
M_P *CA_Z#MU_WY2C_A4</_0=NO\ ORE'('L:O9??_P  T_.B_P">J?\ ?0H\
MZ+_GJG_?0K,_X5'#_P!!VZ_[\I1_PJ.'_H.W7_?E*.0/8U>R^_\ X!I^=%_S
MU3_OH52?[/'JT4R&(/*A61P1D@=.:A_X5'#_ -!VZ_[\I6/?_#Q;/Q1I&DKK
M%PT=\D[-(8DROEJ",?7--0#V-7LOO_X!O7MAINH36\MTD4CV[[XR6Z'^HZ<>
MU7#+$5(\U1GN&%9O_"HX?^@[=?\ ?E*/^%1P_P#0=NO^_*4E32=RY1Q$HJ,G
M=+;5Z>@C7S:>_EN(I(CR&3 _EQFK4.JV<W'G*A]'.*\V\7V%IH>J+I.D:E<Z
ME?@XF41+M0_W>!DMZ^GUZ6]$^'WC'5V5YXUTZW(SONE ;\$'S9^N*KDT$X5'
MT5_7_@'>>#6#>.M9*D$&%>0?=:]"KDO"O@6'PU-]J;4KFZN638W2.,C_ '1S
MU]2:ZVFE8WH0<(6D%%%%!L%%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !6=JE]>6""6&U@FBW(A+W!1MS,%'
M0\<CO6C5/4[5[RS\F,J&\V-\L>,*ZL?T% $)U46KLFH>1 RHK$1R-)C<VT?P
M#O\ Y[TJZYI[,%\V0'>$;=!(NQCT#97Y<Y&,XS4.H:5/=W_GQO&$Q",,3GY)
M=Y[>E%SI4\RZ@%>,?:9XI$R3P%"9SQU^4T+S![EQ=3LWN_LRRDR;BH.QMI8=
M5#8VDCGC.>*MU@6VA2P7: A7@CG,RNUU,3R20/*SL!!/7/X<UOT= ZA1110
M4444 %%%4I;F:*\52\/EDY*8.Y4QRQ.< 9'I^- %VN4T$$?$'Q<2#@K98/\
MVS:MR&]EDAO9&C"^428P0<XV!AGWYH74\N(OLL_GE0WE?)DK_>^]C'&.N: +
M]%4SJ< MC/MD*!@I&.<D _UJ*'68);R.U:*6*:09"2%0<8)!QNSC ZX]C@T
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M]+NVD\KR[B)O.4M%M<'>HZE?4<CIZT 34444 %%,EFB@4-+(D:E@H+L "2<
M?4D@4^@ HJK>ZE8::BO?WMM:HQPK3RJ@)]!DU91UD171@RL,A@<@B@!:***
M"BBB@ HHID<T4V[RY$?8Q1MK [6'4'WH ?1110 56^P6_GR38?=(<N/-;:W&
M.5SCI[59J.>XAM83-<31Q1+U>1@H'XF@"**PM(!,(;>.,3?ZP(,;N,=J66QM
MYI/,96#X"[DD93@9P,@CU-1P:KIURY2#4+65P"Q6.96( ZG@TZ+4K">.22&]
MMI$B&9&252$'N0>* &MI=FQ&8VP,?*)&"\# .,XSCO4ALK=K@3E#O!!'S'&0
M, XSC..]/>X@C"EYHUW@E=S ;@!DD?AS4<VH65M'')/>6\4<@RC22JH;Z$GF
M@"S15>:^M+= \UU!&C+N#/( "..>>W(_,5#'K6E2N$CU.S=B< +.I)[>M %Z
MBF-+&LJQ-(HD<$JI/+ =<"GT %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !15#5-2-@+
M>.* W%U<R>7#$&V@G!));LH ))P?H35>#6)H9C!JUE]CD+(L<D3M-#(7.  ^
MU<'/&"!U'6@#7HK.N-=TZU:1))G:2.7R3'%"\CE]H;"JH);Y2"< X[U4?Q-;
M&5O)"-"(8Y1*[,O+2&/:1M)!!'<=>#CK0!N45G)KNG27_P!C69S+O,8;R7\L
MN.JB3&PMP>,YX-0:AJM]#K,&FV%C;W$DENT[-/=-$%"LJX&(WR?F]J -BBL2
M#Q) SF.Z5+26)Y$N4DD)\LHH<D$#!7:0<DKP>F>*D'B;2?(DF>XDA6-D5A/;
MR1,-YPIVLH)!/ .,4 :]%4(]9L9;::=976.%UCDWQ.C(S!2 5(!SAU[=ZAB\
M2:5-="W2X<MYK0;C!((_,!(*;RNW=D=,Y/;K0'F:M%85CXGM[TI^[> -<RP?
MZ1')&3L#'(W( >%R02,<\Y&#/%XETF6*:47+*D41G9I(9$W1CJZ[E&]?=<CD
M>M &M15&QU>RU&:6*VD<R1 ,RR1/&2ISAAN W*<'D9%7J "BFJZ,6"L"5.&
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _
"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>imrx-20211231x10k008.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 imrx-20211231x10k008.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 'J \L# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M &5.],5IF;_PG&K^EO\ ]^S_ (T?\)QJ_I;_ /?L_P"-:7_"OO\ J*?^2_\
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M^_ZBG_DO_P#94[TQ6F9O_"<:OZ6__?L_XT?\)QJ_I;_]^S_C6E_PK[_J*?\
MDO\ _94?\*^_ZBG_ )+_ /V5%Z86F9O_  G&K^EO_P!^S_C1_P )QJ_I;_\
M?L_XUI?\*^_ZBG_DO_\ 94?\*^_ZBG_DO_\ 947IA:9F_P#"<:OZ6_\ W[/^
M-'_"<:OZ6_\ W[/^-:7_  K[_J*?^2__ -E1_P *^_ZBG_DO_P#947IA:9F_
M\)QJ_I;_ /?L_P"-'_"<:OZ6_P#W[/\ C6E_PK[_ *BG_DO_ /94?\*^_P"H
MI_Y+_P#V5%Z86F9O_"<:OZ6__?L_XT?\)QJ_I;_]^S_C6E_PK[_J*?\ DO\
M_94?\*^_ZBG_ )+_ /V5%Z86F9O_  G&K^EO_P!^S_C1_P )QJ_I;_\ ?L_X
MUI?\*^_ZBG_DO_\ 94?\*^_ZBG_DO_\ 947IA:9N1:I</X2.IG9]H\AI.G&1
MGM7(_P#"<:OZ6_\ W[/^-=I'H_E^'CI/GYS$8_-V>N><9]_6N=_X5]_U%/\
MR7_^RJ8N&MRI*6EC-_X3C5_2W_[]G_&C_A.-7]+?_OV?\:TO^%??]13_ ,E_
M_LJ/^%??]13_ ,E__LJJ],FTS-_X3C5_2W_[]G_&C_A.-7]+?_OV?\:TO^%?
M?]13_P E_P#[*C_A7W_44_\ )?\ ^RHO3"TS-_X3C5_2W_[]G_&C_A.-7]+?
M_OV?\:TO^%??]13_ ,E__LJ/^%??]13_ ,E__LJ+TPM,S?\ A.-7]+?_ +]G
M_&C_ (3C5_2W_P"_9_QK2_X5]_U%/_)?_P"RH_X5]_U%/_)?_P"RHO3"TS-_
MX3C5_2W_ ._9_P :/^$XU?TM_P#OV?\ &M+_ (5]_P!13_R7_P#LJ/\ A7W_
M %%/_)?_ .RHO3"TS-_X3C5_2W_[]G_&C_A.-7]+?_OV?\:TO^%??]13_P E
M_P#[*C_A7W_44_\ )?\ ^RHO3"TS-_X3C5_2W_[]G_&C_A.-7]+?_OV?\:TO
M^%??]13_ ,E__LJ/^%??]13_ ,E__LJ+TPM,ATKQ=J=YJMK;2^1Y<L@5L)@X
M_.MWQ3K%UH]I!+:[-SR%3O7/&*HZ?X)^PZA!=?VAO\IP^WR<9Q[[JUM?T/\
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M?_/\W_?M/\*/^$KUO_G^;_OVG^%;O_"OO^HI_P"2_P#]E1_PK[_J*?\ DO\
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M-'M(!R2.,_MG5/\ H)7G_?\ ;_&C^V=4_P"@E>?]_P!O\:[/_A!M*_Y^KO\
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MV.+SYUN87B98_P"]A@"1QVJ2W\5:1<17;^>\/V2,2S+<0M$RH>C88 D'!YH
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MN^.2!CH.I(Y%5?#^L7E]>:EIVHI;_:K"14:6VSY<@9=PX))4^HR: -VBBB@
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MX@\276D^!4UV&&%[AA:G8X.S][)&IZ'/ <XYJ>\\::'8W]U93W$HFM"OVC;
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M>%M,5P0PMUR#]*YLPBK*74Z\N;NX]#9HHHKS#U0HHHH **** "BBB@ HHHH
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M_7=/;5M U#3T<(]S;O$K'H"RD"M"LS6?$.E^'UM&U2Z^SK=SK;PDHS!I#T'
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MEUO5H;.-25)S(W]U>]>]PQ+# D2#"HH4#V%8_ASPU9^'K0QPC?,_^LE(Y;_
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M:UIRPW>M>'7M=.E('G)(&9,]-R]1]#BNKDUK2X21+J5I&0@D(>95(4XPQ!/
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M110 4444 %%%% $L'\51GJ:D@_BJ,]30 E%%% !1110 4444 %%%% !1110
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M^)KP>I;BVGM)C#<P20RCDI(A4C\#3^I4^[#^T*O9?U\SW/\ X6/X5_Z"3?\
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MV]'_ )]_B>FGX9:<$!&I7!)_A CR/UH'PRTXH2=3N 1_"1'D_K7F5%'LJO\
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MQG^[B/)_7%>944>RJ_S_ (![>C_S[_$].C^&&GR,0-1N0<>D9S^1IR_"RT+
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M)10!&TC+C$+MD=BO'YFCS&V;O)?.?NY7/\\5)10!&LC,#F%UQV)7G]:%D=F
M,$BCU)7'Z&I** (C*X./L\A]\K_C2O(RM@0NX]5*_P!34E% #/,8!2(7)/\
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M#E"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KJO
MFOSZ1K<=N%:2WNF"/&O)![,*Y6O5/AQX7%O"-9O(_P![(,0*P^ZO][ZFL,1*
M,:;YCHPL)RJKE/0Z***\4^@"BBB@ HHHH G'^H_"H*G'^H_"H* "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@!R??'UJ2;[H^M1I]\?6I)ONCZT 0T444
M %%%% !1110 4444 %%%% !1110 4444 %%%% $L'\51GJ:D@_BJ,]30 E%%
M% !1110 4444 %%%% !1110 4444 %%%% "C[P^M2S?='UJ(?>'UJ6;[H^M
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MLZ$!L$Y&,':?SK6\0V=O-"MUJ.JW-EIMJC23)!<-;[SC@M(A#8'/R@X)(SG
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M*NN:>6/  )YI7^%MS&Q5];T]6'4$D$5A?\)WXG_Z"\W_ 'RO^%'_  G?B?\
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M_"W[W_H$P?\ ?T_X4?\ "W[W_H$P?]_3_A1SXC^5!R87^9_U\CE?^$)\2_\
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MBB@ HHHH **** "BBB@ HHHH **** )8/XJC/4U)!_%49ZF@!**** "BBB@
MHHHH **** "BBB@ HHHH *Y;6/\ D??#_P#N3?\ H)KJ:Y;6/^1]\/\ ^Y-_
MZ":WP_Q/T?Y,SJ[+U7YG5#[P^M2S?='UJ(?>'UJ6;[H^M8&A#1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 20_?/TJ>H(?OGZ5/0 4444 %%%% '
M"_%C_D4H?^OQ/_07KQ>OH?Q3KEIX?TI+R]M6N8FE$810#R03GGZ5Q_\ PL_0
M/^@'+_WQ'7H8:I.,+1C<\O%TJ<JEY3L>445ZO_PL_0/^@'+_ -\1T?\ "S]
M_P"@'+_WQ'71[:I_)^)S>PI?\_/P/***]7_X6?H'_0#E_P"^(Z/^%GZ!_P!
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M%_X$O_C1_9'PT_Y_(O\ P)?_ !H^LK^5_<'U27\R^\\HHKU?^R/AI_S^1?\
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MHHHH **** "BBB@ HHHH **** "BBB@ HHHH G'^H_"H*G'^H_"H* "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@!R??'UJ2;[H^M1I]\?6I)ONCZT 0T
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% $L'\51GJ:D@_BJ,]30
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M>5B\/5J5>:".,O?%VNZC9O:7-^S0R??58T0O_O%0"?QI/^$LUW^SOL']H/\
M9]GEXVKNV^F_&['MFNT_X4]+_P!!M/\ P&/_ ,51_P *>E_Z#:?^ Q_^*K7V
MV'\ON,?J^*WU^_\ X)Y\FKWZ:2^E+<,+)Y/,:+ Y;USC/;I6A%XQU^&TCM4U
M B&./RE4Q(3LQC!)&2,>M=C_ ,*>E_Z#:?\ @,?_ (JC_A3TO_0;3_P&/_Q5
M-U\.]_R$L-B5LG]__!.(7Q1K*7=O=+>L);>'R(R$7 C_ +I&,,.>^:=)XJUN
M:>XFDOBSSP_9Y/W:8,?]T#&!^&*[7_A3TO\ T&T_\!C_ /%4?\*>E_Z#:?\
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M4HP5HLF=+$5'>46</17<?\*J\0_\]+'_ +^M_P#$T?\ "JO$/_/2Q_[^M_\
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MTKPH[98'/U(J2B@!AA0J%(.!TY-((4"%0#@]>34E% $:0QH<J#GZFD%O&""
M<C_:-2T4 -$$;R@L#DG^\:DN(8V5 0>.!R:$^^/K4DWW1]: *ODILV8.W.>I
MH6%$S@'D8/)J2B@"-8(U8, <C_:-(;>-B20<G_:-2T4 ,>%'.6!S]2*0PH4"
MD' Z<FI** (Q"BJ5 .#UY-"PQHVY0<_4U)10!%]GC!S@Y_WC2M!&[;F!S_O&
MI** &-"C  @X'3DTGDH$*8.T^YJ2B@"-843.T'D8ZFA8(U8$ Y'^T:DHH C:
MWC9B2#D_[1H>%'(+ \#'4U)10 L4$90H0=H.?O&HQ"B[@ <'KR:L0?Q5&>IH
M B6"-&#*#D?[1I/L\6<X.?\ >-2T4 1O#&[;F!S]30T*,H4@X'3DU)10!&(4
M"%<'!Z\FA840Y4'.,=34E% $0MXU8$ Y'^T:5H(V8L0<G_:-244 1M"CXW \
M# Y-'DILV8.W.>IJ2B@"-88U! !YX/)H6"-&#*#D?[1J2B@"(V\9.<'/^\:5
MX4<Y8'/U(J2B@!GDHP52#@=.34LL$:Q[0#@GGYC2#[P^M2S?='UH JK#&ARH
M.?J:06\8((!R.?O&I:* (V@C=BQ!R?\ :-#0HP (/' Y-244 1^2FS9@[<YZ
MFA843.T'D8/)J2B@"-8(U8, <C_:-(;>-B20<G_:-2T4 1O"CG+ YQCJ1084
M*!2#@=.34E% $8A15*@'!Z\FA(8T;*@Y^IJ2B@"+[/'G.#GK]XTK01NVY@<_
M[QJ2B@"-H48 $' Z<FCR4"%,':>>IJ2B@ MX41VV@\KCJ:M]!4$/WS]*GH *
M*** "BBB@ K/UG5!I&GFZ,/FX8+MW;>OOBM"L#QCSH)!_P">J?SK'$2<*4I1
MW2-L/",ZL8RV;)KCQ##%9V-S%%YJ7;A!\V-N?P[5K-+&KA&D0,>BEAFN!U*U
METO5+:Q )M'N4GA_V<D96EN(VGO-4^TW%E#*LV ]P&\Q1VV8[?A7$L9.+:DM
M?^!K]YWO!4Y).+TW[]=/N.^WIOV;EWXSMSS3?/AQGS8\9QG<.M<PDZ67BJ&2
M\G10;!<R,<!CWZUA(J3Z79J>4?4&_$'%:3QO+LM=?T_S,H8'FW>FG3O?_(]%
M\Z+9O\U-F<;MPQ2^8GE^9O79UW9X_.N8U*WL[?7M/MKA(XM-$3%4.!'YF3U[
M?G68T4<UA?PQW:V]@+L?9V<$QMURN?3_  JI8IQ;5MO/RO\ <3#"1DD[[^7G
M;[SNDD209C=6'3*G--$T;E@DB,P[!A7%6MR\=OJMO!:P)<B#>9;.0F,CCMD@
M'&>E7=*&B+_9SPOB]:W((C)Y;'S%\=^O6B&+YFE9??YV[!/!\J;N_N\K]SHK
M2[>:U\ZXB2W.2"OFAQ^8XJ?SHQ'YGF)L/\6X8_.O/8S*=)TM"8A;-<R[_.SY
M>[/&[';K4UY#Y7A^_"75O-$;A2$MPVR,YY SV^E9QQKY=MEW\KFLL!'F^+=V
MV\['>++&[%4D5F'4 Y(H$T1D\L2)O_N[AG\JY(VR6/B.P6R3RVDLF)V_Q-M;
M!/X@5%I']C_8[&:[D(U#[0V[8Q\QGR<;L<XZ5HL4[\K27S]/\S)X2/+S)MKT
MUZ^?D=D98Q((S(H<_P .>?RI]>>"-YVNS<W-E!<BY^_*&\Y3GC;CM^%>@QY$
M2;CEL#)]36F'KNK?2QEB,.J-M;CJ***Z3F()OO\ X5'4DWW_ ,*CH **** "
MBBB@ HHHH **** "BBB@ HHHH *E7_4-]:BJ5?\ 4-]: (J*** "BBB@ HHH
MH **** "BBB@ HHHH **** )Q_J/PJ"IQ_J/PJ"@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH <GWQ]:DF^Z/K4:??'UJ2;[H^M $-%%% !1110 4444
M %%%% !1110 4444 %%%% !1110!+!_%49ZFI(/XJC/4T )1110 4444 %%%
M% !1110 4444 %%%% !1110 H^\/K4LWW1]:B'WA]:EF^Z/K0!#1110 4444
M %%%% !1110 4444 %%%% !1110 4444 20_?/TJ>H(?OGZ5/0 4444 %%%%
M !4<T$-PFR:))4SG:ZAA^M5-6U'^R[19_*\W+A=N['8^WM6+_P )B?\ GQ_\
MB_\ V-93JTXOEDR7447N=)+;6\Y0S01R%#E"Z [3[9Z4V2SM9IEFEMH7E7H[
M1@L/QKG?^$Q/_/C_ .1?_L:/^$Q/_/C_ .1?_L:AUZ+_ .&!5TMF='-:V]PR
MM/!%*4Y4N@;;],TT6%F%51:085MX'ECAO7IUKGO^$Q/_ #X_^1?_ +&C_A,3
M_P ^/_D7_P"QH]M1>OZ JZ6ESI9H(;F/RYXHY4SG:ZAA^1I/LT'V?[/Y,?DX
MQY>T;<>F.E<W_P )B?\ GQ_\B_\ V-'_  F)_P"?'_R+_P#8T>WH[W_ /;+:
MYTD%K;VJE;>"*%2<D1H%!/X4V*RM()&DAM88W;[S)& 3]2*YW_A,3_SX_P#D
M7_[&C_A,3_SX_P#D7_[&CV]'^D'MUW.B^Q6HMS;_ &:'R2<F/RQM/X=*/L5I
M]G%O]EA\@'(C\L;<_3I7._\ "8G_ )\?_(O_ -C1_P )B?\ GQ_\B_\ V-'M
MJ/\ 2#VZ[G2?9X#,DWDQ^:@VJ^T94>@/:FBRM1<&X%M")SSY@C&[\^M<[_PF
M)_Y\?_(O_P!C1_PF)_Y\?_(O_P!C1[>C_2#VZ[G1M9VKW N'MH6F'20H"P_'
MK4U<M_PF)_Y\?_(O_P!C1_PF)_Y\?_(O_P!C36(I+9B=:+W9U-%<M_PF)_Y\
M?_(O_P!C1_PF)_Y\?_(O_P!C1]9I=Q>UCW.BF^_^%1USLGB[<V?L/_D7_P"M
M3/\ A+/^G+_R+_\ 6H^LTNX>UCW.EHKFO^$L_P"G+_R+_P#6H_X2S_IR_P#(
MO_UJ/K-+N'M8]SI:*YK_ (2S_IR_\B__ %J/^$L_Z<O_ "+_ /6H^LTNX>UC
MW.EHKFO^$L_Z<O\ R+_]:M;2]4CU*)F"['4\IG-5&M"3LF-3BW9%^BBBM2PH
MHHH **** "I5_P!0WUJ*I5_U#?6@"*BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@"<?ZC\*@J<?ZC\*@H **** "BBB@ HHHH **** "BBB@ HHHH ****
M ')]\?6I)ONCZU&GWQ]:DF^Z/K0!#1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 2P?Q5&>IJ2#^*HSU- "4444 %%%% !1110 4444 %%%% !111
M0 4444 */O#ZU+-]T?6HA]X?6I9ONCZT 0T444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 Y/OCZU)-]T?6HT^^/K4DWW1]:
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MS?='UH AHHHH B:V@9][0QENN2HS3V1&.652<8Y':G44 ,6&)$*+&BJ>H"@
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M* $95=2K %2,$'N*P(_!'A^(H5LI#LBD@C#W4K".-QAD4%CM4CL, =L5T%%
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MBNG?]-O^^_\ ZU'_  BNG?\ 3;_OO_ZU+ZK4%[*1Q-%=M_PBNG?]-O\ OO\
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M6]J (Z*D\EO:CR6]J (Z*D\EO:CR6]J (Z*D\EO:CR6]J (Z*D\EO:CR6]J
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
$% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>imrx-20211231x10k009.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 imrx-20211231x10k009.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %6 L\# 2(  A$! Q$!_\0
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MO4O(7!/WI4)RS=S@4 >OP2K<013H&"R(' =2&&>>1U!I^*HZ-!>VVB6$&I7
MN;Z.!5N)AT=P.35[OU_S_G_/:@ H[44?Y_S_ )_^N %%'^?\_P"?_K% !_*C
MO1W_ ,_Y_P _A10 =JDA_P!<M1T^''FK0!?'2EI!TI: "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH P]:_Y".G?]=A5GO\ Y_S_ )_"JVM?\A'3O^NM6N<]#0 G%':C!]*,'T-
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M+?\ UZ5'4EO_ *]:<=R9;&D.E%(.E+72<H4444 %%%% !1110 4444 %%%%
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M<SL2U*VHIE_L^9;R+Y=K 2J.CH3@Y]QU%=9C#8]ZY:"!M4F2.-&^S!@TLA&
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M\LB]U(KK= \5;;/48YX+*(Q63>5^[ \QAT4^N:Y35=5DU.9;B2"&(HFT+"F
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M-M MO;10+G;&@09] ,4U%D5*\''W5JR>BBBM#D"BBB@ HHHH **** "BBB@
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M['9Z+=^()S=1R0GS'57#;HS[X _"NKU3X<S:G<^)I/MR0C4Y;.:T8*287@7
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MPQ?>$EU#3OM:3:.9S+81\[X%8Y*'U&>E==0!RW_";0_] 36__ )J/^$VA_Z
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M<Q1,RO(BE4WD$]%]?I3XI%EC61&#(PW*1W!H DHHS433(DB1LX#/D*">3]*
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M<NE6$]T+F6SA><='9<FM<+7C2;<E>Y->E*HERNQ1LK_6);&WDDTQ2[1JS$S
M9)'7':I_MFJ_] M?^_ZUIT5DYIN]C10:6YF?:]5_Z!:_]_UH^UZK_P! M?\
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M<H^N16HWAFR!B\DRPK';-;;8VP&C.>#^))J2[\/65[96-K.K-'9E#&<\G:,
M'U!QS1SQ>X<LNAARWU]#'96]YJCQSM;"21((M\A=CW'91T]ZIVMS=ZM=>&KN
M:Z=9";E6VJ!G8#SCU(&#747>A075^;U9IX)GC$;F%\;U'(!_.HH?#-G;P6D4
M$D\?V25Y8F#<C=]X>X.::G&P<LKG/6VN:S=VR:E MU(SR96V6#]T4W8QN]<<
MYJ?4Y-0U72=?N%O/*@MS-;K!L!#*JX)8^IYK:'AFT23Y)[E+?S/-^SI)A,YS
M]<9[4E[X8M+U[DF6XBCNO]?%&^%<XQDCUHYX7#EE8CU;!\ 7/'']G_\ LE44
M?4M.;28Y+_S5OU,)78!Y3>62&7V&*Z*?3X;G27TZ0MY+0^4<'G;C%4K7P_;6
M4\=P)+B9K="L"2/D1C&/E]\<4E)6L-Q=S-T_6+R_.D68DVW8>3[<<=!%\I'M
MN8BH_&]E_:$NC6H.UI)W"-Z-Y9(/Y@5?T#3G74]2U:>U:VDNW 2)OO*H')/U
M/-:=YIL-[=6=Q*6WVDADC /&2".?SI\\8SN@LW&S.(\0W_\ ;WA^'/2"T^U7
M"^DF0B@_CO/X5?'G#Q=K'DZ9'?9CM\[RHV?(?7U_I6U_PC-@+;4;<"14OWWR
MX;ISG ]!G/YTMQX<BFU":]2\NK>68*K^4X .T8':J]I&UOZZ$\LMS$UY[F*+
M0Y4TU(;@:A\MNI&"VU@#D<5<\+!7O+Y]0&=:1]LY;^%/X=G^SBM%- A/V8S7
M-S.UO<>?&TC@D-C&/IS4\^D0S:I#J*L\5S&ACW(<;U/9O7U%0YQ<>4I1=[FG
M11161H%%%% !1110 4444 %%%% !1110 4444 %%%% &)K/_ "$M._ZZ_P!#
M4M1:S_R$M._ZZ_T-2BLJFYM2"BBBLC8**** "BBB@ HHHH **** "BBB@ HH
MHH **** (+F[AM# )GVF>80Q^[D$@?H:G!XKBO%OB:TTS5=/MM0#P^1>1W2.
M!D21!7!Q[AB!CW%=9I]S)=V$-S+"86E7>(V/*@\@'WQBJ<;*Y":;L<U>> [2
MZF4)=S0VJNT@MU4$*6QNP??%=1:6L-E:Q6MNFR&)0JKZ"IJ*J52<E:3"-.,7
M=(****S+"BBB@ HHHH ****!!1110,**** "I(/]>M1U)!_KTIQW)EL:( ZT
MN*!THKI.43%+BBB@ I  *6B@ Q1BBB@ HQ110 48HHH *3 I:* $VBEHHH ,
M48HHH ,4A -+10 F *6BB@ HHHH **** #%)BEHH **** "DQ2T4 ( !2T44
M &**** #%&*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH Q-8
M_P"0EIW_ %U_H:EJIXC&9K,!F7,F,J<$?C5+RF_Y[W'_ '\-859)/4Z*,6U=
M&Q^!H_"L?RF_Y^+C_OX:/*;'_'Q<?]_#6/M(FWLY&Q^!H_ UC^6V<_:+C_OX
M:/*;_GXN/^_AH]I$/9R-C\*.?0UC^6W_ #\7'_?PT>6W_/Q<?]_#1[2(>SD;
M'X&C\#6/Y38_X^+C_OX:7RVSGS[C_OX:/:1#V<C7_ T?@:Q_*;'_ !\7'_?P
MT>6V?^/BX_[^&CVD0]G(V,&C\#6/Y3?\_%Q_W\-'E-C_ (^+C_OX:?M(A[.1
ML8^M&/K61Y;?\][C_OX:3RCC'VBX_P"_AI>TB'LY&Q^!H_ UC^4V?^/BX_[^
M&CRC_P _%Q_W\-'M(A[.0S7_  Y8:]+ISWH -I<"1<_Q]RGXX'Y5M_A7#:U=
MVQO=/MVO95EM]0B:17EP54HQ#?3W^M;=I,E[;)<P7-P8I.4;S"-PSU'M5N:L
MB8P=W8WOP-'YUC^4V,?:+C_OX:/+;/\ Q\7'_?PU'M(E>SD;'X&BL?RF_P"?
MBX_[^&CRFQ_Q\7'_ '\-'M(A[.1L?A161Y39SY]QZ_ZP_6D\IL8^T7'_ '\/
MTI^TB'LY&QCZT?A6/Y;9_P"/BX_[^&CRF_Y^+C_OX?\ />E[2(>SD;%%8_E-
MT^T7'_?P_P">U+Y;9SY]Q_W\/UH]I$/9R-?\#1^%8_E'&/M%Q_W\/IBCRFS_
M *^X_P"_AH]I$/9R-C\#1^!K'\IO^?BX_P"_A_SWH\IN?](N/^_A_P ]J?M(
MA[.1L5)!_KU-8GEMG/GW'K_K#ZYJQI\9%]"?.F;!Z,^0>,4XS39,Z<E%G2#I
M2T@Z4M=9QA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 <_XA_P"/FQ_ZZ55JUXA_X^;'_KI56N/$
M;G;AOA84445SG0%%%% !1110 4444P"BBBD 4444 %%%%, HHHH Y7Q9X13Q
M'=:=,"$:&0+.>[0]2/P_K74(BQQK'&H5$ 55'8#H*S-6N7CETQ892-VH1Q2!
M3U&UCM/Y"M-'5URC!@#C(.1D53;<5<B*BI-H=1114%A1113 **BNIUM;2:X<
M$I#&TC =< 9JA;W6H[(;FXC@:"2(R%(L[TXR ,_>]*:5Q-V-2BL5/$44C^4M
MK,T_FK&(E*GEE+ YSC^$U+#KT5SY?V>UN)<H'DVJ/W0+%>>>N0>G84<K%SQ-
M6BL)?%=C(DKI'*RJF]-N#O 8+QZ')'7%;<;,\:LZ&-B.4)!(/IQ0TUN--/8=
M1114C"BBB@ JS8?\?T7U_I5:K-A_Q_1?7^E7#XD34^%G0#I2T@Z4M>B>8%%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M"H9_"TLM])*MP@B,PVJ<Y$+<RK]6/-5:/<F\NQHKXDTQI0AN%0;I%WL<#*$
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MH'M[B-)89!M>.1<JP/J#UK/G2TW1MR-Z[,R;&]TOQ9:VLFF7,,\#;F#@D&/
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<* "BBB@ HHHH **** "BBB@ HHHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>imrx-20211231x10k010.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 imrx-20211231x10k010.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" (/ \L# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M,$NX;=N,[L^F.<UY[H&="T.R[:?K.GGZ1W0C/_H:C\UJ]>WUO!X$\/6%Q<)
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_E7W&/\ \(KH/_0)M?\ OW1_PBN@_P#0)M?^_=;%%'M9_P S#V-/^5?<8_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M?R6OD3C9&LGFE/W;9)& W<C'(]Q7->$X;VRU;4+.6.*VM!''(EG]O^TO"Q+
MD9&55@!@'N#BLGQ=-,EYXJV2R)MT2%EVL1M.^3D>](9Z'FJFJ:C!I.F7.H7
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MZCZYIUIH.EV$D+VME%$T/F>5M!^3S""^/3) K/'B&UM+K6I;V]D2"S\DM%)
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MEN85FU.\+R-E@2JIDX7@')/7H*7Q18R2ZO;W3:7>SQ+ 46[TR8I<Q-G.TC<
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MBO?ZH:KHNGZW:FWO[9)E_A)X93Z@]16T:[VGJ9NEUB8'ACQ[8:^4MIP+2_/
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MY&[J1ZUHUSM6T9NG<****0!1110 4444 %%%% !1110 4444 %%%% !1110
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M2LOX8>(_)G;0KE_DD)>V)/1NK+^/4?C71-*I'G6YE%N$N5GJM%%%<QL%%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MF^=/S'(_$5V-I?6M_")K2XBGC/\ %&P8?I6$H2CNC523V)R0H))  Y)-9_\
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M'%.X6.5UPE;'QR5)!^WVG(./X8:U5T2TUSQYXABU#S9K:**U(MQ*RH6*M\Q
M(R1CCZFN@N?#.FW<6I1RQR%=1E26XQ(1EDV[<>GW15R#3+:VU.\U"-6%Q=B,
M2DL2"$!"X';J:5]/Z\@:U//K:25-(TFU,TKQVOBDVT1=RS"-7<*I)Y.!QS6C
MI&CV7BN;6+_63--<17\UM$HG=!;(APH4*1@G[V?>ND7PSIJHB".3"7YU ?O#
M_KB22?IDGBH-0\':1J-[+=R1W$4D^//%O<O$L^!CYPI ;CBB_P#7W#>^G];G
M.WOV+4(]$TU+K4/$(%M)(L44JHEPH8*)97R.AX'J><5BR++;>&/&-@T+6T%O
M<6WE6OV@S"'=L) 8^IYQVS7?W_A+2+];0&&6V:TC\J![29H61/[F5(^7@<5
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MQN?A_P#\)++?7']L-9&\.HBX<,DFTM@#.T*#\NW&,58M[4>)O%5F=4\WRY=
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M.,@?WA^M=37M8W6Z,%^[E;H>[T5!9WEO?VD=U:RK+!*NY'4\$5/7*;A1110
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M)V:.@HHHK Z0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /-
M_''@$W+RZMH\?[XY::V4??/=E]_4=_K7,>$_&]WX;<6EPK3V&[F(_>B/?;G^
M7\J]OKD/%7@*RU\M=6Q6UOSR9 /ED_WA_7^=;PJIKEGL92@T^:)T6F:M8ZQ:
M+<V-PDT9ZX/*GT([&KM> 3VFO^#-2#GSK27HLJ'*2#Z]"/8UV&C?%; 6+6;0
MYZ>?;C^:G^E$J#WCJ@C56TCT^BLG3O$VBZJH-IJ,#L?X"VUOR/-:N0:Q::W-
M$TQ:***0PHJ"YO;6SC\RYN8H4_O2.%'ZUR>K?$O1+ ,EJ7OI1VB&$_[Z/],U
M48RELA.26YV1( R3@5PGBOXBVVFA[/2&2YN^0TO6.(_^S'VZ5PNM^-=;\1,;
M;>8;=S@6]N#\WL3U;_/%;/AKX:7=ZT=SK&;6WZB ?ZQQ[_W?Y_2MU2C#69DZ
MCEI$PM!\/:GXPU621G<QE]UQ=R<X_P 3[5[;I6E6FC:=%8V<>R*,?BQ[DGN3
M4UG9VVGVJ6UI"D,*#"H@P!4]9U*CGZ%P@HA1116184444 %%%% !1110 444
M4 %%%% $5U:P7MK);7,:RPRJ5=&'!!KQ+Q;X/N_#%X+FW+R6#/F*8?>C/8,>
MQ]#WKW*HY[>&Z@>">-9(I!M9'&01[UI3J.#(G!21YUX0^(R2K'I^N.$E^ZEV
M>C>@?T/OTKTA6#J&4@@C(([UY5XH^&DT#/=Z$#+">6M2?F7_ '3W'MU^M<]H
M7C'6?#,AM@3+ APUM<9^3Z=U_E[5K*G&?O0(4W'21[O17(:/\1M#U(*EQ*;&
M<\%)_NY]FZ?GBNLBFBG0/%(CH>C*<@UA*+CNC523V'T445(PHHIDDL<*%Y'5
M%'4L< 4 /I"0H))  ZDUR>K_ !$T+3 R13&]G'&RWY&?=NE>;Z]XUUCQ&WV8
M$P6SG MX,Y?V)ZM].E:PHREY&<JD4=CXN^(T5J)+#1'66X^Z]R.53_=]3[]/
MK7'>%O"E[XJOFGF=TLP^9[AN2Y[A2>K>_:MSPQ\-+BZ9+K6PT$'46P.'?_>_
MNC]?I7JEM;06=M';VT210QC:J(, "M'.--<L-R%%S=Y#;*SM]/LXK2UB6*")
M=J(O85/117,;A1110 4444 %%%% !1110 4444 %</XW\#+K2MJ.G*J:@H^=
M.@F _DWO7<4549.+NA2BI*S/"/#GBK4?"5Z\#1L]OOQ-:R<%3W(]#_.O9-%\
M0:=K]J)[&</C[\9X=#Z$5F^*/!EAXDC,AQ;WH&%N$'7V8=Q^M>3ZEHFN^$+]
M9V$D)4_N[J G:?Q_H:Z+0J[:,Q]ZGZ'OM%>4Z+\5+B$+%K%MYZCCSH,!OQ7H
M?PQ7=:;XOT+55'V?480Y_P"6<IV-^1K&5*4=T:1G%FY12!@P!!!!]*6LRPHH
MJ*>Y@MHS)/-'$@ZL[!1^M $M%<EJOQ%T'305BG-[*/X+<9'XMTKS[7/B%K.L
MAH(&%E;-QLA/SL/0MU_+%:QHRD9RJ11WWBKQ[8Z$CVUH4NK_ *; <K'_ +Q'
M\NOTKS"QL-8\:ZZYWF6=SNEG?[L:_P!!Z 5K^&_AUJ.KE+C4-UE9GGYA^\<>
MP[?4UZYIFE66CV:VEC L,2^G5CZD]S6CE&DK1U9"C*;N]BMX?T"S\.Z:MG:+
MDGYI)6'S2-ZG^@[5JT45SMMN[-DK:(****0PHHHH **** "BBB@ KFM:'^GE
MAT( _*NEK#\01;(EG SR<CWQ6M%VF88A7@89=0X0L-QZ"K>GC-]$3T5MQKFF
MN9'G$Q(##I[5U7AQ3=DS,,8'/YUVU8\L;G!1ESSLCJ****\T]8**** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **SM:US3O#]A]MU.X\BWWA
M-^PM\QZ# !/:L6T^)/A*]NH[:'6(Q)(P5?,C= 2>V2 *+7!NQU=%%5-3U*TT
M?3I]0OI?*MH%W2/M)P,XZ#F@"W163'XETF74;&P2ZS<WT'VFW38WSQXSG.,#
MIWK1NKF*SM)KJ=]D,*&1VQG"@9)HV!:[$M%4]+U2SUG38=0L)?-M9@3&^TKD
M D=#SU!J.PUS3M3OKZSM+CS+BQ<1W"["-C'.!DCGH>E%@-"BBB@ HHHH **C
MN)XK6WDN)W"11*7=VZ*H&2:RKCQ7HEKHUOJ\E\AL+AQ'%,BEPS$D # ]C0!L
MT444 %%%% !1110 4444 %%%% $5Q;07<#0W$*2Q,,,CJ"#^!KB-6^%NEW9:
M33II+*0\[/OQ_D>1^==Y151G*.S)<4]SQ&_^&WB&SRT4,5V@[PN,_D<&LTP>
M*-(/W-6M<?W?, _3BOH"BMEB'U1'L5T/ 1XF\41?+_:5^/\ >SG]133JOBB^
M^3[7JLN[^%2_/Y5[^0#U H(XH]NOY1>R?<\&M_!WB;4Y 6TZYR?X[EMO_H1S
M73:9\)[AV#ZI?I&O_/.W&X_F>!^1JSI7CF30]<N]%UIVDMH;AXX[D\M&,\!O
M48QSU%>D12QSQ++$ZO&XRK*<@CU!IU*M1"A"#,K1?"^D:"O^@VJB7O,_S.?Q
M/3\*V***YVV]6;));!1112&%%%% !1110 4444 %%%% !1110 4444 %%%%
M!6/K/AC2=>0_;K16DQ@3)\KC\1_6MBBFFUJA-7W/*-5^%-W%N?2[Q)U[1S#8
MWYC@_I7+RZ/XF\/2;A;7]J0?OP$[?S7BO?Z*V5>2WU,W270\&A\<>)[/Y?[3
ME/M-&K']14__  L?Q+C'VZ+Z^0M>VRVMO/\ ZV".3_?0'^=5_P"Q],SG^SK3
M/KY"_P"%/VT.L1>SEW/$YO'/B>[^7^TY!GM%&JG]!4,>E^)O$,F3!J%WD_?F
M+;1^+<5[S%:V\'^J@BC_ -Q *FH]NE\,0]DWNSR;2OA3>S8?5+N.V7_GG#\[
M?GT'ZUW^B^%=(T%0;.U7SN\TGS.?Q[?ABMJBLY592W9<81CL%%%%9EA1110
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MR4MAU%%%(H**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#SWXR_\
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M7,%NFU2YR3SDD_4DUH4GOH-;:A1112&%%%% !1110 4444 >(?$BS^R^,IY
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MU3?O+@_[1_A^@''YUU?PJ?FS#XY>2.@    & *6BBN4W"BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ KG-5OGEG:)&PB\<5T$IQ"Y'I7'RG,SD_WC6]"*
M;N<V(DTDD,K.N=0*N4AQQU8U9O9?*MF(^\W K%KOIQ3U9YM2;6B+WVM3<1S-
MC(C.1[TL6IOO_>*-O^SVI;>*.33W)0;QGGO6?5I1>A#E)69T*.KJ&4Y!Z$5>
ML;Z2WG7+$H3@YK TR4[FB)XQD5I5A."V9T4YOXD=JI#*".AYI:KV+%K.,GTJ
MQ7G-6=CU4[JX4444AA1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ K%U_Q';Z&D4?E/<WLYVP6L7WG/\
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MBYU"0[I[J3YF9N^">@K6K;DBC'VDC._X6)H/]^[_ / 5_P#"C_A8F@_W[O\
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MHU"'+C]UR/4<&NXHR?4T6'<X;QGIUW;7+75A;R30:C)!'=QQJ3MD212DF![
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M $-T UG.I&08F!_(TWP$2? ^E9_YY$?^/&GW/_'K-_US;^1J/P#_ ,B/I?\
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M#6[>6.:$V^H6K>7<VY/W6]1Z@]J4H65T7&:EH;=%%%9EA1110 4444 %%%%
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MZ@_SU)KNO 4#VNC7=O)C?%>R(V#D9  -=9X>\,Z?X<M/*M$W2L/WD[CYW/\
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MG[T_)'$>&/AG+<%+O7-T475;53AF_P!X]A[=?I7J%M:P65NEO;0I%"@PJ(,
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M(AO+D<^9,!@'V7H/UKJZ*SG6E(J-.*#&****R- HHHH **** "BBB@ HHHH
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M2ZMW)@-]#IEH!#YFQ_\ EI)M'+')( ]5JJVOZS:6FJA9=1N(4TZ:>.ZN]/\
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M -&X9ZUYUI=K>6FHZ+=V\=O:BXD"RS/JS3F]0J2?E(PS?Q CI@]JH6]BEO\
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M?<*@$ 9&&SWS64NJZJ8H-4PQU/\ X1664-MY+>8N&QZ]\4?U^ _Z_$]1!!.
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MT*QLKQD J-O\)W=^1CJ:7M)]_P"MPY(]B?\ X5WHO_/74/\ P+:C_A7>B_\
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M,#CCK[=*ZJ@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MTU32FU%H)8;VYL[BW),<D+#'(P0RG(8?6JD/AUK:QO$AU*Z6]O'#SWQ"F0D
M# &-H  P!CBB^@%'PA,^M27GB.:)HVN@EO"C#E$C&&_.0O\ D*ZJJVGV,&F:
M?!8VJE8($"("<G ]3W-6:&""BBBD,**9%-',I:*17 .TE3G!]*?0 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 5RFG>,S?^.;_P -_P!F31BU4L+@GAL8ZC'
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D4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>imrx-20211231x10k011.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 imrx-20211231x10k011.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %: R$# 2(  A$! Q$!_\0
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MYX4\<<TL.@PS6XN1?[+=R%C:9%C.3G.=S 8&.JEOTI^YV#WA/^$NUW_G^_\
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M:]DHH]L^P>R1XW]AN_\ GUG_ ._9H^PW?_/K/_W[->R44>V?8/9(\;^PW?\
MSZS_ /?LT?8;O_GUG_[]FO9**/;/L'LD>-_8;O\ Y]9_^_9H^PW?_/K/_P!^
MS7LE%'MGV#V2/&_L-W_SZS_]^S1]AN_^?6?_ +]FO9**/;/L'LD>-_8;O_GU
MG_[]FC[#=_\ /K/_ -^S7LE%'MGV#V2/)](LKI=:L&:VF"BXC))C. -PKUBB
MBHG/F+C'E.9\-?\ (3U?_K\E_P#0S735S/AK_D)ZO_U^2_\ H9KIJ@H****
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M18K <31[GE#<94@ $>N#U]O85 TRS2.H=&0YPPP<'!_,4M%(HA1FC;RY/N@
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M_GJ__?1J,WX%TEL;AO.=&D";CG:" 3^;"CE%S'2T5SWG2_\ /5_^^C1YTO\
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MC7)/^T.G0UK1>(M5GEAF5;*.V'V+S8L&1F^T,%.V17VX4G(.""/2NT^QS_\
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MDXYA<#^534 <SX:_Y">K_P#7Y+_Z&:Z:N9\-?\A/5_\ K\E_]#-=-0 4444
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M )Z/_P!]&CD#VJ[&K165YTG_ #T?_OHT>=)_ST?_ +Z-'('M5V-6BLKSI/\
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MCIZKG\<C_@524Z\6.XA"]"5+JQ!RI&""!CGG'%5X+@2P)(5() RN#P3V_ T
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M "BBB@ HHJ"2]M8KE+:2YA2>3E(FD 9OH.III-[";2W)Z*K?VC8[IE^V6^Z
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M5?T /XU9J.WA6VMHH$^[&@0?@,5)0 445AZ]H]YJ<]N]M<K&L?4,2,'U&.]
M&TZ)(C(ZAD88*L,@BFPP16T0BAC6-!T51@4J1LJJ#*S$ @D@<_I1L;!'F-T
MSQ^?2@!]5;R1K;R;M>D,@+_[AX;\LY_"K&TYSO;KG''Y=*:T0="CL65@000.
M0?PH T&/[Q!GU_AS^O:J$B^1?,O2.8;U]F'WA^/!_.C3GEN+*(O)('4-$Y&W
M 925)Y[G%37]D;VU:)9WCDW!XW 'R,.GX>OU- #*@D9XHEF0/NB;<5/)([C\
MLX_"BW=R6CE9?-3AU[@\_IZ>U218\L8VX_V3D4 :"LKJ&4@J1D$=Q2;3D?.W
M4GMS[=*IZ>_EM+:'_EF=T?\ N'M^!R/IBKU #-C;<>:^=N,X'7UZ=:\1U[_D
M8M3_ .ON7_T,U[C7)WGP_P!-O;V>ZDN;L/-(TC!67 ).3CY?>NW!5X49-S//
MS##SKQ2AT.0NK:UN/$,-S<S6KV$@B1BMTF?]6!R VX $<GM4(MM-L;%GG2TN
M;I+=&*"Y+*SF5@1E&Y(3;T/O]>O_ .%;:5_S]WO_ 'TO_P 31_PK;2O^?N]_
M[Z7_ .)KK^MT;)<S_P"&.+ZE6NWRJ[OU[G._V1IQMKMX;>*6("[996G(9=F=
MFP9^=>G.#UZ\8KDJ]53P%:1VKVJ:IJ2V[G+Q+* C'CDC&#T'Y5#_ ,*VTK_G
M[O?^^E_^)JJ>-I1O>39-7+ZTK<L4CS"BO3_^%;:5_P _=[_WTO\ \31_PK;2
MO^?N]_[Z7_XFM/[0H=S+^S,1V7WGF%%>G_\ "MM*_P"?N]_[Z7_XFC_A6VE?
M\_=[_P!]+_\ $T?VA0[A_9F([+[SCM*_Y%'Q!];;_P!#-8->M6_@?3[;3;VQ
M2XNC'=F,N25R-A)&./>JG_"MM*_Y^[W_ +Z7_P")J(8ZBG)M[O\ 1&D\NKN,
M4ELOU;-ZU1R\\=S)=KMDVAY'"K)GIM(Q^7_UZL3Z=#+ Z 9<CY&E)D"MV.&)
MZ'FEO85(^T>2TS(I4Q \.I(SD'@D8R/R[U(QE@8M\\Z.XX  ,8/\Q^OUKQ^9
MO9GM\D5NKD,!MX[42QP1;P=C"!/XP=I Z=\]:I>1<16EUI44BB5P6BE[[7)W
M.1GDABQXZY%68Y VJEQ*JVYS&BCCS)<98_[7RC'MM;KV2[3_ $V.Z>'8(6,7
MG^9@B,@,3CH1N55QUZT];A96T%,L%P+*2W\TQ3*KJ8Q@;!AE)'IDC\S4LMQY
ML;-&_EVZC+S>OLO^/Y>U"P#ZF;I)Y"L,;&$VZC:0.6&?3Y64>^.>XJV)!-N=
MPRVUJ3G/\;+WX[#&?K]*=DG8S<FU==?Z^XA@M\R22,FWRXSA?[A(.!]<$D^I
M;V%5;^SCU"PGLYFD6.>,QL8V*L 1C@CH:V(HG6T8,/WL@+,/]H]OPZ?A57[+
M-_<_44^:[U$J;BE9%2V@2UM8;>,L4B144NQ8D 8&2>I]ZP;WP[/<Z[<:M%<[
M)D2$VB[SL$B;PV]<8((?;GD@$D8/-=3]EF_N?J*/LLW]S]13N@2DNAQK^%;B
M6XN+YY?])DODNOLWVN7[/(@504=1A>H)!V]0N<C*T^T\-ZE:W\6I_P!H[[N6
M25KJ"0*T*K(.0A"!VVE8\;CR$QQGCK_LLW]S]11]EF_N?J*6@_>[''V7AV_*
M7-M<2&PM9K9H"ME?RS9)(PR+*NV$* P"KD8;_9%5'\(ZC!:6T45P+OR+Z6<*
M]VUF0C*R@!X(P0>02 ,=1TXKN_LLW]S]11]EF_N?J*- ][L8^@V$VF:1':SL
M#('D<@2-(%#.S!=[ ,V <;CR<9/6M*IOLLW]S]11]EF_N?J*=T3RR[$-%3?9
M9O[GZBC[+-_<_4470<LNQ#14WV6;^Y^HH^RS?W/U%%T'++L0T5-]EF_N?J*/
MLLW]S]11=!RR[%&XM9KJ>R\E=WE7*2OSC"C.3^M=!52UADCE)=<#;CK5NHG*
M]EV-:--1O+JPHHHK,V,3Q'_S"?\ L)0_UK;K$\1_\PG_ +"4/]:VZI[(2W8R
M:.*:%XYT1XF'S*X!4CW!JC;7.E:_9-Y0AN[=&VE9(N 0,CAAZ&I=6M[F[TJY
MM[1T2>5"BM(3@9X)X![9K!D\+74,DB6URD]H_D,T5R0-YB(&P[5QM*@#H>@R
M#6E.,6M969A5E-2TC==3:M8-*N4D6VMK<I$7MF A  Y^=>G0D\]C4XTZQ$WG
M"RMQ+MV;_*7=MQC&<=,<8KDO^$.O68%GMQ'OD80Q2[1%N8$%&:-L'C' !X'/
M:KLGABZ:]ENHYH8YWOO.6<$^8L10J1G'7)SCI6CA"^DS.,YVUIF_)IMA-'%'
M+96SI",1*T2D)_NC''0=*5=/LDNC=+9VXN"<F41+OSC&<XST)KF(_"MZL*+_
M *'&$6%9($=MEV4?<6D^7@D>S4NH>&M1N]/M[6)-.B$2MMVYS&Q?< &96;&/
M3;^7%')&]N?^OO'[25K^S_K[CHUTG3DBDB33[58Y  ZB%0& .1D8YYYH>UL6
MC33WLXVAQN6(V^8Q@_3:#STK$F\,RO)?S8MGDGO$G"MG$D0()C<XX!(ST(X%
M07?A>]N+1(D-G#BUEA"([[5+.&&"021@?X#%)1B]Y@YS2=J?]7]#H_[+T[[,
M+;[!:^0&WB+R5VAO7&,9]Z4:98*\3K8VP:$8B81+E!G/R\<<D]*YY_"]PEVS
MQ)9R68F2464A*QN?*V,3A2,Y&>ASWJLO@RY(S-+;3.#;X=RV0J9WJ..F" /4
M#G%-0C_S\_K[Q.<[Z4_Z^XZ>31M+ED:233;-W8EF9H%))/4DXJU'#%$SM'$B
M-(VYRJ@%CZGU-<=<^%-4ET]+-&L-D;2-&Q^\F7W  E"0,=AM^IZ5VE9U%9*T
MKFM)N3=X6"BBBL3<**** "O(;30[ICXB633=3A,UE=B9X;4^8S&X+!6+;1=%
ME)P5(PF4Y+ UZ]10!Y9;^&K^Z\+RS-&8TM-4DN=/M(].>(,F% $<+-N@)D#D
M,<[0Q8C!KIO!KZO#=ZEI^I6H"PR>9]I$#Q^=*SN6.YCAP<!AMP%!"]JZVB@"
M*XCEE@9(9C#(<8D"AL<^AJC]AU/_ *#+?^ Z5IT4 9GV'4_^@RW_ (#I69X=
MT77=.U*_GU'63<6LT\CQ6VW. 6)!R?N_[HXKIJ*=Q6"N:O\ 2[V7Q&MS';;X
M&EMW+!P%PA;)8$[MPS\NW@]\UTM%5"HX.Z(J4U423.2TS0+P//9WJ,+9HI%\
MX"+=N,NY2A W8QR0W>GZ7IFKZ=J5N8PPM9.)A(R-M4;\*3USR#\O&6;M7545
MH\1)WNEJ9+"P5K-Z!1116!TA1110 4V5=T3KL5\J1M;H?8]>*=10!RT6BRWD
M.H?:K*6T5_*>%(Y(]X**1L7&4VCH,@'DY[5-H=AJ^GZ@8IN;-H][DE2-^U0
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M:I=)_>6.3\\K_P"R5+0 4444 ,L^=4NCZ0Q#]7_^M6C5"P&;N\?T9$_)<_\
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MYHH0S8\QB>0?5=P^E=.[K%&TCL%1068GL!6;I_B"QU"SENLM;1Q%=_VG"8#
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M%'V,#M8=0?0^U<#:>#;I? =G926\D.H64]P\%O%)&$8/.Y56/(";2I.W# #
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M5<9.#QFF_;[7_GK_ ..G_"DJU5;2?WL;H47O%?<BS4%RX#1!O+V;MS;^O'3
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MK+_WR0W]*L4$ @@C(/:@"ZC*Z*ZD%6&01W%+5+2CBP6+IY+-%CT .!^F*NT
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M\4A\,WOGW$,:%WC;" % 6&[ + ME0>HX.?IS73]2H_SG)_:%?^0]7_M[1_\
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MLK.[5KF%V4QG^(*<;E/1E[Y':G9BNC;HHJE-J]C;WJV<DQ$[%5P$8@%L[06
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@"EJU__9>E7%[Y7F^2N[9NVY_'!K%B
M\:6SWEM%)!Y44EN99I6D_P!2P#$IC'S'Y?U'%;VH6,6I:?-9S,ZQS+M8H0"/
MIFL>7P9I4LDKMYP\V220@,  7&,#CH.H_7(XKHI.CRVJ;G+65?FO3>A;?7[<
MSV:0(TBSSM Y961HV5=QRI&<^W'6GMX@TU(Y'>:1/+=4=7MY%8,WW1M*YY^E
M0IX:LTCA59)$,,C2*\21Q')7;SL4#@'@]:AM_"-A;QLBS7!#212$_(.8\[>B
MCKGGN:+4.[_I_P"07Q'9?TO\RVWB+2UC5S<-SORHA<LNPX8LN,J ?4"F/XFT
MA)6C^U,S*Q3Y(9&!(&2 0N#QSQ4;^%[0R3R1W-U%).9?,9&7YED.67E3QGIW
M]Z$\+V$97RWG54F>95## +($QTZ  46H=V%\1V7]?,N?VU89MOWK[;G;Y+B%
M]C%N@W8P#[$YJ_7/Q^$;&.>UE%Q<L;7R_+#%#C8<CG;D ]P" :Z"LZB@O@9K
M3=1WYU8****S-0HHHH **** "BBB@ KFXM(U:SC\0WMJ]FVL:A,6MI)6;RTC
M50L2M@9X^9L 'ECSS7244 </:^#+F3PP]KJ$-NVK_:#<?:_MLD@DF8 -*^$3
M(XXCP5(10?4:7ACP_J&A7U^DMV9-.8*EI$9WD( +<E6&$."H.W.[&X\FNFHH
M **** "JMIIME823R6MK%%)/(TDKJOS.Q.22>IY-6J* "L2_T_4;S6[>9OL\
MFGP,KI"9F1C(/XFPISCL,BMNBJA)Q=T1."FK,PTTBYN=2N9M2%LT$L)A(B9L
MOALJ>>4P.RDY/-5;#P]>V&HV\\5PD<.2T\:RN1_$ H!'S#!49;G()ZFNFHJ_
M;3LT9_5X73ZH****R-PHHHH *Q_$.DW&L67D0W$48"OE)8RRNQ4A>01C&2>_
M.#CBMBBJA)PES(F<%.+C+8YD^';N2[L'D:V"P>0TDL32*S&//!3)5NP#'! S
M[4R^\+3>?+-ICI;-D>6!.Z]0=Q)Y(YVX XP#ZFNIHK58BHG<Q>%IM6L-0,L:
MAVW,  6QC)]:=116!T!1110!S/AK_D)ZO_U^2_\ H9KIJYGPU_R$]7_Z_)?_
M $,UTU !1110 4444 %4-2_UU@._GD_^0W_QJ_6;<GS=5C4<B&(EOJQ&/T4_
MG0 3OY=O(_\ =4G]*MV:".QMT P%C4?I5&]_X\;C_KDW\JTH?]1'_NC^5 #Z
M*** "BBB@#*M?E26/_GG,ZX]!N)'Z$47(WR6T?\ ?G3_ ,=^?_V6DM.5G)^^
M9Y-WX,0/T I9SY<UK.?NQ2@M]&!7/X;L_3- &K1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4455::[#$+:H1Z^;C^E %JBJG
MGWG_ #Z)_P!_?_L://O/^?1/^_O_ -C0!;HJIY]Y_P ^B?\ ?W_[&CS[S_GT
M3_O[_P#8T 6Z*J>?>?\ /HG_ ']_^QH\^\_Y]$_[^_\ V- %NBJGGWG_ #Z)
M_P!_?_L://O/^?1/^_O_ -C0!;HJIY]Y_P ^B?\ ?W_[&CS[S_GT3_O[_P#8
MT 6Z*J>?>?\ /HG_ ']_^QH\^\_Y]$_[^_\ V- %NBJGGWG_ #Z)_P!_?_L:
M//O/^?1/^_O_ -C0!;HJIY]Y_P ^B?\ ?W_[&CS[S_GT3_O[_P#8T 6Z*J>?
M>?\ /HG_ ']_^QH\^\_Y]$_[^_\ V- %NBJGGWG_ #Z)_P!_?_L://O/^?1/
M^_O_ -C0!;HJIY]Y_P ^B?\ ?W_[&CS[S_GT3_O[_P#8T 6Z*J>?>?\ /HG_
M ']_^QH\^\_Y]$_[^_\ V- %NBJGGWG_ #Z)_P!_?_L://O/^?1/^_O_ -C0
M!;HJIY]Y_P ^B?\ ?W_[&CS[S_GT3_O[_P#8T 6Z*J>?>?\ /HG_ ']_^QH\
M^\_Y]$_[^_\ V- %NBJGGWG_ #Z)_P!_?_L://O/^?1/^_O_ -C0!;HJIY]Y
M_P ^B?\ ?W_[&CS[S_GT3_O[_P#8T 6Z*J>?>?\ /HG_ ']_^QH\^\_Y]$_[
M^_\ V- %NBJGGWG_ #Z)_P!_?_L://O/^?1/^_O_ -C0!;HJIY]Y_P ^B?\
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MUB_[]'_XJC;<_P#/6+_OT?\ XJIJ* (=MS_SUB_[]'_XJC;<_P#/6+_OT?\
MXJIJ* (=MS_SUB_[]'_XJC;<_P#/6+_OT?\ XJIJ* (=MS_SUB_[]'_XJC;<
M_P#/6+_OT?\ XJIJ* (=MS_SUB_[]'_XJC;<_P#/6+_OT?\ XJIJ* (=MS_S
MUB_[]'_XJC;<_P#/6+_OT?\ XJIJ* (=MS_SUB_[]'_XJC;<_P#/6+_OT?\
MXJIJ* (=MS_SUB_[]'_XJC;<_P#/6+_OT?\ XJIJ* (=MS_SUB_[]'_XJC;<
M_P#/6+_OT?\ XJIJ* (=MS_SUB_[]'_XJC;<_P#/6+_OT?\ XJIJ* (=MS_S
MUB_[]'_XJC;<_P#/6+_OT?\ XJIJ* (=MS_SUB_[]'_XJC;<_P#/6+_OT?\
MXJIJ* (=MS_SUB_[]'_XJC;<_P#/6+_OT?\ XJIJ* (=MS_SUB_[]'_XJC;<
M_P#/6+_OT?\ XJIJ* (=MS_SUB_[]'_XJC;<_P#/6+_OT?\ XJIJ* (=MS_S
MUB_[]'_XJC;<_P#/6+_OT?\ XJIJ* (=MS_SUB_[]'_XJC;<_P#/6+_OT?\
MXJIJ* (=MS_SUB_[]'_XJC;<_P#/6+_OT?\ XJIJ* (=MS_SUB_[]'_XJC;<
M_P#/6+_OT?\ XJIJ* (E6XW#=+&1W C(_P#9JEHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
3 HHHH **** "BBB@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>imrx-20211231x10k012.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 imrx-20211231x10k012.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %S LT# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH ***IOJVFQR-')J%HKJ2&5IE!!
M'8\T6 N452_MG2_^@E9_]_U_QH_MG2_^@E9_]_U_QIV8KHNT52_MG2_^@E9_
M]_U_QH_MG2_^@E9_]_U_QHLPNB[15+^V=+_Z"5G_ -_U_P :/[9TO_H)6?\
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M]LZ7_P!!*S_[_K_C19A=%VBJ7]LZ7_T$K/\ [_K_ (T?VSI?_02L_P#O^O\
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M]K(/9Q.'_P"$#U3_ )^+/_OMO_B:/^$#U3_GXL_^^V_^)KN**/:R#V<3A_\
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M9_\ ?;?_ !-=Q11[60>SB</_ ,('JG_/Q9_]]M_\31_P@>J?\_%G_P!]M_\
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MZ/;R%XK?[(/."<D1&4L04!/9 V !N[D N>(%U$V\36=[)96R,SW4UO!YUQL
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M2I9;([_M2T45X9[X4444 %%%% !1110 55?[[?6K557^^WUH 2BBB@ HHHH
M**** "BBB@ HHHH **** 'Q?ZP42_P"L-$7^L%$O^L- #**** "BBB@ HHHH
M **** "BBB@ HHHH 5/OK]:=+_K#34^^OUITO^L- #**** "BBB@ HHHH **
M** "BBB@ HHHH 5/OK]:=+_K#34^^OUITO\ K#0 RBBB@ HHHH **** "BBB
M@ HHHH **** %3[Z_6GS??'TIB??7ZT^;[X^E $=%%% !1110 4444 %%%%
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M#^T8_P I]"45\]_\)'KG_09U'_P*?_&C_A(]<_Z#.H_^!3_XT?49=P_M&/\
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M5W+H6D^^OUITO^L--3[Z_6G2_P"L->:>J,HHHH **** "BBB@ HHHH ****
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M .2G_P!G1_PIW_J._P#DI_\ 9UY=11[.M_/^"#VM#_GW^+/4?^%._P#4=_\
M)3_[.C_A3O\ U'?_ "4_^SKRZBCV=;^?\$'M:'_/O\6>H_\ "G?^H[_Y*?\
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M_N68_?3T^H_E6595Z<>92O\ )&U!X>K/E<+?-E+_ (5)_P!1O_R4_P#LZ/\
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MT?\ "%> _P#H9O\ R?@_^)KRZBG[&?\ .P^L0_Y]H]1_X0KP'_T,W_D_!_\
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MLM3.:A%R9=.#G)1CU/3O!7V__A%;/^T<^9M_=Y^]Y?\ #GWQ_2N@I  H
MX %+7A2ES2;/HX1Y8J/8****DH**** 'Q?ZP42_ZPT1?ZP42_P"L- #****
M"BBB@ HHHH **** "BBB@ HHHH 5/OK]:=+_ *PTU/OK]:=+_K#0 RBBB@ H
MHHH **** "BBB@ HHHH **** %3[Z_6G2_ZPTU/OK]:=+_K#0 RBBB@ HHHH
M **** "BBB@ HHHH **** %3[Z_6GS??'TIB??7ZT^;[X^E $=%%% !1110
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MD(/_ (JO+J*/JT.[^\/K<^R^X]1_X37P'_T+/_DA!_\ %4?\)KX#_P"A9_\
M)"#_ .*KRZBCZM#N_O#ZW/LON/4?^$U\!_\ 0L_^2$'_ ,541\9>!B21X;X_
MZ\8/_BJ\SHH^K0[O[P^MS[+[CTS_ (3'P/\ ]"W_ .2,'_Q5'_"8^!_^A;_\
MD8/_ (JO,Z*/JT.[^\/K<^R^X],_X3'P/_T+?_DC!_\ %4?\)CX'_P"A;_\
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MNH+"_P!0U-KBZ6:)\M$C%60;%;N21G YK/MK6_\ #OC+6K2PTN/4K,H3)9Y
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M66=MJF0D*#CO@&G]6HVO;\Q+%XANU_P1Z+_PN+_J!?\ DW_]A1_PN+_J!?\
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M !1110 4444 *GWU^M/F^^/I3$^^OUI\WWQ]* (Z*** "BBB@ HHHH ****
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M %%%% !1110 4444 *GWU^M/F^^/I3$^^OUI\WWQ]* (Z*** "BBB@ HHHH
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M%%%(84444 /B_P!8*)?]8:(O]8*)?]8: &4444 %%%% !1110 4444 %%%%
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M%% !1110 4444 %%%% !1110 4444 %%%% !55_OM]:M5 T;EB0.] $=%/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
F%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>imrx-20211231x10k013.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 imrx-20211231x10k013.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &; Z@# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M&YN8K2%I9G"J/UH E9E12S$!1R2:YW4O$@3=%989NAD/0?2LO5=9FU!BBDI
M#PH[_6LNMX4NK,)U>B'RS23R%Y79V/4DTRBBMC$**** "BBB@ HHHH ****
M"BBB@ HHHH T].UNYL"%)\R'^XW;Z&NML=1M]0CW0M\PZJ>HKS^I()Y;:598
M7*.O0BLY4U(TC4<3T>BL?2-<CO@(I<)/Z=F^E;%<[33LSH335T%%%%(84444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%-DD6*-G<X51DF@".ZN8K2!II6PJ_K7$:EJ<VHS;G.(Q]U!VI^KZH^HW!
MQQ"IPJ_UK.KIIPMJSFJ3OH@HHHK0S"BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH 56*,&4D$'(([5UVB:T+P"WN& G X/][_ .O7(4J.R.'4D,#D
M$5,HJ2*C)Q9Z5167HNJKJ%OM<@3I]X>OO6I7*TT[,ZD[JZ"BBBD,**** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *Y;Q'JF]
M_L<+?*/OD=SZ5MZK?"PL7DS\YX0>]<&[,[EF.6)R36U*-]68U96T0E%%%;F
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 3VEU)9W
M*3QGYE/3U%=]:7*7ELD\9^5A^5>=5N>&]0\BZ-LY_=R]/8UG4C=7-*<K.QU]
M%%%<QTA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MANY!'7-7KG6-.M+!;ZXO(8[5@"LI;AOIZUQOA:PM);'Q)-);QO(UQ*I9E!.
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MK]G\"VBVZJB_NVD..N>YI=0M=6ET+_2M2TT6)08(B/'ICWKKOL<'V(6;1AH
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MD-O,.L3C_@)HN%B.BE*,.JD?44E !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 5UWA:/;82/_>>N1KN="A\G2(01RPW?G6=5^Z:4
ME[QI4445S'2%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444A( R30
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M:Q[(LGJW-3T45!84444@'*[+T/'I4Z2!_8^E5J*8[ERBH8Y>S?G4U,H****
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M(/!%Y>?V UMB^CFAMTCQ/)$K<LPSU]J] M+C^T-#25(98C)#Q'*NU@<=".U
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M)+;VMK%YADD8*05'TR>:V=9^(FDZ[\.=2U?2M8O=+-K*D<TJVH>>W8L.#&6
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MV\WBNRCM;BSDP)58LN P!X., _C7HVHZ+%I_B+X>^';'G^SS).Y'9$CP6/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1102!U- !1110 5GZSHUGKVG-97JL8]ZR*R-M9'4Y5E/8@BM"B@!%&U0N2<
M#&32T44 %%%% !1110 4444 %%%!( R3@4 <TG@+PXGBQ_$YL"^K,VX3/*S!
M3C&0I. <#TK5BT:TBUR?6,.UY+$L.YFR$0'.%';)Y/K6A10 4444 %%%% !1
M110 4V1MJ$TZH)FRP7TIH3>A%1115D!1110 4444 %%%% !1110 4444 %%%
M% $,]M'<)M<<]B.HK'N;*2W))&Y/[PK>H(!&",BFI6)<;G,'I7"ZXQ;7(\]@
M:]2N=,CD!:+Y&].U>8^([>2VUN/S%QDD9[5M3DG./J93BU%E2BBBO9/."M3P
M[_R,%E_UTK+K4\._\C!9?]=*SJ? _0J'Q(ZOXA_\>=E_UT;^0K@*[_XA_P#'
MG9?]=&_D*X"L<'_!1KBOXK/5-;_Y$Z3_ *XK_2O*Z]4UO_D3I/\ KBO]*\KJ
M,%\,O4O%_$O0****[3E&N0(WSTVFO1='8OI%HQ[QC^5>=29\I\=2,"O4=)L'
M33;97^4",?RKS,>US([<*M&.52QPHR:NP6@7YI.3Z5/'$D0PH_&GUYSD=:04
M445(PHHHH **** "BBB@ HHHH **** "BBB@">%LC:>U2U51MK@U:IHI!111
M3&%%%% &)J7B>TTS5H-/ECD9Y<991PN3@?6MNJTUA:7%Q'<36\;S1_<=ER15
MFJDXV5D1%2N[L*\DNO%$OA7Q/X\U18&N_)FLU6'=C.Y%''YUZW7EWB'P+K6H
MWGBN6W2 KJ5Q:26^Z7&1&%W9].AJ2RY)XV\70:Y;Z--X7M%O;^(RV@%YE4 ^
M]YIQQ@>F:9<_$J_L/#&J7MYHR?VGIM]'9RVT4V4<N5P5;'HU=%?Z)>7'Q TC
M6(U3[):VTT4A+?-N;&,"N!\=:%J>F>'O$=R?*5K_ %BUFM3NR,;D'S>G(H Z
M<>-M>TK4K*#Q+H4%G;ZAE+6:WN/,VR8R$D&!@D ]..*S;3XI:G/HS:U)X=*:
M<6-O WG#?<3[MH55_NY[GWJ>\T3QAXMU#34UVQL-/LM-D-P3#<>:US*%*K@8
M&U>3UYJ0>!M3E^&UAHXD@@U6RF^TQ$G='O$A8 D=C0!9B\8^(;#4[;3_ !!H
M=M:R7Z-]CDM[@R(9 ,^6^0,'Z<4)\1#/X,L=7@L VHW=T+,61?&V;?M*D^W6
MHH=)\5>)?$6E7OB&PL],L]+<RB.&X\YIY,8SP/E7Z\U%8>!+^U^(TVH,\7]@
MB5KV"(-\PN&7:W'IW^IH ???$#5)+W4/[%TNRN;/37,<[W%V(I)6'WA&O?'O
MBNKL-:76_#$6KZ6@?[1!YD22-MYQT)[<UYQ?_#R_LM8U1K3PQHVLPW\S3175
MW-L>W9NH88^89YXKTKP_I3Z/X>M-.D,)DBBVN84V)N[X'84 >.3:UXDG^'&H
MW&HQ"3RM441,ERSNS"493D< =J[RT\::QI^K6UEXETFWLH+JW>:"6"X,A4(,
ME7&!SCTK'_X0_P 2G0=0T1K6S,)U%;N"=;CEU\P,05(XP*Z+Q/X6NM=UW2)0
M$%I!#-%.V[!&]<# [T 8J?$W4%MX=9GTBUCT":4(KB[!N54G <Q^GMG-7=/\
M>:MJOB#4+*QT'S;+3IBEQ="3.5QD;%'+,?2N7LOAOJUM%!I!\,:!B&0?\3EG
MW,T8.?\ 5$9WXX]*Z_2?"VJV.G>*+>.6.VGU&9GM)4;.T%< G'2@#._X6'KE
ME=Z7+J^AVMG8ZC.(8XS<G[5'GH7C(X^E/B\<^*-3N=5&C^'+::VTV=HI))KD
MH9<=D&.OUKD_^%?^*/L6F^5X9TB"[L+A)9KHWN^:[(/)#$?*._)J_P"%[CQE
M"WB)-'TNQO+>>_D7,MUY;0/@9)X^8?2@#??XFG4(]-M]!L89M1O(FE>.\G\J
M.W"G!W-ZYX&*6#XE,^G/Y^GQQZE;7T=G=0++N0;^C*PZC%<_/\*KS3?[,U"'
M3]/UVYBB>.\L[I_+5RS;MR,1Q@GO5U/A_K'_  C=V\-AI-CJ#W<=S!8VYQ&@
M3HC/CDGUZ4 =3XE\37VGZG#I.GV<4UQ<VLDJ-)(4 *CUQ7"Z'K>I7'@_0Y]?
MMOM ?4PD$PNV+D[CRW'0>E=#;:/XMUGQ?::QK%A9:?;0VLD ACN?-<%A]XG
M'Y5GV7@WQ*NA:;I%S:VBII^I"=9H[C/F1[B2<$<'GI0!KR>-?$%_<:A-X?\
M#\-[IMA(8Y)))RDDS+]X1J <_C77VVJ)+H::I-#-;(8?->*9"KIQD@@]ZX:W
MT?QKX:;4=-T.SL+JSO)WF@NY;C8UN6Z[EQ\V/:NUCTV>7PY_9NH71N)W@,4T
M^,;F(P3B@#S;Q)XP\2ZKX*O]2@T")-%F4K'*+G]^%SC?MQC'XYK3@\;Z@J6^
MD:#8VEW/9V<3W4EY=>2H)7A5[EOTJA<Z!X^3PE-X2M[#37ME!2/4&NL;H\\#
M9C(;]*AO/AS?V.JG4(?#NEZZMU;QI+#=S>6T$BK@D,1@K0!J'XHW=^FDQ:+H
MHN;V_:2)X9)MHAD3ALD=1[T^\\8^(6L=9TFYTFWM=<M[5ID\NY/E/%@Y=6QG
M(]*YN;1->\-Z[X8AT^WTQM3'GS/;1YBA(/\  #CKCN17567AOQ!K.IZIK6N0
M6MA<3V+6=M:Q3>;L!!^9F QU]* .._MKQ&=/\ WDUH+J^DE80H+DDS@KPSL1
MQ[]:](\,^)M2U'6M0T76M.@L]0LT27_1Y3)&Z-T() -<YI'A3Q(H\))?VEI$
M-%E99&BN-^]-N PX'/M73V.B7MO\0]5UIU3['<V<4,9#?-N4DG(H Y3XR:G;
M6-OHXNII);83LUQI\$Q22=,<'CG /X5O?#1I(?"EO:7>H13W)S.D/V@2O%"Q
MR@)R2<#O5/Q%X?UZW\:MXBTC3[/5HI[3[++:7,WE%/=201@]ZH?#[P7K_A'7
M[NYNK>Q:UU%=SK!*2;0@\(-WWE^E '2^)?%%[IVJV>BZ-I\=]JETID"S2>7'
M&@ZLQ_PKB+?Q3J^F>)O%&J:KIBP7=A8QDVZS;XWYZJ?0YKK?%&B:TGB.Q\2:
M!#;W5S;Q&":TGD\OS$)S\K= 1[U@?\(?XIUZY\1W&LQ65FVIV:PP)#,9!&0<
M@,<?J* .IU?Q<^F6V@S"U5_[4F6,@MCR\KG/O6#8?$37=32]NK/PM)-863O$
M\B2;GE<' "*.2/4]JHRZ#XXUJ;P[%?Z;I]G:Z3.K2%+KS&FPN-P&.![=:T!X
M/UV/X>:EH]M)%#J$]R\J;92 ZE\[2PZ9'% $EKXWU^/7[32-4TG3HKB_B=[9
M;>\+LK 9VR C(^M<KINN:S/X0UJ77[47-K'J>Q2+QBX;S -HXX45>TSP;X@M
MO$^A:K#X8TC3+>S9EGB@NM\K[A@NS8P?IUJR?!OB5=&UK1?LUFUO<7XN[>X%
MQRP+AB"I''% &U/XOUN\U:ZTSPOHL%Z-/11<RW-QY:[R,[$XY/UXJF_Q/N+F
MUT?^R]$:>^U":2V:UDDV&&5.H)]!R<^E._L;Q7X7US4KO0-/LM2MM3(E:.:X
M\IH)<8)Z?,OTYJ'1O 6JZ9J/A^[GE@FFANI[J_=&PH:1>B@]10!T'AGQ+J6H
MZQJ&C:UI\%GJ%DJ2'[/*9(W1LX() /8UF:]=C4OB3I^ESMC3]+M'U*=>S29P
MF?H,FM>PT2\M_B!J^LR*GV2ZM88HR&^;<N<Y'XUBZW9"U^)]M/<9%GK.FR6)
M?^[*O('XJ3^5 &,GQ8U^]@GUC2_"$MWX>AG,)N%E_?/@X)5.I'X5@ZGJ2S_%
M'Q1<NL[6K:&DAA+E#@QJ<>QK2TSPK\2_#FF2>%]%DTY---PTD6J>;B2)&;)&
MWUY]/QJYJ'P^\07'B_7=2#Q3PWFDK:1S/( SR!%4DCMR#0!D>'OB1<:/HGAO
M1]"\//=R:A%(T$4EUE@P=NK'MP3FK.I_$.77?!7BW3_$&B-:7NEK&+BWAN,;
M@9% PXSCGTIWA?X;>(=)UKPC=74=N(M+AE2YVS D%BQ&/7J*?K7PX\07UWX[
MDACMRNLQPK:9E R5<$[O3@4 6+7XB75M:Z%X<\+:$VHZE+8I.T4T^%ACQ_$Q
MQD].?<5K0?$?59?"MS>GPEJ)U>WN1:M8I&S L?X]P'W..M<_%X#\7^&-4TKQ
M#X>BL;J^33ULKRSGEV@X Y5N!U4=Z=K_ ()^(&O>"S'J&IPW.HO?"X>P679%
MY0!_=!L#/X\>_% %F'XE:G>ZIJ/A?6]*MK6\DTZ::-[2Y$H7$9.&QT-:/P-D
M>7X9VK2.SM]HFY8Y/WS7*Z3\-/$D/B]=7.BZ5IEH=/FMA;6EQNV,R,H+9ZDD
MYR*[_P"%WAK4?"?@F#2M46-;I)I'(C?<,,Q(YH KZ3\09-2F\8QFP1/^$>DF
M12')\[9NZ^F=M>;^,/B+XEUK0?#&K:=;/8075YM_<797S7# >6WM]?6MR[\$
M^.M,\0^+(]#ATV;3?$32NUQ/+M:'?NR-O7/S$=".E5[KX7>)S\-= TVW6T.J
MZ5>M<F)Y?E<$Y&&_ 4 0^)=3,OBW7HKW3I+76#X:EDE9+HM&GR#@*.,^]4M$
MU&&%/AJDEI-=7TL$A@?[244,&X##OD^M=!J'@7Q7K/BC4M:N[:SB>]T%[(I'
M-P)V4#'TXZTFG?#CQ!;7W@&:2.WV:(C"\Q,.,MGY?6@#G?#GC[QGI6H>-=0G
MTYM0ALIU:X@EO"PL_F?Y8QW'T_NBN_O_ (A6^J-X8TJTT^.^7Q+!OFC9^(HB
M/GS]/F'X5C6/AK5?"/BCQ;>ZQ_9__")ZRS275T\IWQJ=VT;?7Y\'K7/? G1/
M-UC4]=GG,VGZ8KV=C,_"[2S.Q&>@Y)_X%0!Z=\-[R=M"N](NI6EFT6]ET\2,
M<EXT/R$^^W'Y5V5<1\,XVN-+U;7"I6/6-3GNX 1@F$MA#^(&:[>@ HHHH **
M** "BBB@ JHQRQ-67.$)JK51)D%%%%42%%%% !1110 4444 %%%% !1110 4
M444 %%%% !7 >.[1@HG4<J0U=_61X@L1>6#C&2!1>VH'EJD,H(Z$9I:C"-:W
M$EK)P4.4/JM25[E.:G%21Y,X.$FF%:GAW_D8++_KI66.37H&B>#HH9+341=N
M6 #[-HJ*]2,(/FZET82E+3H'Q#_X\[+_ *Z-_(5Y_7?_ !#_ ./.R_ZZ-_(5
MP%1@_P""BL5_%9ZIK?\ R)TG_7%?Z5Y77L$MBNI: MHSE!)$HW 9QQ7G_B/P
MXFA)"4N&E\S/5<8K#!U(J\'NV;8J$G:2VL<_111TKT3B+&GVK7NJ6EJHSYD@
MS]!R:]?50JA1T Q7$>!=*)>75IE(W#RX ?[O<_C7<5X6*J^TJ-K9'J4(<D$F
M%%%%<QJ%%%% !1110 4444 %%%% !1110 4444 %%%% !5J,[D%5:F@/44T-
M$U%%%,H**** "BBB@ HHHH *KWEC:ZA!Y-Y!'/$&#['&1D'(/X&K%% !1110
M 4444 %%%% !1110 4444 %06ME:V0D%M D7FN7?8,;F/4GWJ>B@ HHHH **
M** "BBB@ HHHH KR65K-=Q74D$;7$0(CD(Y7/7!JQ110 4444 %%%% !1110
M 4444 %%%% !1110 5#<V=O>",7$*2B-Q(FX9VL.A'O4U% !1110 4444 %%
M%% !1110 4444 %%%% $5S:P7EN]O<PI-"XPT<BY5A[BHH],L8K!K"*TACM&
M4JT*(%4@]1@>M6J* &0PQV\,<,*+'%&H5$48"@<  4^BB@ HHHH **** "BB
MB@".8_NZKU//]T?6H*I;$2W"BBBJ$%%%(QPI/H* ,?6O%FA>'61-5U*&WD?[
ML9.6/T YJ71?$6D>(86ETJ_ANE0X<(W*_4=17%?#NPMM7U3Q!X@OXDN+]KY[
M=6E ;RHUZ*,]*C\3V<'AWXD^'M3TM%MY=0+V]U'&,"48R"1ZBD%CTVHIKB"W
M"F:5(P[;5WL!D^@KRS0]3^(GB?3+W4[35]/LX;6>2.*)K,.;C:>C'^$=N*RO
M$VM:QXN\,^'-4M[J"R;^T%@F@,._;<*V-P.>GM[T7"Q[$NIV3ZD^G+<(;Q$\
MQH<_,%]:MUYG>ZYJ^DZQK$4LMK->6>D>=]H6W"EI >OT]JR+OQ+\0=.\/:5X
MCEU'3)8KUXXOL'V7 7?P&+YSG-%PL>Q$A02> .35:PU&SU2!I[*X2>)7*%D.
M0&'45PEGJ_BS1/&MCHVNZE9ZC!J-M+*IBMA$864=!@\CZU'H]YK^I^$I;W3]
M6L-(\B\G\YWLU92BGTR,'WHN%CTFBO)-+\;>)[#PUJWB+6+FWN].C/EV!^S"
M'SFSC>0.BU4LOB/J.GZGILM[XJT?6+>\E6.>SMH-CV^[IM;JV/>BX6/9N@JK
M8ZE9ZDDCV5PDRQN8W*'.&'45P$6J^,?%FH:G/H.IV6FZ=8S-!''+;"5KAEZ[
MB?NCZ59^$C7+^'[]KQ46Y-]+YH3[H;/./:@+'H%(RAE*GH:6BF!Y]XM\/N'^
MTVXPPY!_I7*12^8""-KKPRGJ#7L]Q;I<1%'&0:\]\1^%I(YC<6ORL.A _0UO
M0KND_(QK4E47F<]4XO;M0 MU, .@$AJEYS1/Y=RGE/Z_PG\:FZUZL9PJ*ZU/
M/E&4'9DDMQ-, )9I) .F]B<5'115DDXOKL  74X ["0TR6XFFQYLTDF.FYB:
MCIKR)&N78*/>E9+4>KT'5=T;29M=OQ @(M4.9I?_ &4>]/TG0+W6I%)5K>TS
M\SD89A[>E>FZ=IMMI=JMO;1A$4=J\[%8O3DA]YV4,/9\TR:W@CM;=(8E"H@P
M *EHHKS#L"BH;PD64Y!P1&V#^%>+>#-#T'6?"0U'6/$M];7S22[F&I^64PQ
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MK.&UU+5)_$,>HRC5%:;=;"W#'&!TQC 'OF@#WJBBB@04444 %20G#U'3X_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_C#6VU*ZT/5=(M[76E@,]JL<Q>&<#L&Z@U2L_B>VJ/8:;I^FE]=FF,=S9NQ
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MT^BD(@HIS+M/M0B[C[=Z '1K_$?PI]'\J*S;N4%%%%( HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "I84R=QZ"F(I=L"K( 48%-#2%HHHIE!111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% $4L>?F'6H*N5')%NY'6J3):*]%!&#@T51(4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%.1"YXZ>M(! GF<4K)L^7'%654*,"AE##!J6[E*
M)4HISH4/--J!!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %*H+'
M H52QP*LH@0>_K3&D"($7%.HHIE!1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 -= XYZ^M5V
M0IUZ>M6J*:8FKE.BIVA!Z<5$T;+U'%5<AJPVBBBF 4444 %%%% !1110 444
M8STH **D6%CUXJ945>@Y]:5QI$20D\MP/2IP !@445+=RDK!1112&(0&&#4#
MQ%>1R*L44!8IT58>(-R.#4+1LO4<>M(FPVBBBD(**** "BBB@ HHHH ****
M"BBG*C-T% #:>D9;V%2K"!R>34E.Q5A%4*,"EHHIC"BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
H0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>imrx-20211231x10k014.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 imrx-20211231x10k014.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %3 N\# 2(  A$! Q$!_\0
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M%LTO!<*P,;(S,HP<_P"SGTH U**K6>H66HQM)97EO<HK;6:"57 /H2#UJS0
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M6G]TT >?:GX2<P>+VM=(C\ZXN;>2Q*(H)VI'DI_=^8-Z<UF^)[<6D>LVUUI
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M3Q@^E:U[!/<6Y6VNFMI<@B14#?A@U7T[3!IMM<;IWGGGD:665P!N8@#H. ,
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M]* K8;CM_6FTH'#?3^M !M;TI2K;1QWIM./W1]30 FQO2G,K;NG:F4Y^OX4
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MJ#V-;L/^J7Z4R!]%%%, HHHH **** "BBB@ HHHH AN?]2?PJDO4_0U=N?\
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M)/(!KYM^(7_)1]6_Z^(__0$KZ1C^XGT%;U8*,8M=4)&K1116(PHHHH ****
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M;Y1V[FDW#^X/S-  ?NK^->,_%?GQ9;?]>2_^AM7LY(VK\H[^M>,_%<@^+;?
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MC.[.,8C_ -DTW7/B$VC6.DW TH3-?PO*4^T;1'M(&,[3GKZ"L'X1?\?FN?\
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M"\NGVT=G:RMJ(NDA$S-&B! N VW.<Y/3O5;P;INN^%AK%D;2QN662.5V%TR
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M3?TI6]VS&YQC-5*2M;YG*^&?"WB/PYI.IV1@TZ?[<20XNF79\FWIL.:B\6^
M]8UR_L9K*6S"P6:6[B5V4[E)Z8!XKTD_=7\?YTB_>'UH<4X\O0(XFK&I[5/W
MCB_"E_J5EX:\/P3V%M]FD6*W$J7)+#(.#MV#T]:]$A_U*?2N TS_ )%3PO\
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M?_7:;^:TE2BZ?,.<VDFC8\8_%%O"^N7.DQZ3]H>.)'$QN-O++D?+M/3ZUNZ
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M_P A#1_^O.X_] 2O(/B'QXUUKZI_Z+6O8+@9U#1_^O.X_P#0$K*G\4CU,9_
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M^(MJD!C$IU1PID!*YWMUQS73A_M>A,E='JWB_P#Y 'B__L&VO_HR6N,^#_\
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M9O\ T-J^I+G_ %)^HKY;\.?\E.L?^PLW_H;5T4-I^@F>W_$7_DGNM_\ 7O\
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M@_E2I]]?K0 VG+T;Z?UIM.7[K?3^M #:<?N#ZFFTX_<7ZF@!M.?[WX4VG/\
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M;"[#>3*,'8=I'XT[3=*LM)M'AL81#&\A<J"<;CU-6ZS;;=V,(T2"&**-0$1
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M '[@^I_I24XXV#@]3W^E-X]#^= #GZCZ#^5(OWQ]:5\9'!Z#O[4+C>.#U]:
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M1L]0M]1UF2!X8(9H[ES.[F16&-P4C"C'85W:??%-QD<T>S0UC*B32M;;\_\
M,X_P%8N+6ZOY6:1<BUM'92"8(R<'!]<_H*V=:TR?4;K29(60+9W@GDW'JH&.
M/>M@#",/I24U!*-B*F(E*JZJ_KH<;=>%M2EUB653:^5+?+=B]+'SXU'_ "S
MQT[=<5V1IQ^ZOXTVB,5'8BK6E424N@Y_OGZU?A_U2_2J#_?/UJ_#_JE^E69#
MZ*** "BBB@ HHHH **** "BBB@"&Y_U)_"OESPW_ ,E.L?\ L*O_ .AM7U'<
M_P"I/X5Q5MI7@^/Q0]O!I-@FKPK]IWK;@,"<_,#Z\'\Q6E.IR7\T)HZ60(8V
M#J&3'*L 01^-9FA:A8ZG;33V=E]FV2F)MT2H3@^W;_/-:M*!A#CUS60Q*5NW
MTI*5NWTH 3N*5OOM]32=Q2M]]OJ: !>_T-)2KW^AI* '?\L_^!4VG?\ +/\
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M!\P^8=:"O)^84B\,,],T'K2 <H&&^8=*;M_VA0.C?2DH ?M^0?,.I_I3=O\
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M6*:2&21<M"V]#Z'!'\B:99W]IJ$;26EQ',BG!*-G!]ZGWKYFS<-^,[<\X]:
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MFW6P@56)<*<Y#$#&W.<FL_PQIYL[R26&#44AN 9&:9X6C<GIC9SZXQQR:O\
MBF/S+*W!M+BYC$X\P6P/FH,'YE((P1_+- !X<D20W4C3S3W4PBGE>1%4$,@V
M[0.@ &/J#67=:?X=L+B[CN--^VW;2K)@Q@N[3.VU 21Z'KT K7\-06EO9R+:
M6E[ -P#-> [WP !R3R  !^%5M1@FB\2+??V,U\B0*(IHW16B;+9ZD9X/7MSC
MK0!-;6B7/@N.TTN1T1[3RX&D.UE&,8..A[<5FP^&;&6"2[TM8_,^T1^03D?9
MO+<"0+GD9(;([YKI=,$2Z9;B"$0Q>6-L88-M'ID$@_G7"I+9+K%U<"UBC<W
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MB)Y(+."\CGAC^RSK*5GE\M)1@C:6[=<CW J'P[>-J4]]?--;D2,BB&"?S1&
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M03]:NV.F6.FHZ6-I#;*YRPB0*"??%6J* "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "C&:** $V+C&!2T44 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% "$ ]1FC:/04M% !1110
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MQ=^-V.<=,T .HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
%BB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>imrx-20211231x10k015.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 imrx-20211231x10k015.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %N R0# 2(  A$! Q$!_\0
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M3_KE_45OK]T?2L#QO_R)>J?]<OZBM]?NCZ5*^)FTOX,?5_E$6BBBJ,0HHHH
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M-4V.PL\6S9<$A4\L)O.< 8!SS70ZQJ.I'2],MK0BUU;4611E0WDX7=(<'(X
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M=#LKJZ-Q>A[QMVY([AMT<?IMC^[D<_-C=R>:K6QSM4HU&GJOZ\_\_F7UE62
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MS#)P2P[ '@TKHI4IM)I?U_2-BBBBF0%%%% !2CJ*2E'44 ?.'B#_ )&35?\
MK\F_]#-9U:/B#_D9-5_Z_)O_ $,UG5Q/<^[I?!'T1V7PP_Y'2/\ ZX2?RKVV
MO$OAA_R.D?\ UPD_E7MM=%'X3YG.?]Y^2_4****U/*"BBB@ HHHH *Y7XC_\
MB-??[\7_ *&*ZJN5^(__ "(U]_OQ?^ABIE\+.C"?[Q#U7YGA) 8$$ @]C0JJ
M@PJ@#T%+17&?;<JO>VIZ]\)/^0!?_P#7U_[**]!KS[X2?\@"_P#^OK_V45Z#
M773^%'QV8_[U/U"BBBK.(**** "BBB@ KF?%/C2V\+7%M#/9S7!G0N#&P&,'
M'>NFKR?XO?\ (2TO_K@__H0J)MJ-T=F HPK5U">VOY%?Q#\1=,U>;26;3+I/
MLMX)LB1<G"D #\36U%\6=,C1(H](NE4< >8O%>0R0"5E8LPV\@ U,GWU^HK%
MU961[D,IH<\N:.G35GTZK;T5AT8 TM,A_P!1%_N+_*GUTGRX4444 %%%% !1
M110 4444 %%%% !0.M% ZT 74^XOTIU-3[B_2G5N<S,#QO\ \B9JG_7+^HK>
M7[H^E8/C?_D3-4_ZY?U%;R_='TJ5\3-I?P8^K_*(M%%%48A1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% &5X@>RL]*NM3O(#,MK;2_*&()5
M@-R_C@<]JY+3;2+2]126[T>QCE@OXK9GMIY3Y?F(I0C=][#-@]..:ZOQ)<WM
MMHT[6.DC5)&1@;=G !&#U!^\#TP*Y31=)CBUV.2TT3#I,&D\_6/M"6X VY6/
M<<, -HXXH ]"HJEJCJMLJ8G=Y&VK' ^UG."<9XP, DG(Z51M[:.*\CCDM)K.
M5@3'+'<%U<CDAO4X]1Z\T ;=%%% !1110!SGB'_D8?#?_7Q-_P"B'K4K+\0_
M\C#X;_Z^)O\ T0]:E93W-J>P4445)84444 %(S*BEG8*JC)8G  I:, C# $'
M@@]Z (+.]MM0M_/M)EFA+%0Z]"0<''XU1C\2:3(DKBZQ'%&TI=HV5613ABI(
M^8 ^F:CTRTN+'3)+9K9@9;J;_5E?W:.S$-UZ8(X'-<Y<:#JE_IFGV'V-HGTR
MV=-[LNR=]R$!2#T(3J<=:EMV.NG2I.34GI?NMM3L;'4K741)]G=R8R Z/&R,
MN1D9# 'D5;K(TN.YFU?4=2GM9;5)TABCCE(W'8&RQP2!RV/PK7IHYZD5&5D%
M%%%,@**** "BBB@ H )Z4H!/05S'C;39]1M-,C@FGA?[?'DQ2%,K@[@<=>E-
M(3=C=B GFDF;)4-L09XXZG\\_E4=]9R75WITJ,H6VG,C@]P49>/Q-6XH?)B2
M-5.U1@4ZDQQ?+JC$U:UU>^$<48A6VWOYJ)<-&TJ?PC<%)'?('YU4N?#$D_V>
M:"<V<J/!F"/:T<:QG.$)7/J?0GK7344K(VC7E%)1T"BBBF8A1110 4HZBDI1
MU% 'SAX@_P"1DU7_ *_)O_0S6=6CX@_Y&35?^OR;_P!#-9U<3W/NZ7P1]$=E
M\,/^1TC_ .N$G\J]MKQ+X8?\CI'_ -<)/Y5[;711^$^9SG_>?DOU"BBBM3R@
MHHHH **** "N5^(__(C7W^_%_P"ABNJKE?B/_P B-??[\7_H8J9?"SHPG^\0
M]5^9X51117&?;GKWPD_Y %__ -?7_LHKT&O/OA)_R +_ /Z^O_917H-==/X4
M?&YC_O4_4****LX@HHHH **** "O)_B]_P A+2_^N#_^A"O6*\G^+W_(2TO_
M *X/_P"A"LZOPGHY5_O4?G^1YQ2I]]?J*2E3[Z_45RGUQ]-P_P"HB_W%_E3Z
M9#_J(O\ <7^5/KN/@&%%%% !1110 4444 %%%% !1110 4#K10.M %U/N+]*
M=34^XOTIU;G,S \;_P#(F:I_UR_J*WE^Z/I6!XW_ .1,U3_KE_45OK]T?2I7
MQ,VE_!CZO\HBT4451B%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 9?B.*XG\-ZC%:SK!.\#!)&?8%./[W;TSVKE(+.UN;W3HM&\)76D7=O
M<1O+=/;)"J1*?G4NI_>;AE<<YSGWKH?$^H6\5H-*>UNKN?48Y$2"V1&?8 -S
M?/\ +@;AU[D52\-65Q=6EG?Q>)=8GME)4VUW%"K94E2KX3=D$$'GMUH W-4"
M[(&$CI<"4>243>2V"""/3&<]/K5&RNI[G5$6\D9Q&SK"\4'EQ.XX;DLQ) R.
MPZXS5O6O-2TCF@@N)9HY 5^S[=RY!!.&ZC!Y%4=(VSW%NJ*RPVR'"&920YZL
MZX#;CD]<=>E &^V=IVD XXS6-X:NKVZM;[[?.DTT-]-"&1-B[5;  &3_ #-;
M55ET^U1'1(0JO-Y[!21E\YW?F* .*U/6=3L=)BU:*^E:2[NYK8PL%*1+EU4J
M,=5V G/7G-='I+W,&MZCILMS-<PP1031R3$%@7WAE) &?N _\"JP?#VEM<S3
MM:AFE#AU9V*?/]\A2=H)[D#)JQ8:9:::DBVJ,/,8,[/(TC,0,#+,2> /6@#'
M\0_\C#X;_P"OB;_T0]:E<_KL8@\:Z',MK(#*\H><RY5OW+?*%SP> <@#^=;G
MFC_GFOYFDZ;EJ6I\JL245'YH_P">:_F:#*H&2B@#W-+V+'[5%35-:TS1(8Y=
M3O8;2.1BJ-*<!B.<5<BE2>%)8F#QNH96'0@\@UBZSIDGB"T14NOL2(X>.00K
M(S>X#<"M6#]S;Q1-B0H@4N1C=@=<#I1[)A[4L45'YH_YYK^9IDVR>%XGC&UP
M5.">E'L6'M4-GN'\S[/; --_$3]V,>I_PJ>-"D:JSLY Y9NIJK9P0V,)BAC^
M4G/S,2?YU8\T?\\U_,T_9,7M22BH_-'_ #S7\S1YH_YYK^9I>Q8_:HDHJ/S1
M_P \U_,T>:/^>:_F:/8L/:HDHI@E&?\ 5K^9KR'5/$VM0ZM>11ZC,D:3NJJ"
M,  G K:C@Y56TF9U,2H;H]AHKQ/_ (2O7O\ H*3_ )C_  K8\+>(M7N_$EG!
M<WTLL+L=R,>#\IK:66U(INZ,UC8MVL6/BW<36[Z3Y4\D61+G8Y7/W?2O*[R_
MNBD>Z\G.) 1F4_XU]+3P6MUM^T6<$VW[OF)NQ],U =+TIOO:38GZP+7GO#2<
MN:Y[=/-80PWL>37O\SYX.HWF#_IMQ_W^;_&OH[326TJR)))-O&23W^45#_9N
ME_\ 0*LO^_(JV'55"K$H & !GBB&&E'J3CLSAB5%1A:Q+14?FC_GFOYFCS1_
MSS7\S6GL6>=[5$E%1^:/^>:_F:/-'_/-?S-'L6'M4245D^(+N2V\/W\T'[N5
M(2RNI.0:\I_X2O7O^@I/^8_PKHHX&=573,JF*C!V:/;*4=17B7_"5Z]_T%)_
MS'^%>@>!-3N]0T>XEO96N)%G*AG/(&T<<557 3IQYFT*&+C-V2/'?$!'_"2:
MKS_R^3?^AFLW(]:^D6T_37=G?3+-F8Y+&($DTG]FZ7_T"K+_ +\BO.>$EW/I
MH9_",4N3;S_X!Y%\,#_Q6D?_ %PD_E7MM4X;2QMI/,@L+:)\8W)&%/YBK'FC
M_GFOYFM88=Q5KGE8W'K$U?:*-M"2BH_-'_/-?S-'FC_GFOYFJ]BSD]JB2BH_
M-'_/-?S-'FC_ )YK^9H]BP]JB2BN \>ZUJ&G:A:)973VZ/$2P0]3GWKDO^$K
MU[_H*3_F/\*ZZ>73G%231A+&1B[-'ME<I\1_^1&OO]^+_P!#%>??\)7KW_04
MG_,?X5[(XAN(!'/;Q2H0"5<9!_ UE7P4Z:LWN;X7&Q513MLTSYGR/6C(]:^D
M/[-TO_H%67_?D4?V;I?_ $"K+_OR*X?J<NY]%_K##_GV_O\ ^ <=\(_^0!?_
M /7U_P"RBO0:K01VUJI6WM(85)R1&NT$_A4OFC_GFOYFMXT&E:YXF)Q:K595
M$K7)**C\T?\ /-?S-'FC_GFOYFG[%F'M4245'YH_YYK^9I1(,C]VOYFCV+#V
MJ'T5XQ<>*=<6ZF5=3G #L  1P,U%_P )7KW_ $%)_P Q_A7;_9E3^9'-]>CV
M/;*\G^+W_(2TO_K@_P#Z$*L^$/$&JWOB6W@N[V6:%E<E'/!PIQ7HD]O:714W
M%E;S%> 9$W8_.N7$8.4/<;._ 9A&E557EO:_Y'S5D>M.0C>O/<5]'?V;I?\
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MN_;*Y0'@CJ >>?2JZPZC<:C:S7-O:11P;SF.=G8Y&,8*+_.@#4HHHH ****
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MXD99>:I:?X9U&U\,6UI?Z+?2W,5Y=LLNG:H$N+<2,Q5XW9UW@YYWL#G!*GG
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MGW%^@KP2O>T^XOT%<V.^S\S7"]1:***\\ZPHHHH **** "E'WA]:2E'WA]:
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M  <=*Q;JSLKKX@Z]]K\*_P!N[;>TVGRK9_)X?/\ KG7&?;/3GM0!WUS:V]Y
M8+J"*>(D$QRH&4D$$'!]" 1[BH+#2M.TN!X-/T^ULX7;<T=O"L:L<8R0  3@
M"N(\3V5BEIX5MT\,*ELVJ,6TD16XR?)EZJ&\K_:^]^O%2^&8K2X\;7,FD:)_
M8$.GVYM]0M62*-KB1R&B/EQL5VJ%<B3/.X@9 . #L+#1M+TI)$T[3;.S27'F
M+;P+&'QTSM SU-+9Z/IFG%#8Z=:6NQ"B^1 J;5)R0,#@$\X]:\K\(7+:WIGA
MG0]<MY[/1&M ;6-\;-2F0\JY!X0=0AQOQD\  ^OQQI#$D42*D: *JJ,!0.@
M["@!EO;06D(AMH8X8@20D:!5!)R>!ZDD_C4M%% !1110 4444 4=8U Z3HUY
MJ @:<VT32>4IP6P,XSVJG9S>)))X3=VFEQV[<N8KEW8#VR@!JYJ<=Q/!);I;
MPS6\L$BR>9,T9W8&U> >#ELG.1@=:XCPUIUN-3M'M+/21'%(4#6WB"><H5'(
M"$;6(!'!]: .[OS<"WS;1F1P>4#JF1@]20:P-$O3<ZLB27Z7#HK;4-W!*5]>
M$0,/SKH[L1M93B9BL1C8.1U QS63IUO.;Y)6$@BQO!: +D[ O7<< @ XQUH
MW**** "BBB@#FO$G_(>\.?\ 7Q-_Z(>KU9GB..7_ (2GP[(9R83-,!#M& ?)
M?YL]?PK3K2.Q+"BBBJ$%%%% !1110 4444 %%%% !1110 HZBO#]8_Y#=_\
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ME$!9XR<A7!!S@\C&",FM2B@#GG\':;)X2MO#C/<_9K94\B<.!-$R'*NK 8#
M]\?SK>A1HX8XWE>5E4 R. &<@=3@ 9/L /:GT4 %%%% !1110 4444 9GB*W
M%WX<U&W-VEH)+=U,[G"ID=3[>M<I!8:F^II]LTFSTN ZA!.DXN48*414V1@
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M[MY1^==Y<KCWZ5I&12?XO^^34GF-ZT;V]:3DWN"BEL1^8O\ M?\ ?)H\Q?\
M:_[Y-2;V]:-[>M(9'YBXS\W_ 'R:-X_VO^^34F]O6C>WK0!'YB_[7_?)HWK_
M +7_ 'R:DWMZT>8WK0!'YB_[7_?)H\Q?]K_ODU)O;UHWMZT#(_,7_:_[Y-'F
M+_M?]\FI-[>M'F-ZT"(_,7_:_P"^31YB_P"U_P!\FI-[>M'F-ZT 1[U_VO\
MODT>8O\ M?\ ?)J3>WK1O;UH CWC_:_[Y-'F+_M?]\FI/,;UH\QO6@"/>O\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M->%M;L/$-I=76GR1PQL2SDC X(]:[*E6FX.TEL<\(24E='I%%%%>,>@%%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MZ99SJ%FM[2*)U!R RH ?U%:%% '.:M;7U_XETKR]/F6ULY))'NC)'L;=$5
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MD96D &XJ, GO@<XIU',PL1PAE0*5(QW.*DHHJ1A1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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? **** "BBB@ HHHH **** "BBB@ HHHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>imrx-20211231x10k016.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 imrx-20211231x10k016.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" (S \L# 2(  A$! Q$!_\0
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M]ZK:IJ=MH]BUY=EA"K*I*C)RQ 'ZFFVDKF<82E)02U>EBY12*P90PZ$9I:9
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MCM9;+;7[]PHHHK8\H**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MR7C_ 'I*]L,2<GU]:Z+0(9(-#M(Y!M8*3CTR20/R- &E1112&%%%% !1110
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MCD\3:3$SJ]T0RXROE/GIG &.2 <D=N]1ZCX<AU.]DN9[AV#Q"-8WC1U09!.
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** +-O_ *L_6IJAM_\
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M*F^RM_ST'_?/_P!>@VK=I!_WS_\ 7H AHJ;[*W_/0?\ ?/\ ]>C[*W_/0?\
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M=<+_ /7H BHJ;[*W_/0?]\__ %Z/LK?\]!_WS_\ 7H AHJ;[*W_/0?\ ?/\
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MVNI6M9)VA-JP6.,A<29&#GK6'+#XFMKF2!9;RYA54!F4;6R,=.2#DY).!@4
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MOL!=HYGR" <?+]XY [9 X(]:[VN)TBX>[\81WNR 17,4KH(67>H&!B3OG^5
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M7=W&IRVLD%M!:^>QMS*?G"X"X'Y\T0JWO<K%9?[-1Y-W?1OLD^J7=]$:U%9
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M:+XOR\O\_N[E>ZD@\L1EFVA@25ZYSQS5Q,>6NWICC--/EP1?.1C/)QU-/!!
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M6<-E8PQ6D#QQ^<I(B("CD?>R<G\*VJP;N^@U2QCF@C)"3+D295EY'..^:WJ
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MFV08CSG:1R?K0Q1LG=BHHD0#G9W/]XU/TH P /2BF2W<****!!1110 4444
M%%%% !1110 4444 %%%% !7(>&+8+XCU:=K>:*1G8?,A5",]5R._UKKCG!QC
M/;-<3X65SXNU26:*T63!7=;P+&3R,[\'.?3- '3ZAH]MJ3J\S2JZKM5HVP1R
M#G\Q6</!NEK]UKA2/ND2<J3C)''?'-;\DB1(7D=40=68X J(7MJ02+F$@ $G
M>._2@#+MK:&U\0K# L*(MM@*L1#=1U;//Y5MUE[L^(U&Z0C[.2 4^7J.A[UJ
M4 %%%% !1110 444TRQJ<%U!]": '5A:CJ$]]=MI.E.1*/\ CYN0,K OH/5S
MV':G:CJ%Q=7ATG2F N,9N+@C*VZ_U8]A6CIVGP:99K;6ZG:.68\L['JQ/<F@
M"I;^'-,MDA6. @Q9*MO.23U8G/)/<UJ@8  [444 %%%(S!5)- #7D2/&]@,^
MM,+F08C!QW;I4+Q/=,CE@JJ<CC-6BRH/Z#FD,:L; 8W87L%_QILOD1[6EV]>
M"W-.+DCDA!WSUK,U36M,TDQ/>2(&=L(7ZY]J3:2NQI-NR-0\C+<+Z5E7&J2W
M3FVTL!CG:UP1E5]<?WC^E0/]IU@@OOBM&^[%T:0>I]![=?I6S;6T=M&%10,#
M' X ]![4KN6VP[*.^Y6L-+BL]TAS)._+R/RQ/UJ_115)):(EMO5A2,0H)/04
MM,'[QMW\(Z4Q H).YNIZ>U/IKNL8RS #IS3J "BBB@ HHHH **** "BBB@ H
MHHH **** "N-U2-9_']GM\\-%$"VV8!2#_L["?\ QX5V5<1K#Q2^.;%9+6=)
M(R,3J6*X[9PVT9]QF@#J=6TR/5K$VTA"_,K*Y7=M((.1[US<O@1IVF,FI+B;
MY7VV^"$VX&#NX;W_ $KLJ,CUH YC^Q6TNQ7>_P!HD:5-SQ@QHH! 'R[C73UD
MZZ(C%;%_(+"9=GF+ELY'W3V-:U !1110 4444 %%%% !4-U<I:Q;WR23M51U
M8^@HN;F.UA,CY)Z*B\LQ]![U!:VKM-]KNP#.1A%ZB('L/?U- %&[T"/68MVI
MMEV.0BHC+&,Y &Y3^)[UJ6=K'96J6\7W$&!\JK^B@#]*GHH **** "BBB@ H
MHHH **** "BBB@ HHHH **0D $DX ZFA65U#*00>A% "T444 %%%% !1110
M4444 %<UIL5FWB[49X[]?M'W'M%C(/ 'S$L3G_@.T>H-=+7%:+'!)X^U692J
MR)(RD>7\S':O)?J1TPIZ=J .IU:T>^TJYMHPA>1"J[^@/K7)7'A&_COIC:[7
MM#M'DRS<.!&$7!"@J!C)!)Z9KN:* ,.S@GMM;M8I[JXN&6RD&Z54"YW19VX
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M. !ZFN>,]WXH&RSDEM-'/WKI1MDN5](\_=0_W^I'W<<&G1V%UX@D%SJT;06
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MTZ/Q]:>]W(F-VD7_ "<#YX3S_P!_*MZ7=27FF6]Q*A621,L"FWGZ9/\ .K=
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M'('3IWYS6S0 4444 %%%% !1110 4444 ,,,1F$QC3S0NT/M&X#TSZ4^BB@
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MH Z2UOH+TR"!BVS&3C@Y&01ZBK-9VEZ1%I2R+$[,K !0QSM '3-:- !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@"EJ]O/=:5<0VTCQSLGR,C;3GZ]JYZ]TO6_.W1/<
MRQM("56X (_=D<<C@-@D?SKKJ* ,RSN;E=1^Q7%S!,P@WML3:5.0.>3ZUIUF
M*''B0EA&%-L<%>I^8=:TZ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M#R2< ?G5FLKQ#_R#H/\ K]M?_1Z4 :<<BRQJZ'*L,@XQ3J** "BBB@ HHHH
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M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%5[RZ-I#O%O/.Q.
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M@ K&\2VLMUINU+F"VB#9FDF<H G?G_'BMFN:\=&8^')$BW8D8(Q49(!_$8H
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M3[">UY,DICQGZDY(]L5Z!142A?J5&?*]C'Q>GHUO'_P%G_J*/+O3UN80/]F
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M[$V7<AM/^/9/Q_G4U9/A70;S2M($%QJL\[%V8'C Y]^:W/LC_P#/W/\ FO\
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M_<?_ -EJQ5/9#,<VSQ\V\I3_ &&^93_4?A6'JVK:I::UIUK'IT<B3.0)/,.
M>_;TYKM*JW(!N[0XZ,W\JUHU$I7DKZ/\AQ>NIFZGYGV!O+8J=R[MK;21D9 /
MJ:PFGG:Z-G%'.8_.&V%Y2I(V9(W9XYP<5VLT$5Q"T,R*\;#!5AD&JYTFP-N(
M#:IY8;?CON]<]<U@28D5[<0^$IYT9S.G[L\\J=^T\^W/-.6"Y>*XMD9XI(]D
MCHUTQ4J0>C8R/4_2MQ;"T2,1K;1A ACV[>-IZBDATVSMX9(8K=$23[X'\7UH
M RM'U!FG6*Y:5I6"QJQ'R\+G\R.:WZKBQM1="Y%O'YX7:)-O('UJQ0 4444
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M@-N.1^!R/PK<UC_D"WO_ %P?^1I+7,.H75N22'Q,F<]^#S]1T'K[T 7J***
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M#4U4+(?9[NYM?X2WFI]&ZC\\U?H **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "O//B;9K=SZ.)0PA\QA(_RD$?*=IR.,XZC!&.M>
MAUYW\1+2/5=6TRSDMI2D/[UIT1'V[F"A0&D0C)&,\]1B@#NM-L(M+TRVL(&=
MHK>-8D+G+$ 8R?>K5%% &0ZJ/%MLP@*L;*;,O'S?/%Q6O60^/^$MMN9<_8IN
M"#L^_%T]ZUZ "BBB@ HHHH **** "BBB@ HHHH H1*+;5YD  CNE$O\ VT4
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M&>!^\49QZDE<_P#?% &A1110 4444 %%%0W<<\UJ\=M<?9YB/EEV!]I^AZT
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MXV (8$'-5]-D+V:HV-\1,; 8X(^G3C%6ZH(#;:PP'^KN4W8ST=?08[CJ<]J
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MU#%G"C&1T^4"J^G*L4<]BP^:V8A>V8VY4@9Z#E>>I4U8L47^S[?C_EDO?VH
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MSJ-N_KW"BBBJ.<**** "BBB@ HHHH *\R\<Z5"WC72+J.Q#2R,H>00%F?##
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M  Z"E  Z#%+V7F4JOD5=.N);O3X9YH_+D=<E:M445JC%A1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M[&M&1Q'&SD@!03EN@KC-/\7RW%U:;8;>X6[NS;FZME8IL4#&>3ALD\$].<4
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M,-NUR4E4O(F ?FP&7.1D8'US6_ISW4NG027HC%RR N(@0H/L"3_.@"U1110
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MBSOY8VMGYNP..A^M6ZY2U\%QZ??)+:73B+S8W9& QA/IU)QUZ_6NKH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH R]4\0Z;HT]O#?2RI)<'$02WDDW'TR
MJFI8-;TNY1&COX/GQM5G"L<^QYINIZ1'J=Q92R2NAM)3(H4#YB5*X/YURL?P
MNTM!'FZF9DD:3>47)R5[^VW]30!V+:C9+!)/]IB:.,[796W;3G&..^34::SI
MLDTD2WL.^-@K MC!(R!]:YO3?A_;:-H]W8VE[-(9Y4D#38XVL" <#GIUILGP
M]@ED#OJ,PQ*LFU8U ^7;@''7[O4^IH ZJ74;*(9>ZA'R[@ P)(]AU-6(Y$FB
M62-@R,,@CN*XN'P$%1)OM)BN$=V14P0JG.U V,X XYS_ %KKK"V^QV$%L6W&
M- I/K0!8HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BO)_%7QJ3PWXS.@#1I)P&C'G,Y0_-C^$KGO\
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M[DCV]:MUQ]EX#2RO5G6_++GD&$;@-V["MGBNPH **** "BBB@ HHHH ****
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M$M;&*2)9(9(G8L3@A3SCBJ,OAF[?2K^U$L&^XO?M"G)P%W X/'6NI9@JEB<
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MN^6P_I0!B?9+C[0)+RVN98P[XV$DC*KCH?7-7;F.\_L.",QNTFX;@<L57/<
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M*HM2AEFLE11O<.I.T8[\U>HH P;R^):]BGE5XP&3R0HST&#Z\DU7A@FS:2W
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M32SW(BM[D7"S*(Y&?*Q@ 9!YKK*15522J@9.3@=30!R+V>I2WG^IF5)-PDV
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
0@ HHHH **** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>imrx-20211231x10k017.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 imrx-20211231x10k017.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" (/ \L# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MPOHEVMZL^GQN+YE:Y!)_>%3E2>>WM6O14A8S[30M,L;[[;:V:17'DB#>I/\
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M>$Q$G;)LR:2VOY1X?D8S;IP&\LD_,R@\''>M.?3H+B\2XF4/M0KL9015@0Q
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M&8I86U9)[EKB07IS(RA2?D7L.* -ZBBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***R-5U6_T^6/R].B
MGBDE2)'-SL.YC@9&T\9/K0!KT5%;O,\"M/$L4I^\BON _' S4M !1110!E>(
MO^00_P#OK_,5JUE>(O\ D$/_ +Z_S%:M !1110 4444 %%%% !1110 4444
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M-MM_+#?-VX&:Z&L2T6\7Q1<&ZE@=#;_NQ%$5*C=W)8Y/TQ6W0 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 -DD2&)Y9&"HBEF8] !U-<9!JDOB+5##;>(+^R5LM!'#IWE J #R\J'<<,
M#Q@8(X[UVC*&4JP!!&"#WK@_$<$R>*+"SL$U-4CLF*)I9A1U^8#EI2!CV!H
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M]^U/\+JBG50EH;5?MIQ$0HV_(O\ =)% &_1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %9&O_P"IL?\
MK^@_]#%:]9&O_P"IL?\ K^@_]#% &O1110 4444 97B+_D$/_OK_ #%:M97B
M+_D$/_OK_,5JT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% #9)$B0O(ZH@ZLQP!5>VU*QO79+6\MYF7J(Y Q'Y5@>*X]2N)%CCAL
M/L$49FDDN[=Y1N'8!7 _ T:$WAK5X[62WBTPW\:+(ZVH52C8YZ>_;)H ZFBJ
M>JDC2KDB\%EB,_Z00#Y?OS7!0WFH3S6]M'J.H1Z3>3XAN99B)BJH22&/(4G&
M,_RH ])HKRBT\0ZO-8MJ+ZG,\]F\444 ;"S@R,I9@/O$A1S6MH.KZC]LL[EK
MB[U![U;AI;02)A"CD*$#$!<  =10!T5@ULWBJ[$%T\SB#YU:4ML.[H >E;]8
M&G7<]UXBF,VF7-D1;# G:(EOF[;';]:WZ "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MS%:M97B+_D$/_OK_ #%:M !1110 4444 %%%% !1110 4444 %%%% !1110
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MQ2V(]'_Y UG_ -<5_E5VJ6C_ /(&L_\ KBO\JNTEL$=D%%%%,84444 %%%%
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M#%+8CT?_ ) UG_UQ7^57:I:/_P @:S_ZXK_*KM);!'9!1113&%%%% !1110
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M0!E>(O\ D$/_ +Z_S%:M97B+_D$/_OK_ #%:M !1110 4444 %%%% !1110
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MOXENHK)[ABL #^=+*^#N[%R?TKI*Q;62Y?Q1<">W6)5M\(PDW;ANZXQQ6U0
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M[2S"&,0-ND,7F!1CKM[_ $K@OA593VDMX1X9CL;60934/*:!KC_MFY+*/R%
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MTAN=.9R< 1W\;LW^Z!R:WKBY@M(6FN)HX8E&6>1@JCZDTD[B4D]42TA( R2
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M'*O1U##\:DID48AA2)?NHH4?A3ZXW:^A 4444@"BBB@ HHHH **** "BBB@
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MUHHH ,GUHR?6BB@"6 _O:M55@_UH^E6J "BBB@ HHHH **** "BBB@ HHHH
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MK]X,Q/&/0BMVO+O#]]-)\11)]K9C/<74,MKY[-+&%4%3)&>%3Y?E( Y<<G-
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M/M=::^M:;IT/B".34XU@>:\?4 (U4?P1KN^<O]#QR3TH [S_ (1O2/M_VO\
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M2!F4>9YC(N<\!F7D+GKR*\UBU!6LH%U#4Y$MXK:Z^Q2K=L%FG65=NQLY? )
M!ST- 'LE%5M.:5],M6GSYIB4OGKG'-6: "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@!&.U"<9P,UPVA:SJK7MG///->K?+.QME5
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MF8E3@ =S7E^O67B6#P[X8ATRVU:-X]&O%G2VCD!27R/D#!>C;NF><]* /9B
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M6=U);P7$<L$:S;+F(IOC8XW#VKHXW$D:N.C &@!U%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% ''_\(WJ+:X QM_[-%\;X2!SYFXJ!
MLVXQC(ZYKL*** ,GQ$FLR:1)'H?D"\<@!IG*A1W(.#S^%-\-6$^FZ.EO<6T<
M$P8LX2<R[R>K%B!DGZ5L44 %<?=^#[Y_%]OK<.JL4$V^2*2-?E7;@*IQTKL*
M* "LCQ/H[Z[X?NM/C=4>0 J6)P2#G!QVK7HH Y[PKHUQI$-WYT,%JL\@9+6W
M<O'%@8."0.OTKH:** .%\3^#;S6=?6^BCMG.U!%/+(RM:E6R2% P^?>NY'
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M)HHHHXX;>*0(&"J=S9"$@9(4=<\5V]%%PL<Y+X6::YN@U^_V&YG%Q)!L&2V
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MQJ]K8^0J6=J)!)>/"%=U8 8#!CNZ>G%7K[P/=Z6ES>6<GVPR7*7!MS").C9
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MX0U[3+JQNH397<ML%!5Y#&#QCLIZ?K0!W&GZI9ZI9BZM)2\1)4[D9&4CJ"K
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M)-=S5273K:?48+^1"9X$9$.> &QGC\!0!P>F>,=4N[ZW6XN[>.\>[CA;2?+
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MRAY2Q<?<)&"_7 SGVKK/"SWTD%R;EKUK?S!]G:^CV3%<<Y& 1SZB@#?HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***,@#.>* "B
MHHKB"<,89HY IPQ1@<'WQ3RZ @%E&>G/6@!U%1)<P2R/''-&[I]Y58$K]14M
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M9-K-QY=LL A,LW'S=!\V* -VBL*?4+LQ7!\VW14+1;22&+ =1_A31J=Y!%'
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M^N14$!DD6!9[B0)-.T;X<C 48"Y[9(_6@#H#!$5VF),9SC:.M1#3K(1-$+2
M1L<E?+&"?I4-@8(GG@AN))@C]&);8<?=!/7_ .O5B*X:23:;>9!_><#'\Z '
M&UMS&8S!'L("E=@P0.@ID5C:0@B*UA0'KMC K)A,#V[7US>RQS+.RDB0X7#$
M!=O3ICMWJ:YOUF,$L)D4K(ORG@.K<9H T8;*UMQB&VBC&=WRH!SZT/96LB%'
MMH64G)!0$?YYK$BU*:S@M85*OYLDB9D8DIAS@D^G:I-0ENK>^E NGV/", #
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M:TB8G)* DT 34444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4THA<.5&X @-CG![?H*=10!7CL;2)BT=K"K$Y)$8
M!)SG^?-2-;P.,-#&1DG!4=3UJ2B@"&*TMX%588(HPIRH5 ,&BXL[:[V_:+>*
M7;]W>@.*FHH B6V@12J0QJK#! 4 $>GZTD=G;11B..WB1 VX*J  'U^M344
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)%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>imrx-20211231x10k018.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 imrx-20211231x10k018.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" () \L# 2(  A$! Q$!_\0
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M;+'/_K5$8P_UJ"?Q)I5MJHTZ:YV7!8)RAVAB,A2W3) Z573QEHDEO<3BZ8)
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M10@L 1G9G]:Z@=!7-^+)@D5M&;]H2TT?[D1@B3YQWQQ71CH* %HHHH ****
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M1;X6A+,WSCHV1C]:ZL=!7-^*9!!;VL*7=I"K31#R9(\O)\X^Z=PQ^1KI!T%
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M &.T[0/J* .GHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH R-,_P"0WJ_^]'_Z":UZR-,_
MY#>K_P"]'_Z":UZ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH Y3QPR);Z<\GV8*+CDW2%XAP?O*.M7O"\D,EC(8#IQ7?\
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MH<JI48'TKG_&2.VEY6TLYE'WI)I2KQ\CE!L.X_B.@H Z2BBB@ HHHH ****
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M1]]_GW%FZ=.,TAFV/&&AM:27(O#Y<;*K Q,&RWW<+C)S[4]O%FC(\"/=E&F
M90T3# )P"W'RY/KBN270]3OK!Y]7\.W-Q>M<I+,GVN./*J" (MCXPN>C$9J.
M'PWXA@M[NWDLVG_M&.- [7"DVH5NCDG+8'=<\T =/XL56AM6\F[?]]'AXGQ&
MOSC[PR,_D:Z,=!7)^(+**T@M\R:G([31?=FD:(?,.HS@5U@Z"@!:*** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M-P(&$<:NC,=R[\DC;CJ,U%#XTUNY2[E1;%%TP+]J4Q,?/);!V'=\@QSSNYH
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M#N9N_L.U<V8M5_L_6KG3];O3&US'8VGVN\P,B11(X8C@G)4?3WI#/2ZYOQE
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M-'B"7&^7YQ]W)!_0UT8Z"@!:*** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "LG2?^0EJ_\ U\+_ .@"M:LG2?\
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M3;<GW^5B/UJQ0.@HH **** "LG2?^0EJ_P#U\+_Z *UJR=)_Y"6K_P#7PO\
MZ * -:N)N,^-?$QM <Z!I,H,_I=W(Y">Z)U/J<>E7_%NL7,1MM!T@YUC4LK&
M1R+>(??F;T ' ]20*V-&TFVT/2;?3K12(H5QD]6/4L?4DY- %^BFNBR(4=0R
MD8((X-9\%C:?;[D?9HL+L*_(..#4R;32144FG<TJ***HD**** *M_P#ZA?\
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M110 4444 %%%% !1110 5E>)/^0!<_\  /\ T,5JUE>)/^0!<_\  /\ T,4
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M_P @U?\ KO'_ .A"@"]:6L-E;K# I6,<@%BWZFIZ!THH *RO$G_( N?^ ?\
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MOG@'TKI-)EO)M,A>_C6.X*_, ?U/H?:L(5U*M*G9Z&\Z#C1C4NM2:^!:PN%
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MPKU2FQ(**1MP4[0"V. 3@$UQ$_C75K*#5Y;S1K(+IYBC#P7SNCRNP&PDQ C
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M?[5=?X1T.Y\/Z,UI=2Q22M,TA,6=HSCCGZ59\0_\@P?]=8__ $(5JT %%%%
M&5XD_P"0%<?0?SK5[5E>)/\ D!7'T'\ZU>U !1110 5'-"EQ"\4@)1Q@X.*D
MHH S+30-.L;CS[>)UD)R3YC')]\FM.BB@ HHHH **** "BBB@ HHK!UI+>.6
M-_M\\4CRJ&5;ME !]L\5I3ASRY12=E<WJ*KV<<4< $,SRIG[SRF0_F2:L5#5
MF,****0!1110 4444 %%%% !1110 4444 %%%% !1110!QOQ%NY(-*LX!-Y4
M5Q/LDVVXG<C&?E4]:M>!@J:0\:7%S,BO@>?:"W(^BBCQM8R7NGVWE6EU<212
M[U^S72P,IQUW,#4?@2X:6QNXI$O4EAF*.MY="=@?J .*?074ZRN?U7P_+J6I
MW$XDC2&;3WM3UW!B2<XQTY]:Z"BD,X(>$]=:YAU20Z>-1M)(O(A69S$ZHK*=
MS;,@G=G@'&.]11>"M9MH[F*.2Q==2"_;&:1P82&R=@V_.,<<[:]"HH Y+Q#I
M5I:PP21:69'\Z+=<*X 0[QU!;/Y"NL'05SGBR(/%;.;.>4K-'^]20!4^<=06
M!/Y&NC'04 +1110 4444 %%%% !1110 4444 %%%% !1110 4444 %97B'_D
M&K_UWC_]"%:M97B'_D&K_P!=X_\ T(4 :HZ44#I10 5E>)/^0!<_\ _]#%:M
M>8_%SXC#P9#::>=+-Y]O0OY@G\O9L9>VTYS^% 'IN0JY)  &237'7GB#4/$=
MU)I?A1U2)&V76KNNZ.'U6(?QO^@J'PMKEK\5?!375U936-N\YB>".Y)+A<'!
M8!>#GD5V5I:6]A:QVMI!'!!&NU(XUPJCV% %#0O#UAX?MFCM%=Y9#NFN9FW2
MS-_>9N_\JU:** "JMK_Q\77_ %T'\A5JJMK_ ,?%U_UT'\A4RW14=F6J**JW
M=X+:(F.-IY<@"*/DY/3/H/>FVDKL23;LBQ*S+$[(F]@"0N<9-<-HFLZS/XGF
MCE@++(<2Q8P(P.AS_G-=M;F9H$-PB)*1\RH<@?C4%NBC4;Q@H!(3)QUX-<]:
MG*I*$E)JS.BC4C3C.+BG=#KRWN+@((;Q[91G=L0$M^)Z5%)I,$YC,\D\I10O
M,A ..Y P,U?HK9TXMZF*J22LBNMC:K,9A;Q^:>K[1G\ZL8QTHHJDDMB6V]RK
MJ !MUR ?WB?^A"K55;__ %"_]=$_]"%6J2^)C?PH*RK:%UFU. CYI&WJ3W!7
M']*U:*)1O8(RLF8O]G7<%GICPK')/:)M:-FP&!7!P?6JG]D7\JS[HTB626)T
MB,Q?:%8$\FNEHK-T(O\ KY&JQ$E_7G<S-4TR6_=&CEB0*,'?&S?R847%A+_8
MWV4)!<.,91LJK8.<=216G15.E%MON0JLDDNQAQ:9<_V5?0^6D33DF.$/N"<>
MM6;S2UN1$5B02X"M*>J@#M_+\:TZ*7LHVL-UI7N<XUG?QV4MO<-O,LB)$H<O
MCGD]!@8QQ[5T8X&***<*:@*=1SW"BBBM#,*R/%.I3Z1X7U'4+7;Y]O"73<,C
M(]JUZAN[2"^M);6ZB66"5=KHPX8>E 'G>F2>';G6+2[/A?51>RSK)Y\L3&-9
M&.=^"V  3GIQ7I5(BJB*BC"J, #L*6@2"L)?#GDZ1/9VVH3P3RW)N?M*@%MY
M?=R#P1QC!ZBMVB@9Q[> P,S0ZO<17DRRI=SB-#YZ2$%AMQA<%1@CISUS4GBB
MVAT_1([>V-A$BH$Q.O[QP-H&PY'/Y]JZRN<\8LXTHA8[-@1R9WPXY'W!@Y/Y
M=J .CHHHH **** "BBB@ HHHH **** "BBB@!&)5"0I8@=!WK'M]=EN+Y[3^
MR+U'3:7+&/"@YP>&]JV"0JDL0 .I-85CJ-B_B/4 MY;DM'$%Q*O)^;IS0!O5
MSFIZO?:C$]IX7>VFN5F\F>Y=@4M>,DD?Q'V'XT3R:QJ^LRV LEM=%C!2>>4D
M27&1TCVD;1_M&MC3=,L](LH[.PMT@@0<*H_4^I]Z (M.T>VT]WN B/?3!?M%
MUL"O*0,9./Y5H444 97B'_D&#_KK'_Z$*U:P?$ETXMQ;1V5Y.^]'S# 67 ;U
M'TK8M;@74 E$4L8/\,J%&_(T 34444 87B>Y*Z;);1VMU-)( 1Y,+..OJ*U;
M2[6\A\Q8IHQG&)8RA_(UFZUKXT=CO%J1C($ET(V/T!%7-,O_ .T(6D'V<J#@
M&"<2#\P!6KHS4.=K0GF5[%ZBBBLB@HHJ.=IDB)@C623LK-M!_'!II7T DHK+
MM-0O[FXDC:PB18WV.WVC/Y#;6I3G!P=F).X4R;S?*;R-GF8^7?G'XXIQ( R3
M@>IK(U;6["!'LO[3B@O9%Q$%.Y@3T..:=.$IRM%7"326H6MWJ\U[/ \=D%A*
MAB&?)SZ<5L5XMX0U3QE>>-KBSN;N>6*!_P#2L(B@X^[DXXS[5Z;#_P ))=B8
M3BPTY&7$1C)GD4^ISA:]#'8%T)J+E'9/1]_Q,:57G5[,W*IWVK:?IL8DO;R&
M!3P"[@9K/C\.&:RDM]5U2]U#S&#,2XA QV CQ@>V35VUT73;.".&"RA"1DE
M5W$$]3DUQ\M&.\F_3_-_Y&EY/H5;CQ'!'-%%;6=[>&50RM;PDKM/?<<"O-_B
M5X8U?6M:MKRWL/(C>18/,$^XOGHQ4#C'UKV   8 P!V%9^K_ .KMO^OA/YUU
M8'&?5JRG2CKY_P!(BK3YXVDQVB:7%HNCVNGPYVPH%)/4GN?SJW/*(+>24C(1
M2Q'T&:DIKHLD;(PRK @CVKAE-SES2UN:I65D>?RZ;%JG@>YURZDN#>21R3HR
M3N@7G@8! X ICV2V6BZ':6=Q<P-K$B)<S^>[-C;D[=Q.,^U=)IFB2+X>N=#O
M=RP9>..1",F,G(QUP15J]\-V-]HT&F2M,$MPODRH^V1"O1@<=?PKU/KD8RY6
M].9^EK:?=O8Y_9-J]M;'-6\=AH7B>"ULGU*U$RO&T4RO)%.<9R&9N"*V/!]S
M(?"B3RF29U:0]<L<,>*;!X-B&H6]_>ZMJ5]<6Q/E&>1<*",8P% _&M;3M'MM
M-TO^SHR\D'S9\P@D[CST ]:RQ->E.'*G=Z7?I?Y]5N5"$D[VLC/M?%/VFZC@
M_L;4X][8WR1*%'UYK&\:WEP-<T^RC^WSP-#)));:>^R7<.C$\?+^-;]OX2T*
MUN$G@TV%)4.Y6&<@_G1J_AR/5+V&^BOKNQO(D,8FMBN60]00P(-*E5PT*RE%
M65GOW^]_@$HS<;,XO1KF^\22VUA<ZG=QQ6]FTK>5*4D9]Q W$<DC%+:WGB.X
MMX;UI[UXHE 26.55C^4_,9 >3D5TC^!K)8[?['?WUG<1(R-<1.N^56Y(;((-
M:JZ#:QZ3!IL;2+;1$$C.2^.<$^YKIJ8VA?W$K/I;;>_W_P##D*E/J9&DZQ:7
M[7%I=WC?;+PG]WSM08X4'IG'-7_"5[+>Z&//8M)!*\!8_P 6TXS4;^&+:VO7
MU"W>Z=D9IH[3S!Y0D(^\!C/ZXJWX=TQ]*TA()2#,[-++C^\QR:Y*\Z,J;<.M
MOUO^AI!235S5HHHK@-@HHHH **** . \4:M;3>(9-(U33+N_LXXEEC6T1BRL
M>N2".*WO"*Z:NFR+IFEW.GQ;_F2X0JS'UY))K:6RMDO'NUA47#J%:3') Z"I
MZ8K!4<Z&2"1%E>$LI D3&4]QD$9^H-24C ,I4C((P:0SSD77B9M,N)K'5KZ\
M6>^6"V+BV641KG<RDHJDDCN#Q447B35+F&[GM]4O$72XXRT5Q'"6G<MAA(57
M'L-N*[J?0-+N--33Y;1#;1MO1 2-K>H(Y!Y-0'PGH1: _P!G1#R  F,C@'(S
MS\W//.: ,KQ!<?:X+=GLM00K-%AU<K']X=0&P?Q%=:.@KG/%@C\JUW+>[A-'
MM\DN(Q\X^]@X_.NC'04 +1110 4444 %%%% !1110 4444 %%%-<,48(P5B.
M"1G!^E #J*Y^R;7)-8N;>;4K1H;<H2%LR"X(R1G?Q704 %%%0W5W;6-NT]W/
M'!"O5Y&"@?B: )JX[QQXOT'04AL=3U&*WN9&CF6-\Y*;\9_0_E5NU\:6FIZA
M';:/97FH1EL2744>V&,>N]L9_#->9?&_P-J7B7Q%8ZC9W%E'%%:I;LLTX1MQ
MD8YQZ?,.: /7K7Q'I5[X?&N6UVLVG;683("00"0<#KU!%8W_  E^HZC\N@>&
M[VZ!Z7%X?LL/URP+'\%H^&>AW'AWX?Z;I-Y)!+/!YF]H7#H<R,PP?H1774 <
MK::/XKO+R*ZUGQ!#;1(X?[%I<&U3CLTCY9AZX"UE_$/X>P^,9[6]GO$B6T0H
M(VM_,W;B.<[ABN^K(\0ZK:Z;IY\]OG<@*@ZGFLZTHQ@W(THQE*:42CX(\)+X
M,T-M,2Z6X4RF0,L/E@9QQC)]*Z6J]E>P:A:I<6T@>-AP1V]C42:O8RLZQW =
MD4LP4$\#K34X)+7<3A-MZ;%VBJ":O#+%))%#<OLQP(B"<^F>M)_:,[6_F1Z=
M<EMVW8V%/UY/2E[6'1C]E/JC0JK:_P#'Q=?]=!_(4YGN7L&>.)8[DH2J.V0&
M[9(KCO"SZZ==N?M 8Q%C]H\WH#VV^_\ 2LJM;EG"-F[FM*AS0G*Z5CJY+JXE
MO?LT%NPC7_6SL< <=%]3^E265A#8HPCW,[G+R.<LY]2:M45LH:W>K,7/2RT0
M55@_Y"%U]$_D:M55@_Y"%U]$_D:);K^N@H[/^NJ+5%%%62%%%% %6_\ ]0O_
M %T3_P!"%6JJW_\ J%_ZZ)_Z$*M5*^)E/X48>MZS>:??6=I96L$\MSNYFF\L
M+@9ZX-+#K<EI;-/K@L[)"P5&CG\P,?3H*H^*=.DN]2TVX.EOJ%O#O\R)2 >1
MQU(JL-,-S]@2WT&2QBAODFD60J00 >>":AN7,SCE*:F[?U^'ZF]_PD>D&Q-Y
M]NB\@/L+=]WICKFD?Q)I"6D=R;Z/RI"50C))(ZC'7BN<N-&O[;Q!)JB6)N((
M[SS1 A&74Q[=P!XR#3X[;4;;5H]9?0AY;I)&;:#;O3)!#MDXR<<XHYY![6IU
M7X/[SH9/$6D1K 6OX?WXS%@YWC..*0>)-):X>!+V-I5W?*,\D=0#WKG]$T"]
MMM4BNKBU1089W"G!$3.P(7ZXK-@TG63J&GS365ZS07#-,"R"( Y&44=N>II<
M\NPG6JZ.WX'2:9XNL[G3/MU[)!;(\K)$H8L6 _#K]*O3^)-'MXXGDOX0LREX
M\'.X#TKDI?#^HP#3;DPWA6%94>.T=1(I9L@C=P1ZU=T3P[<VNI6<TUHRQK;S
M9$KARK,P(!.!SC-"E/:PHU*OPM&EJ?BN&R7SH#;SV_D"8-YN"1N"],=.>M:N
MG:Q8:KO%G<I*T>-ZCJ,UP<GAK5A"=MEO(MG0)N')\X,!^5=+H]K=W'B*75)K
M!K&(6JVXC<C<[;LD\=A1&4F]1TZE1RU1TM%%%;'6%%%% !1110!'.2MO(5."
M%)!].*\@M+IK>RDM&NK>XAF-M+>W]I/+\D33@.C[C\IP3R,<9XKV.HA;0*KJ
ML,85_O *,-]?6@#R5KJ)IYHKN_E7288+QM+?SV >19$"X;/S$ G:.>":ZK5?
M[5N?#,,M]8Z>Q$*$RO.WF@G;DA?+P#[9KL#;0%$0P1E4Y52@POTK \96WG:7
MYGV""X\L9\V0@-%R.5X_SB@#I**** "BBB@ HHHH ***KW=_9Z?%YMY=0V\?
M]Z60*/UH L45@^*KXIX&U:^LKDJ18R20SQ/@CY20RD?SKRKP[K6I/XLM(GUG
M4)(S=PIY<E[(ZD$\@@L0: /<ZS[C7-*M+R.SFU"W6ZD.U(/,!=CZ;>M4M5\,
M+K.H)/=:OJB6R ?Z%;W'DQ,?5BH#'_OJK]OHNF6EW)=P:?;1W,AR\RQC>Q]2
MW4T 9\VKPZMX>U*:W@ND2-'3][ R%B!U4'DBO#M$!&M0*+2Y#JT&?]&<$<\Y
MXXKZ&O[M+2TDD:>")@IV&9@JY]^17C.A_$O6I?&4L5S;Z9''.ZQSRHLC!57/
M*X)SG-=>'P5;$1E*G&Z6YG.K&#2D]SV^BL>7Q-I\5XMKMNGD;&"ENY7GISC%
M*GB".2_:T33[\E209# 0G'N:R^KU;7Y2N>/<UZ*Q8-;O+@R@:#?Q[%)4R[%#
MGT'-)'J6MRVLT@T(1S*1Y<<MTHW^O(SBCZO-;V^]?YASHFU'66TYR&LGD0$
M,LL8SGV+ U=L[E[J$N\)B.<8+JWZJ2*\K^)/AK6-9M+/539I;WJR""2*"8R
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M@ HHHH **** "BBB@ I&940NQ 51DD]A2U4U2)KC2KN%5=F>%E"QL QR.Q/
M- %5/$NBR6LMTFI0&"(A7?=P">@I[>(-(1K=6U&W!N #%\_W@>E<!:Z3JEL]
MI-%9:I-I5C<Q2_9;S#RD[&5MOJ 2./KBH[?0M5MX;^)]*N&;4U3R"%!%OAR<
M-_=QUH ['Q81Y5K^\O%_?1_+",QGYQ][BNC'05R&OV\]I#;K+K6I/OFBQ!Y,
M)C^\."PBW#_OJNO'04 +1110 4444 %%%% !114-T':VD5'E1B,!H@"R^XR"
M/S% $U%<SI<6IKJLWVC5=4GBCD 6.2. *01_%MC!Z^A%=(\B1(7D=40<EF.
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MLJ2??YI?YARS[HS]>U2SN=+FTJ/3K^X%Q;X18;8[0&'')X'XUY)\/_#VM?\
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M^],H*;L6PV'^+KVKLM0L[N[V?9=3FLMO7RXT;=]=P-=6+I485%&FW:V[_P"
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MM32)[Z:$+Y)(9(LN3@9Z8Z^U8JO3=1TD]4;.A45-56M&;M%<O>^(-<F0#1=
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ME7:O('7^*I$:_G2?WOTJ.9I)HRGFNF>Z'!_.LV?59;>!YI=+OE1!ECM7@?\
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M9M/O(1(X0.ZKC)^AH WARH^E+2#A1]*6@ HHHH **** "BBB@ HHHH ****
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M7^\RA58,1VR&Z5M32>3!)+L=]BEMB#+-@=![TP.>9]9758['_0,M"TN[Y^Q
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M7,C3M#N]1TVVO"(,3QK)M:YF.,C/K5BUT2_MM4(BM;-=D899C)*P))(QR?\
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MA:#_ %P$ZYC_ -[GC\:D_M&R^Q?;?MEO]DQGS_,&S'^]G%<1;>"[^2*-;E5
M15BVO,'!7.6Z(.OH<UJ>+98=/CTT!(/*BDRL$@*H^!P,@'GVH"YNC6])9$9=
M3LBLAVH1.I#'T'/)I8]9TN9I5BU*S=H3B0+.IV'WYXKC])\*WDVGFYEA@@GE
M@D>-",>7(Y],<<5)-X:U2XC@F6SM(&MDCC6W27AP#DDMCC/TH"[.NN=6TVSW
M?:M0M8-OWO-F5<?7)IL>JVTMY#!$ZR">,R1RHP96 ]"*XK^S=8_X23S9+"TG
MN27G*-(=B C:O)')%;'A_27M[^)3S%8Q-&7 PK2,<MCV&: N=71112&%%%%
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MAB!\QXP-^W+#.,X]2>E:&G>)9+OQ9)I<L31PS64=[:^9&4D /#*ZGD$''YT
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MR7+8S(1R<=*230X#HUUIL+&)+DNSN!R2YRQ_6M2B@#)@\,Z-;V<EK'I\ BE
M#C;]['3Z8_2K5KI-A9>7]FM(HO*W;"J\C/7\3ZU<HH YW7O"L>OW:/<S)Y 3
M84,(+ 9R=K=1FM271M.FMI+>2SB:*5@SKCJP  /U  _*KU% &7+X;T::WBMY
M--MVBB)**5X&>OUSWS5:U\)Z7;7TEV;:)Y=RF$E>(@J@* /;%;M% %/3M/33
M[=D5C))(YDED;J['J:N444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M&W?^OOCKS5/Q+I%_/JZ?8(6:WU2-;2_93C8BG(8_52R_B*Z_<,XR,^E 92<
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M[I<LEVSR!;B1()GCV--$#\K%>,=QTYQGO6W110 4444 %%%% !1110 4444
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MAD08RRD#/TI]%*=2=1WF[@VWN>(6'P5UFT-JS7U@?)6%M@D?:)%<%V'R=U
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !0>!110!YIJ'AW7==&
MK:I%<QVQ:7,%O);$R$1GY</N&W)]C4VM:@VM:.]K?Z=J=K<2PJ\1M5;]\Y'*
MN ,<'L:]%HIW%8Y#['?:C=Z%I]]!MM[: 7%R%7"-(H 5?3@\X]JR=>M+7^T-
M1:&PU6/69&4VTL3N48]B,?*!ZYKT6BBX6.6\6)/_ ,(W9O/\QBN('N,=P"-Q
MK"U.UM#XFU=[^'5BDZ)Y#67FA7X.<[>#^->A3P17,#PS('C<893T(I8HD@A2
M*,81 %49S@"BX6/-M-\/ZC<:CH,5R;ZSBBMIP)(&\MT4GY0Q ZD4L^EZE9/K
M6CVANIGOIXA'>7"[V"D?,6;C(%>ET47"QYG<:'K&BW&H6SN+V#4;/;NMK8Q*
MCIP,C<W)'>NJ\/>'(-/M;:?S[YI?) :.:Y=U&1S\I.*Z*BBX6,6/PMIT-F]M
M")H@TQG$B/\ .KGT/]*B'@_2AA<3^7@"2/S#ME(S@L.YY-;]%(=C!_X1*Q"K
MBXO1(I!27SOG0#HH..E4M4M3!K&AVT<\\\JSLY>9MS;<<\^E=74!LX#>"[,8
M,X38')Z#TH%8Y3QGH\VKZA8QQ1L=L4I#@<(X&5_45S]OIVM:E<V^K3VDL-]-
MOB 8<H%3 )],GFO4J*=PL>2Z/I-Y^Y0_:/M4%M*LZBP\KDJ1AI,_/DU#?6=^
M]@+5K*2*46*)'MLC,\IQR-Q.$Q],U[!11<+'FEOH@OM-UBYGT]I)VM(UA:2,
M[LA>V>^:B-J8["_M;_2[BXU2Y5/LTODENPQAOX<5ZA11<+'F,WAIY=)U%KFP
M,MXUW%\Y3+$#&<'TZT_5=/FL&U.*UTU1:27,!SY#2(@"\L$4C=7I=%%PL<7X
M#2:!]6299@&F$D;26WDAE(ZA1P/I69JFFZGJ>O-XIAL]JZ>XC@M7C^:X0'YF
M/OZ5Z/11<+'E6M6=W>:QJ,\ZW"B\1#:@:?YS;<?=#$C80:MIX=9[/Q!+<6+R
MW>8A!)(F7.%'(_'TKTJBBX6/+C9NEMJ-G>:9<2ZO<3JUO/Y1;Y>,$-_#CTJI
M)#':Z8+:_P!/EEU?^T59[OR]P(W<'?\ 3C%>N5C_ /"+:/\ V@;[[(?.+^9C
MS7V;_P"]LSMS^%%Q6.,72GL_"U].-+5KJ>_<R/)"SD)NX;:""P]JH0:;/<R7
MB/:S3QR7-O)&S67DJRCAB$[#]:]:HHN.QR_A6T2QU/6X1:& M=%T/E[59".,
M&I[NVF;QQ8W B8PK:NI?' .>E=#12"QYI(;I8H])_L^[,ZZOY[,(CL";B0=W
M3O3K3PS&ZZ,T^F NVHRM<%H^2OS8W>W2O2:*=PL>906']G:LLU_ITLFDQ7,X
M6)82ZHQ(VMM';&:ET;0FN==L);K3F%B#<2PQRIQ&"PVY';OQ7I%%%PL<EXST
ME]5NM%MUA9XO.D#E1D(#&0"?3FN8CTS6+X6]]=6DJW<=W';QY'W8T5AN^A)S
M7JE%%PL>7+8R7%AI]A8:=/!K<$S-/<M$5VC!SE^^<BH_L(GCTBWL-)N(=3M_
M,%Q.82NUBA'+=\FO5:*+A8\CL=)NW$**+C[3!;RB55T_RL$KC#/GY\GZUU^H
MVEP_@*VMUA<S 0Y0#D889XKK:*+A8\V.@'^SM5N?[/)O6U82))L^?9O'(/IC
M-=!XLM=0U4Z;I=D?*$D@FEG>(NB!.0",C.3[UU-%%PL>6W>C:AIL6H:?>0_;
MX3=Q7R2PVQ5<%OW@"Y./IFK=SH0EL=?NTT\FZ?4$>W?R_FV@IROZUZ/11<+'
MG2:=<?\ "9G1?+/]GB7^TSZ D8V_]]9-0Z+X8A6#PR9]+&X&5KG?'SGMN_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!56\O/LGE@0O*\C;552!_.K59^J6+7JP[8X)?+?<4F/RG]#0 L.KV\J;W_=
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M;K7S!']HCWD9QNK.DTJX2]:Y@\ALY'ER9 P1UZ4PZ/=&-X,V_EN_F%P"&!]
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M%*SQG<<##=3UK/&ESPE9(3"TBR.V'R =W]:I/X:GP#'<HK ;AP<!\DY^G)%
M&D==L!-Y?G#AMI;L#C-6IKV**".8'>DCJJE3ZG&:H0:.T%VC QF&/&W/7[N*
ME.FN=.AM@Z[HY1(3VQNSB@"275[**&203HXC^\%/3G%)-JUK% TRN)(U4L2I
M'&*JR:*[P1QAX_E5@>.N6S27>BRSR7+QR1CS5(4,#@9QU_*@"Z^JVBQ>:LJO
M&"0Q4],#-":I:-$)6E5$) 4L>O&:HOI%S/*9I6@1SQM3., $?UI(](NH729&
M@:0 J5;.W!4#KCKQ0!IC4+-I1$+F,N>@#4VXOO*N#!'"TT@3>P4@8'XU2MM&
M>"W:,R(6,JR9QZ=JL^3(FK3/MS'/$!N_ND=OUH BCUAI(XR+*7S)3^[3<N2!
MU.>U2_VGA%WVTJ2%BNPXSD#/XU"=-GCBMFA:)I80RE7R%93V]J@M]*N+4F9C
M%Q(9!%'G XQ@9H ORZE#%8+=D,4;& .M/L[^*^!,(8J "2>Q/:H[2U9-*6"1
M$+D$E7&0"3FJMGI%Q:7PE%P?*QEE#-R>_P O3\>M &Q5::[\JZB@\LL7!8L#
MT JK<Z.MQ>_:"\8.0<&%2>/>I9U8:K:N$8H$92P' ^M $MG>QWJR-$& 1RAW
M#'(JS5:WM3%]HW-D2R%AM)! -$=FD0?;).VX8^>5F_F: *KZNP6-X[.22.23
MRT8,HR?QK10ED!9=I(Y&>E9EO9RO96L3@(UO-DY_B )Z?G5Q86FB=)C(GSD@
MI(5./J#0!)<2O#"TB1&4C^$$#^=165V]W;>>;=HP1E0S D_E4B6XC@:-7D;(
M/,CEC^9K-:WNK9((T,K&->#&Q"YSSD=^* )Y-8@CACD*M\^[*]UQZT'5');R
MK.:18\>801\I],=ZSAIES)#<2NF&;YHTS_M9J\MO?QF4VS1*DYWYDSNC)Z\=
M#0!IJVY0PSR,\U#=W*VD!E8%N0 J]23VJ..W>6U5+AY0P/+*Y4G\C3;FP,EF
M(H9&WJP=6E8MR/4GF@!]K=R32/'+;20.H!^;!!'U%0R:HL9<&)B8Y1&XR.,]
M#]*AN(]2=2\KX7( BMB>/?=P:JO;W3F65XGWR21JHQV7J30!KO?6Z1&3S P"
M[\)R2/H*K-K,(CC=8I7#)YC8'W%]33+'2I+26Y<R1M]I!+X7&UO;VICZ7=)&
M%ADB.Z'R9-V>!GJ/SH E.N6Z[F*2>2"5$N."1U%26>JPWKA(U;?SN!Q\M5K?
M29X6C@+Q-:QR&0==QSV(Z4QM&N!>+/%,L7SY*QLR@#L !P?QH TKF]CM[1KA
M1YJ@@ (1R2<4D5V?^7F+[.3]T.X.?7I4-U:S7VE/ \<22,1\K<J<'//UJG/H
MLEU:_9O)L[2/=O/V=<Y(Z=A^- &DNI63RB);F(NW0!J/[2LL.?M,6(_O'=TK
M)BTV^E>:.001QF57+@'/ ["F1Z!=>;NEEC8$*#EV;.&SP#P/H* -AM3LDA$I
MN8]AS@YZXI(=3M)EB_?(K2J"J$\\U3DTNY2\FN(# WF@KMDS@ ]ZJ1>'9D*(
MTB,N5+'S9!@CT4$ _C0!KKJ=K)>I:1R*\C!C\IZ;<?XU$^J/'=2PO:.JQIO9
M]ZXV\\_I4-IIMS#>VTDA@\JWC= 4SN;=CD_E5F>P,]Q<.S@)- (L=P03S^M
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M),.,LNYN21S\OW>N3GKSCI0!=DU.QBE:*2ZC5UX*D\@^GUIQU"T#1K]ICS(
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
L* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>imrx-20211231x10k019.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 imrx-20211231x10k019.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" '; \L# 2(  A$! Q$!_\0
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M@((!!R#T-0?;[,13RFZA\N!BDS[QB,C&03V/(_.@"Q15:'4+.XLS>0W4,EL
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MLK64YDA@2-N<\A0#5RBBX6"BBBD,**** "BBB@ HHHH **** "BBB@ HHHH
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M Q.0" /:NTMK2&TM$M84Q$B[0IY_//6G"WA'2&,=N%% &-87"PP:HUG,T]K
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MEB<GCCKVICZ/8N#F 9RC9W$\H,*>O;_]= %'^V;B>U<+;?9YI$A:$E@^1(2
M2/48)Q5;2O$LUY9J!;^=.)!"26"!G.3T[ *.O?MFKFE^'H-.E,COYS@KLX("
M[0P'!)[.>.@[ 4MUX<LY80MN@@D4!0X+'@$MV8'J3SG/- $%]K,[^&&U"V1H
M9O-6,* '(_>A#C/![U0DUS4H(_+=V#B[$?[Z$(Y0Q.W(''WEX(]*VX-#M(]%
M72I0TL .3\Q4D[MV<@Y'/O3ET+35B$?V;($GF9:1BQ;!7)).3P2.: *.EWE_
M_P 2MKJZCN%OX/,*F,*R-L#<8ZCG'Y5836RVH- UJ5A%R;7S=^<OMW#Y<=.U
M6+'1=/TU]]K 5<+L#-(SE5]!N)P/85%;Z#:Q7UQ>/NDEEE:099@%RH7@9QG&
M><9YH )-79+YH1:EH$G2W>;> 0[ $87N/F _&IENW76WLGY1X/.C..F#M8?J
MI_.FC1=/%REP(#YB8Q^\;&0, D9P2!QD\U);Z=#;W7GIDE85@C!.=B#MD\G)
M_D* +E%%% !1110 4444 %%%% !1110 4444 %%%><:@NJQMK5S:>(9X+6.Y
MALHC>W.U V]6E;<%.WAM@XXY]J /1Z*\L3Q'?&&W<:I+%-#'$+:+SQ(+V0W;
MQ28)4&12JKC X# ^]=_?:E>V4I8Z>CVOF(GFBXP?F(&=NWU/K0!J4444 %%%
M% '):A$+B\OA</*A6\3YE@\T+&(OEROIN+=CS44<=Q)Y9N+-TNW$'V;9$0$4
M-\WLO')!]<5V'EH)#)L7>1M+8Y(],TZ@#'U&WN;B.SDF3][%=QL!"[;=NX9)
M'?\ 'I6-=6UPTUPD$$PO]]RTD@0C=&48)ANAZJ /45V-% &!I"RK<7#V$ CL
MV,8VRJR<A?F*@CZ#ZBH+FQ\NWU.,_:%B>[C??L,QQA<G!.2,CW^E=-10!Q$D
M,KP-YUI(V;9H[(QP%?WF\X; ^X2-IYQT-;6LIJ+,!;7%Q%Y=I(_[D#YI 5V@
MY!]^*W:* .3NI;^SD,$MY?"V5W;SE4-(2(U*C[O3);MC@"JR)JU[;VFIP*6N
M_+6.-I!V$3$M]2S$#MP*ZZZLK6]14NK>*95.0)$# '\:F "@   #@ =J .03
M4+O^U+56N;U2UU'$L3I\IB,>26./O9SGG/MBFZ[:RR7^H>7$6D<1&("U9V<C
ML)!PGUKJOL-I]K^U_9H?M'_/78-W3'7Z58H Y1H4345EOK1W@^T7!(\EI!R$
MQP ?0\UJZ1'=0:( D060N[113$C:A<E0>I''^%:U% &):O>R^&"VI0/)*8?F
M2)B)'&.>PP?I6+%"BW,DDMJ[Z7YY8!+=U7)C '[O&>",9[DUVM% '/O#?G2-
M&MUEN(9&D19VC^\J;&SDG..0*SXI=6@M8OM-U>%9HXFF<H-T9+$,% '7&/4]
MZ["HY[>&ZA,4\22QGJKC(H XUS?:I8YC$T_V64&*29,%V,X S@?PJO/'\5/N
MKZ_AMLSW-[#,D6<(F0TOF$-GCA<8QTX/K780PQ6\2Q0QK'&HPJH, ?A44UC:
M7,T<T]M%))']QG0$K]* ,G5PD>JVMS>6KW-FD#J%6,N%ER""1[@$ UCV*VYN
MX[BZT^8696<1PO;LYCRRD+@ XZ&NVHH Y_28IH+JPCD5D<VDF]&ZJN\% ?H"
M1^==!31&@D,@1=Y 4MCD@=!^IIU !1110 4444 %%%% !1110!!9_P#'I']*
MGJ"S_P"/2/Z5/0 5&T$3SI.T:F6-65'(Y4-C(!]]H_(5)6#KFK:EIVH6$%G;
MVLZW<HC"N[*X RSMP,8"C/N<#O0!:7PWHB0W,*Z59B.ZP9U$*XDP<C/X\_7F
MI9[*"WTC[';6Z1P1J%2*.0P*H'8,O2N9'C:]V6:M80"74A$;("4XP[[?WG'&
M!SQGTK0AU^TU+0B;\V=M.9IK>2*X'F1[XI&C; XR,KD?44 7O"PQX6TT8QB!
M>-V?U[UKUC^%<?\ "*Z9MV[?LZXVC _#VK8H **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ JC-H^GW%I<VLMK&\%S)YLJ'^)\@[O8Y .1TP*O5QUWXOU&QU*]LY
M=,MY/(,$:/%<,099I D2-E1@\[CC.!CU% &T?"^BE+=#81E8"60;FY);>=W/
MS?, WS9YYJ#Q)&&6S;RW;;<1_,)R@'SKU7/S5E_\)O/^_4::I>P#MJ \[[@6
M0I\G'S< MSCCCK5OQ%>6$]Q:PB:R>YCN(AMD&9%)=?N^E '3T444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4QHHW1D:-61OO*1D'ZT^N)N-?\0PZM=6T;Z=
M);)<P6:3&W=<32,"<CS#N"H1Z9+ <8H [+[/#F,^3'F/[AVCY?IZ5SGB]+5C
MI[3/I@E6X3RA=1AI2=Z?ZHDC!]< ]JRO^$QU;9+)Y=GML@OVH>6V9LW4D!V'
M=\O$9;G=R0*U_$MSYGE0I<7T)CGBWHEFQBERZ]7*$ ?1A0!TM%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 06?_ !Z1_2IZ@L_^/2/Z5/0 55FT^"?4;>^<
M,9K>.2-.>,/MW9'K\@_6K58E_P")[2PUN+2O)GGN&6-I/* /EK(Q521G)Y5B
M< X"DGB@" >"],$;IYET2-@MV,@S;!'WJ(^.,-ZYXX/'%7H=.@T;0_L=FURB
M(2V^,>9*S,Q9F.0<DL23QWK*@\<V5S;33Q6LSJLZ6\2K)&S32,VU5 #97U^;
M''-:46IVVM:&;B%)<,SQM"9/*D5T<JZDY&"&4CKVH /"_/A?322Q/D+RPP?Q
MK7K(\+#'A?31@C]PO!.?U[UKT %%%% !1110 4444 %%%0W5Y;6,/G7=Q%;Q
M9 WRN%&3T&30&Y-152?5=.M;N*TN+^UAN9<>7#),JN^3@8!.3S0-5TXZ@=/%
M_:F]'6W$R^8.,_=SGIS3LQ\K[%NBBBD(**9--';P23S.$BC4N['H !DFJVFZ
MK8:Q:_:=/NH[B'."R'H< X/H<$?G3L]QV=KERBBLS5?$.D:(8UU+4(+9I/N*
M[<GWQUQ[T)-Z($FW9&G156+4K&XN$@ANX))9(A.BHX):,G 88ZCWJU2L#5MP
MHHHH$%%%% !1110 4444 %%%% !1110!B:K=:M;:E80VL]D(;RX,"B6W9F3$
M3R$DAQG_ %>.@Z^W.S&'$:B0JSX&XJ, GO@9.*R=9_Y"OA[_ +"#_P#I+/6Q
M0 4444 %8]QX<LKBSO;=FE4W5TMVTBL-R2J5*LIQV*+CZ5L5R\OCK3XH+ZX-
MO<&"U!_>KM(D.\1XZ_+EB,;L9&2.E #CX)L2N/M=WF7=]J8,N;H,YD(?CCDG
M[N.#BK/B.1D2T13.%:>/(CBW*?G7[S8^6JY\9VJ0PRM97&UHO/E*,CB&(OM#
MDJQ!!.3QG@&I_$99EM-D4CJ+B/<R3!0OSKU7/S4 ;U%%% !1110 4444 %%%
M% !112%@" 2,GH/6@!:*:)$+;0ZEO3/-"NCYVLK8ZX.:+ .HHHH **BN+F"T
MA,US/'#$" 7D<*,G@<FI%970.C!E(R"#D&G9VN M%%5WOK..Z2U>Z@6X<96)
MI '8>PZFA)O8"Q134DCD+!'5BIPP!S@^].I %%%% !1110 4444 %%%% !11
M10 4444 8@GUO^V3:?:-/\H1B7/V=]VW=C'W^OO^E;=9H_Y&9O\ KS'_ *&:
MTJ "BBB@ K.FT+3;BRN;22WS#<RF:0!V#&3(.X,#E2" 001C'%:-<&/B5')%
M<R0:<LH1E6W42R;Y@9A%G:(CP,Y^3?CH<$B@#HO^$3T3=9G[%_QYX\H>:^#A
MMPWC/[S#?-\V>>>M0^*8/-AM9/+NF\N>,[HK@QHOSK]]0PW_ (@UG_\ "<,8
MTFCL(98$BCENG2X8>4'F:(!0T8+$%&R"%(QBG>*KS1I[FUMY+C1Y+^"XC"QS
MR(;B,EU/R#J"10!UU%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% &1;27Q\1W5K)>![>&WB
MF">4 27:48S[;!6O65;_ /(V:C_UXVO_ *,N*U: "BBB@""S_P"/2/Z5FW/B
MK1[6X>![B:1X_P#6&"VEF5/]YD4A?Q-74CDETHQPRF&5XV5) ,["<X..^*YF
MR:X\/:[)8H-8U=VMDDE"N&5"SL ?WD@ X7&%&3C+$DT =;;W,%W;I/;RI+$X
MRKH<@US6M>"X=6UUM3$\<1E2W2;="'<"&4R*8VS\A.2#P>,5U*@*ORJ%!YQB
MJ-YK>FZ?>0VEW>1Q3S8V(<]VVC/H"QP,XR>* .=;P1-),ER]_;B[MC&;:2*S
M$8RDF_,BJ0&)Y!QMZG&*O1Z%8Z3H)6]%G=2K++/)<7<0VEY9"[G'.T;F.!]*
MNCQ-HS13RB_CV0%0YP?XFVKCCYLMP,9YJ9]0@NM(%]93M+"XRDD$?F$\XX7^
MG:@"OX5VGPKIFW;M^SKC9TQCM[5L5D>%R6\+Z:3G)@7J,'\JUZ "BBB@ HHH
MH **** "N'^)^G1W7AZ&X6!I+F*YB"%<D@%N>!7<454)<LDRZ<^22DCR;Q=$
MO]M>);>2V=M0O7LCIK>26+!2F[:V.,8.>G2F:9 8]8M+&:W<ZXGB&2XFD\AL
M^1M;+;L?=.01S7K> 2"0,CH:,#.<#/K6GMM+6-EB/=Y;?U:QYUXW74KCQ+/#
M;WE_!;Q:++<*MLY4-*I<J#CZ#BL:2X\0V%E.;>^U2:2ZT>"ZE9LNR.9@K[!C
M@A,\=>]>OXJKJ.G6VJV$UE=H6@E #!6*G@Y&".1R!1&K9)-!"NDDFM#RNTO#
M?7NH^'[#4-3O;6]-K!&]V&W1QG>TS<@$# (SCJ1U%2Z3_:-AXRFB*S0:*^L7
M"QK "N9MJ[ ^/^6? QCC.<UZ'HWAVQT,SO;&>6><KYL]Q*9)'"C"@L>P'2M4
M@$8(INJM4D.6(5VDM#R;POJ%RWB?P\DNIZM)>7!N#J-O=!EC5Q&Y  ( [=!G
MIVK2\;+!!XKCNS>2V$YLO+$TUE]IMY5W?<Q@D-^'XUU.F^#M)TK44O8!<O)$
M&$"S3M(D ;[VP$\9K>*AAA@#]11*JN:Z"5>//S170\:@M+W598[HVT^DO#X?
MDDCCLMT:[ED<J.YP3@XS3[K4]4G@636;_4K5UTJ.33OLX8>?/CDL .6W<8..
M/SKV/%(5!QD XZ<4>V\@^LZZQ/)-6O?%-O?10JUX))((-2<*#M4QPGS8N.Q8
M#CWJW96^JZW<Z1]KO=2MH=16\NI4BE92@+#RT)[ #H*]1HQ2]MIL+ZQII$Y_
MP1<WEWX-TV:_:1KDQD.T@^8X) S^ KH***RD[NYA)\TFPHHHI$A1110 4444
M %%%% &/K/\ R%?#W_80?_TEGK8K'UG_ )"OA[_L(/\ ^DL];% %>]O[33H/
M.O+F*"/.-TC  GTJKIWB#2=6?997T4LG/R<JWY'!K,\46UXL5QJ0U1[:SM;4
MR".-!GS!N.2VQFP<KT_NXP<\:>F7:ZA&KR6ERDT( \RYM_+))&"5S_GF@#2K
MC(_ ?D,_V>[MH@N_R?\ 0E;<'E64B7)/F#Y<#H0"3G.#79UDOXFT:-[A7U")
M3;@F3(.!A@IP<?-AB!QGD@4 82>!9(HYUBU&.,7H=;T+;X4JTA?$8W?)U(YS
MUSUJ_P"(H8(9+1DBLE>2XCW-(,2'#K]WUJ\?$VC!+=C?Q[;@D1G![-L.>/E^
M;Y><<\5!XD:4+:!))%0W$>Y5AW!OG7JW\- &[1110 4444 %%%% !1110 5P
MVJVJQ?%G0)Q),QFAG)5G)5<1D?*.WO7<TTQHSJY12Z]&(Y%;X>M[%M]TU]ZL
M-.QXS'<_9)KEK+^S=1O;^&_D-Q;0R+<V[[6;)W'(Y. ,#I6_X'%DGB>!=',7
MV5M%B:[\HY'G[S][_:Q7H:6EM%,\T=O$DK_>=4 9OJ>]+#;06^[R((XMQRVQ
M N3[XKT*V9QJ4Y047JN_YZ=.GWENI=6/+=5UWQ"FK:E-;ZU+%%;ZQ'91P>4A
M4*X//3)Q[TQO$FMI,-(NM;:VMX]6N+675&C4,J(H*J3C:,DG\J]6-O"<YBC.
M6W'Y1R?7ZUFZOH2:HD7E7<]E+&Y<- 1AB>N]""K?B#BG3S"@[1E327>R[;[=
M]>HU-=CA-.U&?Q1!9V-W>&_%H]S>SS;0H=49DA.!CJV6Q_L\]:S-(\3ZW9^%
M[L&1K66RTRW^Q6XC#*\3,JM<9Y+$ GCH.XS7J6BZ):Z'IRV=N7DY9GEE.7<L
M222?J34NH:7!?V,EKNDM]Z;!+;ML=!U^5AT^E-YA0YW#DO"ZM]]WI:VNWH'.
MK[:'+>"]3N;K6]4LVUXZQ;000-'-M489MVX94<]!7)^(VL++4];NG_LR_P#]
M,#2VUUOAO$(VX$3 Y*]Q^->D:'X=CT6>ZN3=S75S<A%DDE"K\J9V@!0 .I^M
M:<EE:2SK/):PO*O21HP6'XU"QU.EB)3@KII+33:U^BZ]K"YTI71Y%!>:I9W6
MO:S87\MJB:M"KVK(K!PY (8D9R ?YUIGQ+JK:K)<MK/EW2ZL+)='\M2##N S
MC[V<<[O:O33!"=V8D.X[F^4<GU--^R6QN/M!MXO/QCS-@W8^O6G+,J<W>5-=
MNFUEIMY;[^8<Z?0\CN_&'B;2WO(Y;QI5TOS;6XD:( O*_F>2^,=/E7IZU8U#
M5/%%I%K4C:Y,DFD0VDAB,2$.[A=P;CIDFO5FMX&W;H8SN(+94<D=,T-!$V_=
M$AWXW94?-CU]:/[2HW35%>>W=/MZKT:[#YUV$M96FM(96QN>-6./4BI:  !@
M<"BO)>YD%%%%( HHHH **** "BBB@#-'_(S-_P!>8_\ 0S6E6:/^1F;_ *\Q
M_P"AFM*@!&8(I9C@ 9)K _X2M#)N&C:R;/=M^V?9?DQ_>V9\S;[[/?IS6GJN
MG+JM@UH\KQJSJS%#]X!@=I]CC!KB] U>/2/$E]H=G'9+;_;A$1=:FJ3YV("R
MP[26SUSD%B<T =^CK(BNARK#(/J*YL>";)))'BO]1B8;OLOERJ!9[G#MY8VX
M(+ $A]PP,=.*Z:N<_P"$UTTF<)#>.$<1QLD.1.Y?8%0YZ[O[V..>G- #/^$'
MT[-O_I5[M3!N%\Q<79$AE'F_+_?9F^7;UQTXJ;Q3/Y4-K'YMPGF3QC;';-(K
M?.OWG"D)^)%-_P"$TTO,'[NZVN 96\KBWS(8AYG/'SJR\9Z'MS3_ !0&,%KB
MWNY )X\O#,%1/G7[ZE@6'T#4 ;]%%% !1110 4444 %%%% '":M\2(]*^U%M
M.>06^H&R.).N 3NZ>W2K.H^/X;'7;S34LVF%M9O=&4/@-M3?MZ>F/SK-O? .
MH7M]<N\MKY$^K->$;VSY10KC[OWN>GZU3M?AWK20!KBZLY+EK*YMY'WMRSH$
M3^'H HS7OQI9=RIMZV[O?_@6?WEVB:<WQ,MXO#>GZL+!V>[G:$P;^8\'&2<>
MX_,5UNL:O#HNE27\\4TJH,A(8R[$XSVZ#CJ>*\[D^&FL-;S0+<V?E[(C"I=L
M+)F+S2?EZ'RN/Z5VL?AE+2SU1+>\NY9;V%DQ=3ET0D'[H[#FN?$T\#'E=-]7
M=>6EE?I9"=C1T;4EUC1K/44C,:W,0D"$Y*Y[5BP>.;&:76LVUQ%#I40ED>5"
MID!!/"GD=.,]<T:9X1\K3=$2\O+I+G38D0K:W#+$Y4YY&/F'U[57OO"-S?ZC
MXGDDFB2#5;:.*$@DLC*N,L,=,XZ&L80PG/-2>G3R]Y??[H:%G3?&<5S'>G4+
M";3I+6W6Z*2.K[HFS@@CZ8Q5_P ,Z^GB323?I;26V)7B,<ARP*G!S7,0^"M6
MU6=[K6+R*RE2."&(61\P,L1)RV\8(+$'&.PK<\':#?>']-N;>^NUN'ENI)E*
M@8 8_0<GJ?TJL33PD:<G3:YM-->VMN_W@[&];W,%U&9+>9)4#%2R-D CJ*YG
M1_'%MK&O:GID=LZ?9 [1REN)PAPQ'T./SK8\K45T>[C2.SCO6$GD",D1Y.=I
M;C/UXKBK+X>ZOI4FBW-KJJ3S6A=9HI0%3;(#YFUE7+9)S\U<*C#6[*HJ,H-S
MW+$?Q0MY/"=UK9T]P\-R+<6_F<L3SG./0'\JNMXVO;VY2UT/16OYTM8KFYS.
ML:Q!UW!03U:N9C^&&LK8QVINK+R_LTGF(';!GS($;[O0+)R:TI/!>MZ?YRV"
M6%W!J%I;P7L,\KQ[7B7 967DCKZ&K:I]#H<:/0[C3]3^VZ*FHRVLUJ2A=X)E
MVNA&<@_E6'HOC.35H)+N32)H+)(3*)4G29FY&!Y:$ODY].U4=$\!S6FCVD=]
MJ$_VVU\P*L-P_D/EV9=ZG[PYP<]N*3PMX3U'3_$2:G>6NF6"0VAMO+TX$"X)
M;.]A@8Z>YJ+0U,^6FE+4N1^.X9_#\.IP:=</+<7AL[>U+!7=]V!DGA>GX5L>
M'M=C\0:?)<+ ]O+#,UO/ Y!,<B]1D<'@@_C7-'P?JL&A6Z026C7]IJKZA$K.
MWEN"Y.TG&0<'TK;\(Z)=:+I]V;YHC>7MW)=S+$240M@;03UP *)*%M!35/E?
M*=!11161@%%%% !1110 4444 95O_P C9J/_ %XVO_HRXK5K*M_^1LU'_KQM
M?_1EQ6K0 4444 06?_'I']*X'Q9IL]]XX5[:QTV]9+*'>M_8).(QYDF"C-,F
M"><X!Z"N^L_^/2/Z5@:OH"W>O-JGVK35VVR1R1WMD)MJJS$,#O7;U(_"@#I5
MX0# '':N+UWPQJEUXJEU.PF9%N8;6(R+<-'Y'E2NS$H.) RN0 >ASZYKLXW2
M2)'C971@"K*<@CU%137EK;RI%-<PQR2<(CN 6^@/6@#A1X4U@KITAA@#Z.(5
MA3S>+K9)N)S_  _+C&?XOSK<TO1[K3M (G61KM[B>Y:"VGV*IEF:3:"< [=V
M,^U;8U*Q(E(O;<B'_6?O5^3MSSQ3+^1)=+>2-K:1&4%6F;]V1ZY% %7POG_A
M%]-R"#Y"Y!.2/QK7K(\+?\BMIGW?^/=?N]/PK7H **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
MQ]9_Y"OA[_L(/_Z2SUL5CZS_ ,A7P]_V$'_])9ZV* ,;Q<JOX/UA&E:)6M)%
M+JI8C*GL""?S%8W@#3KO3K>[2ZTZVL\E=H@C9 P /7,LG]*Z'7K$:GH&H6+3
MK +BW>(RMT3(QD\CBJ'AG1QHGGV[#2DD8*VRPMVAXY&6!=L^W2@#H*\Y_P"$
M-UJ./RH6.RUN!<J);MF2[9;E)D&T\1\*5)]6[XKT:H?M=MN=?M$6Z,9<;Q\O
MU]* .$_X1761_:$@A@WZNLB3*9>+4-,7!SCYOE8]/XAZ<UOZ]:21M!*CWDB-
M<1;@)P(T^=?X3U_"MQ;JW81E9XB)#A,./F/H/6L7Q,@8V+$6V5N(\>8Y#_?7
M[H[T =!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_P"SFN@\Q/E^=?F^[SUKG_%9(CLQY=JV9X_FEN3&Z_.OW%"D/^)% '14444
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MR+4+=W9MW%N=<8R/^[8S8;)_AST.,87T%=3HC7=QX27[0T,EIY]PL;WSLK-
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M.O\ $.%_&@#?HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MW=Y;VV)&0>;,HW;>IZ^XJ#_A)]*6.Z,EW$CVV_?&7&_"]P,]^WU%<[K.@:E
MUTFGPFX-]#+"S%00@9@1DE@1WYY%;4GAMI+0P^>H):X8MM_YZ*5_3/Z53HX:
M,5)RW':)NPS)<01S1,&CD4,I'<&GU%;H\5M%'(5+J@5BO0D"I:X':^AF%%%%
M( HHHH *QIY]17Q-;6:74 M9H)9RI@)8;&C7&[=WWGG%;-8]P?\ BL=/_P"P
M?=?^C(* -BJFI:I8Z/8R7NHW45M;1CYI)&P/8>Y/IWK#O/%C7-\VF>&[4:G>
MIQ--N*VUM_OR=S_LKD^N*?IGA-%O%U/7+IM6U0'<DDJXBM_:*/HH]SECZT 5
M?M.O^*F062S:'HYY:YF3%W./]A#Q&/=LGT ZUNZ/H6G:#;-!I]N(_,;?+(Q+
M23-_>=SRQ]R:T:* ,W0_^/&;_K\N?_1[UI5FZ'_QXS?]?ES_ .CWK2H ****
M "BBB@#*M_\ D;-1_P"O&U_]&7%:M8]LM[_PDEU<R6+);S6\4*R&13@HTI)P
M#G!WBMB@ HHHH @L_P#CTC^E8'B/5H-%N;=5TI9VFCED+B'(!4 \G'O6_9_\
M>D?TKF=?\62Z5XA32TGTJV!@2;??3NA?<S+A0JGIM[GO0!UBG*@^HKG]:\3Q
MZ9K6G:9#&)IKB91<'=_J(V#;6/N2I 'L?2N@4Y4'CD=JR=1\+:%JU[#>WVE6
M<UW"ZR+.\*E\KT!;&2/:@#GAXUU ):*UC;^=J8B:P =MJAWV_O/HOS<=>GO6
MI:^(H[_1 ]V@M[GS9K>1!"TZ!XI&C;&!R,J2,XX-/'@W2A&R9N3C9Y+&8YMP
MC;U$9_AP?\.E78]/AT?1#:627)1"S?NF#2LS,69LMU))))/K0 SPL0?"VFD8
MP8%Z#'Z=JUZR/"^?^$7TW.X'R%^]U_&M>@ HHHH RM6T"PUD,MYO^=%3Y&P0
M X;CWR/RJI+X0T]IGFAEN()9#)O:-ER5?&5Y!Q]T8(Y'K4VJS?9-<TZZ>"YD
MA6*96:"!Y=I.S&0H)'0UB76HZS)>3M:F^28RMY<)M6\L6_E$J_*CY]V.,YSQ
MBM8\UM&;P4[:,V)O"EE.94:>Y%NYD/D*RA5:12K$'&>03U/6HI?!UA+.\CW%
MQM<R'8"@'[Q2K<[<GKQD\8K!.J:Q_8RL&O\ *W!4OL?,GR#&T^5N'S9X*XSQ
MFM+Q#%]J33I=0LYY[3[+)F+R&D9;@JNPLJ@X/W@#V)IVDGN5:::39T#Z5;/%
M>HQ?;=Q"*7YOX0NWCTX-9[>$[218?.N[R9[=%6V=V7,&UE8%<*!G*+U!Z5AO
MI%_:!+MS/=W4UE&+N#!VD!4# D9+9*\ #@-)USBMJ]U#4)O#T-RMO/:R/,JS
MB*-FD2+?AF52 W3G[N0#TXI6:V9-I*W*Q)/"EDT<D?VNY22Y$BW,BL@>X#_>
MW?+[#IC %3:5I*6FMZA?N81+.$B14D+$(@P"<@88\9 X^4=:SM%MKJZUNVO[
MH7+I%#/'!)-'M)0R#:6! PQ'TR *P;33+F/77N192><FLSS #371WC+MS]H/
M&W!SCOTIV;NFRK-W3D=C<^&--N[C4IY4?S-0B2*5@V"H7H5]#G!SZJ/2DF\-
M6DDL#+-<1+%%'"RQL!O2,DJ"<9').<$9!Q7*6NKZY):W!E_M"(%() 989 0=
MS^8NX1?+_!D ,!ZGDU8@U+Q)+JEJK17,,1%OY0D1CO4G]Z7Q'C/4<E,<''-'
M+)=0]G474O2^$IXY8+?3KGR]/!B:0-,=QV2%_N[3GKC@K[YK6;PU9&TAMT>=
M! &$;JPRI,BRYY&/O(M9-G;:B8=+M5^U6J,ENDSQQ[6"BWDR"2./G"#GH<#O
M5'3M1\2S76EBZ2XCE=;?S$>)U4KM'FDCR\!OO=6&#CCU&I/J#4WUV.]' ZYH
MHHK$Y@HHHH *^?/CG?>(W\96EKX?NM5,4-G$9XK"23:DIE?86"' 8X7&>>!B
MO8?$6NW,%Q'HNBHLVMW2%DW#*6T?0RR>P[#N>*@.AP:#H4,$<DD\\NH6TMS=
M2\R3R&:/+L?PZ=   .E &=\-?#JV_AK3M8U5+NXUVXMU\Z?49&DFC_V%W\H/
M8?C7=444 %%%% &7%_R--S_UYQ?^AO6I6:GA_1H[@7":79K,#D2"%=V>O7%:
M5 !1110 4444 %%%% %6_LK*]M]M]9PW4:?,$EB$G/L"#S6)X2O].O8Y#I^C
MQ:<K0Q3,$A$98L6'3:,XV]?>M?6M2&CZ)?:D8_,%K"TNPMMW;1G&>WUK,\+:
MS!K$4[PG13Y85?\ B67PN0!S@-A%V]\#ZT =#7$W/CQQJ>HVMG9QRI%]ECM)
M6DP)Y)IVAR<=$5AUZG!]J[:N=?P+X;-Q<7$.E6]K-.B(SVT8B(*/O5AM PV[
M!SWP/2@#*_X374/])46-L9--#MJ \QL$+*4_=\=PI;GV'O6GX@O$D>VACD0%
M;B(.KVSL3\Z_=?H/UIY\&Z4552;GG=YQ\XYN,OO(D_O?,<_ITJ3Q&90EH$-R
M$\^/<(PFS[Z_>SS^5 &[1110 4U@LL9&<JPQD>E$@S&P'7!KD+*^G@\,:59K
M#J%NT*1)=L+20,B 8;!*\G.!QGC)K:E1=177=?J-*YIIX0TI)%<+-E3"1\_&
M8L;>W?:,^N*<GA:T2$1BXN,1E3 <K^YVG(V\<GW.>.*Q!J&MI>V._P"W/&Q"
MJ@A969?-8;F^0@_)MR"5QUK2\.7>H37-Y'=?:)"B@AI594W9/&"HP>G0L*[*
MD<1&+DYWM_PQ;4K;EG_A%K,)(//N#([;VD8J26WE\X(QU)[8HB\*V$4=S&9)
MW^T0M"Y9AG:S%CC ZY8TW3KC5I=2"ZHLL!RWEQ01!H<<_>DY)/UV_2I(;=K/
MQ-J=V4N'A>SA;=AG!8-+E5_#'RCU]ZRE.JKIS\].NJ%=]RW>:7'=W<-RMS/!
M/%&T:M$5SM8@D'(/]T52B\+V-NL<4$D\=N-A>$,-LI5MP+'&<YY.",US@TJX
MN?%UPS+<1&>XF5F$#!EB,.T-YN,%<@83L<>E7-/BO-&O((H;*:[@WR1I)L95
MC!<;]J@':">F2!A.#S6SI2A%1A4Z7M]_7R_X*'9K9EZ[\)Q_V;/;VDTDCM:M
M:0+<R_) A(/&!G((!&>> ,UJKIUF-#;2R_\ HPA-NY#8(&,'GL><UC:[=ZM%
MJ<R6GVD,L<1LDCB+1RN6.\2''   ZD8!S5&XTJXC\ :E;I;SO<37+R%#$6=O
MWPYV@9/R@'Z4N6<XQYY[M?CU^7YW"S=KLZ"/P_I9FAG2/?Y5H;-?FR/+.._7
M/&,^YJ'_ (16S-HUO)-/.N %$K< !64 @8SPQR>I]:YV,7VFBZ^R6\ZPSSQ?
MO+>Q:U ^5\C9M9@.%^8#DD"I],U+7'N=--VMX[R(BR1>4T>TC<&9LI@CIGD$
M=LU3HUDFXU-/Z8[/N:NB:!<V5PUUJ5R'E B2)1*7"A%=1R5'7S#QCMG))-:-
MAHUKI]QY]N\G,/E$%@01N9@>G7+'\ZXQ6UZ_^R"YBN95CN('E5HF.R3)W8RB
M@ #J!D#CGFKY;Q#!''-;_:LI<01+;>3A/+,"[CC'0.3ST!!%.K1J2;YIJ[^[
M38&GW.VHKG/"UQJ-P+@WS3$!(^)58$/SO W(OMP,@>M='7G5:;IS<'T,VK.P
M4445F(*^6/&^I^,;KXF:C_8^H:\]DMXT<#6<TQC0# <)M.!CN!^->^:MJ%WX
M@U&7P_HLTD$43!=2U&,X\@$9\J,_\]2._P#"#D\D5<BTVTTC4M$L+&%8;:"&
M941>PPOZT 3Z!X<T_0;8FVC=[F;#7%U.YDFF;N6<\GZ=!V%;%%% !113)8TF
MB:-QE&&" <<?A0!FZ/\ \?FL_P#7]_[2CK5JC::/86,[36T&R1CECO8Y.,9.
M3R< 5>H **** "BBB@ HHHH *YW4-8U:#Q'%8P:9*;)C#NNL J=S8;H<C ]1
MV^E=%7$1Z[?+XOFLKZ]NX$^V".""."'RFC(&W+$E\GG/3VH [>O-H?B#<ZIK
M]]8V-Q;) \EI':,4RZAY9$D=@>_RK@?[0KTFJ-WHVG7S7#75I'*UQ&D<I8<L
MJ,60>V"Q((Y!- '&?\)7K'ERR>=!BQ">:OE?\?.;N2 XY^7Y8\C'=JW_ !)+
M+(D:*+Z-(YXMQC1/*DRZ_>)!./IBKO\ PC6C;K1O[.@S9X\CC[N#N'U^;GG/
M//6JOBF+?!:OLSMGCY^TM'C]XO\ ".'_ !H WZ**9)+'"F^6144?Q,<"C<!]
M85KKTMYK'V/R$M$5B-MTVV:7&>44<8]\_A6LEY;R7$MNDJF6)59UST!Z']*C
M@OK&^@MYXYHG27YH2V,D^P/.:V@N5/FC?]!HJ22W$7B:*-[G_17M9'\O  4J
M4Y)[]36->:E=OJTYM=1*2BZB@MX 5*/&Z EL=^23G_9KJ0;::4X,4DBJ5/0D
M ]OIQ52233+?4K:,Q0"[962-E1=R*%R1GJ!BM:51)ZQN[?\ !&F8"ZU>:/-&
MFLSM*J.06A(;)P."<+D#.< 9^8 9P:U-;U>XL)S' UO'LMGN29P?GVD?(.1S
M[_3BM(O8-&DA:V,9DW*Q*XW^H/K3IHK*[E2.>.":2,[U5U#%3Z@'I]:'5@Y*
M3AZCNNQS,=W>-H7B*]DN'$HD?R_F8>4 BD <\=>V*+CQ-=6RR0F:TED5QMFB
M0E679N( W8R..2PX-=.1:!G@(AW29=XSC+>I([U7$&D"U4"*R^SK)O4!4V!_
M4=L^]6JU-OWH?U9?Y!==CFX?&-TY65X8?*, <(F6+-Y)DVY!X.1T(Z=ZIWOB
M2^ND@W,T>QF8F%C'N!MY6VG#'H0"#]#75L='M+F"00VB2L3"DJ(HV84L03V&
M :>L6EQ;H1:VT<2_O,^6JH2P()!Z9P#GV-:*M1B[JGT'==C$NO$=_90379AA
MEMXI7A6( [V*Q%\EL^HQTK0\.ZS<:JUTD\: PB,JZ# ;<,XQD],>O((K3_T)
M7C7_ $<,Q\Q!QDG&,C\.]5K"\TQ82+)8H;;:9"Z($CZE3[9R*QE.$J;2AKW_
M *_K[A736QI45&;B!=F9HQO^[EA\WTJ2N2S1 4444@"BBD9@JEF(  R2>U #
M9IH[>%YIG6.)%+.[' 4#J37S]JGA?6_&OQ:AUFVBN#X>O661?,N#"9;>,1I(
MP7((5B01TR#FO4/G\?7?_+1/"T#?3^TG!_\ 1((_X$?8<[DRA?%^G*H  T^Y
M  [?O(* -&SLK73[5+6SMXK>WC&$BB0*JCV J>BB@ IDTT5O"\TTBQQ(I9W<
MX"@=23VI]% &%X9U.POK6XCM+VWG=;JX=EBD#$*9G(/'8UNT44 %%%% !111
M0 4444 %%%% $%G_ ,>D?TKR[QQ=6]]K\,L%U.75!%Y.)@J$-*K$[. <E&YZ
MA1V:O4;/_CTC^E>=^,UL+;Q+)"+8?Z59K]K9;.)RJ*9&RK,P(8@.>A^Z.^*
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M9!88[8]^M5+CPG>RRX'V3"R7#_:#GS)1(20K<=!G'7I79T4_KE13<UU_X/\
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MPV>3Q@,,XR,UZ=7G%Q8W,'CE+C3Y]099M01[B!;>=(2O 9C)O\LX '\/.,4
M>CUBMXLT1/.W7RCR?O?(WS?.$^7CYOF(7C/)%;5<#/X>UK4I[FXU+2[2:02J
M8$^VLJ)"LH?8@4 JQV@ELG)4=N@!U#>)=)1[=)+KRVN "@>-E/+;1G(^7+<#
M.,FH/$\CK;6ZJ]PJM/'D1Q;E/[Q?O''R_I7.CPGK7D^0S0NMW'%%,\D[,;9$
MN7E !(R^$?:.G*CM6YXDM2JQS(MR^^>(L1=$(GSK_!G!_ 4 ='1110 4444
M%%%% !1110 4444 %%9U]JOV&Z@@^Q7,QF.U&B"X)P6QR1V4UH*<J#@C(Z'M
M0 M%1SW$-K"\UQ+'%$@RSR,%51ZDGI7-?\)HFI%D\-Z=<:P0=OVA/W5MG_KJ
MW!_X"&H ZFO*['XCVOB?Q!>Z)X4ED&HW<@S<30X6WC10'?!^\P/ 'J>>*ZE/
M#^NZN"_B#6FBC;_EQTK,* >C2'YV_#;]*R_!_P ./#GACQ5J%_ID$R7$0$2%
MYBPVNH)X/O0!UVB:-::#IB65H&*@EI)9#N>5S]YV/=B>]:-%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% $%G_QZ1_2O//%=JMMXFVV[
MW2R^2D\,2K<S?:9"[ IE'Q&!@?\ ?6>@->AV?_'I']*Y_6]#M-?UV..2_P#L
M\MM$DN+9 EQ@LV/WO4*<$8'H?6@#IDSL7(P<<CTI: , #T]:X/Q;<0-XKL+2
M'4;J"_\ W4@;SG2&!%D)/RCAWD^Y@YX&>.X!WE5K]&DLI%5)')_ACF,1/_ @
M1BO+UFN?L\"K=WY@E^SG6V,TF8V,WS8.<IZ';CY?:NHT9[N3PBAN9+9[(33J
MCZF&8O )F$)8GK\@7D\G@T ;7A<8\+Z:"",0+P3D_GWK7K'\*X_X173-NS;]
MG7&S[O3M[5L4 %%%% !1110 445'/<0VL+37$T<42C+/(P4#ZDT 245S,GCK
M2'+)I:W6KR@XV:="91GTW\(/Q:HXY_&>J_,EII^AP'H;AS<S_P#?*X0?]]&@
M \=^,M(\'Z.'U9Y5%X'BB\N,MEMO?TK.TGXHZ+K>GQG0K74=3NB?+%M#;$$$
M <LQPJ+[DBLGQS\*I/%.FK-J/B?49I[8-)^\5?+Z=%C4 +]>373?#WP=%X'\
M,C2XKMKH/*TYD9 I^8#C]* "2P\5ZZ +V_BT.T/WH; B2X8>AE8;5_X"I^M:
M>E>%]'T:4SVEFINB,-<S,9)F^KMDUL44 %9EUHL5U=K<O=WJNI+*$G*JI(QP
M/I6G10 @&% R3@=32T44 %%%% !1110 4444 %%<[=^*9;754TXZ%J,DTGF&
M(H8L2*A&6&7Z<CKZTZ;Q3B:<6VDWUU#;';<2Q!,1MC)4 MEB,\XJ^21I[*1T
M%%4;758+N^>UB#DK!'<;R, JY;'OGY35ZI:MN0TUN%%9^L:U9:'9FYO9"J=%
M51EF/H*K:EXDM=-F,36]W.4B$\Q@C#"%#G#-R/0],GBFHM[#4)/9&S16#<>*
M8+>>)#IVHO'-(L<4R1 I(6Z$'=R/PJ6+Q/I\T<KKYPV!60-&090S;5*9ZY;B
MCDEV'[.6]C9HH'3THJ2##\6VXF\-WLF+AS#"\@CAE9/,P#P=O)'M6-\/HDMU
MOX(9TNH 487,(E6,D@Y4!R>1QD@]QTKJ-7,0T>\\]K=8O*8,URNZ,#'\0[CV
MJCX;\/MH%M-&=0N+I96WB-V)CA]HP22J^V: -NBBO*+NZ%S>:G+IM_?):I.D
M-X6N9#+-&;A/.D5<XC5$WJ"N"02>@!(!ZO6%XD1V6T80W#J+B/+QS;47YU^\
MN1N_(UPAGN-DN;N_$40D_L0B:3,K"X(7//S\;1\V?E]JZ_Q$S?:;07<>E_\
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M\LJ#&6;'0#(K0MKV&[EF2'+"(@,_\.2,X'O@C\ZF5*<5=H+,LT445F(@L_\
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MD=CD\GZTY0<4FQ2IN*3?4DHHHJ" HHHH **** "BBB@ HHHH **** "BBB@
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M&3ZT44 &3ZT9/K110 9/K1D^M%% !D^M&3ZT44 &3ZT9/K110 9/K1D^M%%
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M['M2TB0HHHH **** "BBB@ HHHH **9YL9./,7/IFGT %%%% !1110 4444
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M5T/]VXB/_LU2#6KT??\ #VHC_=:$_P#L]:.^\Q_Q[P9Q_P ]CU_[YHWW>?\
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M "T_/M0!+14.^XQ_J4SCIYG?/TI=\^?]4F,_W^WY4 2T5#ON,?ZE,X_YZ?\
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M "T_^M5+$UEM)_>/GEW&P6%G:C$%K#%_N(!5BH=]Q_SQ3O\ \M/R[4NZ?/\
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MAZ[N;:012J%"RD B/+!2V#QP"3SZ4 5=$T"*'1;2.?[4DJQ@,IN'&#^=69-
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MHM^UF_BV]L\\^E=!##%;01P01I%#&H2.-%"JJ@8  '0 =JXZ#PY?K:6]M/%
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M3$S7'V5X]IC$QS+N=G?>>X);]*V=+L7LXIGG96N;B0RS%/N@G  'L  /?&:
MU+V****0PHHHH @L_P#CTC^E3U!9_P#'I']*GH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "D"JI8A0"QR2!U/2EHH :Z)(A1U5
ME(P589!IU%% "*BHNU%"KZ 8I:** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHH) ZF@ HHJ*>Y@M55KB:.)68(ID8*"QZ 9[GTH EHJI<ZII]D[I
M=7UM R()&$LJJ54G 8Y/3/&?6JW_  DFA>29O[9T_P H-M+_ &E-N>N,YZT
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M],FH+C7-(M$A>YU2RA29=\323JH=?5<GD?2@"_38XTBC6.-%2- %55& H'0
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M$W$L5E>+$C1G;!YP4J7#%MH8] .V:U;OQB[21I9Z==B'[>EH;V1$\EB)ECD
MPVX'EL$@ [30!UE%<OX?\>:5XDFGCLHYU\N'[0C.4(D3.,C:Q([<, >1Q6</
M$6O6^F:9KL[V4ECJ$D:?9$C(>%9!\A#Y^8@[<C ZG'3D [FBN*\/Z[KCVWAV
M\U2>SN+?6XE(6&$QO [1&4?Q$,N 1V[5<N_'5C8S70NK&_BMK>26'[450I))
M&A=E4!]V< X)4#(QF@#J:*R--UT:C]MC.G7EM=V>TR6L_E[R&7<I!5BISR.O
M4'.*I>(-8U*"_P!.T[31##<75O<7+/<KN"K$$^3 /4F0<YX /6@#I**Y>7QI
M%!H>E:@VFWEPU_9F\\JVV$QHJ!VR79>@;MR:B3Q];2R>1'HVJ/>8WBV AWF/
M8'\S/F;=N".,YR<8H ZVBO/[OXBK!J6EW(C8:5>QQ[(B@\YI7B,BH/FV@_-&
M.N.O-=!;>*X;G5H;$:;?(DTLD"7+"/RS)&"67ARW&",XP2.#0!T%%<3J'C"[
MTU+^RN%C748;\11':=K6Y7S?-QGHL8D!_P!I/>H5^(\6HM8C2=/NII'O(X9;
M?,)=HWBE=2I$FT',?.X@C!XH [RBN-L?'D%](QM;&^O&F*&&UBBC21!Y0=LE
MI #C/J.3@9ZU4C^)EE:/)#J4$XF\^;Y4"*8HEE**6#."3P<A03P>* .]HKAO
M%_BC4])UE;:QE"Q+I[7>!8R7!D8-@*=A&T'U-0Q>*=9U>^MK6QN+*W^T31 2
M>7YRA6M1*<889^8]?2@#OZ*YBT\4/!X=U&^U* RSZ;<O:S+:+_K65@ 4#$8S
MN'!/!SS44GCVVBFN+=M'U0W=I&\MW;A8MUO&H4[F/F;2"&! 4D]>.* .LHID
M,T=Q!'/$P:.10Z,.X(R#3Z "BBB@ HHHH **** (+/\ X](_I4]06?\ QZ1_
M2IZ "C-5[Y;Q[.1;"6"*Z(^1YXS(@/NH92?SKYM^)7A_XC7?C>[FMX-2NXRD
M>)=,AEC@/RCH-S<^O/6@#Z:J-YX4FCA>5%EDSL0L 6QUP.^*Q/"UOX@@TVV7
M6;JSD46T86.&V>.16P,[RSMD_@.:P?'-E?-XIT+5[.RN;DZ7;W,_[B,L2=\
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MTO4[][*UFE:90Q!>WD1) IVL4=E"N >#M)K6H **** (+/\ X](_I4]06?\
MQZ1_2IZ "BH+R6XAM))+6V^TS@?+%O";OQ/2N$USQ1XRL]8TR"W\/+'',^"@
MF$OF^HW 83 YJX0<]C2G2=1Z?F>A45F:7>:I=22#4-)6R4 %6%RLNX^G &*Y
M7QOJ=WI7B_P]=1WDT-E;P7-Q=Q*Y"21AX$)<=#M$C,/3%2U8AJSL=[17C2ZI
MJMXQFN+J3;=ZLTJ07&J2V21Q-:JZ)O3)7 (.W&,YK:$FGOJ4$.JZS)86J:69
M5-OKLSHLGG-DB4LID(']X<=,8%(1Z717DMOXBUF32KB.>:\:^O[.P@A6(G>#
M(9MTBKT5S&I?MR/:E35_$$DNAP6$]VVH:2;R.XM+ER&O4C\HJ).3\[1N"&.?
MF/UH ]9HKE/ VKG5]%CNOMI<3SW;I%-GS=HN' ZG("C"XQQQ63K=SJ5CJ7B8
M/JTYA-M:,I!$:VL;S2*Y7'0A.K=>,\8& #T&J46CZ;#J#ZA%86R7CY+3K& Y
MS@'GKV%>8WFH2QWNJV4FM7D&EV,=[+8W O7W-*B0$ N6S(%9WPI)!Z$'%=5J
MFN:W!9::ML;:&ZETV6\N//A9OFC5"5 ##&2Q'M0!UMQ;PW5O);W$22PR*5>-
MURK ]00>M166GV>FPF&RM8;>,L6*Q(%!)[\=ZX>?Q;K-IJ-IIUW=Z=;BYQ(=
M0E@9885,1?RR"_+$@X.X< \5SEQXOUV]AT?Q-:I+.Q6.$6%O*XCDD^SR2R,5
M'W@-T?')_=G')H ]DHKS=?'UY)K%M##>Z=)"^JV^GB'RR))HY(5D,Z_/PI+$
M 8/ ZYI^K^(;R'QFVHV\MV=*TVXCLKG9S;D,#YI8YQN5GBYQQM8=S0!Z+17B
MFJ^(-7B\+Z_I":C>K>^=<W\-R)2'2U5Y>%;.0!)%MQQ@,!WK9N]8MHHK_4-1
MU/45U6"^D1[:WU$0_9D5SY0$+,JN'3:?NL6W&@#U*BO._%^H:AJKZ=%:W/\
M8\<;3S2Q7]U)9M=!$&-CQ')4;B3DCL<'%-N-1U5+.SU33[B\#7'A>YN;:PD)
MD\N54A*9)^:1\OC+9/TR<@'H36\+7"7#1(9D4JDA'S*#C(!]\#\JDKA_#ETT
M3:O#IFI7&I0QZ?;W*--<-.5N'23(!8DC(6-MN<#=P!FN=N-6M;:QTB;1_$E[
M=ZO>(QNXGNWD\Q&B=I&\LG;&49>-H&W&WO0!ZU17FO@^]A5O"OV'6;F]O+ZP
M5]2MY;][@*/*#&0AF;8=Y XQG..U277CS4[2[U-U^QW*VM]<V<=C&I\XB.!I
M1(3N]5P1MZ'.<\4 >C52L='TW2VD:PL+:V:3 <PQA=V,XSCZG\ZQO#NMW=]=
MW]G=7-I<_9X(9UN[>,J@\P$[2-QY  /7HPJ/7KC[1;^'HI=2(L[R<">ZM)6A
M64>4S+AU;*JS $8;T&30!T5[86FI6_D7MM%<0[@VR5 PR.AY[T^VMH+.VCM[
M:&.&",;4CC4*JCT %<=;ZSJJ^%O#8L[B&2YU"Y%M]IN5,F8]DC!^"-QP@/7G
M-9-KXYULV]H;Q]/B-_!'(DPB8);9G\HELM\PY!ZC!./>@#TRBO*KCQ7JFJA)
M8)_M/]EWJB7^SF*+=YNUBB49;!W*DN021R.<5:N/'VI+8BX%SI=O)':17#PS
M*V9I'E=&B3D$%-N"<'+'H!0!Z717'^*M8NO#.JQ:@IDEM[VV>TCA+$HMT,M%
MQVW?.I([A:XG4O%6N:7X:U726N9))+6VN[0W+-MF\R.%F\X/YF[);! VC 88
M/'(![-17F-]XOUG2M0DMKS[/<3V,32B2+?&C!K<O\Z[CD*0>3VYX-,U'Q=JV
MF:W/B^L]0:"V$0:U#",%Y8!N="VW<H<]&Y&,D9- 'ICVT$ES%<O"C3Q*RQR%
M?F4-C< >V=HS]!4M>>:MK^H7_P --2O&D\FZANEM_-BE,&X"9%)+(S%,@D'!
M..:P;36+^*^DLEU"4!-4@(2WU)[R)$:WERHF;#-EDR48#& 1G- 'L-%>:>';
MZ.*]\)KINL7-[=7T!.I6\E\]R%00EC(0S-Y9$FT<8SNQ5O6/&NI:7=ZK+']D
MNH[*X>!-/C4^?)BW\T-NSZ\8V]* /0**Y;PQK]YJ6I7-E<W-E>".T@NA<6:E
M54R;OW9&X\@*"#GD'I74T (Y8(Q0 MC@$X!-<5XKF\6FSAFTZ#[(R2!'$,PD
M+[B ."O8_P Z[:BMZ%949J7*GZE1ERN]C(TE]9CBM[?4+6,[4Q)<?:-S,<==
MH4=36-\1QJ#:#9)I<\D-XVH0^448C<PR0I]B0 :["D(!Z@''-9SGSN]K>@F[
MGA^L^(+K7=6DU2"[FBTZ^M+=889)WA14%U"K;BO*Y+2 L.0*VFMM+CNM%M+J
M\MH;*>]E^T_9-<GF4@0.4W2,RLOS#H.#BO5#%&1@QKCIC%)Y$.,>5'CTVBH$
M>6PZ^VDZB)K:\N;W2;5[\61DE9S, D)";CRX$C.JDD\=ZIVESX@^PIX;O;G4
M=-UB2[MKN"XN61F?=_K" KL"@D7[I(^5P,5[!Y:8 V+@=!CI2E5+!BH)'0XH
M X7PAK=_JNO:N;J1;26.ZAAGM9<GYU@^98\D?Q#=G!R/SJMJ=V4\8W3G4KB/
M4HM4LX+*T68A9+=TC,G[OHP^:8EB"04'(Q7H6Q<YVC.<YQ2&*,R"0HID P&Q
MR!]: .4U?5]<BUF>"QFLH[>*>V@"RP,['S>K9##IQ@8KF-2^(6M65OJ&Z73K
M>73U4+Y\3?Z:QN)(CY8W<;0@)'/+=A7JFT9S@5CZIX9L=8NEEO'N&C 0/;B3
M]U)L;>NY?KUQC/ .0* .#_MW4M.\407D9;[+JY,MQ<3$R1VJ&79$=@(^\J1I
MGH"V36YX9\67VK>(K.RGN]/E2YT^:[D@@0B2U=98U$;$L>0'(/ Y':NW$:!0
MH10H& ,<8K)TWPU9:9J37Z2W,]P8VA1[B4N8T9MQ4$\X) ZY/ YXH X;5=9O
M]%MKK2+>*XN9=%EN-1*F0DO;H \2EMVXC=(J^XC:DT_Q/XBUS6;2%7MK=X'D
MQ-F.17!AW$,D4KC((&,MT;IQ7J.U<D[1DC!..M-2&*(8CC1!G.%4"@#RW3O&
MNH7.HS%[G3M,^T0Q7$ES=!WCW?9HGV %P 27)XQPAX)YJF_C[6M-N;Z&UCAG
M!>>Z629T5'PRC8#+(A50/3<1N'R^OKK00NNUXD8<'!4&E>&*3&^)&P<C*@X/
MK0!QWBJ>Q?5]/B\074EGH_V.:=E%PT2O,I0[69""=J[B!G!YX.*XW1+ZSUC7
M((M9U:1M%@COAI]R=0>(SQI/&J,SJREB 749Z@ ]>:]CDBCF39+&CKZ,H(J*
M*PLX=_E6D$?F.9'VQ@;F. 2?4\#GVH XRTUZ]L?AYI]\;U=SW@MX[S4%/S0&
MX*1R/T))CVG)ZDY/6L^Y\=ZI"+\)=Z9_H-L]Q"YC;&I%9'79%\W!P@'!;EQQ
MBO0;[3K?48(X;A28XY4E4#CYE.1^&14WV>'"#R8\1_<&T?+]/2@" 32O>6X\
MV*-'A9FMW'[PGY>0<]!D@\=Q7):Y]OMM3\2,NK%!+I*M 9B5BM>77(V@M[D\
MG\!7;X&<X&?6@J#G(!R,&@#RF.YM_P"T[73+J\,6B)/.9[V'4YRDDHA1HP)&
M?<,9?Y0<94'K6['K>O+X?\)QH\$5]J%N3<R7$1<@I 7S@$<DC]:[7[-!Y0B\
MB/RP<A=@P#]*DVCC@<=/:@#S:+QKK@_LM+N;3X%U&.WF-TT+".T$BRL0V6YR
M8U4'(Y>LVX\1ZOJUI::Y;*+V>PE%ND%FQCCNG>X8<;C_ '(8^O\ ST/TKT[4
M]*AU.W2)Y;B QN)$>WDV,",\'L1R>""/TI=*TFTT?3HK&SC(BCYR[%F8DY+,
M3R222<^] '!6_CN_N);9EU'3!OO+*W^S- RRS+,RAV4%N,;F7&#@QMGTIGQ
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M,^YK<6K;)UN5\LQ':&^8'H,$'- '"CX>:J=4AM!?)%H<$S3@!PSNS0-$?EV
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M,8!]Q5B2WAF;=)#&[;2F64$[3U'T.!4E% &3JWAVQUB*-)O,A\M@P,#;,X&
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M<Y821E,+GL,]^PKH[W4;+3K87-[=PV\!(422N%4D]!DTB:E8R&V"7<#&Z4M
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MDG;N)P,ECQ6W10 4444 06?_ !Z1_2IZ@L_^/2/Z5/0 4444 %%%% !1110
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MJ+8W-A:K&9;B]F\N- <8 !9F)]  ?QP*P9M U>;61-<):7MA;E!9P3W<@"
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MK-=1$6,LHBFN=W$!/W2W^R3P3VS7/Z7X8UC2;%;!$TVXCFBMEGEF+-L,:*K
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M:Q/[.-RPB>&2-D:1Y9-GW_G#*.>&Z#\*=IHN[(S13Q2)%M#"4#+=%P!V[L,
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MHH **** "BBB@ HHHH **** "BBB@""S_P"/2/Z5/4%G_P >D?TJ>@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH *.M%% !C P****    8' HHH
MH *0(JDD* 6ZD#K2T4 %& <<=*** "BBB@!" 1@@$'L:" 1@@&EHH **** "
MD*JP(*@Y&#D=J6B@  P,"BBB@ HHHH *0@'&0#CD>U+10 4444 %%%% !111
M0 4444 %%%% !1110 @ &< #//%+110 4444 %!&1@]*** $50JA5  '0 4M
M%% "*JH,*H SG@4M%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
L4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>imrx-20211231x10k020.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 imrx-20211231x10k020.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" (Z \L# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MO/)_&NVI,:V"BBBD,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MZ# R^&QGI\W.<=J[CP3H<WAWPG9:=<,#.BEI,'(#$Y(!I,%<Z"BBBD4%%%%
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M 6=KL?:&;+;@>@'(XYI+".\US4IIY&MC;@PAS$&VL%W':"0-QR1GZX[5V%%
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MN[=+3['Y4SB/]\K%@>>>#TK63=L7?C=CG'3-9NK?\?.G?]?(_D:TZ "BBB@
MHHHH **** "BBB@ HHHH **** "BL/Q;>7]AX?EGT]G24.@:1(P[1H6 9E4@
M@D#/&#]*XK3_ !+K.KZO-H=OK-U%%!+*4U![:)9I46)'564IM'+GD*,@#IUH
M ]1K)\4?\BIJ_P#UYR_^@&N%A\5Z[?Z9>:PNH&W73;>V<VJ11E+AG!+EB5+
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M_,VYAQ],GVH W(_]4G^Z*=3(O]4G^Z*?0 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5DP?\
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MOEZ##;OS H Z*BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MO^R30!U-%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MVZ_ZXO\ R-0:'_R K'_K@O\ *@#0HHHH **** "BBB@ HHHH **** "BBB@
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M=^@H Z2BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M#\7FY'A74_LZQ$?99=_F$C V'ICO0!M1_P"J3_=%.ID7^J3_ '13Z "BBB@
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MI<Q7/\-]<J><>L:'OT)Z9 S0!9\+Z;=ZQJ;^+M<B*3R@IIEH_P#RYVY[D?\
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M_G7=1J5C56.X@ $^M9T:KJ2EHTEWZFE:BJ<8ZIM]N@ZBBBN@YPHHHH ****
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MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHJ"]O(-/LY;NYD6.&)2SL3T
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M/*9B?N^X% '2T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M\0;RU:ZTZ%Q970MW9YK*[N'A1P1\I)56R1SU&.:[ZLS7]:CT#1YM0EAFF$>
M$BB>0DD_[() ]\8H S_!<UO/HS-;:=8V*>8?W5G,94^N2B\_A71UEZ'K*ZU;
M2SI"\2H^T!U*L>.X8 CZ$5J4 %&.<T44 &*QM5_Y#NC_ /71_P#T&MFN=U)+
MP>*M*9YH3:EGV1B,AP=O=LX/Y4 =%1110 4444 %%%% !1110 4444 %%%%
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MX?$6DM>ZC#<QEWPJ6WED';Z[C0!U-%%% !1110 4444 %%%% !1110 4444
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M7M$7AG4O%4R7OB\JMFK!X-&B;,2GL9C_ ,M#[=![UKZU-:VFL:%YK1Q(LL@
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MD0QZ+AF .W4<G\!MK=UVVTZ\M(;?4IMD3SIM4L )&SD*?4'TJP-)TY6!%A;
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M\TMA=O>VB7#6[0AP&568$X(R.E)JO_()N_\ KDW\J73/^039_P#7!/\ T$4
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M,**** *FI1&6PFVS2Q,J%@T;8.0*AT6)DTR%WN)IGD0,6E;/.*M7O_'C<?\
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MG^0]JVI[2VTR$WMPK7<XX,DQR1GT["H=24OX:^;V_P W_6IHJ<8O]X_DM_\
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M7.>_I0!U&D^*[#6+W[-!'<QEE+PO,@59U!P63GD9]<5)JO\ R'='_P"NC_\
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MI]EZ"MP *    .@%+15**6Q+DY;A114<\7GQ%/,=,_Q(<&F24]#_ .0%8_\
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ME:UMG9))?X05Z\]ZBL?%FCZA:75S!<,([9=\HDC*$+C.<$<Y[5SG@_1[._\
M#FNZ2\02TDO9H]B<;1GM6=JVGG19+EGNY]4^RPI+<F;:@VJ0(X^!C&>2?:J]
ME!R<1<SM<]*MKA;JUBN$5U610P#C!P?45+7->&/$%[JEW=65_%8B:!$D#V4I
M="K#@<\@BNEKGG%Q=F6G=!1114C"BBB@ KG?%#Z"\NGVFO.PBGD81JTS)$S
M X?! (]CD5T5<;\08HI+2Q-['<-IBRM]I:U0-*O'RX'7'7.WGI0!TVF#34LU
MCTO[,+9. +;;L'Y<5<KE/ *JFB2B!)5M/.;[/YZA92G^V!W^O-=70 4444 %
M8VJ_\AW1_P#KH_\ Z#6S7/:E90)XITJ[5,3.SAFR>1M]* .AHHHH ***YW6_
M&>FZ1.+*%9=1U1O]78V:[Y#]>RCW.* .B) !). .]<KJ/CBV6[;3M#M9=9U(
M<&.W_P!7&?\ ;DZ+_.J:Z!XA\48E\37@T^Q/(TJPD.2/267JQ]EP*Z6RM=+T
M2U6TL8(H(EZ1Q+R?RI2DHJ[8TF]CC-5^'VH^-+)O^$OUF<*2&CL--81PQ?4E
M27/N?PJ;X;>%-.\'^'4>P:XEEU!$E=)9 W..V%&!^=;NO:S;VVGNUP"J#HH!
M>0GV5<FL;P7-<ZAH$$,(DM$AC5)9)8F5\XY"[A^M<<\3>?)!'3##^[S2T.GE
MNHK67,Q,]VWW8HQDCZ>GUIOV*ZU []0?RX>HMHSP?]X]_ITK/.LZ9ILK6FEP
M2:C?G[R0?,<_[;GA?Q-.&E:QK'S:Q>BUMS_RYV1(X]&DZG\,4XPOI+7R6WS?
M7^M!N2CK'3S>_P ET_K4L77B#3=.86=LK7-P.%MK5=S?CC@?C58V>O:W_P ?
MMS_95F?^6%JV9F'^T_\ #^'YULV.F66F0^59VZ1+WVCD_4]ZMUT<C>YASI;?
MB<XWAS1[&_TSR+"$,LC'>PW.3M/)8\D_6NCK)U&Y5-2L_P!S<L(F8NT=N[@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M/K5VLP,C6-)EU&^TJ>.1%6SN/-<-G+#&,"HM>T6YOYK6^T^X2"^M23&9%RC
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M0A28($6SOYH.@P=P1@#7444 4=+TN'2;4V\,]W,I.[==7+SM_P!].2:O444
M%%%% !7AOQ"^%[^(/B$NHI?1J;ME CW#(V*.HQQTKW*N<UJV@7Q#I5PL2"9G
M<,X')&VDU<:=B]9VXM+2&%0!Y:!>/858W'U-)13$+N/J:-Q]3244 +N/J:-Q
M]3244 +N/J:-Q]3244 +N/J:-Q]3244 +N/J:-Q]3244 +N/J:-Q]3244 +N
M/J:-Q]3244 +N/J:-Q]3244 +N/J:-Q]3244 +N/J:-Q]3244 +N/J:-Q]32
M44 +N/J:-Q]3244 +N/J:-Q]3244 +N/J:-Q]3244 +N/J:-Q]3244 +N/J:
M-Q]3244 +N/J:-Q]3244 +N/J:-Q]3244 +N/J:-Q]3244 3VY))R:GJO;]3
M5B@ HHHH **** "BBB@ HHHH **** *][<M9V4MPEO-<,BY$4(!=SZ#.!7)V
M_C/4+_2M+DM-,B%_?+/(899<+&L3$$9'4\ ?C7:'D5R0\'7%M8:>EAJ(BNK/
MSU$KQ;@R2L21C/49&/I0!3'CZ:X@DOK33T;3[2&&6\9Y"'7S.<(,8.T<G/7-
M;GBJ]M$\,:O$US"LALY<(9 #]P]JQO\ A 6A@:RM=1\NPN(88KN-H\L_EYY4
MYXR.#]*V/%5A9OX9U>9[2!I19RD.8P6X0XYH O1?ZI/]T4ZFQ?ZI/]T4Z@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 5?OCZU=JDOWQ]:NT %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% &%XF\02Z!;
M6\D6GS77FS+&SK@)$"P&6.??@"LVZ\97%K?/(U@ITJ.Z%G)-O_>!R/O!>FW/
M'K6[KFE#6=--F9?+S(C[L9^ZP;^E8EUX,DNKYE;4,:8]T+N2V\OYC(!TW>F>
M: 'Z+XKN;^^MX[RR2W@O(6GM763)V@_Q^AQS4VK7=M<:WI"PW$4C"1\A'!(^
M7VJ/1_"<NGW\$MU?BY@M(FAM8O+QM0GG<>_I3]5LK2VUO2'@M88F+ODQQA2?
ME]J ->BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH FM^IJQ5>
MWZFK% !1110 4444 %%%% !1110 4444 %%%% !6)XNN8+?PIJ@FE2,O:2JN
MXXR=AX%;=8_BN-)/"FK;T5L6<I&1G!V&@"Q%_JD_W13J;'_JD_W13J "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@!5^^/K5VJ2_?'UJ[0 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7.:U<P-
MX@TF!94,RNY9 >0-OI71US^MQH-<TAPBAS(^6QR?EH TJ*** "BBB@ HHHH
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MO7&?7TH'C;PN55AK^GX958?OUZ-TKJD4*BCC(%4]4L6OK9(D95*RH^2.P.:
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M;POC/]OZ?C#'_7KT4X-=4R!D*X'(Q532K(V&FPVSE69 02!UYH P?^$T\,9
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M_;VG9RP_X^%_AZ]ZZK ]!5+3+!K&*9'96,D[R# Z!CG% &$/&GADD :]I_)
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MXSCZUMU0DL&?7;:_#*$BMY(BN.269"/_ $$U?H **** "BBB@ HHHH ****
M"BBB@ HHHH *YCQ67GU+0M->ZN+:SN[EUG>WG:%VVQ,RKO4@C)'8C.,5T]5;
M_3K+5+8VU_;17$)(;9(N1D=#0!E>#+J>[\.1M/,\YCFFB29VW-(BR,JDGN<
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MKB25Y9'@7>[]6;N35O4=)T_5HEBU"SAN44[E$J!L&K,44<$211(J1H,*JC
MH \Z\=7E]9ZG>3K-J&V"R$EJ+2[,20R9.6D4, P/'W@1VQ7>PM<W.DQL'$-U
M)"IW%,A'(]/KVJ.\T73-0NH;F\L+>>>'_5R2("5^E7Z /,[26_DTVWT^^U>]
MD276)8)[H3M%(RCH RD%1GL,5TGAJ:^OO",R)?/YR2S0PW4G[UBJN0K')^8X
M[GKBMJ;1=,N+26TFL8'MY7,CQL@PS'J3[U9M[6"TMDMK>%(H4&U8T& !Z8H
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M]O#:P)!;Q)%$@PJ(, #VH X7QO/J,VO6^GVSS);K8RW)$5^]IN93UWIR2!R
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M.6+,5Z9/I0!;HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** .)
M\5:+93^)=%=UF!N[AEG"SNH<!.!@'VK)C\0:O:3SZ;HRV<20&_F8W(>3*PS;
M0!\W&0:]$N+&VNI[>:>(/);L7B8D_*2,$_E51?#VE)/).MF@DD657;<>1*VZ
M3OW/- '"7_CW7M(ME^U06MQ/>1VKVPMH'/E&9G4@KNR^-G&,9)Q6]H'BJ_NM
M!UB[U*R=9],WGF$Q&4*FX?(22I[5N3^'-(N8'AFL8WC>!+<J2?\ 5J25'7C!
M)(/6IM-T;3])M&M;*V6.%R6<$EBY/4L6))_&@#SA=;UJ7PL;*RN8(YCH;:G=
M3W&YVD:522$((VX).#VXI\_CW4M-GMHX/*NK6&2VMI@EK*P!=$SOF.$#Y;[H
MW'&,]>.KB\#:3+I%MIVIP+>16JM# Q9E(A)X1MI&0!@<^F:GF\$>')[@SR:8
MC.2C$;W"[E "MM!QN  YQF@#FI?'FJLTUA:VMFVJV27+WR.Y5$"$+$ 3@ N6
M!&2.%-5W\4:A<^&I-5NG=+W2=1MLPBUDMY"DCJC(\;Y!RLAP02.AKJM.\*0Q
MSZS<ZJ8;V?5BJSXCVKY2+M1,9[#)SZFE?P?IZ06MI9I]GM$NTNKA=S.T[1\H
M"S$G 8*?^ @4 =$.11110 4444 %95OJSOK%W931A$1]L#C/SD(K,#[_ #5J
MUF3:29H[P>8%DEG$\+C_ )9L$51_Z#^M %FPN_M6GV]Q)M1I8U<J#TR*KZQJ
M4NFV#7$%JUQCJ0RA4&1R<G/?L#5,^&TFM;1)Y(FD@@6(L8$?..XW#/>KD^E;
M]#?3HG5<KM#; H'/H* (]3U&\LUN)HK=/(MH_,=I21YG<JOOC]:U$;?&KX(W
M '!&"*RKW3[NYU 3'[/+ F#'%+NPK>N!P3]:T87G:242QJJJ0$(_BXY_6@"I
M'KEC+<>2CR_ZPQ;S X3>#C;N(QG/O2KK5B\_E"23.64.8G",0"2 V,$\'H>U
M9MI87US:"";RDMA=22="'P)&('X^OI20^'9HWCC9HS%&[,K&20D]<?+G:#S0
M!LV>H6U_:_:;=V,/4.R,@(]1D#(JJGB#3GSF25!Y9E#/!(H9 ,D@E>1]*L+9
MA='%DY) @\IBG?Y<<5SL45YJI@M2 L<=J\1<PNF"5"C.X?H* -PZ[8^6D@-P
MPD!90MM(25'\6-N=O/7I5A=1M'CDD68%(U#N0#P",@_I56XL;I+L7%F8<F'R
M663.  <@C'XU2.BWL$$MO:RPE)H4C9Y <J1GD#\: +[:]IZRLADD(4A7<0.4
M0GIN;&!^-:5<U%IM_-#J%F#$EO.^QG93N"X )'K72@8&* "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **9++'!&9)9%C0=
M6<X _&N3OOB?X1T[7DT6YU4"]=E4*L3LN6Z?,!M_6@#KZ*B@N8+E2T$T<JC@
ME&#8_*N?;QKI\6J:W8S12QOI,0E=FQB5=H)V_3*@_44 =+17%VGQ!&H-&+/1
MIWW1)(WF74,17=VPS#)X[5:C\:'SG:;1KR*Q2Y^RF\\R-D#Y Y4-N R0,XH
MZJBN6D\=6$5GI]RUO/MO)I(@!@F,([(7;GIE?UI3XZTU;K5[8Q3";3>64@#S
MEP"2A[XW#/U% '445EW^O6ECH[ZC\T\:D(J18+.Y. HS@9R<<U':>([.73[F
M[O =/%K(8[A;AE_=GCN"01SZT ;%%8L'B_P[<LRPZQ9NR@L0)!P!UJM>^-=)
M@L?M5G,E^!*(V6!P2IQDY^@YH Z.BL9O%FA1VD=Q-J=M$DG3=(.#C)'X9J:3
M6[:._LK?!:.\C+PSJ04.!G'XCF@#3HKG;3QIHUTC_P"DI'*&<)"[C?(%)&0/
M?!Q19>-=&U"SMY[:ZA8R;/,C,JAHMWKD_P J .BHKGCXTT,W<,,5]#+&^\O,
ML@VQ;5+?-^53WGB?3H/#MYK5M*M[;VJ%V$+#)QVYX!^M &U17)0>/('#+/IU
MQ#*KHI42QR#YNAW(Q'X=:GTSQ>;Z2S^T:1=V<%Z2MO.[QNCGT.UB1G'<4 =-
M169)XBT:&_>QDU*V2Z0X:)I "#C.#4NG:SINK;_[/O8;GR_O>6V<4 7J***
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MJ&4@J1D$'@T >?6G@/4K430^;8O'<O'(\Q#;X-K$[4XY'/'(KT*BB@ HHHH
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M>C'5M.%W]D-];BXX_=&0;N1D<?0BKE $=O&\5M%')(9'1 K.>K$#K^-2444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 07<,MQ;/'#<O;2'I*BJQ7\&!%<9?> +Z]\36FKMX
MEOLPKAAM09(^[\H7:?Q%=U16D*LH?")Q3W*EA:W-K&RW-_+>,3D-(B*1[?*!
M7G.KZ+K2^)M:N+"SN#%JTHLYG53A8_+0B7W"X=?JU>HT5#=]1GD&D:9+IET$
MN[75[=!!&D8@T?[2IP3P6,;;>WI6A'9RW2S6-OH-XFH-JGVA;R2S,21Q[@=W
MF,!G@$8&:]/HI >2IX=\0:K86]O%!]D&F>?.GVJ!\R2O/(5V<CG;WY^\*9-H
M^NS:=JVLVFGW27-]<".ZLI$96DC*)AU![JV[ZC(KUVB@#*@MX;_0YK66*Z\N
M0,CI<;E8^N.^/2N!N+3[-H6EZ-+H=XH=94ENH]/DG:"+S&PJA5.&(QR>@YKU
M.B@#S[2=-GM?&+36EGJ*-).7N'NX1Y?E; %*OCKP!C.1SFFWFFZ[<:C)-]KU
MA%>^E7;%(RH(1%E< =!N[UZ'10!X_%K6LPW5E'<3ZK+J1N=CQ(VZ)H]A^4J/
MXO4=>_2I%LO$?AW^T)8O.BM6B.UE&Q4F*9+L3QMSD G@'%>IKIUBM\;Y;*W%
MV1@SB)?,(]-V,U/)&DL;1R(KHPPRL,@CW% ' Z%=3:EI_B.&W?4IH5B18$O2
M6DW%#D#OUQ_^JN>B\/ZY!<WC6^GW*KJ*):3DH1M3RE^;\""/QKUFTL;33X?)
MLK6"VBSG9#&$7/T%6* /&[#P_KNFOYUCIURK3V\=A(&0C"%3\W_ 2!GVKK/#
M^@:@GA5M*OHX?[.6)T2W,3K,2"<9;=@@_2NXHH Y?0M-U)= TVQE%O%8"V\N
M>"2)Q-] =P _*N671)[#2[-)-(N9K=#=1) D!<QLSG8VWJ!_M5ZC10!YMIFA
M>)+7Q=HE[J%K;S)&CQ><EPY\F/RR,%=F <^_)Q5'7]*O9_$FI^18ZA-/)<Q2
M0(MB##(!C),Y VCZ,/I7J]% 'EEM;/I^J2R:CX?OKQ)%F6-([%I06+<<XPN?
M4XK1O$O]$\(:!9W3W\4AG"31V)+2A220@V\G (''I7H5,>*.0J9(T8H<J67.
MT^HH \UMAXI$JK<_VO\ :F,9LMN?*$>X[O.(X#8QG=@^E>FT44 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 51N[6]FW^1?&($8"^6#C\>
MM7J*F<%)6949.+NC)L+#4H((UGU'<5/S (#D>F3S5'QUI;:SX8DT]89)5FGA
M5UC&3L\P;C^ R:Z2BE3IJFK+\[CJ5'4=W^5CQ?5=%\0WZ_;;_3[QKB&#['^Z
MA,A*QLF7"@'.X[B/4 5N2"'[)8O]@U>\B@OTDG671&B;;L<<(L:[QGV.,UZ9
M15D'EGV75[34)-7T_1+J&*7[4UI:^3@QEUB52RC[F6!;!Z#/I5=O!^J6PM_#
M]]"UU8W5Q%<-<6D3J(G"L&8DDX;.ULYZUZW10!P?A>WU>TUS45UJ"[:;SXXX
M[J%"([A53 D;' !&,CL:O>(]$DN?$EE>VEO(T[6US$TPSA,IA1GH,FNNHH X
MCPK:3QSWEQ%IUQ8HNGPVS++"8S).F\LP'<?,HW=\5E6>G>(H1%<-=ZT\BBQD
MV22,5+-*HF!'<!2V1VKTRB@#R72K[4-8U&QTYI-2G:X@C>_,C[X0PD#%XR"1
MM., C@@_7$>GOKVB6&GV>KF^BLI!%L%IE&6(*08MO7S V&..64\#Y2*]5M=.
ML;%Y7M+.WMVE.Z0Q1*A<^IP.33KNSM;^ P7EM#<0DY,<R!U/X'B@#SN_%[JW
MPTT.9EOKF07D$LC)!Y\P0.<L4P=V![&J"V'B".U2.PMM1MX)KIRLZP>5,4>>
MVRS(!^[.WS.,#@$XKUB.-(8UCB1411A548 'H!3J /,+RQ\1IKDMI;RZM]C%
MRD:W&69O*+(6P^,X^]S4=W9>+K>VD&GW.J%Y'O$=IB\FV)+G$14<?,8AD8(+
M ^]>IT4 >0/I_B!A%>2MK%U+]EOH;9GM)$V@O R!D+,0#ME(+X)VJ,<#.A<6
M?B2**P9&U2<W+(]U'*&=49;Z#& 1\O[HR'Z GM7I]% 'GWP^L]4LV@AD34XK
M:*T*W$5\K!1,7)7R\\8V^G'3OFN6TW1=473S%%IFH-<QQWZS)/8^2D:OYFW9
M)M!D)RN!ENO:O:J* /,+NSED37M-30KV74[RYB:UN19D(B_9X%W><V%&UE;C
M.>.E7O%=QJ0\1?8+6XU4S'22UNMD#M-QOPK/CH/=L*.YZ5Z#3/)B\[SO+3S=
MNS?M&[;UQGTH X;1U\0KXD@6[;4&F$\IO"P(M/)V_)Y9/&<XX'(^;-=Y110
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M*X<NS6,?DM&GV8@^9=[F(W1\\#C/0]:]'J+[-!N5O)CW+PIVC(^E2T %%%%
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M15FUM(;*#R8%*IDMRQ8DDY)R>: )Z*** "BBB@ HHHH **** "BBB@ HHHH
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MY14*#:V.I8XSS[8I4T18K1HUE)D.TAB.A'/\ZF?289'=FDE42',L:/A7/TH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
; "BBB@ HHHH **** "BBB@ HHHH **** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>imrx-20211231x10k021.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 imrx-20211231x10k021.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" *5 K0# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M86DMW=2I#;PH7DD<X"J.I-84WC;3(]'TS4H8;ZZCU+_CVBMK9I)7&"Q.P<@
M T ='17/7GC&PL;.RFFM=2\^\5FBLTLW:XVK]XM&.0!QU]16QI^H6NJ:?!?6
M4PEMIT#QN.,@_7I0!9HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MI>W>JSW)F@5VC>*)5!(!XVJ#^M &U1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 <_';W4/C*!I[TW"/9W!C0Q*OEC?%QD<G\?2N@KGTBNX_&
M4!N;J.9&L[@QJL.PH-\7!.3N_2N@H **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** (KK_CTF_W#_*J>@?\B[IO_7K'_P"@BKEU
M_P >DW^X?Y53T#_D7=-_Z]8__010!HT444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M[G-E/MV6XCV_/%G^(YKHZ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MYT$.G:D$9RGF/;%5!!P<G/8@UM5D>'!_Q+)/^OJX_P#1K5KT %%%% !1110
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M,^N!0!/1110 4444 %8^C_\ (3UO_K[7_P!%)6Q6/H__ "$];_Z^U_\ 124
M;%%%% !1110 4444 %%%% &1X<_Y!DG_ %]7'_HUJUZR/#G_ "#)/^OJX_\
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M_6*<X]O6NKZ5PL(U[QE)<WUKJL6DZ9%/)!:JEG'/+-L8JSL9 0 6!PH'0=:
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M*** "BBB@ HHHH **** ,G5_^0EHG_7VW_HJ2M:LG5_^0EHG_7VW_HJ2M:@
MHHHH **** "L?1_^0GK?_7VO_HI*V*Q]'_Y">M_]?:_^BDH V**** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M_P#V%;  50J@ #@ 4M '/6VM:S=R7*1Z+!FWE\I\WP^]M#<?)Z,*L?;M>_Z
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M*W\=F=$@\V2)I1_IXQA2 ?X/]H5T%)M&[=@;@,9Q0!C_ &[7O^@+;_\ @?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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ML-1NVU%&%C>6+QWR?= ,$RYW1@#(S@ 9KO\ 2<_\+$\0B+_4_9K8R>GF?/\
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MRJJ6-@I-M$&+,TK9W2.3U/)_,FN@HIW%8****0PHHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHR** "BBB@ HHS1F@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **,T4 %%%% !1110
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MEN !G(XKN_)C\SS/+3?_ 'MHS^=<[K7A :KJ,E[;:M?:;)<0BWNA:E,3Q@G
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MR>!5_1_"QT[4O[1OM6O=4O$B,$,EUL'E1D@D ( "3@98\G% '0T444 %%%%
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M$=IKC7$*075I=VY'G6MW%Y<J ]#C)!!P>036Q0 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %9\NAZ7-
M*\LEC SN<LQ3DFM"BJC.4?A=AIM'#:)\.K#3?$VJ:C-!#+;S$?98B,B,'EN/
MKP/:NOM-.L[%F:UMHH2PPQ1<9JU16U?%5J[O4E?9?<.4Y2W95U&![G3+J",
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MNW96Z].O-7+6SET6+PCJ=M>W\UY?+MN?.N7<3 P,P!4G P0,8%%@N>I45Y-
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MB!K1+DQSP>>DCPLJ[<XQGIGVK6KQ6SU34-/T!7L[B6,IH6Y=K';&3-@N!TR
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M+5HHY0!QM+!GR/3 &:W[.T2RM4MT9W1!A?,;<0.PJ5(HX]^Q%7>=S8'4^IH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
H* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>imrx-20211231x10k022.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 imrx-20211231x10k022.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" (* [\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBF3,4@
MD<9RJD\#)Z>G>@!]%<!INL:@]DYEOI&#QVSR2AP_EAV(=B<?NVQ_#R%]:OMJ
M$FR..;4Y8;$2W 2[#@%P@79\W?JWUVT =6KL;N1"?E"*0/<EO\!4M9FD3S7$
M4<MRI6=K6%I 1CYCN)K2.<'&,]LT +16 FK:@T.IR-]C"63;3+\VUB%RX^HX
M'USZ4Z35]1MH=-FGM80+GRUF4%OW;-@'YL8XSWZT ;M%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 (% S@#GK1M& ,#
M [4M% $"?\?\O_7)/YM4]0)_Q_R_]<D_FU3T 8<^I>&K:.73I]0TZ)0Y,D#W
M"@ABVXY!.<Y.:6.[\.:OJ41BO;*[NUYC1+@,?EYSM!P2.N<<5\Z^.1_Q7FN_
M]?CUJ_"?_DH^G?[DW_HMJ /I"BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@"!/^/\ E_ZY)_-JGJ!/^/\ E_ZY
M)_-JGH ^6_'/_(^:[_U^/6I\*/\ DH^G?[DW_HMJR_'/_(^:[_U^/6I\*/\
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M]J]G'HR:-<O%=37FP*K8$G&0I]0:=@OI<[BBN0NO$HU;X;ZAJ]A(\%REI)N
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M,_E3Z "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MDK(([F"X=IC;D])4W$GZ_P"<7O$4UWXC\9Z7I>D3V^S3X_[0DEE4R1ECQ'D
MC/7(Y[UW<]O#=0/!<0QS0N,/'(H96'H0>M06FEZ?8.SV5C;6S.H5C#"J$@=
M<#H.U%PL<)>1ZMX<\<:9KNJW-G)#?XT^=K:)HU7/*,VYCWXSZ"K=[=^'M<US
M4-(\5:?:6]Q;./LTDKE#-$1PROP?P!KM+NRM+^'R;RUAN8LAMDT8=<CH<&H[
MW2]/U)%2^L+6Z5?NB>%7 _,47"QQ7A-(+#QG=Z;HFI3WNC"T\R17D\U()MP
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M'EB*W4^3LR&W,.^>.OIVKG_"GA?^WQ--]L^S_9W7@1[MV>>N1CI77ZK"]O\
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MH X4?V_K6HZC]CU2PTR*UN6@6W:T61R !AF+>N<C%='H-GJ5G!,NI:E#?.S
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M7%V%@'1,!!@>W%23D?\ "&>/!GG[;<?^@K7<OH6F/<Z?.;1%DTX,+782HB#
M @*#@\ =156;PCH<]S>W$EE^\OD*7.V9U$@/7(#8SP.0,T7%8YF<QZ1#X.\0
MG"1K;165T_;RY$&TGV#?S-8>JP7+?#74-:.5EU>_2XG+ _+!OP@..V #^->F
MW6B:=?:*-'N;826 C6,1%F^ZN,<YSQ@<YJPMC:K8"Q$"&U$?E>41E=N,8Y]J
M+A8X35]*U6_L=-^V:MX<M+>*>.2UFAA>-L@\*A9R.?2N^N/^/67/78?Y5BV7
M@GP[I]VEU;Z:@EC.Z/?([JA]55B0/P%;S*'4JPR",&@:/*? .D>([SPI%)I_
MB8V-JTL@$ LXWV_,<G<1FKWB[P]%X?\ AKJZ"XENKFXE6:XN9OO2N6')]*[S
M2M(L=$L5LM.@\FW5BP3>S<DY/+$FEU32K+6M/DL-0A\ZVDQO3<5S@YZ@@T7U
M%;0Y?Q=!:PZKX5AGC1--%X5=2,)N"'RP?QZ4OB81+XS\*FT"B^-PX?9C/D;#
MNS[=*ZG4-.L]5LWM+ZW2XMW^\CCC_P"L?>J6E>%]&T29I["R6.9AM,CNTC8]
M 6)('M1<=C@(?^1.^(/_ %^S_P#H*UK6ID'B/3S#GS?^$9?9CUW1XKJQX:TA
M;/4+06G[C47:2Z7S'_>,W!.<Y'3MBIX='L+>]AO(H-L\-O\ 98WWL=L60=N,
MXZ@<]:+BL><>%+35;SP#Y<5UH"64BR"Y^TV\AD5BQW%VW@9]\>E=[X5M6LO"
M^GVS7L5[Y4047$1RKJ#Q@_3 _"J]UX(\.7EX]U-IB&21MSA9'1'/JR A3^(K
M=BBC@B2*)%2- %55&  .P%#8TCE?#8'_  G'BTM_K=]OC/\ <V-C]<T?$7_D
M6X?^OZW_ /0Q5VXTFYMO&%OK5DF^.XB^S7L>0.!RDG/7!X/?!K5U'3+/5K9;
M>^A\V)9%D"[BOS*<@\$=Z MH)JM\NF:1>WS_ ';>!Y3_ ,!4G^E8W@/3C8^%
M;::49N[TF[N'/5G?G]!@?A6YJ%A;:I836-Y'YMM,NV1-Q7</J"#4T,,=O!'#
M$NV.-0JKZ <"D!C>*DTR]\+ZC#J-UY-H% EECRQB(8$' R>& -<5XJL=:ET/
M3K34=<MKL27,*6L5M#L:X;</F<DG("Y/  SBN_MM TNT6_6&T4+J$C2W2LQ8
M2,W4D$G'7H.*K:;X0T'2+L75EIZI.H(5VD=]@_V=Q.W\,4TP:N1:_H^@"*?6
M-5M0WD1[I&WLH<+R R@@/[ @USMO_:Z7NGV\<YTW4==,MY<W'E+(T2(!LB4-
MQP&&?Q]:[F^T^UU*!8+R+S8E=9-A8@$J<C..HSV/%0ZKHNGZU%''?V_FB-MR
M%79&4^S*01^=%PL5?"VI7&JZ%'<791IUEDA=T& Y1RNX#MG&:Q+01-\5]3^V
M8,HL8OL?F?W/XMO_  +-=;9V=MI]I':VD*PP1C"(O0"J>K^'M*UT1_VC:+,T
M?W'#LCK]&4@_K0!R,6G6VJ>,?%FG6P3['<64:3A,;1.0>?KC%4M$O9O%>I>'
M=.G!SHR/+?J?^>T9\M,^YQN_$UZ#I>D:?HUM]GTZUCMXR<D+R6/J2>2?<TVR
MT73M.OKR]M+58KB]</<."3O([X)P/PHN%C@/"D>NS2Z]]GGT99S?S"Z2]@D>
M7KQDAP-N.G%0S:6EEX=T&S>]L[^!O$$9!MN8E!+$H.3P#GC-=SJ7A#0=7O#=
MWE@&N&&&D21XRP_VMI&?QJPWA_2C:6=J+*-(+*59K>-"5".O0\'GKWHN*QB^
M)KR&/Q#HUE;:5#>ZJ1)+;F:8Q1Q# #,>N3^!-8MC->O\3YEO_P"SUN3I+>8M
MD20/F.-Q/5OZ8KM-7\/Z7KR1+J5H)O*.8V#LC(>^&4@C\ZALO"NB:;<I<V=@
ML,R1M$'5VR5;KNY^8\=3DT7'8X73O^0)\/\ _K]?_P!GKH?%^1XM\'^7_KOM
MDG3KLV?-^E;L?AS288-/A2TQ'I[F2U'F/^[8YYZ\]3US59-+N+OQ@^JWD.R"
MSA\BR!8$L6Y>3@\?W1GWHN*QO4444B@HHHH **** "BBB@ HJ&YNH+2%YIY
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MUEJUW'<W5E<",M%$J+M*A@1CV/(/0BN6OH-!N;F>\GTWQ8A=C(Y4.JCN>-V
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M1LQ^5,8Y) )ZC'XUJ4AA12$@=2!2Y'K0 449&<9I,C.,C/I0 M%(2!U(%&X
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M](4444 %%%% !1110 4444 %%%% !1110!%<6\-U$(YXUD0,K[6'&5((/X$
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MN_X$V374TF-!1112&%%%% !1110 4444 <7XX_X\9/\ =->85Z?XX_X\9/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M/?')'4#%=?10!R$8TP3:-]F(^VF=?/P3N)V-NW^^?7WKKZ** "BBB@ HHHH
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M?48[GSVN@\BP/"P5L;2-PSD#IG(.>U=+XJU>]T#P?>ZI!'#/>VT(8(RG8[9
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M 4U_N-\VWC[WI[TZD(!!!&0>HH Y&/4+L6EU);ZG)/9O-#%'<R;"ZY;$CC
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M>PS6;=> ?"U]=27-UH\,T\AR\CLQ9CZDYH \7^$G_)1++_KE+_Z :];^*?\
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MG3&TR*1&NGN#(V]GD10Q/<D@<TDVA6%P094F8KT_TB0?R:HO^$;TL'_4S?\
M@3+_ /%4 :U4-4TUM16V N#%Y$ZSC"@Y*G(I_P#9EM_TV_[_ +_XT?V7:_\
M3;_O^_\ C0!<HJG_ &9;#_GM_P!_W_QH_LRV/_/;_O\ O_C0 W3[![%[IFN#
M+]HE,I&P#:2,?T%7JI_V7:_]-O\ O^_^-']F6W_3;_O^_P#C0 S5]-.JV:VW
MGF$"6.4D*#DHX<?JHJ\,A0"<GN:J?V7:_P#3;_O^_P#C1_9=L/\ GM_W_?\
MQH N50LM/>TO;VX:X,GVIPY78!M( 4?H!3_[,MC_ ,]O^_[_ .-']EVO_3;_
M +_O_C0!<JCJNGG4K1;<3F'$B2;@H/*L&'Z@4[^S+;_IM_W_ '_QH_LNU_Z;
M?]_W_P : +:@A0&.3CDXZTM4_P"R[;_IM_W_ '_QH_LRV/\ SV_[_O\ XT -
MM]/>#5+J]:X+_:%5?+V ;0N<<_B:O53_ ++M?^FW_?\ ?_&C^S+;_IM_W_?_
M !H 35;#^U-.EL_.,0DQE@N3@'/]*MH&5%#MN8#EL8R:J_V7:_\ 3;_O^_\
MC1_9=M_TV_[_ +_XT 7*H0:<T.KW5^;@M]HC2,Q[   I;'/_  (T_P#LRV_Z
M;?\ ?]_\:/[+M?\ IM_W_?\ QH N55U&S.H:=/:>:8Q,A0N!D@'K3?[,MO\
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MU$W(9>F!U_'&<4 ;OVI?[IH^U+_=-8NAO?2Z'9R:F8S>M$&E,?W<GI^F*T*
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M****HQ"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MUS_C>#4KCPS*FEW*6\XD0LSCJN>@].<'\*W+)+B.Q@2[E66Y6-1+(HP&;')
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M]103+8;YA]J/,/M43ABA"G!]:500H!.3ZTC,N1R'RUZ5G1.?^$GNS_TYP_\
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MMIMH)<C.5!Y'MD4 ;J.0B].E.\P^U4M-BN8-,M8KR<3W*1*LLH& [8Y.*M4
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M\)9=G=Q]CAX_X')4O<WCL:?ECU-'ECU-/ILBED(4X/K2&)Y8]31Y8]32H"J
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M.J:80V )'X_X : +_ECU-'ECU-/H/3B@!GECU-'ECU-$2LBD.VXYI] &5JJ
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M!)[T /\ ,/M6?I[D7^J?]?"_^BTJ]6!H&AZCI6I:I<WNKO>QWDH>.-EQY?\
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M/VVSC"-';SQ1R&6=MF"_1>$(R/0D=:F@U:6;44@82K;RS2013;E)9TSN!7'
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M)(K2>[$KLJD^8NY@P .5P#D?+[U+'X7>W73YXM*,H@OGG>WN'B)"M$4RN %
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M6;ODG+?R_G6E10-4XIW"BBB@L*9-'YL,D><;U*Y],BGT4-7T RFT1&&#.?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
L@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>imrx-20211231x10k023.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 imrx-20211231x10k023.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 'W \(# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HIH<&0
MI_$ "?Q__53J "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% $*_\?DG_7-?YM4U
M0K_Q^2?]<U_FU34 ?+/C?_D>=;_Z_)/YUN_"#_DH5O\ ]>\O\A6%XW_Y'G6_
M^OR3^=;OP@_Y*%;_ /7O+_(4 ?1-%%% !1110 4444 %%%% !1110 4444 (
MS*BEF8*HY))P!66/$V@M/Y*ZWIQESC8+I-V?IFN2^,<E['X.C%J9!$URHN"G
M]S!Z^V<5P6IZ9X(3X<PWME/G6F5!@3,7,F1N#)G  &>WI5)$MGNUYJ%EI]L+
MB]NX+: D 232!%R>@R>*S_\ A+O#7_0P:5_X&1_XUSGA#P\-;^&^GZ?XFMGG
M0,9(XY'96"Y.S)!!Z'\B*YSXC>%?"/A?PT9K32Q'?W#B. FXE8CN6P6P<#^8
MI66P-O<]2M=8TR^MI;FTU&TN((?]9)%,K*G&>2#QQ65I_CKPSJFHBPL]7ADN
M2<*I5E#'T!( /X&O.[+P_=:;\#]1EA60W-]MN)%7KY09>/\ OD$GV)K-U*ZT
MG4='\&6>A^4VJ1N@E6%,.IXSN_')IV#F9[C>7EOI]G+=W<JQ01*6=VZ 5#I6
MK6.MZ>E]ITQFMG)"N49,XX/# &O._$5U<>/_ !2GA?3I6&DV;!]0N(^C,/X<
M_7@>_P!*]+M+2"QM(K6UB6*")0B(O10*5AIW)J***0PHHHH **** "BBN;LM
M5O9OB!JFEO-FS@LXI8X]H^5F/)SC)_.@#I**YGQ#JU[8^*/#5G;3[+>]FE6X
M38IWA5!')&1U[8JUJ'B_0]+NI+6ZO&\Z( R+%#)+Y?\ O;5./QHL*YN45F)X
MATJ3^S_+O%8:B2+5E4E9"!DC., _7%3RZK90ZI#ILDV+N:-I4C"D_*O4D@8
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MOKBP\9RZ9<SM+;7\1N;3?_RS9<!XQ[=&'XUT-(84444 %%%% !1110 4444
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M+F=@ 9)K9'8XZ<D9IH31QFC1Z=8?$:.T\,,G]GRV;/?Q0-OB1@?D/4@-VXK
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M=XYWB,>03GA3VS7+W^DOJ_Q9O88]2O; KIT;>9:2;&//0GTKTE55%"HH50,
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MNJ^)]$T258M2U*"WD89",WS8]<#F@#6HK-?Q!I,>E1ZHU_#]AD8*LX;*DDX
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MKW5K:&X'6-FY7Z^GXT!<VJ*Y+Q'XWLM"UK2;-[JW6"Y+/<2-D[(\?*1CU/\
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MX<#KZ8JQH&KRWEQJ&FWK*;^PFVOM& \;<H^/<?J#0*YMT444#"BBB@ HHHH
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M5]"4(R/K3$\(:#';7MM'IZ)!?(J7"([*'"C Z'CZC&:5PL9#?\E3TW_L"O\
M^C!1;%A\7KX1_<.E1F7'KO./TKI3I-D=5CU/R/\ 3(H#;I)O;B,G.,9QU[XS
M6;X>TJ>"\U+5[^+R[Z_E'R;@WE1+PBY&1GJ3@]_:@=C?HHHI#"BBB@ HHHH
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MB![]>3^5<WY,G_/-_P#ODT>3)_SS?_ODU/LX;7'[:IO;7T^0RBG^3)_SS?\
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M&YBQ '/&.N<^E94?CJRUEM+DB75;,G6VTTQ (I:18RQ$@.?D^F#D#M0!T?\
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M-]?6FFSMC L!MX?*4Y6/8-H^@J:B@"%?^/N3_KFO\VJ:H5_X_)/^N:_S:IJ
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M** "BBB@ HHHH **** (5_X_)/\ KFO\VJ:H5_X_)/\ KFO\VJ:@#Y9\;_\
M(\ZW_P!?DG\ZW?A!_P E"M_^O>7^0K"\;_\ (\ZW_P!?DG\ZW?A!_P E"M_^
MO>7^0H ^B:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 0K_Q^2?]<U_FU35"O_'Y)_US7^;5-0!\L^-_^1YUO_K\D_G6[\(/
M^2A6_P#U[R_R%87C?_D>=;_Z_)/YUN_"#_DH5O\ ]>\O\A0!]$T444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% $*_\?DG_ %S7^;5-4*_\?DG_ %S7^;5-0!\L^-_^1YUO_K\D_G6[\(/^
M2A6__7O+_(5A>-_^1YUO_K\D_G6[\(/^2A6__7O+_(4 ?0TLJ0Q-+(VU$&6/
MH*H#Q!I3(CB]C(D<QKC.2PY(QC/<5HG.#C&>V:YZ?P]</H\=LDL1O2)&>[8L
M&21^6=,>_0>PH Z*BD4$* 220.I[U@ZQ!=G6K.XLUGD==JF,J/)V[OF);((8
M#)'T'6@#?HK!T6'5H]8U"744PDJ(4*R[D!!;Y5'; V_6MN8;H9 -W*D?+UZ=
MJ 'T5QL5MJ":%<VS07; 2 6LK1?O3\HR74..^0#QZX[GJ[)9$L+=9@1*(U#A
MFW'..<GO0!/167K%]=V1M_LOV=VD<)Y#@[Y.1]T@\8&220:99ZC>MK,UG>Q1
MQHV]K?8N=ZJ0,DACZC@@4 :]%%8,OB":"TNI'M 98+L6VR-B^<A3D +D\-T
M)XH WJ*IZ5?'4M*MKTQB,S(&*;L[3Z9INI:C_9QM"83(D]PD!8,!L+' ..]
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M2_LFP_Y]E_,TO]E6/_/NOYF@"Y15/^RK'_GW7\S5M%5$5%&%48 ]J %HHHH
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M![.&54MTC4 KD!AVS]TCKWKI,'TH F^TO1]I>N;\7/K,.@22:'+'%=JZ_-(
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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ME5O#^[^P;/=U\L5:G_UOX4[Z%02;,Z[=_P"T]/Y'WI.W^S5W>_J/RK-O=_\
M:NG;<;=SY_[YK1I79KRH7>_J/RJAH[M]BDY'_'S/V_Z:M5J<2FWD$#*LI4[&
M89 ;'!(],US_ ()CUB/0Y%UJ2&2Y^U2X,73&XYS_ ,"W?ABB[#E1TN]_4?E6
M7J[M]MT;D?\ ']Z?],9:TZY3Q6FM-K?AXZ=) ML+O]X'Z[MK?ILW_CBB[#E1
MUF]_4?E1O?U'Y4E%%V'*C/T=V\BZY'_'W-V_VS6CO?U'Y5E:'O\ (NM^/^/N
M;_T,UJ478<J*.J.V;'D?\?:=OK5_>_J/RKEO&::X\>E_V)) CB\7S/.Z>WX=
M<UU Z<]:+L.5"[W]1^59^FNWVG4N1_Q\^G^PM7ZY?PI'KJ:EKAU>:V>(W7[D
M1#D<?RV[?UHNPY4=3O?U'Y51U=V^P#D?ZZ'M_P!-%J[6=K0<Z>-A'^OASG_K
MHM%V'*C2WOZC\J-[^H_*DHHNPY49>F.W]LZWR/\ CXC[?],4K5WOZC\JY/PT
MFM+XG\0G4)(&MO/7RQ'USM&/_'-OXUU=%V'*BAKKM_8\W(^\G;_;6M$R.3U'
MY5E:_N_L:;;C.Y/_ $,5I#.!GK1=ARH=O?U'Y50M9&_MF_Y'W(NWLU7JS;3?
M_;NH9QMV1?R-%V'*C3WOZC\JI:P[_P!B7W(_X]W[?[)JY5#6]W]AWVW&?(?^
M1HNPY47HW?RDY'W1VIV]_4?E4<.?(CSUVBGT78<J,Q)&_P"$KGY'_'C'V_Z:
M/6IO?U'Y5CQ[O^$NGSC;]AC_ /0WK7HNPY45=4=_[(O>1_J).W^R:ELY'^PV
M_(_U2]O85F^*%OF\,Z@-.:-;GR6VE^F._P"F:D\/+?+X?L1J31M=^4-YCZ>W
MZ8HNPY4:F]_4?E6>9&_X2)>1_P >A[?[8J_7+2IKO_"Q8F26W_LG[(=RD?/C
M_'=C\*+L.5'5;W]1^5,GD<6\G(^Z>WM3JBN,_9I<==A_E1=ARH@T=W_L6QY'
M^H3M["KN]_4?E6?HN?[$L=W7R$_E5^B[#E10N9&_MW3^1_J9^W_7.M#>_J/R
MKEM1BUP^/M*D@G@&EB"3>A'S9XW?^R8^AKJ*+L.5%B)2Z9)YS4X& !45O_J_
MQJ6K1A+<****!!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M D\SVK/TU\7.I<?\O/\ [(M7*SM,W_:=2W$?\?/'_?"T :OF>U4=6DS8=/\
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M'\'\0'OC- &Q'&/*3G^$4[RQZU7TL7:Z5:"^:-KL1+YQC&%+8YQ5N@#(1/\
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M>M<SJ,>NGQ]I;P36XTOR)-R$?-VW?^R8_&NIH FMXAY?7O5D# Q45O\ ZO\
M&I:M'/+<****9(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MXM<?Q-HC:?<6T=BKM]H21<LP_BQQ_=Z=.:Z.D;#_ #/:J&CR?Z%)Q_R\S_\
MHUJLS"0PR"%E64J=A89 ..,BL7PI9ZU8Z0\.N3P371G=PT/3:QSSP.Y)Z=Z
M.@\SVK,U9\WFC\=+W_VC)6A65J^[[;H^",?;/_:4E &QYGM1YGM3** *6COB
M"YX_Y>YO_0S6AYGM65HH;R+K<1_Q]S?^AFM*@!_F>U'F>U0R!SC80.><T^@!
M_F>U9^FOBYU'C_EY_P#9%J[6=IF_[3J6X@_Z3QC_ '%H U/,]JHZM)FPZ?\
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MW[H]VL2B9HQA2V.<5:H R$3_ (JJ<9_Y<8__ $-ZU/+]ZYZWT_7D\=7-_-/
M=(>W$<:#[PQR!^9;GWKI* &>7[T>7[TK[BAV?>[4)NV#=][O0 GE^]9Y3_BH
M5&?^70_^ABM.LPA_^$F7D;?LA_\ 0Q0!H>7[U'/'B"0Y_A/\JGJ*YS]FEQUV
M'^5 %32$SHUD<_\ +!/Y"KOE^]5-%S_8ECNZ^0G\JO4 9ERG_$\L!G_EC-_[
M)6AY?O7,ZC#KI\?:7)!<0#2Q#)NC*_-VW?G\F*ZF@":WB'E]>]60,#%16_\
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M_II^E6Z*+(.>1#';A%QNS^%3 8&***9+=PHHHH **** "BBB@ HHHH ****
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MT^%]6BU(L_G10/ HR-NUV5C^.4'ZU0_X1R".3S+6[N[5_F4M"R_<9MVSE2,
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
G %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>imrx-20211231x10k024.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 imrx-20211231x10k024.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" (_ O # 2(  A$! Q$!_\0
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MUK7&K6%MI3:I)<H;%4WF9,NNWU&W.?PJ2WTZSM+!;&"VB2U5=@B"C;CW'?\
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M6 2-"A)1=X8DKD'^$#DYZUZ?12YK+0.4\6\5^ =:TO2K2*WU+4-9A63:MK'
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M6C^T2S"6*6,HS MP3D9Z8P?I4'AQ-5T==1\,WMO=3V\$;&PO!$Q1XR/N%@,
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M?_Y\]3_[]1__ !='_"X?#_\ SYZG_P!^H_\ XNCDEV#F1Z#17GW_  N'P_\
M\^>I_P#?J/\ ^+H_X7#X?_Y\]3_[]1__ !=')+L',CT&BO/O^%P^'_\ GSU/
M_OU'_P#%T?\ "X?#_P#SYZG_ -^H_P#XNCDEV#F1Z#17GW_"X?#_ /SYZG_W
MZC_^+H_X7#X?_P"?/4_^_4?_ ,71R2[!S(]!HKS[_A</A_\ Y\]3_P"_4?\
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M9(5 C3(*!"<_/T_>#]:.278?,CN:*\^_X7#X?_Y\]3_[]1__ !='_"X?#_\
MSYZG_P!^H_\ XNCDEV%S(]!HKS[_ (7#X?\ ^?/4_P#OU'_\71_PN'P__P ^
M>I_]^H__ (NCDEV#F1Z#17GW_"X?#_\ SYZG_P!^H_\ XNC_ (7#X?\ ^?/4
M_P#OU'_\71R2[!S(]!HKS[_A</A__GSU/_OU'_\ %T?\+A\/_P#/GJ?_ 'ZC
M_P#BZ.278.9'H-%>??\ "X?#_P#SYZG_ -^H_P#XNC_A</A__GSU/_OU'_\
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MX?#_ /SYZG_WZC_^+H_X7#X?_P"?/4_^_4?_ ,71R2[!S(]!HKS[_A</A_\
MY\]3_P"_4?\ \71_PN'P_P#\^>I_]^H__BZ.278.9'H-%>??\+A\/_\ /GJ?
M_?J/_P"+H_X7#X?_ .?/4_\ OU'_ /%T<DNP<R/0:*\^_P"%P^'_ /GSU/\
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M75W/;S33227#"54#$*R1B09P!G[I'3-+W0U*B^-=21]#<06F=&5EM_D;Y@5
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MXLO=4T&3:FH:7/'<6S?WEVJ?ZE3]5-9GB72K;6?B[I%K>*KP"Q$C1MT?:TA
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M#; Q8$'G!Q]ZMG1O#$$4][+J$EE<VZ:<UY;.6F\J89 W90!L*<@@X.<<8YK
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M)BK,6*\%1P!QD9P?>N1IIIB:"M:X_P"12T[_ *_KK_T7;UDUK7'_ "*6G?\
M7]=?^B[>FP,FBBB@0445U'AJPT6\TZ?[>8C<&4J0\Q1XX_+8JT:Y&]B^!C#=
MN.<T-V!&3IVJ_8-.U.T\CS/MT*Q;M^-F'#9QCGICM6A)XH#Z5Y LRM\;%=/-
MR)?E\D-G[FW[Q&%)ST["HO$.CG2OL\<=G*(XE\J:\*L4FGYWA6^[A3E>/[IS
M4>F>&[K4[>*9;BUM_M$IAM4N'*M<. "53 ([@9) R0,U.FX]2SJ7B@7^GW,2
MV1CNKQ8%NYS+N5Q$,#:NT;<\$\GIVJM8Z]]BTJWL?LV_R=12^W^9C.U<;<8_
M7]*MZMI=GIWA+29U2!KV[>0RN3*)%VMC: <* .AR,YZ9'-4W\.W$=G%-)=6B
M7$L"W$=HSD2O&QP".-I)ZA=V[':A6#4V(/';0:I;7@T\%(I[N5XC-Q(LY!VY
MV\;2 <]\=JQ-5UN35;&R@ECQ);M,SR[L^89'WDXQQU]35Q_!]\MQ'!'=6<TO
MVN.SG6)V/V:5^ )/EZ9R,KN&5(SFKVD^"1=:M;0W6HV[VDD\MO(]L7W)*B;B
MGS)U[YY& >>E'NK4>I67QKJ5OJMK/937-O86PB1+ 7+&,H@ (/8[L$DX[U%;
M>(-.T^Y:]L-&:WO521(F^U%HT#;AN*%<E@K8^\!P#MI(_"-U,MAY5[9.]]N:
M! S@LBE@SG*@!0%)YYQT&>*MV'AF-(;VXN6AO+9M+GN;2>!G"ET8 \$*<@GH
M1CFCW0U*R^,+U]'U"PN(;:5KN.*(3"WB4HJ<#.$RW& "3E<9%0SZ[:+H]S8:
M?IGV0WAC-RQG,BG9R @(RH+<\ECVS6'7?V7A72T'A^"YB,US/J#6]]\Y !"J
M3&,'C;G!(YSFAV0E=G 45KZOH4FFP1W:7-M<VLLLD2O;LQ"LN,J=P'/(Y&0?
M6LBJ3N(**** -:X_Y%+3O^OZZ_\ 1=O636M<?\BEIW_7]=?^B[>LFA#84444
M""BBB@ HHHH **** "BBB@ K2\/ZM_8>NVFI^1Y_V=BWE[]N[@CK@XZ^E9M%
M '32>,KC_A.&\36UOY+,ZEK?S-P9=H4J3@=0/3C\*FUWQS<ZIXILM>L[864]
MI$L:H9/,!PS$Y.!P0Q!%<G12Y4.[.]/Q'MX[N?4[3PY:P:Q/'L>[,Q8?4)C
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M"C_W_F_^*H_X5WX._P"@4?\ O_-_\51[5!R,\!HKW[_A7?@[_H%'_O\ S?\
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M;VPN[5[BTN_+9A'*(W5D)*D,58?Q,""._:O:O^%=^#O^@4?^_P#-_P#%4?\
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M_(I8L?XCR.<"FZ=XQ.GO&PL=^S49+X_O<9#IL*?=_7]*]6_X5WX._P"@4?\
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M@[_H%'_O_-_\51[5!R,\!HKW[_A7?@[_ *!1_P"_\W_Q5'_"N_!W_0*/_?\
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M<DZ!VN'D4,S.QY)))YK.:=]/7PWX1\,ZN3%<).3J+E+AXX8<?*O&TME@HR"
M >,T =[17F^M>(]?\-V7B;3Y[\7=U8Z='J%E?&!%<JSLI5U VD@J<$ 9!Z5I
MF?Q%HWBG0K2^UH7T.K>?%-']FCC$$BQ&0&,@9(^4C#$]1S0!V4<T<N_RY$?8
MQ1MK [6'8^AI]>0Z=/K>@^%-9NK+69);E_$KVR^?!$5R;O8[$*H/SYY';^';
M732S:\?$MMX4@\03"1;)M0N=1>UA,Q4R;$C5=NP<[B25/ _&@#L[FZM[* SW
M4\4$(*J9)7"J"2 !D^I( ]R*EKRWQ!J>I2^&?$6BZK,MU<:7J&G!+M8PGG1R
M30NNY1P&'(., XX KU*@ HHHH **** "BBB@ HHHH LP_P"J'X_SI],A_P!4
M/Q_G3Z "J\_^L_"K%038W\D].PH BHI?E]6_+_Z]'R^K?E_]>@!**7Y?5OR_
M^O1\OJWY?_7H Y"_\'7LESJHTO7GT^QU9B]Y;BV$C!RH5WB?<-A8 9R&YY&*
MV8])FLWTB#3;W[)IM@ABELQ"K^>FS:@W'E=I .1UZ&M;Y?5OR_\ KT?+ZM^7
M_P!>@#$UC0/[6UG1-0^T^5_9=P\WE^7N\W<A3&<C'7/>K>M:?+JVDSV$5TUK
MYX"22HN6\LD;PO(P2N0#VSGG%:'R^K?E_P#7H^7U;\O_ *] '+ZSX1:_EW:=
M?C3DDL#IL\8MQ(#;D\!/F&QAD@'YASRIKH;6VBLK."U@7;##&L:+Z*!@#\A4
M_P OJWY?_7H^7U;\O_KT <-I_@_Q/I-DUAI_B^""S\V61 -)5I$\QV<X8R$9
MRQY(_"K<O@.U'AJQT6UNY(Q;WT5])<2KYDD\BR;V+<CECGGMZ5UWR^K?E_\
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MSR,58O/"/ES:9=:#>C2[O3K8V<;- )HWM^/D=,J3@J"""#G/7-=/\OJWY?\
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M/)'05B6_Q$\+W-W!;#4)8I)W$<?VBSGA5F/1=SH!GVS47Q.++\.M6* ,P$6
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MK;0N%P!@84=<UJX7U/Y487U/Y4 -HIV%]3^5&%]3^5 #:*=A?4_E1A?4_E0
MVBG87U/Y487U/Y4 )_"/J:2G$+M')ZGM28'][]* ,[7-'M]?T:XTN[>5()]N
MYHB PVL&&,@CJ!VK0I<#^]^E&!Z_I0!S5SX,M9]4O;V'4]4LUOR#=V]K.$CF
M(4+D_*64X &59>E+IO@K3=*AT.&WFNC'HTDTEJ&93GS%=2&^7D .<=#P,DUT
MF%]3^5+A?4_E0!S=YX/M[G6+O4H-4U2QDO0@NX[2<(D^U=H)RI93M &4*FJ\
M'@#2;30K'2K2:]MUT^>2>QN(Y0)K<NS%@K;<$?.1A@<CKFNLPOJ?RHPOJ?RH
M Y:P\!Z59_VS]HFO=1.LQQQWQO9@YD"!@#P!CAL<8 P, 8I]AX+M+2_L[NYU
M+5-2:RS]D2^G#I 2,9 "C<<'&6W$>M=+\OJ?RH^7U/Y4 <J_@+2I-%N-.DGO
M'EGO?M[7[2+]H%P&RL@8+@%0 HXP!QBK4_@_2[L:RMWY\ZZLT3W 9P-K1HJJ
MR%0"I^13]?RKH/E]3^5+A?4_E0!RR>!M/D%V=2O-0U62YM6LS+>RJ62%OO*N
MQ5 SQDXR<#FH1X!M))=/DN]9UF\?3ITGM#/.A$94\#:$ ;(X)8%L9P1FNOPO
MJ?RI,+ZG\J ,[2M'M]'^W?9WE;[9=R7<GF$'#OC(& ...^?K59O#-A)JVJZA
M(99'U.U2TN(F(V>6H8<#&<D,<\FMK _O?I1A?4_E0!RMMX"TJUT'2M'CFO#!
MIM\E_'(TBF2657+Y<[>023G 'X5J:%H%IX?MKF*V>65[JZDNYYIB"\DCG))(
M 'H!QT K6^7U/Y4?+ZM^7_UZ .8N/ VF7!U@>?=QQ:K<P74\4;J%66)E;<N5
MR-Q0;LYSVQ734OR^K?E_]>CY?5OR_P#KT 9=AH5KIVMZMJT,DQN-4:)IE<C:
MIC38NW R.!SDGGTJ+2/#5EHFJ:G>V,D\::C*)YK7(\I9<89U&,@MWYP:V?E]
M6_+_ .O1\OJWY?\ UZ ,FWT"TM_$MYK_ )DTEY=01V^)"I6*-,G:F ",DY.2
M>?2HK[PMIVHZ_#K$XD\];22REC&WR[B%^J2 @D@'D8(Z]ZV_E]6_+_Z]'R^K
M?E_]>@#E].\#V.GW5C(U_J-W!IYS8VMU,KQ6QP5!4!020I(&XM@=*$\#6$8D
MC6]O_LYU*/4X[<R(4BE60R$+\N=K,>02?8BNH^7U;\O_ *]'R^K?E_\ 7H P
M[_PKINH^)]-\03B7[98*RQJK (V00"PQR5W-CGC<:AOO",%UK-QJEOJFJ:?/
M=(B7*V<RJLX487.Y200"1E2#71?+ZM^7_P!>CY?5OR_^O0!R:?#_ $N#0;;2
M+:[U"WBM+YKZUFCE4R02$L< E2"/G8?,&X/)[U;D\':7/;:O;W)GF35)EGFW
M/@I(JJJLA4 J1L4Y]?RKH?E]6_+_ .O1\OJWY?\ UZ .>TSPE;6&J1ZG<ZAJ
M.IWL,1A@FOY5<PH<;@H55&3@9;&3CK2+X.T]?!UMX8$UU]BM_*V2;E\P^7(L
MBY.W'51GCI71?+ZM^7_UZ/E]6_+_ .O0 E%+\OJWY?\ UZ/E]6_+_P"O0!8A
M_P!4/Q_G3Z9%CRQBGT %5Y_]9^%6*KS_ .L_"@".BBB@ HHHH :[K'&SN<*H
M))]!7)1?%#PA+$DJZG,L+XQ-)8W"1\G )<H% ]R<5U%[_P >%Q_UR;^1KR7P
M_8^-+WX0VUO97.B?8)M/95B:&03&,@Y&\L4#$9&=N.E 'JDFK6,>H65BUP/M
M%[&\ENJ@D2*FW<00,<;EZGG/%7:\^T;5DNM0\ C3&N+?3;C2KG_1FD)&$2$*
M&QPQ7D X[GUK!L!JEM\,M%\6-X@U:;5 ]J7$MTS0R(\RQE&CSM/RMRQ^8GG/
MH >J6^IV=UJ-Y80R[KFRV?:$V$;-XRO)&#D>F:MUYCXIU34[=?'IM=0N87M1
MI_V4K*V(2VW=M&>,]P.O>K=SHMU:^.=/T>/Q!K365]8S37:O>N6=XV0 HW6+
M)?D)MZ8H ]#I&940LQPJC))["O*+K7=9T_PS)IEK=WEU,_B=M(BF,R_:?(Y?
M DD.-^ 5#,>_K6C86'B 7UW:RV6NVNAW%C()FO\ 5$FDCF&"K1NDC. 1D$9Q
MTZ4 =K'X@TN4Z9Y=VKC5-WV,JK$380N<'&!\H)YQ6E7E?A)9=-TOX;PV]Y>>
M3?"62>-[EW5O]$8A<$X"@J"%Z \BH'BU.3P%K_B/_A(-66_L+F]>T"W3>7&L
M<SX5DZ.#@CYLX& , 4 >CWOB/2M/DOTNKKRVT^V6ZN1Y;'RXCNPW Y^ZW R>
M*TD=9(U=#E6 (/J*\Q\6WUU<1>-(9)Y# /#<,JP[SL5F\[<0O0$X'/L*NR6E
M[X5G\+WD.LZE>&_O(K*\ANK@R1RB2-CN1#PA4J" N..N: /0Z*** "BBB@ I
MS=?P'\J;3FZ_@/Y4 -HHHH **** *FI:G9:/82WVH7*6]M%C?(YX&3@#W))
M ')JMH_B'2]>\\:=<F1X"!+%)$\4D>>A9' 8 X.#C!P:PO')8ZEX0C89@?7(
MRX/0L(Y"N?Q&?J!2RY3XPVWE8S)H<GG\]0LZ;"?Q9L?4T =>S*B,[L%51DDG
M  K)B\3:1<>'CKT%T9],!8":&%WW;7*'"@%C\P(X'OTYJ37-!L?$5BECJ(D>
MU$JR/$DA59<9^5\=5YSCV%<[\)55?AKIBJ %$MR  . /M$E %RV^(GAF[U&U
ML(KRY%U=2>7 DFGW";V],M&!_A5J?QKX>M]2:PEU$"9)1 [B)S$DA.-C2A=B
MMG P6!YK+\.+_P )%XNU;Q'/\T%C*^F::IZ*%(\Z0>[/\N?1<=ZRO&>F ^ K
MQO#TVGOX?7S;N_AC<M)<@2%Y@DV6 )PPZ$YX!% 'I%%065U'?6%O>1!A'/$L
MJ!A@X8 C(_&IZ "BBB@ IQ^X/J?Z4VG'[@^I_I0 VBBB@ HHHH **** *FIZ
ME9Z/IMQJ.H7"6]I;IOEE?HH_#DGL .2>*EM;J&]LX+NW??!/&LL;8(RK#(.#
MR.#WKRSXAZO;ZHFO6.HPWT5EIUC,+6(6,S)<W1B.)&=4*A$S@9(^;+'[HKN_
M!5[#?>#-(D@\S:EI%&?,B:,[E0 \, 2/?H>U #M5\8:%HMXUI?7VR9$$DH2&
M200J>C2%5(0>[$58U3Q'I.C0V\M[=@"Y.($BC:9Y>,G8B LPP<Y XKGO!B)<
M7/C4WJ*QDUN:*3?WB$,04'VVG]:H> X(KOP5X=G2:S7Q'%I+):&=BYC@+@;O
M+# E?E09_#- ';Z7JUCK5BMYIUPL\!)7< 058'!5@<%2.X(!%)8:SIVIW5[;
M65TD\MC((K@)G".1G;GH3].G0\UQW@VT>XM?%?A_4Y95U+[<SWUU:R%!(9HU
M*M&0/D^0 8Y(QUYI?AYIEGHVO>+].T^!8+2WO8$CC7H!Y"?F>Y/>@#OJ***
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M+,+HGHJK]N7_ )Y'_OO_ .M1]N7_ )Y'_OO_ .M19A=%JBJOVY?^>1_[[_\
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MFW,QGGTR.<"WD8G+9&W< 3R5#!3Z5T/VY?\ GD?^^_\ ZU'VY?\ GD?^^_\
MZU%F%T65541410JJ,  8 %+57[<O_/(_]]__ %J/MR_\\C_WW_\ 6HLPNBU1
M57[<O_/(_P#??_UJ/MR_\\C_ -]__6HLPNBU3C]P?4_TJG]N7_GD?^^__K4\
MWJB%6\H\L1C?Z >WO19A=$]%5?MR_P#/(_\ ??\ ]:C[<O\ SR/_ 'W_ /6H
MLPNBU157[<O_ #R/_??_ -:C[<O_ #R/_??_ -:BS"Z+5%5?MR_\\C_WW_\
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MW_Z]*Z'9G,:EX9T?5]4LM3O;/??61S;SK*Z,G.<?*1D9['(Y/J:UJT?[*/\
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MT%F9U%:/]E'_ )[?^.__ %Z/[*/_ #V_\=_^O1S(+,SJ*T?[*/\ SV_\=_\
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MQFK^ _"^O:J-3U+1X9[P!09-[KOV]-P4@-V'(/  Z"M]8HTA$*1JD2KL"*,
M#I@ 5J?V5_TV_P#'?_KT?V5_TV_\=_\ KT7069REMX1T&T\.RZ!%IR?V5+G?
M;.[.#DYSEB3G(!!SP1D8IF@>#?#WA>2:71M,CMI9E"O)O:1B.N 7)(&>PZX'
MH*Z[^RO^FW_CO_UZ/[*_Z;?^._\ UZ+H+,SJ*T?[*_Z;?^.__7H_LK_IM_X[
M_P#7HYD%F9U%:/\ 97_3;_QW_P"O1_97_3;_ ,=_^O1S(+,SJ*T?[*_Z;?\
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M+R[BL+.:ZG)$42EF(&3BA)MV0-I*[)Z*BMITNK6&XC#!)45U##!P1GFLV_\
M$=EIVM6VESI-YUP%*.H&P;F*C)SGJ/2G&$I.R1,JD8KF;T->BH;NYCL[2:ZF
M.(XD+MCT S531=:M]=LFN[6.5(UD,>)0 <@ ]B?6CDDX\UM!N<5+EOJ:-%%4
M8-5@N-7NM-1)!-;*K.Q VD,,C'.>_I246[VZ#<DK7ZEZBBBD,**** "BBB@
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M+O7KL(Z9SU]JPP\DN>[^RSHQ47+DLOM(/$6L7]AXET:TMI]D%S(JRIL4[@7
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M?S0?G73G0[V3Q]-J$EOG3Y(MA?>O.8PI&,YZ^U9/A_PGJ5@NK-=6P#26DD$
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MO7Z?C)H?_"0Z)IWV,>'O/ D9]_VR-,Y/IS5FPTC4Y)=7U*_CCCN[R Q1V\;
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MP0 ,]2,]<=/PK2O].NIO&&DW\<6ZV@CD65]P&TE2!QG)ZU3J03M&UK2_6W_
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M .PKD'T2[73+&_79(E[(8XHT)+[@2,8QZBEU?1)]$>**ZGMVG==QAC8LT?\
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M?^8?VCB?YOP7^1Z#_P +._ZA'_DS_P#84?\ "SO^H1_Y,_\ V%>?44?4</\
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M+<S20Q_<C:0E5^@Z"KIX=PGSI[WO^A%3$JI3Y&MDK?)6?WD%%%%=1QFAK/\
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MWKCKGQ5J5QK<6K#RH;F-!&!&IVLO/!!)SUJZOCO44,QCL]/C$V?,"0E=Q/\
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M< #)R:(=4O+=+98IMHMI#+"-H.UCCGIST'6B-*:ARI_U;_/4)5J<JG,U=?\
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M  H_L'6/^@3??^ [_P"%'M(=P]G/LS/HK0_L'6/^@3??^ [_ .%']@ZQ_P!
MF^_\!W_PH]I#N'LY]F9]%:']@ZQ_T";[_P !W_PH_L'6/^@3??\ @._^%'M(
M=P]G/LS/K0T;_C^D_P"O2Y_]$O1_8.L?] F^_P# =_\ "KVDZ+JL=Y(SZ9>J
M#;7"Y:!AR87 '3N2!43J0Y7J73ISYUH]S!HK0_L+5_\ H%7W_@._^%']A:O_
M - J^_\  =_\*OVD.Y'LY]F;^E7=IJ>GQ6+P2ND"1EXC@1@JYY4D_>D+*O0=
M3R:Q-=M+N&]-S=313&X9SYD1;;E6*LOS '@C'IC&*?%IWB"&W:"+3K](V=9#
MMMF!++TYQGC-/OK+Q%J,BO=:;>L5! "VA0#))/"J!DDDD]ZPBE&=TU8Z)MSI
M\KB[KR+#Z'91K/;LUPUY;6JW<C!@(W!P2J\9!PPPW/.>*=XE3[9XL2PC>1(P
M8H8P[[E3(7[HP,#D<?XU"\'B9[$6;6%\8=H3_CT.XJ#D*6V[B >Q.*AN=/\
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M *!-]_X#O_A1[2'</9S[,SZ*T/[!UC_H$WW_ (#O_A1_8.L?] F^_P# =_\
M"CVD.X>SGV9GT5H?V#K'_0)OO_ =_P#"C^P=8_Z!-]_X#O\ X4>TAW#V<^S,
M^BM#^P=8_P"@3??^ [_X4?V#K'_0)OO_  '?_"CVD.X>SGV9GT5H?V#K'_0)
MOO\ P'?_  H_L'6/^@3??^ [_P"%'M(=P]G/LS/HK0_L'6/^@3??^ [_ .%'
M]@ZQ_P! F^_\!W_PH]I#N'LY]F9]%:']@ZQ_T";[_P !W_PH_L'6/^@3??\
M@._^%'M(=P]G/LS/HK0_L'6/^@3??^ [_P"%']@ZQ_T";[_P'?\ PH]I#N'L
MY]F9]%:']@ZQ_P! F^_\!W_PH_L'6/\ H$WW_@._^%'M(=P]G/LS/HK0_L'6
M/^@3??\ @._^%']@ZQ_T";[_ ,!W_P */:0[A[.?9F?7N.@_\B[IG_7I%_Z
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M910 _P U_P"]^E'FO_>_2F44 /\ -?U_2CS']?TIE% #_,?U_2CS']?TIE%
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M.5..*](TF[DO]&L;R:,1RW%O'*Z#.%9E!(Y^M %RBBB@ I1UI*5>M "4444
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M-&@/NS.<#T1O2NKH **** "BBB@ HHHH *M1_P"K7Z"JM6H_]6OT% #J***
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M'MW[XX65A'U&,[1SS]#0!%X(\,1>%_#T=MY,$=[<,;F],*!%,K<E5 X"K]T
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MHD&,993T+' P#WM<E-X0OUNM:%CK:6UEK$GF7*-:;YD8H$;RY-X"Y"C&4;%
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MW^\JGJ,UV=<;K>EZKJ'A[3?"]W<&_GNI$6^OTMC$GD1L&8MRP#OA4QGDL2
M#CLJ "K4?^K7Z55JU'_JU^E #J*** "BBB@"M<.JR?,P!Q47FQ_WQ^1IE_\
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M@ZE=+:V.MZ;=7#9*Q07:.Y Y) !STHY(A[21T/F1?\]!^1_PH\R+_GH/R/\
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M_P!T?RIE/E^^/]T?RIE);#>X5RGQ(UB_T#P#J>IZ9/Y%Y!Y7ER;5;&Z5%/#
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M+,N?X1R<<'D ]#6U>WUIIMI)=W]U!:VT>-\T\@1%R<#+'@<D#\:.>0<D2'[
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M*#(RW09%'/(.2(?V>>TO_CM)_9Y_YZ#\JB7Q'H;Z;_:2:UIS6&XI]J%TABW
M9(W9QG'/6G+X@T5KRVLUU>P-U=1B6WA%RF^9""0R+G+ @$@CCBCGD')$?_9Y
M_P">@_*C^SS_ ,]!^52W^HV.E6K76HWEO9VRD S7$JQH">G+$"J\^OZ-:I9O
M<:O81)? &T:2Y11< XQY>3\WWEZ9ZCUHYY!R1'_8#_ST'Y4?8#_ST'Y4RXU_
M1K2^2QN=7L(;R1PB6\ERBR,Q ( 4G)/S+Q[CUJ-/$^@26'V]-<TQK/>8_M"W
M<9CWA=Q7=G&0H)QZ#-'/(.2)/]@/_/0?E1]@/_/0?E45KXCT.^N8+:TUG3KB
M>=#)#%%=([2(,Y90#DC@\CT/I3XM?T:>:\AAU:PDEL@QND2Y0M %Z[P#\N,'
M.<=*.>0<D1WV _\ /0?E1_9Y_P">@_*J\GBGP]#9_;)=>TM+7S3#YS7D83S!
MR4W9QN'IUIH\0VT,VKMJ$MG966GRQI]JDO(]K!T1@7&?W?+[0&Z\$<$4<\@Y
M(EQ[$LV?,[ =*;]@/_/0?E6#KWCJUTJW@N;&.'4K::PO;U)H;D;&%N@;:" 0
M=Q.,]L=#6[;:S87%C%=&[MD5W2(YF7"RM@"//][) QUR1Q1SL.2(OV _\]!^
M5']GG_GI^E-O]>T;2I5BU'5K"SD;:0EQ<I&3NR%X8CKM;'K@^E2S:II]N+DS
MW]K%]E"M<;YE7R0W0OD_*#VSUHYY!R1&_P!G_P#37_QW_P"O1_9__37_ ,=I
MC:]HZ75Q:OJUBMQ;1M+/$;A \2+]YF&<J!D9)X%9-]XXT>TGTAX[ZPGTZ_EE
MC>_6\3RH?+C+\MR#D@#J,9_"CGD')$V/[//_ #T'_?-+_9__ $U_\=_^O45S
MXAT2RL(+^ZUC3X+.XQY-Q+<HL<F1D;6)P>.>*=/KND6MQ:V]QJMC#/>8^S1R
M7"*T^3@; 3ELD@#'K1SR#DB._L\_\]/T_P#KTO\ 9Y_YZ?\ CM#ZQI<>JQZ4
M^I6:ZC(NY+0SJ)F&"<A,Y(P">G8UEZIXPTZPU:PTN"XM;N^N+U+6:W2Y7S+<
M,K-O9!D_PC@X^]UHYY!R1-/[ ?\ GH/RH_L\_P#/0?E5ZBCGD')$H_V>?^>@
M_*C^SS_ST_2KU%'/(.2)1_L\_P#/3_QVE_L__IK_ ..__7J[11SR#DB4O[/_
M .FO_CO_ ->@Z?\ ]-?_ !VKM%'/(.2)1_L\_P#/3]*/[//_ #T_2KU%'/(.
M2)1_L\_\]!^5'V _\]!^57J*.>0<D2C_ &>?^>@_*E_L\_\ /3]*NT4<\@Y(
ME+^S_P#IK_X[_P#7H_L__IK_ ..__7J[11SR#DB4O[/_ .FO_CO_ ->C^S_^
MFO\ X[_]>KM%'/(.2)2_L_\ Z:_^._\ UZ0Z>?\ GI^E7J*.>0<D2C]@/_/0
M?E1]@/\ ST'Y5>HHYY!R1*/V _\ /0?E5R-=D:KG.!BG44G)O<:BEL%%%%(H
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K
M$\/>%K'PU+JLEE+<N=2O'O9O/DW;7;J%X''UR?4FMNB@ HHHH \HTWPG?0:=
M:VT'A(V&NIJ#3'70ULNR,W#.3O20RMF(E-I7!S@\5K:)X8U2U\66-]<V2B"&
M\UB8R%T.T3S(T1 !S\RAOIT.*]!HH \>3P-KYT"*SETU68:196C1F6,C?'>&
M1U^]C 3GT/3KQ6_JWA;4KB7Q7+;V"&2_U33;BW<.@,D</V?><YXV[).#SUQU
MY]"HH \SL?">LP>(5BN4U*6UCUN34TG2>U2VVL68,?D,Y?#>65Z$9^8# K,N
M/!GB*70FL4TQ_,BTC4[%29H@)))9D>,K\_ 8 ]<8P<@<9]?HH \Z\0>%M6N]
M9N9;.R!MWATI$VR(HS!=,\@QD8VH0??H/2H]+\/:R)[6QGT0VJ0>(;C5#J'F
MQ%6C+R%> Q?>P95QC 7J<_+7I-% ''^,-/UN]U73VTV"9K;[/<0R2VHMQ*CN
M4VAGF!*Q$!MWE@MP.#@5SUAX0UI-$N8;C3@+AO!L.DH&EC)\]1,&CSNZ?,G/
M3ISQQZC10!Y7K/ACQ VB^(--BT4ZA)J]O:-%/Y\06!HHT5HWW,#D,A92H8$O
MR5Y-=5XYT?4=5M-*FTTSF2POTNGCMS$)74*R_)YH,>Y2P8;N/EX(.#7544 >
M>:'X6U&VUO1+^>SN0L=WJ%U.;R>!Y8VF50K$1*J*6PQ(3<!N.6.:@T70-9T"
M/3+N;0Y-1,=A<V4EG%-#OB+SF13\[A"K+@'!R,+P><>E44 >;7GAG6'&J:<F
MCQ*NJ7%G<1W4,R>38")8PT?)5SL\MBFU,'</N\XM2Z%K=MX>UJ.UL0;FYU_[
M8JJ('D:#SD)>/S,QB0*I*[^A [XKOZ* /,]+\,Z^CQO=6EP6/B==2+W$\+2>
M0;8(6;9A=P;@JHP#TR.:BT?P?K=K?6EM=QZE*EC<W=PEQ]HM4MF,@D *A4\]
MF82<JY SD[C@9]1HH \GN_!FN-X3TBQATX"X@\+7>GS(LL8Q<2+%M3.[!R5;
MGD>IYJS<>&];EF\0Z>-#.S5;RTEBU'SHML2QQPAF8%M^5*-M !R<]!R?3Z*
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M])HH BMI7GMTDDMY+=V&3%*5++]=I(_(FI:** "BBB@ HHHH **** "BBB@
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:*** "BBB@ HHHH **** "BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>imrx-20211231x10k025.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 imrx-20211231x10k025.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $U M0# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W/5=2ATC3
M9;ZX61HHL;A& 6Y('&2/6N:_X63H_P#S[7W_ '[3_P"*K1\<?\B??_\ ;/\
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MW_?M/_BJ/^%DZ/\ \^U]_P!^T_\ BJX2U\,ZS>V)O+>PD>#!(;(!8#T4G)_
M<U'IN@ZIJXD-C:-*(SAR6"@'TR2.:KZGA===O,GZ]C-%;?;0[_\ X63H_P#S
M[7W_ '[3_P"*H_X63H__ #[7W_?M/_BJY/0_"S76OS:9JR3V[1P&7",,GD8Y
MP01R>E*_A&X7PG'JZAWF8^8T>Y0J0X)W=>3T_/I4/#X5.S?;KW-%BL:X\R7?
MIV.K_P"%DZ/_ ,^U]_W[3_XJC_A9.C_\^U]_W[3_ .*KG=8\#7D5XJ:1;SW$
M'DJ[O*Z#YB3P.F> /SKG9])OK:PCOIK<I;R2&-6)&=PR"",Y!X/4=J<,+A9J
MZ?XDU,9C*;:DOP/1/^%DZ/\ \^U]_P!^T_\ BJ/^%DZ/_P ^U]_W[3_XJO.;
MW3+S3E@-W#Y7GH)(P6!)7U(!R/QK>\/Z#H][H-SJ>K75S!'!-Y9:+&,$+CC:
M3U:G/"8:,>;5KR"&-Q<Y<FB?GH=1_P +)T?_ )]K[_OVG_Q5'_"R='_Y]K[_
M +]I_P#%5S&K^']'706U;1;^:>&*7RI1,N,DXZ?*.F1V[^U9]SX3URS@>>>Q
M*1H0"?,0\D@   Y/) XJ8X;"R7;UT'/%XR+MOUT5T=O_ ,+)T?\ Y]K[_OVG
M_P 51_PLG1_^?:^_[]I_\57#W?A76[&S:ZN+!DA099@ZL0/4@'-2W/A]VBTA
M+&UNC<WT1?$TD>UR #\F#P.3][!Z4_JN%Z/\1?7,9K=?A\CL_P#A9.C_ //M
M??\ ?M/_ (JC_A9.C_\ /M??]^T_^*KAKGPMK=G9R7<]@Z0QYWMN4D8.,X!S
MCW].>E8]7'!8>6L=?F1/,,5#22M\CU'_ (63H_\ S[7W_?M/_BJ/^%DZ/_S[
M7W_?M/\ XJO+J*K^SZ)']J8CNON/8Y_%VGP:%;:NT-R;>XD,:*%7>""PY&['
M\)[UF_\ "R='_P"?:^_[]I_\57.ZE_R3'1_^OI_YR5R%94<%2FG?HVC>OF%:
M#BEU2?WH]=TKQMINKZE%8V\%VLLN=ID10O )YPQ]*Z6O'O __(X6'_;3_P!%
MM7L-<.-HQHU%&/8]# 5YUZ3E/>_^04445R'<4]5U*'2--EOKA9&BBQN$8!;D
M@<9(]:YK_A9.C_\ /M??]^T_^*K1\<?\B??_ /;/_P!&+7CM>G@L+3K4W*7<
M\C'XRK0JJ,-K?YGJ/_"R='_Y]K[_ +]I_P#%4?\ "R='_P"?:^_[]I_\57EU
M%=?]GT3A_M3$=U]QZC_PLG1_^?:^_P"_:?\ Q5'_  LG1_\ GVOO^_:?_%5Y
M=11_9]$/[4Q'=?<>H_\ "R='_P"?:^_[]I_\51_PLG1_^?:^_P"_:?\ Q5>7
M44?V?1#^U,1W7W'J/_"R='_Y]K[_ +]I_P#%4?\ "R='_P"?:^_[]I_\57EU
M%']GT0_M3$=U]QZC_P +)T?_ )]K[_OVG_Q5'_"R='_Y]K[_ +]I_P#%5Y=1
M1_9]$/[4Q'=?<>H_\+)T?_GVOO\ OVG_ ,51_P +)T?_ )]K[_OVG_Q5>744
M?V?1#^U,1W7W'J/_  LG1_\ GVOO^_:?_%4?\+)T?_GVOO\ OVG_ ,57EU%'
M]GT0_M3$=U]QZC_PLG1_^?:^_P"_:?\ Q5'_  LG1_\ GVOO^_:?_%5Y=11_
M9]$/[4Q'=?<>H_\ "R='_P"?:^_[]I_\51_PLG1_^?:^_P"_:?\ Q5>75N>%
M]#AUJ^F%W(\5G!$9)9$(!'H,G/N?PJ9X+#PBY.Y=/,,34DHQM=G:_P#"R='_
M .?:^_[]I_\ %4?\+)T?_GVOO^_:?_%5Q&H:$-/\5+I4C.87F14?N48C!^O.
M/J*N7_@^\.N7UEI$$EQ#;% 6DD0,-R!N<X]ZCZMA=+O=7W-/K>,ULMG;;K_2
M.K_X63H__/M??]^T_P#BJ/\ A9.C_P#/M??]^T_^*KF='\&3R:TMEK,4MLKP
MM(GE2(2<$#MGUK(O?#NKZ?8K>7=C)% V/F)!(STR <K^./2A8;"N7*G^(2Q>
M-C'F:_#;U.]_X63H_P#S[7W_ '[3_P"*H_X63H__ #[7W_?M/_BJX4>&-:.G
M_;_[/E^S[=V<C=CUVYW?ITYZ4_\ L42^'[*[@M[HW-S<^0K,\?E,3N  &=P/
M Y/'6G]4PO?RW)6-QG;I?8[?_A9.C_\ /M??]^T_^*H_X63H_P#S[7W_ '[3
M_P"*KBI?!^OPQ/*^FR%4Z[65C^ !R?PJKJ/A_5=)$1O;-XQ*=J$,&R?3Y2>?
M:A83"MV3_$)8W&Q5W&WR._\ ^%DZ/_S[7W_?M/\ XJC_ (63H_\ S[7W_?M/
M_BJX2Z\,ZS96(O;BPD2# );()4'U .1^(XIR>%=:>R%X+/\ T8Q>=YAE0#9C
M.>3Z4?5,+:]_Q#Z[C;VY?P.Y_P"%DZ/_ ,^U]_W[3_XJC_A9.C_\^U]_W[3_
M .*KC]2\/(^J6EIH8GNA<6JS_O, C)//08& .OK[UG:GH>I:/L^WVK0A_NMN
M# ^V02,T1PF&E;N^E]0GC<7&[:T76VGWGH/_  LG1_\ GVOO^_:?_%4?\+)T
M?_GVOO\ OVG_ ,57%>%-&M]=U=K2Z>5(Q$SYB(!R"/4'UK9C\,^'-6BFBT/5
MIY+U$WJDPP&]N57\QTJ)X?#0ERM,TIXK%U(\T6M?O9N?\+)T?_GVOO\ OVG_
M ,51_P +)T?_ )]K[_OVG_Q5</)I"CPY:WL=M>&YFN/)W$H8V^]PJ@[]W ZC
M'7VI+SPMK6GVC75S8,D*_>8.K8^H!)%6L)A=K_B9O&XRUTO/8[G_ (63H_\
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MW_?M/_BJ\NHH_L^B']J8CNON/4?^%DZ/_P ^U]_W[3_XJC_A9.C_ //M??\
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MY&[$=NI_CF;^$>@ZGM5?P/>:M+-KUAK%^;Z>QOA&)O*$8PT2.0 .P+''4XH
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MA20 P R2QXR.*XW0M(\4>-M;@N8M0U?R)) EYJ"7#*ODG[ZA^%.1P%12 >]
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MMSN_AQ2Z;;W6D>(_[6OM/O'LA=:C&ICM9)7B:29660(JEMK*I&X#T[&O1:*
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MED+JI5<N[%B &;"DX&3Q2WOAG2-1O6N[JU9Y7V>:JS.L<VPY7S$!"R8[;@:
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MPJ@8 I//;T%+Y[>@H 5[2WEN8KF2"-IX01'*5!9 >H!ZC-35!Y[>@H\]O04
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MZ+9N$SRIA_FR,?,6/0YS4%A\.9;2ZL8)_$%S<Z'I]Q]IM--:%04<$E=T@.6
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M]BQ.X=\MU_/-4I_!5M>7?VN^U74[JXVHF^1HA\JRQRJ-JH%'S1CD $@G)/&
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M]L8;5((MC@PQ.ZN2N[!W'&TJ1D\],=?X@O!9:0\GV]K)F=(UF2W,[Y9@,)&
M2S'.!P<'D@@8H U**Y/PCJFIW>JZQ9:@U\4MUMY(1?QPK.HD5LAO)^7'RY'<
M9.:QM,N-0TP&]CU"3[/-XEN+5K/RD\LH]PZDDXW[@3G(8#@#'7(!Z+17!Z?K
M7B;4YH]1M+2_DMWO6C,)^RBU$"R&-CG?YV\ %O3<"-N*CN_$&I1ZQ:366H7]
MW:2:HEK*WV.*.S"M(8RBEAYKL,??4LI/IT !Z!17C6G6\O\ PC-Y+]LGV?\
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M_P JE6(VC Z>@QOHBQQK&@PJ@ #T IU% !1110 ^+_6"K-5HO]8*LT %%%%
M#)?]6:I3P1W-O)!,@>*52CJ>C*1@BKLO^K-5J ,VVT#3;3_50R9-L+0M).[D
MQ DA<LQ/5CSU[=A59_".B.D"&T=8X8$M@B7$BK)$G"I( V)% SP^>I]35^SU
M?3-0GF@LM1M+F:'B6.&=79.<?, >.?6KE &9IN@:;H\F^PA>$^2D&//=E*(
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M?Q.EO))9T\O1_,)$[[1^\*GY,X(QSC&,\XSS711:/I<&H/J$.FV<=[)G?<I
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M.L]2ND\3:Q+_ &-KBV=NDL^X2(S+GS>/GZCKP.>.:]@&BZ4K!AIED"LPN 1
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ML#<RD&28VR;W((89;&3RJGZ@>E CSFTTJW?P/X9!DO,2:TH.+R88S*XXPW'
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M@#@-#GOK2T\)WRWU_=W6HQSK<+/=22+)B%W4;"=H(**,@ GG).34VCS/]O\
M!MV-:O9Y]5CEFNXGNV9)6\EF.(R<(%<XVJ !QD9 KNETZR2.W2*U@C%MG[/L
MB4>3D$$IQ\O!(X]:P-+\(&SUF+4[NXLI9XB[B2VT];>29V!!>9@Q#M@MT"C+
M$XH H^)(Y[KQ!JL?]H7\$-MH?GQQVUT\($N^7#_*1D@#H>#W!P,8.IZGJ>EP
MZ;+;ZC=,VJ:9'->27%TP1&::!6=3AA",2N,HH"Y!QP*]/>SMI))))+>%Y)(_
M*=F0$LG/RD]QR>.G)IATZQ(4&SMR%A-NH\I>(CC*#C[IP..G H X+4AK.FZ5
MJUN=12UR;0Q10ZK+=W$#-.JL^^10P5A@8.1D'U(J'5XKC3T\7-;ZIJJKI,$5
MS9JU_*WENR9;)+$N"4'RL2HR< 9-=[;Z)I-I:/:6VEV4-L[B1H8[=%1F&"&*
M@8)&!S["II-/LIA<"6SMY!<J%GW1*?- & &X^88]: .%:\NO[..N?VC=_P!J
MC6C:"U\]_**^?Y7D^3G;_J_GSC=GYLT\17IT37=9BO\ 49+RRU.XDC3[4Y3R
M8ILF(1[MI!56'3/.,X %=K_96G?VE_:7V"U^WXQ]J\E?-QC&-^,]..M-NK%C
MIUS;Z<UO9RS%F,A@WKN8Y9BH*Y)YYSU.3GH0"CH%[]NLKS5VG=K:YG=[?+$J
ML*?(I4>C;"__  /\!YYJ&JWT,=C>V5SJ4$&H65Y+')=ZJTDUPHM7D$GDKF.+
M#;2"A!' P,XKU>RM(=/L+>RMUVPV\2Q1CT50 /T%4U\-Z$AD*:+IR^:VZ3%J
M@WG##)XY.&8?1CZF@#B[R\U'0!,;&]O9YI?#TEXQN)GG_?(R#S K$A?OL=J@
M+P..*T--LK6R^(UDMKJ%S=+)H<LF+BZ:=L&:+#@L20&]!A?EX YKL5M+99TG
M6WB$R1F)) @W*A(.T'L,@<>PJM8Z)I.F2F6PTNRM)"""\%ND9(.,C('?:/R'
MI0!?JVGW%^E5*MI]Q?I0 M%%% !55_OM]:M55?[[?6@#SCQ#)=1MXQU)=1OT
MDTPPO:1QW3I'&1$C'Y <,">H8$=>.3E=2FUK4-5\0O#=06C:;(JP2SZM+;);
M+Y:LLCQ+&4D4L6)+D@@%>,9KNY=/LIDN4EL[>1;G'GJ\2D2X&!NX^;@ <^E1
MW6CZ9?7<-W=Z=:7%S#CRII8%=TP<C:Q&1SSQ0!Q.NZM=P:+XXD_M!XI;>. P
MM'.0(BT*?ZLYX!;.,=3[U8U&XOK>[\9ZG!=7;W&G1*;.'SG,49^S*2?+!VMR
M<X(/(R.2:ZV\T32=0N1<WNF65S.(S$)9K='8(<Y7)&<?,>/<^M6H[>&*666.
M&-))B#(ZJ 7(& 2>_  H X'599-&$\.EZM>W,=SH5U<R-+=/,59%'ES*Q)V;
MBS?=P#@8'%#&[TZY-I!K<\#7>@27+W5_=,Z1SJR 2?.2$_UAR%P.G' KM+;1
M-*LX;B&UTRR@BN1B=(K=564<CY@!\W4]?6IC8VC.':U@+B(PAC&,B,XRG^Z<
M#CIP* .;\+2RVVJWNF7<=]#=+"DWERZ@;R%D)91)&[_O!D@Y5@!QP.IKGKW_
M $ZQTW5+S4+H7[>)8H&MVG81C;<[5B$6=H(15;(&XX)S@FO0;#2M.TI'33M/
MM;-'.76WA6,,?4[0,TR31-)FO_M\NEV3WF5/VAK=#)E<%3NQGC QZ8% ''3:
MK=+IBYOYA*?%2VP_?'<4^TC]WU^[L_AZ8]J9(]U'H&MZG_:%^;D:R;>,FZDV
MQQ"[1=JKG:.,C.,X)&<<5VKZ)I,E^U^^F637C%2UPUNAD)4@KEL9X*KCTVCT
MJ8V%F8'@-I 8I)/->,QC:S[MVXC')W<Y]>: ."62ZA_XFG]HW[S_ /"2FS5&
MNG\H0M/Y93R\[2,$D$C(XP< 88]S-);Z?JLFKWL>H7'B 6DMNMTRQ[!.4\GR
ML[1A%4GC)Y))#&N_.GV138;.W*>=Y^WREQYN=V_I][/.>N>:Y]O![7&NKJ-Y
M<V<NRY%P)$T]([E]IRB/,#\R+A?X03M7GCD B\3SZA/XDTO2;;'D3P32E#?R
M6?G2*5PHDC5FX4L=HQGJ?NXK-^T7D]KIVE3W,VHZ@#<.JV&JF*'RTD5<SW"A
M9&9 P7Y022"64]1V]]IUCJ=O]GU"SM[N'<&\NXB61<CO@C&:AN-#TB\M(+2Y
MTJQGMH!B&&6W1DC&,?*I&!QZ4 <'X&GN]:U"T>]U.\GC@L3(BI>N4=ENYT5F
M((\SY4 RW##J#Q5?1KR]T[0]+M(;J<#6M-CM[7#\0SB0(S)_=.R3?_VR)KTJ
MWTZRM)GEMK.WAE?.YXXE4MEBQR0.?F)/U)-4SHJ?VE83)]GBLK!&-O;10;2D
MA!4MN!QMVL1M"CDYSVH I^*9TAL[&Q0:A)/<S^7!#:7/D-,RHS;7E)!5?ER2
MIW' ZY(/&Z%)>ZGX@CTNZU*\%K%?7T;16^IRR95([<A/.^5V"L[<G!'(Z9!]
M+O;"SU*W-O?VD%U 2"8YXPZY'0X(Q4=OI&FV<JRVVGVD$B#:K10JI4;0N 0/
M15'T4#M0!Q&AW5SK#:)IM_?7JVIBO2'CN7CDN)(9_+0-(I#'"9)&>3R<XK:^
M'6W_ (0FUV3_ &A/M%UMFR#Y@^T2?-QQSUK;GT72KFR6RN-,LI;57,@@D@5D
M#DDEMI&,DL3GW/K5FVM;>S@6"U@B@A4DB.) J@DDG@>I)/XT >66-R9_"ME;
MVS7QFL])6:9AJ;65O;JWF$.2GSN_R=""H 'W<G,.GWEY;:'J.JQ74_VR[33%
MN+B6Z=5598XS(Y/S!.I^8*=N>.!BO3GT'1Y&MF?2;%FM<?9RULA,.#D;./EY
MYXIT6C:7#N\K3;./=#]G.R!1F+^YT^[[=* .'U)=8TW2M6MVU%+4$VACAAU6
M6[N(&:=59M\BJP5A@8.1D'U(KT"TM8[*V2WB:9D3.#-,\K=<\LY+'\35:WT3
M2;2T>TMM+LH;9W$C0QVZ*C,,$,5 P2,#GV%7Z "I8/OGZ5%4L'WS]* )Z***
M &2_ZLU6JS+_ *LUSGC'_D2-?_[!MQ_Z+:@#:HKS5_#FC_VY-:G3K=K<Z L[
M1LF5>4,P$K#HTF"?G/S<GGFN9U6]MK[PU)<2)IT.IPVENWG71>>_G811/YD0
MR#"@RQW#<#AB0.: /:+.^MM0CDDM9/,6.9X'.TC#HQ5ASZ$$5);SI<V\<T8D
M".H8"2-D8#W5@"#[$5YKH.(?$OVC5S'-IDVK7L6GY'R6]U]H<@MG@LXR%;MM
MP.6YH:%I5AJ>G(;ZTBN1%X4MS&LJA@K;I_F /1AC@]1DXZT >NT5Y5<3Z;=6
M1N/$[H]Q+H5L^F-.26:0H2YA[^;OV9Q\WW>U=]H#[/!^F/M=MMA$=J?>/[L<
M#WH UZ*\,U&>QDMHKJR32;4SZ;?"6"RW2SINM';;<SDC>Y92=K*""IY.":ZB
M^L9-)N;FV\/V[03W'AYI7%J-LDTBR*-^1RTF'?#?>R>M 'H1U"U&IKIQE_TM
MH3.(]I^X&"DYQCJ1QG-6:\_\._\ "-_\+ C_ .$:-K]F_L=_,%ICR]WFQXSC
MC?C&>_3/:CQ3IEEJ'B'Q ]Y;1SF#PZK1>8NX(V^XPP]&&.&ZCG'6@#T"BO(M
M6M#8KI[:>BP1WNE13ZK*(V<RIYT7F22A2&DX=]QSDJ6YJS=6=DWA[5DLM5L+
MJRFNK!&ATFT:"VB?[1'DJP=EWD%<A2",*2.>0#U2BO*]8T;3+1?&;VUC!";!
M;>:S$:!1;2&-26C X1B57)7!.!G-3*+0F+:%_P"$S&L_/C_CY\OSCG=W\G[/
MT_AQM[T >G45YQ!HMN_AS7=6MK2-M5MM7N[J*8*/,8Q7+,$#=<$*1CI\Q]:Z
MSPN?M6FRZLRE6U.9KD;@0?+.%BZ_],U0X]2: +MGJ]GJ%W=6UJ\DDEJYCE;R
M7"!AU4.1M8CN 3BKU>9Q6-M9^'M>:VM$@MFUXI?FWCVDVBRKO!V\[ I;([*6
M]ZAU2'3IK36XM$$7]@22Z:O^BD" W!N5$GE[>/N>7G;W]\T >I45YSK^@Z2V
ML:Y"=.MA#:^'%:WB$0"1-ON#N51PK ]".1DXZFL^\2PTE[%SI\<L6H:1$]Z'
MF:%)G,T0\VXD )(&]BS,#D$@\$T >G75];63VR7$FQKF801#:3N<@D#CIPIZ
M^E20SI.K,@D 5V0[XV0Y!P<!@,CC@C@]1D5XS:V^E?\ "0AIQHLMG'J%D^^T
MMA%:+NBF5B@8L,%D0%@<%E'<5MVG]G?VH/\ A(?L_P#8GV[5-OVS'V?[3]I^
M7?N^7=LW[=W^UCF@#T^BO,]*TV'4M1\,V^I6QN+$1:DUK#=KNW6XEB\G>K=<
M(5(SZ ]172^![J(>%-.MY)T$A:>*&-G^8I'*R@*#R0JA1[#% '51?ZP59JM%
M_K!5F@ HHHH 9+_JS5:K,O\ JS6!XH%\?"VJ#3/-^V_9G\GR?O[L?P_[7I[T
M 73J%JNIIIIE_P!+>%IUCVGE%8*3G&.K#C.>:LUY1-_97]LW1\#B$7!\.7&T
M6/9_,BQT_P"6N.N?F^[GM4EM"HLK^;POJ^G279TJ4?9='L'B9F(!1I3YCXE!
MSMW8<DMUYP >GSSI;Q&1Q(5! Q'&SGDXZ*">_P"'4\5)7F^HCPH- N/^$<-O
MYI^QB<6N2N!<1[?-Q\OF<G[WSGYO0TFFFPLO&</V=]/U.XFO9E=U#P:C;EBY
M/FK_ ,M(@.!N"@?(1GB@#T6"=+F!)D$@5QD"2-D;\58 C\14E>2Z*-&.FV8\
M5"$V!T:+[!]IQLW;I/-\O/\ RU_U>,?-C&*NVNE?VI< >(K07-W%X:B+I=J&
M*OOE^8@_QCUZC)]30!Z;17.>&;S6+C0="D:VM9;:6PMWEN)+MQ+N,8).SRR#
MS_MUQF@Z#I;P^"O,L87^VP7 N]RY^T ('"R?WU!52 V0-HQT% 'JU5X+ZVN;
MJZMH9-TUJRI,NTC:64,.3P>"#Q7D0DT^XTW^SKFVTM'@CN8[>;4U>8NGVB=5
MBMH 1EQM0;E.X?*,' PFBR-(L-_JLBW.@*M@+^)N<R&TBVRRD_>17QE3QEMQ
MSM& #V*&=)PY02#:Y0[XV3D'!QD#(]".#VJ2O,K"PL]4\364%[!%<V_V_5V,
M4BAD?]XF,J>&'?GN >H%0Z:VFFST-?$?D?V%$M_%"+O'V=9DN"L8.>-PB#A<
M]@V.: /4ZKWU];:;:FYNY/+A#*A;:3RS!5X'/4@5QWAY(9?A1+']INK6!TNU
M\]$=Y8U,LGS;?O$COWKG9)($T+6+33(M&?#6;K>Z46%LY^T*%#Q E4D&,G#$
MD8SCB@#U>6=(3&&$A\Q]B[(V;!P3S@':..IP/SJEI^NZ;JCQI97/FM);K<J-
MC+F-B5#<@=U/'7BN%M/*ANM-M;K!UZ+74&HS-]^X_=3>7)_N%<;1T7E1TK*L
M(K:?2;:.[O19P'1+,O*\)ECP+F0XD48S&<8;) P3D@4 >P5'#.DX<H)!M<H=
M\;)R#@XR!D>A'![5R_@2:%[*_@M[6PCBAN/]=IDC-:3$J"3$#PF. 57(#9Y)
MS7/V.GVFI^)[*WOK>.X@_M#5V,4JAD8B5,;E/!]>>X!Z@4 >F45SG@1B?"%L
MO\,4UQ$@_NHD\BJ![!0!^%<7X4.D)9^%Y-%"/K(9CJ AYF,'EOO$O?;N$>W=
MQ]S;Q0!ZE<W$5G:S7,[[(84:21L$X4#).!STIL%Y#<L@B\Q@\2S*_E,%*MT^
M8C&?;.1Z5XM=C3M0:PEMK72(C<070FM+96GN%)M9&5;F9OO2&1<A67.Y<@G!
M-:U\5%JO]CM"MG_8UCY[6T>]!#]H?SCM0@D8W;@"#C=S0!ZU5>^OK;3;1[J[
MD\N%"H9MI."2%' YZD5YG=6ED?#^LI8:MI]S9RR6:/#I%HT%O&_GKEE82.OF
M$$ A2#@*2.AJ37M,TZU'BNPBL+6*P@33[D0K$HCC8NP=PN,#Y5Y/H.: /4**
M\QU Z39^)?M=H^EZBYN8/*LV#0WD*[45/LSK]^+'S;0-I!;+=:]*BN(9]_DS
M1R>6YC?8P.UAU!QT/M0!)5M/N+]*J5;3[B_2@!:*** "JK_?;ZU:JJ_WV^M
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M3>1_M?I1Y'^U^E &#J>@?VG-*QU74;>&>+R9[>&1?+D7G/#*Q0D$@E"IZ<Y
M-:L,,=O!'!$H2.-0B*.P P!5GR/]K]*/(_VOTH AHJ;R/]K]*/(_VOTH AHJ
M;R/]K]*/(_VOTH AHJ;R/]K]*/(_VOTH AHJ;R/]K]*/(_VOTH H:A9F_L9;
M47,]MY@VF2#;O [@;@0,CCIGTP>:FABC@ACAB4)'&H5%'0 < 59\C_:_2CR/
M]K]* (:*F\C_ &OTH\C_ &OTH AHJ;R/]K]*/(_VOTH AHJ;R/\ :_2CR/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
J**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>29
<FILENAME>imrx-20211231x10k026.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 imrx-20211231x10k026.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #L M$# 2(  A$! Q$!_\0
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MLC1_^?:^_P"_:?\ Q5>744?V?1#^T\1W7W'J/_"R-'_Y]K[_ +]I_P#%4?\
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MLC1_^?:^_P"_:?\ Q5'_  LC1_\ GVOO^_:?_%5Y=11_9]$/[3Q'=?<>H_\
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M_P#%5-:>/]*O+V"UCM[T/-(L:ED7 ).!GYO>O**T-!_Y&+3/^ON+_P!#%3/
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MG_-+[_\ @'E#^&?&$LDDDD=P[R)Y;LUVI++_ '2=W(]JBG\(>*;EP\]I)*X
M4-)<HQ '0<M7KE%-9C46R7]?,3RND]Y/[_\ @'CW_"$>(O\ H'?^1H__ (JC
M_A"/$7_0._\ (T?_ ,57L-%/^TJO9?C_ )B_LFCW?X?Y'CW_  A'B+_H'?\
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M5[#11_:57LOQ_P P_LFCW?X?Y'CW_"$>(O\ H'?^1H__ (JC_A"/$7_0._\
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ML5@MXFED(&2%49/% %FBLK1->BUH7*BTNK.XMG59;>Z50Z[E#*?E9A@@CO\
M7%:O6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M;!A^]'&5Z?C6#J'@?4'U'1FLY;9H-.@M8EGED"R#RFRV 8G(W  91X\YPVX
M5O1>+[5[OR9-/OX8U>..6>14"1.\:R*K8<MG# < @'OC!I?#GC+2O$\TT5@Q
MW1(LF#)$^Y&SAL([%>GW6VL.XH Y?5/A_J%UIQLK2WTN)!=7LJL'"X$T@:-]
MK0NNY5^7@!@%&UP"17HENKI;1)*=TBH QSG)QSS6;I^I7ESKNIV-S;Q0Q6R1
M/"5<LSJQD&6[#[G &>.IYP-:@#EM+LIO$>GQ:O=:GJ$)N<R00VLYB6%/X00/
MO-CD[L\]L5'9>,+:P-SI^KR7<MY9S-"TT&GS2+*HP58F-"H;!&1Z@\ 8J_\
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M .IHHHH **** "BBB@ HHHH **R]3\0Z?I4RVTCO/>N,QV=LADF<>H4=![G
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M_P!@RS_]&7% %O\ X1+PW_T+VD_^ 4?^%'_")>&_^A>TG_P"C_PK8HH Q_\
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M-,_\"X_\:G_L72O^@99_]^%_PH_L72O^@99_]^%_PH @_P"$GT#_ *#FF?\
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M'P9IUA'$L<LS>5)"Z';&I_=DE0=J#/7DG)..M='0 5X1K#6T'C+5[_Q!KO\
M8WB6RU+SM'GO$=[9[/;A4 '!!!.['(->[TQXHY<>9&KXZ;AF@#QN[U;7/B1I
M-[X:M?$G@R8W4>'6W,XEP"#E0W7IZ&I)_@R\MI87*6'AR+4K:1Q- J3_ &6Y
MC90!N^;<&!R>..:]#U[PI:ZU<Z1=(RVMQIMZEVDL<0W,%SNCSQ@,#S704 <E
MH/P[\-:.]I?+H.G0ZI$H+2P*Q59,<E-Q)'.<=ZZVBB@ HHHH **** "BBB@
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M EN/+;G[P Q@_P ^.E=-HWPU\+Z5I%M8RZ18WTD2X>YN+9&>1B<DDD>_ [#
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MML:R-M5L%]S G)PH9@.6 K2F\<VD1N2-,U*2.#4%TT.BQ8DG+!=J@R XY')
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M*\B#^$-G;^>T_E4U !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M8?\ @K/_ ,>K7LH[J*SC2]N([BX&=\L<7EJW)QA<G'&!UJQ10 4444 %%%%
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M ^BN7F^(OA**0QC6H)F'!^S(\X_- :?;?$'PG=3+"NMVT4C' 6XW0D_]]@4
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MY?\ PD?BG0P/^76>2X4)[8E5A^1H,WA"]&PZMXI\2$_\NT;W$BM]0H5/S.*
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M3_O@_P"- #Z*9B7^^G_?!_QI,2_WT_[X/^- $E%,Q+_?3_O@_P"-&)?[Z?\
M?!_QH ?14>)?[Z?]\'_&C$O]]/\ O@_XT 244S$O]]/^^#_C1B7^^G_?!_QH
M ?13,2_WT_[X/^-)B7^^G_?!_P : )**9B7^^G_?!_QHQ+_?3_O@_P"- #Z*
M9B7^^G_?!_QHQ+_?3_O@_P"- #Z*9B7^^G_?!_QHQ+_?3_O@_P"- #Z*9B7^
M^G_?!_QI,2_WT_[X/^- $E%1XE_OI_WP?\:7$O\ ?3_O@_XT /HIF)?[Z?\
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MV;MISC.16S0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M//;'85UU% '#2>#]6?Q>+P74"Z2-374?+60[MXAV'Y-GWB<<^9C'1,UW-%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
:%%% !1110 4444 %%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>30
<FILENAME>imrx-20211231x10k027.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 imrx-20211231x10k027.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #R \L# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M=Q_WZ;_"CD@'-(ZC_A/[C_GPB_[[/^%'_"?W'_/A%_WV?\*Y?^S[W_GSN/\
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MHO$5F\EM,BACEFC( ^4UM>,=(O\ 4-3@EM+9Y46$*2N.#N-0XQ4RTY.)E?\
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MZ1!I'V,7-_>K;;KN-G1058YPK ]O6I;"'QHM]$=0O=">T#?O5M[257(]B9"
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MU?AD=/:/Q =*55L3J3^2%&!C Z>V<T =Y5B+_5BJ]6(O]6* *]%%% !1110
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M$TRI)<2 ,((^[A21N/M7#^'7FUKQ[IU^-:NM4%G!,'E731;QJ&&-C,6R3G!
MP>E=3XY\5_\ "*:,DT4)ENKB010@J2JD_P 38[#K0!4TB^UK3?&O_"/ZCJ@U
M:&6T-RD[0)%)"0<;6V #![<5V=<)X#NM#:YG\G4FU'6[H>9=7+QLN['\*Y'"
MCL*[N@ HHHH **** '1_ZP4Z;[P^E-C_ -8*=-]X?2@".BBB@ HHHH K:C*\
M&EW<T3;9(X793C."%)%<%H5MXMU7P?9ZW_PFLR3SVHG\N6QM_*!(S@D(#C\:
M[K5@3HU\ ,DV\G'_  $UP'@WP'INH>"-(DOY]5836J&6V:^E6(Y'*[ < >U
M$=O\19C)X.O]1N%L[+4K&XENH5CW;Y%VA=O!;J3@#U[UVECXNT+4=)N=3M]0
M3[):DB=Y%,9B([,K $?B*P]3L(;?XE>$(K>V5+:WL[Q4"I\L8VH !Z5B7=Q=
MZ9>>/;JVTU+MOM%L1'+#O0C9RVW^+'6@#L=+\;^']8U%;"TO'^TNI9$E@DBW
M@=U+* WX5&OC_P -/J*V(U']ZTODJ_E/Y329QM$F-I.>,9K@8M2N-6\:>%YS
MJ<VIPQS2;BFGF"&,E.%!.23[9J W9TYUM/#]S?/(+M<>'M1L1(JGS!DJ^/E
MY(.3B@#TO6?&>@Z#>BSO[QEN=GF&**%Y61/[S! =H]S6S:7=O?V<5W:3)-;S
M*'CD0Y5@>X->47SZAX>\9Z_/=:S)I,>H21RPR?V=]I69 @&T-D8*D$;:[+X<
MV+Z?X-MXF^T@/++*BW$(B90SDXV G:.20,]#0!3U^3Q1'-J>H?VU;Z+IMFN;
M5&ACE^TX&29"W*C/&!@UTGAS49]7\.:?J%S#Y,UQ LCQXQ@D5Q_BG6M%O)K[
M2/%>C2X@;=8LJ/)Y^5X9"HX;/&*Z+P1#J4'A&PCU7S/M(4\2G+A<_*&/KC%
M'0T444 %%%% #XO]95BJ\7^LJQ0 4444 13']Q)Z[37SK(29'+=23GZU]&,,
MJ0>AKP;Q'I[Z;X@O+9AA?,+IQU4\C_"O0R^24FF>;F$6XQ9E5W'ALD^ ->YS
M\W]!7#]J[CPWQX U[/'S=_H*Z\5\/S1PX;XOD9/@7_D<+#_@?_H#52\2D_\
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MY%DU2Y5$!R8H>2?^!&M)U:"?/U,X4:S7)T.4\/Z#<Z_J"P0J1$I_>R$<(/\
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M !1110 4444 %30_=/UJ&IH?NGZT ,E_UAIE/E_UAIE !1110 4444 %%%%
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M']AZG_SYR?I1_8>I_P#/G)^E'LY]@Y7V,^F'K6G_ &'J?_/G)^E1G1=1R?\
M1'_2CV<^P<K[%"BK_P#8NH_\^C_I1_8NH_\ /H_Z4>SGV#E?8H45?_L74?\
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M?_O@?XT?\)5IWI/_ -\#_&N*HH^M5 ]K([7_ (2K3O2?_O@?XT?\)5IWI/\
M]\#_ !KBJ*/K50/:R.U_X2K3O2?_ +X'^-'_  E6G>D__? _QKBJ*/K50/:R
M.U_X2K3O2?\ [X'^-'_"5:=Z3_\ ? _QKBJ*/K50/:R.U_X2K3O2?_O@?XU
MWB>P+$XFZ_W1_C7(TP]:/K50/:R.P_X2:P])O^^1_C1_PDUAZ3?]\C_&N/HH
M^M5 ]K([#_A)K#TF_P"^1_C1_P )-8>DW_?(_P :X^BCZU4#VLCL/^$FL/2;
M_OD?XT?\)-8>DW_?(_QKCZ*/K50/:R.P_P"$FL/2;_OD?XT?\)-8>DW_ 'R/
M\:X^BCZU4#VLCL1XEL"0,3#/<J/\:UT=70.I!4C((KS>NB\/:KL864[?*?\
M5D]CZ5K1Q+E*TRX5;NS.GHHHKM-PHHHH **** "I5_U!J*I5_P!0: (J***
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ JQ%_JQ5>K$7^K% %>BBB@
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M444 %,/6GTP]: "BBB@ HHHH **** "BBB@ I02""#@CO24Z.-I9%1 2S'
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M10 4444 %%%% !1110 4444 %%%% #H_]8*=-]X?2FQ_ZP4Z;[P^E $=%%%
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M "4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !4J_Z@T44 14444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !5B+_5BBB@"O1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !4T/W3]:** &2_ZPTRBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!T?^L%.F^\/I110
M!'1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% #XO]95BBB@
&HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>31
<FILENAME>imrx-20211231x10k028.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 imrx-20211231x10k028.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %1 LX# 2(  A$! Q$!_\0
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MR5VX[>YKI*R[S_D8]+_ZY3_^R4 6K*R^QJR_:KF?<<YG?<1].*M444 %%%%
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M\7_?8HLPNB6BHOM5O_SWB_[[%.26.3/ENK8Z[3G%*P[CZ*** "BBB@ HHHH
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M_P!?5M_Z/2M2LG7G632%9&#+]JMN0<C_ %Z5K4 %%%% !1110 4444 %%%%
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M4 >:^-!_Q4;_ /7)*Y[%=%XT_P"1B?\ ZY)7/5U0^%&$MQ,48I:*JPA,55@
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M 9FH_P#(4T?_ *^'_P#1+UIUF:C_ ,A31_\ KX?_ -$O6G0 4444 >;>-/\
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MI6I0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5@^,_\
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M"JD'_(3O/]V+^358EFB@3?-(D:9QN=@!^M9T.HV0U&[8WEN RQX/FCG@^]#
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M^J?^ABMZL'QG_P BM=_5/_0Q6E'^)'U,ZO\ #EZ'E-%%%>V>,%%%% !1110
M4444 %%%% !7>_#K_4:A_OI_(UP5=[\.O]1J'^^G\C7/BOX3-\+_ !4=O111
M7D'K!1110 4444 %%%% !1110!A^+S?CPO=_V8+LW68P!9[?.*^8N_86X!V[
MN>W6LWP1]J_T_P"TV_B*'_5[?[9G63/WL[-O3W_"I_'=II[^&KJ[O;"&[\N,
M0XG=E14>6,LSE>=JE$<XYPE87PKDT>2WO7TG3K.VWV]I)/+:.[*9&C):,AR<
M,C;N 3PZYYS0!Z)1110 4444 9FH_P#(4T?_ *^'_P#1+UIUF:C_ ,A31_\
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M0 4444 %%%%,#M? /W+[ZI_6NUKBO /W+[ZI_6NUKEJ?$S:.P4445!04444
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M** "BBB@ HHHH **** "BBB@#+\0?\@I?^OJV_\ 1Z5J5E^(/^04O_7U;?\
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M9*?-^A4PKGU4UZ110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
C!1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>32
<FILENAME>imrx-20211231x10k029.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 imrx-20211231x10k029.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %' M<# 2(  A$! Q$!_\0
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MMO\ 4W4*RJ,],C.#[CI5V@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ J&[NH;&RGO+E]D$$;2R/@G:JC).!R>!4U8_BW_D3-=_[!
M]Q_Z+:@#G_\ A;_@3_H._P#DI/\ _$5V-G>6VH6<5W:3I/;S*&CDC.58>H-?
M/&@:7XMNO!D)L/ ?AZ^LY(7"7TL$37#C+ MDR!MP.<<=A7J_PDDL'^&^F)8/
M*ZQ[UE\U0&$NXEAQQC)X]L9YS0,[>BBB@04444 %%%% !1110 4444 %%%%
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M)'.2./KU/94""BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"LW7=<M/#VE2:A>"5HTX"1(79S@G  ]@3D\#'-:59^N6,FJ:#?V$3*DES \2
MLW0%@1DT 4[[Q/;6.H&U:VN)$C\K[1.@79!YC;4W9.3D]< X')HL/$]KJ&HI
M:I!.B3>;]FN'"^7<>6</MP2>.V0,CD51U/P]J%U?7BV\ML++4/L_V@R%@\?E
MGYMH PVY0!R1CKS3='\,7EC>:?'.]N;#3/M'V<HS&27S#QO!&!M4D<$Y//%
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M **** "BBB@ HHHH **** "BBB@ HHHH @M_]9<_]=?_ &5:GJ"W_P!9<_\
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M_P!_F_QH^R)_STG_ ._S?XT 3T5!]D3_ )Z3_P#?YO\ &C[(G_/2?_O\W^-
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M4T?_ *\H?_0!6K0 4444 %%%% !1110 4444 %%0W%W;VH4SRK'N8*N3R22
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M/T-" 2*19H4E0Y5U# ^QI]9?AZ0MHT43GY[<M WU4X_EBM2A@@HHHH ****
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ML= !1110 5!>_P#'A<?]<F_D:GJ"]_X\+C_KDW\C0!1\,_\ (J:/_P!>4/\
MZ *U:RO#/_(J:/\ ]>4/_H K5H **** "J]Y=I96YGDCF=00-L,32-_WRH)J
MQ10!CZ=XDL=5N##:Q7V0[1LTEG*BJR]0690 :V*P?"W^HU3_ +"ES_Z&:WJ
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MM/BLH&=HX\X+D$\DGL!ZU;HHK%MR=V:QBHI16R"BBBD,**** "BBB@ HHHH
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MH[?=7 ZL<@8&3DXJ&3Q7H\5M%.]TP23>?]2Y*!#M<N,90*2 2V,4 ;507O\
MQX7'_7)OY&J)\1Z4+V6T:["R1!]S,C!,JNY@'QM) .2 <@41:Q9:OIMXUG(S
M>7&0ZO&T;#*Y!VL <$'(/>@ \,_\BIH__7E#_P"@"M6LKPS_ ,BIH_\ UY0_
M^@"M6@ HK'\1:Q)HME'/'$LI>39AB1V)_I7-?\)]=?\ /C#_ -]FJ4&]4)R2
M.]HK@O\ A/;K_GQA_P"^S1_PGUU_SXP_]]FG[.0N9'0>%O\ 4:I_V%+G_P!#
M-;M>6Z#XVN;>&_ LXCOOYWY<]WS6K_PGMU_SXP_]]FCV<@YD=[17!?\ ">W7
M_/C#_P!]FK.G^-+F\U"WMFLXE660(6#'(R:.20<R.THHHJ"@HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH Q_$
MVKZ/H^BROKL@6RN,VY0HS&4LI^0!>22 :YGP.D4NNWT]MI6KQP6\?V;[5J]Z
MTDJ$B.01+&Q)12K*V3Z#\.UOM/L]3M6M;^UANH&ZQS('4_@:RM$\(Z=X=U":
MXTN2[@@F4A[+SRT&[Y?G"MDAL*!P<8XQP, &A<:-IMW?1WMQ8V\MU%C9*Z L
M,'(Y]CR/2EM](TZTOIKVWLH(KJ;/F2H@#-DY//N>3ZFKM% $%O\ ZRY_ZZ_^
MRK4]06_^LN?^NO\ [*M3T %%%% !1110 5GZYH]OK^CSZ9=/*D$^W<T1 8;6
M##&01U [5H44 <)#\*-'MTE2'4]8C29=DBI<( Z^APG(^M6D^'=HB6\9US77
MAMW1XH9+I6C4J?E^4ICBNQHJN=BY48]]X;L]0M[N&66X47*;"RN"R@C!P2#G
M(&.<^V*YNX^$^C7D[SW.IZQ/,_+22SHS-]24R:[RBA2:V"R.8T_P1::=]K:+
M5=6>6Y@%N9I+@&2-0<C8VWC%4S\.+,R-(=?U\NTBRLQO!DNHP&)V]0.AKLZ*
M.9A9'"S_  KTFZ1$N-5UF98RQ19+A&"ECEL93C)Y/J:[JBBDVWN"205D:#^Y
MCO+/_GVN751_LM\P_G6O7-:3J0G\6:G 86BW*,!NK%#C/X@BA;,&=+1112&%
M%%% !1110 4444 %%%% !6-K7A^/6;FTF>XEB-NV<)_%R#^!XZULT4XR<7="
ME%25F8ME_H/B*\LSQ'=*+J+_ 'NCC^1_&MJL;Q IMX[;4T!W64H9\=XSPX_(
MY_"MA2&4,IR",@^M.6J3)CHW$6BBBI+"BBB@ HHHH **** "BBB@ HHHH \F
M\2+/IWBN[M+3PY;- ;?%C'%HJRQRRYA(+2 <;LSH>0% #<DBO6:\WU^*[?QQ
M.NG:Y;Z#*%BEFF>],IG4[$!-L?D7YF5 202>G6O2* .2U#P]=M=ZA<6D4.#=
M6EU!$&"B0Q'+*>.">>?6L^7P]K0:]NX[6%I]3@N8)83<86V\Q@5;./FP/O8[
M],UWM% 'GTO@_4Y;!]$'EK9QS7,\=XTF6<RQNJJ5QD8,AR?11Z\:L.DWEU!K
M-WJD)LVNK:*$16]P=P$08[MZX(R6/'H.>N*ZRH+W_CPN/^N3?R- %'PS_P B
MIH__ %Y0_P#H K5K*\,_\BIH_P#UY0_^@"M6@#E?'G_('M_^NX_]!->?5Z#X
M\_Y ]O\ ]=Q_Z":\_KHI_"93W"DI:2M"2AI/^KO/^OR;_P!"J_5#2?\ 5WG_
M %^3?^A5H4D E:&A_P#(=L/^NZ?SJA5_0_\ D.V'_7=?YT/8$>MT445R&X44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110!!;_P"LN?\ KK_[*M3U!;_ZRY_ZZ_\ LJU/0 4444 %
M%%% !1110 4444 %%%% !1110 4444 %9&K_ +B]TV]'&R?RG/\ LN,?SQ6O
M5#6K8W>CW42_?V%D_P!X<C]136XF7Z*KV-R+RPM[E>DL:O\ F*L4AA1110 4
M444 %%%% !1110 4444 ,FB2>!XI!N1U*L/4&LOP]*XLGL9FS/9.8&)ZE1]T
M_BN*UZQ+S_B7>(+>\Z07@^SS>@<<H?YC\JJ.J:(EHU(VZ*BFN(;=0TTL<:DX
M!=@ 3Z<U(.:DL6BBB@ HHHH **** "BBB@ HHHH X'Q?X/A:;5O$$FJ7$%FU
MG(U];16Z.TL82/>%9L;25@0#T()&,FN^KA-0\(^#[;?::CK-W%YB8:&XUJ1=
MRGCE6?D&N[H **** "H+W_CPN/\ KDW\C4]07O\ QX7'_7)OY&@"CX9_Y%31
M_P#KRA_] %:M97AG_D5-'_Z\H?\ T 5JT <KX\_Y ]O_ -=Q_P"@FO/J]!\>
M?\@>W_Z[C_T$UY]713^$RGN+24M%:$F?I/\ J[S_ *_)O_0JT*S])_U=Y_U^
M3?\ H5:%) PJ_H?_ "';#_KNG\ZSZT-#_P"0[8?]=T_G0]@1ZW1117(;A111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M))5?X#_>%;)U[3P?]:W_ 'P:/9S[![:G_,C2HK-_M[3_ /GJW_?!I/[>T_\
MYZM_WP:/93[![>G_ #(TZ*JVE_;WQ?R'+;,9R"*M5+33LS2,E)704444AA11
M10 4444 %%%% !7%Z%X?U*SO=+M;B!4M-)^T[+D2AC<>8?EP!RN 3G/?&,]:
M[2B@#$AT&V>:Y)NM2'[WM?S#^%?]JI?^$?M?^?O4_P#P8S__ !5:44?EM*<Y
MWON^G ']*DH R?\ A'[7_G[U/_P8S_\ Q5'_  C]K_S]ZG_X,9__ (JM:B@#
M)_X1^U_Y^]3_ /!C/_\ %4?\(_:_\_>I_P#@QG_^*K6HH R?^$?M?^?O4_\
MP8S_ /Q5'_"/VO\ S]ZG_P"#&?\ ^*K6HH R?^$?M?\ G[U/_P &,_\ \51_
MPC]K_P _>I_^#&?_ .*K6) &2<"@$$9'2@#)_P"$?M?^?O4__!C/_P#%4?\
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MG0>&.MS_ ,!_K70USWACK<_\!_K70UY.(_BL]S"?P4%%%%8G2%%%% !1110
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M_O%0A6&2.H;C\JCMO"5Q#XGAU:2*QF"7+2!F)WHIMH(LK\IYW1-QD<-G.>*
M.PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MZG+%))>I!G;=23MO0,&)9U7@Y! 4 #)   !/4T %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
+!1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>33
<FILENAME>imrx-20211231x10k030.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 imrx-20211231x10k030.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" '? \L# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBN5\8^
M([O0#:_94C;S=V[>,]*TI4Y5)*$=S.K5C2@YRV1U5%>6_P#"Q=6_YY6__?)_
MQH_X6+JW_/*W_P"^3_C75_9U;R.+^U,/Y_<>I45Y;_PL75O^>5O_ -\G_&C_
M (6+JW_/*W_[Y/\ C1_9U;R#^U,/Y_<>I45Y;_PL75O^>5O_ -\G_&C_ (6+
MJW_/*W_[Y/\ C1_9U;R#^U,/Y_<>I45Y;_PL75O^>5O_ -\G_&C_ (6+JW_/
M*W_[Y/\ C1_9U;R#^U,/Y_<>I45Y;_PL75O^>5O_ -\G_&C_ (6+JW_/*W_[
MY/\ C1_9U;R#^U,/Y_<>I45Y;_PL75O^>5O_ -\G_&C_ (6+JW_/*W_[Y/\
MC1_9U;R#^U,/Y_<>I45Y;_PL75O^>5O_ -\G_&C_ (6+JW_/*W_[Y/\ C1_9
MU;R#^U,/Y_<>I45Y;_PL75O^>5O_ -\G_&C_ (6+JW_/*W_[Y/\ C1_9U;R#
M^U,/Y_<>I45Y;_PL75O^>5O_ -\G_&C_ (6+JW_/*W_[Y/\ C1_9U;R#^U,/
MY_<>I45Y;_PL75O^>5O_ -\G_&C_ (6+JW_/*W_[Y/\ C1_9U;R#^U,/Y_<>
MI45Y;_PL75O^>5O_ -\G_&C_ (6+JW_/*W_[Y/\ C1_9U;R#^U,/Y_<>I45Y
M;_PL75O^>5O_ -\G_&C_ (6+JW_/*W_[Y/\ C1_9U;R#^U,/Y_<>I45Y;_PL
M75O^>-O_ -\'_&C_ (6+JW_/&W_[Y/\ C1_9];R#^U,/Y_<>I45Y;_PL75O^
M>5O_ -\G_&C_ (6+JW_/*W_[Y/\ C1_9U;R#^U,/Y_<>I45Y;_PL75O^>5O_
M -\G_&C_ (6+JW_/*W_[Y/\ C1_9U;R#^U,/Y_<>I45Y;_PL75O^>5O_ -\G
M_&C_ (6+JW_/&W_[Y/\ C1_9U;R#^U,/Y_<>I45Y;_PL75O^>5O_ -\G_&C_
M (6+JW_/*W_[Y/\ C1_9U;R#^U,/Y_<>I45Y;_PL75O^>5O_ -\G_&C_ (6+
MJW_/*W_[Y/\ C1_9U;R#^U,/Y_<>I45Y;_PL75O^>5O_ -\G_&C_ (6+JW_/
M*W_[Y/\ C1_9U;R#^U,/Y_<>I45Y;_PL75O^>5O_ -\G_&C_ (6+JW_/*W_[
MY/\ C1_9U;R#^U,/Y_<>I45Y;_PL75O^>5O_ -\G_&C_ (6+JW_/*W_[Y/\
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M !H_LZMY!_:F'\_N/4J*\M_X6+JW_/*W_P"^3_C1_P +%U;_ )Y6_P#WR?\
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M0 4444 %%%% !1110 4444 %6=.57U*U5@"IE4$'OS5:I;686]W#.5+"-PQ
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M_.G^'?\ D8;'_KJ*9KW_ "'K[_KLW\ZP_P"7WR_4W_Y<?/\ 0SCT->W>&O\
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M0?\ H&0_K_C1_P (GH/_ $#(?U_QK9HH]M4_F?WA["E_*ON1C?\ ")Z#_P!
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MPB>@_P#0,A_7_&MFBCVU3^9_>'L*7\J^Y&-_PB>@_P#0,A_7_&C_ (1/0?\
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M&0_K_C6S11[:I_,_O#V%+^5?<,ABC@A2*)0L:#"J.PI]%%9FNP4444 %%%%
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MAD:Q.7_M.*".^(!E6!U)*YQRWRGGWH ]0HKRR;5-=M;^\\+IK,[.=0@AAOG
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M7:"%SM51V R?SK=HH *J3?\ (3MO]Q_Z5;JI-_R$[;_<?^E %NBBB@ HHHH
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M_<?^E6ZJ3?\ (3MO]Q_Z4 6Z*** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBJ6HZQIFD(CZGJ-I9(YPC7
M,ZQAC[;B,T 7:*H:=KFDZOO_ +,U2RO?+QO^S7"2;?KM)Q5^@ HHHH *H:O_
M ,>D?_7>+_T,5?JAJ_\ QZ1_]=XO_0Q30,OT444@"BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M%-"9JT444AA1110 445C2>*-(BE>-[G#*2I&T]132;V$VD;-%8G_  EFC?\
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M[BO/ICI[T<K"Z.DHJEI5\=1T^.Y,8C+_ ,&[./KP*NTAA1110 4444 %%%%
M!1110 4444 %%%% !7D_Q/\ #.F3^(-)OUCU:ZU2X=UCLK.Y,8FPO)W$XCP.
MI YKUBO*/BCXE\-PZMIVG7FLWFE:O;.TL-Y!$W[@%>K?*=RGI@4 :/PULK+3
M[[4K>32=1T[5PL9GCO;TW68^=I5_3K7HU>8_"V_T_4-2U::#6[K7KLI'YVHR
MQE$QSB-5(!&.OXUZ=0 4444 %4-7_P"/2/\ Z[Q?^ABK]4-7_P"/2/\ Z[Q?
M^ABF@9?HHHI %%%% !7CVH_\A*Z_Z[/_ #->PUX]J/\ R$KK_KL_\S6U'=F5
M0K4445N9!1110 4444 %%%% !1110 4=Z*.] 'L.G_\ (.MO^N2_RJS5;3_^
M0=;?]<E_E5FN-[G4@HHHI %%%% !1110 4444 %%%% !1110 5%-<P6Y032J
MF]@JY/4GH*EKE?$WAR^UB^@FMITA1< E2P8\]SG!7V S[TU:^HF=+/<PVT)F
MFE5(QU8GBG":-HA('4H1D-GBN;USP_>W_A^WLH)(DEB^\T6Y2?\ =))Q^.:$
M\.WH\,?V;]HB$^[=YHW[OKG=][WZ>U%D%V=#;W,-W LUO(LD;#*LIR#4U<]X
M2T6[T73VBNY%=WP>22PQG@G.#^ %=#0]QH****0!1110 4444 %%%% !1110
M 4444 %%%% !7EOQ0OKBSUBQ&F:K+_:31#;I7]G_ &J.9=QPQX.SGC->I5Y!
M\6/$E_H/B/3S%JATJW$4;^8D.6NCYN'C+]@JX;'?- 'H/A"[UF]T"&77-*BT
MR[Z>1&P(QV.!TSZ5O5QGPVU[4?$&@3W5])]HC6ZD2VNA'Y?GQ@G#;3T]*[.@
M#FSXYT(:N=--Q*)!-]G\TPMY7F_W-^,9[43>.M"M]8;39+B42),('E\EO*20
MC(4OC -<9XHUG3]1U2UL+ W$>KV6I(?[%:(;+C$BDS$+V RP;/&.1574-0@&
MAZOX29'_ .$@NM1=HK?;EG#2;Q(#_="X&?:@#U'6-9L]"T]KV]9Q$&"@1H79
MF)P %')-9B^.-";1I=3^T2"**86[QF%O-$IQA-F,YY%4?$VL6,?V+43=*]II
M5^OVXID^5P5R1[$BN0-Y!+J%UXJC1VT-=7@D,X7AE52#*/51D<^U '>+XZT%
MM'GU(W,B102B&6)X6$JR'HNS&<G(Q5_0_$.G^(()9+%Y-T+[)8Y8RCQMZ%37
MF5Q>PW>K7WBR!))="74[:1IU3B15B*&0#N%8@9]JZ[P?=PZSXFU_6]/)?3+A
M8(H9@,+*R;]S#U'S#F@#M*J3?\A.V_W'_I5NLP)=+J\!GGBD0H^T)$5(Z=\F
MF@-.BBBD 4444 %%%% !1110 4444 %%%% !1110 4444 8?B[_D7I_J/YUY
MC7IWB[_D7I_J/YUYC731^$QJ;A1116AF%%%% !1110!WG@+_ (\;K_KH/Y5U
MU<CX"_X\;K_KH/Y5UU<M3XF=$/A"BBBH*"BBB@ HHHH *@^R6_VG[1Y*>=C;
MOQSBIZ* (9;2WGDCDEA1WC.4)'(-+-;0W";)HE=>.&%96H1SIK-B$O;E(YF8
M-&K#;P,^E;5 "*H484 #VI:** "BBB@ HHHH **** "BBB@ HHHH **** "O
M.?%/AP7>OKJ-IXNM;2\@.8[:^2*9(R1@X#<KD5Z-7DOBWP_X"E^(276KW>EK
M.;=FO;.Y+;G &5=2",' _$4 =EX/N-4=;B'4I=$G,>-LVF29W_[RX&*ZBN)^
M'P\"217<_@N.V0$A;CRMP/'3(:NVH *YG0_&5IX@\0ZAIEE!*8;-%/VEAA92
M693M]0"I&:VM6LYM0TFZLX+I[66:,HLZ#+)GN*XKPOX/UW0?%K33:HD^G)9)
M"NVW";\$\?>.,=<]\T >@U0U;_CTC_Z[Q?\ H8J_65K%M$T<<I#;_/B_C./O
MCMG%-;B9JT444AA1110 5X]J/_(2NO\ KL_\S7L->/:C_P A*Z_Z[/\ S-;4
M=V95"M1116YD%%%% !1110 4444 %%%% !1WHH[T >PZ?_R#K;_KDO\ *K-5
MM/\ ^0=;?]<E_E5FN-[G4@HHHI %%%% !1110 4444 %%0W0N# PM6C67L9
M2OZ5G>7K_P#SWT__ +]O_C3 UZ*R/+U__GOI_P#W[?\ QH\O7_\ GOI__?M_
M\:+"N:]%9'EZ_P#\]]/_ ._;_P"-'EZ__P ]]/\ ^_;_ .-%@N:]%9'EZ_\
M\]]/_P"_;_XT>7K_ /SWT_\ []O_ (T6"YKT5D>7K_\ SWT__OV_^-'EZ_\
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M( HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M.P.2!745Y)X37Q!HOB:ZEMOAS+IEA>F-#'!>PB.$#JY4=3SVQ7K8Z4 %%%%
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M_P"LU#Z+7H=?/8[^/+^NA]1EW^[1^?YA1117(=P4444 %%%% !1110 4444
M%%%% !BBBB@".>9+:WDGDSLC4NV!DX STKG=,\90WVIP6%SI>H:?)=(SVS74
M043!<9QSP>1P?6N@NYS;6DTXBDF,:%A'&,L^!T ]37$>&);K5=>&J:Y9:BE_
MM9;:)[*2.&TC.,KN(P6.!D^U '>U0U?_ (](_P#KO%_Z&*OUE:Q 3'')Y\P'
MGQ?(&&W[X]J:$S5HHHI#"BBB@ KQ[4?^0E=?]=G_ )FO8:\>U'_D)77_ %V?
M^9K:CNS*H5J***W,@HHHH **** "BBB@ HHHH *.]%'>@#V'3_\ D'6W_7)?
MY59JMI__ "#K;_KDO\JLUQO<ZD%%%%( HHHH **** "BBB@#B?B5_P @FU_Z
M[_T->9UZ9\2O^03:_P#7?^AKS.OH,O\ X"/F<S_WA_(****[#SPHHHH ****
M "BBB@ HHHH *ZKX?_\ (RK_ -<VKE:ZKX?_ /(RK_US:L,5_!EZ'1@_]XAZ
MGK%%%%?-'UP4444 %%%% !1110 4444 %>7Z[JVL7/Q%63P;J&A7ES%8FWN;
M.ZO#G(<MG8IZC/4>IS7ILN?)?;UVG&*^=]-L[_1VT2>'P=JXU2SU-[B^NXXE
MS<1$G*@[N<C'!H ]S\.2^()=.+>([>P@O-YPMD[,FWM][G-;%96@ZR^N6!NG
MTV\L"&*^5=J%?Z\$\5JT %%%% !C'2BBB@ HHHH *J3?\A.V_P!Q_P"E6ZJ3
M?\A.V_W'_I0!;HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ,/Q=_
MR+T_U'\Z\QKT[Q=_R+T_U'\Z\QKIH_"8U-PHHHK0S"BBB@ HHHH [SP%_P >
M-U_UT'\JZZN1\!?\>-U_UT'\JZZN6I\3.B'PA1114%!1110!RGQ _P"1=_[:
M"O**]7^('_(N_P#;05Y17O9=_!^9\WFO\?Y!1117<>:%%%% !1110!W_ ,,_
M]9J'T6O0Z\\^&?\ K-0^BUZ'7SV._CR_KH?49=_NT?G^84445R'<%%%% !11
M10 4444 %%%% !1110 4444 %%%% !5#5_\ CTC_ .N\7_H8J_5#5_\ CTC_
M .N\7_H8IH&7Z***0!1110 5X]J/_(2NO^NS_P S7L->/:C_ ,A*Z_Z[/_,U
MM1W9E4*U%%%;F04444 %%%% !1110 4444 %'>BCO0![#I__ "#K;_KDO\JL
MU6T__D'6W_7)?Y59KC>YU(****0!1110 4444 %%%% '$_$K_D$VO_7?^AKS
M.O3/B5_R";7_ *[_ -#7F=?09?\ P$?,YG_O#^04445V'GA1110 4444 %%%
M% !1110 5U7P_P#^1E7_ *YM7*UU7P__ .1E7_KFU88K^#+T.C!_[Q#U/6**
M**^:/K@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ JI-_R
M$[;_ ''_ *5;JI-_R$[;_<?^E %NBBB@ HHHH ***KWMY%86CW,^_P M.NU"
MQ_(<T 6**R=(\0V>LPO);[_W>2WRDCKV.,'Z5%I?BBPU:^EM(-^]#Q\IY ZY
MX^7Z&G9BNC;HK"7Q78/K?]EC?YOW?N-G=G&,8Z>_2MVAJP[A1112 **** "B
MBB@##\7?\B]/]1_.O,:].\7?\B]/]1_.O,:Z:/PF-3<****T,PHHHH ****
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MVL0]G(X6BNZ_X0&W_P"?Y_\ OW_]>C_A ;?_ )_G_P"_?_UZ/:Q#V<CI]/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@!AAC)),:$DY/RCDT/#%(P9XT8@8!90:?10 UD5T*,H*GC!'%.  & , 444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 5!+96LTZ3RVT+RI]V1HP67Z'J*GHH 9)#%+M\R-'VG(W*
M#@^M+L3>7VKN(P3CG%.HH B>V@D5%>&-E3[H* A?IZ4YX8Y(O*>-6CZ;2 1^
M5/HH ;L7(.T948!QTIU%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M']@Z9_SYI^9_QK1HH SO[!TS_GS3\S_C1_8.F?\ /FGYG_&M&B@#._L'3/\
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M95O:7)"GJ//P>.]?0U<CK7P]TW7=3U2^NKB?=J&G_870;=J -N#KD?>!]>*
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M^*H10LNX@<GG@BNK\=?$+7O#]].ECJ^EV\=O;H\5FMNUQ+*>^]AQ&/K73O\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MCUI<YH I?VB?^?*[_P"^!_C1_:)_Y\KO_O@?XU=SBDR/44 4_P"T3_SY7?\
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M/\:/[1/_ #Y7?_? _P :NT4 4O[1/_/E=_\ ? _QH_M$_P#/E=_]\#_&KM%
M%+^T3_SY7?\ WP/\:/[1/_/E=_\ ? _QJ[10!2_M$_\ /E=_]\#_ !H_M$_\
M^5W_ -\#_&KM% %+^T3_ ,^5W_WP/\:/[1/_ #Y7?_? _P :NT4 4)-4$<;.
M]G=!5&2=@_QJZC!T5@" 1GFJ^H_\@VX_ZYFIX?\ 41_[H_E0 ^BBB@ HHHH
M**** *4FI(EQ)"MO<2,F,E%!'\Z/[1/_ #Y7?_? _P :2V_Y"5Y_P'^57J *
M7]HG_GRN_P#O@?XTC:F$4L;.[P!D_(/\:MQRQR@F-U8 X.#T--NO^/2;_</\
MJ *L>JB6-9$L[LJPR#L'^-._M$_\^5W_ -\#_&GZ;_R#;;_KFO\ *K5 %+^T
M3_SY7?\ WP/\:/[1/_/E=_\ ? _QJ[10!2_M$_\ /E=_]\#_ !H_M$_\^5W_
M -\#_&KM% %+^T3_ ,^5W_WP/\:/[1/_ #Y7?_? _P :NT4 4O[1/_/E=_\
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M(Z4^YM(+Q%2>,.JL' /8CI0!YQXDU7Q'!J4?VZ.WT]6M7 DM;EI-H+ %CE0
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MGKFNV;2[-K&>S,(-O/N\Q/[V[K6=<^#]%NGC=K5D*HL9$4K('4# # 'YA]:
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M\,W7AGP_';:A?27E\P'FNS$JF!@(@[*/ZT ;6K_\@V3ZK_,5=3[B_2J6K_\
M(-D^J_S%74^XOTH 6BBB@ HHHH **** "BBB@ HHHH *Y7Q19:E=ZWHQTZ3R
M71I"TS1;U4;>_85U5% 'G6M>'[C35LYVU*[2ZN+\3W5[;6HD*$(5&$V, ,>H
MJ:\L!K%MIMJ][>ZLBW1,D]Q:")H\H<'"HH&#WQ7?T4 >>Z!;ZK_PF.K_ -HV
MMR6ATZ.W%T\9VW!#,0RG&"<$9]Z?:6LMGX2\/2W-A.\=K-OGA$)+H-S88KC/
M&0:[^B@#@_$$MKX@F\VUL+J_M(;:070AB9#*I&!&I(&3GG'M67MO2;BUM+R\
MU>T:PE&Z[M,36K8X0,%&<^AR>*]/  Z"@ #.!UH XCP;O@6RBF\0:G<L( IL
M[BP6)$..FX1*>/=J)M*UJY\9ZG+8W0LX'AC4O);[P_7H2,<5W%% 'GUMX5NX
M?%DD-KJ.H64,5B@-Q#&N)6+$G)92.IZ"J^B6MQH6IPWNIK=2VJ2W$?GR0DE'
M)!$C #@$<9 KTF@@$8- 'FU_;Q:EJ^HZDMKJ,.G/Y*K=VL15]X)_>!2,D+ZX
MJC/'K%X+NUMYY-2B$ENT&J/9;9,[QE6PH# #GI7J^!C%(  , 8% 'GWB?PWJ
M<F@WMQ<WDE[>N$BB%O !L7>"2 !R?KFC5]/U/1-8L]0^VZKJ_EQRX0PJVUBO
M&-BCG/K7H5% ' >'-/\ $&C:U;/J45J]O>Q[9FM4<D2=07SP.O6G7-E<CP+J
M40CN()6NW8%(2SJ-X.X+@Y]>AKO:* .8\.2'[7(K>(=1U(E>$NK%80ON"L2?
MSK*&@:MJ6H:]%]M-II\]T=R&W!9UVC)4L*[RB@#S/^S=?ANFU:UMX39VLR"&
M.1)/M/DIP0/8]<8YKK+")G\0:E<B!UBE@B*,T9&>#QSWKH** /,G\.ZH?"T\
M@U'5!FX9A8B)=I&[TV[L?C4HTB[U'6&TN:QE73[1&N%+QG8[LOR[3TRIKTBB
M@#S"!-;U>T7;IK17EW*L<BWL+A%BC&#N]F/YU8.DZB?#EQI]W'(FI64X,%S:
M(W^K8]$)SQ@D8[5Z/10!4TVQ@TW3X;6VC\N)%&!_,GWJW110 4444 %%%% !
M1110 4444 %%%% %74O^0;<?]<S4\/\ J(_]T?RJ#4?^0=<?]<S4\/\ J(_]
MT?RH ?1110 4444 %%%% %&V_P"0E>?\!_E5UONFJ5K_ ,A*\_X#_*EU73H]
M6TV:RE>1%D'#QN592.001Z&@#%\$_P#'CJ'_ &$)_P#T(UT5U_QZ3?[A_E7'
M> /!^J>'$O)=9U-[ZZEF<QG<=JH3G./4]378W7_'I-_N'^5 $6F_\@VV_P"N
M:_RJU573?^0;;?\ 7-?Y5:H **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ IDHS$X']TT^B@#S/P\SZ-K>EW%_;74,7]C20EOLTC /\ :-VTX4X.
M.>:U/&<&O:WH-S!911_8I'@D62+=YY02(S?(1S\H/!'/2NXHH XSPM%-%KVH
M?9OM<NF-!&5GNX=CF7/*J2 2H&.O0Y XK/TWP_J]UI-U%=WSP:<US,[VRVH\
MQDWDX!([^HYYXKT.B@#SK3;77K74K;7KFSMS;W=TS2I''(;E(I<*H<'@!0$)
M&.,'WJ_;65PLOC(_990)F'E?NR/,_<X^7CGGCBNVHH \U7P[J<&E^%Y'U'4[
MI4NK5I+22)=L0[YPH8 >Y^M0KX=U'4?[2@FM)%.CQ%--9T(5W+^8I7UV[8QD
M>XKU"B@#S""TUO6IH5@TZ.-G+7MR=2AD",[#RT48Q\P"YQVR*M7VFWUWH6BE
MX;B/4(KN+3KQX(V^> N%DSD9*;><]NN:]%HH C@@BMK>.""-8XHU"HBC 4#H
M!4E%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %':BB@"GIO_
M ![-_P!=&_G5RJ>F_P#'LW_71OYU<H **** "BBB@ K/728DW;+BY0%BV%DP
M.?PK0HH H_V8O_/W=?\ ?S_ZU']F+_S]W7_?RKU% &=+H\<T91[FZ*GMYG_U
MJ?\ V8H'_'W=?]_/_K5>HH H_P!F+_S]W7_?S_ZU']F+_P _=U_W\_\ K5>H
MH H_V8O_ #]W7_?S_P"M1_9B_P#/W=?]_/\ ZU7J* */]F+_ ,_=U_W\_P#K
M4?V8O_/W=?\ ?S_ZU7J* */]F+_S]W7_ '\_^M1_9B_\_=U_W\_^M5ZB@"C_
M &8O_/W=?]_/_K4?V8O_ #]W7_?S_P"M5ZB@"C_9B_\ /W=?]_/_ *U']F+_
M ,_=U_W\_P#K5>HH H_V8O\ S]W7_?S_ .M1_9B_\_=U_P!_/_K5>HH H_V8
MO_/W=?\ ?S_ZU']F+_S]W7_?S_ZU7J* */\ 9B_\_=U_W\_^M1_9B_\ /W=?
M]_/_ *U7J* */]F+_P _=U_W\_\ K4?V8O\ S]W7_?S_ .M5ZB@"C_9B_P#/
MW=?]_/\ ZU']F+_S]W7_ '\_^M5ZB@"C_9B_\_=U_P!_/_K4?V8O_/W=?]_/
M_K5>HH H_P!F+_S]W7_?S_ZU']F+_P _=U_W\_\ K5>HH H_V8O_ #]W7_?S
M_P"M1_9B_P#/W=?]_/\ ZU7J* */]F+_ ,_=U_W\_P#K4?V8O_/W=?\ ?S_Z
MU7J* */]F+_S]W7_ '\_^M1_9B_\_=U_W\_^M5ZB@"C_ &8O_/W=?]_/_K4?
MV8O_ #]W7_?S_P"M4.M:TFC1P%HU=II/+7?*L:@^['@5 ?%&GV\,+7TJPR2_
M=6+,R]<#YD! _&@"[_9B_P#/W=?]_/\ ZU']F+_S]W7_ '\_^M5&W\6:5/="
MU:9DN"Y0)Y;,/Q8# _$BKEEKFG:A<R6]M<;Y8^JE&7/T) S^&: '?V8O_/W=
M?]_/_K4?V8O_ #]W7_?S_P"M6='XD8NSR:?*MHLY@\\2*V"#C)7J!4MKXJTB
MZF6!;I?.8$X"L5'U;&!T[F@"Y_9B_P#/W=?]_/\ ZU']F+_S]W7_ '\_^M5/
M_A+=#^S2W'VX>7$^QOW3Y)]AC+?49%68]>TN6V-PEXAB! W8(Y/3M0 _^S%_
MY^[K_OY_]:C^S%_Y^[K_ +^?_6JJWBG1EMY)VO,1QN(VS$^<G@8&,D>XXJQ:
M:WIU\\*6URLC3(9$ 4C*@X)Y'K0 [^S%_P"?NZ_[^?\ UJ/[,7_G[NO^_G_U
MJR(_%\;R,3:@0"<P%O/4ON!QG9UQ4EWXUT.UW@W,CNK!2JP2<Y.,CY<$9[B@
M#3_LQ?\ G[NO^_G_ -:C^S%_Y^[K_OY_]:FVVMZ==WC6D-P&F SM*, ?H2,$
M^P-.?5[);]+$2E[A_P"%$+ ?4@8'XF@ _LQ?^?NZ_P"_G_UJ/[,7_G[NO^_G
M_P!:JMUKZVU^]O\ 99'BB9$FF# !"W(XZFB]UY;.\>$6SR1PA3/*& $8;H<=
MZ +#Z2DB,C75T588(\S_ .M5]%"(JC. ,#-86A^)H]<N)4A@$:(6 +2C<<'&
M=OI6]0 4444 %%%% !1110!2DTV.2X>83SHSXR$? I/[,7_G[NO^_G_UJO44
M 4?[,7_G[NO^_E(VE(RE3=71!&#^\_\ K5?HH STTF..-46ZN@JC 'F?_6IW
M]F+_ ,_=U_W\_P#K5>HH H_V8O\ S]W7_?S_ .M1_9B_\_=U_P!_/_K5>HH
MH_V8O_/W=?\ ?S_ZU']F+_S]W7_?S_ZU7J* */\ 9B_\_=U_W\_^M1_9B_\
M/W=?]_/_ *U7J* */]F+_P _=U_W\_\ K4?V8O\ S]W7_?S_ .M5ZB@"C_9B
M_P#/W=?]_/\ ZU']F+_S]W7_ '\_^M5ZB@"C_9B_\_=U_P!_/_K4?V8O_/W=
M?]_/_K5>HH H_P!F+_S]W7_?S_ZU']F+_P _=U_W\_\ K5>HH H_V8O_ #]W
M7_?S_P"M1_9B_P#/W=?]_/\ ZU7J* */]F+_ ,_=U_W\_P#K4?V8O_/W=?\
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M^'+BUU:.]NKR&40(\<*Q6XC.UB/O')R>!70T44 %%%% !1110 4444 %%%%
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<T+VL;K(P^S 2%AZ/G@5U%% !1110 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>34
<FILENAME>imrx-20211231x10k031.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 imrx-20211231x10k031.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" *C I$# 2(  A$! Q$!_\0
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MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBD)Q0
M&F/(B*2S  =S56YO5B4UA7-W)<MEF(7L*N%-R,YU%$V9M8MXSA,N?:JYUWT@
M/_?58_6BM_911SNM)FQ_;I_Y]_\ QZC^W#_S[_\ C]8]+1[.(O:R-?\ MT_\
M^_\ X]2?VZ?^??\ \>K(HH]G$?M9=S8_MUO^??\ \>H_MT_\^_\ X]6/2T>S
MB+VLC7_MP_\ /O\ ^/T?VZ?^>'_CU8]%'LHC]K(V/[=/_/#_ ,>I/[=;_GW'
M_?=9%%'LHA[67<U_[=;_ )]Q_P!]T?VZW_/N/^^ZR**/91#VLNYL?VZ?^>'_
M (]1_;I_Y]__ !ZL?\:*/9Q#VLNYK_VZ?^> _P"^J/[=/_/O_P"/5D44>SB'
MM9=S8_MUO^??_P >I/[=;_GW_P#'JR**/9Q#VLNYL?VZ?^??_P >H_MT_P#/
MO_X]6/BEH]G$7M9&O_;I_P"??_QZC^W3_P ^_P#X]6.:*/91'[61L?VZW_/O
M_P"/4?VZW_/#_P >K'HH]E$7M9&Q_;I_Y]__ !ZC^W3_ ,\/_'ZQZ*/9Q#VL
MC8_MQO\ GW_\?H_MT_\ /O\ ^/5CT4>RB/VLNYK_ -NG_GW_ /'J/[<;_GW_
M /'JR**/9Q#VLNYL?VXW_/O_ ./T?VZ?^?<_]]5CT4>RB'M9&Q_;IS_Q[G_O
MJC^W3_S[_P#CU8]%'LHA[61L?VZ?^??_ ,>H_MT_\^__ (]6/11[*(O:R-C^
MW3_S[_\ CU']NG_GW_\ 'JQZ*/9Q#VLC8_MP_P#/O_X]1_;I_P"??_QZLBDH
M]G$?M9&Q_;I_Y]__ !ZD_MT_\^__ (]6111[.(>UEW-C^W3_ ,^__CU']N-_
MS[_^/5CYHH]E$/:R[FQ_;C?\^_\ X_2?VZ?^??\ \>K)I*/9Q#VLNYL?VZ?^
M??\ \>I/[</_ #[C_OJLBBCV40]K+N:_]NG_ )]__'J/[=/_ #[_ /CU9%%'
MLHA[61K_ -N'_GW_ /'J7^W3_P ^_P#X]6/11[.(O:R-C^W3_P ^_P#X]1_;
MI_Y]_P#QZL>EH]G$/:R-?^W3_P ^_P#X]1_;I_Y]_P#QZLC-)FCV<1^UD;']
MNG_GW_\ 'J/[=/\ S[_^/5C]:*/9Q#VLC8_MT_\ /O\ ^/5;L+_[8[CR]NT>
MN:YRM;0Q^]E_W143II(JG4DY69MCI2T45@=04444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !FJ5Y<"-#S5ISA:YW5;@CB@"O-.TSY)XJ*D'"TM=D5
M9'!*5V'>BBBJ)%I*6DH **** "B@<TN#Z&@!**,44!<**** "BBB@ I3244
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MTOT%15^$TI?$;@I:04M<9VA1113 **** "BBB@ HHHH **** "BBB@ HHHH
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MK\)I2^(VQ2T@I:Y#M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M@N?]77(:G_K/QKK[G_5FN0U+_6?C0@>Q)VHH[45VK8\][A2YI**8A:2BB@ H
MHHH ***7M0 E%%% !1110 8HI:2@ I<TE% !1110!QOQ' _L2WP!GSAVJKX\
M4-X4T]0 ,E!T]A6OXUTJ^U?2H8;&'S9%E#%2<<5#XKT:_P!3T*RMK.#S)8BI
M==P&,5#1HF6KJU@TWP=(]K;HDB6O#HO.2.>:J?#^S@B\-1W*HIGG8M(Y&2?:
MNC^R+-I8LY_NO"(W'X5Q5C8^*O"CRVNGV<-_8LQ,>Y\;: 3$U"*+3/B7:&T4
M(+B+,BKP,FD\'64,WBW6)Y8U9HV^3<,XK0T/P]J4NMOKFNE5N<$1PJ<A0:F\
M+Z-?Z;K6K7%W!LCN'S&V[.?>E8&]#&U#3K:3XG6L9A388_,*XX)]:M?$&&-)
M=(E1%603XR!CBK]UHVH2>/K?5$@S9K%M:3<.#]*=XRT>^U7^SQ90^;Y4NY^0
M,"G8+G2Q_P"H3_='\JX?Q8OVSQEH]E.,V^0V#T/M7<Q#;$BG@A0#7.>+/#\^
MKQP7=@^R_MFW1YZ-]:;1*>I+XOT^VG\+7BO$@\B,M'_LXKD=0Y^%ECW_ 'B?
MSJ]J2^,]?TM["73H;90OS,K\RD=JGO?#NJS> ;33([;-Y'(I:/>!@#WJ=RUL
M2^(-"O-6T/2Y[ JT]JH98F_CK)O/$C211V?BK0&$*D 21 @ CWK=U[0-4NM,
MT^73IVCO;11F+?A7^O:LW4%\8^(K)=,NM*M[>(D"28OG%%@3T*GC>XCFAT2"
MQ0RVC_,D9)P_H*NW6I:Y=:8U@?"R"%DVCYNGN*T-6\'M=>'K&TM)@MW9#,3G
MN>]49KKQU<67]F_V9#&Y&PW(DY ]:+,+H70;4V/@R[MM?C>&U4DGYN2/05!I
MOB"06(L]!\./+;XPK3# ;\:TI/"5R_@U]+:Z>6\8[][L3\WI]*IZ=/XTM=.3
M2H])MT\L;!<%^@]<4 K%'P5;R7-[KEM,@MWDR&1#D(?2FV4OB#P=#)9RZ3'>
M6)8G>G)(_#K^-7_#OA?5K&[U*&_&([I#BZ1\?-].M,L!XS\/1O816$=_$6/E
MRR2<T6"Y)I.IZ.^@ZK/I%K):76TF:-SSGU%9'A*_U33],+V6A"[,CDM<$\M7
M1>&_"]U;F_N]65%N+W(:*,\(#5*RL?%/A.2:WTVUCOK!V+)N?&TT68[JY7TN
MVUB3QM'J3Z2;**0;90IXKT4]:X_0='URXUMM8UJ0P'_EG;H^5_'M7852,Y,*
M***9(4444P"BBB@ HHHH ,TN:2B@ HHHH ***6D F****8!1110 5K:&/WLO
MT%96:UM$_P!;+]!45/A-*7Q&V****Y#M"BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH @N?\ 5FN0U+_6GZUU]S_JZY#4_P#6_C0@>Q)VHH["BNY;
M'GO<***.U @HH-'>@ HHHH **** "BBB@ HHHH *7ZTE% !1110 44HI* "B
MBB@ I<TE% "TE,FF2WA>:5@L:*68GL*QM&UV?5;&ZOFMQ';(2(3WD [T#2T-
MRBL3PWX@/B"TFG,/D^7(8\9ZX[UMTK@PHH[]*/\ )]J8D%%)WI?PH ***S-9
MURUT1(C<!RTS[$51UI7&NQIT9I%.Y W0$ C-+WIB"BN:UKQA;:9J=OI\ 6>>
M1MKX/"5T$SRBV=X5!E"Y4'H3BE=#LT2T5C^']=&M6\N]!%=PN4EA':MBFM0L
M%+244A!2TE%,!:2BB@ HHHH **** "BBB@ HHHH **** "BEI* "BBB@ HHH
MH *UM#_UDOT%9-:VA_ZV7Z"HJ_":4OB-RBBBN0[0HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** (+G_5UR&I_ZS/O77W/^K-<AJ?^L_&A"9)V'THH
M[#Z45W+8X'N%%% H$'6EQ0**0"4444P"BBB@ [4444 %'>BB@!<4GM2TE !1
M0*6@!**** "BBB@ HHS2]J .1^(-Z\&C0VD3;7NY F?;O6S;VB6/AM;>,85+
M?^E<W\0UVW.BRM_JUGY]JZZY8'2I2.AAX^F*A[EK9'&^!)6A\-ZI-&<.DKL#
M[U7T?5O%OB2"1;*YBMUB8JT[#ECZ5+X)X\*:OG_GI)6C\.1CP]+@<_:&-)#?
M<9X9U_5'UFYT76=CW,0)64=ZS+37/$VLZQ>:;8SQQK&YS,PSY8JU:_\ )4+C
M'_/%OY4WP1<P#Q#K%NS!9GDRH/4_2BX^Y/8ZUK6B^((=+UZ9;F.X.(KA5QDU
M<GUF]3Q['I2R_P"B-%N*X[UF^,Y4O/$^BV4!W3QR[GV]5'O27SK;?%"T,KA0
MT 4$\ FBXK:&UXTU6[T;1TN+*39*9E4DC/!KE?&RZG,VESM<IY4FWRUV\JWJ
M:UOB5=Q+I5O;;U,CS*P7/. :J^,B!IVA$\ ,N2?PH;".AV.C1:A!IJ+J,Z3W
M/4.HP,5+J5M->:;/;6\YAED3:LG]VIXF#0QD$'Y1SGVI^:M;$=3RW6_#5MX>
MO-(\N1YKB67]Y,QY8YKU%#\J_05Q/CW_ )"6B_\ 77^M=LOW%^@J5N4WH<-(
M_P#8OQ)14.(;Y<%>V[UKNCUKA/$P$OCS1HT'SALGVKNSUIH)(****H@****
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M8ZV@:XF"@?+GYC7311B.)47@#I56RM1$@XJ]@5S3E=G73ARH!2T45!H%%%%
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MNM^S)Z"@6Z#M1=ARHP+?2L$$BM>VLUC'2K:HJC@4ZE<-A  !@4ZBB@84444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %07G_'G-_N'^53U!>?\ 'G-_N'^5-;BEL4?#O_(%
MA_'^=:E9?AW_ ) L/X_SK4IS^)DP^%"T445)84444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 =J@N_\ CSF_W#_*I^U07?\ QYS?[A_E36XI;%'P]_R!H?Q_G6I67X>_
MY T/X_SK4IS^)DP^%"T445)84444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5!>?\
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M_P :V-+T>QT:V\C3[=8(B<E5S6A10Y-[@HQ6R!:6BBD4%%%% !1110 4444
M%17/_'M+_NFI:0@'@CB@#PWP-XUT?PO=:Q%J4KJTMRQ78I/>MCQ#\2H]>TZ7
M2O#5E<W%Q<CRS)L.%!Z\5Z@=+T]B2;&V)/4F%?\ "GPV5K;G=#;0QGU2,+_*
MG="L>;7/@.YMOA5)I,0#7QQ.X'.6'.![XXK+\/>(_!%OH$4.M6,4.HP+MFC>
M#+$BO9,5G7&AZ7=3B>;3K:27.=QC&?QHN%CB_!-W>:C%JFI6>B6UC;[2MF0F
MUI#VS[5DVGB[PSK5O<VWC2RMH-0B<JZ^4>1ZYKUA$6-0B*JJ. %& !5&[T+2
MKZ42W6GV\LG]YHQD_6BX'F'PWMXF\8ZI/H:RKH6PA-P(4GMC/O3O NL6FB^,
M=;TJ_9H;NYFQ$A4G=R:]8M[6"TB$5O#'%&/X44 4PV%FUR+@VL!G'23RQN_.
MBX6/.OAI_P C-XG'?SA_,U5\87B^&_BAIVN7B.+%H/*:0*3M/?\ &O4X[:"%
MF:*&-&?[Q5 "?K3;BUM[N/R[F".9/21 PHN%CQ;XC^-;'Q)I]O;:0));6.96
MFG*$*#G@5M>/].O([#P_XALXGE^P!#*JC)Q@8->E1:7I\,!ACLK=8B<E!&,$
MU:*(8]A12N,;2.,47"QYKK'Q7TR30\:)*\VJS +'%Y9RK>OO53Q['JLOPPL+
MC507O5FCDN !C;S7I,.CZ;!,9HK"V27^\L0%6I8HYXS'-&CH>JL 0:+@>2>.
M->L->^&=C<V$I>-+N&-LJ00PZBNYU?2%UWP(]@0-TEJ-A]&QP16XFG620>0M
MG (<[MGEC;GUQ5D* NT !<8Q0%CPKP,+OQ3XHTNVO4(MM"C("G^\.@/UK>^)
MNF26/B32_$CVAN;&$A;E N< =,CTYKU.*UMX&9H8(HV;[S*@!;ZTZ2-)4*2(
MKH>"K#(/X47"QY+J_BOP.FF$Z)IEM>:C*,0P^01\Q]:]#\*0W$'AZU%U:PVL
M[KO>&%<*F>V*LV^A:3:SF:#3K:.4\[EC&:T1UZ47!(6BBBD,**** "BBB@ H
MHHH *0CFEI#0 A%>;^/?!GG"35]-C_>KS-&O?_:'O7I)%-*D]<$=ZJ$G!W1$
MX*:LSS?P-XW\Y4TK59,2#Y8I6/WO]DUZ0#TKS;QIX#\QI-4TA<29W20KW/J*
MK>$OB"]J5T[6R^U3M69A\R^S5M*"FN:)A"HX/EF>J Y-+44$T5Q$)89%DC8<
M,IR*DR,XKG.E"T4F:.M P/2L6YU98WN+2Y&Q]IV-V88K:/2L'Q'8^?;"X49>
M/K]*NG9O4SJW4="OINJQVNF06Z O.Q("^G/>ND3=Y:[L;L<XKEO#=CYDING'
M"\+]:ZL=*=5)2T)HW<;L!2TG2C-9FP4F<&ER*S=7UJQT6V-Q?3B->R_Q-]!3
M2;V$VEJR\\BHA=R%0<DDXP*\V\8?$ ?O--T=BS'Y7N%/3V7_ !K$UOQ9JWBV
MZ&G:; \<#-\J)]YQZL?2NL\)?#Z#2ME[J2K+>=0G58ZV4%3UGN<TIRJ.T-C(
M\'^ Y;B5=4UM25/SQQ,<ECZM7I\<:1HJHH55X  P!3MOTIPZ5E.;F[LVA34%
M9  *6BBI- HHHH **** "BDR*K-J-FM\+)KJ(717<(2XW$>N* +5%-+ #).
M*RSXFT,7'D'5K,2YQL\Y<YH UJ*:KJRAE(*GH15&[US2K"80W>HVT$IZ))(
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MX?#JCT=6##(((/3!IPKQ.*3QAX1E):.=H5^\&R\9_&MVP^+'W4O]/.?XGC;
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M<8)[UP?Q6UV8_8+1+"Z5$D287 ;"O_L\=ZU/B[*HTS3(LC<;Q"!^-1?%$_\
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M/\:#::W<TF><4U)K9DN*>Z."N?A5I$@)@N;B,]MS9 K-/PC'.-4&/^N5>GY
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M<OE74+;X7[ ^E<H#\4$LQI:VUD<+L^T[N<>N?6O4B#1UXS1<5CD/"G@J/1=
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M9K\7^LLX3_O*17KK1QO]]%;ZBHFL;1_O6L)/O&*KVL>L1>QGTD>4_P#"V-5
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MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ I,9I:* $Q[4N*** #%&***
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MLM_^>R?]]"BS"Z)Z*@^V6_\ SV3_ +Z%'VRW_P">R?\ ?0HLPNB>BH/MEO\
M\]D_[Z%'VRW_ .>R?]]"BS"Z)Z*@^V6__/:/_OH4GVRW_P">\?\ WT*+,+HL
M<4<5!]LM_P#GO'_WT*/MEO\ \]D_[ZIV871/Q1Q4'VRW_P">R?\ ?0H^V6__
M #V3_OH46871/Q1Q4'VRW_Y[)_WT*/MEO_SWC_[Z%%F%T3\4<5!]LM_^>R?]
M]4?;+?\ Y[)_WT*+,+HGXHXJ#[9;_P#/9/\ OH4?;+?_ )[)_P!]"BS"Z)^*
M.*@^V6__ #V3_OH4?;+?_GLG_?0HLPNB?BCBH/MEO_SWC_[Z%'VRW_Y[Q_\
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M9"9,9[T(3V(P<K[TM & *7%=L=C@;U$HHHIB"EI** "BBEH 2BBB@ HHS10
M=J*** "BBB@ HHHH **6D- !1110 4444 %%%% !12TE !1THHH **** "BB
MB@ HHHH .]%%% !1110 4444 %+244 *:*2@4 +2444 %%%% !1110 4444
M'>BBB@ H%%% "TE%% !1FBB@ HHHH **** "BBB@ HHHH 6DH%% "C[R_6NO
M7[@^E<@OWA]177K]P?2N>MT.FAU'4445B= 4444 %%%% !1110!!<_<KD=3_
M -9^-==<_<KD-3_UOXT(3)!T%+0.@HS7<MCSQ**** "E[TE% !THHHH ****
M %I*** "BBB@ HHHH 444@I<T@"DI30:8"4444 %%+24 %%%% !1110 4444
M %%%% !1110 4444 %%%% !12XI* "BBB@ HHHH *7O2=J* "EI*6@ I*6C%
M !24M)0 4444 %%%% !1110 4444 +0:2B@ HHHH **** %I*** "BBB@ HH
MHH 4?>7ZUUZ_='TKD!]Y?K77K]T?2L*W0Z:'4=1116!T!1110 4444 %%%%
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M'XA9[_Q5':RL1'N5 ,_K6AJND:A/XKCNXK21X X.\=,59\2^&Y[R=;ZQYF4
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MO\,$CM[DW$0(VRD8R,^E=AH;#^P['T\I??M36Y+V-#IZYHH_SFBK,PHI:2@
MHHHH **** "BBB@ HHHH *6DHH 6DHHH 5?O+]177K]Q?I7(#[R_6NO'W1]*
MYZW0Z:'4=1116)T!1110 4444 %%%% $%S_JZY'4_P#6?C777/\ JZY'4_\
M6?C30/8?VI>])VHKM6QY[W%[TE+24""BBB@ HHHH **.U+VH 2BBB@ HHHH
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M-_JSZ@5V-%%D',S&3PY OAP:++/)-"%VK(0 PK+M? R6^EW6GOJMU+#-@*&
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MM4O+QRN%+MPA]15V?P;!<:)::9)?3;+:02+)M&3[&NDHHL+F8V)/*B2/.0H
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MKD=3_P!9^-==<_ZNN0U/_6'ZT('L2=J*.U%=RV//>XM)1FB@04444  HHHH
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M(ZG_ *T_6A"8_M11V%%=RV.![A111TH$%%%% !1110 4444 %%%+0 E%+24
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M?C*77EB*V42>7&S#&ZJ=IJL/A?QMJ3:F&B@N6W1R[217HL<4<*!(T5%'\*
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MC_N"BBF >5'_ '!1Y4?]P444@#RH_P"X*/*C_N"BB@ \J/\ N"FF),_=%%%
M"^4G]T4>5'_<%%%,!?*C_N"@Q)_=%%%( $49_@%'E1_W!113 3RT_NBE\J/^
MX*** #RH_P"X*#%'_<%%%(!OEI_=%.\J/^X***8!Y4?]P4>5'_<%%%(!OE)_
M=%+Y4?'R"BBF HBC_N"CRH_[@HHH /*C_N"D\I/[HHHI 'E)_=%'E)_=%%%
M!Y2?W12^5'_<%%% !Y4?]P4>5'_<%%% ">6G]T4>4G]T444P#RH_[HH\J/\
MN"BBD GE)_=%.\J/^X*** $,:#HHI/+3^Z*** %\J/\ N"D\I/[HHHH <(H_
M[@H,4>/N"BB@!OEI_=%+Y4?]P444P%$4?]P4ODQ_W!110 >3'_<%)Y4?]P44
M4 (8H_[@H\J/^X***0!Y2?W12^3'_<%%%, \M >%%3Q(O'RBBBDP+\*@=A5@
;=J**$#%HHHH **** "BBB@ HHHH **** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>35
<FILENAME>imrx-20211231x10k032.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 imrx-20211231x10k032.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $G H # 2(  A$! Q$!_\0
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M .H_LZR/_+G;_P#?I:/[-L?^?*W_ ._2UR_V_P"(7_0"T'_P82?_ !NC[?\
M$+_H!:#_ .#"3_XW0!U']FV/_/E;_P#?I:/[-L?^?*W_ ._2UR_V_P"(7_0"
MT+_P82?_ !NC^T/B%_T M"_\&$G_ ,;H ZC^S;'_ )\K?_OTM']FV/\ SY6_
M_?I:Y?[?\0_^@#H/_@PD_P#B*/M_Q#_Z 6@_^#"3_P"(H ZC^S;'_GRM_P#O
MTM']FV/_ #Y6_P#WZ6N7^W_$+_H!:#_X,)/_ (W1]O\ B%_T M!_\&$G_P ;
MH ZC^S;'_GRM_P#OTM']FV/_ #Y6_P#WZ6N7^W_$+_H!:#_X,)/_ (W1]O\
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M+_P82?\ QNC[?\0_^@#H/_@PD_\ C= '4?V=8_\ /G;?]^EH_LZQ/_+G;_\
M?I:Y5M2^(,8W'PYHLH'5(]28,?IE,5J^&_$]OXA2YB-O/8ZC9L$N[&X&)(2>
MAXX93V8<&@#5_LVQ_P"?*W_[]+1_9MC_ ,^5O_WZ6K0.110!5_LVQ_Y\K?\
M[]+1_9MC_P ^5O\ ]^EJU10!5_LVQ_Y\K?\ []+1_9MC_P ^5O\ ]^EJU10!
M5_LVQ_Y\K?\ []+1_9MC_P ^5O\ ]^EJU10!5_LVQ_Y\K?\ []+1_9UC_P ^
M=O\ ]^EJU10!5_LVQ_Y\K?\ []+1_9MC_P ^5O\ ]^EJU10!5_LVQ_Y\K?\
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M.F: *OB'5-0M;O2]/TS[.ES?S.@EN%+)&JH6/R@@DG&.M0BU\9G_ )BNC_\
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MBNGW/V*[/GF 2\?N\C::Z32K&X3Q!J5_.&"O'#;QE@ 9-@8L^/<M^E96K_\
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MD/\ :'@G_H=?%/\ W_N/_B*7^T/!/_0Z^*O_  (N/_B* /7<48KR'^T/!/\
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M?\E7\-?]>%Y_[3H [$<#FJ&N_P#(O:G_ ->DO_H!K0K/UW_D7M3_ .O27_T
MT 9?P_\ ^2>^'_\ KPA_]!%=)7-_#_\ Y)[X?_Z\(?\ T$5TE "$<UQNI?\
M)7M!_P"P7=_^AQUV=<3KKK9?$_PQ>3D+!<6US9(YZ>:VQE'XA3B@#(^-3 >&
M+'D _:QR?]UJ\LUK5-'FM+2WT6UDM$\H?:][9,L@_F.M?2]Q:6]X@CN;>*90
M<A9$# '\:YN_TMDOIUM=(LS B1E/]%0[F+?,.GI790Q"@E%K8UA.RL>2^!M2
MTVVM-2@>W=M2D :&8'Y44>WKGFMDN"22V3]:[Y!<(Q\KPS:Q';U\H#/3C@5/
M'+=%HQ)HEO'ND6(@Q^O\7TXZ5NL6HMNWXGGXO!RKU.>]C"\!D'6[C!!_<?\
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M:#8::G-U?:G;1P1CJVV178_0*I-=L#S0 M%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %5=1_Y!=W_UQ?\ D:M55U'_
M )!=W_UQ?^1H -._X\(_JW\S5JJNG?\ 'C']3_,U:H *XV?_ )+)9?\ 8"E_
M]'I795QL_P#R62R_[ 4O_HY* .RH/2B@T <=X5_Y'?QI_P!?5O\ ^B17,>-M
M0UC5-2U3R)IX-&\/2PM>VMK(R3W2.NYW#+R JG('?::MS2ZU#J/Q!_L"$2:G
MYUMY:Y&Y5,0RR@]6 S@=R*YNP;1O"-Q#XKTK5[FZTAPMAK5A?L6GAR?OE3\P
M(8\K_M'% $L3:)H&GZC:7FLG5_!_B*.22*Y9O,DAN=N2AQU9AR.,[EKL_A[X
M9M] \%13'3A9ZC=VRM=@YW9"\#'\/'.T< DUG?#[P+H\.DV^J76@0PW0N)9K
M/SD_>1PEB8MR]-P4]^1Q7H5R0MG.6.!L;)/TH YOX9_\DXT3_K@?_0FKK*Y/
MX9C'PXT//>WS_P"/&NLH #7G6M7FN3>*=5M=,FUHRP>2+5;9(OLJLR _O2W.
M,]?:O1#TJ"*U@AGFGCB599B#*P'+X&!G\* .3/BO6)+IK2VTVS::2[DM+9I+
M@JK-$"79OEX'' &368?'^HH]S?FQ1[/[+ (;9&+/]H>5HSR!RN5ZCT]Z[*[\
M/Z3?VCVEUI\,L#RF9D9?^6AZM]:;)X<T:9=CZ9;,OV?[+MV8'E9R$^F>: .7
ME\;7Z64=W)I4T5TL4P-K(YC5V62-0?F7=@[^IQCGBM1+V_UWP]J(GDETN^LI
MI(Y&LI0P+(-W#,OW3D=JU(_#>CP6L=LFFP"&(%47;G +!C^J@_A5V.RMHTG5
M($5;AR\P ^^Q&"3^% '!GQ%?^&_"NGW1NFU6\N[7[9(+R3Y@H0%@BQQ].>IX
M'K5\^--1GD_T/3+<I+)!!;F:XVYEEC$GS8'"A2?<FMZ]\,Z-J,%O!>:9;SPV
MR[(4=.$7&-OT]J@U;PK9:AHTNG6ZQV:2-&Q9(5<'8 %!5O8 ?A0!SA^(]Z6M
MDAT.2>78TMRD!:0*HE:/Y65<9^4G+8%='X9U#4M0753J A_<ZA+##Y1_Y9KC
M /O4=EX*T.TTZPLY+&.Y^PY\J25><EMQZ=L\XZ5L6NGVMG-<2V\"1/<R>;,5
M'WVQC)]Z +E%%% !1110 5Y[XPU*72OB/X;NH=-N]0<6=VOD6J@OSY?/)'%>
MA5QFK?\ )6/#7_7A>?SCH 3_ (3G4O\ H1_$7_?J/_XJJVI>,=4O-+N[5/!'
MB$/-"\:DQ1XR5(_O5WM% &#X-L[C3O!FBV5W$8KB"SCCEC/56"C(K>HHH *R
M]<T*P\0Z7+I^HPF2%B&!5MK(PZ,IZAAZUJ44 <9%X9\66B>3;>-Y7@7A/M5A
M'+(![MQN^M2?V%XT_P"ASA_\%4?_ ,577T4 <A_8/C3_ *'.'_P51_\ Q5']
MA>,_^ASA_P#!5'_\577T4 <A_87C3_H<X?\ P51__%4?V%XT_P"ASA_\%4?_
M ,577T4 <A_87C3_ *'.'_P51_\ Q5']A>-/^ASA_P#!5'_\577T4 <A_8?C
M3_H<X?\ P51__%5B>&&\:>(]-GNV\5P0&*\GMMHTQ&SY;E<_>[XKTJN*^&/_
M "+=_P#]A>]_]'-0!-_87C3_ *'.'_P51_\ Q5']A>-/^ASA_P#!5'_\577T
M4 <A_87C3_H<X?\ P51__%4?V%XT_P"ASA_\%4?_ ,577T4 <A_87C3_ *'.
M'_P51_\ Q5']A>-/^ASA_P#!5'_\577T4 <A_87C3_H<X?\ P51__%4?V%XT
MQ_R.D/\ X*H__BJZ^B@#EM%\'K9:J-8U;4KC6-6"E([BX556%3U$<:\+GN>M
M=0!BEHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH *JZC_P @N[_ZXO\ R-6JJZC_ ,@N[_ZXO_(T &G?\>,?X_S-
M6JJ:=_QXQ?C_ #-6Z "N+NV$7QBTQG&U9M%GCC)_B9948C\N:[2N?\3^&X_$
M%M T=S)9:C9R^=9WD0RT+].G=2."O>@#?!!H(S7&1S?$2!?*DM/#UV5X\\3R
MQ;_<KM.*D^V?$'_H$Z!_X&2?_$4 3:WX<U#^VEU_P]>06NJ>4(9XKE2T%U&#
ME0^.589.&'K7/WGA_P 3:AJD>IWGA/PC/?1D%9VGDW9'3/R<X]ZVOMGQ!_Z!
M&@?^!DG_ ,11]L^(/_0)T#_P,D_^(H ;]J^(@_YA7AW_ ,#)?_B*@NM+\:^(
MH&T_59],TK3I?EN3I[R23RIW168 )GIGDU:^V?$'_H$:!_X&2?\ Q%)]L^(/
M_0(T#_P,D_\ B* .IL[2"PLH+.VC6*"!%CC1>BJ!@"IZX_[9\0?^@3H'_@9)
M_P#$4OVSX@_] G0/_ R3_P"(H Z^BN/^V?$'_H$:!_X&2?\ Q%'VSX@_] C0
M/_ V3_XB@#L**X_[9\0?^@3H'_@9)_\ $4?;/B#_ - C0/\ P-D_^(H ["BN
M/^V?$'_H$:!_X&R?_$4?;/B#_P! C0/_  -D_P#B* .PHKC_ +9\0?\ H$Z!
M_P"!DG_Q%'VSX@_] G0/_ R3_P"(H ["BN/^V?$'_H$Z!_X&R?\ Q%'VSX@_
M] C0/_ V3_XB@#L**X_[9\0?^@3H'_@9)_\ $4?;/B#_ - G0/\ P-D_^(H
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M^AB\3?\ @T>D_P"%>VW_ $,7B;_P:/0!TFIO>1Z9<R:='')>I&S0)+G:S <
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MRJ.1PRL <'KD5W(- "T444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MVGR3;=ER%(#'[V1C(.#C(K7G\07.F0:=:S6%UJ&I30>=/';(H**,;VQNQP6
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M;/\ ]"-=E7&_$3_CRT#_ +#MG_Z$:[(4 %%%% !1110 4444 %%%% !1110
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M_P"A(7_P:Q?X4?\ "0>,O^A(7_P:Q?X4 =?17(?\)!XQ_P"A(7_P:Q?X4?\
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M ,&L7^%'_"0>,O\ H2%_\&L7^% '7T5R'_"0>,O^A(7_ ,&L7^%'_"0>,?\
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MEJ/BK3(?EM+756:",=(Q(BNP'MN)_.NUKC?!O_(S^,_^PFG_ *)2@#LJ***
M"JNH_P#(+N_^N+_R-6JJZC_R"[O_ *XO_(T &F_\>,?X_P S5JJNF_\ 'C'^
M/\S5J@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MO^AZU_\ \@__ !N@#L:*X[_A"M6_Z'K7_P#R#_\ &Z/^$+U;_H>M?_\ (/\
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MRQQR>S;%4D>V:ZZUM8+*VBMK:%(8(E"1QQKA54= !0!/1110 55U'_D%W?\
MUQ?^1JU574?^07=_]<7_ )&@ T[_ (\(_JW\S5JJFG?\>,7X_P S5N@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MQ1]KMO\ GXB_[[% $U%("",CD4M !1110 4444 %%%% !1110 4444 %%%%
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MO017'?$3_CRT#_L.V?\ Z$:[$<4 +1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !574?^09=_\ 7%__ $$U:JM?_P#'
MC,O]Y=GY\?UH ;'^[OY4[2@.OU'!_I5NJURC%5EC&9(CN ]1W%31NLB!U.58
M9!H ?1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 9^N#_ (I_4@.OV67_ - -<1X+\>^$K'P3HMK=>(=.
MAGALXTDC>< JP49!KT8C(P>E4_[(TWOI]I_WY7_"@##_ .%D>"_^AGTS_O\
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M /"P(O\ H6/$_P#X+3_C1_PL"+_H6/$__@M/^- '845Q_P#PL"+_ *%CQ/\
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M03A>N37<@8H 6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !_:]O\ W9/R'^-']KV_]V3\A_C110 ?VO;_ -V3\A_C1_:]O_=D_(?XT44
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/!]!TJQBBB@!:*** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>36
<FILENAME>imrx-20211231x10k033.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 imrx-20211231x10k033.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #C K # 2(  A$! Q$!_\0
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M^L'_ '[%/^T0_P#/5/\ OH4?:(?^>L?_ 'T*=F*Z&?8;3_GU@_[]BC[#:?\
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M?K]W^]_2MX5SIT_3H]5MK VUSE(]T;[V*$ YP>?7!YKH@,"@!:*** "BBB@
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MH<9<AA)G"J0#NXX)SP* +NCF0Z7#YMJ;8@8$3-D@>Y]:T <UBW=_JFTV]M8
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MDAB <<]1FI'\7Z=&Q7;.V(O-&U,Y'&1P>O-%A7.BHK$MO$^GW6H0V4;2&65
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MZ6< +@+@ 8Q@YXJA<:<VE&6^L[A@S2;Y$D.5?/0>W)ZULVLPN+:.4#&X9Q3
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M(C_NCU/OUQBMWR3ZT& ^HH DB_U8I]-1=J@4Z@ HHHH **** "BBB@ JO?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M<YR./E/N* U)=6UMM,U&S@$>VV:-I99=N=JCH /7FG_\)3:92/[/<BX>01B
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M .*H^PZK_P!!9?\ P&'_ ,50!J45E_8=5_Z"R_\ @,/_ (JD^PZK_P!!=?\
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M7.JI+;QW$\Z;68-S[C )V\_I5J"ZU#>?)FN)B6_>*\?"'/ !QZ5I?VW/_P!
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MHOM,'_/6/_OJC[3!_P ]4_[Z% $M%1?:8/\ GM'_ -]"C[3!_P ]H_\ OH4
M2T5%]I@_Y[1_]]"C[3!_SUC_ .^J ):*B^TP?\]H_P#OH4?:8/\ GLG_ 'T*
M ):*B^TP?\]H_P#OH4?:8/\ GM'_ -]"@"6BHOM,'_/6/_OJC[3#_P ]D_[Z
M% $M%1?:8/\ GM'_ -]"C[3!_P ]D_[Z% $M%1?:8/\ GM'_ -]"C[3!_P ]
M8_\ OJ@"6BHOM,'_ #VC_P"^A1]I@_Y[)_WT* ):*B^TP?\ /:/_ +Z%(;J
M?\MH_P#OH4 34TL ,DXJ#[6&_P!4CR>X&!^9H$+S',Y&/^>:]/Q]:   W#AB
M/W2GC/\ $?6K-(  *6@ HHHH *K2*T,AE0$J?OJ/YU9I",T (KJR@J<@]Z=5
M9H61B\#!2>J'[I_PH%T5_P!;&Z>_4?F* +.!Z45"+J _\MH_^^A2_:8/^>T?
M_?0H EHJ+[3!_P ]H_\ OH4?:8?^>L?_ 'U0!+1BHOM,'_/:/_OH4?:8?^>R
M?]]"@"6BHOM,'_/9/^^A1]IA_P">L?\ WU0!+147VF#_ )[1_P#?0H^TP?\
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944 %%%% !1110 4444 %%%% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>37
<FILENAME>imrx-20211231x10k034.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 imrx-20211231x10k034.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #. K$# 2(  A$! Q$!_\0
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M%OQ/3\OSIPL;?JT?F'UD);^=6:* *W]GV9ZVEN?^V0H_L^R_Y\[?_OTM6:*
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M]GV7_/G;_P#?I:EBW>0F]55]HRH.0#4E(96_L^R_Y\[?_OTM']GV7_/G;_\
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M#9;<<G<?7% 7/0%MM/*H3:VZE^BM&H/3.,>M!MM-$OE>1:>9_=V+G\JXZ_\
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MN*D_L^R_Y\[?_OTM<3:>%I+AX%U#2T:U2VO/)MY2'6#S)%,<?7&0N?IVKK-
MBN8/#NFPW@87,=M&LH<Y(8*,Y-("T;&V/2%4([Q_*?TI/*N(>89O,']R7^C?
MXYJU10,@AN%ERI!61?O(W4?Y]:GJ&:$2@$$K(O*N.HI()3(&5QMD0X9?Z_2@
M">BBB@"HO[^]9S]R'Y5_WCU/Y<?G5#5?%>@Z'=+:ZGJEO:SLGF!)#@E<XS^A
MK1LA_H<;'J^7/_ CG^M>&_&G_D=+7_KQ7_T-Z:5Q2=D>I_\ "Q?"'_0?L_\
MOH_X4?\ "Q?"'_0?L_\ OH_X5\S9HS5<I'.SZ9_X6+X0_P"@_9_]]'_"C_A8
MOA#_ *#]G_WT?\*^>='T<ZO]M<WD-I#9P?:)9)59AMW!> H)SEA5F[\(ZU;7
MU]:I:_:39G$DD+ @_+ORH."?E.<8R*.5!S,]]_X6+X0_Z#]G_P!]'_"C_A8O
MA#_H/V?_ 'T?\*^?1X9UA;:"\FL)XK*9HOWY ("R$!6Z]#FH];T2YT2^FBD5
MVMQ<2PPSL-OG>6VTL!GIFCE0<S/H;_A8OA#_ *#]G_WT?\*/^%B^$/\ H/V?
M_?1_PKYFYHYHY0YV?3L7C[PK-YGE:Y:-Y:&1\,?E4=3TJ/\ X6+X0_Z#]G_W
MT?\ "OGG1O\ F)_]@V;_ -EK,HY0YV?3/_"Q?"'_ $'[/_OH_P"%'_"Q?"'_
M $'[/_OH_P"%?,V:,T<H<[/IG_A8OA#_ *#]G_WT?\*7_A8OA#_H/V?_ 'T?
M\*^;M.L+G5=1M["T3?<7#A(U)P,^Y]*T'\.7$UX+;2;JWU9P&,AM-P$>TX);
M>%P.>&Z&CE0<[/H#_A8OA ?\Q^S_ .^C_A1_PL7PA_T'[/\ [Z/^%?/T'A37
M[EYXX=)NF>"0Q2KM *N!NV]>N.??M1_PBVO?:EMO[*N/.:'SPG'^K!P6Z]B<
M'T[T<J#F9] _\+%\(?\ 0?L_^^C_ (4?\+%\(?\ 0?L_^^C_ (5\_1>%=>FO
M;BSCTJX-Q;[?-3@;=WW1G.#GMCK59-%U-Q%MLI?WRRN@/!*Q?ZS_ +YP<T<J
M#F9]!Q>./ T-Q)/%JVFQS2??D089OJ<<U/\ \+%\(?\ 0?L_^^C_ (5\]7'A
MO6K6R2\GTVX2WD*!9, YW_<X'/S=JL:MX8OM%T:UO=01X)Y[B2#[.X' 4 [L
M@^Y&.V*.5!S,]]_X6+X0_P"@_9_]]'_"C_A8OA#_ *#]G_WT?\*^9J,T<H<[
M/IG_ (6+X0_Z#]G_ -]'_"A?'/A&X+SKK-DYMT+E^\:DA2<XXY(%?,U:>E?\
M>.M?]>/_ +6CHY0YV?0;?$#P8SH[:Y8ET^XQ/*Y].*?_ ,+%\(?]!^S_ .^C
M_A7SMHFDRZYJL=A%/%"S([F27.U552QZ<]!5ZY\(ZK&!+9HE_:-;)=+=6YPG
ME-NVL=V"/NMU]*.5!S,][_X6+X0_Z#]G_P!]'_"C_A8OA#_H/V?_ 'T?\*^>
MG\.:U&UJK:;<;KI@D*A<EF(R%Q_"<<X..*TKWP?<:=8)-=/.MP;%KMH%B#;"
M)=@4L&Z'@[AGK1RH.9GN?_"Q?"'_ $'[/_OH_P"%'_"Q?"'_ $'[/_OH_P"%
M>#Q>"/$+Q73O8^3]FA\YEFD525SC YZ^QQ5!M UA+:WN#IUQY5PRK$0N2Q;[
MHQU&[MGK1RH.9GT/_P +%\(?]!^S_P"^C_A1_P +%\'_ /0?L_\ OH_X5X#K
M7AJ[T+3=-N+T-%<7CRJT# ?N]C  [@3G.?TK3N? 5S97]O;S7R3))=-:/]FA
M<R+(J;_E5MN\8[@XHY4',SVO_A8OA#_H/V?_ 'T?\*/^%B^$/^@_9_\ ?1_P
MKYYE\/:Q#IG]I2:=.MEM5_.P,;6^ZW7.#6Q;>!;\6D$NHI<VDDUY]G6!80[D
M>4TFX#=U^7&TT<J#F9[?_P +%\(?]!^S_P"^C_A2?\+%\(?]!^S_ .^C_A7S
MS+X<UF'31J,FFSBS94<2X!!5ONGUP:34]!U71HHI=2LI+9)B50NR\D=1P>U'
M*@YF?0__  L3PA_T'[/_ +Z/^%+_ ,+%\(?]!^S_ .^C_A7@D_A#4H+72)M\
M+G4Y%B2-6^:%F 91)G@94[JWIOALUO-,)+VY:-;Q;.,Q6Z,\C8RS;=_3T[^H
M%*R'S,]<_P"%B^$/^@_9_P#?1_PI?^%B^$/^@_9_]]'_  KYY?P[JZ:>VHG3
MY_L(&_S\#&S=C=C.<5J7?@75T$LEG"]Q MW]D0/MCE9MH/*;N.N.M/E0N9GN
M/_"Q?"'_ $'[/_OH_P"%:6D>)-'U]IETK4(;LPX\P1G.W/3^1KY<FL;JVMH+
MF:%XX;@L(G;^/:<-CZ'BO5/@9_Q\:Y_NP_\ L])QL-2;9[+1114EA1110 44
M44 %%%% !16'>^(X;/64T\VTTB@Q+-,I&V%I6*Q@CJ<E3TZ<57O_ !A::=>7
M,4]K<?9K<M$]RNT@S"/S?+"YS]WOTSQ0!TE%<O/XP%I:+-<Z;-$R70M;B(RI
MOC<[2H49^?(<'Y?>K.F>)[>_FU%9E6T2Q=@YFE ;:K,I<K_"ORY!H WZ*X6S
MBTWQ;XMUJ1=2N+FTMX;98C9ZA(D:E@Y;_5L!G@5L?\(5I7_/;5?_  :W/_QR
M@#HJ*YW_ (0K2?\ GMJO_@UN?_BZ/^$*TG_GMJO_ (-;G_XN@#HJ*YW_ (0G
M2?\ GMJO_@UN?_BZ/^$)TG_GMJO_ (-;G_XY0!T5%<Z/!6DCI-JO_@UN?_CE
M'_"%:3U\[5?_  :W/_Q= '145SG_  A&D?\ /75?_!K<_P#QRE_X0K2?^>VJ
M_P#@UN?_ (Y0!T55TLK2.Y:Y2UA6X?[TJQ@.WU/6L3_A"-(_YZZK_P"#6Y_^
M+H_X0C2,Y\W5?_!K<_\ Q= '1T5SA\$Z0?\ EKJO_@UN?_CE+_PA.D<?O=5_
M\&MS_P#%T =%17._\(3I(_Y:ZK_X-;G_ .+H_P"$*TG_ )[:K_X-;G_XY0!T
M5%<[_P (5I/_ #VU7_P:W/\ \71_PA6DC_EMJO\ X-;G_P".4 ;PC19&D"*'
M< ,P')QTS4E<Z?!6DGK-JO\ X-;G_P".4?\ "%:2/^6VJ_\ @UN?_CE '145
MSG_"%:0?^6VJ\_\ 45N?_BZ!X)T@?\M=5Y_ZBMS_ /'* .CHKG!X)T@?\M=5
M_P#!K<__ !RE_P"$)TG_ )[:K_X-;G_XN@#HJ*YW_A"M)_Y[:K_X-;G_ ..4
M?\(5I/\ SUU7_P &MS_\<H Z*BN2L=-AT;QQ!;VL]Z89M.F=XY[N692RR1 '
M#L<'#'\ZZV@ JK<?N98[@= =C_[I_P #_6K51S1B6&2,_P 2E: )**YS^VIO
M2B@#:L.=.M3_ -,D_D*\.^-7_(YVO_7BO_H;U[CI_P#R#+7_ *XI_P"@BN?\
M1:-H6H:@DVIZ/;WDXB"B23J%R>/YTT["DKH^9Z*^@O\ A&/"/_0LV?YFC_A&
M/"/_ $+%G^M5S$<AXIH7B"Z\/C4'LRZ7-S;>3',C;3$=ZMN]_NXQ[UT%KX_M
MK6\OKM-$"S7<S3LR3C.YH]C DJ3MSE@ 1C/>O2_^$8\(_P#0L6?ZT?\ ",>$
M?^A8L_UHYD/E9Y&?%N5D'V$_-I]K8_ZW_G@ZMNZ?Q;>G;-0>*/$O_"3W,=W-
M9^3=(SKY@?(:(L612,=5R1N[U['_ ,(QX1_Z%BS_ %H_X1CPC_T+%G^M',A<
MK/GVBOH+_A&/"/\ T+%G^M'_  C'A'_H6+/]:.8.0\0T;_F)_P#8-F_]EK,K
MZ(M_#GA:/SO*\.6B;H65\?Q*<96H?^$8\(_]"Q9T<P<A\^XHKZ"_X1CPC_T+
M%G^M'_",>$?^A8L_UHY@Y#PO1]4FT36;74K=4>6W?>$?HPZ$'Z@FM2+7-&@C
MO[6'1;A;'4(MEQ&;W+C#AEV-LX (Z$'.:]@_X1CPC_T+%G^M'_",>$?^A8L_
MUHYD'*SRYO'CO?07+Z<,0ZE%>JBR_P ,<0C5,D=<#[WZ4ND>*+ :9/8ZC PB
MCTZ\@4"4@SM-*K[00/E/7FO4/^$8\(_]"Q9T?\(QX1_Z%BS_ %HNA\K/*Y?&
M=M=OY=WI#O9PS6\UK%'=%'C:%-BAFV_,".O ]J5/&ZO'YEWI8EOE^V!)HY]B
M*+G);*X.2">.:]3_ .$8\(_]"Q9_K1_PC'A'_H6+/]:5T'*SR=?&LD5Q-<16
M0$KQ6*+NDR%-L5()XYW8_#-4];U^UU/3H[*STZ2TC6\FO&,EQYI9I,;A]T<<
M5[)_PC'A'_H6+/\ 6C_A&/"/_0L6?ZT^9"Y6?/M%?07_  C'A'_H6+.C_A&/
M"/\ T+%G^M','(?/M:>E?\>6M?\ 7C_[6CKV_P#X1CPC_P!"S9_K4T'ASPLD
M5P(_#EHJO%MD _B7<IQ^8!_"CF#D/#/#VLMH&M1ZBL/G-''(@3=MY9"N>AZ9
MS4K^)+VXTK4;6]>2ZGO'MV\^1ON"(DA=N,8YZ=J]H_X1CPC_ -"Q9_K1_P (
MQX1_Z%BSHYD'*SS6?XBRS:E!??8I=PF\V>!K@>4^8VC;: @*G#'!);%4AXQA
MM[*.TL-,:&*&R^R0^;/YA&)EE#-\HSR,8KU?_A&/"/\ T+%G^M'_  C'A'_H
M6+/]:5T/E9Y'-XETV:]U>8:/,L>KP.ETAN\G>SA]R';P 1TY^M7W^(=RTEE<
M+:R+<0/ \B></(D\H8^[MW<^['':O3?^$8\(_P#0L6?ZT?\ ",>$?^A9L_UH
MN@Y6>,:SK=MJ.GZ?8V=A):6]E+-(OF3^:S>8P8Y.!W%=!/\ $4/J*72:;.P%
MY]K9+B\\S:?+*;(OE^1><GZ5Z/\ \(QX1_Z%BSH_X1CPC_T+-G^M%T+E9Y%_
MPES"+:EGAQI<.GJ3)D QR"3?C'?'W?UK1'CVWBO/M,&CNCOJ+:A-NNMVZ1HV
MC('R_*/FS7IG_",>$?\ H6+.C_A&/"/_ $+%G^M.Z'RL\GMO%L?G1)-;-%$=
M/M].>17W%%CE5S(!WZ?=_6K'CC5='U.[LY;*Y%PBSS/+! NR,*SAB<[%.]N_
M7ZUZA_PC'A'_ *%BS_6C_A%_"/\ T+%G^M%T'*SRJ^\</J*7T5QI=JL,]S#<
MP"$!&B:)AMW-CY_D&VFP>,Q!J?VT:=D_VRVK;?-_O*5V9Q[_ 'J]7_X1CPC_
M -"Q9_K1_P (QX1_Z%FS_6E=!RL\A;Q7N@$7V+II+:;GS?[TF_?T_#%2ZCXQ
M_M W+K8F"X?4EU&VE6;_ %,@55PPV_,,+[5ZS_PC'A'_ *%BS_6C_A&/"/\
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MWKNF)'=Z??VL<$D\%N(I;4N07<(6W;A_>SC':@#JJ*Q[._DM;@Z;J-TMS?I
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M^(*,_G2_8;C_ )]S^0H YJPU2XU'6;>0.T=JT$D9AQP94V;S^#,5_ UOU/\
M8;C/^H/Z4?8[G_GBU(+$%%3_ &*Y_P">+4?8[G_GBU $%%3_ &*Y_P">+4?8
MKG_G@U $%:^A_>G_ . _UK/^Q7/_ #P:M/1X)83-YB%<XQF@#6HHHH&%%%%
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M]5=.MFLM/AMF2)3&NW$6[;_X]SGUSWJU0 4444 .3^/_ '33:?'_ !_[IIE
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M='-N0*8FD7G Y^7!'XU%%XB=XUN'LU%MA<E9<ON:'S<!<=.W6BP7.L_M!?\
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M2#S?+/ Z<_SK;CA2)Y'C0*\C;W(ZL< 9_("HA86BA += (QA./NC=N_]"YH
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M_'_HK>E[_P"TI*V*Q]<.+G1S_P!/R_\ H#UL53V1$=V%%%%26%%%% '/S_\
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MNS8&W-C'.#0(Z7[9;?WI/^^/_KT?;+;^_)_WQ_\ 7KEGU2YAT&VOIH8TFF9
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M 8/_ (FNCI#TH XW6K#Q3I^DS75GXENKF="NV(:?"V[+ '@+GH2?PK0_L/Q
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M5@"".0: '454%M)%@VTNU?\ GF_*_AW%5YM66T;;<1$'_IF=W\\4 :=%8O\
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M_P"$GLO^>=Q_WRO^- &U16+_ ,)/9?\ /.X_[Y7_ !H_X2>R_P">=Q_WRO\
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MEHK22,L%!*QJ"0. .O:@#H**Q?\ A)[+_GG<?]\K_C1_PD]E_P \[C_OE?\
M&@#:HK%_X2>R_P">=Q_WRO\ C1_PD]E_SSN/^^5_QH VJ*Q?^$GLO^>=Q_WR
MO^-'_"3V7_/.X_[Y7_&@#:HK%_X2>R_YYW'_ 'RO^-'_  D]E_SSN/\ OE?\
M: -JBLJ'6XKD[8(G+?[9"C],U;\F>8XFFVJ?X(N/S;K^6* %DF9W,,'+_P 3
C=D_^O[5+%$L4810?J>I/K3HXTB0)&H51T IU !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>38
<FILENAME>imrx-20211231.xsd
<DESCRIPTION>EX-101.SCH
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.8042.36810 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/10/2022 12:29:41 AM-->
<!--Modified on: 3/10/2022 12:29:41 AM-->
<xsd:schema targetNamespace="http://immuneering.com/20211231" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:currency="http://xbrl.sec.gov/currency/2021" xmlns:us-roles="http://fasb.org/us-roles/2021-01-31" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:sic="http://xbrl.sec.gov/sic/2021" xmlns:us-types="http://fasb.org/us-types/2021-01-31" xmlns:srt-roles="http://fasb.org/srt-roles/2021-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2021" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:srt-types="http://fasb.org/srt-types/2021-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2021" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:naics="http://xbrl.sec.gov/naics/2021" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:attributeFormDefault="unqualified" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:deprecated="http://www.xbrl.org/2009/role/deprecated" xmlns:net="http://www.xbrl.org/2009/role/net" xmlns:imrx="http://immuneering.com/20211231" xmlns:dei="http://xbrl.sec.gov/dei/2021q4">
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://immuneering.com/role/StatementConsolidatedBalanceSheets" id="StatementConsolidatedBalanceSheets">
        <link:definition>00100 - Statement - CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immuneering.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" id="StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss">
        <link:definition>00200 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immuneering.com/role/StatementConsolidatedStatementsOfCashFlows" id="StatementConsolidatedStatementsOfCashFlows">
        <link:definition>00400 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immuneering.com/role/DisclosureMarketableSecuritiesDetails" id="DisclosureMarketableSecuritiesDetails">
        <link:definition>40301 - Disclosure - Marketable Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immuneering.com/role/DisclosureFairValueMeasurementsDetails" id="DisclosureFairValueMeasurementsDetails">
        <link:definition>40401 - Disclosure - Fair Value Measurements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immuneering.com/role/DisclosurePropertyAndEquipmentNetDetails" id="DisclosurePropertyAndEquipmentNetDetails">
        <link:definition>40501 - Disclosure - Property and Equipment, net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immuneering.com/role/DisclosureBusinessCombinationAssetsAcquiredAndLiabilitiesAssumedDetails" id="DisclosureBusinessCombinationAssetsAcquiredAndLiabilitiesAssumedDetails">
        <link:definition>40602 - Disclosure - Business Combination - Assets Acquired and Liabilities Assumed (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immuneering.com/role/DisclosureAccruedExpensesDetails" id="DisclosureAccruedExpensesDetails">
        <link:definition>40701 - Disclosure - Accrued Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immuneering.com/role/DisclosureCommitmentsAndContingenciesMaturitiesOfLeaseLiabilitiesDueDetailsCalc2" id="DisclosureCommitmentsAndContingenciesMaturitiesOfLeaseLiabilitiesDueDetailsCalc2">
        <link:definition>40902 - Disclosure - Commitments and Contingencies - Maturities of the lease liabilities due (Details) - Calc2</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immuneering.com/role/DisclosureIncomeTaxesNetLossAndEffectiveIncomeTaxRateDetails" id="DisclosureIncomeTaxesNetLossAndEffectiveIncomeTaxRateDetails">
        <link:definition>41201 - Disclosure - Income Taxes - Net loss and the effective income tax rate (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immuneering.com/role/DisclosureIncomeTaxesNetDeferredTaxAssetsDetails" id="DisclosureIncomeTaxesNetDeferredTaxAssetsDetails">
        <link:definition>41202 - Disclosure - Income Taxes - Net deferred tax assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immuneering.com/role/DisclosureCommitmentsAndContingenciesMaturitiesOfLeaseLiabilitiesDueDetails" id="DisclosureCommitmentsAndContingenciesMaturitiesOfLeaseLiabilitiesDueDetails">
        <link:definition>41302 - Disclosure - Commitments and Contingencies - Maturities of the lease liabilities due (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immuneering.com/role/DisclosureCommitmentsAndContingenciesLeaseCostDetails" id="DisclosureCommitmentsAndContingenciesLeaseCostDetails">
        <link:definition>41303 - Disclosure - Commitments and Contingencies - Lease cost (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immuneering.com/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
        <link:definition>00090 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immuneering.com/role/StatementConsolidatedBalanceSheetsParentheticals" id="StatementConsolidatedBalanceSheetsParentheticals">
        <link:definition>00105 - Statement - CONSOLIDATED BALANCE SHEETS (Parentheticals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immuneering.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" id="StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit">
        <link:definition>00300 - Statement - CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immuneering.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParentheticals" id="StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParentheticals">
        <link:definition>00305 - Statement - CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT) (Parentheticals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immuneering.com/role/DisclosureOrganizationAndNatureOfBusinessDetails" id="DisclosureOrganizationAndNatureOfBusinessDetails">
        <link:definition>40101 - Disclosure - Organization and Nature of Business (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immuneering.com/role/DisclosureSummaryOfSignificantAccountingPoliciesConcentrationOfCreditRiskDetails" id="DisclosureSummaryOfSignificantAccountingPoliciesConcentrationOfCreditRiskDetails">
        <link:definition>40202 - Disclosure - Summary of Significant Accounting Policies - Concentration of Credit Risk (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immuneering.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails" id="DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails">
        <link:definition>40203 - Disclosure - Summary of Significant Accounting Policies - Property and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immuneering.com/role/DisclosureBusinessCombinationNarrativeDetails" id="DisclosureBusinessCombinationNarrativeDetails">
        <link:definition>40601 - Disclosure - Business Combination - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immuneering.com/role/DisclosureConvertiblePreferredStockSeriesDetails" id="DisclosureConvertiblePreferredStockSeriesDetails">
        <link:definition>40801 - Disclosure - Convertible Preferred Stock - Series A (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immuneering.com/role/DisclosureConvertiblePreferredStockSeriesBDetails" id="DisclosureConvertiblePreferredStockSeriesBDetails">
        <link:definition>40802 - Disclosure - Convertible Preferred Stock - Series B (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immuneering.com/role/DisclosureCommonStockClassCommonStockDetails" id="DisclosureCommonStockClassCommonStockDetails">
        <link:definition>40901 - Disclosure - Common Stock - Class A common stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immuneering.com/role/DisclosureCommonStockDetails" id="DisclosureCommonStockDetails">
        <link:definition>40902 - Disclosure - Common Stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immuneering.com/role/DisclosureCommonStockClassBCommonStockDetails" id="DisclosureCommonStockClassBCommonStockDetails">
        <link:definition>40903 - Disclosure - Common Stock - Class B common stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immuneering.com/role/DisclosureCommonStockIpoDetails" id="DisclosureCommonStockIpoDetails">
        <link:definition>40905 - Disclosure - Common Stock - IPO (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immuneering.com/role/DisclosureNetLossPerShareAttributableToCommonStockholdersAntidilutiveEffectDetails" id="DisclosureNetLossPerShareAttributableToCommonStockholdersAntidilutiveEffectDetails">
        <link:definition>41002 - Disclosure - Net Loss Per Share Attributable to Common Stockholders - Antidilutive effect (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immuneering.com/role/DisclosureStockBasedCompensationNarrativesDetails" id="DisclosureStockBasedCompensationNarrativesDetails">
        <link:definition>41101 - Disclosure - Stock-Based Compensation - Narratives (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immuneering.com/role/DisclosureStockBasedCompensationAssumptionsDetails" id="DisclosureStockBasedCompensationAssumptionsDetails">
        <link:definition>41102 - Disclosure - Stock-Based Compensation - Assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immuneering.com/role/DisclosureStockBasedCompensationShareBasedCompensationExpenseDetails" id="DisclosureStockBasedCompensationShareBasedCompensationExpenseDetails">
        <link:definition>41104 - Disclosure - Stock-Based Compensation - Share-based compensation expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immuneering.com/role/DisclosureIncomeTaxesNarrativeDetails" id="DisclosureIncomeTaxesNarrativeDetails">
        <link:definition>41203 - Disclosure - Income Taxes - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immuneering.com/role/DisclosureCommitmentsAndContingenciesNarrativesDetails" id="DisclosureCommitmentsAndContingenciesNarrativesDetails">
        <link:definition>41301 - Disclosure - Commitments and Contingencies - Narratives (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immuneering.com/role/DisclosureOrganizationAndNatureOfBusiness" id="DisclosureOrganizationAndNatureOfBusiness">
        <link:definition>10101 - Disclosure - Organization and Nature of Business</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immuneering.com/role/DisclosureSummaryOfSignificantAccountingPolicies" id="DisclosureSummaryOfSignificantAccountingPolicies">
        <link:definition>10201 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immuneering.com/role/DisclosureMarketableSecurities" id="DisclosureMarketableSecurities">
        <link:definition>10301 - Disclosure - Marketable Securities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immuneering.com/role/DisclosureFairValueMeasurements" id="DisclosureFairValueMeasurements">
        <link:definition>10401 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immuneering.com/role/DisclosurePropertyAndEquipmentNet" id="DisclosurePropertyAndEquipmentNet">
        <link:definition>10501 - Disclosure - Property and Equipment, net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immuneering.com/role/DisclosureBusinessCombination" id="DisclosureBusinessCombination">
        <link:definition>10601 - Disclosure - Business Combination</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immuneering.com/role/DisclosureAccruedExpenses" id="DisclosureAccruedExpenses">
        <link:definition>10701 - Disclosure - Accrued Expenses</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immuneering.com/role/DisclosureConvertiblePreferredStock" id="DisclosureConvertiblePreferredStock">
        <link:definition>10801 - Disclosure - Convertible Preferred Stock</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immuneering.com/role/DisclosureCommonStock" id="DisclosureCommonStock">
        <link:definition>10901 - Disclosure - Common Stock</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immuneering.com/role/DisclosureNetLossPerShareAttributableToCommonStockholders" id="DisclosureNetLossPerShareAttributableToCommonStockholders">
        <link:definition>11001 - Disclosure - Net Loss Per Share Attributable to Common Stockholders</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immuneering.com/role/DisclosureStockBasedCompensation" id="DisclosureStockBasedCompensation">
        <link:definition>11101 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immuneering.com/role/DisclosureIncomeTaxes" id="DisclosureIncomeTaxes">
        <link:definition>11201 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immuneering.com/role/DisclosureCommitmentsAndContingencies" id="DisclosureCommitmentsAndContingencies">
        <link:definition>11301 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immuneering.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" id="DisclosureSummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>20202 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immuneering.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" id="DisclosureSummaryOfSignificantAccountingPoliciesTables">
        <link:definition>30203 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immuneering.com/role/DisclosureMarketableSecuritiesTables" id="DisclosureMarketableSecuritiesTables">
        <link:definition>30303 - Disclosure - Marketable Securities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immuneering.com/role/DisclosureFairValueMeasurementsTables" id="DisclosureFairValueMeasurementsTables">
        <link:definition>30403 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immuneering.com/role/DisclosurePropertyAndEquipmentNetTables" id="DisclosurePropertyAndEquipmentNetTables">
        <link:definition>30503 - Disclosure - Property and Equipment, net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immuneering.com/role/DisclosureBusinessCombinationTables" id="DisclosureBusinessCombinationTables">
        <link:definition>30603 - Disclosure - Business Combination (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immuneering.com/role/DisclosureAccruedExpensesTables" id="DisclosureAccruedExpensesTables">
        <link:definition>30703 - Disclosure - Accrued Expenses (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immuneering.com/role/DisclosureCommonStockTables" id="DisclosureCommonStockTables">
        <link:definition>30903 - Disclosure - Common Stock (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immuneering.com/role/DisclosureNetLossPerShareAttributableToCommonStockholdersTables" id="DisclosureNetLossPerShareAttributableToCommonStockholdersTables">
        <link:definition>31003 - Disclosure - Net Loss Per Share Attributable to Common Stockholders (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immuneering.com/role/DisclosureStockBasedCompensationTables" id="DisclosureStockBasedCompensationTables">
        <link:definition>31103 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immuneering.com/role/DisclosureIncomeTaxesTables" id="DisclosureIncomeTaxesTables">
        <link:definition>31203 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immuneering.com/role/DisclosureCommitmentsAndContingenciesTables" id="DisclosureCommitmentsAndContingenciesTables">
        <link:definition>31303 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immuneering.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails" id="DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails">
        <link:definition>40201 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immuneering.com/role/DisclosurePropertyAndEquipmentNetDepreciationDetails" id="DisclosurePropertyAndEquipmentNetDepreciationDetails">
        <link:definition>40502 - Disclosure - Property and Equipment, net - Depreciation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immuneering.com/role/DisclosureCommonStockCommonStockWarrantDetails" id="DisclosureCommonStockCommonStockWarrantDetails">
        <link:definition>40904 - Disclosure - Common Stock - Common stock warrant (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immuneering.com/role/DisclosureNetLossPerShareAttributableToCommonStockholdersBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails" id="DisclosureNetLossPerShareAttributableToCommonStockholdersBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails">
        <link:definition>41001 - Disclosure - Net Loss Per Share Attributable to Common Stockholders - Basic and diluted net loss per share attributable to common stockholders (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immuneering.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails" id="DisclosureStockBasedCompensationStockOptionActivityDetails">
        <link:definition>41103 - Disclosure - Stock-Based Compensation - stock option activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immuneering.com/role/DisclosureIncomeTaxesUnrecognizedTaxBenefitsDetails" id="DisclosureIncomeTaxesUnrecognizedTaxBenefitsDetails">
        <link:definition>41204 - Disclosure - Income Taxes - Unrecognized tax benefits (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="imrx-20211231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="imrx-20211231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="imrx-20211231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="imrx-20211231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:roleType roleURI="http://immuneering.com/role/DisclosureStandardAndCustomAxisDomainDefaults" id="DisclosureStandardAndCustomAxisDomainDefaults">
        <link:definition>99900 - Disclosure - Standard And Custom Axis Domain Defaults</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:import namespace="http://xbrl.sec.gov/dei/2021q4" schemaLocation="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://fasb.org/us-gaap/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/srt/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
  <xsd:element name="OfferingCostPayable" id="imrx_OfferingCostPayable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="AccruedLiabilitiesDisclosureTextBlock" id="imrx_AccruedLiabilitiesDisclosureTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="AccruedContractResearchExpensesCurrent" id="imrx_AccruedContractResearchExpensesCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="SeriesBConvertiblePreferredStockMember" id="imrx_SeriesBConvertiblePreferredStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="SeriesConvertiblePreferredStockMember" id="imrx_SeriesConvertiblePreferredStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="StockIssuedDuringPeriodValueWarrantsExercised" id="imrx_StockIssuedDuringPeriodValueWarrantsExercised" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="StockIssuedDuringPeriodSharesWarrantsExercised" id="imrx_StockIssuedDuringPeriodSharesWarrantsExercised" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" id="imrx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="ReclassificationOfLiabilityOfPreferredStock" id="imrx_ReclassificationOfLiabilityOfPreferredStock" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="TemporaryEquityDisclosureTextBlock" id="imrx_TemporaryEquityDisclosureTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="TemporaryEquityIssuancePrice" id="imrx_TemporaryEquityIssuancePrice" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="TemporaryEquityNumberOfSharesExcessOfAuthorized" id="imrx_TemporaryEquityNumberOfSharesExcessOfAuthorized" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="ProceedsFromIssuanceOfConvertiblePreferredStockExcessOfAuthorizedAmount" id="imrx_ProceedsFromIssuanceOfConvertiblePreferredStockExcessOfAuthorizedAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="TemporaryEquityDueToExcessAuthorizedAmount" id="imrx_TemporaryEquityDueToExcessAuthorizedAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="SeriesBConvertiblePreferredStockTrancheTwoMember" id="imrx_SeriesBConvertiblePreferredStockTrancheTwoMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="SeriesBConvertiblePreferredStocksTrancheOneMember" id="imrx_SeriesBConvertiblePreferredStocksTrancheOneMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="NumberOfTranches" id="imrx_NumberOfTranches" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="TemporaryEquityContingentlyIssuableShares" id="imrx_TemporaryEquityContingentlyIssuableShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="TemporaryEquityConversionPrice" id="imrx_TemporaryEquityConversionPrice" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="PercentageOfEquitySecuritiesOwnedToGetConvertedStock" id="imrx_PercentageOfEquitySecuritiesOwnedToGetConvertedStock" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="NumberOfVotesPerShare" id="imrx_NumberOfVotesPerShare" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="WarrantsIssuedInLieuOfCashPayment" id="imrx_WarrantsIssuedInLieuOfCashPayment" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="WarrantsExercised" id="imrx_WarrantsExercised" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="OfficeSpaceInCambridgeMassachusettsNewYorkMember" id="imrx_OfficeSpaceInCambridgeMassachusettsNewYorkMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="StorageSpaceInSomervilleMassachusettsMember" id="imrx_StorageSpaceInSomervilleMassachusettsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="OfficeLeaseInSanDiegoCalifornia2020Member" id="imrx_OfficeLeaseInSanDiegoCalifornia2020Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="OperatingLeaseAdditionalInformationAbstract" id="imrx_OperatingLeaseAdditionalInformationAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="LeasePayments" id="imrx_LeasePayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="StockIncentivePlan2015Member" id="imrx_StockIncentivePlan2015Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="TwoThousandTwentyOneIncentiveAwardPlanMember" id="imrx_TwoThousandTwentyOneIncentiveAwardPlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="TwoThousandTwentyOneEmployeeStockPurchasePlanMember" id="imrx_TwoThousandTwentyOneEmployeeStockPurchasePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="PercentageOfAggregateNumberOfSharesOutstanding" id="imrx_PercentageOfAggregateNumberOfSharesOutstanding" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRepurchased" id="imrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRepurchased" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsRepurchasedInPeriodWeightedAverageExercisePrice" id="imrx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsRepurchasedInPeriodWeightedAverageExercisePrice" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract" id="imrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="StockIssuanceCosts" id="imrx_StockIssuanceCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="GovernmentSecuritiesMember" id="imrx_GovernmentSecuritiesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="MarketableSecuritiesCurrentAbstract" id="imrx_MarketableSecuritiesCurrentAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="MarketableSecuritiesNonCurrentAbstract" id="imrx_MarketableSecuritiesNonCurrentAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="MarketableSecuritiesAmortizedCostBasisCurrent" id="imrx_MarketableSecuritiesAmortizedCostBasisCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit" />
  <xsd:element name="MarketableSecuritiesAccumulatedUnrealizedLossesCurrent" id="imrx_MarketableSecuritiesAccumulatedUnrealizedLossesCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit" />
  <xsd:element name="MarketableSecuritiesAccumulatedUnrealizedGainsCurrent" id="imrx_MarketableSecuritiesAccumulatedUnrealizedGainsCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="MarketableSecuritiesAmortizedCostBasisNonCurrent" id="imrx_MarketableSecuritiesAmortizedCostBasisNonCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit" />
  <xsd:element name="MarketableSecuritiesAccumulatedUnrealizedLossesNonCurrent" id="imrx_MarketableSecuritiesAccumulatedUnrealizedLossesNonCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit" />
  <xsd:element name="MarketableSecuritiesFairValueDisclosure" id="imrx_MarketableSecuritiesFairValueDisclosure" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit" />
  <xsd:element name="MarketableSecuritiesAmortizedCostBasis" id="imrx_MarketableSecuritiesAmortizedCostBasis" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit" />
  <xsd:element name="MarketableSecuritiesAccumulatedUnrealizedGains" id="imrx_MarketableSecuritiesAccumulatedUnrealizedGains" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="MarketableSecuritiesAccumulatedUnrealizedLosses" id="imrx_MarketableSecuritiesAccumulatedUnrealizedLosses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit" />
  <xsd:element name="LabEquipmentMember" id="imrx_LabEquipmentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="EffectiveIncomeTaxRateReconciliationTaxCreditStateResearchAndDevelopmentPercent" id="imrx_EffectiveIncomeTaxRateReconciliationTaxCreditStateResearchAndDevelopmentPercent" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="EffectiveIncomeTaxRateReconciliationUncertainTaxPositions" id="imrx_EffectiveIncomeTaxRateReconciliationUncertainTaxPositions" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="BioArkiveIncMember" id="imrx_BioArkiveIncMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="LeaseTerminationOnApril302032Member" id="imrx_LeaseTerminationOnApril302032Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="LeaseTerminationOnDecember312022Member" id="imrx_LeaseTerminationOnDecember312022Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="LeaseTerminationOnMarch312024Member" id="imrx_LeaseTerminationOnMarch312024Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="NumberOfLeasesObligationsAssumed" id="imrx_NumberOfLeasesObligationsAssumed" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="AreaOfPropertyUnderLease" id="imrx_AreaOfPropertyUnderLease" type="dtr-types:areaItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="TaxCreditCarryforwardIncreaseDecreaseCaresAct" id="imrx_TaxCreditCarryforwardIncreaseDecreaseCaresAct" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="PatentCostsPolicyPolicyTextBlock" id="imrx_PatentCostsPolicyPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="ResearchAndManufacturingContractCostsAndAccrualsPolicyTextBlock" id="imrx_ResearchAndManufacturingContractCostsAndAccrualsPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock" id="imrx_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="CustomerOneMember" id="imrx_CustomerOneMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="CustomerTwoMember" id="imrx_CustomerTwoMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="CustomerThreeMember" id="imrx_CustomerThreeMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="CustomerFourMember" id="imrx_CustomerFourMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="CustomerFiveMember" id="imrx_CustomerFiveMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="BusinessCombinationPurchasePrice" id="imrx_BusinessCombinationPurchasePrice" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="BusinessCombinationSharesIssuedSharePriceThresholdTradingDays" id="imrx_BusinessCombinationSharesIssuedSharePriceThresholdTradingDays" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="BusinessCombinationSharesIssuedLockInPeriod" id="imrx_BusinessCombinationSharesIssuedLockInPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="BusinessCombinationSharesIssuedDiscountDueToMarketabilityPercentage" id="imrx_BusinessCombinationSharesIssuedDiscountDueToMarketabilityPercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets" id="imrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit" />
  <xsd:element name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIncludingGoodwill" id="imrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIncludingGoodwill" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit" />
  <xsd:element name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAccruedExpensesAndOtherLiabilities" id="imrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAccruedExpensesAndOtherLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>39
<FILENAME>imrx-20211231_cal.xml
<DESCRIPTION>EX-101.CAL
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.8042.36810 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/10/2022 12:29:41 AM-->
<!--Modified on: 3/10/2022 12:29:41 AM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <roleRef xlink:type="simple" xlink:href="imrx-20211231.xsd#StatementConsolidatedBalanceSheets" roleURI="http://immuneering.com/role/StatementConsolidatedBalanceSheets" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="imrx-20211231.xsd#StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" roleURI="http://immuneering.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="imrx-20211231.xsd#StatementConsolidatedStatementsOfCashFlows" roleURI="http://immuneering.com/role/StatementConsolidatedStatementsOfCashFlows" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="imrx-20211231.xsd#DisclosureMarketableSecuritiesDetails" roleURI="http://immuneering.com/role/DisclosureMarketableSecuritiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="imrx-20211231.xsd#DisclosureFairValueMeasurementsDetails" roleURI="http://immuneering.com/role/DisclosureFairValueMeasurementsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="imrx-20211231.xsd#DisclosurePropertyAndEquipmentNetDetails" roleURI="http://immuneering.com/role/DisclosurePropertyAndEquipmentNetDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="imrx-20211231.xsd#DisclosureBusinessCombinationAssetsAcquiredAndLiabilitiesAssumedDetails" roleURI="http://immuneering.com/role/DisclosureBusinessCombinationAssetsAcquiredAndLiabilitiesAssumedDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="imrx-20211231.xsd#DisclosureAccruedExpensesDetails" roleURI="http://immuneering.com/role/DisclosureAccruedExpensesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="imrx-20211231.xsd#DisclosureCommitmentsAndContingenciesMaturitiesOfLeaseLiabilitiesDueDetailsCalc2" roleURI="http://immuneering.com/role/DisclosureCommitmentsAndContingenciesMaturitiesOfLeaseLiabilitiesDueDetailsCalc2" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="imrx-20211231.xsd#DisclosureIncomeTaxesNetLossAndEffectiveIncomeTaxRateDetails" roleURI="http://immuneering.com/role/DisclosureIncomeTaxesNetLossAndEffectiveIncomeTaxRateDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="imrx-20211231.xsd#DisclosureIncomeTaxesNetDeferredTaxAssetsDetails" roleURI="http://immuneering.com/role/DisclosureIncomeTaxesNetDeferredTaxAssetsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="imrx-20211231.xsd#DisclosureCommitmentsAndContingenciesMaturitiesOfLeaseLiabilitiesDueDetails" roleURI="http://immuneering.com/role/DisclosureCommitmentsAndContingenciesMaturitiesOfLeaseLiabilitiesDueDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="imrx-20211231.xsd#DisclosureCommitmentsAndContingenciesLeaseCostDetails" roleURI="http://immuneering.com/role/DisclosureCommitmentsAndContingenciesLeaseCostDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <calculationLink xlink:role="http://immuneering.com/role/StatementConsolidatedBalanceSheets" xlink:type="extended" xlink:title="00100 - Statement - CONSOLIDATED BALANCE SHEETS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent_637824689801810281" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherAssetsNoncurrent_637824689801810281" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesNoncurrent" xlink:label="us-gaap_MarketableSecuritiesNoncurrent_637824689801810281" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_MarketableSecuritiesNoncurrent_637824689801810281" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_637824689801810281" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_637824689801810281" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_637824689801810281" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_637824689801810281" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_637824689801810281" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_637824689801810281" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill_637824689801810281" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Goodwill_637824689801810281" order="6" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_637824689801820289" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent_637824689801820289" order="7" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_637824689801820289" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_637824689801820289" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_637824689801820289" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent_637824689801820289" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_637824689801820289" xlink:to="us-gaap_AccountsReceivableNetCurrent_637824689801820289" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_637824689801820289" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_637824689801820289" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_637824689801820289" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="us-gaap_MarketableSecuritiesCurrent_637824689801820289" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_637824689801820289" xlink:to="us-gaap_MarketableSecuritiesCurrent_637824689801820289" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_637824689801820289" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity_637824689801820289" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue_637824689801820289" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_637824689801820289" xlink:to="us-gaap_CommonStockValue_637824689801820289" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital_637824689801830290" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_637824689801820289" xlink:to="us-gaap_AdditionalPaidInCapital_637824689801830290" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_637824689801830290" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_637824689801820289" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_637824689801830290" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_637824689801830290" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_637824689801820289" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_637824689801830290" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue_637824689801830290" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_637824689801820289" xlink:to="us-gaap_PreferredStockValue_637824689801830290" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_637824689801830290" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_637824689801830290" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies_637824689801830290" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies_637824689801830290" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_637824689801840213" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities_637824689801840213" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_637824689801840213" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_637824689801840213" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_637824689801840213" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_637824689801840213" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_637824689801840213" xlink:to="us-gaap_LiabilitiesCurrent_637824689801840213" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent_637824689801840213" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_637824689801840213" xlink:to="us-gaap_AccountsPayableCurrent_637824689801840213" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent_637824689801840213" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_637824689801840213" xlink:to="us-gaap_AccruedLiabilitiesCurrent_637824689801840213" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_637824689801840213" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_637824689801840213" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_637824689801840213" order="3" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://immuneering.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="extended" xlink:title="00200 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:label="us-gaap_MarketableSecuritiesUnrealizedGainLoss_637824689801850205" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_MarketableSecuritiesUnrealizedGainLoss_637824689801850205" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_637824689802010377" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_NetIncomeLoss_637824689802010377" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit_637824689802010377" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss_637824689802010377" xlink:to="us-gaap_IncomeTaxExpenseBenefit_637824689802010377" order="1" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_637824689802010377" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss_637824689802010377" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_637824689802010377" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest_637824689802010377" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_637824689802010377" xlink:to="us-gaap_InvestmentIncomeInterest_637824689802010377" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_637824689802020262" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_637824689802010377" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_637824689802020262" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_637824689802020262" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_637824689802010377" xlink:to="us-gaap_OperatingIncomeLoss_637824689802020262" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses_637824689802020262" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_637824689802020262" xlink:to="us-gaap_OperatingExpenses_637824689802020262" order="1" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense_637824689802020262" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses_637824689802020262" xlink:to="us-gaap_GeneralAndAdministrativeExpense_637824689802020262" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_637824689802020262" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses_637824689802020262" xlink:to="us-gaap_ResearchAndDevelopmentExpense_637824689802020262" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GrossProfit" xlink:label="us-gaap_GrossProfit_637824689802020262" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_637824689802020262" xlink:to="us-gaap_GrossProfit_637824689802020262" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues_637824689802020262" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_GrossProfit_637824689802020262" xlink:to="us-gaap_Revenues_637824689802020262" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfRevenue" xlink:label="us-gaap_CostOfRevenue_637824689802020262" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_GrossProfit_637824689802020262" xlink:to="us-gaap_CostOfRevenue_637824689802020262" order="2" use="optional" weight="-1" />
  </calculationLink>
  <calculationLink xlink:role="http://immuneering.com/role/StatementConsolidatedStatementsOfCashFlows" xlink:type="extended" xlink:title="00400 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_637824689802030230" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_637824689802030230" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation_637824689802030230" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637824689802030230" xlink:to="us-gaap_Depreciation_637824689802030230" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_637824689802030230" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637824689802030230" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_637824689802030230" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_637824689802030230" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637824689802030230" xlink:to="us-gaap_ShareBasedCompensation_637824689802030230" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_637824689802030230" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637824689802030230" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_637824689802030230" order="4" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_637824689802030230" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637824689802030230" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_637824689802030230" order="5" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_637824689802030230" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637824689802030230" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_637824689802030230" order="6" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_637824689802040340" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637824689802030230" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_637824689802040340" order="7" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_637824689802040340" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637824689802030230" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_637824689802040340" order="8" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets_637824689802040340" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637824689802030230" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets_637824689802040340" order="9" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_637824689802040340" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637824689802030230" xlink:to="us-gaap_NetIncomeLoss_637824689802040340" order="10" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:label="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_637824689802040340" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637824689802030230" xlink:to="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_637824689802040340" order="11" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_637824689802040340" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637824689802030230" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_637824689802040340" order="12" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_637824689802040340" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_637824689802040340" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_637824689802050231" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_637824689802040340" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_637824689802050231" order="1" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAcquiredInExcessOfPaymentsToAcquireBusiness" xlink:label="us-gaap_CashAcquiredInExcessOfPaymentsToAcquireBusiness_637824689802050231" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_637824689802040340" xlink:to="us-gaap_CashAcquiredInExcessOfPaymentsToAcquireBusiness_637824689802050231" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities_637824689802050231" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_637824689802040340" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities_637824689802050231" order="3" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_637824689802050231" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_637824689802050231" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_637824689802050231" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_637824689802050231" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_637824689802050231" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_637824689802050231" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_637824689802050231" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_637824689802050231" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises_637824689802050231" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_637824689802050231" xlink:to="us-gaap_ProceedsFromWarrantExercises_637824689802050231" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_637824689802060303" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_637824689802050231" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_637824689802060303" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_637824689802060303" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_637824689802050231" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_637824689802060303" order="5" use="optional" weight="-1" />
  </calculationLink>
  <calculationLink xlink:role="http://immuneering.com/role/DisclosureMarketableSecuritiesDetails" xlink:type="extended" xlink:title="40301 - Disclosure - Marketable Securities (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_MarketableSecuritiesAmortizedCostBasis" xlink:label="imrx_MarketableSecuritiesAmortizedCostBasis" />
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_MarketableSecuritiesAccumulatedUnrealizedGains" xlink:label="imrx_MarketableSecuritiesAccumulatedUnrealizedGains_637824689802060303" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="imrx_MarketableSecuritiesAmortizedCostBasis" xlink:to="imrx_MarketableSecuritiesAccumulatedUnrealizedGains_637824689802060303" order="1" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_MarketableSecuritiesAccumulatedUnrealizedLosses" xlink:label="imrx_MarketableSecuritiesAccumulatedUnrealizedLosses_637824689802060303" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="imrx_MarketableSecuritiesAmortizedCostBasis" xlink:to="imrx_MarketableSecuritiesAccumulatedUnrealizedLosses_637824689802060303" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecurities" xlink:label="us-gaap_MarketableSecurities_637824689802060303" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="imrx_MarketableSecuritiesAmortizedCostBasis" xlink:to="us-gaap_MarketableSecurities_637824689802060303" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_MarketableSecuritiesAmortizedCostBasisCurrent" xlink:label="imrx_MarketableSecuritiesAmortizedCostBasisCurrent" />
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_MarketableSecuritiesAccumulatedUnrealizedGainsCurrent" xlink:label="imrx_MarketableSecuritiesAccumulatedUnrealizedGainsCurrent_637824689802060303" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="imrx_MarketableSecuritiesAmortizedCostBasisCurrent" xlink:to="imrx_MarketableSecuritiesAccumulatedUnrealizedGainsCurrent_637824689802060303" order="1" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_MarketableSecuritiesAccumulatedUnrealizedLossesCurrent" xlink:label="imrx_MarketableSecuritiesAccumulatedUnrealizedLossesCurrent_637824689802070365" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="imrx_MarketableSecuritiesAmortizedCostBasisCurrent" xlink:to="imrx_MarketableSecuritiesAccumulatedUnrealizedLossesCurrent_637824689802070365" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="us-gaap_MarketableSecuritiesCurrent_637824689802070365" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="imrx_MarketableSecuritiesAmortizedCostBasisCurrent" xlink:to="us-gaap_MarketableSecuritiesCurrent_637824689802070365" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_MarketableSecuritiesAmortizedCostBasisNonCurrent" xlink:label="imrx_MarketableSecuritiesAmortizedCostBasisNonCurrent" />
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_MarketableSecuritiesAccumulatedUnrealizedLossesNonCurrent" xlink:label="imrx_MarketableSecuritiesAccumulatedUnrealizedLossesNonCurrent_637824689802070365" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="imrx_MarketableSecuritiesAmortizedCostBasisNonCurrent" xlink:to="imrx_MarketableSecuritiesAccumulatedUnrealizedLossesNonCurrent_637824689802070365" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesNoncurrent" xlink:label="us-gaap_MarketableSecuritiesNoncurrent_637824689802070365" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="imrx_MarketableSecuritiesAmortizedCostBasisNonCurrent" xlink:to="us-gaap_MarketableSecuritiesNoncurrent_637824689802070365" order="2" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://immuneering.com/role/DisclosureFairValueMeasurementsDetails" xlink:type="extended" xlink:title="40401 - Disclosure - Fair Value Measurements (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure" />
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_MarketableSecuritiesFairValueDisclosure" xlink:label="imrx_MarketableSecuritiesFairValueDisclosure_637824689802070365" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="imrx_MarketableSecuritiesFairValueDisclosure_637824689802070365" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_637824689802080313" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure_637824689802080313" order="2" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://immuneering.com/role/DisclosurePropertyAndEquipmentNetDetails" xlink:type="extended" xlink:title="40501 - Disclosure - Property and Equipment, net (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_637824689802080313" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_637824689802080313" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_637824689802080313" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_637824689802080313" order="2" use="optional" weight="-1" />
  </calculationLink>
  <calculationLink xlink:role="http://immuneering.com/role/DisclosureBusinessCombinationAssetsAcquiredAndLiabilitiesAssumedDetails" xlink:type="extended" xlink:title="40602 - Disclosure - Business Combination - Assets Acquired and Liabilities Assumed (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation_637824689802080313" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation_637824689802080313" order="1" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_637824689802080313" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_637824689802080313" order="2" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAccruedExpensesAndOtherLiabilities" xlink:label="imrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAccruedExpensesAndOtherLiabilities_637824689802080313" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:to="imrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAccruedExpensesAndOtherLiabilities_637824689802080313" order="3" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIncludingGoodwill" xlink:label="imrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIncludingGoodwill_637824689802090216" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:to="imrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIncludingGoodwill_637824689802090216" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill_637824689802090216" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="imrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIncludingGoodwill_637824689802090216" xlink:to="us-gaap_Goodwill_637824689802090216" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_637824689802090216" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="imrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIncludingGoodwill_637824689802090216" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_637824689802090216" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_637824689802090216" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="imrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIncludingGoodwill_637824689802090216" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_637824689802090216" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_637824689802090216" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="imrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIncludingGoodwill_637824689802090216" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_637824689802090216" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_637824689802090216" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="imrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIncludingGoodwill_637824689802090216" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_637824689802090216" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_637824689802090216" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="imrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIncludingGoodwill_637824689802090216" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_637824689802090216" order="6" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets" xlink:label="imrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets_637824689802090216" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="imrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIncludingGoodwill_637824689802090216" xlink:to="imrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets_637824689802090216" order="7" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://immuneering.com/role/DisclosureAccruedExpensesDetails" xlink:type="extended" xlink:title="40701 - Disclosure - Accrued Expenses (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent_637824689802100198" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent_637824689802100198" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedEmployeeBenefitsCurrentAndNoncurrent" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrentAndNoncurrent_637824689802100198" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedEmployeeBenefitsCurrentAndNoncurrent_637824689802100198" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_AccruedContractResearchExpensesCurrent" xlink:label="imrx_AccruedContractResearchExpensesCurrent_637824689802100198" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="imrx_AccruedContractResearchExpensesCurrent_637824689802100198" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent_637824689802100198" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent_637824689802100198" order="4" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://immuneering.com/role/DisclosureCommitmentsAndContingenciesMaturitiesOfLeaseLiabilitiesDueDetailsCalc2" xlink:type="extended" xlink:title="40902 - Disclosure - Commitments and Contingencies - Maturities of the lease liabilities due (Details) - Calc2" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_637824689802100198" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_637824689802100198" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_637824689802100198" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_637824689802100198" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_637824689802100198" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_637824689802100198" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_637824689802110219" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_637824689802110219" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_637824689802110219" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_637824689802110219" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_637824689802110219" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_637824689802110219" order="6" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_637824689802110219" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeaseLiability_1" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_637824689802110219" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_637824689802110219" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeaseLiability_1" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_637824689802110219" order="2" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://immuneering.com/role/DisclosureIncomeTaxesNetLossAndEffectiveIncomeTaxRateDetails" xlink:type="extended" xlink:title="41201 - Disclosure - Income Taxes - Net loss and the effective income tax rate (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_637824689802110219" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_637824689802110219" order="1" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_637824689802120280" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_637824689802120280" order="2" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_EffectiveIncomeTaxRateReconciliationUncertainTaxPositions" xlink:label="imrx_EffectiveIncomeTaxRateReconciliationUncertainTaxPositions_637824689802120280" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="imrx_EffectiveIncomeTaxRateReconciliationUncertainTaxPositions_637824689802120280" order="3" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_EffectiveIncomeTaxRateReconciliationTaxCreditStateResearchAndDevelopmentPercent" xlink:label="imrx_EffectiveIncomeTaxRateReconciliationTaxCreditStateResearchAndDevelopmentPercent_637824689802120280" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="imrx_EffectiveIncomeTaxRateReconciliationTaxCreditStateResearchAndDevelopmentPercent_637824689802120280" order="4" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_637824689802120280" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_637824689802120280" order="5" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_637824689802120280" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_637824689802120280" order="6" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_637824689802120280" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_637824689802120280" order="7" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_637824689802120280" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_637824689802120280" order="8" use="optional" weight="-1" />
  </calculationLink>
  <calculationLink xlink:role="http://immuneering.com/role/DisclosureIncomeTaxesNetDeferredTaxAssetsDetails" xlink:type="extended" xlink:title="41202 - Disclosure - Income Taxes - Net deferred tax assets (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_637824689802130393" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_637824689802130393" order="1" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" xlink:label="us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_637824689802130393" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilities_637824689802130393" xlink:to="us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_637824689802130393" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_637824689802130393" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilities_637824689802130393" xlink:to="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_637824689802130393" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet_637824689802130393" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsNet_637824689802130393" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross_637824689802130393" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet_637824689802130393" xlink:to="us-gaap_DeferredTaxAssetsGross_637824689802130393" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_637824689802130393" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_637824689802130393" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_637824689802130393" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsUnrealizedCurrencyLosses" xlink:label="us-gaap_DeferredTaxAssetsUnrealizedCurrencyLosses_637824689802130393" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_637824689802130393" xlink:to="us-gaap_DeferredTaxAssetsUnrealizedCurrencyLosses_637824689802130393" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_637824689802130393" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_637824689802130393" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_637824689802130393" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_637824689802140324" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_637824689802130393" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_637824689802140324" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_637824689802140324" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet_637824689802130393" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_637824689802140324" order="2" use="optional" weight="-1" />
  </calculationLink>
  <calculationLink xlink:role="http://immuneering.com/role/DisclosureCommitmentsAndContingenciesMaturitiesOfLeaseLiabilitiesDueDetails" xlink:type="extended" xlink:title="41302 - Disclosure - Commitments and Contingencies - Maturities of the lease liabilities due (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_637824689802140324" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_637824689802140324" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability_637824689802140324" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_OperatingLeaseLiability_637824689802140324" order="2" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://immuneering.com/role/DisclosureCommitmentsAndContingenciesLeaseCostDetails" xlink:type="extended" xlink:title="41303 - Disclosure - Commitments and Contingencies - Lease cost (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_LeasePayments" xlink:label="imrx_LeasePayments" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments_637824689802140324" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="imrx_LeasePayments" xlink:to="us-gaap_OperatingLeasePayments_637824689802140324" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermLeasePayments" xlink:label="us-gaap_ShortTermLeasePayments_637824689802150309" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="imrx_LeasePayments" xlink:to="us-gaap_ShortTermLeasePayments_637824689802150309" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost_637824689802150309" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_OperatingLeaseCost_637824689802150309" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermLeaseCost" xlink:label="us-gaap_ShortTermLeaseCost_637824689802150309" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_ShortTermLeaseCost_637824689802150309" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableLeaseCost" xlink:label="us-gaap_VariableLeaseCost_637824689802150309" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_VariableLeaseCost_637824689802150309" order="3" use="optional" weight="1" />
  </calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>40
<FILENAME>imrx-20211231_def.xml
<DESCRIPTION>EX-101.DEF
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.8042.36810 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/10/2022 12:29:41 AM-->
<!--Modified on: 3/10/2022 12:29:42 AM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <roleRef xlink:type="simple" xlink:href="imrx-20211231.xsd#DocumentDocumentAndEntityInformation" roleURI="http://immuneering.com/role/DocumentDocumentAndEntityInformation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="imrx-20211231.xsd#StatementConsolidatedBalanceSheets" roleURI="http://immuneering.com/role/StatementConsolidatedBalanceSheets" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="imrx-20211231.xsd#StatementConsolidatedBalanceSheetsParentheticals" roleURI="http://immuneering.com/role/StatementConsolidatedBalanceSheetsParentheticals" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="imrx-20211231.xsd#StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" roleURI="http://immuneering.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="imrx-20211231.xsd#StatementConsolidatedStatementsOfCashFlows" roleURI="http://immuneering.com/role/StatementConsolidatedStatementsOfCashFlows" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="imrx-20211231.xsd#DisclosureOrganizationAndNatureOfBusinessDetails" roleURI="http://immuneering.com/role/DisclosureOrganizationAndNatureOfBusinessDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="imrx-20211231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesConcentrationOfCreditRiskDetails" roleURI="http://immuneering.com/role/DisclosureSummaryOfSignificantAccountingPoliciesConcentrationOfCreditRiskDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="imrx-20211231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails" roleURI="http://immuneering.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="imrx-20211231.xsd#DisclosureMarketableSecuritiesDetails" roleURI="http://immuneering.com/role/DisclosureMarketableSecuritiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="imrx-20211231.xsd#DisclosureFairValueMeasurementsDetails" roleURI="http://immuneering.com/role/DisclosureFairValueMeasurementsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="imrx-20211231.xsd#DisclosurePropertyAndEquipmentNetDetails" roleURI="http://immuneering.com/role/DisclosurePropertyAndEquipmentNetDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="imrx-20211231.xsd#DisclosureBusinessCombinationNarrativeDetails" roleURI="http://immuneering.com/role/DisclosureBusinessCombinationNarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="imrx-20211231.xsd#DisclosureBusinessCombinationAssetsAcquiredAndLiabilitiesAssumedDetails" roleURI="http://immuneering.com/role/DisclosureBusinessCombinationAssetsAcquiredAndLiabilitiesAssumedDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="imrx-20211231.xsd#DisclosureConvertiblePreferredStockSeriesDetails" roleURI="http://immuneering.com/role/DisclosureConvertiblePreferredStockSeriesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="imrx-20211231.xsd#DisclosureConvertiblePreferredStockSeriesBDetails" roleURI="http://immuneering.com/role/DisclosureConvertiblePreferredStockSeriesBDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="imrx-20211231.xsd#DisclosureCommonStockClassCommonStockDetails" roleURI="http://immuneering.com/role/DisclosureCommonStockClassCommonStockDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="imrx-20211231.xsd#DisclosureCommonStockDetails" roleURI="http://immuneering.com/role/DisclosureCommonStockDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="imrx-20211231.xsd#DisclosureCommonStockClassBCommonStockDetails" roleURI="http://immuneering.com/role/DisclosureCommonStockClassBCommonStockDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="imrx-20211231.xsd#DisclosureCommonStockIpoDetails" roleURI="http://immuneering.com/role/DisclosureCommonStockIpoDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="imrx-20211231.xsd#DisclosureNetLossPerShareAttributableToCommonStockholdersAntidilutiveEffectDetails" roleURI="http://immuneering.com/role/DisclosureNetLossPerShareAttributableToCommonStockholdersAntidilutiveEffectDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="imrx-20211231.xsd#DisclosureStockBasedCompensationNarrativesDetails" roleURI="http://immuneering.com/role/DisclosureStockBasedCompensationNarrativesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="imrx-20211231.xsd#DisclosureStockBasedCompensationAssumptionsDetails" roleURI="http://immuneering.com/role/DisclosureStockBasedCompensationAssumptionsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="imrx-20211231.xsd#DisclosureStockBasedCompensationShareBasedCompensationExpenseDetails" roleURI="http://immuneering.com/role/DisclosureStockBasedCompensationShareBasedCompensationExpenseDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="imrx-20211231.xsd#DisclosureIncomeTaxesNarrativeDetails" roleURI="http://immuneering.com/role/DisclosureIncomeTaxesNarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="imrx-20211231.xsd#DisclosureCommitmentsAndContingenciesNarrativesDetails" roleURI="http://immuneering.com/role/DisclosureCommitmentsAndContingenciesNarrativesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="imrx-20211231.xsd#DisclosureCommitmentsAndContingenciesMaturitiesOfLeaseLiabilitiesDueDetails" roleURI="http://immuneering.com/role/DisclosureCommitmentsAndContingenciesMaturitiesOfLeaseLiabilitiesDueDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:roleRef roleURI="http://immuneering.com/role/DisclosureStandardAndCustomAxisDomainDefaults" xlink:href="imrx-20211231.xsd#DisclosureStandardAndCustomAxisDomainDefaults" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" />
  <link:arcroleRef arcroleURI="http://www.esma.europa.eu/xbrl/esef/arcrole/wider-narrower" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd#wider-narrower" />
  <link:definitionLink xlink:role="http://immuneering.com/role/DisclosureStandardAndCustomAxisDomainDefaults" xlink:type="extended" xlink:title="99900 - Disclosure - Standard And Custom Axis Domain Defaults">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_1" xlink:title="us-gaap_SubsidiarySaleOfStockAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_1" xlink:title="us-gaap_SaleOfStockNameOfTransactionDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_1" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_SubsidiarySaleOfStockAxis_1 To us-gaap_SaleOfStockNameOfTransactionDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" xlink:title="us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_1" xlink:title="us-gaap_PropertyPlantAndEquipmentTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_PropertyPlantAndEquipmentByTypeAxis_1 To us-gaap_PropertyPlantAndEquipmentTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_1" xlink:title="us-gaap_StatementClassOfStockAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_1" xlink:title="us-gaap_ClassOfStockDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_StatementClassOfStockAxis_1" xlink:to="us-gaap_ClassOfStockDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_StatementClassOfStockAxis_1 To us-gaap_ClassOfStockDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_1" xlink:title="us-gaap_StatementEquityComponentsAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_1" xlink:title="us-gaap_EquityComponentDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_StatementEquityComponentsAxis_1" xlink:to="us-gaap_EquityComponentDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_StatementEquityComponentsAxis_1 To us-gaap_EquityComponentDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_1" xlink:title="srt_RangeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember_1" xlink:title="srt_RangeMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_RangeAxis_1" xlink:to="srt_RangeMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_RangeAxis_1 To srt_RangeMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1" xlink:title="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_1" xlink:title="us-gaap_AntidilutiveSecuritiesNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1 To us-gaap_AntidilutiveSecuritiesNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis_1" xlink:title="dei_LegalEntityAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_1" xlink:title="dei_EntityDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="dei_LegalEntityAxis_1" xlink:to="dei_EntityDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:dei_LegalEntityAxis_1 To dei_EntityDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1" xlink:title="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_1" xlink:title="us-gaap_RelatedPartyDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1" xlink:to="us-gaap_RelatedPartyDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1 To us-gaap_RelatedPartyDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis_1" xlink:title="us-gaap_IncomeStatementLocationAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_1" xlink:title="us-gaap_IncomeStatementLocationDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_IncomeStatementLocationAxis_1" xlink:to="us-gaap_IncomeStatementLocationDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_IncomeStatementLocationAxis_1 To us-gaap_IncomeStatementLocationDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis_1" xlink:title="us-gaap_BalanceSheetLocationAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain_1" xlink:title="us-gaap_BalanceSheetLocationDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_BalanceSheetLocationAxis_1" xlink:to="us-gaap_BalanceSheetLocationDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_BalanceSheetLocationAxis_1 To us-gaap_BalanceSheetLocationDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_1" xlink:title="us-gaap_PlanNameAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_1" xlink:title="us-gaap_PlanNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_PlanNameAxis_1" xlink:to="us-gaap_PlanNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_PlanNameAxis_1 To us-gaap_PlanNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis_1" xlink:title="us-gaap_SubsequentEventTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_1" xlink:title="us-gaap_SubsequentEventTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_SubsequentEventTypeAxis_1" xlink:to="us-gaap_SubsequentEventTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_SubsequentEventTypeAxis_1 To us-gaap_SubsequentEventTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis_1" xlink:title="us-gaap_FinancialInstrumentAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1" xlink:title="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_FinancialInstrumentAxis_1" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_FinancialInstrumentAxis_1 To us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_1" xlink:title="us-gaap_FairValueByMeasurementFrequencyAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_1" xlink:title="us-gaap_FairValueMeasurementFrequencyDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis_1" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_FairValueByMeasurementFrequencyAxis_1 To us-gaap_FairValueMeasurementFrequencyDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_1" xlink:title="us-gaap_FairValueByFairValueHierarchyLevelAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" xlink:title="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis_1" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_FairValueByFairValueHierarchyLevelAxis_1 To us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis_1" xlink:title="us-gaap_FairValueByAssetClassAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_1" xlink:title="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_FairValueByAssetClassAxis_1" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_FairValueByAssetClassAxis_1 To us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis_1" xlink:title="us-gaap_BusinessAcquisitionAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_1" xlink:title="us-gaap_BusinessAcquisitionAcquireeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_BusinessAcquisitionAxis_1" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_BusinessAcquisitionAxis_1 To us-gaap_BusinessAcquisitionAcquireeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="us-gaap_LeaseContractualTermAxis_1" xlink:title="us-gaap_LeaseContractualTermAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain_1" xlink:title="us-gaap_LeaseContractualTermDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_LeaseContractualTermAxis_1" xlink:to="us-gaap_LeaseContractualTermDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_LeaseContractualTermAxis_1 To us-gaap_LeaseContractualTermDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis_1" xlink:title="us-gaap_IncomeTaxAuthorityAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_1" xlink:title="us-gaap_IncomeTaxAuthorityDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_IncomeTaxAuthorityAxis_1" xlink:to="us-gaap_IncomeTaxAuthorityDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_IncomeTaxAuthorityAxis_1 To us-gaap_IncomeTaxAuthorityDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis_1" xlink:title="us-gaap_TaxCreditCarryforwardAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_1" xlink:title="us-gaap_TaxCreditCarryforwardNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_TaxCreditCarryforwardAxis_1" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_TaxCreditCarryforwardAxis_1 To us-gaap_TaxCreditCarryforwardNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis_1" xlink:title="us-gaap_ConcentrationRiskByBenchmarkAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_1" xlink:title="us-gaap_ConcentrationRiskBenchmarkDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis_1" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_ConcentrationRiskByBenchmarkAxis_1 To us-gaap_ConcentrationRiskBenchmarkDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis_1" xlink:title="us-gaap_ConcentrationRiskByTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain_1" xlink:title="us-gaap_ConcentrationRiskTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_ConcentrationRiskByTypeAxis_1" xlink:to="us-gaap_ConcentrationRiskTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_ConcentrationRiskByTypeAxis_1 To us-gaap_ConcentrationRiskTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis" xlink:label="srt_MajorCustomersAxis_1" xlink:title="srt_MajorCustomersAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="srt_NameOfMajorCustomerDomain_1" xlink:title="srt_NameOfMajorCustomerDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_MajorCustomersAxis_1" xlink:to="srt_NameOfMajorCustomerDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_MajorCustomersAxis_1 To srt_NameOfMajorCustomerDomain_1" order="1" />
  </link:definitionLink>
  <definitionLink xlink:role="http://immuneering.com/role/DocumentDocumentAndEntityInformation" xlink:type="extended" xlink:title="00090 - Document - Document and Entity Information" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassAMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassBMember" xlink:label="us-gaap_CommonClassBMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassBMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_DocumentType" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_DocumentAnnualReport" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_DocumentTransitionReport" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_DocumentPeriodEndDate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_EntityFileNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_EntityRegistrantName" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_EntityTaxIdentificationNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_EntityAddressAddressLine1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_EntityAddressAddressLine2" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_EntityAddressCityOrTown" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_EntityAddressStateOrProvince" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_EntityAddressPostalZipCode" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_CityAreaCode" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_LocalPhoneNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_Security12bTitle" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="18" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_TradingSymbol" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="19" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_SecurityExchangeName" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="20" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_EntityWellKnownSeasonedIssuer" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="21" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_EntityVoluntaryFilers" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="22" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_EntityCurrentReportingStatus" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="23" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_EntityInteractiveDataCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="24" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_EntityFilerCategory" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="25" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_EntitySmallBusiness" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="26" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_EntityEmergingGrowthCompany" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="27" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_EntityExTransitionPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="28" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_IcfrAuditorAttestationFlag" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="29" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_EntityShellCompany" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="30" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_EntityPublicFloat" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="31" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="32" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorName" xlink:label="dei_AuditorName" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="33" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_AuditorName" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="34" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_AuditorFirmId" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="35" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_AuditorLocation" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="36" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_EntityCentralIndexKey" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="37" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_CurrentFiscalYearEndDate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="38" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_DocumentFiscalYearFocus" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="39" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="40" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_AmendmentFlag" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://immuneering.com/role/StatementConsolidatedBalanceSheets" xlink:type="extended" xlink:title="00100 - Statement - CONSOLIDATED BALANCE SHEETS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_SeriesConvertiblePreferredStockMember" xlink:label="imrx_SeriesConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="imrx_SeriesConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_SeriesBConvertiblePreferredStockMember" xlink:label="imrx_SeriesBConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="imrx_SeriesBConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassAMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassBMember" xlink:label="us-gaap_CommonClassBMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassBMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="us-gaap_MarketableSecuritiesCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_MarketableSecuritiesCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AccountsReceivableNetCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesNoncurrent" xlink:label="us-gaap_MarketableSecuritiesNoncurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_MarketableSecuritiesNoncurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Goodwill" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_Liabilities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityAbstract" xlink:label="us-gaap_TemporaryEquityAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_TemporaryEquityAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_TemporaryEquityAbstract" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://immuneering.com/role/StatementConsolidatedBalanceSheetsParentheticals" xlink:type="extended" xlink:title="00105 - Statement - CONSOLIDATED BALANCE SHEETS (Parentheticals)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_SeriesConvertiblePreferredStockMember" xlink:label="imrx_SeriesConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="imrx_SeriesConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_SeriesBConvertiblePreferredStockMember" xlink:label="imrx_SeriesBConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="imrx_SeriesBConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassAMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassBMember" xlink:label="us-gaap_CommonClassBMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassBMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="us-gaap_TemporaryEquitySharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesIssued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://immuneering.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" xlink:type="extended" xlink:title="00300 - Statement - CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_PreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_SeriesConvertiblePreferredStockMember" xlink:label="imrx_SeriesConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="imrx_SeriesConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_SeriesBConvertiblePreferredStockMember" xlink:label="imrx_SeriesBConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="imrx_SeriesBConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassAMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_SharesOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockholdersEquity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_StockIssuedDuringPeriodValueWarrantsExercised" xlink:label="imrx_StockIssuedDuringPeriodValueWarrantsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="imrx_StockIssuedDuringPeriodValueWarrantsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:label="imrx_StockIssuedDuringPeriodSharesWarrantsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="imrx_StockIssuedDuringPeriodSharesWarrantsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="us-gaap_StockIssuedDuringPeriodValueAcquisitions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodValueAcquisitions" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_NetIncomeLoss" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:to="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:label="imrx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:to="imrx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://immuneering.com/role/StatementConsolidatedStatementsOfCashFlows" xlink:type="extended" xlink:title="00400 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_SeriesConvertiblePreferredStockMember" xlink:label="imrx_SeriesConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="imrx_SeriesConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_SeriesBConvertiblePreferredStockMember" xlink:label="imrx_SeriesBConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="imrx_SeriesBConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_Depreciation" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:label="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAcquiredInExcessOfPaymentsToAcquireBusiness" xlink:label="us-gaap_CashAcquiredInExcessOfPaymentsToAcquireBusiness" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_CashAcquiredInExcessOfPaymentsToAcquireBusiness" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromWarrantExercises" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssued1" xlink:label="us-gaap_StockIssued1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_StockIssued1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:label="us-gaap_BusinessCombinationAcquisitionRelatedCosts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_BusinessCombinationAcquisitionRelatedCosts" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="us-gaap_ConversionOfStockSharesIssued1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_ConversionOfStockSharesIssued1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_ReclassificationOfLiabilityOfPreferredStock" xlink:label="imrx_ReclassificationOfLiabilityOfPreferredStock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="imrx_ReclassificationOfLiabilityOfPreferredStock" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://immuneering.com/role/DisclosureOrganizationAndNatureOfBusinessDetails" xlink:type="extended" xlink:title="40101 - Disclosure - Organization and Nature of Business (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" xlink:label="us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassAMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_OfferingCostPayable" xlink:label="imrx_OfferingCostPayable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="imrx_OfferingCostPayable" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://immuneering.com/role/DisclosureSummaryOfSignificantAccountingPoliciesConcentrationOfCreditRiskDetails" xlink:type="extended" xlink:title="40202 - Disclosure - Summary of Significant Accounting Policies - Concentration of Credit Risk (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTable" xlink:label="us-gaap_ConcentrationRiskTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalesRevenueNetMember" xlink:label="us-gaap_SalesRevenueNetMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_SalesRevenueNetMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableMember" xlink:label="us-gaap_AccountsReceivableMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_AccountsReceivableMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="us-gaap_ConcentrationRiskByTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="us-gaap_CustomerConcentrationRiskMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_CustomerConcentrationRiskMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis" xlink:label="srt_MajorCustomersAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="srt_MajorCustomersAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="srt_NameOfMajorCustomerDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_NameOfMajorCustomerDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_CustomerOneMember" xlink:label="imrx_CustomerOneMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="imrx_CustomerOneMember" use="optional" />
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_CustomerTwoMember" xlink:label="imrx_CustomerTwoMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="imrx_CustomerTwoMember" use="optional" />
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_CustomerThreeMember" xlink:label="imrx_CustomerThreeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="imrx_CustomerThreeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_CustomerFourMember" xlink:label="imrx_CustomerFourMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="imrx_CustomerFourMember" use="optional" />
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_CustomerFiveMember" xlink:label="imrx_CustomerFiveMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="imrx_CustomerFiveMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="us-gaap_ConcentrationRiskLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="us-gaap_ConcentrationRiskTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="us-gaap_AccountsReceivableNetCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="us-gaap_ConcentrationRiskPercentage1" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://immuneering.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails" xlink:type="extended" xlink:title="40203 - Disclosure - Summary of Significant Accounting Policies - Property and Equipment (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_LabEquipmentMember" xlink:label="imrx_LabEquipmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="imrx_LabEquipmentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdsAndLeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdsAndLeaseholdImprovementsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdsAndLeaseholdImprovementsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://immuneering.com/role/DisclosureMarketableSecuritiesDetails" xlink:type="extended" xlink:title="40301 - Disclosure - Marketable Securities (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesTable" xlink:label="us-gaap_MarketableSecuritiesTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_MarketableSecuritiesTable" xlink:to="us-gaap_FinancialInstrumentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USTreasurySecuritiesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_GovernmentSecuritiesMember" xlink:label="imrx_GovernmentSecuritiesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="imrx_GovernmentSecuritiesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CommercialPaperMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesLineItems" xlink:label="us-gaap_MarketableSecuritiesLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="us-gaap_MarketableSecuritiesTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfInvestments" xlink:label="us-gaap_ImpairmentOfInvestments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="us-gaap_ImpairmentOfInvestments" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesRealizedGainLoss" xlink:label="us-gaap_MarketableSecuritiesRealizedGainLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="us-gaap_MarketableSecuritiesRealizedGainLoss" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_MarketableSecuritiesCurrentAbstract" xlink:label="imrx_MarketableSecuritiesCurrentAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="imrx_MarketableSecuritiesCurrentAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_MarketableSecuritiesAmortizedCostBasisCurrent" xlink:label="imrx_MarketableSecuritiesAmortizedCostBasisCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="imrx_MarketableSecuritiesCurrentAbstract" xlink:to="imrx_MarketableSecuritiesAmortizedCostBasisCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_MarketableSecuritiesAccumulatedUnrealizedGainsCurrent" xlink:label="imrx_MarketableSecuritiesAccumulatedUnrealizedGainsCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="imrx_MarketableSecuritiesCurrentAbstract" xlink:to="imrx_MarketableSecuritiesAccumulatedUnrealizedGainsCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_MarketableSecuritiesAccumulatedUnrealizedLossesCurrent" xlink:label="imrx_MarketableSecuritiesAccumulatedUnrealizedLossesCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="imrx_MarketableSecuritiesCurrentAbstract" xlink:to="imrx_MarketableSecuritiesAccumulatedUnrealizedLossesCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="us-gaap_MarketableSecuritiesCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="imrx_MarketableSecuritiesCurrentAbstract" xlink:to="us-gaap_MarketableSecuritiesCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_MarketableSecuritiesNonCurrentAbstract" xlink:label="imrx_MarketableSecuritiesNonCurrentAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="imrx_MarketableSecuritiesNonCurrentAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_MarketableSecuritiesAmortizedCostBasisNonCurrent" xlink:label="imrx_MarketableSecuritiesAmortizedCostBasisNonCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="imrx_MarketableSecuritiesNonCurrentAbstract" xlink:to="imrx_MarketableSecuritiesAmortizedCostBasisNonCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_MarketableSecuritiesAccumulatedUnrealizedLossesNonCurrent" xlink:label="imrx_MarketableSecuritiesAccumulatedUnrealizedLossesNonCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="imrx_MarketableSecuritiesNonCurrentAbstract" xlink:to="imrx_MarketableSecuritiesAccumulatedUnrealizedLossesNonCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesNoncurrent" xlink:label="us-gaap_MarketableSecuritiesNoncurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="imrx_MarketableSecuritiesNonCurrentAbstract" xlink:to="us-gaap_MarketableSecuritiesNoncurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesAbstract" xlink:label="us-gaap_MarketableSecuritiesAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="us-gaap_MarketableSecuritiesAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_MarketableSecuritiesAmortizedCostBasis" xlink:label="imrx_MarketableSecuritiesAmortizedCostBasis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_MarketableSecuritiesAbstract" xlink:to="imrx_MarketableSecuritiesAmortizedCostBasis" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_MarketableSecuritiesAccumulatedUnrealizedGains" xlink:label="imrx_MarketableSecuritiesAccumulatedUnrealizedGains" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_MarketableSecuritiesAbstract" xlink:to="imrx_MarketableSecuritiesAccumulatedUnrealizedGains" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_MarketableSecuritiesAccumulatedUnrealizedLosses" xlink:label="imrx_MarketableSecuritiesAccumulatedUnrealizedLosses" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_MarketableSecuritiesAbstract" xlink:to="imrx_MarketableSecuritiesAccumulatedUnrealizedLosses" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecurities" xlink:label="us-gaap_MarketableSecurities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_MarketableSecuritiesAbstract" xlink:to="us-gaap_MarketableSecurities" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://immuneering.com/role/DisclosureFairValueMeasurementsDetails" xlink:type="extended" xlink:title="40401 - Disclosure - Fair Value Measurements (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByAssetClassAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_CommercialPaperMember" use="optional" />
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_GovernmentSecuritiesMember" xlink:label="imrx_GovernmentSecuritiesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="imrx_GovernmentSecuritiesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_USTreasurySecuritiesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_MoneyMarketFundsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosureAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_MarketableSecuritiesFairValueDisclosure" xlink:label="imrx_MarketableSecuritiesFairValueDisclosure" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="imrx_MarketableSecuritiesFairValueDisclosure" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_AssetsFairValueDisclosure" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecurities" xlink:label="us-gaap_MarketableSecurities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_MarketableSecurities" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://immuneering.com/role/DisclosurePropertyAndEquipmentNetDetails" xlink:type="extended" xlink:title="40501 - Disclosure - Property and Equipment, net (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_LabEquipmentMember" xlink:label="imrx_LabEquipmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="imrx_LabEquipmentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://immuneering.com/role/DisclosureBusinessCombinationNarrativeDetails" xlink:type="extended" xlink:title="40601 - Disclosure - Business Combination - Narrative (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_BusinessAcquisitionAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_BioArkiveIncMember" xlink:label="imrx_BioArkiveIncMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="imrx_BioArkiveIncMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="imrx_BioArkiveIncMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_IncomeStatementLocationAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_BalanceSheetLocationAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesMember" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_BusinessCombinationPurchasePrice" xlink:label="imrx_BusinessCombinationPurchasePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="imrx_BusinessCombinationPurchasePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_NumberOfLeasesObligationsAssumed" xlink:label="imrx_NumberOfLeasesObligationsAssumed" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="imrx_NumberOfLeasesObligationsAssumed" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_BusinessCombinationSharesIssuedSharePriceThresholdTradingDays" xlink:label="imrx_BusinessCombinationSharesIssuedSharePriceThresholdTradingDays" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="imrx_BusinessCombinationSharesIssuedSharePriceThresholdTradingDays" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_BusinessCombinationSharesIssuedLockInPeriod" xlink:label="imrx_BusinessCombinationSharesIssuedLockInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="imrx_BusinessCombinationSharesIssuedLockInPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_BusinessCombinationSharesIssuedDiscountDueToMarketabilityPercentage" xlink:label="imrx_BusinessCombinationSharesIssuedDiscountDueToMarketabilityPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="imrx_BusinessCombinationSharesIssuedDiscountDueToMarketabilityPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationConsiderationTransferred1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_RelatedPartyTransactionAmountsOfTransaction" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent" xlink:label="us-gaap_DueToRelatedPartiesCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_DueToRelatedPartiesCurrent" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://immuneering.com/role/DisclosureBusinessCombinationAssetsAcquiredAndLiabilitiesAssumedDetails" xlink:type="extended" xlink:title="40602 - Disclosure - Business Combination - Assets Acquired and Liabilities Assumed (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_BusinessAcquisitionAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_BioArkiveIncMember" xlink:label="imrx_BioArkiveIncMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="imrx_BioArkiveIncMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets" xlink:label="imrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract" xlink:to="imrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract" xlink:to="us-gaap_Goodwill" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIncludingGoodwill" xlink:label="imrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIncludingGoodwill" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="imrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIncludingGoodwill" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAccruedExpensesAndOtherLiabilities" xlink:label="imrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAccruedExpensesAndOtherLiabilities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="imrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAccruedExpensesAndOtherLiabilities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:label="us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://immuneering.com/role/DisclosureConvertiblePreferredStockSeriesDetails" xlink:type="extended" xlink:title="40801 - Disclosure - Convertible Preferred Stock - Series A (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityByClassOfStockTable" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_SeriesConvertiblePreferredStockMember" xlink:label="imrx_SeriesConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="imrx_SeriesConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityLineItems" xlink:label="us-gaap_TemporaryEquityLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquityByClassOfStockTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="us-gaap_TemporaryEquitySharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquitySharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_TemporaryEquityIssuancePrice" xlink:label="imrx_TemporaryEquityIssuancePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="imrx_TemporaryEquityIssuancePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquitySharesIssued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_TemporaryEquityNumberOfSharesExcessOfAuthorized" xlink:label="imrx_TemporaryEquityNumberOfSharesExcessOfAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="imrx_TemporaryEquityNumberOfSharesExcessOfAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_ProceedsFromIssuanceOfConvertiblePreferredStockExcessOfAuthorizedAmount" xlink:label="imrx_ProceedsFromIssuanceOfConvertiblePreferredStockExcessOfAuthorizedAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="imrx_ProceedsFromIssuanceOfConvertiblePreferredStockExcessOfAuthorizedAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_TemporaryEquityDueToExcessAuthorizedAmount" xlink:label="imrx_TemporaryEquityDueToExcessAuthorizedAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="imrx_TemporaryEquityDueToExcessAuthorizedAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_TemporaryEquityConversionPrice" xlink:label="imrx_TemporaryEquityConversionPrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="imrx_TemporaryEquityConversionPrice" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://immuneering.com/role/DisclosureConvertiblePreferredStockSeriesBDetails" xlink:type="extended" xlink:title="40802 - Disclosure - Convertible Preferred Stock - Series B (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityByClassOfStockTable" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_SeriesBConvertiblePreferredStockMember" xlink:label="imrx_SeriesBConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="imrx_SeriesBConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_SeriesBConvertiblePreferredStocksTrancheOneMember" xlink:label="imrx_SeriesBConvertiblePreferredStocksTrancheOneMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="imrx_SeriesBConvertiblePreferredStocksTrancheOneMember" use="optional" />
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_SeriesBConvertiblePreferredStockTrancheTwoMember" xlink:label="imrx_SeriesBConvertiblePreferredStockTrancheTwoMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="imrx_SeriesBConvertiblePreferredStockTrancheTwoMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityLineItems" xlink:label="us-gaap_TemporaryEquityLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquityByClassOfStockTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="us-gaap_TemporaryEquitySharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquitySharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_TemporaryEquityIssuancePrice" xlink:label="imrx_TemporaryEquityIssuancePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="imrx_TemporaryEquityIssuancePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_NumberOfTranches" xlink:label="imrx_NumberOfTranches" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="imrx_NumberOfTranches" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquitySharesIssued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_TemporaryEquityContingentlyIssuableShares" xlink:label="imrx_TemporaryEquityContingentlyIssuableShares" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="imrx_TemporaryEquityContingentlyIssuableShares" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_TemporaryEquityConversionPrice" xlink:label="imrx_TemporaryEquityConversionPrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="imrx_TemporaryEquityConversionPrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_PercentageOfEquitySecuritiesOwnedToGetConvertedStock" xlink:label="imrx_PercentageOfEquitySecuritiesOwnedToGetConvertedStock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="imrx_PercentageOfEquitySecuritiesOwnedToGetConvertedStock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:label="us-gaap_PreferredStockDividendRatePercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_PreferredStockDividendRatePercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DividendsPreferredStock" xlink:label="us-gaap_DividendsPreferredStock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_DividendsPreferredStock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://immuneering.com/role/DisclosureCommonStockClassCommonStockDetails" xlink:type="extended" xlink:title="40901 - Disclosure - Common Stock - Class A common stock (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassAMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesIssued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_NumberOfVotesPerShare" xlink:label="imrx_NumberOfVotesPerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="imrx_NumberOfVotesPerShare" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://immuneering.com/role/DisclosureCommonStockDetails" xlink:type="extended" xlink:title="40902 - Disclosure - Common Stock (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_SeriesConvertiblePreferredStockMember" xlink:label="imrx_SeriesConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="imrx_SeriesConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_SeriesBConvertiblePreferredStockMember" xlink:label="imrx_SeriesBConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="imrx_SeriesBConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_WarrantMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_EmployeeStockOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://immuneering.com/role/DisclosureCommonStockClassBCommonStockDetails" xlink:type="extended" xlink:title="40903 - Disclosure - Common Stock - Class B common stock (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassBMember" xlink:label="us-gaap_CommonClassBMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassBMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesIssued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_NumberOfVotesPerShare" xlink:label="imrx_NumberOfVotesPerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="imrx_NumberOfVotesPerShare" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://immuneering.com/role/DisclosureCommonStockIpoDetails" xlink:type="extended" xlink:title="40905 - Disclosure - Common Stock - IPO (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassAMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassBMember" xlink:label="us-gaap_CommonClassBMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassBMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_OfferingCostPayable" xlink:label="imrx_OfferingCostPayable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="imrx_OfferingCostPayable" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://immuneering.com/role/DisclosureNetLossPerShareAttributableToCommonStockholdersAntidilutiveEffectDetails" xlink:type="extended" xlink:title="41002 - Disclosure - Net Loss Per Share Attributable to Common Stockholders - Antidilutive effect (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_SeriesConvertiblePreferredStockMember" xlink:label="imrx_SeriesConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="imrx_SeriesConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_SeriesBConvertiblePreferredStockMember" xlink:label="imrx_SeriesBConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="imrx_SeriesBConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_WarrantMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://immuneering.com/role/DisclosureStockBasedCompensationNarrativesDetails" xlink:type="extended" xlink:title="41101 - Disclosure - Stock-Based Compensation - Narratives (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_StockIncentivePlan2015Member" xlink:label="imrx_StockIncentivePlan2015Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PlanNameDomain" xlink:to="imrx_StockIncentivePlan2015Member" use="optional" />
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_TwoThousandTwentyOneEmployeeStockPurchasePlanMember" xlink:label="imrx_TwoThousandTwentyOneEmployeeStockPurchasePlanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PlanNameDomain" xlink:to="imrx_TwoThousandTwentyOneEmployeeStockPurchasePlanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_TwoThousandTwentyOneIncentiveAwardPlanMember" xlink:label="imrx_TwoThousandTwentyOneIncentiveAwardPlanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_PlanNameDomain" xlink:to="imrx_TwoThousandTwentyOneIncentiveAwardPlanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassAMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_PercentageOfAggregateNumberOfSharesOutstanding" xlink:label="imrx_PercentageOfAggregateNumberOfSharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="imrx_PercentageOfAggregateNumberOfSharesOutstanding" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://immuneering.com/role/DisclosureStockBasedCompensationAssumptionsDetails" xlink:type="extended" xlink:title="41102 - Disclosure - Stock-Based Compensation - Assumptions (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://immuneering.com/role/DisclosureStockBasedCompensationShareBasedCompensationExpenseDetails" xlink:type="extended" xlink:title="41104 - Disclosure - Stock-Based Compensation - Share-based compensation expense (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_IncomeStatementLocationAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfSalesMember" xlink:label="us-gaap_CostOfSalesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_CostOfSalesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://immuneering.com/role/DisclosureIncomeTaxesNarrativeDetails" xlink:type="extended" xlink:title="41203 - Disclosure - Income Taxes - Narrative (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_TaxCreditCarryforwardAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_ResearchMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_BusinessAcquisitionAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_BioArkiveIncMember" xlink:label="imrx_BioArkiveIncMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="imrx_BioArkiveIncMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxesBusinessCombinationValuationAllowanceAvailableToReduceIncomeTaxExpense" xlink:label="us-gaap_DeferredTaxesBusinessCombinationValuationAllowanceAvailableToReduceIncomeTaxExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_DeferredTaxesBusinessCombinationValuationAllowanceAvailableToReduceIncomeTaxExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefits" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_TaxCreditCarryforwardIncreaseDecreaseCaresAct" xlink:label="imrx_TaxCreditCarryforwardIncreaseDecreaseCaresAct" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="imrx_TaxCreditCarryforwardIncreaseDecreaseCaresAct" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://immuneering.com/role/DisclosureCommitmentsAndContingenciesNarrativesDetails" xlink:type="extended" xlink:title="41301 - Disclosure - Commitments and Contingencies - Narratives (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_OfficeSpaceInCambridgeMassachusettsNewYorkMember" xlink:label="imrx_OfficeSpaceInCambridgeMassachusettsNewYorkMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="imrx_OfficeSpaceInCambridgeMassachusettsNewYorkMember" use="optional" />
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_StorageSpaceInSomervilleMassachusettsMember" xlink:label="imrx_StorageSpaceInSomervilleMassachusettsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="imrx_StorageSpaceInSomervilleMassachusettsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_OfficeLeaseInSanDiegoCalifornia2020Member" xlink:label="imrx_OfficeLeaseInSanDiegoCalifornia2020Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="imrx_OfficeLeaseInSanDiegoCalifornia2020Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="us-gaap_LeaseContractualTermAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LeaseContractualTermAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_LeaseTerminationOnApril302032Member" xlink:label="imrx_LeaseTerminationOnApril302032Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="imrx_LeaseTerminationOnApril302032Member" use="optional" />
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_LeaseTerminationOnDecember312022Member" xlink:label="imrx_LeaseTerminationOnDecember312022Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="imrx_LeaseTerminationOnDecember312022Member" use="optional" />
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_LeaseTerminationOnMarch312024Member" xlink:label="imrx_LeaseTerminationOnMarch312024Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="imrx_LeaseTerminationOnMarch312024Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_BusinessAcquisitionAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_BioArkiveIncMember" xlink:label="imrx_BioArkiveIncMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="imrx_BioArkiveIncMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseLiability" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_NumberOfLeasesObligationsAssumed" xlink:label="imrx_NumberOfLeasesObligationsAssumed" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="imrx_NumberOfLeasesObligationsAssumed" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_AreaOfPropertyUnderLease" xlink:label="imrx_AreaOfPropertyUnderLease" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="imrx_AreaOfPropertyUnderLease" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://immuneering.com/role/DisclosureCommitmentsAndContingenciesMaturitiesOfLeaseLiabilitiesDueDetails" xlink:type="extended" xlink:title="41302 - Disclosure - Commitments and Contingencies - Maturities of the lease liabilities due (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_OfficeLeaseInSanDiegoCalifornia2020Member" xlink:label="imrx_OfficeLeaseInSanDiegoCalifornia2020Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="imrx_OfficeLeaseInSanDiegoCalifornia2020Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseLiability" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" priority="1" use="optional" />
  </definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>41
<FILENAME>imrx-20211231_lab.xml
<DESCRIPTION>EX-101.LAB
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.8042.36810 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/10/2022 12:29:41 AM-->
<!--Modified on: 3/10/2022 12:29:41 AM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document and Entity Information</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Stock [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfStockDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Stock [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonClassAMember" xlink:to="us-gaap_CommonClassAMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonClassAMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class A Common Stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassBMember" xlink:label="us-gaap_CommonClassBMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonClassBMember" xlink:to="us-gaap_CommonClassBMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonClassBMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class B Common Stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Type</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Annual Report</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Transition Report</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Period End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity File Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Registrant Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Incorporation, State or Country Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Tax Identification Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Address Line One</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Address Line Two</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, City or Town</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address State Or Province</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Postal Zip Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">City Area Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Local Phone Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Title of 12(b) Security</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trading Symbol</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Security Exchange Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Well-known Seasoned Issuer</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Voluntary Filers</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Current Reporting Status</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Interactive Data Current</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Filer Category</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Small Business</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Emerging Growth Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Ex Transition Period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ICFR Auditor Attestation Flag</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Shell Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Public Float</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Common Stock, Shares Outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Documents Incorporated by Reference [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Documents Incorporated by Reference</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorName" xlink:label="dei_AuditorName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Auditor Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorFirmId_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Auditor Firm ID</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorLocation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Auditor Location</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Central Index Key</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current Fiscal Year End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Fiscal Year Focus</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Fiscal Period Focus</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amendment Flag</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">CONDENSED CONSOLIDATED BALANCE SHEETS</label>
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_SeriesBConvertiblePreferredStockMember" xlink:label="imrx_SeriesBConvertiblePreferredStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imrx_SeriesBConvertiblePreferredStockMember" xlink:to="imrx_SeriesBConvertiblePreferredStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="imrx_SeriesBConvertiblePreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series B preferred stock that may be exchanged into common shares or other types of securities at the owner's option.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imrx_SeriesBConvertiblePreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series B Preferred Stock</label>
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_SeriesConvertiblePreferredStockMember" xlink:label="imrx_SeriesConvertiblePreferredStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imrx_SeriesConvertiblePreferredStockMember" xlink:to="imrx_SeriesConvertiblePreferredStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="imrx_SeriesConvertiblePreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series A preferred stock that may be exchanged into common shares or other types of securities at the owner's option.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imrx_SeriesConvertiblePreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series A Preferred Stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ASSETS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current assets:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents, at Carrying Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalents</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="us-gaap_MarketableSecuritiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesCurrent" xlink:to="us-gaap_MarketableSecuritiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MarketableSecuritiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Marketable Securities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_MarketableSecuritiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Marketable securities, current</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Receivable, after Allowance for Credit Loss, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts receivable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid Expense and Other Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaids and other current assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total current assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesNoncurrent" xlink:label="us-gaap_MarketableSecuritiesNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesNoncurrent" xlink:to="us-gaap_MarketableSecuritiesNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MarketableSecuritiesNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Marketable Securities, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MarketableSecuritiesNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Marketable securities, non-current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_MarketableSecuritiesNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Marketable securities, non-current</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property and equipment, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property and equipment, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Goodwill" xlink:to="us-gaap_Goodwill_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Goodwill_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Goodwill</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Goodwill_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Goodwill</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finite-Lived Intangible Assets, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Intangible asset</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Right-of-Use Asset</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Right-of-use assets, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Right of use asset</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Assets, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities and Equity [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">LIABILITIES, CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current liabilities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Payable, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts payable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Liability, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease liabilities, current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current portion lease liability</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total current liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities, Noncurrent [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-term liabilities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Liability, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease liabilities, non-current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease liability, noncurrent</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and Contingencies</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and contingencies (Note 13)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityAbstract" xlink:label="us-gaap_TemporaryEquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityAbstract" xlink:to="us-gaap_TemporaryEquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary Equity [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TemporaryEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible preferred stock:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary Equity, Carrying Amount, Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ending Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Beginning Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible preferred stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' Equity Attributable to Parent [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' deficit:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Value, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock, $0.001 par value; 10,000,000 and 0 shares authorized at December 31, 2021 and December 31, 2020, respectively; No shares issued or outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Value, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional Paid in Capital</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional paid-in capital</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated Other Comprehensive Income (Loss), Net of Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated other comprehensive loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Retained Earnings (Accumulated Deficit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated deficit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated deficit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' Equity Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ending Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Beginning Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total stockholders' equity (deficit)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities and Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total liabilities, convertible preferred stock and stockholders' equity (deficit)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary Equity, Par or Stated Value Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible preferred stock, par value per share (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="us-gaap_TemporaryEquitySharesAuthorized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesAuthorized" xlink:to="us-gaap_TemporaryEquitySharesAuthorized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquitySharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary Equity, Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TemporaryEquitySharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible preferred stock, authorized (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesIssued" xlink:to="us-gaap_TemporaryEquitySharesIssued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquitySharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary Equity, Shares Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TemporaryEquitySharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible preferred stock, issued (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesOutstanding" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary Equity, Shares Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ending Balance (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Beginning Balance (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible preferred stock, outstanding (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Par or Stated Value Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock, par value per share (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock authorized (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Shares Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock, shares issued (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Shares Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock, outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock, shares outstanding (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, par value per share (in dollars per share)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, par value per share (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, shares authorized (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, shares authorized (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Shares, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, shares issued (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Shares, Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, shares outstanding (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfRevenue" xlink:label="us-gaap_CostOfRevenue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfRevenue" xlink:to="us-gaap_CostOfRevenue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfRevenue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cost of Revenue</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CostOfRevenue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cost of revenue</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GrossProfit" xlink:label="us-gaap_GrossProfit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_GrossProfit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GrossProfit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gross Profit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_GrossProfit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gross profit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Expenses [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General and Administrative Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General and administrative</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total operating expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Income (Loss)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss from operations</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeNonoperatingAbstract" xlink:label="us-gaap_InvestmentIncomeNonoperatingAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeNonoperatingAbstract" xlink:to="us-gaap_InvestmentIncomeNonoperatingAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentIncomeNonoperatingAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Investment Income, Nonoperating [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InvestmentIncomeNonoperatingAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other income (expense)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeInterest" xlink:to="us-gaap_InvestmentIncomeInterest_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Investment Income, Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest income</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Nonoperating Income (Expense)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss before income taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Expense (Benefit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income tax benefit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Income (Loss) Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share, Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss per share attributable to common stockholders, basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss per share, basic</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share, Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss per share attributable to common stockholders, diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss per share, diluted</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Number of Shares Outstanding, Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted-average common shares outstanding, basic</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Number of Shares Outstanding, Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted-average common shares outstanding, diluted</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other comprehensive loss:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:label="us-gaap_MarketableSecuritiesUnrealizedGainLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:to="us-gaap_MarketableSecuritiesUnrealizedGainLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MarketableSecuritiesUnrealizedGainLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Marketable Securities, Unrealized Gain (Loss)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MarketableSecuritiesUnrealizedGainLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrealized losses from marketable securities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Comprehensive Loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Components [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Component [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockMember" xlink:to="us-gaap_PreferredStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional Paid-In Capital</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated other comprehensive loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated Deficit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Stockholders' Equity [Roll Forward]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares, Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ending Balance (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Beginning Balance (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Value, Stock Options Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock upon exercise of stock options</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercised (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock upon exercise of stock options (in shares)</label>
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_StockIssuedDuringPeriodValueWarrantsExercised" xlink:label="imrx_StockIssuedDuringPeriodValueWarrantsExercised" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imrx_StockIssuedDuringPeriodValueWarrantsExercised" xlink:to="imrx_StockIssuedDuringPeriodValueWarrantsExercised_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="imrx_StockIssuedDuringPeriodValueWarrantsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Value of stock issued as a result of the exercise of warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imrx_StockIssuedDuringPeriodValueWarrantsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Value, Warrants Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imrx_StockIssuedDuringPeriodValueWarrantsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock upon exercise of warrants</label>
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:label="imrx_StockIssuedDuringPeriodSharesWarrantsExercised" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imrx_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:to="imrx_StockIssuedDuringPeriodSharesWarrantsExercised_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="imrx_StockIssuedDuringPeriodSharesWarrantsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of share warrants exercised during the current period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imrx_StockIssuedDuringPeriodSharesWarrantsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Shares, Warrants Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imrx_StockIssuedDuringPeriodSharesWarrantsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock upon exercise of warrants (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Value, Conversion of Convertible Securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Conversion of Preferred Stock into common stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Shares, Conversion of Convertible Securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Conversion of Preferred Stock into common stock (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Value, New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock upon initial public offering, net of issuance costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Shares, New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock upon initial public offering, net of issuance costs (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="us-gaap_StockIssuedDuringPeriodValueAcquisitions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:to="us-gaap_StockIssuedDuringPeriodValueAcquisitions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueAcquisitions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Value, Acquisitions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueAcquisitions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock for acquisition</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:to="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Shares, Acquisitions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock for acquisition, shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares issued</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">APIC, Share-based Payment Arrangement, Increase for Cost Recognition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-based compensation expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Comprehensive Income (Loss), Net of Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other comprehensive loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:to="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Temporary Equity [Roll Forward]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary Equity, Stock Issued During Period, Value, New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of convertible preferred stock, net of issuance costs</label>
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:label="imrx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imrx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:to="imrx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="imrx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of new stock classified as temporary equity issued during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imrx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary Equity, Stock Issued During Period, Shares, New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imrx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of convertible preferred stock, net of issuance costs (in shares)</label>
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_StockIssuanceCosts" xlink:label="imrx_StockIssuanceCosts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imrx_StockIssuanceCosts" xlink:to="imrx_StockIssuanceCosts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="imrx_StockIssuanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of stock issuance costs.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imrx_StockIssuanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issuance Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imrx_StockIssuanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">CONSOLIDATED STATEMENTS OF CASH FLOWS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash flows from operating activities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustment to reconcile to net loss to net cash used in operating activities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Depreciation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Depreciation expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Right-of-Use Asset, Amortization Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Right-of-use asset amortization</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement, Noncash Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock based compensation expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:label="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:to="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Investment Income, Net, Amortization of Discount and Premium</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net amortization of premium (accretion of discount) on marketable securities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Income Tax Expense (Benefit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred tax benefit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Operating Capital [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Change in assets and liabilities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Operating Assets [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">(Increase) decrease in:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Accounts Receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts receivable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Prepaid Expense and Other Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid expenses and other current assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Other Operating Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Operating Liabilities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (decrease) in:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Accounts Payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts payable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Accrued Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Operating Lease Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease liability</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Operating Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net cash used in operating activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Investing Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash flows from investing activities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments to Acquire Property, Plant, and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchases of property and equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireMarketableSecurities" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments to Acquire Marketable Securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchases of marketable securities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAcquiredInExcessOfPaymentsToAcquireBusiness" xlink:label="us-gaap_CashAcquiredInExcessOfPaymentsToAcquireBusiness" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAcquiredInExcessOfPaymentsToAcquireBusiness" xlink:to="us-gaap_CashAcquiredInExcessOfPaymentsToAcquireBusiness_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAcquiredInExcessOfPaymentsToAcquireBusiness_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash Acquired in Excess of Payments to Acquire Business</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAcquiredInExcessOfPaymentsToAcquireBusiness_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash acquired in business combination</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Investing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net cash used in investing activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Financing Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash flows from financing activities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Issuance of Convertible Preferred Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from the issuance of preferred stock, net of issuance costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gross proceeds from issuance of convertible stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Issuance of Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aggregate net proceeds</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from initial public offering of common stock, net of commissions and underwriting</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments of Stock Issuance Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payment of initial public offering costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Stock Options Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from exercise of stock options</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Warrant Exercises</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from exercise of warrants</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Financing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net cash provided by financing activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net increase in cash and cash equivalents</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalents at end of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalents at beginning of period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Supplemental Cash Flow Information [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Supplemental disclosures of noncash investing and financing information :</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssued1" xlink:label="us-gaap_StockIssued1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssued1" xlink:to="us-gaap_StockIssued1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssued1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssued1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Conversion of convertible Series A and B preferred stock into common stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:label="us-gaap_BusinessCombinationAcquisitionRelatedCosts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:to="us-gaap_BusinessCombinationAcquisitionRelatedCosts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationAcquisitionRelatedCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business Combination, Acquisition Related Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessCombinationAcquisitionRelatedCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business combination non cash</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="us-gaap_ConversionOfStockSharesIssued1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesIssued1" xlink:to="us-gaap_ConversionOfStockSharesIssued1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConversionOfStockSharesIssued1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Conversion of Stock, Shares Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ConversionOfStockSharesIssued1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class A common stock issued for business combination</label>
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_ReclassificationOfLiabilityOfPreferredStock" xlink:label="imrx_ReclassificationOfLiabilityOfPreferredStock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imrx_ReclassificationOfLiabilityOfPreferredStock" xlink:to="imrx_ReclassificationOfLiabilityOfPreferredStock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="imrx_ReclassificationOfLiabilityOfPreferredStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The liability of preferred stock reclassified during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imrx_ReclassificationOfLiabilityOfPreferredStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reclassification of Liability of Preferred Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imrx_ReclassificationOfLiabilityOfPreferredStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reclassification of liability for Series A preferred stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Organization and Nature of Business</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Organization and Nature of Business</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of Significant Accounting Policies</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Significant Accounting Policies [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of Significant Accounting Policies</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Marketable Securities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:to="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Marketable Securities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Measurements</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Disclosures [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Measurements</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property and Equipment, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property and Equipment, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="us-gaap_BusinessCombinationsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="us-gaap_BusinessCombinationsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business Combination</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationDisclosureTextBlock" xlink:to="us-gaap_BusinessCombinationDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business Combination Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business Combination.</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:label="us-gaap_AccruedLiabilitiesCurrentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Expenses</label>
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_AccruedLiabilitiesDisclosureTextBlock" xlink:label="imrx_AccruedLiabilitiesDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imrx_AccruedLiabilitiesDisclosureTextBlock" xlink:to="imrx_AccruedLiabilitiesDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="imrx_AccruedLiabilitiesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The entire disclosure for accrued liabilities at the end of the reporting period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imrx_AccruedLiabilitiesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Liabilities Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imrx_AccruedLiabilitiesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityDisclosureAbstract" xlink:label="us-gaap_TemporaryEquityDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityDisclosureAbstract" xlink:to="us-gaap_TemporaryEquityDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquityDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible Preferred Stock</label>
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_TemporaryEquityDisclosureTextBlock" xlink:label="imrx_TemporaryEquityDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imrx_TemporaryEquityDisclosureTextBlock" xlink:to="imrx_TemporaryEquityDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="imrx_TemporaryEquityDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The entire disclosure for  temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imrx_TemporaryEquityDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary Equity Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imrx_TemporaryEquityDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible Preferred Stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock.</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' Equity Note Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Loss Per Share Attributable to Common Stockholders</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Loss Per Share Attributable to Common Stockholders</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-Based Compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-Based Compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and Contingencies.</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and Contingencies Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and Contingencies</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basis of Accounting, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basis of Presentation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityPolicyTextBlock" xlink:label="us-gaap_StockholdersEquityPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityPolicyTextBlock" xlink:to="us-gaap_StockholdersEquityPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' Equity, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Split</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Use of Estimates, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Use of Estimates</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Segment Reporting, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Segments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationsPolicy" xlink:label="us-gaap_BusinessCombinationsPolicy" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationsPolicy" xlink:to="us-gaap_BusinessCombinationsPolicy_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationsPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business Combinations Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessCombinationsPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business Combination</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:label="us-gaap_MarketableSecuritiesPolicy" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesPolicy" xlink:to="us-gaap_MarketableSecuritiesPolicy_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MarketableSecuritiesPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Marketable Securities, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MarketableSecuritiesPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Marketable Securities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value of Financial Instruments, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value of Financial Instruments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TradeAndOtherAccountsReceivableUnbilledReceivablesPolicy" xlink:label="us-gaap_TradeAndOtherAccountsReceivableUnbilledReceivablesPolicy" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TradeAndOtherAccountsReceivableUnbilledReceivablesPolicy" xlink:to="us-gaap_TradeAndOtherAccountsReceivableUnbilledReceivablesPolicy_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TradeAndOtherAccountsReceivableUnbilledReceivablesPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trade and Other Accounts Receivable, Unbilled Receivables, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TradeAndOtherAccountsReceivableUnbilledReceivablesPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Receivable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration Risk, Credit Risk, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration of Credit Risk</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property and Equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Impairment of Long-lived Assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Leases [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Leases</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue from Contract with Customer [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue Recognition</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentPolicy" xlink:label="us-gaap_InProcessResearchAndDevelopmentPolicy" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InProcessResearchAndDevelopmentPolicy" xlink:to="us-gaap_InProcessResearchAndDevelopmentPolicy_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InProcessResearchAndDevelopmentPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">In Process Research and Development, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InProcessResearchAndDevelopmentPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development</label>
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_ResearchAndManufacturingContractCostsAndAccrualsPolicyTextBlock" xlink:label="imrx_ResearchAndManufacturingContractCostsAndAccrualsPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imrx_ResearchAndManufacturingContractCostsAndAccrualsPolicyTextBlock" xlink:to="imrx_ResearchAndManufacturingContractCostsAndAccrualsPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="imrx_ResearchAndManufacturingContractCostsAndAccrualsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of accounting policy for research and manufacturing contract costs and accruals.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imrx_ResearchAndManufacturingContractCostsAndAccrualsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Manufacturing Contract Costs and Accruals [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imrx_ResearchAndManufacturingContractCostsAndAccrualsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Manufacturing Contract Costs and Accruals</label>
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_PatentCostsPolicyPolicyTextBlock" xlink:label="imrx_PatentCostsPolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imrx_PatentCostsPolicyPolicyTextBlock" xlink:to="imrx_PatentCostsPolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="imrx_PatentCostsPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of accounting policy for patent costs.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imrx_PatentCostsPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Patent Costs Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imrx_PatentCostsPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Patent Costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Comprehensive Income, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Comprehensive Loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredChargesPolicyTextBlock" xlink:label="us-gaap_DeferredChargesPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredChargesPolicyTextBlock" xlink:to="us-gaap_DeferredChargesPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredChargesPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Charges, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredChargesPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Offering Costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Income (Loss) per Share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-based Compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:label="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:to="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Goodwill</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">New Accounting Pronouncements, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Recently Issued Accounting Pronouncements</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:label="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:to="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedules of Concentration of Risk, by Risk Factor [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of concentration of credit risk</label>
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock" xlink:label="imrx_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imrx_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock" xlink:to="imrx_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="imrx_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tabular disclosure of the useful life of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imrx_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Property, Plant and Equipment, Useful Life [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imrx_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of property and equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesTextBlock" xlink:label="us-gaap_MarketableSecuritiesTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesTextBlock" xlink:to="us-gaap_MarketableSecuritiesTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MarketableSecuritiesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Marketable Securities [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MarketableSecuritiesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of marketable securities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Assets Measured on Recurring Basis [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of cash equivalents and marketable securities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of property and equipment, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:label="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:to="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Assets Acquired and Liabilities Assumed at Fair Value</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Accrued Liabilities [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of accrued expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTextBlock" xlink:label="us-gaap_ScheduleOfStockByClassTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockByClassTextBlock" xlink:to="us-gaap_ScheduleOfStockByClassTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockByClassTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Stock by Class [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfStockByClassTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of common stock for conversion of preferred stock, exercise of warrants and exercise of stock options</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of basic and diluted net loss per share attributable to common stockholders</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of potentially dilutive securities that have been excluded from the calculation of diluted net loss per share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of assumptions in its application of the Black-Scholes option pricing model for grants</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement, Option, Activity [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of stock option activity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:to="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement, Cost by Plan [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of recognized share-based compensation expense recognized</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of federal statutory rate to the net loss and the effective income tax rate</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of net deferred tax assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:to="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of unrecognized tax benefits</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Maturities of the lease liabilities due</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostTableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease, Cost [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Quantitative information regarding the Company's leases</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" xlink:label="us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" xlink:to="us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Subsidiary or Equity Method Investee [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale of Stock [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale of Stock [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IPOMember" xlink:to="us-gaap_IPOMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IPOMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">IPO</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsidiary or Equity Method Investee [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Organization and Nature of Business</label>
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_OfferingCostPayable" xlink:label="imrx_OfferingCostPayable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imrx_OfferingCostPayable" xlink:to="imrx_OfferingCostPayable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="imrx_OfferingCostPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of offering costs payable by the Company.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imrx_OfferingCostPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Offering Cost Payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imrx_OfferingCostPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Offering costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible Preferred Stock, Shares Issued upon Conversion</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares issued upon conversion</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' Equity Note, Stock Split, Conversion Ratio</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock split, ratio</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Operating Segments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of operating segments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables" xlink:label="us-gaap_AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables" xlink:to="us-gaap_AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Allowance for Doubtful Accounts, Premiums and Other Receivables</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Allowance for doubtful accounts</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsFinitelived_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsFinitelived_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Impairment of Intangible Assets, Finite-lived</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsFinitelived_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Impairment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasePracticalExpedientsPackage" xlink:label="us-gaap_LeasePracticalExpedientsPackage" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasePracticalExpedientsPackage" xlink:to="us-gaap_LeasePracticalExpedientsPackage_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeasePracticalExpedientsPackage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease, Practical Expedients, Package [true false]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeasePracticalExpedientsPackage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease, practical expedients</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions" xlink:label="us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions" xlink:to="us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tax Adjustments, Settlements, and Unusual Provisions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Uncertain tax positions</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredOfferingCosts" xlink:label="us-gaap_DeferredOfferingCosts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredOfferingCosts" xlink:to="us-gaap_DeferredOfferingCosts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredOfferingCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Offering Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredOfferingCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred offering costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected dividend yield</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="us-gaap_GoodwillImpairmentLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillImpairmentLoss" xlink:to="us-gaap_GoodwillImpairmentLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillImpairmentLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Goodwill, Impairment Loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GoodwillImpairmentLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Goodwill impairments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTable" xlink:label="us-gaap_ConcentrationRiskTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="us-gaap_ConcentrationRiskTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration Risk [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration Risk Benchmark [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration Risk Benchmark [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalesRevenueNetMember" xlink:label="us-gaap_SalesRevenueNetMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesRevenueNetMember" xlink:to="us-gaap_SalesRevenueNetMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SalesRevenueNetMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableMember" xlink:label="us-gaap_AccountsReceivableMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableMember" xlink:to="us-gaap_AccountsReceivableMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts receivable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskByTypeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskByTypeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration Risk Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_ConcentrationRiskTypeDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskTypeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration Risk Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="us-gaap_CustomerConcentrationRiskMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CustomerConcentrationRiskMember" xlink:to="us-gaap_CustomerConcentrationRiskMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CustomerConcentrationRiskMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Customer risk</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis" xlink:label="srt_MajorCustomersAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_MajorCustomersAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MajorCustomersAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Customer [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="srt_NameOfMajorCustomerDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="srt_NameOfMajorCustomerDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_NameOfMajorCustomerDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Customer [Domain]</label>
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_CustomerOneMember" xlink:label="imrx_CustomerOneMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imrx_CustomerOneMember" xlink:to="imrx_CustomerOneMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="imrx_CustomerOneMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information relating to customer 1.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imrx_CustomerOneMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Customer 1</label>
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_CustomerTwoMember" xlink:label="imrx_CustomerTwoMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imrx_CustomerTwoMember" xlink:to="imrx_CustomerTwoMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="imrx_CustomerTwoMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information relating to customer 2.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imrx_CustomerTwoMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Customer 2</label>
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_CustomerThreeMember" xlink:label="imrx_CustomerThreeMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imrx_CustomerThreeMember" xlink:to="imrx_CustomerThreeMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="imrx_CustomerThreeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information relating to customer 3.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imrx_CustomerThreeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Customer 3</label>
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_CustomerFourMember" xlink:label="imrx_CustomerFourMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imrx_CustomerFourMember" xlink:to="imrx_CustomerFourMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="imrx_CustomerFourMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information relating to customer 4.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imrx_CustomerFourMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Customer 4</label>
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_CustomerFiveMember" xlink:label="imrx_CustomerFiveMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imrx_CustomerFiveMember" xlink:to="imrx_CustomerFiveMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="imrx_CustomerFiveMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information relating to customer 5.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imrx_CustomerFiveMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Customer 5</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="us-gaap_ConcentrationRiskLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="us-gaap_ConcentrationRiskLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration Risk [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue from Contract with Customer, Including Assessed Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskPercentage1" xlink:to="us-gaap_ConcentrationRiskPercentage1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskPercentage1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration Risk, Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConcentrationRiskPercentage1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Risk percentage</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-Lived Tangible Asset [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-Lived Tangible Asset [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerEquipmentMember" xlink:to="us-gaap_ComputerEquipmentMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Computer equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Furniture and fixtures</label>
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_LabEquipmentMember" xlink:label="imrx_LabEquipmentMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imrx_LabEquipmentMember" xlink:to="imrx_LabEquipmentMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="imrx_LabEquipmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lab equipment.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imrx_LabEquipmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lab equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imrx_LabEquipmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lab equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdsAndLeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdsAndLeaseholdImprovementsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdsAndLeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdsAndLeaseholdImprovementsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseholdsAndLeaseholdImprovementsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Leaseholds and Leasehold Improvements [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statistical Measurement [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statistical Measurement [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Minimum</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property and Equipment, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment, Useful Life</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Estimated Useful Lives</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesTable" xlink:label="us-gaap_MarketableSecuritiesTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesTable" xlink:to="us-gaap_MarketableSecuritiesTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MarketableSecuritiesTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Marketable Securities [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_FinancialInstrumentAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinancialInstrumentAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financial Instrument [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financial Instruments [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USTreasurySecuritiesMember" xlink:to="us-gaap_USTreasurySecuritiesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_USTreasurySecuritiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">U.S. Treasuries</label>
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_GovernmentSecuritiesMember" xlink:label="imrx_GovernmentSecuritiesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imrx_GovernmentSecuritiesMember" xlink:to="imrx_GovernmentSecuritiesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="imrx_GovernmentSecuritiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to government securities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imrx_GovernmentSecuritiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Government securities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommercialPaperMember" xlink:to="us-gaap_CommercialPaperMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommercialPaperMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commerical paper</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesLineItems" xlink:label="us-gaap_MarketableSecuritiesLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="us-gaap_MarketableSecuritiesLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MarketableSecuritiesLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Marketable Securities [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MarketableSecuritiesLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Marketable Securities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfInvestments" xlink:label="us-gaap_ImpairmentOfInvestments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfInvestments" xlink:to="us-gaap_ImpairmentOfInvestments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOfInvestments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other than Temporary Impairment Losses, Investments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ImpairmentOfInvestments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Impairment on available-for-sale marketable securities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesRealizedGainLoss" xlink:label="us-gaap_MarketableSecuritiesRealizedGainLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesRealizedGainLoss" xlink:to="us-gaap_MarketableSecuritiesRealizedGainLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MarketableSecuritiesRealizedGainLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Marketable Securities, Realized Gain (Loss)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MarketableSecuritiesRealizedGainLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Realized gains or losses on marketable securities</label>
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_MarketableSecuritiesCurrentAbstract" xlink:label="imrx_MarketableSecuritiesCurrentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imrx_MarketableSecuritiesCurrentAbstract" xlink:to="imrx_MarketableSecuritiesCurrentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="imrx_MarketableSecuritiesCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">No definition available.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imrx_MarketableSecuritiesCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Marketable Securities, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imrx_MarketableSecuritiesCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Marketable securities, current</label>
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_MarketableSecuritiesAmortizedCostBasisCurrent" xlink:label="imrx_MarketableSecuritiesAmortizedCostBasisCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imrx_MarketableSecuritiesAmortizedCostBasisCurrent" xlink:to="imrx_MarketableSecuritiesAmortizedCostBasisCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="imrx_MarketableSecuritiesAmortizedCostBasisCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amortized cost of investment in current marketable securities measured at fair value with change in fair value recognized in other comprehensive income.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imrx_MarketableSecuritiesAmortizedCostBasisCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Marketable Securities, Amortized Cost Basis, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="imrx_MarketableSecuritiesAmortizedCostBasisCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Marketable securities at amortized cost, current</label>
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_MarketableSecuritiesAccumulatedUnrealizedGainsCurrent" xlink:label="imrx_MarketableSecuritiesAccumulatedUnrealizedGainsCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imrx_MarketableSecuritiesAccumulatedUnrealizedGainsCurrent" xlink:to="imrx_MarketableSecuritiesAccumulatedUnrealizedGainsCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="imrx_MarketableSecuritiesAccumulatedUnrealizedGainsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in current marketable securities measured at fair value with change in fair value recognized in other comprehensive income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imrx_MarketableSecuritiesAccumulatedUnrealizedGainsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Marketable Securities, Accumulated Unrealized Gains, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imrx_MarketableSecuritiesAccumulatedUnrealizedGainsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Marketable securities unrealized gains, current</label>
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_MarketableSecuritiesAccumulatedUnrealizedLossesCurrent" xlink:label="imrx_MarketableSecuritiesAccumulatedUnrealizedLossesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imrx_MarketableSecuritiesAccumulatedUnrealizedLossesCurrent" xlink:to="imrx_MarketableSecuritiesAccumulatedUnrealizedLossesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="imrx_MarketableSecuritiesAccumulatedUnrealizedLossesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in current marketable securities measured at fair value with change in fair value recognized in other comprehensive income.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imrx_MarketableSecuritiesAccumulatedUnrealizedLossesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Marketable Securities, Accumulated Unrealized Losses, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="imrx_MarketableSecuritiesAccumulatedUnrealizedLossesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Marketable securities unrealized losses, current</label>
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_MarketableSecuritiesNonCurrentAbstract" xlink:label="imrx_MarketableSecuritiesNonCurrentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imrx_MarketableSecuritiesNonCurrentAbstract" xlink:to="imrx_MarketableSecuritiesNonCurrentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="imrx_MarketableSecuritiesNonCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">No definition available.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imrx_MarketableSecuritiesNonCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Marketable Securities, Non-current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imrx_MarketableSecuritiesNonCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Marketable securities, non-current</label>
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_MarketableSecuritiesAmortizedCostBasisNonCurrent" xlink:label="imrx_MarketableSecuritiesAmortizedCostBasisNonCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imrx_MarketableSecuritiesAmortizedCostBasisNonCurrent" xlink:to="imrx_MarketableSecuritiesAmortizedCostBasisNonCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="imrx_MarketableSecuritiesAmortizedCostBasisNonCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amortized cost of investment in Non-current marketable securities measured at fair value with change in fair value recognized in other comprehensive income.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imrx_MarketableSecuritiesAmortizedCostBasisNonCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Marketable Securities, Amortized Cost Basis, Non-current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="imrx_MarketableSecuritiesAmortizedCostBasisNonCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Marketable securities at amortized cost, non-current</label>
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_MarketableSecuritiesAccumulatedUnrealizedLossesNonCurrent" xlink:label="imrx_MarketableSecuritiesAccumulatedUnrealizedLossesNonCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imrx_MarketableSecuritiesAccumulatedUnrealizedLossesNonCurrent" xlink:to="imrx_MarketableSecuritiesAccumulatedUnrealizedLossesNonCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="imrx_MarketableSecuritiesAccumulatedUnrealizedLossesNonCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in Non-current marketable securities measured at fair value with change in fair value recognized in other comprehensive income.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imrx_MarketableSecuritiesAccumulatedUnrealizedLossesNonCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Marketable Securities, Accumulated Unrealized Losses, Non-current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="imrx_MarketableSecuritiesAccumulatedUnrealizedLossesNonCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Marketable securities unrealized losses, non-current</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesAbstract" xlink:label="us-gaap_MarketableSecuritiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesAbstract" xlink:to="us-gaap_MarketableSecuritiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MarketableSecuritiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Marketable Securities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MarketableSecuritiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Marketable securities</label>
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_MarketableSecuritiesAmortizedCostBasis" xlink:label="imrx_MarketableSecuritiesAmortizedCostBasis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imrx_MarketableSecuritiesAmortizedCostBasis" xlink:to="imrx_MarketableSecuritiesAmortizedCostBasis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="imrx_MarketableSecuritiesAmortizedCostBasis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amortized cost of investment in  marketable securities measured at fair value with change in fair value recognized in other comprehensive income.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imrx_MarketableSecuritiesAmortizedCostBasis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Marketable Securities, Amortized Cost Basis</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="imrx_MarketableSecuritiesAmortizedCostBasis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Marketable securities at amortized cost</label>
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_MarketableSecuritiesAccumulatedUnrealizedGains" xlink:label="imrx_MarketableSecuritiesAccumulatedUnrealizedGains" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imrx_MarketableSecuritiesAccumulatedUnrealizedGains" xlink:to="imrx_MarketableSecuritiesAccumulatedUnrealizedGains_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="imrx_MarketableSecuritiesAccumulatedUnrealizedGains_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in  marketable securities measured at fair value with change in fair value recognized in other comprehensive income .</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imrx_MarketableSecuritiesAccumulatedUnrealizedGains_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Marketable Securities, Accumulated Unrealized Gains</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imrx_MarketableSecuritiesAccumulatedUnrealizedGains_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Marketable securities unrealized gains</label>
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_MarketableSecuritiesAccumulatedUnrealizedLosses" xlink:label="imrx_MarketableSecuritiesAccumulatedUnrealizedLosses" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imrx_MarketableSecuritiesAccumulatedUnrealizedLosses" xlink:to="imrx_MarketableSecuritiesAccumulatedUnrealizedLosses_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="imrx_MarketableSecuritiesAccumulatedUnrealizedLosses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in  marketable securities measured at fair value with change in fair value recognized in other comprehensive income.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imrx_MarketableSecuritiesAccumulatedUnrealizedLosses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Marketable Securities, Accumulated Unrealized Losses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="imrx_MarketableSecuritiesAccumulatedUnrealizedLosses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Marketable securities unrealized losses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecurities" xlink:label="us-gaap_MarketableSecurities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecurities" xlink:to="us-gaap_MarketableSecurities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MarketableSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Marketable Securities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MarketableSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Marketable securities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Recurring and Nonrecurring [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Measurement Frequency [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Measurement Frequency [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Recurring</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Hierarchy and NAV [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Hierarchy and NAV [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Level 1</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Level 2</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueByAssetClassAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByAssetClassAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Asset Class [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Asset Class [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsMember" xlink:to="us-gaap_MoneyMarketFundsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Money market</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Measurements</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_AssetsFairValueDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets, Fair Value Disclosure [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents, Fair Value Disclosure</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total cash equivalents</label>
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_MarketableSecuritiesFairValueDisclosure" xlink:label="imrx_MarketableSecuritiesFairValueDisclosure" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imrx_MarketableSecuritiesFairValueDisclosure" xlink:to="imrx_MarketableSecuritiesFairValueDisclosure_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="imrx_MarketableSecuritiesFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair value portion of marketable securities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imrx_MarketableSecuritiesFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Marketable Securities, Fair Value Disclosure</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imrx_MarketableSecuritiesFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total marketable securities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_AssetsFairValueDisclosure_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets, Fair Value Disclosure</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total cash equivalents and marketable securities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Transfers, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financial liabilities classified as Level 3</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Leasehold improvements</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Leasehold improvements</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property and equipment, gross</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated depreciation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Business Acquisitions, by Acquisition [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business Acquisition [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business Acquisition, Acquiree [Domain]</label>
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_BioArkiveIncMember" xlink:label="imrx_BioArkiveIncMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imrx_BioArkiveIncMember" xlink:to="imrx_BioArkiveIncMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="imrx_BioArkiveIncMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information relating to Bio Arkive Inc.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imrx_BioArkiveIncMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">BioArkive Inc</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Statement Location [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Statement Location [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BalanceSheetLocationAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance Sheet Location [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_BalanceSheetLocationDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BalanceSheetLocationDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance Sheet Location [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesMember" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesMember" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts payable or accrued expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessAcquisitionLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business Acquisition [Line Items]</label>
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_BusinessCombinationPurchasePrice" xlink:label="imrx_BusinessCombinationPurchasePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imrx_BusinessCombinationPurchasePrice" xlink:to="imrx_BusinessCombinationPurchasePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="imrx_BusinessCombinationPurchasePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of purchase price payable for the acquisition.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imrx_BusinessCombinationPurchasePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business Combination, Purchase Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imrx_BusinessCombinationPurchasePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Market value of acquisition</label>
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_NumberOfLeasesObligationsAssumed" xlink:label="imrx_NumberOfLeasesObligationsAssumed" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imrx_NumberOfLeasesObligationsAssumed" xlink:to="imrx_NumberOfLeasesObligationsAssumed_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="imrx_NumberOfLeasesObligationsAssumed_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of lease obligations acquired in business combination.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imrx_NumberOfLeasesObligationsAssumed_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Leases Obligations Assumed</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imrx_NumberOfLeasesObligationsAssumed_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of lease obligations acquired</label>
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_BusinessCombinationSharesIssuedSharePriceThresholdTradingDays" xlink:label="imrx_BusinessCombinationSharesIssuedSharePriceThresholdTradingDays" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imrx_BusinessCombinationSharesIssuedSharePriceThresholdTradingDays" xlink:to="imrx_BusinessCombinationSharesIssuedSharePriceThresholdTradingDays_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="imrx_BusinessCombinationSharesIssuedSharePriceThresholdTradingDays_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Threshold number of specified trading days that common stock price daily volume weighted average prices of the common stock on the Nasdaq Stock Exchange for valuation of shares issued in acquisition.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imrx_BusinessCombinationSharesIssuedSharePriceThresholdTradingDays_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business Combination Shares Issued, Share Price, Threshold Trading Days</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imrx_BusinessCombinationSharesIssuedSharePriceThresholdTradingDays_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trading days for share price</label>
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_BusinessCombinationSharesIssuedLockInPeriod" xlink:label="imrx_BusinessCombinationSharesIssuedLockInPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imrx_BusinessCombinationSharesIssuedLockInPeriod" xlink:to="imrx_BusinessCombinationSharesIssuedLockInPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="imrx_BusinessCombinationSharesIssuedLockInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lock in period for shares issued in acquisition.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imrx_BusinessCombinationSharesIssuedLockInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business Combination Shares Issued, Lock in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imrx_BusinessCombinationSharesIssuedLockInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lock in period for shares issued</label>
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_BusinessCombinationSharesIssuedDiscountDueToMarketabilityPercentage" xlink:label="imrx_BusinessCombinationSharesIssuedDiscountDueToMarketabilityPercentage" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imrx_BusinessCombinationSharesIssuedDiscountDueToMarketabilityPercentage" xlink:to="imrx_BusinessCombinationSharesIssuedDiscountDueToMarketabilityPercentage_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="imrx_BusinessCombinationSharesIssuedDiscountDueToMarketabilityPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of discount due to lack of marketability for shares issued in business acquisition.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imrx_BusinessCombinationSharesIssuedDiscountDueToMarketabilityPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business Combination Shares Issued, Discount Due To Marketability, Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imrx_BusinessCombinationSharesIssuedDiscountDueToMarketabilityPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares issued discount due to lack of marketability</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationConsiderationTransferred1" xlink:to="us-gaap_BusinessCombinationConsiderationTransferred1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business Combination, Consideration Transferred</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Consideration transferred</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:to="us-gaap_RelatedPartyTransactionAmountsOfTransaction_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party Transaction, Amounts of Transaction</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of related party expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent" xlink:label="us-gaap_DueToRelatedPartiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DueToRelatedPartiesCurrent" xlink:to="us-gaap_DueToRelatedPartiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DueToRelatedPartiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Due to Related Parties, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DueToRelatedPartiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount owned to related party</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets Acquired and Liabilities Assumed at Fair Value</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Other</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other currents assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other long term assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, plant and equipment, net</label>
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets" xlink:label="imrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets" xlink:to="imrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="imrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of right of use assets recognized as of the acquisition date.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Right of Use Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Right of use assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Intangible asset</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Technology</label>
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIncludingGoodwill" xlink:label="imrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIncludingGoodwill" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIncludingGoodwill" xlink:to="imrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIncludingGoodwill_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="imrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIncludingGoodwill_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount recognized as of the acquisition date for the identifiable assets including goowill acquired in excess of (less than) the aggregate liabilities assumed.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIncludingGoodwill_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Including Goodwill</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="imrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIncludingGoodwill_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total assets acquired</label>
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAccruedExpensesAndOtherLiabilities" xlink:label="imrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAccruedExpensesAndOtherLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAccruedExpensesAndOtherLiabilities" xlink:to="imrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAccruedExpensesAndOtherLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="imrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAccruedExpensesAndOtherLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of accounts payable, accrued expenses and other liabilities due within one year or within the normal operating cycle, if longer, assumed at the acquisition date.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAccruedExpensesAndOtherLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable, Accrued Expenses And Other Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAccruedExpensesAndOtherLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts payable, accrued expenses and other liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred tax liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business Combination, Recognized Identifiable Asset Acquired and Liability Assumed, Lease Obligation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net assets acquired</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:label="us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:to="us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Acquired Finite-lived Intangible Assets, Weighted Average Useful Life</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Life, technology</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Professional Fees</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued professional services</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedEmployeeBenefitsCurrentAndNoncurrent" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrentAndNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedEmployeeBenefitsCurrentAndNoncurrent" xlink:to="us-gaap_AccruedEmployeeBenefitsCurrentAndNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrentAndNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Employee Benefits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrentAndNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued employee expenses</label>
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_AccruedContractResearchExpensesCurrent" xlink:label="imrx_AccruedContractResearchExpensesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imrx_AccruedContractResearchExpensesCurrent" xlink:to="imrx_AccruedContractResearchExpensesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="imrx_AccruedContractResearchExpensesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Carrying value as of the balance sheet date of obligations incurred and payable, related to contract research due within one year or within the normal operating cycle if longer.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imrx_AccruedContractResearchExpensesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Contract Research Expenses, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imrx_AccruedContractResearchExpensesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued contract research expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Accrued Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued other</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityByClassOfStockTable" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_TemporaryEquityByClassOfStockTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary Equity, by Class of Stock [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityLineItems" xlink:label="us-gaap_TemporaryEquityLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquityLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquityLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary Equity [Line Items]</label>
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_TemporaryEquityIssuancePrice" xlink:label="imrx_TemporaryEquityIssuancePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imrx_TemporaryEquityIssuancePrice" xlink:to="imrx_TemporaryEquityIssuancePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="imrx_TemporaryEquityIssuancePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance price of temporary equity.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imrx_TemporaryEquityIssuancePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary Equity, Issuance Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imrx_TemporaryEquityIssuancePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible preferred stock, issuance price (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:to="us-gaap_DebtConversionConvertedInstrumentSharesIssued1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Conversion, Converted Instrument, Shares Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares issued upon conversion of debt</label>
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_TemporaryEquityNumberOfSharesExcessOfAuthorized" xlink:label="imrx_TemporaryEquityNumberOfSharesExcessOfAuthorized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imrx_TemporaryEquityNumberOfSharesExcessOfAuthorized" xlink:to="imrx_TemporaryEquityNumberOfSharesExcessOfAuthorized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="imrx_TemporaryEquityNumberOfSharesExcessOfAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders excess of authorized by the articles of incorporation.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imrx_TemporaryEquityNumberOfSharesExcessOfAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary Equity, Number of Shares Excess of Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imrx_TemporaryEquityNumberOfSharesExcessOfAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares excess of authorized</label>
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_ProceedsFromIssuanceOfConvertiblePreferredStockExcessOfAuthorizedAmount" xlink:label="imrx_ProceedsFromIssuanceOfConvertiblePreferredStockExcessOfAuthorizedAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imrx_ProceedsFromIssuanceOfConvertiblePreferredStockExcessOfAuthorizedAmount" xlink:to="imrx_ProceedsFromIssuanceOfConvertiblePreferredStockExcessOfAuthorizedAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="imrx_ProceedsFromIssuanceOfConvertiblePreferredStockExcessOfAuthorizedAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock excess of amount authorized by the articles of incorporation.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imrx_ProceedsFromIssuanceOfConvertiblePreferredStockExcessOfAuthorizedAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Issuance of Convertible Preferred Stock Excess of Authorized Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imrx_ProceedsFromIssuanceOfConvertiblePreferredStockExcessOfAuthorizedAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from issuance of shares excess of amount authorized</label>
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_TemporaryEquityDueToExcessAuthorizedAmount" xlink:label="imrx_TemporaryEquityDueToExcessAuthorizedAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imrx_TemporaryEquityDueToExcessAuthorizedAmount" xlink:to="imrx_TemporaryEquityDueToExcessAuthorizedAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="imrx_TemporaryEquityDueToExcessAuthorizedAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of liability recognized due to shares issued in excess of amount authorized by the articles of incorporation.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imrx_TemporaryEquityDueToExcessAuthorizedAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary Equity, Due to Excess Authorized Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imrx_TemporaryEquityDueToExcessAuthorizedAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible preferred stock liability</label>
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_TemporaryEquityConversionPrice" xlink:label="imrx_TemporaryEquityConversionPrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imrx_TemporaryEquityConversionPrice" xlink:to="imrx_TemporaryEquityConversionPrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="imrx_TemporaryEquityConversionPrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of conversion price of temporary equity.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imrx_TemporaryEquityConversionPrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary Equity, Conversion Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imrx_TemporaryEquityConversionPrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible preferred stock, conversion price</label>
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_SeriesBConvertiblePreferredStocksTrancheOneMember" xlink:label="imrx_SeriesBConvertiblePreferredStocksTrancheOneMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imrx_SeriesBConvertiblePreferredStocksTrancheOneMember" xlink:to="imrx_SeriesBConvertiblePreferredStocksTrancheOneMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="imrx_SeriesBConvertiblePreferredStocksTrancheOneMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to series B preferred stock tranche one.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imrx_SeriesBConvertiblePreferredStocksTrancheOneMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series B Preferred Stock Tranche One</label>
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_SeriesBConvertiblePreferredStockTrancheTwoMember" xlink:label="imrx_SeriesBConvertiblePreferredStockTrancheTwoMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imrx_SeriesBConvertiblePreferredStockTrancheTwoMember" xlink:to="imrx_SeriesBConvertiblePreferredStockTrancheTwoMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="imrx_SeriesBConvertiblePreferredStockTrancheTwoMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to series B preferred stock tranche two.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imrx_SeriesBConvertiblePreferredStockTrancheTwoMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series B Preferred Stock Tranche Two</label>
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_NumberOfTranches" xlink:label="imrx_NumberOfTranches" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imrx_NumberOfTranches" xlink:to="imrx_NumberOfTranches_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="imrx_NumberOfTranches_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The number of tranches.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imrx_NumberOfTranches_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Tranches</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imrx_NumberOfTranches_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of tranches</label>
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_TemporaryEquityContingentlyIssuableShares" xlink:label="imrx_TemporaryEquityContingentlyIssuableShares" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imrx_TemporaryEquityContingentlyIssuableShares" xlink:to="imrx_TemporaryEquityContingentlyIssuableShares_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="imrx_TemporaryEquityContingentlyIssuableShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of convertible preferred shares does not meet the definition of a freestanding financial instrument and are issuable subject to the company meeting certain development milestones and other conditions as specified.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imrx_TemporaryEquityContingentlyIssuableShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary Equity, Contingently Issuable Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imrx_TemporaryEquityContingentlyIssuableShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares not meet the definition of a freestanding financial instrument</label>
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_PercentageOfEquitySecuritiesOwnedToGetConvertedStock" xlink:label="imrx_PercentageOfEquitySecuritiesOwnedToGetConvertedStock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imrx_PercentageOfEquitySecuritiesOwnedToGetConvertedStock" xlink:to="imrx_PercentageOfEquitySecuritiesOwnedToGetConvertedStock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="imrx_PercentageOfEquitySecuritiesOwnedToGetConvertedStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of equity securities to be owned may elect to receive a portion of their converted shares upon conversion.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imrx_PercentageOfEquitySecuritiesOwnedToGetConvertedStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of Equity Securities Owned, To Get Converted Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imrx_PercentageOfEquitySecuritiesOwnedToGetConvertedStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of equity securities to be own</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:label="us-gaap_PreferredStockDividendRatePercentage" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockDividendRatePercentage" xlink:to="us-gaap_PreferredStockDividendRatePercentage_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockDividendRatePercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Dividend Rate, Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockDividendRatePercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Dividend, Percentage</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DividendsPreferredStock" xlink:label="us-gaap_DividendsPreferredStock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DividendsPreferredStock" xlink:to="us-gaap_DividendsPreferredStock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DividendsPreferredStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Dividends, Preferred Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DividendsPreferredStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Dividend declared</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ScheduleOfStockByClassTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Stock by Class [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Stock [Line Items]</label>
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_NumberOfVotesPerShare" xlink:label="imrx_NumberOfVotesPerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imrx_NumberOfVotesPerShare" xlink:to="imrx_NumberOfVotesPerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="imrx_NumberOfVotesPerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of votes per share.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imrx_NumberOfVotesPerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Votes Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imrx_NumberOfVotesPerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of votes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock warrants</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock options</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares reserved for future issuance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares reserved for future issuance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants issued for common shares</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right, Exercise Price of Warrants or Rights</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrant exercise price</label>
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_WarrantsIssuedInLieuOfCashPayment" xlink:label="imrx_WarrantsIssuedInLieuOfCashPayment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imrx_WarrantsIssuedInLieuOfCashPayment" xlink:to="imrx_WarrantsIssuedInLieuOfCashPayment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="imrx_WarrantsIssuedInLieuOfCashPayment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of warrants issued to board of director's in lieu of cash payments.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imrx_WarrantsIssuedInLieuOfCashPayment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants Issued in Lieu of Cash Payment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imrx_WarrantsIssuedInLieuOfCashPayment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants in lieu of cash payment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants and Rights Outstanding, Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Term of warrant</label>
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_WarrantsExercised" xlink:label="imrx_WarrantsExercised" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imrx_WarrantsExercised" xlink:to="imrx_WarrantsExercised_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="imrx_WarrantsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of warrants exercised.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imrx_WarrantsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imrx_WarrantsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrant exercised</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstanding" xlink:to="us-gaap_WarrantsAndRightsOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants and Rights Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WarrantsAndRightsOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Issuance Initial Public Offering</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Stock issued</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDilutedAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share, Basic and Diluted [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Numerator:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share, Basic and Diluted, Other Disclosures [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Denominator - basic and diluted:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities, Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total shares of common stock equivalents</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Plan Name [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Plan Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_StockIncentivePlan2015Member" xlink:label="imrx_StockIncentivePlan2015Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imrx_StockIncentivePlan2015Member" xlink:to="imrx_StockIncentivePlan2015Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="imrx_StockIncentivePlan2015Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to Stock incentive plan 2015.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imrx_StockIncentivePlan2015Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Incentive Plan</label>
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_TwoThousandTwentyOneEmployeeStockPurchasePlanMember" xlink:label="imrx_TwoThousandTwentyOneEmployeeStockPurchasePlanMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imrx_TwoThousandTwentyOneEmployeeStockPurchasePlanMember" xlink:to="imrx_TwoThousandTwentyOneEmployeeStockPurchasePlanMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="imrx_TwoThousandTwentyOneEmployeeStockPurchasePlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to 2021 Employee Stock Purchase Plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imrx_TwoThousandTwentyOneEmployeeStockPurchasePlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2021 ESPP</label>
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_TwoThousandTwentyOneIncentiveAwardPlanMember" xlink:label="imrx_TwoThousandTwentyOneIncentiveAwardPlanMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imrx_TwoThousandTwentyOneIncentiveAwardPlanMember" xlink:to="imrx_TwoThousandTwentyOneIncentiveAwardPlanMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="imrx_TwoThousandTwentyOneIncentiveAwardPlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to 2021 Incentive Award Plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imrx_TwoThousandTwentyOneIncentiveAwardPlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2021 Plan</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vesting period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement, Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-based compensation expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based compensation expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Compensation expense remaining to be recognized</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Compensation expense recognized over a weighted-average period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Granted (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Grant date weighted average fair value</label>
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_PercentageOfAggregateNumberOfSharesOutstanding" xlink:label="imrx_PercentageOfAggregateNumberOfSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imrx_PercentageOfAggregateNumberOfSharesOutstanding" xlink:to="imrx_PercentageOfAggregateNumberOfSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="imrx_PercentageOfAggregateNumberOfSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of aggregate number of shares outstanding.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imrx_PercentageOfAggregateNumberOfSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aggregate number of shares outstanding (as a percent)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted-average risk-free interest rate, minimum</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted-average risk-free interest rate, maximum</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected term (in years)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected volatility, minimum</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected volatility, maximum</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of options</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding at the end (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding at the beginning (in shares)</label>
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRepurchased" xlink:label="imrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRepurchased" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRepurchased" xlink:to="imrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRepurchased_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="imrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRepurchased_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares repurchased during the period under share based payment award.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRepurchased_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Based Compensation Arrangement by Share Based Payment Award, Options Repurchased</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="imrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRepurchased_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Repurchased (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vested and exercisable (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vested and expected to vest (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Exercise Price per Share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Exercise Price per Share Outstanding at the end (in dollars per share)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Exercise Price per Share Outstanding at the beginning (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Exercise Price per Share Granted (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Exercise Price per Share Exercised (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsRepurchasedInPeriodWeightedAverageExercisePrice" xlink:label="imrx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsRepurchasedInPeriodWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imrx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsRepurchasedInPeriodWeightedAverageExercisePrice" xlink:to="imrx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsRepurchasedInPeriodWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="imrx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsRepurchasedInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average exercise price of shares repurchased during the period under share based payment award.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imrx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsRepurchasedInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Based Compensation Arrangements By Share Based Payment Award Options, Repurchased In Period Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imrx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsRepurchasedInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Exercise Price per Share Repurchased (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Exercise Price per Share Vested and Exercisable (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Exercise Price per Share Vested and Expected to Vest exercisable (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Remaining Contractual Contractual Term</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Remaining Contractual Term (in years)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Remaining Contractual Term, Vested and exercisable (in Years)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Remaining Contractual Term, Vested and expected to vest (in Years)</label>
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract" xlink:label="imrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract" xlink:to="imrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="imrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">No definition available.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Intrinsic Value [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aggregate Intrinsic Value</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aggregate Intrinsic Value Outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aggregate Intrinsic Value Vested and exercisable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aggregate Intrinsic Value Vested and expected to vest</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfSalesMember" xlink:label="us-gaap_CostOfSalesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfSalesMember" xlink:to="us-gaap_CostOfSalesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfSalesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cost of service</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General and administrative</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Percent [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reconciliation of the effect of applying the federal statutory rate to the net loss and the effective income tax rate</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statutory federal income tax rate</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">State tax, net of federal benefit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Permanent differences</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Federal research and development credits</label>
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_EffectiveIncomeTaxRateReconciliationTaxCreditStateResearchAndDevelopmentPercent" xlink:label="imrx_EffectiveIncomeTaxRateReconciliationTaxCreditStateResearchAndDevelopmentPercent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imrx_EffectiveIncomeTaxRateReconciliationTaxCreditStateResearchAndDevelopmentPercent" xlink:to="imrx_EffectiveIncomeTaxRateReconciliationTaxCreditStateResearchAndDevelopmentPercent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="imrx_EffectiveIncomeTaxRateReconciliationTaxCreditStateResearchAndDevelopmentPercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state research and development tax credit.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imrx_EffectiveIncomeTaxRateReconciliationTaxCreditStateResearchAndDevelopmentPercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Tax Credit, State Research And Development , Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imrx_EffectiveIncomeTaxRateReconciliationTaxCreditStateResearchAndDevelopmentPercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">State research and development credits</label>
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_EffectiveIncomeTaxRateReconciliationUncertainTaxPositions" xlink:label="imrx_EffectiveIncomeTaxRateReconciliationUncertainTaxPositions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imrx_EffectiveIncomeTaxRateReconciliationUncertainTaxPositions" xlink:to="imrx_EffectiveIncomeTaxRateReconciliationUncertainTaxPositions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="imrx_EffectiveIncomeTaxRateReconciliationUncertainTaxPositions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to uncertain tax positions.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imrx_EffectiveIncomeTaxRateReconciliationUncertainTaxPositions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Uncertain Tax Positions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imrx_EffectiveIncomeTaxRateReconciliationUncertainTaxPositions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Uncertain tax positions</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Other Adjustments, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other differences</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Change in valuation allowance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective income tax rate</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Components of Deferred Tax Assets and Liabilities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Components and tax effects of each type of item that gave rise to the net deferred tax assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Components of Deferred Tax Assets [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred tax assets:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-based compensation expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsUnrealizedCurrencyLosses" xlink:label="us-gaap_DeferredTaxAssetsUnrealizedCurrencyLosses" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsUnrealizedCurrencyLosses" xlink:to="us-gaap_DeferredTaxAssetsUnrealizedCurrencyLosses_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsUnrealizedCurrencyLosses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Unrealized Currency Losses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsUnrealizedCurrencyLosses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrealized losses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Tax Credit Carryforwards, Research</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">R&amp;D credit carryforward</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Operating Loss Carryforwards</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">NOL carryforward</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gross deferred tax assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Valuation Allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Valuation allowance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Net of Valuation Allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net deferred tax assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:label="us-gaap_DeferredTaxLiabilitiesNetAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesNetAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilitiesNetAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Liabilities, Net [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxLiabilitiesNetAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net deferred tax liabilities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" xlink:label="us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" xlink:to="us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Liabilities, Prepaid Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid expenses deducted for tax</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:to="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Liabilities, Property, Plant and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tax depreciation in excess of book</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Liabilities, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total deferred tax liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net deferred taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_OperatingLossCarryforwardsTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwardsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Loss Carryforwards [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Authority [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_IncomeTaxAuthorityDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Authority [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DomesticCountryMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Domestic Tax Authority [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalJurisdictionMember" xlink:to="us-gaap_StateAndLocalJurisdictionMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">State and Local Jurisdiction [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxCreditCarryforwardAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tax Credit Carryforward [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tax Credit Carryforward, Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchMember" xlink:to="us-gaap_ResearchMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research Tax Credit Carryforward [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Loss Carryforwards [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxesBusinessCombinationValuationAllowanceAvailableToReduceIncomeTaxExpense" xlink:label="us-gaap_DeferredTaxesBusinessCombinationValuationAllowanceAvailableToReduceIncomeTaxExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxesBusinessCombinationValuationAllowanceAvailableToReduceIncomeTaxExpense" xlink:to="us-gaap_DeferredTaxesBusinessCombinationValuationAllowanceAvailableToReduceIncomeTaxExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxesBusinessCombinationValuationAllowanceAvailableToReduceIncomeTaxExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Taxes, Business Combination, Valuation Allowance, Available to Reduce Income Tax Expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Loss Carryforwards</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAmount" xlink:to="us-gaap_TaxCreditCarryforwardAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tax Credit Carryforward, Amount</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefits" xlink:to="us-gaap_UnrecognizedTaxBenefits_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrecognized Tax Benefits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ending balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Beginning balance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued</label>
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_TaxCreditCarryforwardIncreaseDecreaseCaresAct" xlink:label="imrx_TaxCreditCarryforwardIncreaseDecreaseCaresAct" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imrx_TaxCreditCarryforwardIncreaseDecreaseCaresAct" xlink:to="imrx_TaxCreditCarryforwardIncreaseDecreaseCaresAct_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="imrx_TaxCreditCarryforwardIncreaseDecreaseCaresAct_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of increase (decrease) in t tax credit carryforward from application of the Coronavirus Aid, Relief, and Economic Security (CARES) Act.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imrx_TaxCreditCarryforwardIncreaseDecreaseCaresAct_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tax Credit Carryforward, Increase (Decrease), CARES Act</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:label="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase due to current year tax provision</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LesseeLeaseDescriptionTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeaseDescriptionTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Lease, Description [Table]</label>
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_OfficeSpaceInCambridgeMassachusettsNewYorkMember" xlink:label="imrx_OfficeSpaceInCambridgeMassachusettsNewYorkMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imrx_OfficeSpaceInCambridgeMassachusettsNewYorkMember" xlink:to="imrx_OfficeSpaceInCambridgeMassachusettsNewYorkMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="imrx_OfficeSpaceInCambridgeMassachusettsNewYorkMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to leases office space in Cambridge, Massachusetts, New York.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imrx_OfficeSpaceInCambridgeMassachusettsNewYorkMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Office Space In Cambridge, Massachusetts, New York [Member]</label>
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_StorageSpaceInSomervilleMassachusettsMember" xlink:label="imrx_StorageSpaceInSomervilleMassachusettsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imrx_StorageSpaceInSomervilleMassachusettsMember" xlink:to="imrx_StorageSpaceInSomervilleMassachusettsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="imrx_StorageSpaceInSomervilleMassachusettsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to leases storage space for its electronic data equipment in Somerville, Massachusetts.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imrx_StorageSpaceInSomervilleMassachusettsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Storage Space In Somerville, Massachusetts [Member]</label>
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_OfficeLeaseInSanDiegoCalifornia2020Member" xlink:label="imrx_OfficeLeaseInSanDiegoCalifornia2020Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imrx_OfficeLeaseInSanDiegoCalifornia2020Member" xlink:to="imrx_OfficeLeaseInSanDiegoCalifornia2020Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="imrx_OfficeLeaseInSanDiegoCalifornia2020Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to office lease in San Diego, California 2020.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imrx_OfficeLeaseInSanDiegoCalifornia2020Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2020 San Diego Lease</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="us-gaap_LeaseContractualTermAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseContractualTermAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease Contractual Term [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="us-gaap_LeaseContractualTermDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseContractualTermDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease Contractual Term [Domain]</label>
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_LeaseTerminationOnApril302032Member" xlink:label="imrx_LeaseTerminationOnApril302032Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imrx_LeaseTerminationOnApril302032Member" xlink:to="imrx_LeaseTerminationOnApril302032Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="imrx_LeaseTerminationOnApril302032Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information relating to lease termination on April 30, 2032.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imrx_LeaseTerminationOnApril302032Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease Termination on April 30, 2032 [Member]</label>
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_LeaseTerminationOnDecember312022Member" xlink:label="imrx_LeaseTerminationOnDecember312022Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imrx_LeaseTerminationOnDecember312022Member" xlink:to="imrx_LeaseTerminationOnDecember312022Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="imrx_LeaseTerminationOnDecember312022Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information relating to lease termination on December 31, 2022.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imrx_LeaseTerminationOnDecember312022Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease Termination on December 31, 2022 [Member]</label>
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_LeaseTerminationOnMarch312024Member" xlink:label="imrx_LeaseTerminationOnMarch312024Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imrx_LeaseTerminationOnMarch312024Member" xlink:to="imrx_LeaseTerminationOnMarch312024Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="imrx_LeaseTerminationOnMarch312024Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information relating to lease termination on March 31, 2024.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imrx_LeaseTerminationOnMarch312024Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease Termination on March 31, 2024 [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Lease, Description [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, to be Paid, Year One</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2022</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Minimum lease payment due 2022</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Term of Contract</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease term</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total lease liabilities</label>
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_AreaOfPropertyUnderLease" xlink:label="imrx_AreaOfPropertyUnderLease" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imrx_AreaOfPropertyUnderLease" xlink:to="imrx_AreaOfPropertyUnderLease_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="imrx_AreaOfPropertyUnderLease_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Area of property under lease.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imrx_AreaOfPropertyUnderLease_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Area of Property Under Lease</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, to be Paid, Year Two</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2023</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, to be Paid, Year Three</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2024</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, to be Paid, Year Four</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2025</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, to be Paid, Year Five</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2026</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, to be Paid, after Year Five</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Thereafter</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, to be Paid</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total future lease payments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Less: Imputed interest</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCostAbstract" xlink:label="us-gaap_LeaseCostAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_LeaseCostAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCostAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease, Cost [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeaseCostAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease costs:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating lease cost</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermLeaseCost" xlink:label="us-gaap_ShortTermLeaseCost" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermLeaseCost" xlink:to="us-gaap_ShortTermLeaseCost_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermLeaseCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Short-term Lease, Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShortTermLeaseCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Short-term lease cost</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableLeaseCost" xlink:label="us-gaap_VariableLeaseCost" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableLeaseCost" xlink:to="us-gaap_VariableLeaseCost_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VariableLeaseCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Variable Lease, Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_VariableLeaseCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Variable lease cost</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_LeaseCost_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease, Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LeaseCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total lease costs</label>
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_OperatingLeaseAdditionalInformationAbstract" xlink:label="imrx_OperatingLeaseAdditionalInformationAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imrx_OperatingLeaseAdditionalInformationAbstract" xlink:to="imrx_OperatingLeaseAdditionalInformationAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="imrx_OperatingLeaseAdditionalInformationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">No definition available.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imrx_OperatingLeaseAdditionalInformationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Additional Information [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="imrx_OperatingLeaseAdditionalInformationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash paid for amounts included in the measurement of lease liabilities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasePayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasePayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating cash flows from operating leases</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermLeasePayments" xlink:label="us-gaap_ShortTermLeasePayments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermLeasePayments" xlink:to="us-gaap_ShortTermLeasePayments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermLeasePayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Short-term Lease Payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShortTermLeasePayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating cash flows from short-term leases</label>
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_LeasePayments" xlink:label="imrx_LeasePayments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="imrx_LeasePayments" xlink:to="imrx_LeasePayments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="imrx_LeasePayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total cash paid towards operating lease payment including short term lease payment.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="imrx_LeasePayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease Payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="imrx_LeasePayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total lease Payment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Weighted Average Remaining Lease Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted-average remaining lease term - operating leases</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Weighted Average Discount Rate, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted-average discount rate - operating leases</label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>42
<FILENAME>imrx-20211231_pre.xml
<DESCRIPTION>EX-101.PRE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.8042.36810 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/10/2022 12:29:41 AM-->
<!--Modified on: 3/10/2022 12:29:41 AM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <roleRef xlink:type="simple" xlink:href="imrx-20211231.xsd#DocumentDocumentAndEntityInformation" roleURI="http://immuneering.com/role/DocumentDocumentAndEntityInformation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="imrx-20211231.xsd#StatementConsolidatedBalanceSheets" roleURI="http://immuneering.com/role/StatementConsolidatedBalanceSheets" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="imrx-20211231.xsd#StatementConsolidatedBalanceSheetsParentheticals" roleURI="http://immuneering.com/role/StatementConsolidatedBalanceSheetsParentheticals" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="imrx-20211231.xsd#StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" roleURI="http://immuneering.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="imrx-20211231.xsd#StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" roleURI="http://immuneering.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="imrx-20211231.xsd#StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParentheticals" roleURI="http://immuneering.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParentheticals" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="imrx-20211231.xsd#StatementConsolidatedStatementsOfCashFlows" roleURI="http://immuneering.com/role/StatementConsolidatedStatementsOfCashFlows" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="imrx-20211231.xsd#DisclosureOrganizationAndNatureOfBusiness" roleURI="http://immuneering.com/role/DisclosureOrganizationAndNatureOfBusiness" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="imrx-20211231.xsd#DisclosureSummaryOfSignificantAccountingPolicies" roleURI="http://immuneering.com/role/DisclosureSummaryOfSignificantAccountingPolicies" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="imrx-20211231.xsd#DisclosureMarketableSecurities" roleURI="http://immuneering.com/role/DisclosureMarketableSecurities" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="imrx-20211231.xsd#DisclosureFairValueMeasurements" roleURI="http://immuneering.com/role/DisclosureFairValueMeasurements" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="imrx-20211231.xsd#DisclosurePropertyAndEquipmentNet" roleURI="http://immuneering.com/role/DisclosurePropertyAndEquipmentNet" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="imrx-20211231.xsd#DisclosureBusinessCombination" roleURI="http://immuneering.com/role/DisclosureBusinessCombination" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="imrx-20211231.xsd#DisclosureAccruedExpenses" roleURI="http://immuneering.com/role/DisclosureAccruedExpenses" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="imrx-20211231.xsd#DisclosureConvertiblePreferredStock" roleURI="http://immuneering.com/role/DisclosureConvertiblePreferredStock" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="imrx-20211231.xsd#DisclosureCommonStock" roleURI="http://immuneering.com/role/DisclosureCommonStock" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="imrx-20211231.xsd#DisclosureNetLossPerShareAttributableToCommonStockholders" roleURI="http://immuneering.com/role/DisclosureNetLossPerShareAttributableToCommonStockholders" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="imrx-20211231.xsd#DisclosureStockBasedCompensation" roleURI="http://immuneering.com/role/DisclosureStockBasedCompensation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="imrx-20211231.xsd#DisclosureIncomeTaxes" roleURI="http://immuneering.com/role/DisclosureIncomeTaxes" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="imrx-20211231.xsd#DisclosureCommitmentsAndContingencies" roleURI="http://immuneering.com/role/DisclosureCommitmentsAndContingencies" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="imrx-20211231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://immuneering.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="imrx-20211231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesTables" roleURI="http://immuneering.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="imrx-20211231.xsd#DisclosureMarketableSecuritiesTables" roleURI="http://immuneering.com/role/DisclosureMarketableSecuritiesTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="imrx-20211231.xsd#DisclosureFairValueMeasurementsTables" roleURI="http://immuneering.com/role/DisclosureFairValueMeasurementsTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="imrx-20211231.xsd#DisclosurePropertyAndEquipmentNetTables" roleURI="http://immuneering.com/role/DisclosurePropertyAndEquipmentNetTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="imrx-20211231.xsd#DisclosureBusinessCombinationTables" roleURI="http://immuneering.com/role/DisclosureBusinessCombinationTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="imrx-20211231.xsd#DisclosureAccruedExpensesTables" roleURI="http://immuneering.com/role/DisclosureAccruedExpensesTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="imrx-20211231.xsd#DisclosureCommonStockTables" roleURI="http://immuneering.com/role/DisclosureCommonStockTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="imrx-20211231.xsd#DisclosureNetLossPerShareAttributableToCommonStockholdersTables" roleURI="http://immuneering.com/role/DisclosureNetLossPerShareAttributableToCommonStockholdersTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="imrx-20211231.xsd#DisclosureStockBasedCompensationTables" roleURI="http://immuneering.com/role/DisclosureStockBasedCompensationTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="imrx-20211231.xsd#DisclosureIncomeTaxesTables" roleURI="http://immuneering.com/role/DisclosureIncomeTaxesTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="imrx-20211231.xsd#DisclosureCommitmentsAndContingenciesTables" roleURI="http://immuneering.com/role/DisclosureCommitmentsAndContingenciesTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="imrx-20211231.xsd#DisclosureOrganizationAndNatureOfBusinessDetails" roleURI="http://immuneering.com/role/DisclosureOrganizationAndNatureOfBusinessDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="imrx-20211231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails" roleURI="http://immuneering.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="imrx-20211231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesConcentrationOfCreditRiskDetails" roleURI="http://immuneering.com/role/DisclosureSummaryOfSignificantAccountingPoliciesConcentrationOfCreditRiskDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="imrx-20211231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails" roleURI="http://immuneering.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="imrx-20211231.xsd#DisclosureMarketableSecuritiesDetails" roleURI="http://immuneering.com/role/DisclosureMarketableSecuritiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="imrx-20211231.xsd#DisclosureFairValueMeasurementsDetails" roleURI="http://immuneering.com/role/DisclosureFairValueMeasurementsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="imrx-20211231.xsd#DisclosurePropertyAndEquipmentNetDetails" roleURI="http://immuneering.com/role/DisclosurePropertyAndEquipmentNetDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="imrx-20211231.xsd#DisclosurePropertyAndEquipmentNetDepreciationDetails" roleURI="http://immuneering.com/role/DisclosurePropertyAndEquipmentNetDepreciationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="imrx-20211231.xsd#DisclosureBusinessCombinationNarrativeDetails" roleURI="http://immuneering.com/role/DisclosureBusinessCombinationNarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="imrx-20211231.xsd#DisclosureBusinessCombinationAssetsAcquiredAndLiabilitiesAssumedDetails" roleURI="http://immuneering.com/role/DisclosureBusinessCombinationAssetsAcquiredAndLiabilitiesAssumedDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="imrx-20211231.xsd#DisclosureAccruedExpensesDetails" roleURI="http://immuneering.com/role/DisclosureAccruedExpensesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="imrx-20211231.xsd#DisclosureConvertiblePreferredStockSeriesDetails" roleURI="http://immuneering.com/role/DisclosureConvertiblePreferredStockSeriesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="imrx-20211231.xsd#DisclosureConvertiblePreferredStockSeriesBDetails" roleURI="http://immuneering.com/role/DisclosureConvertiblePreferredStockSeriesBDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="imrx-20211231.xsd#DisclosureCommonStockClassCommonStockDetails" roleURI="http://immuneering.com/role/DisclosureCommonStockClassCommonStockDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="imrx-20211231.xsd#DisclosureCommonStockDetails" roleURI="http://immuneering.com/role/DisclosureCommonStockDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="imrx-20211231.xsd#DisclosureCommonStockClassBCommonStockDetails" roleURI="http://immuneering.com/role/DisclosureCommonStockClassBCommonStockDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="imrx-20211231.xsd#DisclosureCommonStockCommonStockWarrantDetails" roleURI="http://immuneering.com/role/DisclosureCommonStockCommonStockWarrantDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="imrx-20211231.xsd#DisclosureCommonStockIpoDetails" roleURI="http://immuneering.com/role/DisclosureCommonStockIpoDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="imrx-20211231.xsd#DisclosureNetLossPerShareAttributableToCommonStockholdersBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails" roleURI="http://immuneering.com/role/DisclosureNetLossPerShareAttributableToCommonStockholdersBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="imrx-20211231.xsd#DisclosureNetLossPerShareAttributableToCommonStockholdersAntidilutiveEffectDetails" roleURI="http://immuneering.com/role/DisclosureNetLossPerShareAttributableToCommonStockholdersAntidilutiveEffectDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="imrx-20211231.xsd#DisclosureStockBasedCompensationNarrativesDetails" roleURI="http://immuneering.com/role/DisclosureStockBasedCompensationNarrativesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="imrx-20211231.xsd#DisclosureStockBasedCompensationAssumptionsDetails" roleURI="http://immuneering.com/role/DisclosureStockBasedCompensationAssumptionsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="imrx-20211231.xsd#DisclosureStockBasedCompensationStockOptionActivityDetails" roleURI="http://immuneering.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="imrx-20211231.xsd#DisclosureStockBasedCompensationShareBasedCompensationExpenseDetails" roleURI="http://immuneering.com/role/DisclosureStockBasedCompensationShareBasedCompensationExpenseDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="imrx-20211231.xsd#DisclosureIncomeTaxesNetLossAndEffectiveIncomeTaxRateDetails" roleURI="http://immuneering.com/role/DisclosureIncomeTaxesNetLossAndEffectiveIncomeTaxRateDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="imrx-20211231.xsd#DisclosureIncomeTaxesNetDeferredTaxAssetsDetails" roleURI="http://immuneering.com/role/DisclosureIncomeTaxesNetDeferredTaxAssetsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="imrx-20211231.xsd#DisclosureIncomeTaxesNarrativeDetails" roleURI="http://immuneering.com/role/DisclosureIncomeTaxesNarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="imrx-20211231.xsd#DisclosureIncomeTaxesUnrecognizedTaxBenefitsDetails" roleURI="http://immuneering.com/role/DisclosureIncomeTaxesUnrecognizedTaxBenefitsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="imrx-20211231.xsd#DisclosureCommitmentsAndContingenciesNarrativesDetails" roleURI="http://immuneering.com/role/DisclosureCommitmentsAndContingenciesNarrativesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="imrx-20211231.xsd#DisclosureCommitmentsAndContingenciesMaturitiesOfLeaseLiabilitiesDueDetails" roleURI="http://immuneering.com/role/DisclosureCommitmentsAndContingenciesMaturitiesOfLeaseLiabilitiesDueDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="imrx-20211231.xsd#DisclosureCommitmentsAndContingenciesLeaseCostDetails" roleURI="http://immuneering.com/role/DisclosureCommitmentsAndContingenciesLeaseCostDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <presentationLink xlink:role="http://immuneering.com/role/DocumentDocumentAndEntityInformation" xlink:type="extended" xlink:title="00090 - Document - Document and Entity Information" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract" xlink:label="CoverAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_637824689803200419" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="us-gaap_StatementTable_637824689803200419" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_637824689803210370" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637824689803200419" xlink:to="us-gaap_StatementClassOfStockAxis_637824689803210370" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_637824689803210370" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_637824689803210370" xlink:to="us-gaap_ClassOfStockDomain_637824689803210370" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember_637824689803210370" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_637824689803210370" xlink:to="us-gaap_CommonClassAMember_637824689803210370" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassBMember" xlink:label="us-gaap_CommonClassBMember_637824689803210370" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_637824689803210370" xlink:to="us-gaap_CommonClassBMember_637824689803210370" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_637824689803210370" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637824689803200419" xlink:to="us-gaap_StatementLineItems_637824689803210370" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:label="dei_DocumentType_637824689803210370" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637824689803210370" xlink:to="dei_DocumentType_637824689803210370" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport_637824689803210370" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637824689803210370" xlink:to="dei_DocumentAnnualReport_637824689803210370" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport_637824689803210370" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637824689803210370" xlink:to="dei_DocumentTransitionReport_637824689803210370" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate_637824689803210370" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637824689803210370" xlink:to="dei_DocumentPeriodEndDate_637824689803210370" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber_637824689803210370" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637824689803210370" xlink:to="dei_EntityFileNumber_637824689803210370" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName_637824689803210370" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637824689803210370" xlink:to="dei_EntityRegistrantName_637824689803210370" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode_637824689803220273" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637824689803210370" xlink:to="dei_EntityIncorporationStateCountryCode_637824689803220273" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber_637824689803220273" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637824689803210370" xlink:to="dei_EntityTaxIdentificationNumber_637824689803220273" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1_637824689803220273" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637824689803210370" xlink:to="dei_EntityAddressAddressLine1_637824689803220273" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2_637824689803220273" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637824689803210370" xlink:to="dei_EntityAddressAddressLine2_637824689803220273" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown_637824689803220273" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637824689803210370" xlink:to="dei_EntityAddressCityOrTown_637824689803220273" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince_637824689803220273" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637824689803210370" xlink:to="dei_EntityAddressStateOrProvince_637824689803220273" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode_637824689803220273" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637824689803210370" xlink:to="dei_EntityAddressPostalZipCode_637824689803220273" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode_637824689803220273" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637824689803210370" xlink:to="dei_CityAreaCode_637824689803220273" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber_637824689803220273" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637824689803210370" xlink:to="dei_LocalPhoneNumber_637824689803220273" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle_637824689803230264" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637824689803210370" xlink:to="dei_Security12bTitle_637824689803230264" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol_637824689803230264" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637824689803210370" xlink:to="dei_TradingSymbol_637824689803230264" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName_637824689803230264" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637824689803210370" xlink:to="dei_SecurityExchangeName_637824689803230264" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer_637824689803230264" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637824689803210370" xlink:to="dei_EntityWellKnownSeasonedIssuer_637824689803230264" order="19" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers_637824689803230264" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637824689803210370" xlink:to="dei_EntityVoluntaryFilers_637824689803230264" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus_637824689803230264" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637824689803210370" xlink:to="dei_EntityCurrentReportingStatus_637824689803230264" order="21" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent_637824689803230264" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637824689803210370" xlink:to="dei_EntityInteractiveDataCurrent_637824689803230264" order="22" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory_637824689803240355" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637824689803210370" xlink:to="dei_EntityFilerCategory_637824689803240355" order="23" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness_637824689803240355" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637824689803210370" xlink:to="dei_EntitySmallBusiness_637824689803240355" order="24" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany_637824689803240355" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637824689803210370" xlink:to="dei_EntityEmergingGrowthCompany_637824689803240355" order="25" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod_637824689803240355" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637824689803210370" xlink:to="dei_EntityExTransitionPeriod_637824689803240355" order="26" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag_637824689803240355" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637824689803210370" xlink:to="dei_IcfrAuditorAttestationFlag_637824689803240355" order="27" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany_637824689803240355" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637824689803210370" xlink:to="dei_EntityShellCompany_637824689803240355" order="28" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat_637824689803240355" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637824689803210370" xlink:to="dei_EntityPublicFloat_637824689803240355" order="29" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding_637824689803250378" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637824689803210370" xlink:to="dei_EntityCommonStockSharesOutstanding_637824689803250378" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_637824689803250378" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637824689803210370" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_637824689803250378" order="31" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorName" xlink:label="dei_AuditorName_637824689803250378" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637824689803210370" xlink:to="dei_AuditorName_637824689803250378" order="32" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId_637824689803250378" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637824689803210370" xlink:to="dei_AuditorFirmId_637824689803250378" order="33" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation_637824689803250378" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637824689803210370" xlink:to="dei_AuditorLocation_637824689803250378" order="34" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey_637824689803260336" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637824689803210370" xlink:to="dei_EntityCentralIndexKey_637824689803260336" order="35" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate_637824689803260336" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637824689803210370" xlink:to="dei_CurrentFiscalYearEndDate_637824689803260336" order="36" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus_637824689803260336" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637824689803210370" xlink:to="dei_DocumentFiscalYearFocus_637824689803260336" order="37" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus_637824689803260336" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637824689803210370" xlink:to="dei_DocumentFiscalPeriodFocus_637824689803260336" order="38" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag_637824689803260336" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637824689803210370" xlink:to="dei_AmendmentFlag_637824689803260336" order="39" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://immuneering.com/role/StatementConsolidatedBalanceSheets" xlink:type="extended" xlink:title="00100 - Statement - CONSOLIDATED BALANCE SHEETS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_637824689803270251" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable_637824689803270251" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_637824689803270251" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637824689803270251" xlink:to="us-gaap_StatementClassOfStockAxis_637824689803270251" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_637824689803270251" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_637824689803270251" xlink:to="us-gaap_ClassOfStockDomain_637824689803270251" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_SeriesBConvertiblePreferredStockMember" xlink:label="imrx_SeriesBConvertiblePreferredStockMember_637824689803270251" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_637824689803270251" xlink:to="imrx_SeriesBConvertiblePreferredStockMember_637824689803270251" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_SeriesConvertiblePreferredStockMember" xlink:label="imrx_SeriesConvertiblePreferredStockMember_637824689803270251" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_637824689803270251" xlink:to="imrx_SeriesConvertiblePreferredStockMember_637824689803270251" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember_637824689803270251" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_637824689803270251" xlink:to="us-gaap_CommonClassAMember_637824689803270251" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassBMember" xlink:label="us-gaap_CommonClassBMember_637824689803270251" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_637824689803270251" xlink:to="us-gaap_CommonClassBMember_637824689803270251" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_637824689803270251" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637824689803270251" xlink:to="us-gaap_StatementLineItems_637824689803270251" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract_637824689803270251" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637824689803270251" xlink:to="us-gaap_AssetsAbstract_637824689803270251" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract_637824689803280252" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_637824689803270251" xlink:to="us-gaap_AssetsCurrentAbstract_637824689803280252" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_637824689803280252" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_637824689803280252" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_637824689803280252" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="us-gaap_MarketableSecuritiesCurrent_637824689803280252" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_637824689803280252" xlink:to="us-gaap_MarketableSecuritiesCurrent_637824689803280252" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent_637824689803280252" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_637824689803280252" xlink:to="us-gaap_AccountsReceivableNetCurrent_637824689803280252" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_637824689803280252" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_637824689803280252" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_637824689803280252" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_637824689803280252" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_637824689803280252" xlink:to="us-gaap_AssetsCurrent_637824689803280252" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesNoncurrent" xlink:label="us-gaap_MarketableSecuritiesNoncurrent_637824689803280252" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_637824689803270251" xlink:to="us-gaap_MarketableSecuritiesNoncurrent_637824689803280252" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_637824689803280252" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_637824689803270251" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_637824689803280252" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill_637824689803289943" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_637824689803270251" xlink:to="us-gaap_Goodwill_637824689803289943" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_637824689803289943" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_637824689803270251" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_637824689803289943" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_637824689803289943" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_637824689803270251" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_637824689803289943" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent_637824689803289943" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_637824689803270251" xlink:to="us-gaap_OtherAssetsNoncurrent_637824689803289943" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets_637824689803289943" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_637824689803270251" xlink:to="us-gaap_Assets_637824689803289943" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637824689803289943" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637824689803270251" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637824689803289943" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract_637824689803289943" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637824689803289943" xlink:to="us-gaap_LiabilitiesCurrentAbstract_637824689803289943" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent_637824689803289943" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_637824689803289943" xlink:to="us-gaap_AccountsPayableCurrent_637824689803289943" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent_637824689803300334" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_637824689803289943" xlink:to="us-gaap_AccruedLiabilitiesCurrent_637824689803300334" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_637824689803300334" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_637824689803289943" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_637824689803300334" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_637824689803300334" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_637824689803289943" xlink:to="us-gaap_LiabilitiesCurrent_637824689803300334" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_637824689803300334" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637824689803289943" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract_637824689803300334" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_637824689803300334" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract_637824689803300334" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_637824689803300334" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_637824689803300334" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract_637824689803300334" xlink:to="us-gaap_Liabilities_637824689803300334" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies_637824689803300334" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637824689803289943" xlink:to="us-gaap_CommitmentsAndContingencies_637824689803300334" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityAbstract" xlink:label="us-gaap_TemporaryEquityAbstract_637824689803310309" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637824689803289943" xlink:to="us-gaap_TemporaryEquityAbstract_637824689803310309" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_637824689803310309" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityAbstract_637824689803310309" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_637824689803310309" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract_637824689803310309" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637824689803289943" xlink:to="us-gaap_StockholdersEquityAbstract_637824689803310309" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue_637824689803310309" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_637824689803310309" xlink:to="us-gaap_PreferredStockValue_637824689803310309" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue_637824689803310309" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_637824689803310309" xlink:to="us-gaap_CommonStockValue_637824689803310309" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital_637824689803310309" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_637824689803310309" xlink:to="us-gaap_AdditionalPaidInCapital_637824689803310309" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_637824689803320543" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_637824689803310309" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_637824689803320543" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_637824689803320543" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_637824689803310309" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_637824689803320543" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_637824689803320543" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_637824689803310309" xlink:to="us-gaap_StockholdersEquity_637824689803320543" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_637824689803320543" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637824689803289943" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_637824689803320543" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://immuneering.com/role/StatementConsolidatedBalanceSheetsParentheticals" xlink:type="extended" xlink:title="00105 - Statement - CONSOLIDATED BALANCE SHEETS (Parentheticals)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_637824689803320543" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract_1" xlink:to="us-gaap_StatementTable_637824689803320543" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_637824689803330425" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637824689803320543" xlink:to="us-gaap_StatementClassOfStockAxis_637824689803330425" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_637824689803330425" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_637824689803330425" xlink:to="us-gaap_ClassOfStockDomain_637824689803330425" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_SeriesBConvertiblePreferredStockMember" xlink:label="imrx_SeriesBConvertiblePreferredStockMember_637824689803330425" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_637824689803330425" xlink:to="imrx_SeriesBConvertiblePreferredStockMember_637824689803330425" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_SeriesConvertiblePreferredStockMember" xlink:label="imrx_SeriesConvertiblePreferredStockMember_637824689803330425" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_637824689803330425" xlink:to="imrx_SeriesConvertiblePreferredStockMember_637824689803330425" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember_637824689803330425" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_637824689803330425" xlink:to="us-gaap_CommonClassAMember_637824689803330425" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassBMember" xlink:label="us-gaap_CommonClassBMember_637824689803330425" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_637824689803330425" xlink:to="us-gaap_CommonClassBMember_637824689803330425" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_637824689803330425" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637824689803320543" xlink:to="us-gaap_StatementLineItems_637824689803330425" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare_637824689803330425" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637824689803330425" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare_637824689803330425" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="us-gaap_TemporaryEquitySharesAuthorized_637824689803330425" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637824689803330425" xlink:to="us-gaap_TemporaryEquitySharesAuthorized_637824689803330425" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued_637824689803330425" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637824689803330425" xlink:to="us-gaap_TemporaryEquitySharesIssued_637824689803330425" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_637824689803330425" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637824689803330425" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_637824689803330425" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_637824689803330425" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637824689803330425" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_637824689803330425" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized_637824689803340219" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637824689803330425" xlink:to="us-gaap_PreferredStockSharesAuthorized_637824689803340219" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued_637824689803340219" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637824689803330425" xlink:to="us-gaap_PreferredStockSharesIssued_637824689803340219" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding_637824689803340219" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637824689803330425" xlink:to="us-gaap_PreferredStockSharesOutstanding_637824689803340219" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_637824689803340219" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637824689803330425" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_637824689803340219" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized_637824689803340219" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637824689803330425" xlink:to="us-gaap_CommonStockSharesAuthorized_637824689803340219" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued_637824689803340219" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637824689803330425" xlink:to="us-gaap_CommonStockSharesIssued_637824689803340219" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding_637824689803340219" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637824689803330425" xlink:to="us-gaap_CommonStockSharesOutstanding_637824689803340219" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://immuneering.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="extended" xlink:title="00200 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues_637824689803350223" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_Revenues_637824689803350223" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfRevenue" xlink:label="us-gaap_CostOfRevenue_637824689803350223" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_CostOfRevenue_637824689803350223" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GrossProfit" xlink:label="us-gaap_GrossProfit_637824689803350223" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_GrossProfit_637824689803350223" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract_637824689803350223" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_637824689803350223" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_637824689803350223" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_637824689803350223" xlink:to="us-gaap_ResearchAndDevelopmentExpense_637824689803350223" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense_637824689803350223" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_637824689803350223" xlink:to="us-gaap_GeneralAndAdministrativeExpense_637824689803350223" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses_637824689803350223" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_637824689803350223" xlink:to="us-gaap_OperatingExpenses_637824689803350223" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_637824689803350223" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_OperatingIncomeLoss_637824689803350223" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeNonoperatingAbstract" xlink:label="us-gaap_InvestmentIncomeNonoperatingAbstract_637824689803350223" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_InvestmentIncomeNonoperatingAbstract_637824689803350223" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest_637824689803350223" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentIncomeNonoperatingAbstract_637824689803350223" xlink:to="us-gaap_InvestmentIncomeInterest_637824689803350223" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_637824689803350223" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentIncomeNonoperatingAbstract_637824689803350223" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_637824689803350223" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_637824689803360213" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentIncomeNonoperatingAbstract_637824689803350223" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_637824689803360213" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit_637824689803360213" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentIncomeNonoperatingAbstract_637824689803350223" xlink:to="us-gaap_IncomeTaxExpenseBenefit_637824689803360213" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_637824689803360213" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_NetIncomeLoss_637824689803360213" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic_637824689803360213" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_EarningsPerShareBasic_637824689803360213" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted_637824689803360213" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_EarningsPerShareDiluted_637824689803360213" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_637824689803360213" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_637824689803360213" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_637824689803360213" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_637824689803360213" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_637824689803360213" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_637824689803360213" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:label="us-gaap_MarketableSecuritiesUnrealizedGainLoss_637824689803360213" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_637824689803360213" xlink:to="us-gaap_MarketableSecuritiesUnrealizedGainLoss_637824689803360213" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_637824689803370333" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_637824689803360213" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_637824689803370333" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://immuneering.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" xlink:type="extended" xlink:title="00300 - Statement - CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_637824689803370333" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable_637824689803370333" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_637824689803370333" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637824689803370333" xlink:to="us-gaap_StatementEquityComponentsAxis_637824689803370333" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember_637824689803370333" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_637824689803370333" xlink:to="us-gaap_PreferredStockMember_637824689803370333" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_637824689803370333" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_637824689803370333" xlink:to="us-gaap_CommonStockMember_637824689803370333" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember_637824689803370333" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_637824689803370333" xlink:to="us-gaap_AdditionalPaidInCapitalMember_637824689803370333" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_637824689803370333" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_637824689803370333" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_637824689803370333" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember_637824689803370333" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_637824689803370333" xlink:to="us-gaap_RetainedEarningsMember_637824689803370333" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_637824689803370333" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_637824689803370333" xlink:to="us-gaap_EquityComponentDomain_637824689803370333" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_637824689803380237" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637824689803370333" xlink:to="us-gaap_StatementClassOfStockAxis_637824689803380237" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_SeriesConvertiblePreferredStockMember" xlink:label="imrx_SeriesConvertiblePreferredStockMember_637824689803380237" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_637824689803380237" xlink:to="imrx_SeriesConvertiblePreferredStockMember_637824689803380237" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_SeriesBConvertiblePreferredStockMember" xlink:label="imrx_SeriesBConvertiblePreferredStockMember_637824689803380237" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_637824689803380237" xlink:to="imrx_SeriesBConvertiblePreferredStockMember_637824689803380237" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember_637824689803380237" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_637824689803380237" xlink:to="us-gaap_CommonClassAMember_637824689803380237" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_637824689803380237" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_637824689803380237" xlink:to="us-gaap_ClassOfStockDomain_637824689803380237" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_637824689803380237" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637824689803370333" xlink:to="us-gaap_StatementLineItems_637824689803380237" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637824689803380237" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637824689803380237" xlink:to="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637824689803380237" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_637824689803380237" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637824689803380237" xlink:to="us-gaap_SharesOutstanding_637824689803380237" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_637824689803380237" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637824689803380237" xlink:to="us-gaap_StockholdersEquity_637824689803380237" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_637824689803390925" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637824689803380237" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_637824689803390925" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_637824689803390925" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637824689803380237" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_637824689803390925" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_StockIssuedDuringPeriodValueWarrantsExercised" xlink:label="imrx_StockIssuedDuringPeriodValueWarrantsExercised_637824689803390925" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637824689803380237" xlink:to="imrx_StockIssuedDuringPeriodValueWarrantsExercised_637824689803390925" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:label="imrx_StockIssuedDuringPeriodSharesWarrantsExercised_637824689803390925" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637824689803380237" xlink:to="imrx_StockIssuedDuringPeriodSharesWarrantsExercised_637824689803390925" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_637824689803390925" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637824689803380237" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_637824689803390925" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_637824689803390925" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637824689803380237" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_637824689803390925" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_637824689803390925" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637824689803380237" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_637824689803390925" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_637824689803390925" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637824689803380237" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_637824689803390925" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="us-gaap_StockIssuedDuringPeriodValueAcquisitions_637824689803400260" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637824689803380237" xlink:to="us-gaap_StockIssuedDuringPeriodValueAcquisitions_637824689803400260" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_637824689803400260" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637824689803380237" xlink:to="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_637824689803400260" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_637824689803400260" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637824689803380237" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_637824689803400260" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_637824689803400260" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637824689803380237" xlink:to="us-gaap_NetIncomeLoss_637824689803400260" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax_637824689803410323" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637824689803380237" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax_637824689803410323" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_637824689803410323" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637824689803380237" xlink:to="us-gaap_StockholdersEquity_637824689803410323" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_637824689803410323" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637824689803380237" xlink:to="us-gaap_SharesOutstanding_637824689803410323" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_637824689803410323" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637824689803380237" xlink:to="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_637824689803410323" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_637824689803410323" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_637824689803410323" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_637824689803410323" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_637824689803410323" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_637824689803410323" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_637824689803410323" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_637824689803420359" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_637824689803410323" xlink:to="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_637824689803420359" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:label="imrx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_637824689803420359" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_637824689803410323" xlink:to="imrx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_637824689803420359" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_637824689803420359" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_637824689803410323" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_637824689803420359" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_637824689803420359" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_637824689803410323" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_637824689803420359" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://immuneering.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParentheticals" xlink:type="extended" xlink:title="00305 - Statement - CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT) (Parentheticals)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_1" />
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_StockIssuanceCosts" xlink:label="imrx_StockIssuanceCosts_637824689803430260" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract_1" xlink:to="imrx_StockIssuanceCosts_637824689803430260" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://immuneering.com/role/StatementConsolidatedStatementsOfCashFlows" xlink:type="extended" xlink:title="00400 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_637824689803430260" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementTable_637824689803430260" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_637824689803430260" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637824689803430260" xlink:to="us-gaap_StatementClassOfStockAxis_637824689803430260" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_637824689803430260" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_637824689803430260" xlink:to="us-gaap_ClassOfStockDomain_637824689803430260" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_SeriesConvertiblePreferredStockMember" xlink:label="imrx_SeriesConvertiblePreferredStockMember_637824689803430260" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_637824689803430260" xlink:to="imrx_SeriesConvertiblePreferredStockMember_637824689803430260" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_SeriesBConvertiblePreferredStockMember" xlink:label="imrx_SeriesBConvertiblePreferredStockMember_637824689803430260" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_637824689803430260" xlink:to="imrx_SeriesBConvertiblePreferredStockMember_637824689803430260" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_637824689803430260" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637824689803430260" xlink:to="us-gaap_StatementLineItems_637824689803430260" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_637824689803430260" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637824689803430260" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_637824689803430260" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_637824689803430260" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_637824689803430260" xlink:to="us-gaap_NetIncomeLoss_637824689803430260" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637824689803430260" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_637824689803430260" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637824689803430260" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation_637824689803430260" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637824689803430260" xlink:to="us-gaap_Depreciation_637824689803430260" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_637824689803440254" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637824689803430260" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_637824689803440254" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_637824689803440254" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637824689803430260" xlink:to="us-gaap_ShareBasedCompensation_637824689803440254" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:label="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_637824689803440254" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637824689803430260" xlink:to="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_637824689803440254" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_637824689803440254" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637824689803430260" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_637824689803440254" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637824689803440254" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637824689803430260" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637824689803440254" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_637824689803440254" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637824689803440254" xlink:to="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_637824689803440254" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_637824689803440254" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_637824689803440254" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_637824689803440254" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_637824689803440254" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_637824689803440254" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_637824689803440254" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets_637824689803450390" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_637824689803440254" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets_637824689803450390" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract_637824689803450390" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637824689803440254" xlink:to="us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract_637824689803450390" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_637824689803450390" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract_637824689803450390" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_637824689803450390" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_637824689803450390" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract_637824689803450390" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_637824689803450390" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_637824689803450390" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract_637824689803450390" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_637824689803450390" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_637824689803450390" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_637824689803430260" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_637824689803450390" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_637824689803450390" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637824689803430260" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_637824689803450390" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_637824689803450390" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_637824689803450390" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_637824689803450390" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities_637824689803460250" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_637824689803450390" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities_637824689803460250" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAcquiredInExcessOfPaymentsToAcquireBusiness" xlink:label="us-gaap_CashAcquiredInExcessOfPaymentsToAcquireBusiness_637824689803460250" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_637824689803450390" xlink:to="us-gaap_CashAcquiredInExcessOfPaymentsToAcquireBusiness_637824689803460250" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_637824689803460250" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_637824689803450390" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_637824689803460250" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637824689803460250" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637824689803430260" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637824689803460250" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_637824689803460250" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637824689803460250" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_637824689803460250" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_637824689803460250" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637824689803460250" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_637824689803460250" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_637824689803460250" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637824689803460250" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_637824689803460250" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_637824689803460250" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637824689803460250" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_637824689803460250" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises_637824689803470249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637824689803460250" xlink:to="us-gaap_ProceedsFromWarrantExercises_637824689803470249" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_637824689803470249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637824689803460250" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_637824689803470249" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_637824689803470249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637824689803430260" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_637824689803470249" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_637824689803470249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637824689803430260" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_637824689803470249" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6378246898034702491" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637824689803430260" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6378246898034702491" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_637824689803470249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637824689803430260" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_637824689803470249" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssued1" xlink:label="us-gaap_StockIssued1_637824689803480273" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract_637824689803470249" xlink:to="us-gaap_StockIssued1_637824689803480273" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:label="us-gaap_BusinessCombinationAcquisitionRelatedCosts_637824689803480273" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract_637824689803470249" xlink:to="us-gaap_BusinessCombinationAcquisitionRelatedCosts_637824689803480273" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="us-gaap_ConversionOfStockSharesIssued1_637824689803480273" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract_637824689803470249" xlink:to="us-gaap_ConversionOfStockSharesIssued1_637824689803480273" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_ReclassificationOfLiabilityOfPreferredStock" xlink:label="imrx_ReclassificationOfLiabilityOfPreferredStock_637824689803480273" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract_637824689803470249" xlink:to="imrx_ReclassificationOfLiabilityOfPreferredStock_637824689803480273" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://immuneering.com/role/DisclosureOrganizationAndNatureOfBusiness" xlink:type="extended" xlink:title="10101 - Disclosure - Organization and Nature of Business" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_637824689803490877" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_637824689803490877" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://immuneering.com/role/DisclosureSummaryOfSignificantAccountingPolicies" xlink:type="extended" xlink:title="10201 - Disclosure - Summary of Significant Accounting Policies" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_637824689803490877" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_637824689803490877" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://immuneering.com/role/DisclosureMarketableSecurities" xlink:type="extended" xlink:title="10301 - Disclosure - Marketable Securities" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_637824689803500263" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_1" xlink:to="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_637824689803500263" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://immuneering.com/role/DisclosureFairValueMeasurements" xlink:type="extended" xlink:title="10401 - Disclosure - Fair Value Measurements" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock_637824689803500263" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock_637824689803500263" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://immuneering.com/role/DisclosurePropertyAndEquipmentNet" xlink:type="extended" xlink:title="10501 - Disclosure - Property and Equipment, net" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_637824689803500263" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_637824689803500263" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://immuneering.com/role/DisclosureBusinessCombination" xlink:type="extended" xlink:title="10601 - Disclosure - Business Combination" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="us-gaap_BusinessCombinationsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock_637824689803510717" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="us-gaap_BusinessCombinationDisclosureTextBlock_637824689803510717" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://immuneering.com/role/DisclosureAccruedExpenses" xlink:type="extended" xlink:title="10701 - Disclosure - Accrued Expenses" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:label="us-gaap_AccruedLiabilitiesCurrentAbstract" />
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_AccruedLiabilitiesDisclosureTextBlock" xlink:label="imrx_AccruedLiabilitiesDisclosureTextBlock_637824689803510717" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="imrx_AccruedLiabilitiesDisclosureTextBlock_637824689803510717" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://immuneering.com/role/DisclosureConvertiblePreferredStock" xlink:type="extended" xlink:title="10801 - Disclosure - Convertible Preferred Stock" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityDisclosureAbstract" xlink:label="us-gaap_TemporaryEquityDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_TemporaryEquityDisclosureTextBlock" xlink:label="imrx_TemporaryEquityDisclosureTextBlock_637824689803510717" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityDisclosureAbstract" xlink:to="imrx_TemporaryEquityDisclosureTextBlock_637824689803510717" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://immuneering.com/role/DisclosureCommonStock" xlink:type="extended" xlink:title="10901 - Disclosure - Common Stock" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_637824689803510717" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_637824689803510717" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://immuneering.com/role/DisclosureNetLossPerShareAttributableToCommonStockholders" xlink:type="extended" xlink:title="11001 - Disclosure - Net Loss Per Share Attributable to Common Stockholders" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock_637824689803570235" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock_637824689803570235" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://immuneering.com/role/DisclosureStockBasedCompensation" xlink:type="extended" xlink:title="11101 - Disclosure - Stock-Based Compensation" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_637824689803580313" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_637824689803580313" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://immuneering.com/role/DisclosureIncomeTaxes" xlink:type="extended" xlink:title="11201 - Disclosure - Income Taxes" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_637824689803580313" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_637824689803580313" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://immuneering.com/role/DisclosureCommitmentsAndContingencies" xlink:type="extended" xlink:title="11301 - Disclosure - Commitments and Contingencies" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_637824689803580313" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_637824689803580313" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://immuneering.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended" xlink:title="20202 - Disclosure - Summary of Significant Accounting Policies (Policies)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_637824689803580313" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_1" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_637824689803580313" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityPolicyTextBlock" xlink:label="us-gaap_StockholdersEquityPolicyTextBlock_637824689803580313" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_1" xlink:to="us-gaap_StockholdersEquityPolicyTextBlock_637824689803580313" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates_637824689803590303" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_1" xlink:to="us-gaap_UseOfEstimates_637824689803590303" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_637824689803590303" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_1" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_637824689803590303" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationsPolicy" xlink:label="us-gaap_BusinessCombinationsPolicy_637824689803590303" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_1" xlink:to="us-gaap_BusinessCombinationsPolicy_637824689803590303" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_637824689803590303" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_1" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_637824689803590303" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:label="us-gaap_MarketableSecuritiesPolicy_637824689803590303" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_1" xlink:to="us-gaap_MarketableSecuritiesPolicy_637824689803590303" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_637824689803590303" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_1" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_637824689803590303" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TradeAndOtherAccountsReceivableUnbilledReceivablesPolicy" xlink:label="us-gaap_TradeAndOtherAccountsReceivableUnbilledReceivablesPolicy_637824689803590303" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_1" xlink:to="us-gaap_TradeAndOtherAccountsReceivableUnbilledReceivablesPolicy_637824689803590303" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk_637824689803590303" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_1" xlink:to="us-gaap_ConcentrationRiskCreditRisk_637824689803590303" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_637824689803590303" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_1" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_637824689803590303" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_637824689803590303" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_1" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_637824689803590303" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_637824689803600354" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_1" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_637824689803600354" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_637824689803600354" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_1" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_637824689803600354" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_637824689803600354" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_1" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_637824689803600354" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentPolicy" xlink:label="us-gaap_InProcessResearchAndDevelopmentPolicy_637824689803600354" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_1" xlink:to="us-gaap_InProcessResearchAndDevelopmentPolicy_637824689803600354" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_ResearchAndManufacturingContractCostsAndAccrualsPolicyTextBlock" xlink:label="imrx_ResearchAndManufacturingContractCostsAndAccrualsPolicyTextBlock_637824689803600354" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_1" xlink:to="imrx_ResearchAndManufacturingContractCostsAndAccrualsPolicyTextBlock_637824689803600354" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_PatentCostsPolicyPolicyTextBlock" xlink:label="imrx_PatentCostsPolicyPolicyTextBlock_637824689803600354" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_1" xlink:to="imrx_PatentCostsPolicyPolicyTextBlock_637824689803600354" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_637824689803600354" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_1" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_637824689803600354" order="19" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredChargesPolicyTextBlock" xlink:label="us-gaap_DeferredChargesPolicyTextBlock_637824689803600354" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_1" xlink:to="us-gaap_DeferredChargesPolicyTextBlock_637824689803600354" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_637824689803610309" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_1" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_637824689803610309" order="21" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_637824689803610309" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_1" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_637824689803610309" order="22" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:label="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_637824689803610309" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_1" xlink:to="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_637824689803610309" order="23" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_637824689803610309" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_1" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_637824689803610309" order="24" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://immuneering.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" xlink:type="extended" xlink:title="30203 - Disclosure - Summary of Significant Accounting Policies (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract_3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:label="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_637824689803610309" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_3" xlink:to="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_637824689803610309" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock" xlink:label="imrx_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock_637824689803610309" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_3" xlink:to="imrx_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock_637824689803610309" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://immuneering.com/role/DisclosureMarketableSecuritiesTables" xlink:type="extended" xlink:title="30303 - Disclosure - Marketable Securities (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesTextBlock" xlink:label="us-gaap_MarketableSecuritiesTextBlock_637824689803620252" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_MarketableSecuritiesTextBlock_637824689803620252" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://immuneering.com/role/DisclosureFairValueMeasurementsTables" xlink:type="extended" xlink:title="30403 - Disclosure - Fair Value Measurements (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_637824689803620252" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract_1" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_637824689803620252" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://immuneering.com/role/DisclosurePropertyAndEquipmentNetTables" xlink:type="extended" xlink:title="30503 - Disclosure - Property and Equipment, net (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_637824689803620252" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract_1" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_637824689803620252" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://immuneering.com/role/DisclosureBusinessCombinationTables" xlink:type="extended" xlink:title="30603 - Disclosure - Business Combination (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="us-gaap_BusinessCombinationsAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:label="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_637824689803630237" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationsAbstract_1" xlink:to="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_637824689803630237" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://immuneering.com/role/DisclosureAccruedExpensesTables" xlink:type="extended" xlink:title="30703 - Disclosure - Accrued Expenses (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:label="us-gaap_AccruedLiabilitiesCurrentAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_637824689803630237" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract_1" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_637824689803630237" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://immuneering.com/role/DisclosureCommonStockTables" xlink:type="extended" xlink:title="30903 - Disclosure - Common Stock (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTextBlock" xlink:label="us-gaap_ScheduleOfStockByClassTextBlock_637824689803630237" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract_1" xlink:to="us-gaap_ScheduleOfStockByClassTextBlock_637824689803630237" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://immuneering.com/role/DisclosureNetLossPerShareAttributableToCommonStockholdersTables" xlink:type="extended" xlink:title="31003 - Disclosure - Net Loss Per Share Attributable to Common Stockholders (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_637824689803640233" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract_1" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_637824689803640233" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_637824689803640233" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract_1" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_637824689803640233" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://immuneering.com/role/DisclosureStockBasedCompensationTables" xlink:type="extended" xlink:title="31103 - Disclosure - Stock-Based Compensation (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_637824689803640233" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_637824689803640233" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_637824689803640233" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_637824689803640233" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_637824689803640233" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1" xlink:to="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_637824689803640233" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://immuneering.com/role/DisclosureIncomeTaxesTables" xlink:type="extended" xlink:title="31203 - Disclosure - Income Taxes (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_637824689803650334" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_1" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_637824689803650334" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_637824689803650334" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_1" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_637824689803650334" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_637824689803650334" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_1" xlink:to="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_637824689803650334" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://immuneering.com/role/DisclosureCommitmentsAndContingenciesTables" xlink:type="extended" xlink:title="31303 - Disclosure - Commitments and Contingencies (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_637824689803650334" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_637824689803650334" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock_637824689803650334" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1" xlink:to="us-gaap_LeaseCostTableTextBlock_637824689803650334" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://immuneering.com/role/DisclosureOrganizationAndNatureOfBusinessDetails" xlink:type="extended" xlink:title="40101 - Disclosure - Organization and Nature of Business (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" xlink:label="us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable_637824689803650334" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1" xlink:to="us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable_637824689803650334" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_637824689803650334" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable_637824689803650334" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_637824689803650334" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_637824689803650334" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_637824689803650334" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_637824689803650334" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember_637824689803660232" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_637824689803650334" xlink:to="us-gaap_IPOMember_637824689803660232" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_637824689803660232" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable_637824689803650334" xlink:to="us-gaap_StatementClassOfStockAxis_637824689803660232" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_637824689803660232" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_637824689803660232" xlink:to="us-gaap_ClassOfStockDomain_637824689803660232" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember_637824689803660232" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_637824689803660232" xlink:to="us-gaap_CommonClassAMember_637824689803660232" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems_637824689803660232" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable_637824689803650334" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems_637824689803660232" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_637824689803660232" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems_637824689803660232" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_637824689803660232" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_637824689803660232" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems_637824689803660232" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_637824689803660232" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_OfferingCostPayable" xlink:label="imrx_OfferingCostPayable_637824689803660232" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems_637824689803660232" xlink:to="imrx_OfferingCostPayable_637824689803660232" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_637824689803660232" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems_637824689803660232" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_637824689803660232" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_637824689803660232" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems_637824689803660232" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_637824689803660232" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_637824689803670505" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems_637824689803660232" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_637824689803670505" order="6" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://immuneering.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended" xlink:title="40201 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract_2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_637824689803670505" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_2" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_637824689803670505" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments_637824689803670505" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_2" xlink:to="us-gaap_NumberOfOperatingSegments_637824689803670505" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables" xlink:label="us-gaap_AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables_637824689803670505" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_2" xlink:to="us-gaap_AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables_637824689803670505" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsFinitelived_637824689803670505" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_2" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsFinitelived_637824689803670505" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasePracticalExpedientsPackage" xlink:label="us-gaap_LeasePracticalExpedientsPackage_637824689803670505" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_2" xlink:to="us-gaap_LeasePracticalExpedientsPackage_637824689803670505" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions" xlink:label="us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions_637824689803670505" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_2" xlink:to="us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions_637824689803670505" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredOfferingCosts" xlink:label="us-gaap_DeferredOfferingCosts_637824689803670505" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_2" xlink:to="us-gaap_DeferredOfferingCosts_637824689803670505" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_637824689803670505" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_2" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_637824689803670505" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="us-gaap_GoodwillImpairmentLoss_637824689803680340" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_2" xlink:to="us-gaap_GoodwillImpairmentLoss_637824689803680340" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://immuneering.com/role/DisclosureSummaryOfSignificantAccountingPoliciesConcentrationOfCreditRiskDetails" xlink:type="extended" xlink:title="40202 - Disclosure - Summary of Significant Accounting Policies - Concentration of Credit Risk (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract_4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTable" xlink:label="us-gaap_ConcentrationRiskTable_637824689803680340" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_4" xlink:to="us-gaap_ConcentrationRiskTable_637824689803680340" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis_637824689803680340" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTable_637824689803680340" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis_637824689803680340" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_637824689803680340" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis_637824689803680340" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain_637824689803680340" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalesRevenueNetMember" xlink:label="us-gaap_SalesRevenueNetMember_637824689803680340" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain_637824689803680340" xlink:to="us-gaap_SalesRevenueNetMember_637824689803680340" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableMember" xlink:label="us-gaap_AccountsReceivableMember_637824689803680340" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain_637824689803680340" xlink:to="us-gaap_AccountsReceivableMember_637824689803680340" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis_637824689803680340" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTable_637824689803680340" xlink:to="us-gaap_ConcentrationRiskByTypeAxis_637824689803680340" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain_637824689803680340" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByTypeAxis_637824689803680340" xlink:to="us-gaap_ConcentrationRiskTypeDomain_637824689803680340" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="us-gaap_CustomerConcentrationRiskMember_637824689803680340" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTypeDomain_637824689803680340" xlink:to="us-gaap_CustomerConcentrationRiskMember_637824689803680340" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis" xlink:label="srt_MajorCustomersAxis_637824689803690322" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTable_637824689803680340" xlink:to="srt_MajorCustomersAxis_637824689803690322" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="srt_NameOfMajorCustomerDomain_637824689803690322" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_MajorCustomersAxis_637824689803690322" xlink:to="srt_NameOfMajorCustomerDomain_637824689803690322" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_CustomerOneMember" xlink:label="imrx_CustomerOneMember_637824689803690322" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_NameOfMajorCustomerDomain_637824689803690322" xlink:to="imrx_CustomerOneMember_637824689803690322" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_CustomerTwoMember" xlink:label="imrx_CustomerTwoMember_637824689803690322" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_NameOfMajorCustomerDomain_637824689803690322" xlink:to="imrx_CustomerTwoMember_637824689803690322" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_CustomerThreeMember" xlink:label="imrx_CustomerThreeMember_637824689803690322" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_NameOfMajorCustomerDomain_637824689803690322" xlink:to="imrx_CustomerThreeMember_637824689803690322" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_CustomerFourMember" xlink:label="imrx_CustomerFourMember_637824689803690322" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_NameOfMajorCustomerDomain_637824689803690322" xlink:to="imrx_CustomerFourMember_637824689803690322" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_CustomerFiveMember" xlink:label="imrx_CustomerFiveMember_637824689803690322" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_NameOfMajorCustomerDomain_637824689803690322" xlink:to="imrx_CustomerFiveMember_637824689803690322" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="us-gaap_ConcentrationRiskLineItems_637824689803690322" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTable_637824689803680340" xlink:to="us-gaap_ConcentrationRiskLineItems_637824689803690322" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_637824689803690322" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskLineItems_637824689803690322" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_637824689803690322" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent_637824689803700586" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskLineItems_637824689803690322" xlink:to="us-gaap_AccountsReceivableNetCurrent_637824689803700586" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1_637824689803700586" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskLineItems_637824689803690322" xlink:to="us-gaap_ConcentrationRiskPercentage1_637824689803700586" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://immuneering.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails" xlink:type="extended" xlink:title="40203 - Disclosure - Summary of Significant Accounting Policies - Property and Equipment (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract_5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_637824689803700586" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_5" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_637824689803700586" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_637824689803700586" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_637824689803700586" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_637824689803700586" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_637824689803700586" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis_637824689803700586" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_637824689803700586" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember_637824689803700586" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_637824689803700586" xlink:to="us-gaap_ComputerEquipmentMember_637824689803700586" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember_637824689803700586" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_637824689803700586" xlink:to="us-gaap_FurnitureAndFixturesMember_637824689803700586" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_LabEquipmentMember" xlink:label="imrx_LabEquipmentMember_637824689803700586" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_637824689803700586" xlink:to="imrx_LabEquipmentMember_637824689803700586" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdsAndLeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdsAndLeaseholdImprovementsMember_637824689803710269" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_637824689803700586" xlink:to="us-gaap_LeaseholdsAndLeaseholdImprovementsMember_637824689803710269" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_637824689803710269" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_637824689803700586" xlink:to="srt_RangeAxis_637824689803710269" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember_637824689803710269" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_637824689803710269" xlink:to="srt_RangeMember_637824689803710269" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_637824689803710269" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_637824689803710269" xlink:to="srt_MinimumMember_637824689803710269" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_637824689803710269" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_637824689803710269" xlink:to="srt_MaximumMember_637824689803710269" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_637824689803710269" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_637824689803700586" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_637824689803710269" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_637824689803710269" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_637824689803710269" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_637824689803710269" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://immuneering.com/role/DisclosureMarketableSecuritiesDetails" xlink:type="extended" xlink:title="40301 - Disclosure - Marketable Securities (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesTable" xlink:label="us-gaap_MarketableSecuritiesTable_637824689803710269" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_2" xlink:to="us-gaap_MarketableSecuritiesTable_637824689803710269" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis_637824689803710269" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesTable_637824689803710269" xlink:to="us-gaap_FinancialInstrumentAxis_637824689803710269" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_637824689803720250" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis_637824689803710269" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_637824689803720250" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember_637824689803720250" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_637824689803720250" xlink:to="us-gaap_USTreasurySecuritiesMember_637824689803720250" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_GovernmentSecuritiesMember" xlink:label="imrx_GovernmentSecuritiesMember_637824689803720250" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_637824689803720250" xlink:to="imrx_GovernmentSecuritiesMember_637824689803720250" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember_637824689803720250" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_637824689803720250" xlink:to="us-gaap_CommercialPaperMember_637824689803720250" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesLineItems" xlink:label="us-gaap_MarketableSecuritiesLineItems_637824689803720250" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesTable_637824689803710269" xlink:to="us-gaap_MarketableSecuritiesLineItems_637824689803720250" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfInvestments" xlink:label="us-gaap_ImpairmentOfInvestments_637824689803720250" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesLineItems_637824689803720250" xlink:to="us-gaap_ImpairmentOfInvestments_637824689803720250" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesRealizedGainLoss" xlink:label="us-gaap_MarketableSecuritiesRealizedGainLoss_637824689803720250" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesLineItems_637824689803720250" xlink:to="us-gaap_MarketableSecuritiesRealizedGainLoss_637824689803720250" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_MarketableSecuritiesCurrentAbstract" xlink:label="imrx_MarketableSecuritiesCurrentAbstract_637824689803720250" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesLineItems_637824689803720250" xlink:to="imrx_MarketableSecuritiesCurrentAbstract_637824689803720250" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_MarketableSecuritiesAmortizedCostBasisCurrent" xlink:label="imrx_MarketableSecuritiesAmortizedCostBasisCurrent_637824689803720250" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="imrx_MarketableSecuritiesCurrentAbstract_637824689803720250" xlink:to="imrx_MarketableSecuritiesAmortizedCostBasisCurrent_637824689803720250" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_MarketableSecuritiesAccumulatedUnrealizedGainsCurrent" xlink:label="imrx_MarketableSecuritiesAccumulatedUnrealizedGainsCurrent_637824689803720250" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="imrx_MarketableSecuritiesCurrentAbstract_637824689803720250" xlink:to="imrx_MarketableSecuritiesAccumulatedUnrealizedGainsCurrent_637824689803720250" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_MarketableSecuritiesAccumulatedUnrealizedLossesCurrent" xlink:label="imrx_MarketableSecuritiesAccumulatedUnrealizedLossesCurrent_637824689803720250" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="imrx_MarketableSecuritiesCurrentAbstract_637824689803720250" xlink:to="imrx_MarketableSecuritiesAccumulatedUnrealizedLossesCurrent_637824689803720250" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="us-gaap_MarketableSecuritiesCurrent_637824689803720250" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="imrx_MarketableSecuritiesCurrentAbstract_637824689803720250" xlink:to="us-gaap_MarketableSecuritiesCurrent_637824689803720250" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_MarketableSecuritiesNonCurrentAbstract" xlink:label="imrx_MarketableSecuritiesNonCurrentAbstract_637824689803730332" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesLineItems_637824689803720250" xlink:to="imrx_MarketableSecuritiesNonCurrentAbstract_637824689803730332" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_MarketableSecuritiesAmortizedCostBasisNonCurrent" xlink:label="imrx_MarketableSecuritiesAmortizedCostBasisNonCurrent_637824689803730332" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="imrx_MarketableSecuritiesNonCurrentAbstract_637824689803730332" xlink:to="imrx_MarketableSecuritiesAmortizedCostBasisNonCurrent_637824689803730332" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_MarketableSecuritiesAccumulatedUnrealizedLossesNonCurrent" xlink:label="imrx_MarketableSecuritiesAccumulatedUnrealizedLossesNonCurrent_637824689803730332" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="imrx_MarketableSecuritiesNonCurrentAbstract_637824689803730332" xlink:to="imrx_MarketableSecuritiesAccumulatedUnrealizedLossesNonCurrent_637824689803730332" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesNoncurrent" xlink:label="us-gaap_MarketableSecuritiesNoncurrent_637824689803730332" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="imrx_MarketableSecuritiesNonCurrentAbstract_637824689803730332" xlink:to="us-gaap_MarketableSecuritiesNoncurrent_637824689803730332" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesAbstract" xlink:label="us-gaap_MarketableSecuritiesAbstract_637824689803730332" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesLineItems_637824689803720250" xlink:to="us-gaap_MarketableSecuritiesAbstract_637824689803730332" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_MarketableSecuritiesAmortizedCostBasis" xlink:label="imrx_MarketableSecuritiesAmortizedCostBasis_637824689803730332" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesAbstract_637824689803730332" xlink:to="imrx_MarketableSecuritiesAmortizedCostBasis_637824689803730332" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_MarketableSecuritiesAccumulatedUnrealizedGains" xlink:label="imrx_MarketableSecuritiesAccumulatedUnrealizedGains_637824689803730332" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesAbstract_637824689803730332" xlink:to="imrx_MarketableSecuritiesAccumulatedUnrealizedGains_637824689803730332" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_MarketableSecuritiesAccumulatedUnrealizedLosses" xlink:label="imrx_MarketableSecuritiesAccumulatedUnrealizedLosses_637824689803730332" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesAbstract_637824689803730332" xlink:to="imrx_MarketableSecuritiesAccumulatedUnrealizedLosses_637824689803730332" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecurities" xlink:label="us-gaap_MarketableSecurities_637824689803730332" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesAbstract_637824689803730332" xlink:to="us-gaap_MarketableSecurities_637824689803730332" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://immuneering.com/role/DisclosureFairValueMeasurementsDetails" xlink:type="extended" xlink:title="40401 - Disclosure - Fair Value Measurements (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract_2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_637824689803740242" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract_2" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_637824689803740242" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_637824689803740242" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_637824689803740242" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_637824689803740242" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_637824689803740242" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis_637824689803740242" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_637824689803740242" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_637824689803740242" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain_637824689803740242" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_637824689803740242" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_637824689803740242" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_637824689803740242" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_637824689803740242" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_637824689803740242" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis_637824689803740242" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_637824689803740242" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member_637824689803740242" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_637824689803740242" xlink:to="us-gaap_FairValueInputsLevel1Member_637824689803740242" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member_637824689803740242" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_637824689803740242" xlink:to="us-gaap_FairValueInputsLevel2Member_637824689803740242" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis_637824689803740242" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_637824689803740242" xlink:to="us-gaap_FairValueByAssetClassAxis_637824689803740242" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_637824689803750337" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByAssetClassAxis_637824689803740242" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_637824689803750337" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember_637824689803750337" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_637824689803750337" xlink:to="us-gaap_MoneyMarketFundsMember_637824689803750337" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember_637824689803750337" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_637824689803750337" xlink:to="us-gaap_CommercialPaperMember_637824689803750337" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember_637824689803750337" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_637824689803750337" xlink:to="us-gaap_USTreasurySecuritiesMember_637824689803750337" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_GovernmentSecuritiesMember" xlink:label="imrx_GovernmentSecuritiesMember_637824689803750337" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_637824689803750337" xlink:to="imrx_GovernmentSecuritiesMember_637824689803750337" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_637824689803750337" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_637824689803740242" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_637824689803750337" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract_637824689803750337" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_637824689803750337" xlink:to="us-gaap_AssetsFairValueDisclosureAbstract_637824689803750337" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_637824689803750337" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract_637824689803750337" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure_637824689803750337" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_MarketableSecuritiesFairValueDisclosure" xlink:label="imrx_MarketableSecuritiesFairValueDisclosure_637824689803750337" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract_637824689803750337" xlink:to="imrx_MarketableSecuritiesFairValueDisclosure_637824689803750337" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure_637824689803750337" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract_637824689803750337" xlink:to="us-gaap_AssetsFairValueDisclosure_637824689803750337" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet_637824689803760299" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_637824689803750337" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet_637824689803760299" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecurities" xlink:label="us-gaap_MarketableSecurities_637824689803760299" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_637824689803750337" xlink:to="us-gaap_MarketableSecurities_637824689803760299" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://immuneering.com/role/DisclosurePropertyAndEquipmentNetDetails" xlink:type="extended" xlink:title="40501 - Disclosure - Property and Equipment, net (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_637824689803760299" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract_2" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_637824689803760299" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_637824689803760299" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_637824689803760299" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_637824689803760299" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_637824689803760299" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis_637824689803760299" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_637824689803760299" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember_637824689803760299" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_637824689803760299" xlink:to="us-gaap_ComputerEquipmentMember_637824689803760299" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember_637824689803760299" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_637824689803760299" xlink:to="us-gaap_FurnitureAndFixturesMember_637824689803760299" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_LabEquipmentMember" xlink:label="imrx_LabEquipmentMember_637824689803760299" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_637824689803760299" xlink:to="imrx_LabEquipmentMember_637824689803760299" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember_637824689803760299" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_637824689803760299" xlink:to="us-gaap_LeaseholdImprovementsMember_637824689803760299" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_637824689803770463" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_637824689803760299" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_637824689803770463" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_637824689803770463" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_637824689803770463" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_637824689803770463" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_637824689803770463" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_637824689803770463" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_637824689803770463" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_637824689803770463" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_637824689803770463" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_637824689803770463" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://immuneering.com/role/DisclosurePropertyAndEquipmentNetDepreciationDetails" xlink:type="extended" xlink:title="40502 - Disclosure - Property and Equipment, net - Depreciation (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation_637824689803770463" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract_3" xlink:to="us-gaap_Depreciation_637824689803770463" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://immuneering.com/role/DisclosureBusinessCombinationNarrativeDetails" xlink:type="extended" xlink:title="40601 - Disclosure - Business Combination - Narrative (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="us-gaap_BusinessCombinationsAbstract_2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_637824689803770463" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationsAbstract_2" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_637824689803770463" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis_637824689803780345" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_637824689803770463" xlink:to="us-gaap_BusinessAcquisitionAxis_637824689803780345" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_637824689803780345" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis_637824689803780345" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_637824689803780345" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_BioArkiveIncMember" xlink:label="imrx_BioArkiveIncMember_637824689803780345" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain_637824689803780345" xlink:to="imrx_BioArkiveIncMember_637824689803780345" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_637824689803780345" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_637824689803770463" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_637824689803780345" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_637824689803780345" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_637824689803780345" xlink:to="us-gaap_RelatedPartyDomain_637824689803780345" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_BioArkiveIncMember" xlink:label="imrx_BioArkiveIncMember_6378246898037803451" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain_637824689803780345" xlink:to="imrx_BioArkiveIncMember_6378246898037803451" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis_637824689803780345" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_637824689803770463" xlink:to="us-gaap_IncomeStatementLocationAxis_637824689803780345" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_637824689803780345" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis_637824689803780345" xlink:to="us-gaap_IncomeStatementLocationDomain_637824689803780345" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_637824689803780345" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_637824689803780345" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_637824689803780345" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis_637824689803780345" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_637824689803770463" xlink:to="us-gaap_BalanceSheetLocationAxis_637824689803780345" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain_637824689803780345" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis_637824689803780345" xlink:to="us-gaap_BalanceSheetLocationDomain_637824689803780345" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesMember" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesMember_637824689803780345" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationDomain_637824689803780345" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesMember_637824689803780345" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems_637824689803790333" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_637824689803770463" xlink:to="us-gaap_BusinessAcquisitionLineItems_637824689803790333" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_BusinessCombinationPurchasePrice" xlink:label="imrx_BusinessCombinationPurchasePrice_637824689803790333" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_637824689803790333" xlink:to="imrx_BusinessCombinationPurchasePrice_637824689803790333" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_NumberOfLeasesObligationsAssumed" xlink:label="imrx_NumberOfLeasesObligationsAssumed_637824689803790333" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_637824689803790333" xlink:to="imrx_NumberOfLeasesObligationsAssumed_637824689803790333" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_637824689803790333" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_637824689803790333" xlink:to="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_637824689803790333" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_BusinessCombinationSharesIssuedSharePriceThresholdTradingDays" xlink:label="imrx_BusinessCombinationSharesIssuedSharePriceThresholdTradingDays_637824689803790333" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_637824689803790333" xlink:to="imrx_BusinessCombinationSharesIssuedSharePriceThresholdTradingDays_637824689803790333" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_BusinessCombinationSharesIssuedLockInPeriod" xlink:label="imrx_BusinessCombinationSharesIssuedLockInPeriod_637824689803790333" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_637824689803790333" xlink:to="imrx_BusinessCombinationSharesIssuedLockInPeriod_637824689803790333" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_BusinessCombinationSharesIssuedDiscountDueToMarketabilityPercentage" xlink:label="imrx_BusinessCombinationSharesIssuedDiscountDueToMarketabilityPercentage_637824689803790333" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_637824689803790333" xlink:to="imrx_BusinessCombinationSharesIssuedDiscountDueToMarketabilityPercentage_637824689803790333" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1_637824689803790333" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_637824689803790333" xlink:to="us-gaap_BusinessCombinationConsiderationTransferred1_637824689803790333" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction_637824689803800340" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_637824689803790333" xlink:to="us-gaap_RelatedPartyTransactionAmountsOfTransaction_637824689803800340" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent" xlink:label="us-gaap_DueToRelatedPartiesCurrent_637824689803800340" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_637824689803790333" xlink:to="us-gaap_DueToRelatedPartiesCurrent_637824689803800340" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://immuneering.com/role/DisclosureBusinessCombinationAssetsAcquiredAndLiabilitiesAssumedDetails" xlink:type="extended" xlink:title="40602 - Disclosure - Business Combination - Assets Acquired and Liabilities Assumed (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="us-gaap_BusinessCombinationsAbstract_3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_637824689803800340" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationsAbstract_3" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_637824689803800340" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis_637824689803800340" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_637824689803800340" xlink:to="us-gaap_BusinessAcquisitionAxis_637824689803800340" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_637824689803800340" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis_637824689803800340" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_637824689803800340" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_BioArkiveIncMember" xlink:label="imrx_BioArkiveIncMember_637824689803800340" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain_637824689803800340" xlink:to="imrx_BioArkiveIncMember_637824689803800340" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems_637824689803800340" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_637824689803800340" xlink:to="us-gaap_BusinessAcquisitionLineItems_637824689803800340" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract_637824689803810368" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_637824689803800340" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract_637824689803810368" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_637824689803810368" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract_637824689803810368" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_637824689803810368" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_637824689803810368" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract_637824689803810368" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_637824689803810368" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_637824689803810368" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract_637824689803810368" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_637824689803810368" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_637824689803810368" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract_637824689803810368" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_637824689803810368" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets" xlink:label="imrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets_637824689803810368" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract_637824689803810368" xlink:to="imrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets_637824689803810368" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract_637824689803810368" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_637824689803800340" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract_637824689803810368" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_637824689803810368" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract_637824689803810368" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_637824689803810368" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill_637824689803810368" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract_637824689803810368" xlink:to="us-gaap_Goodwill_637824689803810368" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIncludingGoodwill" xlink:label="imrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIncludingGoodwill_637824689803810368" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_637824689803800340" xlink:to="imrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIncludingGoodwill_637824689803810368" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAccruedExpensesAndOtherLiabilities" xlink:label="imrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAccruedExpensesAndOtherLiabilities_637824689803810368" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_637824689803800340" xlink:to="imrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAccruedExpensesAndOtherLiabilities_637824689803810368" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_637824689803820257" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_637824689803800340" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_637824689803820257" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation_637824689803820257" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_637824689803800340" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation_637824689803820257" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_637824689803820257" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_637824689803800340" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_637824689803820257" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:label="us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_637824689803820257" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_637824689803800340" xlink:to="us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_637824689803820257" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://immuneering.com/role/DisclosureAccruedExpensesDetails" xlink:type="extended" xlink:title="40701 - Disclosure - Accrued Expenses (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:label="us-gaap_AccruedLiabilitiesCurrentAbstract_2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent_637824689803820257" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract_2" xlink:to="us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent_637824689803820257" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedEmployeeBenefitsCurrentAndNoncurrent" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrentAndNoncurrent_637824689803820257" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract_2" xlink:to="us-gaap_AccruedEmployeeBenefitsCurrentAndNoncurrent_637824689803820257" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_AccruedContractResearchExpensesCurrent" xlink:label="imrx_AccruedContractResearchExpensesCurrent_637824689803820257" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract_2" xlink:to="imrx_AccruedContractResearchExpensesCurrent_637824689803820257" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent_637824689803820257" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract_2" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent_637824689803820257" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent_637824689803830209" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract_2" xlink:to="us-gaap_AccruedLiabilitiesCurrent_637824689803830209" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://immuneering.com/role/DisclosureConvertiblePreferredStockSeriesDetails" xlink:type="extended" xlink:title="40801 - Disclosure - Convertible Preferred Stock - Series A (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityDisclosureAbstract" xlink:label="us-gaap_TemporaryEquityDisclosureAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityByClassOfStockTable" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable_637824689803830209" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityDisclosureAbstract_1" xlink:to="us-gaap_TemporaryEquityByClassOfStockTable_637824689803830209" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_637824689803830209" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable_637824689803830209" xlink:to="us-gaap_StatementClassOfStockAxis_637824689803830209" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_637824689803830209" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_637824689803830209" xlink:to="us-gaap_ClassOfStockDomain_637824689803830209" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_SeriesConvertiblePreferredStockMember" xlink:label="imrx_SeriesConvertiblePreferredStockMember_637824689803830209" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_637824689803830209" xlink:to="imrx_SeriesConvertiblePreferredStockMember_637824689803830209" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_637824689803830209" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable_637824689803830209" xlink:to="srt_RangeAxis_637824689803830209" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember_637824689803830209" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_637824689803830209" xlink:to="srt_RangeMember_637824689803830209" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_637824689803830209" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_637824689803830209" xlink:to="srt_MinimumMember_637824689803830209" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityLineItems" xlink:label="us-gaap_TemporaryEquityLineItems_637824689803830209" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable_637824689803830209" xlink:to="us-gaap_TemporaryEquityLineItems_637824689803830209" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="us-gaap_TemporaryEquitySharesAuthorized_637824689803830209" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_637824689803830209" xlink:to="us-gaap_TemporaryEquitySharesAuthorized_637824689803830209" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare_637824689803840254" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_637824689803830209" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare_637824689803840254" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_TemporaryEquityIssuancePrice" xlink:label="imrx_TemporaryEquityIssuancePrice_637824689803840254" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_637824689803830209" xlink:to="imrx_TemporaryEquityIssuancePrice_637824689803840254" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued_637824689803840254" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_637824689803830209" xlink:to="us-gaap_TemporaryEquitySharesIssued_637824689803840254" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_637824689803840254" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_637824689803830209" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_637824689803840254" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1_637824689803840254" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_637824689803830209" xlink:to="us-gaap_DebtConversionConvertedInstrumentSharesIssued1_637824689803840254" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_637824689803840254" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_637824689803830209" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_637824689803840254" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_TemporaryEquityNumberOfSharesExcessOfAuthorized" xlink:label="imrx_TemporaryEquityNumberOfSharesExcessOfAuthorized_637824689803840254" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_637824689803830209" xlink:to="imrx_TemporaryEquityNumberOfSharesExcessOfAuthorized_637824689803840254" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_ProceedsFromIssuanceOfConvertiblePreferredStockExcessOfAuthorizedAmount" xlink:label="imrx_ProceedsFromIssuanceOfConvertiblePreferredStockExcessOfAuthorizedAmount_637824689803840254" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_637824689803830209" xlink:to="imrx_ProceedsFromIssuanceOfConvertiblePreferredStockExcessOfAuthorizedAmount_637824689803840254" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_TemporaryEquityDueToExcessAuthorizedAmount" xlink:label="imrx_TemporaryEquityDueToExcessAuthorizedAmount_637824689803840254" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_637824689803830209" xlink:to="imrx_TemporaryEquityDueToExcessAuthorizedAmount_637824689803840254" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_637824689803840254" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_637824689803830209" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_637824689803840254" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_TemporaryEquityConversionPrice" xlink:label="imrx_TemporaryEquityConversionPrice_637824689803850261" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_637824689803830209" xlink:to="imrx_TemporaryEquityConversionPrice_637824689803850261" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://immuneering.com/role/DisclosureConvertiblePreferredStockSeriesBDetails" xlink:type="extended" xlink:title="40802 - Disclosure - Convertible Preferred Stock - Series B (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityDisclosureAbstract" xlink:label="us-gaap_TemporaryEquityDisclosureAbstract_2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityByClassOfStockTable" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable_637824689803850261" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityDisclosureAbstract_2" xlink:to="us-gaap_TemporaryEquityByClassOfStockTable_637824689803850261" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_637824689803850261" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable_637824689803850261" xlink:to="us-gaap_StatementClassOfStockAxis_637824689803850261" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_637824689803850261" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_637824689803850261" xlink:to="us-gaap_ClassOfStockDomain_637824689803850261" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_SeriesBConvertiblePreferredStockMember" xlink:label="imrx_SeriesBConvertiblePreferredStockMember_637824689803850261" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_637824689803850261" xlink:to="imrx_SeriesBConvertiblePreferredStockMember_637824689803850261" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_SeriesBConvertiblePreferredStocksTrancheOneMember" xlink:label="imrx_SeriesBConvertiblePreferredStocksTrancheOneMember_637824689803850261" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_637824689803850261" xlink:to="imrx_SeriesBConvertiblePreferredStocksTrancheOneMember_637824689803850261" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_SeriesBConvertiblePreferredStockTrancheTwoMember" xlink:label="imrx_SeriesBConvertiblePreferredStockTrancheTwoMember_637824689803850261" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_637824689803850261" xlink:to="imrx_SeriesBConvertiblePreferredStockTrancheTwoMember_637824689803850261" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_637824689803850261" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable_637824689803850261" xlink:to="srt_RangeAxis_637824689803850261" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember_637824689803850261" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_637824689803850261" xlink:to="srt_RangeMember_637824689803850261" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_637824689803860247" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_637824689803850261" xlink:to="srt_MinimumMember_637824689803860247" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityLineItems" xlink:label="us-gaap_TemporaryEquityLineItems_637824689803860247" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable_637824689803850261" xlink:to="us-gaap_TemporaryEquityLineItems_637824689803860247" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="us-gaap_TemporaryEquitySharesAuthorized_637824689803860247" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_637824689803860247" xlink:to="us-gaap_TemporaryEquitySharesAuthorized_637824689803860247" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare_637824689803860247" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_637824689803860247" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare_637824689803860247" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_TemporaryEquityIssuancePrice" xlink:label="imrx_TemporaryEquityIssuancePrice_637824689803860247" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_637824689803860247" xlink:to="imrx_TemporaryEquityIssuancePrice_637824689803860247" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_NumberOfTranches" xlink:label="imrx_NumberOfTranches_637824689803860247" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_637824689803860247" xlink:to="imrx_NumberOfTranches_637824689803860247" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued_637824689803860247" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_637824689803860247" xlink:to="us-gaap_TemporaryEquitySharesIssued_637824689803860247" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_637824689803860247" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_637824689803860247" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_637824689803860247" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_637824689803860247" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_637824689803860247" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_637824689803860247" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_TemporaryEquityContingentlyIssuableShares" xlink:label="imrx_TemporaryEquityContingentlyIssuableShares_637824689803860247" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_637824689803860247" xlink:to="imrx_TemporaryEquityContingentlyIssuableShares_637824689803860247" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_TemporaryEquityConversionPrice" xlink:label="imrx_TemporaryEquityConversionPrice_637824689803870231" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_637824689803860247" xlink:to="imrx_TemporaryEquityConversionPrice_637824689803870231" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_PercentageOfEquitySecuritiesOwnedToGetConvertedStock" xlink:label="imrx_PercentageOfEquitySecuritiesOwnedToGetConvertedStock_637824689803870231" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_637824689803860247" xlink:to="imrx_PercentageOfEquitySecuritiesOwnedToGetConvertedStock_637824689803870231" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:label="us-gaap_PreferredStockDividendRatePercentage_637824689803870231" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_637824689803860247" xlink:to="us-gaap_PreferredStockDividendRatePercentage_637824689803870231" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DividendsPreferredStock" xlink:label="us-gaap_DividendsPreferredStock_637824689803870231" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_637824689803860247" xlink:to="us-gaap_DividendsPreferredStock_637824689803870231" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding_637824689803870231" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_637824689803860247" xlink:to="us-gaap_PreferredStockSharesOutstanding_637824689803870231" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_637824689803870231" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_637824689803860247" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_637824689803870231" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://immuneering.com/role/DisclosureCommonStockClassCommonStockDetails" xlink:type="extended" xlink:title="40901 - Disclosure - Common Stock - Class A common stock (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract_2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable_637824689803880209" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract_2" xlink:to="us-gaap_ScheduleOfStockByClassTable_637824689803880209" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_637824689803880209" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_637824689803880209" xlink:to="us-gaap_StatementClassOfStockAxis_637824689803880209" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_637824689803880209" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_637824689803880209" xlink:to="us-gaap_ClassOfStockDomain_637824689803880209" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember_637824689803880209" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_637824689803880209" xlink:to="us-gaap_CommonClassAMember_637824689803880209" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems_637824689803880209" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_637824689803880209" xlink:to="us-gaap_ClassOfStockLineItems_637824689803880209" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized_637824689803880209" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_637824689803880209" xlink:to="us-gaap_CommonStockSharesAuthorized_637824689803880209" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_637824689803880209" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_637824689803880209" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_637824689803880209" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued_637824689803880209" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_637824689803880209" xlink:to="us-gaap_CommonStockSharesIssued_637824689803880209" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding_637824689803880209" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_637824689803880209" xlink:to="us-gaap_CommonStockSharesOutstanding_637824689803880209" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_NumberOfVotesPerShare" xlink:label="imrx_NumberOfVotesPerShare_637824689803880209" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_637824689803880209" xlink:to="imrx_NumberOfVotesPerShare_637824689803880209" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://immuneering.com/role/DisclosureCommonStockDetails" xlink:type="extended" xlink:title="40902 - Disclosure - Common Stock (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract_3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable_637824689803890494" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract_3" xlink:to="us-gaap_ScheduleOfStockByClassTable_637824689803890494" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_637824689803890494" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_637824689803890494" xlink:to="us-gaap_StatementClassOfStockAxis_637824689803890494" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_637824689803890494" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_637824689803890494" xlink:to="us-gaap_ClassOfStockDomain_637824689803890494" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_SeriesConvertiblePreferredStockMember" xlink:label="imrx_SeriesConvertiblePreferredStockMember_637824689803890494" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_637824689803890494" xlink:to="imrx_SeriesConvertiblePreferredStockMember_637824689803890494" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_SeriesBConvertiblePreferredStockMember" xlink:label="imrx_SeriesBConvertiblePreferredStockMember_637824689803890494" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_637824689803890494" xlink:to="imrx_SeriesBConvertiblePreferredStockMember_637824689803890494" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember_637824689803890494" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_637824689803890494" xlink:to="us-gaap_WarrantMember_637824689803890494" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember_637824689803890494" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_637824689803890494" xlink:to="us-gaap_EmployeeStockOptionMember_637824689803890494" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems_637824689803890494" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_637824689803890494" xlink:to="us-gaap_ClassOfStockLineItems_637824689803890494" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_637824689803890494" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_637824689803890494" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_637824689803890494" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://immuneering.com/role/DisclosureCommonStockClassBCommonStockDetails" xlink:type="extended" xlink:title="40903 - Disclosure - Common Stock - Class B common stock (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract_4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable_637824689803899997" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract_4" xlink:to="us-gaap_ScheduleOfStockByClassTable_637824689803899997" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_637824689803899997" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_637824689803899997" xlink:to="us-gaap_StatementClassOfStockAxis_637824689803899997" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_637824689803899997" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_637824689803899997" xlink:to="us-gaap_ClassOfStockDomain_637824689803899997" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassBMember" xlink:label="us-gaap_CommonClassBMember_637824689803899997" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_637824689803899997" xlink:to="us-gaap_CommonClassBMember_637824689803899997" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems_637824689803899997" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_637824689803899997" xlink:to="us-gaap_ClassOfStockLineItems_637824689803899997" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized_637824689803899997" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_637824689803899997" xlink:to="us-gaap_CommonStockSharesAuthorized_637824689803899997" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_637824689803899997" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_637824689803899997" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_637824689803899997" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued_637824689803899997" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_637824689803899997" xlink:to="us-gaap_CommonStockSharesIssued_637824689803899997" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding_637824689803899997" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_637824689803899997" xlink:to="us-gaap_CommonStockSharesOutstanding_637824689803899997" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_NumberOfVotesPerShare" xlink:label="imrx_NumberOfVotesPerShare_637824689803910321" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_637824689803899997" xlink:to="imrx_NumberOfVotesPerShare_637824689803910321" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://immuneering.com/role/DisclosureCommonStockCommonStockWarrantDetails" xlink:type="extended" xlink:title="40904 - Disclosure - Common Stock - Common stock warrant (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract_5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_637824689803910321" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract_5" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_637824689803910321" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_637824689803910321" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract_5" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_637824689803910321" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_WarrantsIssuedInLieuOfCashPayment" xlink:label="imrx_WarrantsIssuedInLieuOfCashPayment_637824689803910321" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract_5" xlink:to="imrx_WarrantsIssuedInLieuOfCashPayment_637824689803910321" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_637824689803910321" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract_5" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm_637824689803910321" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_WarrantsExercised" xlink:label="imrx_WarrantsExercised_637824689803910321" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract_5" xlink:to="imrx_WarrantsExercised_637824689803910321" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding_637824689803910321" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract_5" xlink:to="us-gaap_WarrantsAndRightsOutstanding_637824689803910321" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://immuneering.com/role/DisclosureCommonStockIpoDetails" xlink:type="extended" xlink:title="40905 - Disclosure - Common Stock - IPO (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract_6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable_637824689803920236" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract_6" xlink:to="us-gaap_ScheduleOfStockByClassTable_637824689803920236" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_637824689803920236" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_637824689803920236" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_637824689803920236" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_637824689803920236" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_637824689803920236" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_637824689803920236" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember_637824689803920236" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_637824689803920236" xlink:to="us-gaap_IPOMember_637824689803920236" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_637824689803920236" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_637824689803920236" xlink:to="us-gaap_StatementClassOfStockAxis_637824689803920236" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_637824689803920236" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_637824689803920236" xlink:to="us-gaap_ClassOfStockDomain_637824689803920236" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember_637824689803920236" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_637824689803920236" xlink:to="us-gaap_CommonClassAMember_637824689803920236" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassBMember" xlink:label="us-gaap_CommonClassBMember_637824689803920236" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_637824689803920236" xlink:to="us-gaap_CommonClassBMember_637824689803920236" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems_637824689803920236" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_637824689803920236" xlink:to="us-gaap_ClassOfStockLineItems_637824689803920236" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_637824689803920236" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_637824689803920236" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_637824689803920236" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_637824689803930236" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_637824689803920236" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_637824689803930236" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_OfferingCostPayable" xlink:label="imrx_OfferingCostPayable_637824689803930236" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_637824689803920236" xlink:to="imrx_OfferingCostPayable_637824689803930236" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_637824689803930236" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_637824689803920236" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_637824689803930236" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized_637824689803930236" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_637824689803920236" xlink:to="us-gaap_CommonStockSharesAuthorized_637824689803930236" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_637824689803930236" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_637824689803920236" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_637824689803930236" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized_637824689803930236" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_637824689803920236" xlink:to="us-gaap_PreferredStockSharesAuthorized_637824689803930236" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://immuneering.com/role/DisclosureNetLossPerShareAttributableToCommonStockholdersBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails" xlink:type="extended" xlink:title="41001 - Disclosure - Net Loss Per Share Attributable to Common Stockholders - Basic and diluted net loss per share attributable to common stockholders (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract_2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedAbstract_637824689803930236" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract_2" xlink:to="us-gaap_EarningsPerShareBasicAndDilutedAbstract_637824689803930236" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_637824689803940349" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicAndDilutedAbstract_637824689803930236" xlink:to="us-gaap_NetIncomeLoss_637824689803940349" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_637824689803940349" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract_2" xlink:to="us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_637824689803940349" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_637824689803940349" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_637824689803940349" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_637824689803940349" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_637824689803940349" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_637824689803940349" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_637824689803940349" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic_637824689803940349" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_637824689803940349" xlink:to="us-gaap_EarningsPerShareBasic_637824689803940349" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted_637824689803940349" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_637824689803940349" xlink:to="us-gaap_EarningsPerShareDiluted_637824689803940349" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://immuneering.com/role/DisclosureNetLossPerShareAttributableToCommonStockholdersAntidilutiveEffectDetails" xlink:type="extended" xlink:title="41002 - Disclosure - Net Loss Per Share Attributable to Common Stockholders - Antidilutive effect (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract_3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_637824689803940349" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract_3" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_637824689803940349" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_637824689803940349" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_637824689803940349" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_637824689803940349" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_637824689803940349" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_637824689803940349" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_637824689803940349" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_SeriesConvertiblePreferredStockMember" xlink:label="imrx_SeriesConvertiblePreferredStockMember_637824689803950342" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_637824689803940349" xlink:to="imrx_SeriesConvertiblePreferredStockMember_637824689803950342" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_SeriesBConvertiblePreferredStockMember" xlink:label="imrx_SeriesBConvertiblePreferredStockMember_637824689803950342" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_637824689803940349" xlink:to="imrx_SeriesBConvertiblePreferredStockMember_637824689803950342" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember_637824689803950342" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_637824689803940349" xlink:to="us-gaap_WarrantMember_637824689803950342" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember_637824689803950342" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_637824689803940349" xlink:to="us-gaap_EmployeeStockOptionMember_637824689803950342" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_637824689803950342" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_637824689803940349" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_637824689803950342" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_637824689803950342" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_637824689803950342" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_637824689803950342" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://immuneering.com/role/DisclosureStockBasedCompensationNarrativesDetails" xlink:type="extended" xlink:title="41101 - Disclosure - Stock-Based Compensation - Narratives (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637824689803950342" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637824689803950342" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_637824689803950342" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637824689803950342" xlink:to="us-gaap_PlanNameAxis_637824689803950342" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_637824689803950342" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis_637824689803950342" xlink:to="us-gaap_PlanNameDomain_637824689803950342" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_StockIncentivePlan2015Member" xlink:label="imrx_StockIncentivePlan2015Member_637824689803960242" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_637824689803950342" xlink:to="imrx_StockIncentivePlan2015Member_637824689803960242" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_TwoThousandTwentyOneEmployeeStockPurchasePlanMember" xlink:label="imrx_TwoThousandTwentyOneEmployeeStockPurchasePlanMember_637824689803960242" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_637824689803950342" xlink:to="imrx_TwoThousandTwentyOneEmployeeStockPurchasePlanMember_637824689803960242" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_TwoThousandTwentyOneIncentiveAwardPlanMember" xlink:label="imrx_TwoThousandTwentyOneIncentiveAwardPlanMember_637824689803960242" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_637824689803950342" xlink:to="imrx_TwoThousandTwentyOneIncentiveAwardPlanMember_637824689803960242" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_637824689803960242" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637824689803950342" xlink:to="srt_RangeAxis_637824689803960242" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember_637824689803960242" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_637824689803960242" xlink:to="srt_RangeMember_637824689803960242" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_637824689803960242" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_637824689803960242" xlink:to="srt_MaximumMember_637824689803960242" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_637824689803960242" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637824689803950342" xlink:to="us-gaap_StatementClassOfStockAxis_637824689803960242" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_637824689803960242" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_637824689803960242" xlink:to="us-gaap_ClassOfStockDomain_637824689803960242" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember_637824689803960242" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_637824689803960242" xlink:to="us-gaap_CommonClassAMember_637824689803960242" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637824689803960242" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637824689803950342" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637824689803960242" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_637824689803960242" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637824689803960242" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_637824689803960242" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_637824689803970232" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637824689803960242" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_637824689803970232" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_637824689803970232" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637824689803960242" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_637824689803970232" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_637824689803970232" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637824689803960242" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_637824689803970232" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_637824689803970232" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637824689803960242" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_637824689803970232" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_637824689803970232" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637824689803960242" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_637824689803970232" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_637824689803970232" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637824689803960242" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_637824689803970232" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="2" />
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_PercentageOfAggregateNumberOfSharesOutstanding" xlink:label="imrx_PercentageOfAggregateNumberOfSharesOutstanding_637824689803970232" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637824689803960242" xlink:to="imrx_PercentageOfAggregateNumberOfSharesOutstanding_637824689803970232" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://immuneering.com/role/DisclosureStockBasedCompensationAssumptionsDetails" xlink:type="extended" xlink:title="41102 - Disclosure - Stock-Based Compensation - Assumptions (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637824689803980216" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637824689803980216" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_637824689803980216" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637824689803980216" xlink:to="srt_RangeAxis_637824689803980216" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember_637824689803980216" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_637824689803980216" xlink:to="srt_RangeMember_637824689803980216" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_637824689803980216" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_637824689803980216" xlink:to="srt_MinimumMember_637824689803980216" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_637824689803980216" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_637824689803980216" xlink:to="srt_MaximumMember_637824689803980216" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637824689803980216" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637824689803980216" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637824689803980216" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_637824689803980216" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637824689803980216" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_637824689803980216" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_637824689803980216" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637824689803980216" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_637824689803980216" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_637824689803980216" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637824689803980216" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_637824689803980216" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_637824689803980216" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637824689803980216" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_637824689803980216" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_637824689803980216" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637824689803980216" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_637824689803980216" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_637824689803980216" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637824689803980216" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_637824689803980216" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://immuneering.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails" xlink:type="extended" xlink:title="41103 - Disclosure - Stock-Based Compensation - stock option activity (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_637824689804040229" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_637824689804040229" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_637824689804040229" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_637824689804040229" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_637824689804040229" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_637824689804040229" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_637824689804040229" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_637824689804040229" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_637824689804040229" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_637824689804040229" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_637824689804040229" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRepurchased" xlink:label="imrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRepurchased_637824689804040229" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_637824689804040229" xlink:to="imrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRepurchased_637824689804040229" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6378246898040402291" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_637824689804040229" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6378246898040402291" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_637824689804040229" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_637824689804040229" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_637824689804040229" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_637824689804050258" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_637824689804040229" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_637824689804050258" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_637824689804050258" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_637824689804050258" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_637824689804050258" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_637824689804050258" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_637824689804050258" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_637824689804050258" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_637824689804050258" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_637824689804050258" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_637824689804050258" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_637824689804050258" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_637824689804050258" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsRepurchasedInPeriodWeightedAverageExercisePrice" xlink:label="imrx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsRepurchasedInPeriodWeightedAverageExercisePrice_637824689804050258" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_637824689804050258" xlink:to="imrx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsRepurchasedInPeriodWeightedAverageExercisePrice_637824689804050258" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6378246898040502581" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_637824689804050258" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6378246898040502581" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_637824689804050258" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_637824689804050258" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_637824689804050258" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_637824689804050258" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_637824689804050258" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_637824689804050258" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_637824689804050258" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_637824689804050258" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_637824689804060213" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_637824689804050258" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_637824689804060213" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_637824689804060213" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_637824689804050258" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_637824689804060213" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_637824689804060213" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_637824689804050258" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_637824689804060213" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract" xlink:label="imrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract_637824689804060213" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4" xlink:to="imrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract_637824689804060213" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_637824689804060213" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="imrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract_637824689804060213" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_637824689804060213" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_637824689804060213" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="imrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract_637824689804060213" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_637824689804060213" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_637824689804060213" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="imrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract_637824689804060213" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_637824689804060213" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://immuneering.com/role/DisclosureStockBasedCompensationShareBasedCompensationExpenseDetails" xlink:type="extended" xlink:title="41104 - Disclosure - Stock-Based Compensation - Share-based compensation expense (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637824689804070230" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637824689804070230" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis_637824689804070230" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637824689804070230" xlink:to="us-gaap_IncomeStatementLocationAxis_637824689804070230" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_637824689804070230" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis_637824689804070230" xlink:to="us-gaap_IncomeStatementLocationDomain_637824689804070230" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfSalesMember" xlink:label="us-gaap_CostOfSalesMember_637824689804070230" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_637824689804070230" xlink:to="us-gaap_CostOfSalesMember_637824689804070230" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_637824689804070230" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_637824689804070230" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_637824689804070230" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_637824689804070230" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_637824689804070230" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_637824689804070230" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637824689804070230" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637824689804070230" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637824689804070230" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_637824689804070230" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637824689804070230" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_637824689804070230" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://immuneering.com/role/DisclosureIncomeTaxesNetLossAndEffectiveIncomeTaxRateDetails" xlink:type="extended" xlink:title="41201 - Disclosure - Income Taxes - Net loss and the effective income tax rate (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_637824689804070230" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_2" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_637824689804070230" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_637824689804080242" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_637824689804070230" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_637824689804080242" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_637824689804080242" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_637824689804070230" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_637824689804080242" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_637824689804080242" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_637824689804070230" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_637824689804080242" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_637824689804080242" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_637824689804070230" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_637824689804080242" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_EffectiveIncomeTaxRateReconciliationTaxCreditStateResearchAndDevelopmentPercent" xlink:label="imrx_EffectiveIncomeTaxRateReconciliationTaxCreditStateResearchAndDevelopmentPercent_637824689804080242" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_637824689804070230" xlink:to="imrx_EffectiveIncomeTaxRateReconciliationTaxCreditStateResearchAndDevelopmentPercent_637824689804080242" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_EffectiveIncomeTaxRateReconciliationUncertainTaxPositions" xlink:label="imrx_EffectiveIncomeTaxRateReconciliationUncertainTaxPositions_637824689804080242" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_637824689804070230" xlink:to="imrx_EffectiveIncomeTaxRateReconciliationUncertainTaxPositions_637824689804080242" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_637824689804080242" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_637824689804070230" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_637824689804080242" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_637824689804080242" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_637824689804070230" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_637824689804080242" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_637824689804080242" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_637824689804070230" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_637824689804080242" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://immuneering.com/role/DisclosureIncomeTaxesNetDeferredTaxAssetsDetails" xlink:type="extended" xlink:title="41202 - Disclosure - Income Taxes - Net deferred tax assets (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_637824689804080242" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_3" xlink:to="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_637824689804080242" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_637824689804090230" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_637824689804080242" xlink:to="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_637824689804090230" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_637824689804090230" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_637824689804090230" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_637824689804090230" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsUnrealizedCurrencyLosses" xlink:label="us-gaap_DeferredTaxAssetsUnrealizedCurrencyLosses_637824689804090230" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_637824689804090230" xlink:to="us-gaap_DeferredTaxAssetsUnrealizedCurrencyLosses_637824689804090230" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_637824689804090230" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_637824689804090230" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_637824689804090230" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_637824689804090230" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_637824689804090230" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_637824689804090230" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross_637824689804090230" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_637824689804090230" xlink:to="us-gaap_DeferredTaxAssetsGross_637824689804090230" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_637824689804090230" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_637824689804090230" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_637824689804090230" order="6" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet_637824689804090230" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_637824689804090230" xlink:to="us-gaap_DeferredTaxAssetsNet_637824689804090230" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:label="us-gaap_DeferredTaxLiabilitiesNetAbstract_637824689804090230" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_637824689804080242" xlink:to="us-gaap_DeferredTaxLiabilitiesNetAbstract_637824689804090230" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" xlink:label="us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_637824689804090230" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesNetAbstract_637824689804090230" xlink:to="us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_637824689804090230" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_637824689804090230" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesNetAbstract_637824689804090230" xlink:to="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_637824689804090230" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_637824689804100312" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesNetAbstract_637824689804090230" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_637824689804100312" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_637824689804100312" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesNetAbstract_637824689804090230" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_637824689804100312" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://immuneering.com/role/DisclosureIncomeTaxesNarrativeDetails" xlink:type="extended" xlink:title="41203 - Disclosure - Income Taxes - Narrative (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable_637824689804100312" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_5" xlink:to="us-gaap_OperatingLossCarryforwardsTable_637824689804100312" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis_637824689804100312" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsTable_637824689804100312" xlink:to="us-gaap_BusinessAcquisitionAxis_637824689804100312" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_637824689804100312" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis_637824689804100312" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_637824689804100312" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_BioArkiveIncMember" xlink:label="imrx_BioArkiveIncMember_637824689804100312" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain_637824689804100312" xlink:to="imrx_BioArkiveIncMember_637824689804100312" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis_637824689804100312" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsTable_637824689804100312" xlink:to="us-gaap_IncomeTaxAuthorityAxis_637824689804100312" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_637824689804100312" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis_637824689804100312" xlink:to="us-gaap_IncomeTaxAuthorityDomain_637824689804100312" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember_637824689804100312" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain_637824689804100312" xlink:to="us-gaap_DomesticCountryMember_637824689804100312" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember_637824689804110367" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain_637824689804100312" xlink:to="us-gaap_StateAndLocalJurisdictionMember_637824689804110367" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis_637824689804110367" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsTable_637824689804100312" xlink:to="us-gaap_TaxCreditCarryforwardAxis_637824689804110367" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_637824689804110367" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardAxis_637824689804110367" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain_637824689804110367" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember_637824689804110367" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain_637824689804110367" xlink:to="us-gaap_ResearchMember_637824689804110367" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems_637824689804110367" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsTable_637824689804100312" xlink:to="us-gaap_OperatingLossCarryforwardsLineItems_637824689804110367" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_637824689804110367" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems_637824689804110367" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_637824689804110367" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxesBusinessCombinationValuationAllowanceAvailableToReduceIncomeTaxExpense" xlink:label="us-gaap_DeferredTaxesBusinessCombinationValuationAllowanceAvailableToReduceIncomeTaxExpense_637824689804110367" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems_637824689804110367" xlink:to="us-gaap_DeferredTaxesBusinessCombinationValuationAllowanceAvailableToReduceIncomeTaxExpense_637824689804110367" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards_637824689804110367" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems_637824689804110367" xlink:to="us-gaap_OperatingLossCarryforwards_637824689804110367" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount_637824689804110367" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems_637824689804110367" xlink:to="us-gaap_TaxCreditCarryforwardAmount_637824689804110367" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_637824689804110367" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems_637824689804110367" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_637824689804110367" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits_637824689804110367" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems_637824689804110367" xlink:to="us-gaap_UnrecognizedTaxBenefits_637824689804110367" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_637824689804120348" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems_637824689804110367" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_637824689804120348" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_TaxCreditCarryforwardIncreaseDecreaseCaresAct" xlink:label="imrx_TaxCreditCarryforwardIncreaseDecreaseCaresAct_637824689804120348" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems_637824689804110367" xlink:to="imrx_TaxCreditCarryforwardIncreaseDecreaseCaresAct_637824689804120348" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://immuneering.com/role/DisclosureIncomeTaxesUnrecognizedTaxBenefitsDetails" xlink:type="extended" xlink:title="41204 - Disclosure - Income Taxes - Unrecognized tax benefits (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:label="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_637824689804120348" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_6" xlink:to="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_637824689804120348" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits_637824689804120348" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_637824689804120348" xlink:to="us-gaap_UnrecognizedTaxBenefits_637824689804120348" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_637824689804120348" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_637824689804120348" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_637824689804120348" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits_6378246898041203481" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_637824689804120348" xlink:to="us-gaap_UnrecognizedTaxBenefits_6378246898041203481" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://immuneering.com/role/DisclosureCommitmentsAndContingenciesNarrativesDetails" xlink:type="extended" xlink:title="41301 - Disclosure - Commitments and Contingencies - Narratives (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable_637824689804130365" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_2" xlink:to="us-gaap_LesseeLeaseDescriptionTable_637824689804130365" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_637824689804130365" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable_637824689804130365" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_637824689804130365" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_637824689804130365" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis_637824689804130365" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_637824689804130365" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_OfficeSpaceInCambridgeMassachusettsNewYorkMember" xlink:label="imrx_OfficeSpaceInCambridgeMassachusettsNewYorkMember_637824689804130365" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_637824689804130365" xlink:to="imrx_OfficeSpaceInCambridgeMassachusettsNewYorkMember_637824689804130365" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_StorageSpaceInSomervilleMassachusettsMember" xlink:label="imrx_StorageSpaceInSomervilleMassachusettsMember_637824689804130365" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_637824689804130365" xlink:to="imrx_StorageSpaceInSomervilleMassachusettsMember_637824689804130365" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_OfficeLeaseInSanDiegoCalifornia2020Member" xlink:label="imrx_OfficeLeaseInSanDiegoCalifornia2020Member_637824689804130365" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_637824689804130365" xlink:to="imrx_OfficeLeaseInSanDiegoCalifornia2020Member_637824689804130365" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="us-gaap_LeaseContractualTermAxis_637824689804130365" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable_637824689804130365" xlink:to="us-gaap_LeaseContractualTermAxis_637824689804130365" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain_637824689804130365" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermAxis_637824689804130365" xlink:to="us-gaap_LeaseContractualTermDomain_637824689804130365" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_LeaseTerminationOnApril302032Member" xlink:label="imrx_LeaseTerminationOnApril302032Member_637824689804130365" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermDomain_637824689804130365" xlink:to="imrx_LeaseTerminationOnApril302032Member_637824689804130365" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_LeaseTerminationOnDecember312022Member" xlink:label="imrx_LeaseTerminationOnDecember312022Member_637824689804130365" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermDomain_637824689804130365" xlink:to="imrx_LeaseTerminationOnDecember312022Member_637824689804130365" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_LeaseTerminationOnMarch312024Member" xlink:label="imrx_LeaseTerminationOnMarch312024Member_637824689804140341" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermDomain_637824689804130365" xlink:to="imrx_LeaseTerminationOnMarch312024Member_637824689804140341" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis_637824689804140341" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable_637824689804130365" xlink:to="us-gaap_BusinessAcquisitionAxis_637824689804140341" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_637824689804140341" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis_637824689804140341" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_637824689804140341" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_BioArkiveIncMember" xlink:label="imrx_BioArkiveIncMember_637824689804140341" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain_637824689804140341" xlink:to="imrx_BioArkiveIncMember_637824689804140341" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_637824689804140341" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable_637824689804130365" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems_637824689804140341" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_637824689804140341" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_637824689804140341" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_637824689804140341" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_637824689804140341" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_637824689804140341" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract_637824689804140341" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_637824689804140341" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_637824689804140341" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_637824689804140341" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability_637824689804140341" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_637824689804140341" xlink:to="us-gaap_OperatingLeaseLiability_637824689804140341" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_NumberOfLeasesObligationsAssumed" xlink:label="imrx_NumberOfLeasesObligationsAssumed_637824689804140341" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_637824689804140341" xlink:to="imrx_NumberOfLeasesObligationsAssumed_637824689804140341" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_AreaOfPropertyUnderLease" xlink:label="imrx_AreaOfPropertyUnderLease_637824689804150613" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_637824689804140341" xlink:to="imrx_AreaOfPropertyUnderLease_637824689804150613" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://immuneering.com/role/DisclosureCommitmentsAndContingenciesMaturitiesOfLeaseLiabilitiesDueDetails" xlink:type="extended" xlink:title="41302 - Disclosure - Commitments and Contingencies - Maturities of the lease liabilities due (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable_637824689804150613" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_3" xlink:to="us-gaap_LesseeLeaseDescriptionTable_637824689804150613" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_637824689804150613" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable_637824689804150613" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_637824689804150613" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_637824689804150613" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis_637824689804150613" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_637824689804150613" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_OfficeLeaseInSanDiegoCalifornia2020Member" xlink:label="imrx_OfficeLeaseInSanDiegoCalifornia2020Member_637824689804150613" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_637824689804150613" xlink:to="imrx_OfficeLeaseInSanDiegoCalifornia2020Member_637824689804150613" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_637824689804150613" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable_637824689804150613" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems_637824689804150613" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_637824689804150613" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_637824689804150613" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_637824689804150613" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_637824689804150613" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_637824689804150613" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_637824689804150613" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_637824689804160467" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_637824689804150613" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_637824689804160467" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_637824689804160467" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_637824689804150613" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_637824689804160467" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_637824689804160467" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_637824689804150613" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_637824689804160467" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_637824689804160467" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_637824689804150613" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_637824689804160467" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_637824689804160467" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_637824689804150613" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_637824689804160467" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_637824689804160467" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_637824689804150613" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_637824689804160467" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability_637824689804160467" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_637824689804150613" xlink:to="us-gaap_OperatingLeaseLiability_637824689804160467" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_637824689804160467" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_637824689804150613" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_637824689804160467" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_637824689804160467" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_637824689804150613" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_637824689804160467" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://immuneering.com/role/DisclosureCommitmentsAndContingenciesLeaseCostDetails" xlink:type="extended" xlink:title="41303 - Disclosure - Commitments and Contingencies - Lease cost (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCostAbstract" xlink:label="us-gaap_LeaseCostAbstract_637824689804170217" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_4" xlink:to="us-gaap_LeaseCostAbstract_637824689804170217" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost_637824689804170217" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract_637824689804170217" xlink:to="us-gaap_OperatingLeaseCost_637824689804170217" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermLeaseCost" xlink:label="us-gaap_ShortTermLeaseCost_637824689804170217" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract_637824689804170217" xlink:to="us-gaap_ShortTermLeaseCost_637824689804170217" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableLeaseCost" xlink:label="us-gaap_VariableLeaseCost_637824689804170217" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract_637824689804170217" xlink:to="us-gaap_VariableLeaseCost_637824689804170217" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost_637824689804170217" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract_637824689804170217" xlink:to="us-gaap_LeaseCost_637824689804170217" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_OperatingLeaseAdditionalInformationAbstract" xlink:label="imrx_OperatingLeaseAdditionalInformationAbstract_637824689804170217" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_4" xlink:to="imrx_OperatingLeaseAdditionalInformationAbstract_637824689804170217" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments_637824689804170217" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="imrx_OperatingLeaseAdditionalInformationAbstract_637824689804170217" xlink:to="us-gaap_OperatingLeasePayments_637824689804170217" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermLeasePayments" xlink:label="us-gaap_ShortTermLeasePayments_637824689804170217" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="imrx_OperatingLeaseAdditionalInformationAbstract_637824689804170217" xlink:to="us-gaap_ShortTermLeasePayments_637824689804170217" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="imrx-20211231.xsd#imrx_LeasePayments" xlink:label="imrx_LeasePayments_637824689804170217" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="imrx_OperatingLeaseAdditionalInformationAbstract_637824689804170217" xlink:to="imrx_LeasePayments_637824689804170217" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_637824689804170217" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_4" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_637824689804170217" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_637824689804180227" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_4" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_637824689804180227" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140649900344968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Mar. 03, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-40675<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Immuneering Corp<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">26-1976972<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">245 Main St<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Second Floor<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Cambridge<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address State Or Province</a></td>
<td class="text">MA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02142<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">617<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">500-8080<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Class A common Stock, par value $0.001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">IMRX<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 136,900,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:3pt 0pt 0pt 0pt;">Portions of the registrant&#8217;s Definitive Proxy Statement relating to the registrant&#8217;s 2022 Annual Meeting of Stockholders to be filed with the Securities and Exchange Commission within 120 days of the end of the registrant&#8217;s fiscal year ended December&#160;31, 2021 are incorporated by reference into Part III of this Annual Report on Form 10-K to the extent stated herein.</p><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">RSM US LLP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">49<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Boston, Massachusetts<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001790340<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Class A Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,377,299<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember', window );">Class B Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140649895722008">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 74,888,145<span></span>
</td>
<td class="nump">$ 37,090,151<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities, current</a></td>
<td class="nump">74,311,203<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">246,040<span></span>
</td>
<td class="nump">500,110<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaids and other current assets</a></td>
<td class="nump">2,888,608<span></span>
</td>
<td class="nump">140,958<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">152,333,996<span></span>
</td>
<td class="nump">37,731,219<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesNoncurrent', window );">Marketable securities, non-current</a></td>
<td class="nump">996,560<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">807,223<span></span>
</td>
<td class="nump">64,363<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">6,701,726<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible asset</a></td>
<td class="nump">439,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets, net</a></td>
<td class="nump">5,324,198<span></span>
</td>
<td class="nump">613,103<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">102,129<span></span>
</td>
<td class="nump">14,333<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">166,704,832<span></span>
</td>
<td class="nump">38,423,018<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">1,394,340<span></span>
</td>
<td class="nump">1,480,537<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">3,965,447<span></span>
</td>
<td class="nump">698,992<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Lease liabilities, current</a></td>
<td class="nump">274,039<span></span>
</td>
<td class="nump">76,322<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">5,633,826<span></span>
</td>
<td class="nump">2,255,851<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Long-term liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Lease liabilities, non-current</a></td>
<td class="nump">5,090,897<span></span>
</td>
<td class="nump">544,767<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">10,724,723<span></span>
</td>
<td class="nump">2,800,618<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 13)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityAbstract', window );"><strong>Convertible preferred stock:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58,103,850<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' deficit:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.001 par value; 10,000,000 and 0 shares authorized at December 31, 2021 and December 31, 2020, respectively; No shares issued or outstanding</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">215,276,186<span></span>
</td>
<td class="nump">3,251,240<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(49,009)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(59,273,388)<span></span>
</td>
<td class="num">(25,737,640)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity (deficit)</a></td>
<td class="nump">155,980,109<span></span>
</td>
<td class="num">(22,481,450)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities, convertible preferred stock and stockholders' equity (deficit)</a></td>
<td class="nump">166,704,832<span></span>
</td>
<td class="nump">38,423,018<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=imrx_SeriesBConvertiblePreferredStockMember', window );">Series B Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityAbstract', window );"><strong>Convertible preferred stock:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,983,910<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=imrx_SeriesConvertiblePreferredStockMember', window );">Series A Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityAbstract', window );"><strong>Convertible preferred stock:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,119,940<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Class A Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' deficit:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock</a></td>
<td class="nump">26,320<span></span>
</td>
<td class="nump">4,950<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember', window );">Class B Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' deficit:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=imrx_SeriesBConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=imrx_SeriesBConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=imrx_SeriesConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=imrx_SeriesConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140649898240216">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS (Parentheticals) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value per share (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock authorized (in shares)</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=imrx_SeriesBConvertiblePreferredStockMember', window );">Series B Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Convertible preferred stock, par value per share (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Convertible preferred stock, authorized (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">6,032,183<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Convertible preferred stock, issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,619,292<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Convertible preferred stock, outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,619,292<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=imrx_SeriesConvertiblePreferredStockMember', window );">Series A Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Convertible preferred stock, par value per share (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Convertible preferred stock, authorized (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,495,933<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Convertible preferred stock, issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,495,933<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Convertible preferred stock, outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,495,933<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Class A Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value per share (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">22,026,200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">26,320,199<span></span>
</td>
<td class="nump">4,950,129<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">26,320,199<span></span>
</td>
<td class="nump">4,950,129<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember', window );">Class B Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value per share (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">20,000,000<span></span>
</td>
<td class="nump">6,032,183<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=d3e177068-122764<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (27)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=imrx_SeriesBConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=imrx_SeriesBConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=imrx_SeriesConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=imrx_SeriesConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140649895649496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">$ 2,079,961<span></span>
</td>
<td class="nump">$ 2,311,535<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Cost of revenue</a></td>
<td class="nump">1,153,073<span></span>
</td>
<td class="nump">1,280,325<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
<td class="nump">926,888<span></span>
</td>
<td class="nump">1,031,210<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">26,540,959<span></span>
</td>
<td class="nump">15,003,786<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">8,271,998<span></span>
</td>
<td class="nump">3,109,978<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">34,812,957<span></span>
</td>
<td class="nump">18,113,764<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(33,886,069)<span></span>
</td>
<td class="num">(17,082,554)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeNonoperatingAbstract', window );"><strong>Other income (expense)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">169,899<span></span>
</td>
<td class="nump">42,656<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other expense</a></td>
<td class="num">(127,063)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income taxes</a></td>
<td class="num">(33,843,233)<span></span>
</td>
<td class="num">(17,039,898)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefit</a></td>
<td class="nump">307,485<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (33,535,748)<span></span>
</td>
<td class="num">$ (17,039,898)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share attributable to common stockholders, basic</a></td>
<td class="num">$ (2.46)<span></span>
</td>
<td class="num">$ (3.44)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share attributable to common stockholders, diluted</a></td>
<td class="num">$ (2.46)<span></span>
</td>
<td class="num">$ (3.44)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average common shares outstanding, basic</a></td>
<td class="nump">13,612,677<span></span>
</td>
<td class="nump">4,950,129<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average common shares outstanding, diluted</a></td>
<td class="nump">13,612,677<span></span>
</td>
<td class="nump">4,950,129<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Other comprehensive loss:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesUnrealizedGainLoss', window );">Unrealized losses from marketable securities</a></td>
<td class="num">$ (49,009)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive Loss</a></td>
<td class="num">$ (33,584,757)<span></span>
</td>
<td class="num">$ (17,039,898)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate cost of goods produced and sold and services rendered during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 18: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1,2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123384075&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeNonoperatingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeNonoperatingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in marketable security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140649892945880">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT) - USD ($)<br></strong></div></th>
<th class="th">
<div>Preferred Stock </div>
<div>Series A Preferred Stock</div>
</th>
<th class="th">
<div>Preferred Stock </div>
<div>Series B Preferred Stock</div>
</th>
<th class="th"><div>Preferred Stock</div></th>
<th class="th">
<div>Common Stock </div>
<div>Class A Common Stock</div>
</th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Accumulated other comprehensive loss</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Series A Preferred Stock</div></th>
<th class="th"><div>Series B Preferred Stock</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning Balance (in shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,950,129<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning Balance at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,950<span></span>
</td>
<td class="nump">$ 2,164,471<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (8,697,742)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (6,528,321)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,086,769<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,086,769<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(17,039,898)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(17,039,898)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,950<span></span>
</td>
<td class="nump">3,251,240<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(25,737,640)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(22,481,450)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,950,129<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Beginning Balance at Dec. 31, 2019</a></td>
<td class="nump">$ 16,611,832<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,611,832<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Beginning Balance (in shares) at Dec. 31, 2019</a></td>
<td class="nump">1,966,043<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,966,043<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward', window );"><strong>Increase (Decrease) in Temporary Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues', window );">Issuance of convertible preferred stock, net of issuance costs</a></td>
<td class="nump">$ 4,508,108<span></span>
</td>
<td class="nump">$ 36,983,910<span></span>
</td>
<td class="nump">$ 36,983,910<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imrx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues', window );">Issuance of convertible preferred stock, net of issuance costs (in shares)</a></td>
<td class="nump">529,890<span></span>
</td>
<td class="nump">3,619,292<span></span>
</td>
<td class="nump">4,508,108<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Ending Balance at Dec. 31, 2020</a></td>
<td class="nump">$ 21,119,940<span></span>
</td>
<td class="nump">$ 36,983,910<span></span>
</td>
<td class="nump">$ 58,103,850<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21,119,940<span></span>
</td>
<td class="nump">$ 36,983,910<span></span>
</td>
<td class="nump">58,103,850<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Ending Balance (in shares) at Dec. 31, 2020</a></td>
<td class="nump">2,495,933<span></span>
</td>
<td class="nump">3,619,292<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,495,933<span></span>
</td>
<td class="nump">3,619,292<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 118<span></span>
</td>
<td class="nump">354,316<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 354,434<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">117,846<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">117,847<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imrx_StockIssuedDuringPeriodValueWarrantsExercised', window );">Issuance of common stock upon exercise of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 308<span></span>
</td>
<td class="nump">926,817<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 927,125<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imrx_StockIssuedDuringPeriodSharesWarrantsExercised', window );">Issuance of common stock upon exercise of warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">308,308<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Conversion of Preferred Stock into common stock</a></td>
<td class="num">$ (21,119,940)<span></span>
</td>
<td class="num">$ (61,772,761)<span></span>
</td>
<td class="num">(82,892,701)<span></span>
</td>
<td class="nump">$ 11,939<span></span>
</td>
<td class="nump">82,880,762<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">82,892,701<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of Preferred Stock into common stock (in shares)</a></td>
<td class="num">(2,495,933)<span></span>
</td>
<td class="num">(6,032,145)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,939,281<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock upon initial public offering, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,625<span></span>
</td>
<td class="nump">118,185,808<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">118,194,433<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock upon initial public offering, net of issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,625,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions', window );">Issuance of common stock for acquisition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 380<span></span>
</td>
<td class="nump">7,874,620<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,875,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Issuance of common stock for acquisition, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">379,635<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,802,623<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,802,623<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(33,535,748)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(33,535,748)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (49,009)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(49,009)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26,320<span></span>
</td>
<td class="nump">$ 215,276,186<span></span>
</td>
<td class="num">$ (49,009)<span></span>
</td>
<td class="num">$ (59,273,388)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 155,980,109<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balance (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,320,199<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward', window );"><strong>Increase (Decrease) in Temporary Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues', window );">Issuance of convertible preferred stock, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24,788,851<span></span>
</td>
<td class="nump">$ 24,788,851<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imrx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues', window );">Issuance of convertible preferred stock, net of issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,412,853<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Ending Balance (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imrx_StockIssuedDuringPeriodSharesWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share warrants exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imrx_StockIssuedDuringPeriodSharesWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imrx_StockIssuedDuringPeriodValueWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imrx_StockIssuedDuringPeriodValueWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imrx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock classified as temporary equity issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imrx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123468992&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInTemporaryEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period pursuant to acquisitions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued pursuant to acquisitions during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of new stock classified as temporary equity issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140649897954664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT) (Parentheticals)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfStockholdersEquityAbstract', window );"><strong>CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imrx_StockIssuanceCosts', window );">Issuance costs</a></td>
<td class="nump">$ 2,124,317<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imrx_StockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of stock issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imrx_StockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140649895719800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Jan. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (33,535,748)<span></span>
</td>
<td class="num">$ (17,039,898)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustment to reconcile to net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45,467<span></span>
</td>
<td class="nump">24,328<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">Right-of-use asset amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">113,605<span></span>
</td>
<td class="nump">54,977<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,802,623<span></span>
</td>
<td class="nump">1,086,769<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium', window );">Net amortization of premium (accretion of discount) on marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130,240<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred tax benefit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(307,485)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract', window );"><strong>(Increase) decrease in:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">279,713<span></span>
</td>
<td class="num">(290,170)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,408,986)<span></span>
</td>
<td class="num">(69,740)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(14,333)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract', window );"><strong>Increase (decrease) in:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(130,398)<span></span>
</td>
<td class="nump">1,185,589<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,240,940<span></span>
</td>
<td class="nump">488,644<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Lease liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(80,853)<span></span>
</td>
<td class="num">(46,991)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(30,850,882)<span></span>
</td>
<td class="num">(14,620,825)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(60,786)<span></span>
</td>
<td class="num">(53,415)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Purchases of marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(75,625,529)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAcquiredInExcessOfPaymentsToAcquireBusiness', window );">Cash acquired in business combination</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70,348<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(75,615,967)<span></span>
</td>
<td class="num">(53,415)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from initial public offering of common stock, net of commissions and underwriting</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">120,318,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payment of initial public offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,124,317)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">354,434<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from exercise of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">927,125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">144,264,843<span></span>
</td>
<td class="nump">37,982,216<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase in cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,797,994<span></span>
</td>
<td class="nump">23,307,976<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at beginning of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,782,175<span></span>
</td>
<td class="nump">37,090,151<span></span>
</td>
<td class="nump">13,782,175<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at end of period</a></td>
<td class="nump">$ 13,782,175<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">74,888,145<span></span>
</td>
<td class="nump">37,090,151<span></span>
</td>
<td class="nump">$ 13,782,175<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosures of noncash investing and financing information :</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssued1', window );">Conversion of convertible Series A and B preferred stock into common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">82,892,701<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationAcquisitionRelatedCosts', window );">Business combination non cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,804,652<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesIssued1', window );">Class A common stock issued for business combination</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,875,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imrx_ReclassificationOfLiabilityOfPreferredStock', window );">Reclassification of liability for Series A preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,509,802<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=imrx_SeriesConvertiblePreferredStockMember', window );">Series A Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock', window );">Proceeds from the issuance of preferred stock, net of issuance costs</a></td>
<td class="nump">$ 4,004,975<span></span>
</td>
<td class="nump">1,021,413<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">998,306<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payment of initial public offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (23,610)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (200,587)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=imrx_SeriesBConvertiblePreferredStockMember', window );">Series B Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock', window );">Proceeds from the issuance of preferred stock, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24,788,851<span></span>
</td>
<td class="nump">$ 36,983,910<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imrx_ReclassificationOfLiabilityOfPreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The liability of preferred stock reclassified during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imrx_ReclassificationOfLiabilityOfPreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAcquisitionRelatedCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 25<br> -Paragraph 23<br> -URI http://asc.fasb.org/extlink&amp;oid=123586518&amp;loc=d3e1043-128460<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAcquisitionRelatedCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAcquiredInExcessOfPaymentsToAcquireBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the acquisition of a business when the cash held by the acquired business exceeds the cash payments to acquire the business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAcquiredInExcessOfPaymentsToAcquireBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accretion (amortization) of purchase discount (premium) on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for purchase of marketable security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fair value of stock issued in noncash financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4313-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=imrx_SeriesConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=imrx_SeriesConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=imrx_SeriesBConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=imrx_SeriesBConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140649898041032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Nature of Business<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization and Nature of Business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Organization and Nature of Business</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Note&#160;1&#160;&#8211; Organization and Nature of Business</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Immuneering Corporation, a Delaware corporation, (&#8220;Immuneering&#8221; or the &#8220;Company&#8221;) was incorporated in 2008. The Company aims to improve patient outcomes by advancing a unique pipeline of oncology and neuroscience product candidates developed using the Company&#8217;s translational bioinformatics platform. The Company has more than a decade of experience applying translational bioinformatics to generate insights into drug mechanism of action and patient treatment response. Building on this experience, the Company&#8217;s disease-agnostic discovery platform enables the Company to create product candidates based on 1) biological insights that are both counterintuitive and deeply rooted in data, and 2) novel chemistry.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On October&#160;30, 2019, Immuneering formed a wholly owned subsidiary, Immuneering Securities Corporation (&#8220;ISC&#8221;), a Massachusetts securities corporation, for the sole purpose of buying, selling and holding securities on the Company&#8217;s behalf. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On December 22, 2021, <span style="background:#ffffff;">the Company acquired all outstanding shares of capital stock of BioArkive, Inc. (&#8220;BioArkive&#8221;), a California corporation, which as a result became a wholly owned subsidiary. &#160;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Immuneering, ISC and BioArkive are collectively referred to as &#8220;the Company&#8221; throughout these &#160;consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company is subject to a number of inherent risks associated with any biotechnology company that has substantial expenditures for research and development. These risks include, but are not limited to, the need to obtain adequate additional funding, possible failure of clinical trials or other events demonstrating lack of clinical safety or efficacy of its product candidates, dependence on key personnel, reliance on third-party service providers for manufacturing drug product and conducting clinical trials, the ability to successfully secure its proprietary technology, and risks related to the regulatory approval and commercialization of a product candidate. There can be no assurance that the Company&#8217;s research and development program will be successful. In addition, the Company operates in an environment of rapid technological change and is largely dependent on the services of its employees, advisors, and consultants.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On August 3, 2021, the Company completed its initial public offering (&#8220;IPO&#8221;) pursuant to which it issued and sold 8,625,000 shares of its Class A common stock, inclusive of 1,125,000 shares of its Class A common stock sold pursuant to the full exercise of the underwriters&#8217; option to purchase additional shares. The aggregate net proceeds received by the Company from the IPO were $120,318,750, after deducting underwriting discounts and commissions, but before deducting offering costs payable by the Company, which were $2,124,317. Upon the closing of the IPO, all 8,528,078 shares of the Company&#8217;s convertible preferred stock then outstanding automatically converted into 11,939,281 shares of Class A common stock. Upon the conversion of the convertible preferred stock, the Company reclassified the carrying value of the convertible preferred stock to common stock (at par value) and additional&#160;paid-in&#160;capital (see Note 8). </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">To date, the Company has funded its operations through service revenues, and with proceeds from the sale of its capital stock and convertible notes and, most recently, with proceeds from the IPO. The Company has incurred recurring losses over the past several&#160;years and as of December&#160;31, 2021, the Company had an accumulated deficit of $59,273,388. The Company expects to continue to generate operating losses for the foreseeable future. The future viability of the Company is dependent on its ability to raise additional capital to finance its operations. The Company&#8217;s inability to raise capital as and when needed could have a negative impact on its financial condition and ability to pursue its business strategies. There can be no assurances that additional funding will be available on terms acceptable to the Company, or at all. If the Company is unable to raise additional funds when needed, it may be required to delay, reduce the scope of, or eliminate development programs, which may adversely affect its business and operations. Management considers that there are no conditions or events, in the aggregate, that raise substantial doubt about the entity&#8217;s ability to continue as a going concern and estimates that its cash and cash equivalents will be sufficient to fund its operating expenses and capital expenditure requirements for at least 12&#160;months from the issuance date of the consolidated financial statements. The full extent to which coronavirus (&#8220;COVID-19&#8221;) pandemic will directly or indirectly impact the Company&#8217;s business, results of operations and financial </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">condition, including expenses and research and development costs, will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning COVID-19 and its variants and the actions taken to contain or treat COVID-19 and its variants, as well as the economic impact on local, regional, national and international markets. The Company has considered potential impacts arising from the pandemic related to COVID-19 and its variants and is not presently aware of any events or circumstances that would require the Company to update its estimates, judgements or revise the carrying values of its assets or liabilities.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140649897990120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Note&#160;2 - Summary of Significant Accounting Policies</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Basis of Presentation</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The consolidated financial statements have been prepared in accordance with accounting standards set by the Financial Accounting Standards Board (&#8220;FASB&#8221;). The FASB sets generally accepted accounting principles (&#8220;GAAP&#8221;) to ensure the consolidated financial statements are consistently reported. References to GAAP issued by the FASB in these footnotes are to the FASB Accounting Standards Codifications (&#8220;ASC&#8221;). The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Stock Split</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;">On July 23, 2021, the Company approved a </span><span style="font-weight:normal;">one</span><span style="font-weight:normal;white-space:pre-wrap;">-for-1.4 stock split which was consummated in connection with the Company&#8217;s IPO.  All information in the accompanying financial statements and notes thereto regarding share amounts of common stock, price per share of common stock and the conversion factor for Series A and Series B Preferred Stock into common stock have been adjusted to reflect the application of the stock split on a retroactive basis.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Use of Estimates&#160;</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses during the reporting periods. These estimates and assumptions are based on current facts, historical experience and various other factors believe to be reasonable under the circumstances, the results of which form the basis for making judgements about the carrying values of assets, liabilities and the recording of expenses that are not readily apparent from other sources. Significant estimates reflected in these &#160;consolidated financial statements included but are not limited to, the research and development expenses, determination of fair value of stock-based awards, the valuation of common stock prior to the IPO, business combination, and the right-to-use assets and operating lease liability. Actual results may differ materially and adversely from these estimates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Segments</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker (&#8220;CODM&#8221;) in making decisions regarding resource allocation and assessing performance. The Company&#8217;s chief executive officer is the CODM, and he uses consolidated financial information in determining how to allocate resources and assess performance. The Company has determined that it operates in one segment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="display:inline-block;visibility:hidden;width:0pt;">&#8203;</span><br/><span style="font-size:13.5pt;visibility:hidden;background:#ffffff;">&#8203;</span><span style="font-size:13.5pt;visibility:hidden;background:#ffffff;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:13.5pt;visibility:hidden;background:#ffffff;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:13.5pt;visibility:hidden;background:#ffffff;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:13.5pt;visibility:hidden;background:#ffffff;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:13.5pt;visibility:hidden;background:#ffffff;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;background:#ffffff;">Business Combination</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:13.5pt;font-weight:bold;visibility:hidden;background:#ffffff;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="background:#ffffff;">Results of operations of acquired companies are included in the Company&#8217;s results of operations as of the respective acquisition dates. Acquired businesses are accounted for using the acquisition method of accounting, which requires that assets acquired and liabilities assumed be recorded at fair value, with limited exceptions. Any excess of the purchase price over the fair value of the net assets acquired is recorded as goodwill. Transaction costs and costs to restructure the acquired Company are expensed as incurred. The operating results of the acquired business are reflected in the consolidated financial statements after the date of acquisition. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:13.5pt;visibility:hidden;background:#ffffff;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">If the acquired net assets do not constitute a business under the acquisition method of accounting, the transaction is accounted for as an asset acquisition and no goodwill is recognized.&#160;Refer to Note 6, Business Combination for more information.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Cash and Cash </b><b style="font-weight:bold;">Equivalents</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">Cash and cash equivalents are comprised of deposits at major financial banking institutions and highly liquid investments with an original maturity of three&#160;months or less at the date of purchase. Cash is maintained at Federal Deposit Insurance Company (&#8220;FDIC&#8221;) insured financial institutions. At times, the Company has maintained cash in excess of FDIC limits, however it has not experienced any losses with respect to its cash balances. The Company regularly monitors the financial condition of the institutions in which it has depository accounts and believes the risk of loss is minimal.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Marketable Securities </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our marketable securities are classified as available-for-sale pursuant to ASC 320,<span style="background:#ffffff;"> Investments &#8211; Debt and Equity Securities</span> and are recorded at fair value. Unrealized gains/(losses) are included as a component of accumulated other comprehensive loss in the &#160;consolidated balance sheets and statements of convertible preferred stock and stockholders&#8217; equity (deficit) and a component of total comprehensive loss in the consolidated statements of comprehensive loss, until realized. The Company assesses its available-for-sale marketable securities for impairment on a quarterly basis. There were no impairments of the Company&#8217;s available-for-sale marketable securities measured and carried at fair value during the year ended December 31, 2021. &#160;Realized gains and losses are included in other expense on a specific-identification basis.&#160;There were&#160;no&#160;realized gains or losses on marketable securities for the year ended December 31, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Fair Value Measurements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We record cash equivalents and marketable securities at fair value. ASC 820,&#160;Fair Value Measurements and Disclosures, establishes a fair value hierarchy for those instruments measured at fair value that distinguishes between assumptions based on market data (observable inputs) and our own assumptions (unobservable inputs). The hierarchy consists of three levels:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Level 1</i>&#160;&#8211; Unadjusted quoted prices in active markets for identical assets or liabilities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Level 2</i>&#160;&#8211; Quoted prices for similar assets and liabilities in active markets, quoted prices in markets that are not active, or inputs which are observable, directly or indirectly, for substantially the full term of the asset or liability.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Level 3</i>&#160;&#8211; Unobservable inputs that reflect our own assumptions about the assumptions market participants would use in pricing the asset or liability in which there is little, if any, market activity for the asset or liability at the measurement date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Our financial assets, which include cash equivalents and marketable securities, have been initially valued at the transaction price, and subsequently revalued at the end of each reporting period, utilizing third-party pricing services or other observable market data. The pricing services utilize industry standard valuation models, including both income and market based approaches, and observable market inputs to determine value. After completing our validation procedures, we did not adjust or override any fair value measurements provided by the pricing services as of December&#160;31, 2021. Fair value </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">information for these assets, including their classification in the fair value hierarchy is included in Note 4 &#160;Fair Value Measurements<b style="font-weight:bold;">.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:13.5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">There have been no changes to the valuation methods during the year ended December&#160;31, 2021. We evaluate transfers between levels at the end of each reporting period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:13.5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The carrying amounts reflected in the consolidated balance sheets for cash, accounts receivable, accounts payable and accrued expenses approximate their respective fair values because of the short-term maturity of those financial instruments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Accounts Receivable</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">Accounts receivable are stated at the amount management expects to collect from outstanding balances. An allowance for doubtful accounts is estimated for those accounts receivable considered to be uncollectible based upon historical experience and management&#8217;s evaluation of outstanding accounts receivable. Bad debts are written off against the allowance when identified. At December&#160;31, 2021 and 2020 there was no allowance for doubtful accounts.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Concentration of Credit Risk</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">Financial instruments that potentially subject the Company to significant concentration of credit risk consist primarily of accounts receivable and revenue. To manage accounts receivable credit risk, the Company continuously evaluates the creditworthiness of its customers and the need for an allowance for potential credit losses. The Company has not experienced any losses in such accounts.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">The following customers comprised 10% or more of the Company&#8217;s total accounts receivable or revenues as of or for the period ended December&#160;31, 2021 (customers with an asterisk are less than 10%): </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:47.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:47.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:22.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="color:#231f20;font-weight:bold;">Year Ended December&#160;31,&#160;2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:23.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="color:#231f20;font-weight:bold;">As&#160;of&#160;December&#160;31,&#160;2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:47.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Revenue</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">%&#160;of&#160;Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Accounts&#160;Receivable</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">%&#160;of&#160;Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:47.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Customer #1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 745,030</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 35.8</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 235,500</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">95.7%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:47.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Customer #2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 380,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 18.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:47.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Customer #5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 353,050</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 17.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:47.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:47.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:22.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="color:#231f20;font-weight:bold;">Year Ended December&#160;31,&#160;2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:23.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="color:#231f20;font-weight:bold;">As&#160;of&#160;December&#160;31,&#160;2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:47.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Revenue</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">%&#160;of&#160;Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Accounts&#160;Receivable</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">%&#160;of&#160;Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:47.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Customer #1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 676,710</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 29.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 214,345</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 42.9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:47.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Customer #2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 570,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 24.7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 71,250</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 14.2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:47.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Customer #3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 306,900</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 13.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:47.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Customer #4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 250,880</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 10.9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 63,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12.6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:47.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Customer #5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 91,975</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 18.4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Property and Equipment</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">Property and equipment are recorded at cost, net of accumulated depreciation. Expenditures for major replacements and improvements are capitalized, while expenditures for general repairs and maintenance are expensed as incurred. Upon retirements or disposition of property and equipment, the related cost and accumulated depreciation are removed from the consolidated balance sheet and any resulting gain or loss is recorded in the consolidated statement of operations. Depreciation is calculated using the straight-line method once assets are placed in service. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:86.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:86.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Estimated</b></p></td></tr><tr><td style="vertical-align:bottom;width:86.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Asset Class</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Useful&#160;Lives</b></p></td></tr><tr><td style="vertical-align:bottom;width:86.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Computer equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">3 years</p></td></tr><tr><td style="vertical-align:bottom;width:86.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Furniture and fixtures</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">5 years</p></td></tr><tr><td style="vertical-align:bottom;width:86.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Lab equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">7 years</p></td></tr><tr><td style="vertical-align:bottom;width:86.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Leasehold improvements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1-10 years</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Impairment of Long-lived Assets</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">Periodically, the Company evaluates its long-lived assets, which consist primarily of property and equipment, for impairment whenever events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted net cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the asset exceeds the fair value of the asset. To date, no impairments have occurred.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Leases</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">In February&#160;2016 the FASB issued Accounting Standards Update (&#8220;ASU&#8221;) No. 2016-02, Leases (Topic 842) (&#8220;ASC 842&#8221;), a standard issued to increase transparency and comparability among organizations related to their leasing activities. This standard established a right-of-use model that requires the recognition of right-of-use assets and lease liabilities for most leases as well as provides disclosure with respect to certain qualitative and quantitative information related to a company&#8217;s leasing arrangements to meet the objective of allowing users of financial statements to assess the amount, timing and uncertainty of cash flows arising from leases.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">The Company adopted the leasing standard using the modified retrospective transition approach as of January&#160;1, 2020, with no restatement of prior periods or cumulative adjustment to retained earnings. Upon adoption, the Company elected the package of transition practical expedients, which allowed the Company to carry forward prior conclusions related to whether any expired or existing contracts are or contain leases, the lease classification for any expired or existing leases, and initial direct costs for existing leases. The Company also made an accounting policy election to not recognize leases with an initial term of 12&#160;months or less within its consolidated balance sheets, and to recognize those lease payments on a straight-line basis in its consolidated statements of operations over the lease term. The adoption of the leasing standard did not have an impact on the consolidated statement of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">The Company determines if an arrangement is a lease at contract inception. Right-of-use assets represent the Company&#8217;s right to use an underlying asset for the lease term and lease liabilities represent its obligation to make lease payments arising from the lease. Right-of-use assets and lease liabilities are recognized at the commencement date of the lease based upon the present value of future lease payments over the expected lease term. When determining the lease term, the Company includes options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. As most of the Company&#8217;s leases do not provide an implicit interest rate, the Company uses its incremental borrowing rate, which is based on rates that would be incurred to borrow on a collateralized basis over a term equal to the lease payments in a similar economic environment, in determining the present value of lease payments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">The Company has elected not to separate lease and non-lease components as a single lease component. The Company&#8217;s lease are reflected in right-of-use assets and lease liabilities (current and non-current) in the consolidated balance sheets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Revenue Recognition</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="font-weight:bold;letter-spacing:-0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">In accordance with ASC 606, revenue is recognized when a customer obtains control of promised goods and services. The core principle of the standard is to recognize revenue to depict the transfer of promised goods or services to customers in </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods or services. To achieve that core principle, the Company applies the following five-step model:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt 0pt 0pt 18pt;">&#8226; Identify the contract with a customer</p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt 0pt 0pt 18pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt 0pt 0pt 18pt;">&#8226; Identify the performance obligations in the contract</p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt 0pt 0pt 18pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt 0pt 0pt 18pt;">&#8226; Determine the transaction price</p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt 0pt 0pt 18pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt 0pt 0pt 18pt;">&#8226; Allocate the transaction price to the performance obligations in the contract</p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt 0pt 0pt 18pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt 0pt 0pt 18pt;">&#8226; Recognize revenue when or as performance obligations are satisfied</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">The Company&#8217;s contracts generally consist of the promise to provide computational biology professional services to pharmaceutical and biotechnology companies, which the Company has concluded constitutes one performance obligation that is delivered over time. The transaction price is the amount of consideration to which the Company expects to be entitled in exchange for transferring the services to the customer. The Company&#8217;s contracts provide for either agreed upon rates per hour based on the level of the professional working on the project or a fixed fee for a defined scope of work. The Company recognizes revenue over time by measuring the progress toward complete satisfaction of the performance obligation using a single method of measuring progress, which depicts the performance in transferring control of the associated services to the customer. The Company uses input methods to measure the progress toward the complete satisfaction of performance obligations and evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenue and net loss in the period of adjustment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">The Company&#8217;s contract terms do not allow for a right of return or refund and do not contain significant financing components. Receivables associated with the contract will generally be collected within thirty to sixty days, in accordance with the underlying payment terms.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Income Taxes</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">The Company provides for income taxes in accordance with ASC Topic 740, Income Taxes. Deferred tax assets and liabilities are determined based on the difference between the financial reporting and tax bases of assets and liabilities using enacted tax rates and laws in effect in the&#160;years in which the differences are expected to reverse. A valuation allowance is provided if, based upon the weighted available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;">The Company accounts for uncertainty in income taxes recognized in the consolidated financial statements by applying a two-step process to determine the amount of tax benefit to be recognized. First, the tax position must be evaluated to determine the likelihood that it will be sustained upon external examination by the taxing authorities. If the tax position is deemed more likely than not to be sustained, the tax position is then assessed to determine the amount of benefit to recognize in the consolidated financial statements. The amount of the benefit that may be recognized is the largest amount that has a greater than 50% likelihood of being realized upon ultimate settlement. The provision for income taxes includes the effects of any resulting tax reserves (i.e., unrecognized tax benefits) that are considered appropriate as well as the related net interest. <span style="color:#222222;background:#ffffff;">As of December 31, 2021 and 2020, the Company had uncertain tax positions of </span><span style="color:#222222;background:#ffffff;">$380,902</span><span style="color:#222222;background:#ffffff;"> and </span><span style="color:#222222;background:#ffffff;">$174,950</span><span style="color:#222222;background:#ffffff;">.&#160;&#160; The Company has classified the unrecognized tax benefits as reductions of its tax credit carryforwards.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Research and Development</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;">Research and development costs are expensed as incurred. Research and development costs consist of expenses incurred in performing research and development activities, including salaries and benefits, materials and supplies, preclinical expenses, stock-based compensation expense, depreciation of equipment, contract services, and other outside expenses. The Company also incurs costs to develop software programs for internal use in identifying potential human drug targets which may then lead to the development of human drug candidates. To date the software programs have primarily been used for internal research and development activities and the costs incurred have been expensed as research and development.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Research and Manufacturing Contract Costs and Accruals</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company has entered into various research, development and manufacturing contracts with research institutions and other companies in the United States. These agreements are generally cancelable, and related costs are recorded as research and development expenses as incurred. The Company records accruals for estimated ongoing research, development and manufacturing costs. When billing terms under these contracts do not coincide with the timing of when the work is performed, the Company is required to make estimates of outstanding obligations to those third parties as of period end. Any accrual estimates are based on a number of factors, including the Company&#8217;s knowledge of the progress towards completion of the research, development and manufacturing activities, invoicing to date under the contracts, communication from the research institutions and other companies of any actual costs incurred during the period that have not yet been invoiced and the costs included in the contracts. Significant judgments and estimates may be made in determining the accrued balances at the end of any reporting period. Actual results could differ from the estimates made by the Company. The historical accrual estimates made by the Company have not been materially different from the actual costs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="color:#231f20;font-weight:bold;">Patent </b><b style="font-weight:bold;">Costs</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">All patent-related costs incurred in connection with filing and prosecuting patent applications are expensed as incurred due to the uncertainty about the recovery of the expenditure. Amounts incurred are classified as general and administrative expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="color:#231f20;font-weight:bold;">Com</b><b style="font-weight:bold;background:#ffffff;">prehensive Loss</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Comprehensive loss includes net loss as well as other changes in stockholders&#8217; equity (deficit) that result from transactions and economic events other than those with stockholders. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;background:#ffffff;">Deferred Offering Costs</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">The Company capitalizes certain legal, professional accounting and other third-party fees that are directly associated with&#160;in-process&#160;equity financings as deferred offering costs until such financings are consummated. After consummation of an equity financing, these costs are recorded as a reduction of the proceeds from the offering, either as a reduction of the carrying value of the preferred stock or in stockholder&#8217;s equity (deficit) as a reduction of additional&#160;paid-in&#160;capital generated as a result of the offering. Should the&#160;in-process&#160;equity financing be abandoned, the deferred offering costs would be expensed immediately as a charge to operating expenses in the statements of operations and comprehensive loss. There were&#160;</span><span style="background:#ffffff;">no</span><span style="background:#ffffff;">&#160;deferred offering costs as of December&#160;31,2021 or December 31, 2020.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="color:#231f20;font-weight:bold;">Net Income (Loss) per Share</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Prior to the closing of the IPO, the Company followed the two-class method when computing net income (loss) per share, as the Company had issued shares that meet the definition of participating securities. The two-class method determines net income (loss) per share for each class of common and participating securities according to dividends declared or accumulated and participation rights in undistributed earnings. The two-class method requires income available to common stockholders for the period to be allocated between common and participating securities based upon their respective rights to receive dividends as if all income for the period had been distributed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Basic net income (loss) per share attributable to common stockholders is computed by dividing the net income (loss) attributable to common stockholders by the weighted average number of common shares outstanding for the period. Diluted net income (loss) attributable to common stockholders is computed by adjusting net income (loss) attributable to common stockholders to reallocate undistributed earnings based on the potential impact of dilutive securities. Diluted net income (loss) per share attributable to common stockholders is computed by dividing the diluted net income (loss) attributable to common stockholders by the weighted average number of common shares outstanding for the period, including potential dilutive common shares assuming the dilutive effect of common stock equivalents.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s convertible preferred stock contractually entitled the holders of such shares to participate in dividends but does not contractually require the holders of such shares to participate in losses of the Company. Accordingly, in periods in which the Company reports a net loss, such losses are not allocated to such participating securities. In periods in which the Company reports a net loss attributable to common stockholders, diluted net loss per share attributable to common stockholders is the same as basic net loss per share attributable to common stockholders, since dilutive common shares are not assumed to have been issued if their effect is anti-dilutive.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Subsequent to the closing of its IPO, the Company only has one class of shares outstanding and basic net income (loss) per common share is computed by dividing the net income (loss) by the weighted average number of shares of common stock outstanding for the period. Diluted net income (loss) per common share is computed by dividing net income (loss) by the weighted average number of shares of common stock outstanding for the period, including potential dilutive common shares assuming the dilutive effect of outstanding stock awards. For periods in which the Company reports a net loss, diluted net loss per common share is the same as basic net loss per common share, since dilutive common shares are not assumed to have been issued if their effect is anti-dilutive. The Company reported a net loss attributable to common stockholders for each of the years ended December&#160;31, 2021 and 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Stock-based Compensation</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="font-weight:bold;letter-spacing:-0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company issues stock-based awards to employees and nonemployees in the form of stock options. The Company accounts for stock-based awards in accordance with ASC 718, Compensation&#8201;&#8212;&#8201;Stock Compensation (&#8220;ASC 718&#8221;), which requires all stock-based payments to employees and nonemployees, including grants of employee stock options and modifications to existing stock options, to be recognized in the consolidated statement of operations based on their fair values.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The fair value of options is estimated on the grant date using the Black-Scholes option-pricing model (&#8220;Black-Scholes&#8221;). Black-Scholes requires the Company to make assumptions and judgments about the variables used in the calculation including the expected term of its stock option, the volatility of the Company&#8217;s common stock, and an assumed risk-free interest rate. The Company uses the simplified calculation of expected life and volatility is based on an average of the historical volatility of a group of publicly traded companies in a similar industry that the Company believes would be considered a peer group had it been a publicly held company for the duration of the expected life of the award. The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of grant for periods corresponding with the expected life of the option. Forfeitures are recognized as they occur. No dividend yield was assumed as the Company does not pay, and does not expect to pay, dividends on its common stock. The assumptions underlying these valuations represent management&#8217;s best estimates, which involve inherent uncertainties and the application of management&#8217;s judgement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In accordance with ASU No. 2018-07, Compensation-Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting, compensation expense for stock-based awards granted to nonemployees is recognized over the period during which services are rendered by such nonemployees. The new standard largely aligns the accounting for share-based payment awards issued to employees and nonemployees by expanding the scope of ASC 718 to apply to nonemployee share-based transactions, as long as the transaction is not effectively a form of financing. There was no adjustment to the financial statements upon adoption of this standard as of January&#160;1, 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As there had been no public market for the Company&#8217;s common stock prior to the IPO, the estimated fair value of its common stock has been determined by its board of directors as of the date of each option grant, with input from management, considering the Company&#8217;s most recently available third-party valuations of common stock and its board of directors&#8217; assessment of additional objective and subjective factors that it believed were relevant and which may have changed from the date of the most recent valuation through the date of the grant. These third-party valuations were performed in accordance with the guidance outlined in the American Institute of Certified Public Accountants&#8217; Accounting and Valuation Guide, Valuation of Privately-Held-Company Equity Securities Issued as Compensation. Each valuation methodology includes estimates and assumptions that require the Company&#8217;s judgment. These estimates and assumptions include a number of objective and subjective factors, including external market conditions, the prices at which the Company sold shares of preferred stock, the superior rights and preferences of securities senior to the Company&#8217;s common stock at the time of, and the likelihood of, achieving a liquidity event, such as an initial public offering or sale.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The assumptions underlying these valuations represent management&#8217;s best estimates, which involve inherent uncertainties and the application of management&#8217;s judgment. As a result, if the Company had used different assumptions or estimates, the fair value of its common stock and its stock-based compensation expense could be materially different.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Goodwill</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Goodwill represents the excess of the fair value of the acquiree over the recognized bases of the net identifiable assets acquired and includes the future economic benefits from other assets that could not be individually identified and separately recognized. Goodwill is not amortized, but instead is periodically reviewed for impairment and an impairment charge is recorded in the periods in which the recorded carrying value of goodwill exceeds its fair value.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">On a quarterly basis, the Company performs a review of its business to determine if events or changes in circumstances have occurred which could have a material adverse effect on the fair value of the Company and its goodwill. If such events or changes in circumstances were deemed to have occurred, the Company would perform an impairment test of goodwill as of the end of the quarter and record any noted impairment loss.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">The goodwill test is performed at least annually, or more frequently if events or changes in circumstances indicate that the asset might be impaired. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">The Company performs its annual impairment test during the fourth quarter of each fiscal year. There were </span><span style="background:#ffffff;">no</span><span style="background:#ffffff;"> impairments in 2021.</span><span style="background:#ffffff;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Intangible Assets</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Intangible assets are recognized at fair value, as an asset apart from goodwill if the asset (i) arises from contractual or other legal rights, or (ii) is separable. Intangible assets, principally representing technology acquired, are capitalized and amortized on the straight-line method over their expected useful lives.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company reviews the recoverability of its long-lived assets (including amortizable intangible assets), other than goodwill, when events or changes in circumstances occur that indicate that the carrying value of the asset may not be recoverable. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Recently Issued Accounting Pronouncements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies and adopted by the Company as of the specified effective date. The Company is an &#8220;emerging growth company&#8221; as defined in the Jumpstart Our Business Startups Act of 2012, as amended (&#8220;JOBS Act&#8221;). The Jobs Act provides that an emerging growth company can take advantage of an extended transition period for complying with new or revised accounting standards. Thus, an emerging growth company can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. The Company elected to avail itself of this extended transition period and, as a result, we will not be required to adopt new or revised accounting standards on the relevant dates on which adoption of such standards is required for other public companies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In 2016, the FASB issued ASU 2016-13, Financial Instruments&#160;&#8211; Credit Losses (Topic 326): Measurement of Credit Losses on Financial Statements. The new standard, as amended, requires that expected credit losses relating to financial assets measured on an amortized cost basis and available-for-sale debt securities be recorded through an allowance for credit losses. It also limits the amount of credit losses to be recognized for available-for-sale debt securities to the amount by which carrying value exceeds fair value and also requires the reversal of previously recognized credit losses if fair value increases. The targeted transition relief standard allows filers an option to irrevocably elect the fair value option of ASC 825-10, Financial Instruments-Overall, applied on an instrument-by-instrument basis for eligible instruments.&#160;ASU No.&#160;2016-13, Financial Instruments&#160;- Credit Losses (Topic 326) will become effective for the Company on January&#160;1, 2023. The Company is currently assessing the impact of the adoption of this guidance on its consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In December&#160;2019, the FASB issued ASU No.&#160;2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes, which simplifies the accounting for income taxes by removing certain exceptions to the general principles in the existing guidance for income taxes and making other minor improvements. The amendments are effective for annual reporting periods beginning after December&#160;15, 2020 with early adoption permitted. The adoption of this standard did not have a material impact to the financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In January 2017, the FASB issued ASU No. ASU 2017-04, &#160;Intangibles&#8212;Goodwill and Other (Topic 350<i style="font-style:italic;">)</i>, which eliminates Step 2 from the goodwill impairment test. Step 2 measures a goodwill impairment loss by comparing the implied fair value of a reporting unit&#8217;s goodwill with the carrying amount of that goodwill. Instead, entities will record an impairment charge based on the excess of a reporting unit&#8217;s carrying amount over its fair value (i.e., measure the charge based on today&#8217;s Step 1). This update is effective for annual and interim impairment tests performed in periods beginning after December 15, 2022. Early adoption of the standard is permitted. The Company is currently evaluating the new guidance and assessing the potential impact on its consolidated financial statements. &#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140649898084568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable Securities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Marketable Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock', window );">Marketable Securities</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Note 3 &#8211; Marketable Securities </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Marketable securities as of December 31, 2021 consisted of the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:29.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:11.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:12.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:12.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:14.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:29.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:67.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, 2021</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:29.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:middle;width:13.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amortized Cost</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:middle;width:14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Unrealized Gains</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:middle;width:14.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Unrealized Losses</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:middle;width:16.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair Value</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:29.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Assets:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:11.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:12.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:12.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:14.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:29.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;">             Current:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:29.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">U.S. Treasuries</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 42,147,385</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (28,575)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 42,118,810</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:29.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">Government securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 19,218,057</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (13,689)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 19,204,368</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:29.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">Commercial Paper</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12,992,165</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 57</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (4,197)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12,988,025</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:29.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;">Total Current</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 74,357,607</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 57</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (46,461)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 74,311,203</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:29.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:29.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;">           Non-current:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:29.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">U.S. Treasuries</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 999,186</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,626)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 996,560</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:29.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">Government securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> -</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:29.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;">Total Non-current</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 999,186</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,626)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 996,560</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:29.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;">Total marketable securities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 75,356,793</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 57</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (49,087)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 75,307,763</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">There were no marketable securities as of December 31, 2020. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">There were no impairments of the Company&#8217;s available-for-sale marketable securities measured and carried at fair value during the year ended December 31, 2021.  Realized gains and losses are included in other expense on a specific-identification basis.&#160;There were&#160;no&#160;realized gains or losses on marketable securities for the year ended December 31, 2021.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for  investments in certain debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2209399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2324412<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2176304<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher SEC<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1403<br> -Paragraph (b)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140649898115160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Note 4 &#8211; Fair Value Measurements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The following table summarizes our cash equivalents and marketable securities measured at fair value on a recurring basis as of December 31, 2021:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:39.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:39.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Level 1</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Level 2</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Level 3</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:39.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:39.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:39.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">       Money market</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 33,961,344</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 33,961,344</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:39.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">       Commercial paper</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,000,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,000,000</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:39.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">        Total cash equivalents</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 33,961,344</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,000,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 35,961,344</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:39.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:39.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Marketable securities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:39.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">      U.S. Treasuries</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 43,115,370</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 43,115,370</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:39.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">      Government securities</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 19,204,368</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 19,204,368</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:39.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">      Commercial paper</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12,988,025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12,988,025</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:39.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">        Total marketable securities</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 43,115,370</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 32,192,393</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 75,307,763</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:39.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total cash equivalents and marketable securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.04%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 77,076,714</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 34,192,393</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.43%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 111,269,107</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">There were no transfers between Level 1 and Level 2 and we had no&#160;financial assets or <span style="-sec-ix-hidden:Hidden_tlcK7EHhSU-TZzE4mXesaw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">liabilities</span></span> that were classified as Level 3 at any point during the year ended December 31, 2021. There were no marketable securities as of December 31, 2020. </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140649898060456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, net<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property and Equipment, net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment, net</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Note&#160;5&#160;&#8211; Property and Equipment, net</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Property and equipment, net consisted of the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Computer equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 281,666</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 174,317</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Furniture and fixtures</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 84,477</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 18,798</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Lab equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 463,182</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">-</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Leasehold improvements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 152,117</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">-</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 981,442</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 193,115</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accumulated depreciation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (174,219)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (128,752)</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Property and equipment, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 807,223</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 64,363</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Depreciation expense totaled $45,467 and $24,328 for the year ended December 31, 2021 and 2020, respectively. </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140649898158040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Combination<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combination</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationDisclosureTextBlock', window );">Business Combination.</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Note&#160;6&#160;&#8211; Business Combination</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;background:#ffffff;">BioArkive Acquisition</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">On December&#160;22, 2021, the Company completed the acquisition of all outstanding shares of capital stock of BioArkive, Inc., a California corporation (&#8220;BioArkive&#8221;), for a market value of </span><span style="background:#ffffff;">$8.75</span><span style="background:#ffffff;"> million.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">BioArkive is a San Diego based contract research organization that has previously provided preclinical research services and biosample storage to the Company and other biotechnology companies. BioArkive is in the process of being fully integrated into the Company to exclusively support the Company's internal preclinical research activities for its oncology pipeline.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">In connection with the acquisition,&#160;the Company has assumed the obligations under BioArkive&#8217;s </span><span style="background:#ffffff;">three</span><span style="background:#ffffff;"> lease agreements.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">The purchase price was paid by Immuneering through the issuance of an aggregate of </span><span style="background:#ffffff;">379,635</span><span style="background:#ffffff;"> shares of Immuneering&#8217;s Class&#160;A common stock. The number of shares of common stock issued was calculated using a value based on the average of the daily volume weighted average prices of the common stock on the Nasdaq Stock Exchange for the </span><span style="background:#ffffff;">30</span><span style="background:#ffffff;">-trading day period ending on and including the trading day immediately prior to the closing date.</span> The sellers of BioArkive are restricted from selling these shares for a 6 month period from the date of the acquisition. As such, we estimated that there was an approximate 10% discount for the lack of marketability of the shares. The fair value of the purchase price in the acquisition has been preliminarily estimated to be $7,875,000.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">Prior to the acquistion, Brett Hall, Chief Scientific Officer of Immuneering and the Founder and Chairman of the board of directors of BioArkive, held the majority of the outstanding shares of BioArkive capital stock.</span> &#160;BioArkive provided contract services to the Company. <span style="background:#ffffff;">Research and development expenses in the consolidated statement of operations include the cost of services provided by BioArkive to the Company which amounted to </span><span style="background:#ffffff;">$4,548,780</span><span style="background:#ffffff;"> in 2021 through date of the acquisition and </span><span style="background:#ffffff;">$2,744,051</span><span style="background:#ffffff;"> in 2020. As of December&#160;31, 2020, </span><span style="background:#ffffff;">$279,153</span><span style="background:#ffffff;"> was owed to BioArkive and is included in accounts payable or accrued contract research expenses in the consolidated balance sheets. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;">Assets Acquired and Liabilities Assumed at Fair Value</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The BioArkive Acquisition has been accounted for using the acquisition method of accounting. This method requires that assets acquired and liabilities assumed in a business combination to be recognized at their fair values as of the acquisition date. As of December&#160;31, 2021, certain amounts relating to working capital have not been finalized. The finalization of these matters could result in changes to goodwill.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;">Intangible Assets</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The estimated fair value of the intangible assets was determined using the relief from royalty approach.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;">Goodwill</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Goodwill is the excess of the consideration transferred over the net assets recognized and represents the expected cost savings of the combined company and assembled workforce. One of the key factors that contributes to the recognition of goodwill, and a driver for the Company's acquisition of BioArkive, is the planned investment in the internal preclinical research activities for our oncology pipeline.&#160;Goodwill recognized as a result of this acquisition is non-deductible for income tax purposes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Pro forma results are not presented for this acquisition as they are not material to the consolidated results of the Company&#8217;s operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:99.4%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:52.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:22.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:52.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';">&#160;&#160;&#160;&#160;</span></p></td><td colspan="2" style="vertical-align:bottom;width:23.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Preliminary Valuation</b></p></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;width:19.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted Average Life</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:52.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash</p></td><td style="vertical-align:bottom;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 70,348</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:52.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other currents assets</p></td><td style="vertical-align:bottom;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 225,790</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:52.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other long term assets</p></td><td style="vertical-align:bottom;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 87,796</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:52.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Property, plant and equipment, net</p></td><td style="vertical-align:bottom;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 727,539</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:52.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Right of use assets</p></td><td style="vertical-align:bottom;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,824,700</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:52.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Intangible asset</p></td><td style="vertical-align:bottom;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:52.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">   Technology</span></p></td><td style="vertical-align:bottom;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 439,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">15 years</p></td></tr><tr><td style="vertical-align:bottom;width:52.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Goodwill</p></td><td style="vertical-align:bottom;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,701,726</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:52.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:52.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total assets acquired</b></p></td><td style="vertical-align:bottom;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 13,076,899</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:52.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:52.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accounts payable, accrued expenses and other liabilities</p></td><td style="vertical-align:bottom;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 69,714</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:52.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Deferred tax liabilities</p></td><td style="vertical-align:bottom;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 307,485</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:52.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Lease liabilities</p></td><td style="vertical-align:bottom;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,824,700</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:52.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Net assets acquired</b></p></td><td style="vertical-align:bottom;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.26%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,875,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -URI http://asc.fasb.org/topic&amp;trid=2303972<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140649898150824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAbstract', window );"><strong>Accrued Expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imrx_AccruedLiabilitiesDisclosureTextBlock', window );">Accrued Expenses</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Note&#160;7&#160;&#8211; Accrued Expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Accrued expenses consisted of the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued professional services</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 250,977</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 269,302</p></td></tr><tr><td style="vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued employee expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,917,282</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 163,668</p></td></tr><tr><td style="vertical-align:bottom;width:73.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued contract research expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 585,416</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 266,022</p></td></tr><tr><td style="vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 211,772</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:73.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,965,447</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 698,992</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imrx_AccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imrx_AccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140649898081304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Preferred Stock<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityDisclosureAbstract', window );"><strong>Convertible Preferred Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imrx_TemporaryEquityDisclosureTextBlock', window );">Convertible Preferred Stock</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Note&#160;8&#160;&#8211; Convertible Preferred Stock</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Series&#160;A Preferred Stock</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In September&#160;2019, the Company authorized the sale and issuance of up to 1,987,979 shares of Series&#160;A Preferred Stock, $0.001 par value per share, at an original issuance price of $8.5514 per share. In January&#160;2020, the number of shares authorized for the Series&#160;A Preferred Stock was increased to 2,495,933 shares. The Series&#160;A Preferred Stock financing was structured to be issued in rolling closes during 2019 and 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On September&#160;20, 2019, the Company issued an additional 1,122,458 shares of Series&#160;A Preferred Stock for gross cash proceeds of $9,598,847 and issued 785,706 shares of Series&#160;A Preferred Stock in conjunction with the conversion of the outstanding amount of the Convertible Notes. In 2019, the Company incurred issuance costs of $200,587 in connection with this offering.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company received funds for issuance of an additional 468,315 shares of Series&#160;A Preferred Stock for gross cash proceeds of $4,004,975 through December&#160;31, 2019. Of these shares, 410,436 shares of Series&#160;A Preferred Stock for gross cash proceeds of $3,509,802 exceeded the authorized amount allowed by the articles of incorporation, resulting in a liability of $3,509,802 and a total of 1,966,043 shares of Series&#160;A Preferred Stock outstanding at December&#160;31, 2019. In January&#160;2020, the shares that were previously classified as a liability as of December&#160;31, 2019 were reclassified to temporary equity upon the approved increase to authorized shares of Series&#160;A Preferred Stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In January&#160;2020, the Company issued 119,454 additional shares of Series&#160;A Preferred Stock for gross cash proceeds of $1,021,413. The Company incurred issuance costs of $23,610 in connection with the financing in January&#160;2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Series&#160;B Preferred Stock</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In December&#160;2020, the Company authorized the sale and issuance of up to 6,032,183 shares of Series&#160;B Preferred Stock, $0.001 par value per share, at an original issuance price of $10.2782 per share. The Series&#160;B Preferred Stock financing was structured to close in two tranches. The first tranche closed in December&#160;2020 and the Company issued 3,619,292 shares of Series&#160;B Preferred Stock for gross cash proceeds of $37,199,929. The Company incurred issuance costs of $216,019 in connection with the financing in December&#160;2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company determined the right of the investors to purchase 2,412,853 shares of Series&#160;B Preferred Stock in the second tranche does not meet the definition of a freestanding financial instrument as it is not separable from the Series&#160;B Preferred Stock issued in the first tranche. The issuance of the second tranche is subject to the Company meeting certain development milestones or at the election of the holders of at least a majority of the then outstanding shares of Series&#160;B Preferred Stock which must include one specific shareholder (the &#8220;Requisite Holders&#8221;). Each holder of Series&#160;B Preferred Stock may elect to purchase their requisite shares of the second tranche at any time. As of March 31, 2021, the Company had not met these development milestones nor did the Requisite Holders elect to purchase the second tranche prior to meeting these milestones and therefore no shares of the second tranche were issued.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In April&#160;and May&#160;2021, all 2,412,853 shares of the second tranche of Series&#160;B Preferred Stock were issued based on the voluntary election of substantially all of the holders of Series&#160;B Preferred Stock. The Company received gross proceeds of $24,799,786. The Company incurred issuance costs of $10,935 in connection with the second tranche of Series&#160;B Preferred Stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The rights and preferences of the Series&#160;A Preferred Stock and Series&#160;B Preferred Stock (&#8220;Preferred Stock&#8221;) were as described below:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;">Conversion</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Each share of Preferred Stock may be converted at any time, at the option of the holder, into shares of Class&#160;A common stock, subject to the applicable conversion rate as determined by dividing the original issue price by the conversion price. The conversion price for the Series&#160;A Preferred Stock and Series&#160;B Preferred Stock (as may be adjusted for certain customary dilutive events) is $6.1081 and $7.3416, respectively. The Preferred Stock automatically convert into shares of Class&#160;A common stock at the then effective conversion rate upon the closing of a public offering of the Company&#8217;s securities with gross proceeds to the Company of at least $75,000,000 and a share price of at least $7.3416 or at the election of the holders of the Requisite Holders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Holders of Series&#160;B Preferred Stock that would beneficially own at least 9.9% of any then outstanding class of equity securities may elect to receive a portion of their converted Series&#160;B Preferred Stock as Class&#160;B common stock upon conversion.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Upon the closing of the IPO on August&#160;3, 2021, all 8,528,078 shares of the Company&#8217;s convertible preferred stock then outstanding automatically converted into 11,939,281 shares of Class A common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;">Dividends</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Preferred Stockholders are entitled to receive per annum dividends of 7% of the original issue price share, payable only when, as and if declared by the Board of Directors. The right to receive these dividends is not cumulative, and therefore, if not declared in any&#160;year, the right to receive such dividends shall terminate and not carry forward into the next&#160;year. As of December&#160;31, 2021 and December&#160;31, 2020, no dividends had been declared.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;">Voting Rights</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Preferred Stock and common stock vote together as one class on an as converted basis. Common stock voting rights on certain matters are subject to the powers, preferences, and rights of the Preferred Stock. Preferred Stockholders are entitled to vote on all matters and shall have the number of votes equal to the number of shares of common stock into which the shares of Preferred Stock held by such holder are then convertible. As long as 2,132,029 shares of Preferred Stock are outstanding, certain actions such as mergers, acquisition, liquidation, dissolution, wind up of business, and deemed liquidation events, must be approved by the holders of at least a majority of the then-outstanding shares of Preferred Stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;">Liquidation Preference</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Upon liquidation, dissolution, or winding up of business, holders of Preferred Stock are entitled to receive a liquidation preference in priority to holders of common stock at the original respective Preferred Stock issue price for such series. If assets available for distribution are insufficient to satisfy the liquidation payment to holders of Preferred Stock in full, assets available for distribution will be allocated among holders of Preferred Stock on a pari passu basis at an amount per share equal to the greater of the respective original Preferred Stock issue price for such series plus any declared but unpaid dividends or such amount had all shares been converted to common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">When holders of Preferred Stock are satisfied in full, any excess assets available for distribution will be allocated ratably among common stock holders based on their pro rata shareholdings. Upon a deemed liquidation event, as defined in the articles of incorporation, holders have the option to redeem their shares at the liquidation payment amounts summarized above.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;">Redemption</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Other than described above, the shares of Preferred Stock are not redeemable.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imrx_TemporaryEquityDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for  temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imrx_TemporaryEquityDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140649898102328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Common Stock.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Common Stock</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Note&#160;9&#160;- Common Stock</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company had 200,000,000 authorized shares of Class&#160;A common stock, $0.001 par value per share as of December 31, 2021 and 22,026,200 authorized shares of Class A common stock, $0.001 par value per share as of December 31, 2020, respectively, of which 26,320,199 and 4,950,129 were <span style="-sec-ix-hidden:Hidden_hTzGFl4AukOhSIQvrJVGbw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">issued</span></span> and <span style="-sec-ix-hidden:Hidden_lP6rYH5NMkSWKz0be_vdHw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">outstanding</span></span>, respectively. The holders of Class&#160;A common stock are entitled one vote for each share of common stock. Dividends may be paid when, and if declared by the Board of Directors, subject to the limitations, powers and preferences granted to the Preferred Stockholders and on a proportionate basis with holders of Class&#160;B common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As of December 31, 2021 and December&#160;31, 2020, the following number of shares of Class&#160;A common stock have been reserved:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:75.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:75.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Conversion of Series A Preferred</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,494,306</p></td></tr><tr><td style="vertical-align:bottom;width:75.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Conversion of Series B Preferred</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,066,995</p></td></tr><tr><td style="vertical-align:bottom;width:75.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exercise of common stock warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 308,308</p></td></tr><tr><td style="vertical-align:bottom;width:75.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exercise of common stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,859,544</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,801,263</p></td></tr><tr><td style="vertical-align:bottom;width:75.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,859,544</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,670,872</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company had 20,000,000 authorized shares of Class&#160;B common stock, $0.001 par value per share as of December 31, 2021 and 6,032,183 authorized shares of Class&#160;B common stock, $0.001 par value per share as of December 31, 2020, of which no shares have been issued nor are outstanding. The holders of Class&#160;B common stock have no voting rights. Dividends may be paid when, and if, declared by the Board of Directors, subject to the limitations, powers and preferences granted to the preferred stockholders and on a proportionate basis with holders of Class&#160;A common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Common Stock Warrants</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">During 2019, the Company issued warrants to purchase an aggregate of 308,308 shares of Class A common stock at an exercise price of $3.01 per share to several advisors, including 200,984 shares to entities related to members of the Board of Directors of the Company, in lieu of cash payments. These warrants vested immediately upon issuance, became exercisable on January&#160;9, 2021 and have a 10-year term set to expire on January&#160;9, 2030. The Company evaluated the terms of these warrants and determined that equity classification was appropriate. As of December&#160;31, 2020, no warrants had been exercised. During June&#160;2021, all warrant holders exercised their warrants to purchase an aggregate of 308,308 shares of common stock. As of December 31, 2021, there were no warrants outstanding.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Initial Public Offering</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On August 3, 2021, the Company completed its initial public offering pursuant to which it issued and sold 8,625,000 shares of its Class A common stock, inclusive of 1,125,000 shares of its Class A common stock sold pursuant to the full exercise of the underwriters&#8217; option to purchase additional shares. The aggregate net proceeds received by the Company from the IPO were $120,318,750, after deducting underwriting discounts and commissions, but before deducting offering costs payable by the Company, which were $2,124,317. Upon the closing of the IPO, all 8,528,078 shares of the Company&#8217;s convertible preferred stock then outstanding automatically converted into 11,939,281 shares of Class A common stock. Upon the conversion of the convertible preferred stock, the Company reclassified the carrying value of the convertible preferred stock to common stock (at par value) and additional&#160;paid-in&#160;capital. &#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On August 3, 2021 in connection with the closing of the IPO, the Company filed a restated certificate of incorporation, which amended and restated the Company&#8217;s certificate of incorporation to, among other things: (i)&#160;increase the number of </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">authorized shares of common stock to 200,000,000 shares of Class&#160;A common stock, 20,000,000 shares of Class&#160;B common stock, par value $0.001 per share, and (ii) authorize 10,000,000 shares of Preferred Stock; and (iii)&#160;authorize the Board of Directors to establish the rights, preferences and restrictions on any unissued series of Preferred Stock.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140649898135176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share Attributable to Common Stockholders<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net Loss Per Share Attributable to Common Stockholders</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss Per Share Attributable to Common Stockholders</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Note&#160;10&#160;- Net Loss Per Share Attributable to Common Stockholders</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Basic and diluted net loss per share attributable to common stockholders was calculated at December&#160;31, 2021 and 2020 as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:70.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:70.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Numerator:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:70.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (33,535,748)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (17,039,898)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Denominator - basic and diluted:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted-average common shares outstanding, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 13,612,677</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,950,129</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net loss per share - basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_wHopsXwjskSWOmAaEI9k1w;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2.46)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_--dUy7H6lkGzBYeWkeucsA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3.44)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The following table sets forth the potentially dilutive securities that have been excluded from the calculation of diluted net loss per share because to include them would be anti-dilutive (in common stock equivalent shares) at December&#160;31, 2021 and 2020:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:75.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:75.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Series A Preferred</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,494,306</p></td></tr><tr><td style="vertical-align:bottom;width:75.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Series B Preferred</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,066,995</p></td></tr><tr><td style="vertical-align:bottom;width:75.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Warrants to purchase common stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 308,308</p></td></tr><tr><td style="vertical-align:bottom;width:75.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Options to purchase common stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,859,544</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,801,263</p></td></tr><tr><td style="vertical-align:bottom;width:75.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total shares of common stock equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,859,544</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 10,670,872</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140649898017288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Stock-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Note&#160;11&#160;&#8211; Stock-Based Compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">During 2015, the Company established the Long Term Incentive Plan (&#8220;Incentive Plan&#8221;), under which incentive stock options, nonqualified stock options, restricted stock or other awards may be awarded to employees, directors or consultants of the Company. The options typically vest over a four-year period. As of December&#160;31, 2021, the maximum number of shares available for issuance under the Incentive Plan was 2,825,173 shares. Upon the effectiveness of the Company&#8217;s 2021 Incentive Award Plan, the Company ceased granting awards under the Incentive Plan. However, the Incentive Plan continues to goven awards outstanding thereunder.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On July 23, 2021, the Company&#8217;s Board of Directors adopted, and on July 23, 2021 its stockholders approved, the 2021 Incentive Award Plan (the &#8220;2021 Plan&#8221;), which became effective on July 29, 2021. The 2021 Plan provides for the grant of incentive stock options, stock appreciation rights, restricted stock awards, restricted stock units, and other stock-based awards. The number of shares reserved for issuance under the 2021 Plan was initially equal to 2,590,000 plus an annual increase on the first day of each calendar year, beginning on January 1, 2022 and ending on and including January 1, 2031, equal to the lesser of (i) 4% of the aggregate number of shares of Class A common stock outstanding on the final day of the immediately preceding calendar year and (ii) such smaller number of shares of Class A common stock as determined by the Board of Directors. No more than 15,350,000 shares of Class A common stock may be issued under the 2021 Plan upon the exercise of incentive stock options. Shares issued under the 2021 Plan may be authorized but unissued shares, shares purchased on the open market or treasury shares. If an award under the 2021 Plan expires, lapses or is terminated, exchanged for or settled in cash, surrendered, repurchased, cancelled without having been fully exercised/settled or forfeited, any unused shares subject to the award will, as applicable, become or again be available for new grants under the 2021 Plan. In addition, shares subject to stock options issued under the Incentive Plan may become available for issuance under the 2021 Plan to the extent such stock options are canceled, forfeited, exchanged, settled in cash or </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">otherwise terminated. As of December 31, 2021, there were 2,298,432 shares available for future issuance under the 2021 Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On July 23, 2021, the Company&#8217;s Board of Directors adopted, and on July 23, 2021 its stockholders approved, the 2021 Employee Stock Purchase Plan (the &#8220;2021 ESPP&#8221;), which became effective on July 29, 2021. A total of 250,000 shares of Class A common stock were initially reserved for issuance under this plan. The number of shares of Class A common stock that may be issued under the 2021 ESPP will automatically increase on the first day of each calendar year, beginning on January 1, 2022 and ending on and including January 1, 2031, equal to the lesser of (i) 1% of the shares of Class A common stock outstanding on the final day of the immediately preceding calendar year and (ii) such smaller number of shares of Class A common stock as determined by the board of directors, provided that not more than 3,340,000 shares of Class A common stock may be issued under the 2021 ESPP. As of December 31, 2021, no shares had been issued under the 2021 ESPP.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">During the year ended December 31, 2021 and 2020, the Company recognized stock-based compensation expense of $1,802,623 and $1,086,769, respectively. As of December&#160;31, 2021, compensation expense remaining to be recognized for outstanding stock options was $8,403,600 and to be recognized over a weighted-average period of 2.93 years.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The fair value of options granted is calculated on the grant date using the Black-Scholes option valuation model. <span style="background:#ffffff;">The Company historically has been a private company and lacks company-specific historical and implied volatility information. Therefore, it estimates its expected stock volatility based on the historical volatility of a publicly traded set of peer public companies and expects to continue to do so until such time as it has adequate historical data regarding the volatility of its own traded stock price.</span> For the year ended December 31, 2021, the Company granted 1,452,462 shares of stock options at a weighted-average grant date fair value of $6.29. For the year ended December 31, 2020, the Company granted 343,169 shares at a weighted-average grant date fair value of $3.06.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company used the following assumptions in its application of the Black-Scholes option pricing model for grants during the year ended December 31, 2021 and 2020:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:67.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:67.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:30.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted-average risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">0.89% - 1.71%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">0.36% - 1.45%</p></td></tr><tr><td style="vertical-align:bottom;width:67.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected term (in years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">5.83 - 10 years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">5.92 - 10 years</p></td></tr><tr><td style="vertical-align:bottom;width:67.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">0%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">0%</p></td></tr><tr><td style="vertical-align:bottom;width:67.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">66.76% - 80.99%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">67.30% - 80.85%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The following table summarizes the stock option activity during the year ended December 31, 2021 under the Plan:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:51.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:51.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted-</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Remaining</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exercise Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Contractual</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Aggregate</b></p></td></tr><tr><td style="vertical-align:bottom;width:51.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;">    </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Options</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;">    </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">per Share</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Term (in Years)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;">    </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;"> Intrinsic Value</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:51.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding at of December&#160;31,&#160;2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,801,263</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3.01</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:51.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,452,462</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10.07</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:51.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (117,847)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3.01</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:51.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cancelled</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (276,334)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3.58</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:51.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding at December&#160;31,&#160;2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,859,544</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6.55</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8.30</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 27,615,466</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Vested and exercisable at December&#160;31,&#160;2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,102,543</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3.01</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7.14</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 14,507,723</p></td></tr><tr><td style="vertical-align:bottom;width:51.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Vested and expected to vest at December&#160;31,&#160;2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,859,544</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6.55</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8.30</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 27,615,466</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">For the year &#160;ended December 31, 2021 and 2020, the Company recognized share-based compensation expense recognized on the accompanying &#160;consolidated statements of operations as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cost of revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 103,329</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 108,027</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 768,679</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 503,111</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 930,615</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 475,631</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,802,623</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,086,769</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140649902484072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Note&#160;12&#160;&#8211; Income Taxes</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">A reconciliation of the effect of applying the federal statutory rate to the net loss and the effective income tax rate are as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:74.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Statutory federal income tax rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 21.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 21.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:74.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">State tax, net of federal benefit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:74.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Permanent differences</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.6)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1.5)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:74.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Federal research and development credits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5.6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:74.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">State research and development credits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:74.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Uncertain tax positions</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.6)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1.0)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:74.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other differences</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2.6)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:74.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Change in valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (31.1)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (27.3)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:74.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Effective income tax rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:12pt 0pt 12pt 0pt;">As of December 31, 2021 and 2020, the components and tax effects of each type of item that gave rise to the net deferred tax assets were as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Deferred tax assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:73.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Stock-based compensation expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 373,602</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 73,984</p></td></tr><tr><td style="vertical-align:bottom;width:73.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Unrealized losses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12,990</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:73.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">R&amp;D credit carryforward</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,346,097</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,574,596</p></td></tr><tr><td style="vertical-align:bottom;width:73.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">NOL carryforward</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 14,699,524</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,525,123</p></td></tr><tr><td style="vertical-align:bottom;width:73.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Gross deferred tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 18,432,213</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,173,703</p></td></tr><tr><td style="vertical-align:bottom;width:73.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (17,677,899)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (7,127,448)</p></td></tr><tr><td style="vertical-align:bottom;width:73.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net deferred tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 754,314</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 46,255</p></td></tr><tr><td style="vertical-align:bottom;width:73.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net deferred tax liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:73.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Prepaid expenses deducted for tax</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (425,755)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (28,671)</p></td></tr><tr><td style="vertical-align:bottom;width:73.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Tax depreciation in excess of book</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (328,559)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (17,584)</p></td></tr><tr><td style="vertical-align:bottom;width:73.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total deferred tax liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (754,314)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (46,255)</p></td></tr><tr><td style="vertical-align:bottom;width:73.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net deferred taxes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Federal net operating losses (&#8220;NOL&#8221;) generated in tax years ended after December 31, 2017 are limited to 80% of taxable income, only carried forward and carried forward indefinitely under the Internal Revenue Code (&#8220;IRC&#8221;). The Company recorded a deferred tax liability of $304,485 on the acquisition of BioArkive. It had pre-existing deferred tax assets for which there was a fuill valuation allowance. As a result of the taxable temporary differences recognized in the business combination, the Company released $304,485<span style="white-space:pre-wrap;"> of its valuation allowance and recognized the income tax benefit in the income statement at the acquisition date in accordance with ASC 740  There was no income tax expense or benefit in 2020. The Company has provided a valuation allowance for the full amount of the net deferred tax assets as, based on all available evidence, it is considered more likely than not that all the recorded deferred tax assets will not be realized in a future period. At December 31, 2021, the Company has federal and state NOLs of </span>$56,544,731 and $51,310,112, </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">respectively all generated after the tax year ended December 31, 2017. At December 31, 2021, the Company has federal and state research and development credit carryforwards, $3,034,827 and $394,013, respectively, that start to expire beginning in 2025.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'TimesNewRomanPSMT';visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:9.95pt;background:#ffffff;margin:0pt 8.55pt 0pt 0pt;">As the Company has not yet achieved profitable operations, management believes the tax benefits as of December 31, 2021 did not satisfy the realization criteria set forth in ASC Topic 740, Income Taxes and, therefore, has recorded a full valuation allowance for the entire deferred tax asset. The valuation allowance increased in 2021 by $10,550,451 due to the increase in the deferred tax assets by the same amount, primarily due to NOL and research and development credit carryforwards. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:9.95pt;background:#ffffff;margin:0pt 8.55pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:9.95pt;text-align:justify;background:#ffffff;margin:0pt 8.55pt 0pt 0pt;">Utilization of the U.S. net operating loss carryforwards and research and development tax credit carryforwards may be subject to a substantial annual limitation under Section 382 of the Internal Revenue Code of 1986, and corresponding provisions of state law, due to ownership changes that have occurred previously or that could occur in the future. These ownership changes may limit the amount of carryforwards that can be utilized annually to offset future taxable income. In general, an ownership change, as defined by Section 382, results from transactions increasing the ownership of certain stockholders or public groups in the stock of a corporation by more than 50% over a three-year period. The Company has not conducted a study to assess whether a change of control has occurred or whether there have been multiple changes of control since inception due to the significant complexity and cost associated with such a study. If the Company has experienced a change of control, as defined by Section 382, at any time since inception, utilization of the net operating loss carryforwards or research and development tax credit carryforwards would be subject to an annual limitation under Section 382, which is determined by first multiplying the value of the Company&#8217;s stock at the time of the ownership change by the applicable long-term tax-exempt rate, and then could be subject to additional adjustments, as required. Any limitation may result in expiration of a portion of the net operating loss carryforwards or research and development tax credit carryforwards before utilization. Further, until a study is completed by the Company and any limitation is known, some amounts are being presented as an uncertain tax position.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:9.95pt;text-align:justify;background:#ffffff;margin:0pt 8.55pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">As of December 31, 2021 and 2020, the Company had uncertain tax positions of $380,902 and $174,950 which have been classified as reductions of its tax carrforwards. The Company has elected to recognize interest and penalties related to income tax matters as a component of income tax expense, of which no interest or penalties were recorded for the years ended December 31, 2021 and 2020. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">As of December 31, 2021 and 2020, unrecognized tax benefits were as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:9.95pt;text-align:justify;background:#ffffff;margin:0pt 8.55pt 0pt 0pt;"><span style="font-family:'TimesNewRomanPSMT';font-weight:bold;margin-right:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:70.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:70.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:70.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Beginning balance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 174,950</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 96,952</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:70.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Increase due to current year tax position</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 205,952</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 77,998</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:70.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Ending balance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 380,902</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 174,950</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:9.95pt;text-align:justify;background:#ffffff;margin:0pt 8.55pt 0pt 0pt;"><span style="font-family:'TimesNewRomanPSMT';font-weight:bold;margin-right:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The Company files tax returns in the United States including California, New York, Pennsylvania, Massachusetts and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Texas. All tax years from 2017 to 2021 remain open to examination by the major taxing jurisdictions to which the Company is subject, as carryforward attributes generated in years past may still be adjusted upon examination by the Internal Revenue Service (&#8220;IRS&#8221;) or other authorities if they have or will be used in a future period. The Company is not currently under examination by the IRS or any other jurisdictions for any tax years.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'TimesNewRomanPSMT';visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On March 27, 2020, the Coronavirus Aid, Relief, and Economic Security Act (the &#8220;CARES Act&#8221;) was enacted in response to the COVID-19 pandemic. The CARES Act, among other things, permits NOL carryovers and carrybacks to offset 100% of taxable income for taxable years beginning before 2021. In addition, the CARES Act allows NOLs incurred in 2019, 2020, and 2021 to be carried back to each of the five preceding taxable years to generate a refund of previously paid income taxes. The enactment of the CARES Act resulted in increased federal and state research and development carryforwards from 2013 through 2018 of $93,437 and decreased federal NOL of $759,794 from 2018.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140649902449208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Note&#160;13&#160;&#8211; Commitments and Contingencies</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;">Operating Leases</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company leases office space in Cambridge, Massachusetts, New York, New York and as of July&#160;2021, San Francisco, California, pursuant to short-term arrangements. The Cambridge and San Francisco leases are on a&#160;month-to-month basis, requiring one&#160;month&#8217;s notice before termination. The New York lease is renewable on a quarterly basis and the last renewal extended the lease term until March&#160;31, 2022. These lease agreements include payments for lease and non-lease components and the Company has elected to not separate such components and these payments were recognized as rent expense.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As of December 31, 2021, total future minimum lease payments for its short-term leases in Cambridge, Massachusetts, New York, New York and San Francisco, California was $30,840 due in 2022. The Company leases storage space for its electronic data equipment in Somerville, Massachusetts. This lease is renewable on an annual basis effective every March&#160;1st. Prior to December 31, 2021, the Company renewed the lease through March&#160;31, 2022. As of December 31, 2021, total future minimum lease payments for this lease were $3,569 due in 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In October&#160;2020, the Company entered into an office lease in San Diego, California with a lease term of 67 months. At the lease commencement date, a right-to-use asset and <span style="-sec-ix-hidden:Hidden_XdPatEybTkShRMLsu6QibA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">lease liability</span></span> was recognized by the Company for $637,863.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As part of the BioArkive acquisition, the Company assumed the obligations of three leases in San Diego, California, one is for 38,613 square feet of office and laboratory space, under a lease that terminates on April 30, 2032, a second is a 6,100 square feet of office and laboratory space under a lease that terminates on December 31, 2022, and third is a lease for 4,760 square feet of office and laboratory space under a lease that terminates on March 31, 2024. &#160;As a result, we recorded right-to-use assets and <span style="-sec-ix-hidden:Hidden_CeuFDcEWwUiE1feAvMT7Lw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">lease liabilities</span></span> of $4,824,700 on the acquisition date of December 22, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-size:9.5pt;">Future minimum lease payments for operating leases with initial or remaining terms in excess of one year at December&#160;31, 2021 were as follows</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amount</b></p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 659,990</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 880,121</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 894,044</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 906,839</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 819,210</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Thereafter</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,467,246</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total future lease payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,627,450</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Less: Imputed interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,262,514</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,364,936</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Current portion lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 274,039</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Lease liabilities, noncurrent</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,090,897</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,364,936</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Quantitative information regarding the Company&#8217;s leases for the year ended December 31, 2021 and 2020 is as follows: </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Lease costs:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Operating lease cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 160,872</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 66,652</p></td></tr><tr><td style="vertical-align:bottom;width:73.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Short-term lease cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 258,357</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 252,796</p></td></tr><tr><td style="vertical-align:bottom;width:73.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Variable lease cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 14,700</p></td></tr><tr><td style="vertical-align:bottom;width:73.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total lease costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 419,229</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 334,148</p></td></tr><tr><td style="vertical-align:bottom;width:73.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash paid for amounts included in the measurement of lease liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:73.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Operating cash flows from operating leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 111,527</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 58,666</p></td></tr><tr><td style="vertical-align:bottom;width:73.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Operating cash flows from short-term leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 236,700</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 252,796</p></td></tr><tr><td style="vertical-align:bottom;width:73.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 348,227</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 311,462</p></td></tr><tr><td style="vertical-align:bottom;width:73.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted-average remaining lease term - operating leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">9.62 years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">5.33 years</p></td></tr><tr><td style="vertical-align:bottom;width:73.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted-average discount rate - operating leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">9.7%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">6.0%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As the Company&#8217;s leases typically do not provide an implicit rate, the Company uses an estimate of its incremental borrowing rate based on the information available at the lease commencement date in determining the present value of lease payments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;">Litigation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">From time to time, the Company may have certain contingent liabilities that arise in the ordinary course of its business activities and may be exposed to litigation in connection with its products and operations. The Company&#8217;s policy is to assess the likelihood of any adverse judgments or outcomes related to legal matters, as well as ranges of probable losses. When it is probable that future expenditures will be made and can be reasonably estimated the Company will accrue a liability for such matters. Significant judgement is required to determine both probability and estimated amount. The Company is not aware of any material legal matters.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;">Clinical Research Contracts</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company may enter into contracts in the normal course of business with clinical research organizations for clinical trials, with contract manufacturing organizations for clinical supplies, and with other vendors for preclinical studies, supplies and other services for our operating purposes. These contracts generally provide for termination with a 30-day notice.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140649895884536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Basis of Presentation</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The consolidated financial statements have been prepared in accordance with accounting standards set by the Financial Accounting Standards Board (&#8220;FASB&#8221;). The FASB sets generally accepted accounting principles (&#8220;GAAP&#8221;) to ensure the consolidated financial statements are consistently reported. References to GAAP issued by the FASB in these footnotes are to the FASB Accounting Standards Codifications (&#8220;ASC&#8221;). The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityPolicyTextBlock', window );">Stock Split</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Stock Split</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;">On July 23, 2021, the Company approved a </span><span style="font-weight:normal;">one</span><span style="font-weight:normal;white-space:pre-wrap;">-for-1.4 stock split which was consummated in connection with the Company&#8217;s IPO.  All information in the accompanying financial statements and notes thereto regarding share amounts of common stock, price per share of common stock and the conversion factor for Series A and Series B Preferred Stock into common stock have been adjusted to reflect the application of the stock split on a retroactive basis.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Use of Estimates&#160;</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses during the reporting periods. These estimates and assumptions are based on current facts, historical experience and various other factors believe to be reasonable under the circumstances, the results of which form the basis for making judgements about the carrying values of assets, liabilities and the recording of expenses that are not readily apparent from other sources. Significant estimates reflected in these &#160;consolidated financial statements included but are not limited to, the research and development expenses, determination of fair value of stock-based awards, the valuation of common stock prior to the IPO, business combination, and the right-to-use assets and operating lease liability. Actual results may differ materially and adversely from these estimates.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segments</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Segments</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker (&#8220;CODM&#8221;) in making decisions regarding resource allocation and assessing performance. The Company&#8217;s chief executive officer is the CODM, and he uses consolidated financial information in determining how to allocate resources and assess performance. The Company has determined that it operates in one segment.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsPolicy', window );">Business Combination</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;background:#ffffff;">Business Combination</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:13.5pt;font-weight:bold;visibility:hidden;background:#ffffff;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="background:#ffffff;">Results of operations of acquired companies are included in the Company&#8217;s results of operations as of the respective acquisition dates. Acquired businesses are accounted for using the acquisition method of accounting, which requires that assets acquired and liabilities assumed be recorded at fair value, with limited exceptions. Any excess of the purchase price over the fair value of the net assets acquired is recorded as goodwill. Transaction costs and costs to restructure the acquired Company are expensed as incurred. The operating results of the acquired business are reflected in the consolidated financial statements after the date of acquisition. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:13.5pt;visibility:hidden;background:#ffffff;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">If the acquired net assets do not constitute a business under the acquisition method of accounting, the transaction is accounted for as an asset acquisition and no goodwill is recognized.&#160;Refer to Note 6, Business Combination for more information.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Cash and Cash </b><b style="font-weight:bold;">Equivalents</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">Cash and cash equivalents are comprised of deposits at major financial banking institutions and highly liquid investments with an original maturity of three&#160;months or less at the date of purchase. Cash is maintained at Federal Deposit Insurance Company (&#8220;FDIC&#8221;) insured financial institutions. At times, the Company has maintained cash in excess of FDIC limits, however it has not experienced any losses with respect to its cash balances. The Company regularly monitors the financial condition of the institutions in which it has depository accounts and believes the risk of loss is minimal.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesPolicy', window );">Marketable Securities</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Marketable Securities </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our marketable securities are classified as available-for-sale pursuant to ASC 320,<span style="background:#ffffff;"> Investments &#8211; Debt and Equity Securities</span> and are recorded at fair value. Unrealized gains/(losses) are included as a component of accumulated other comprehensive loss in the &#160;consolidated balance sheets and statements of convertible preferred stock and stockholders&#8217; equity (deficit) and a component of total comprehensive loss in the consolidated statements of comprehensive loss, until realized. The Company assesses its available-for-sale marketable securities for impairment on a quarterly basis. There were no impairments of the Company&#8217;s available-for-sale marketable securities measured and carried at fair value during the year ended December 31, 2021. &#160;Realized gains and losses are included in other expense on a specific-identification basis.&#160;There were&#160;no&#160;realized gains or losses on marketable securities for the year ended December 31, 2021.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Fair Value Measurements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We record cash equivalents and marketable securities at fair value. ASC 820,&#160;Fair Value Measurements and Disclosures, establishes a fair value hierarchy for those instruments measured at fair value that distinguishes between assumptions based on market data (observable inputs) and our own assumptions (unobservable inputs). The hierarchy consists of three levels:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Level 1</i>&#160;&#8211; Unadjusted quoted prices in active markets for identical assets or liabilities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Level 2</i>&#160;&#8211; Quoted prices for similar assets and liabilities in active markets, quoted prices in markets that are not active, or inputs which are observable, directly or indirectly, for substantially the full term of the asset or liability.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Level 3</i>&#160;&#8211; Unobservable inputs that reflect our own assumptions about the assumptions market participants would use in pricing the asset or liability in which there is little, if any, market activity for the asset or liability at the measurement date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Our financial assets, which include cash equivalents and marketable securities, have been initially valued at the transaction price, and subsequently revalued at the end of each reporting period, utilizing third-party pricing services or other observable market data. The pricing services utilize industry standard valuation models, including both income and market based approaches, and observable market inputs to determine value. After completing our validation procedures, we did not adjust or override any fair value measurements provided by the pricing services as of December&#160;31, 2021. Fair value </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">information for these assets, including their classification in the fair value hierarchy is included in Note 4 &#160;Fair Value Measurements<b style="font-weight:bold;">.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:13.5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">There have been no changes to the valuation methods during the year ended December&#160;31, 2021. We evaluate transfers between levels at the end of each reporting period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:13.5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The carrying amounts reflected in the consolidated balance sheets for cash, accounts receivable, accounts payable and accrued expenses approximate their respective fair values because of the short-term maturity of those financial instruments.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TradeAndOtherAccountsReceivableUnbilledReceivablesPolicy', window );">Accounts Receivable</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Accounts Receivable</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">Accounts receivable are stated at the amount management expects to collect from outstanding balances. An allowance for doubtful accounts is estimated for those accounts receivable considered to be uncollectible based upon historical experience and management&#8217;s evaluation of outstanding accounts receivable. Bad debts are written off against the allowance when identified. At December&#160;31, 2021 and 2020 there was no allowance for doubtful accounts.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Concentration of Credit Risk</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">Financial instruments that potentially subject the Company to significant concentration of credit risk consist primarily of accounts receivable and revenue. To manage accounts receivable credit risk, the Company continuously evaluates the creditworthiness of its customers and the need for an allowance for potential credit losses. The Company has not experienced any losses in such accounts.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">The following customers comprised 10% or more of the Company&#8217;s total accounts receivable or revenues as of or for the period ended December&#160;31, 2021 (customers with an asterisk are less than 10%): </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:47.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:47.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:22.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="color:#231f20;font-weight:bold;">Year Ended December&#160;31,&#160;2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:23.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="color:#231f20;font-weight:bold;">As&#160;of&#160;December&#160;31,&#160;2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:47.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Revenue</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">%&#160;of&#160;Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Accounts&#160;Receivable</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">%&#160;of&#160;Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:47.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Customer #1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 745,030</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 35.8</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 235,500</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">95.7%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:47.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Customer #2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 380,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 18.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:47.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Customer #5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 353,050</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 17.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:47.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:47.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:22.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="color:#231f20;font-weight:bold;">Year Ended December&#160;31,&#160;2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:23.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="color:#231f20;font-weight:bold;">As&#160;of&#160;December&#160;31,&#160;2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:47.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Revenue</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">%&#160;of&#160;Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Accounts&#160;Receivable</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">%&#160;of&#160;Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:47.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Customer #1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 676,710</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 29.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 214,345</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 42.9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:47.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Customer #2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 570,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 24.7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 71,250</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 14.2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:47.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Customer #3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 306,900</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 13.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:47.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Customer #4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 250,880</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 10.9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 63,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12.6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:47.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Customer #5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 91,975</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 18.4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Property and Equipment</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">Property and equipment are recorded at cost, net of accumulated depreciation. Expenditures for major replacements and improvements are capitalized, while expenditures for general repairs and maintenance are expensed as incurred. Upon retirements or disposition of property and equipment, the related cost and accumulated depreciation are removed from the consolidated balance sheet and any resulting gain or loss is recorded in the consolidated statement of operations. Depreciation is calculated using the straight-line method once assets are placed in service. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:86.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:86.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Estimated</b></p></td></tr><tr><td style="vertical-align:bottom;width:86.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Asset Class</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Useful&#160;Lives</b></p></td></tr><tr><td style="vertical-align:bottom;width:86.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Computer equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">3 years</p></td></tr><tr><td style="vertical-align:bottom;width:86.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Furniture and fixtures</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">5 years</p></td></tr><tr><td style="vertical-align:bottom;width:86.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Lab equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">7 years</p></td></tr><tr><td style="vertical-align:bottom;width:86.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Leasehold improvements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1-10 years</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-lived Assets</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Impairment of Long-lived Assets</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">Periodically, the Company evaluates its long-lived assets, which consist primarily of property and equipment, for impairment whenever events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted net cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the asset exceeds the fair value of the asset. To date, no impairments have occurred.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Leases</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">In February&#160;2016 the FASB issued Accounting Standards Update (&#8220;ASU&#8221;) No. 2016-02, Leases (Topic 842) (&#8220;ASC 842&#8221;), a standard issued to increase transparency and comparability among organizations related to their leasing activities. This standard established a right-of-use model that requires the recognition of right-of-use assets and lease liabilities for most leases as well as provides disclosure with respect to certain qualitative and quantitative information related to a company&#8217;s leasing arrangements to meet the objective of allowing users of financial statements to assess the amount, timing and uncertainty of cash flows arising from leases.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">The Company adopted the leasing standard using the modified retrospective transition approach as of January&#160;1, 2020, with no restatement of prior periods or cumulative adjustment to retained earnings. Upon adoption, the Company elected the package of transition practical expedients, which allowed the Company to carry forward prior conclusions related to whether any expired or existing contracts are or contain leases, the lease classification for any expired or existing leases, and initial direct costs for existing leases. The Company also made an accounting policy election to not recognize leases with an initial term of 12&#160;months or less within its consolidated balance sheets, and to recognize those lease payments on a straight-line basis in its consolidated statements of operations over the lease term. The adoption of the leasing standard did not have an impact on the consolidated statement of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">The Company determines if an arrangement is a lease at contract inception. Right-of-use assets represent the Company&#8217;s right to use an underlying asset for the lease term and lease liabilities represent its obligation to make lease payments arising from the lease. Right-of-use assets and lease liabilities are recognized at the commencement date of the lease based upon the present value of future lease payments over the expected lease term. When determining the lease term, the Company includes options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. As most of the Company&#8217;s leases do not provide an implicit interest rate, the Company uses its incremental borrowing rate, which is based on rates that would be incurred to borrow on a collateralized basis over a term equal to the lease payments in a similar economic environment, in determining the present value of lease payments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">The Company has elected not to separate lease and non-lease components as a single lease component. The Company&#8217;s lease are reflected in right-of-use assets and lease liabilities (current and non-current) in the consolidated balance sheets.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Revenue Recognition</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="font-weight:bold;letter-spacing:-0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">In accordance with ASC 606, revenue is recognized when a customer obtains control of promised goods and services. The core principle of the standard is to recognize revenue to depict the transfer of promised goods or services to customers in </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods or services. To achieve that core principle, the Company applies the following five-step model:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt 0pt 0pt 18pt;">&#8226; Identify the contract with a customer</p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt 0pt 0pt 18pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt 0pt 0pt 18pt;">&#8226; Identify the performance obligations in the contract</p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt 0pt 0pt 18pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt 0pt 0pt 18pt;">&#8226; Determine the transaction price</p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt 0pt 0pt 18pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt 0pt 0pt 18pt;">&#8226; Allocate the transaction price to the performance obligations in the contract</p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt 0pt 0pt 18pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt 0pt 0pt 18pt;">&#8226; Recognize revenue when or as performance obligations are satisfied</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">The Company&#8217;s contracts generally consist of the promise to provide computational biology professional services to pharmaceutical and biotechnology companies, which the Company has concluded constitutes one performance obligation that is delivered over time. The transaction price is the amount of consideration to which the Company expects to be entitled in exchange for transferring the services to the customer. The Company&#8217;s contracts provide for either agreed upon rates per hour based on the level of the professional working on the project or a fixed fee for a defined scope of work. The Company recognizes revenue over time by measuring the progress toward complete satisfaction of the performance obligation using a single method of measuring progress, which depicts the performance in transferring control of the associated services to the customer. The Company uses input methods to measure the progress toward the complete satisfaction of performance obligations and evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenue and net loss in the period of adjustment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">The Company&#8217;s contract terms do not allow for a right of return or refund and do not contain significant financing components. Receivables associated with the contract will generally be collected within thirty to sixty days, in accordance with the underlying payment terms.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Income Taxes</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;">The Company provides for income taxes in accordance with ASC Topic 740, Income Taxes. Deferred tax assets and liabilities are determined based on the difference between the financial reporting and tax bases of assets and liabilities using enacted tax rates and laws in effect in the&#160;years in which the differences are expected to reverse. A valuation allowance is provided if, based upon the weighted available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;">The Company accounts for uncertainty in income taxes recognized in the consolidated financial statements by applying a two-step process to determine the amount of tax benefit to be recognized. First, the tax position must be evaluated to determine the likelihood that it will be sustained upon external examination by the taxing authorities. If the tax position is deemed more likely than not to be sustained, the tax position is then assessed to determine the amount of benefit to recognize in the consolidated financial statements. The amount of the benefit that may be recognized is the largest amount that has a greater than 50% likelihood of being realized upon ultimate settlement. The provision for income taxes includes the effects of any resulting tax reserves (i.e., unrecognized tax benefits) that are considered appropriate as well as the related net interest. <span style="color:#222222;background:#ffffff;">As of December 31, 2021 and 2020, the Company had uncertain tax positions of </span><span style="color:#222222;background:#ffffff;">$380,902</span><span style="color:#222222;background:#ffffff;"> and </span><span style="color:#222222;background:#ffffff;">$174,950</span><span style="color:#222222;background:#ffffff;">.&#160;&#160; The Company has classified the unrecognized tax benefits as reductions of its tax credit carryforwards.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InProcessResearchAndDevelopmentPolicy', window );">Research and Development</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Research and Development</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;">Research and development costs are expensed as incurred. Research and development costs consist of expenses incurred in performing research and development activities, including salaries and benefits, materials and supplies, preclinical expenses, stock-based compensation expense, depreciation of equipment, contract services, and other outside expenses. The Company also incurs costs to develop software programs for internal use in identifying potential human drug targets which may then lead to the development of human drug candidates. To date the software programs have primarily been used for internal research and development activities and the costs incurred have been expensed as research and development.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imrx_ResearchAndManufacturingContractCostsAndAccrualsPolicyTextBlock', window );">Research and Manufacturing Contract Costs and Accruals</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Research and Manufacturing Contract Costs and Accruals</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company has entered into various research, development and manufacturing contracts with research institutions and other companies in the United States. These agreements are generally cancelable, and related costs are recorded as research and development expenses as incurred. The Company records accruals for estimated ongoing research, development and manufacturing costs. When billing terms under these contracts do not coincide with the timing of when the work is performed, the Company is required to make estimates of outstanding obligations to those third parties as of period end. Any accrual estimates are based on a number of factors, including the Company&#8217;s knowledge of the progress towards completion of the research, development and manufacturing activities, invoicing to date under the contracts, communication from the research institutions and other companies of any actual costs incurred during the period that have not yet been invoiced and the costs included in the contracts. Significant judgments and estimates may be made in determining the accrued balances at the end of any reporting period. Actual results could differ from the estimates made by the Company. The historical accrual estimates made by the Company have not been materially different from the actual costs.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imrx_PatentCostsPolicyPolicyTextBlock', window );">Patent Costs</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="color:#231f20;font-weight:bold;">Patent </b><b style="font-weight:bold;">Costs</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">All patent-related costs incurred in connection with filing and prosecuting patent applications are expensed as incurred due to the uncertainty about the recovery of the expenditure. Amounts incurred are classified as general and administrative expenses.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Loss</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="color:#231f20;font-weight:bold;">Com</b><b style="font-weight:bold;background:#ffffff;">prehensive Loss</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Comprehensive loss includes net loss as well as other changes in stockholders&#8217; equity (deficit) that result from transactions and economic events other than those with stockholders. </p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredChargesPolicyTextBlock', window );">Deferred Offering Costs</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;background:#ffffff;">Deferred Offering Costs</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">The Company capitalizes certain legal, professional accounting and other third-party fees that are directly associated with&#160;in-process&#160;equity financings as deferred offering costs until such financings are consummated. After consummation of an equity financing, these costs are recorded as a reduction of the proceeds from the offering, either as a reduction of the carrying value of the preferred stock or in stockholder&#8217;s equity (deficit) as a reduction of additional&#160;paid-in&#160;capital generated as a result of the offering. Should the&#160;in-process&#160;equity financing be abandoned, the deferred offering costs would be expensed immediately as a charge to operating expenses in the statements of operations and comprehensive loss. There were&#160;</span><span style="background:#ffffff;">no</span><span style="background:#ffffff;">&#160;deferred offering costs as of December&#160;31,2021 or December 31, 2020.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Income (Loss) per Share</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="color:#231f20;font-weight:bold;">Net Income (Loss) per Share</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Prior to the closing of the IPO, the Company followed the two-class method when computing net income (loss) per share, as the Company had issued shares that meet the definition of participating securities. The two-class method determines net income (loss) per share for each class of common and participating securities according to dividends declared or accumulated and participation rights in undistributed earnings. The two-class method requires income available to common stockholders for the period to be allocated between common and participating securities based upon their respective rights to receive dividends as if all income for the period had been distributed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Basic net income (loss) per share attributable to common stockholders is computed by dividing the net income (loss) attributable to common stockholders by the weighted average number of common shares outstanding for the period. Diluted net income (loss) attributable to common stockholders is computed by adjusting net income (loss) attributable to common stockholders to reallocate undistributed earnings based on the potential impact of dilutive securities. Diluted net income (loss) per share attributable to common stockholders is computed by dividing the diluted net income (loss) attributable to common stockholders by the weighted average number of common shares outstanding for the period, including potential dilutive common shares assuming the dilutive effect of common stock equivalents.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s convertible preferred stock contractually entitled the holders of such shares to participate in dividends but does not contractually require the holders of such shares to participate in losses of the Company. Accordingly, in periods in which the Company reports a net loss, such losses are not allocated to such participating securities. In periods in which the Company reports a net loss attributable to common stockholders, diluted net loss per share attributable to common stockholders is the same as basic net loss per share attributable to common stockholders, since dilutive common shares are not assumed to have been issued if their effect is anti-dilutive.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Subsequent to the closing of its IPO, the Company only has one class of shares outstanding and basic net income (loss) per common share is computed by dividing the net income (loss) by the weighted average number of shares of common stock outstanding for the period. Diluted net income (loss) per common share is computed by dividing net income (loss) by the weighted average number of shares of common stock outstanding for the period, including potential dilutive common shares assuming the dilutive effect of outstanding stock awards. For periods in which the Company reports a net loss, diluted net loss per common share is the same as basic net loss per common share, since dilutive common shares are not assumed to have been issued if their effect is anti-dilutive. The Company reported a net loss attributable to common stockholders for each of the years ended December&#160;31, 2021 and 2020.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-based Compensation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Stock-based Compensation</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"><span style="font-weight:bold;letter-spacing:-0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company issues stock-based awards to employees and nonemployees in the form of stock options. The Company accounts for stock-based awards in accordance with ASC 718, Compensation&#8201;&#8212;&#8201;Stock Compensation (&#8220;ASC 718&#8221;), which requires all stock-based payments to employees and nonemployees, including grants of employee stock options and modifications to existing stock options, to be recognized in the consolidated statement of operations based on their fair values.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The fair value of options is estimated on the grant date using the Black-Scholes option-pricing model (&#8220;Black-Scholes&#8221;). Black-Scholes requires the Company to make assumptions and judgments about the variables used in the calculation including the expected term of its stock option, the volatility of the Company&#8217;s common stock, and an assumed risk-free interest rate. The Company uses the simplified calculation of expected life and volatility is based on an average of the historical volatility of a group of publicly traded companies in a similar industry that the Company believes would be considered a peer group had it been a publicly held company for the duration of the expected life of the award. The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of grant for periods corresponding with the expected life of the option. Forfeitures are recognized as they occur. No dividend yield was assumed as the Company does not pay, and does not expect to pay, dividends on its common stock. The assumptions underlying these valuations represent management&#8217;s best estimates, which involve inherent uncertainties and the application of management&#8217;s judgement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In accordance with ASU No. 2018-07, Compensation-Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting, compensation expense for stock-based awards granted to nonemployees is recognized over the period during which services are rendered by such nonemployees. The new standard largely aligns the accounting for share-based payment awards issued to employees and nonemployees by expanding the scope of ASC 718 to apply to nonemployee share-based transactions, as long as the transaction is not effectively a form of financing. There was no adjustment to the financial statements upon adoption of this standard as of January&#160;1, 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As there had been no public market for the Company&#8217;s common stock prior to the IPO, the estimated fair value of its common stock has been determined by its board of directors as of the date of each option grant, with input from management, considering the Company&#8217;s most recently available third-party valuations of common stock and its board of directors&#8217; assessment of additional objective and subjective factors that it believed were relevant and which may have changed from the date of the most recent valuation through the date of the grant. These third-party valuations were performed in accordance with the guidance outlined in the American Institute of Certified Public Accountants&#8217; Accounting and Valuation Guide, Valuation of Privately-Held-Company Equity Securities Issued as Compensation. Each valuation methodology includes estimates and assumptions that require the Company&#8217;s judgment. These estimates and assumptions include a number of objective and subjective factors, including external market conditions, the prices at which the Company sold shares of preferred stock, the superior rights and preferences of securities senior to the Company&#8217;s common stock at the time of, and the likelihood of, achieving a liquidity event, such as an initial public offering or sale.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The assumptions underlying these valuations represent management&#8217;s best estimates, which involve inherent uncertainties and the application of management&#8217;s judgment. As a result, if the Company had used different assumptions or estimates, the fair value of its common stock and its stock-based compensation expense could be materially different.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy', window );">Goodwill</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Goodwill</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Goodwill represents the excess of the fair value of the acquiree over the recognized bases of the net identifiable assets acquired and includes the future economic benefits from other assets that could not be individually identified and separately recognized. Goodwill is not amortized, but instead is periodically reviewed for impairment and an impairment charge is recorded in the periods in which the recorded carrying value of goodwill exceeds its fair value.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">On a quarterly basis, the Company performs a review of its business to determine if events or changes in circumstances have occurred which could have a material adverse effect on the fair value of the Company and its goodwill. If such events or changes in circumstances were deemed to have occurred, the Company would perform an impairment test of goodwill as of the end of the quarter and record any noted impairment loss.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">The goodwill test is performed at least annually, or more frequently if events or changes in circumstances indicate that the asset might be impaired. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">The Company performs its annual impairment test during the fourth quarter of each fiscal year. There were </span><span style="background:#ffffff;">no</span><span style="background:#ffffff;"> impairments in 2021.</span><span style="background:#ffffff;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Intangible Assets</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Intangible assets are recognized at fair value, as an asset apart from goodwill if the asset (i) arises from contractual or other legal rights, or (ii) is separable. Intangible assets, principally representing technology acquired, are capitalized and amortized on the straight-line method over their expected useful lives.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company reviews the recoverability of its long-lived assets (including amortizable intangible assets), other than goodwill, when events or changes in circumstances occur that indicate that the carrying value of the asset may not be recoverable. </p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Issued Accounting Pronouncements</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Recently Issued Accounting Pronouncements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies and adopted by the Company as of the specified effective date. The Company is an &#8220;emerging growth company&#8221; as defined in the Jumpstart Our Business Startups Act of 2012, as amended (&#8220;JOBS Act&#8221;). The Jobs Act provides that an emerging growth company can take advantage of an extended transition period for complying with new or revised accounting standards. Thus, an emerging growth company can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. The Company elected to avail itself of this extended transition period and, as a result, we will not be required to adopt new or revised accounting standards on the relevant dates on which adoption of such standards is required for other public companies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In 2016, the FASB issued ASU 2016-13, Financial Instruments&#160;&#8211; Credit Losses (Topic 326): Measurement of Credit Losses on Financial Statements. The new standard, as amended, requires that expected credit losses relating to financial assets measured on an amortized cost basis and available-for-sale debt securities be recorded through an allowance for credit losses. It also limits the amount of credit losses to be recognized for available-for-sale debt securities to the amount by which carrying value exceeds fair value and also requires the reversal of previously recognized credit losses if fair value increases. The targeted transition relief standard allows filers an option to irrevocably elect the fair value option of ASC 825-10, Financial Instruments-Overall, applied on an instrument-by-instrument basis for eligible instruments.&#160;ASU No.&#160;2016-13, Financial Instruments&#160;- Credit Losses (Topic 326) will become effective for the Company on January&#160;1, 2023. The Company is currently assessing the impact of the adoption of this guidance on its consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In December&#160;2019, the FASB issued ASU No.&#160;2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes, which simplifies the accounting for income taxes by removing certain exceptions to the general principles in the existing guidance for income taxes and making other minor improvements. The amendments are effective for annual reporting periods beginning after December&#160;15, 2020 with early adoption permitted. The adoption of this standard did not have a material impact to the financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In January 2017, the FASB issued ASU No. ASU 2017-04, &#160;Intangibles&#8212;Goodwill and Other (Topic 350<i style="font-style:italic;">)</i>, which eliminates Step 2 from the goodwill impairment test. Step 2 measures a goodwill impairment loss by comparing the implied fair value of a reporting unit&#8217;s goodwill with the carrying amount of that goodwill. Instead, entities will record an impairment charge based on the excess of a reporting unit&#8217;s carrying amount over its fair value (i.e., measure the charge based on today&#8217;s Step 1). This update is effective for annual and interim impairment tests performed in periods beginning after December 15, 2022. Early adoption of the standard is permitted. The Company is currently evaluating the new guidance and assessing the potential impact on its consolidated financial statements. &#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imrx_PatentCostsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for patent costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imrx_PatentCostsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imrx_ResearchAndManufacturingContractCostsAndAccrualsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for research and manufacturing contract costs and accruals.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imrx_ResearchAndManufacturingContractCostsAndAccrualsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -Subparagraph (a)-(d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6909625&amp;loc=d3e227-128457<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4273-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123345438&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredChargesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for deferral and amortization of significant deferred charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredChargesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13279-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109226317&amp;loc=d3e202-110218<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InProcessResearchAndDevelopmentPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs assigned to identifiable tangible and intangible assets of an acquired entity to be used in the research and development activities of the combined enterprise. An entity also may disclose the appraisal method or significant assumptions used to value acquired research and development assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.15)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420387&amp;loc=d3e23199-108380<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InProcessResearchAndDevelopmentPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment classified as marketable security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123599081&amp;loc=d3e62652-112803<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130561-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130563-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130563-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130564-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its capital stock transactions, including dividends and accumulated other comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21459-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TradeAndOtherAccountsReceivableUnbilledReceivablesPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for treatment of receivables that are billable but have not been billed as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -URI http://asc.fasb.org/topic&amp;trid=2196771<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TradeAndOtherAccountsReceivableUnbilledReceivablesPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140649898121352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock', window );">Schedule of concentration of credit risk</a></td>
<td class="text"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:47.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:47.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:22.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="color:#231f20;font-weight:bold;">Year Ended December&#160;31,&#160;2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:23.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="color:#231f20;font-weight:bold;">As&#160;of&#160;December&#160;31,&#160;2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:47.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Revenue</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">%&#160;of&#160;Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Accounts&#160;Receivable</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">%&#160;of&#160;Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:47.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Customer #1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 745,030</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 35.8</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 235,500</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">95.7%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:47.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Customer #2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 380,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 18.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:47.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Customer #5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 353,050</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 17.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:47.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:47.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:22.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="color:#231f20;font-weight:bold;">Year Ended December&#160;31,&#160;2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:23.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="color:#231f20;font-weight:bold;">As&#160;of&#160;December&#160;31,&#160;2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:47.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Revenue</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">%&#160;of&#160;Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Accounts&#160;Receivable</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">%&#160;of&#160;Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:47.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Customer #1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 676,710</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 29.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 214,345</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 42.9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:47.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Customer #2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 570,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 24.7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 71,250</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 14.2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:47.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Customer #3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 306,900</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 13.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:47.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Customer #4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 250,880</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 10.9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 63,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12.6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:47.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Customer #5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 91,975</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 18.4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imrx_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock', window );">Schedule of property and equipment</a></td>
<td class="text"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:86.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:86.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Estimated</b></p></td></tr><tr><td style="vertical-align:bottom;width:86.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Asset Class</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Useful&#160;Lives</b></p></td></tr><tr><td style="vertical-align:bottom;width:86.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Computer equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">3 years</p></td></tr><tr><td style="vertical-align:bottom;width:86.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Furniture and fixtures</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">5 years</p></td></tr><tr><td style="vertical-align:bottom;width:86.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Lab equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">7 years</p></td></tr><tr><td style="vertical-align:bottom;width:86.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Leasehold improvements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1-10 years</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imrx_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the useful life of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imrx_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6327-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6442-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140649898100936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable Securities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Marketable Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesTextBlock', window );">Schedule of marketable securities</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:29.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:11.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:12.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:12.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:14.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:29.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:67.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, 2021</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:29.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:middle;width:13.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amortized Cost</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:middle;width:14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Unrealized Gains</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:middle;width:14.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Unrealized Losses</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:middle;width:16.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair Value</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:29.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Assets:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:11.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:12.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:12.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:14.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:29.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;">             Current:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:29.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">U.S. Treasuries</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 42,147,385</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (28,575)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 42,118,810</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:29.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">Government securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 19,218,057</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (13,689)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 19,204,368</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:29.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">Commercial Paper</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12,992,165</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 57</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (4,197)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12,988,025</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:29.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;">Total Current</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 74,357,607</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 57</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (46,461)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 74,311,203</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:29.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:29.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;">           Non-current:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:29.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">U.S. Treasuries</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 999,186</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,626)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 996,560</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:29.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">Government securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> -</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:29.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;">Total Non-current</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 999,186</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,626)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 996,560</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:29.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;">Total marketable securities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 75,356,793</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 57</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (49,087)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 75,307,763</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140649898119864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock', window );">Schedule of cash equivalents and marketable securities</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:39.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:39.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Level 1</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Level 2</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Level 3</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:39.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:39.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:39.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">       Money market</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 33,961,344</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 33,961,344</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:39.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">       Commercial paper</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,000,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,000,000</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:39.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">        Total cash equivalents</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 33,961,344</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,000,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 35,961,344</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:39.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:39.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Marketable securities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:39.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">      U.S. Treasuries</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 43,115,370</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 43,115,370</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:39.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">      Government securities</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 19,204,368</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 19,204,368</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:39.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">      Commercial paper</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12,988,025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12,988,025</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:39.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">        Total marketable securities</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 43,115,370</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 32,192,393</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 75,307,763</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:39.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total cash equivalents and marketable securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.04%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 77,076,714</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 34,192,393</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.43%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 111,269,107</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140649898085128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, net (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property and Equipment, net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of property and equipment, net</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Computer equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 281,666</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 174,317</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Furniture and fixtures</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 84,477</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 18,798</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Lab equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 463,182</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">-</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Leasehold improvements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 152,117</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">-</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 981,442</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 193,115</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accumulated depreciation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (174,219)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (128,752)</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Property and equipment, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 807,223</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 64,363</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140649898048648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Combination (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combination</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock', window );">Schedule of Assets Acquired and Liabilities Assumed at Fair Value</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:99.4%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:52.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:22.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:52.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';">&#160;&#160;&#160;&#160;</span></p></td><td colspan="2" style="vertical-align:bottom;width:23.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Preliminary Valuation</b></p></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;width:19.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted Average Life</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:52.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash</p></td><td style="vertical-align:bottom;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 70,348</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:52.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other currents assets</p></td><td style="vertical-align:bottom;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 225,790</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:52.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other long term assets</p></td><td style="vertical-align:bottom;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 87,796</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:52.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Property, plant and equipment, net</p></td><td style="vertical-align:bottom;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 727,539</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:52.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Right of use assets</p></td><td style="vertical-align:bottom;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,824,700</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:52.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Intangible asset</p></td><td style="vertical-align:bottom;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:52.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">   Technology</span></p></td><td style="vertical-align:bottom;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 439,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">15 years</p></td></tr><tr><td style="vertical-align:bottom;width:52.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Goodwill</p></td><td style="vertical-align:bottom;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,701,726</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:52.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:52.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total assets acquired</b></p></td><td style="vertical-align:bottom;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 13,076,899</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:52.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:52.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accounts payable, accrued expenses and other liabilities</p></td><td style="vertical-align:bottom;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 69,714</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:52.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Deferred tax liabilities</p></td><td style="vertical-align:bottom;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 307,485</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:52.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Lease liabilities</p></td><td style="vertical-align:bottom;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,824,700</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:52.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Net assets acquired</b></p></td><td style="vertical-align:bottom;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.26%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,875,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140649898037512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAbstract', window );"><strong>Accrued Expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of accrued expenses</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued professional services</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 250,977</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 269,302</p></td></tr><tr><td style="vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued employee expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,917,282</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 163,668</p></td></tr><tr><td style="vertical-align:bottom;width:73.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued contract research expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 585,416</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 266,022</p></td></tr><tr><td style="vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 211,772</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:73.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,965,447</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 698,992</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140649898041864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Common Stock.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfStockByClassTextBlock', window );">Schedule of common stock for conversion of preferred stock, exercise of warrants and exercise of stock options</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:75.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:75.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Conversion of Series A Preferred</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,494,306</p></td></tr><tr><td style="vertical-align:bottom;width:75.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Conversion of Series B Preferred</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,066,995</p></td></tr><tr><td style="vertical-align:bottom;width:75.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exercise of common stock warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 308,308</p></td></tr><tr><td style="vertical-align:bottom;width:75.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exercise of common stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,859,544</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,801,263</p></td></tr><tr><td style="vertical-align:bottom;width:75.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,859,544</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,670,872</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockByClassTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's stock, including par or stated value per share, number and dollar amount of share subscriptions, shares authorized, shares issued, shares outstanding, number and dollar amount of shares held in an employee trust, dividend per share, total dividends, share conversion features, par value plus additional paid in capital, the value of treasury stock and other information necessary to a fair presentation, and EPS information.  Stock by class includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. Includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity. If more than one issue is outstanding, state the title of each issue and the corresponding dollar amount; dollar amount of any shares subscribed but unissued and the deduction of subscriptions receivable there from; number of shares authorized, issued, and outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=65888546&amp;loc=d3e21300-112643<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21553-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=d3e177068-122764<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21538-112644<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21521-112644<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21488-112644<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21506-112644<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21484-112644<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockByClassTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140649899051960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share Attributable to Common Stockholders (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net Loss Per Share Attributable to Common Stockholders</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of basic and diluted net loss per share attributable to common stockholders</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:70.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:70.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Numerator:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:70.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (33,535,748)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (17,039,898)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Denominator - basic and diluted:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted-average common shares outstanding, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 13,612,677</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,950,129</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net loss per share - basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_wHopsXwjskSWOmAaEI9k1w;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2.46)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_--dUy7H6lkGzBYeWkeucsA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3.44)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of potentially dilutive securities that have been excluded from the calculation of diluted net loss per share</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:75.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:75.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Series A Preferred</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,494,306</p></td></tr><tr><td style="vertical-align:bottom;width:75.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Series B Preferred</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,066,995</p></td></tr><tr><td style="vertical-align:bottom;width:75.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Warrants to purchase common stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 308,308</p></td></tr><tr><td style="vertical-align:bottom;width:75.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Options to purchase common stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,859,544</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,801,263</p></td></tr><tr><td style="vertical-align:bottom;width:75.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total shares of common stock equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,859,544</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 10,670,872</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140649986944472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Stock-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of assumptions in its application of the Black-Scholes option pricing model for grants</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:67.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:67.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:30.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted-average risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">0.89% - 1.71%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">0.36% - 1.45%</p></td></tr><tr><td style="vertical-align:bottom;width:67.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected term (in years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">5.83 - 10 years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">5.92 - 10 years</p></td></tr><tr><td style="vertical-align:bottom;width:67.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">0%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">0%</p></td></tr><tr><td style="vertical-align:bottom;width:67.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">66.76% - 80.99%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">67.30% - 80.85%</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of stock option activity</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:51.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:51.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted-</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Remaining</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exercise Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Contractual</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Aggregate</b></p></td></tr><tr><td style="vertical-align:bottom;width:51.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;">    </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Options</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;">    </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">per Share</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Term (in Years)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;">    </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;"> Intrinsic Value</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:51.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding at of December&#160;31,&#160;2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,801,263</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3.01</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:51.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,452,462</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10.07</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:51.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (117,847)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3.01</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:51.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cancelled</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (276,334)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3.58</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:51.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding at December&#160;31,&#160;2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,859,544</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6.55</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8.30</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 27,615,466</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Vested and exercisable at December&#160;31,&#160;2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,102,543</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3.01</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7.14</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 14,507,723</p></td></tr><tr><td style="vertical-align:bottom;width:51.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Vested and expected to vest at December&#160;31,&#160;2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,859,544</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6.55</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8.30</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 27,615,466</p></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock', window );">Summary of recognized share-based compensation expense recognized</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cost of revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 103,329</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 108,027</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 768,679</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 503,111</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 930,615</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 475,631</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,802,623</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,086,769</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140649997493352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of federal statutory rate to the net loss and the effective income tax rate</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:74.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Statutory federal income tax rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 21.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 21.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:74.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">State tax, net of federal benefit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:74.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Permanent differences</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.6)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1.5)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:74.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Federal research and development credits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5.6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:74.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">State research and development credits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:74.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Uncertain tax positions</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.6)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1.0)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:74.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other differences</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2.6)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:74.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Change in valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (31.1)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (27.3)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:74.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Effective income tax rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of net deferred tax assets</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Deferred tax assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:73.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Stock-based compensation expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 373,602</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 73,984</p></td></tr><tr><td style="vertical-align:bottom;width:73.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Unrealized losses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12,990</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:73.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">R&amp;D credit carryforward</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,346,097</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,574,596</p></td></tr><tr><td style="vertical-align:bottom;width:73.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">NOL carryforward</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 14,699,524</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,525,123</p></td></tr><tr><td style="vertical-align:bottom;width:73.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Gross deferred tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 18,432,213</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,173,703</p></td></tr><tr><td style="vertical-align:bottom;width:73.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (17,677,899)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (7,127,448)</p></td></tr><tr><td style="vertical-align:bottom;width:73.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net deferred tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 754,314</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 46,255</p></td></tr><tr><td style="vertical-align:bottom;width:73.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net deferred tax liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:73.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Prepaid expenses deducted for tax</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (425,755)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (28,671)</p></td></tr><tr><td style="vertical-align:bottom;width:73.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Tax depreciation in excess of book</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (328,559)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (17,584)</p></td></tr><tr><td style="vertical-align:bottom;width:73.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total deferred tax liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (754,314)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (46,255)</p></td></tr><tr><td style="vertical-align:bottom;width:73.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net deferred taxes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock', window );">Schedule of unrecognized tax benefits</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:9.95pt;text-align:justify;background:#ffffff;margin:0pt 8.55pt 0pt 0pt;"><span style="font-family:'TimesNewRomanPSMT';font-weight:bold;margin-right:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:70.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:70.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:70.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Beginning balance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 174,950</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 96,952</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:70.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Increase due to current year tax position</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 205,952</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 77,998</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:70.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Ending balance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 380,902</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 174,950</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 55<br> -Paragraph 217<br> -URI http://asc.fasb.org/extlink&amp;oid=124434304&amp;loc=d3e36027-109320<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140649899061912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Maturities of the lease liabilities due</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amount</b></p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 659,990</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 880,121</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 894,044</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 906,839</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 819,210</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Thereafter</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,467,246</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total future lease payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,627,450</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Less: Imputed interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,262,514</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,364,936</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Current portion lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 274,039</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Lease liabilities, noncurrent</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,090,897</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,364,936</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Schedule of Quantitative information regarding the Company's leases</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Lease costs:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Operating lease cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 160,872</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 66,652</p></td></tr><tr><td style="vertical-align:bottom;width:73.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Short-term lease cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 258,357</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 252,796</p></td></tr><tr><td style="vertical-align:bottom;width:73.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Variable lease cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 14,700</p></td></tr><tr><td style="vertical-align:bottom;width:73.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total lease costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 419,229</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 334,148</p></td></tr><tr><td style="vertical-align:bottom;width:73.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash paid for amounts included in the measurement of lease liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:73.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Operating cash flows from operating leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 111,527</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 58,666</p></td></tr><tr><td style="vertical-align:bottom;width:73.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Operating cash flows from short-term leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 236,700</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 252,796</p></td></tr><tr><td style="vertical-align:bottom;width:73.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 348,227</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 311,462</p></td></tr><tr><td style="vertical-align:bottom;width:73.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted-average remaining lease term - operating leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">9.62 years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">5.33 years</p></td></tr><tr><td style="vertical-align:bottom;width:73.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted-average discount rate - operating leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">9.7%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">6.0%</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140649892918424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Nature of Business (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Aug. 03, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems', window );"><strong>Organization and Nature of Business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Aggregate net proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 120,318,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Convertible preferred stock, outstanding (in shares)</a></td>
<td class="nump">8,528,078<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Shares issued upon conversion</a></td>
<td class="nump">11,939,281<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 59,273,388<span></span>
</td>
<td class="nump">$ 25,737,640<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Class A Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems', window );"><strong>Organization and Nature of Business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued</a></td>
<td class="nump">1,125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Convertible preferred stock, outstanding (in shares)</a></td>
<td class="nump">11,939,281<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems', window );"><strong>Organization and Nature of Business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Aggregate net proceeds</a></td>
<td class="nump">$ 120,318,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imrx_OfferingCostPayable', window );">Offering costs</a></td>
<td class="nump">$ 2,124,317<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Convertible preferred stock, outstanding (in shares)</a></td>
<td class="nump">8,528,078<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO | Class A Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems', window );"><strong>Organization and Nature of Business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued</a></td>
<td class="nump">8,625,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imrx_OfferingCostPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of offering costs payable by the Company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imrx_OfferingCostPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for each share of convertible preferred stock that is converted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496180-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21506-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140649893436248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 23, 2021</div></th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>segment</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Stock split, ratio</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables', window );">Allowance for doubtful accounts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived', window );">Impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasePracticalExpedientsPackage', window );">Lease, practical expedients</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions', window );">Uncertain tax positions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 380,902<span></span>
</td>
<td class="nump">174,950<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredOfferingCosts', window );">Deferred offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill impairments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The valuation allowance as of the balance sheet date to reduce the gross amount of receivables to estimated net realizable value, which would be presented in parentheses on the face of the balance sheet.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5074-111524<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.A)<br> -URI http://asc.fasb.org/extlink&amp;oid=122040515&amp;loc=d3e105025-122735<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13777-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsFinitelived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasePracticalExpedientsPackage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates (true false) whether practical expedients are elected for not reassessing whether any expired or existing contract is or contains lease, lease classification for expired or existing lease, and initial direct cost for any existing lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (j)<br> -URI http://asc.fasb.org/extlink&amp;oid=123341672&amp;loc=SL77916155-209984<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123341672&amp;loc=SL77916155-209984<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasePracticalExpedientsPackage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB TOPIC 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) to previously recorded tax expense. Includes, but is not limited to, significant settlements of income tax disputes, and unusual tax positions or infrequent actions taken by the entity, including tax assessment reversal, and IRS tax settlement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=123452999&amp;loc=d3e28511-109314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123452999&amp;loc=d3e28446-109314<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140649896611432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Concentration of Credit Risk (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">$ 246,040<span></span>
</td>
<td class="nump">$ 500,110<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember', window );">Revenue | Customer risk | Customer 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 745,030<span></span>
</td>
<td class="nump">$ 676,710<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Risk percentage</a></td>
<td class="nump">35.80%<span></span>
</td>
<td class="nump">29.30%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember', window );">Revenue | Customer risk | Customer 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 380,000<span></span>
</td>
<td class="nump">$ 570,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Risk percentage</a></td>
<td class="nump">18.30%<span></span>
</td>
<td class="nump">24.70%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember', window );">Revenue | Customer risk | Customer 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 306,900<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Risk percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.30%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember', window );">Revenue | Customer risk | Customer 4</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,880<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Risk percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.90%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember', window );">Revenue | Customer risk | Customer 5</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 353,050<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Risk percentage</a></td>
<td class="nump">17.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember', window );">Accounts receivable | Customer risk | Customer 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">$ 235,500<span></span>
</td>
<td class="nump">$ 214,345<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Risk percentage</a></td>
<td class="nump">95.70%<span></span>
</td>
<td class="nump">42.90%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember', window );">Accounts receivable | Customer risk | Customer 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 71,250<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Risk percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14.20%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember', window );">Accounts receivable | Customer risk | Customer 4</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 63,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Risk percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.60%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember', window );">Accounts receivable | Customer risk | Customer 5</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 91,975<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Risk percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18.40%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=imrx_CustomerOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=imrx_CustomerOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=imrx_CustomerTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=imrx_CustomerTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=imrx_CustomerThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=imrx_CustomerThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=imrx_CustomerFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=imrx_CustomerFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=imrx_CustomerFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=imrx_CustomerFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140649900232936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Property and Equipment (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Useful Lives</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Useful Lives</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=imrx_LabEquipmentMember', window );">Lab equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Useful Lives</a></td>
<td class="text">7 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdsAndLeaseholdImprovementsMember', window );">Leaseholds and Leasehold Improvements [Member] | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Useful Lives</a></td>
<td class="text">1 year<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdsAndLeaseholdImprovementsMember', window );">Leaseholds and Leasehold Improvements [Member] | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Useful Lives</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=imrx_LabEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=imrx_LabEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdsAndLeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdsAndLeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140649896694424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable Securities (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesLineItems', window );"><strong>Marketable Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfInvestments', window );">Impairment on available-for-sale marketable securities</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesRealizedGainLoss', window );">Realized gains or losses on marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imrx_MarketableSecuritiesCurrentAbstract', window );"><strong>Marketable securities, current</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imrx_MarketableSecuritiesAmortizedCostBasisCurrent', window );">Marketable securities at amortized cost, current</a></td>
<td class="nump">74,357,607<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imrx_MarketableSecuritiesAccumulatedUnrealizedGainsCurrent', window );">Marketable securities unrealized gains, current</a></td>
<td class="nump">57<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imrx_MarketableSecuritiesAccumulatedUnrealizedLossesCurrent', window );">Marketable securities unrealized losses, current</a></td>
<td class="num">(46,461)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities, current</a></td>
<td class="nump">74,311,203<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imrx_MarketableSecuritiesNonCurrentAbstract', window );"><strong>Marketable securities, non-current</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imrx_MarketableSecuritiesAmortizedCostBasisNonCurrent', window );">Marketable securities at amortized cost, non-current</a></td>
<td class="nump">999,186<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imrx_MarketableSecuritiesAccumulatedUnrealizedLossesNonCurrent', window );">Marketable securities unrealized losses, non-current</a></td>
<td class="num">(2,626)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesNoncurrent', window );">Marketable securities, non-current</a></td>
<td class="nump">996,560<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesAbstract', window );"><strong>Marketable securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imrx_MarketableSecuritiesAmortizedCostBasis', window );">Marketable securities at amortized cost</a></td>
<td class="nump">75,356,793<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imrx_MarketableSecuritiesAccumulatedUnrealizedGains', window );">Marketable securities unrealized gains</a></td>
<td class="nump">57<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imrx_MarketableSecuritiesAccumulatedUnrealizedLosses', window );">Marketable securities unrealized losses</a></td>
<td class="num">(49,087)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecurities', window );">Marketable securities</a></td>
<td class="nump">75,307,763<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. Treasuries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imrx_MarketableSecuritiesCurrentAbstract', window );"><strong>Marketable securities, current</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imrx_MarketableSecuritiesAmortizedCostBasisCurrent', window );">Marketable securities at amortized cost, current</a></td>
<td class="nump">42,147,385<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imrx_MarketableSecuritiesAccumulatedUnrealizedLossesCurrent', window );">Marketable securities unrealized losses, current</a></td>
<td class="num">(28,575)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities, current</a></td>
<td class="nump">42,118,810<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imrx_MarketableSecuritiesNonCurrentAbstract', window );"><strong>Marketable securities, non-current</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imrx_MarketableSecuritiesAmortizedCostBasisNonCurrent', window );">Marketable securities at amortized cost, non-current</a></td>
<td class="nump">999,186<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imrx_MarketableSecuritiesAccumulatedUnrealizedLossesNonCurrent', window );">Marketable securities unrealized losses, non-current</a></td>
<td class="num">(2,626)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesNoncurrent', window );">Marketable securities, non-current</a></td>
<td class="nump">996,560<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=imrx_GovernmentSecuritiesMember', window );">Government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imrx_MarketableSecuritiesCurrentAbstract', window );"><strong>Marketable securities, current</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imrx_MarketableSecuritiesAmortizedCostBasisCurrent', window );">Marketable securities at amortized cost, current</a></td>
<td class="nump">19,218,057<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imrx_MarketableSecuritiesAccumulatedUnrealizedLossesCurrent', window );">Marketable securities unrealized losses, current</a></td>
<td class="num">(13,689)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities, current</a></td>
<td class="nump">19,204,368<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commerical paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imrx_MarketableSecuritiesCurrentAbstract', window );"><strong>Marketable securities, current</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imrx_MarketableSecuritiesAmortizedCostBasisCurrent', window );">Marketable securities at amortized cost, current</a></td>
<td class="nump">12,992,165<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imrx_MarketableSecuritiesAccumulatedUnrealizedGainsCurrent', window );">Marketable securities unrealized gains, current</a></td>
<td class="nump">57<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imrx_MarketableSecuritiesAccumulatedUnrealizedLossesCurrent', window );">Marketable securities unrealized losses, current</a></td>
<td class="num">(4,197)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities, current</a></td>
<td class="nump">$ 12,988,025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imrx_MarketableSecuritiesAccumulatedUnrealizedGains">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in  marketable securities measured at fair value with change in fair value recognized in other comprehensive income .</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imrx_MarketableSecuritiesAccumulatedUnrealizedGains</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imrx_MarketableSecuritiesAccumulatedUnrealizedGainsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in current marketable securities measured at fair value with change in fair value recognized in other comprehensive income</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imrx_MarketableSecuritiesAccumulatedUnrealizedGainsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imrx_MarketableSecuritiesAccumulatedUnrealizedLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in  marketable securities measured at fair value with change in fair value recognized in other comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imrx_MarketableSecuritiesAccumulatedUnrealizedLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imrx_MarketableSecuritiesAccumulatedUnrealizedLossesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in current marketable securities measured at fair value with change in fair value recognized in other comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imrx_MarketableSecuritiesAccumulatedUnrealizedLossesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imrx_MarketableSecuritiesAccumulatedUnrealizedLossesNonCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in Non-current marketable securities measured at fair value with change in fair value recognized in other comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imrx_MarketableSecuritiesAccumulatedUnrealizedLossesNonCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imrx_MarketableSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in  marketable securities measured at fair value with change in fair value recognized in other comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imrx_MarketableSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imrx_MarketableSecuritiesAmortizedCostBasisCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in current marketable securities measured at fair value with change in fair value recognized in other comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imrx_MarketableSecuritiesAmortizedCostBasisCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imrx_MarketableSecuritiesAmortizedCostBasisNonCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in Non-current marketable securities measured at fair value with change in fair value recognized in other comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imrx_MarketableSecuritiesAmortizedCostBasisNonCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imrx_MarketableSecuritiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imrx_MarketableSecuritiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imrx_MarketableSecuritiesNonCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imrx_MarketableSecuritiesNonCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount by which the fair value of an investment is less than the amortized cost basis or carrying amount of that investment at the balance sheet date and the decline in fair value is deemed to be other than temporary, before considering whether or not such amount is recognized in earnings or other comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8A<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=SL6284422-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesRealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain (loss) on investment in marketable security, including other-than-temporary impairment (OTTI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesRealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=imrx_GovernmentSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=imrx_GovernmentSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140649895857784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet', window );">Financial liabilities classified as Level 3</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecurities', window );">Marketable securities</a></td>
<td class="nump">75,307,763<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total cash equivalents</a></td>
<td class="nump">35,961,344<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imrx_MarketableSecuritiesFairValueDisclosure', window );">Total marketable securities</a></td>
<td class="nump">75,307,763<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total cash equivalents and marketable securities</a></td>
<td class="nump">111,269,107<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Money market</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total cash equivalents</a></td>
<td class="nump">33,961,344<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Commerical paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total cash equivalents</a></td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imrx_MarketableSecuritiesFairValueDisclosure', window );">Total marketable securities</a></td>
<td class="nump">12,988,025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | U.S. Treasuries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imrx_MarketableSecuritiesFairValueDisclosure', window );">Total marketable securities</a></td>
<td class="nump">43,115,370<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imrx_MarketableSecuritiesFairValueDisclosure', window );">Total marketable securities</a></td>
<td class="nump">19,204,368<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total cash equivalents</a></td>
<td class="nump">33,961,344<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imrx_MarketableSecuritiesFairValueDisclosure', window );">Total marketable securities</a></td>
<td class="nump">43,115,370<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total cash equivalents and marketable securities</a></td>
<td class="nump">77,076,714<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level 1 | Money market</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total cash equivalents</a></td>
<td class="nump">33,961,344<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level 1 | U.S. Treasuries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imrx_MarketableSecuritiesFairValueDisclosure', window );">Total marketable securities</a></td>
<td class="nump">43,115,370<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total cash equivalents</a></td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imrx_MarketableSecuritiesFairValueDisclosure', window );">Total marketable securities</a></td>
<td class="nump">32,192,393<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total cash equivalents and marketable securities</a></td>
<td class="nump">34,192,393<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level 2 | Commerical paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total cash equivalents</a></td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imrx_MarketableSecuritiesFairValueDisclosure', window );">Total marketable securities</a></td>
<td class="nump">12,988,025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level 2 | Government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imrx_MarketableSecuritiesFairValueDisclosure', window );">Total marketable securities</a></td>
<td class="nump">$ 19,204,368<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imrx_MarketableSecuritiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of marketable securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imrx_MarketableSecuritiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transfers of financial instrument classified as a liability into (out of) level 3 of the fair value hierarchy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=imrx_GovernmentSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=imrx_GovernmentSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140649900302872">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property and Equipment, net (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and Equipment, net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 981,442<span></span>
</td>
<td class="nump">$ 193,115<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation</a></td>
<td class="num">(174,219)<span></span>
</td>
<td class="num">(128,752)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">807,223<span></span>
</td>
<td class="nump">64,363<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and Equipment, net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">281,666<span></span>
</td>
<td class="nump">174,317<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and Equipment, net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">84,477<span></span>
</td>
<td class="nump">$ 18,798<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=imrx_LabEquipmentMember', window );">Lab equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and Equipment, net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">463,182<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and Equipment, net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 152,117<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=imrx_LabEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=imrx_LabEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140649899026056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, net - Depreciation (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property and Equipment, net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">$ 45,467<span></span>
</td>
<td class="nump">$ 24,328<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140649893371944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Combination - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 22, 2021 </div>
<div>USD ($) </div>
<div>agreement </div>
<div>D </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=imrx_BioArkiveIncMember', window );">BioArkive Inc | Accounts payable or accrued expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrent', window );">Amount owned to related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 279,153<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=imrx_BioArkiveIncMember', window );">BioArkive Inc | Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction', window );">Amount of related party expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,548,780<span></span>
</td>
<td class="nump">$ 2,744,051<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=imrx_BioArkiveIncMember', window );">BioArkive Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imrx_BusinessCombinationPurchasePrice', window );">Market value of acquisition</a></td>
<td class="nump">$ 8,750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imrx_NumberOfLeasesObligationsAssumed', window );">Number of lease obligations acquired</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Shares issued | shares</a></td>
<td class="nump">379,635<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imrx_BusinessCombinationSharesIssuedSharePriceThresholdTradingDays', window );">Trading days for share price | D</a></td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imrx_BusinessCombinationSharesIssuedLockInPeriod', window );">Lock in period for shares issued</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imrx_BusinessCombinationSharesIssuedDiscountDueToMarketabilityPercentage', window );">Shares issued discount due to lack of marketability</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Consideration transferred</a></td>
<td class="nump">$ 7,875,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imrx_BusinessCombinationPurchasePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of purchase price payable for the acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imrx_BusinessCombinationPurchasePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imrx_BusinessCombinationSharesIssuedDiscountDueToMarketabilityPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of discount due to lack of marketability for shares issued in business acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imrx_BusinessCombinationSharesIssuedDiscountDueToMarketabilityPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imrx_BusinessCombinationSharesIssuedLockInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lock in period for shares issued in acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imrx_BusinessCombinationSharesIssuedLockInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imrx_BusinessCombinationSharesIssuedSharePriceThresholdTradingDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Threshold number of specified trading days that common stock price daily volume weighted average prices of the common stock on the Nasdaq Stock Exchange for valuation of shares issued in acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imrx_BusinessCombinationSharesIssuedSharePriceThresholdTradingDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imrx_NumberOfLeasesObligationsAssumed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of lease obligations acquired in business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imrx_NumberOfLeasesObligationsAssumed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6613-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6578-128477<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(C))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transactions with related party during the financial reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAmountsOfTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period pursuant to acquisitions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=imrx_BioArkiveIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=imrx_BioArkiveIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccountsPayableAndAccruedLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_AccountsPayableAndAccruedLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=imrx_BioArkiveIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=imrx_BioArkiveIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140649895891832">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Business Combination - Assets Acquired and Liabilities Assumed (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 22, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract', window );"><strong>Intangible asset</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,701,726<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=imrx_BioArkiveIncMember', window );">BioArkive Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract', window );"><strong>Assets Acquired and Liabilities Assumed at Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents', window );">Cash</a></td>
<td class="nump">$ 70,348<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther', window );">Other currents assets</a></td>
<td class="nump">225,790<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets', window );">Other long term assets</a></td>
<td class="nump">87,796<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment', window );">Property, plant and equipment, net</a></td>
<td class="nump">727,539<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets', window );">Right of use assets</a></td>
<td class="nump">4,824,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract', window );"><strong>Intangible asset</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Technology</a></td>
<td class="nump">439,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">6,701,726<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIncludingGoodwill', window );">Total assets acquired</a></td>
<td class="nump">13,076,899<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAccruedExpensesAndOtherLiabilities', window );">Accounts payable, accrued expenses and other liabilities</a></td>
<td class="nump">69,714<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities', window );">Deferred tax liabilities</a></td>
<td class="nump">307,485<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation', window );">Lease liabilities</a></td>
<td class="nump">4,824,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet', window );">Net assets acquired</a></td>
<td class="nump">$ 7,875,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Weighted Average Life, technology</a></td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAccruedExpensesAndOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accounts payable, accrued expenses and other liabilities due within one year or within the normal operating cycle, if longer, assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAccruedExpensesAndOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIncludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount recognized as of the acquisition date for the identifiable assets including goowill acquired in excess of (less than) the aggregate liabilities assumed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIncludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of right of use assets recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lease obligation assumed in business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of other assets expected to be realized or consumed before one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of identifiable intangible assets recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI http://asc.fasb.org/extlink&amp;oid=123455525&amp;loc=d3e2207-128464<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of other assets expected to be realized or consumed after one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of property, plant, and equipment recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI http://asc.fasb.org/extlink&amp;oid=123455525&amp;loc=d3e2207-128464<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=imrx_BioArkiveIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=imrx_BioArkiveIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140649902903752">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Expenses (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAbstract', window );"><strong>Accrued Expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent', window );">Accrued professional services</a></td>
<td class="nump">$ 250,977<span></span>
</td>
<td class="nump">$ 269,302<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedEmployeeBenefitsCurrentAndNoncurrent', window );">Accrued employee expenses</a></td>
<td class="nump">2,917,282<span></span>
</td>
<td class="nump">163,668<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imrx_AccruedContractResearchExpensesCurrent', window );">Accrued contract research expenses</a></td>
<td class="nump">585,416<span></span>
</td>
<td class="nump">266,022<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent', window );">Accrued other</a></td>
<td class="nump">211,772<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total</a></td>
<td class="nump">$ 3,965,447<span></span>
</td>
<td class="nump">$ 698,992<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imrx_AccruedContractResearchExpensesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, related to contract research due within one year or within the normal operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imrx_AccruedContractResearchExpensesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedEmployeeBenefitsCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.15(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedEmployeeBenefitsCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.15(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.15(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140649893256344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Preferred Stock - Series A (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Sep. 20, 2019</div></th>
<th class="th"><div>Jan. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Aug. 03, 2021</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,124,317<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Convertible preferred stock, outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,528,078<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=imrx_SeriesConvertiblePreferredStockMember', window );">Series A Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Convertible preferred stock, authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,495,933<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,495,933<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,987,979<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Convertible preferred stock, par value per share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imrx_TemporaryEquityIssuancePrice', window );">Convertible preferred stock, issuance price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.5514<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Convertible preferred stock, issued (in shares)</a></td>
<td class="nump">468,315<span></span>
</td>
<td class="nump">1,122,458<span></span>
</td>
<td class="nump">119,454<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,495,933<span></span>
</td>
<td class="nump">468,315<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock', window );">Gross proceeds from issuance of convertible stock</a></td>
<td class="nump">$ 4,004,975<span></span>
</td>
<td class="nump">$ 9,598,847<span></span>
</td>
<td class="nump">$ 1,021,413<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 998,306<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Number of shares issued upon conversion of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">785,706<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23,610<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,587<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imrx_TemporaryEquityNumberOfSharesExcessOfAuthorized', window );">Number of shares excess of authorized</a></td>
<td class="nump">410,436<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">410,436<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imrx_ProceedsFromIssuanceOfConvertiblePreferredStockExcessOfAuthorizedAmount', window );">Proceeds from issuance of shares excess of amount authorized</a></td>
<td class="nump">$ 3,509,802<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imrx_TemporaryEquityDueToExcessAuthorizedAmount', window );">Convertible preferred stock liability</a></td>
<td class="nump">$ 3,509,802<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,509,802<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Convertible preferred stock, outstanding (in shares)</a></td>
<td class="nump">1,966,043<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,495,933<span></span>
</td>
<td class="nump">1,966,043<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imrx_TemporaryEquityConversionPrice', window );">Convertible preferred stock, conversion price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.1081<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=imrx_SeriesConvertiblePreferredStockMember', window );">Series A Preferred Stock | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imrx_TemporaryEquityIssuancePrice', window );">Convertible preferred stock, issuance price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.3416<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock', window );">Gross proceeds from issuance of convertible stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imrx_ProceedsFromIssuanceOfConvertiblePreferredStockExcessOfAuthorizedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock excess of amount authorized by the articles of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imrx_ProceedsFromIssuanceOfConvertiblePreferredStockExcessOfAuthorizedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imrx_TemporaryEquityConversionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of conversion price of temporary equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imrx_TemporaryEquityConversionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imrx_TemporaryEquityDueToExcessAuthorizedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of liability recognized due to shares issued in excess of amount authorized by the articles of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imrx_TemporaryEquityDueToExcessAuthorizedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imrx_TemporaryEquityIssuancePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance price of temporary equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imrx_TemporaryEquityIssuancePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imrx_TemporaryEquityNumberOfSharesExcessOfAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders excess of authorized by the articles of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imrx_TemporaryEquityNumberOfSharesExcessOfAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=d3e177068-122764<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (27)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=imrx_SeriesConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=imrx_SeriesConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140649893163880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Preferred Stock - Series B (Details)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">2 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>tranche </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>May 31, 2021 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>tranche </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 03, 2021 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Issuance costs | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,124,317<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockDividendRatePercentage', window );">Dividend, Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsPreferredStock', window );">Dividend declared | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Shares issued upon conversion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,939,281<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,132,029<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=imrx_SeriesBConvertiblePreferredStockMember', window );">Series B Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Convertible preferred stock, authorized (in shares)</a></td>
<td class="nump">6,032,183<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">6,032,183<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Convertible preferred stock, par value per share (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imrx_TemporaryEquityIssuancePrice', window );">Convertible preferred stock, issuance price (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 10.2782<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.2782<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imrx_NumberOfTranches', window );">Number of tranches | tranche</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Convertible preferred stock, issued (in shares)</a></td>
<td class="nump">3,619,292<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,619,292<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock', window );">Gross proceeds from issuance of convertible stock | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24,788,851<span></span>
</td>
<td class="nump">$ 36,983,910<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imrx_TemporaryEquityContingentlyIssuableShares', window );">Number of shares not meet the definition of a freestanding financial instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,412,853<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imrx_TemporaryEquityConversionPrice', window );">Convertible preferred stock, conversion price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.3416<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imrx_PercentageOfEquitySecuritiesOwnedToGetConvertedStock', window );">Percentage of equity securities to be own</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=imrx_SeriesBConvertiblePreferredStocksTrancheOneMember', window );">Series B Preferred Stock Tranche One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Convertible preferred stock, issued (in shares)</a></td>
<td class="nump">3,619,292<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,619,292<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock', window );">Gross proceeds from issuance of convertible stock | $</a></td>
<td class="nump">$ 37,199,929<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Issuance costs | $</a></td>
<td class="nump">$ 216,019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=imrx_SeriesBConvertiblePreferredStockTrancheTwoMember', window );">Series B Preferred Stock Tranche Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Convertible preferred stock, issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,412,853<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock', window );">Gross proceeds from issuance of convertible stock | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24,799,786<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Issuance costs | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,935<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imrx_NumberOfTranches">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of tranches.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imrx_NumberOfTranches</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imrx_PercentageOfEquitySecuritiesOwnedToGetConvertedStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of equity securities to be owned may elect to receive a portion of their converted shares upon conversion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imrx_PercentageOfEquitySecuritiesOwnedToGetConvertedStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imrx_TemporaryEquityContingentlyIssuableShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of convertible preferred shares does not meet the definition of a freestanding financial instrument and are issuable subject to the company meeting certain development milestones and other conditions as specified.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imrx_TemporaryEquityContingentlyIssuableShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imrx_TemporaryEquityConversionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of conversion price of temporary equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imrx_TemporaryEquityConversionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imrx_TemporaryEquityIssuancePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance price of temporary equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imrx_TemporaryEquityIssuancePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for each share of convertible preferred stock that is converted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496180-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21506-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsPreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid preferred stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 405<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6957935&amp;loc=d3e64057-112817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsPreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDividendRatePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage rate used to calculate dividend payments on preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockDividendRatePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=d3e177068-122764<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (27)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=imrx_SeriesBConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=imrx_SeriesBConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=imrx_SeriesBConvertiblePreferredStocksTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=imrx_SeriesBConvertiblePreferredStocksTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=imrx_SeriesBConvertiblePreferredStockTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=imrx_SeriesBConvertiblePreferredStockTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140649893162344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock - Class A common stock (Details) - Class A Common Stock<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>Vote </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>Vote </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">22,026,200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value per share (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">26,320,199<span></span>
</td>
<td class="nump">4,950,129<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">26,320,199<span></span>
</td>
<td class="nump">4,950,129<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imrx_NumberOfVotesPerShare', window );">Number of votes | Vote</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imrx_NumberOfVotesPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of votes per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imrx_NumberOfVotesPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140649893436152">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Common Stock (Details) - shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares reserved for future issuance</a></td>
<td class="nump">2,859,544<span></span>
</td>
<td class="nump">10,670,872<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=imrx_SeriesConvertiblePreferredStockMember', window );">Series A Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares reserved for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,494,306<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=imrx_SeriesBConvertiblePreferredStockMember', window );">Series B Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares reserved for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,066,995<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_WarrantMember', window );">Common stock warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares reserved for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">308,308<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_EmployeeStockOptionMember', window );">Common stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares reserved for future issuance</a></td>
<td class="nump">2,859,544<span></span>
</td>
<td class="nump">1,801,263<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=imrx_SeriesConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=imrx_SeriesConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=imrx_SeriesBConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=imrx_SeriesBConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140649895897464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock - Class B common stock (Details) - Class B Common Stock<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>Vote </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>Vote </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">20,000,000<span></span>
</td>
<td class="nump">6,032,183<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value per share (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imrx_NumberOfVotesPerShare', window );">Number of votes | Vote</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imrx_NumberOfVotesPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of votes per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imrx_NumberOfVotesPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140649896599960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock - Common stock warrant (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Common Stock.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants issued for common shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">308,308<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imrx_WarrantsIssuedInLieuOfCashPayment', window );">Warrants in lieu of cash payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,984<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Term of warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imrx_WarrantsExercised', window );">Warrant exercised</a></td>
<td class="nump">308,308<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrants outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imrx_WarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants exercised.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imrx_WarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imrx_WarrantsIssuedInLieuOfCashPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants issued to board of director's in lieu of cash payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imrx_WarrantsIssuedInLieuOfCashPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140649892914152">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Common Stock - IPO (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Aug. 03, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Convertible preferred stock, outstanding (in shares)</a></td>
<td class="nump">8,528,078<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Class A Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued</a></td>
<td class="nump">1,125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Convertible preferred stock, outstanding (in shares)</a></td>
<td class="nump">11,939,281<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">22,026,200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value per share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember', window );">Class B Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="nump">6,032,183<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value per share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from Stock issued</a></td>
<td class="nump">$ 120,318,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imrx_OfferingCostPayable', window );">Offering costs</a></td>
<td class="nump">$ 2,124,317<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Convertible preferred stock, outstanding (in shares)</a></td>
<td class="nump">8,528,078<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock authorized (in shares)</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO | Class A Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued</a></td>
<td class="nump">8,625,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO | Class B Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value per share (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imrx_OfferingCostPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of offering costs payable by the Company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imrx_OfferingCostPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140649896681880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share Attributable to Common Stockholders - Basic and diluted net loss per share attributable to common stockholders (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (33,535,748)<span></span>
</td>
<td class="num">$ (17,039,898)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract', window );"><strong>Denominator - basic and diluted:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average common shares outstanding, basic</a></td>
<td class="nump">13,612,677<span></span>
</td>
<td class="nump">4,950,129<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average common shares outstanding, diluted</a></td>
<td class="nump">13,612,677<span></span>
</td>
<td class="nump">4,950,129<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share, basic</a></td>
<td class="num">$ (2.46)<span></span>
</td>
<td class="num">$ (3.44)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share, diluted</a></td>
<td class="num">$ (2.46)<span></span>
</td>
<td class="num">$ (3.44)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140649893438632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share Attributable to Common Stockholders - Antidilutive effect (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total shares of common stock equivalents</a></td>
<td class="nump">2,859,544<span></span>
</td>
<td class="nump">10,670,872<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=imrx_SeriesConvertiblePreferredStockMember', window );">Series A Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total shares of common stock equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,494,306<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=imrx_SeriesBConvertiblePreferredStockMember', window );">Series B Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total shares of common stock equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,066,995<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Common stock warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total shares of common stock equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">308,308<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Common stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total shares of common stock equivalents</a></td>
<td class="nump">2,859,544<span></span>
</td>
<td class="nump">1,801,263<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=imrx_SeriesConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=imrx_SeriesConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=imrx_SeriesBConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=imrx_SeriesBConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140649896704712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Narratives (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 23, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,802,623<span></span>
</td>
<td class="nump">$ 1,086,769<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,452,462<span></span>
</td>
<td class="nump">343,169<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Grant date weighted average fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.29<span></span>
</td>
<td class="nump">$ 3.06<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares reserved for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,859,544<span></span>
</td>
<td class="nump">10,670,872<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=imrx_StockIncentivePlan2015Member', window );">Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,802,623<span></span>
</td>
<td class="nump">$ 1,086,769<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Compensation expense remaining to be recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,403,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Compensation expense recognized over a weighted-average period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 11 months 4 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=imrx_StockIncentivePlan2015Member', window );">Incentive Plan | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares reserved for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,825,173<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=imrx_TwoThousandTwentyOneEmployeeStockPurchasePlanMember', window );">2021 ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=imrx_TwoThousandTwentyOneEmployeeStockPurchasePlanMember', window );">2021 ESPP | Class A Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares reserved for future issuance</a></td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imrx_PercentageOfAggregateNumberOfSharesOutstanding', window );">Aggregate number of shares outstanding (as a percent)</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=imrx_TwoThousandTwentyOneEmployeeStockPurchasePlanMember', window );">2021 ESPP | Maximum | Class A Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">3,340,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=imrx_TwoThousandTwentyOneIncentiveAwardPlanMember', window );">2021 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares reserved for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,298,432<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=imrx_TwoThousandTwentyOneIncentiveAwardPlanMember', window );">2021 Plan | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares reserved for future issuance</a></td>
<td class="nump">2,590,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imrx_PercentageOfAggregateNumberOfSharesOutstanding', window );">Aggregate number of shares outstanding (as a percent)</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=imrx_TwoThousandTwentyOneIncentiveAwardPlanMember', window );">2021 Plan | Maximum | Class A Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">15,350,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imrx_PercentageOfAggregateNumberOfSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of aggregate number of shares outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imrx_PercentageOfAggregateNumberOfSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=imrx_StockIncentivePlan2015Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=imrx_StockIncentivePlan2015Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=imrx_TwoThousandTwentyOneEmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=imrx_TwoThousandTwentyOneEmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=imrx_TwoThousandTwentyOneIncentiveAwardPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=imrx_TwoThousandTwentyOneIncentiveAwardPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140649895876440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Assumptions (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Weighted-average risk-free interest rate, minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.36%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Weighted-average risk-free interest rate, maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.45%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Expected volatility, minimum</a></td>
<td class="nump">66.76%<span></span>
</td>
<td class="nump">67.30%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Expected volatility, maximum</a></td>
<td class="nump">80.99%<span></span>
</td>
<td class="nump">80.85%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Weighted-average risk-free interest rate, minimum</a></td>
<td class="nump">0.89%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">5 years 9 months 29 days<span></span>
</td>
<td class="text">5 years 11 months 1 day<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">10 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140649892958072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - stock option activity (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at the beginning (in shares)</a></td>
<td class="nump">1,801,263<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">1,452,462<span></span>
</td>
<td class="nump">343,169<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares)</a></td>
<td class="num">(117,847)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRepurchased', window );">Repurchased (in shares)</a></td>
<td class="num">(276,334)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at the end (in shares)</a></td>
<td class="nump">2,859,544<span></span>
</td>
<td class="nump">1,801,263<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber', window );">Vested and exercisable (in shares)</a></td>
<td class="nump">1,102,543<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Vested and expected to vest (in shares)</a></td>
<td class="nump">2,859,544<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted Average Exercise Price per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price per Share Outstanding at the beginning (in dollars per share)</a></td>
<td class="nump">$ 3.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price per Share Granted (in dollars per share)</a></td>
<td class="nump">10.07<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price per Share Exercised (in dollars per share)</a></td>
<td class="nump">3.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imrx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsRepurchasedInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price per Share Repurchased (in dollars per share)</a></td>
<td class="nump">3.58<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price per Share Outstanding at the end (in dollars per share)</a></td>
<td class="nump">6.55<span></span>
</td>
<td class="nump">$ 3.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price per Share Vested and Exercisable (in dollars per share)</a></td>
<td class="nump">3.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price per Share Vested and Expected to Vest exercisable (in dollars per share)</a></td>
<td class="nump">$ 6.55<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Weighted Average Remaining Contractual Contractual Term</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Term (in years)</a></td>
<td class="text">8 years 3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contractual Term, Vested and exercisable (in Years)</a></td>
<td class="text">7 years 1 month 20 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contractual Term, Vested and expected to vest (in Years)</a></td>
<td class="text">8 years 3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract', window );"><strong>Aggregate Intrinsic Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value Outstanding</a></td>
<td class="nump">$ 27,615,466<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue', window );">Aggregate Intrinsic Value Vested and exercisable</a></td>
<td class="nump">14,507,723<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Aggregate Intrinsic Value Vested and expected to vest</a></td>
<td class="nump">$ 27,615,466<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRepurchased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares repurchased during the period under share based payment award.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRepurchased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imrx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsRepurchasedInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average exercise price of shares repurchased during the period under share based payment award.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imrx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsRepurchasedInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140649895654632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Share-based compensation expense (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">$ 1,802,623<span></span>
</td>
<td class="nump">$ 1,086,769<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember', window );">Cost of service</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">103,329<span></span>
</td>
<td class="nump">108,027<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">768,679<span></span>
</td>
<td class="nump">503,111<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">$ 930,615<span></span>
</td>
<td class="nump">$ 475,631<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140649895875736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Net loss and the effective income tax rate (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract', window );"><strong>Reconciliation of the effect of applying the federal statutory rate to the net loss and the effective income tax rate</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Statutory federal income tax rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State tax, net of federal benefit</a></td>
<td class="nump">5.50%<span></span>
</td>
<td class="nump">6.30%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense', window );">Permanent differences</a></td>
<td class="num">(0.60%)<span></span>
</td>
<td class="num">(1.50%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch', window );">Federal research and development credits</a></td>
<td class="nump">5.60%<span></span>
</td>
<td class="nump">4.50%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imrx_EffectiveIncomeTaxRateReconciliationTaxCreditStateResearchAndDevelopmentPercent', window );">State research and development credits</a></td>
<td class="nump">0.40%<span></span>
</td>
<td class="nump">0.60%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imrx_EffectiveIncomeTaxRateReconciliationUncertainTaxPositions', window );">Uncertain tax positions</a></td>
<td class="num">(0.60%)<span></span>
</td>
<td class="num">(1.00%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Other differences</a></td>
<td class="nump">0.70%<span></span>
</td>
<td class="num">(2.60%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="num">(31.10%)<span></span>
</td>
<td class="num">(27.30%)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective income tax rate</a></td>
<td class="nump">0.90%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imrx_EffectiveIncomeTaxRateReconciliationTaxCreditStateResearchAndDevelopmentPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state research and development tax credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imrx_EffectiveIncomeTaxRateReconciliationTaxCreditStateResearchAndDevelopmentPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imrx_EffectiveIncomeTaxRateReconciliationUncertainTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to uncertain tax positions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imrx_EffectiveIncomeTaxRateReconciliationUncertainTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140649896523752">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Net deferred tax assets (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 373,602<span></span>
</td>
<td class="nump">$ 73,984<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsUnrealizedCurrencyLosses', window );">Unrealized losses</a></td>
<td class="nump">12,990<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">R&amp;D credit carryforward</a></td>
<td class="nump">3,346,097<span></span>
</td>
<td class="nump">1,574,596<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">NOL carryforward</a></td>
<td class="nump">14,699,524<span></span>
</td>
<td class="nump">5,525,123<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Gross deferred tax assets</a></td>
<td class="nump">18,432,213<span></span>
</td>
<td class="nump">7,173,703<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(17,677,899)<span></span>
</td>
<td class="num">(7,127,448)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Net deferred tax assets</a></td>
<td class="nump">754,314<span></span>
</td>
<td class="nump">46,255<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesNetAbstract', window );"><strong>Net deferred tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses', window );">Prepaid expenses deducted for tax</a></td>
<td class="num">(425,755)<span></span>
</td>
<td class="num">(28,671)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment', window );">Tax depreciation in excess of book</a></td>
<td class="num">(328,559)<span></span>
</td>
<td class="num">(17,584)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Total deferred tax liabilities</a></td>
<td class="num">$ (754,314)<span></span>
</td>
<td class="num">$ (46,255)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfDeferredTaxAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(15)(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsUnrealizedCurrencyLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from unrealized losses on foreign currency transactions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsUnrealizedCurrencyLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax consequences attributable to taxable temporary differences derived from prepaid expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPrepaidExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140649895838760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 27, 2020</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 22, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,550,451<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized Tax Benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">380,902<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 174,950<span></span>
</td>
<td class="nump">$ 96,952<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued', window );">Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Domestic Tax Authority [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating Loss Carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56,544,731<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Domestic Tax Authority [Member] | Research Tax Credit Carryforward [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax Credit Carryforward, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,034,827<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imrx_TaxCreditCarryforwardIncreaseDecreaseCaresAct', window );">Tax Credit Carryforward, Increase (Decrease), CARES Act</a></td>
<td class="nump">$ 759,794<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State and Local Jurisdiction [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating Loss Carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51,310,112<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State and Local Jurisdiction [Member] | Research Tax Credit Carryforward [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax Credit Carryforward, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 394,013<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imrx_TaxCreditCarryforwardIncreaseDecreaseCaresAct', window );">Tax Credit Carryforward, Increase (Decrease), CARES Act</a></td>
<td class="nump">$ 93,437<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=imrx_BioArkiveIncMember', window );">BioArkive Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 307,485<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxesBusinessCombinationValuationAllowanceAvailableToReduceIncomeTaxExpense', window );">Deferred Taxes, Business Combination, Valuation Allowance, Available to Reduce Income Tax Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 304,485<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 304,485<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imrx_TaxCreditCarryforwardIncreaseDecreaseCaresAct">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in t tax credit carryforward from application of the Coronavirus Aid, Relief, and Economic Security (CARES) Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imrx_TaxCreditCarryforwardIncreaseDecreaseCaresAct</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxesBusinessCombinationValuationAllowanceAvailableToReduceIncomeTaxExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the valuation allowance recorded in a business combination against deductible temporary differences for which related tax benefits will be recorded as a reduction of the acquired entity's income tax expense (after such benefits are first being applied to reduce goodwill and then other noncurrent intangible assets to zero).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 740<br> -Section 25<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123403335&amp;loc=d3e9901-128506<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxesBusinessCombinationValuationAllowanceAvailableToReduceIncomeTaxExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=imrx_BioArkiveIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=imrx_BioArkiveIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140649895682520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Unrecognized tax benefits (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward', window );"><strong>Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Beginning balance</a></td>
<td class="nump">$ 174,950<span></span>
</td>
<td class="nump">$ 96,952<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Increase due to current year tax provision</a></td>
<td class="nump">205,952<span></span>
</td>
<td class="nump">77,998<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Ending balance</a></td>
<td class="nump">$ 380,902<span></span>
</td>
<td class="nump">$ 174,950<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140649893265000">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Narratives (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Dec. 22, 2021 </div>
<div>agreement</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right of use asset</a></td>
<td class="nump">$ 5,324,198<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 613,103<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=imrx_BioArkiveIncMember', window );">BioArkive Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right of use asset</a></td>
<td class="nump">4,824,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Lease liability</a></td>
<td class="nump">$ 4,824,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imrx_NumberOfLeasesObligationsAssumed', window );">Number of Leases Obligations Assumed</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseContractualTermAxis=imrx_LeaseTerminationOnApril302032Member', window );">Lease Termination on April 30, 2032 [Member] | BioArkive Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imrx_AreaOfPropertyUnderLease', window );">Area of Property Under Lease | ft&#178;</a></td>
<td class="nump">38,613<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseContractualTermAxis=imrx_LeaseTerminationOnDecember312022Member', window );">Lease Termination on December 31, 2022 [Member] | BioArkive Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imrx_AreaOfPropertyUnderLease', window );">Area of Property Under Lease | ft&#178;</a></td>
<td class="nump">6,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseContractualTermAxis=imrx_LeaseTerminationOnMarch312024Member', window );">Lease Termination on March 31, 2024 [Member] | BioArkive Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imrx_AreaOfPropertyUnderLease', window );">Area of Property Under Lease | ft&#178;</a></td>
<td class="nump">4,760<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=imrx_OfficeSpaceInCambridgeMassachusettsNewYorkMember', window );">Office Space In Cambridge, Massachusetts, New York [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">Minimum lease payment due 2022</a></td>
<td class="nump">$ 30,840<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=imrx_StorageSpaceInSomervilleMassachusettsMember', window );">Storage Space In Somerville, Massachusetts [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">Minimum lease payment due 2022</a></td>
<td class="nump">3,569<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=imrx_OfficeLeaseInSanDiegoCalifornia2020Member', window );">2020 San Diego Lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">Minimum lease payment due 2022</a></td>
<td class="nump">659,990<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">67 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right of use asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 637,863<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Lease liability</a></td>
<td class="nump">$ 5,364,936<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 637,863<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imrx_AreaOfPropertyUnderLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area of property under lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imrx_AreaOfPropertyUnderLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imrx_NumberOfLeasesObligationsAssumed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of lease obligations acquired in business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imrx_NumberOfLeasesObligationsAssumed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=imrx_BioArkiveIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=imrx_BioArkiveIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=imrx_LeaseTerminationOnApril302032Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=imrx_LeaseTerminationOnApril302032Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=imrx_LeaseTerminationOnDecember312022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=imrx_LeaseTerminationOnDecember312022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=imrx_LeaseTerminationOnMarch312024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=imrx_LeaseTerminationOnMarch312024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=imrx_OfficeSpaceInCambridgeMassachusettsNewYorkMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=imrx_OfficeSpaceInCambridgeMassachusettsNewYorkMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=imrx_StorageSpaceInSomervilleMassachusettsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=imrx_StorageSpaceInSomervilleMassachusettsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=imrx_OfficeLeaseInSanDiegoCalifornia2020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=imrx_OfficeLeaseInSanDiegoCalifornia2020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140649893373688">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Maturities of the lease liabilities due (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Oct. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion lease liability</a></td>
<td class="nump">$ 274,039<span></span>
</td>
<td class="nump">$ 76,322<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Lease liability, noncurrent</a></td>
<td class="nump">5,090,897<span></span>
</td>
<td class="nump">$ 544,767<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=imrx_OfficeLeaseInSanDiegoCalifornia2020Member', window );">2020 San Diego Lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2022</a></td>
<td class="nump">659,990<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2023</a></td>
<td class="nump">880,121<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2024</a></td>
<td class="nump">894,044<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2025</a></td>
<td class="nump">906,839<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2026</a></td>
<td class="nump">819,210<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">4,467,246<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total future lease payments</a></td>
<td class="nump">8,627,450<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: Imputed interest</a></td>
<td class="nump">3,262,514<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total lease liabilities</a></td>
<td class="nump">5,364,936<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 637,863<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion lease liability</a></td>
<td class="nump">274,039<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Lease liability, noncurrent</a></td>
<td class="nump">$ 5,090,897<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=imrx_OfficeLeaseInSanDiegoCalifornia2020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=imrx_OfficeLeaseInSanDiegoCalifornia2020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140649893257128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Lease cost (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCostAbstract', window );"><strong>Lease costs:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">$ 160,872<span></span>
</td>
<td class="nump">$ 66,652<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermLeaseCost', window );">Short-term lease cost</a></td>
<td class="nump">258,357<span></span>
</td>
<td class="nump">252,796<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,700<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total lease costs</a></td>
<td class="nump">419,229<span></span>
</td>
<td class="nump">334,148<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imrx_OperatingLeaseAdditionalInformationAbstract', window );"><strong>Cash paid for amounts included in the measurement of lease liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating cash flows from operating leases</a></td>
<td class="nump">111,527<span></span>
</td>
<td class="nump">58,666<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermLeasePayments', window );">Operating cash flows from short-term leases</a></td>
<td class="nump">236,700<span></span>
</td>
<td class="nump">252,796<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imrx_LeasePayments', window );">Total lease Payment</a></td>
<td class="nump">$ 348,227<span></span>
</td>
<td class="nump">$ 311,462<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average remaining lease term - operating leases</a></td>
<td class="text">9 years 7 months 13 days<span></span>
</td>
<td class="text">5 years 3 months 29 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average discount rate - operating leases</a></td>
<td class="nump">9.70%<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imrx_LeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total cash paid towards operating lease payment including short term lease payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imrx_LeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imrx_OperatingLeaseAdditionalInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imrx_OperatingLeaseAdditionalInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term lease cost, excluding expense for lease with term of one month or less.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for short-term lease payment excluded from lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>imrx-20211231x10k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2021q4"
  xmlns:imrx="http://immuneering.com/20211231"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2021-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="imrx-20211231.xsd" xlink:type="simple"/>
    <context id="As_Of_8_3_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_boKn2a2ouUyMVqODG0-nIw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790340</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-03</instant>
        </period>
    </context>
    <context id="As_Of_5_31_2021_us-gaap_StatementClassOfStockAxis_imrx_SeriesBConvertiblePreferredStockTrancheTwoMember_-1LYWcxnHk6UK-Jcbi7Lpw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790340</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">imrx:SeriesBConvertiblePreferredStockTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-05-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2021_us-gaap_StatementClassOfStockAxis_imrx_SeriesBConvertiblePreferredStockTrancheTwoMember_h-jV1278D0iiS0qgsgtv3A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790340</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">imrx:SeriesBConvertiblePreferredStockTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_imrx_SeriesBConvertiblePreferredStocksTrancheOneMember_bShZaSXyFkGkXYNwg6aJxA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790340</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">imrx:SeriesBConvertiblePreferredStocksTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_9_20_2019_us-gaap_StatementClassOfStockAxis_imrx_SeriesConvertiblePreferredStockMember_CgdZd9wu3UC4tGQyNK6KPA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790340</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">imrx:SeriesConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-20</instant>
        </period>
    </context>
    <context id="As_Of_1_31_2020_us-gaap_StatementClassOfStockAxis_imrx_SeriesConvertiblePreferredStockMember_Tref9-4zckC3A4JsB3VTMA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790340</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">imrx:SeriesConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_imrx_SeriesConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_S2X3YlpbP0KTx8Hppox5ig">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790340</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">imrx:SeriesConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_imrx_SeriesBConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_QCBVyWaLKkO0RDEZzs9qkw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790340</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">imrx:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_LnfVME6pk0eWF42mjJCPCQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790340</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_StatementClassOfStockAxis_imrx_SeriesConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_gIVkAxfsP0yONnc4vwzOSw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790340</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">imrx:SeriesConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_QXRL0wO1MkWoDTBf_1Gh7w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790340</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember_8yiTbINkMkqUQTRVdOLgQw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790340</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember_CoisecZ1RkWQ4NibnKtk2g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790340</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_MxWqlzAiY0eQbIPd0DtYAA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790340</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_8_3_2021_To_8_3_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_nbYOiYQZAUed9mAOrNTolQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790340</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-03</startDate>
            <endDate>2021-08-03</endDate>
        </period>
    </context>
    <context id="Duration_8_3_2021_To_8_3_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_G9SnpifyxEmaJU1UE794ew">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790340</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-03</startDate>
            <endDate>2021-08-03</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_imrx_SeriesConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_IX7LGz4dkECxr-BxWs_jAw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790340</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">imrx:SeriesConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_7_23_2021_To_7_23_2021_He5Glc1OZUuR4Os2aqbeew">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790340</identifier>
        </entity>
        <period>
            <startDate>2021-07-23</startDate>
            <endDate>2021-07-23</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_ovzfxk9860SdXNv_qQhcsg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790340</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_dPK7_g2dsk-p4OLSSYVc-g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790340</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_bsF1orxDUUG1aHLclUMt2g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790340</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_VV_zTjXofUy1ORoRFXwUxw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790340</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_bPrhx3BPa0qPRD7gVwy7FA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790340</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_h6gPSE4xM0ayt1JfJR8qkA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790340</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_9W3qoLMgdUiyVG8R6gDuuQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790340</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_5hpgxWyzr0iIgVEP8sXbRw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790340</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_EWjFOikEMEGNPdcpkhlgHw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790340</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_jy9qZmEtiE6UB1aH8SvR-w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790340</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="Duration_7_23_2021_To_7_23_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_PlanNameAxis_imrx_TwoThousandTwentyOneIncentiveAwardPlanMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember__dnvok_t1k-ok2gZh6_g4Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790340</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">imrx:TwoThousandTwentyOneIncentiveAwardPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-23</startDate>
            <endDate>2021-07-23</endDate>
        </period>
    </context>
    <context id="Duration_7_23_2021_To_7_23_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_PlanNameAxis_imrx_TwoThousandTwentyOneEmployeeStockPurchasePlanMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_EGe_9LAr1062vI9kah96gg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790340</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">imrx:TwoThousandTwentyOneEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-23</startDate>
            <endDate>2021-07-23</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_imrx_TwoThousandTwentyOneEmployeeStockPurchasePlanMember_ZkFEiJ1N4E69ZN1lBj-gpw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790340</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">imrx:TwoThousandTwentyOneEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MinimumMember_kkvfHzsY3kuLg_xs_U9vtw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790340</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_SGUutfcD1kqmyGRE2MRtsg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790340</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_srt_RangeAxis_srt_MinimumMember_Ozt2OiOHCkmkib6hyeBSlQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790340</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_srt_RangeAxis_srt_MaximumMember_a5iqF3xs7Uao9VNTsL_jaw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790340</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_imrx_BioArkiveIncMember_TX8VFVwjvkmlDFzOu0fzHw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790340</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">imrx:BioArkiveIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_imrx_BioArkiveIncMember_sa3-bf410kC_Z3vN1a5IFw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790340</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">imrx:BioArkiveIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdsAndLeaseholdImprovementsMember_avFoqBKbtEy-F0FmYKH8ng">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790340</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdsAndLeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdsAndLeaseholdImprovementsMember_SvHfzMjnikSnHY-nhQSILg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790340</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdsAndLeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_HoHJdekunkWYrj04U5neCw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790340</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_twFlKCzRuEusunTslMr32A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790340</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_imrx_LabEquipmentMember_GI3DHb_K8EizCH_U5WinCA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790340</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">imrx:LabEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_bZau0xYq2Eux-_CkfhyDgw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790340</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_XLMYvLxYDEmGm0OC6_nT-A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790340</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember__c5PFKa--kCuxwpGGlOIrg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790340</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_imrx_LabEquipmentMember_WQeNLQggXkGO-8Q1oHgFeQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790340</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">imrx:LabEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_ZN2vm0JtIkGqEGwjZuOpmA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790340</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_ISSEkI2XdEmI7m0_HrAVEw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790340</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_StatementClassOfStockAxis_imrx_SeriesConvertiblePreferredStockMember_ArKyrrqRQE6HOj-7SNUhxw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790340</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">imrx:SeriesConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_imrx_SeriesBConvertiblePreferredStockMember_-C13Ii99_069N31zQd1hmQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790340</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">imrx:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementClassOfStockAxis_imrx_SeriesConvertiblePreferredStockMember_hF8oI6VuEUaTinProxudjw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790340</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">imrx:SeriesConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementClassOfStockAxis_imrx_SeriesBConvertiblePreferredStockMember_b0zil8ikRUOsnQGwGFI2sw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790340</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">imrx:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_8_3_2021_To_8_3_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_7enA8yNRQkat6QV_1FoEOw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790340</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-03</startDate>
            <endDate>2021-08-03</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2021_srt_RangeAxis_srt_MinimumMember_0vGLrM36lEegdT0dgFrRAQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790340</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="Duration_4_1_2021_To_5_31_2021_us-gaap_StatementClassOfStockAxis_imrx_SeriesBConvertiblePreferredStockTrancheTwoMember_3Z1Gf_8wlESSr2qfBuPkyQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790340</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">imrx:SeriesBConvertiblePreferredStockTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-05-31</endDate>
        </period>
    </context>
    <context id="Duration_12_1_2020_To_12_31_2020_us-gaap_StatementClassOfStockAxis_imrx_SeriesBConvertiblePreferredStocksTrancheOneMember_CqCA_MA7zUSGLHpsb-XgQQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790340</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">imrx:SeriesBConvertiblePreferredStocksTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_1_31_2020_us-gaap_StatementClassOfStockAxis_imrx_SeriesConvertiblePreferredStockMember_YK2LK50_8US_qyrO8ejjbA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790340</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">imrx:SeriesConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-01-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementClassOfStockAxis_imrx_SeriesConvertiblePreferredStockMember_gEfHGMh_TEuDzZN3KX78bg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790340</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">imrx:SeriesConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_TI6BHD47C0iaSPM1OYc68Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790340</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_E6Pqm-5XGEGHnxL47x05BA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790340</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_6VOCtAPe5UC8u2hi-12dxg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790340</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_5VXgVFJHWUybWtDAZklDIQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790340</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_ZzxD3WXn2kaEmrcG06sDqg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790340</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_10_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_imrx_OfficeLeaseInSanDiegoCalifornia2020Member_fOyKDK4i2USSpVi4_ouoxw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790340</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">imrx:OfficeLeaseInSanDiegoCalifornia2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_imrx_StorageSpaceInSomervilleMassachusettsMember_kCYYiCYXakieYFKlIrPRQg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790340</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">imrx:StorageSpaceInSomervilleMassachusettsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_imrx_OfficeSpaceInCambridgeMassachusettsNewYorkMember_Qma-pjDe6kSAepAJusrqDA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790340</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">imrx:OfficeSpaceInCambridgeMassachusettsNewYorkMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_imrx_OfficeLeaseInSanDiegoCalifornia2020Member_1elFJvUqZUChk73Bzb2TRg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790340</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">imrx:OfficeLeaseInSanDiegoCalifornia2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_PlanNameAxis_imrx_StockIncentivePlan2015Member_yJ3Soj1ueEaHyYoF06Bg_g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790340</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">imrx:StockIncentivePlan2015Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_BalanceSheetLocationAxis_us-gaap_AccountsPayableAndAccruedLiabilitiesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_imrx_BioArkiveIncMember_Fdx8Pw88t0GYE-WWz9kZLQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790340</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsPayableAndAccruedLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">imrx:BioArkiveIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2017_To_12_31_2017_us-gaap_BusinessAcquisitionAxis_imrx_BioArkiveIncMember_eCOuV4siy0CntVgmBRHjJw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790340</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">imrx:BioArkiveIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="Duration_9_20_2019_To_9_20_2019_us-gaap_StatementClassOfStockAxis_imrx_SeriesConvertiblePreferredStockMember_lHzkW0d_2keHgOLQonVBGg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790340</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">imrx:SeriesConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-09-20</startDate>
            <endDate>2019-09-20</endDate>
        </period>
    </context>
    <context id="As_Of_8_3_2021_atfZ3VjOmEGor-TZ8PR3vw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790340</identifier>
        </entity>
        <period>
            <instant>2021-08-03</instant>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_MajorCustomersAxis_imrx_CustomerTwoMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_Otularec102-GYy-rhKAFA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790340</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">imrx:CustomerTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_MajorCustomersAxis_imrx_CustomerOneMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_oWqze6TNHUeol6NT43Q40A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790340</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">imrx:CustomerOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_MajorCustomersAxis_imrx_CustomerOneMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_P-jE_XQSn0Kh-0-xrDlmZQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790340</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">imrx:CustomerOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_MajorCustomersAxis_imrx_CustomerFiveMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_gk7zsuubm020Nb-hEXSapw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790340</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">imrx:CustomerFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_srt_MajorCustomersAxis_imrx_CustomerTwoMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_aTYR5oNrDkmFoJWCgdwsfQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790340</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">imrx:CustomerTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_srt_MajorCustomersAxis_imrx_CustomerTwoMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_lmfLr2N_xUWRAFF-XxH5Jg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790340</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">imrx:CustomerTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_srt_MajorCustomersAxis_imrx_CustomerThreeMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_8wa3w0Ph8ke11E8Tb0NuUA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790340</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">imrx:CustomerThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_srt_MajorCustomersAxis_imrx_CustomerOneMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_cn0C_B-BXUyAAsOsAChyRA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790340</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">imrx:CustomerOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_srt_MajorCustomersAxis_imrx_CustomerOneMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_0Q_fVsZyC0qSpcRATuE8jw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790340</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">imrx:CustomerOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_srt_MajorCustomersAxis_imrx_CustomerFourMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_wyidH8d1zk-PDM7YDj9tdg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790340</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">imrx:CustomerFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_srt_MajorCustomersAxis_imrx_CustomerFourMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_FbdxXK1INke9vC8EPGq7hQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790340</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">imrx:CustomerFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_srt_MajorCustomersAxis_imrx_CustomerFiveMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_DPXYIsD2zUO9cvTMSKl0VA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790340</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">imrx:CustomerFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_8_3_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_d6wIH2lUEkOg0doA4WJViw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790340</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-03</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_4sABCVevMkafGdslrmVHRg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790340</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_Mo7QF875vUy5d2OcEbQ2fA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790340</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_8_3_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_ncRRUXx0q0atI42UV2_87w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790340</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-03</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_B1xkq5tyC0Czi0WWYygW9Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790340</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_IvXJ6RHxqkyGTfDbgXwHsw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790340</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_PlanNameAxis_imrx_StockIncentivePlan2015Member_hVx7NwJaA026vu03npu7HA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790340</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">imrx:StockIncentivePlan2015Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_EmployeeStockOptionMember_rlnPrQOdyEaM-QEeHvlTjQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790340</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_PlanNameAxis_imrx_TwoThousandTwentyOneIncentiveAwardPlanMember_LI5PlJ73VUKxQRLedBtGOQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790340</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">imrx:TwoThousandTwentyOneIncentiveAwardPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_7_23_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_PlanNameAxis_imrx_TwoThousandTwentyOneIncentiveAwardPlanMember_MwQmN40XTUqTS51FC7b-vQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790340</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">imrx:TwoThousandTwentyOneIncentiveAwardPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-23</instant>
        </period>
    </context>
    <context id="As_Of_7_23_2021_us-gaap_PlanNameAxis_imrx_TwoThousandTwentyOneEmployeeStockPurchasePlanMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_oj9jqMIrFkaE72Eovxv2mw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790340</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">imrx:TwoThousandTwentyOneEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-23</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_WarrantMember_7wU2uI3NZ0SsDzZ_Fr8ZyQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790340</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_EmployeeStockOptionMember_me35404Y-kWEl2teCnSUVg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790340</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_imrx_SeriesConvertiblePreferredStockMember_LQiWJpT45k-D9eZ63E0DAw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790340</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">imrx:SeriesConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_g3mjqkDWB0-f2XKJf0YL-A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790340</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_FairValueByAssetClassAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_tGSOwi1HF0iLCEdWOlktoQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790340</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_FairValueByAssetClassAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_N9UIc66mekClPPydSVC05g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790340</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_l3XprlCXTkaFiHyKLJ8O2Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790340</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_7uvXNSojR0qxLk1Ubdsmfg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790340</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_VHW5LVIB6Ee8uLYurHx4cw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790340</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_imrx_SeriesConvertiblePreferredStockMember_zQGWKL5kWkOEqyx46cK5mg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790340</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">imrx:SeriesConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_imrx_SeriesBConvertiblePreferredStockMember_HJNQLItNRU-hYpDpxqiSoQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790340</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">imrx:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_ZzhQndqazkWQw1a8tNpx5w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790340</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_q0lSZG3emUWjV7QOWezTNQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790340</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_dQH6PYSm8ke4t8B5Xp8bAw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790340</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_imrx_StockIncentivePlan2015Member_1tvXqAKRfEm4AKlfifgVpg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790340</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">imrx:StockIncentivePlan2015Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_PenqHZkD4kiUSIeznQQKKw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790340</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_hOzxdtEG0UaD56zlDOhRBw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790340</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_hRS8KqtkvEKMap0WY0snUg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790340</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_PlanNameAxis_imrx_StockIncentivePlan2015Member_za8LgT3DyUmYmEzDhCQL2Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790340</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">imrx:StockIncentivePlan2015Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_QLhYrVZJX02K66IZYiKorA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790340</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2021_srt_MajorCustomersAxis_imrx_CustomerOneMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_BcRwAfOKVEeK4vZFJJoMnw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790340</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">imrx:CustomerOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_srt_MajorCustomersAxis_imrx_CustomerTwoMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_HSU6DmbswUiywLkXXqH83Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790340</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">imrx:CustomerTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_srt_MajorCustomersAxis_imrx_CustomerOneMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_7bxZ7DlQSkOfAj7fvd-5pw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790340</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">imrx:CustomerOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_srt_MajorCustomersAxis_imrx_CustomerFourMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_Aa9AiVV9H0q60bn77lAIvQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790340</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">imrx:CustomerFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_srt_MajorCustomersAxis_imrx_CustomerFiveMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_odT76IUTqEO-M3mGDrx6QQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790340</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">imrx:CustomerFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_12_31_2019_Q2tKCguYn0Sp3Siw9cnC0w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790340</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="Duration_6_1_2021_To_6_30_2021_xjkMHQi3F0anA1B9rBC7Fg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790340</identifier>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_imrx_SeriesBConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_8mJv2jJa6UumRofouB70lA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790340</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">imrx:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementClassOfStockAxis_imrx_SeriesConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_JPabAp5qAEmR2gD7LN_b7A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790340</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">imrx:SeriesConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementClassOfStockAxis_imrx_SeriesBConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_39QT10BRPUmkcB-ZGBN9mQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790340</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">imrx:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_uitXKHVUDEugKPJ0WrK0pw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790340</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_StatementClassOfStockAxis_imrx_SeriesConvertiblePreferredStockMember_DFd25cydBkuiug-BF6zGWQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790340</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">imrx:SeriesConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2019_us-gaap_StatementClassOfStockAxis_imrx_SeriesConvertiblePreferredStockMember_O1RMY__04UyGW5MdXmEk9Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790340</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">imrx:SeriesConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_StatementClassOfStockAxis_imrx_SeriesConvertiblePreferredStockMember_ncQIkgAZqEWsymLXhsJ6yg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790340</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">imrx:SeriesConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_imrx_SeriesConvertiblePreferredStockMember_DzBbn1vSGECYmtSe-hivlw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790340</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">imrx:SeriesConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementClassOfStockAxis_imrx_SeriesBConvertiblePreferredStockMember_TDIXNGLBjEmH6HPuewiRjg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790340</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">imrx:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="Duration_3_27_2020_To_3_27_2020_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember_5FkHeRTRFUWenXHcqclDDQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790340</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-27</startDate>
            <endDate>2020-03-27</endDate>
        </period>
    </context>
    <context id="Duration_3_27_2020_To_3_27_2020_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember_SFNqtQEhiUilg2XoqHi-NA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790340</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-27</startDate>
            <endDate>2020-03-27</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_E-RNnZgaG06hPQcsgQNOlA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790340</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_GoNlf5JQWEKfwIjieg6jCA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790340</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_12_31_2019_To_12_31_2019_us-gaap_StatementClassOfStockAxis_imrx_SeriesConvertiblePreferredStockMember___WeTNXDqEKrDBAIVc3wUA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790340</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">imrx:SeriesConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-31</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_imrx_SeriesBConvertiblePreferredStockMember_lxbE9uvMQU-NU7BxZ_aTNg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790340</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">imrx:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="Duration_7_23_2021_To_7_23_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_PlanNameAxis_imrx_TwoThousandTwentyOneIncentiveAwardPlanMember_BLWmGGSlg0221-_bauHKMg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790340</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">imrx:TwoThousandTwentyOneIncentiveAwardPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-23</startDate>
            <endDate>2021-07-23</endDate>
        </period>
    </context>
    <context id="Duration_7_23_2021_To_7_23_2021_us-gaap_PlanNameAxis_imrx_TwoThousandTwentyOneEmployeeStockPurchasePlanMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_wllzZzefAkGrL1ozzU9u1Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790340</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">imrx:TwoThousandTwentyOneEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-23</startDate>
            <endDate>2021-07-23</endDate>
        </period>
    </context>
    <context id="As_Of_8_3_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_kxYscz4Wf02VzWLhksRRxw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790340</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-03</instant>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_6Dv2gap2qUy2S6CUjLz70A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790340</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_Vps21bPl-0ucIcde4LcmUQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790340</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_J2SvXNqcwUW3WhIW-fbZTA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790340</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_XcWBVd3ItkaUL02nw_Pu2g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790340</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_imrx_SeriesBConvertiblePreferredStockMember_-Ckh5K8N7U-_9nyMHjiJxQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790340</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">imrx:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_BusinessAcquisitionAxis_imrx_BioArkiveIncMember__OkMddmPKES0gb3KLXJAbw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790340</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">imrx:BioArkiveIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasurySecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_TueSJDcFvk-6KVBcFb4yWg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790340</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_FairValueByAssetClassAxis_us-gaap_CommercialPaperMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_sHUMvfiqDEWTLNwGi2V19w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790340</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_FairValueByAssetClassAxis_imrx_GovernmentSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_rv952rznEk2GkuC-bXIEgw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790340</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">imrx:GovernmentSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasurySecuritiesMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_GndZSZIX5kONkZeJ-uwZvA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790340</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_XD-w4rYEvkOhxL7DPVZDYA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790340</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_DcZ3E7WdG0qTM9kwKkYCCA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790340</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_FairValueByAssetClassAxis_us-gaap_CommercialPaperMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_0brBfUV_8k-73Ah2xvo5vA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790340</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_FairValueByAssetClassAxis_imrx_GovernmentSecuritiesMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_hYwzM8-hekGhWFHX6of5Fg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790340</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">imrx:GovernmentSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_NZFKYXEtB0ypESwMFRZYaA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790340</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_ypcv1cNyLUqWUpUVKo2bMg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790340</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_imrx_GovernmentSecuritiesMember__6KtOh0dNkKDNENoMm1rTg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790340</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">imrx:GovernmentSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember_CWayHsb0d0ChYaEcAr7tvw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790340</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_J_O9OcmviUi8EDFgokrY1Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790340</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_12_22_2021_To_12_22_2021_us-gaap_BusinessAcquisitionAxis_imrx_BioArkiveIncMember_jaVHRkxuBESGO6YkECH_Bw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790340</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">imrx:BioArkiveIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-22</startDate>
            <endDate>2021-12-22</endDate>
        </period>
    </context>
    <context id="As_Of_12_22_2021_us-gaap_BusinessAcquisitionAxis_imrx_BioArkiveIncMember_eZfDAI7yG0yVohELE3M0sA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790340</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">imrx:BioArkiveIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-22</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_BusinessAcquisitionAxis_imrx_BioArkiveIncMember_us-gaap_LeaseContractualTermAxis_imrx_LeaseTerminationOnMarch312024Member_Foc4ig67vEu40iyOKMsf_Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790340</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">imrx:BioArkiveIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">imrx:LeaseTerminationOnMarch312024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_BusinessAcquisitionAxis_imrx_BioArkiveIncMember_us-gaap_LeaseContractualTermAxis_imrx_LeaseTerminationOnDecember312022Member_dRAvJgmyQ02SlSKbOR13YQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790340</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">imrx:BioArkiveIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">imrx:LeaseTerminationOnDecember312022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_BusinessAcquisitionAxis_imrx_BioArkiveIncMember_us-gaap_LeaseContractualTermAxis_imrx_LeaseTerminationOnApril302032Member_dW7b99b4G0eqpEl5CucuWA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790340</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">imrx:BioArkiveIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">imrx:LeaseTerminationOnApril302032Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_TBpjtOXgEkKQahJJAv0aWg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790340</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_OUSLyqWONEO8ccGPC6rBdg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790340</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_3_3_2022_p8E7gto4PE--fHqym2mFLg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790340</identifier>
        </entity>
        <period>
            <instant>2022-03-03</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2021_20XVqP3RqUOqbOiTPzCGHQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790340</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="As_Of_3_3_2022_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_weiDmNWAfEO5BLuMYcU-IQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790340</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-03</instant>
        </period>
    </context>
    <context id="As_Of_3_3_2022_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_OPmYWjUA4Uatqa9PkXwy4Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790340</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-03</instant>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001790340</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <unit id="Unit_Standard_segment_tQmfuIJwOkyVlCDJy8sORg">
        <measure>imrx:segment</measure>
    </unit>
    <unit id="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ">
        <measure>shares</measure>
    </unit>
    <unit id="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Unit_Standard_sqft_pKK1i40-n0WN8q6DXkNohQ">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="Unit_Standard_pure_iothMaWWqUCV2N7d1PVg4w">
        <measure>pure</measure>
    </unit>
    <unit id="Unit_Standard_D_qWJwQorwfUaf88ueMyElMA">
        <measure>imrx:D</measure>
    </unit>
    <unit id="Unit_Standard_agreement_qexq1bbkzU-JqgEPv8PRCQ">
        <measure>imrx:agreement</measure>
    </unit>
    <unit id="Unit_Standard_tranche_5kfv1Y9uXkefgNW7HJS6Rw">
        <measure>imrx:tranche</measure>
    </unit>
    <unit id="Unit_Standard_Vote_y6IkSxDgD0SxcVMkCx6yHg">
        <measure>imrx:Vote</measure>
    </unit>
    <unit id="Unit_Divide_USD_shares_0VraXufKhkCSOUw2U_zvgQ">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <us-gaap:CommitmentsAndContingencies
      contextRef="As_Of_12_31_2021_TBpjtOXgEkKQahJJAv0aWg"
      id="Hidden_OhL8gcvAuECVVyj9LyojJg"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="As_Of_12_31_2020_OUSLyqWONEO8ccGPC6rBdg"
      id="Hidden_J5Pumsw9HUmipxi7ENxUPQ"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="As_Of_12_31_2021_TBpjtOXgEkKQahJJAv0aWg"
      id="Hidden_p0qpzbFkjUmIXyLPEuHubA"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="As_Of_12_31_2020_OUSLyqWONEO8ccGPC6rBdg"
      id="Hidden_k_f9J9mo9EKzdMWk3hhDaQ"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow"
      xsi:nil="true"/>
    <us-gaap:CommonStockValue
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_4sABCVevMkafGdslrmVHRg"
      id="Hidden_Ji_C-gw4jEO9BLC9_O7x-g"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow"
      xsi:nil="true"/>
    <us-gaap:CommonStockValue
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_B1xkq5tyC0Czi0WWYygW9Q"
      id="Hidden_opmngYKGQ0qph4W2tUy_MA"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow"
      xsi:nil="true"/>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ"
      decimals="2"
      id="Hidden_vIExmlqSA0il2FwIIjljsA"
      unitRef="Unit_Divide_USD_shares_0VraXufKhkCSOUw2U_zvgQ">-2.46</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2020_To_12_31_2020_J_O9OcmviUi8EDFgokrY1Q"
      decimals="2"
      id="Hidden_xSYZT51g4Ui4zgZUNzyrYw"
      unitRef="Unit_Divide_USD_shares_0VraXufKhkCSOUw2U_zvgQ">-3.44</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ"
      decimals="0"
      id="Hidden_xxMTkP-lV0-EgjeSauJGCQ"
      unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ">13612677</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2020_To_12_31_2020_J_O9OcmviUi8EDFgokrY1Q"
      decimals="0"
      id="Hidden_LgjYDMLh-0OSLo7VEn1Dag"
      unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ">4950129</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ"
      decimals="0"
      id="Hidden_ZBQ4Vc7h-U2qlaqOgmKYLA"
      unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ">13612677</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2020_To_12_31_2020_J_O9OcmviUi8EDFgokrY1Q"
      decimals="0"
      id="Hidden_EOmO9C6eMEyMPTXbq4Turg"
      unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ">4950129</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ"
      decimals="2"
      id="Hidden_wHopsXwjskSWOmAaEI9k1w"
      unitRef="Unit_Divide_USD_shares_0VraXufKhkCSOUw2U_zvgQ">-2.46</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2020_To_12_31_2020_J_O9OcmviUi8EDFgokrY1Q"
      decimals="2"
      id="Hidden_--dUy7H6lkGzBYeWkeucsA"
      unitRef="Unit_Divide_USD_shares_0VraXufKhkCSOUw2U_zvgQ">-3.44</us-gaap:EarningsPerShareDiluted>
    <dei:EntityCentralIndexKey
      contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ"
      id="Tc_OJuW22KhmUKXUGTPs5ImOw_2_1">0001790340</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ"
      id="Tc_j6iy_Nic5ECtbyOu55MOWw_3_1">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ"
      id="Tc_sMnNb6kjcES09Q__KWApSQ_4_1">2021</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ"
      id="Tc_t4DUm_EdPEywovp7vgv7-Q_5_1">FY</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ"
      id="Tc_LK4BPxeyG02cde1R1KUlhw_6_1">false</dei:AmendmentFlag>
    <dei:EntityRegistrantName
      contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ"
      id="Hidden_fgCtgpgTukmrynqB0FP_2Q">Immuneering Corp</dei:EntityRegistrantName>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_imrx_SeriesBConvertiblePreferredStockMember_-Ckh5K8N7U-_9nyMHjiJxQ"
      decimals="INF"
      id="Hidden_wF_0nJs4AUW7wStGe8GcEw"
      unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ">3619292</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_imrx_SeriesBConvertiblePreferredStockMember_lxbE9uvMQU-NU7BxZ_aTNg"
      decimals="INF"
      id="Hidden_xHMzK-FTbUiWCV2uN0nvTQ"
      unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ">0</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_imrx_SeriesConvertiblePreferredStockMember_DzBbn1vSGECYmtSe-hivlw"
      decimals="INF"
      id="Hidden_zcaSLU112UGCpUs8KvFQ0g"
      unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ">0</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_IvXJ6RHxqkyGTfDbgXwHsw"
      decimals="INF"
      id="Hidden_hQaWYsqo90Sb_sJvpMwkJA"
      unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ">4950129</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_Mo7QF875vUy5d2OcEbQ2fA"
      decimals="INF"
      id="Hidden_gM7yvl_Iukyupu2DzdISow"
      unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ">26320199</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_B1xkq5tyC0Czi0WWYygW9Q"
      decimals="INF"
      id="Hidden_mnf3gfljw0OxVAZJj6gZiA"
      unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ">0</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_B1xkq5tyC0Czi0WWYygW9Q"
      decimals="INF"
      id="Hidden_APJYaMAFZ06Y2loH3L6lNQ"
      unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ">0</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_4sABCVevMkafGdslrmVHRg"
      decimals="INF"
      id="Hidden_l9rZoBbeYUGiLVsuqepJnw"
      unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ">0</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:OperatingLeaseLiability
      contextRef="As_Of_10_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_imrx_OfficeLeaseInSanDiegoCalifornia2020Member_fOyKDK4i2USSpVi4_ouoxw"
      decimals="0"
      id="Hidden_XdPatEybTkShRMLsu6QibA"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">637863</us-gaap:OperatingLeaseLiability>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_imrx_SeriesConvertiblePreferredStockMember_LQiWJpT45k-D9eZ63E0DAw"
      decimals="INF"
      id="Hidden_2vNVcAnmu0eNuJvoPM638Q"
      unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ">2495933</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet
      contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ"
      decimals="0"
      id="Hidden_tlcK7EHhSU-TZzE4mXesaw"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_Mo7QF875vUy5d2OcEbQ2fA"
      decimals="INF"
      id="Hidden_lP6rYH5NMkSWKz0be_vdHw"
      unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ">26320199</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_IvXJ6RHxqkyGTfDbgXwHsw"
      decimals="INF"
      id="Hidden_hTzGFl4AukOhSIQvrJVGbw"
      unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ">4950129</us-gaap:CommonStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="As_Of_12_31_2020_OUSLyqWONEO8ccGPC6rBdg"
      decimals="INF"
      id="Hidden_xAjxILI03ki2sJwBPGEg8w"
      unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="As_Of_12_31_2021_TBpjtOXgEkKQahJJAv0aWg"
      decimals="INF"
      id="Hidden_EJkC4Tf1N0ygjQLvvTdsyA"
      unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ">0</us-gaap:PreferredStockSharesIssued>
    <dei:EntityPublicFloat
      contextRef="As_Of_6_30_2021_20XVqP3RqUOqbOiTPzCGHQ"
      decimals="-6"
      id="Hidden_NIPTNUHQak-BWzbjyzG2cw"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">0</dei:EntityPublicFloat>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_4sABCVevMkafGdslrmVHRg"
      decimals="INF"
      id="Hidden_lih2VwcAz0CbONCF8ELgIQ"
      unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ">0</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:OperatingLeaseLiability
      contextRef="As_Of_12_31_2021_us-gaap_BusinessAcquisitionAxis_imrx_BioArkiveIncMember__OkMddmPKES0gb3KLXJAbw"
      decimals="0"
      id="Hidden_CeuFDcEWwUiE1feAvMT7Lw"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">4824700</us-gaap:OperatingLeaseLiability>
    <dei:DocumentType
      contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ"
      id="Narr_2y4duOtGC0C97t5PWjNzDA">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ"
      id="Narr_nhVNZsQuAUKFaFF7BoupJw">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ"
      id="Narr_cC81JmeMX0qb3XZrthpnAA">2021-12-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ"
      id="Narr_Ed8UHnH9GEK7b7UjJSnCYw">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ"
      id="Narr_GZme4wgFREO9ke6_pVu52Q">001-40675</dei:EntityFileNumber>
    <dei:EntityIncorporationStateCountryCode
      contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ"
      id="Tc__hz45fiExUu7P-VUyMxKDQ_1_0">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ"
      id="Tc_UYp6ali34UW1ODYE8EeffQ_1_1">26-1976972</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ"
      id="Narr_rDLdcRWTuE6OXoMffCBnmg">245 Main St</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ"
      id="Narr_Me1MS0r_KUGWS1xZdFR2oA">Second Floor</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ"
      id="Narr_7QdLv-Wq_UqHaWqCt1N5hQ">Cambridge</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ"
      id="Narr_y_AyTNHgP0G3OPy0FWh5fw">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ"
      id="Narr_MxFx42XTxU2AFhVMORy4xQ">02142</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ"
      id="Narr_PBpZpNKtekarR1KNdcLxfw">617</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ"
      id="Narr_1zH5TmbT-kSVALW3Vd71Pg">500-8080</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ"
      id="Tc_Cy1uyUvOAE6jae--cca_LQ_2_0">Class A common Stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ"
      id="Tc_tJ_E766uG0a-LhSJl9Jung_2_2">IMRX</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ"
      id="Tc_HV9SkY2VRkOW6Odm9fGu9w_2_4">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ"
      id="Narr_TpDVNSNBOkGEtVQnhTNgqQ">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ"
      id="Narr_nrwFOWDlv0uAr0fbfJ72iQ">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ"
      id="Narr_XlxA4alyTEWGcH4hw8lbCg">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ"
      id="Narr_T21sPV326EyxPuQ0X6OrNA">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ"
      id="Tc_m8-H8smZQkCx-0uRiDlL_A_2_0">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ"
      id="Tc_OOUmGj_FMEKSvOfEqNijTA_2_3">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ"
      id="Tc_rxEBAH2wEk-uiAbzwkyZXQ_2_5">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod
      contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ"
      id="Narr_t4eMEeVoYUOYUm_fGIHxsw">false</dei:EntityExTransitionPeriod>
    <dei:IcfrAuditorAttestationFlag
      contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ"
      id="Narr_PVdroTc080ite5R-7I_oMA">false</dei:IcfrAuditorAttestationFlag>
    <dei:EntityShellCompany
      contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ"
      id="Narr_KReOYEtve0CL8w7X6gMbvA">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="As_Of_6_30_2021_20XVqP3RqUOqbOiTPzCGHQ"
      decimals="0"
      id="Narr_s0tITiBaAEypnba4bEd7jQ"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">0</dei:EntityPublicFloat>
    <dei:EntityPublicFloat
      contextRef="As_Of_3_3_2022_p8E7gto4PE--fHqym2mFLg"
      decimals="-5"
      id="Narr_0NtWfCKK80mO7TsXawl4WA"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">136900000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="As_Of_3_3_2022_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_OPmYWjUA4Uatqa9PkXwy4Q"
      decimals="INF"
      id="Narr_ZdP-Q77zekqnfYt-EJZS8A"
      unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ">26377299</dei:EntityCommonStockSharesOutstanding>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="As_Of_3_3_2022_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_weiDmNWAfEO5BLuMYcU-IQ"
      decimals="INF"
      id="Narr_TWO-MWv1gEKVlN08SMK_ew"
      unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ">0</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ"
      id="Tb_yn2GtPRkw0-5sFGYk_xC0w">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:3pt 0pt 0pt 0pt;"&gt;Portions of the registrant&#x2019;s Definitive Proxy Statement relating to the registrant&#x2019;s 2022 Annual Meeting of Stockholders to be filed with the Securities and Exchange Commission within 120 days of the end of the registrant&#x2019;s fiscal year ended December&#160;31, 2021 are incorporated by reference into Part III of this Annual Report on Form 10-K to the extent stated herein.&lt;/p&gt;</dei:DocumentsIncorporatedByReferenceTextBlock>
    <dei:AuditorFirmId
      contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ"
      id="Narr_xsV1-nvWcUmLGGhr35kEtA">49</dei:AuditorFirmId>
    <dei:AuditorName
      contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ"
      id="Narr_tGDmj-Iym0682hfrgFKbTw">RSM US LLP</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ"
      id="Narr_UwhcT2byQ0-wu3gkD8iOLQ">Boston, Massachusetts</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2021_TBpjtOXgEkKQahJJAv0aWg"
      decimals="0"
      id="Tc_Q-6GlEjgkEi-S2GsUzGcxw_5_3"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">74888145</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2020_OUSLyqWONEO8ccGPC6rBdg"
      decimals="0"
      id="Tc_wa_KapMYvUqWJgg2UiYZuw_5_6"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">37090151</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="As_Of_12_31_2021_TBpjtOXgEkKQahJJAv0aWg"
      decimals="0"
      id="Tc_IwFixIMC-0qe9awCxCha0A_6_3"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">74311203</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="As_Of_12_31_2021_TBpjtOXgEkKQahJJAv0aWg"
      decimals="0"
      id="Tc_QW6v4UUUCEuW5RZsZ2BeWQ_7_3"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">246040</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="As_Of_12_31_2020_OUSLyqWONEO8ccGPC6rBdg"
      decimals="0"
      id="Tc_qZYyybmKCU2gY5tmVP10Sw_7_6"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">500110</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="As_Of_12_31_2021_TBpjtOXgEkKQahJJAv0aWg"
      decimals="0"
      id="Tc_ZyQik3--T0KfhriocBezPA_8_3"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">2888608</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="As_Of_12_31_2020_OUSLyqWONEO8ccGPC6rBdg"
      decimals="0"
      id="Tc_BEX_4WsGuk2ag8UpnSPrTA_8_6"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">140958</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="As_Of_12_31_2021_TBpjtOXgEkKQahJJAv0aWg"
      decimals="0"
      id="Tc__7hMqetkikiN6G3FhpxKXg_9_3"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">152333996</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="As_Of_12_31_2020_OUSLyqWONEO8ccGPC6rBdg"
      decimals="0"
      id="Tc_kk7xSNAv8EmkZP8Lkbm5ng_9_6"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">37731219</us-gaap:AssetsCurrent>
    <us-gaap:MarketableSecuritiesNoncurrent
      contextRef="As_Of_12_31_2021_TBpjtOXgEkKQahJJAv0aWg"
      decimals="0"
      id="Tc_6pbUVNQb9k23NDnDjgnivQ_11_3"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">996560</us-gaap:MarketableSecuritiesNoncurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_12_31_2021_TBpjtOXgEkKQahJJAv0aWg"
      decimals="0"
      id="Tc_V-xS8PsXZku6XgECrepA2Q_12_3"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">807223</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_12_31_2020_OUSLyqWONEO8ccGPC6rBdg"
      decimals="0"
      id="Tc_vodyQGjYZU-riaunSgearw_12_6"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">64363</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Goodwill
      contextRef="As_Of_12_31_2021_TBpjtOXgEkKQahJJAv0aWg"
      decimals="0"
      id="Tc_OTmA1WVNZE2PKzNUqLkBmA_13_3"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">6701726</us-gaap:Goodwill>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="As_Of_12_31_2021_TBpjtOXgEkKQahJJAv0aWg"
      decimals="0"
      id="Tc_-ko1-DaLZE6uWBmssv-Mtw_14_3"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">439000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_12_31_2021_TBpjtOXgEkKQahJJAv0aWg"
      decimals="0"
      id="Tc_AquINwWVckOdcSEtr5wBww_15_3"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">5324198</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_12_31_2020_OUSLyqWONEO8ccGPC6rBdg"
      decimals="0"
      id="Tc_96hE3lsqcUapDgN8AyJKWw_15_6"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">613103</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="As_Of_12_31_2021_TBpjtOXgEkKQahJJAv0aWg"
      decimals="0"
      id="Tc_h0cUbr53CEKI53ndVIitkA_16_3"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">102129</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="As_Of_12_31_2020_OUSLyqWONEO8ccGPC6rBdg"
      decimals="0"
      id="Tc_QOmP-DAecEqi1c4mBji_1w_16_6"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">14333</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="As_Of_12_31_2021_TBpjtOXgEkKQahJJAv0aWg"
      decimals="0"
      id="Tc_vFfiOUx9jke0XhO8t2twIw_17_3"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">166704832</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="As_Of_12_31_2020_OUSLyqWONEO8ccGPC6rBdg"
      decimals="0"
      id="Tc_eYXVXUbFSk6BxL3szpbbqQ_17_6"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">38423018</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="As_Of_12_31_2021_TBpjtOXgEkKQahJJAv0aWg"
      decimals="0"
      id="Tc_1CPnnIwapkKRuLJ0028GvQ_21_3"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">1394340</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="As_Of_12_31_2020_OUSLyqWONEO8ccGPC6rBdg"
      decimals="0"
      id="Tc_j3akNlw_z0a9Z2lHTS86MQ_21_6"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">1480537</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2021_TBpjtOXgEkKQahJJAv0aWg"
      decimals="0"
      id="Tc_4gdnCtALzE2dhFqjMWfDTw_22_3"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">3965447</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2020_OUSLyqWONEO8ccGPC6rBdg"
      decimals="0"
      id="Tc_C9dVE6pYyEK4WhWQKMMM-A_22_6"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">698992</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="As_Of_12_31_2021_TBpjtOXgEkKQahJJAv0aWg"
      decimals="0"
      id="Tc_-CIO1WYpSE6YERZfmincxw_23_3"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">274039</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="As_Of_12_31_2020_OUSLyqWONEO8ccGPC6rBdg"
      decimals="0"
      id="Tc_OHaXMkWoQ0q0FhZ50sTZsA_23_6"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">76322</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="As_Of_12_31_2021_TBpjtOXgEkKQahJJAv0aWg"
      decimals="0"
      id="Tc_D15yOK4PakKcNUklvNIazg_24_3"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">5633826</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="As_Of_12_31_2020_OUSLyqWONEO8ccGPC6rBdg"
      decimals="0"
      id="Tc_Ns4SOBCLvU-Uc4fRdXZ1KA_24_6"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">2255851</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="As_Of_12_31_2021_TBpjtOXgEkKQahJJAv0aWg"
      decimals="0"
      id="Tc_ia-6R1OSR0-x6sivg6vMRQ_27_3"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">5090897</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="As_Of_12_31_2020_OUSLyqWONEO8ccGPC6rBdg"
      decimals="0"
      id="Tc_HNd5-udbiUOe3wSUw0wltA_27_6"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">544767</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:Liabilities
      contextRef="As_Of_12_31_2021_TBpjtOXgEkKQahJJAv0aWg"
      decimals="0"
      id="Tc_64Be6xs0EUOA-ITIzbCAgw_28_3"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">10724723</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="As_Of_12_31_2020_OUSLyqWONEO8ccGPC6rBdg"
      decimals="0"
      id="Tc_5DBTHV_zJkCMwAmjTwL3Xw_28_6"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">2800618</us-gaap:Liabilities>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_imrx_SeriesBConvertiblePreferredStockMember_-Ckh5K8N7U-_9nyMHjiJxQ"
      decimals="INF"
      id="Narr_npAndejvG0O0zI_L5uqgKA"
      unitRef="Unit_Divide_USD_shares_0VraXufKhkCSOUw2U_zvgQ">0.001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_imrx_SeriesBConvertiblePreferredStockMember_lxbE9uvMQU-NU7BxZ_aTNg"
      decimals="INF"
      id="Narr_Bj_ffFbLLEKke04VDfYZMw"
      unitRef="Unit_Divide_USD_shares_0VraXufKhkCSOUw2U_zvgQ">0.001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_imrx_SeriesBConvertiblePreferredStockMember_lxbE9uvMQU-NU7BxZ_aTNg"
      decimals="INF"
      id="Narr__GvOhS9jeEe44h_wBu83kw"
      unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ">0</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_imrx_SeriesBConvertiblePreferredStockMember_-Ckh5K8N7U-_9nyMHjiJxQ"
      decimals="INF"
      id="Narr_5Bxji6PW4EyhAIBSADRleQ"
      unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ">6032183</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_imrx_SeriesBConvertiblePreferredStockMember_lxbE9uvMQU-NU7BxZ_aTNg"
      decimals="INF"
      id="Narr_0NXTg5Ec-kGDadl3VHS9VA"
      unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ">0</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_imrx_SeriesBConvertiblePreferredStockMember_-Ckh5K8N7U-_9nyMHjiJxQ"
      decimals="INF"
      id="Narr__IeATAVZeE6UVjpfa_VDHg"
      unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ">3619292</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_imrx_SeriesBConvertiblePreferredStockMember_-Ckh5K8N7U-_9nyMHjiJxQ"
      decimals="0"
      id="Tc_nc2KMoiTL0OIFsmcjGbFIA_31_6"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">36983910</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_imrx_SeriesConvertiblePreferredStockMember_LQiWJpT45k-D9eZ63E0DAw"
      decimals="INF"
      id="Narr_gScqLLScl0OGdgho-Dneug"
      unitRef="Unit_Divide_USD_shares_0VraXufKhkCSOUw2U_zvgQ">0.001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_imrx_SeriesConvertiblePreferredStockMember_DzBbn1vSGECYmtSe-hivlw"
      decimals="INF"
      id="Narr_5Uz8ZFYaMEy9EPNZ8NVupA"
      unitRef="Unit_Divide_USD_shares_0VraXufKhkCSOUw2U_zvgQ">0.001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_imrx_SeriesConvertiblePreferredStockMember_DzBbn1vSGECYmtSe-hivlw"
      decimals="INF"
      id="Narr_-5PJmzMjoU2MxMCCHSRIAQ"
      unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ">0</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_imrx_SeriesConvertiblePreferredStockMember_LQiWJpT45k-D9eZ63E0DAw"
      decimals="INF"
      id="Narr_v6LDdX67NEqaWwwLzZFZRA"
      unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ">2495933</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_imrx_SeriesConvertiblePreferredStockMember_DzBbn1vSGECYmtSe-hivlw"
      decimals="INF"
      id="Narr_s6Ah7bUeaEitAMgXZMI4Ww"
      unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ">0</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_imrx_SeriesConvertiblePreferredStockMember_LQiWJpT45k-D9eZ63E0DAw"
      decimals="INF"
      id="Narr_oCe9tzdXd0S9FTiOF6xmbw"
      unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ">2495933</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_imrx_SeriesConvertiblePreferredStockMember_LQiWJpT45k-D9eZ63E0DAw"
      decimals="0"
      id="Tc_ivzRCH0wyUSZcXuZXyoQpw_32_6"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">21119940</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="As_Of_12_31_2020_OUSLyqWONEO8ccGPC6rBdg"
      decimals="0"
      id="Tc_XaB3Jnb1OEqqkuMJpCikCw_33_6"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">58103850</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2020_OUSLyqWONEO8ccGPC6rBdg"
      decimals="3"
      id="Narr_5arq0xRZwE2X2pWxG71FFw"
      unitRef="Unit_Divide_USD_shares_0VraXufKhkCSOUw2U_zvgQ">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2021_TBpjtOXgEkKQahJJAv0aWg"
      decimals="3"
      id="Narr_hoY3GObMFkqgHlXFHdJtBg"
      unitRef="Unit_Divide_USD_shares_0VraXufKhkCSOUw2U_zvgQ">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="As_Of_12_31_2021_TBpjtOXgEkKQahJJAv0aWg"
      decimals="INF"
      id="Narr_SV-QibJ--U6qgC2dphmvzA"
      unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="As_Of_12_31_2020_OUSLyqWONEO8ccGPC6rBdg"
      decimals="INF"
      id="Narr_PUVP-FVOhk-AZ6c0wGAo5g"
      unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ">0</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="As_Of_12_31_2020_OUSLyqWONEO8ccGPC6rBdg"
      decimals="INF"
      id="Narr_ufa5sxDVO0KrCUw6iSVGEA"
      unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="As_Of_12_31_2021_TBpjtOXgEkKQahJJAv0aWg"
      decimals="INF"
      id="Narr_GthL0GLlMEGBDowbhjTG6g"
      unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_IvXJ6RHxqkyGTfDbgXwHsw"
      decimals="INF"
      id="Narr_PePS-eWi1Uy1GgqZGkB7fw"
      unitRef="Unit_Divide_USD_shares_0VraXufKhkCSOUw2U_zvgQ">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_Mo7QF875vUy5d2OcEbQ2fA"
      decimals="INF"
      id="Narr_HmUHmM-MPUiKVOG4AX3qGA"
      unitRef="Unit_Divide_USD_shares_0VraXufKhkCSOUw2U_zvgQ">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_Mo7QF875vUy5d2OcEbQ2fA"
      decimals="INF"
      id="Narr_F1rRceMfS0CecfwWGMGu_A"
      unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_IvXJ6RHxqkyGTfDbgXwHsw"
      decimals="INF"
      id="Narr_D5sSwSjilk6FNqA8j0M69Q"
      unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ">22026200</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_Mo7QF875vUy5d2OcEbQ2fA"
      decimals="INF"
      id="Narr_bEgfXr6xfUCBg24S95lSNg"
      unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ">26320199</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_IvXJ6RHxqkyGTfDbgXwHsw"
      decimals="INF"
      id="Narr_Gs5ktAjOLEeWV4F9UvwzAw"
      unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ">4950129</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_Mo7QF875vUy5d2OcEbQ2fA"
      decimals="0"
      id="Tc_PLt3dHxXvUaABcWVa9jHaA_36_3"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">26320</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_IvXJ6RHxqkyGTfDbgXwHsw"
      decimals="0"
      id="Tc_B2uzVg2dIUm04T3eAkmQdw_36_6"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">4950</us-gaap:CommonStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_B1xkq5tyC0Czi0WWYygW9Q"
      decimals="INF"
      id="Narr_EHJ0frEiO0qE50u2QmPvUw"
      unitRef="Unit_Divide_USD_shares_0VraXufKhkCSOUw2U_zvgQ">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_4sABCVevMkafGdslrmVHRg"
      decimals="INF"
      id="Narr_3O50ZHr5pEmDzOHPHti7Ng"
      unitRef="Unit_Divide_USD_shares_0VraXufKhkCSOUw2U_zvgQ">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_4sABCVevMkafGdslrmVHRg"
      decimals="INF"
      id="Narr_-Qr7oBQ_MUaP0VbcAitVUQ"
      unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ">20000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_B1xkq5tyC0Czi0WWYygW9Q"
      decimals="INF"
      id="Narr_Q_9_ozpWOk6sm72fYs45rg"
      unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ">6032183</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_B1xkq5tyC0Czi0WWYygW9Q"
      decimals="INF"
      id="Narr_oXOFWBhns06va6fmVTHSgA"
      unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ">0</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_4sABCVevMkafGdslrmVHRg"
      decimals="INF"
      id="Narr_GUeW-UFCx0my0U6j9N6C7Q"
      unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ">0</us-gaap:CommonStockSharesIssued>
    <us-gaap:AdditionalPaidInCapital
      contextRef="As_Of_12_31_2021_TBpjtOXgEkKQahJJAv0aWg"
      decimals="0"
      id="Tc_DHxigKfvJkKBaWvFS-Omsg_38_3"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">215276186</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="As_Of_12_31_2020_OUSLyqWONEO8ccGPC6rBdg"
      decimals="0"
      id="Tc_aqXSVBTTUE-J29V4tpHamw_38_6"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">3251240</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="As_Of_12_31_2021_TBpjtOXgEkKQahJJAv0aWg"
      decimals="0"
      id="Tc_ZyAWJ65MC0ebYjcW48i8Ew_39_3"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">-49009</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_12_31_2021_TBpjtOXgEkKQahJJAv0aWg"
      decimals="0"
      id="Tc_OPaHfW8EpES35dobDTS8hg_40_3"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">-59273388</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_12_31_2020_OUSLyqWONEO8ccGPC6rBdg"
      decimals="0"
      id="Tc_gBIzErnHUECR2uleoBXraQ_40_6"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">-25737640</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_TBpjtOXgEkKQahJJAv0aWg"
      decimals="0"
      id="Tc_vqNKiPPLpUudBPni0hetLg_41_3"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">155980109</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_OUSLyqWONEO8ccGPC6rBdg"
      decimals="0"
      id="Tc_hwTeFV3NP02ak4QT1_xy0Q_41_6"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">-22481450</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="As_Of_12_31_2021_TBpjtOXgEkKQahJJAv0aWg"
      decimals="0"
      id="Tc_FyjOYBIJgkGLXtUtmhGxtA_42_3"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">166704832</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="As_Of_12_31_2020_OUSLyqWONEO8ccGPC6rBdg"
      decimals="0"
      id="Tc_oc_kxb4V7UOdtIL7qKnt9w_42_6"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">38423018</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ"
      decimals="0"
      id="Tc_lOM4Xif49E6lfROE5BLXvQ_4_3"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">2079961</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2020_To_12_31_2020_J_O9OcmviUi8EDFgokrY1Q"
      decimals="0"
      id="Tc_KnHr-Hm59UCXWDeKmDB47w_4_6"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">2311535</us-gaap:Revenues>
    <us-gaap:CostOfRevenue
      contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ"
      decimals="0"
      id="Tc_cIfsWnIQAUSk8kbJU-2qfQ_5_3"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">1153073</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="Duration_1_1_2020_To_12_31_2020_J_O9OcmviUi8EDFgokrY1Q"
      decimals="0"
      id="Tc_jiwNvhs1hkScNW-W2h2iGQ_5_6"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">1280325</us-gaap:CostOfRevenue>
    <us-gaap:GrossProfit
      contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ"
      decimals="0"
      id="Tc_HeI0abhgVEeEAF4VZMtihA_7_3"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">926888</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="Duration_1_1_2020_To_12_31_2020_J_O9OcmviUi8EDFgokrY1Q"
      decimals="0"
      id="Tc_kWe_DU9c2UC11Bi9TwoBQA_7_6"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">1031210</us-gaap:GrossProfit>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ"
      decimals="0"
      id="Tc_uaOH4RLS30WklGJ1CxP4pA_10_3"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">26540959</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2020_To_12_31_2020_J_O9OcmviUi8EDFgokrY1Q"
      decimals="0"
      id="Tc_qvVpd4MxCkyjCYi8WzWMdw_10_6"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">15003786</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ"
      decimals="0"
      id="Tc_psVtn6Wzc0ahLiXae3NFuQ_11_3"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">8271998</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2020_To_12_31_2020_J_O9OcmviUi8EDFgokrY1Q"
      decimals="0"
      id="Tc_cemfq8W3Z0uHeNyjQTi7Qw_11_6"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">3109978</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ"
      decimals="0"
      id="Tc_c2dCHNHu50e9eoqYpNnofA_12_3"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">34812957</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="Duration_1_1_2020_To_12_31_2020_J_O9OcmviUi8EDFgokrY1Q"
      decimals="0"
      id="Tc_bIyQBL6orUma2uQQl1llaQ_12_6"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">18113764</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ"
      decimals="0"
      id="Tc_Jg6uTdoRSEmR-WFUWogmPA_13_3"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">-33886069</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2020_To_12_31_2020_J_O9OcmviUi8EDFgokrY1Q"
      decimals="0"
      id="Tc_E6kbV38QyUyqhCDJWKG1gQ_13_6"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">-17082554</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeInterest
      contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ"
      decimals="0"
      id="Tc_tGBQVSaxDU2jzRh9grMOBg_16_3"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">169899</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="Duration_1_1_2020_To_12_31_2020_J_O9OcmviUi8EDFgokrY1Q"
      decimals="0"
      id="Tc_P54kGOYBFkGsMoYmp8Btmw_16_6"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">42656</us-gaap:InvestmentIncomeInterest>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ"
      decimals="0"
      id="Tc_YCL_669GQUqv0hVPKVk-KQ_17_3"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">-127063</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ"
      decimals="0"
      id="Tc_-_KfbSsiL0-QTvnrlNx7RA_18_3"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">-33843233</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="Duration_1_1_2020_To_12_31_2020_J_O9OcmviUi8EDFgokrY1Q"
      decimals="0"
      id="Tc_7qeBGOLlckOpl49uOg-7iQ_18_6"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">-17039898</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ"
      decimals="0"
      id="Tc_hF1ljQIK-U6QAKMQF5_mRQ_19_3"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">-307485</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ"
      decimals="0"
      id="Tc_GbWKC8hCZUaxWnn5_lF-rQ_20_3"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">-33535748</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2020_To_12_31_2020_J_O9OcmviUi8EDFgokrY1Q"
      decimals="0"
      id="Tc_i__OR-W07kiFfjvUb3PaAA_20_6"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">-17039898</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ"
      decimals="2"
      id="Tc_XDnwGwSChESzmhiHJsWGKQ_22_3"
      unitRef="Unit_Divide_USD_shares_0VraXufKhkCSOUw2U_zvgQ">-2.46</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2020_To_12_31_2020_J_O9OcmviUi8EDFgokrY1Q"
      decimals="2"
      id="Tc_XuKF3dS0v0apc6bLwXJwXg_22_6"
      unitRef="Unit_Divide_USD_shares_0VraXufKhkCSOUw2U_zvgQ">-3.44</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ"
      decimals="0"
      id="Tc_Z-zJvwx0HESCMkHa5pbFrg_23_3"
      unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ">13612677</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2020_To_12_31_2020_J_O9OcmviUi8EDFgokrY1Q"
      decimals="0"
      id="Tc_lCAkyx54CkqZdG0mtfR_3Q_23_6"
      unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ">4950129</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:MarketableSecuritiesUnrealizedGainLoss
      contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ"
      decimals="0"
      id="Tc_yzJUzOHUKkO5ISkwH992VA_26_3"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">-49009</us-gaap:MarketableSecuritiesUnrealizedGainLoss>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ"
      decimals="0"
      id="Tc_-pGfnfaCjk2zakWZZp8nrg_27_3"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">-33584757</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="Duration_1_1_2020_To_12_31_2020_J_O9OcmviUi8EDFgokrY1Q"
      decimals="0"
      id="Tc_rBgJbDRa6UGiwfuizsiv0g_27_6"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">-17039898</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="As_Of_12_31_2019_us-gaap_StatementClassOfStockAxis_imrx_SeriesConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_gIVkAxfsP0yONnc4vwzOSw"
      decimals="INF"
      id="Tc_YWU36xVKS0aWsyL245An6g_6_8"
      unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ">1966043</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="As_Of_12_31_2019_us-gaap_StatementClassOfStockAxis_imrx_SeriesConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_gIVkAxfsP0yONnc4vwzOSw"
      decimals="0"
      id="Tc_qTQutgFoyUOShiSmPzI8pA_6_11"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">16611832</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_QXRL0wO1MkWoDTBf_1Gh7w"
      decimals="0"
      id="Tc_hDM6TZzcaEW8JDhiAVAunw_6_14"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">16611832</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_12_31_2019_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_jy9qZmEtiE6UB1aH8SvR-w"
      decimals="INF"
      id="Tc_2oKJU_GtGkaFYMIta0Nd5Q_6_18"
      unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ">4950129</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2019_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_jy9qZmEtiE6UB1aH8SvR-w"
      decimals="0"
      id="Tc_eyDOpshuYkaNFOz0zudagA_6_21"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">4950</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_9W3qoLMgdUiyVG8R6gDuuQ"
      decimals="0"
      id="Tc_1FvdGBfJ3EC0NsW5hoUdBg_6_29"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">2164471</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_h6gPSE4xM0ayt1JfJR8qkA"
      decimals="0"
      id="Tc_DeEdpzzyjEyWe4C4bDB3CQ_6_35"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">-8697742</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2019_g3mjqkDWB0-f2XKJf0YL-A"
      decimals="0"
      id="Tc_41iM5kc_JU6vMa58hghgpQ_6_38"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">-6528321</us-gaap:StockholdersEquity>
    <imrx:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementClassOfStockAxis_imrx_SeriesConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_JPabAp5qAEmR2gD7LN_b7A"
      decimals="INF"
      id="Tc_XPTVIsyYdEuAqbGWOep40g_8_8"
      unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ">529890</imrx:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementClassOfStockAxis_imrx_SeriesConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_JPabAp5qAEmR2gD7LN_b7A"
      decimals="0"
      id="Tc_PnQEywtXgkOPXfKZyFTmtA_8_11"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">4508108</us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues>
    <imrx:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_uitXKHVUDEugKPJ0WrK0pw"
      decimals="0"
      id="Tc_xuH0DJUFcUGn1JxuCjlbXA_8_14"
      unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ">4508108</imrx:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues>
    <imrx:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementClassOfStockAxis_imrx_SeriesBConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_39QT10BRPUmkcB-ZGBN9mQ"
      decimals="INF"
      id="Tc__m3FuXPhoUipf1mI0JDEcw_10_2"
      unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ">3619292</imrx:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementClassOfStockAxis_imrx_SeriesBConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_39QT10BRPUmkcB-ZGBN9mQ"
      decimals="0"
      id="Tc_Ue_dT9TviEuH8G2eKr71bA_10_5"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">36983910</us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues>
    <us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_uitXKHVUDEugKPJ0WrK0pw"
      decimals="0"
      id="Tc_X4HtJZ7pY0mMw6ImVE-cTQ_10_14"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">36983910</us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_QLhYrVZJX02K66IZYiKorA"
      decimals="0"
      id="Tc_5dbY7-gnF0OuLcUdPZsvGQ_12_29"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">1086769</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2020_To_12_31_2020_J_O9OcmviUi8EDFgokrY1Q"
      decimals="0"
      id="Tc_UPk5DtkJwkm_ahR2M7UwCw_12_38"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">1086769</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_ZzxD3WXn2kaEmrcG06sDqg"
      decimals="0"
      id="Tc_wyxfxoVAGUuBVQwLuMyyFA_14_35"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">-17039898</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2020_To_12_31_2020_J_O9OcmviUi8EDFgokrY1Q"
      decimals="0"
      id="Tc_hrLZ2-4_UUqtLpeg5EnS8g_14_38"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">-17039898</us-gaap:NetIncomeLoss>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_imrx_SeriesBConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_QCBVyWaLKkO0RDEZzs9qkw"
      decimals="INF"
      id="Tc_SJzPRQ0gEUuDNb6sQjbPZg_16_2"
      unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ">3619292</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_imrx_SeriesBConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_QCBVyWaLKkO0RDEZzs9qkw"
      decimals="0"
      id="Tc_1VgNgMLh1k2--B_IN1HUXg_16_5"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">36983910</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_imrx_SeriesConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_S2X3YlpbP0KTx8Hppox5ig"
      decimals="INF"
      id="Tc_2Fx_ReqqfUeN9mcjoJjNVA_16_8"
      unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ">2495933</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_imrx_SeriesConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_S2X3YlpbP0KTx8Hppox5ig"
      decimals="0"
      id="Tc_LycaEba_AECnlivaTQe1Gg_16_11"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">21119940</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_LnfVME6pk0eWF42mjJCPCQ"
      decimals="0"
      id="Tc_Queayp7no0edY0fpJ1Hkxg_16_14"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">58103850</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_EWjFOikEMEGNPdcpkhlgHw"
      decimals="INF"
      id="Tc_AJj_Fs-qekyhVCq9yC33Fg_16_18"
      unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ">4950129</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_EWjFOikEMEGNPdcpkhlgHw"
      decimals="0"
      id="Tc_xC0Oh4OUpUuVYaO3DRtacQ_16_21"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">4950</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_bPrhx3BPa0qPRD7gVwy7FA"
      decimals="0"
      id="Tc_FO52rH1ABkmUlGR976AKzg_16_29"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">3251240</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_VV_zTjXofUy1ORoRFXwUxw"
      decimals="0"
      id="Tc_2cAjvraEHEqNaGS9rsA1yw_16_35"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">-25737640</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_OUSLyqWONEO8ccGPC6rBdg"
      decimals="0"
      id="Tc_kHp949J4-0qlxUEptMNOzA_16_38"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">-22481450</us-gaap:StockholdersEquity>
    <imrx:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_imrx_SeriesBConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_8mJv2jJa6UumRofouB70lA"
      decimals="INF"
      id="Tc_7rgoZ7s0TkqOj_ZqhIAjlA_18_2"
      unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ">2412853</imrx:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_imrx_SeriesBConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_8mJv2jJa6UumRofouB70lA"
      decimals="0"
      id="Tc_s0qcLgagEEmwAVF_I6cxEQ_18_5"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">24788851</us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues>
    <us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_MxWqlzAiY0eQbIPd0DtYAA"
      decimals="0"
      id="Tc_YrINbTkMlki8GZNa4qSpxQ_18_14"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">24788851</us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_GoNlf5JQWEKfwIjieg6jCA"
      decimals="INF"
      id="Tc_ssPvqQsWE0qeF4vyN3AJug_20_18"
      unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ">117846</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_GoNlf5JQWEKfwIjieg6jCA"
      decimals="0"
      id="Tc_VNP7m9Z3pkyXN_Gmk8PH8A_20_21"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">118</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_E-RNnZgaG06hPQcsgQNOlA"
      decimals="0"
      id="Tc_HWIM0kyzBkuAqplpgta1xQ_20_29"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">354316</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ"
      decimals="0"
      id="Tc_l9xkoaIx5U-ZhQKct3vYSg_20_38"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">354434</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <imrx:StockIssuedDuringPeriodSharesWarrantsExercised
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_GoNlf5JQWEKfwIjieg6jCA"
      decimals="INF"
      id="Tc_ElVVzRVCl0uSay0edpU7-g_22_18"
      unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ">308308</imrx:StockIssuedDuringPeriodSharesWarrantsExercised>
    <imrx:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_GoNlf5JQWEKfwIjieg6jCA"
      decimals="0"
      id="Tc_uYVo-Pk6U0K1PR_mPNxpNw_22_21"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">308</imrx:StockIssuedDuringPeriodValueWarrantsExercised>
    <imrx:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_E-RNnZgaG06hPQcsgQNOlA"
      decimals="0"
      id="Tc_zpnvYY5doEK9aeYEKWW5pw_22_29"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">926817</imrx:StockIssuedDuringPeriodValueWarrantsExercised>
    <imrx:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ"
      decimals="0"
      id="Tc_7qDns1GqTk6s4zruHO6qkg_22_38"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">927125</imrx:StockIssuedDuringPeriodValueWarrantsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_imrx_SeriesBConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_8mJv2jJa6UumRofouB70lA"
      decimals="INF"
      id="Tc_hGme46Jge0yfcTL1Nh88MQ_24_2"
      unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ">-6032145</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_imrx_SeriesBConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_8mJv2jJa6UumRofouB70lA"
      decimals="0"
      id="Tc_UD-D-fMhuEKgTk0GAaaeuQ_24_5"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">-61772761</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_imrx_SeriesConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_IX7LGz4dkECxr-BxWs_jAw"
      decimals="INF"
      id="Tc_7f2ae949q0WRpzsUWb7vjQ_24_8"
      unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ">-2495933</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_imrx_SeriesConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_IX7LGz4dkECxr-BxWs_jAw"
      decimals="0"
      id="Tc_TQBYTM1zbU2fWqW5q1X5NQ_24_11"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">-21119940</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_MxWqlzAiY0eQbIPd0DtYAA"
      decimals="0"
      id="Tc_EKog_ZCr5ECv3MXWt-zIMQ_24_14"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">-82892701</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_GoNlf5JQWEKfwIjieg6jCA"
      decimals="INF"
      id="Tc_NM91b91K1EqqraV3-xYCUw_24_18"
      unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ">11939281</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_GoNlf5JQWEKfwIjieg6jCA"
      decimals="0"
      id="Tc_TMcRiPyGtkWUqETRaRDigA_24_21"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">11939</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_E-RNnZgaG06hPQcsgQNOlA"
      decimals="0"
      id="Tc_fXkgZtzRCkS5mdt0UB2MxQ_24_29"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">82880762</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ"
      decimals="0"
      id="Tc_9Phk6-g5cUeLATkhy0_arQ_24_38"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">82892701</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <imrx:StockIssuanceCosts
      contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ"
      decimals="-3"
      id="Narr_vRj86CTMfkiQudd0wxruTQ"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">2124317000</imrx:StockIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_GoNlf5JQWEKfwIjieg6jCA"
      decimals="INF"
      id="Tc_t49sCRFsNECdwmpdEy89AA_26_18"
      unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ">8625000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_GoNlf5JQWEKfwIjieg6jCA"
      decimals="0"
      id="Tc__QFG7F3tf0m-cVnhsQH26g_26_21"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">8625</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_E-RNnZgaG06hPQcsgQNOlA"
      decimals="0"
      id="Tc_8BPmEqtyRUm6AsKi4baX4Q_26_29"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">118185808</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ"
      decimals="0"
      id="Tc_oZ8YPwfvK0e1Jt-i_G-3lg_26_38"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">118194433</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_GoNlf5JQWEKfwIjieg6jCA"
      decimals="INF"
      id="Tc_HzlFuZwpIkKeOZPFVDFz3w_28_18"
      unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ">379635</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_GoNlf5JQWEKfwIjieg6jCA"
      decimals="0"
      id="Tc_--IjP0t3XUqEuw9EavGsZw_28_21"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">380</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_E-RNnZgaG06hPQcsgQNOlA"
      decimals="0"
      id="Tc_IfyVFRG1FEucVoCsV4Bwgg_28_29"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">7874620</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ"
      decimals="0"
      id="Tc_9G-DQ6dhV0ycWpgoNdkSHQ_28_38"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">7875000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_E-RNnZgaG06hPQcsgQNOlA"
      decimals="0"
      id="Tc_cYEAF7-DUUiyXbAj7Ddy-Q_30_29"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">1802623</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ"
      decimals="0"
      id="Tc_luOM3f7yZUG2C5IPK9Cj1A_30_38"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">1802623</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_5VXgVFJHWUybWtDAZklDIQ"
      decimals="0"
      id="Tc_f_W1rtGY9USH0LkByi-ADA_32_35"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">-33535748</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ"
      decimals="0"
      id="Tc_m9ioWoAeTECWRtt-43x7oA_32_38"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">-33535748</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_TI6BHD47C0iaSPM1OYc68Q"
      decimals="0"
      id="Tc_Uh1LO-xx8UyIG_M9oW8zmA_34_32"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">-49009</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ"
      decimals="0"
      id="Tc_heRCodgOkUqUU033Dfe7qQ_34_38"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">-49009</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_5hpgxWyzr0iIgVEP8sXbRw"
      decimals="INF"
      id="Tc_0lQbOnbn00mgxDzNoZFJwg_36_18"
      unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ">26320199</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_5hpgxWyzr0iIgVEP8sXbRw"
      decimals="0"
      id="Tc_sydh2X-a102Gw2JTa6bAwA_36_21"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">26320</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_dPK7_g2dsk-p4OLSSYVc-g"
      decimals="0"
      id="Tc_rxEgfmA4iE-aBYXaxCWZ0A_36_29"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">215276186</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_bsF1orxDUUG1aHLclUMt2g"
      decimals="0"
      id="Tc_sZdzMh2NpUGI_W3zg8OnGg_36_32"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">-49009</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_ovzfxk9860SdXNv_qQhcsg"
      decimals="0"
      id="Tc_J_oQyQIcmE6ISeJflBgNqw_36_35"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">-59273388</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_TBpjtOXgEkKQahJJAv0aWg"
      decimals="0"
      id="Tc_QO_IPgUFiE6EXjXqCK94og_36_38"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">155980109</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ"
      decimals="0"
      id="Tc_EDzg1bdky0OAekCIxqKNYw_4_3"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">-33535748</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2020_To_12_31_2020_J_O9OcmviUi8EDFgokrY1Q"
      decimals="0"
      id="Tc_x-OeXePhZEC2w1qp1iQV4w_4_6"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">-17039898</us-gaap:NetIncomeLoss>
    <us-gaap:Depreciation
      contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ"
      decimals="0"
      id="Tc_CvqwyHS82EajbRPBldP2ew_6_3"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">45467</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="Duration_1_1_2020_To_12_31_2020_J_O9OcmviUi8EDFgokrY1Q"
      decimals="0"
      id="Tc_jbluDu53KkqepM0iEDCdow_6_6"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">24328</us-gaap:Depreciation>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ"
      decimals="0"
      id="Tc_6hyWZXSB-kq5SGIRdHpDmA_7_3"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">113605</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="Duration_1_1_2020_To_12_31_2020_J_O9OcmviUi8EDFgokrY1Q"
      decimals="0"
      id="Tc_W_xXMMZWXkuFD1d1JNZVuA_7_6"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">54977</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ"
      decimals="0"
      id="Tc_UcBdTgeSCkGEmY-VoL_56w_8_3"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">1802623</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2020_To_12_31_2020_J_O9OcmviUi8EDFgokrY1Q"
      decimals="0"
      id="Tc_rv5OSpO2i0uQvqfC_LsECw_8_6"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">1086769</us-gaap:ShareBasedCompensation>
    <us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium
      contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ"
      decimals="0"
      id="Tc_ZeVolLeYREGmpbDXCZocLA_9_3"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">-130240</us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ"
      decimals="0"
      id="Tc_7uipiNRmQ0eZY1iTT8QWcg_10_3"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">-307485</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ"
      decimals="0"
      id="Tc_xEsb3Qm4-UOObEFKPNxrNQ_13_3"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">-279713</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="Duration_1_1_2020_To_12_31_2020_J_O9OcmviUi8EDFgokrY1Q"
      decimals="0"
      id="Tc_Ay2fdurPk0ioTXTeE5Cilw_13_6"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">290170</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ"
      decimals="0"
      id="Tc_hzA0KLj4PkWVtgieC0n8Qg_14_3"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">2408986</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="Duration_1_1_2020_To_12_31_2020_J_O9OcmviUi8EDFgokrY1Q"
      decimals="0"
      id="Tc_Hl91OLBm4kSlSCYB68KMwA_14_6"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">69740</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="Duration_1_1_2020_To_12_31_2020_J_O9OcmviUi8EDFgokrY1Q"
      decimals="0"
      id="Tc_mC9jDEAi5US9KaRqvSSmIQ_15_6"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">14333</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ"
      decimals="0"
      id="Tc_KPrsrvjnTk26hlPl1e_OGQ_17_3"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">-130398</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="Duration_1_1_2020_To_12_31_2020_J_O9OcmviUi8EDFgokrY1Q"
      decimals="0"
      id="Tc_kOOJ_FQkXUWZBBLdfXmKRg_17_6"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">1185589</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ"
      decimals="0"
      id="Tc_kP-TQmtf6E-u68ddEegigg_18_3"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">3240940</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="Duration_1_1_2020_To_12_31_2020_J_O9OcmviUi8EDFgokrY1Q"
      decimals="0"
      id="Tc_2Df-buhgX0-T6Hm-BeBlqg_18_6"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">488644</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ"
      decimals="0"
      id="Tc_r_bLYmp-L0-UNJlT3OLEvg_19_3"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">-80853</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="Duration_1_1_2020_To_12_31_2020_J_O9OcmviUi8EDFgokrY1Q"
      decimals="0"
      id="Tc_bEhCvH1jY0mhZebZl6H2YQ_19_6"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">-46991</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ"
      decimals="0"
      id="Tc_3kWKBKU8eEe3dgend7NLbA_20_3"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">-30850882</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2020_To_12_31_2020_J_O9OcmviUi8EDFgokrY1Q"
      decimals="0"
      id="Tc_9t_1zKNbI0GRGpTBf2CkZA_20_6"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">-14620825</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ"
      decimals="0"
      id="Tc_I-CWsuzUDESJdjriYAQXTQ_22_3"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">60786</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="Duration_1_1_2020_To_12_31_2020_J_O9OcmviUi8EDFgokrY1Q"
      decimals="0"
      id="Tc_bw1BgKcE-0milYHNYeiBOg_22_6"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">53415</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ"
      decimals="0"
      id="Tc_iq06kW5kXUWlak8V5X0Q0w_23_3"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">75625529</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:CashAcquiredInExcessOfPaymentsToAcquireBusiness
      contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ"
      decimals="0"
      id="Tc_Ht1hWIj6eUWRxhbp4ATHkw_24_3"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">70348</us-gaap:CashAcquiredInExcessOfPaymentsToAcquireBusiness>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ"
      decimals="0"
      id="Tc_LAijq2Qm70OdvFA-U8LXJQ_25_3"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">-75615967</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="Duration_1_1_2020_To_12_31_2020_J_O9OcmviUi8EDFgokrY1Q"
      decimals="0"
      id="Tc_oImnbqHvoEybRfMZd9y8Aw_25_6"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">-53415</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementClassOfStockAxis_imrx_SeriesConvertiblePreferredStockMember_hF8oI6VuEUaTinProxudjw"
      decimals="0"
      id="Tc_TjP7HxCPtEytZlLcfB9VEA_27_6"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">998306</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
    <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_imrx_SeriesBConvertiblePreferredStockMember_-C13Ii99_069N31zQd1hmQ"
      decimals="0"
      id="Tc_5ecJwhq7vEymlhyOqcaHJw_28_3"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">24788851</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
    <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementClassOfStockAxis_imrx_SeriesBConvertiblePreferredStockMember_b0zil8ikRUOsnQGwGFI2sw"
      decimals="0"
      id="Tc_lpsfp0Y_dUW3DTwxF3fXlQ_28_6"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">36983910</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ"
      decimals="0"
      id="Tc_hIEF6Vsw40GIEn2DZGv2Gw_29_3"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">120318750</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ"
      decimals="0"
      id="Tc_R4aPmc-OO02X87h99R8ODQ_30_3"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">2124317</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ"
      decimals="0"
      id="Tc_zHfks0juuk2l3XkjhntvaQ_31_3"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">354434</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ"
      decimals="0"
      id="Tc_2VVJcCl93UyxYpGPt5kB9g_32_3"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">927125</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ"
      decimals="0"
      id="Tc_ljo3yNeJYUGlTlfRE_P5uQ_33_3"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">144264843</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="Duration_1_1_2020_To_12_31_2020_J_O9OcmviUi8EDFgokrY1Q"
      decimals="0"
      id="Tc_wOSTrclr80SFM_5LYfvoLQ_33_6"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">37982216</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ"
      decimals="0"
      id="Tc_9zzKDYMN-0CfCjiLmE_R0w_34_3"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">37797994</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="Duration_1_1_2020_To_12_31_2020_J_O9OcmviUi8EDFgokrY1Q"
      decimals="0"
      id="Tc_2538VChCGE6jU2ffPc2XFQ_34_6"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">23307976</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2020_OUSLyqWONEO8ccGPC6rBdg"
      decimals="0"
      id="Tc_Uf4ilmZ8K0utMht9_0jguw_35_3"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">37090151</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2019_g3mjqkDWB0-f2XKJf0YL-A"
      decimals="0"
      id="Tc_X44SF6Z7fUOcEWmhH6vf-w_35_6"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">13782175</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2021_TBpjtOXgEkKQahJJAv0aWg"
      decimals="0"
      id="Tc_o0x_uP3ML0efsrwi0RcQyA_36_3"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">74888145</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2020_OUSLyqWONEO8ccGPC6rBdg"
      decimals="0"
      id="Tc_96PXifPhWUajhMteLikEVw_36_6"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">37090151</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:StockIssued1
      contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ"
      decimals="0"
      id="Tc_1xT5YWLhokWVvvAoFTxPiw_38_3"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">82892701</us-gaap:StockIssued1>
    <us-gaap:BusinessCombinationAcquisitionRelatedCosts
      contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ"
      decimals="0"
      id="Tc_T0ytlyyl2U6KR2bzzR3vQw_39_3"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">7804652</us-gaap:BusinessCombinationAcquisitionRelatedCosts>
    <us-gaap:ConversionOfStockSharesIssued1
      contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ"
      decimals="0"
      id="Tc_r_UhI3F-U0CVXwsm7O8I1Q_40_3"
      unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ">7875000</us-gaap:ConversionOfStockSharesIssued1>
    <imrx:ReclassificationOfLiabilityOfPreferredStock
      contextRef="Duration_1_1_2020_To_12_31_2020_J_O9OcmviUi8EDFgokrY1Q"
      decimals="0"
      id="Tc_OY0BmCrB80i6oE-JWn1qBg_41_6"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">3509802</imrx:ReclassificationOfLiabilityOfPreferredStock>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ"
      id="Tb_JWMXGq4bKE29Fx9wviYNBQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Note&#160;1&#160;&#x2013; Organization and Nature of Business&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Immuneering Corporation, a Delaware corporation, (&#x201c;Immuneering&#x201d; or the &#x201c;Company&#x201d;) was incorporated in 2008. The Company aims to improve patient outcomes by advancing a unique pipeline of oncology and neuroscience product candidates developed using the Company&#x2019;s translational bioinformatics platform. The Company has more than a decade of experience applying translational bioinformatics to generate insights into drug mechanism of action and patient treatment response. Building on this experience, the Company&#x2019;s disease-agnostic discovery platform enables the Company to create product candidates based on 1) biological insights that are both counterintuitive and deeply rooted in data, and 2) novel chemistry.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;On October&#160;30, 2019, Immuneering formed a wholly owned subsidiary, Immuneering Securities Corporation (&#x201c;ISC&#x201d;), a Massachusetts securities corporation, for the sole purpose of buying, selling and holding securities on the Company&#x2019;s behalf. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;On December 22, 2021, &lt;span style="background:#ffffff;"&gt;the Company acquired all outstanding shares of capital stock of BioArkive, Inc. (&#x201c;BioArkive&#x201d;), a California corporation, which as a result became a wholly owned subsidiary. &#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Immuneering, ISC and BioArkive are collectively referred to as &#x201c;the Company&#x201d; throughout these &#160;consolidated financial statements.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Company is subject to a number of inherent risks associated with any biotechnology company that has substantial expenditures for research and development. These risks include, but are not limited to, the need to obtain adequate additional funding, possible failure of clinical trials or other events demonstrating lack of clinical safety or efficacy of its product candidates, dependence on key personnel, reliance on third-party service providers for manufacturing drug product and conducting clinical trials, the ability to successfully secure its proprietary technology, and risks related to the regulatory approval and commercialization of a product candidate. There can be no assurance that the Company&#x2019;s research and development program will be successful. In addition, the Company operates in an environment of rapid technological change and is largely dependent on the services of its employees, advisors, and consultants.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;On August 3, 2021, the Company completed its initial public offering (&#x201c;IPO&#x201d;) pursuant to which it issued and sold 8,625,000 shares of its Class A common stock, inclusive of 1,125,000 shares of its Class A common stock sold pursuant to the full exercise of the underwriters&#x2019; option to purchase additional shares. The aggregate net proceeds received by the Company from the IPO were $120,318,750, after deducting underwriting discounts and commissions, but before deducting offering costs payable by the Company, which were $2,124,317. Upon the closing of the IPO, all 8,528,078 shares of the Company&#x2019;s convertible preferred stock then outstanding automatically converted into 11,939,281 shares of Class A common stock. Upon the conversion of the convertible preferred stock, the Company reclassified the carrying value of the convertible preferred stock to common stock (at par value) and additional&#160;paid-in&#160;capital (see Note 8). &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;To date, the Company has funded its operations through service revenues, and with proceeds from the sale of its capital stock and convertible notes and, most recently, with proceeds from the IPO. The Company has incurred recurring losses over the past several&#160;years and as of December&#160;31, 2021, the Company had an accumulated deficit of $59,273,388. The Company expects to continue to generate operating losses for the foreseeable future. The future viability of the Company is dependent on its ability to raise additional capital to finance its operations. The Company&#x2019;s inability to raise capital as and when needed could have a negative impact on its financial condition and ability to pursue its business strategies. There can be no assurances that additional funding will be available on terms acceptable to the Company, or at all. If the Company is unable to raise additional funds when needed, it may be required to delay, reduce the scope of, or eliminate development programs, which may adversely affect its business and operations. Management considers that there are no conditions or events, in the aggregate, that raise substantial doubt about the entity&#x2019;s ability to continue as a going concern and estimates that its cash and cash equivalents will be sufficient to fund its operating expenses and capital expenditure requirements for at least 12&#160;months from the issuance date of the consolidated financial statements. The full extent to which coronavirus (&#x201c;COVID-19&#x201d;) pandemic will directly or indirectly impact the Company&#x2019;s business, results of operations and financial &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;condition, including expenses and research and development costs, will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning COVID-19 and its variants and the actions taken to contain or treat COVID-19 and its variants, as well as the economic impact on local, regional, national and international markets. The Company has considered potential impacts arising from the pandemic related to COVID-19 and its variants and is not presently aware of any events or circumstances that would require the Company to update its estimates, judgements or revise the carrying values of its assets or liabilities.&lt;/p&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_8_3_2021_To_8_3_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_nbYOiYQZAUed9mAOrNTolQ"
      decimals="INF"
      id="Narr_5GaAZJ-Ds0SM3o11INV8mQ"
      unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ">8625000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_8_3_2021_To_8_3_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_G9SnpifyxEmaJU1UE794ew"
      decimals="INF"
      id="Narr_yWLzTY6-TEmNGoFLyI7hAQ"
      unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ">1125000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_8_3_2021_To_8_3_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_7enA8yNRQkat6QV_1FoEOw"
      decimals="0"
      id="Narr_WlmIWJhEdEmj_MBEQUp2OQ"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">120318750</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <imrx:OfferingCostPayable
      contextRef="As_Of_8_3_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_kxYscz4Wf02VzWLhksRRxw"
      decimals="0"
      id="Narr_048q5eCg_U6gsMnEc0MhqA"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">2124317</imrx:OfferingCostPayable>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="As_Of_8_3_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_kxYscz4Wf02VzWLhksRRxw"
      decimals="INF"
      id="Narr_zpUsu3C1NU-QubfONpalhg"
      unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ">8528078</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="As_Of_8_3_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_boKn2a2ouUyMVqODG0-nIw"
      decimals="INF"
      id="Narr_cPaTqMe8S0mZNoJAAeiBFA"
      unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ">11939281</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_12_31_2021_TBpjtOXgEkKQahJJAv0aWg"
      decimals="0"
      id="Narr_Q4p5YkiFxEWAgczNQFP7rQ"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">-59273388</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ"
      id="Tb_hTOft3WF_0avV4xSFcC6Vg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Note&#160;2 - Summary of Significant Accounting Policies&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Basis of Presentation&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The consolidated financial statements have been prepared in accordance with accounting standards set by the Financial Accounting Standards Board (&#x201c;FASB&#x201d;). The FASB sets generally accepted accounting principles (&#x201c;GAAP&#x201d;) to ensure the consolidated financial statements are consistently reported. References to GAAP issued by the FASB in these footnotes are to the FASB Accounting Standards Codifications (&#x201c;ASC&#x201d;). The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Stock Split&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-weight:normal;"&gt;On July 23, 2021, the Company approved a &lt;/span&gt;&lt;span style="font-weight:normal;"&gt;one&lt;/span&gt;&lt;span style="font-weight:normal;white-space:pre-wrap;"&gt;-for-1.4 stock split which was consummated in connection with the Company&#x2019;s IPO.  All information in the accompanying financial statements and notes thereto regarding share amounts of common stock, price per share of common stock and the conversion factor for Series A and Series B Preferred Stock into common stock have been adjusted to reflect the application of the stock split on a retroactive basis.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Use of Estimates&#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses during the reporting periods. These estimates and assumptions are based on current facts, historical experience and various other factors believe to be reasonable under the circumstances, the results of which form the basis for making judgements about the carrying values of assets, liabilities and the recording of expenses that are not readily apparent from other sources. Significant estimates reflected in these &#160;consolidated financial statements included but are not limited to, the research and development expenses, determination of fair value of stock-based awards, the valuation of common stock prior to the IPO, business combination, and the right-to-use assets and operating lease liability. Actual results may differ materially and adversely from these estimates.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Segments&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"&gt;Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker (&#x201c;CODM&#x201d;) in making decisions regarding resource allocation and assessing performance. The Company&#x2019;s chief executive officer is the CODM, and he uses consolidated financial information in determining how to allocate resources and assess performance. The Company has determined that it operates in one segment.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="display:inline-block;visibility:hidden;width:0pt;"&gt;&#x200b;&lt;/span&gt;&lt;br/&gt;&lt;span style="font-size:13.5pt;visibility:hidden;background:#ffffff;"&gt;&#x200b;&lt;/span&gt;&lt;span style="font-size:13.5pt;visibility:hidden;background:#ffffff;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:13.5pt;visibility:hidden;background:#ffffff;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:13.5pt;visibility:hidden;background:#ffffff;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:13.5pt;visibility:hidden;background:#ffffff;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:13.5pt;visibility:hidden;background:#ffffff;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;b style="font-weight:bold;background:#ffffff;"&gt;Business Combination&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="font-size:13.5pt;font-weight:bold;visibility:hidden;background:#ffffff;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="background:#ffffff;"&gt;Results of operations of acquired companies are included in the Company&#x2019;s results of operations as of the respective acquisition dates. Acquired businesses are accounted for using the acquisition method of accounting, which requires that assets acquired and liabilities assumed be recorded at fair value, with limited exceptions. Any excess of the purchase price over the fair value of the net assets acquired is recorded as goodwill. Transaction costs and costs to restructure the acquired Company are expensed as incurred. The operating results of the acquired business are reflected in the consolidated financial statements after the date of acquisition. &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="font-size:13.5pt;visibility:hidden;background:#ffffff;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"&gt;If the acquired net assets do not constitute a business under the acquisition method of accounting, the transaction is accounted for as an asset acquisition and no goodwill is recognized.&#160;Refer to Note 6, Business Combination for more information.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Cash and Cash &lt;/b&gt;&lt;b style="font-weight:bold;"&gt;Equivalents&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"&gt;Cash and cash equivalents are comprised of deposits at major financial banking institutions and highly liquid investments with an original maturity of three&#160;months or less at the date of purchase. Cash is maintained at Federal Deposit Insurance Company (&#x201c;FDIC&#x201d;) insured financial institutions. At times, the Company has maintained cash in excess of FDIC limits, however it has not experienced any losses with respect to its cash balances. The Company regularly monitors the financial condition of the institutions in which it has depository accounts and believes the risk of loss is minimal.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Marketable Securities &lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Our marketable securities are classified as available-for-sale pursuant to ASC 320,&lt;span style="background:#ffffff;"&gt; Investments &#x2013; Debt and Equity Securities&lt;/span&gt; and are recorded at fair value. Unrealized gains/(losses) are included as a component of accumulated other comprehensive loss in the &#160;consolidated balance sheets and statements of convertible preferred stock and stockholders&#x2019; equity (deficit) and a component of total comprehensive loss in the consolidated statements of comprehensive loss, until realized. The Company assesses its available-for-sale marketable securities for impairment on a quarterly basis. There were no impairments of the Company&#x2019;s available-for-sale marketable securities measured and carried at fair value during the year ended December 31, 2021. &#160;Realized gains and losses are included in other expense on a specific-identification basis.&#160;There were&#160;no&#160;realized gains or losses on marketable securities for the year ended December 31, 2021.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair Value Measurements&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;We record cash equivalents and marketable securities at fair value. ASC 820,&#160;Fair Value Measurements and Disclosures, establishes a fair value hierarchy for those instruments measured at fair value that distinguishes between assumptions based on market data (observable inputs) and our own assumptions (unobservable inputs). The hierarchy consists of three levels:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Level 1&lt;/i&gt;&#160;&#x2013; Unadjusted quoted prices in active markets for identical assets or liabilities.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Level 2&lt;/i&gt;&#160;&#x2013; Quoted prices for similar assets and liabilities in active markets, quoted prices in markets that are not active, or inputs which are observable, directly or indirectly, for substantially the full term of the asset or liability.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Level 3&lt;/i&gt;&#160;&#x2013; Unobservable inputs that reflect our own assumptions about the assumptions market participants would use in pricing the asset or liability in which there is little, if any, market activity for the asset or liability at the measurement date.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Our financial assets, which include cash equivalents and marketable securities, have been initially valued at the transaction price, and subsequently revalued at the end of each reporting period, utilizing third-party pricing services or other observable market data. The pricing services utilize industry standard valuation models, including both income and market based approaches, and observable market inputs to determine value. After completing our validation procedures, we did not adjust or override any fair value measurements provided by the pricing services as of December&#160;31, 2021. Fair value &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;information for these assets, including their classification in the fair value hierarchy is included in Note 4 &#160;Fair Value Measurements&lt;b style="font-weight:bold;"&gt;.&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="font-size:13.5pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;There have been no changes to the valuation methods during the year ended December&#160;31, 2021. We evaluate transfers between levels at the end of each reporting period.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="font-size:13.5pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;The carrying amounts reflected in the consolidated balance sheets for cash, accounts receivable, accounts payable and accrued expenses approximate their respective fair values because of the short-term maturity of those financial instruments.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Accounts Receivable&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"&gt;Accounts receivable are stated at the amount management expects to collect from outstanding balances. An allowance for doubtful accounts is estimated for those accounts receivable considered to be uncollectible based upon historical experience and management&#x2019;s evaluation of outstanding accounts receivable. Bad debts are written off against the allowance when identified. At December&#160;31, 2021 and 2020 there was no allowance for doubtful accounts.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Concentration of Credit Risk&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"&gt;Financial instruments that potentially subject the Company to significant concentration of credit risk consist primarily of accounts receivable and revenue. To manage accounts receivable credit risk, the Company continuously evaluates the creditworthiness of its customers and the need for an allowance for potential credit losses. The Company has not experienced any losses in such accounts.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"&gt;The following customers comprised 10% or more of the Company&#x2019;s total accounts receivable or revenues as of or for the period ended December&#160;31, 2021 (customers with an asterisk are less than 10%): &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"&gt;&lt;span style="letter-spacing:0.2pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:47.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:47.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:22.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="color:#231f20;font-weight:bold;"&gt;Year Ended December&#160;31,&#160;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:23.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="color:#231f20;font-weight:bold;"&gt;As&#160;of&#160;December&#160;31,&#160;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:47.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Revenue&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;%&#160;of&#160;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Accounts&#160;Receivable&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;%&#160;of&#160;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:47.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Customer #1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 745,030&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 35.8&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 235,500&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;95.7%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:47.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Customer #2&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 380,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 18.3&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;*&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;*&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:47.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Customer #5&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 353,050&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 17.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;*&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;*&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:47.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:47.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:22.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="color:#231f20;font-weight:bold;"&gt;Year Ended December&#160;31,&#160;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:23.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="color:#231f20;font-weight:bold;"&gt;As&#160;of&#160;December&#160;31,&#160;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:47.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Revenue&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;%&#160;of&#160;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Accounts&#160;Receivable&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;%&#160;of&#160;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:47.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Customer #1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 676,710&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 29.3&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 214,345&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 42.9&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:47.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Customer #2&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 570,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 24.7&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 71,250&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 14.2&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:47.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Customer #3&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 306,900&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 13.3&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;*&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;*&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:47.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Customer #4&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 250,880&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 10.9&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 63,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 12.6&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:47.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Customer #5&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;*&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;*&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 91,975&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 18.4&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Property and Equipment&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"&gt;Property and equipment are recorded at cost, net of accumulated depreciation. Expenditures for major replacements and improvements are capitalized, while expenditures for general repairs and maintenance are expensed as incurred. Upon retirements or disposition of property and equipment, the related cost and accumulated depreciation are removed from the consolidated balance sheet and any resulting gain or loss is recorded in the consolidated statement of operations. Depreciation is calculated using the straight-line method once assets are placed in service. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"&gt;&lt;span style="letter-spacing:0.2pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:86.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:86.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Estimated&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Asset Class&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Useful&#160;Lives&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Computer equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;3 years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Furniture and fixtures&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;5 years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Lab equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;7 years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;1-10 years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Impairment of Long-lived Assets&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"&gt;Periodically, the Company evaluates its long-lived assets, which consist primarily of property and equipment, for impairment whenever events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted net cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the asset exceeds the fair value of the asset. To date, no impairments have occurred.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Leases&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"&gt;In February&#160;2016 the FASB issued Accounting Standards Update (&#x201c;ASU&#x201d;) No. 2016-02, Leases (Topic 842) (&#x201c;ASC 842&#x201d;), a standard issued to increase transparency and comparability among organizations related to their leasing activities. This standard established a right-of-use model that requires the recognition of right-of-use assets and lease liabilities for most leases as well as provides disclosure with respect to certain qualitative and quantitative information related to a company&#x2019;s leasing arrangements to meet the objective of allowing users of financial statements to assess the amount, timing and uncertainty of cash flows arising from leases.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"&gt;The Company adopted the leasing standard using the modified retrospective transition approach as of January&#160;1, 2020, with no restatement of prior periods or cumulative adjustment to retained earnings. Upon adoption, the Company elected the package of transition practical expedients, which allowed the Company to carry forward prior conclusions related to whether any expired or existing contracts are or contain leases, the lease classification for any expired or existing leases, and initial direct costs for existing leases. The Company also made an accounting policy election to not recognize leases with an initial term of 12&#160;months or less within its consolidated balance sheets, and to recognize those lease payments on a straight-line basis in its consolidated statements of operations over the lease term. The adoption of the leasing standard did not have an impact on the consolidated statement of operations.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"&gt;The Company determines if an arrangement is a lease at contract inception. Right-of-use assets represent the Company&#x2019;s right to use an underlying asset for the lease term and lease liabilities represent its obligation to make lease payments arising from the lease. Right-of-use assets and lease liabilities are recognized at the commencement date of the lease based upon the present value of future lease payments over the expected lease term. When determining the lease term, the Company includes options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. As most of the Company&#x2019;s leases do not provide an implicit interest rate, the Company uses its incremental borrowing rate, which is based on rates that would be incurred to borrow on a collateralized basis over a term equal to the lease payments in a similar economic environment, in determining the present value of lease payments.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"&gt;The Company has elected not to separate lease and non-lease components as a single lease component. The Company&#x2019;s lease are reflected in right-of-use assets and lease liabilities (current and non-current) in the consolidated balance sheets.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Revenue Recognition&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"&gt;&lt;span style="font-weight:bold;letter-spacing:-0.2pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;In accordance with ASC 606, revenue is recognized when a customer obtains control of promised goods and services. The core principle of the standard is to recognize revenue to depict the transfer of promised goods or services to customers in &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods or services. To achieve that core principle, the Company applies the following five-step model:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt 0pt 0pt 18pt;"&gt;&#x2022; Identify the contract with a customer&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt 0pt 0pt 18pt;"&gt;&#x200b;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt 0pt 0pt 18pt;"&gt;&#x2022; Identify the performance obligations in the contract&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt 0pt 0pt 18pt;"&gt;&#x200b;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt 0pt 0pt 18pt;"&gt;&#x2022; Determine the transaction price&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt 0pt 0pt 18pt;"&gt;&#x200b;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt 0pt 0pt 18pt;"&gt;&#x2022; Allocate the transaction price to the performance obligations in the contract&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt 0pt 0pt 18pt;"&gt;&#x200b;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt 0pt 0pt 18pt;"&gt;&#x2022; Recognize revenue when or as performance obligations are satisfied&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;"&gt;&#x200b;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"&gt;The Company&#x2019;s contracts generally consist of the promise to provide computational biology professional services to pharmaceutical and biotechnology companies, which the Company has concluded constitutes one performance obligation that is delivered over time. The transaction price is the amount of consideration to which the Company expects to be entitled in exchange for transferring the services to the customer. The Company&#x2019;s contracts provide for either agreed upon rates per hour based on the level of the professional working on the project or a fixed fee for a defined scope of work. The Company recognizes revenue over time by measuring the progress toward complete satisfaction of the performance obligation using a single method of measuring progress, which depicts the performance in transferring control of the associated services to the customer. The Company uses input methods to measure the progress toward the complete satisfaction of performance obligations and evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenue and net loss in the period of adjustment.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"&gt;The Company&#x2019;s contract terms do not allow for a right of return or refund and do not contain significant financing components. Receivables associated with the contract will generally be collected within thirty to sixty days, in accordance with the underlying payment terms.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Income Taxes&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"&gt;The Company provides for income taxes in accordance with ASC Topic 740, Income Taxes. Deferred tax assets and liabilities are determined based on the difference between the financial reporting and tax bases of assets and liabilities using enacted tax rates and laws in effect in the&#160;years in which the differences are expected to reverse. A valuation allowance is provided if, based upon the weighted available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"&gt;The Company accounts for uncertainty in income taxes recognized in the consolidated financial statements by applying a two-step process to determine the amount of tax benefit to be recognized. First, the tax position must be evaluated to determine the likelihood that it will be sustained upon external examination by the taxing authorities. If the tax position is deemed more likely than not to be sustained, the tax position is then assessed to determine the amount of benefit to recognize in the consolidated financial statements. The amount of the benefit that may be recognized is the largest amount that has a greater than 50% likelihood of being realized upon ultimate settlement. The provision for income taxes includes the effects of any resulting tax reserves (i.e., unrecognized tax benefits) that are considered appropriate as well as the related net interest. &lt;span style="color:#222222;background:#ffffff;"&gt;As of December 31, 2021 and 2020, the Company had uncertain tax positions of &lt;/span&gt;&lt;span style="color:#222222;background:#ffffff;"&gt;$380,902&lt;/span&gt;&lt;span style="color:#222222;background:#ffffff;"&gt; and &lt;/span&gt;&lt;span style="color:#222222;background:#ffffff;"&gt;$174,950&lt;/span&gt;&lt;span style="color:#222222;background:#ffffff;"&gt;.&#160;&#160; The Company has classified the unrecognized tax benefits as reductions of its tax credit carryforwards.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Research and Development&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"&gt;Research and development costs are expensed as incurred. Research and development costs consist of expenses incurred in performing research and development activities, including salaries and benefits, materials and supplies, preclinical expenses, stock-based compensation expense, depreciation of equipment, contract services, and other outside expenses. The Company also incurs costs to develop software programs for internal use in identifying potential human drug targets which may then lead to the development of human drug candidates. To date the software programs have primarily been used for internal research and development activities and the costs incurred have been expensed as research and development.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"&gt;&lt;span style="letter-spacing:0.2pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Research and Manufacturing Contract Costs and Accruals&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Company has entered into various research, development and manufacturing contracts with research institutions and other companies in the United States. These agreements are generally cancelable, and related costs are recorded as research and development expenses as incurred. The Company records accruals for estimated ongoing research, development and manufacturing costs. When billing terms under these contracts do not coincide with the timing of when the work is performed, the Company is required to make estimates of outstanding obligations to those third parties as of period end. Any accrual estimates are based on a number of factors, including the Company&#x2019;s knowledge of the progress towards completion of the research, development and manufacturing activities, invoicing to date under the contracts, communication from the research institutions and other companies of any actual costs incurred during the period that have not yet been invoiced and the costs included in the contracts. Significant judgments and estimates may be made in determining the accrued balances at the end of any reporting period. Actual results could differ from the estimates made by the Company. The historical accrual estimates made by the Company have not been materially different from the actual costs.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="color:#231f20;font-weight:bold;"&gt;Patent &lt;/b&gt;&lt;b style="font-weight:bold;"&gt;Costs&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;All patent-related costs incurred in connection with filing and prosecuting patent applications are expensed as incurred due to the uncertainty about the recovery of the expenditure. Amounts incurred are classified as general and administrative expenses.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="color:#231f20;font-weight:bold;"&gt;Com&lt;/b&gt;&lt;b style="font-weight:bold;background:#ffffff;"&gt;prehensive Loss&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Comprehensive loss includes net loss as well as other changes in stockholders&#x2019; equity (deficit) that result from transactions and economic events other than those with stockholders. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;background:#ffffff;"&gt;Deferred Offering Costs&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="background:#ffffff;"&gt;The Company capitalizes certain legal, professional accounting and other third-party fees that are directly associated with&#160;in-process&#160;equity financings as deferred offering costs until such financings are consummated. After consummation of an equity financing, these costs are recorded as a reduction of the proceeds from the offering, either as a reduction of the carrying value of the preferred stock or in stockholder&#x2019;s equity (deficit) as a reduction of additional&#160;paid-in&#160;capital generated as a result of the offering. Should the&#160;in-process&#160;equity financing be abandoned, the deferred offering costs would be expensed immediately as a charge to operating expenses in the statements of operations and comprehensive loss. There were&#160;&lt;/span&gt;&lt;span style="background:#ffffff;"&gt;no&lt;/span&gt;&lt;span style="background:#ffffff;"&gt;&#160;deferred offering costs as of December&#160;31,2021 or December 31, 2020.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="color:#231f20;font-weight:bold;"&gt;Net Income (Loss) per Share&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Prior to the closing of the IPO, the Company followed the two-class method when computing net income (loss) per share, as the Company had issued shares that meet the definition of participating securities. The two-class method determines net income (loss) per share for each class of common and participating securities according to dividends declared or accumulated and participation rights in undistributed earnings. The two-class method requires income available to common stockholders for the period to be allocated between common and participating securities based upon their respective rights to receive dividends as if all income for the period had been distributed.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Basic net income (loss) per share attributable to common stockholders is computed by dividing the net income (loss) attributable to common stockholders by the weighted average number of common shares outstanding for the period. Diluted net income (loss) attributable to common stockholders is computed by adjusting net income (loss) attributable to common stockholders to reallocate undistributed earnings based on the potential impact of dilutive securities. Diluted net income (loss) per share attributable to common stockholders is computed by dividing the diluted net income (loss) attributable to common stockholders by the weighted average number of common shares outstanding for the period, including potential dilutive common shares assuming the dilutive effect of common stock equivalents.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Company&#x2019;s convertible preferred stock contractually entitled the holders of such shares to participate in dividends but does not contractually require the holders of such shares to participate in losses of the Company. Accordingly, in periods in which the Company reports a net loss, such losses are not allocated to such participating securities. In periods in which the Company reports a net loss attributable to common stockholders, diluted net loss per share attributable to common stockholders is the same as basic net loss per share attributable to common stockholders, since dilutive common shares are not assumed to have been issued if their effect is anti-dilutive.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Subsequent to the closing of its IPO, the Company only has one class of shares outstanding and basic net income (loss) per common share is computed by dividing the net income (loss) by the weighted average number of shares of common stock outstanding for the period. Diluted net income (loss) per common share is computed by dividing net income (loss) by the weighted average number of shares of common stock outstanding for the period, including potential dilutive common shares assuming the dilutive effect of outstanding stock awards. For periods in which the Company reports a net loss, diluted net loss per common share is the same as basic net loss per common share, since dilutive common shares are not assumed to have been issued if their effect is anti-dilutive. The Company reported a net loss attributable to common stockholders for each of the years ended December&#160;31, 2021 and 2020.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Stock-based Compensation&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"&gt;&lt;span style="font-weight:bold;letter-spacing:-0.2pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Company issues stock-based awards to employees and nonemployees in the form of stock options. The Company accounts for stock-based awards in accordance with ASC 718, Compensation&#x2009;&#x2014;&#x2009;Stock Compensation (&#x201c;ASC 718&#x201d;), which requires all stock-based payments to employees and nonemployees, including grants of employee stock options and modifications to existing stock options, to be recognized in the consolidated statement of operations based on their fair values.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The fair value of options is estimated on the grant date using the Black-Scholes option-pricing model (&#x201c;Black-Scholes&#x201d;). Black-Scholes requires the Company to make assumptions and judgments about the variables used in the calculation including the expected term of its stock option, the volatility of the Company&#x2019;s common stock, and an assumed risk-free interest rate. The Company uses the simplified calculation of expected life and volatility is based on an average of the historical volatility of a group of publicly traded companies in a similar industry that the Company believes would be considered a peer group had it been a publicly held company for the duration of the expected life of the award. The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of grant for periods corresponding with the expected life of the option. Forfeitures are recognized as they occur. No dividend yield was assumed as the Company does not pay, and does not expect to pay, dividends on its common stock. The assumptions underlying these valuations represent management&#x2019;s best estimates, which involve inherent uncertainties and the application of management&#x2019;s judgement.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;In accordance with ASU No. 2018-07, Compensation-Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting, compensation expense for stock-based awards granted to nonemployees is recognized over the period during which services are rendered by such nonemployees. The new standard largely aligns the accounting for share-based payment awards issued to employees and nonemployees by expanding the scope of ASC 718 to apply to nonemployee share-based transactions, as long as the transaction is not effectively a form of financing. There was no adjustment to the financial statements upon adoption of this standard as of January&#160;1, 2020.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;As there had been no public market for the Company&#x2019;s common stock prior to the IPO, the estimated fair value of its common stock has been determined by its board of directors as of the date of each option grant, with input from management, considering the Company&#x2019;s most recently available third-party valuations of common stock and its board of directors&#x2019; assessment of additional objective and subjective factors that it believed were relevant and which may have changed from the date of the most recent valuation through the date of the grant. These third-party valuations were performed in accordance with the guidance outlined in the American Institute of Certified Public Accountants&#x2019; Accounting and Valuation Guide, Valuation of Privately-Held-Company Equity Securities Issued as Compensation. Each valuation methodology includes estimates and assumptions that require the Company&#x2019;s judgment. These estimates and assumptions include a number of objective and subjective factors, including external market conditions, the prices at which the Company sold shares of preferred stock, the superior rights and preferences of securities senior to the Company&#x2019;s common stock at the time of, and the likelihood of, achieving a liquidity event, such as an initial public offering or sale.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The assumptions underlying these valuations represent management&#x2019;s best estimates, which involve inherent uncertainties and the application of management&#x2019;s judgment. As a result, if the Company had used different assumptions or estimates, the fair value of its common stock and its stock-based compensation expense could be materially different.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Goodwill&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Goodwill represents the excess of the fair value of the acquiree over the recognized bases of the net identifiable assets acquired and includes the future economic benefits from other assets that could not be individually identified and separately recognized. Goodwill is not amortized, but instead is periodically reviewed for impairment and an impairment charge is recorded in the periods in which the recorded carrying value of goodwill exceeds its fair value.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="background:#ffffff;"&gt;On a quarterly basis, the Company performs a review of its business to determine if events or changes in circumstances have occurred which could have a material adverse effect on the fair value of the Company and its goodwill. If such events or changes in circumstances were deemed to have occurred, the Company would perform an impairment test of goodwill as of the end of the quarter and record any noted impairment loss.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="background:#ffffff;"&gt;The goodwill test is performed at least annually, or more frequently if events or changes in circumstances indicate that the asset might be impaired. &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="background:#ffffff;"&gt;The Company performs its annual impairment test during the fourth quarter of each fiscal year. There were &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;no&lt;/span&gt;&lt;span style="background:#ffffff;"&gt; impairments in 2021.&lt;/span&gt;&lt;span style="background:#ffffff;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Intangible Assets&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Intangible assets are recognized at fair value, as an asset apart from goodwill if the asset (i) arises from contractual or other legal rights, or (ii) is separable. Intangible assets, principally representing technology acquired, are capitalized and amortized on the straight-line method over their expected useful lives.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Company reviews the recoverability of its long-lived assets (including amortizable intangible assets), other than goodwill, when events or changes in circumstances occur that indicate that the carrying value of the asset may not be recoverable. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Recently Issued Accounting Pronouncements&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies and adopted by the Company as of the specified effective date. The Company is an &#x201c;emerging growth company&#x201d; as defined in the Jumpstart Our Business Startups Act of 2012, as amended (&#x201c;JOBS Act&#x201d;). The Jobs Act provides that an emerging growth company can take advantage of an extended transition period for complying with new or revised accounting standards. Thus, an emerging growth company can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. The Company elected to avail itself of this extended transition period and, as a result, we will not be required to adopt new or revised accounting standards on the relevant dates on which adoption of such standards is required for other public companies.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;In 2016, the FASB issued ASU 2016-13, Financial Instruments&#160;&#x2013; Credit Losses (Topic 326): Measurement of Credit Losses on Financial Statements. The new standard, as amended, requires that expected credit losses relating to financial assets measured on an amortized cost basis and available-for-sale debt securities be recorded through an allowance for credit losses. It also limits the amount of credit losses to be recognized for available-for-sale debt securities to the amount by which carrying value exceeds fair value and also requires the reversal of previously recognized credit losses if fair value increases. The targeted transition relief standard allows filers an option to irrevocably elect the fair value option of ASC 825-10, Financial Instruments-Overall, applied on an instrument-by-instrument basis for eligible instruments.&#160;ASU No.&#160;2016-13, Financial Instruments&#160;- Credit Losses (Topic 326) will become effective for the Company on January&#160;1, 2023. The Company is currently assessing the impact of the adoption of this guidance on its consolidated financial statements.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;In December&#160;2019, the FASB issued ASU No.&#160;2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes, which simplifies the accounting for income taxes by removing certain exceptions to the general principles in the existing guidance for income taxes and making other minor improvements. The amendments are effective for annual reporting periods beginning after December&#160;15, 2020 with early adoption permitted. The adoption of this standard did not have a material impact to the financial statements.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;In January 2017, the FASB issued ASU No. ASU 2017-04, &#160;Intangibles&#x2014;Goodwill and Other (Topic 350&lt;i style="font-style:italic;"&gt;)&lt;/i&gt;, which eliminates Step 2 from the goodwill impairment test. Step 2 measures a goodwill impairment loss by comparing the implied fair value of a reporting unit&#x2019;s goodwill with the carrying amount of that goodwill. Instead, entities will record an impairment charge based on the excess of a reporting unit&#x2019;s carrying amount over its fair value (i.e., measure the charge based on today&#x2019;s Step 1). This update is effective for annual and interim impairment tests performed in periods beginning after December 15, 2022. Early adoption of the standard is permitted. The Company is currently evaluating the new guidance and assessing the potential impact on its consolidated financial statements. &#160;&lt;/p&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ"
      id="Tb_p6IXcqzObE-kel0ai_bhDA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Basis of Presentation&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The consolidated financial statements have been prepared in accordance with accounting standards set by the Financial Accounting Standards Board (&#x201c;FASB&#x201d;). The FASB sets generally accepted accounting principles (&#x201c;GAAP&#x201d;) to ensure the consolidated financial statements are consistently reported. References to GAAP issued by the FASB in these footnotes are to the FASB Accounting Standards Codifications (&#x201c;ASC&#x201d;). The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation.&lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:StockholdersEquityPolicyTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ"
      id="Tb_gl5ZFufieUeqyxPG-c1OvA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Stock Split&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-weight:normal;"&gt;On July 23, 2021, the Company approved a &lt;/span&gt;&lt;span style="font-weight:normal;"&gt;one&lt;/span&gt;&lt;span style="font-weight:normal;white-space:pre-wrap;"&gt;-for-1.4 stock split which was consummated in connection with the Company&#x2019;s IPO.  All information in the accompanying financial statements and notes thereto regarding share amounts of common stock, price per share of common stock and the conversion factor for Series A and Series B Preferred Stock into common stock have been adjusted to reflect the application of the stock split on a retroactive basis.&lt;/span&gt;&lt;/p&gt;</us-gaap:StockholdersEquityPolicyTextBlock>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="Duration_7_23_2021_To_7_23_2021_He5Glc1OZUuR4Os2aqbeew"
      decimals="INF"
      id="Narr_PmJfsXGaNESUU25MtnMKFQ"
      unitRef="Unit_Standard_pure_iothMaWWqUCV2N7d1PVg4w">1</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <us-gaap:UseOfEstimates
      contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ"
      id="Tb_Sd-K4-ZPt0CVgXq3I3C_2g">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Use of Estimates&#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses during the reporting periods. These estimates and assumptions are based on current facts, historical experience and various other factors believe to be reasonable under the circumstances, the results of which form the basis for making judgements about the carrying values of assets, liabilities and the recording of expenses that are not readily apparent from other sources. Significant estimates reflected in these &#160;consolidated financial statements included but are not limited to, the research and development expenses, determination of fair value of stock-based awards, the valuation of common stock prior to the IPO, business combination, and the right-to-use assets and operating lease liability. Actual results may differ materially and adversely from these estimates.&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ"
      id="Tb_UDrXh7IE9USCA2zcYGg4BQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Segments&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"&gt;Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker (&#x201c;CODM&#x201d;) in making decisions regarding resource allocation and assessing performance. The Company&#x2019;s chief executive officer is the CODM, and he uses consolidated financial information in determining how to allocate resources and assess performance. The Company has determined that it operates in one segment.&lt;/p&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ"
      decimals="INF"
      id="Narr_p62sbgIC6EKASVlEcPi1Dg"
      unitRef="Unit_Standard_segment_tQmfuIJwOkyVlCDJy8sORg">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:BusinessCombinationsPolicy
      contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ"
      id="Tb_23eSFnAsH0uL4kFQf4_LxQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;b style="font-weight:bold;background:#ffffff;"&gt;Business Combination&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="font-size:13.5pt;font-weight:bold;visibility:hidden;background:#ffffff;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="background:#ffffff;"&gt;Results of operations of acquired companies are included in the Company&#x2019;s results of operations as of the respective acquisition dates. Acquired businesses are accounted for using the acquisition method of accounting, which requires that assets acquired and liabilities assumed be recorded at fair value, with limited exceptions. Any excess of the purchase price over the fair value of the net assets acquired is recorded as goodwill. Transaction costs and costs to restructure the acquired Company are expensed as incurred. The operating results of the acquired business are reflected in the consolidated financial statements after the date of acquisition. &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="font-size:13.5pt;visibility:hidden;background:#ffffff;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"&gt;If the acquired net assets do not constitute a business under the acquisition method of accounting, the transaction is accounted for as an asset acquisition and no goodwill is recognized.&#160;Refer to Note 6, Business Combination for more information.&lt;/p&gt;</us-gaap:BusinessCombinationsPolicy>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ"
      id="Tb_p-J-ljxBHkuEPSs1K3HKCA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Cash and Cash &lt;/b&gt;&lt;b style="font-weight:bold;"&gt;Equivalents&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"&gt;Cash and cash equivalents are comprised of deposits at major financial banking institutions and highly liquid investments with an original maturity of three&#160;months or less at the date of purchase. Cash is maintained at Federal Deposit Insurance Company (&#x201c;FDIC&#x201d;) insured financial institutions. At times, the Company has maintained cash in excess of FDIC limits, however it has not experienced any losses with respect to its cash balances. The Company regularly monitors the financial condition of the institutions in which it has depository accounts and believes the risk of loss is minimal.&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:MarketableSecuritiesPolicy
      contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ"
      id="Tb_pzuaLW5-GkKDJUtWdfLcYQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Marketable Securities &lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Our marketable securities are classified as available-for-sale pursuant to ASC 320,&lt;span style="background:#ffffff;"&gt; Investments &#x2013; Debt and Equity Securities&lt;/span&gt; and are recorded at fair value. Unrealized gains/(losses) are included as a component of accumulated other comprehensive loss in the &#160;consolidated balance sheets and statements of convertible preferred stock and stockholders&#x2019; equity (deficit) and a component of total comprehensive loss in the consolidated statements of comprehensive loss, until realized. The Company assesses its available-for-sale marketable securities for impairment on a quarterly basis. There were no impairments of the Company&#x2019;s available-for-sale marketable securities measured and carried at fair value during the year ended December 31, 2021. &#160;Realized gains and losses are included in other expense on a specific-identification basis.&#160;There were&#160;no&#160;realized gains or losses on marketable securities for the year ended December 31, 2021.&lt;/p&gt;</us-gaap:MarketableSecuritiesPolicy>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy
      contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ"
      id="Tb_qfjCoFJAT0a0exarFjEsEg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair Value Measurements&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;We record cash equivalents and marketable securities at fair value. ASC 820,&#160;Fair Value Measurements and Disclosures, establishes a fair value hierarchy for those instruments measured at fair value that distinguishes between assumptions based on market data (observable inputs) and our own assumptions (unobservable inputs). The hierarchy consists of three levels:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Level 1&lt;/i&gt;&#160;&#x2013; Unadjusted quoted prices in active markets for identical assets or liabilities.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Level 2&lt;/i&gt;&#160;&#x2013; Quoted prices for similar assets and liabilities in active markets, quoted prices in markets that are not active, or inputs which are observable, directly or indirectly, for substantially the full term of the asset or liability.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Level 3&lt;/i&gt;&#160;&#x2013; Unobservable inputs that reflect our own assumptions about the assumptions market participants would use in pricing the asset or liability in which there is little, if any, market activity for the asset or liability at the measurement date.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Our financial assets, which include cash equivalents and marketable securities, have been initially valued at the transaction price, and subsequently revalued at the end of each reporting period, utilizing third-party pricing services or other observable market data. The pricing services utilize industry standard valuation models, including both income and market based approaches, and observable market inputs to determine value. After completing our validation procedures, we did not adjust or override any fair value measurements provided by the pricing services as of December&#160;31, 2021. Fair value &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;information for these assets, including their classification in the fair value hierarchy is included in Note 4 &#160;Fair Value Measurements&lt;b style="font-weight:bold;"&gt;.&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="font-size:13.5pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;There have been no changes to the valuation methods during the year ended December&#160;31, 2021. We evaluate transfers between levels at the end of each reporting period.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="font-size:13.5pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;The carrying amounts reflected in the consolidated balance sheets for cash, accounts receivable, accounts payable and accrued expenses approximate their respective fair values because of the short-term maturity of those financial instruments.&lt;/p&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:TradeAndOtherAccountsReceivableUnbilledReceivablesPolicy
      contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ"
      id="Tb_l6wuEhXZbkmaY4eEI6B_iw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Accounts Receivable&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"&gt;Accounts receivable are stated at the amount management expects to collect from outstanding balances. An allowance for doubtful accounts is estimated for those accounts receivable considered to be uncollectible based upon historical experience and management&#x2019;s evaluation of outstanding accounts receivable. Bad debts are written off against the allowance when identified. At December&#160;31, 2021 and 2020 there was no allowance for doubtful accounts.&lt;/p&gt;</us-gaap:TradeAndOtherAccountsReceivableUnbilledReceivablesPolicy>
    <us-gaap:AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables
      contextRef="As_Of_12_31_2020_OUSLyqWONEO8ccGPC6rBdg"
      decimals="0"
      id="Narr_2X2alUC46EefC-_t2__dtw"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">0</us-gaap:AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables>
    <us-gaap:AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables
      contextRef="As_Of_12_31_2021_TBpjtOXgEkKQahJJAv0aWg"
      decimals="0"
      id="Narr_4kKmyV1Vvkmn0bEreSldnA"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">0</us-gaap:AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ"
      id="Tb_PALbY50xuE-uwxFaUqcMuQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Concentration of Credit Risk&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"&gt;Financial instruments that potentially subject the Company to significant concentration of credit risk consist primarily of accounts receivable and revenue. To manage accounts receivable credit risk, the Company continuously evaluates the creditworthiness of its customers and the need for an allowance for potential credit losses. The Company has not experienced any losses in such accounts.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"&gt;The following customers comprised 10% or more of the Company&#x2019;s total accounts receivable or revenues as of or for the period ended December&#160;31, 2021 (customers with an asterisk are less than 10%): &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"&gt;&lt;span style="letter-spacing:0.2pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:47.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:47.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:22.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="color:#231f20;font-weight:bold;"&gt;Year Ended December&#160;31,&#160;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:23.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="color:#231f20;font-weight:bold;"&gt;As&#160;of&#160;December&#160;31,&#160;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:47.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Revenue&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;%&#160;of&#160;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Accounts&#160;Receivable&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;%&#160;of&#160;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:47.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Customer #1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 745,030&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 35.8&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 235,500&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;95.7%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:47.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Customer #2&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 380,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 18.3&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;*&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;*&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:47.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Customer #5&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 353,050&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 17.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;*&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;*&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:47.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:47.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:22.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="color:#231f20;font-weight:bold;"&gt;Year Ended December&#160;31,&#160;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:23.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="color:#231f20;font-weight:bold;"&gt;As&#160;of&#160;December&#160;31,&#160;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:47.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Revenue&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;%&#160;of&#160;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Accounts&#160;Receivable&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;%&#160;of&#160;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:47.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Customer #1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 676,710&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 29.3&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 214,345&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 42.9&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:47.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Customer #2&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 570,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 24.7&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 71,250&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 14.2&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:47.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Customer #3&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 306,900&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 13.3&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;*&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;*&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:47.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Customer #4&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 250,880&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 10.9&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 63,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 12.6&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:47.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Customer #5&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;*&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;*&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 91,975&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 18.4&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ"
      id="Tb_8aSQ6mI_4U6GgswXOYISnw">&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:47.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:47.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:22.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="color:#231f20;font-weight:bold;"&gt;Year Ended December&#160;31,&#160;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:23.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="color:#231f20;font-weight:bold;"&gt;As&#160;of&#160;December&#160;31,&#160;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:47.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Revenue&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;%&#160;of&#160;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Accounts&#160;Receivable&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;%&#160;of&#160;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:47.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Customer #1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 745,030&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 35.8&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 235,500&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;95.7%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:47.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Customer #2&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 380,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 18.3&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;*&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;*&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:47.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Customer #5&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 353,050&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 17.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;*&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;*&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:47.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:47.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:22.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="color:#231f20;font-weight:bold;"&gt;Year Ended December&#160;31,&#160;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:23.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="color:#231f20;font-weight:bold;"&gt;As&#160;of&#160;December&#160;31,&#160;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:47.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Revenue&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;%&#160;of&#160;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Accounts&#160;Receivable&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;%&#160;of&#160;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:47.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Customer #1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 676,710&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 29.3&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 214,345&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 42.9&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:47.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Customer #2&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 570,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 24.7&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 71,250&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 14.2&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:47.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Customer #3&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 306,900&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 13.3&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;*&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;*&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:47.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Customer #4&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 250,880&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 10.9&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 63,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 12.6&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:47.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Customer #5&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;*&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;*&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 91,975&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 18.4&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_MajorCustomersAxis_imrx_CustomerOneMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_oWqze6TNHUeol6NT43Q40A"
      decimals="0"
      id="Tc_KCTWMhSB80uV2jk9di6jew_3_3"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">745030</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_MajorCustomersAxis_imrx_CustomerOneMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_oWqze6TNHUeol6NT43Q40A"
      decimals="3"
      id="Tc_TFKO0ofFakq2s9fmb0nBRw_3_5"
      unitRef="Unit_Standard_pure_iothMaWWqUCV2N7d1PVg4w">0.358</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="As_Of_12_31_2021_srt_MajorCustomersAxis_imrx_CustomerOneMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_BcRwAfOKVEeK4vZFJJoMnw"
      decimals="0"
      id="Tc_sDUlw8oYXkmb4_DM4UB--w_3_8"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">235500</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_MajorCustomersAxis_imrx_CustomerOneMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_P-jE_XQSn0Kh-0-xrDlmZQ"
      decimals="3"
      id="Tc_N0ar_kiSTEKvPI2vG3ba3Q_3_10"
      unitRef="Unit_Standard_pure_iothMaWWqUCV2N7d1PVg4w">0.957</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_MajorCustomersAxis_imrx_CustomerTwoMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_Otularec102-GYy-rhKAFA"
      decimals="0"
      id="Tc_mw0f3v4PcEC_QKuUTNZuYA_4_3"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">380000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_MajorCustomersAxis_imrx_CustomerTwoMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_Otularec102-GYy-rhKAFA"
      decimals="3"
      id="Tc_-RXWAxFCV0WnMV84QLSqPA_4_5"
      unitRef="Unit_Standard_pure_iothMaWWqUCV2N7d1PVg4w">0.183</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_MajorCustomersAxis_imrx_CustomerFiveMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_gk7zsuubm020Nb-hEXSapw"
      decimals="0"
      id="Tc_1e5yZjmwPEmx813yJYyZTw_5_3"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">353050</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_MajorCustomersAxis_imrx_CustomerFiveMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_gk7zsuubm020Nb-hEXSapw"
      decimals="3"
      id="Tc_w945rKWcSUeOkeO2tg1TLw_5_5"
      unitRef="Unit_Standard_pure_iothMaWWqUCV2N7d1PVg4w">0.170</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="Duration_1_1_2020_To_12_31_2020_srt_MajorCustomersAxis_imrx_CustomerOneMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_cn0C_B-BXUyAAsOsAChyRA"
      decimals="0"
      id="Tc_UHpyBUJvSki5roS5CniJWA_3_3"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">676710</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="Duration_1_1_2020_To_12_31_2020_srt_MajorCustomersAxis_imrx_CustomerOneMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_cn0C_B-BXUyAAsOsAChyRA"
      decimals="3"
      id="Tc_fz-IScsKykuM0ZjhoJsjrg_3_5"
      unitRef="Unit_Standard_pure_iothMaWWqUCV2N7d1PVg4w">0.293</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="As_Of_12_31_2020_srt_MajorCustomersAxis_imrx_CustomerOneMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_7bxZ7DlQSkOfAj7fvd-5pw"
      decimals="0"
      id="Tc_PzEIf0qKXEWhD2xN4gHsmA_3_8"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">214345</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="Duration_1_1_2020_To_12_31_2020_srt_MajorCustomersAxis_imrx_CustomerOneMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_0Q_fVsZyC0qSpcRATuE8jw"
      decimals="3"
      id="Tc_Zz03ft7k80qoJwaJ24PC5A_3_10"
      unitRef="Unit_Standard_pure_iothMaWWqUCV2N7d1PVg4w">0.429</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="Duration_1_1_2020_To_12_31_2020_srt_MajorCustomersAxis_imrx_CustomerTwoMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_aTYR5oNrDkmFoJWCgdwsfQ"
      decimals="0"
      id="Tc_VIqK7CEXGkGhU4QB6JoRzw_4_3"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">570000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="Duration_1_1_2020_To_12_31_2020_srt_MajorCustomersAxis_imrx_CustomerTwoMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_aTYR5oNrDkmFoJWCgdwsfQ"
      decimals="3"
      id="Tc_2bq1Aowxm0mqF53u8kYV8g_4_5"
      unitRef="Unit_Standard_pure_iothMaWWqUCV2N7d1PVg4w">0.247</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="As_Of_12_31_2020_srt_MajorCustomersAxis_imrx_CustomerTwoMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_HSU6DmbswUiywLkXXqH83Q"
      decimals="0"
      id="Tc_5I55O0jfwkaizvHqmFoFpQ_4_8"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">71250</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="Duration_1_1_2020_To_12_31_2020_srt_MajorCustomersAxis_imrx_CustomerTwoMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_lmfLr2N_xUWRAFF-XxH5Jg"
      decimals="3"
      id="Tc_cFCXtoNJgEWy-D-mlFBYVw_4_10"
      unitRef="Unit_Standard_pure_iothMaWWqUCV2N7d1PVg4w">0.142</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="Duration_1_1_2020_To_12_31_2020_srt_MajorCustomersAxis_imrx_CustomerThreeMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_8wa3w0Ph8ke11E8Tb0NuUA"
      decimals="0"
      id="Tc_zFrdrvXa2U2YsWX8cu4CJg_5_3"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">306900</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="Duration_1_1_2020_To_12_31_2020_srt_MajorCustomersAxis_imrx_CustomerThreeMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_8wa3w0Ph8ke11E8Tb0NuUA"
      decimals="3"
      id="Tc_FwczFv7t7EWLAGy6BcLDNw_5_5"
      unitRef="Unit_Standard_pure_iothMaWWqUCV2N7d1PVg4w">0.133</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="Duration_1_1_2020_To_12_31_2020_srt_MajorCustomersAxis_imrx_CustomerFourMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_wyidH8d1zk-PDM7YDj9tdg"
      decimals="0"
      id="Tc_6wZ8yCAuzkenHiiRW-flHw_6_3"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">250880</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="Duration_1_1_2020_To_12_31_2020_srt_MajorCustomersAxis_imrx_CustomerFourMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_wyidH8d1zk-PDM7YDj9tdg"
      decimals="3"
      id="Tc_9jm9dSYKykGLxKpSfdjupA_6_5"
      unitRef="Unit_Standard_pure_iothMaWWqUCV2N7d1PVg4w">0.109</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="As_Of_12_31_2020_srt_MajorCustomersAxis_imrx_CustomerFourMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_Aa9AiVV9H0q60bn77lAIvQ"
      decimals="0"
      id="Tc_HPtu1UZ5sUydP6SIQMVLDQ_6_8"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">63000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="Duration_1_1_2020_To_12_31_2020_srt_MajorCustomersAxis_imrx_CustomerFourMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_FbdxXK1INke9vC8EPGq7hQ"
      decimals="3"
      id="Tc_KtArs1VQKUmNEzDqDKY7_Q_6_10"
      unitRef="Unit_Standard_pure_iothMaWWqUCV2N7d1PVg4w">0.126</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="As_Of_12_31_2020_srt_MajorCustomersAxis_imrx_CustomerFiveMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_odT76IUTqEO-M3mGDrx6QQ"
      decimals="0"
      id="Tc_Kx8uzkxIBEetkWk7nH_iDg_7_8"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">91975</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="Duration_1_1_2020_To_12_31_2020_srt_MajorCustomersAxis_imrx_CustomerFiveMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_DPXYIsD2zUO9cvTMSKl0VA"
      decimals="3"
      id="Tc_ZUlSZD3T60q9-QPK6sRLKw_7_10"
      unitRef="Unit_Standard_pure_iothMaWWqUCV2N7d1PVg4w">0.184</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ"
      id="Tb_WGX7SA3Ci0Ky2K_BFhonkw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Property and Equipment&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"&gt;Property and equipment are recorded at cost, net of accumulated depreciation. Expenditures for major replacements and improvements are capitalized, while expenditures for general repairs and maintenance are expensed as incurred. Upon retirements or disposition of property and equipment, the related cost and accumulated depreciation are removed from the consolidated balance sheet and any resulting gain or loss is recorded in the consolidated statement of operations. Depreciation is calculated using the straight-line method once assets are placed in service. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"&gt;&lt;span style="letter-spacing:0.2pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:86.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:86.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Estimated&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Asset Class&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Useful&#160;Lives&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Computer equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;3 years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Furniture and fixtures&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;5 years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Lab equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;7 years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;1-10 years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <imrx:ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ"
      id="Tb_GUeYSca55ku0in2IYbkyjQ">&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:86.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:86.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Estimated&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Asset Class&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Useful&#160;Lives&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Computer equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;3 years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Furniture and fixtures&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;5 years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Lab equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;7 years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;1-10 years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</imrx:ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_twFlKCzRuEusunTslMr32A"
      id="Tc_zN4P5LDYlUeUaBwv-vy6jQ_3_2">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_HoHJdekunkWYrj04U5neCw"
      id="Tc_LZ68bYyneUigxvfI2twI-Q_4_2">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_imrx_LabEquipmentMember_GI3DHb_K8EizCH_U5WinCA"
      id="Tc_8mM6_PG2I0uE_kdgeggltA_5_2">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdsAndLeaseholdImprovementsMember_avFoqBKbtEy-F0FmYKH8ng"
      id="Narr_OCZyeeHwhkGC2tvUByryJQ">P1Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdsAndLeaseholdImprovementsMember_SvHfzMjnikSnHY-nhQSILg"
      id="Narr_v1f6SoKJeEylMn31Iqja6g">P10Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ"
      id="Tb_JmTSj41w-kW7Pzbd_M5Cuw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Impairment of Long-lived Assets&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"&gt;Periodically, the Company evaluates its long-lived assets, which consist primarily of property and equipment, for impairment whenever events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted net cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the asset exceeds the fair value of the asset. To date, no impairments have occurred.&lt;/p&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ"
      decimals="0"
      id="Narr_p_sl-F64wEiMa8A0jWhKvA"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">0</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ"
      id="Tb_uNRVy_A2ikOumn9MJ1kv5A">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Leases&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"&gt;In February&#160;2016 the FASB issued Accounting Standards Update (&#x201c;ASU&#x201d;) No. 2016-02, Leases (Topic 842) (&#x201c;ASC 842&#x201d;), a standard issued to increase transparency and comparability among organizations related to their leasing activities. This standard established a right-of-use model that requires the recognition of right-of-use assets and lease liabilities for most leases as well as provides disclosure with respect to certain qualitative and quantitative information related to a company&#x2019;s leasing arrangements to meet the objective of allowing users of financial statements to assess the amount, timing and uncertainty of cash flows arising from leases.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"&gt;The Company adopted the leasing standard using the modified retrospective transition approach as of January&#160;1, 2020, with no restatement of prior periods or cumulative adjustment to retained earnings. Upon adoption, the Company elected the package of transition practical expedients, which allowed the Company to carry forward prior conclusions related to whether any expired or existing contracts are or contain leases, the lease classification for any expired or existing leases, and initial direct costs for existing leases. The Company also made an accounting policy election to not recognize leases with an initial term of 12&#160;months or less within its consolidated balance sheets, and to recognize those lease payments on a straight-line basis in its consolidated statements of operations over the lease term. The adoption of the leasing standard did not have an impact on the consolidated statement of operations.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"&gt;The Company determines if an arrangement is a lease at contract inception. Right-of-use assets represent the Company&#x2019;s right to use an underlying asset for the lease term and lease liabilities represent its obligation to make lease payments arising from the lease. Right-of-use assets and lease liabilities are recognized at the commencement date of the lease based upon the present value of future lease payments over the expected lease term. When determining the lease term, the Company includes options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. As most of the Company&#x2019;s leases do not provide an implicit interest rate, the Company uses its incremental borrowing rate, which is based on rates that would be incurred to borrow on a collateralized basis over a term equal to the lease payments in a similar economic environment, in determining the present value of lease payments.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"&gt;The Company has elected not to separate lease and non-lease components as a single lease component. The Company&#x2019;s lease are reflected in right-of-use assets and lease liabilities (current and non-current) in the consolidated balance sheets.&lt;/p&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:LeasePracticalExpedientsPackage
      contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ"
      id="Narr_mi7QqDUS0kmvOTH0FmbnLg">true</us-gaap:LeasePracticalExpedientsPackage>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ"
      id="Tb_JLwTjSfZbkWwAQlObBzRLA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Revenue Recognition&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"&gt;&lt;span style="font-weight:bold;letter-spacing:-0.2pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;In accordance with ASC 606, revenue is recognized when a customer obtains control of promised goods and services. The core principle of the standard is to recognize revenue to depict the transfer of promised goods or services to customers in &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods or services. To achieve that core principle, the Company applies the following five-step model:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt 0pt 0pt 18pt;"&gt;&#x2022; Identify the contract with a customer&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt 0pt 0pt 18pt;"&gt;&#x200b;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt 0pt 0pt 18pt;"&gt;&#x2022; Identify the performance obligations in the contract&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt 0pt 0pt 18pt;"&gt;&#x200b;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt 0pt 0pt 18pt;"&gt;&#x2022; Determine the transaction price&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt 0pt 0pt 18pt;"&gt;&#x200b;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt 0pt 0pt 18pt;"&gt;&#x2022; Allocate the transaction price to the performance obligations in the contract&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt 0pt 0pt 18pt;"&gt;&#x200b;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt 0pt 0pt 18pt;"&gt;&#x2022; Recognize revenue when or as performance obligations are satisfied&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;"&gt;&#x200b;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"&gt;The Company&#x2019;s contracts generally consist of the promise to provide computational biology professional services to pharmaceutical and biotechnology companies, which the Company has concluded constitutes one performance obligation that is delivered over time. The transaction price is the amount of consideration to which the Company expects to be entitled in exchange for transferring the services to the customer. The Company&#x2019;s contracts provide for either agreed upon rates per hour based on the level of the professional working on the project or a fixed fee for a defined scope of work. The Company recognizes revenue over time by measuring the progress toward complete satisfaction of the performance obligation using a single method of measuring progress, which depicts the performance in transferring control of the associated services to the customer. The Company uses input methods to measure the progress toward the complete satisfaction of performance obligations and evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenue and net loss in the period of adjustment.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"&gt;The Company&#x2019;s contract terms do not allow for a right of return or refund and do not contain significant financing components. Receivables associated with the contract will generally be collected within thirty to sixty days, in accordance with the underlying payment terms.&lt;/p&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ"
      id="Tb_vxXoQUco2k-_928sTKgAIA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Income Taxes&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"&gt;The Company provides for income taxes in accordance with ASC Topic 740, Income Taxes. Deferred tax assets and liabilities are determined based on the difference between the financial reporting and tax bases of assets and liabilities using enacted tax rates and laws in effect in the&#160;years in which the differences are expected to reverse. A valuation allowance is provided if, based upon the weighted available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"&gt;The Company accounts for uncertainty in income taxes recognized in the consolidated financial statements by applying a two-step process to determine the amount of tax benefit to be recognized. First, the tax position must be evaluated to determine the likelihood that it will be sustained upon external examination by the taxing authorities. If the tax position is deemed more likely than not to be sustained, the tax position is then assessed to determine the amount of benefit to recognize in the consolidated financial statements. The amount of the benefit that may be recognized is the largest amount that has a greater than 50% likelihood of being realized upon ultimate settlement. The provision for income taxes includes the effects of any resulting tax reserves (i.e., unrecognized tax benefits) that are considered appropriate as well as the related net interest. &lt;span style="color:#222222;background:#ffffff;"&gt;As of December 31, 2021 and 2020, the Company had uncertain tax positions of &lt;/span&gt;&lt;span style="color:#222222;background:#ffffff;"&gt;$380,902&lt;/span&gt;&lt;span style="color:#222222;background:#ffffff;"&gt; and &lt;/span&gt;&lt;span style="color:#222222;background:#ffffff;"&gt;$174,950&lt;/span&gt;&lt;span style="color:#222222;background:#ffffff;"&gt;.&#160;&#160; The Company has classified the unrecognized tax benefits as reductions of its tax credit carryforwards.&lt;/span&gt;&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:TaxAdjustmentsSettlementsAndUnusualProvisions
      contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ"
      decimals="0"
      id="Narr_Dd05obD2nECqnNBGu8xDPw"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">380902</us-gaap:TaxAdjustmentsSettlementsAndUnusualProvisions>
    <us-gaap:TaxAdjustmentsSettlementsAndUnusualProvisions
      contextRef="Duration_1_1_2020_To_12_31_2020_J_O9OcmviUi8EDFgokrY1Q"
      decimals="0"
      id="Narr_nezOacZvGUGtbvIu4q3cqQ"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">174950</us-gaap:TaxAdjustmentsSettlementsAndUnusualProvisions>
    <us-gaap:InProcessResearchAndDevelopmentPolicy
      contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ"
      id="Tb_nKbWMT5SxkGFkhOP5ssIBg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Research and Development&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;"&gt;Research and development costs are expensed as incurred. Research and development costs consist of expenses incurred in performing research and development activities, including salaries and benefits, materials and supplies, preclinical expenses, stock-based compensation expense, depreciation of equipment, contract services, and other outside expenses. The Company also incurs costs to develop software programs for internal use in identifying potential human drug targets which may then lead to the development of human drug candidates. To date the software programs have primarily been used for internal research and development activities and the costs incurred have been expensed as research and development.&lt;/p&gt;</us-gaap:InProcessResearchAndDevelopmentPolicy>
    <imrx:ResearchAndManufacturingContractCostsAndAccrualsPolicyTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ"
      id="Tb_uzGmrtyGikKkcssomoxS7g">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Research and Manufacturing Contract Costs and Accruals&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Company has entered into various research, development and manufacturing contracts with research institutions and other companies in the United States. These agreements are generally cancelable, and related costs are recorded as research and development expenses as incurred. The Company records accruals for estimated ongoing research, development and manufacturing costs. When billing terms under these contracts do not coincide with the timing of when the work is performed, the Company is required to make estimates of outstanding obligations to those third parties as of period end. Any accrual estimates are based on a number of factors, including the Company&#x2019;s knowledge of the progress towards completion of the research, development and manufacturing activities, invoicing to date under the contracts, communication from the research institutions and other companies of any actual costs incurred during the period that have not yet been invoiced and the costs included in the contracts. Significant judgments and estimates may be made in determining the accrued balances at the end of any reporting period. Actual results could differ from the estimates made by the Company. The historical accrual estimates made by the Company have not been materially different from the actual costs.&lt;/p&gt;</imrx:ResearchAndManufacturingContractCostsAndAccrualsPolicyTextBlock>
    <imrx:PatentCostsPolicyPolicyTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ"
      id="Tb_r2PQ_z5aEUG6dG3Qx9XgEg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="color:#231f20;font-weight:bold;"&gt;Patent &lt;/b&gt;&lt;b style="font-weight:bold;"&gt;Costs&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;All patent-related costs incurred in connection with filing and prosecuting patent applications are expensed as incurred due to the uncertainty about the recovery of the expenditure. Amounts incurred are classified as general and administrative expenses.&lt;/p&gt;</imrx:PatentCostsPolicyPolicyTextBlock>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ"
      id="Tb_AgRBo_Q500OCW41sBj55hA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="color:#231f20;font-weight:bold;"&gt;Com&lt;/b&gt;&lt;b style="font-weight:bold;background:#ffffff;"&gt;prehensive Loss&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Comprehensive loss includes net loss as well as other changes in stockholders&#x2019; equity (deficit) that result from transactions and economic events other than those with stockholders. &lt;/p&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:DeferredChargesPolicyTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ"
      id="Tb_hPKsQCRnz0uaPFFJjynqOg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;background:#ffffff;"&gt;Deferred Offering Costs&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="background:#ffffff;"&gt;The Company capitalizes certain legal, professional accounting and other third-party fees that are directly associated with&#160;in-process&#160;equity financings as deferred offering costs until such financings are consummated. After consummation of an equity financing, these costs are recorded as a reduction of the proceeds from the offering, either as a reduction of the carrying value of the preferred stock or in stockholder&#x2019;s equity (deficit) as a reduction of additional&#160;paid-in&#160;capital generated as a result of the offering. Should the&#160;in-process&#160;equity financing be abandoned, the deferred offering costs would be expensed immediately as a charge to operating expenses in the statements of operations and comprehensive loss. There were&#160;&lt;/span&gt;&lt;span style="background:#ffffff;"&gt;no&lt;/span&gt;&lt;span style="background:#ffffff;"&gt;&#160;deferred offering costs as of December&#160;31,2021 or December 31, 2020.&lt;/span&gt;&lt;/p&gt;</us-gaap:DeferredChargesPolicyTextBlock>
    <us-gaap:DeferredOfferingCosts
      contextRef="As_Of_12_31_2020_OUSLyqWONEO8ccGPC6rBdg"
      decimals="INF"
      id="Narr_sFvo3gLVx0SbfRQ6lbwT6g"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">0</us-gaap:DeferredOfferingCosts>
    <us-gaap:DeferredOfferingCosts
      contextRef="As_Of_12_31_2021_TBpjtOXgEkKQahJJAv0aWg"
      decimals="INF"
      id="Narr_MiY-w1vtu0SJaNUjSsG4WQ"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">0</us-gaap:DeferredOfferingCosts>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ"
      id="Tb_zuJHu9NFYkubUnNPJN8oSg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="color:#231f20;font-weight:bold;"&gt;Net Income (Loss) per Share&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Prior to the closing of the IPO, the Company followed the two-class method when computing net income (loss) per share, as the Company had issued shares that meet the definition of participating securities. The two-class method determines net income (loss) per share for each class of common and participating securities according to dividends declared or accumulated and participation rights in undistributed earnings. The two-class method requires income available to common stockholders for the period to be allocated between common and participating securities based upon their respective rights to receive dividends as if all income for the period had been distributed.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Basic net income (loss) per share attributable to common stockholders is computed by dividing the net income (loss) attributable to common stockholders by the weighted average number of common shares outstanding for the period. Diluted net income (loss) attributable to common stockholders is computed by adjusting net income (loss) attributable to common stockholders to reallocate undistributed earnings based on the potential impact of dilutive securities. Diluted net income (loss) per share attributable to common stockholders is computed by dividing the diluted net income (loss) attributable to common stockholders by the weighted average number of common shares outstanding for the period, including potential dilutive common shares assuming the dilutive effect of common stock equivalents.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Company&#x2019;s convertible preferred stock contractually entitled the holders of such shares to participate in dividends but does not contractually require the holders of such shares to participate in losses of the Company. Accordingly, in periods in which the Company reports a net loss, such losses are not allocated to such participating securities. In periods in which the Company reports a net loss attributable to common stockholders, diluted net loss per share attributable to common stockholders is the same as basic net loss per share attributable to common stockholders, since dilutive common shares are not assumed to have been issued if their effect is anti-dilutive.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Subsequent to the closing of its IPO, the Company only has one class of shares outstanding and basic net income (loss) per common share is computed by dividing the net income (loss) by the weighted average number of shares of common stock outstanding for the period. Diluted net income (loss) per common share is computed by dividing net income (loss) by the weighted average number of shares of common stock outstanding for the period, including potential dilutive common shares assuming the dilutive effect of outstanding stock awards. For periods in which the Company reports a net loss, diluted net loss per common share is the same as basic net loss per common share, since dilutive common shares are not assumed to have been issued if their effect is anti-dilutive. The Company reported a net loss attributable to common stockholders for each of the years ended December&#160;31, 2021 and 2020.&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ"
      id="Tb_arr5kK9U3UuLzciLoZqF0Q">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Stock-based Compensation&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt;"&gt;&lt;span style="font-weight:bold;letter-spacing:-0.2pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Company issues stock-based awards to employees and nonemployees in the form of stock options. The Company accounts for stock-based awards in accordance with ASC 718, Compensation&#x2009;&#x2014;&#x2009;Stock Compensation (&#x201c;ASC 718&#x201d;), which requires all stock-based payments to employees and nonemployees, including grants of employee stock options and modifications to existing stock options, to be recognized in the consolidated statement of operations based on their fair values.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The fair value of options is estimated on the grant date using the Black-Scholes option-pricing model (&#x201c;Black-Scholes&#x201d;). Black-Scholes requires the Company to make assumptions and judgments about the variables used in the calculation including the expected term of its stock option, the volatility of the Company&#x2019;s common stock, and an assumed risk-free interest rate. The Company uses the simplified calculation of expected life and volatility is based on an average of the historical volatility of a group of publicly traded companies in a similar industry that the Company believes would be considered a peer group had it been a publicly held company for the duration of the expected life of the award. The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of grant for periods corresponding with the expected life of the option. Forfeitures are recognized as they occur. No dividend yield was assumed as the Company does not pay, and does not expect to pay, dividends on its common stock. The assumptions underlying these valuations represent management&#x2019;s best estimates, which involve inherent uncertainties and the application of management&#x2019;s judgement.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;In accordance with ASU No. 2018-07, Compensation-Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting, compensation expense for stock-based awards granted to nonemployees is recognized over the period during which services are rendered by such nonemployees. The new standard largely aligns the accounting for share-based payment awards issued to employees and nonemployees by expanding the scope of ASC 718 to apply to nonemployee share-based transactions, as long as the transaction is not effectively a form of financing. There was no adjustment to the financial statements upon adoption of this standard as of January&#160;1, 2020.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;As there had been no public market for the Company&#x2019;s common stock prior to the IPO, the estimated fair value of its common stock has been determined by its board of directors as of the date of each option grant, with input from management, considering the Company&#x2019;s most recently available third-party valuations of common stock and its board of directors&#x2019; assessment of additional objective and subjective factors that it believed were relevant and which may have changed from the date of the most recent valuation through the date of the grant. These third-party valuations were performed in accordance with the guidance outlined in the American Institute of Certified Public Accountants&#x2019; Accounting and Valuation Guide, Valuation of Privately-Held-Company Equity Securities Issued as Compensation. Each valuation methodology includes estimates and assumptions that require the Company&#x2019;s judgment. These estimates and assumptions include a number of objective and subjective factors, including external market conditions, the prices at which the Company sold shares of preferred stock, the superior rights and preferences of securities senior to the Company&#x2019;s common stock at the time of, and the likelihood of, achieving a liquidity event, such as an initial public offering or sale.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The assumptions underlying these valuations represent management&#x2019;s best estimates, which involve inherent uncertainties and the application of management&#x2019;s judgment. As a result, if the Company had used different assumptions or estimates, the fair value of its common stock and its stock-based compensation expense could be materially different.&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ"
      decimals="2"
      id="Narr_wlhUXsaOO0CNF56o0Wjh7g"
      unitRef="Unit_Standard_pure_iothMaWWqUCV2N7d1PVg4w">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy
      contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ"
      id="Tb_Yn-2NJdTZE-pQCV4FHppGA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Goodwill&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Goodwill represents the excess of the fair value of the acquiree over the recognized bases of the net identifiable assets acquired and includes the future economic benefits from other assets that could not be individually identified and separately recognized. Goodwill is not amortized, but instead is periodically reviewed for impairment and an impairment charge is recorded in the periods in which the recorded carrying value of goodwill exceeds its fair value.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="background:#ffffff;"&gt;On a quarterly basis, the Company performs a review of its business to determine if events or changes in circumstances have occurred which could have a material adverse effect on the fair value of the Company and its goodwill. If such events or changes in circumstances were deemed to have occurred, the Company would perform an impairment test of goodwill as of the end of the quarter and record any noted impairment loss.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="background:#ffffff;"&gt;The goodwill test is performed at least annually, or more frequently if events or changes in circumstances indicate that the asset might be impaired. &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="background:#ffffff;"&gt;The Company performs its annual impairment test during the fourth quarter of each fiscal year. There were &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;no&lt;/span&gt;&lt;span style="background:#ffffff;"&gt; impairments in 2021.&lt;/span&gt;&lt;span style="background:#ffffff;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Intangible Assets&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Intangible assets are recognized at fair value, as an asset apart from goodwill if the asset (i) arises from contractual or other legal rights, or (ii) is separable. Intangible assets, principally representing technology acquired, are capitalized and amortized on the straight-line method over their expected useful lives.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Company reviews the recoverability of its long-lived assets (including amortizable intangible assets), other than goodwill, when events or changes in circumstances occur that indicate that the carrying value of the asset may not be recoverable. &lt;/p&gt;</us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ"
      decimals="0"
      id="Narr_S70y5nkZHEmi0No3oPDK3g"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ"
      id="Tb_eGXEccogmEmeCL-nBH4m2w">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Recently Issued Accounting Pronouncements&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies and adopted by the Company as of the specified effective date. The Company is an &#x201c;emerging growth company&#x201d; as defined in the Jumpstart Our Business Startups Act of 2012, as amended (&#x201c;JOBS Act&#x201d;). The Jobs Act provides that an emerging growth company can take advantage of an extended transition period for complying with new or revised accounting standards. Thus, an emerging growth company can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. The Company elected to avail itself of this extended transition period and, as a result, we will not be required to adopt new or revised accounting standards on the relevant dates on which adoption of such standards is required for other public companies.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;In 2016, the FASB issued ASU 2016-13, Financial Instruments&#160;&#x2013; Credit Losses (Topic 326): Measurement of Credit Losses on Financial Statements. The new standard, as amended, requires that expected credit losses relating to financial assets measured on an amortized cost basis and available-for-sale debt securities be recorded through an allowance for credit losses. It also limits the amount of credit losses to be recognized for available-for-sale debt securities to the amount by which carrying value exceeds fair value and also requires the reversal of previously recognized credit losses if fair value increases. The targeted transition relief standard allows filers an option to irrevocably elect the fair value option of ASC 825-10, Financial Instruments-Overall, applied on an instrument-by-instrument basis for eligible instruments.&#160;ASU No.&#160;2016-13, Financial Instruments&#160;- Credit Losses (Topic 326) will become effective for the Company on January&#160;1, 2023. The Company is currently assessing the impact of the adoption of this guidance on its consolidated financial statements.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;In December&#160;2019, the FASB issued ASU No.&#160;2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes, which simplifies the accounting for income taxes by removing certain exceptions to the general principles in the existing guidance for income taxes and making other minor improvements. The amendments are effective for annual reporting periods beginning after December&#160;15, 2020 with early adoption permitted. The adoption of this standard did not have a material impact to the financial statements.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;In January 2017, the FASB issued ASU No. ASU 2017-04, &#160;Intangibles&#x2014;Goodwill and Other (Topic 350&lt;i style="font-style:italic;"&gt;)&lt;/i&gt;, which eliminates Step 2 from the goodwill impairment test. Step 2 measures a goodwill impairment loss by comparing the implied fair value of a reporting unit&#x2019;s goodwill with the carrying amount of that goodwill. Instead, entities will record an impairment charge based on the excess of a reporting unit&#x2019;s carrying amount over its fair value (i.e., measure the charge based on today&#x2019;s Step 1). This update is effective for annual and interim impairment tests performed in periods beginning after December 15, 2022. Early adoption of the standard is permitted. The Company is currently evaluating the new guidance and assessing the potential impact on its consolidated financial statements. &#160;&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ"
      id="Tb_Zwu3RFwsukKGldUFY5H8Cg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Note 3 &#x2013; Marketable Securities &lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Marketable securities as of December 31, 2021 consisted of the following:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:29.84%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:11.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:12.17%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:12.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:14.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:29.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:67.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31, 2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:29.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;width:13.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Amortized Cost&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;width:14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Unrealized Gains&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;width:14.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Unrealized Losses&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;width:16.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:29.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Assets:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:11.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:12.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:12.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:14.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:29.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;white-space:pre-wrap;"&gt;             Current:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:12.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:12.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:29.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;U.S. Treasuries&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 42,147,385&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (28,575)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 42,118,810&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:29.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;Government securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 19,218,057&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (13,689)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 19,204,368&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:29.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;Commercial Paper&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 12,992,165&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 57&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.94%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (4,197)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 12,988,025&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:29.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total Current&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 74,357,607&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 57&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (46,461)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 74,311,203&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:29.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:29.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;white-space:pre-wrap;"&gt;           Non-current:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:29.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;U.S. Treasuries&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 999,186&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (2,626)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 996,560&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:29.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;Government securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:29.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total Non-current&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 999,186&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.94%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (2,626)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 996,560&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:29.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total marketable securities&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 75,356,793&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 57&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (49,087)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 75,307,763&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;There were no marketable securities as of December 31, 2020. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;There were no impairments of the Company&#x2019;s available-for-sale marketable securities measured and carried at fair value during the year ended December 31, 2021.  Realized gains and losses are included in other expense on a specific-identification basis.&#160;There were&#160;no&#160;realized gains or losses on marketable securities for the year ended December 31, 2021.&lt;/p&gt;</us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock>
    <us-gaap:MarketableSecuritiesTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ"
      id="Tb_ggXUIA_E20WmNSctDckHIg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:29.84%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:11.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:12.17%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:12.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:14.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:29.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:67.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31, 2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:29.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;width:13.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Amortized Cost&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;width:14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Unrealized Gains&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;width:14.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Unrealized Losses&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;width:16.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:29.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Assets:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:11.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:12.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:12.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:14.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:29.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;white-space:pre-wrap;"&gt;             Current:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:12.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:12.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:29.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;U.S. Treasuries&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 42,147,385&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (28,575)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 42,118,810&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:29.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;Government securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 19,218,057&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (13,689)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 19,204,368&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:29.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;Commercial Paper&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 12,992,165&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 57&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.94%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (4,197)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 12,988,025&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:29.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total Current&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 74,357,607&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 57&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (46,461)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 74,311,203&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:29.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:29.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;white-space:pre-wrap;"&gt;           Non-current:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:29.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;U.S. Treasuries&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 999,186&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (2,626)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 996,560&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:29.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;Government securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:29.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total Non-current&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 999,186&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.94%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (2,626)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 996,560&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:29.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total marketable securities&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 75,356,793&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 57&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (49,087)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 75,307,763&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:MarketableSecuritiesTextBlock>
    <imrx:MarketableSecuritiesAmortizedCostBasisCurrent
      contextRef="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_ypcv1cNyLUqWUpUVKo2bMg"
      decimals="0"
      id="Tc_Pvy4To_yw0Gt2HpZL0ykHA_5_3"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">42147385</imrx:MarketableSecuritiesAmortizedCostBasisCurrent>
    <imrx:MarketableSecuritiesAccumulatedUnrealizedLossesCurrent
      contextRef="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_ypcv1cNyLUqWUpUVKo2bMg"
      decimals="0"
      id="Tc_6xANhtIaakuXj_LiiwEBMw_5_9"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">28575</imrx:MarketableSecuritiesAccumulatedUnrealizedLossesCurrent>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_ypcv1cNyLUqWUpUVKo2bMg"
      decimals="0"
      id="Tc_6SFBVV_oXEqG3OwsTlsYyg_5_12"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">42118810</us-gaap:MarketableSecuritiesCurrent>
    <imrx:MarketableSecuritiesAmortizedCostBasisCurrent
      contextRef="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_imrx_GovernmentSecuritiesMember__6KtOh0dNkKDNENoMm1rTg"
      decimals="0"
      id="Tc_5-H4qKIxxki4uPOAGOh4Bw_6_3"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">19218057</imrx:MarketableSecuritiesAmortizedCostBasisCurrent>
    <imrx:MarketableSecuritiesAccumulatedUnrealizedLossesCurrent
      contextRef="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_imrx_GovernmentSecuritiesMember__6KtOh0dNkKDNENoMm1rTg"
      decimals="0"
      id="Tc_L8RGWxUOu0ahGn9GG_VJkQ_6_9"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">13689</imrx:MarketableSecuritiesAccumulatedUnrealizedLossesCurrent>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_imrx_GovernmentSecuritiesMember__6KtOh0dNkKDNENoMm1rTg"
      decimals="0"
      id="Tc_AlVxUrNppUufV2TzmIDFlw_6_12"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">19204368</us-gaap:MarketableSecuritiesCurrent>
    <imrx:MarketableSecuritiesAmortizedCostBasisCurrent
      contextRef="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember_CWayHsb0d0ChYaEcAr7tvw"
      decimals="0"
      id="Tc_lOrl0c7nDUKk7Nar-WYeJg_7_3"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">12992165</imrx:MarketableSecuritiesAmortizedCostBasisCurrent>
    <imrx:MarketableSecuritiesAccumulatedUnrealizedGainsCurrent
      contextRef="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember_CWayHsb0d0ChYaEcAr7tvw"
      decimals="0"
      id="Tc_6GYqmETaEU6S3dNV0R0gWA_7_6"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">57</imrx:MarketableSecuritiesAccumulatedUnrealizedGainsCurrent>
    <imrx:MarketableSecuritiesAccumulatedUnrealizedLossesCurrent
      contextRef="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember_CWayHsb0d0ChYaEcAr7tvw"
      decimals="0"
      id="Tc_kT_HJr7_50ym6iqnWjILDQ_7_9"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">4197</imrx:MarketableSecuritiesAccumulatedUnrealizedLossesCurrent>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember_CWayHsb0d0ChYaEcAr7tvw"
      decimals="0"
      id="Tc_IsL13cfMZUecnORFk32AeA_7_12"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">12988025</us-gaap:MarketableSecuritiesCurrent>
    <imrx:MarketableSecuritiesAmortizedCostBasisCurrent
      contextRef="As_Of_12_31_2021_TBpjtOXgEkKQahJJAv0aWg"
      decimals="0"
      id="Tc_sm9ip-9kvEmvdJtiinTasw_8_3"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">74357607</imrx:MarketableSecuritiesAmortizedCostBasisCurrent>
    <imrx:MarketableSecuritiesAccumulatedUnrealizedGainsCurrent
      contextRef="As_Of_12_31_2021_TBpjtOXgEkKQahJJAv0aWg"
      decimals="0"
      id="Tc_K6pocdW_TEaKaIg7ZBsAOQ_8_6"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">57</imrx:MarketableSecuritiesAccumulatedUnrealizedGainsCurrent>
    <imrx:MarketableSecuritiesAccumulatedUnrealizedLossesCurrent
      contextRef="As_Of_12_31_2021_TBpjtOXgEkKQahJJAv0aWg"
      decimals="0"
      id="Tc_ao49vdkkAEWZzrxx0gYLKg_8_9"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">46461</imrx:MarketableSecuritiesAccumulatedUnrealizedLossesCurrent>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="As_Of_12_31_2021_TBpjtOXgEkKQahJJAv0aWg"
      decimals="0"
      id="Tc_LZIDGXeEHEm1d5xEoj7Acw_8_12"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">74311203</us-gaap:MarketableSecuritiesCurrent>
    <imrx:MarketableSecuritiesAmortizedCostBasisNonCurrent
      contextRef="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_ypcv1cNyLUqWUpUVKo2bMg"
      decimals="0"
      id="Tc_Z-1oN3YPukCq3WZJGEFdHw_11_3"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">999186</imrx:MarketableSecuritiesAmortizedCostBasisNonCurrent>
    <imrx:MarketableSecuritiesAccumulatedUnrealizedLossesNonCurrent
      contextRef="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_ypcv1cNyLUqWUpUVKo2bMg"
      decimals="0"
      id="Tc_GSAApjh7-Uu4MsF1jhH4ZA_11_9"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">2626</imrx:MarketableSecuritiesAccumulatedUnrealizedLossesNonCurrent>
    <us-gaap:MarketableSecuritiesNoncurrent
      contextRef="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_ypcv1cNyLUqWUpUVKo2bMg"
      decimals="0"
      id="Tc_UQiOn--KrUa2RCFRbBsn1w_11_12"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">996560</us-gaap:MarketableSecuritiesNoncurrent>
    <imrx:MarketableSecuritiesAmortizedCostBasisNonCurrent
      contextRef="As_Of_12_31_2021_TBpjtOXgEkKQahJJAv0aWg"
      decimals="0"
      id="Tc_nMEqo830PESQDGXftJ8I2A_13_3"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">999186</imrx:MarketableSecuritiesAmortizedCostBasisNonCurrent>
    <imrx:MarketableSecuritiesAccumulatedUnrealizedLossesNonCurrent
      contextRef="As_Of_12_31_2021_TBpjtOXgEkKQahJJAv0aWg"
      decimals="0"
      id="Tc_cNI6bh8siUuBzaqPxcSCwg_13_9"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">2626</imrx:MarketableSecuritiesAccumulatedUnrealizedLossesNonCurrent>
    <us-gaap:MarketableSecuritiesNoncurrent
      contextRef="As_Of_12_31_2021_TBpjtOXgEkKQahJJAv0aWg"
      decimals="0"
      id="Tc_2oaDnF_AHEeSUfY4xDQeww_13_12"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">996560</us-gaap:MarketableSecuritiesNoncurrent>
    <imrx:MarketableSecuritiesAmortizedCostBasis
      contextRef="As_Of_12_31_2021_TBpjtOXgEkKQahJJAv0aWg"
      decimals="0"
      id="Tc_MADVwPbx0UevtRhULYFSiA_14_3"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">75356793</imrx:MarketableSecuritiesAmortizedCostBasis>
    <imrx:MarketableSecuritiesAccumulatedUnrealizedGains
      contextRef="As_Of_12_31_2021_TBpjtOXgEkKQahJJAv0aWg"
      decimals="0"
      id="Tc_6P6ExhQeWE2XRuyKZxXapQ_14_6"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">57</imrx:MarketableSecuritiesAccumulatedUnrealizedGains>
    <imrx:MarketableSecuritiesAccumulatedUnrealizedLosses
      contextRef="As_Of_12_31_2021_TBpjtOXgEkKQahJJAv0aWg"
      decimals="0"
      id="Tc_IUxZ1oeKp0edjdy6xoP2_w_14_9"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">49087</imrx:MarketableSecuritiesAccumulatedUnrealizedLosses>
    <us-gaap:MarketableSecurities
      contextRef="As_Of_12_31_2021_TBpjtOXgEkKQahJJAv0aWg"
      decimals="0"
      id="Tc_K9AibAPlj0eTLm2uNBvoYg_14_12"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">75307763</us-gaap:MarketableSecurities>
    <us-gaap:MarketableSecurities
      contextRef="As_Of_12_31_2020_OUSLyqWONEO8ccGPC6rBdg"
      decimals="0"
      id="Narr_LhUIPQrX4Eq0-v9reMijQA"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">0</us-gaap:MarketableSecurities>
    <us-gaap:ImpairmentOfInvestments
      contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ"
      decimals="0"
      id="Narr_SOSyg0jydkGF-1tQ2UuTlQ"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">0</us-gaap:ImpairmentOfInvestments>
    <us-gaap:MarketableSecuritiesRealizedGainLoss
      contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ"
      decimals="0"
      id="Narr_rf1qFu5Fl06VZjo6CdosNw"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">0</us-gaap:MarketableSecuritiesRealizedGainLoss>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ"
      id="Tb_MSI1na2ypUyKfSGalbsVtg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Note 4 &#x2013; Fair Value Measurements&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The following table summarizes our cash equivalents and marketable securities measured at fair value on a recurring basis as of December 31, 2021:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:39.88%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.4%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.43%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:39.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level 1&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level 2&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level 3&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:39.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Assets:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:39.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Cash equivalents&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:39.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;       Money market&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 33,961,344&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 33,961,344&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:39.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;       Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,000,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,000,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:39.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;        Total cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 33,961,344&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,000,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 35,961,344&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:39.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:39.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Marketable securities:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:39.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;      U.S. Treasuries&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 43,115,370&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 43,115,370&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:39.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;      Government securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 19,204,368&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 19,204,368&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:39.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;      Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 12,988,025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 12,988,025&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:39.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;        Total marketable securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 43,115,370&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 32,192,393&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 75,307,763&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:39.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total cash equivalents and marketable securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.04%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 77,076,714&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 34,192,393&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.43%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 111,269,107&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="font-weight:bold;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;There were no transfers between Level 1 and Level 2 and we had no&#160;financial assets or &lt;span style="-sec-ix-hidden:Hidden_tlcK7EHhSU-TZzE4mXesaw;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;liabilities&lt;/span&gt;&lt;/span&gt; that were classified as Level 3 at any point during the year ended December 31, 2021. There were no marketable securities as of December 31, 2020. &lt;/p&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ"
      id="Tb_w9LWMx5x8kOu-CS09RI5qQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:39.88%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.4%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.43%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:39.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level 1&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level 2&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level 3&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:39.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Assets:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:39.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Cash equivalents&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:39.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;       Money market&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 33,961,344&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 33,961,344&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:39.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;       Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,000,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,000,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:39.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;        Total cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 33,961,344&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,000,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 35,961,344&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:39.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:39.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Marketable securities:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:39.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;      U.S. Treasuries&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 43,115,370&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 43,115,370&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:39.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;      Government securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 19,204,368&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 19,204,368&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:39.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;      Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 12,988,025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 12,988,025&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:39.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;        Total marketable securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 43,115,370&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 32,192,393&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 75,307,763&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:39.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total cash equivalents and marketable securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.04%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 77,076,714&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 34,192,393&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.43%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 111,269,107&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="As_Of_12_31_2021_us-gaap_FairValueByAssetClassAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_tGSOwi1HF0iLCEdWOlktoQ"
      decimals="0"
      id="Tc_TsxWBqq0-kmA5n4YUccwdw_4_3"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">33961344</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="As_Of_12_31_2021_us-gaap_FairValueByAssetClassAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_N9UIc66mekClPPydSVC05g"
      decimals="0"
      id="Tc_L8LyZf-THU-qbR2UPkgYhQ_4_12"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">33961344</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="As_Of_12_31_2021_us-gaap_FairValueByAssetClassAxis_us-gaap_CommercialPaperMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_sHUMvfiqDEWTLNwGi2V19w"
      decimals="0"
      id="Tc_uOHxDlVN5kmp1Jea29yU1A_5_6"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">2000000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="As_Of_12_31_2021_us-gaap_FairValueByAssetClassAxis_us-gaap_CommercialPaperMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_0brBfUV_8k-73Ah2xvo5vA"
      decimals="0"
      id="Tc_tYnEiuBdMUeUEtyk1HnfXA_5_12"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">2000000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="As_Of_12_31_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_DcZ3E7WdG0qTM9kwKkYCCA"
      decimals="0"
      id="Tc_l_ZG4V8pe0euw8hZhHhuwA_6_3"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">33961344</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="As_Of_12_31_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_XD-w4rYEvkOhxL7DPVZDYA"
      decimals="0"
      id="Tc_OeqQ6EJ2pkKtsoOYtnhxjA_6_6"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">2000000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="As_Of_12_31_2021_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_NZFKYXEtB0ypESwMFRZYaA"
      decimals="0"
      id="Tc_45VVUaBxFUiKQkLAAtqt8g_6_12"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">35961344</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <imrx:MarketableSecuritiesFairValueDisclosure
      contextRef="As_Of_12_31_2021_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasurySecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_TueSJDcFvk-6KVBcFb4yWg"
      decimals="0"
      id="Tc_TOLlfWM7CESNclC2ZrK_pg_9_3"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">43115370</imrx:MarketableSecuritiesFairValueDisclosure>
    <imrx:MarketableSecuritiesFairValueDisclosure
      contextRef="As_Of_12_31_2021_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasurySecuritiesMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_GndZSZIX5kONkZeJ-uwZvA"
      decimals="0"
      id="Tc_R6H0l-g_EkiEBKahjOKOhw_9_12"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">43115370</imrx:MarketableSecuritiesFairValueDisclosure>
    <imrx:MarketableSecuritiesFairValueDisclosure
      contextRef="As_Of_12_31_2021_us-gaap_FairValueByAssetClassAxis_imrx_GovernmentSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_rv952rznEk2GkuC-bXIEgw"
      decimals="0"
      id="Tc_HD57mL5rG0qQTuDjCGwZWA_10_6"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">19204368</imrx:MarketableSecuritiesFairValueDisclosure>
    <imrx:MarketableSecuritiesFairValueDisclosure
      contextRef="As_Of_12_31_2021_us-gaap_FairValueByAssetClassAxis_imrx_GovernmentSecuritiesMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_hYwzM8-hekGhWFHX6of5Fg"
      decimals="0"
      id="Tc_H4ED9AepXk2mHwcPfsjSfQ_10_12"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">19204368</imrx:MarketableSecuritiesFairValueDisclosure>
    <imrx:MarketableSecuritiesFairValueDisclosure
      contextRef="As_Of_12_31_2021_us-gaap_FairValueByAssetClassAxis_us-gaap_CommercialPaperMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_sHUMvfiqDEWTLNwGi2V19w"
      decimals="0"
      id="Tc_FU5ngA-nDUqfueOHyTJB2Q_11_6"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">12988025</imrx:MarketableSecuritiesFairValueDisclosure>
    <imrx:MarketableSecuritiesFairValueDisclosure
      contextRef="As_Of_12_31_2021_us-gaap_FairValueByAssetClassAxis_us-gaap_CommercialPaperMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_0brBfUV_8k-73Ah2xvo5vA"
      decimals="0"
      id="Tc_9nIRyU75iEGpC31ecCtegg_11_12"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">12988025</imrx:MarketableSecuritiesFairValueDisclosure>
    <imrx:MarketableSecuritiesFairValueDisclosure
      contextRef="As_Of_12_31_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_DcZ3E7WdG0qTM9kwKkYCCA"
      decimals="0"
      id="Tc_T7vFDc4gjUCSTVvHsw_GFA_12_3"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">43115370</imrx:MarketableSecuritiesFairValueDisclosure>
    <imrx:MarketableSecuritiesFairValueDisclosure
      contextRef="As_Of_12_31_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_XD-w4rYEvkOhxL7DPVZDYA"
      decimals="0"
      id="Tc_PMr8pBebek6NKElwW0Q3Fg_12_6"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">32192393</imrx:MarketableSecuritiesFairValueDisclosure>
    <imrx:MarketableSecuritiesFairValueDisclosure
      contextRef="As_Of_12_31_2021_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_NZFKYXEtB0ypESwMFRZYaA"
      decimals="0"
      id="Tc_Pe-B2xAdKECYPovvGu5_6w_12_12"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">75307763</imrx:MarketableSecuritiesFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_12_31_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_DcZ3E7WdG0qTM9kwKkYCCA"
      decimals="0"
      id="Tc_gEgVg57JEU6HINm9WUmkcA_13_3"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">77076714</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_12_31_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_XD-w4rYEvkOhxL7DPVZDYA"
      decimals="0"
      id="Tc_kmPfUV2VTEG7BcnYRdofuw_13_6"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">34192393</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_12_31_2021_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_NZFKYXEtB0ypESwMFRZYaA"
      decimals="0"
      id="Tc_l1H6cW2F50SLNwtjwkKIMg_13_12"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">111269107</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:MarketableSecurities
      contextRef="As_Of_12_31_2020_OUSLyqWONEO8ccGPC6rBdg"
      decimals="0"
      id="Narr_QcuXiEylUUu8Gt2Swlqt3g"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">0</us-gaap:MarketableSecurities>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ"
      id="Tb_BaK3T6QdzkyNNVUp2xK1WA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Note&#160;5&#160;&#x2013; Property and Equipment, net&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Property and equipment, net consisted of the following:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Computer equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 281,666&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 174,317&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Furniture and fixtures&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 84,477&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 18,798&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Lab equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 463,182&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;-&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 152,117&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;-&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 981,442&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 193,115&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Accumulated depreciation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (174,219)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (128,752)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Property and equipment, net&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 807,223&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 64,363&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Depreciation expense totaled $45,467 and $24,328 for the year ended December 31, 2021 and 2020, respectively. &lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ"
      id="Tb_cgr4MvVR0ECBEnteqpDFjA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Computer equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 281,666&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 174,317&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Furniture and fixtures&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 84,477&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 18,798&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Lab equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 463,182&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;-&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 152,117&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;-&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 981,442&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 193,115&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Accumulated depreciation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (174,219)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (128,752)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Property and equipment, net&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 807,223&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 64,363&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember__c5PFKa--kCuxwpGGlOIrg"
      decimals="0"
      id="Tc_Aob7Wdf2AkqwlJm4D6qntA_4_3"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">281666</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_ISSEkI2XdEmI7m0_HrAVEw"
      decimals="0"
      id="Tc_AuT47o8ry0SkYVU8yimLFQ_4_6"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">174317</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_XLMYvLxYDEmGm0OC6_nT-A"
      decimals="0"
      id="Tc_V2WZo12HUEeHfT3fEMreQw_5_3"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">84477</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_ZN2vm0JtIkGqEGwjZuOpmA"
      decimals="0"
      id="Tc__ERoMRqLwE2rB6g1V8Bg7Q_5_6"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">18798</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_imrx_LabEquipmentMember_WQeNLQggXkGO-8Q1oHgFeQ"
      decimals="0"
      id="Tc_mzDb5Xjlt0eDKvtUGiIfPw_6_3"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">463182</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_bZau0xYq2Eux-_CkfhyDgw"
      decimals="0"
      id="Tc_-8_vnp0MtEmoaR-99G2D2Q_7_3"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">152117</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2021_TBpjtOXgEkKQahJJAv0aWg"
      decimals="0"
      id="Tc_Pa9GB8fBpEWVXKKdMsJcrQ_8_3"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">981442</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2020_OUSLyqWONEO8ccGPC6rBdg"
      decimals="0"
      id="Tc_fmppGZFR802QAyp-DalOsQ_8_6"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">193115</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="As_Of_12_31_2021_TBpjtOXgEkKQahJJAv0aWg"
      decimals="0"
      id="Tc_DIl5le-kP0ermw9CeKN1Bg_9_3"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">174219</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="As_Of_12_31_2020_OUSLyqWONEO8ccGPC6rBdg"
      decimals="0"
      id="Tc_ad7Pkh0pHk6aJfoOZRF_nQ_9_6"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">128752</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_12_31_2021_TBpjtOXgEkKQahJJAv0aWg"
      decimals="0"
      id="Tc_wMjCwnPmEEugL5gpVEhKPA_10_3"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">807223</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_12_31_2020_OUSLyqWONEO8ccGPC6rBdg"
      decimals="0"
      id="Tc_afMPc58gf0GT1VzLJTP5Vg_10_6"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">64363</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation
      contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ"
      decimals="0"
      id="Narr_4AZd3gyM5UqPdJuSNaL8tA"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">45467</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="Duration_1_1_2020_To_12_31_2020_J_O9OcmviUi8EDFgokrY1Q"
      decimals="0"
      id="Narr_Ru6dyTgxvUyHpfwNbVa6XA"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">24328</us-gaap:Depreciation>
    <us-gaap:BusinessCombinationDisclosureTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ"
      id="Tb_LWV6DgjBPUe7ZaejeCXT6g">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Note&#160;6&#160;&#x2013; Business Combination&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;background:#ffffff;"&gt;BioArkive Acquisition&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="background:#ffffff;"&gt;On December&#160;22, 2021, the Company completed the acquisition of all outstanding shares of capital stock of BioArkive, Inc., a California corporation (&#x201c;BioArkive&#x201d;), for a market value of &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;$8.75&lt;/span&gt;&lt;span style="background:#ffffff;"&gt; million.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="background:#ffffff;"&gt;BioArkive is a San Diego based contract research organization that has previously provided preclinical research services and biosample storage to the Company and other biotechnology companies. BioArkive is in the process of being fully integrated into the Company to exclusively support the Company's internal preclinical research activities for its oncology pipeline.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="background:#ffffff;"&gt;In connection with the acquisition,&#160;the Company has assumed the obligations under BioArkive&#x2019;s &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;three&lt;/span&gt;&lt;span style="background:#ffffff;"&gt; lease agreements.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="background:#ffffff;"&gt;The purchase price was paid by Immuneering through the issuance of an aggregate of &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;379,635&lt;/span&gt;&lt;span style="background:#ffffff;"&gt; shares of Immuneering&#x2019;s Class&#160;A common stock. The number of shares of common stock issued was calculated using a value based on the average of the daily volume weighted average prices of the common stock on the Nasdaq Stock Exchange for the &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;30&lt;/span&gt;&lt;span style="background:#ffffff;"&gt;-trading day period ending on and including the trading day immediately prior to the closing date.&lt;/span&gt; The sellers of BioArkive are restricted from selling these shares for a 6 month period from the date of the acquisition. As such, we estimated that there was an approximate 10% discount for the lack of marketability of the shares. The fair value of the purchase price in the acquisition has been preliminarily estimated to be $7,875,000.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="background:#ffffff;"&gt;Prior to the acquistion, Brett Hall, Chief Scientific Officer of Immuneering and the Founder and Chairman of the board of directors of BioArkive, held the majority of the outstanding shares of BioArkive capital stock.&lt;/span&gt; &#160;BioArkive provided contract services to the Company. &lt;span style="background:#ffffff;"&gt;Research and development expenses in the consolidated statement of operations include the cost of services provided by BioArkive to the Company which amounted to &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;$4,548,780&lt;/span&gt;&lt;span style="background:#ffffff;"&gt; in 2021 through date of the acquisition and &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;$2,744,051&lt;/span&gt;&lt;span style="background:#ffffff;"&gt; in 2020. As of December&#160;31, 2020, &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;$279,153&lt;/span&gt;&lt;span style="background:#ffffff;"&gt; was owed to BioArkive and is included in accounts payable or accrued contract research expenses in the consolidated balance sheets. &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="text-decoration-line:underline;text-decoration-style:solid;"&gt;Assets Acquired and Liabilities Assumed at Fair Value&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The BioArkive Acquisition has been accounted for using the acquisition method of accounting. This method requires that assets acquired and liabilities assumed in a business combination to be recognized at their fair values as of the acquisition date. As of December&#160;31, 2021, certain amounts relating to working capital have not been finalized. The finalization of these matters could result in changes to goodwill.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="text-decoration-line:underline;text-decoration-style:solid;"&gt;Intangible Assets&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The estimated fair value of the intangible assets was determined using the relief from royalty approach.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="text-decoration-line:underline;text-decoration-style:solid;"&gt;Goodwill&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Goodwill is the excess of the consideration transferred over the net assets recognized and represents the expected cost savings of the combined company and assembled workforce. One of the key factors that contributes to the recognition of goodwill, and a driver for the Company's acquisition of BioArkive, is the planned investment in the internal preclinical research activities for our oncology pipeline.&#160;Goodwill recognized as a result of this acquisition is non-deductible for income tax purposes.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Pro forma results are not presented for this acquisition as they are not material to the consolidated results of the Company&#x2019;s operations.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:99.4%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:52.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:22.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:52.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;width:23.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Preliminary Valuation&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;width:19.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted Average Life&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:52.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Cash&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:22.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 70,348&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:52.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Other currents assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:22.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 225,790&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:52.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Other long term assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:22.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 87,796&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:52.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Property, plant and equipment, net&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:22.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 727,539&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:52.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Right of use assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:22.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,824,700&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:52.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Intangible asset&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:22.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:52.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;   Technology&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:22.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 439,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;15 years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:52.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Goodwill&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:22.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,701,726&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:52.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:22.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:52.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total assets acquired&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:22.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 13,076,899&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:52.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:22.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:52.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Accounts payable, accrued expenses and other liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:22.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 69,714&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:52.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Deferred tax liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:22.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 307,485&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:52.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Lease liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:22.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,824,700&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:52.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Net assets acquired&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.26%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:22.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7,875,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:BusinessCombinationDisclosureTextBlock>
    <imrx:BusinessCombinationPurchasePrice
      contextRef="As_Of_12_22_2021_us-gaap_BusinessAcquisitionAxis_imrx_BioArkiveIncMember_eZfDAI7yG0yVohELE3M0sA"
      decimals="4"
      id="Narr_dE1BMsXCjE64P-mEy3tkGQ"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">8750000</imrx:BusinessCombinationPurchasePrice>
    <imrx:NumberOfLeasesObligationsAssumed
      contextRef="As_Of_12_22_2021_us-gaap_BusinessAcquisitionAxis_imrx_BioArkiveIncMember_eZfDAI7yG0yVohELE3M0sA"
      decimals="INF"
      id="Narr_iJHn-IbgkUK8L5vlO11W8A"
      unitRef="Unit_Standard_agreement_qexq1bbkzU-JqgEPv8PRCQ">3</imrx:NumberOfLeasesObligationsAssumed>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions
      contextRef="Duration_12_22_2021_To_12_22_2021_us-gaap_BusinessAcquisitionAxis_imrx_BioArkiveIncMember_jaVHRkxuBESGO6YkECH_Bw"
      decimals="INF"
      id="Narr_GwuF8RDgJ0mYQYAzvoH1fg"
      unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ">379635</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <imrx:BusinessCombinationSharesIssuedSharePriceThresholdTradingDays
      contextRef="Duration_12_22_2021_To_12_22_2021_us-gaap_BusinessAcquisitionAxis_imrx_BioArkiveIncMember_jaVHRkxuBESGO6YkECH_Bw"
      decimals="INF"
      id="Narr_DAOqxSamwESkllsXV27uiQ"
      unitRef="Unit_Standard_D_qWJwQorwfUaf88ueMyElMA">30</imrx:BusinessCombinationSharesIssuedSharePriceThresholdTradingDays>
    <imrx:BusinessCombinationSharesIssuedLockInPeriod
      contextRef="Duration_12_22_2021_To_12_22_2021_us-gaap_BusinessAcquisitionAxis_imrx_BioArkiveIncMember_jaVHRkxuBESGO6YkECH_Bw"
      id="Narr_LHVdJj0yMUW8i7YMyspEVw">P6M</imrx:BusinessCombinationSharesIssuedLockInPeriod>
    <imrx:BusinessCombinationSharesIssuedDiscountDueToMarketabilityPercentage
      contextRef="Duration_12_22_2021_To_12_22_2021_us-gaap_BusinessAcquisitionAxis_imrx_BioArkiveIncMember_jaVHRkxuBESGO6YkECH_Bw"
      decimals="2"
      id="Narr_peMFNFsB2kSQ5hufG3llpw"
      unitRef="Unit_Standard_pure_iothMaWWqUCV2N7d1PVg4w">0.10</imrx:BusinessCombinationSharesIssuedDiscountDueToMarketabilityPercentage>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="Duration_12_22_2021_To_12_22_2021_us-gaap_BusinessAcquisitionAxis_imrx_BioArkiveIncMember_jaVHRkxuBESGO6YkECH_Bw"
      decimals="0"
      id="Narr_gr2cy1ETgUSWXV6j0C8nlA"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">7875000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_imrx_BioArkiveIncMember_TX8VFVwjvkmlDFzOu0fzHw"
      decimals="0"
      id="Narr_qISp4tD4gkqYMJlj0Fjz4A"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">4548780</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_imrx_BioArkiveIncMember_sa3-bf410kC_Z3vN1a5IFw"
      decimals="0"
      id="Narr_t3UNa9c7IEyQG8gX12SeVA"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">2744051</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:DueToRelatedPartiesCurrent
      contextRef="As_Of_12_31_2020_us-gaap_BalanceSheetLocationAxis_us-gaap_AccountsPayableAndAccruedLiabilitiesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_imrx_BioArkiveIncMember_Fdx8Pw88t0GYE-WWz9kZLQ"
      decimals="0"
      id="Narr_hdCnI4ozEka9hP3drSsGcw"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">279153</us-gaap:DueToRelatedPartiesCurrent>
    <us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ"
      id="Tb_tlzzUtZpakixSuMzNJzyGw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:99.4%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:52.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:22.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:52.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;width:23.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Preliminary Valuation&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;width:19.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted Average Life&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:52.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Cash&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:22.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 70,348&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:52.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Other currents assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:22.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 225,790&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:52.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Other long term assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:22.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 87,796&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:52.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Property, plant and equipment, net&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:22.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 727,539&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:52.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Right of use assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:22.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,824,700&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:52.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Intangible asset&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:22.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:52.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;   Technology&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:22.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 439,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;15 years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:52.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Goodwill&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:22.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,701,726&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:52.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:22.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:52.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total assets acquired&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:22.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 13,076,899&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:52.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:22.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:52.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Accounts payable, accrued expenses and other liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:22.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 69,714&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:52.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Deferred tax liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:22.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 307,485&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:52.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Lease liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:22.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,824,700&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:52.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Net assets acquired&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.26%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:22.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7,875,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents
      contextRef="As_Of_12_22_2021_us-gaap_BusinessAcquisitionAxis_imrx_BioArkiveIncMember_eZfDAI7yG0yVohELE3M0sA"
      decimals="0"
      id="Tc_2fzGbORspEqCjrUfktRS2A_2_3"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">70348</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther
      contextRef="As_Of_12_22_2021_us-gaap_BusinessAcquisitionAxis_imrx_BioArkiveIncMember_eZfDAI7yG0yVohELE3M0sA"
      decimals="0"
      id="Tc_hEsvXETcnkym9Li719u_tw_3_3"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">225790</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets
      contextRef="As_Of_12_22_2021_us-gaap_BusinessAcquisitionAxis_imrx_BioArkiveIncMember_eZfDAI7yG0yVohELE3M0sA"
      decimals="0"
      id="Tc_XhH979z6CE6IXcF5NwUmEQ_4_3"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">87796</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment
      contextRef="As_Of_12_22_2021_us-gaap_BusinessAcquisitionAxis_imrx_BioArkiveIncMember_eZfDAI7yG0yVohELE3M0sA"
      decimals="0"
      id="Tc_Q0LklAO9Y0SHrjgnzhZcTQ_5_3"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">727539</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment>
    <imrx:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets
      contextRef="As_Of_12_22_2021_us-gaap_BusinessAcquisitionAxis_imrx_BioArkiveIncMember_eZfDAI7yG0yVohELE3M0sA"
      decimals="0"
      id="Tc_Z8hi34EDW0aPWyJEFYEuew_6_3"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">4824700</imrx:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="As_Of_12_22_2021_us-gaap_BusinessAcquisitionAxis_imrx_BioArkiveIncMember_eZfDAI7yG0yVohELE3M0sA"
      decimals="0"
      id="Tc_H7OcizgiK0icjTorjuiTDA_8_3"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">439000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="Duration_12_22_2021_To_12_22_2021_us-gaap_BusinessAcquisitionAxis_imrx_BioArkiveIncMember_jaVHRkxuBESGO6YkECH_Bw"
      id="Tc_qPDY_jewwk-IvLrzAAkrQg_8_6">P15Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:Goodwill
      contextRef="As_Of_12_22_2021_us-gaap_BusinessAcquisitionAxis_imrx_BioArkiveIncMember_eZfDAI7yG0yVohELE3M0sA"
      decimals="0"
      id="Tc_XPJYLYWmdUKMo1MZ3p22Cg_9_3"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">6701726</us-gaap:Goodwill>
    <imrx:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIncludingGoodwill
      contextRef="As_Of_12_22_2021_us-gaap_BusinessAcquisitionAxis_imrx_BioArkiveIncMember_eZfDAI7yG0yVohELE3M0sA"
      decimals="0"
      id="Tc_lWDGZXYxR0udGD-MEGlpDw_11_3"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">13076899</imrx:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIncludingGoodwill>
    <imrx:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAccruedExpensesAndOtherLiabilities
      contextRef="As_Of_12_22_2021_us-gaap_BusinessAcquisitionAxis_imrx_BioArkiveIncMember_eZfDAI7yG0yVohELE3M0sA"
      decimals="0"
      id="Tc_BdQkTQ_jNke3q7BFD8tbmQ_13_3"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">69714</imrx:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAccruedExpensesAndOtherLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities
      contextRef="As_Of_12_22_2021_us-gaap_BusinessAcquisitionAxis_imrx_BioArkiveIncMember_eZfDAI7yG0yVohELE3M0sA"
      decimals="0"
      id="Tc_idAS0zhfQkmPtwwLpsno2Q_14_3"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">307485</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation
      contextRef="As_Of_12_22_2021_us-gaap_BusinessAcquisitionAxis_imrx_BioArkiveIncMember_eZfDAI7yG0yVohELE3M0sA"
      decimals="0"
      id="Tc_mJOAvbELqEiwYr2cI7SPvQ_15_3"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">4824700</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet
      contextRef="As_Of_12_22_2021_us-gaap_BusinessAcquisitionAxis_imrx_BioArkiveIncMember_eZfDAI7yG0yVohELE3M0sA"
      decimals="0"
      id="Tc_Z4sKPb21U0C3L3v8Tud-Gg_16_3"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">7875000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet>
    <imrx:AccruedLiabilitiesDisclosureTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ"
      id="Tb_0Z6Mqss9c0a_9Yz5bl1lwA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Note&#160;7&#160;&#x2013; Accrued Expenses&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Accrued expenses consisted of the following:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Accrued professional services&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 250,977&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 269,302&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Accrued employee expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,917,282&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 163,668&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Accrued contract research expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 585,416&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 266,022&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Accrued other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 211,772&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,965,447&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 698,992&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</imrx:AccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ"
      id="Tb_4ERb0B2gpUSdKuwmatk1PQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Accrued professional services&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 250,977&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 269,302&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Accrued employee expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,917,282&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 163,668&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Accrued contract research expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 585,416&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 266,022&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Accrued other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 211,772&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,965,447&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 698,992&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:AccruedProfessionalFeesCurrentAndNoncurrent
      contextRef="As_Of_12_31_2021_TBpjtOXgEkKQahJJAv0aWg"
      decimals="0"
      id="Tc_cFaxT2SnREqJHIkdMLfqkg_4_3"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">250977</us-gaap:AccruedProfessionalFeesCurrentAndNoncurrent>
    <us-gaap:AccruedProfessionalFeesCurrentAndNoncurrent
      contextRef="As_Of_12_31_2020_OUSLyqWONEO8ccGPC6rBdg"
      decimals="0"
      id="Tc_hKoliSTHZ0iCSUL2WpsCyA_4_6"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">269302</us-gaap:AccruedProfessionalFeesCurrentAndNoncurrent>
    <us-gaap:AccruedEmployeeBenefitsCurrentAndNoncurrent
      contextRef="As_Of_12_31_2021_TBpjtOXgEkKQahJJAv0aWg"
      decimals="0"
      id="Tc_vcJqntuHAECY7jb0BGVSfw_5_3"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">2917282</us-gaap:AccruedEmployeeBenefitsCurrentAndNoncurrent>
    <us-gaap:AccruedEmployeeBenefitsCurrentAndNoncurrent
      contextRef="As_Of_12_31_2020_OUSLyqWONEO8ccGPC6rBdg"
      decimals="0"
      id="Tc_Zp8qP2t5kECZerJwbakk3Q_5_6"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">163668</us-gaap:AccruedEmployeeBenefitsCurrentAndNoncurrent>
    <imrx:AccruedContractResearchExpensesCurrent
      contextRef="As_Of_12_31_2021_TBpjtOXgEkKQahJJAv0aWg"
      decimals="0"
      id="Tc_xGvsKxR6jUinT9FlOqO4mA_6_3"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">585416</imrx:AccruedContractResearchExpensesCurrent>
    <imrx:AccruedContractResearchExpensesCurrent
      contextRef="As_Of_12_31_2020_OUSLyqWONEO8ccGPC6rBdg"
      decimals="0"
      id="Tc_gpKFe7LZW0aECFoAG-PQHg_6_6"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">266022</imrx:AccruedContractResearchExpensesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrentAndNoncurrent
      contextRef="As_Of_12_31_2021_TBpjtOXgEkKQahJJAv0aWg"
      decimals="0"
      id="Tc_q5Nj140K_0KtjFCGbEBoBQ_7_3"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">211772</us-gaap:OtherAccruedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2021_TBpjtOXgEkKQahJJAv0aWg"
      decimals="0"
      id="Tc_Osb3WLIf4ECmaqveQz_Lzw_8_3"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">3965447</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2020_OUSLyqWONEO8ccGPC6rBdg"
      decimals="0"
      id="Tc_OKXom-kEt0OcNyPktBIk1w_8_6"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">698992</us-gaap:AccruedLiabilitiesCurrent>
    <imrx:TemporaryEquityDisclosureTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ"
      id="Tb_MXA5JjSgL0uR3SggiUskfw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Note&#160;8&#160;&#x2013; Convertible Preferred Stock&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Series&#160;A Preferred Stock&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;In September&#160;2019, the Company authorized the sale and issuance of up to 1,987,979 shares of Series&#160;A Preferred Stock, $0.001 par value per share, at an original issuance price of $8.5514 per share. In January&#160;2020, the number of shares authorized for the Series&#160;A Preferred Stock was increased to 2,495,933 shares. The Series&#160;A Preferred Stock financing was structured to be issued in rolling closes during 2019 and 2020.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;On September&#160;20, 2019, the Company issued an additional 1,122,458 shares of Series&#160;A Preferred Stock for gross cash proceeds of $9,598,847 and issued 785,706 shares of Series&#160;A Preferred Stock in conjunction with the conversion of the outstanding amount of the Convertible Notes. In 2019, the Company incurred issuance costs of $200,587 in connection with this offering.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Company received funds for issuance of an additional 468,315 shares of Series&#160;A Preferred Stock for gross cash proceeds of $4,004,975 through December&#160;31, 2019. Of these shares, 410,436 shares of Series&#160;A Preferred Stock for gross cash proceeds of $3,509,802 exceeded the authorized amount allowed by the articles of incorporation, resulting in a liability of $3,509,802 and a total of 1,966,043 shares of Series&#160;A Preferred Stock outstanding at December&#160;31, 2019. In January&#160;2020, the shares that were previously classified as a liability as of December&#160;31, 2019 were reclassified to temporary equity upon the approved increase to authorized shares of Series&#160;A Preferred Stock.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;In January&#160;2020, the Company issued 119,454 additional shares of Series&#160;A Preferred Stock for gross cash proceeds of $1,021,413. The Company incurred issuance costs of $23,610 in connection with the financing in January&#160;2020.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Series&#160;B Preferred Stock&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;In December&#160;2020, the Company authorized the sale and issuance of up to 6,032,183 shares of Series&#160;B Preferred Stock, $0.001 par value per share, at an original issuance price of $10.2782 per share. The Series&#160;B Preferred Stock financing was structured to close in two tranches. The first tranche closed in December&#160;2020 and the Company issued 3,619,292 shares of Series&#160;B Preferred Stock for gross cash proceeds of $37,199,929. The Company incurred issuance costs of $216,019 in connection with the financing in December&#160;2020.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Company determined the right of the investors to purchase 2,412,853 shares of Series&#160;B Preferred Stock in the second tranche does not meet the definition of a freestanding financial instrument as it is not separable from the Series&#160;B Preferred Stock issued in the first tranche. The issuance of the second tranche is subject to the Company meeting certain development milestones or at the election of the holders of at least a majority of the then outstanding shares of Series&#160;B Preferred Stock which must include one specific shareholder (the &#x201c;Requisite Holders&#x201d;). Each holder of Series&#160;B Preferred Stock may elect to purchase their requisite shares of the second tranche at any time. As of March 31, 2021, the Company had not met these development milestones nor did the Requisite Holders elect to purchase the second tranche prior to meeting these milestones and therefore no shares of the second tranche were issued.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;In April&#160;and May&#160;2021, all 2,412,853 shares of the second tranche of Series&#160;B Preferred Stock were issued based on the voluntary election of substantially all of the holders of Series&#160;B Preferred Stock. The Company received gross proceeds of $24,799,786. The Company incurred issuance costs of $10,935 in connection with the second tranche of Series&#160;B Preferred Stock.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The rights and preferences of the Series&#160;A Preferred Stock and Series&#160;B Preferred Stock (&#x201c;Preferred Stock&#x201d;) were as described below:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="text-decoration-line:underline;text-decoration-style:solid;"&gt;Conversion&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Each share of Preferred Stock may be converted at any time, at the option of the holder, into shares of Class&#160;A common stock, subject to the applicable conversion rate as determined by dividing the original issue price by the conversion price. The conversion price for the Series&#160;A Preferred Stock and Series&#160;B Preferred Stock (as may be adjusted for certain customary dilutive events) is $6.1081 and $7.3416, respectively. The Preferred Stock automatically convert into shares of Class&#160;A common stock at the then effective conversion rate upon the closing of a public offering of the Company&#x2019;s securities with gross proceeds to the Company of at least $75,000,000 and a share price of at least $7.3416 or at the election of the holders of the Requisite Holders.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Holders of Series&#160;B Preferred Stock that would beneficially own at least 9.9% of any then outstanding class of equity securities may elect to receive a portion of their converted Series&#160;B Preferred Stock as Class&#160;B common stock upon conversion.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Upon the closing of the IPO on August&#160;3, 2021, all 8,528,078 shares of the Company&#x2019;s convertible preferred stock then outstanding automatically converted into 11,939,281 shares of Class A common stock.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="text-decoration-line:underline;text-decoration-style:solid;"&gt;Dividends&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Preferred Stockholders are entitled to receive per annum dividends of 7% of the original issue price share, payable only when, as and if declared by the Board of Directors. The right to receive these dividends is not cumulative, and therefore, if not declared in any&#160;year, the right to receive such dividends shall terminate and not carry forward into the next&#160;year. As of December&#160;31, 2021 and December&#160;31, 2020, no dividends had been declared.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="text-decoration-line:underline;text-decoration-style:solid;"&gt;Voting Rights&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Preferred Stock and common stock vote together as one class on an as converted basis. Common stock voting rights on certain matters are subject to the powers, preferences, and rights of the Preferred Stock. Preferred Stockholders are entitled to vote on all matters and shall have the number of votes equal to the number of shares of common stock into which the shares of Preferred Stock held by such holder are then convertible. As long as 2,132,029 shares of Preferred Stock are outstanding, certain actions such as mergers, acquisition, liquidation, dissolution, wind up of business, and deemed liquidation events, must be approved by the holders of at least a majority of the then-outstanding shares of Preferred Stock.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="text-decoration-line:underline;text-decoration-style:solid;"&gt;Liquidation Preference&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Upon liquidation, dissolution, or winding up of business, holders of Preferred Stock are entitled to receive a liquidation preference in priority to holders of common stock at the original respective Preferred Stock issue price for such series. If assets available for distribution are insufficient to satisfy the liquidation payment to holders of Preferred Stock in full, assets available for distribution will be allocated among holders of Preferred Stock on a pari passu basis at an amount per share equal to the greater of the respective original Preferred Stock issue price for such series plus any declared but unpaid dividends or such amount had all shares been converted to common stock.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;When holders of Preferred Stock are satisfied in full, any excess assets available for distribution will be allocated ratably among common stock holders based on their pro rata shareholdings. Upon a deemed liquidation event, as defined in the articles of incorporation, holders have the option to redeem their shares at the liquidation payment amounts summarized above.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="text-decoration-line:underline;text-decoration-style:solid;"&gt;Redemption&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Other than described above, the shares of Preferred Stock are not redeemable.&lt;/p&gt;</imrx:TemporaryEquityDisclosureTextBlock>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="As_Of_9_30_2019_us-gaap_StatementClassOfStockAxis_imrx_SeriesConvertiblePreferredStockMember_O1RMY__04UyGW5MdXmEk9Q"
      decimals="INF"
      id="Narr_oTUjqcnusUS3Vq_QTcyypw"
      unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ">1987979</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="As_Of_9_30_2019_us-gaap_StatementClassOfStockAxis_imrx_SeriesConvertiblePreferredStockMember_O1RMY__04UyGW5MdXmEk9Q"
      decimals="INF"
      id="Narr_tyFYzZtVYkmQf6ZBdfhnuw"
      unitRef="Unit_Divide_USD_shares_0VraXufKhkCSOUw2U_zvgQ">0.001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <imrx:TemporaryEquityIssuancePrice
      contextRef="As_Of_9_30_2019_us-gaap_StatementClassOfStockAxis_imrx_SeriesConvertiblePreferredStockMember_O1RMY__04UyGW5MdXmEk9Q"
      decimals="4"
      id="Narr_Ya9Ir_tBAU2BphNVO-yZrw"
      unitRef="Unit_Divide_USD_shares_0VraXufKhkCSOUw2U_zvgQ">8.5514</imrx:TemporaryEquityIssuancePrice>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="As_Of_1_31_2020_us-gaap_StatementClassOfStockAxis_imrx_SeriesConvertiblePreferredStockMember_Tref9-4zckC3A4JsB3VTMA"
      decimals="INF"
      id="Narr_cToBHJPWmUqzijq0GonoEA"
      unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ">2495933</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="As_Of_9_20_2019_us-gaap_StatementClassOfStockAxis_imrx_SeriesConvertiblePreferredStockMember_CgdZd9wu3UC4tGQyNK6KPA"
      decimals="INF"
      id="Narr_ScQNL3C-zEa4jjn87oqLTQ"
      unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ">1122458</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock
      contextRef="Duration_9_20_2019_To_9_20_2019_us-gaap_StatementClassOfStockAxis_imrx_SeriesConvertiblePreferredStockMember_lHzkW0d_2keHgOLQonVBGg"
      decimals="0"
      id="Narr_JieNrEQUsUSYD-S1SlMj2w"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">9598847</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1
      contextRef="Duration_9_20_2019_To_9_20_2019_us-gaap_StatementClassOfStockAxis_imrx_SeriesConvertiblePreferredStockMember_lHzkW0d_2keHgOLQonVBGg"
      decimals="INF"
      id="Narr_vFVAWrow2EiV1FwffE8FlA"
      unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ">785706</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementClassOfStockAxis_imrx_SeriesConvertiblePreferredStockMember_gEfHGMh_TEuDzZN3KX78bg"
      decimals="0"
      id="Narr_1CFpSKefWEGZSAGxQqX5Mg"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">200587</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="As_Of_12_31_2019_us-gaap_StatementClassOfStockAxis_imrx_SeriesConvertiblePreferredStockMember_ncQIkgAZqEWsymLXhsJ6yg"
      decimals="INF"
      id="Narr_3aiNvCHuZk-GqOG68_NWqA"
      unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ">468315</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock
      contextRef="Duration_12_31_2019_To_12_31_2019_us-gaap_StatementClassOfStockAxis_imrx_SeriesConvertiblePreferredStockMember___WeTNXDqEKrDBAIVc3wUA"
      decimals="0"
      id="Narr_KnV0dn3WdEaZXeESK7oCZQ"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">4004975</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
    <imrx:TemporaryEquityNumberOfSharesExcessOfAuthorized
      contextRef="As_Of_12_31_2019_us-gaap_StatementClassOfStockAxis_imrx_SeriesConvertiblePreferredStockMember_ncQIkgAZqEWsymLXhsJ6yg"
      decimals="INF"
      id="Narr_XG6zgi1Y1EGnHlaSJeRbMQ"
      unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ">410436</imrx:TemporaryEquityNumberOfSharesExcessOfAuthorized>
    <imrx:ProceedsFromIssuanceOfConvertiblePreferredStockExcessOfAuthorizedAmount
      contextRef="Duration_12_31_2019_To_12_31_2019_us-gaap_StatementClassOfStockAxis_imrx_SeriesConvertiblePreferredStockMember___WeTNXDqEKrDBAIVc3wUA"
      decimals="0"
      id="Narr_BkOV1Me0skmr-ZF26EIfLQ"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">3509802</imrx:ProceedsFromIssuanceOfConvertiblePreferredStockExcessOfAuthorizedAmount>
    <imrx:TemporaryEquityDueToExcessAuthorizedAmount
      contextRef="As_Of_12_31_2019_us-gaap_StatementClassOfStockAxis_imrx_SeriesConvertiblePreferredStockMember_ncQIkgAZqEWsymLXhsJ6yg"
      decimals="0"
      id="Narr_wckDTQ7srk2ZDjDIAYSa3w"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">3509802</imrx:TemporaryEquityDueToExcessAuthorizedAmount>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="As_Of_12_31_2019_us-gaap_StatementClassOfStockAxis_imrx_SeriesConvertiblePreferredStockMember_ncQIkgAZqEWsymLXhsJ6yg"
      decimals="INF"
      id="Narr_cHHoQIRdn0Os2jt3JNFVIw"
      unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ">1966043</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="As_Of_1_31_2020_us-gaap_StatementClassOfStockAxis_imrx_SeriesConvertiblePreferredStockMember_Tref9-4zckC3A4JsB3VTMA"
      decimals="INF"
      id="Narr_PZGt50kiCky3Tus0QsmnXQ"
      unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ">119454</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock
      contextRef="Duration_1_1_2020_To_1_31_2020_us-gaap_StatementClassOfStockAxis_imrx_SeriesConvertiblePreferredStockMember_YK2LK50_8US_qyrO8ejjbA"
      decimals="0"
      id="Narr_fv7ZOeBKE0q8Jpdd5jA-Cg"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">1021413</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="Duration_1_1_2020_To_1_31_2020_us-gaap_StatementClassOfStockAxis_imrx_SeriesConvertiblePreferredStockMember_YK2LK50_8US_qyrO8ejjbA"
      decimals="0"
      id="Narr_97KzF151NU6QJnEGuORzhg"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">23610</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_imrx_SeriesBConvertiblePreferredStockMember_-Ckh5K8N7U-_9nyMHjiJxQ"
      decimals="INF"
      id="Narr_OKdDxg7cwU6c2pGPLT6gfQ"
      unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ">6032183</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_imrx_SeriesBConvertiblePreferredStockMember_-Ckh5K8N7U-_9nyMHjiJxQ"
      decimals="INF"
      id="Narr_wW1HF5ba3k-exztpr5Riug"
      unitRef="Unit_Divide_USD_shares_0VraXufKhkCSOUw2U_zvgQ">0.001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <imrx:TemporaryEquityIssuancePrice
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_imrx_SeriesBConvertiblePreferredStockMember_-Ckh5K8N7U-_9nyMHjiJxQ"
      decimals="4"
      id="Narr_uQgd3pfr00mXuaZcfkl_0g"
      unitRef="Unit_Divide_USD_shares_0VraXufKhkCSOUw2U_zvgQ">10.2782</imrx:TemporaryEquityIssuancePrice>
    <imrx:NumberOfTranches
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_imrx_SeriesBConvertiblePreferredStockMember_-Ckh5K8N7U-_9nyMHjiJxQ"
      decimals="INF"
      id="Narr_CqrhZcjDrEadDcDZNtcwcg"
      unitRef="Unit_Standard_tranche_5kfv1Y9uXkefgNW7HJS6Rw">2</imrx:NumberOfTranches>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_imrx_SeriesBConvertiblePreferredStocksTrancheOneMember_bShZaSXyFkGkXYNwg6aJxA"
      decimals="INF"
      id="Narr_d0Ij0IbIo0KqjZyMOBkfAw"
      unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ">3619292</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock
      contextRef="Duration_12_1_2020_To_12_31_2020_us-gaap_StatementClassOfStockAxis_imrx_SeriesBConvertiblePreferredStocksTrancheOneMember_CqCA_MA7zUSGLHpsb-XgQQ"
      decimals="0"
      id="Narr_QNGGbLtaJU61s7fYYKddLg"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">37199929</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="Duration_12_1_2020_To_12_31_2020_us-gaap_StatementClassOfStockAxis_imrx_SeriesBConvertiblePreferredStocksTrancheOneMember_CqCA_MA7zUSGLHpsb-XgQQ"
      decimals="0"
      id="Narr_sDLz0YuW20-Jq4LUWrtDiA"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">216019</us-gaap:PaymentsOfStockIssuanceCosts>
    <imrx:TemporaryEquityContingentlyIssuableShares
      contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementClassOfStockAxis_imrx_SeriesBConvertiblePreferredStockMember_TDIXNGLBjEmH6HPuewiRjg"
      decimals="INF"
      id="Narr_qZxAUXwd-UqU9687QdovkQ"
      unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ">2412853</imrx:TemporaryEquityContingentlyIssuableShares>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="As_Of_3_31_2021_us-gaap_StatementClassOfStockAxis_imrx_SeriesBConvertiblePreferredStockTrancheTwoMember_h-jV1278D0iiS0qgsgtv3A"
      decimals="INF"
      id="Narr_9InkLRnVk0mQsh3cQbygVA"
      unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ">0</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="As_Of_5_31_2021_us-gaap_StatementClassOfStockAxis_imrx_SeriesBConvertiblePreferredStockTrancheTwoMember_-1LYWcxnHk6UK-Jcbi7Lpw"
      decimals="INF"
      id="Narr_s43SZKB_qU2ITCMJpRk-Dg"
      unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ">2412853</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock
      contextRef="Duration_4_1_2021_To_5_31_2021_us-gaap_StatementClassOfStockAxis_imrx_SeriesBConvertiblePreferredStockTrancheTwoMember_3Z1Gf_8wlESSr2qfBuPkyQ"
      decimals="0"
      id="Narr_xulpin2iIkWzGLWCldpZeQ"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">24799786</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="Duration_4_1_2021_To_5_31_2021_us-gaap_StatementClassOfStockAxis_imrx_SeriesBConvertiblePreferredStockTrancheTwoMember_3Z1Gf_8wlESSr2qfBuPkyQ"
      decimals="0"
      id="Narr_Z9N6mgUIckOPu3JjwX0M8Q"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">10935</us-gaap:PaymentsOfStockIssuanceCosts>
    <imrx:TemporaryEquityConversionPrice
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_imrx_SeriesConvertiblePreferredStockMember_DzBbn1vSGECYmtSe-hivlw"
      decimals="4"
      id="Narr_6frQH9eRp0ChrrOnKH_mIQ"
      unitRef="Unit_Divide_USD_shares_0VraXufKhkCSOUw2U_zvgQ">6.1081</imrx:TemporaryEquityConversionPrice>
    <imrx:TemporaryEquityConversionPrice
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_imrx_SeriesBConvertiblePreferredStockMember_lxbE9uvMQU-NU7BxZ_aTNg"
      decimals="4"
      id="Narr_cRu_vz9JX0W90e93LuYAGw"
      unitRef="Unit_Divide_USD_shares_0VraXufKhkCSOUw2U_zvgQ">7.3416</imrx:TemporaryEquityConversionPrice>
    <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_StatementClassOfStockAxis_imrx_SeriesConvertiblePreferredStockMember_ArKyrrqRQE6HOj-7SNUhxw"
      decimals="0"
      id="Narr_AIxPy5DgcUGF1cAJNs-BGw"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">75000000</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
    <imrx:TemporaryEquityIssuancePrice
      contextRef="As_Of_12_31_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_StatementClassOfStockAxis_imrx_SeriesConvertiblePreferredStockMember_DFd25cydBkuiug-BF6zGWQ"
      decimals="4"
      id="Narr_t2WbOJUFaEaBtQSxrIaosQ"
      unitRef="Unit_Divide_USD_shares_0VraXufKhkCSOUw2U_zvgQ">7.3416</imrx:TemporaryEquityIssuancePrice>
    <imrx:PercentageOfEquitySecuritiesOwnedToGetConvertedStock
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_imrx_SeriesBConvertiblePreferredStockMember_lxbE9uvMQU-NU7BxZ_aTNg"
      decimals="3"
      id="Narr_J7V3cwptb0-ASRGEvxFo9g"
      unitRef="Unit_Standard_pure_iothMaWWqUCV2N7d1PVg4w">0.099</imrx:PercentageOfEquitySecuritiesOwnedToGetConvertedStock>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="As_Of_8_3_2021_atfZ3VjOmEGor-TZ8PR3vw"
      decimals="INF"
      id="Narr_VMxtbiPPGUm8dbY2_f2_dQ"
      unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ">8528078</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion
      contextRef="As_Of_8_3_2021_atfZ3VjOmEGor-TZ8PR3vw"
      decimals="INF"
      id="Narr_8J31G5NFykmDK-TIi7Lydg"
      unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ">11939281</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
    <us-gaap:PreferredStockDividendRatePercentage
      contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ"
      decimals="2"
      id="Narr_r-Zx0ZE0D0WdeW9zPtqjoA"
      unitRef="Unit_Standard_pure_iothMaWWqUCV2N7d1PVg4w">0.07</us-gaap:PreferredStockDividendRatePercentage>
    <us-gaap:DividendsPreferredStock
      contextRef="Duration_1_1_2020_To_12_31_2020_J_O9OcmviUi8EDFgokrY1Q"
      decimals="0"
      id="Narr_pEnD3V8PrUGdH5lPqPpxTA"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">0</us-gaap:DividendsPreferredStock>
    <us-gaap:DividendsPreferredStock
      contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ"
      decimals="0"
      id="Narr_hMaqAR7SukmQ3mgGPJlIOQ"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">0</us-gaap:DividendsPreferredStock>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="As_Of_12_31_2021_srt_RangeAxis_srt_MinimumMember_0vGLrM36lEegdT0dgFrRAQ"
      decimals="INF"
      id="Narr_YYe_Lm4Ie0eYr0wTDAJrcw"
      unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ">2132029</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ"
      id="Tb_gD66OqR_JE6T7wUdrIyDJw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Note&#160;9&#160;- Common Stock&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Company had 200,000,000 authorized shares of Class&#160;A common stock, $0.001 par value per share as of December 31, 2021 and 22,026,200 authorized shares of Class A common stock, $0.001 par value per share as of December 31, 2020, respectively, of which 26,320,199 and 4,950,129 were &lt;span style="-sec-ix-hidden:Hidden_hTzGFl4AukOhSIQvrJVGbw;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;issued&lt;/span&gt;&lt;/span&gt; and &lt;span style="-sec-ix-hidden:Hidden_lP6rYH5NMkSWKz0be_vdHw;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;outstanding&lt;/span&gt;&lt;/span&gt;, respectively. The holders of Class&#160;A common stock are entitled one vote for each share of common stock. Dividends may be paid when, and if declared by the Board of Directors, subject to the limitations, powers and preferences granted to the Preferred Stockholders and on a proportionate basis with holders of Class&#160;B common stock.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;As of December 31, 2021 and December&#160;31, 2020, the following number of shares of Class&#160;A common stock have been reserved:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:75.66%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Conversion of Series A Preferred&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,494,306&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Conversion of Series B Preferred&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,066,995&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Exercise of common stock warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 308,308&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Exercise of common stock options&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,859,544&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,801,263&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,859,544&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10,670,872&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Company had 20,000,000 authorized shares of Class&#160;B common stock, $0.001 par value per share as of December 31, 2021 and 6,032,183 authorized shares of Class&#160;B common stock, $0.001 par value per share as of December 31, 2020, of which no shares have been issued nor are outstanding. The holders of Class&#160;B common stock have no voting rights. Dividends may be paid when, and if, declared by the Board of Directors, subject to the limitations, powers and preferences granted to the preferred stockholders and on a proportionate basis with holders of Class&#160;A common stock.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Common Stock Warrants&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;During 2019, the Company issued warrants to purchase an aggregate of 308,308 shares of Class A common stock at an exercise price of $3.01 per share to several advisors, including 200,984 shares to entities related to members of the Board of Directors of the Company, in lieu of cash payments. These warrants vested immediately upon issuance, became exercisable on January&#160;9, 2021 and have a 10-year term set to expire on January&#160;9, 2030. The Company evaluated the terms of these warrants and determined that equity classification was appropriate. As of December&#160;31, 2020, no warrants had been exercised. During June&#160;2021, all warrant holders exercised their warrants to purchase an aggregate of 308,308 shares of common stock. As of December 31, 2021, there were no warrants outstanding.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Initial Public Offering&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;On August 3, 2021, the Company completed its initial public offering pursuant to which it issued and sold 8,625,000 shares of its Class A common stock, inclusive of 1,125,000 shares of its Class A common stock sold pursuant to the full exercise of the underwriters&#x2019; option to purchase additional shares. The aggregate net proceeds received by the Company from the IPO were $120,318,750, after deducting underwriting discounts and commissions, but before deducting offering costs payable by the Company, which were $2,124,317. Upon the closing of the IPO, all 8,528,078 shares of the Company&#x2019;s convertible preferred stock then outstanding automatically converted into 11,939,281 shares of Class A common stock. Upon the conversion of the convertible preferred stock, the Company reclassified the carrying value of the convertible preferred stock to common stock (at par value) and additional&#160;paid-in&#160;capital. &#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;On August 3, 2021 in connection with the closing of the IPO, the Company filed a restated certificate of incorporation, which amended and restated the Company&#x2019;s certificate of incorporation to, among other things: (i)&#160;increase the number of &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;authorized shares of common stock to 200,000,000 shares of Class&#160;A common stock, 20,000,000 shares of Class&#160;B common stock, par value $0.001 per share, and (ii) authorize 10,000,000 shares of Preferred Stock; and (iii)&#160;authorize the Board of Directors to establish the rights, preferences and restrictions on any unissued series of Preferred Stock.&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_Mo7QF875vUy5d2OcEbQ2fA"
      decimals="INF"
      id="Narr_mDUSY89wqkSHNTXy5n450A"
      unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_Mo7QF875vUy5d2OcEbQ2fA"
      decimals="INF"
      id="Narr_BVax2mmfl0ClUFLBIrrE-Q"
      unitRef="Unit_Divide_USD_shares_0VraXufKhkCSOUw2U_zvgQ">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_IvXJ6RHxqkyGTfDbgXwHsw"
      decimals="INF"
      id="Narr_UOh0-7nFIEuYMZNiQ190VQ"
      unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ">22026200</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_IvXJ6RHxqkyGTfDbgXwHsw"
      decimals="INF"
      id="Narr_pE-jOVxcT0mYn5UR5QMljg"
      unitRef="Unit_Divide_USD_shares_0VraXufKhkCSOUw2U_zvgQ">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_Mo7QF875vUy5d2OcEbQ2fA"
      decimals="INF"
      id="Narr_oRHS3JIWwUGosfH3ZOjrBA"
      unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ">26320199</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_IvXJ6RHxqkyGTfDbgXwHsw"
      decimals="INF"
      id="Narr_LRRFnxtvgkOiCUePHqN22w"
      unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ">4950129</us-gaap:CommonStockSharesOutstanding>
    <imrx:NumberOfVotesPerShare
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_XcWBVd3ItkaUL02nw_Pu2g"
      decimals="INF"
      id="Narr_iyZqWU5Sgk-Jcgf_xnhq9g"
      unitRef="Unit_Standard_Vote_y6IkSxDgD0SxcVMkCx6yHg">1</imrx:NumberOfVotesPerShare>
    <imrx:NumberOfVotesPerShare
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_Vps21bPl-0ucIcde4LcmUQ"
      decimals="INF"
      id="Narr_HWZ9DdpXnUKfhzYnF4oekQ"
      unitRef="Unit_Standard_Vote_y6IkSxDgD0SxcVMkCx6yHg">1</imrx:NumberOfVotesPerShare>
    <us-gaap:ScheduleOfStockByClassTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ"
      id="Tb_YWccSn3JBkO18Y9nBRkh7A">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:75.66%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Conversion of Series A Preferred&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,494,306&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Conversion of Series B Preferred&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,066,995&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Exercise of common stock warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 308,308&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Exercise of common stock options&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,859,544&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,801,263&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,859,544&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10,670,872&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfStockByClassTextBlock>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_imrx_SeriesConvertiblePreferredStockMember_LQiWJpT45k-D9eZ63E0DAw"
      decimals="INF"
      id="Tc_nL5zehwOwEiM-nkiIXZ9RQ_4_4"
      unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ">3494306</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_imrx_SeriesBConvertiblePreferredStockMember_-Ckh5K8N7U-_9nyMHjiJxQ"
      decimals="INF"
      id="Tc_qaxzwLUpU0O18byIBvJeGw_5_4"
      unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ">5066995</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_WarrantMember_7wU2uI3NZ0SsDzZ_Fr8ZyQ"
      decimals="INF"
      id="Tc_uf7TYpePmEqF5MV8rv652A_6_4"
      unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ">308308</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_EmployeeStockOptionMember_rlnPrQOdyEaM-QEeHvlTjQ"
      decimals="INF"
      id="Tc_g62oUPejC0ypxAlhJtf2CQ_7_2"
      unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ">2859544</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_EmployeeStockOptionMember_me35404Y-kWEl2teCnSUVg"
      decimals="INF"
      id="Tc_Cqm7XMA3XEeS9bQhZRE_lw_7_4"
      unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ">1801263</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="As_Of_12_31_2021_TBpjtOXgEkKQahJJAv0aWg"
      decimals="INF"
      id="Tc_H3CYPQoQvUaLedWdR-q-Yg_8_2"
      unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ">2859544</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="As_Of_12_31_2020_OUSLyqWONEO8ccGPC6rBdg"
      decimals="INF"
      id="Tc_o0NF76Rv6U2fHvdSrsD3eA_8_4"
      unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ">10670872</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_4sABCVevMkafGdslrmVHRg"
      decimals="INF"
      id="Narr_QFJaMceefkWum5nD5uD0Cg"
      unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ">20000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_4sABCVevMkafGdslrmVHRg"
      decimals="INF"
      id="Narr_TPmmgHI0LEurwU6NCrwBMw"
      unitRef="Unit_Divide_USD_shares_0VraXufKhkCSOUw2U_zvgQ">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_B1xkq5tyC0Czi0WWYygW9Q"
      decimals="INF"
      id="Narr_jehBzIxa70WsAdebHIwAzQ"
      unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ">6032183</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_B1xkq5tyC0Czi0WWYygW9Q"
      decimals="INF"
      id="Narr_Zd_afTw4UkSexQdLQH08Jw"
      unitRef="Unit_Divide_USD_shares_0VraXufKhkCSOUw2U_zvgQ">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_B1xkq5tyC0Czi0WWYygW9Q"
      decimals="INF"
      id="Narr_2kNa6knqbUSmAaZqMcRROA"
      unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ">0</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_4sABCVevMkafGdslrmVHRg"
      decimals="INF"
      id="Narr_dRf97eZHkUCXqXD8Nuz09g"
      unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ">0</us-gaap:CommonStockSharesIssued>
    <imrx:NumberOfVotesPerShare
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_J2SvXNqcwUW3WhIW-fbZTA"
      decimals="INF"
      id="Narr_SP0Gi_O5gUSbAJSK-7XUyA"
      unitRef="Unit_Standard_Vote_y6IkSxDgD0SxcVMkCx6yHg">0</imrx:NumberOfVotesPerShare>
    <imrx:NumberOfVotesPerShare
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_6Dv2gap2qUy2S6CUjLz70A"
      decimals="INF"
      id="Narr_-HscR83Hq0CPpA_TYh6CHw"
      unitRef="Unit_Standard_Vote_y6IkSxDgD0SxcVMkCx6yHg">0</imrx:NumberOfVotesPerShare>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_12_31_2019_g3mjqkDWB0-f2XKJf0YL-A"
      decimals="INF"
      id="Narr_ijiGBSYv3ES7L9bXzDBVDA"
      unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ">308308</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_12_31_2019_g3mjqkDWB0-f2XKJf0YL-A"
      decimals="2"
      id="Narr_QYk6JZNrkU2ssifOB-YmvQ"
      unitRef="Unit_Divide_USD_shares_0VraXufKhkCSOUw2U_zvgQ">3.01</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <imrx:WarrantsIssuedInLieuOfCashPayment
      contextRef="Duration_1_1_2019_To_12_31_2019_Q2tKCguYn0Sp3Siw9cnC0w"
      decimals="INF"
      id="Narr_dbYofG9uTU6idUjHD7SSqA"
      unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ">200984</imrx:WarrantsIssuedInLieuOfCashPayment>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="As_Of_12_31_2019_g3mjqkDWB0-f2XKJf0YL-A"
      id="Narr_hlP80C8Yfki336TbPU1k4g">P10Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <imrx:WarrantsExercised
      contextRef="Duration_1_1_2020_To_12_31_2020_J_O9OcmviUi8EDFgokrY1Q"
      decimals="INF"
      id="Narr_j4Obend910SlNftTkMb1xw"
      unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ">0</imrx:WarrantsExercised>
    <imrx:WarrantsExercised
      contextRef="Duration_6_1_2021_To_6_30_2021_xjkMHQi3F0anA1B9rBC7Fg"
      decimals="INF"
      id="Narr_lMufSJ14-0WUqXhT0v9zgQ"
      unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ">308308</imrx:WarrantsExercised>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="As_Of_12_31_2021_TBpjtOXgEkKQahJJAv0aWg"
      decimals="INF"
      id="Narr_H1_WcZCnUkybh7BnTmSrvQ"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">0</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_8_3_2021_To_8_3_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_nbYOiYQZAUed9mAOrNTolQ"
      decimals="INF"
      id="Narr_FCyK4kv4mEiSVtKoUC5ecw"
      unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ">8625000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_8_3_2021_To_8_3_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_G9SnpifyxEmaJU1UE794ew"
      decimals="INF"
      id="Narr_sRhC1mgED02G0CaHfcsPmQ"
      unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ">1125000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="Duration_8_3_2021_To_8_3_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_7enA8yNRQkat6QV_1FoEOw"
      decimals="0"
      id="Narr_D8WKO_QXr0aYF0i_a0BOaw"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">120318750</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <imrx:OfferingCostPayable
      contextRef="As_Of_8_3_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_kxYscz4Wf02VzWLhksRRxw"
      decimals="0"
      id="Narr_7c91BLQovkGDHN-ZMCVDcQ"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">2124317</imrx:OfferingCostPayable>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="As_Of_8_3_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_kxYscz4Wf02VzWLhksRRxw"
      decimals="INF"
      id="Narr_oVsQelsATke12Dg8ml-ecw"
      unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ">8528078</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="As_Of_8_3_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_boKn2a2ouUyMVqODG0-nIw"
      decimals="INF"
      id="Narr_02NKWp_V70qHuu9P_HFzqw"
      unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ">11939281</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_8_3_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_d6wIH2lUEkOg0doA4WJViw"
      decimals="INF"
      id="Narr_DC6kCzQ490OnU3vDTRPZmw"
      unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_8_3_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_ncRRUXx0q0atI42UV2_87w"
      decimals="INF"
      id="Narr_M0BGRtkXNECwAT0PUy7iPw"
      unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ">20000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_8_3_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_ncRRUXx0q0atI42UV2_87w"
      decimals="INF"
      id="Narr_lKwM3oW5-0O2P8DfRQx97g"
      unitRef="Unit_Divide_USD_shares_0VraXufKhkCSOUw2U_zvgQ">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="As_Of_8_3_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_kxYscz4Wf02VzWLhksRRxw"
      decimals="INF"
      id="Narr_yrWRN_6L506X-AZZ3N3gGA"
      unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ"
      id="Tb_tgil1DKdxEGxXeSl2uqTmQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Note&#160;10&#160;- Net Loss Per Share Attributable to Common Stockholders&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Basic and diluted net loss per share attributable to common stockholders was calculated at December&#160;31, 2021 and 2020 as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:70.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Numerator:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Net loss&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (33,535,748)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (17,039,898)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Denominator - basic and diluted:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Weighted-average common shares outstanding, basic and diluted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 13,612,677&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,950,129&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Net loss per share - basic and diluted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_wHopsXwjskSWOmAaEI9k1w;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2.46)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_--dUy7H6lkGzBYeWkeucsA;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (3.44)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The following table sets forth the potentially dilutive securities that have been excluded from the calculation of diluted net loss per share because to include them would be anti-dilutive (in common stock equivalent shares) at December&#160;31, 2021 and 2020:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:75.91%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Series A Preferred&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,494,306&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Series B Preferred&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,066,995&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Warrants to purchase common stock&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 308,308&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Options to purchase common stock&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,859,544&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,801,263&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total shares of common stock equivalents&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,859,544&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 10,670,872&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ"
      id="Tb_cXC2FtZ11U61Rj0LcJSlIA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:70.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Numerator:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Net loss&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (33,535,748)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (17,039,898)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Denominator - basic and diluted:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Weighted-average common shares outstanding, basic and diluted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 13,612,677&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,950,129&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Net loss per share - basic and diluted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_wHopsXwjskSWOmAaEI9k1w;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2.46)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_--dUy7H6lkGzBYeWkeucsA;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (3.44)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ"
      decimals="0"
      id="Tc_vEa2UYbCG0iHOC-7ZuPz2g_5_3"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">-33535748</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2020_To_12_31_2020_J_O9OcmviUi8EDFgokrY1Q"
      decimals="0"
      id="Tc_mwIJ8EatmEu0-sZfC3pioQ_5_6"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">-17039898</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ"
      decimals="0"
      id="Tc_vFfrFtDtqkGq8nhH9yHxJw_7_3"
      unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ">13612677</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2020_To_12_31_2020_J_O9OcmviUi8EDFgokrY1Q"
      decimals="0"
      id="Tc_Ntg6zMboekyI-2KJDbn65A_7_6"
      unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ">4950129</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ"
      decimals="2"
      id="Tc_rL_1XQWPPEm8kDIDIIogaw_8_3"
      unitRef="Unit_Divide_USD_shares_0VraXufKhkCSOUw2U_zvgQ">-2.46</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2020_To_12_31_2020_J_O9OcmviUi8EDFgokrY1Q"
      decimals="2"
      id="Tc_1ZbuUcK99E61Bapi-HovZQ_8_6"
      unitRef="Unit_Divide_USD_shares_0VraXufKhkCSOUw2U_zvgQ">-3.44</us-gaap:EarningsPerShareBasic>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ"
      id="Tb_50lBPwS8WUWDzj7WvoPQbg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:75.91%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Series A Preferred&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,494,306&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Series B Preferred&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,066,995&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Warrants to purchase common stock&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 308,308&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Options to purchase common stock&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,859,544&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,801,263&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total shares of common stock equivalents&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,859,544&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 10,670,872&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_imrx_SeriesConvertiblePreferredStockMember_zQGWKL5kWkOEqyx46cK5mg"
      decimals="INF"
      id="Tc_me0Vn8txck-NPeViV24Nag_3_4"
      unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ">3494306</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_imrx_SeriesBConvertiblePreferredStockMember_HJNQLItNRU-hYpDpxqiSoQ"
      decimals="INF"
      id="Tc_qdOZyppG10iX93e-nxAZeQ_4_4"
      unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ">5066995</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_7uvXNSojR0qxLk1Ubdsmfg"
      decimals="INF"
      id="Tc_VyV7aCn1Ok-tXo8UGmyqjA_5_4"
      unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ">308308</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_l3XprlCXTkaFiHyKLJ8O2Q"
      decimals="INF"
      id="Tc_gvaNjYE0f02dYX7aVLBBgw_6_2"
      unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ">2859544</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_VHW5LVIB6Ee8uLYurHx4cw"
      decimals="INF"
      id="Tc_HugvgD80ME-V49wCdmuAjA_6_4"
      unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ">1801263</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ"
      decimals="INF"
      id="Tc_GI2YGlxDgU2DmkVmOYXI2g_7_2"
      unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ">2859544</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2020_To_12_31_2020_J_O9OcmviUi8EDFgokrY1Q"
      decimals="INF"
      id="Tc_SE4WcYdV40yE_qMr-zKBWQ_7_4"
      unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ">10670872</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ"
      id="Tb_n9dAAcSV402eglza2cJpoA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Note&#160;11&#160;&#x2013; Stock-Based Compensation&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;During 2015, the Company established the Long Term Incentive Plan (&#x201c;Incentive Plan&#x201d;), under which incentive stock options, nonqualified stock options, restricted stock or other awards may be awarded to employees, directors or consultants of the Company. The options typically vest over a four-year period. As of December&#160;31, 2021, the maximum number of shares available for issuance under the Incentive Plan was 2,825,173 shares. Upon the effectiveness of the Company&#x2019;s 2021 Incentive Award Plan, the Company ceased granting awards under the Incentive Plan. However, the Incentive Plan continues to goven awards outstanding thereunder.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;On July 23, 2021, the Company&#x2019;s Board of Directors adopted, and on July 23, 2021 its stockholders approved, the 2021 Incentive Award Plan (the &#x201c;2021 Plan&#x201d;), which became effective on July 29, 2021. The 2021 Plan provides for the grant of incentive stock options, stock appreciation rights, restricted stock awards, restricted stock units, and other stock-based awards. The number of shares reserved for issuance under the 2021 Plan was initially equal to 2,590,000 plus an annual increase on the first day of each calendar year, beginning on January 1, 2022 and ending on and including January 1, 2031, equal to the lesser of (i) 4% of the aggregate number of shares of Class A common stock outstanding on the final day of the immediately preceding calendar year and (ii) such smaller number of shares of Class A common stock as determined by the Board of Directors. No more than 15,350,000 shares of Class A common stock may be issued under the 2021 Plan upon the exercise of incentive stock options. Shares issued under the 2021 Plan may be authorized but unissued shares, shares purchased on the open market or treasury shares. If an award under the 2021 Plan expires, lapses or is terminated, exchanged for or settled in cash, surrendered, repurchased, cancelled without having been fully exercised/settled or forfeited, any unused shares subject to the award will, as applicable, become or again be available for new grants under the 2021 Plan. In addition, shares subject to stock options issued under the Incentive Plan may become available for issuance under the 2021 Plan to the extent such stock options are canceled, forfeited, exchanged, settled in cash or &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;otherwise terminated. As of December 31, 2021, there were 2,298,432 shares available for future issuance under the 2021 Plan.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;On July 23, 2021, the Company&#x2019;s Board of Directors adopted, and on July 23, 2021 its stockholders approved, the 2021 Employee Stock Purchase Plan (the &#x201c;2021 ESPP&#x201d;), which became effective on July 29, 2021. A total of 250,000 shares of Class A common stock were initially reserved for issuance under this plan. The number of shares of Class A common stock that may be issued under the 2021 ESPP will automatically increase on the first day of each calendar year, beginning on January 1, 2022 and ending on and including January 1, 2031, equal to the lesser of (i) 1% of the shares of Class A common stock outstanding on the final day of the immediately preceding calendar year and (ii) such smaller number of shares of Class A common stock as determined by the board of directors, provided that not more than 3,340,000 shares of Class A common stock may be issued under the 2021 ESPP. As of December 31, 2021, no shares had been issued under the 2021 ESPP.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;During the year ended December 31, 2021 and 2020, the Company recognized stock-based compensation expense of $1,802,623 and $1,086,769, respectively. As of December&#160;31, 2021, compensation expense remaining to be recognized for outstanding stock options was $8,403,600 and to be recognized over a weighted-average period of 2.93 years.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The fair value of options granted is calculated on the grant date using the Black-Scholes option valuation model. &lt;span style="background:#ffffff;"&gt;The Company historically has been a private company and lacks company-specific historical and implied volatility information. Therefore, it estimates its expected stock volatility based on the historical volatility of a publicly traded set of peer public companies and expects to continue to do so until such time as it has adequate historical data regarding the volatility of its own traded stock price.&lt;/span&gt; For the year ended December 31, 2021, the Company granted 1,452,462 shares of stock options at a weighted-average grant date fair value of $6.29. For the year ended December 31, 2020, the Company granted 343,169 shares at a weighted-average grant date fair value of $3.06.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Company used the following assumptions in its application of the Black-Scholes option pricing model for grants during the year ended December 31, 2021 and 2020:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:67.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:30.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Weighted-average risk-free interest rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;0.89% - 1.71%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;0.36% - 1.45%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expected term (in years)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;5.83 - 10 years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;5.92 - 10 years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expected dividend yield&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;0%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;0%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expected volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;66.76% - 80.99%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;67.30% - 80.85%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The following table summarizes the stock option activity during the year ended December 31, 2021 under the Plan:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:51.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.81%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted-&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Remaining&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Contractual&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Aggregate&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;white-space:pre-wrap;"&gt;    &lt;/b&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Options&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;white-space:pre-wrap;"&gt;    &lt;/b&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;per Share&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Term (in Years)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;white-space:pre-wrap;"&gt;    &lt;/b&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; Intrinsic Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:51.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Outstanding at of December&#160;31,&#160;2020&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,801,263&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3.01&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,452,462&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10.07&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (117,847)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3.01&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Cancelled&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (276,334)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3.58&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Outstanding at December&#160;31,&#160;2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,859,544&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6.55&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8.30&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 27,615,466&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:51.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Vested and exercisable at December&#160;31,&#160;2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,102,543&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3.01&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7.14&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 14,507,723&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Vested and expected to vest at December&#160;31,&#160;2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,859,544&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6.55&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8.30&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 27,615,466&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;For the year &#160;ended December 31, 2021 and 2020, the Company recognized share-based compensation expense recognized on the accompanying &#160;consolidated statements of operations as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:72.09%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Cost of revenue&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 103,329&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 108,027&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 768,679&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 503,111&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;General and administrative&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 930,615&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 475,631&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,802,623&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,086,769&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_imrx_StockIncentivePlan2015Member_1tvXqAKRfEm4AKlfifgVpg"
      id="Narr_Q9CYCGn-_Ue1khNcofBnmg">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="As_Of_12_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_PlanNameAxis_imrx_StockIncentivePlan2015Member_hVx7NwJaA026vu03npu7HA"
      decimals="INF"
      id="Narr_XaAWN8sQ50ijajss6YtvOQ"
      unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ">2825173</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="As_Of_7_23_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_PlanNameAxis_imrx_TwoThousandTwentyOneIncentiveAwardPlanMember_MwQmN40XTUqTS51FC7b-vQ"
      decimals="INF"
      id="Narr_Iw4PPwzGiUeItdNX6sijUQ"
      unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ">2590000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <imrx:PercentageOfAggregateNumberOfSharesOutstanding
      contextRef="Duration_7_23_2021_To_7_23_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_PlanNameAxis_imrx_TwoThousandTwentyOneIncentiveAwardPlanMember_BLWmGGSlg0221-_bauHKMg"
      decimals="3"
      id="Narr_pPQvHrDDeke3kfvZAXIpEQ"
      unitRef="Unit_Standard_pure_iothMaWWqUCV2N7d1PVg4w">0.04</imrx:PercentageOfAggregateNumberOfSharesOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_7_23_2021_To_7_23_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_PlanNameAxis_imrx_TwoThousandTwentyOneIncentiveAwardPlanMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember__dnvok_t1k-ok2gZh6_g4Q"
      decimals="INF"
      id="Narr_RyozMgYFqkO7nfX27O01Fw"
      unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ">15350000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="As_Of_12_31_2021_us-gaap_PlanNameAxis_imrx_TwoThousandTwentyOneIncentiveAwardPlanMember_LI5PlJ73VUKxQRLedBtGOQ"
      decimals="INF"
      id="Narr_gi6I9W2kgEGFaSs5yX3cdg"
      unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ">2298432</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="As_Of_7_23_2021_us-gaap_PlanNameAxis_imrx_TwoThousandTwentyOneEmployeeStockPurchasePlanMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_oj9jqMIrFkaE72Eovxv2mw"
      decimals="INF"
      id="Narr_xVlLCK-kSECwvE2Zmn0z5A"
      unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ">250000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <imrx:PercentageOfAggregateNumberOfSharesOutstanding
      contextRef="Duration_7_23_2021_To_7_23_2021_us-gaap_PlanNameAxis_imrx_TwoThousandTwentyOneEmployeeStockPurchasePlanMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_wllzZzefAkGrL1ozzU9u1Q"
      decimals="3"
      id="Narr_890k-J3fbUqAObnkPENVoQ"
      unitRef="Unit_Standard_pure_iothMaWWqUCV2N7d1PVg4w">0.01</imrx:PercentageOfAggregateNumberOfSharesOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_7_23_2021_To_7_23_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_PlanNameAxis_imrx_TwoThousandTwentyOneEmployeeStockPurchasePlanMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_EGe_9LAr1062vI9kah96gg"
      decimals="INF"
      id="Narr_gje2sbhoz0WhazVObcTyhg"
      unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ">3340000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_imrx_TwoThousandTwentyOneEmployeeStockPurchasePlanMember_ZkFEiJ1N4E69ZN1lBj-gpw"
      decimals="INF"
      id="Narr_Y9dLDBAjDEWrfsdLbCSqfw"
      unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_imrx_StockIncentivePlan2015Member_1tvXqAKRfEm4AKlfifgVpg"
      decimals="0"
      id="Narr_8eRqszd9b0KVnekEC1jUPQ"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">1802623</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_PlanNameAxis_imrx_StockIncentivePlan2015Member_za8LgT3DyUmYmEzDhCQL2Q"
      decimals="0"
      id="Narr_eTsrw5x490m40NT62UlYqg"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">1086769</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="As_Of_12_31_2021_us-gaap_PlanNameAxis_imrx_StockIncentivePlan2015Member_yJ3Soj1ueEaHyYoF06Bg_g"
      decimals="0"
      id="Narr_MA9CbALDSUus9xiY2_Y4bw"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">8403600</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_imrx_StockIncentivePlan2015Member_1tvXqAKRfEm4AKlfifgVpg"
      id="Narr_rmSLgy60aUeefsqkLHeGVg">P2Y11M4D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ"
      decimals="INF"
      id="Narr_GS0mDX2tQUabU0pozQbQgA"
      unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ">1452462</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ"
      decimals="2"
      id="Narr_q0465y2YxES35wuIFkLSYQ"
      unitRef="Unit_Divide_USD_shares_0VraXufKhkCSOUw2U_zvgQ">6.29</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_1_1_2020_To_12_31_2020_J_O9OcmviUi8EDFgokrY1Q"
      decimals="INF"
      id="Narr_SZ8W6ws73kK5zeJ-V9pibg"
      unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ">343169</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2020_To_12_31_2020_J_O9OcmviUi8EDFgokrY1Q"
      decimals="2"
      id="Narr_t7w9T75aSEeYJU0XtWfRag"
      unitRef="Unit_Divide_USD_shares_0VraXufKhkCSOUw2U_zvgQ">3.06</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ"
      id="Tb_nMJn_AThAkyewJOXzDo39g">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:67.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:30.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Weighted-average risk-free interest rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;0.89% - 1.71%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;0.36% - 1.45%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expected term (in years)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;5.83 - 10 years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;5.92 - 10 years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expected dividend yield&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;0%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;0%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expected volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;66.76% - 80.99%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;67.30% - 80.85%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MinimumMember_kkvfHzsY3kuLg_xs_U9vtw"
      decimals="5"
      id="Narr_P1ZPKhg5fkunmC3AayUt5Q"
      unitRef="Unit_Standard_pure_iothMaWWqUCV2N7d1PVg4w">0.0089</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="Duration_1_1_2020_To_12_31_2020_J_O9OcmviUi8EDFgokrY1Q"
      decimals="4"
      id="Narr_dYHU94fr5EGUrhQb55SMtg"
      unitRef="Unit_Standard_pure_iothMaWWqUCV2N7d1PVg4w">0.0036</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="Duration_1_1_2020_To_12_31_2020_J_O9OcmviUi8EDFgokrY1Q"
      decimals="4"
      id="Narr_8d9-MvuTuEKpupIC-RaDTg"
      unitRef="Unit_Standard_pure_iothMaWWqUCV2N7d1PVg4w">0.0145</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MinimumMember_kkvfHzsY3kuLg_xs_U9vtw"
      id="Narr_5ZZn181rDUqrIk0FoyAX1A">P5Y9M29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_SGUutfcD1kqmyGRE2MRtsg"
      id="Narr_dxoRgZrMME6XtPIWYOIx9Q">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2020_To_12_31_2020_srt_RangeAxis_srt_MinimumMember_Ozt2OiOHCkmkib6hyeBSlQ"
      id="Narr_GyslcB2IXk-v3NwkpcABWQ">P5Y11M1D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2020_To_12_31_2020_srt_RangeAxis_srt_MaximumMember_a5iqF3xs7Uao9VNTsL_jaw"
      id="Narr_Oc4kN62S2UaDRot3x4ie_g">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ"
      decimals="2"
      id="Tc_yFcA1mAnQ06m19qWFi7D8A_6_2"
      unitRef="Unit_Standard_pure_iothMaWWqUCV2N7d1PVg4w">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="Duration_1_1_2020_To_12_31_2020_J_O9OcmviUi8EDFgokrY1Q"
      decimals="2"
      id="Tc_jo6HNgj1t0qG6k8tnRhfcQ_6_4"
      unitRef="Unit_Standard_pure_iothMaWWqUCV2N7d1PVg4w">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ"
      decimals="4"
      id="Narr_2_K_vHC98EOadIcMRZ1zLA"
      unitRef="Unit_Standard_pure_iothMaWWqUCV2N7d1PVg4w">0.6676</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ"
      decimals="4"
      id="Narr_VRx-fowJgUW7Xlw0jWrpoA"
      unitRef="Unit_Standard_pure_iothMaWWqUCV2N7d1PVg4w">0.8099</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="Duration_1_1_2020_To_12_31_2020_J_O9OcmviUi8EDFgokrY1Q"
      decimals="4"
      id="Narr_e8SFcwEfFUGNm-Jx6d23bA"
      unitRef="Unit_Standard_pure_iothMaWWqUCV2N7d1PVg4w">0.6730</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="Duration_1_1_2020_To_12_31_2020_J_O9OcmviUi8EDFgokrY1Q"
      decimals="4"
      id="Narr_LmnEKdIYG0idLKUd_qNWfg"
      unitRef="Unit_Standard_pure_iothMaWWqUCV2N7d1PVg4w">0.8085</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ"
      id="Tb_cTl0SAeqsUqYz_D20erJ_w">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:51.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.81%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted-&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Remaining&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Contractual&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Aggregate&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;white-space:pre-wrap;"&gt;    &lt;/b&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Options&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;white-space:pre-wrap;"&gt;    &lt;/b&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;per Share&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Term (in Years)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;white-space:pre-wrap;"&gt;    &lt;/b&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; Intrinsic Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:51.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Outstanding at of December&#160;31,&#160;2020&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,801,263&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3.01&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,452,462&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10.07&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (117,847)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3.01&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Cancelled&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (276,334)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3.58&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Outstanding at December&#160;31,&#160;2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,859,544&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6.55&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8.30&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 27,615,466&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:51.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Vested and exercisable at December&#160;31,&#160;2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,102,543&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3.01&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7.14&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 14,507,723&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Vested and expected to vest at December&#160;31,&#160;2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,859,544&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6.55&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8.30&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 27,615,466&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_12_31_2020_OUSLyqWONEO8ccGPC6rBdg"
      decimals="INF"
      id="Tc_i3j-TSyuh0mAqit6T9Ihmg_7_2"
      unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ">1801263</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2020_OUSLyqWONEO8ccGPC6rBdg"
      decimals="2"
      id="Tc_VLa9X3kLkECiQZDyAbGrvg_7_5"
      unitRef="Unit_Divide_USD_shares_0VraXufKhkCSOUw2U_zvgQ">3.01</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ"
      decimals="INF"
      id="Tc_r4JlOrdSZUKqpTs0K8BELQ_8_2"
      unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ">1452462</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ"
      decimals="2"
      id="Tc_9S1tNs6EcEeBgK2VD3rFIQ_8_5"
      unitRef="Unit_Divide_USD_shares_0VraXufKhkCSOUw2U_zvgQ">10.07</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ"
      decimals="INF"
      id="Tc_VnFw6thqHUyOTIL3aalF3g_9_2"
      unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ">117847</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ"
      decimals="2"
      id="Tc_oXOGCvsSkkSR68esl_Y2HQ_9_5"
      unitRef="Unit_Divide_USD_shares_0VraXufKhkCSOUw2U_zvgQ">3.01</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <imrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRepurchased
      contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ"
      decimals="INF"
      id="Tc_XBCibDxOAESIRKJwZKaUmQ_10_2"
      unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ">276334</imrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRepurchased>
    <imrx:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsRepurchasedInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ"
      decimals="2"
      id="Tc_p1Kqp6v9vECrY6UxCqiFyw_10_5"
      unitRef="Unit_Divide_USD_shares_0VraXufKhkCSOUw2U_zvgQ">3.58</imrx:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsRepurchasedInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_12_31_2021_TBpjtOXgEkKQahJJAv0aWg"
      decimals="INF"
      id="Tc_YUwHObjiH0mNj_y5lr31cg_11_2"
      unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ">2859544</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2021_TBpjtOXgEkKQahJJAv0aWg"
      decimals="2"
      id="Tc_Psx5UZlzmEekSnwEnPNPVw_11_5"
      unitRef="Unit_Divide_USD_shares_0VraXufKhkCSOUw2U_zvgQ">6.55</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ"
      id="Tc_RpXQ-XoZqku3WX6BIUyBFQ_11_7">P8Y3M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="As_Of_12_31_2021_TBpjtOXgEkKQahJJAv0aWg"
      decimals="0"
      id="Tc_KDUlUNy4K0q4E9eAP18bkA_11_10"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">27615466</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
      contextRef="As_Of_12_31_2021_TBpjtOXgEkKQahJJAv0aWg"
      decimals="INF"
      id="Tc_ErXq2IumwEWpKm467yujNA_13_2"
      unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ">1102543</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2021_TBpjtOXgEkKQahJJAv0aWg"
      decimals="2"
      id="Tc_S-qEIqFTekSEEL9ZHe1hiw_13_5"
      unitRef="Unit_Divide_USD_shares_0VraXufKhkCSOUw2U_zvgQ">3.01</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
      contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ"
      id="Tc_LBjM4i0dL0SLUNpHQWOH4w_13_7">P7Y1M20D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
      contextRef="As_Of_12_31_2021_TBpjtOXgEkKQahJJAv0aWg"
      decimals="0"
      id="Tc_Flp9buQKFE-jC6SSGYX0cw_13_10"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">14507723</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="As_Of_12_31_2021_TBpjtOXgEkKQahJJAv0aWg"
      decimals="INF"
      id="Tc_6519J5YGXEWBDXcY4SCPEQ_14_2"
      unitRef="Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ">2859544</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2021_TBpjtOXgEkKQahJJAv0aWg"
      decimals="2"
      id="Tc_cVAo0Zhhl0CRLJ_El7e2nQ_14_5"
      unitRef="Unit_Divide_USD_shares_0VraXufKhkCSOUw2U_zvgQ">6.55</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ"
      id="Tc_wgrkTONkYE6o_Y9dnpdCeg_14_7">P8Y3M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="As_Of_12_31_2021_TBpjtOXgEkKQahJJAv0aWg"
      decimals="0"
      id="Tc_kFozl7F120e9myOMgYurPA_14_10"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">27615466</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ"
      id="Tb_I5yio1JZ70Gm_7Fj4ubVQA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:72.09%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Cost of revenue&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 103,329&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 108,027&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 768,679&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 503,111&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;General and administrative&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 930,615&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 475,631&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,802,623&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,086,769&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_dQH6PYSm8ke4t8B5Xp8bAw"
      decimals="0"
      id="Tc_I60qW5QMNUGixi7R-zStUA_4_3"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">103329</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_hRS8KqtkvEKMap0WY0snUg"
      decimals="0"
      id="Tc_sX4L2archkqK9_lVF36j_g_4_6"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">108027</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_ZzhQndqazkWQw1a8tNpx5w"
      decimals="0"
      id="Tc_iaDaHPG270KFcSmYP5bRxQ_5_3"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">768679</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_PenqHZkD4kiUSIeznQQKKw"
      decimals="0"
      id="Tc_3F41n7M_zUKDoqDZM2fUhg_5_6"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">503111</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_q0lSZG3emUWjV7QOWezTNQ"
      decimals="0"
      id="Tc_Eh4BXVwBVU6MSk5mqL2ObQ_6_3"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">930615</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_hOzxdtEG0UaD56zlDOhRBw"
      decimals="0"
      id="Tc_fBJNsbAUe0-769E8RVEjUQ_6_6"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">475631</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ"
      decimals="0"
      id="Tc_uXkzbNeShUWb3W6D6k7fYA_7_3"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">1802623</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2020_To_12_31_2020_J_O9OcmviUi8EDFgokrY1Q"
      decimals="0"
      id="Tc_ErFhfWmVvEO0O4BpP5kQ8Q_7_6"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">1086769</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ"
      id="Tb_XPZTzxDBc0SNIlfVKquasQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Note&#160;12&#160;&#x2013; Income Taxes&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;A reconciliation of the effect of applying the federal statutory rate to the net loss and the effective income tax rate are as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:74.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Statutory federal income tax rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 21.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 21.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;State tax, net of federal benefit&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5.5&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6.3&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Permanent differences&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (0.6)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1.5)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Federal research and development credits&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5.6&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4.5&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;State research and development credits&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0.4&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0.6&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Uncertain tax positions&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (0.6)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1.0)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Other differences&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0.7&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (2.6)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Change in valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (31.1)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (27.3)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Effective income tax rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0.9&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:12pt 0pt 12pt 0pt;"&gt;As of December 31, 2021 and 2020, the components and tax effects of each type of item that gave rise to the net deferred tax assets were as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Deferred tax assets:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Stock-based compensation expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 373,602&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 73,984&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Unrealized losses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 12,990&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;R&amp;amp;D credit carryforward&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,346,097&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,574,596&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;NOL carryforward&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 14,699,524&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,525,123&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Gross deferred tax assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 18,432,213&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7,173,703&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (17,677,899)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (7,127,448)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Net deferred tax assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 754,314&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 46,255&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Net deferred tax liabilities:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Prepaid expenses deducted for tax&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (425,755)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (28,671)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Tax depreciation in excess of book&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (328,559)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (17,584)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total deferred tax liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (754,314)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (46,255)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Net deferred taxes&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Federal net operating losses (&#x201c;NOL&#x201d;) generated in tax years ended after December 31, 2017 are limited to 80% of taxable income, only carried forward and carried forward indefinitely under the Internal Revenue Code (&#x201c;IRC&#x201d;). The Company recorded a deferred tax liability of $304,485 on the acquisition of BioArkive. It had pre-existing deferred tax assets for which there was a fuill valuation allowance. As a result of the taxable temporary differences recognized in the business combination, the Company released $304,485&lt;span style="white-space:pre-wrap;"&gt; of its valuation allowance and recognized the income tax benefit in the income statement at the acquisition date in accordance with ASC 740  There was no income tax expense or benefit in 2020. The Company has provided a valuation allowance for the full amount of the net deferred tax assets as, based on all available evidence, it is considered more likely than not that all the recorded deferred tax assets will not be realized in a future period. At December 31, 2021, the Company has federal and state NOLs of &lt;/span&gt;$56,544,731 and $51,310,112, &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;respectively all generated after the tax year ended December 31, 2017. At December 31, 2021, the Company has federal and state research and development credit carryforwards, $3,034,827 and $394,013, respectively, that start to expire beginning in 2025.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'TimesNewRomanPSMT';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:9.95pt;background:#ffffff;margin:0pt 8.55pt 0pt 0pt;"&gt;As the Company has not yet achieved profitable operations, management believes the tax benefits as of December 31, 2021 did not satisfy the realization criteria set forth in ASC Topic 740, Income Taxes and, therefore, has recorded a full valuation allowance for the entire deferred tax asset. The valuation allowance increased in 2021 by $10,550,451 due to the increase in the deferred tax assets by the same amount, primarily due to NOL and research and development credit carryforwards. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:9.95pt;background:#ffffff;margin:0pt 8.55pt 0pt 0pt;"&gt;&lt;span style="margin-right:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:9.95pt;text-align:justify;background:#ffffff;margin:0pt 8.55pt 0pt 0pt;"&gt;Utilization of the U.S. net operating loss carryforwards and research and development tax credit carryforwards may be subject to a substantial annual limitation under Section 382 of the Internal Revenue Code of 1986, and corresponding provisions of state law, due to ownership changes that have occurred previously or that could occur in the future. These ownership changes may limit the amount of carryforwards that can be utilized annually to offset future taxable income. In general, an ownership change, as defined by Section 382, results from transactions increasing the ownership of certain stockholders or public groups in the stock of a corporation by more than 50% over a three-year period. The Company has not conducted a study to assess whether a change of control has occurred or whether there have been multiple changes of control since inception due to the significant complexity and cost associated with such a study. If the Company has experienced a change of control, as defined by Section 382, at any time since inception, utilization of the net operating loss carryforwards or research and development tax credit carryforwards would be subject to an annual limitation under Section 382, which is determined by first multiplying the value of the Company&#x2019;s stock at the time of the ownership change by the applicable long-term tax-exempt rate, and then could be subject to additional adjustments, as required. Any limitation may result in expiration of a portion of the net operating loss carryforwards or research and development tax credit carryforwards before utilization. Further, until a study is completed by the Company and any limitation is known, some amounts are being presented as an uncertain tax position.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:9.95pt;text-align:justify;background:#ffffff;margin:0pt 8.55pt 0pt 0pt;"&gt;&lt;span style="margin-right:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;As of December 31, 2021 and 2020, the Company had uncertain tax positions of $380,902 and $174,950 which have been classified as reductions of its tax carrforwards. The Company has elected to recognize interest and penalties related to income tax matters as a component of income tax expense, of which no interest or penalties were recorded for the years ended December 31, 2021 and 2020. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;As of December 31, 2021 and 2020, unrecognized tax benefits were as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:9.95pt;text-align:justify;background:#ffffff;margin:0pt 8.55pt 0pt 0pt;"&gt;&lt;span style="font-family:'TimesNewRomanPSMT';font-weight:bold;margin-right:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:70.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:70.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:70.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Beginning balance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 174,950&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 96,952&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:70.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Increase due to current year tax position&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 205,952&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 77,998&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:70.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Ending balance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.45%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 380,902&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.45%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 174,950&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:9.95pt;text-align:justify;background:#ffffff;margin:0pt 8.55pt 0pt 0pt;"&gt;&lt;span style="font-family:'TimesNewRomanPSMT';font-weight:bold;margin-right:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;The Company files tax returns in the United States including California, New York, Pennsylvania, Massachusetts and&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Texas. All tax years from 2017 to 2021 remain open to examination by the major taxing jurisdictions to which the Company is subject, as carryforward attributes generated in years past may still be adjusted upon examination by the Internal Revenue Service (&#x201c;IRS&#x201d;) or other authorities if they have or will be used in a future period. The Company is not currently under examination by the IRS or any other jurisdictions for any tax years.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'TimesNewRomanPSMT';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;On March 27, 2020, the Coronavirus Aid, Relief, and Economic Security Act (the &#x201c;CARES Act&#x201d;) was enacted in response to the COVID-19 pandemic. The CARES Act, among other things, permits NOL carryovers and carrybacks to offset 100% of taxable income for taxable years beginning before 2021. In addition, the CARES Act allows NOLs incurred in 2019, 2020, and 2021 to be carried back to each of the five preceding taxable years to generate a refund of previously paid income taxes. The enactment of the CARES Act resulted in increased federal and state research and development carryforwards from 2013 through 2018 of $93,437 and decreased federal NOL of $759,794 from 2018.&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ"
      id="Tb_05x_REImOUOSa96LHVT8vA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:74.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Statutory federal income tax rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 21.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 21.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;State tax, net of federal benefit&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5.5&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6.3&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Permanent differences&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (0.6)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1.5)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Federal research and development credits&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5.6&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4.5&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;State research and development credits&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0.4&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0.6&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Uncertain tax positions&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (0.6)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1.0)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Other differences&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0.7&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (2.6)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Change in valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (31.1)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (27.3)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Effective income tax rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0.9&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ"
      decimals="3"
      id="Tc_XPKrRFk5hES5IiGvCUXCeA_2_2"
      unitRef="Unit_Standard_pure_iothMaWWqUCV2N7d1PVg4w">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_1_1_2020_To_12_31_2020_J_O9OcmviUi8EDFgokrY1Q"
      decimals="3"
      id="Tc_3bWM-GiApUWowC8XrIIz-A_2_4"
      unitRef="Unit_Standard_pure_iothMaWWqUCV2N7d1PVg4w">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ"
      decimals="3"
      id="Tc_bGK97fNR7kGjjpZRxIYI2A_3_2"
      unitRef="Unit_Standard_pure_iothMaWWqUCV2N7d1PVg4w">0.055</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="Duration_1_1_2020_To_12_31_2020_J_O9OcmviUi8EDFgokrY1Q"
      decimals="3"
      id="Tc_bGVxqDX6TUOHzEVEW8kSiA_3_4"
      unitRef="Unit_Standard_pure_iothMaWWqUCV2N7d1PVg4w">0.063</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ"
      decimals="3"
      id="Tc_LdNaHxCA3UK3dr71KFXIfg_4_2"
      unitRef="Unit_Standard_pure_iothMaWWqUCV2N7d1PVg4w">-0.006</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense
      contextRef="Duration_1_1_2020_To_12_31_2020_J_O9OcmviUi8EDFgokrY1Q"
      decimals="3"
      id="Tc_xdPOgas6xUWneiMbqanJdw_4_4"
      unitRef="Unit_Standard_pure_iothMaWWqUCV2N7d1PVg4w">-0.015</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
      contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ"
      decimals="3"
      id="Tc_T1ighhEvQ020MYC_bgbpAA_5_2"
      unitRef="Unit_Standard_pure_iothMaWWqUCV2N7d1PVg4w">0.056</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
      contextRef="Duration_1_1_2020_To_12_31_2020_J_O9OcmviUi8EDFgokrY1Q"
      decimals="3"
      id="Tc_HJ_0U5mMgkuPPO-1nHHahA_5_4"
      unitRef="Unit_Standard_pure_iothMaWWqUCV2N7d1PVg4w">0.045</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <imrx:EffectiveIncomeTaxRateReconciliationTaxCreditStateResearchAndDevelopmentPercent
      contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ"
      decimals="3"
      id="Tc_0myw2Ly6pEiCiMy-wkqeNA_6_2"
      unitRef="Unit_Standard_pure_iothMaWWqUCV2N7d1PVg4w">0.004</imrx:EffectiveIncomeTaxRateReconciliationTaxCreditStateResearchAndDevelopmentPercent>
    <imrx:EffectiveIncomeTaxRateReconciliationTaxCreditStateResearchAndDevelopmentPercent
      contextRef="Duration_1_1_2020_To_12_31_2020_J_O9OcmviUi8EDFgokrY1Q"
      decimals="3"
      id="Tc_1GnhjE-gaE2MghOEvVDtAw_6_4"
      unitRef="Unit_Standard_pure_iothMaWWqUCV2N7d1PVg4w">0.006</imrx:EffectiveIncomeTaxRateReconciliationTaxCreditStateResearchAndDevelopmentPercent>
    <imrx:EffectiveIncomeTaxRateReconciliationUncertainTaxPositions
      contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ"
      decimals="3"
      id="Tc_JXEoZ4XBqEiGMse5WaYoWg_7_2"
      unitRef="Unit_Standard_pure_iothMaWWqUCV2N7d1PVg4w">-0.006</imrx:EffectiveIncomeTaxRateReconciliationUncertainTaxPositions>
    <imrx:EffectiveIncomeTaxRateReconciliationUncertainTaxPositions
      contextRef="Duration_1_1_2020_To_12_31_2020_J_O9OcmviUi8EDFgokrY1Q"
      decimals="3"
      id="Tc__pNVdtY6qkixjBFMey_ylA_7_4"
      unitRef="Unit_Standard_pure_iothMaWWqUCV2N7d1PVg4w">-0.010</imrx:EffectiveIncomeTaxRateReconciliationUncertainTaxPositions>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ"
      decimals="3"
      id="Tc_ScopayW6vkyWKXExlPFYag_8_2"
      unitRef="Unit_Standard_pure_iothMaWWqUCV2N7d1PVg4w">0.007</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="Duration_1_1_2020_To_12_31_2020_J_O9OcmviUi8EDFgokrY1Q"
      decimals="3"
      id="Tc_tCtf-lDS8UKQUaI6ZpP6wg_8_4"
      unitRef="Unit_Standard_pure_iothMaWWqUCV2N7d1PVg4w">-0.026</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ"
      decimals="3"
      id="Tc_s40FLSmVrUKL-ipJmMyhxA_9_2"
      unitRef="Unit_Standard_pure_iothMaWWqUCV2N7d1PVg4w">-0.311</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="Duration_1_1_2020_To_12_31_2020_J_O9OcmviUi8EDFgokrY1Q"
      decimals="3"
      id="Tc_5RoxT3CvrESLCDOE8FTRJQ_9_4"
      unitRef="Unit_Standard_pure_iothMaWWqUCV2N7d1PVg4w">-0.273</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ"
      decimals="3"
      id="Tc_amiC1-2NPkyNZxTqYDQCbg_10_2"
      unitRef="Unit_Standard_pure_iothMaWWqUCV2N7d1PVg4w">0.009</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="Duration_1_1_2020_To_12_31_2020_J_O9OcmviUi8EDFgokrY1Q"
      decimals="3"
      id="Tc_s9XIFNjpKUSsEo8cUje4pQ_10_4"
      unitRef="Unit_Standard_pure_iothMaWWqUCV2N7d1PVg4w">0.000</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ"
      id="Tb_l6T3AxJQbkC6oIzQP1zsAQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Deferred tax assets:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Stock-based compensation expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 373,602&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 73,984&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Unrealized losses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 12,990&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;R&amp;amp;D credit carryforward&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,346,097&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,574,596&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;NOL carryforward&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 14,699,524&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,525,123&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Gross deferred tax assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 18,432,213&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7,173,703&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (17,677,899)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (7,127,448)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Net deferred tax assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 754,314&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 46,255&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Net deferred tax liabilities:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Prepaid expenses deducted for tax&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (425,755)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (28,671)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Tax depreciation in excess of book&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (328,559)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (17,584)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total deferred tax liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (754,314)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (46,255)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Net deferred taxes&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="As_Of_12_31_2021_TBpjtOXgEkKQahJJAv0aWg"
      decimals="0"
      id="Tc_prP2mnaq10W2xdruo2FoHg_3_3"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">373602</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="As_Of_12_31_2020_OUSLyqWONEO8ccGPC6rBdg"
      decimals="0"
      id="Tc_35OnE3OSlkGIscp0zyQ5ng_3_6"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">73984</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsUnrealizedCurrencyLosses
      contextRef="As_Of_12_31_2021_TBpjtOXgEkKQahJJAv0aWg"
      decimals="0"
      id="Tc_Ak_2j8tpsEeHPzJeY9jpKg_4_3"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">12990</us-gaap:DeferredTaxAssetsUnrealizedCurrencyLosses>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="As_Of_12_31_2021_TBpjtOXgEkKQahJJAv0aWg"
      decimals="0"
      id="Tc_ZAs2VDkQXUaqvLCbc0XbsQ_5_3"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">3346097</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="As_Of_12_31_2020_OUSLyqWONEO8ccGPC6rBdg"
      decimals="0"
      id="Tc_ipi0bVLvFkqZ2wDBGbqUTg_5_6"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">1574596</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="As_Of_12_31_2021_TBpjtOXgEkKQahJJAv0aWg"
      decimals="0"
      id="Tc_gBk241our0aTniJaRWubjg_6_3"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">14699524</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="As_Of_12_31_2020_OUSLyqWONEO8ccGPC6rBdg"
      decimals="0"
      id="Tc_wafbK02RY0KhH2Dpok_xFw_6_6"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">5525123</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="As_Of_12_31_2021_TBpjtOXgEkKQahJJAv0aWg"
      decimals="0"
      id="Tc_RboWd1vaiU6D6nVqiZzDzg_7_3"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">18432213</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="As_Of_12_31_2020_OUSLyqWONEO8ccGPC6rBdg"
      decimals="0"
      id="Tc_I_BfRhqx8kmeyntyLMZ9AQ_7_6"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">7173703</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="As_Of_12_31_2021_TBpjtOXgEkKQahJJAv0aWg"
      decimals="0"
      id="Tc_mGSZrVKrhUW1vbDUAbxOxQ_8_3"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">17677899</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="As_Of_12_31_2020_OUSLyqWONEO8ccGPC6rBdg"
      decimals="0"
      id="Tc_yILfZhJ9GUyNHWPhviWNBQ_8_6"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">7127448</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="As_Of_12_31_2021_TBpjtOXgEkKQahJJAv0aWg"
      decimals="0"
      id="Tc_mJEgYLyFMEmlQqp_8THRIw_9_3"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">754314</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="As_Of_12_31_2020_OUSLyqWONEO8ccGPC6rBdg"
      decimals="0"
      id="Tc_8e3xrq_qiE-j0hNiKh4o0w_9_6"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">46255</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxLiabilitiesPrepaidExpenses
      contextRef="As_Of_12_31_2021_TBpjtOXgEkKQahJJAv0aWg"
      decimals="0"
      id="Tc_D1rYRTiigUebk0v5q8N6Aw_11_3"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">425755</us-gaap:DeferredTaxLiabilitiesPrepaidExpenses>
    <us-gaap:DeferredTaxLiabilitiesPrepaidExpenses
      contextRef="As_Of_12_31_2020_OUSLyqWONEO8ccGPC6rBdg"
      decimals="0"
      id="Tc_ueE3DR8A-U6y9wNC8D_XhQ_11_6"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">28671</us-gaap:DeferredTaxLiabilitiesPrepaidExpenses>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="As_Of_12_31_2021_TBpjtOXgEkKQahJJAv0aWg"
      decimals="0"
      id="Tc_Nu5Ft6NmUEyi2UHCSKQeCQ_12_3"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">328559</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="As_Of_12_31_2020_OUSLyqWONEO8ccGPC6rBdg"
      decimals="0"
      id="Tc_wqQa9c6Ga0Cu7V7VvgfjBw_12_6"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">17584</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="As_Of_12_31_2021_TBpjtOXgEkKQahJJAv0aWg"
      decimals="0"
      id="Tc_DBKPqMFIgUCaQ0Ugj2rZ0w_13_3"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">754314</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="As_Of_12_31_2020_OUSLyqWONEO8ccGPC6rBdg"
      decimals="0"
      id="Tc_82xmEeloOUyY0iJIZsQt4A_13_6"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">46255</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredTaxesBusinessCombinationValuationAllowanceAvailableToReduceIncomeTaxExpense
      contextRef="Duration_1_1_2017_To_12_31_2017_us-gaap_BusinessAcquisitionAxis_imrx_BioArkiveIncMember_eCOuV4siy0CntVgmBRHjJw"
      decimals="0"
      id="Narr_Lyi38PyplUSQlo2kJefKVw"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">304485</us-gaap:DeferredTaxesBusinessCombinationValuationAllowanceAvailableToReduceIncomeTaxExpense>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="Duration_1_1_2017_To_12_31_2017_us-gaap_BusinessAcquisitionAxis_imrx_BioArkiveIncMember_eCOuV4siy0CntVgmBRHjJw"
      decimals="0"
      id="Narr_Q8wznx410UiFsBWO3Gi8nA"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">304485</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:OperatingLossCarryforwards
      contextRef="As_Of_12_31_2021_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_6VOCtAPe5UC8u2hi-12dxg"
      decimals="0"
      id="Narr_TfwTAp4Te0iciw6O6Z3DfQ"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">56544731</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="As_Of_12_31_2021_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_E6Pqm-5XGEGHnxL47x05BA"
      decimals="0"
      id="Narr_x6OPyy7M10S6-J24jjVR0w"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">51310112</us-gaap:OperatingLossCarryforwards>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="As_Of_12_31_2021_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember_CoisecZ1RkWQ4NibnKtk2g"
      decimals="0"
      id="Narr_wnijpU7vI0OxFoWYYbE92g"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">3034827</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="As_Of_12_31_2021_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember_8yiTbINkMkqUQTRVdOLgQw"
      decimals="0"
      id="Narr_hVeATFJYmUaKzSsffDRBKw"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">394013</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ"
      decimals="0"
      id="Narr_LFGB7dA8ckKVGVXDxGOn-g"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">10550451</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="As_Of_12_31_2021_TBpjtOXgEkKQahJJAv0aWg"
      decimals="0"
      id="Narr_jVdzBlFGuEuPnV5xzCKg3g"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">380902</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="As_Of_12_31_2020_OUSLyqWONEO8ccGPC6rBdg"
      decimals="0"
      id="Narr_ZzJAw4T5YkKhl8Aze-1TiQ"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">174950</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="As_Of_12_31_2020_OUSLyqWONEO8ccGPC6rBdg"
      decimals="0"
      id="Narr_Vp3FFp_Fy0aQCz3bF0uKpg"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="As_Of_12_31_2021_TBpjtOXgEkKQahJJAv0aWg"
      decimals="0"
      id="Narr_0Ffc-4ueHkO5n2H0Pmu4oQ"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ"
      id="Tb_bTvsnDyQTUexYY_7J1-7Tg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:9.95pt;text-align:justify;background:#ffffff;margin:0pt 8.55pt 0pt 0pt;"&gt;&lt;span style="font-family:'TimesNewRomanPSMT';font-weight:bold;margin-right:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:70.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:70.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:70.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Beginning balance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 174,950&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 96,952&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:70.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Increase due to current year tax position&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 205,952&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 77,998&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:70.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Ending balance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.45%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 380,902&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.45%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 174,950&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="As_Of_12_31_2020_OUSLyqWONEO8ccGPC6rBdg"
      decimals="0"
      id="Tc_sxbMn3JNsUSe04o5kcaKMQ_2_3"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">174950</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="As_Of_12_31_2019_g3mjqkDWB0-f2XKJf0YL-A"
      decimals="0"
      id="Tc_W8SNqhY8eEea1DO98-6-Rg_2_6"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">96952</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ"
      decimals="0"
      id="Tc_QFvAdBCBk0qpNxG3rx8IHw_3_3"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">205952</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="Duration_1_1_2020_To_12_31_2020_J_O9OcmviUi8EDFgokrY1Q"
      decimals="0"
      id="Tc_knVwJpXYv0O8QetYyC7cEQ_3_6"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">77998</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="As_Of_12_31_2021_TBpjtOXgEkKQahJJAv0aWg"
      decimals="0"
      id="Tc_iQajE8Gk-UiVcnLxoC4SrQ_4_3"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">380902</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="As_Of_12_31_2020_OUSLyqWONEO8ccGPC6rBdg"
      decimals="0"
      id="Tc_gQJA0Ar-jUCkvurkOs3qzQ_4_6"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">174950</us-gaap:UnrecognizedTaxBenefits>
    <imrx:TaxCreditCarryforwardIncreaseDecreaseCaresAct
      contextRef="Duration_3_27_2020_To_3_27_2020_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember_5FkHeRTRFUWenXHcqclDDQ"
      decimals="0"
      id="Narr_e9P9jtR-g0GFTiUkP_zuZQ"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">93437</imrx:TaxCreditCarryforwardIncreaseDecreaseCaresAct>
    <imrx:TaxCreditCarryforwardIncreaseDecreaseCaresAct
      contextRef="Duration_3_27_2020_To_3_27_2020_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember_SFNqtQEhiUilg2XoqHi-NA"
      decimals="0"
      id="Narr_Qn4ANYhwDkK6BMdtn2r0PQ"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">759794</imrx:TaxCreditCarryforwardIncreaseDecreaseCaresAct>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ"
      id="Tb_88m9YkHyT0Oz-YgkGlARXg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Note&#160;13&#160;&#x2013; Commitments and Contingencies&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="text-decoration-line:underline;text-decoration-style:solid;"&gt;Operating Leases&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Company leases office space in Cambridge, Massachusetts, New York, New York and as of July&#160;2021, San Francisco, California, pursuant to short-term arrangements. The Cambridge and San Francisco leases are on a&#160;month-to-month basis, requiring one&#160;month&#x2019;s notice before termination. The New York lease is renewable on a quarterly basis and the last renewal extended the lease term until March&#160;31, 2022. These lease agreements include payments for lease and non-lease components and the Company has elected to not separate such components and these payments were recognized as rent expense.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;As of December 31, 2021, total future minimum lease payments for its short-term leases in Cambridge, Massachusetts, New York, New York and San Francisco, California was $30,840 due in 2022. The Company leases storage space for its electronic data equipment in Somerville, Massachusetts. This lease is renewable on an annual basis effective every March&#160;1st. Prior to December 31, 2021, the Company renewed the lease through March&#160;31, 2022. As of December 31, 2021, total future minimum lease payments for this lease were $3,569 due in 2022.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;In October&#160;2020, the Company entered into an office lease in San Diego, California with a lease term of 67 months. At the lease commencement date, a right-to-use asset and &lt;span style="-sec-ix-hidden:Hidden_XdPatEybTkShRMLsu6QibA;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;lease liability&lt;/span&gt;&lt;/span&gt; was recognized by the Company for $637,863.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;As part of the BioArkive acquisition, the Company assumed the obligations of three leases in San Diego, California, one is for 38,613 square feet of office and laboratory space, under a lease that terminates on April 30, 2032, a second is a 6,100 square feet of office and laboratory space under a lease that terminates on December 31, 2022, and third is a lease for 4,760 square feet of office and laboratory space under a lease that terminates on March 31, 2024. &#160;As a result, we recorded right-to-use assets and &lt;span style="-sec-ix-hidden:Hidden_CeuFDcEWwUiE1feAvMT7Lw;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;lease liabilities&lt;/span&gt;&lt;/span&gt; of $4,824,700 on the acquisition date of December 22, 2021.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-size:9.5pt;"&gt;Future minimum lease payments for operating leases with initial or remaining terms in excess of one year at December&#160;31, 2021 were as follows&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Amount&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 659,990&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 880,121&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 894,044&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 906,839&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2026&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 819,210&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Thereafter&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,467,246&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total future lease payments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8,627,450&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Less: Imputed interest&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,262,514&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total lease liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,364,936&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Current portion lease liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 274,039&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Lease liabilities, noncurrent&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,090,897&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total lease liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,364,936&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Quantitative information regarding the Company&#x2019;s leases for the year ended December 31, 2021 and 2020 is as follows: &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Lease costs:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Operating lease cost&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 160,872&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 66,652&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Short-term lease cost&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 258,357&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 252,796&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Variable lease cost&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 14,700&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total lease costs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 419,229&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 334,148&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Operating cash flows from operating leases&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 111,527&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 58,666&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Operating cash flows from short-term leases&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 236,700&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 252,796&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 348,227&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 311,462&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Weighted-average remaining lease term - operating leases&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;9.62 years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;5.33 years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Weighted-average discount rate - operating leases&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;9.7%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;6.0%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;As the Company&#x2019;s leases typically do not provide an implicit rate, the Company uses an estimate of its incremental borrowing rate based on the information available at the lease commencement date in determining the present value of lease payments.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="text-decoration-line:underline;text-decoration-style:solid;"&gt;Litigation&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;From time to time, the Company may have certain contingent liabilities that arise in the ordinary course of its business activities and may be exposed to litigation in connection with its products and operations. The Company&#x2019;s policy is to assess the likelihood of any adverse judgments or outcomes related to legal matters, as well as ranges of probable losses. When it is probable that future expenditures will be made and can be reasonably estimated the Company will accrue a liability for such matters. Significant judgement is required to determine both probability and estimated amount. The Company is not aware of any material legal matters.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="text-decoration-line:underline;text-decoration-style:solid;"&gt;Clinical Research Contracts&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Company may enter into contracts in the normal course of business with clinical research organizations for clinical trials, with contract manufacturing organizations for clinical supplies, and with other vendors for preclinical studies, supplies and other services for our operating purposes. These contracts generally provide for termination with a 30-day notice.&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_imrx_OfficeSpaceInCambridgeMassachusettsNewYorkMember_Qma-pjDe6kSAepAJusrqDA"
      decimals="0"
      id="Narr_p23O0BE1iUOtkLbOSgSrSA"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">30840</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_imrx_OfficeSpaceInCambridgeMassachusettsNewYorkMember_Qma-pjDe6kSAepAJusrqDA"
      decimals="0"
      id="Narr_fTG9kG4Rm0eH3eEBHeE35g"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">30840</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_imrx_StorageSpaceInSomervilleMassachusettsMember_kCYYiCYXakieYFKlIrPRQg"
      decimals="0"
      id="Narr_gT-jQnpLHEykAdsQUZ9BXg"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">3569</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="As_Of_10_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_imrx_OfficeLeaseInSanDiegoCalifornia2020Member_fOyKDK4i2USSpVi4_ouoxw"
      id="Narr_wEghFj16m0OZfD_WzM-h0g">P67M</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_10_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_imrx_OfficeLeaseInSanDiegoCalifornia2020Member_fOyKDK4i2USSpVi4_ouoxw"
      decimals="0"
      id="Narr_NwlLnXduskSbIur3W9E1_Q"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">637863</us-gaap:OperatingLeaseRightOfUseAsset>
    <imrx:NumberOfLeasesObligationsAssumed
      contextRef="As_Of_12_31_2021_us-gaap_BusinessAcquisitionAxis_imrx_BioArkiveIncMember__OkMddmPKES0gb3KLXJAbw"
      decimals="0"
      id="Narr_i1F4xqNJ60Op1V_EeVScEw"
      unitRef="Unit_Standard_pure_iothMaWWqUCV2N7d1PVg4w">3</imrx:NumberOfLeasesObligationsAssumed>
    <imrx:AreaOfPropertyUnderLease
      contextRef="As_Of_12_31_2021_us-gaap_BusinessAcquisitionAxis_imrx_BioArkiveIncMember_us-gaap_LeaseContractualTermAxis_imrx_LeaseTerminationOnApril302032Member_dW7b99b4G0eqpEl5CucuWA"
      decimals="INF"
      id="Narr_RS2xxMtiTEWudvbzx6NtGQ"
      unitRef="Unit_Standard_sqft_pKK1i40-n0WN8q6DXkNohQ">38613</imrx:AreaOfPropertyUnderLease>
    <imrx:AreaOfPropertyUnderLease
      contextRef="As_Of_12_31_2021_us-gaap_BusinessAcquisitionAxis_imrx_BioArkiveIncMember_us-gaap_LeaseContractualTermAxis_imrx_LeaseTerminationOnDecember312022Member_dRAvJgmyQ02SlSKbOR13YQ"
      decimals="INF"
      id="Narr_2FYnqWIo_06vZ0Rv3-llLw"
      unitRef="Unit_Standard_sqft_pKK1i40-n0WN8q6DXkNohQ">6100</imrx:AreaOfPropertyUnderLease>
    <imrx:AreaOfPropertyUnderLease
      contextRef="As_Of_12_31_2021_us-gaap_BusinessAcquisitionAxis_imrx_BioArkiveIncMember_us-gaap_LeaseContractualTermAxis_imrx_LeaseTerminationOnMarch312024Member_Foc4ig67vEu40iyOKMsf_Q"
      decimals="INF"
      id="Narr_RSjgM-kJKkWDFMKTUpINIg"
      unitRef="Unit_Standard_sqft_pKK1i40-n0WN8q6DXkNohQ">4760</imrx:AreaOfPropertyUnderLease>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_12_31_2021_us-gaap_BusinessAcquisitionAxis_imrx_BioArkiveIncMember__OkMddmPKES0gb3KLXJAbw"
      decimals="0"
      id="Narr_JmDtiUueDEOL6UAQ0YOI8w"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">4824700</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ"
      id="Tb_pgE3yVXIqkOJKKpiB54Hyg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Amount&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 659,990&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 880,121&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 894,044&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 906,839&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2026&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 819,210&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Thereafter&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,467,246&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total future lease payments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8,627,450&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Less: Imputed interest&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,262,514&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total lease liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,364,936&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Current portion lease liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 274,039&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Lease liabilities, noncurrent&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,090,897&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total lease liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,364,936&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_imrx_OfficeLeaseInSanDiegoCalifornia2020Member_1elFJvUqZUChk73Bzb2TRg"
      decimals="0"
      id="Tc_f2XpdHmqjUWq7RwCbGPIhg_2_3"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">659990</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_imrx_OfficeLeaseInSanDiegoCalifornia2020Member_1elFJvUqZUChk73Bzb2TRg"
      decimals="0"
      id="Tc_E0kYZB2kaUGiKXE9YhdVMg_3_3"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">880121</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_imrx_OfficeLeaseInSanDiegoCalifornia2020Member_1elFJvUqZUChk73Bzb2TRg"
      decimals="0"
      id="Tc_9tlr6R7r4EqhC_WKfnpfUQ_4_3"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">894044</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_imrx_OfficeLeaseInSanDiegoCalifornia2020Member_1elFJvUqZUChk73Bzb2TRg"
      decimals="0"
      id="Tc_8mZhuc_ykEuajdcQDsSppw_5_3"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">906839</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_imrx_OfficeLeaseInSanDiegoCalifornia2020Member_1elFJvUqZUChk73Bzb2TRg"
      decimals="0"
      id="Tc_M0eyLCb8Y0mv0W0FUTNqXg_6_3"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">819210</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_imrx_OfficeLeaseInSanDiegoCalifornia2020Member_1elFJvUqZUChk73Bzb2TRg"
      decimals="0"
      id="Tc_1v-qnUAJKEaNArqcFy9Z-w_7_3"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">4467246</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_imrx_OfficeLeaseInSanDiegoCalifornia2020Member_1elFJvUqZUChk73Bzb2TRg"
      decimals="0"
      id="Tc_G_7RNOv04UulSWY_dDlZgQ_8_3"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">8627450</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_imrx_OfficeLeaseInSanDiegoCalifornia2020Member_1elFJvUqZUChk73Bzb2TRg"
      decimals="0"
      id="Tc_DFlbirDb9UGSCHh_Rtn-dg_9_3"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">3262514</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_imrx_OfficeLeaseInSanDiegoCalifornia2020Member_1elFJvUqZUChk73Bzb2TRg"
      decimals="0"
      id="Tc_AfW5VAGILEazatPe3s5lsQ_10_3"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">5364936</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_imrx_OfficeLeaseInSanDiegoCalifornia2020Member_1elFJvUqZUChk73Bzb2TRg"
      decimals="0"
      id="Tc_ADQaU76vpUKFaxzBoq9Z2w_11_3"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">274039</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_imrx_OfficeLeaseInSanDiegoCalifornia2020Member_1elFJvUqZUChk73Bzb2TRg"
      decimals="0"
      id="Tc_UIe-4C6nzEK2bE5w-ZI33g_12_3"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">5090897</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiability
      contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_imrx_OfficeLeaseInSanDiegoCalifornia2020Member_1elFJvUqZUChk73Bzb2TRg"
      decimals="0"
      id="Tc_iYuVdqY0WUyJWA-tHFpbtQ_13_3"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">5364936</us-gaap:OperatingLeaseLiability>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ"
      id="Tb_LC4J9-4Btk-X80nIiraQxQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Lease costs:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Operating lease cost&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 160,872&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 66,652&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Short-term lease cost&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 258,357&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 252,796&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Variable lease cost&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 14,700&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total lease costs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 419,229&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 334,148&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Operating cash flows from operating leases&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 111,527&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 58,666&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Operating cash flows from short-term leases&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 236,700&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 252,796&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 348,227&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 311,462&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Weighted-average remaining lease term - operating leases&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;9.62 years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;5.33 years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Weighted-average discount rate - operating leases&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;9.7%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;6.0%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ"
      decimals="0"
      id="Tc_JIdEyicJhEi8-Kl49FCUjA_4_3"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">160872</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="Duration_1_1_2020_To_12_31_2020_J_O9OcmviUi8EDFgokrY1Q"
      decimals="0"
      id="Tc_t3EGMJq1U02CK2GU-a6J5g_4_6"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">66652</us-gaap:OperatingLeaseCost>
    <us-gaap:ShortTermLeaseCost
      contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ"
      decimals="0"
      id="Tc_NBzIQcSDf0WDky9mjEgZeg_5_3"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">258357</us-gaap:ShortTermLeaseCost>
    <us-gaap:ShortTermLeaseCost
      contextRef="Duration_1_1_2020_To_12_31_2020_J_O9OcmviUi8EDFgokrY1Q"
      decimals="0"
      id="Tc_-dWbDS1hW0Omq628nQlIGw_5_6"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">252796</us-gaap:ShortTermLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="Duration_1_1_2020_To_12_31_2020_J_O9OcmviUi8EDFgokrY1Q"
      decimals="0"
      id="Tc_FqebeqLbk0S3wJeBaiYmTg_6_6"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">14700</us-gaap:VariableLeaseCost>
    <us-gaap:LeaseCost
      contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ"
      decimals="0"
      id="Tc_GpitQWsm9EuRoKtENIR4sA_7_3"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">419229</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="Duration_1_1_2020_To_12_31_2020_J_O9OcmviUi8EDFgokrY1Q"
      decimals="0"
      id="Tc_Z2joknlwOUOx_BzrvD2VoA_7_6"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">334148</us-gaap:LeaseCost>
    <us-gaap:OperatingLeasePayments
      contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ"
      decimals="0"
      id="Tc_MgzXwkBvd02EDHOIJNqfrw_9_3"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">111527</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="Duration_1_1_2020_To_12_31_2020_J_O9OcmviUi8EDFgokrY1Q"
      decimals="0"
      id="Tc_FLafa5X5eUyTLwd4138oGQ_9_6"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">58666</us-gaap:OperatingLeasePayments>
    <us-gaap:ShortTermLeasePayments
      contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ"
      decimals="0"
      id="Tc_88pTjSGRokKjLb32_DNftA_10_3"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">236700</us-gaap:ShortTermLeasePayments>
    <us-gaap:ShortTermLeasePayments
      contextRef="Duration_1_1_2020_To_12_31_2020_J_O9OcmviUi8EDFgokrY1Q"
      decimals="0"
      id="Tc_AvyNaCToDUagX151bPuBfg_10_6"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">252796</us-gaap:ShortTermLeasePayments>
    <imrx:LeasePayments
      contextRef="Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ"
      decimals="0"
      id="Tc_3zSyEbtO1EK3Gtt04L8Fbw_11_3"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">348227</imrx:LeasePayments>
    <imrx:LeasePayments
      contextRef="Duration_1_1_2020_To_12_31_2020_J_O9OcmviUi8EDFgokrY1Q"
      decimals="0"
      id="Tc_c_6CyXgcSEqSSRBmIDarZg_11_6"
      unitRef="Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow">311462</imrx:LeasePayments>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="As_Of_12_31_2021_TBpjtOXgEkKQahJJAv0aWg"
      id="Narr_jvYRNY5DHkqsWIoNbDSfFA">P9Y7M13D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="As_Of_12_31_2020_OUSLyqWONEO8ccGPC6rBdg"
      id="Narr_7dioStN-tE-042StHmRLPw">P5Y3M29D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="As_Of_12_31_2021_TBpjtOXgEkKQahJJAv0aWg"
      decimals="3"
      id="Tc_wACpKkMlikaSR2htRi9lfw_13_3"
      unitRef="Unit_Standard_pure_iothMaWWqUCV2N7d1PVg4w">0.097</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="As_Of_12_31_2020_OUSLyqWONEO8ccGPC6rBdg"
      decimals="3"
      id="Tc_fi_hNk1qNUiM1ZlYfwoWpg_13_6"
      unitRef="Unit_Standard_pure_iothMaWWqUCV2N7d1PVg4w">0.060</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>107
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MJ&YZ-;@XG:LM+F"4DV3W #H,0\+($+$1JPC$+PF?6Z88/GO=\*W#!^I(DUV
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MNF8L ]^C,$Y/>^LLV[P;#%)_S2(O?<LW+!9O5CR)O$S<)G>#=),P;UD(1>$
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M2*4V-K5-@F1BJ >V^%AQ(-1^8M/5QS?E%&A]50]LL.T0W-1L*H:$VAG2<T[
MD,IR(#4005B.Z=/ NMD5ST'M/*?M% RI)*2/L84MVU06:!=HW<2*LJ!VRG+=
M_8#_/5*Y1-]T#$,^4T0J-Y%P]7/HBG/@=L[1OC>$VF-H0]V=$2ROJXD.!JV\
M95.)/;[70'51N-#A+-%?,:;R!&N@T+(<:L#&F%7D![>3G^[[/7W\5)I0Q$\P
MGP;+*IJ T>\];<('7S1^Y6F+[E,DUGS*,&U*J263OB[(NEM5M\7'=-L7/D0:
M8;6_(A,B:C7425SU5_Q29Q*Z')UBM2G*1R^MD)W5@X/OZOD/3#YYR5T@-ITA
M6PD9XZTMA)/=;S9V-QG?%)_:;WF6\:BX7#-OR9(<(-ZO.,\>;_*O]_M?SIS]
M#U!+ P04    " #2-&I4Z1')($$"  #?!   &    'AL+W=O<FMS:&5E=',O
M<VAE970V+GAM;+U446^;,!#^*R=4::TTE4#2=JH(4A*(BM8V&=!.>W3A$JR"
MG=DFZ?[];$-8)JU]W N^.]_WW7?&Y^# Q:NL$!6\-3634Z=2:G?KNK*HL"'R
MDN^0Z9T-%PU1VA5;5^X$DM*"FMKU1Z-KMR&4.6%@8VL1!KQ5-66X%B#;IB'B
MUQQK?I@ZGG,,I'1;*1-PPV!'MIBA>MJMA?;<@:6D#3)).0.!FZDS\V[G$Y-O
M$YXI'N2)#::3%\Y?C9.44V=D!&&-A3(,1"][7&!=&R(MXV?/Z0PE#?#4/K(O
M;>^ZEQ<B<<'K[[14U=3YXD")&]+6*N6'.^S[N3)\!:^E_<*ASQTY4+12\:8'
M:P4-9=U*WOIS. 'XWCL OP?X5G=7R*J,B")A(/@!A,G6;,:PK5JT%D>9^2F9
M$GJ7:IP*%ZO';'6?1+,\CB#+]?(0/^89K):@MY[C-$_F]S&LTW@9IZG-62V^
MPNRQM^Y6]U&<9I\@_O:4Y#_@/(J7R2+)+^!\300R5:&B!:GE!9P!99!7O)6$
ME3)PE99O1+A%+W7>2?7?D>KY\, UH828E5C^3>#JOH?F_6/S<_]#Q@B+2QA[
MG\$?^=Y3%L'YV<4'M./A3,>6]OI_G^D'VB:#MHG5-GY'6R)E2UB!4'"I_OD3
M.OS$XLU([T/?\R=C[R9P]Z>%W9-+UZ#8VM&2FK=EJKM_0W28WEEW:?^D=Z/_
M0,26,@DU;C1T='ESY8#HQJES%-_9*_S"E1X(:U;Z!4)A$O3^AG-U=$R!X4T+
M?P-02P,$%     @ TC1J5/2"NOBU!P  D!\  !@   !X;"]W;W)K<VAE971S
M+W-H965T-RYX;6RU66MOV[@2_2N$<3^TP+KF2Z\B"9 X#;:+M@GJ[MW/LDS'
MO)5%KR3GL;_^#FE9DBV2=G:Q7V++F>$<#H?G#*F+9U7^K%9"U.AEG1?5Y6A5
MUYN/DTF5K<0ZK3ZHC2C@/TM5KM,:'LO'2;4I1;HP3NM\0C$.)^M4%J.K"_/;
M0WEUH;9U+@OQ4*)JNUZGY>N-R-7SY8B,]C]\EX^K6O\PN;K8I(]B)NK?-P\E
M/$W:419R+8I*J@*58GDYNB8?[SC7#L;BOU(\5[WO2$]EKM1/_?!Y<3G"&I'(
M15;K(5+X>!)3D>=Z),#Q9S/HJ(VI'?O?]Z/?F<G#9.9I):8J_T,NZM7E*!ZA
MA5BFV[S^KIY_%<V$ CU>IO+*_$7/C2T>H6Q;U6K=. ."M2QVG^E+DXB> ^$.
M!]HXT',=6./ SG7@C0,_UR%H'()S'<+&(32YWR7+9/HVK=.KBU(]HU);PVCZ
MBUDNXPT)EH6NK%E=PG\E^-57T_MOL_LOGV^O?WRZ1;,?\/'UT[<?,W1_AZ;7
MLU_1W9?[/V9HC'Z?W:)W_WE_,:DAJ':=9$V FUT Z@AP*[(/B)%?$,4DL;A/
M_>Z_I<7>G6*+^^W9T2FQN'\ZW]T6_>YOSWT"Z]0N%FT7BYKQ0M=BI=4*+8$,
M*K0LU1H!OY1I+8O'W0:5M1351T\<UL9A)@YSQ/D&C):KJK+E>^?)C:>FK:>K
M,6,!"R(>7TR>^JFU6)((LR1..LL#>+R%Q[UIN%[\#S8&T%N-:@7TEJDBD[G0
M#T6#?/\]TQG;5F*!9/'F= 4MGL";KEL!I)[)U%"E> '2KX0M=;M1@EY">,##
MZ"AM0RO*&76D+&PAAEZ(1C'&:CF&7*"TJB UZ5J5M?S+H+:A#0<X"&$A#H[@
M#LT"GD21'6[4PHV\<&>URGX:Q5B@3*UU1D]F-QKBC3$-*3L";+'#<1B%B1UR
MW$*.3^Z9?DJ16B(HB[7<KM&[-,M*L?]U(:M,;8OZ/8)GD/.?HD[G4+Z5R+:E
M*4K;].(A;(8IQW;428LZ.5&Z2U&6D.4Z?4%S48BEK&W1DT'T,<.PY0-[>(([
M^<'>O?SN<P&I@85^#_W [AML5=^N)#UI(][)76<FSY6F""&?=)*M"D*&.RY*
M(G)<.!:[,4TP<)HC"1VM$^H%^E"*32H7^^JN4%HLD*I7HH06 )8'B,[L66MA
M-&,?PN(86#8\GH#%,DPB5PV13BZ(7R_N#50GQ$^-^T%@PAECCL"=$!"_$NR+
M![W;%\_[4]73D3KQLWI;/9OTU5DZ0[(>P[9DR;$66@P)B8,@=K .Z8B=^)D=
M8)9;T=6.%>:0I!F42-);^0;FT)#'<<BY V7'Y\1/Z%_,*N4RG<M<UJ]6D$-B
M'L<X#@;;T&+'PR0A#HP=@9/3#'ZR7[ B'W(SL&,<X#BFQ^ MIH2'%,?41:4=
ME9/D3=VA+)Y$]89VAW:D3;&?K[9EMDHU41F1TWFJ7PUIB3^W<J,[,UN>FE$/
M^0=' YZRV06,$T>&:"<(U"\(![C/5EYJX?TH"&D04,?NI;V&WL_\9LW2#+)6
M[FINOJW !!I8:'OFLG!V9W3(Y=!;<T>;2#LJIZ=;_X--8*LB*R +QT.62) ,
M.ER;J6]].SF@?CDXW@%+2" <#<[? 9TX4+\X/)0J$V+1[C08.LW19CO/90;%
M!4V5C@I5!LNXAC:OT@WM+^9(TOPH*WTYLY/Z;;$0Y;.NP.+1FEN+>E#,2!P%
M#NVFG7Y0OWX\I*_F) 6P7-/(5&5O/>A0+L:4P'&%./I_V@D&]0O&88+%BR@S
M"0H"*$TJ@9OUSK"C&@H$"SAG#A&CG4!0OT"X,3VG99D6CB0-*3^A$7'Q/>WX
MGOI[]W:K @,_R05LU_FKM>2MJ(8=/>&<ACSFQX)K,651$E-*0OL46"<DS"\D
M>@JR:-O^W73TCC!?M)@\I;EP))8-98)%T+@G"3^:@<62,CB_))%K!IVD,+^D
M3%V(45K#@>I1%D7#!""24BUL-V!-B/Y-"6%13$ET=-B^94,I8A&&,TA CJ<\
MM!R,>3CE3K/8.9KEF++0)Q?/9&^:P<^9K$7BH!N-"3^^@[!8VM-R=T[TP[3T
M[LR85WQFV\TF%YI+@4+U&3]7U;;<]1J%*DRR>F(*>>KVJBQV[PCT#8'W J^3
M0L;]BZ0@5%DU5PZ9>:JE;G9FL#2 ZMI N-%W%,T5P(Y895&K ]6R;CT^2'A,
M8Z U[.C"6:>LS*^L-Y8&2.?/5)L52S!8TBC&/ RH THGC<POC=,<CK20J'XV
M$.BV/F[!>IW=J[&A3$9:NK%#O%FGDLRODM]%IC'*I<S:2Z?VD&4PMJM]M,ZV
M8SJS"2=.8NS*9*><S*^<+8J'%L5LB.)P\$X'V=O./6_M^G@G5_S$N>>@ :A7
MPE0#!!/-;5\_PVVWU]JX^JB;)FR_A#G&/#FFQ"D?"AG!E/#!797%,$EBAAUZ
MQSN]XR>.4'^_79SRH<Z-*0O)T2W$G=4.XR!V=)6\DR[NEZZF#F_>4(>\$P#N
M%X!_7(>]]Q]^<O^7ZO"V"=M//.412.Z@O;!8LA *+"''G#;IO9O4[ZJ_IB4T
M117*Q1)<\8<(:K3<O?[=/=1J8UY7SE5=J[7YNA(I')"T ?Q_J52]?]!O0-N7
M\%?_!U!+ P04    " #2-&I4+0LE#*<*   \&@  &    'AL+W=O<FMS:&5E
M=',O<VAE970X+GAM;*U9WW/;. [^5SBYG9OMC)K83M.DVS0S;7H[UX=N.]O;
MO6=:@FUN*%+EC[B^O_X^@)(L)TZG#_N2V!0)@!^ #X!\O?7A+FZ(DOK66A??
MG&Q2ZGXY.XOUAEH=3WU'#D]6/K0ZX6M8G\4ND&[D4&O/%K/9R[-6&W=R<RUK
MG\/-M<_)&D>?@XJY;778O2/KMV].YB?#PN]FO4F\<'9SW>DU?:'T1_<YX-O9
M**4Q+;EHO%.!5F].WLY_>?>"]\N&/PUMX^2SXILLO;_C+Q^:-R<S-H@LU8DE
M:/R[IUNRE@7!C*^]S)-1)1^<?AZD_RIWQUV6.M*MM_\U3=J\.;DZ40VM=+;I
M=[_]-_7WN6!YM;=1_JIMV7O^\D35.2;?]H=A06M<^:^_]3A,#ES-GCBPZ \L
MQ.ZB2*Q\KY.^N0Y^JP+OAC3^(%>5TS#..';*EQ3PU.!<NOD4UMJ9_^D"D6O4
M;SKE0,JOU+L<L3G&Z[,$1;S]K.Z%OBM"%T\(G2_41^_2)JI_N8::0P%GL' T
M<S&8^6[Q78GOJ3Y5Y_-*+6:+^7?DG8_7/A=Y+_^N:Q]H>3%J>2%:SO]><+\O
M]#>?2,W5/_]QM9C/7ZL?T*$^M&UV1,&XM;KUH?-!ME=*J_=D]59C?SU=_YFE
M+V:O)P=E!?I\4&E#JM]PZ]M.NUW_\)G:ZJB,&V11@R]PV>SJ5/T'A_K=2ILV
MJN25:;O@[TEU4$LN*9!&[5N*:HD]S;UV-5NL57;F:\8VTQ&CP7?S4&+]>B=7
M=I2#CS5DU-@5?)/KI&H\,0V,B,C2>[!/!W,8D;5<8&+Y_/(US G:12OWUU8M
MC3>N4)ZIH^KP@+\=7F.#R[8>V*6-!O904^M&K*-O'4 3<W37V9TH_9X"@+$F
M1XP9((M,)0PDEIN0UZJE&BI,;%FXKD=?#\ E\'%J^5.@V'D7Z13>-[9AQ=B;
M-B9.C*J.(M"82."WYWKM?(15O%##/6$WWE^1TTL+1"?GV?::]1^%GAFS81/F
MS_C.<)FI<?WQCH N*8Z_I4\;!&%VB<,M9<-L+9=LB "A"M[W 07)NI)'BV?*
MP4*KN%:9F,+N5'URZE.=_)*".I\Q8<Q?50<9P!>!(*VV&V\AV&\=OL:\C*8Q
M*$R'N[]0G0.,P5TFJ;//D"^W0_!S.GW4,>IZDR,E7"[NSQZDUZI/HN@M0,MX
M$B5LEIDCI<(Y:R7R<478*%Z<R!*'/O;?DC;:K@0 T"6UC,!B42CSP..(H*_9
M!,; 6DZZF-AAK&0#5T0VI=:=27 4"E!])V1B_-MP!Y\ '@<R'@ 8UZ<PW&IK
M<$EG].'%MQM3;Q321G.@HG#"Z%JW]+0S3J?.@.HOMX+*J%45[K)2Y1$).^X4
M*/#E$)?0U)OY #!FLK0)/J\WN#^#$UF,@T<D<!NU,H[Y1R#  B=7/$Q_I!3L
M_ N*195R62 '5L9M*$@VFGB'R\;H(8FE;@VBG \C%Q*2VA42JX=4XFQ@6F$
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M+GAM;-5]:W/;2)+@7T%X9R[L#8BF*,FR^Q4AV^U9=W2/'59[)NXC"!1%M$&
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MEY>-IF-]U"-%D072]+^]W8+(($/R13I_$TDI:.AJ>883SO\FZUA.TA\_PMI
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M%\N9R?[S_QF^'H&WY0-X6_[I>'MQ^2*]/%TFJU< >L+;Z7EZ=GZ1G*\6KQY
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M$! WY5<FE OY^>=L;1[RUUY_Q4C:MJE&E*C#3D^ Y_!([Q7>(=$IK']NZAL
MVZV>H4L^DM1&Q;:ZBQ6AH/N@CE.%)V-WQ*QR=HPJ\3J484>HR9)O$-DND[=:
M?AA]MV%CM/3+G(V=;!0#%J,"HYVD%O'),*J(2I3$)F 95K<_Z0<*1H;(L9@
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M9S%Y7PY1E431Q$4IQM=/64UW0K18B;76'-(T$I8S.B0[B)@L:P&$#O) *GN
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M_:BM_#6/3Z18P7[XUE7N-I.@=,A;(=V? V6F9X@M_3,G->F=_1;DW\UV,II
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MKL4!\#N^TUH_X )8:T;;^^'_ %!+ P04    " #2-&I4Q7*3E-$#   M#
M&0   'AL+W=O<FMS:&5E=',O<VAE970Q,"YX;6S%5]MNXS80_15"+8H$D*V;
M=4ML TFV>P%V%T$NVV=:&MM$)-(EZ3CIUW=(V8YB*6G0(MT7BQS.G)DAA\/C
M\4;(.[4$T.2AKKB:.$NM5R>>IXHEU%0-Q0HXKLR%K*G&J5QX:B6!EM:HKKS0
M]Q.OIHP[T[&57<KI6*QUQ3A<2J+6=4WEXSE48C-Q F<GN&*+I38";SI>T05<
M@[Y=74J<>7N4DM7 %1.<2)A/G+/@Y'QD]*W"#P8;U1H3D\E,B#LS^5).'-\$
M!!44VB!0_-S#!525 <(P_MQB.GN7QK ]WJ%_M+EC+C.JX$)4?[!2+R=.YI 2
MYG1=Z2NQ^0S;?&*#5XA*V5^R:73#T"'%6FE1;XTQ@IKQYDL?MOO0,LC\%PS"
MK4%HXVX<V2@_4$VG8RDV1!IM1#,#FZJUQN 8-X=RK26N,K33TV]4WH&FLPK(
M-11KR30#-?8T0AL%K]C"G#<PX0LP04B^":Z7BOS.2RB? W@8TSZP<!?8>?@J
MX@<HAB0*7!+Z8? *7K1/-+)XR;]/]!GN:(\[LKC1?]W UV&^"PTD(K_]DH5!
M<$IZ4=M2]22EBH@YP?V">@9ROV>D$'AUE(;2+.LED+FH\ XROCBQ?OSH]*=]
MN]'N5LYJ(37["Z.^$$J36XZMIK+S3]AB5%OP52B%^7^D3)(?M%H#.4.!5N^?
MWL5:2N#Z_1W=#J^'Y 8S5GC:F.M._BL9A6XP2MTHBUO"06M\%&9NG,;'!S9!
MYF:!3SZ)>Y <NZMNE]*A^R!W0S3PX[2S-.A(CH+(3;+\N!?%'[E1DN&9UC7(
M@M&*7-(5GG]'-W3S',-,XLY23Q!'(S?(TQZ/B))AW&%,;H1&9]L#ZRBF&%:<
MNHG?Q>YUE[BC).CZ,S!!@%E&_]L-^B[XH/C99;C[YGGN!EGREB()W21,NCN8
MYXD;)V^MRR[NVR1-,;2V[ATS:7S5O2W[Z4JF,19@XJ9YU!*V2@_O\2AW_2P]
M/C#R4S=-NN5VLP0)9&-^N'C!>_^#X0\/C%F]PLYJCD+M7A"\OBO*'^TKE9XB
MTCUEE8$?(#T<*(I^^EW6MG2P9U->DH)*K"(<:S(WO?O>]NX2=?G"NGD$*@D8
M(M%]*(;D:M?_%_9!,(A5\Q)0#)SQHEH;2\:)0# $>D &JX 8#DC4"@HV9\6
ME9B8&5'+#I'9,76X _*Y)R%WCM"@/T_<AG_.H(]U>"T*AQUR88FJPC=\S77#
MYO;2/1<^:RC@DWI#I)$E+$RX%<S1U!^FL4-D0TZ;B18K2PAG0B.]M,,E\GF0
M1@'7YP+)R'9B'.S_(4S_!E!+ P04    " #2-&I40'O4!F$#  !2"P  &0
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M;ERK9: -N&4)L@[HH@4B(T 1@4^"ZU+!.YYC_A @,%;UII$[TR[(DXAO,9M
M'/E 0A(]@1?WKL8.;_8KKCY 3GKDQ"''OWZ)3P/])31" J]^FY,H>@,CN'!3
M(A2B,@7%^!8TW538517[!Q6(1D)&50GXK6%[6CD9RG.3-_(6.W;,&LDT,^QU
M"YT#U5!8C7NGT9:,*3O#)JT6D_K,H!CT DQDL-Z@[*-SYDP.XS?_^_=/W&,%
MT0B=C-#C(_J-T+2"<Z50JY?W[O)QM%Y:H2E5_-'E0T_\'>+87\PB/TZ2 ?'U
MR'K ?"GJ&F7&S)7MZ,XDQF-]KX\HQ _#T#[/XFW#<I3<CP5.^/$S>N/I*,R+
M!>94B;Y\ GZ97$_@1KI.8'O"?923V(^BJ1^GX8 XEA(#YC_$'B6W_6K8:_[[
MSJ.%3\+$CV?SYS'_1 I&Q%_,YWY(IL]C;I/P=#-]+';B^OKL(GZT('Z\..X^
MQ^I3@Q&F?CJ+QVI@O,'?QR=-_3"=^6DTK.\X.;+C852C*/+);.%'87K?'TN4
M" ?[X@*TI%P5*!5L4!\0>=^'K55WO=>N#P@ES:U,P3CE+E[4=5D0$BI&-ZQR
M5I_Z+0>#.<<$>^NF.069:+AN1YZ>V@^,Y^V<=,_>3INFSK:,*ZBP,*+A))UZ
M(-L)KMUHL7-3TT9H,X.Y96F&7I26P9P7PORKNXU5T(_1ZW\!4$L#!!0    (
M -(T:E1(CU6>_P(  '0'   9    >&PO=V]R:W-H965T<R]S:&5E=#$R+GAM
M;*U5;6^;,!#^*Q:KIE5B 1L"-$LBM5VK3>JF:MW+9P<NP1I@9INF_?<[FX22
MK<N';5_ =[[GN3O?^3S?2O5=EP"&/-15HQ=>:4P["P*=EU!S/9$M-+BSEJKF
M!D6U"72K@!<.5%<!"\,DJ+EHO.7<Z6[5<BX[4XD&;A7175US]7@!E=PN/.KM
M%9_$IC16$2SG+=_ '9@O[:U"*1A8"E%#HX5LB(+UPCNGLXO8VCN#KP*V>K0F
M-I.5E-^M\+Y8>*$-""K(C67@^+N'2Z@J2X1A_-AQ>H-+"QRO]^S7+G?,9<4U
M7,KJFRA,N? RCQ2PYEUE/LGM.]CE,[5\N:RT^Y)M;\O0..^TD?4.C!'4HNG_
M_&%W#B- %OX!P'8 YN+N';DHWW+#EW,EMT19:V2S"Y>J0V-PHK%%N3,*=P7B
MS/)687V5>22\*<C5CTZT>.+&)PV8>6#0@34+\AW914_&_D!&&?D@&U-J<M44
M4!P2!!C9$![;AW?!CC*^A7Q"(NH3%C)ZA"\:THT<7_*OZ1ZPQP-[[-BC_W.8
M1\GL;9SIEN>P\/"Z:5#WX"T_2@-D2EZ^R!BE;\@1AX=[<+B72[Q5VD!!Y)J8
M$LA:5G@]1;.9.>XP>O//?RP=U"M0KGP'PJ^6MK9C(?QKGY>R;CN#;H9\AZT3
MPC+J)TDRTM T]B.:DNM.-<)T"MQ9K<6#7>O!,(O].$T'D69^>I:1&[YZQLW^
M'R>13S/VF_XUN0$<(J6L"B+J5LE[L/@G9W3*?$K3$>"S-+P:Y#/,(HZ?B.D9
M.J)3<I[G7=U5W!:U .R87' W]_:&KVRVC)Z=CC0,4YFRTZ.]\G1<69CZC$4C
M38+GET2CDH_\P@,^'!J(L>%C4"?QU(^3U+DX80AD&;:=<NWW"!QK9F?&8:>X
MSK  VQ4^/@*Z!3?&J\<)>>["!J-)6(/:N'FOL=^[QO1#<= .3\IY/TF?S/OW
MZ -7&]%H4L$:H>$DG7I$]3.^%XQLW5Q=28-3VBU+?!9!60/<7TN\K#O!.A@>
MVN5/4$L#!!0    ( -(T:E3"[_!*Z@<  +04   9    >&PO=V]R:W-H965T
M<R]S:&5E=#$S+GAM;*58;7/;-A+^*QA=YGJ=826*DBRY?IFQG:;-3)IXXES[
M&2(A$34),  H6?WU]RQ 4K0LN9/<%Y$@%XM]>?;9%2^WVCS:7 C'GLI"V:M!
M[ESU\VADTUR4W YU)13>K+0IN</2K$>V,H)G?E-9C)(X/AN57*K!]:5_=F^N
M+W7M"JG$O6&V+DMN=K>BT-NKP7C0/O@LU[FC!Z/KRXJOQ8-P_ZWN#5:C3DLF
M2Z&LU(H9L;H:W(Q_OIV2O!?X0XJM[=TS\F2I]2,MWF=7@Y@,$H5('6G@N&S$
MG2@*4@0SOC8Z!]V1M+%_WVI_YWV'+TMNQ9TN_I29RZ\&BP'+Q(K7A?NLM[^)
MQI\9Z4MU8?TOVP;9)!FPM+9.E\UF6%!*%:[\J8E#;\,B/K$A:38DWNYPD+?R
M+7?\^M+H+3,D#6UTXUWUNV&<5)24!V?P5F*?N[ZM+9Y8R^YTN92*4Z@N1PZ:
MZ?TH;;3<!BW)"2WCA/VNE<LM^T5E(GNN8 23.KN2UJ[;Y%6-;T4Z9)-QQ)(X
M&;^B;]+Y.?'ZSK[;SV=JIYW:J5<[^0:UPV/Q>UW-1^T$.V/__M<B&8\OV#&M
M[%;J&_,("+.;]&LMK?1//RF&4(ER*0Q+DA"NB+E<T-Z*JQU+<2V$$YE_RGM[
M]8KQHF H5>NXRJ1:,YMS(RR]27DE'2\8$)@^TH/N_(B]5^DP8IS=\4*"%Y3D
M.,54V@1+_T-^)/%%M\.OQQ<_1@S2V(?R?P3?;'A1"U+]9C&<SX#NHJ#P]3R5
M%M(/'#Y*L=:^_#(<I9Q!-8,3K. FS1DXB2OY=SC=Y=RQG%L&DMI(7=MBAUN]
MD0 F/4L1?)G"LVZ[%68C4[B-(+"EU)93Q,AS UYB3C^+)PEI/# DZD2:*UWH
M=8@SK!#VP &I_':8D%)*X>Y24*A7=0'+I')BC;C!-MP^/PE+\906 ,-&0-36
M%4+L^B(_6*_ *+ASU#5/>L@VG*/02P<#5!H,KF0E"(A#Y)."JAJBW$J7'V+E
M.:0HNMR"QQM0Z64AUS[ZEM4@ ,.>I7X\O["0,T*P0B"%C*]Q#V9'.V%?*#8U
M;*47E4$>V):2QR5RL6/OR[)60AB*&%3H>AULDSB>J]3#!_C@:ZB$"7X]F9]'
M9Y-9#\P]+9U!=P5<8#>4MQ)>>YP'<U3MRPG[>N70D_*'PW6R$]%.Z\+GCXIV
M#;P&6 >LZI!\OA$>2E!$RXQ+Y'.C"T20;7WC@&PKY(-@6]EG!S?J/G*;\:_L
MP3_[Y0FQ4]A'"::WDYC]A +Q]9QQY!E^ZXR)4.'4"16!#<#*0E0!\9ZX+)%6
M"8]\W4A2&F"9%MH&(0?,W/=?!:0$H-P:X1S[#<P2L;M<BA5[2"5R+5<R99]6
M^ VQ[6>6+"(][W2 #ZWO<B[1=E4;B*7F)J-%)H%TU*8]8*5<%$%+R?_21KI=
MN_,XP>V+]!G5#=GGKGA@1290>[HBL*(8,0I9T94T:L;J0F8^^SC!>4R3;LQ,
MIJF'$&C1;+#^=4<X'2\!Z7M[#FA@FTLRID1L/(MK]F8:S::+:+Z(R12B_*XV
MLJ8&#KF>?'F31//I-(IGXV9;/&0W/A9="VDZ;AQ!&%4TGDT\RO4V'+RWT6.H
M\X[PA.-2,I%J=\>7(%#B^C0U]5'.?C682U[XXO9SC24K+:ZA\1DJ%9S^0?*E
M+ *WW31D!.9_!]2P/WP)4BT?[YI$8$LA.INQE:HG5/!AZ$KA<NV1UTA#B(@"
M[C>OC/!VV=![>#"6]XTM>L:VS$DA8\NVU:>]5H](+P6TIGJ-MA;\@E5P;$7>
M>8(A/<<2':KS>%KQB^)SG$XN0ZZ, 'EYK[6?G^FVK8<<C,24=B%4*UA7D#6!
M))LE;R<)V&&I]!S:$7E3%Q07B^&8' T49>F4M=;9%JV>V@ZJ<BT)*DV"2;$
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M^"+5Q0-3LJZJ4U=7GM1*L5:XT, MD^>T+,V-!:6LKNB*7,&6)G5&XGW?3=&
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M.$+%C:;QI)\K%[-O$MW%X^'D4QW(U'V%1HV ]T/UJW7!J>[7ER_$V"2)XL5
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M6,%GV20YGTR2Z6SV?/<0//)),AI-GXL/3X1'M]UXE RSG?0P03X>'Y(!->>
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M[CBATP\($@&6873O4!!)8?6\(?WV#G6"=&M))0/HZCQ-FD#J@,E8TZSY//1
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M8.;,XQ ^\F&E[D!,W_?.+I3Q4?5E4HDYQ ,TT"#*<R[*9OAT[&;)2HL^(HI
M1'4"6*(A8,55M+5D98J44"I4/X;.3AYF /QBV0_\XY.P7W(6'?>22QYC'<S$
M;E2&S3Z[%P6\(@88*J"<J3HV14!CO4PK30?BT7'Q#!Y%,A58 U+14 Z)*MP_
M@'--F=>G*]EC].E"3+ 3UA@\AZ'4&%DJF52,4LCT.0,*M)@1=MJ@+F^)JL92
MQO -!#B]47'J3LERG22Y^K8\B(XP:#\/'D -<N$V4]RA;.S>$48\R\TPOH?Q
M&=7(%+U%%<!ZMT-_(8%,\TS\#@+G.@?3>,U./Q&MK(]OBBE.(PM1YI_H&0]S
M'6. Q:Q*HF4PIN:BUS!J2V&H)M'L81.,P8[WELTY2>B^=Q+-:;XZ 65#F<^F
M66,6*_U<"WY<69:A1]R>0M22VR5B5= ;2[9:+G$!EIXTI+B%TU)::,&IU&PG
M8TY1W30L^_@%"68',?A&?,NPRD/=E93XIY8WZ:8T A,\!DDP(YD-?:%X.IJ,
M,=.@>%?]NG>$!;$,D*8E1@Z!>NH=*%FFNBN:NF)#I!B>X@ _XE''J1B=URJ1
M$)+HZ=<$8J%?2EZKSH3E^RQD3$Y)D"Y*)P_TQ_',71FOGP=XNF+U6"L.=$WR
M^<D)0<U)Y=SG?"^F4[?5Y?C!ZX:CFOH7CQ*J[?V"/%2HG\^?NXJ..'^0:2YS
M\0/@9TALEKEN78HYNZ.  J8@,G0U)*_%9XWQ%7>^4L>I[;&@TX50I@$8 $&*
M!J8R#F<$=N%R %!=<=$%1/5*[3+1P0DWK#M0M T=>_9&G=.G?'1TA2%R4)%+
M1BRP[,@8#T*<@]60:9=A3OF=,* 8%(/ZL;(0\\!';C:@$I[9UNS9E.!HR/(Y
MG"5'(.]U*RP$61'QYQ4ZC09O!5GF@:"R <+SH/U!7KL$D-'DF<'S5YKK/OZX
M\*FO7<V' >80TG+*[+%!*30.?UM2[_NNM='2 *>Z^M)2=>]HEC7C)6Y(A<::
M/&\T*8J!HB[K6\P#JC=8DD!?AKB[WV:PV+7I6$6G_,2B;LUZ6_&;+A$^'<'6
M+=<52A:*STFV5!,P#@HI(<#\2'1@D6I-0K[82>G!\,"*T#3C2IT_C)*$S%V"
M2P@=0@/!["/U&^Z0] !(]2_8*+EMC.H\+&ZQI'&+R4I.#+/ Q#PT?Z;^J+ A
M .4WJ=)44S0;40U=I^BM-CQEAI7\9+?9-2B[5%$&+_<S7 5SK4-=!WMT,K'[
MR8O@&C: 9G%-AICD6RD>RPGILL</FTU;)UE]*KJ?2J=1!&,>; >C(EF&AQ5(
M!/%MU>@Y-_EI1RAZ$R:9N3PG\B1DK@R[#P#1<L>!<)3PT><:Q?)U"A8L/,-H
M%A2^FZ(]4AG,A 8[/Q5C?3A0,#NG(K")K,<<N'^X7(/]EL[RMW'DB+4^[R(
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MI@;C6#[@!%AQ2LO[X7\ 4$L#!!0    ( -(T:E0)433K9 ,  -D)   9
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MD!%H%J![5GJEF7%Y/2V_@7N0+9!73NV3LKS>U]V@K 1Q[_KN6#SW_PO$>G%
M>4F*+ ]I2DF:1T/4?DE8FH<YI6241\4K/#F8L9-,TB$-*>HFPR@]$;X^LSJ
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M:51@977WD.@V5FW\\%XHBUWBEVM\>X%V"BA?*F7W&^>@?\U-OP)02P,$%
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MFAE%EE-,N=%B64P.4Z'-'%(L%V;P VD!YOU,"+W=6 /5*#G\ U!+ P04
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MWD,C_.><YZ)J6FW2]$/HCSXBDF$_29*!!Z>Q'^$47;6R9KJ5X :X8L]VK_K
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M")3J"Q)&[TE,DVE"XR [*"U/**4TR#(ZG:;DABG%:J/M/="T*B]Q5#VZ$!Z
M@PG"3LA?C<W=&8.(3M(I39.$A'02A#3*8O)5&B:&=MT^-H#O+;]C BR-(^,
M.S6@DW%TJH7\H]F%QW7G)K1&W+8VW1@;I,-/P&4W^Q[4NS^(3TSM. 8D8(NF
MP6B,55;=5.X61C9N$FZDP;GJ/DO\D0%E%7!_*[$I^X5U,/P:+?X%4$L#!!0
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MP=-8-.^'9J)X;>[L4Z[P!6!^%_CD J$9<'W&N6HG>@/[B)O\#5!+ P04
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M'915P/]S*<UV83=H!__IWU!+ P04    " #2-&I4Q3?70>T#  !@"@  &0
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M$O3)_;-Y?L6^@ ,;#F-@]YA]%SC#5^=C2J> \LR9VK/B:1CVK"/X7.C,7;^
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MX/J ^K]F3#YO]#S7#/R3/U!+ P04    " #2-&I43+*YCQ,#  "9"0  &0
M 'AL+W=O<FMS:&5E=',O<VAE970S-"YX;6RE5FMOVR 4_2O(VJ1.ZN)7GE42
MJ6WVZ+154:-NGXE]G:!B\  GJ;0?/\"NE[0VZ[0O,=B<<\\]EUR8[KEXD%L
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MW+>E5/4@5&^,+/WP,9?&CC)^N;3#(RAG8.\+*<UFXP(TX^CH#U!+ P04
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M.#MJTEJM>6M_@][1)1)+(3*T[R&6/,2G[_'/8M19N.GI$H/6,J0IYG6Y.JM
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M++(Z-Z'G@9&'NH];2X-=87V[Q\8=E'T!GV^E-&\#VQJV?P5F/P%02P,$%
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M+]@7LBX>@3 5DL4E6'D0TZ3X'[R41#0 R.H X!* AP+,$F .!5@EP!H*L$N
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M2BT2T*P2O^?IHTJ8;4"]JRD$O;[L3/F2XB^2-9F<IZEE )IU8' P1JS!2VG
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M!^K5C63[\CSWD4G)TO)R1\*8\,) O=\P)H\W18#FWQJ+_P%02P,$%     @
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M Y6#EX><Y8UDV^+8;\&D9&EQN:$DHEPW4+^O&).O-_HDL3YJ'O\#4$L#!!0
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M,&MCT,H-2?4VODBNGA*%D]T7R<;S2E\M1(P&C*KL$-BL;P7UA-K;A>X(=/L
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MDZK\-,V9^D( KB>HYQ/&Y+ZC ^3?'-T_4$L#!!0    ( -(T:E3Z]'B_?P0
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MGJ">+QF3^QL=H#Y_F_T 4$L#!!0    ( -(T:E0 K\R3^@(  $(*   9
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MB".\ @  NP8  !D   !X;"]W;W)K<VAE971S+W-H965T-C N>&ULC55-;]I
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M7./7!90-P/NEE&:WL07:[]7H#U!+ P04    " #2-&I4WBU'&&0$   S$@
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M,?Z$F!2R:Q3@*^1[/AZ!KU\/]T;@Z3S\STQ/P5U3U:ZT?E=:OXY')^+=@5(
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M>>7&TJL_G2VWVCQ4U<!==-%MU''8?^Z">.'^3QCM>JU3-;9IF2OC=W%T*JL
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M%86XLOE2FP,Y4U[I,XL%.H(K%43N!2HIFJV.4DF?VR76/%6I6]4GYDZME7-
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M%93-S*V5J_U.QOTNS!__ E!+ P04    " #2-&I4)V75I0P"  "$)0  &@
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M#?]VFKT!4$L! A0#%     @ TC1J5 =!36*!    L0   !
M ( !     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4    " #2-&I48.VWZ^X
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M=V]R:W-H965T<R]S:&5E=#(N>&UL4$L! A0#%     @ TC1J5$_09"W< P
M^A,  !@              ("!1Q8  'AL+W=O<FMS:&5E=',O<VAE970S+GAM
M;%!+ 0(4 Q0    ( -(T:E3_;VZ,] 0  +,1   8              " @5D:
M  !X;"]W;W)K<VAE971S+W-H965T-"YX;6Q02P$"% ,4    " #2-&I4&.%3
M3TX'  !%(P  &               @(&#'P  >&PO=V]R:W-H965T<R]S:&5E
M=#4N>&UL4$L! A0#%     @ TC1J5.D1R2!! @  WP0  !@
M ("!!R<  'AL+W=O<FMS:&5E=',O<VAE970V+GAM;%!+ 0(4 Q0    ( -(T
M:E3T@KKXM0<  ) ?   8              " @7XI  !X;"]W;W)K<VAE971S
M+W-H965T-RYX;6Q02P$"% ,4    " #2-&I4+0LE#*<*   \&@  &
M        @(%I,0  >&PO=V]R:W-H965T<R]S:&5E=#@N>&UL4$L! A0#%
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M+GAM;%!+ 0(4 Q0    ( -(T:E3"[_!*Z@<  +04   9              "
M@6=N  !X;"]W;W)K<VAE971S+W-H965T,3,N>&UL4$L! A0#%     @ TC1J
M5"4E4J>+ @  ;08  !D              ("!B'8  'AL+W=O<FMS:&5E=',O
M<VAE970Q-"YX;6Q02P$"% ,4    " #2-&I4FW:M==$*   F(0  &0
M        @(%*>0  >&PO=V]R:W-H965T<R]S:&5E=#$U+GAM;%!+ 0(4 Q0
M   ( -(T:E1B@P=\X08  . 2   9              " @5*$  !X;"]W;W)K
M<VAE971S+W-H965T,38N>&UL4$L! A0#%     @ TC1J5)&'01VC P  Z D
M !D              ("!:HL  'AL+W=O<FMS:&5E=',O<VAE970Q-RYX;6Q0
M2P$"% ,4    " #2-&I4NH(VE=4)   -'P  &0              @(%$CP
M>&PO=V]R:W-H965T<R]S:&5E=#$X+GAM;%!+ 0(4 Q0    ( -(T:E00.I?O
M'0P  ,0@   9              " @5"9  !X;"]W;W)K<VAE971S+W-H965T
M,3DN>&UL4$L! A0#%     @ TC1J5,> )8W3"   2!<  !D
M ("!I*4  'AL+W=O<FMS:&5E=',O<VAE970R,"YX;6Q02P$"% ,4    " #2
M-&I4Z<G7GJPH  !<C   &0              @(&NK@  >&PO=V]R:W-H965T
M<R]S:&5E=#(Q+GAM;%!+ 0(4 Q0    ( -(T:E0)433K9 ,  -D)   9
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M970R-BYX;6Q02P$"% ,4    " #2-&I4G9YTQ(("   M!@  &0
M    @('PYP  >&PO=V]R:W-H965T<R]S:&5E=#(W+GAM;%!+ 0(4 Q0    (
M -(T:E2>0=8E? (  !<&   9              " @:GJ  !X;"]W;W)K<VAE
M971S+W-H965T,C@N>&UL4$L! A0#%     @ TC1J5 B%XD=F P  )@D  !D
M             ("!7.T  'AL+W=O<FMS:&5E=',O<VAE970R.2YX;6Q02P$"
M% ,4    " #2-&I45:[ YH8$  #0#0  &0              @('Y\   >&PO
M=V]R:W-H965T<R]S:&5E=#,P+GAM;%!+ 0(4 Q0    ( -(T:E2OMV 4<P0
M  0,   9              " @;;U  !X;"]W;W)K<VAE971S+W-H965T,S$N
M>&UL4$L! A0#%     @ TC1J5,4WUT'M P  8 H  !D              ("!
M8/H  'AL+W=O<FMS:&5E=',O<VAE970S,BYX;6Q02P$"% ,4    " #2-&I4
M4"&KAS0#  #\"P  &0              @(&$_@  >&PO=V]R:W-H965T<R]S
M:&5E=#,S+GAM;%!+ 0(4 Q0    ( -(T:E1,LKF/$P,  )D)   9
M      " @>\! 0!X;"]W;W)K<VAE971S+W-H965T,S0N>&UL4$L! A0#%
M  @ TC1J5!0^TA]C!   YA8  !D              ("!.04! 'AL+W=O<FMS
M:&5E=',O<VAE970S-2YX;6Q02P$"% ,4    " #2-&I4J-*'ZN "  ":"@
M&0              @('3"0$ >&PO=V]R:W-H965T<R]S:&5E=#,V+GAM;%!+
M 0(4 Q0    ( -(T:E1L9__5@ 0  &P7   9              " @>H, 0!X
M;"]W;W)K<VAE971S+W-H965T,S<N>&UL4$L! A0#%     @ TC1J5-"X#XJ$
M!   (Q<  !D              ("!H1$! 'AL+W=O<FMS:&5E=',O<VAE970S
M."YX;6Q02P$"% ,4    " #2-&I4;NT2IO8"   *"P  &0
M@(%<%@$ >&PO=V]R:W-H965T<R]S:&5E=#,Y+GAM;%!+ 0(4 Q0    ( -(T
M:E13?0QK)P(  !$%   9              " @8D9 0!X;"]W;W)K<VAE971S
M+W-H965T-# N>&UL4$L! A0#%     @ TC1J5-VM$"JB P  H0L  !D
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M=#0U+GAM;%!+ 0(4 Q0    ( -(T:E3WO%#=U0(  $D(   9
M  " @?$P 0!X;"]W;W)K<VAE971S+W-H965T-#8N>&UL4$L! A0#%     @
MTC1J5-#'%<"M @  K0D  !D              ("!_3,! 'AL+W=O<FMS:&5E
M=',O<VAE970T-RYX;6Q02P$"% ,4    " #2-&I4:URG=\<"   M"   &0
M            @('A-@$ >&PO=V]R:W-H965T<R]S:&5E=#0X+GAM;%!+ 0(4
M Q0    ( -(T:E2#'?35S (  *X(   9              " @=\Y 0!X;"]W
M;W)K<VAE971S+W-H965T-#DN>&UL4$L! A0#%     @ TC1J5-"@!I_F P
MS!$  !D              ("!XCP! 'AL+W=O<FMS:&5E=',O<VAE970U,"YX
M;6Q02P$"% ,4    " #2-&I4A;?LHNP"  "4"   &0              @('_
M0 $ >&PO=V]R:W-H965T<R]S:&5E=#4Q+GAM;%!+ 0(4 Q0    ( -(T:E37
MI!+@*P,  ,L+   9              " @2)$ 0!X;"]W;W)K<VAE971S+W-H
M965T-3(N>&UL4$L! A0#%     @ TC1J5(LTJR>F!   =A8  !D
M     ("!A$<! 'AL+W=O<FMS:&5E=',O<VAE970U,RYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( -(T:E2?>P@G9@,  +T*   9              "
M@4I; 0!X;"]W;W)K<VAE971S+W-H965T-3@N>&UL4$L! A0#%     @ TC1J
M5*'A<XMM!   !1(  !D              ("!YUX! 'AL+W=O<FMS:&5E=',O
M<VAE970U.2YX;6Q02P$"% ,4    " #2-&I4P*6(([P"  "[!@  &0
M        @(&+8P$ >&PO=V]R:W-H965T<R]S:&5E=#8P+GAM;%!+ 0(4 Q0
M   ( -(T:E3>+4<89 0  #,2   9              " @7YF 0!X;"]W;W)K
M<VAE971S+W-H965T-C$N>&UL4$L! A0#%     @ TC1J5*5?%9-\ P  \PL
M !D              ("!&6L! 'AL+W=O<FMS:&5E=',O<VAE970V,BYX;6Q0
M2P$"% ,4    " #2-&I4/P,@EX@#  !M"P  &0              @(',;@$
M>&PO=V]R:W-H965T<R]S:&5E=#8S+GAM;%!+ 0(4 Q0    ( -(T:E3[K;H_
M( ,  #02   -              "  8MR 0!X;"]S='EL97,N>&UL4$L! A0#
M%     @ TC1J5)>*NQS     $P(   L              ( !UG4! %]R96QS
M+RYR96QS4$L! A0#%     @ TC1J5"3"TV$!!0  "2H   \
M ( !OW8! 'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    ( -(T:E0G9=6E# (
M (0E   :              "  >U[ 0!X;"]?<F5L<R]W;W)K8F]O:RYX;6PN
M<F5L<U!+ 0(4 Q0    ( -(T:E3NU>T8Y@$  /4D   3              "
M 3%^ 0!;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@    !' $< :!,  $B  0
!  $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>171</ContextCount>
  <ElementCount>429</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>61</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>10</UnitCount>
  <MyReports>
    <Report instance="imrx-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00090 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immuneering.com/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="imrx-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00100 - Statement - CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immuneering.com/role/StatementConsolidatedBalanceSheets</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="imrx-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00105 - Statement - CONSOLIDATED BALANCE SHEETS (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immuneering.com/role/StatementConsolidatedBalanceSheetsParentheticals</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="imrx-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00200 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immuneering.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="imrx-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00300 - Statement - CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immuneering.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="imrx-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00305 - Statement - CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT) (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immuneering.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParentheticals</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT) (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="imrx-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>00400 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immuneering.com/role/StatementConsolidatedStatementsOfCashFlows</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="imrx-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>10101 - Disclosure - Organization and Nature of Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immuneering.com/role/DisclosureOrganizationAndNatureOfBusiness</Role>
      <ShortName>Organization and Nature of Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="imrx-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>10201 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immuneering.com/role/DisclosureSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="imrx-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>10301 - Disclosure - Marketable Securities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immuneering.com/role/DisclosureMarketableSecurities</Role>
      <ShortName>Marketable Securities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="imrx-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>10401 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immuneering.com/role/DisclosureFairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="imrx-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>10501 - Disclosure - Property and Equipment, net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immuneering.com/role/DisclosurePropertyAndEquipmentNet</Role>
      <ShortName>Property and Equipment, net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="imrx-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>10601 - Disclosure - Business Combination</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immuneering.com/role/DisclosureBusinessCombination</Role>
      <ShortName>Business Combination</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="imrx-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>10701 - Disclosure - Accrued Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immuneering.com/role/DisclosureAccruedExpenses</Role>
      <ShortName>Accrued Expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="imrx-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>10801 - Disclosure - Convertible Preferred Stock</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immuneering.com/role/DisclosureConvertiblePreferredStock</Role>
      <ShortName>Convertible Preferred Stock</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="imrx-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>10901 - Disclosure - Common Stock</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immuneering.com/role/DisclosureCommonStock</Role>
      <ShortName>Common Stock</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="imrx-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>11001 - Disclosure - Net Loss Per Share Attributable to Common Stockholders</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immuneering.com/role/DisclosureNetLossPerShareAttributableToCommonStockholders</Role>
      <ShortName>Net Loss Per Share Attributable to Common Stockholders</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="imrx-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>11101 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immuneering.com/role/DisclosureStockBasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="imrx-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>11201 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immuneering.com/role/DisclosureIncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="imrx-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>11301 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immuneering.com/role/DisclosureCommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="imrx-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>20202 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immuneering.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://immuneering.com/role/DisclosureSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="imrx-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>30203 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immuneering.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://immuneering.com/role/DisclosureSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="imrx-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>30303 - Disclosure - Marketable Securities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immuneering.com/role/DisclosureMarketableSecuritiesTables</Role>
      <ShortName>Marketable Securities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://immuneering.com/role/DisclosureMarketableSecurities</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="imrx-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>30403 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immuneering.com/role/DisclosureFairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://immuneering.com/role/DisclosureFairValueMeasurements</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="imrx-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>30503 - Disclosure - Property and Equipment, net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immuneering.com/role/DisclosurePropertyAndEquipmentNetTables</Role>
      <ShortName>Property and Equipment, net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://immuneering.com/role/DisclosurePropertyAndEquipmentNet</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="imrx-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>30603 - Disclosure - Business Combination (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immuneering.com/role/DisclosureBusinessCombinationTables</Role>
      <ShortName>Business Combination (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://immuneering.com/role/DisclosureBusinessCombination</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="imrx-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>30703 - Disclosure - Accrued Expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immuneering.com/role/DisclosureAccruedExpensesTables</Role>
      <ShortName>Accrued Expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://immuneering.com/role/DisclosureAccruedExpenses</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="imrx-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>30903 - Disclosure - Common Stock (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immuneering.com/role/DisclosureCommonStockTables</Role>
      <ShortName>Common Stock (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://immuneering.com/role/DisclosureCommonStock</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="imrx-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>31003 - Disclosure - Net Loss Per Share Attributable to Common Stockholders (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immuneering.com/role/DisclosureNetLossPerShareAttributableToCommonStockholdersTables</Role>
      <ShortName>Net Loss Per Share Attributable to Common Stockholders (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://immuneering.com/role/DisclosureNetLossPerShareAttributableToCommonStockholders</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="imrx-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>31103 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immuneering.com/role/DisclosureStockBasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://immuneering.com/role/DisclosureStockBasedCompensation</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="imrx-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>31203 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immuneering.com/role/DisclosureIncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://immuneering.com/role/DisclosureIncomeTaxes</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="imrx-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>31303 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immuneering.com/role/DisclosureCommitmentsAndContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://immuneering.com/role/DisclosureCommitmentsAndContingencies</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="imrx-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>40101 - Disclosure - Organization and Nature of Business (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immuneering.com/role/DisclosureOrganizationAndNatureOfBusinessDetails</Role>
      <ShortName>Organization and Nature of Business (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://immuneering.com/role/DisclosureOrganizationAndNatureOfBusiness</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="imrx-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>40201 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immuneering.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="imrx-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>40202 - Disclosure - Summary of Significant Accounting Policies - Concentration of Credit Risk (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immuneering.com/role/DisclosureSummaryOfSignificantAccountingPoliciesConcentrationOfCreditRiskDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Concentration of Credit Risk (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="imrx-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>40203 - Disclosure - Summary of Significant Accounting Policies - Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immuneering.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="imrx-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>40301 - Disclosure - Marketable Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immuneering.com/role/DisclosureMarketableSecuritiesDetails</Role>
      <ShortName>Marketable Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://immuneering.com/role/DisclosureMarketableSecuritiesTables</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="imrx-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>40401 - Disclosure - Fair Value Measurements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immuneering.com/role/DisclosureFairValueMeasurementsDetails</Role>
      <ShortName>Fair Value Measurements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://immuneering.com/role/DisclosureFairValueMeasurementsTables</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="imrx-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>40501 - Disclosure - Property and Equipment, net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immuneering.com/role/DisclosurePropertyAndEquipmentNetDetails</Role>
      <ShortName>Property and Equipment, net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://immuneering.com/role/DisclosurePropertyAndEquipmentNetTables</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="imrx-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>40502 - Disclosure - Property and Equipment, net - Depreciation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immuneering.com/role/DisclosurePropertyAndEquipmentNetDepreciationDetails</Role>
      <ShortName>Property and Equipment, net - Depreciation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="imrx-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>40601 - Disclosure - Business Combination - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immuneering.com/role/DisclosureBusinessCombinationNarrativeDetails</Role>
      <ShortName>Business Combination - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="imrx-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>40602 - Disclosure - Business Combination - Assets Acquired and Liabilities Assumed (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immuneering.com/role/DisclosureBusinessCombinationAssetsAcquiredAndLiabilitiesAssumedDetails</Role>
      <ShortName>Business Combination - Assets Acquired and Liabilities Assumed (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="imrx-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>40701 - Disclosure - Accrued Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immuneering.com/role/DisclosureAccruedExpensesDetails</Role>
      <ShortName>Accrued Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://immuneering.com/role/DisclosureAccruedExpensesTables</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="imrx-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>40801 - Disclosure - Convertible Preferred Stock - Series A (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immuneering.com/role/DisclosureConvertiblePreferredStockSeriesDetails</Role>
      <ShortName>Convertible Preferred Stock - Series A (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="imrx-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>40802 - Disclosure - Convertible Preferred Stock - Series B (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immuneering.com/role/DisclosureConvertiblePreferredStockSeriesBDetails</Role>
      <ShortName>Convertible Preferred Stock - Series B (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="imrx-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>40901 - Disclosure - Common Stock - Class A common stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immuneering.com/role/DisclosureCommonStockClassCommonStockDetails</Role>
      <ShortName>Common Stock - Class A common stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="imrx-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>40902 - Disclosure - Common Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immuneering.com/role/DisclosureCommonStockDetails</Role>
      <ShortName>Common Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://immuneering.com/role/DisclosureCommonStockTables</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="imrx-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>40903 - Disclosure - Common Stock - Class B common stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immuneering.com/role/DisclosureCommonStockClassBCommonStockDetails</Role>
      <ShortName>Common Stock - Class B common stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="imrx-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>40904 - Disclosure - Common Stock - Common stock warrant (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immuneering.com/role/DisclosureCommonStockCommonStockWarrantDetails</Role>
      <ShortName>Common Stock - Common stock warrant (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="imrx-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>40905 - Disclosure - Common Stock - IPO (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immuneering.com/role/DisclosureCommonStockIpoDetails</Role>
      <ShortName>Common Stock - IPO (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="imrx-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>41001 - Disclosure - Net Loss Per Share Attributable to Common Stockholders - Basic and diluted net loss per share attributable to common stockholders (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immuneering.com/role/DisclosureNetLossPerShareAttributableToCommonStockholdersBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails</Role>
      <ShortName>Net Loss Per Share Attributable to Common Stockholders - Basic and diluted net loss per share attributable to common stockholders (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="imrx-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>41002 - Disclosure - Net Loss Per Share Attributable to Common Stockholders - Antidilutive effect (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immuneering.com/role/DisclosureNetLossPerShareAttributableToCommonStockholdersAntidilutiveEffectDetails</Role>
      <ShortName>Net Loss Per Share Attributable to Common Stockholders - Antidilutive effect (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="imrx-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>41101 - Disclosure - Stock-Based Compensation - Narratives (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immuneering.com/role/DisclosureStockBasedCompensationNarrativesDetails</Role>
      <ShortName>Stock-Based Compensation - Narratives (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="imrx-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>41102 - Disclosure - Stock-Based Compensation - Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immuneering.com/role/DisclosureStockBasedCompensationAssumptionsDetails</Role>
      <ShortName>Stock-Based Compensation - Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="imrx-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>41103 - Disclosure - Stock-Based Compensation - stock option activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immuneering.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails</Role>
      <ShortName>Stock-Based Compensation - stock option activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="imrx-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>41104 - Disclosure - Stock-Based Compensation - Share-based compensation expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immuneering.com/role/DisclosureStockBasedCompensationShareBasedCompensationExpenseDetails</Role>
      <ShortName>Stock-Based Compensation - Share-based compensation expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="imrx-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>41201 - Disclosure - Income Taxes - Net loss and the effective income tax rate (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immuneering.com/role/DisclosureIncomeTaxesNetLossAndEffectiveIncomeTaxRateDetails</Role>
      <ShortName>Income Taxes - Net loss and the effective income tax rate (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="imrx-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>41202 - Disclosure - Income Taxes - Net deferred tax assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immuneering.com/role/DisclosureIncomeTaxesNetDeferredTaxAssetsDetails</Role>
      <ShortName>Income Taxes - Net deferred tax assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="imrx-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>41203 - Disclosure - Income Taxes - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immuneering.com/role/DisclosureIncomeTaxesNarrativeDetails</Role>
      <ShortName>Income Taxes - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="imrx-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>41204 - Disclosure - Income Taxes - Unrecognized tax benefits (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immuneering.com/role/DisclosureIncomeTaxesUnrecognizedTaxBenefitsDetails</Role>
      <ShortName>Income Taxes - Unrecognized tax benefits (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="imrx-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>41301 - Disclosure - Commitments and Contingencies - Narratives (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immuneering.com/role/DisclosureCommitmentsAndContingenciesNarrativesDetails</Role>
      <ShortName>Commitments and Contingencies - Narratives (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="imrx-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>41302 - Disclosure - Commitments and Contingencies - Maturities of the lease liabilities due (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immuneering.com/role/DisclosureCommitmentsAndContingenciesMaturitiesOfLeaseLiabilitiesDueDetails</Role>
      <ShortName>Commitments and Contingencies - Maturities of the lease liabilities due (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="imrx-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>41303 - Disclosure - Commitments and Contingencies - Lease cost (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immuneering.com/role/DisclosureCommitmentsAndContingenciesLeaseCostDetails</Role>
      <ShortName>Commitments and Contingencies - Lease cost (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" original="imrx-20211231x10k.htm">imrx-20211231x10k.htm</File>
    <File>imrx-20211231.xsd</File>
    <File>imrx-20211231_cal.xml</File>
    <File>imrx-20211231_def.xml</File>
    <File>imrx-20211231_lab.xml</File>
    <File>imrx-20211231_pre.xml</File>
    <File>imrx-20211231xex21d1.htm</File>
    <File>imrx-20211231xex23d1.htm</File>
    <File>imrx-20211231xex31d1.htm</File>
    <File>imrx-20211231xex31d2.htm</File>
    <File>imrx-20211231xex32d1.htm</File>
    <File>imrx-20211231xex32d2.htm</File>
    <File>imrx-20211231xex4d3.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>imrx-20211231x10k006.jpg</File>
    <File>imrx-20211231x10k007.jpg</File>
    <File>imrx-20211231x10k008.jpg</File>
    <File>imrx-20211231x10k009.jpg</File>
    <File>imrx-20211231x10k010.jpg</File>
    <File>imrx-20211231x10k011.jpg</File>
    <File>imrx-20211231x10k012.jpg</File>
    <File>imrx-20211231x10k013.jpg</File>
    <File>imrx-20211231x10k014.jpg</File>
    <File>imrx-20211231x10k015.jpg</File>
    <File>imrx-20211231x10k016.jpg</File>
    <File>imrx-20211231x10k017.jpg</File>
    <File>imrx-20211231x10k018.jpg</File>
    <File>imrx-20211231x10k019.jpg</File>
    <File>imrx-20211231x10k020.jpg</File>
    <File>imrx-20211231x10k021.jpg</File>
    <File>imrx-20211231x10k022.jpg</File>
    <File>imrx-20211231x10k023.jpg</File>
    <File>imrx-20211231x10k024.jpg</File>
    <File>imrx-20211231x10k025.jpg</File>
    <File>imrx-20211231x10k026.jpg</File>
    <File>imrx-20211231x10k027.jpg</File>
    <File>imrx-20211231x10k028.jpg</File>
    <File>imrx-20211231x10k029.jpg</File>
    <File>imrx-20211231x10k030.jpg</File>
    <File>imrx-20211231x10k031.jpg</File>
    <File>imrx-20211231x10k032.jpg</File>
    <File>imrx-20211231x10k033.jpg</File>
    <File>imrx-20211231x10k034.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="609">http://fasb.org/us-gaap/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy items="42">http://xbrl.sec.gov/dei/2021q4</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>113
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "imrx-20211231x10k.htm": {
   "axisCustom": 0,
   "axisStandard": 21,
   "contextCount": 171,
   "dts": {
    "calculationLink": {
     "local": [
      "imrx-20211231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "imrx-20211231_def.xml"
     ]
    },
    "inline": {
     "local": [
      "imrx-20211231x10k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "imrx-20211231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "imrx-20211231_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "imrx-20211231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"
     ]
    }
   },
   "elementCount": 525,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2021-01-31": 31,
    "http://xbrl.sec.gov/dei/2021q4": 7,
    "total": 38
   },
   "keyCustom": 48,
   "keyStandard": 381,
   "memberCustom": 21,
   "memberStandard": 32,
   "nsprefix": "imrx",
   "nsuri": "http://immuneering.com/20211231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "imrx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00090 - Document - Document and Entity Information",
     "role": "http://immuneering.com/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "imrx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "imrx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10301 - Disclosure - Marketable Securities",
     "role": "http://immuneering.com/role/DisclosureMarketableSecurities",
     "shortName": "Marketable Securities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "imrx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "imrx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10401 - Disclosure - Fair Value Measurements",
     "role": "http://immuneering.com/role/DisclosureFairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "imrx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "imrx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10501 - Disclosure - Property and Equipment, net",
     "role": "http://immuneering.com/role/DisclosurePropertyAndEquipmentNet",
     "shortName": "Property and Equipment, net",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "imrx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "imrx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10601 - Disclosure - Business Combination",
     "role": "http://immuneering.com/role/DisclosureBusinessCombination",
     "shortName": "Business Combination",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "imrx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "imrx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "imrx:AccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10701 - Disclosure - Accrued Expenses",
     "role": "http://immuneering.com/role/DisclosureAccruedExpenses",
     "shortName": "Accrued Expenses",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "imrx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "imrx:AccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "imrx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "imrx:TemporaryEquityDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10801 - Disclosure - Convertible Preferred Stock",
     "role": "http://immuneering.com/role/DisclosureConvertiblePreferredStock",
     "shortName": "Convertible Preferred Stock",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "imrx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "imrx:TemporaryEquityDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "imrx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10901 - Disclosure - Common Stock",
     "role": "http://immuneering.com/role/DisclosureCommonStock",
     "shortName": "Common Stock",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "imrx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "imrx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11001 - Disclosure - Net Loss Per Share Attributable to Common Stockholders",
     "role": "http://immuneering.com/role/DisclosureNetLossPerShareAttributableToCommonStockholders",
     "shortName": "Net Loss Per Share Attributable to Common Stockholders",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "imrx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "imrx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11101 - Disclosure - Stock-Based Compensation",
     "role": "http://immuneering.com/role/DisclosureStockBasedCompensation",
     "shortName": "Stock-Based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "imrx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "imrx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11201 - Disclosure - Income Taxes",
     "role": "http://immuneering.com/role/DisclosureIncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "imrx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "imrx-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_TBpjtOXgEkKQahJJAv0aWg",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00100 - Statement - CONSOLIDATED BALANCE SHEETS",
     "role": "http://immuneering.com/role/StatementConsolidatedBalanceSheets",
     "shortName": "CONSOLIDATED BALANCE SHEETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "imrx-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_TBpjtOXgEkKQahJJAv0aWg",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "imrx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11301 - Disclosure - Commitments and Contingencies",
     "role": "http://immuneering.com/role/DisclosureCommitmentsAndContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "imrx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "imrx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "20202 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "role": "http://immuneering.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "imrx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:ConcentrationRiskCreditRisk",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "imrx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30203 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "role": "http://immuneering.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:ConcentrationRiskCreditRisk",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "imrx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "imrx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:MarketableSecuritiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30303 - Disclosure - Marketable Securities (Tables)",
     "role": "http://immuneering.com/role/DisclosureMarketableSecuritiesTables",
     "shortName": "Marketable Securities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "imrx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:MarketableSecuritiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "imrx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30403 - Disclosure - Fair Value Measurements (Tables)",
     "role": "http://immuneering.com/role/DisclosureFairValueMeasurementsTables",
     "shortName": "Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "imrx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "imrx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30503 - Disclosure - Property and Equipment, net (Tables)",
     "role": "http://immuneering.com/role/DisclosurePropertyAndEquipmentNetTables",
     "shortName": "Property and Equipment, net (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "imrx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "imrx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30603 - Disclosure - Business Combination (Tables)",
     "role": "http://immuneering.com/role/DisclosureBusinessCombinationTables",
     "shortName": "Business Combination (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "imrx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "imrx:AccruedLiabilitiesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "imrx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30703 - Disclosure - Accrued Expenses (Tables)",
     "role": "http://immuneering.com/role/DisclosureAccruedExpensesTables",
     "shortName": "Accrued Expenses (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "imrx:AccruedLiabilitiesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "imrx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "imrx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockByClassTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30903 - Disclosure - Common Stock (Tables)",
     "role": "http://immuneering.com/role/DisclosureCommonStockTables",
     "shortName": "Common Stock (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "imrx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockByClassTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "imrx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "31003 - Disclosure - Net Loss Per Share Attributable to Common Stockholders (Tables)",
     "role": "http://immuneering.com/role/DisclosureNetLossPerShareAttributableToCommonStockholdersTables",
     "shortName": "Net Loss Per Share Attributable to Common Stockholders (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "imrx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "imrx-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_TBpjtOXgEkKQahJJAv0aWg",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Divide_USD_shares_0VraXufKhkCSOUw2U_zvgQ",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00105 - Statement - CONSOLIDATED BALANCE SHEETS (Parentheticals)",
     "role": "http://immuneering.com/role/StatementConsolidatedBalanceSheetsParentheticals",
     "shortName": "CONSOLIDATED BALANCE SHEETS (Parentheticals)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "imrx-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_TBpjtOXgEkKQahJJAv0aWg",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Divide_USD_shares_0VraXufKhkCSOUw2U_zvgQ",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "imrx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "31103 - Disclosure - Stock-Based Compensation (Tables)",
     "role": "http://immuneering.com/role/DisclosureStockBasedCompensationTables",
     "shortName": "Stock-Based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "imrx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "imrx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "31203 - Disclosure - Income Taxes (Tables)",
     "role": "http://immuneering.com/role/DisclosureIncomeTaxesTables",
     "shortName": "Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "imrx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "imrx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "31303 - Disclosure - Commitments and Contingencies (Tables)",
     "role": "http://immuneering.com/role/DisclosureCommitmentsAndContingenciesTables",
     "shortName": "Commitments and Contingencies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "imrx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "imrx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProceedsFromIssuanceOfCommonStock",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40101 - Disclosure - Organization and Nature of Business (Details)",
     "role": "http://immuneering.com/role/DisclosureOrganizationAndNatureOfBusinessDetails",
     "shortName": "Organization and Nature of Business (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "imrx-20211231x10k.htm",
      "contextRef": "Duration_8_3_2021_To_8_3_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_7enA8yNRQkat6QV_1FoEOw",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:ProceedsFromIssuanceOfCommonStock",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:StockholdersEquityPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "imrx-20211231x10k.htm",
      "contextRef": "Duration_7_23_2021_To_7_23_2021_He5Glc1OZUuR4Os2aqbeew",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquityNoteStockSplitConversionRatio1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_pure_iothMaWWqUCV2N7d1PVg4w",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40201 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details)",
     "role": "http://immuneering.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails",
     "shortName": "Summary of Significant Accounting Policies - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:StockholdersEquityPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "imrx-20211231x10k.htm",
      "contextRef": "Duration_7_23_2021_To_7_23_2021_He5Glc1OZUuR4Os2aqbeew",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquityNoteStockSplitConversionRatio1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_pure_iothMaWWqUCV2N7d1PVg4w",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "imrx-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_TBpjtOXgEkKQahJJAv0aWg",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40202 - Disclosure - Summary of Significant Accounting Policies - Concentration of Credit Risk (Details)",
     "role": "http://immuneering.com/role/DisclosureSummaryOfSignificantAccountingPoliciesConcentrationOfCreditRiskDetails",
     "shortName": "Summary of Significant Accounting Policies - Concentration of Credit Risk (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
       "us-gaap:ConcentrationRiskCreditRisk",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "imrx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_srt_MajorCustomersAxis_imrx_CustomerOneMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_oWqze6TNHUeol6NT43Q40A",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "imrx:ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "imrx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_twFlKCzRuEusunTslMr32A",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40203 - Disclosure - Summary of Significant Accounting Policies - Property and Equipment (Details)",
     "role": "http://immuneering.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails",
     "shortName": "Summary of Significant Accounting Policies - Property and Equipment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "imrx:ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "imrx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_twFlKCzRuEusunTslMr32A",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "imrx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ImpairmentOfInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40301 - Disclosure - Marketable Securities (Details)",
     "role": "http://immuneering.com/role/DisclosureMarketableSecuritiesDetails",
     "shortName": "Marketable Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "imrx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ImpairmentOfInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:MarketableSecuritiesTextBlock",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "imrx-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_TBpjtOXgEkKQahJJAv0aWg",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:MarketableSecurities",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40401 - Disclosure - Fair Value Measurements (Details)",
     "role": "http://immuneering.com/role/DisclosureFairValueMeasurementsDetails",
     "shortName": "Fair Value Measurements (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "imrx-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_NZFKYXEtB0ypESwMFRZYaA",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "imrx-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_TBpjtOXgEkKQahJJAv0aWg",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40501 - Disclosure - Property and Equipment, net (Details)",
     "role": "http://immuneering.com/role/DisclosurePropertyAndEquipmentNetDetails",
     "shortName": "Property and Equipment, net (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "imrx-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_TBpjtOXgEkKQahJJAv0aWg",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "imrx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00200 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS",
     "role": "http://immuneering.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss",
     "shortName": "CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "imrx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "imrx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40502 - Disclosure - Property and Equipment, net - Depreciation (Details)",
     "role": "http://immuneering.com/role/DisclosurePropertyAndEquipmentNetDepreciationDetails",
     "shortName": "Property and Equipment, net - Depreciation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "imrx-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2020_us-gaap_BalanceSheetLocationAxis_us-gaap_AccountsPayableAndAccruedLiabilitiesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_imrx_BioArkiveIncMember_Fdx8Pw88t0GYE-WWz9kZLQ",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DueToRelatedPartiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40601 - Disclosure - Business Combination - Narrative (Details)",
     "role": "http://immuneering.com/role/DisclosureBusinessCombinationNarrativeDetails",
     "shortName": "Business Combination - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "imrx-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2020_us-gaap_BalanceSheetLocationAxis_us-gaap_AccountsPayableAndAccruedLiabilitiesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_imrx_BioArkiveIncMember_Fdx8Pw88t0GYE-WWz9kZLQ",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DueToRelatedPartiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "imrx-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_TBpjtOXgEkKQahJJAv0aWg",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40602 - Disclosure - Business Combination - Assets Acquired and Liabilities Assumed (Details)",
     "role": "http://immuneering.com/role/DisclosureBusinessCombinationAssetsAcquiredAndLiabilitiesAssumedDetails",
     "shortName": "Business Combination - Assets Acquired and Liabilities Assumed (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "imrx-20211231x10k.htm",
      "contextRef": "As_Of_12_22_2021_us-gaap_BusinessAcquisitionAxis_imrx_BioArkiveIncMember_eZfDAI7yG0yVohELE3M0sA",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "imrx:AccruedLiabilitiesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "imrx-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_TBpjtOXgEkKQahJJAv0aWg",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccruedProfessionalFeesCurrentAndNoncurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40701 - Disclosure - Accrued Expenses (Details)",
     "role": "http://immuneering.com/role/DisclosureAccruedExpensesDetails",
     "shortName": "Accrued Expenses (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "imrx:AccruedLiabilitiesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "imrx-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_TBpjtOXgEkKQahJJAv0aWg",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccruedProfessionalFeesCurrentAndNoncurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "imrx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:PaymentsOfStockIssuanceCosts",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40801 - Disclosure - Convertible Preferred Stock - Series A (Details)",
     "role": "http://immuneering.com/role/DisclosureConvertiblePreferredStockSeriesDetails",
     "shortName": "Convertible Preferred Stock - Series A (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "imrx:TemporaryEquityDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "imrx-20211231x10k.htm",
      "contextRef": "As_Of_1_31_2020_us-gaap_StatementClassOfStockAxis_imrx_SeriesConvertiblePreferredStockMember_Tref9-4zckC3A4JsB3VTMA",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:TemporaryEquitySharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "imrx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:PaymentsOfStockIssuanceCosts",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40802 - Disclosure - Convertible Preferred Stock - Series B (Details)",
     "role": "http://immuneering.com/role/DisclosureConvertiblePreferredStockSeriesBDetails",
     "shortName": "Convertible Preferred Stock - Series B (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "imrx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ",
      "decimals": "2",
      "lang": null,
      "name": "us-gaap:PreferredStockDividendRatePercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_pure_iothMaWWqUCV2N7d1PVg4w",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "imrx-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_Mo7QF875vUy5d2OcEbQ2fA",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockSharesAuthorized",
      "reportCount": 1,
      "unitRef": "Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40901 - Disclosure - Common Stock - Class A common stock (Details)",
     "role": "http://immuneering.com/role/DisclosureCommonStockClassCommonStockDetails",
     "shortName": "Common Stock - Class A common stock (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "imrx:NumberOfVotesPerShare",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "imrx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_Vps21bPl-0ucIcde4LcmUQ",
      "decimals": "INF",
      "lang": null,
      "name": "imrx:NumberOfVotesPerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_Vote_y6IkSxDgD0SxcVMkCx6yHg",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockByClassTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "imrx-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_TBpjtOXgEkKQahJJAv0aWg",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "reportCount": 1,
      "unitRef": "Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40902 - Disclosure - Common Stock (Details)",
     "role": "http://immuneering.com/role/DisclosureCommonStockDetails",
     "shortName": "Common Stock (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockByClassTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "imrx-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_imrx_SeriesConvertiblePreferredStockMember_LQiWJpT45k-D9eZ63E0DAw",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "imrx-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_4sABCVevMkafGdslrmVHRg",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockSharesAuthorized",
      "reportCount": 1,
      "unitRef": "Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40903 - Disclosure - Common Stock - Class B common stock (Details)",
     "role": "http://immuneering.com/role/DisclosureCommonStockClassBCommonStockDetails",
     "shortName": "Common Stock - Class B common stock (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "imrx:NumberOfVotesPerShare",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "imrx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_6Dv2gap2qUy2S6CUjLz70A",
      "decimals": "INF",
      "lang": null,
      "name": "imrx:NumberOfVotesPerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_Vote_y6IkSxDgD0SxcVMkCx6yHg",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "imrx-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2019_g3mjqkDWB0-f2XKJf0YL-A",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40904 - Disclosure - Common Stock - Common stock warrant (Details)",
     "role": "http://immuneering.com/role/DisclosureCommonStockCommonStockWarrantDetails",
     "shortName": "Common Stock - Common stock warrant (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "imrx-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2019_g3mjqkDWB0-f2XKJf0YL-A",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "imrx-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2019_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_jy9qZmEtiE6UB1aH8SvR-w",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:SharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00300 - Statement - CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT)",
     "role": "http://immuneering.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit",
     "shortName": "CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "imrx-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2019_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_jy9qZmEtiE6UB1aH8SvR-w",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:SharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "imrx-20211231x10k.htm",
      "contextRef": "As_Of_8_3_2021_atfZ3VjOmEGor-TZ8PR3vw",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:TemporaryEquitySharesOutstanding",
      "reportCount": 1,
      "unitRef": "Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40905 - Disclosure - Common Stock - IPO (Details)",
     "role": "http://immuneering.com/role/DisclosureCommonStockIpoDetails",
     "shortName": "Common Stock - IPO (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "imrx-20211231x10k.htm",
      "contextRef": "Duration_8_3_2021_To_8_3_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_7enA8yNRQkat6QV_1FoEOw",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:ProceedsFromIssuanceInitialPublicOffering",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "imrx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41001 - Disclosure - Net Loss Per Share Attributable to Common Stockholders - Basic and diluted net loss per share attributable to common stockholders (Details)",
     "role": "http://immuneering.com/role/DisclosureNetLossPerShareAttributableToCommonStockholdersBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails",
     "shortName": "Net Loss Per Share Attributable to Common Stockholders - Basic and diluted net loss per share attributable to common stockholders (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "imrx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41002 - Disclosure - Net Loss Per Share Attributable to Common Stockholders - Antidilutive effect (Details)",
     "role": "http://immuneering.com/role/DisclosureNetLossPerShareAttributableToCommonStockholdersAntidilutiveEffectDetails",
     "shortName": "Net Loss Per Share Attributable to Common Stockholders - Antidilutive effect (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "imrx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "imrx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41101 - Disclosure - Stock-Based Compensation - Narratives (Details)",
     "role": "http://immuneering.com/role/DisclosureStockBasedCompensationNarrativesDetails",
     "shortName": "Stock-Based Compensation - Narratives (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "imrx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ",
      "decimals": "2",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Divide_USD_shares_0VraXufKhkCSOUw2U_zvgQ",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "imrx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_J_O9OcmviUi8EDFgokrY1Q",
      "decimals": "4",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_pure_iothMaWWqUCV2N7d1PVg4w",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41102 - Disclosure - Stock-Based Compensation - Assumptions (Details)",
     "role": "http://immuneering.com/role/DisclosureStockBasedCompensationAssumptionsDetails",
     "shortName": "Stock-Based Compensation - Assumptions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "imrx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_J_O9OcmviUi8EDFgokrY1Q",
      "decimals": "4",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_pure_iothMaWWqUCV2N7d1PVg4w",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "imrx-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2020_OUSLyqWONEO8ccGPC6rBdg",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41103 - Disclosure - Stock-Based Compensation - stock option activity (Details)",
     "role": "http://immuneering.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails",
     "shortName": "Stock-Based Compensation - stock option activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "imrx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ",
      "decimals": "INF",
      "lang": null,
      "name": "imrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRepurchased",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_fERHuiEhq06dDsrDeSKnfQ",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "imrx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41104 - Disclosure - Stock-Based Compensation - Share-based compensation expense (Details)",
     "role": "http://immuneering.com/role/DisclosureStockBasedCompensationShareBasedCompensationExpenseDetails",
     "shortName": "Stock-Based Compensation - Share-based compensation expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "imrx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_dQH6PYSm8ke4t8B5Xp8bAw",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "imrx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_pure_iothMaWWqUCV2N7d1PVg4w",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41201 - Disclosure - Income Taxes - Net loss and the effective income tax rate (Details)",
     "role": "http://immuneering.com/role/DisclosureIncomeTaxesNetLossAndEffectiveIncomeTaxRateDetails",
     "shortName": "Income Taxes - Net loss and the effective income tax rate (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "imrx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_pure_iothMaWWqUCV2N7d1PVg4w",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "imrx-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_TBpjtOXgEkKQahJJAv0aWg",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41202 - Disclosure - Income Taxes - Net deferred tax assets (Details)",
     "role": "http://immuneering.com/role/DisclosureIncomeTaxesNetDeferredTaxAssetsDetails",
     "shortName": "Income Taxes - Net deferred tax assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "imrx-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_TBpjtOXgEkKQahJJAv0aWg",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "imrx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41203 - Disclosure - Income Taxes - Narrative (Details)",
     "role": "http://immuneering.com/role/DisclosureIncomeTaxesNarrativeDetails",
     "shortName": "Income Taxes - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "imrx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "imrx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "imrx:StockIssuanceCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00305 - Statement - CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT) (Parentheticals)",
     "role": "http://immuneering.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParentheticals",
     "shortName": "CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT) (Parentheticals)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "imrx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "imrx:StockIssuanceCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "imrx-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2020_OUSLyqWONEO8ccGPC6rBdg",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41204 - Disclosure - Income Taxes - Unrecognized tax benefits (Details)",
     "role": "http://immuneering.com/role/DisclosureIncomeTaxesUnrecognizedTaxBenefitsDetails",
     "shortName": "Income Taxes - Unrecognized tax benefits (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "imrx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "imrx-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_TBpjtOXgEkKQahJJAv0aWg",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41301 - Disclosure - Commitments and Contingencies - Narratives (Details)",
     "role": "http://immuneering.com/role/DisclosureCommitmentsAndContingenciesNarrativesDetails",
     "shortName": "Commitments and Contingencies - Narratives (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "imrx-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_us-gaap_BusinessAcquisitionAxis_imrx_BioArkiveIncMember__OkMddmPKES0gb3KLXJAbw",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "imrx-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_TBpjtOXgEkKQahJJAv0aWg",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseLiabilityCurrent",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41302 - Disclosure - Commitments and Contingencies - Maturities of the lease liabilities due (Details)",
     "role": "http://immuneering.com/role/DisclosureCommitmentsAndContingenciesMaturitiesOfLeaseLiabilitiesDueDetails",
     "shortName": "Commitments and Contingencies - Maturities of the lease liabilities due (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "imrx-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_imrx_OfficeLeaseInSanDiegoCalifornia2020Member_1elFJvUqZUChk73Bzb2TRg",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "imrx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41303 - Disclosure - Commitments and Contingencies - Lease cost (Details)",
     "role": "http://immuneering.com/role/DisclosureCommitmentsAndContingenciesLeaseCostDetails",
     "shortName": "Commitments and Contingencies - Lease cost (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "imrx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "imrx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00400 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "role": "http://immuneering.com/role/StatementConsolidatedStatementsOfCashFlows",
     "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "imrx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_tcWu-XqjXkmlhRGVPsfTow",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "imrx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10101 - Disclosure - Organization and Nature of Business",
     "role": "http://immuneering.com/role/DisclosureOrganizationAndNatureOfBusiness",
     "shortName": "Organization and Nature of Business",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "imrx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "imrx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10201 - Disclosure - Summary of Significant Accounting Policies",
     "role": "http://immuneering.com/role/DisclosureSummaryOfSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "imrx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_l6a6jUNHq0StfWm4Mw-tOQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 61,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://immuneering.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditorFirmId": {
     "auth_ref": [
      "r547",
      "r548",
      "r549"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PCAOB issued Audit Firm Identifier",
        "label": "Auditor Firm ID"
       }
      }
     },
     "localname": "AuditorFirmId",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://immuneering.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "nonemptySequenceNumberItemType"
    },
    "dei_AuditorLocation": {
     "auth_ref": [
      "r547",
      "r548",
      "r549"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "localname": "AuditorLocation",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://immuneering.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_AuditorName": {
     "auth_ref": [
      "r547",
      "r548",
      "r549"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "localname": "AuditorName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://immuneering.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://immuneering.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Document and Entity Information"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://immuneering.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r547",
      "r548",
      "r549"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://immuneering.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://immuneering.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://immuneering.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://immuneering.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r550"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://immuneering.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://immuneering.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r545"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]",
        "terseLabel": "Documents Incorporated by Reference"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://immuneering.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://immuneering.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://immuneering.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://immuneering.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://immuneering.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address State Or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://immuneering.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r544"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://immuneering.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://immuneering.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://immuneering.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r544"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://immuneering.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r561"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Entity Ex Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://immuneering.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://immuneering.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r544"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://immuneering.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://immuneering.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r559"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://immuneering.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://immuneering.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r544"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://immuneering.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r544"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://immuneering.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r544"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://immuneering.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r544"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://immuneering.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://immuneering.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r560"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://immuneering.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r547",
      "r548",
      "r549"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://immuneering.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://immuneering.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r543"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://immuneering.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r546"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://immuneering.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://immuneering.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "imrx_AccruedContractResearchExpensesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://immuneering.com/role/DisclosureAccruedExpensesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, related to contract research due within one year or within the normal operating cycle if longer.",
        "label": "Accrued Contract Research Expenses, Current",
        "terseLabel": "Accrued contract research expenses"
       }
      }
     },
     "localname": "AccruedContractResearchExpensesCurrent",
     "nsuri": "http://immuneering.com/20211231",
     "presentation": [
      "http://immuneering.com/role/DisclosureAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imrx_AccruedLiabilitiesDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for accrued liabilities at the end of the reporting period.",
        "label": "Accrued Liabilities Disclosure [Text Block]",
        "terseLabel": "Accrued Expenses"
       }
      }
     },
     "localname": "AccruedLiabilitiesDisclosureTextBlock",
     "nsuri": "http://immuneering.com/20211231",
     "presentation": [
      "http://immuneering.com/role/DisclosureAccruedExpenses"
     ],
     "xbrltype": "textBlockItemType"
    },
    "imrx_AreaOfPropertyUnderLease": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area of property under lease.",
        "label": "Area of Property Under Lease"
       }
      }
     },
     "localname": "AreaOfPropertyUnderLease",
     "nsuri": "http://immuneering.com/20211231",
     "presentation": [
      "http://immuneering.com/role/DisclosureCommitmentsAndContingenciesNarrativesDetails"
     ],
     "xbrltype": "areaItemType"
    },
    "imrx_BioArkiveIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information relating to Bio Arkive Inc.",
        "label": "BioArkive Inc"
       }
      }
     },
     "localname": "BioArkiveIncMember",
     "nsuri": "http://immuneering.com/20211231",
     "presentation": [
      "http://immuneering.com/role/DisclosureBusinessCombinationAssetsAcquiredAndLiabilitiesAssumedDetails",
      "http://immuneering.com/role/DisclosureBusinessCombinationNarrativeDetails",
      "http://immuneering.com/role/DisclosureCommitmentsAndContingenciesNarrativesDetails",
      "http://immuneering.com/role/DisclosureIncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "imrx_BusinessCombinationPurchasePrice": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of purchase price payable for the acquisition.",
        "label": "Business Combination, Purchase Price",
        "terseLabel": "Market value of acquisition"
       }
      }
     },
     "localname": "BusinessCombinationPurchasePrice",
     "nsuri": "http://immuneering.com/20211231",
     "presentation": [
      "http://immuneering.com/role/DisclosureBusinessCombinationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAccruedExpensesAndOtherLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://immuneering.com/role/DisclosureBusinessCombinationAssetsAcquiredAndLiabilitiesAssumedDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accounts payable, accrued expenses and other liabilities due within one year or within the normal operating cycle, if longer, assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable, Accrued Expenses And Other Liabilities",
        "terseLabel": "Accounts payable, accrued expenses and other liabilities"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAccruedExpensesAndOtherLiabilities",
     "nsuri": "http://immuneering.com/20211231",
     "presentation": [
      "http://immuneering.com/role/DisclosureBusinessCombinationAssetsAcquiredAndLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIncludingGoodwill": {
     "auth_ref": [],
     "calculation": {
      "http://immuneering.com/role/DisclosureBusinessCombinationAssetsAcquiredAndLiabilitiesAssumedDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount recognized as of the acquisition date for the identifiable assets including goowill acquired in excess of (less than) the aggregate liabilities assumed.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Including Goodwill",
        "totalLabel": "Total assets acquired"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIncludingGoodwill",
     "nsuri": "http://immuneering.com/20211231",
     "presentation": [
      "http://immuneering.com/role/DisclosureBusinessCombinationAssetsAcquiredAndLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets": {
     "auth_ref": [],
     "calculation": {
      "http://immuneering.com/role/DisclosureBusinessCombinationAssetsAcquiredAndLiabilitiesAssumedDetails": {
       "order": 7.0,
       "parentTag": "imrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIncludingGoodwill",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of right of use assets recognized as of the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Right of Use Assets",
        "terseLabel": "Right of use assets"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets",
     "nsuri": "http://immuneering.com/20211231",
     "presentation": [
      "http://immuneering.com/role/DisclosureBusinessCombinationAssetsAcquiredAndLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imrx_BusinessCombinationSharesIssuedDiscountDueToMarketabilityPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of discount due to lack of marketability for shares issued in business acquisition.",
        "label": "Business Combination Shares Issued, Discount Due To Marketability, Percentage",
        "terseLabel": "Shares issued discount due to lack of marketability"
       }
      }
     },
     "localname": "BusinessCombinationSharesIssuedDiscountDueToMarketabilityPercentage",
     "nsuri": "http://immuneering.com/20211231",
     "presentation": [
      "http://immuneering.com/role/DisclosureBusinessCombinationNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "imrx_BusinessCombinationSharesIssuedLockInPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lock in period for shares issued in acquisition.",
        "label": "Business Combination Shares Issued, Lock in Period",
        "terseLabel": "Lock in period for shares issued"
       }
      }
     },
     "localname": "BusinessCombinationSharesIssuedLockInPeriod",
     "nsuri": "http://immuneering.com/20211231",
     "presentation": [
      "http://immuneering.com/role/DisclosureBusinessCombinationNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "imrx_BusinessCombinationSharesIssuedSharePriceThresholdTradingDays": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Threshold number of specified trading days that common stock price daily volume weighted average prices of the common stock on the Nasdaq Stock Exchange for valuation of shares issued in acquisition.",
        "label": "Business Combination Shares Issued, Share Price, Threshold Trading Days",
        "terseLabel": "Trading days for share price"
       }
      }
     },
     "localname": "BusinessCombinationSharesIssuedSharePriceThresholdTradingDays",
     "nsuri": "http://immuneering.com/20211231",
     "presentation": [
      "http://immuneering.com/role/DisclosureBusinessCombinationNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "imrx_CustomerFiveMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information relating to customer 5.",
        "label": "Customer 5"
       }
      }
     },
     "localname": "CustomerFiveMember",
     "nsuri": "http://immuneering.com/20211231",
     "presentation": [
      "http://immuneering.com/role/DisclosureSummaryOfSignificantAccountingPoliciesConcentrationOfCreditRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "imrx_CustomerFourMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information relating to customer 4.",
        "label": "Customer 4"
       }
      }
     },
     "localname": "CustomerFourMember",
     "nsuri": "http://immuneering.com/20211231",
     "presentation": [
      "http://immuneering.com/role/DisclosureSummaryOfSignificantAccountingPoliciesConcentrationOfCreditRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "imrx_CustomerOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information relating to customer 1.",
        "label": "Customer 1"
       }
      }
     },
     "localname": "CustomerOneMember",
     "nsuri": "http://immuneering.com/20211231",
     "presentation": [
      "http://immuneering.com/role/DisclosureSummaryOfSignificantAccountingPoliciesConcentrationOfCreditRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "imrx_CustomerThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information relating to customer 3.",
        "label": "Customer 3"
       }
      }
     },
     "localname": "CustomerThreeMember",
     "nsuri": "http://immuneering.com/20211231",
     "presentation": [
      "http://immuneering.com/role/DisclosureSummaryOfSignificantAccountingPoliciesConcentrationOfCreditRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "imrx_CustomerTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information relating to customer 2.",
        "label": "Customer 2"
       }
      }
     },
     "localname": "CustomerTwoMember",
     "nsuri": "http://immuneering.com/20211231",
     "presentation": [
      "http://immuneering.com/role/DisclosureSummaryOfSignificantAccountingPoliciesConcentrationOfCreditRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "imrx_EffectiveIncomeTaxRateReconciliationTaxCreditStateResearchAndDevelopmentPercent": {
     "auth_ref": [],
     "calculation": {
      "http://immuneering.com/role/DisclosureIncomeTaxesNetLossAndEffectiveIncomeTaxRateDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state research and development tax credit.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, State Research And Development , Percent",
        "terseLabel": "State research and development credits"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditStateResearchAndDevelopmentPercent",
     "nsuri": "http://immuneering.com/20211231",
     "presentation": [
      "http://immuneering.com/role/DisclosureIncomeTaxesNetLossAndEffectiveIncomeTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "imrx_EffectiveIncomeTaxRateReconciliationUncertainTaxPositions": {
     "auth_ref": [],
     "calculation": {
      "http://immuneering.com/role/DisclosureIncomeTaxesNetLossAndEffectiveIncomeTaxRateDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to uncertain tax positions.",
        "label": "Effective Income Tax Rate Reconciliation, Uncertain Tax Positions",
        "terseLabel": "Uncertain tax positions"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationUncertainTaxPositions",
     "nsuri": "http://immuneering.com/20211231",
     "presentation": [
      "http://immuneering.com/role/DisclosureIncomeTaxesNetLossAndEffectiveIncomeTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "imrx_GovernmentSecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to government securities.",
        "label": "Government securities"
       }
      }
     },
     "localname": "GovernmentSecuritiesMember",
     "nsuri": "http://immuneering.com/20211231",
     "presentation": [
      "http://immuneering.com/role/DisclosureFairValueMeasurementsDetails",
      "http://immuneering.com/role/DisclosureMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "imrx_LabEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lab equipment.",
        "label": "Lab equipment",
        "terseLabel": "Lab equipment"
       }
      }
     },
     "localname": "LabEquipmentMember",
     "nsuri": "http://immuneering.com/20211231",
     "presentation": [
      "http://immuneering.com/role/DisclosurePropertyAndEquipmentNetDetails",
      "http://immuneering.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "imrx_LeasePayments": {
     "auth_ref": [],
     "calculation": {
      "http://immuneering.com/role/DisclosureCommitmentsAndContingenciesLeaseCostDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total cash paid towards operating lease payment including short term lease payment.",
        "label": "Lease Payments",
        "totalLabel": "Total lease Payment"
       }
      }
     },
     "localname": "LeasePayments",
     "nsuri": "http://immuneering.com/20211231",
     "presentation": [
      "http://immuneering.com/role/DisclosureCommitmentsAndContingenciesLeaseCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imrx_LeaseTerminationOnApril302032Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information relating to lease termination on April 30, 2032.",
        "label": "Lease Termination on April 30, 2032 [Member]"
       }
      }
     },
     "localname": "LeaseTerminationOnApril302032Member",
     "nsuri": "http://immuneering.com/20211231",
     "presentation": [
      "http://immuneering.com/role/DisclosureCommitmentsAndContingenciesNarrativesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "imrx_LeaseTerminationOnDecember312022Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information relating to lease termination on December 31, 2022.",
        "label": "Lease Termination on December 31, 2022 [Member]"
       }
      }
     },
     "localname": "LeaseTerminationOnDecember312022Member",
     "nsuri": "http://immuneering.com/20211231",
     "presentation": [
      "http://immuneering.com/role/DisclosureCommitmentsAndContingenciesNarrativesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "imrx_LeaseTerminationOnMarch312024Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information relating to lease termination on March 31, 2024.",
        "label": "Lease Termination on March 31, 2024 [Member]"
       }
      }
     },
     "localname": "LeaseTerminationOnMarch312024Member",
     "nsuri": "http://immuneering.com/20211231",
     "presentation": [
      "http://immuneering.com/role/DisclosureCommitmentsAndContingenciesNarrativesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "imrx_MarketableSecuritiesAccumulatedUnrealizedGains": {
     "auth_ref": [],
     "calculation": {
      "http://immuneering.com/role/DisclosureMarketableSecuritiesDetails": {
       "order": 1.0,
       "parentTag": "imrx_MarketableSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in  marketable securities measured at fair value with change in fair value recognized in other comprehensive income .",
        "label": "Marketable Securities, Accumulated Unrealized Gains",
        "terseLabel": "Marketable securities unrealized gains"
       }
      }
     },
     "localname": "MarketableSecuritiesAccumulatedUnrealizedGains",
     "nsuri": "http://immuneering.com/20211231",
     "presentation": [
      "http://immuneering.com/role/DisclosureMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imrx_MarketableSecuritiesAccumulatedUnrealizedGainsCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://immuneering.com/role/DisclosureMarketableSecuritiesDetails": {
       "order": 1.0,
       "parentTag": "imrx_MarketableSecuritiesAmortizedCostBasisCurrent",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in current marketable securities measured at fair value with change in fair value recognized in other comprehensive income",
        "label": "Marketable Securities, Accumulated Unrealized Gains, Current",
        "terseLabel": "Marketable securities unrealized gains, current"
       }
      }
     },
     "localname": "MarketableSecuritiesAccumulatedUnrealizedGainsCurrent",
     "nsuri": "http://immuneering.com/20211231",
     "presentation": [
      "http://immuneering.com/role/DisclosureMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imrx_MarketableSecuritiesAccumulatedUnrealizedLosses": {
     "auth_ref": [],
     "calculation": {
      "http://immuneering.com/role/DisclosureMarketableSecuritiesDetails": {
       "order": 2.0,
       "parentTag": "imrx_MarketableSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in  marketable securities measured at fair value with change in fair value recognized in other comprehensive income.",
        "label": "Marketable Securities, Accumulated Unrealized Losses",
        "negatedLabel": "Marketable securities unrealized losses"
       }
      }
     },
     "localname": "MarketableSecuritiesAccumulatedUnrealizedLosses",
     "nsuri": "http://immuneering.com/20211231",
     "presentation": [
      "http://immuneering.com/role/DisclosureMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imrx_MarketableSecuritiesAccumulatedUnrealizedLossesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://immuneering.com/role/DisclosureMarketableSecuritiesDetails": {
       "order": 2.0,
       "parentTag": "imrx_MarketableSecuritiesAmortizedCostBasisCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in current marketable securities measured at fair value with change in fair value recognized in other comprehensive income.",
        "label": "Marketable Securities, Accumulated Unrealized Losses, Current",
        "negatedLabel": "Marketable securities unrealized losses, current"
       }
      }
     },
     "localname": "MarketableSecuritiesAccumulatedUnrealizedLossesCurrent",
     "nsuri": "http://immuneering.com/20211231",
     "presentation": [
      "http://immuneering.com/role/DisclosureMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imrx_MarketableSecuritiesAccumulatedUnrealizedLossesNonCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://immuneering.com/role/DisclosureMarketableSecuritiesDetails": {
       "order": 1.0,
       "parentTag": "imrx_MarketableSecuritiesAmortizedCostBasisNonCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in Non-current marketable securities measured at fair value with change in fair value recognized in other comprehensive income.",
        "label": "Marketable Securities, Accumulated Unrealized Losses, Non-current",
        "negatedLabel": "Marketable securities unrealized losses, non-current"
       }
      }
     },
     "localname": "MarketableSecuritiesAccumulatedUnrealizedLossesNonCurrent",
     "nsuri": "http://immuneering.com/20211231",
     "presentation": [
      "http://immuneering.com/role/DisclosureMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imrx_MarketableSecuritiesAmortizedCostBasis": {
     "auth_ref": [],
     "calculation": {
      "http://immuneering.com/role/DisclosureMarketableSecuritiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in  marketable securities measured at fair value with change in fair value recognized in other comprehensive income.",
        "label": "Marketable Securities, Amortized Cost Basis",
        "totalLabel": "Marketable securities at amortized cost"
       }
      }
     },
     "localname": "MarketableSecuritiesAmortizedCostBasis",
     "nsuri": "http://immuneering.com/20211231",
     "presentation": [
      "http://immuneering.com/role/DisclosureMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imrx_MarketableSecuritiesAmortizedCostBasisCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://immuneering.com/role/DisclosureMarketableSecuritiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in current marketable securities measured at fair value with change in fair value recognized in other comprehensive income.",
        "label": "Marketable Securities, Amortized Cost Basis, Current",
        "totalLabel": "Marketable securities at amortized cost, current"
       }
      }
     },
     "localname": "MarketableSecuritiesAmortizedCostBasisCurrent",
     "nsuri": "http://immuneering.com/20211231",
     "presentation": [
      "http://immuneering.com/role/DisclosureMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imrx_MarketableSecuritiesAmortizedCostBasisNonCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://immuneering.com/role/DisclosureMarketableSecuritiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in Non-current marketable securities measured at fair value with change in fair value recognized in other comprehensive income.",
        "label": "Marketable Securities, Amortized Cost Basis, Non-current",
        "totalLabel": "Marketable securities at amortized cost, non-current"
       }
      }
     },
     "localname": "MarketableSecuritiesAmortizedCostBasisNonCurrent",
     "nsuri": "http://immuneering.com/20211231",
     "presentation": [
      "http://immuneering.com/role/DisclosureMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imrx_MarketableSecuritiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "Marketable Securities, Current [Abstract]",
        "terseLabel": "Marketable securities, current"
       }
      }
     },
     "localname": "MarketableSecuritiesCurrentAbstract",
     "nsuri": "http://immuneering.com/20211231",
     "presentation": [
      "http://immuneering.com/role/DisclosureMarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "imrx_MarketableSecuritiesFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://immuneering.com/role/DisclosureFairValueMeasurementsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of marketable securities.",
        "label": "Marketable Securities, Fair Value Disclosure",
        "terseLabel": "Total marketable securities"
       }
      }
     },
     "localname": "MarketableSecuritiesFairValueDisclosure",
     "nsuri": "http://immuneering.com/20211231",
     "presentation": [
      "http://immuneering.com/role/DisclosureFairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imrx_MarketableSecuritiesNonCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "Marketable Securities, Non-current [Abstract]",
        "terseLabel": "Marketable securities, non-current"
       }
      }
     },
     "localname": "MarketableSecuritiesNonCurrentAbstract",
     "nsuri": "http://immuneering.com/20211231",
     "presentation": [
      "http://immuneering.com/role/DisclosureMarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "imrx_NumberOfLeasesObligationsAssumed": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of lease obligations acquired in business combination.",
        "label": "Number of Leases Obligations Assumed",
        "terseLabel": "Number of lease obligations acquired"
       }
      }
     },
     "localname": "NumberOfLeasesObligationsAssumed",
     "nsuri": "http://immuneering.com/20211231",
     "presentation": [
      "http://immuneering.com/role/DisclosureBusinessCombinationNarrativeDetails",
      "http://immuneering.com/role/DisclosureCommitmentsAndContingenciesNarrativesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "imrx_NumberOfTranches": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of tranches.",
        "label": "Number of Tranches",
        "terseLabel": "Number of tranches"
       }
      }
     },
     "localname": "NumberOfTranches",
     "nsuri": "http://immuneering.com/20211231",
     "presentation": [
      "http://immuneering.com/role/DisclosureConvertiblePreferredStockSeriesBDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "imrx_NumberOfVotesPerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of votes per share.",
        "label": "Number of Votes Per Share",
        "terseLabel": "Number of votes"
       }
      }
     },
     "localname": "NumberOfVotesPerShare",
     "nsuri": "http://immuneering.com/20211231",
     "presentation": [
      "http://immuneering.com/role/DisclosureCommonStockClassBCommonStockDetails",
      "http://immuneering.com/role/DisclosureCommonStockClassCommonStockDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "imrx_OfferingCostPayable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of offering costs payable by the Company.",
        "label": "Offering Cost Payable",
        "terseLabel": "Offering costs"
       }
      }
     },
     "localname": "OfferingCostPayable",
     "nsuri": "http://immuneering.com/20211231",
     "presentation": [
      "http://immuneering.com/role/DisclosureCommonStockIpoDetails",
      "http://immuneering.com/role/DisclosureOrganizationAndNatureOfBusinessDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imrx_OfficeLeaseInSanDiegoCalifornia2020Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to office lease in San Diego, California 2020.",
        "label": "2020 San Diego Lease"
       }
      }
     },
     "localname": "OfficeLeaseInSanDiegoCalifornia2020Member",
     "nsuri": "http://immuneering.com/20211231",
     "presentation": [
      "http://immuneering.com/role/DisclosureCommitmentsAndContingenciesMaturitiesOfLeaseLiabilitiesDueDetails",
      "http://immuneering.com/role/DisclosureCommitmentsAndContingenciesNarrativesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "imrx_OfficeSpaceInCambridgeMassachusettsNewYorkMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to leases office space in Cambridge, Massachusetts, New York.",
        "label": "Office Space In Cambridge, Massachusetts, New York [Member]"
       }
      }
     },
     "localname": "OfficeSpaceInCambridgeMassachusettsNewYorkMember",
     "nsuri": "http://immuneering.com/20211231",
     "presentation": [
      "http://immuneering.com/role/DisclosureCommitmentsAndContingenciesNarrativesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "imrx_OperatingLeaseAdditionalInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "Operating Lease, Additional Information [Abstract]",
        "terseLabel": "Cash paid for amounts included in the measurement of lease liabilities:"
       }
      }
     },
     "localname": "OperatingLeaseAdditionalInformationAbstract",
     "nsuri": "http://immuneering.com/20211231",
     "presentation": [
      "http://immuneering.com/role/DisclosureCommitmentsAndContingenciesLeaseCostDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "imrx_PatentCostsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for patent costs.",
        "label": "Patent Costs Policy [Policy Text Block]",
        "terseLabel": "Patent Costs"
       }
      }
     },
     "localname": "PatentCostsPolicyPolicyTextBlock",
     "nsuri": "http://immuneering.com/20211231",
     "presentation": [
      "http://immuneering.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "imrx_PercentageOfAggregateNumberOfSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of aggregate number of shares outstanding.",
        "label": "Aggregate number of shares outstanding (as a percent)"
       }
      }
     },
     "localname": "PercentageOfAggregateNumberOfSharesOutstanding",
     "nsuri": "http://immuneering.com/20211231",
     "presentation": [
      "http://immuneering.com/role/DisclosureStockBasedCompensationNarrativesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "imrx_PercentageOfEquitySecuritiesOwnedToGetConvertedStock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of equity securities to be owned may elect to receive a portion of their converted shares upon conversion.",
        "label": "Percentage of Equity Securities Owned, To Get Converted Stock",
        "terseLabel": "Percentage of equity securities to be own"
       }
      }
     },
     "localname": "PercentageOfEquitySecuritiesOwnedToGetConvertedStock",
     "nsuri": "http://immuneering.com/20211231",
     "presentation": [
      "http://immuneering.com/role/DisclosureConvertiblePreferredStockSeriesBDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "imrx_ProceedsFromIssuanceOfConvertiblePreferredStockExcessOfAuthorizedAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock excess of amount authorized by the articles of incorporation.",
        "label": "Proceeds from Issuance of Convertible Preferred Stock Excess of Authorized Amount",
        "terseLabel": "Proceeds from issuance of shares excess of amount authorized"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfConvertiblePreferredStockExcessOfAuthorizedAmount",
     "nsuri": "http://immuneering.com/20211231",
     "presentation": [
      "http://immuneering.com/role/DisclosureConvertiblePreferredStockSeriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imrx_ReclassificationOfLiabilityOfPreferredStock": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The liability of preferred stock reclassified during the period.",
        "label": "Reclassification of Liability of Preferred Stock",
        "terseLabel": "Reclassification of liability for Series A preferred stock"
       }
      }
     },
     "localname": "ReclassificationOfLiabilityOfPreferredStock",
     "nsuri": "http://immuneering.com/20211231",
     "presentation": [
      "http://immuneering.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imrx_ResearchAndManufacturingContractCostsAndAccrualsPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for research and manufacturing contract costs and accruals.",
        "label": "Research and Manufacturing Contract Costs and Accruals [Policy Text Block]",
        "terseLabel": "Research and Manufacturing Contract Costs and Accruals"
       }
      }
     },
     "localname": "ResearchAndManufacturingContractCostsAndAccrualsPolicyTextBlock",
     "nsuri": "http://immuneering.com/20211231",
     "presentation": [
      "http://immuneering.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "imrx_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the useful life of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.",
        "label": "Schedule of Property, Plant and Equipment, Useful Life [Table Text Block]",
        "terseLabel": "Schedule of property and equipment"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock",
     "nsuri": "http://immuneering.com/20211231",
     "presentation": [
      "http://immuneering.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "imrx_SeriesBConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series B preferred stock that may be exchanged into common shares or other types of securities at the owner's option.",
        "label": "Series B Preferred Stock"
       }
      }
     },
     "localname": "SeriesBConvertiblePreferredStockMember",
     "nsuri": "http://immuneering.com/20211231",
     "presentation": [
      "http://immuneering.com/role/DisclosureCommonStockDetails",
      "http://immuneering.com/role/DisclosureConvertiblePreferredStockSeriesBDetails",
      "http://immuneering.com/role/DisclosureNetLossPerShareAttributableToCommonStockholdersAntidilutiveEffectDetails",
      "http://immuneering.com/role/StatementConsolidatedBalanceSheets",
      "http://immuneering.com/role/StatementConsolidatedBalanceSheetsParentheticals",
      "http://immuneering.com/role/StatementConsolidatedStatementsOfCashFlows",
      "http://immuneering.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "imrx_SeriesBConvertiblePreferredStockTrancheTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to series B preferred stock tranche two.",
        "label": "Series B Preferred Stock Tranche Two"
       }
      }
     },
     "localname": "SeriesBConvertiblePreferredStockTrancheTwoMember",
     "nsuri": "http://immuneering.com/20211231",
     "presentation": [
      "http://immuneering.com/role/DisclosureConvertiblePreferredStockSeriesBDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "imrx_SeriesBConvertiblePreferredStocksTrancheOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to series B preferred stock tranche one.",
        "label": "Series B Preferred Stock Tranche One"
       }
      }
     },
     "localname": "SeriesBConvertiblePreferredStocksTrancheOneMember",
     "nsuri": "http://immuneering.com/20211231",
     "presentation": [
      "http://immuneering.com/role/DisclosureConvertiblePreferredStockSeriesBDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "imrx_SeriesConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series A preferred stock that may be exchanged into common shares or other types of securities at the owner's option.",
        "label": "Series A Preferred Stock"
       }
      }
     },
     "localname": "SeriesConvertiblePreferredStockMember",
     "nsuri": "http://immuneering.com/20211231",
     "presentation": [
      "http://immuneering.com/role/DisclosureCommonStockDetails",
      "http://immuneering.com/role/DisclosureConvertiblePreferredStockSeriesDetails",
      "http://immuneering.com/role/DisclosureNetLossPerShareAttributableToCommonStockholdersAntidilutiveEffectDetails",
      "http://immuneering.com/role/StatementConsolidatedBalanceSheets",
      "http://immuneering.com/role/StatementConsolidatedBalanceSheetsParentheticals",
      "http://immuneering.com/role/StatementConsolidatedStatementsOfCashFlows",
      "http://immuneering.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "imrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Intrinsic Value [Abstract]",
        "terseLabel": "Aggregate Intrinsic Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract",
     "nsuri": "http://immuneering.com/20211231",
     "presentation": [
      "http://immuneering.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "imrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRepurchased": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares repurchased during the period under share based payment award.",
        "label": "Share Based Compensation Arrangement by Share Based Payment Award, Options Repurchased",
        "negatedLabel": "Repurchased (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRepurchased",
     "nsuri": "http://immuneering.com/20211231",
     "presentation": [
      "http://immuneering.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "imrx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsRepurchasedInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average exercise price of shares repurchased during the period under share based payment award.",
        "label": "Share Based Compensation Arrangements By Share Based Payment Award Options, Repurchased In Period Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price per Share Repurchased (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsRepurchasedInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://immuneering.com/20211231",
     "presentation": [
      "http://immuneering.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "imrx_StockIncentivePlan2015Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Stock incentive plan 2015.",
        "label": "Incentive Plan"
       }
      }
     },
     "localname": "StockIncentivePlan2015Member",
     "nsuri": "http://immuneering.com/20211231",
     "presentation": [
      "http://immuneering.com/role/DisclosureStockBasedCompensationNarrativesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "imrx_StockIssuanceCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of stock issuance costs.",
        "label": "Stock Issuance Costs",
        "terseLabel": "Issuance costs"
       }
      }
     },
     "localname": "StockIssuanceCosts",
     "nsuri": "http://immuneering.com/20211231",
     "presentation": [
      "http://immuneering.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParentheticals"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imrx_StockIssuedDuringPeriodSharesWarrantsExercised": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share warrants exercised during the current period.",
        "label": "Stock Issued During Period, Shares, Warrants Exercised",
        "terseLabel": "Issuance of common stock upon exercise of warrants (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesWarrantsExercised",
     "nsuri": "http://immuneering.com/20211231",
     "presentation": [
      "http://immuneering.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "imrx_StockIssuedDuringPeriodValueWarrantsExercised": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of warrants.",
        "label": "Stock Issued During Period, Value, Warrants Exercised",
        "terseLabel": "Issuance of common stock upon exercise of warrants"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueWarrantsExercised",
     "nsuri": "http://immuneering.com/20211231",
     "presentation": [
      "http://immuneering.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imrx_StorageSpaceInSomervilleMassachusettsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to leases storage space for its electronic data equipment in Somerville, Massachusetts.",
        "label": "Storage Space In Somerville, Massachusetts [Member]"
       }
      }
     },
     "localname": "StorageSpaceInSomervilleMassachusettsMember",
     "nsuri": "http://immuneering.com/20211231",
     "presentation": [
      "http://immuneering.com/role/DisclosureCommitmentsAndContingenciesNarrativesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "imrx_TaxCreditCarryforwardIncreaseDecreaseCaresAct": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in t tax credit carryforward from application of the Coronavirus Aid, Relief, and Economic Security (CARES) Act.",
        "label": "Tax Credit Carryforward, Increase (Decrease), CARES Act"
       }
      }
     },
     "localname": "TaxCreditCarryforwardIncreaseDecreaseCaresAct",
     "nsuri": "http://immuneering.com/20211231",
     "presentation": [
      "http://immuneering.com/role/DisclosureIncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imrx_TemporaryEquityContingentlyIssuableShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of convertible preferred shares does not meet the definition of a freestanding financial instrument and are issuable subject to the company meeting certain development milestones and other conditions as specified.",
        "label": "Temporary Equity, Contingently Issuable Shares",
        "terseLabel": "Number of shares not meet the definition of a freestanding financial instrument"
       }
      }
     },
     "localname": "TemporaryEquityContingentlyIssuableShares",
     "nsuri": "http://immuneering.com/20211231",
     "presentation": [
      "http://immuneering.com/role/DisclosureConvertiblePreferredStockSeriesBDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "imrx_TemporaryEquityConversionPrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of conversion price of temporary equity.",
        "label": "Temporary Equity, Conversion Price",
        "terseLabel": "Convertible preferred stock, conversion price"
       }
      }
     },
     "localname": "TemporaryEquityConversionPrice",
     "nsuri": "http://immuneering.com/20211231",
     "presentation": [
      "http://immuneering.com/role/DisclosureConvertiblePreferredStockSeriesBDetails",
      "http://immuneering.com/role/DisclosureConvertiblePreferredStockSeriesDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "imrx_TemporaryEquityDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for  temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity Disclosure [Text Block]",
        "terseLabel": "Convertible Preferred Stock"
       }
      }
     },
     "localname": "TemporaryEquityDisclosureTextBlock",
     "nsuri": "http://immuneering.com/20211231",
     "presentation": [
      "http://immuneering.com/role/DisclosureConvertiblePreferredStock"
     ],
     "xbrltype": "textBlockItemType"
    },
    "imrx_TemporaryEquityDueToExcessAuthorizedAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of liability recognized due to shares issued in excess of amount authorized by the articles of incorporation.",
        "label": "Temporary Equity, Due to Excess Authorized Amount",
        "terseLabel": "Convertible preferred stock liability"
       }
      }
     },
     "localname": "TemporaryEquityDueToExcessAuthorizedAmount",
     "nsuri": "http://immuneering.com/20211231",
     "presentation": [
      "http://immuneering.com/role/DisclosureConvertiblePreferredStockSeriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imrx_TemporaryEquityIssuancePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance price of temporary equity.",
        "label": "Temporary Equity, Issuance Price",
        "terseLabel": "Convertible preferred stock, issuance price (in dollars per share)"
       }
      }
     },
     "localname": "TemporaryEquityIssuancePrice",
     "nsuri": "http://immuneering.com/20211231",
     "presentation": [
      "http://immuneering.com/role/DisclosureConvertiblePreferredStockSeriesBDetails",
      "http://immuneering.com/role/DisclosureConvertiblePreferredStockSeriesDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "imrx_TemporaryEquityNumberOfSharesExcessOfAuthorized": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders excess of authorized by the articles of incorporation.",
        "label": "Temporary Equity, Number of Shares Excess of Authorized",
        "terseLabel": "Number of shares excess of authorized"
       }
      }
     },
     "localname": "TemporaryEquityNumberOfSharesExcessOfAuthorized",
     "nsuri": "http://immuneering.com/20211231",
     "presentation": [
      "http://immuneering.com/role/DisclosureConvertiblePreferredStockSeriesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "imrx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock classified as temporary equity issued during the period.",
        "label": "Temporary Equity, Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Issuance of convertible preferred stock, net of issuance costs (in shares)"
       }
      }
     },
     "localname": "TemporaryEquityStockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://immuneering.com/20211231",
     "presentation": [
      "http://immuneering.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "imrx_TwoThousandTwentyOneEmployeeStockPurchasePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to 2021 Employee Stock Purchase Plan.",
        "label": "2021 ESPP"
       }
      }
     },
     "localname": "TwoThousandTwentyOneEmployeeStockPurchasePlanMember",
     "nsuri": "http://immuneering.com/20211231",
     "presentation": [
      "http://immuneering.com/role/DisclosureStockBasedCompensationNarrativesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "imrx_TwoThousandTwentyOneIncentiveAwardPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to 2021 Incentive Award Plan.",
        "label": "2021 Plan"
       }
      }
     },
     "localname": "TwoThousandTwentyOneIncentiveAwardPlanMember",
     "nsuri": "http://immuneering.com/20211231",
     "presentation": [
      "http://immuneering.com/role/DisclosureStockBasedCompensationNarrativesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "imrx_WarrantsExercised": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of warrants exercised.",
        "label": "Warrants Exercised",
        "terseLabel": "Warrant exercised"
       }
      }
     },
     "localname": "WarrantsExercised",
     "nsuri": "http://immuneering.com/20211231",
     "presentation": [
      "http://immuneering.com/role/DisclosureCommonStockCommonStockWarrantDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "imrx_WarrantsIssuedInLieuOfCashPayment": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of warrants issued to board of director's in lieu of cash payments.",
        "label": "Warrants Issued in Lieu of Cash Payment",
        "terseLabel": "Warrants in lieu of cash payment"
       }
      }
     },
     "localname": "WarrantsIssuedInLieuOfCashPayment",
     "nsuri": "http://immuneering.com/20211231",
     "presentation": [
      "http://immuneering.com/role/DisclosureCommonStockCommonStockWarrantDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "srt_MajorCustomersAxis": {
     "auth_ref": [
      "r169",
      "r280",
      "r281",
      "r525"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Axis]"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureSummaryOfSignificantAccountingPoliciesConcentrationOfCreditRiskDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r232",
      "r245",
      "r294",
      "r296",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r473",
      "r524",
      "r526",
      "r540",
      "r541"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureStockBasedCompensationAssumptionsDetails",
      "http://immuneering.com/role/DisclosureStockBasedCompensationNarrativesDetails",
      "http://immuneering.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r232",
      "r245",
      "r294",
      "r296",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r473",
      "r524",
      "r526",
      "r540",
      "r541"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureConvertiblePreferredStockSeriesBDetails",
      "http://immuneering.com/role/DisclosureConvertiblePreferredStockSeriesDetails",
      "http://immuneering.com/role/DisclosureStockBasedCompensationAssumptionsDetails",
      "http://immuneering.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_NameOfMajorCustomerDomain": {
     "auth_ref": [
      "r169",
      "r280",
      "r281",
      "r525"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Domain]"
       }
      }
     },
     "localname": "NameOfMajorCustomerDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureSummaryOfSignificantAccountingPoliciesConcentrationOfCreditRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r232",
      "r245",
      "r283",
      "r294",
      "r296",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r473",
      "r524",
      "r526",
      "r540",
      "r541"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureConvertiblePreferredStockSeriesBDetails",
      "http://immuneering.com/role/DisclosureConvertiblePreferredStockSeriesDetails",
      "http://immuneering.com/role/DisclosureStockBasedCompensationAssumptionsDetails",
      "http://immuneering.com/role/DisclosureStockBasedCompensationNarrativesDetails",
      "http://immuneering.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r232",
      "r245",
      "r283",
      "r294",
      "r296",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r473",
      "r524",
      "r526",
      "r540",
      "r541"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureConvertiblePreferredStockSeriesBDetails",
      "http://immuneering.com/role/DisclosureConvertiblePreferredStockSeriesDetails",
      "http://immuneering.com/role/DisclosureStockBasedCompensationAssumptionsDetails",
      "http://immuneering.com/role/DisclosureStockBasedCompensationNarrativesDetails",
      "http://immuneering.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing accounts payable and accrued liabilities.",
        "label": "Accounts payable or accrued expenses"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureBusinessCombinationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r34",
      "r442"
     ],
     "calculation": {
      "http://immuneering.com/role/StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableMember": {
     "auth_ref": [
      "r535"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Due from customers or clients for goods or services that have been delivered or sold.",
        "label": "Accounts receivable"
       }
      }
     },
     "localname": "AccountsReceivableMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureSummaryOfSignificantAccountingPoliciesConcentrationOfCreditRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r4",
      "r18",
      "r170",
      "r171"
     ],
     "calculation": {
      "http://immuneering.com/role/StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureSummaryOfSignificantAccountingPoliciesConcentrationOfCreditRiskDetails",
      "http://immuneering.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedEmployeeBenefitsCurrentAndNoncurrent": {
     "auth_ref": [
      "r495",
      "r517"
     ],
     "calculation": {
      "http://immuneering.com/role/DisclosureAccruedExpensesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them.",
        "label": "Accrued Employee Benefits",
        "terseLabel": "Accrued employee expenses"
       }
      }
     },
     "localname": "AccruedEmployeeBenefitsCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r37"
     ],
     "calculation": {
      "http://immuneering.com/role/DisclosureAccruedExpensesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://immuneering.com/role/StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued expenses",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureAccruedExpensesDetails",
      "http://immuneering.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Expenses"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent": {
     "auth_ref": [
      "r495",
      "r517"
     ],
     "calculation": {
      "http://immuneering.com/role/DisclosureAccruedExpensesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received.",
        "label": "Accrued Professional Fees",
        "terseLabel": "Accrued professional services"
       }
      }
     },
     "localname": "AccruedProfessionalFeesCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r31",
      "r207"
     ],
     "calculation": {
      "http://immuneering.com/role/DisclosurePropertyAndEquipmentNetDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Accumulated depreciation"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosurePropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r21",
      "r47",
      "r48",
      "r49",
      "r512",
      "r531",
      "r532"
     ],
     "calculation": {
      "http://immuneering.com/role/StatementConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r46",
      "r49",
      "r57",
      "r58",
      "r59",
      "r100",
      "r101",
      "r102",
      "r386",
      "r527",
      "r528",
      "r562"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife": {
     "auth_ref": [
      "r201"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Acquired Finite-lived Intangible Assets, Weighted Average Useful Life",
        "terseLabel": "Weighted Average Life, technology"
       }
      }
     },
     "localname": "AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureBusinessCombinationAssetsAcquiredAndLiabilitiesAssumedDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r19",
      "r323",
      "r442"
     ],
     "calculation": {
      "http://immuneering.com/role/StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r100",
      "r101",
      "r102",
      "r320",
      "r321",
      "r322",
      "r393"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-In Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r297",
      "r298",
      "r326",
      "r327"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustment to reconcile to net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r298",
      "r316",
      "r325"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based Payment Arrangement, Expense",
        "terseLabel": "Stock-based compensation expense",
        "verboseLabel": "Share-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureStockBasedCompensationNarrativesDetails",
      "http://immuneering.com/role/DisclosureStockBasedCompensationShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables": {
     "auth_ref": [
      "r172"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The valuation allowance as of the balance sheet date to reduce the gross amount of receivables to estimated net realizable value, which would be presented in parentheses on the face of the balance sheet.",
        "label": "Allowance for Doubtful Accounts, Premiums and Other Receivables",
        "terseLabel": "Allowance for doubtful accounts"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r122"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Total shares of common stock equivalents"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureNetLossPerShareAttributableToCommonStockholdersAntidilutiveEffectDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r122"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureNetLossPerShareAttributableToCommonStockholdersAntidilutiveEffectDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureNetLossPerShareAttributableToCommonStockholdersAntidilutiveEffectDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r122"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureNetLossPerShareAttributableToCommonStockholdersAntidilutiveEffectDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r93",
      "r150",
      "r159",
      "r165",
      "r183",
      "r219",
      "r220",
      "r221",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r230",
      "r231",
      "r384",
      "r387",
      "r410",
      "r440",
      "r442",
      "r492",
      "r511"
     ],
     "calculation": {
      "http://immuneering.com/role/StatementConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r6",
      "r7",
      "r45",
      "r93",
      "r183",
      "r219",
      "r220",
      "r221",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r230",
      "r231",
      "r384",
      "r387",
      "r410",
      "r440",
      "r442"
     ],
     "calculation": {
      "http://immuneering.com/role/StatementConsolidatedBalanceSheets": {
       "order": 7.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r396"
     ],
     "calculation": {
      "http://immuneering.com/role/DisclosureFairValueMeasurementsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "totalLabel": "Total cash equivalents and marketable securities"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureFairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Fair Value Disclosure [Abstract]",
        "terseLabel": "Assets:"
       }
      }
     },
     "localname": "AssetsFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureFairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureBusinessCombinationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r390",
      "r391"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureBusinessCombinationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [
      "r293",
      "r295"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition, Acquiree [Domain]"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureBusinessCombinationAssetsAcquiredAndLiabilitiesAssumedDetails",
      "http://immuneering.com/role/DisclosureBusinessCombinationNarrativeDetails",
      "http://immuneering.com/role/DisclosureCommitmentsAndContingenciesNarrativesDetails",
      "http://immuneering.com/role/DisclosureIncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r293",
      "r295",
      "r374",
      "r375"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureBusinessCombinationAssetsAcquiredAndLiabilitiesAssumedDetails",
      "http://immuneering.com/role/DisclosureBusinessCombinationNarrativeDetails",
      "http://immuneering.com/role/DisclosureCommitmentsAndContingenciesNarrativesDetails",
      "http://immuneering.com/role/DisclosureIncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Business Acquisition [Line Items]"
       }
      }
     },
     "localname": "BusinessAcquisitionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureBusinessCombinationAssetsAcquiredAndLiabilitiesAssumedDetails",
      "http://immuneering.com/role/DisclosureBusinessCombinationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationAcquisitionRelatedCosts": {
     "auth_ref": [
      "r373"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.",
        "label": "Business Combination, Acquisition Related Costs",
        "terseLabel": "Business combination non cash"
       }
      }
     },
     "localname": "BusinessCombinationAcquisitionRelatedCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationConsiderationTransferred1": {
     "auth_ref": [
      "r379",
      "r380",
      "r381"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.",
        "label": "Business Combination, Consideration Transferred",
        "terseLabel": "Consideration transferred"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferred1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureBusinessCombinationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationDisclosureTextBlock": {
     "auth_ref": [
      "r383"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).",
        "label": "Business Combination Disclosure [Text Block]",
        "terseLabel": "Business Combination."
       }
      }
     },
     "localname": "BusinessCombinationDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureBusinessCombination"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation": {
     "auth_ref": [
      "r377"
     ],
     "calculation": {
      "http://immuneering.com/role/DisclosureBusinessCombinationAssetsAcquiredAndLiabilitiesAssumedDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease obligation assumed in business combination.",
        "label": "Business Combination, Recognized Identifiable Asset Acquired and Liability Assumed, Lease Obligation",
        "terseLabel": "Lease liabilities"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureBusinessCombinationAssetsAcquiredAndLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents": {
     "auth_ref": [
      "r377"
     ],
     "calculation": {
      "http://immuneering.com/role/DisclosureBusinessCombinationAssetsAcquiredAndLiabilitiesAssumedDetails": {
       "order": 3.0,
       "parentTag": "imrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIncludingGoodwill",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents",
        "terseLabel": "Cash"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureBusinessCombinationAssetsAcquiredAndLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther": {
     "auth_ref": [
      "r377"
     ],
     "calculation": {
      "http://immuneering.com/role/DisclosureBusinessCombinationAssetsAcquiredAndLiabilitiesAssumedDetails": {
       "order": 4.0,
       "parentTag": "imrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIncludingGoodwill",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of other assets expected to be realized or consumed before one year or the normal operating cycle, if longer, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Other",
        "terseLabel": "Other currents assets"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureBusinessCombinationAssetsAcquiredAndLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities": {
     "auth_ref": [
      "r377"
     ],
     "calculation": {
      "http://immuneering.com/role/DisclosureBusinessCombinationAssetsAcquiredAndLiabilitiesAssumedDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities",
        "terseLabel": "Deferred tax liabilities"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureBusinessCombinationAssetsAcquiredAndLiabilitiesAssumedDetails",
      "http://immuneering.com/role/DisclosureIncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill [Abstract]",
        "terseLabel": "Intangible asset"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureBusinessCombinationAssetsAcquiredAndLiabilitiesAssumedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles": {
     "auth_ref": [
      "r376",
      "r377"
     ],
     "calculation": {
      "http://immuneering.com/role/DisclosureBusinessCombinationAssetsAcquiredAndLiabilitiesAssumedDetails": {
       "order": 2.0,
       "parentTag": "imrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIncludingGoodwill",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of identifiable intangible assets recognized as of the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles",
        "terseLabel": "Technology"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureBusinessCombinationAssetsAcquiredAndLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets": {
     "auth_ref": [
      "r377"
     ],
     "calculation": {
      "http://immuneering.com/role/DisclosureBusinessCombinationAssetsAcquiredAndLiabilitiesAssumedDetails": {
       "order": 5.0,
       "parentTag": "imrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIncludingGoodwill",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of other assets expected to be realized or consumed after one year or the normal operating cycle, if longer, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets",
        "terseLabel": "Other long term assets"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureBusinessCombinationAssetsAcquiredAndLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment": {
     "auth_ref": [
      "r376",
      "r377"
     ],
     "calculation": {
      "http://immuneering.com/role/DisclosureBusinessCombinationAssetsAcquiredAndLiabilitiesAssumedDetails": {
       "order": 6.0,
       "parentTag": "imrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIncludingGoodwill",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of property, plant, and equipment recognized as of the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment",
        "terseLabel": "Property, plant and equipment, net"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureBusinessCombinationAssetsAcquiredAndLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet": {
     "auth_ref": [
      "r377"
     ],
     "calculation": {
      "http://immuneering.com/role/DisclosureBusinessCombinationAssetsAcquiredAndLiabilitiesAssumedDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net",
        "totalLabel": "Net assets acquired"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureBusinessCombinationAssetsAcquiredAndLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net [Abstract]",
        "terseLabel": "Assets Acquired and Liabilities Assumed at Fair Value"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureBusinessCombinationAssetsAcquiredAndLiabilitiesAssumedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination"
       }
      }
     },
     "localname": "BusinessCombinationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationsPolicy": {
     "auth_ref": [
      "r372"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.",
        "label": "Business Combinations Policy [Policy Text Block]",
        "terseLabel": "Business Combination"
       }
      }
     },
     "localname": "BusinessCombinationsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAcquiredInExcessOfPaymentsToAcquireBusiness": {
     "auth_ref": [],
     "calculation": {
      "http://immuneering.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the acquisition of a business when the cash held by the acquired business exceeds the cash payments to acquire the business.",
        "label": "Cash Acquired in Excess of Payments to Acquire Business",
        "terseLabel": "Cash acquired in business combination"
       }
      }
     },
     "localname": "CashAcquiredInExcessOfPaymentsToAcquireBusiness",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r3",
      "r27",
      "r83"
     ],
     "calculation": {
      "http://immuneering.com/role/StatementConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://immuneering.com/role/DisclosureFairValueMeasurementsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Total cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureFairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r9",
      "r84"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r78",
      "r83",
      "r88"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents at end of period",
        "periodStartLabel": "Cash and cash equivalents at beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r78",
      "r411"
     ],
     "calculation": {
      "http://immuneering.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net increase in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r91",
      "r93",
      "r115",
      "r116",
      "r117",
      "r119",
      "r121",
      "r129",
      "r130",
      "r131",
      "r183",
      "r219",
      "r224",
      "r225",
      "r226",
      "r230",
      "r231",
      "r243",
      "r244",
      "r248",
      "r252",
      "r410",
      "r551"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureCommonStockClassBCommonStockDetails",
      "http://immuneering.com/role/DisclosureCommonStockClassCommonStockDetails",
      "http://immuneering.com/role/DisclosureCommonStockDetails",
      "http://immuneering.com/role/DisclosureCommonStockIpoDetails",
      "http://immuneering.com/role/DisclosureConvertiblePreferredStockSeriesBDetails",
      "http://immuneering.com/role/DisclosureConvertiblePreferredStockSeriesDetails",
      "http://immuneering.com/role/DisclosureOrganizationAndNatureOfBusinessDetails",
      "http://immuneering.com/role/DisclosureStockBasedCompensationNarrativesDetails",
      "http://immuneering.com/role/DocumentDocumentAndEntityInformation",
      "http://immuneering.com/role/StatementConsolidatedBalanceSheets",
      "http://immuneering.com/role/StatementConsolidatedBalanceSheetsParentheticals",
      "http://immuneering.com/role/StatementConsolidatedStatementsOfCashFlows",
      "http://immuneering.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureCommonStockClassBCommonStockDetails",
      "http://immuneering.com/role/DisclosureCommonStockClassCommonStockDetails",
      "http://immuneering.com/role/DisclosureCommonStockDetails",
      "http://immuneering.com/role/DisclosureCommonStockIpoDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r261"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "terseLabel": "Warrant exercise price"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureCommonStockCommonStockWarrantDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "auth_ref": [
      "r261"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.",
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "terseLabel": "Warrants issued for common shares"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureCommonStockCommonStockWarrantDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommercialPaperMember": {
     "auth_ref": [
      "r218"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.",
        "label": "Commerical paper"
       }
      }
     },
     "localname": "CommercialPaperMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureFairValueMeasurementsDetails",
      "http://immuneering.com/role/DisclosureMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r39",
      "r216",
      "r496",
      "r516"
     ],
     "calculation": {
      "http://immuneering.com/role/StatementConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies (Note 13)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies."
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r213",
      "r214",
      "r215",
      "r217",
      "r536"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureCommitmentsAndContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonClassAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Classification of common stock representing ownership interest in a corporation.",
        "label": "Class A Common Stock"
       }
      }
     },
     "localname": "CommonClassAMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureCommonStockClassCommonStockDetails",
      "http://immuneering.com/role/DisclosureCommonStockIpoDetails",
      "http://immuneering.com/role/DisclosureOrganizationAndNatureOfBusinessDetails",
      "http://immuneering.com/role/DisclosureStockBasedCompensationNarrativesDetails",
      "http://immuneering.com/role/DocumentDocumentAndEntityInformation",
      "http://immuneering.com/role/StatementConsolidatedBalanceSheets",
      "http://immuneering.com/role/StatementConsolidatedBalanceSheetsParentheticals",
      "http://immuneering.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonClassBMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Classification of common stock that has different rights than Common Class A, representing ownership interest in a corporation.",
        "label": "Class B Common Stock"
       }
      }
     },
     "localname": "CommonClassBMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureCommonStockClassBCommonStockDetails",
      "http://immuneering.com/role/DisclosureCommonStockIpoDetails",
      "http://immuneering.com/role/DocumentDocumentAndEntityInformation",
      "http://immuneering.com/role/StatementConsolidatedBalanceSheets",
      "http://immuneering.com/role/StatementConsolidatedBalanceSheetsParentheticals"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r41"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Shares reserved for future issuance",
        "terseLabel": "Shares reserved for future issuance"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureCommonStockDetails",
      "http://immuneering.com/role/DisclosureStockBasedCompensationNarrativesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r100",
      "r101",
      "r393"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common stock, par value per share (in dollars per share)",
        "terseLabel": "Common stock, par value per share (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureCommonStockClassBCommonStockDetails",
      "http://immuneering.com/role/DisclosureCommonStockClassCommonStockDetails",
      "http://immuneering.com/role/DisclosureCommonStockIpoDetails",
      "http://immuneering.com/role/StatementConsolidatedBalanceSheetsParentheticals"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common stock, shares authorized (in shares)",
        "terseLabel": "Common stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureCommonStockClassBCommonStockDetails",
      "http://immuneering.com/role/DisclosureCommonStockClassCommonStockDetails",
      "http://immuneering.com/role/DisclosureCommonStockIpoDetails",
      "http://immuneering.com/role/StatementConsolidatedBalanceSheetsParentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureCommonStockClassBCommonStockDetails",
      "http://immuneering.com/role/DisclosureCommonStockClassCommonStockDetails",
      "http://immuneering.com/role/StatementConsolidatedBalanceSheetsParentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r17",
      "r260"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureCommonStockClassBCommonStockDetails",
      "http://immuneering.com/role/DisclosureCommonStockClassCommonStockDetails",
      "http://immuneering.com/role/StatementConsolidatedBalanceSheetsParentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r17",
      "r442"
     ],
     "calculation": {
      "http://immuneering.com/role/StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComponentsOfDeferredTaxAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components of Deferred Tax Assets [Abstract]",
        "terseLabel": "Deferred tax assets:"
       }
      }
     },
     "localname": "ComponentsOfDeferredTaxAssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureIncomeTaxesNetDeferredTaxAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components of Deferred Tax Assets and Liabilities [Abstract]",
        "terseLabel": "Components and tax effects of each type of item that gave rise to the net deferred tax assets"
       }
      }
     },
     "localname": "ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureIncomeTaxesNetDeferredTaxAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r52",
      "r54",
      "r55",
      "r65",
      "r501",
      "r520"
     ],
     "calculation": {
      "http://immuneering.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive Loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for comprehensive income.",
        "label": "Comprehensive Income, Policy [Policy Text Block]",
        "terseLabel": "Comprehensive Loss"
       }
      }
     },
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ComputerEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.",
        "label": "Computer equipment"
       }
      }
     },
     "localname": "ComputerEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosurePropertyAndEquipmentNetDetails",
      "http://immuneering.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r139",
      "r140",
      "r169",
      "r407",
      "r408",
      "r535"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.",
        "label": "Concentration Risk Benchmark [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureSummaryOfSignificantAccountingPoliciesConcentrationOfCreditRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r139",
      "r140",
      "r169",
      "r407",
      "r408",
      "r533",
      "r535"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk Benchmark [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureSummaryOfSignificantAccountingPoliciesConcentrationOfCreditRiskDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "auth_ref": [
      "r139",
      "r140",
      "r169",
      "r407",
      "r408",
      "r533",
      "r535"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
        "label": "Concentration Risk Type [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureSummaryOfSignificantAccountingPoliciesConcentrationOfCreditRiskDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r134",
      "r509"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentration of Credit Risk"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Concentration Risk [Line Items]"
       }
      }
     },
     "localname": "ConcentrationRiskLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureSummaryOfSignificantAccountingPoliciesConcentrationOfCreditRiskDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "auth_ref": [
      "r139",
      "r140",
      "r169",
      "r407",
      "r408"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.",
        "label": "Concentration Risk, Percentage",
        "terseLabel": "Risk percentage"
       }
      }
     },
     "localname": "ConcentrationRiskPercentage1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureSummaryOfSignificantAccountingPoliciesConcentrationOfCreditRiskDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ConcentrationRiskTable": {
     "auth_ref": [
      "r137",
      "r139",
      "r140",
      "r141",
      "r407",
      "r409",
      "r535"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Describes the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.",
        "label": "Concentration Risk [Table]"
       }
      }
     },
     "localname": "ConcentrationRiskTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureSummaryOfSignificantAccountingPoliciesConcentrationOfCreditRiskDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "auth_ref": [
      "r139",
      "r140",
      "r169",
      "r407",
      "r408",
      "r535"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.",
        "label": "Concentration Risk Type [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureSummaryOfSignificantAccountingPoliciesConcentrationOfCreditRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConversionOfStockSharesIssued1": {
     "auth_ref": [
      "r85",
      "r86",
      "r87"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Conversion of Stock, Shares Issued",
        "verboseLabel": "Class A common stock issued for business combination"
       }
      }
     },
     "localname": "ConversionOfStockSharesIssued1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion": {
     "auth_ref": [
      "r15",
      "r16",
      "r255",
      "r261",
      "r264"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued for each share of convertible preferred stock that is converted.",
        "label": "Convertible Preferred Stock, Shares Issued upon Conversion",
        "terseLabel": "Shares issued upon conversion"
       }
      }
     },
     "localname": "ConvertiblePreferredStockSharesIssuedUponConversion",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureConvertiblePreferredStockSeriesBDetails",
      "http://immuneering.com/role/DisclosureOrganizationAndNatureOfBusinessDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CostOfRevenue": {
     "auth_ref": [
      "r70",
      "r93",
      "r183",
      "r219",
      "r220",
      "r221",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r230",
      "r231",
      "r410"
     ],
     "calculation": {
      "http://immuneering.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_GrossProfit",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period.",
        "label": "Cost of Revenue",
        "terseLabel": "Cost of revenue"
       }
      }
     },
     "localname": "CostOfRevenue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfSalesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing cost of sales.",
        "label": "Cost of service"
       }
      }
     },
     "localname": "CostOfSalesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureStockBasedCompensationShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "auth_ref": [
      "r138",
      "r169"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.",
        "label": "Customer risk"
       }
      }
     },
     "localname": "CustomerConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureSummaryOfSignificantAccountingPoliciesConcentrationOfCreditRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtConversionConvertedInstrumentSharesIssued1": {
     "auth_ref": [
      "r85",
      "r87"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or payments in the period.",
        "label": "Debt Conversion, Converted Instrument, Shares Issued",
        "terseLabel": "Number of shares issued upon conversion of debt"
       }
      }
     },
     "localname": "DebtConversionConvertedInstrumentSharesIssued1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureConvertiblePreferredStockSeriesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_DeferredChargesPolicyTextBlock": {
     "auth_ref": [
      "r33"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for deferral and amortization of significant deferred charges.",
        "label": "Deferred Charges, Policy [Policy Text Block]",
        "terseLabel": "Deferred Offering Costs"
       }
      }
     },
     "localname": "DeferredChargesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r81",
      "r94",
      "r356",
      "r363",
      "r364",
      "r365"
     ],
     "calculation": {
      "http://immuneering.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Income Tax Expense (Benefit)",
        "terseLabel": "Deferred tax benefit"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "auth_ref": [
      "r12",
      "r13",
      "r346",
      "r493",
      "r510"
     ],
     "calculation": {
      "http://immuneering.com/role/DisclosureIncomeTaxesNetDeferredTaxAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences.",
        "label": "Deferred Tax Liabilities, Gross",
        "negatedTotalLabel": "Total deferred tax liabilities"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureIncomeTaxesNetDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredOfferingCosts": {
     "auth_ref": [
      "r44",
      "r194"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period.",
        "label": "Deferred Offering Costs",
        "terseLabel": "Deferred offering costs"
       }
      }
     },
     "localname": "DeferredOfferingCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r347"
     ],
     "calculation": {
      "http://immuneering.com/role/DisclosureIncomeTaxesNetDeferredTaxAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Gross deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureIncomeTaxesNetDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "auth_ref": [
      "r349"
     ],
     "calculation": {
      "http://immuneering.com/role/DisclosureIncomeTaxesNetDeferredTaxAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.",
        "label": "Deferred Tax Assets, Net",
        "totalLabel": "Net deferred taxes"
       }
      }
     },
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureIncomeTaxesNetDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "auth_ref": [
      "r349"
     ],
     "calculation": {
      "http://immuneering.com/role/DisclosureIncomeTaxesNetDeferredTaxAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "totalLabel": "Net deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureIncomeTaxesNetDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r354",
      "r355"
     ],
     "calculation": {
      "http://immuneering.com/role/DisclosureIncomeTaxesNetDeferredTaxAssetsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "terseLabel": "NOL carryforward"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureIncomeTaxesNetDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "auth_ref": [
      "r352",
      "r354",
      "r355"
     ],
     "calculation": {
      "http://immuneering.com/role/DisclosureIncomeTaxesNetDeferredTaxAssetsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards, Research",
        "terseLabel": "R&amp;D credit carryforward"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureIncomeTaxesNetDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "auth_ref": [
      "r354",
      "r355"
     ],
     "calculation": {
      "http://immuneering.com/role/DisclosureIncomeTaxesNetDeferredTaxAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureIncomeTaxesNetDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsUnrealizedCurrencyLosses": {
     "auth_ref": [
      "r354",
      "r355"
     ],
     "calculation": {
      "http://immuneering.com/role/DisclosureIncomeTaxesNetDeferredTaxAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from unrealized losses on foreign currency transactions.",
        "label": "Deferred Tax Assets, Unrealized Currency Losses",
        "terseLabel": "Unrealized losses"
       }
      }
     },
     "localname": "DeferredTaxAssetsUnrealizedCurrencyLosses",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureIncomeTaxesNetDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r348"
     ],
     "calculation": {
      "http://immuneering.com/role/DisclosureIncomeTaxesNetDeferredTaxAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedLabel": "Valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureIncomeTaxesNetDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Net [Abstract]",
        "terseLabel": "Net deferred tax liabilities:"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureIncomeTaxesNetDeferredTaxAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesPrepaidExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://immuneering.com/role/DisclosureIncomeTaxesNetDeferredTaxAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax consequences attributable to taxable temporary differences derived from prepaid expenses.",
        "label": "Deferred Tax Liabilities, Prepaid Expenses",
        "negatedLabel": "Prepaid expenses deducted for tax"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesPrepaidExpenses",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureIncomeTaxesNetDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": {
     "auth_ref": [
      "r354",
      "r355"
     ],
     "calculation": {
      "http://immuneering.com/role/DisclosureIncomeTaxesNetDeferredTaxAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.",
        "label": "Deferred Tax Liabilities, Property, Plant and Equipment",
        "negatedTerseLabel": "Tax depreciation in excess of book"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureIncomeTaxesNetDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxesBusinessCombinationValuationAllowanceAvailableToReduceIncomeTaxExpense": {
     "auth_ref": [
      "r382"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of the valuation allowance recorded in a business combination against deductible temporary differences for which related tax benefits will be recorded as a reduction of the acquired entity's income tax expense (after such benefits are first being applied to reduce goodwill and then other noncurrent intangible assets to zero).",
        "label": "Deferred Taxes, Business Combination, Valuation Allowance, Available to Reduce Income Tax Expense"
       }
      }
     },
     "localname": "DeferredTaxesBusinessCombinationValuationAllowanceAvailableToReduceIncomeTaxExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureIncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r81",
      "r205"
     ],
     "calculation": {
      "http://immuneering.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "terseLabel": "Depreciation expense"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosurePropertyAndEquipmentNetDepreciationDetails",
      "http://immuneering.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r328"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement [Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureStockBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-Based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DividendsPreferredStock": {
     "auth_ref": [
      "r268",
      "r508"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of paid and unpaid preferred stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK).",
        "label": "Dividends, Preferred Stock",
        "terseLabel": "Dividend declared"
       }
      }
     },
     "localname": "DividendsPreferredStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureConvertiblePreferredStockSeriesBDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DomesticCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.",
        "label": "Domestic Tax Authority [Member]"
       }
      }
     },
     "localname": "DomesticCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureIncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DueToRelatedPartiesCurrent": {
     "auth_ref": [
      "r34",
      "r97",
      "r222",
      "r224",
      "r225",
      "r229",
      "r230",
      "r231",
      "r438"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Due to Related Parties, Current",
        "terseLabel": "Amount owned to related party"
       }
      }
     },
     "localname": "DueToRelatedPartiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureBusinessCombinationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Loss Per Share Attributable to Common Stockholders"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r66",
      "r105",
      "r106",
      "r107",
      "r108",
      "r109",
      "r113",
      "r115",
      "r119",
      "r120",
      "r121",
      "r125",
      "r126",
      "r394",
      "r395",
      "r502",
      "r521"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Net loss per share attributable to common stockholders, basic",
        "verboseLabel": "Net loss per share, basic"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureNetLossPerShareAttributableToCommonStockholdersBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails",
      "http://immuneering.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDilutedAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic and Diluted [Abstract]",
        "terseLabel": "Numerator:"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDilutedAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureNetLossPerShareAttributableToCommonStockholdersBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic and Diluted, Other Disclosures [Abstract]",
        "terseLabel": "Denominator - basic and diluted:"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureNetLossPerShareAttributableToCommonStockholdersBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r66",
      "r105",
      "r106",
      "r107",
      "r108",
      "r109",
      "r115",
      "r119",
      "r120",
      "r121",
      "r125",
      "r126",
      "r394",
      "r395",
      "r502",
      "r521"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Net loss per share attributable to common stockholders, diluted",
        "verboseLabel": "Net loss per share, diluted"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureNetLossPerShareAttributableToCommonStockholdersBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails",
      "http://immuneering.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r122",
      "r123"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Net Income (Loss) per Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r122",
      "r123",
      "r124",
      "r127"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Net Loss Per Share Attributable to Common Stockholders"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureNetLossPerShareAttributableToCommonStockholders"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r337"
     ],
     "calculation": {
      "http://immuneering.com/role/DisclosureIncomeTaxesNetLossAndEffectiveIncomeTaxRateDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "totalLabel": "Effective income tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureIncomeTaxesNetLossAndEffectiveIncomeTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Percent [Abstract]",
        "terseLabel": "Reconciliation of the effect of applying the federal statutory rate to the net loss and the effective income tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureIncomeTaxesNetLossAndEffectiveIncomeTaxRateDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r95",
      "r337",
      "r366"
     ],
     "calculation": {
      "http://immuneering.com/role/DisclosureIncomeTaxesNetLossAndEffectiveIncomeTaxRateDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "terseLabel": "Statutory federal income tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureIncomeTaxesNetLossAndEffectiveIncomeTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r337",
      "r366"
     ],
     "calculation": {
      "http://immuneering.com/role/DisclosureIncomeTaxesNetLossAndEffectiveIncomeTaxRateDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "terseLabel": "Change in valuation allowance"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureIncomeTaxesNetLossAndEffectiveIncomeTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense": {
     "auth_ref": [
      "r337",
      "r366"
     ],
     "calculation": {
      "http://immuneering.com/role/DisclosureIncomeTaxesNetLossAndEffectiveIncomeTaxRateDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent",
        "terseLabel": "Permanent differences"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureIncomeTaxesNetLossAndEffectiveIncomeTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": {
     "auth_ref": [
      "r337",
      "r366"
     ],
     "calculation": {
      "http://immuneering.com/role/DisclosureIncomeTaxesNetLossAndEffectiveIncomeTaxRateDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Percent",
        "terseLabel": "Other differences"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureIncomeTaxesNetLossAndEffectiveIncomeTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r337",
      "r366"
     ],
     "calculation": {
      "http://immuneering.com/role/DisclosureIncomeTaxesNetLossAndEffectiveIncomeTaxRateDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "terseLabel": "State tax, net of federal benefit"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureIncomeTaxesNetLossAndEffectiveIncomeTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch": {
     "auth_ref": [
      "r337",
      "r366"
     ],
     "calculation": {
      "http://immuneering.com/role/DisclosureIncomeTaxesNetLossAndEffectiveIncomeTaxRateDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent",
        "terseLabel": "Federal research and development credits"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditsResearch",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureIncomeTaxesNetLossAndEffectiveIncomeTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r317"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Compensation expense recognized over a weighted-average period"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureStockBasedCompensationNarrativesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "auth_ref": [
      "r317"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Compensation expense remaining to be recognized"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureStockBasedCompensationNarrativesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r314"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Common stock options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureCommonStockDetails",
      "http://immuneering.com/role/DisclosureNetLossPerShareAttributableToCommonStockholdersAntidilutiveEffectDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r0",
      "r57",
      "r58",
      "r59",
      "r100",
      "r101",
      "r102",
      "r104",
      "r110",
      "r112",
      "r128",
      "r184",
      "r260",
      "r268",
      "r320",
      "r321",
      "r322",
      "r359",
      "r360",
      "r393",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r418",
      "r527",
      "r528",
      "r529",
      "r562"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureFairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r396",
      "r397",
      "r398",
      "r403"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureFairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": {
     "auth_ref": [
      "r396",
      "r397"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Fair Value, Assets Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Schedule of cash equivalents and marketable securities"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureFairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": {
     "auth_ref": [
      "r401"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of asset.",
        "label": "Asset Class [Domain]"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureFairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueByAssetClassAxis": {
     "auth_ref": [
      "r396",
      "r403"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by class of asset.",
        "label": "Asset Class [Axis]"
       }
      }
     },
     "localname": "FairValueByAssetClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureFairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r233",
      "r236",
      "r237",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r292",
      "r397",
      "r446",
      "r447",
      "r448"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureFairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r396",
      "r397",
      "r399",
      "r400",
      "r404"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureFairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r402"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureFairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r233",
      "r284",
      "r285",
      "r290",
      "r292",
      "r397",
      "r446"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureFairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r233",
      "r236",
      "r237",
      "r284",
      "r285",
      "r290",
      "r292",
      "r397",
      "r447"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureFairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureFairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transfers of financial instrument classified as a liability into (out of) level 3 of the fair value hierarchy.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Transfers, Net",
        "terseLabel": "Financial liabilities classified as Level 3"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureFairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r233",
      "r236",
      "r237",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r292",
      "r446",
      "r447",
      "r448"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureFairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r402",
      "r404"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureFairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "auth_ref": [
      "r405",
      "r406"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.",
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "terseLabel": "Fair Value of Financial Instruments"
       }
      }
     },
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r177",
      "r178",
      "r180",
      "r181",
      "r182",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r235",
      "r258",
      "r392",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureMarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r202",
      "r476"
     ],
     "calculation": {
      "http://immuneering.com/role/StatementConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Net",
        "terseLabel": "Intangible asset"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture and fixtures"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosurePropertyAndEquipmentNetDetails",
      "http://immuneering.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r71"
     ],
     "calculation": {
      "http://immuneering.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r67"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureStockBasedCompensationShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r195",
      "r197",
      "r442",
      "r491"
     ],
     "calculation": {
      "http://immuneering.com/role/DisclosureBusinessCombinationAssetsAcquiredAndLiabilitiesAssumedDetails": {
       "order": 1.0,
       "parentTag": "imrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIncludingGoodwill",
       "weight": 1.0
      },
      "http://immuneering.com/role/StatementConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureBusinessCombinationAssetsAcquiredAndLiabilitiesAssumedDetails",
      "http://immuneering.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy": {
     "auth_ref": [
      "r199"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.",
        "label": "Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsGoodwillPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillImpairmentLoss": {
     "auth_ref": [
      "r81",
      "r196",
      "r198",
      "r200"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Impairment Loss",
        "terseLabel": "Goodwill impairments"
       }
      }
     },
     "localname": "GoodwillImpairmentLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GrossProfit": {
     "auth_ref": [
      "r69",
      "r93",
      "r150",
      "r158",
      "r161",
      "r164",
      "r166",
      "r183",
      "r219",
      "r220",
      "r221",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r230",
      "r231",
      "r410"
     ],
     "calculation": {
      "http://immuneering.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.",
        "label": "Gross Profit",
        "totalLabel": "Gross profit"
       }
      }
     },
     "localname": "GrossProfit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IPOMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First sale of stock by a private company to the public.",
        "label": "IPO"
       }
      }
     },
     "localname": "IPOMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureCommonStockIpoDetails",
      "http://immuneering.com/role/DisclosureOrganizationAndNatureOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ImpairmentOfIntangibleAssetsFinitelived": {
     "auth_ref": [
      "r81",
      "r203"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.",
        "label": "Impairment of Intangible Assets, Finite-lived",
        "terseLabel": "Impairment"
       }
      }
     },
     "localname": "ImpairmentOfIntangibleAssetsFinitelived",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOfInvestments": {
     "auth_ref": [
      "r176"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount by which the fair value of an investment is less than the amortized cost basis or carrying amount of that investment at the balance sheet date and the decline in fair value is deemed to be other than temporary, before considering whether or not such amount is recognized in earnings or other comprehensive income.",
        "label": "Other than Temporary Impairment Losses, Investments",
        "terseLabel": "Impairment on available-for-sale marketable securities"
       }
      }
     },
     "localname": "ImpairmentOfInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "auth_ref": [
      "r204",
      "r210"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.",
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "terseLabel": "Impairment of Long-lived Assets"
       }
      }
     },
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InProcessResearchAndDevelopmentPolicy": {
     "auth_ref": [
      "r32",
      "r330"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs assigned to identifiable tangible and intangible assets of an acquired entity to be used in the research and development activities of the combined enterprise. An entity also may disclose the appraisal method or significant assumptions used to value acquired research and development assets.",
        "label": "In Process Research and Development, Policy [Policy Text Block]",
        "terseLabel": "Research and Development"
       }
      }
     },
     "localname": "InProcessResearchAndDevelopmentPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r62",
      "r150",
      "r158",
      "r161",
      "r164",
      "r166",
      "r489",
      "r498",
      "r503",
      "r522"
     ],
     "calculation": {
      "http://immuneering.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Loss before income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r209",
      "r212"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureBusinessCombinationNarrativeDetails",
      "http://immuneering.com/role/DisclosureStockBasedCompensationShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r212"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureBusinessCombinationNarrativeDetails",
      "http://immuneering.com/role/DisclosureStockBasedCompensationShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r340"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureIncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority [Domain]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureIncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r95",
      "r338",
      "r344",
      "r351",
      "r361",
      "r367",
      "r369",
      "r370",
      "r371"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureIncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r96",
      "r111",
      "r112",
      "r149",
      "r336",
      "r362",
      "r368",
      "r523"
     ],
     "calculation": {
      "http://immuneering.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "negatedLabel": "Income tax benefit"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r56",
      "r334",
      "r335",
      "r344",
      "r345",
      "r350",
      "r357"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://immuneering.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://immuneering.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://immuneering.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "terseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Assets [Abstract]",
        "terseLabel": "(Increase) decrease in:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingAssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Change in assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "auth_ref": [
      "r80",
      "r431"
     ],
     "calculation": {
      "http://immuneering.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation for operating lease.",
        "label": "Increase (Decrease) in Operating Lease Liability",
        "terseLabel": "Lease liability"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Liabilities [Abstract]",
        "terseLabel": "Increase (decrease) in:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingAssets": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://immuneering.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating assets classified as other.",
        "label": "Increase (Decrease) in Other Operating Assets",
        "negatedLabel": "Other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://immuneering.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInTemporaryEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Temporary Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInTemporaryEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentIncomeInterest": {
     "auth_ref": [
      "r72",
      "r148"
     ],
     "calculation": {
      "http://immuneering.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.",
        "label": "Investment Income, Interest",
        "terseLabel": "Interest income"
       }
      }
     },
     "localname": "InvestmentIncomeInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium": {
     "auth_ref": [
      "r73"
     ],
     "calculation": {
      "http://immuneering.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accretion (amortization) of purchase discount (premium) on nonoperating securities.",
        "label": "Investment Income, Net, Amortization of Discount and Premium",
        "negatedLabel": "Net amortization of premium (accretion of discount) on marketable securities"
       }
      }
     },
     "localname": "InvestmentIncomeNetAmortizationOfDiscountAndPremium",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeNonoperatingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Income, Nonoperating [Abstract]",
        "terseLabel": "Other income (expense)"
       }
      }
     },
     "localname": "InvestmentIncomeNonoperatingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Marketable Securities"
       }
      }
     },
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r179",
      "r490",
      "r506",
      "r534",
      "r558"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for  investments in certain debt and equity securities.",
        "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]",
        "terseLabel": "Marketable Securities"
       }
      }
     },
     "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureMarketableSecurities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseContractualTermAxis": {
     "auth_ref": [
      "r427"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by contractual term of lease arrangement.",
        "label": "Lease Contractual Term [Axis]"
       }
      }
     },
     "localname": "LeaseContractualTermAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureCommitmentsAndContingenciesNarrativesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LeaseContractualTermDomain": {
     "auth_ref": [
      "r427"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual term of lease arrangement.",
        "label": "Lease Contractual Term [Domain]"
       }
      }
     },
     "localname": "LeaseContractualTermDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureCommitmentsAndContingenciesNarrativesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeaseCost": {
     "auth_ref": [
      "r434",
      "r436"
     ],
     "calculation": {
      "http://immuneering.com/role/DisclosureCommitmentsAndContingenciesLeaseCostDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease cost recognized by lessee for lease contract.",
        "label": "Lease, Cost",
        "totalLabel": "Total lease costs"
       }
      }
     },
     "localname": "LeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureCommitmentsAndContingenciesLeaseCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCostAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease, Cost [Abstract]",
        "terseLabel": "Lease costs:"
       }
      }
     },
     "localname": "LeaseCostAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureCommitmentsAndContingenciesLeaseCostDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r434"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Schedule of Quantitative information regarding the Company's leases"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureCommitmentsAndContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeasePracticalExpedientsPackage": {
     "auth_ref": [
      "r419",
      "r420"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates (true false) whether practical expedients are elected for not reassessing whether any expired or existing contract is or contains lease, lease classification for expired or existing lease, and initial direct cost for any existing lease.",
        "label": "Lease, Practical Expedients, Package [true false]",
        "terseLabel": "Lease, practical expedients"
       }
      }
     },
     "localname": "LeasePracticalExpedientsPackage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "booleanItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r206"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold improvements",
        "terseLabel": "Leasehold improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosurePropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeaseholdsAndLeaseholdImprovementsMember": {
     "auth_ref": [
      "r206"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Assets held by a lessee under a capital lease and any addition or improvement to assets held under a lease arrangement (including addition or improvement to assets held by lessee under an operating lease arrangement).",
        "label": "Leaseholds and Leasehold Improvements [Member]"
       }
      }
     },
     "localname": "LeaseholdsAndLeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Lessee, Lease, Description [Line Items]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureCommitmentsAndContingenciesMaturitiesOfLeaseLiabilitiesDueDetails",
      "http://immuneering.com/role/DisclosureCommitmentsAndContingenciesNarrativesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "auth_ref": [
      "r427"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about lessee's leases.",
        "label": "Lessee, Lease, Description [Table]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureCommitmentsAndContingenciesMaturitiesOfLeaseLiabilitiesDueDetails",
      "http://immuneering.com/role/DisclosureCommitmentsAndContingenciesNarrativesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r425"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r435"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Schedule of Maturities of the lease liabilities due"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureCommitmentsAndContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r435"
     ],
     "calculation": {
      "http://immuneering.com/role/DisclosureCommitmentsAndContingenciesMaturitiesOfLeaseLiabilitiesDueDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://immuneering.com/role/DisclosureCommitmentsAndContingenciesMaturitiesOfLeaseLiabilitiesDueDetailsCalc2": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total future lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureCommitmentsAndContingenciesMaturitiesOfLeaseLiabilitiesDueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "auth_ref": [
      "r435"
     ],
     "calculation": {
      "http://immuneering.com/role/DisclosureCommitmentsAndContingenciesMaturitiesOfLeaseLiabilitiesDueDetailsCalc2": {
       "order": 6.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureCommitmentsAndContingenciesMaturitiesOfLeaseLiabilitiesDueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r435"
     ],
     "calculation": {
      "http://immuneering.com/role/DisclosureCommitmentsAndContingenciesMaturitiesOfLeaseLiabilitiesDueDetailsCalc2": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2022",
        "verboseLabel": "Minimum lease payment due 2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureCommitmentsAndContingenciesMaturitiesOfLeaseLiabilitiesDueDetails",
      "http://immuneering.com/role/DisclosureCommitmentsAndContingenciesNarrativesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "auth_ref": [
      "r435"
     ],
     "calculation": {
      "http://immuneering.com/role/DisclosureCommitmentsAndContingenciesMaturitiesOfLeaseLiabilitiesDueDetailsCalc2": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureCommitmentsAndContingenciesMaturitiesOfLeaseLiabilitiesDueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r435"
     ],
     "calculation": {
      "http://immuneering.com/role/DisclosureCommitmentsAndContingenciesMaturitiesOfLeaseLiabilitiesDueDetailsCalc2": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureCommitmentsAndContingenciesMaturitiesOfLeaseLiabilitiesDueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r435"
     ],
     "calculation": {
      "http://immuneering.com/role/DisclosureCommitmentsAndContingenciesMaturitiesOfLeaseLiabilitiesDueDetailsCalc2": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureCommitmentsAndContingenciesMaturitiesOfLeaseLiabilitiesDueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r435"
     ],
     "calculation": {
      "http://immuneering.com/role/DisclosureCommitmentsAndContingenciesMaturitiesOfLeaseLiabilitiesDueDetailsCalc2": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureCommitmentsAndContingenciesMaturitiesOfLeaseLiabilitiesDueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r435"
     ],
     "calculation": {
      "http://immuneering.com/role/DisclosureCommitmentsAndContingenciesMaturitiesOfLeaseLiabilitiesDueDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "terseLabel": "Less: Imputed interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureCommitmentsAndContingenciesMaturitiesOfLeaseLiabilitiesDueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "auth_ref": [
      "r426"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Term of Contract",
        "terseLabel": "Lease term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureCommitmentsAndContingenciesNarrativesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r35",
      "r93",
      "r160",
      "r183",
      "r219",
      "r220",
      "r221",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r230",
      "r231",
      "r385",
      "r387",
      "r388",
      "r410",
      "r440",
      "r441"
     ],
     "calculation": {
      "http://immuneering.com/role/StatementConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r24",
      "r93",
      "r183",
      "r410",
      "r442",
      "r494",
      "r514"
     ],
     "calculation": {
      "http://immuneering.com/role/StatementConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities, convertible preferred stock and stockholders' equity (deficit)"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "LIABILITIES, CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT)"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r38",
      "r93",
      "r183",
      "r219",
      "r220",
      "r221",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r230",
      "r231",
      "r385",
      "r387",
      "r388",
      "r410",
      "r440",
      "r441",
      "r442"
     ],
     "calculation": {
      "http://immuneering.com/role/StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Noncurrent [Abstract]",
        "terseLabel": "Long-term liabilities:"
       }
      }
     },
     "localname": "LiabilitiesNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MarketableSecurities": {
     "auth_ref": [
      "r497"
     ],
     "calculation": {
      "http://immuneering.com/role/DisclosureMarketableSecuritiesDetails": {
       "order": 3.0,
       "parentTag": "imrx_MarketableSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in marketable security.",
        "label": "Marketable Securities.",
        "terseLabel": "Marketable securities"
       }
      }
     },
     "localname": "MarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureFairValueMeasurementsDetails",
      "http://immuneering.com/role/DisclosureMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MarketableSecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Marketable Securities [Abstract]",
        "terseLabel": "Marketable securities"
       }
      }
     },
     "localname": "MarketableSecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureMarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MarketableSecuritiesCurrent": {
     "auth_ref": [
      "r5",
      "r36"
     ],
     "calculation": {
      "http://immuneering.com/role/DisclosureMarketableSecuritiesDetails": {
       "order": 3.0,
       "parentTag": "imrx_MarketableSecuritiesAmortizedCostBasisCurrent",
       "weight": 1.0
      },
      "http://immuneering.com/role/StatementConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in marketable security, classified as current.",
        "label": "Marketable Securities, Current",
        "verboseLabel": "Marketable securities, current"
       }
      }
     },
     "localname": "MarketableSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureMarketableSecuritiesDetails",
      "http://immuneering.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MarketableSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Marketable Securities [Line Items]",
        "terseLabel": "Marketable Securities"
       }
      }
     },
     "localname": "MarketableSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureMarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MarketableSecuritiesNoncurrent": {
     "auth_ref": [
      "r28"
     ],
     "calculation": {
      "http://immuneering.com/role/DisclosureMarketableSecuritiesDetails": {
       "order": 2.0,
       "parentTag": "imrx_MarketableSecuritiesAmortizedCostBasisNonCurrent",
       "weight": 1.0
      },
      "http://immuneering.com/role/StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in marketable security, classified as noncurrent.",
        "label": "Marketable Securities, Noncurrent",
        "terseLabel": "Marketable securities, non-current",
        "verboseLabel": "Marketable securities, non-current"
       }
      }
     },
     "localname": "MarketableSecuritiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureMarketableSecuritiesDetails",
      "http://immuneering.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MarketableSecuritiesPolicy": {
     "auth_ref": [
      "r505"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for investment classified as marketable security.",
        "label": "Marketable Securities, Policy [Policy Text Block]",
        "terseLabel": "Marketable Securities"
       }
      }
     },
     "localname": "MarketableSecuritiesPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_MarketableSecuritiesRealizedGainLoss": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of realized gain (loss) on investment in marketable security, including other-than-temporary impairment (OTTI).",
        "label": "Marketable Securities, Realized Gain (Loss)",
        "terseLabel": "Realized gains or losses on marketable securities"
       }
      }
     },
     "localname": "MarketableSecuritiesRealizedGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MarketableSecuritiesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about investment in marketable security.",
        "label": "Marketable Securities [Table]"
       }
      }
     },
     "localname": "MarketableSecuritiesTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureMarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MarketableSecuritiesTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets.",
        "label": "Marketable Securities [Table Text Block]",
        "terseLabel": "Schedule of marketable securities"
       }
      }
     },
     "localname": "MarketableSecuritiesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureMarketableSecuritiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_MarketableSecuritiesUnrealizedGainLoss": {
     "auth_ref": [
      "r68"
     ],
     "calculation": {
      "http://immuneering.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized gain (loss) on investment in marketable security.",
        "label": "Marketable Securities, Unrealized Gain (Loss)",
        "terseLabel": "Unrealized losses from marketable securities"
       }
      }
     },
     "localname": "MarketableSecuritiesUnrealizedGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r284"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money market"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureFairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r78"
     ],
     "calculation": {
      "http://immuneering.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r78"
     ],
     "calculation": {
      "http://immuneering.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r78",
      "r79",
      "r82"
     ],
     "calculation": {
      "http://immuneering.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r1",
      "r50",
      "r53",
      "r59",
      "r63",
      "r82",
      "r93",
      "r103",
      "r105",
      "r106",
      "r107",
      "r108",
      "r111",
      "r112",
      "r118",
      "r150",
      "r158",
      "r161",
      "r164",
      "r166",
      "r183",
      "r219",
      "r220",
      "r221",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r230",
      "r231",
      "r395",
      "r410",
      "r499",
      "r518"
     ],
     "calculation": {
      "http://immuneering.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://immuneering.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureNetLossPerShareAttributableToCommonStockholdersBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails",
      "http://immuneering.com/role/StatementConsolidatedStatementsOfCashFlows",
      "http://immuneering.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit",
      "http://immuneering.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recently Issued Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r145"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://immuneering.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r150",
      "r158",
      "r161",
      "r164",
      "r166"
     ],
     "calculation": {
      "http://immuneering.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r428",
      "r436"
     ],
     "calculation": {
      "http://immuneering.com/role/DisclosureCommitmentsAndContingenciesLeaseCostDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "terseLabel": "Operating lease cost"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureCommitmentsAndContingenciesLeaseCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r422"
     ],
     "calculation": {
      "http://immuneering.com/role/DisclosureCommitmentsAndContingenciesMaturitiesOfLeaseLiabilitiesDueDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      },
      "http://immuneering.com/role/DisclosureCommitmentsAndContingenciesMaturitiesOfLeaseLiabilitiesDueDetailsCalc2": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Lease liability",
        "totalLabel": "Total lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureCommitmentsAndContingenciesMaturitiesOfLeaseLiabilitiesDueDetails",
      "http://immuneering.com/role/DisclosureCommitmentsAndContingenciesNarrativesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r422"
     ],
     "calculation": {
      "http://immuneering.com/role/DisclosureCommitmentsAndContingenciesMaturitiesOfLeaseLiabilitiesDueDetailsCalc2": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      },
      "http://immuneering.com/role/StatementConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Lease liabilities, current",
        "verboseLabel": "Current portion lease liability"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureCommitmentsAndContingenciesMaturitiesOfLeaseLiabilitiesDueDetails",
      "http://immuneering.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r422"
     ],
     "calculation": {
      "http://immuneering.com/role/DisclosureCommitmentsAndContingenciesMaturitiesOfLeaseLiabilitiesDueDetailsCalc2": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      },
      "http://immuneering.com/role/StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Lease liabilities, non-current",
        "verboseLabel": "Lease liability, noncurrent"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureCommitmentsAndContingenciesMaturitiesOfLeaseLiabilitiesDueDetails",
      "http://immuneering.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r423",
      "r431"
     ],
     "calculation": {
      "http://immuneering.com/role/DisclosureCommitmentsAndContingenciesLeaseCostDetails": {
       "order": 1.0,
       "parentTag": "imrx_LeasePayments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "terseLabel": "Operating cash flows from operating leases"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureCommitmentsAndContingenciesLeaseCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r421"
     ],
     "calculation": {
      "http://immuneering.com/role/StatementConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Right-of-use assets, net",
        "verboseLabel": "Right of use asset"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureCommitmentsAndContingenciesNarrativesDetails",
      "http://immuneering.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": {
     "auth_ref": [
      "r81"
     ],
     "calculation": {
      "http://immuneering.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense for right-of-use asset from operating lease.",
        "label": "Operating Lease, Right-of-Use Asset, Amortization Expense",
        "terseLabel": "Right-of-use asset amortization"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r433",
      "r436"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted-average discount rate - operating leases"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureCommitmentsAndContingenciesLeaseCostDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r432",
      "r436"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted-average remaining lease term - operating leases"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureCommitmentsAndContingenciesLeaseCostDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r352"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Operating Loss Carryforwards"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureIncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLossCarryforwardsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Operating Loss Carryforwards [Line Items]"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureIncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLossCarryforwardsTable": {
     "auth_ref": [
      "r353"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization.",
        "label": "Operating Loss Carryforwards [Table]"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureIncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization and Nature of Business"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r2",
      "r389"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "terseLabel": "Organization and Nature of Business"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureOrganizationAndNatureOfBusiness"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent": {
     "auth_ref": [
      "r495",
      "r517"
     ],
     "calculation": {
      "http://immuneering.com/role/DisclosureAccruedExpensesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other.",
        "label": "Other Accrued Liabilities",
        "terseLabel": "Accrued other"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r33"
     ],
     "calculation": {
      "http://immuneering.com/role/StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r51",
      "r54",
      "r57",
      "r58",
      "r60",
      "r64",
      "r260",
      "r412",
      "r417",
      "r418",
      "r500",
      "r519"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Other comprehensive loss"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]",
        "terseLabel": "Other comprehensive loss:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r74"
     ],
     "calculation": {
      "http://immuneering.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Other expense"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "auth_ref": [
      "r77"
     ],
     "calculation": {
      "http://immuneering.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.",
        "label": "Payments of Stock Issuance Costs",
        "negatedLabel": "Payment of initial public offering costs",
        "terseLabel": "Issuance costs"
       }
      }
     },
     "localname": "PaymentsOfStockIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureConvertiblePreferredStockSeriesBDetails",
      "http://immuneering.com/role/DisclosureConvertiblePreferredStockSeriesDetails",
      "http://immuneering.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireMarketableSecurities": {
     "auth_ref": [
      "r175"
     ],
     "calculation": {
      "http://immuneering.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for purchase of marketable security.",
        "label": "Payments to Acquire Marketable Securities",
        "negatedLabel": "Purchases of marketable securities"
       }
      }
     },
     "localname": "PaymentsToAcquireMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r75"
     ],
     "calculation": {
      "http://immuneering.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r299",
      "r318"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureStockBasedCompensationNarrativesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureStockBasedCompensationNarrativesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockDividendRatePercentage": {
     "auth_ref": [
      "r244"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage rate used to calculate dividend payments on preferred stock.",
        "label": "Preferred Stock, Dividend Rate, Percentage",
        "terseLabel": "Dividend, Percentage"
       }
      }
     },
     "localname": "PreferredStockDividendRatePercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureConvertiblePreferredStockSeriesBDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_PreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.",
        "label": "Preferred Stock"
       }
      }
     },
     "localname": "PreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r16",
      "r243"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value per share (in dollars per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/StatementConsolidatedBalanceSheetsParentheticals"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred stock authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureCommonStockIpoDetails",
      "http://immuneering.com/role/StatementConsolidatedBalanceSheetsParentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r16",
      "r243"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/StatementConsolidatedBalanceSheetsParentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, outstanding",
        "verboseLabel": "Preferred stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureConvertiblePreferredStockSeriesBDetails",
      "http://immuneering.com/role/StatementConsolidatedBalanceSheetsParentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r16",
      "r442"
     ],
     "calculation": {
      "http://immuneering.com/role/StatementConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock, $0.001 par value; 10,000,000 and 0 shares authorized at December 31, 2021 and December 31, 2020, respectively; No shares issued or outstanding"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r6",
      "r25",
      "r26"
     ],
     "calculation": {
      "http://immuneering.com/role/StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaids and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceInitialPublicOffering": {
     "auth_ref": [
      "r76"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public.",
        "label": "Proceeds from Issuance Initial Public Offering",
        "terseLabel": "Proceeds from Stock issued"
       }
      }
     },
     "localname": "ProceedsFromIssuanceInitialPublicOffering",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureCommonStockIpoDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r76"
     ],
     "calculation": {
      "http://immuneering.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Aggregate net proceeds",
        "verboseLabel": "Proceeds from initial public offering of common stock, net of commissions and underwriting"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureOrganizationAndNatureOfBusinessDetails",
      "http://immuneering.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock": {
     "auth_ref": [
      "r76"
     ],
     "calculation": {
      "http://immuneering.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock.",
        "label": "Proceeds from Issuance of Convertible Preferred Stock",
        "terseLabel": "Proceeds from the issuance of preferred stock, net of issuance costs",
        "verboseLabel": "Gross proceeds from issuance of convertible stock"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfConvertiblePreferredStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureConvertiblePreferredStockSeriesBDetails",
      "http://immuneering.com/role/DisclosureConvertiblePreferredStockSeriesDetails",
      "http://immuneering.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r76",
      "r319"
     ],
     "calculation": {
      "http://immuneering.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from exercise of stock options"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromWarrantExercises": {
     "auth_ref": [
      "r76"
     ],
     "calculation": {
      "http://immuneering.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants.",
        "label": "Proceeds from Warrant Exercises",
        "terseLabel": "Proceeds from exercise of warrants"
       }
      }
     },
     "localname": "ProceedsFromWarrantExercises",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and Equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r31",
      "r208"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureCommitmentsAndContingenciesMaturitiesOfLeaseLiabilitiesDueDetails",
      "http://immuneering.com/role/DisclosureCommitmentsAndContingenciesNarrativesDetails",
      "http://immuneering.com/role/DisclosurePropertyAndEquipmentNetDetails",
      "http://immuneering.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r211",
      "r537",
      "r538",
      "r539"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "Property and Equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosurePropertyAndEquipmentNet"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r30",
      "r206"
     ],
     "calculation": {
      "http://immuneering.com/role/DisclosurePropertyAndEquipmentNetDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Property and equipment, gross"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosurePropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property and Equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosurePropertyAndEquipmentNetDetails",
      "http://immuneering.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r10",
      "r11",
      "r208",
      "r442",
      "r507",
      "r515"
     ],
     "calculation": {
      "http://immuneering.com/role/DisclosurePropertyAndEquipmentNetDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://immuneering.com/role/StatementConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosurePropertyAndEquipmentNetDetails",
      "http://immuneering.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r29",
      "r208",
      "r537",
      "r538"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r10",
      "r208"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Schedule of property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosurePropertyAndEquipmentNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r10",
      "r206"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureCommitmentsAndContingenciesMaturitiesOfLeaseLiabilitiesDueDetails",
      "http://immuneering.com/role/DisclosureCommitmentsAndContingenciesNarrativesDetails",
      "http://immuneering.com/role/DisclosurePropertyAndEquipmentNetDetails",
      "http://immuneering.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Estimated Useful Lives"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]"
       }
      }
     },
     "localname": "ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureIncomeTaxesUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r291",
      "r437",
      "r438"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Domain]"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureBusinessCombinationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionAmountsOfTransaction": {
     "auth_ref": [
      "r437",
      "r439"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transactions with related party during the financial reporting period.",
        "label": "Related Party Transaction, Amounts of Transaction",
        "terseLabel": "Amount of related party expenses"
       }
      }
     },
     "localname": "RelatedPartyTransactionAmountsOfTransaction",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureBusinessCombinationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r291",
      "r437",
      "r439",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureBusinessCombinationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r329",
      "r474",
      "r542"
     ],
     "calculation": {
      "http://immuneering.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureBusinessCombinationNarrativeDetails",
      "http://immuneering.com/role/DisclosureStockBasedCompensationShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchMember": {
     "auth_ref": [
      "r353"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research tax credit carryforwards arising from certain qualifying expenditures incurred to develop new products and processes.",
        "label": "Research Tax Credit Carryforward [Member]"
       }
      }
     },
     "localname": "ResearchMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureIncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r20",
      "r268",
      "r323",
      "r442",
      "r513",
      "r530",
      "r532"
     ],
     "calculation": {
      "http://immuneering.com/role/StatementConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "negatedLabel": "Accumulated deficit",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureOrganizationAndNatureOfBusinessDetails",
      "http://immuneering.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r0",
      "r100",
      "r101",
      "r102",
      "r104",
      "r110",
      "r112",
      "r184",
      "r320",
      "r321",
      "r322",
      "r359",
      "r360",
      "r393",
      "r527",
      "r529"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax": {
     "auth_ref": [
      "r146",
      "r147",
      "r157",
      "r162",
      "r163",
      "r167",
      "r168",
      "r169",
      "r279",
      "r280",
      "r475"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.",
        "label": "Revenue from Contract with Customer, Including Assessed Tax",
        "terseLabel": "Revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerIncludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureSummaryOfSignificantAccountingPoliciesConcentrationOfCreditRiskDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "auth_ref": [
      "r90",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r282"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue from contract with customer.",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Revenues": {
     "auth_ref": [
      "r61",
      "r93",
      "r146",
      "r147",
      "r157",
      "r162",
      "r163",
      "r167",
      "r168",
      "r169",
      "r183",
      "r219",
      "r220",
      "r221",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r230",
      "r231",
      "r410",
      "r503"
     ],
     "calculation": {
      "http://immuneering.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_GrossProfit",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
        "label": "Revenues",
        "terseLabel": "Revenue"
       }
      }
     },
     "localname": "Revenues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureCommonStockIpoDetails",
      "http://immuneering.com/role/DisclosureOrganizationAndNatureOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SalesRevenueNetMember": {
     "auth_ref": [
      "r139",
      "r169"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation.",
        "label": "Revenue"
       }
      }
     },
     "localname": "SalesRevenueNetMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureSummaryOfSignificantAccountingPoliciesConcentrationOfCreditRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of accrued expenses"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureAccruedExpensesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r122"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureNetLossPerShareAttributableToCommonStockholdersAntidilutiveEffectDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r122"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of potentially dilutive securities that have been excluded from the calculation of diluted net loss per share"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureNetLossPerShareAttributableToCommonStockholdersTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "auth_ref": [
      "r374",
      "r375"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table]"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureBusinessCombinationAssetsAcquiredAndLiabilitiesAssumedDetails",
      "http://immuneering.com/role/DisclosureBusinessCombinationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock": {
     "auth_ref": [
      "r315"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.",
        "label": "Share-based Payment Arrangement, Cost by Plan [Table Text Block]",
        "terseLabel": "Summary of recognized share-based compensation expense recognized"
       }
      }
     },
     "localname": "ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureStockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r349"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Schedule of net deferred tax assets"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r121"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Schedule of basic and diluted net loss per share attributable to common stockholders"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureNetLossPerShareAttributableToCommonStockholdersTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r337"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of federal statutory rate to the net loss and the effective income tax rate"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r31",
      "r208"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosurePropertyAndEquipmentNetDetails",
      "http://immuneering.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": {
     "auth_ref": [
      "r378"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.",
        "label": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]",
        "terseLabel": "Schedule of Assets Acquired and Liabilities Assumed at Fair Value"
       }
      }
     },
     "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureBusinessCombinationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r299",
      "r318"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureStockBasedCompensationAssumptionsDetails",
      "http://immuneering.com/role/DisclosureStockBasedCompensationNarrativesDetails",
      "http://immuneering.com/role/DisclosureStockBasedCompensationShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r302",
      "r306",
      "r308"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Summary of stock option activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureStockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r311"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of assumptions in its application of the Black-Scholes option pricing model for grants"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureStockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r40",
      "r91",
      "r129",
      "r130",
      "r238",
      "r240",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r248",
      "r252",
      "r258",
      "r261",
      "r262",
      "r263",
      "r265",
      "r266",
      "r267",
      "r268"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureCommonStockClassBCommonStockDetails",
      "http://immuneering.com/role/DisclosureCommonStockClassCommonStockDetails",
      "http://immuneering.com/role/DisclosureCommonStockDetails",
      "http://immuneering.com/role/DisclosureCommonStockIpoDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfStockByClassTextBlock": {
     "auth_ref": [
      "r15",
      "r16",
      "r17",
      "r239",
      "r240",
      "r242",
      "r261",
      "r262",
      "r263",
      "r265",
      "r266",
      "r267",
      "r268"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's stock, including par or stated value per share, number and dollar amount of share subscriptions, shares authorized, shares issued, shares outstanding, number and dollar amount of shares held in an employee trust, dividend per share, total dividends, share conversion features, par value plus additional paid in capital, the value of treasury stock and other information necessary to a fair presentation, and EPS information.  Stock by class includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. Includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity. If more than one issue is outstanding, state the title of each issue and the corresponding dollar amount; dollar amount of any shares subscribed but unissued and the deduction of subscriptions receivable there from; number of shares authorized, issued, and outstanding.",
        "label": "Schedule of Stock by Class [Table Text Block]",
        "terseLabel": "Schedule of common stock for conversion of preferred stock, exercise of warrants and exercise of stock options"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureCommonStockTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of subsidiary's sales of previously unissued stock made to investors outside the consolidated group. This includes stock issued in a business combination in exchange for shares of an acquired entity.",
        "label": "Schedule of Subsidiary or Equity Method Investee [Table]"
       }
      }
     },
     "localname": "ScheduleOfSubsidiaryOrEquityMethodInvesteeTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureOrganizationAndNatureOfBusinessDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": {
     "auth_ref": [
      "r343",
      "r358"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the change in unrecognized tax benefits.",
        "label": "Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]",
        "terseLabel": "Schedule of unrecognized tax benefits"
       }
      }
     },
     "localname": "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock": {
     "auth_ref": [
      "r137",
      "r139",
      "r140",
      "r141",
      "r407",
      "r409"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.",
        "label": "Schedules of Concentration of Risk, by Risk Factor [Table Text Block]",
        "terseLabel": "Schedule of concentration of credit risk"
       }
      }
     },
     "localname": "SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r151",
      "r152",
      "r153",
      "r154",
      "r155",
      "r156",
      "r168"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Segments"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://immuneering.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock based compensation expense"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r300"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period",
        "terseLabel": "Vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureStockBasedCompensationNarrativesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r313"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Expected dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureStockBasedCompensationAssumptionsDetails",
      "http://immuneering.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum",
        "terseLabel": "Expected volatility, maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureStockBasedCompensationAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum",
        "terseLabel": "Expected volatility, minimum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureStockBasedCompensationAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum",
        "terseLabel": "Weighted-average risk-free interest rate, maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureStockBasedCompensationAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum",
        "terseLabel": "Weighted-average risk-free interest rate, minimum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureStockBasedCompensationAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureStockBasedCompensationAssumptionsDetails",
      "http://immuneering.com/role/DisclosureStockBasedCompensationNarrativesDetails",
      "http://immuneering.com/role/DisclosureStockBasedCompensationShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]",
        "terseLabel": "Weighted Average Remaining Contractual Contractual Term"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Shares issued",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureStockBasedCompensationNarrativesDetails",
      "http://immuneering.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r307"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Grant date weighted average fair value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureStockBasedCompensationNarrativesDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r318"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value Outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r304",
      "r318"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Outstanding at the end (in shares)",
        "periodStartLabel": "Outstanding at the beginning (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Number of options"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r303"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Weighted Average Exercise Price per Share Outstanding at the end (in dollars per share)",
        "periodStartLabel": "Weighted Average Exercise Price per Share Outstanding at the beginning (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted Average Exercise Price per Share"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue": {
     "auth_ref": [
      "r310"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value Vested and exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber": {
     "auth_ref": [
      "r310"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number",
        "terseLabel": "Vested and exercisable (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r310"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price per Share Vested and Exercisable (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "auth_ref": [
      "r308"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value Vested and expected to vest"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "auth_ref": [
      "r309"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "terseLabel": "Vested and expected to vest (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r309"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price per Share Vested and Expected to Vest exercisable (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price per Share Exercised (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price per Share Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r299",
      "r301"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Stock-based Compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r312",
      "r324"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureStockBasedCompensationAssumptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r309"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted Average Remaining Contractual Term (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r310"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted Average Remaining Contractual Term, Vested and exercisable (in Years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r309"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted Average Remaining Contractual Term, Vested and expected to vest (in Years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Ending Balance (in shares)",
        "periodStartLabel": "Beginning Balance (in shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShortTermLeaseCost": {
     "auth_ref": [
      "r429",
      "r436"
     ],
     "calculation": {
      "http://immuneering.com/role/DisclosureCommitmentsAndContingenciesLeaseCostDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less.",
        "label": "Short-term Lease, Cost",
        "terseLabel": "Short-term lease cost"
       }
      }
     },
     "localname": "ShortTermLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureCommitmentsAndContingenciesLeaseCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShortTermLeasePayments": {
     "auth_ref": [
      "r424"
     ],
     "calculation": {
      "http://immuneering.com/role/DisclosureCommitmentsAndContingenciesLeaseCostDetails": {
       "order": 2.0,
       "parentTag": "imrx_LeasePayments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for short-term lease payment excluded from lease liability.",
        "label": "Short-term Lease Payments",
        "terseLabel": "Operating cash flows from short-term leases"
       }
      }
     },
     "localname": "ShortTermLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureCommitmentsAndContingenciesLeaseCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r89",
      "r99"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureSummaryOfSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.",
        "label": "State and Local Jurisdiction [Member]"
       }
      }
     },
     "localname": "StateAndLocalJurisdictionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureIncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r15",
      "r16",
      "r17",
      "r91",
      "r93",
      "r115",
      "r116",
      "r117",
      "r119",
      "r121",
      "r129",
      "r130",
      "r131",
      "r183",
      "r219",
      "r224",
      "r225",
      "r226",
      "r230",
      "r231",
      "r243",
      "r244",
      "r248",
      "r252",
      "r260",
      "r410",
      "r551"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureCommonStockClassBCommonStockDetails",
      "http://immuneering.com/role/DisclosureCommonStockClassCommonStockDetails",
      "http://immuneering.com/role/DisclosureCommonStockDetails",
      "http://immuneering.com/role/DisclosureCommonStockIpoDetails",
      "http://immuneering.com/role/DisclosureConvertiblePreferredStockSeriesBDetails",
      "http://immuneering.com/role/DisclosureConvertiblePreferredStockSeriesDetails",
      "http://immuneering.com/role/DisclosureOrganizationAndNatureOfBusinessDetails",
      "http://immuneering.com/role/DisclosureStockBasedCompensationNarrativesDetails",
      "http://immuneering.com/role/DocumentDocumentAndEntityInformation",
      "http://immuneering.com/role/StatementConsolidatedBalanceSheets",
      "http://immuneering.com/role/StatementConsolidatedBalanceSheetsParentheticals",
      "http://immuneering.com/role/StatementConsolidatedStatementsOfCashFlows",
      "http://immuneering.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r0",
      "r43",
      "r57",
      "r58",
      "r59",
      "r100",
      "r101",
      "r102",
      "r104",
      "r110",
      "r112",
      "r128",
      "r184",
      "r260",
      "r268",
      "r320",
      "r321",
      "r322",
      "r359",
      "r360",
      "r393",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r418",
      "r527",
      "r528",
      "r529",
      "r562"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DocumentDocumentAndEntityInformation",
      "http://immuneering.com/role/StatementConsolidatedBalanceSheets",
      "http://immuneering.com/role/StatementConsolidatedBalanceSheetsParentheticals",
      "http://immuneering.com/role/StatementConsolidatedStatementsOfCashFlows",
      "http://immuneering.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CONSOLIDATED STATEMENTS OF CASH FLOWS"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CONDENSED CONSOLIDATED BALANCE SHEETS"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT)"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r100",
      "r101",
      "r102",
      "r128",
      "r475"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DocumentDocumentAndEntityInformation",
      "http://immuneering.com/role/StatementConsolidatedBalanceSheets",
      "http://immuneering.com/role/StatementConsolidatedBalanceSheetsParentheticals",
      "http://immuneering.com/role/StatementConsolidatedStatementsOfCashFlows",
      "http://immuneering.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssued1": {
     "auth_ref": [
      "r85",
      "r86",
      "r87"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fair value of stock issued in noncash financing activities.",
        "label": "Stock Issued",
        "terseLabel": "Conversion of convertible Series A and B preferred stock into common stock"
       }
      }
     },
     "localname": "StockIssued1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesAcquisitions": {
     "auth_ref": [
      "r16",
      "r17",
      "r268"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued during the period pursuant to acquisitions.",
        "label": "Stock Issued During Period, Shares, Acquisitions",
        "terseLabel": "Issuance of common stock for acquisition, shares",
        "verboseLabel": "Shares issued"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesAcquisitions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureBusinessCombinationNarrativeDetails",
      "http://immuneering.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r42",
      "r234",
      "r260",
      "r261",
      "r268"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.",
        "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities",
        "terseLabel": "Conversion of Preferred Stock into common stock (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r16",
      "r17",
      "r260",
      "r268"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Shares issued",
        "verboseLabel": "Issuance of common stock upon initial public offering, net of issuance costs (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureCommonStockIpoDetails",
      "http://immuneering.com/role/DisclosureOrganizationAndNatureOfBusinessDetails",
      "http://immuneering.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r16",
      "r17",
      "r260",
      "r268",
      "r305"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Exercised (in shares)",
        "terseLabel": "Issuance of common stock upon exercise of stock options (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails",
      "http://immuneering.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueAcquisitions": {
     "auth_ref": [
      "r43",
      "r260",
      "r268"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued pursuant to acquisitions during the period.",
        "label": "Stock Issued During Period, Value, Acquisitions",
        "terseLabel": "Issuance of common stock for acquisition"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueAcquisitions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r43",
      "r260",
      "r268"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities.",
        "label": "Stock Issued During Period, Value, Conversion of Convertible Securities",
        "terseLabel": "Conversion of Preferred Stock into common stock"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r16",
      "r17",
      "r260",
      "r268"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of common stock upon initial public offering, net of issuance costs"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r43",
      "r260",
      "r268"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Issuance of common stock upon exercise of stock options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r17",
      "r22",
      "r23",
      "r93",
      "r173",
      "r183",
      "r410",
      "r442"
     ],
     "calculation": {
      "http://immuneering.com/role/StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending Balance",
        "periodStartLabel": "Beginning Balance",
        "totalLabel": "Total stockholders' equity (deficit)"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/StatementConsolidatedBalanceSheets",
      "http://immuneering.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders' deficit:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock."
       }
      }
     },
     "localname": "StockholdersEquityNoteAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r92",
      "r244",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r256",
      "r257",
      "r259",
      "r268",
      "r270"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureCommonStock"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StockholdersEquityNoteStockSplitConversionRatio1": {
     "auth_ref": [
      "r269"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.",
        "label": "Stockholders' Equity Note, Stock Split, Conversion Ratio",
        "terseLabel": "Stock split, ratio"
       }
      }
     },
     "localname": "StockholdersEquityNoteStockSplitConversionRatio1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "us-gaap_StockholdersEquityPolicyTextBlock": {
     "auth_ref": [
      "r241"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for its capital stock transactions, including dividends and accumulated other comprehensive income.",
        "label": "Stockholders' Equity, Policy [Policy Text Block]",
        "terseLabel": "Stock Split"
       }
      }
     },
     "localname": "StockholdersEquityPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Subsidiary or Equity Method Investee [Line Items]",
        "terseLabel": "Organization and Nature of Business"
       }
      }
     },
     "localname": "SubsidiaryOrEquityMethodInvesteeLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureOrganizationAndNatureOfBusinessDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureCommonStockIpoDetails",
      "http://immuneering.com/role/DisclosureOrganizationAndNatureOfBusinessDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental disclosures of noncash investing and financing information :"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions": {
     "auth_ref": [
      "r331",
      "r332"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) to previously recorded tax expense. Includes, but is not limited to, significant settlements of income tax disputes, and unusual tax positions or infrequent actions taken by the entity, including tax assessment reversal, and IRS tax settlement.",
        "label": "Tax Adjustments, Settlements, and Unusual Provisions",
        "terseLabel": "Uncertain tax positions"
       }
      }
     },
     "localname": "TaxAdjustmentsSettlementsAndUnusualProvisions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "auth_ref": [
      "r352"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Tax Credit Carryforward, Amount"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureIncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TaxCreditCarryforwardAxis": {
     "auth_ref": [
      "r353"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by specific tax credit related to an unused tax credit.",
        "label": "Tax Credit Carryforward [Axis]"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureIncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardNameDomain": {
     "auth_ref": [
      "r353"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name of the tax credit carryforward.",
        "label": "Tax Credit Carryforward, Name [Domain]"
       }
      }
     },
     "localname": "TaxCreditCarryforwardNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureIncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TemporaryEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Temporary Equity [Abstract]",
        "terseLabel": "Convertible preferred stock:"
       }
      }
     },
     "localname": "TemporaryEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TemporaryEquityByClassOfStockTable": {
     "auth_ref": [
      "r8",
      "r239"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Table of capital stock that is classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer. This table may include a description by series, value, shares authorized, shares issued and outstanding, redemption price per share and subscription receivable.",
        "label": "Temporary Equity, by Class of Stock [Table]"
       }
      }
     },
     "localname": "TemporaryEquityByClassOfStockTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureConvertiblePreferredStockSeriesBDetails",
      "http://immuneering.com/role/DisclosureConvertiblePreferredStockSeriesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TemporaryEquityCarryingAmountAttributableToParent": {
     "auth_ref": [
      "r219",
      "r224",
      "r225",
      "r226",
      "r230",
      "r231"
     ],
     "calculation": {
      "http://immuneering.com/role/StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Carrying Amount, Attributable to Parent",
        "periodEndLabel": "Ending Balance",
        "periodStartLabel": "Beginning Balance",
        "terseLabel": "Convertible preferred stock"
       }
      }
     },
     "localname": "TemporaryEquityCarryingAmountAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/StatementConsolidatedBalanceSheets",
      "http://immuneering.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TemporaryEquityDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Preferred Stock"
       }
      }
     },
     "localname": "TemporaryEquityDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_TemporaryEquityLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Temporary Equity [Line Items]"
       }
      }
     },
     "localname": "TemporaryEquityLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureConvertiblePreferredStockSeriesBDetails",
      "http://immuneering.com/role/DisclosureConvertiblePreferredStockSeriesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TemporaryEquityParOrStatedValuePerShare": {
     "auth_ref": [
      "r8",
      "r239"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable.",
        "label": "Temporary Equity, Par or Stated Value Per Share",
        "terseLabel": "Convertible preferred stock, par value per share (in dollars per share)"
       }
      }
     },
     "localname": "TemporaryEquityParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureConvertiblePreferredStockSeriesBDetails",
      "http://immuneering.com/role/DisclosureConvertiblePreferredStockSeriesDetails",
      "http://immuneering.com/role/StatementConsolidatedBalanceSheetsParentheticals"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_TemporaryEquitySharesAuthorized": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Shares Authorized",
        "terseLabel": "Convertible preferred stock, authorized (in shares)"
       }
      }
     },
     "localname": "TemporaryEquitySharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureConvertiblePreferredStockSeriesBDetails",
      "http://immuneering.com/role/DisclosureConvertiblePreferredStockSeriesDetails",
      "http://immuneering.com/role/StatementConsolidatedBalanceSheetsParentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TemporaryEquitySharesIssued": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Shares Issued",
        "terseLabel": "Convertible preferred stock, issued (in shares)"
       }
      }
     },
     "localname": "TemporaryEquitySharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureConvertiblePreferredStockSeriesBDetails",
      "http://immuneering.com/role/DisclosureConvertiblePreferredStockSeriesDetails",
      "http://immuneering.com/role/StatementConsolidatedBalanceSheetsParentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TemporaryEquitySharesOutstanding": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Shares Outstanding",
        "periodEndLabel": "Ending Balance (in shares)",
        "periodStartLabel": "Beginning Balance (in shares)",
        "terseLabel": "Convertible preferred stock, outstanding (in shares)"
       }
      }
     },
     "localname": "TemporaryEquitySharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureCommonStockIpoDetails",
      "http://immuneering.com/role/DisclosureConvertiblePreferredStockSeriesDetails",
      "http://immuneering.com/role/DisclosureOrganizationAndNatureOfBusinessDetails",
      "http://immuneering.com/role/StatementConsolidatedBalanceSheetsParentheticals",
      "http://immuneering.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of new stock classified as temporary equity issued during the period.",
        "label": "Temporary Equity, Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of convertible preferred stock, net of issuance costs"
       }
      }
     },
     "localname": "TemporaryEquityStockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TradeAndOtherAccountsReceivableUnbilledReceivablesPolicy": {
     "auth_ref": [
      "r174"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for treatment of receivables that are billable but have not been billed as of the balance sheet date.",
        "label": "Trade and Other Accounts Receivable, Unbilled Receivables, Policy [Policy Text Block]",
        "terseLabel": "Accounts Receivable"
       }
      }
     },
     "localname": "TradeAndOtherAccountsReceivableUnbilledReceivablesPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r177",
      "r178",
      "r180",
      "r181",
      "r182",
      "r235",
      "r258",
      "r392",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_USTreasurySecuritiesMember": {
     "auth_ref": [
      "r98",
      "r284",
      "r292",
      "r504"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years).",
        "label": "U.S. Treasuries"
       }
      }
     },
     "localname": "USTreasurySecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureFairValueMeasurementsDetails",
      "http://immuneering.com/role/DisclosureMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "auth_ref": [
      "r333",
      "r341"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrecognized tax benefits.",
        "label": "Unrecognized Tax Benefits",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefits",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureIncomeTaxesNarrativeDetails",
      "http://immuneering.com/role/DisclosureIncomeTaxesUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": {
     "auth_ref": [
      "r339"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.",
        "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureIncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": {
     "auth_ref": [
      "r342"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions",
        "terseLabel": "Increase due to current year tax provision"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureIncomeTaxesUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r132",
      "r133",
      "r135",
      "r136",
      "r142",
      "r143",
      "r144"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "auth_ref": [
      "r349"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.",
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount"
       }
      }
     },
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureIncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_VariableLeaseCost": {
     "auth_ref": [
      "r430",
      "r436"
     ],
     "calculation": {
      "http://immuneering.com/role/DisclosureCommitmentsAndContingenciesLeaseCostDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.",
        "label": "Variable Lease, Cost",
        "terseLabel": "Variable lease cost"
       }
      }
     },
     "localname": "VariableLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureCommitmentsAndContingenciesLeaseCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Common stock warrants"
       }
      }
     },
     "localname": "WarrantMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureCommonStockDetails",
      "http://immuneering.com/role/DisclosureNetLossPerShareAttributableToCommonStockholdersAntidilutiveEffectDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantsAndRightsOutstanding": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.",
        "label": "Warrants and Rights Outstanding",
        "terseLabel": "Warrants outstanding"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureCommonStockCommonStockWarrantDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WarrantsAndRightsOutstandingTerm": {
     "auth_ref": [
      "r400"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Warrants and Rights Outstanding, Term",
        "terseLabel": "Term of warrant"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstandingTerm",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureCommonStockCommonStockWarrantDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r114",
      "r121"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted-average common shares outstanding, diluted"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureNetLossPerShareAttributableToCommonStockholdersBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails",
      "http://immuneering.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r113",
      "r121"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted-average common shares outstanding, basic"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://immuneering.com/role/DisclosureNetLossPerShareAttributableToCommonStockholdersBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails",
      "http://immuneering.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 10
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1505-109256"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1278-109256"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2626-109256"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8672-108599"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5074-111524"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "310",
   "URI": "http://asc.fasb.org/topic&trid=2196771"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=SL6284422-111562"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27232-111563"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=SL120269820-111563"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "http://asc.fasb.org/topic&trid=2196928"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.A)",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=122040515&loc=d3e105025-122735"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13777-109266"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "http://asc.fasb.org/topic&trid=2155823"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21459-112644"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21553-112644"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21484-112644"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21488-112644"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21521-112644"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21538-112644"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 4.C)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187143-122770"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130561-203045"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130564-203045"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.12)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "http://asc.fasb.org/topic&trid=49130388"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4534-113899"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.15)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11149-113907"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11178-113907"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123452999&loc=d3e28511-109314"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123452999&loc=d3e28446-109314"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=SL37586934-109318"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "217",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=124434304&loc=d3e36027-109320"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.2)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(a)-(d)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6909625&loc=d3e227-128457"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123586518&loc=d3e1043-128460"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "37",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123455525&loc=d3e2207-128464"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123413009&loc=d3e4845-128472"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123413009&loc=d3e4845-128472"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6578-128477"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6613-128477"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "740",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123403335&loc=d3e9901-128506"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "805",
   "URI": "http://asc.fasb.org/topic&trid=2303972"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "http://asc.fasb.org/topic&trid=2197479"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123477628&loc=d3e90205-114008"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.28,29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=SL6742756-110258"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "60",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123341672&loc=SL77916155-209984"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-30)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(j)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123341672&loc=SL77916155-209984"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918666-209980"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918701-209980"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e637-108580"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e681-108580"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "http://asc.fasb.org/extlink&oid=123384075&loc=d3e41242-110953"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669686-108580"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "940",
   "URI": "http://asc.fasb.org/subtopic&trid=2176304"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.15(5))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.4)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62557-112803"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62652-112803"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/subtopic&trid=2209399"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "405",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6957935&loc=d3e64057-112817"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123345438&loc=d3e61044-112788"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(15)(b)(2))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.15(a))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "946",
   "URI": "http://asc.fasb.org/subtopic&trid=2324412"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=123364037&loc=d3e3115-115594"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=SL120174063-112916"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r543": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r544": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r545": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r546": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r547": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310"
  },
  "r548": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r549": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e557-108580"
  },
  "r550": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r551": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402"
  },
  "r552": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)"
  },
  "r553": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)"
  },
  "r554": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(3)"
  },
  "r555": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)"
  },
  "r556": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)"
  },
  "r557": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)"
  },
  "r558": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1403"
  },
  "r559": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067"
  },
  "r560": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r561": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124507222&loc=d3e1436-108581"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(21))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(7)(c))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1,2)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(27)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4273-108586"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4304-108586"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4313-108586"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4332-108586"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18726-107790"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>114
<FILENAME>0001558370-22-003208-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001558370-22-003208-xbrl.zip
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MP-J.F$M8<=C%-\!^@^[AY#U#@3M<?(-.H?&7*OXB(1UX/&]N5X:TR <NROJ
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M A@W9A"=_!F,4L_S\*N5IB0:6?5!A8[BB.TT&R:;*%_$PJ8T$%<PQ4H8WL@
M>QL.5\5P$C&S]I3,!WI<9J02Y@'?-73]A$B>/XIOX (K2^J8:O;?ZVI&5!6\
M!;(\O!+GA=R YY]E2XI5Q>%K8'0\EVUQ5FH'M -)593_@>[VX=5;DC.1E%VE
M2A%\M-O76N"@Y&7;T9F<G6:)U !H1[,Z\"Z]J6P;5U=,VDAM^.]T9U@BQ8]V
MGU0+'7U915O"Q>PT263XT>XHJJ+KC0+"5L24E*Q=I4NY$="^)ZWW4K#L+5QD
MVA=O3!1GPL?A J/GK/?H@T,[QY)@*5_=*\NWG3XNP8?@TI/9NYC$OR4!OQZ-
MQRV(9X.@X9S]RA\3TMIG;7>R^ZRA-$,4!A^A/ -^"U?P^!H=B8LU:)@R,-\,
M,"MIS(9LON'"U<DI>""BB9>YP;R*@%H:@'P%><B!:P'EA6Y]\?[4E9LXG!D&
M%/"+@,)*[#C>*W\>0,L,E4O!U[CH$R79VFS"/'C/A:N@#_=8[/].PV>A]:I;
ML:BTM4#'D[H?QET_F91LL+D#UBHJ_P!B,^@T7/CUSO-I7JN[G+!M(<(:K+"Y
M$\,J>L.7?6@!:3 ,Q&_A?CN,<\[)"W$\$:%Y1Y@EB4A8<1$[1YME;5.Z HBZ
M)YJA]V/D2_1%66';PJ8U6$'C@2F$O(&I(TRKII9X7#.*#5J".7GB=I$[RG8H
M71Y$S1[1U/(@;]##2<SQEV"03.0NLDC+%J41\ZB9U LN">AO.ASS%#1Y3R5>
M@E EDG>15U5,$M'KI,[;,M.KB)DE!]V5PTR\7\[*H1T5(A8)S?!^S*8L$V8,
ME(B1E%]C69JKEC8DUFI&@?+[]8JRI"G>;75/Z[X)3-%9R:JN#1#O8EO^!7MW
MC$Q,.CN!54Y8>5Z\#E?VGIP ^LC1[OS)(.F=<M:4LE/DT+$!VA#+3&NIT9]!
M4KP.K]#\EP)KCA>+'DC(3]P 3\K<HN!1.<0F-. A!O@C_B[JDOK>F/\;NL6U
MX^.%PV>3D3,8+-O)!/PU+E5&K*"H!O!)3@H%1JW+1,WAX_R5OC TRGK/?0A<
M._^V,T<+=W.ZG-DJ?]]D['WDL5>3V66;*)I2MIT:%="C/921 3>/N0,+I0"J
MDD,N(6V:HU:W<[15Q-!$CO801O40,^VX*)0D6&((JX@7PV-,2Q\W5UQY[F[@
MI#GRI>D-G3#'>!SGAVN#Y_E["7P(;D'2WIA_J@)5)@M?DZ+K<.7#.%HF0#M+
M6<UAG*WRN@Y(!"<<"CH/ 8#/G'6[B:YN-R%*,BPH:OT]@2124J@0NS8OSG$A
M 8+J)M&V.#&>RB8WN[PZ%:) VTH.GST6/! V5G%;?N(TX$^M;JNN,QIJ;M-
M@7;-9=;^28<XL]\1M 8%BF83XJ&3U-CR1D *H"$-0(&GL@D;YBE% &CK_"\F
M$_<!ESDJDZYA?E+37WVU,V]\^O4PM%PT3/O7_P%02P,$%     @ TC1J5(#F
M<H_D.   =PD$ !4   !I;7)X+3(P,C$Q,C,Q7V1E9BYX;6SM?5ESY$:2YON:
M[7_(K7G8'K.E6&1)/2J9-&.9/-2<(9E<,DN:WA=9$(ADH@L)4 & 9/:OWXA
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M=192$G>]^>@1^SP41%W^CY."0(QJ'/?'^(&86[2F/RX(HKM1AZG2>6Z"+DI
M6U$N"J.J>9D<%'Q*\M*AHV77SY*$:SN,0ENJDHAV&?(S#-HOK]L!6V>R2R5T
MX/(G RXFBW!B1WU(Z!3RRX=>-6[GJ+CS41J3LO-6S#8+VKEBT!G4E.J<85V
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M$.1ZP=/#9OT8^@(Y%[YW*^3*)]P"U2"4^>+-6;&'%"1&'G&Q;N5=^>@J)A[
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M?,4QFYVW=RO8UET8(FQ4 \*49XR9DA-P2$T=A^7-B.ZQ@SW^S-LMCM50J:M
MV#H;8Z5F!1Q8]+3UC#SWXNT9!Q&F$\,\7F&2XU:"F5%-"-MN8^B,. *'H E6
M?:(B<9R;#RC@\A=-SK=AX%BO3=E*<)8GVW4IRP4XK.Y(^(Q)O+GS49H(G>Z
MGMFA@\[1TFE.507.TJ2>V%0\@$/IUS!T7SV_>/NZ_!G.ZJ*2_H%><)*^9%+#
MU]X+=J^"& 5/S ";<B0?$;I*<%87%2HZ+L!A-:=#&+$KF_P]RGOO:17/EU^B
ME&8)5)HZ$')4ZI'2, $/J,.N4;L/D)2%D,K2 !@Q\>  24E4;HUA9*HTM;H!
ME/&UAQX]G^\ Z0:#NSA6H4^9C=AF(]YH3*'FU2'LN,QLU>8\04;3S)2MJ@#!
M/&JKGA(<X9N[=^:G.[1AYS(SLUNQ,##$+*QN14X@XD,2[):YDT,D*P_!1F"-
MDHP9<$#E=YT[DC=JM'25("Q>=I#I. *'F_'(ZGU(20P*=O@,8BQEB#P<%,QW
M%*(ZP":_.IL*$7O@()3, _H#KKX>L-V&7$,-YD70Y^ ,D_I!!VZ(F>&2XP <
M BRVSXOY;7(6@Q$&3(-PX,@14=8 MIVPG@25S($#;X'7[/8_V1A9-*2E@>TQ
MK$&3,@8=L%V$TW3-CHK3.";>8\*]EXOP#BG6L KM0%C3-/JJP-2$0W!H6]L<
MP5@9)3ZL.H-T4-;&_(T/54"FL"2$L6:'CI -<+!D,A0I@V1+Q2!L'.TW(GD>
MP*$Q=5TO)> .>>Y5<(:>O1C)8B2DI2%L&>VPD;("#R+'2=:)SZY^<]<H2VY'
M\(K=%WW!+'O4&E^'$0LOF"\7Z$UN\;5K!<*&TA)26Q;!07V/8RH<[%X@$M"-
M4I3AZ)RBX'BR38=)10B;#SM 3;@"AV&91>.-(HS0F;I;0H"8Z/:\%<,'8.#5
MD+U8PB&XC"?I27&%8\]!OGG^DQ_,\Y],_I+OXU\_C E1QH0H8T*4,2&*#(@Q
M(<J8$&5,B#(F1#'"0T4],/&/"5'&A"AC0A0#)R ],,P)9\[EEMX[3'CZ?3/7
MG[PVA-7%#%ECEL 9!PJ4I\\F3)-X1<G\)R[F93>N!6$AJ@1=F95A0,8?W[2"
M:U<#PJ)5 ZH=&\. 2?X@BWDU&*;LRH!U\29+4WYSRY7-M#($PZD9@J8< <?1
M<%G358)PA;0*;@-8U$0$*]<T504(]TZKXP1V11,1JU_0M+4Z1:O2RP/&K("#
M+!.$8[F6&=7LU@9;Z1T#*WX@XV>XABEK=(M7+6.)D@_X."G7+FGI;O&I9?*0
M\@ ?&_V:!>A-S)-:UHVZ+V*V']ZP_V,T7TH=-,+PC$)0F"8(XI/Z$9B'!?WG
MYN)V\3"97[)/OUW<+ZYFUQ>3N_N+RXO[>UYF?O9?D^GM]J>_S:_/+^X?_O?D
MXO]^N5K\??*7\XO+J[.KQ1@QT3BEVRL4X?HY#/C-)H.H"7&=049.B%F!,+<6
M*%,&4$C*0HNA4.E:%AT).Q!0D81W*_V9FCH0HBV4RF80W@[)T5F,[E5B(RL,
MP4%F#(J,"0AH9+9)!D[__D)@)'M!8PP$]$,0OT%8DKHH!!^6,0AP8X\,[I"H
MUQ#S^A"<6.;KB3E?$& <=J"QSBHQ!AH#V"2/@<;=;GW'0./^=[ICH/$8:#Q&
MNGY;D:YT<T=8,K)SG/Y[%93MT/>A[U^&Y!41F;_'NA4(TYT9TM:L@7,/F?J$
M>G<$B6&JJ*&YT3J 0(;A7"R7#*<F<!K";7-.9.H+/D^8_^^.[HG"--""?YMS
M^J*+-WH"]"*IC[Q".Q V)4W!;,?Y4+0@G6D:4 -E0Q"L@>WI@9+UYA1!=M13
M*.?OB! 4Q%),JS0 P4Y8 \LJ+/>%8:I8=4"4M@ AX+TE%*4\#V5.YFJ86BR8
M)3 7A7-X@K#"*FW0)H2 ^I97; ,I#$534E5O6%6,&X40U-_VJOZ.E(4K_RU^
MY5^J3!^9NA!N"+0\362X'0K"J<I6A+A4&<15@K;']P!1YMHY=2CK$0>ERE#.
M5P=Q":'EX9SG>"A8;R]:5 9;5!_$E8:VQS5PN*?N/Y(H?1-B$4J"(SDC+";=
M9=$M.(@0*W2/4\;H%H2\> Y.F;['3OB48JG*8MU^MR!N8C2@7.U+"IQ.WN+X
MD)58HD"%,MVBW9YAK\ 6.&AJ)-H&F%W[I'FKGAVWX/ M<UY(U%'%HZUJ H)C
MIJH[6\47.&2_\==YJBCV>WNRYWVD'3+>Q]<"> B!#T62:UC;JC4%8?)N&O>N
M#7$21YP966H[6YV&8#K*S:"MPS>X>^\H6EWZX:MI0O_OK>ZR3Q_^-KF\GO_^
M\&&\ESY>L!DS^8\7;,8+-B7!CQ=L^M_=O[,+-N,-CR'<\+C%,=M^W9'PQ:-[
MK=GF"Z7H*MB_13]U8N\E?2-*_?1ME88@C#HSO*MP!^XL#=[G($:HNHH.R>N0
M\X$Q!U;@>#[.4;T(FQFJ[70%83 WHRKMR ><QIWC9X(=C_M1)9J2+P)A,FAS
MF&1U(,\Y..SVW%PSH]&]][2*YTO*Z#2*<#Q=AW1S^$].^\4;\Y7+S GVS4 8
MY5WI@+UTP.D)M_W-BE$3LHVXI# $$WA7F,MD  [9*WH$3 622N VKY+SY;D7
M.=QQ%[CTD+CVDK74F5VA)0BV\ZYTHI* P"G,^=90D/*P0&_;66N& PJA;*^H
MK07AAEIWFP*-,,"!7G8O[5G>QM5IS@HV#4"XYM;=G& NER%I!=_;Z Z0%O4A
MG!GL!X$ATD5F!P#TU.$K542'!O9>%)Y&LZK X15KLQI=$9L# )9N/)Z1Y^Z6
MJ.W*1'<D/$HS%80QU&:-03@+-@R^&>,#4 =.;T$4YK.YL#*$8V##<(L9'0*\
M>].$AQX]W\3J:]L(\-%=;^46<CP W'>+TQW:5%J[]_6 +]P*M39;O?>,#@-4
MDF WP[,-KJ6JP =N'6A+O X W;P5>4>]+'^;17W@ZW%EG*4,@P/;W-U8.V@"
M!MR-N>*-N1X*YJF-N(& &65#$'2@5L",DCMP6---Q.Y2,KOA3C!EARIIO+GS
M$;?VL[C[Y[7\(IE- Q!V9-65._?"AP77\#&_0>0KYM?>M#F>#.M"V*"UA+28
M87 @,]:W%%.F+]X<S")O2]S,DHC.<=)8.>M6($S?S0!OS3HX%3"70^WU&X:W
MO!G@;;@>"N:77H "IX&]F[(A"#I0:^^FY X<UI1Z!V,WNJ0"8!<?*>E8\<2N
M;$6W;07P+LY S?/OM%FR/A@5V#\": EZIA[@+5Q#,&>8A0?L=I^QO2RU(_LL
MC*1.+G45P!LS6SB5?,)#,J-]-GGQ#>I!6&^;'Z)#>0$A2_,V._B.7.D055:!
M$&?8/)QE/L$A:<YT[<TRC!#"9E"VX1H<YHQR]G]FJ'M!/N;A4)17SXFQR\_^
M@9O_0Z9DFG6D[-=Q_(0E&;IX<U8H>,+W]"ARL5QBZ2&K:R(@S#!F![2N)?.^
M]+,-=8,Q<W6@/0"5X2%Y?DYOV"-_ETKH*EB&9,VO9VA,.<:U(3S689B<P)0E
M>% >,EB=R/#*%8%@;K'4/TE6[1. <.S,]V?A^I'N6S@WAU3?]Y@_":\Z==LT
M ,&D4@-*&U;! 9U]>(7K9)HS3CT2=94@&%5J *ICK_7TB/?881F!O*7G;.\9
M[F.AYDNE]=J^.@1C206L[!GM./<ANQGJAU%"\)P\H6![8Y1NL&Y1S/ZXW$T;
MYSA&GF^6 ?'[CR<?3R9'DT/C])=L^Q,4N).TATFXG.SZF/QEV\N_?@">"M%9
M83?QJ7@>DL?(<SU$-G.2)KF\P?&*'5^8OQ%C9:Y$VU9ZVKWN:'M G%9=,D5Y
M>4#)%*L!F-_$2OF$L&)FB+I%:_KC@J @HM,3)4J9?=&D(I1LC#K5S.%EP!<$
MX*[NYL)T@8+O( X7QGJ6"ZH^, %!YL-.&"L[*S0PQXT995N?PWK-*-O8\8QY
MXSEU4^7D)2H(8193IS9540]!_+KQ73+&2;=LVOH]YCVU93(WD=G.A8/-E_K^
M'@.5FL+JZ,-07P%]+R%C4G-8#5 [C123V,3FRR6WL#!#JO@.M+P8#!M7!0#D
M+($;/^_C^269<[[.Z!G@VTO26-^L)?S+,]VR[4WE2E>!94L@/.IU(*_$-3@M
MN&<VXP"[%X@$5$^CJ>,DZX2[L\XI,(XT=:!)11!.]3H8FS#9F\_A(5FO&5O+
M!^\IX/Z1(-XFR&![LM"G]/$G/1RZRR9;Y\D9U5(OOO>BKW8^":H^19_$MG_F
M@\A0,#F0,-G1P-YPRI+!JJ2$3!@E@_%<Y)A@E*L<%++"?4WV>6)FFQD.G!4%
M4&6JTU>#XY50@U.8N35<09B9RU3N:%1;Z[35@-CN3%52C5R1.0C(,:M^=(]?
M<,!>7(R5-CU)61!F/4,%+/J)!.Q 0*6<^5$)C+PX!/M-%6SD'$& 1S =+&BG
M=HO3H08<3U*M=>G $$B,&'EVJU&V!MR%J*AY2I2R+(% *8GB<(U)B5"U<TE7
M"^225%; '%0ZGEJ *R)Q!BKZ6Q$F^J<_;M _0K*C+A+,<;)"/4QK$F.S?EJ3
M\="7T-,(BQQ%PKE+4[;G64NM/CNY*^AOPW"_ZV,>B#=5LD)]SBE&*K$WT N(
M;U.0B]=0+\A,H3[WI-4$F2&^54'24@8ZF2O6IR^OHC"SY+<ISLLP(7II9DOU
MZ9>K)LPL]:W*TGLQT,QLJ3[=9!5EF:$>Q-ZXN&LIF?]U!YAK".$\>C;4)Y:!
MA^EL#4PL5('RQN^-_.[%JYW2[6\[LY3_]'_N KU)O5@56@)I -+XL2JP"<Y7
M639@L30,"2'R%*WJ*A""=NR 5/,##K$2<W?TF,FN@#UAQ;U#114(43XU)]\<
M/\"=Q[O4OMFLOK9^XT^U_,8["OBEMST-@_$8'T)GI5F2S2ZYZ:KW%4\I)DIK
MNS>J"<>W; MC(;!2SRJ$R5K.FL[*;U03B+7?0F>-4 1G_0_7STF,R9Y W942
M<6D(UGX+A2Q<-!'S! &>RX10:=*%D/)SZ;VQGR(E0JH*$ XB%4%2L=6&T>4:
M/:I'A+04A$."I9"EO$ 8 ?S=GU7HNQ%E9/_+U?J9A"_<Y* >#^;5(9P5*HX.
M<R;[<J;=LRQR$L=EYAN<,(PJ6[@",[W*6C@H2E\!."=+FI&39-]Z>T.ELD[6
M4FD6OO?MH!1 OW>MYRGM+Y3A32W0_/>^'94J@>8IA;!62J<JG=O"I&)_[@MS
MML37D'4S^& =&U+&OD1XF?C7WE)F*3*J"?J\H,3>B+W>C*FB=['LS*2?RBF_
M#HU.#JT.QO I$HG*TJDHW\\Y/<WDC?RK(*(3 E,UA3E36AJ."5,+2.YT+N,'
MPJ+(<R0M6>!;X#Y@\N*QA.OSI8#FB)VR(O$GI4&SV2Z 6#XU*IV[SMPH_Q"4
MYLO#@F5"3\CFH/Y*.X.J @3C:!NC(*L"*O[;,-#]&KY@$C"B- !I2T/8Y;2%
MCI9Y"&.-)0UA+YX@_P[1=4J;TTI0%H+1M>T1)F$= H*BS8+NR*FIT]]ITXB9
M+#"*K=)@3Y97ZV?D$4;5?)FF/E@K7LN0EH8PMUKC*>4&7+R4B+5[C'SOG]C]
ME4KH.I0^5VQ6%<*\VLAX++/6>G8J$1G;T#O)*R3FU2#XJHQQ,6>K%TRFZY#$
M3#=8,JT9BKQ('"-:I8$^=_ZV2JB$2L%C/Z =,NM\"4AF<%N#IV^HST6L61#U
MO,(!D\W2N!$T"RWUN::U#V>!V4%L6=0Q^<H:?2Z$5< T8JJ707@;!A5W)Z*:
M$#(TUM^@B#@#LD<YD%9]FY)M ^1.1:Z3EIN5+*?0EK@*2)HU!G+?4A52,Y8'
ML=Q1@AWK%2];">0.1@VL*6N# %#SB*BZ"H1$MHV85, MB=470A@N.A-5LUSW
M(*UV_*!9_U@.UZC<T%D<$F;I"MO O@2N*;FI;<A UBZ+-0NNF=EVA]%CK-\E
M\LAOR$_P#8^.2&]CV 7[?5\.]F.M3GBSDVR[@PGWVTN%99"(^:V5[2NM/#:!
M<^3.@WN&(),L>R,UI -N^RM?VU3A@0VVWT\XX8[^V2:#[R7!?R8X<#:JT$*3
MFG#"#!M7A%Q8HHDL($S4HDEB3Z8R\M"H)I2 0G.E%J*H8A$JBM%><]6W=HVJ
M0CBD6*BJ#L0R@Z!0G&WV/_[-PX1*:[6YQB_8-YM]E97AW'/L:@)6B@,4[ED-
M+5-M/1LKVH W+QMHO'94R_D%!?-5\)S$$6?OQ&QN%M6 .B5K-5<(HXA#J*"=
M6H-V"BGBNQ703D&"-MOPM25]RM=H[2R6AY/&O*OELB@!4("FO NXY>Q]"<+'
M"!.>;9#K)OT<!@Z5$<]IE^7-;#%MO#MXZZYX@ AUHW%I0%"MH5T!,;-F-#Y"
MVKX.\DW<M>H"I$'<NQKN'4>SQ;G5X=?:?<>F?#]A@#>I+^0R"5PUL++"$/P_
M78(JDP,$0)O8>5YK[N0UW$=_=_A:$99B.U;G'##8.X(IZWM)'!R4FO@H@WH
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MB.DFMQYG%SE0X*<32DZXQ@\QI9_O\5E7Z@V1L@:<ZWY-3!A*5@&CIYPL-'6
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MQ,@E7ZD9"/L6#2"5^.H*I[VB\'G1'B!Y?0B6A@K(R!EJ836(2)Q9">AOQ56
M_NF/>[:<"1;JPC>0<?O-K= %;GL%0SA$2E][7H2%JI.39-^*?8/>O'6REDJS
M\+W/M5<"_4Z<!4HA[!N'?2-(,I^WNO<?[P^U?B 8[P]!.$ ,^_Z0=N3+!K[.
MG-]$P_T9\IL3B^0>3=T)=[#6^\J2Y?_Y#4?Q_E[*2=.J)^P"PIFX)75L5$[@
MXG>G/F\=NV(^+][8CS*3M&EE".?R=K3#5 +@<-];@S!Y\1PL)O^61:1$E#LN
MB&@1QLC/?F?W=V[#^.\XOL=.^!2P@.>,7UZVZG74-X0(AW:TKB,!?CM*F\[/
MER'9_HF5DRV<71,!X;;8P-18(DEP^EQ9K-LA^BN+3XNN@I3?7TD8-7[04/4$
MX6(<L$V?2ESO7/U^Q][3BHW3%TS0$^8?S^G6Z!)YA-]BZT0U#:B <"MP"&IK
M($IP*OVMO*TAN;38CEJU\A!'3<<R55'F-*5Z.5].GYX(?J*:N4O@J;NJ7ZF%
M3O']W 6^E<0 +!QQ2E5NG<Y>MO&(I>NJBGC$3#=C0"+,@,2!!S9T&7HX!C:\
MO\ &*A5E8$/^.^3 ACRE8Z2(U@$RP$B1T:$Z.E0'H7#[PVYF!WCO15\O"<97
ME&VZ/8[OZ8YY.VLUK9;6W8^.V/HR!&?5:)_U=(GH37MWW;]?1W%W,H2IO8]Z
MUA]-6&<>=2?&[@*3M3*TI:4.WZ]3N4VIP=3)IH;CCMES[\5S<>"RX=C%5"KN
M]_WZBSL0WK>AJ+^%/FW&IWQVO'75$# ZE)N0XC>IP]UM8#4$C-[E)J0(S,ND
MC.ZT]3M];^%WXAT?\2W7Q,E^PFG?HS,*IC/*6CY7 847[R\K7;.N&-GRVW/*
M&N_<@64D PA+GX1 Y64Z31T@]^H,%-8 *5B7[**8:BGR<:2Y8U<J!^&*G9&J
MY<-Z2GQ @(%%%5$!K*:!>XY?L!\^,W:V:ZT2&*.:$ SDUE 9<08!O%]Q@ GR
M*9U3=TW%&\5I&B\3^ SK0K 16P-HR!L$"$??[.B;':\@#L<OVMP5Q):.U.ED
MN4!O++7O-JVCW9GY]..GXIDY;73"6\WFBQS,@7A.3U*(W0UF#Z2<4?(WRY"D
M5YP4QUQMK1Y/.12+[;LW\49[;BT7AG-D-82F?+PI,P5A02_39G#\%!4'=?*4
M:9L:%4CG34H+RP[@G+$\OV2CW!M+RL(Y=\K5*PN(A T(:/#-/-V?L[V\_Y\)
M\2+7<QA%2ERTM2#L.VP0TC($ 2O*RAG!KA=G)V?%DJ,H#R>%88551\$76)BT
MB86UM8 L0UHEU"+56![BABUO1D8V2$N0H:*)+&J0IK59$M&#7A1-G3\3+_(T
M_A]I:3BY$RM,:5*NH +$?B18/:49U ,RJ6E44(=4@:DV+O[.O'!*OM*3/MW5
MR/-&BTI!F*F,-6A_/U?$"82Q(!_;.CNP4<W^#+T6C&6'@W:N&ZQ]=J>S9^'Z
MT0NX4?&0:N?*I=1Z2X_Q.(TB'$=;?7;9(8+^F<7VL(<A6>@/=L^W[]K1%3OS
M43-MMMDQA/-918WK0CS@8@DSA.)(( $69Y::U7T_?&7)**8OR//31Z_OL9LX
M!WNTVK/02D\0G)<5U:T5>8#3+[EPK%<S&)=%&E_. ((F/HJKGK!3UH!P@Z(B
M;$J^P.%6GC(RDPQ?M<Y6S#=Z%2C!M&\&PD6#B@C;,PL.]B\!V>]3*-$S'% 4
M8MD$*RT-(=*^(HA2GH:"U7XEO\.4-KZ1#-S===2IX]#3BFN'IUF+$)*L-8NY
M&=^MYU,3+AR4-H(1N^&0_GO&LH%-G>(\7*4!"-G4+(&LPF9O03<L9Y\7\[@Q
MJD]G8<#XQ('C98)P+#.F?2J_X)KI98("=GLET\\PGW&]IJ<:C*]3.".'>!PO
M54R.LD8_#WB2D*IVO&%/R<44_@MZ\G]. \P6M'/5"ZPF->%$ZAB E7O\TX0[
M"*NNE%!&IOI95I.:0)P-%FIJA&*6Q3;6R/ERR=*4/R-FR3A#ZT?BN4_X!D41
M<E:TPSB.;O'KWT/R5>Z8L&\#@MO"0A_W*Z4]IRV]Q<N2%V_)>*!;+?+B^7Z>
M#N73O.;5(=B2JR!EQ61[ XM/X[1_%)Q[^"D\0[Y']U>!AVB%C[H19509@O6U
M^E R8A'"ZL4)95M!@IPX03Y+ J/8<\B+PPG.LMQHR%F"BH]R4Z&J &0OH=,Y
M'3IM[AMX?ZR3K:=D'DSIN=#_1(?MIU/YQ&94#<+N0*]/^YG,B*=N,*"'==[?
MIQ-:V@H&<4T(JW\M),1L=0/&#8O%XQU_;X.$H!J$-;X6# *>("P:[RXXT7))
M'P,3Q\#$,3!Q (&)XG%=LN@;&7&O(00D&C*4W^$JYK;!!B*F7!V\-HR]7;3:
M9GM?.CI/\"WE8_&*_1=\0YE:J2&OTAR,K5Y%K:C",#BWM(@5MHN:+W?;+@O0
MBQ5A;"$;@;?(&C@@\^3>LQ?GYLLO41JSJ@VY$]:!$'57 3X-5\"1V\\C1IAE
M2D,(MJN-5H:?UB,U=F^S\8ZC^:/O/?&3XRZ46[3KU->!$!%G 8,A5ZV#,248
MS9<[F_Z7@++'J1&!("\+(9+-5OAR;B#&O-R@."'\3L-673*W'.B.QS80IO1T
MH"X0YM#_)%Q.XA6>^(R*B7\@8^(FP\E>,T;)C%$RO>] QB@9N%$R[\R9WWA<
MS("<^:,Y;32GC>:T;\Z<)F+E[QB1Q6M84P/VK;PC0YN2SV'C37M6;^JMVAFH
M=:X"IX-&_3),9!F@[)L9J(W/GM%A0^Z]-#'.TV8&9D^LSNA@(9\N8TP:PKW0
MUL#LF36Y':P&U 0=QFW<%G$>&K1? M>+'';I'[L7;PZ+YE&E3:C8%H2;NTV#
M+N<6G 8,T>UZ\G%(?M=V@3I+",'2,:FKU"ULS5G0='P-!;W;,'"J )BMURV&
MS=F[#%BKY/K]^3@5Y-:?^>__'U!+ P04    " #2-&I42\E'_-5[  "(/P@
M%0   &EM<G@M,C R,3$R,S%?;&%B+GAM;.R]>W/D-I8O^/]&['? ^FY<ER.R
M;%>Y9^+:,WUOI%YN[:B4&DEEW]Z*C0Z*1$IL,\ELDBDI^],O#L 'F$F0(/C
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M.+0.&J*/,)6\_0)M45S'QQ%Q0VN9:^=PZK_8?)7:29Z6H0?_.?_'SG]V L@
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M=SFLL<-\H$'CFIBZ]3S"?^BK5!)I/+?&1M0W5S$H6=B\/Y9GT-XX>SA'UTM
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M%;ITL[#C\ERO)W*(ZZ"^XG+L#%?E7:0?XH)IGT7H-!@X)XO8 0?--7ESC_F
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M=Y+Q(5.,&7TP4TUAAJ#98HXVU%1TGRELMFEC7+JEN#$NRMCDWEZ$@$<\@1D
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MU^R*' :[&*#K>P6(X:B3^).\-(#W^8#1W@9 5>;AGFZV4>S$>_,:#XTDD..
MB4&:JSNH^R/&!2,U!J[K4'!$5]/AP!9]#M@-22&/HCX&DJ/)A [BJ.JECFET
M'891?ND:]7&]%4M5=X?*K*=MD>C#-XL&/*]77%S1T[[Y.+X7(:3PTM\XQ6T6
M(RK8+[7T4ZK_W9:0H8;83W4#)TG\M2\N!Z8%!%$QDF?W!J4K+U:NNMBQ5S=
MMIT(8=%0_?!X['O8P DVOFJ!M[859E15JW5\ ;!H@AT/&R0V#EZ&5<XFVH5I
M]19TZ7>VKNL-IV,)1URKT[K9S02@,X)FE[UG;(.E Q0/]IPZR=-%$+TD^F\T
MU75!"BY=%%:\R'34'O$*3TOL,=Y?6M[]A5Q<K7Z_L^C4US0%I6_BZ-GWJ'>R
M_YQ0[S)<L;D=@^CP<>FF_C._B='BZD:$D > N7'DL.A.!7&P]%#&>*W"9HK
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MEA)_YCYI'JU;.R&' CVE*SLLC3T0A[RFX,,,DW<BNU:P&',NH)%[/+;B@9/
M)$ >Z?D-"X9H;-8]V!U\?Q._\MC]\#&+7/CD;[?4!0'\M>]F[\47=557Z\9K
M:P;=D4:SJ2$@KKOVM1SA7N3N^!H0Q.SY@_9V_?LGJ>INS=4K>" P$X9]Y.UX
M&BY<UQ)[6-^/@@AU&#BY90YY@7&N9$M9O;>'PAREXP!*%FNI Q>R."%:Q8].
MZ/^3"\S&D"0*?$_,#$./V2?)HW"USI)!G.".?<*W:-HJ$@Q%&RD@CV)">18V
M"&'$D[5A]3,-6UD*OLEQ[:2[F&<OJ@HKS24^SXH-U'OZFIX$ZLNE([!YRU';
M8-C! KB&QUN-Y295APCK!:F(Q*-<%@IBO1"+E'*14C#R!40C7#9+9S"H38P/
M.;/7LMAL_(99RFTOH-38 3F:M2LKXY*Z-6*$T1#:_-1QLW%BOF2Y\Q]#/H,/
M4U)R)#E+F\>*I63'IF@;W[4[(_?S;D:H'%)J]43L_QT5,(Z%Y@! , Y.98@Y
M@(*HF"A&>/J05V]/]V7UYM:'F3L00 X.W8U1?9U-MS=BD#!0PC0^M J9VPF%
MRS!3OI3QR RA=TKCU/'#^]CQBD?;]5?,([*;3YB-8FA%4 [*:QXA/([*QB4X
M2L'@=@:(QE=]$A (Z20\(.^@128AR40D0L;O<"VOT=H=&]!>.'[\FQ/L:*EL
MVRRCI0MRP--16 :MIO:(@4=+;%,G!N*$4R>?J .T-Y9O<M6IVS;HM_69H2,W
M#K^-'6;FRL,!LN3+$GT$0]AD:B,)8>7+92W#D4X_Y*&LK?I!M9[F3HA#6E_V
M'E5LR@?J"O*\>B9&']=?JG8D,5?/UUQ2=ND_QW@88PER\))E-4)P+>.LV 47
M9-3D^;<MT%JZ((<$'85;;K?,88&F)?:0-UAP^;#^@*?=>7Y^K3G(Z?6<EZ^/
M >!U7H]K/+-HB*/4]6FS=^(=]?)L;9\FI[LX;E_:Z?1#'O7:JA^D]#1W0ASK
M^K(;OQ,A.)#SURT-:VJP]KB:="Q\^SC5J2-2;^VN?'$12:L7]BM(W93H<_F(
M20&O_);5,/A=$B=SZ: 4 *KHI+P#KS8$?\9T&\4\6<7*;:1IC)1'M\0&QQAN
MP09]$&Z@H?N>;IC3.?%>G)F6VK8,W3K]D()A9]7EH;NU$^*A6U_V?E>NM=X!
M[#&**_5H',*U>B%UV8YJ%X-W>Q?L(W<'#88?MDF:<^?U[]+]]^3^X!/BLY&<
M)"+58T]>_/2)C>,>:\57IVO*;UDD;'QGX[T#]RUV:>)[E _X[!=/F1GR\9]?
MT8\70#*,4B)=5';@#3#VOPF\#19+%U6A\&K$2VD5W']=+F\6?(\SH[-A?T-L
M^<&>BT8WD)[R?58$%V8BX9[ 3\@?\\@UX0(S"F4/F+$X9.V_,H&8$!YE0^F&
MK3[AJVWLPT-V,8'+)8HV'E38A0_9?Y/%,6TP@7A%)#?(4Q1X8!#6Z<F!<@6A
MYXOG5N#7D<S\\N2[3]R\H'#"/"L0UF#V41J:6:!2/6DA?4>\B&:_0M85OH-Z
MY\"=,:?//+4JI"Y;AX,[I)'HRAMNG%=_L]N0<+=Y8,3 KJ+N!+>J&^T"CSS
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M@.&]#.E]V4NHK<"KK33'L6Y?Y"'=R02U[V@T=40<Z-WD'^"!B<J#S!(G? B
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ME$ YMYPM$0\!8D&2R>U463]"77A:UH7/[IC@0ASEE,JXV-N,4$5?>:T";W-
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M"T.GS-#0 P6ZY754F1&S-,FP1\)?5VJSP30C,]7#62=2LT R,XV&",6B"C"
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MA_.H2B1L[X4\UC75/DH;5G=!'-NZDO=,(RXXD)(%^U0P(5_2>,>&/B=(CC,
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MQIW!533>M)%*A<F2+$@A"X]A61J&9E5<6U2!;>H*8ZB-ZDF26 2^._>)>KN
MKM8GN\0/:9(L7:9OPA_C2T[VTK^:ZAH9D$$.9*:&D0&K*PW$P&2LBFFLY SA
MP"MG262>"_*PES] 4'ZHQC0-%X74K9&'1HN:<@0HFB)V]#:)3?VYSH?MWQ2J
MTQ;^C"EMO/*CTV^&7ERK>IL_5SK-S+/K91_2QQ<D9]+KIHPB$>?$CY;Q'_XS
MO0S=VGU2=2ND[MFB5I%)<]P$>]),@\3F)7O8)#KA)ZQ^N([B#6=.8LKFV'!.
MDD:$<26"+6%\)\Z2&4'E@B2H8W'DN*5\'7/CQ-E)C>-F4T'YFX;I3R<"2(/5
MW!CRH*+?&_'H8J"$>=2+)32G:'\.)>O7.&FJ;3@CSU9/BXY;S<13!YKX''BD
M_1O!E_R5@SLV&/.CLBM@U;P:;>Z!W$LUU)7=M:$Y8K_5D=K4@05M4A G.77[
M\*I0NQ%IV_K,TYW5^-O887XN/1 J-SBU?82^9>L6J">W#+TSR#N*^!'#^>N6
MA@EM3/G1ZXG<Q3NH7YUHM'9#[.Y=I#>?B@@>_.C-*[G8W&1TF"XNO7NB5&<F
MTM <N5.W*5K9252T1>R^K2(;[VD(PH131C3UJ%.X>5N\J<,,G;=A(US9>F8.
M/-36M\*%[4\TEJX+C_@E-\X>SD<AV<%UXQVM5N)HF&]T(H#<R;L;XR !2;,W
MXB P4*)'O@MG1;:"%XEB>"@2F!$J9CTVD_YJ#L2N6NI,M71![OTZ"K><=E[-
MH*B3EMC#GN-?J0LM]3G=S'B=1IL'/Q3):<Q03TR0F]@O#58Y<FKO@]1+.ZE<
MGH.V=$!_*JHKOS$(\S=\(8UJF]$E6R!<@/*:H7+Z1!DR%PX]]3'IV#8H@E;B
ML" Y#\*96*@>,+K>HCQ!5D&">8#T$P\(4]<[F"VLUOR63K)Z"/Q'KDNR3!+F
M_%Z=ZAI],,.4KLH%3+5UP Y3VO*;NJI@ $X:  L2E2R$V\;B3>^'/)3=,F@F
MAJL);2%8$(D'R9A8@"L4/C#N].KNR6%VNV3Z4(__S7'XGI%)X/KA?>QX?OAX
MYNP/%PB#$,2,>(,8JVG6ID\-.U8.HYQQ!9*<* F+<$JVU!77W%/!B7B,%9OU
M.2G@Z(8M89(T<O_(9H:>XP=[\AP%3$_R0OW')TAN<)YI[#QFL\<$R,*LL=*=
M_0&?73N)Y_R#W/'/SE_9A"9\%/-,F(DX>1VKA!N%^-PJ@.VH9J 3_F1UTU,B
M^!,AP$+\4\Q4%Z3\C3,Q",B!8P8[I:O+S@SNQ3U*..ATX\05\_++\(;&?E0[
MU>W6?<9C0)TA=!%?[CMS?*]5Q;CR 4 H@\8M)U<Z^2Q@<U!+Z(!D;BW!$A\>
M3NH:TR$@U$^#3::S';V/\I*(O(8/4]6%4'K4W:LT(#MCQ.QB.%TDU:$Y<X3M
MI*)QJ8J"%,Q5O8PE\784KI4$#DQWRUJLG'L]/!<[%FAQ>A)[ZN!W+@AADI#[
MB%1D69!2&GS0/HD-[RJ^I>63",Y7)8N=1F'B>VP=R2^*9P7>8NI]:#G*TR2!
M="CH8Y"Z\UB=_C,XG^VDQK!'/Q5^1&)HI^K2I!:IZIZJ=;=_FU"<72:KM?29
MPH3=*" '"@-S:%PHK.N.&"9,M!CF I=$>4$R?C"P2I_;P8DI35+F#<29<;;<
M. @2M_@<2[*%3Y/3'4,P9?VUQ@[(L:!=63GTU:T11[J&T*9>?":FQG)\\P<D
M,OIVPGA$??.H?0GAL">JQBZNM0 4@7X,_7]2[])CJOMKG^>CBH<"L]/>7Z/(
M>_&#H/IP8';>?$W3EF?RQN>*'#PF,GO+(F5(EHAA;"K-AUT*E2(26<;\ =)<
MR@7)Y5P</4J:R<I+SUM_9A#[KW!@5Y4QB9-*+Z;,#[EK[9@] 2<]_S;LCZC/
M]&WB=D>C#P#;FAS?'FIW5=P*:*N1NG@R4I)U5G@]E?V!Y%M!7['&$"U7Z9/R
MQM_H3+\F]%4:?33T/>+XM:"O6G%LZ"LD)?G3>%S8-P"_P_\ G IQ!>&$.)ST
M&\%CKMLU@R/9;!/\3"J^7Q$J-YI^+&"N9?J58'.S[LC@68!.*6W6<_X /<ZO
M(,P51%!PE\:;MP7279_ZF8KW5P36G1X)FH3Q5P+:X[V$,Q)P3_G^D W\'N\'
M*2VW+5ZDD]YG"X_?E!TVG=S8)+=P.VVU_IS0VOGS%/R00O%DIF[*3!^,V0Q3
MUH?7W?Q.*"5.F<\#Y.&/74*SR1J)2^AUBKN=4L(Z\9R4VL]:QV/2D4:PV_RW
M89):67;@M_SML?N^D;7&)<.7\-$O&O.%U?V3$Q:'TZ.DN_26!>D :-LLHZY-
MM 7Y2M8JW>V!#/E+!:K' E"E(2R2;^::7F/Y-Y.,RT>,-S=@3'%N4.7V58+^
MZ&<$$JNO#KC13LHO_-!/Z?LK_QE(E/*^)00>8)%)W:<P"J)'HSSS";:*+D,W
MV$'!F'QX&7OI4\<0*6Q.9^Q1=HN.N'U-VT5JY7O>(M':%"KJQ_HRMF;;2GXN
M&GF,(CY_E6LYTE<7P)H1?A? 'S#3_4XP>7R,Z2-0#R1 =H2^,]Z&&OZG&FTU
MDO]PN:3C#'91Z@23;$,-;_E[D#UW]&G*4_;-S)*_.'@&0)3ES]XB2A@1OAB3
M.HS] PTCXM<RO [X@XXR( \@W]<TA ]IKOX7OIV#=SL61Z]V\($C$GD_TO !
MA6A>_/2)C>U12,F>.C&\^9%]! -["(]T!P0.FQW^1+>[=X&!O^8)1#1>Y*,\
M7(!Z8X=0&'[ED3.:I2\7I'C_Y2;WHTQ!DFM(F(K9-J?4<^8G7AA^YL.G=W1#
M^(ULC)Y14=+FWGE53V$F98QT8C*]\<?:.:WG^I5LHK8HCVRPR*4E3%Q[N#^C
MWZ$P6,H,]O;0^M39^K / (\^E,]*3/!S*1E_16C=;/SQKHC7<?U*T+I%^0G1
MNAZL]R54<QFE]V?F#]$C&5\8:M;8W%8"9=@?1X/;VT1A73-/4%3I[>&MML:H
MBRA->]:"W>1056J 8Y:!P#576R2%\)R0PSRVW[,GDY;BQ:3/"5WO@BM_??@(
MPD DD</D$ :KOL)M3@\QX VBEOEV838-S%*=@H-4IR(E-1>!9#(0(00!*>S,
M#:W:[<@<0'5!TEZI4(,!%=_PO8FC-0-U!N9.<$&+2J,,K<N+X$K3=J& 'H8Z
MFZ.*.MK=48-,=RUZ'$'P P>9&0%NMG!B>M6WLNH)C9_AY43[D'"^V0;1GM(3
M&M*UGQI @B:%>4!"%W/40().=_R0T$F+OG&1,R,Y-ZN0,*GJ-%>]3QU]1<98
MQN,T"OFMF5N:4!8-3_DY<WV-_&X]D4:T@?I%VI->-^S92!VU,"^'&<=[R-N!
MEWRIE!;\X#"*+B7)$V7+=9X8S+Z17_#V12R)K>8B+2$O4)]&Q,UD9Y\)X8WS
MB<ITHHFSA2;Z%7(PR?F0G%&16&/IA0,;1CAV&P1/E/"$GDQ":5>LPTRK&P6D
MN-S#'/),JT-WQ#,M$RWZU63+0\1ZCL64JN=*1W5%52>$@'LVU8MB)]Y#E:9T
M?[(_#9PD6:WOTLC]XQY&/X6QM#HB#WA]Y>4X;^^%.+P["&]^Q3)C002/!7G8
M$\X&)EN<$?G"61U5![#G^%=^2"]3NE&E7S8TGY>3'RG:X-I%V_DX]+'(0[DQ
M^0*T"2=NY+B*]?"! O!0+ZQ1;F+?/<1>G?9(O5%;U6+%V]08^SI72W;C,B$9
M-;(%<GQI6[@JY?PF7D^.JNWQ:%+HSQE86#J.JB];D#[3..7GF=LX3ZE-8-1<
M\#>UI9_^G1\2+PH")T[(EF:ONG]G\\U+^I *!> X(5,%CCJ3-.81(S]&KGI.
MNS,1I)#7SRB5]S([44 \6!LJ8IZ1_I"2DM^"%!Q)R7)!L@?K!5=+CVU.:YCK
MW>:!X04;.A*AN\\)D]TV"F&K*I,#&GA,LO%F.T(0MOS@8ISS4@NK]7*7/D4Q
M)'1IP*\&":0 T<<@JFE26_^9S9RTU>E3=#8LHX&ZNUAD.KJP8/77OB@K<CC#
M@BH@*7ERGBEYH#0D211XY%T4D\?8"5G@?@='!;#U#_F(Z?[;1 3:$VO&0DNJ
M*>(4JL JF5\E9H._&U#^K1^Z40R,P5QV9W7C_Q)'$[T2I3*$/B_,5O*U/_\;
MW3)':%WG/@-B]$T<N91ZR05#J7QRNUI+$].;?%[*-W..-1:7].M,-QQIS)@^
ML $+K!^(+O8Q8&@U^XP-+CQ!Z8?K('HA\ N72S 6?0?KLZ2H+B4&C0?*SWJE
M!9T?LF'!"<6%]G44;X#*V@\90=\)V-?EI)39UW>=(-A7AQ$WVFS8Q(SSDW%
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M7/#DJJ7JAZHM<@=N5%%VW=J&B)VV65[C5*:#VC17H]3YR ]"?HM2FK!I%M^
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M_ O>\.>//9_YB1M$R8Y9NQ\<-%";-SRTF:D#7*A(S1<^6C4:%4X61+R?+@F
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ML:G2(V%%.GZ^C8+@(HKARY&R8Y3,WBJ,:QEYR)RY>DYO$9[U%,:0 2>)2+Z
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MB .>I+ZT!5S$5]AW)%;(865, \LH- 8?Q* UJKJ]8[M$-9'F47Q1Y%=7*N+
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M?9IMQ-XO43V3^2.I<.EI1X :I!%;$*=X> %)!A$^7>.%4?,,.??BQC0Q(PF
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MJ2)JO8=0^I^,MN!?6&'X03+6KX+$C^NRCC'HI-R.<9QJ38TJV_0(!7 0ZY:
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MZD@:N[G0N%M6W9*.Y:?=J0&'BM7WC3%"[)ILUE[Y08(VR1+O,D&/09ZZB&;
MPL!MHM!G64-7M=E]XU-CF60\.S6#9]W%U5[@"=[%4.D?>0(VC.Y(/LZ6V00D
MLFG#GQ'K,RAB,0(P9BOJR9HO"]^IA2C5M5 2ZQ<LD>/QX&G5%G[&JB^@6$4'
M[8)D7!1=)&'(/K#)K@"1,XIH,XJ<03H[DZ683&-'G7*JR<P;HGJJIG)@CG&J
M)GWT*'\V/4Y7>/HH>_S>GKGIZ^B<"6=N3!I@6,JI<0CI@ QS^ZGEF1L3^*!%
MNU*;3DSX0+FA_\R-"7Q14:P<+<1XH<93FZI/L4:VO2UR.&%V=&TQ"";087?3
M 5\& $[2U%A:Y+J#9]_]$SDW#E:$NW1I*$]IM?)+$#C?7<^K7;7<(5'RBHZ?
M6E;6T7AZ^L6X\8O/+"G?7><B,ROLHE_&UPHPNV:K<,667L)+/M18ON^2K-JZ
M3!NA'WJ,2(ZIDR\M.8]?F%&TW3[TT&.Z[S%R0@<9VZ53CE1T=X%O%^6Y@TY3
M^]Q#O^F\W\C+?3?W00VXZZCF3-W)LP]=J/,NI";[H4;M-1;/O?O\$L^7WR)4
M.YET_KQ##RCU@'[D;58LHH&3QPWFH/_LK@O3>?GQQ?+7:N_$Q]7N78SM6KOW
M?'4@R,-:15J\NUBA%)YF+._[)^VN.M0>.<1RN3,XGO]\(*4"*;E",VO@W8&)
M?N/;7D+.&C&HUOT#C25O TNB)VGMYDH'@UB;N7R+/VSE@TB3060YA\CUZG38
M*%3HFN<:7O'0,WJ0KUE.&@--[\M,#(_6.[L[[>[!925B_">?!]M)>I;:P5,C
MW)M_=<D425)*;#)*["02H^[!!^IKD]J^'&35X6W>;:C=@>3M1*7K)*V>M8&V
MU'FI1*Y=WXW1K?M6=1/\ALCF!!X9WE!H/:-O$5HFWJV[9!UE:M,D1(YJE\=N
M#M]V>+)R:T&A=F3R<_4BLJR]4=[@8 Y!5C,MYB%8_(TJ8;W>KB#+WFP1!DO<
M:R@OK]'F]7QG$R;#QR;3@G&CA91>ZD:(=I!!>NSS06+UZ@4?")TC'RW=N &3
M9%H QJ3&D ?AM<] 7@0^E42>)#T?_>MS-BC4'#H9VD(%&:1(799L04H,)PHM
M#)U!NB"#= $SY:%JK)5%-AU/QF>#9(D:0%V^T=YN3<=#*EZFQ63UMLA?F28W
M?<!55%<S7ZJKF4+[H_4#1O0)^-?T(:/98-8XCVCU&H16^$%">N./PBJ0O\81
MUON]KP%@Z\W./RX\*XKF2ZHB7I(7<47CA@0I+52'A(9( 1SD7U_X4T3,R>?"
M+&\Z%61U6B6'&F0 G"CBY*9MJ18TC@5JRJLJ7Q*B@:E9TIF7.?NSL[5(531.
MT9**VEIV-L=J7C^/PKC0Q_%?V_T;?_7[O>4_HYKQO?2;<<IM/9:+X9F7:45>
MG[5]>>M78W0J5D6-VN!UQ*^N[ZZ2%5-UI=_-4Q[GO<KJ$^,P3X%MEUCK+5>Y
MA15CAQ;"N-L(,8!+A;?P9K?&)/%+$))0#SE>;-<RG1Y\K0I)(047Y-[AEB 6
M5C@/Z<+%^=7R$K1 (96-'&M8M<OB/!Y/3HXAL4<)]B#V#;< DAL[R-69S(O^
M>.6A*+\94) [A+6C9WJMB\KTDM: PH^F4$'N_"W"P$;(B:ZQ9/-.,E\RG1T,
MUBBV HU).N!KVD/4=AN@K@M(T%.<"H($@64B(=&B41PFQ.=:[':L&Y/4&H'&
M+@WH09Y@6%@?!'V^U,P[WD40,3/3\:I HXTR5K.NU9(S>/.+?-,N</5N(^)Z
M8"ZBFS0!A1?:L)MU41:#)XI3<A5Z>F]8'7\T-0V*5UW*9#>W;ND=E^C%8BE*
M&4K)UP;%FI:P<S_?V QF=+EFGR=Q%%L^2?:ALG O5(-"G%9X<\88XAJ6&TLV
MMK^L6V^K1ED4)^/)Z=$@5=\4:J[UCEVY_<7GGJL&Z%9N:)0*T#T_!.CV=@AQ
M9P&ZY@T/]5H0S@BR2 &$%G04H&L>%61U6B6'&F0 G- 6H&L "]245U6^)$1C
M W3/&T?HBFH:IVI)56T9A2W #E#I$;G*WGY!<[\^JK-9(WM"!3G<?4;Z-F1%
MANOQ>]"<%-MM[ DGI&";%W'853"_ 7IN;?>)X>U7,'^/.A6KHD9MAL[8_03S
MGXXGQSUE6Y!12%E]8ASF*=",8/X>U:Q]O:V$V+RIU<1@?O/HP=>JY)Z- .XA
MF%]/,#\X]BC!WO-@_N$JOQE0LX+Y&>K.@Z^RU6?MI1/;94"I50H<R*C[#L]E
M#)<33:&"O)G @',9PV>2#OB:0N=-.Y?1:? \ .:H8AUB\#Q)I.KZSQBGE]I4
MN$>DHZU<C!FC,A0N:$ ]B%#Y;L,-/X_QPR#I7PAU$/'J>+5L$S4\XPDQL[.0
MG80TU>G\NX^<Q^ 7%*\/F]49&8W; 440;0* &<U>MK NW3?70;YS;\5H(SBF
M\2JN"H5*K3$;%MFNZ_1P)H!(:K7#* V-(RHP=Q3ZWNN@(GM"1E +&DV:P,WI
M8HCC5%<H+//T1,&U].TU/UM/K#M6K*QZ2]!HI4L$.=4Z=NQV>BAGM0I\BIWN
MDA?^5CN/<U:7,)^TM3Z 0]L?S49V^G5$OQ[*81P*XB7PL+ZC[-AY$(M.XO K
M]78,Y\%^04[BH<POE,5'\,[?<&J4^\67_G/UB85>'0]4\0$(_NGHN(T)!%!4
M9@T=E+ "((.V<S8FJ%])>36V@1Q$"%JG$S'%.ZN-Z&07-$[KDEJK,P6EL$%0
M=T%$MX)8S]JRQBF]_4@OC].\2/N&_;VPSA&&=G)J&$<&>56R!@%YG"#C.0M"
M4(SEE*@)E2Y*>,T*X.QJ5.&&@#%*0Z6'$*-909Y=44+LU^95@4T.$5"S8D<%
M8<"_!C&*&+,%NR (!2O"VTW YVX\QZJ>XIK,305/\3Z[A*?P7,)GX^.SGK/T
MB87>PB6<X0/@(.C()6P" 125V=@E#(<,VES")JA?27GJ+F$#M&[ W:@&*%I2
M45M&6W.LQFI\5\FV!J[S1F !>()_L\+0\F/NID^IS/"U+@\+0"*'J]6K%WP@
M1,4SIP"XNF:6AZ-W-8B:G"ZF&' :MOL,T'U[*UX>)X!!OAC:9[VZL>6E#L=[
MK+CP#3G707B=Q$F(\H.!8M>L7#O&$4=>[5Q_;0OTN]DPW&&<Z'D+]]]4*E#T
M_! HFCNHC@%Z!?'_]7RB5BST-E[!%!\ 1U!77D$#"*"HS.9>03!DT.<5-$#]
M2LIKX!6$H_5-C.2Y;*#H>>WJJG^M2VJ-90@*L4%0M^:58_]*;S_2R^.$M7+4
M'2AJ !GD52D1O2/ >0@4;1<H"H<N2G@/@:)R091PZ"'$> @458V?A$8.$=!]
M"Q0].QI/)P9=Y2*K8$5XD )%"Q^S?5A5W_&QR'=<]!E_3Y^QU[[CDWX7D9F:
MY^&]^_P2YZS?9!>[L#P/.><?6;DH*RA8;C9MU;CQ0ZP\YE)4JPQ@KE/J!'7U
MCD+;C=*\Z^L?U](Y4B&>J"VX=&N$W*Q5#<- R:&DIO@-GO10,E]>6-%+EDZW
MSE@15AHT$UI !+EJR44Q\YV4[@7+_!&%*WY ';/:H#G2"N0@5BXYLGSHVW9<
MU!<:M%(5((&\OX!'Y@:=?-!<: Q0T]T#1JQ?;UX#U07KB6#!>K.8[_7Z]!1<
M;-,9?N+TU.B>?=HFMBG'!V"G^R%YBES'M<*/!VL-G!?;Q"IO'@$4E5E#!R6L
M$,BP@7EGK5!ZI5>$NPM&PHUU$E<TCQY*RJTA1S/( %B"YVMN"-3Z=_-TWDQG
M5>7S(0+0<3<AKT9PH/VTH(050C"4II!7(]2OI#RF+U@$$< 0H"LWJ@E:E]0:
M*P1!B V6NEM%.$-1-P\;L#']MG6$LPE*;S^QR^,$<$ ^]>;1K:S+A#C^%BAT
M R<-M+I#W^E/;'-/IK)Q%)%7<)W5UQ@RR-""NDMY;WPW=BUOD3QYKCU?+JE#
MF4$AZ?IED4Z'S:)VJ <1/I C()?L+JR/&G<RJQ@(32N! QD<4'OQNWC?4%0-
M!#M:@34K2,#XDU9#YX@J3DT!")Z!S.CXD!4@IBCAU1288 QCZFXR% XG_$J@
M>-( :D:1SYU1I,.PE3L4WP;1^FS)+(Y#]RF)B37V&!3Z3!8E<&Y%KCWSG4O7
M2W#W4:RM%!5S-*[>%8F?-R(/'.$GCN@C1\5GCN*@%#B3/197I.\]PG;#R$G?
M?.3CICS2U"MN*J)-65M-%3,+Y4T-)0CGR@I]K/*-:OCA-ZSBO=T^N?U"6\13
MA,.H;=S Q5-#=:AJ@Q*DOP4/#S<^[K6(C!$,:I3*E$5S/)X>]WRE1!N55@DB
MQ@J2!@(ASN,7%&ZFE:C=6,)JS7AJM1I;E%";Y9+3%?6-2%PS[I)O*+2>T?ID
MW;:7@@J.%0:NTH;QA&I#D2H!V\L&Y-C&$$LF<UD_HF(K!^HI2P?DF%<K=I5I
M<\^()"\#39L<F+!/@<&$R<0J29FL])Z3AB<%3;L=0MJ8XX":^;%+73CN&[I:
M+I&MEAOD:%R]5JZQ4ZGX+B-$7V;O_$/]7T57U,(FK\75N^TEF  DB !K[S5)
M23I?;B.1.\NEXR'&CV.R5]UU)@P (:(M97/^4=\ YUA!AT\TCK$[X&"5^+L6
M,-A>0,X3<<]&B*H9Q\==4T.6G *1&7LAW4ZN(#P[P5*8F$@<@=JV NB:(S=6
M_SNZD! 6 QI!!W \H]WUA  X( \2P%F,;BXK!,0"-<  KBYL:7S="DYTZ6K>
M.+X-<1'%ER: R:RE?&:K(*DDG=3:MG$T[I11V@G,$>+@;WU,SY):$7*(") ?
MT<;NB%5"I*48]GE4#?ND#_A$GS J/H(X[]=/&8SK?0-MOBRBN4<>"4DGYZ$B
MRAGRADZ6-U44I=2NT=["/ L'DK.=M#*)9L2R?:;)**+SCTV9#,#LNQ4ZDMG8
MVK5OW/#77N$\%W\7T@+@UUQXED\,<XX[OEC$.-)TJ^ JH83" ,0)KF>[7,@X
M7@CUQ%8M!Y&);D::H<"WL3RPS4 P3,9')QSG(J=\&?/I>&**%CDJV78@JL(S
M4*6/WX/'ER")+-]Y_(Z!?,Q]5/*%+)+0?L&C&(''UG2#9@ 00!?J/E?@"KQ8
M4YW.9.J$8-4'R@0EN.;YF*,P+DSC^*_M*1Q_]?L],7AJ[+G2;\;I=U>&G%@*
MYOG>Y-5>V_FW?C5&]6)5U*C-T*F\A>*^6N_N*EDQ55?ZW3SE<=ZKK#XQ#O,4
MJ.[^Z2:%[AX-T,TD8]Y<K4P=;0EW32"+DO*JRI>$"&# T)9PUP"M2VJM1MUR
MV "H6SAVLH9.T>9^^X:-H]/.9YQN1 @@,*6Q9.C__(JB>)TZE771J,Y'F,?D
M;IBED<*R4@1Y!'WFT=:SD] 5\5V]DX^L#5FYRF5A?AY/IOM"R1;R@7GD/'=&
MH_#-M5&]5.Y( '1$3NP3D4>/06QYQ=_)9OA=$/\#Q??(#IY]DLFM$";),A)V
M\NS]I7I_X@694K@S<:83W'409E^1<BR[9+<O<>@[/<H99*;EQ@K,AIM?TMO/
M_52,OX3L/'0=/&E_N\.NA GR_FJ]PMM*GD1_O,0&[;7EAC3;\D[Z@_ M#GVE
M3T'OYK;O_G*Q7UBO+IYLTU1A]YA+X1LBD^IU$B<ARB\UX;JN%=K97R[K$557
M^;N5@^H9D4RXIY$X'-R]YLO9\W.(GG$'8R9$K(ME4FMA__BD2T@9D[X,,1-\
M_2F>&>XXJW3@5SW&4TFTQ3G&4WC,X1Q/BV,=_:?C&M0YGB\83<\IW]LKO,;$
MZU1:YNTK=Q7H:0 ]NE6E5* G +6K!WKVJ'JQ*B0#/8>MN*^NSP_T+/YNGO(X
M[[45Z"G$,50%-H_4'98"A3C,BY&'&XFU1W-VQR+<9]:NW9>%A>F]&_UQ'2)T
MX\<(DRJ^Q_9Y-GCKYK;BX\WK =TP4B/U=4@89'17]Q)-I\O>NDSZ^$.7Z47"
M(&/4-NX9OD2?9"1*(OSL&#F/*%QQHW\[>>">=XO=R11D")K6H267X:7[YCK(
M=\C0LHM)H^ZY>]XM=B[:0VR9K"A_#3S<C(>![7@YPGV!0W_I2<:' +6&,MW=
MHH3[ H>.TY.,=Q.1MO/PC<)1B)D=XVDW_E -XY@JA'%$Y*=1*KR1E3WP$-#1
M8G__>&AC;A8E6HB4N@\\[SH(R8\=Q?[6/ZS8SX_Q?R:3GF\+:D\%_=&\"J([
MN#OY\DM#!;NG>/H<X]B]0R9VV@TXXM74 UYIY/Q#;(4QF'Y@S,&G0U_8E8!A
M^O)I1ER\DD#.91*NTSNDX=_%@\57[RBTW8AYF;5Z0P<6EQ.::9%?6S_[64I2
MGQX&<-K3E)67NJ6H[]%KEJAWFX^ZFS^P=),]NV.IMO6"Z^:N(::&22;WT1YR
M?\?RU>323HWN*[_:#WJ[^Z:E_'Y-<SOXSGJW.2!?9?,AB1_LM'O(/OXP8>CL
M-*VD#O+8=4<2W=4L(_OXLD)/QI.3+X=NU(_4-9T7A]6-"J+;R@F1+] 6H6LC
MHNKEKC8#)%_$N*YE^$9!&['"=!KM1K;]=ACC>HDAC.ZMJ_'ZUUYN43 /4\ED
M+M+2T_2]P:&W:>MM'2ME/V<TD5!SN?7:W91>XM#C=M;CVNO%K.,333=U1'(J
M;! TZ$:]O,.A%XEZD3EJ.9RR +06@[,3!64Q=MB[:K.-T4/G:_=2AYEO5UVR
M ST==L8:;9*8TTD/3LQA=%(-OLW#OEM1SC/'<5,Y;':-1&>2.GVF<5W,Q-TT
M=0F:Y?'H.W.*</2[1^1"5?S]1>!3H2:61[)Q3'A=8K=O4E;S*9;0=-ASD3JI
M&1W+ #W />S60KC*AC=+YMH3&VE_P4/G[*!S=JP>N#MQ^F6N/D[NN,\V>,%#
MG]U=G]6E'K/,VHY.9]U@0;A^Y-IIGI+ZQ5F'3S*N8^A<DNU:;H==,[[9719E
M]_MDY><90_5=T[+3G2\)&<-=,'6Z4[&^:&PGW:;Q^QRZE:$Z@+OFZ73OP8AN
M)WZ?0[<S5 >[6;;L/EU@K9")Q/P(J28./%9('$@?_(E:^R.[^!-*GWW((=AB
MN71RN!12_IZ=XS&YRW4\Z/7Q2>T VJFTS+NC3)FN-SX>>?# B"5, -^21Q&Y
M5*^,E*AA'*6Z57^5;JJR@4N@RX X1-4HE-8QCD2J2I6F!0<O &*0\1KW.\M#
M4>UMB,QR0R$ 1WU5"LBA!*#V>ZP>+-H7O.BX1&_("UZ)S#)KFDL$B9H@J=$4
M-X"K"G]!/@HM#R.?.2O7=XDI%[MO2(8N4G5!$J8Y<DTK^$'>;GF[TSM9C2#;
MKLW?CD0(8*";>;1UY'"=30QFRE4VCWW=L*%*NQ;RT61PO:'P*>C)J9G.*(_6
M.XKN$)Y0HHCX>Y=+1&XBV?Q*[H)1<V9.QD?;SLRTM1%]&/X3/V^$?XM&EN^,
MXA<T0OEC1VY:,K;>1WAR&HXK<RVO#6Z!GY)3X_>^3BK6JY_$)KE^@GDT?T4A
MY5R4_72/[,"W7<]-^R@?L:;6C1NP!)JL#CQ="@)D:$&]P+:D$E\CA]BWQ$A.
M\)M\E HK<5*IY;(:OHPGQY-^^=@EO63)W%Z">TMDNLC#<S%9XWF%6;H%@UE-
M'JBK5W0@ TQDI'07$%,PP<7PJH^_*FG:W(&K^L1F5B#Y#GF*O[S Z-PXRKVG
M+5A:;>S 45U",RMPG''400DOG4CJ??8+%-KXG[HS#IH?L:<$W9DHS;I2N@5M
MO_DV"F/+)1)9!!$]6;5M@;9K[$!%74(#F8]'1D3S^ 6%,^>_DRBF>Q$MYO+M
MIO:4G=I%!C(-C8QT+E[(=L6-?YG!Q(5F483BB,1)IRKQO."[Y3.3/VE^RH'1
MG4LS(_N7/2![G9I:N_T/%&TCJ(Q]9VW9%\269\".9*43JNY"3B1V(9WL(73#
MT:*/V=,MQVEOX9ZKU\ G]L-\65$Y\;NZUA/N3[$K3-36H"7C!AR!ANKB0_6
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M,^(K@ 607JV*5B+_<+6X<5Q0T*(,!0P=U'5Y S#:*';MBR#QX_"#FSRTMNP
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MF[UE_DU!730D11_]]]_=3IY._OO__O._*/0?^8NB_OY_:)I2!IE6A9(,T9E
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M>6!@<UAJ2$S.?D@'/Z3UO9H/S:=IXRUE_ZRJ"S'KV=Y<6Y-0VMRZ XS5E4\
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M!Y*"YQ^EG#4D/RJ$^%L8/T=CLL(ONTZB0?>Z;G59SC71FYD3XT(:6 "<SW/
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MA,W76_UT*T=7ZO5RJ5:@VIUTAZ_RM4[[C*)OJT-/CF4KLOM&CSICQ:+2NNX
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M\)!%0A9YQZA%UN6(QH'V3=* SR58*.,\"LJ9(MQ*BD5.CR$A"U^PK^*-V_H
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M<+RO!#ORC5<GK]\^_^>C1X_W'S^^.\P[?YM&8^@]9I[-E&VL<Q>Z?T5(Y5M
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MD2]L;$(H6= Q)O"Z2!94D #DNW4<%XT==&1$K_^A"@W-WFH9.+[_=38YGXR
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MK+\$T9._Y0-NFTJ\O_R=9O(^?U^1\,J!IJX68_K/K.)J5$=#UETA#FT +",
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M2/B%)3O;"F?R4B&;4JADY&8+=IO\XH6P;%3)5.M&V($:ARSVV(/ ']M:-F0
M#7FY&?C&'N9!U&(^.79VH[YQ?#<MN$.:5NJ?'"@V&.T78;WY5"?[YQ <X@_=
M[9RVDS.#/'/Y'SAIA:B7N>;FG+3-4XE(ED*:0DH)QV)=H,O$>Z6:2B7$^_"8
M.6[7RRDVZN3,H=7=DP)^HNY;.DE3^*K<XMBJP$A,P1)9\7&C@;,81WX6I8J<
MNU[D;%W+J8*\PZFQ:*E@OPUUSU=EDKP-BB+ID>X5GJ_&"!KFO7N8+5=%M4%+
M0_$9QS"V:KBFB(R.N02M=,=XDLA:*SIHGBE(A3GH\H9M(DQL7;K ;&J=/'G
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MD1UE620]R?8<UU0.#V+.K8'F;#:,J+5< (R06O<Y6 [P/!)W>;.DTRG<LM8
M5]J$9.5<FB.[JC&7>(L67<?7Z7OV^77\)Y-9#N7H;XUH UF;HK#K-]!>[QS6
M1,EE;R*:ZNS<I9>7='+>BQMMB56IW37@I=+WB0;5Q)#K7NR8_7 E:==)$ND=
M#90')*LRNEW9_(]EV=:\^Z3S>WS:E<!N;2TH?2^VMKZ><$*=T52R5QB^,8OH
M@SD@!Q:]]4HIQ]G#I4<8<:640U9S#=TM)![#[4+L6=8-)&\J&(:-L$H;VS-
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MKCE5.I11<E4K4O?^H[7G>&I.A+=^Z:.D3.9TX\87XK$-KXW/.X?KHN,?3SD
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MI ^3\IB#?8'!?:DH[FDBFC-,%<0!W(";1H+YCHQ%,6>>D 7ERF"<J^=CNLM
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M24Q'$K]@($V!CHX@%HSO,;>,A'AIUN?GUN6B4[G<1ZE@!#\'GW NRY([R*"
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M#7M5536CWO@1FJ]59$.![K3PY<]9BD2Y:O9\75/IT=;-(XGG!\U7S%\IU]^
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MD/H#-:Z"RF8-[FTL<@&+@(HH;R6^NDW\.K0^SS#Y.NPHQL0[>0W:G+2$]^V
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M MXLZ:[K#M%JM3LV3_X.]S]*=H*Z&P0'NN0=0!%R[$ODAKTO 7?Z!0(K1V\
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MB6=*KH;7X8H.L@Y[S@-BZ$16/>1&TNT>N@;DJPZ>:64%G5P8-K3+W+'$0E.
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MXE^J*KVEM".6 C'><#"*!6*:$FA9Y+0YC5ISQ'!Y3C%E^@;P7O(Y91JA&G3
MB<(ON%XY_'H+J3FO,RJ[![0=+$#V81\PIJ?\6B+S]Z9E9DJI(;1-"P)P[R1X
M?5DM:-Y8>4!/73%5CQ"V@(T2-0M].W=$VF06<5MDC%O#X_>&ELE3#'Z' :XS
M]!>,Q)Y4J$--/"8$(":,*>=6QB71R#0H6U,VS,\LG\USJ9R)<!54ZJV("D@J
M-']]\^J7G^GU7/7)\K_@Y6>Z'WX68J^,R^$R0 RK6-H':*%I;%PM ()[65MT
MU4:*8(T$G83=^%NH&I&?"?"/5_)')0Q?,6@JZ"D>G)5EX"SS5M"^,>5U.$O!
MR:=!<KMH18+M5!H1XL0]E8N5\$A0#6K1QQTQP"GFL\5*M,2%0!VIJ22Q!DY*
M("6[6I+:PC6;!";Q6GD.^"N(!85UWLBK-:^ UGR2<0[?DH]HDF=J'R9$FP':
MM+?E -0F Z?OR/(I@)V0L6$?N#, _8/RV$4][]:T-^& WI8J&C]B_=-?.0$5
M[E0.Z90CC=6,\K&88_N!H UKD8<AX3*(.HR?;C> GL(-'8"V23Y$G6,JD=.L
MB0<UMI](A[PB;2=]=L(8)U(X6M5;X>O4<AV^D?^2M?.+H[]G[ZA&X2Q(AHXA
M&Q\J(E$;;MH91( 5XRS?5N);N5,5*[*UX%I44OJ7_@N*QE_$;?JM8IW'&NG!
MJH>O@M!Y..EC30OU7B8''K_@"=3Y6KJR#B1 IDFT1BU7()T^Z%\->@5H=H=%
M1)+8K+_*O*='I&0Y*R?7"]1,J*E1,/E&"IOMEN% XP#P^/Q73A7*]< 6@B8K
M_A'DI+%VKC!P;"%V' !2Q\VU8[7[B[7*%&H^J([1=JY7.::FD%#B2Q%@ARW=
M-$5B<^>!G6=)F2;=VE:EJ4P,GZ]^ IB#)"\IV@*5Z8X'8X^,AUIT9JK"F<-L
MFRQLI+YL\G2/7-.M%I]!9]/)>3 L,]R_)NIN-ED7QEX#<]^W96C5BE'%!MV,
M%'0L96(,OMJ:VGE+:A?CK,-U33&]F1E5PK"YC/]N^T<[><)MPEU@+W-&O:OI
M3DSJ@-^#,A#U(W3PGGQ8X<*S7(AT"< L*?FF/3*\,,>"DGJE(.01HXNZ"4"_
MT:1Y*L4*W+;-<-'J56@)(5MGBX@SD"IIMI^9&KE&M^->G14C0/ BP.,7:J_E
MA!V8.PM'[KEXY'L470[DH(RKCODNG*B1,.#H>D_%WB$MK/8&S77$[)'ICY@M
M(U99S]!J)4"H%%>]XXJ]X#HN?W)AKKS__3T5P!7K#C*N1I??0P>(<F@:R$)1
M+DE%20E$'1%E=#Y%7OKB(=^1B/W(HV_3T-(SIX(0KO="&E+KWHT@CKR 1<,T
M@1\54DX!2TM)J+V)RXCZUI&(D/$C_1&AJQ0I9.4@UX%8[!9U7\O/#<HOR! ]
M5UX<A25TY$M3L^( 6)H\>_'F^=F;YY.G9S\]??ZWO[WXZ<]:O?;K3\^?OZ9_
MCZEX^M WH(OD$8[>\,>3'[N:I(C8BS$KA6#UD%'$U7-T45T%A52:NG%R:H3N
M28V,0R!-I3A37% ^.,YUT'A7['RTR-G]0U[5-:I(-SO>=PV5=\AI:JIE>Y71
ME!CO2J ;E0/"%#?I_(B<=$+\-^=:[<_Q&BNQ\)\.'VQB#(:-]5SZ/*+6M \$
MZ^&RN..$8;\8#BFJG]HY<=LG5M&1'MIO!K?PX);T^7JSJK8(Z1!V-6BWC!W'
M13 "*VF:9Y"$>,O$DCXW\O?AU,Q2L+?J[/3%XB'/5K:4:ZGN(]D#(SRTGKNI
M$**1'8?-1Q2*7()5U6^UM*_C$4N[N)7U0>VME)>^:P%Q7@5TL2JL+N7:ICL>
M_Y#W. BL8KE(M1!B/1PF<RK.5M1,]1RM3-KL;?APFV^:OA;:<498EZ5[G9H&
M"%^6?*TS]%GM9$=]0MT=_J\K@J$LBG3WNX Y_+^.X>21R/0<L-#=(DB?UOK?
M 57G60.N(9*(J5KS$@0P*MT\(Z.#B[_\PO1.Y8^X4J&@\+ZN:9P?&?386W$-
M!6J]PZ!H<C[4C9IQ14M!&0J;W3MY\CH\9O(C5WXADG8/OVHFKZ/324;;*,3W
M& \Y?7(G<U$/#KFH0RYJ#TJJ;@:Q_[,E,<+)5.ZSVS)BSR+43Z*$P=6><M[J
M&96DMVI0_@5]HZ!NT=UG\B:O+PLJ+?^9"D&Q1R]*^$5!V_V9[S=^Y%.<8+85
M7Z(+I)@3_(]B$9\EE;/AQ=AW%^YRT0'4JY-QR*0R%2',TH /,UV+O>#2*81"
MRQ-Z+91@=.$TE["[:KIQM,LXTC56D1&)[(TC/':<Q+BM_63L/#DE8J>.ZG$1
M, )=6*O.*;%IU,6LTZ B=S90JX@#.=;M"(\4#D/$6WPYLP2_\@4O>G]QR&[
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M5G-.BM8GE=%@R!-'8CA-9"]HR)*#+0R8;_-S*@B9 ",4U%ZS QPG=[J[=Z(
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M3=',WN*#H-4=>8_AL::DZ!)<YVYSIL)QY^*EHMLHYS#B;4)P?#:Y41.Q -<
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M=T]@1J$\PM$+-8:KMJ,RP]FL!E(O7\2IN>U&I/ L+/)ZP@Q.M-ZQBIRE[(U
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M '%.7V9;/B\8XKT3>R"*V_A/]_EO]R9="4YDQTDEM-)$QIJ]S5%^KFI7#^*
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M<P7>?%XTRQXLTRV+R\TB@50Y[A+J5[D%.;:3Y8KT+6V?BXYJYED3C4%;ZH^
M,G$1C< ACMKJ2( 1'/(J&J[($8=MI# ,.)>J948&HMK2DJ$B?E-!SGF-,C<B
M3T )/"U$[S-^;A3%9XZI*2<[ZW:JW8IJ82=):]*4@<PB]^4 9=I/8AB+264Y
M_%AOE5O1FT_O,UQ@,4PS< JEU(HWU[,%[!-5_=9ACL<&E\TO0$O$ACES PR
M0U]RE=%GK'?!;@ES0Y(*\CU19&O"5@AHIX?9440A9>DZ9@LC9KVL: 09J$^X
MNLA+X!VI1Q %&P$OR3<M?R>OUXTA/V>(*L\9&PDHYY1;".5*8AD;TXSDQ-)
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M3NZB:_?*M_:3BNV<VZB$3=DV!3?"R>F.(HQU\'(Q!EQPU&Q'>](T+%3:64;
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M,DDBLZK" * 0WRX[>]2BF0HPA&[\<"(;).,@!R4".<LT:3V69-Z)=/8I%@3
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MD((OP5U[*:!;*,]"2M7#L)HCIG$AMRT^ ]50]MVI5>51R2JY 08]DZ*#-.E
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M X*Y'O_<1;9:VM^RQB^#QK2GZ.]E=LR0W<YZE%"'5 ;U#3C0JY+)<16;="-
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MV( ^OI*ESCHA/)W()C[=(3!'E[J#=.L+99[Z"%BE5C<#!6JP0Z;;3.\-8.U
MABH>$'@06]<ZG'R^?JMA+%F!5@97)<\L#C[0J,?WC>!6S?5Z:OYRMP0;&[ND
M]_,\Q%PW_OK<\;F+9%]N[#K@>JK^G=1(4OAKTK?6DB(N9XPY'KEZVAJ*8N7>
MZV-6=?I,;CMSI7X^- BD?EI"#^7HB WP;YHJJ52FX=*QK=)KIT%WS>1D2)9'
M2'=U9TAQ)(F3)P626*0) 7RAJR_D:<EO@)E3V#''*+1QP'$/:G3MJ'!>6*ZY
M$5:M0N;Q.<G#,<CA+5(+FC(ZM*MW+V\WO[3V^Q^N[?=K^_VEM=^#FX)73=JF
M-AF_(]E1![Y%CM28<QW.&^-GH>N8BQ3=*$XLDB"QM8%AQQREH61'VL3T0(&Y
MMD/S62/(&%A1.=[6L0W-*06&IID;NWN$("AW27U% ;N9%E'^"J-V=!O_:+'%
M5&TBJEO Y\<DM#SO0P59_AT:5R0A9X03T\3&KPOA]A'TY^+W*3-TR%0>P.O5
M4W>;/@&>_8,D"^8.."X_MD, 1$6HJ%GN!XDVUHXAZ@#-A<0X':*BM^L/*GI%
M]E$/;6 9E69(/"[]6U*::LGDXLF=BYDU^)$A-K8,F=A8'898^2V$)?*TR=NY
MHS!E&=60C %[)TUSO)/IUPS/7B$IDH&F%Z>:]69.Q1IW!OB=I8<O[$1,EP.'
MV^$4E#E-N"(<Y*'[S)-P+SOV>/DUD*>7Z&B\?@K9G+$XAF*DT O:>3]7*R[&
M!HPD 4CZB@NX"73C88LQ3)I2K"6_X&&GI8ZQ\&GQ'J"17.Y=:@O67V%3U<X6
M[*IFZ]?RD&L(%$'D0O (?*2Q"DRH[U==MD#/Q7>] ]L(:=P=TPX3=L+]?4#N
M<:T%/@-=<(^33,=!85)[<HSER@T@;.[UO 6?, Z^NGI'GDQ;;5UH;R4&;$ W
M<^S P.J<:/CX#/"[=/;BW+ZJ)G[WCII>BRT%/V@O-6*@V&\$=JD$4T=V7-9!
M37R$HC+Z\#YQ)]4J_TW_/E<R(I[=PO ":\U+9^>6V%D,MA>540[&^4UJ.(7*
MJ5!AKYXB_?AL' \;HX80.+@(>4*\34K $*YX>D[MO?4G?A ^L!NMG*;OB8](
M/ABUSN$7NANJ@\[?'5+!FRE]NIE#B W?U,-$QZ-K40> )?,[O-A1L==7#OQJ
M%HB#^NK(D\P>H]@E]^[$!IZ#:^2X:LX[D\-I'$[Y\5$<CNF1]D5NDY=+_^A,
M:%"E##\TWXHCUOX1BFB$<BB[KGW ? \/O"XM#770J6&XY/S+DVFUT2NC):BY
M5L=>T]\P_ALN-19#C;/E% )%TQN5-/$A-@NYW!.EB]8B3SH)*@6_GZ>0ZNV,
MIR@^L*O0L$CY2'QR4[E[:;I3MR1E5S)QDV;(@3)CFA\K"O#JC_YY]QH@XI)B
MYV:IM(?%N0$!.ER7Q+6C>"CLK\32J4!@\8\GR+2TO35M<WPO [.GTV+V9?[K
MVZ[UWU\P3%TNKO].V\$1HMV'#BE\GWH&(G<UPF_*]6-EI29=D,Z'E(TJG&8J
M8Z.23G7R"-![FTF)PJ.<+ VXGWV@VRVQJ1Z/507%_U'F!9X3Z5]X!\()H3=\
M OO%LI^9DIZ3NN'2C]*DK3H6>B$<) T\GK%MHMM=^Z?=FGVAC[2CX6T,R>):
M,JXR6FAX5A?!OW@!*,>$FTCG+3J]$#WH75?>RY&1?(=<T)L_?48/0Q[VBH-Z
M4@CW9.<',.\8_,VVEP>8%PF-!=4KR>$<CAH6L&1I3!*F0\54X+,&0G-#U+;5
MWS6*F7DDIXG0##)^K&;IG[#M%)!:9H8SO),XM'>8,R'@2*&Y5C&E#)A)$]$$
M(/4RWLO,SYP;!<NPC20#V-"1+EGAA\9JX.UCA;=D=/1&MY@$5H" Y&0/?>C=
M]ORND@2<!:I$!6I&&4^.LAB0\7Y'=:+7%\RV0N]K6?D/KK9-6[=W=""OO6%V
M4JOPK^' S?=^VSXPM%LO12]D5['2JYUTE&?A80W01"RI_;VA%B0BR:DKEM6%
MF0?\^(9;1-8B(M(6CM9>0D:/<.JK>-ATQ;C+'T@,LH%E*APT&^ES],)EOFE$
M*FZRP@ZJ_3N32)A6B^H6J1\>1<;FB36*-S"(]PEA7YX'?FE=^'^Y=N&O7?B7
MUH6?2-^=YN,0A&2?;VL(IC*V;MGY$T<+_?*\)XU%7PXC^8>+1#XW'&;U\?&V
M1U+,O5W\Q=\2B9+NZQ@AA(]8M=-RW>Z)Z9/4$U@7'/W(," C11@.2()V?>1
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M/2QG8.G)="=84-$,Y9LY>Y&4LDWEKB P%<:R#Z2>+7$N#2ZI>BTA(2R %K\
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M3%TM\?$<5G)U(U-T82 ;BU'E".F3HLNHP2I'X#_*I$(B'/;1O26^C[.!$\7
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M_0UD'C:.FPIC1(K7GWWTP\WRU;9L[GBFG16HL**A]@^,11@_&QKA:,7ACDF
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M#H*BKRQ3 A>O-977*E8_+'\2:)O0.5H'4R3%T91X:2S![.K>/3 9.WFIJE_
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MRO7<Y1F9YA,RH4Q5_<D3 $AM@Y.;[YU/"DANJR=C;%<5TC[X7M+CDF>D7EO
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M&6GC%1QBAQOE\<=85Q_U2J-/B#G>[>(_\3K/?^Q"1Z+TA,13@7$7":#A%4E
M/$[Y,W.HRT#J4=AZ64"%346%TIN+8<X/O!3!).#'3KSW9)IPI@:#.9GX5"9!
MUO@U_DK*UXD_+:EJIKR;P$%P=[I&NS<*'XX#XUC.19G+\H@*[1]O3Y5(XM.'
MA!GQ!/$5<*\E=_9^:<*"\RT@/K),-:L>'=7+?:92<U$ISDV.)S6)+14)'5V2
MFJ9:YPJ^WTT^8(93$13/E!@T90H=@67?$M?0[>)[4ESDD@5F<FYD4&;Z5$$%
M>YDONV!H(^X U$Q$UG5^R7AQL-<2#0JWMENK9'=,_Y]H?%9$7#U.I047B3EO
M4-47/"6M#3?OXD(@A6 GT1O'Z%' 6%BFI7$%B=X',D^>+C(5YS"?1L[^1;;S
M_W!MYU_;^2^MG6\4*3BC.D^30JJ]U7N-+X>S!CFNT9WSH<,U"C\39_C-J5HW
MGVE+:L+X%\X1@JNK'67V[M'2?G8T.%$UV5"H.Z[>(S#9N =3PH<2CGZH+V+1
M?]7Z4[ZI$)?@>^5BV;4E%?-0^Y*/(@CQ-YS^%-4M2LQ.BR1CB(!R?8,$ZJ%'
MN2F^BO"L>1<XL.D3\P+JVM-ZW[TC]<;JL8:)N8MD@MLO7Y_F[G(2R\ZRCY-D
MUZ$R+OT;=49F%R(CDAX=#CV#&?#AG8 X'VW'^$ACB[KN]/6A G:4*BU4-@GB
M,2[^[CN?,0X[9G*T9>_H1ICW,!,1+]&@;0H#.P9RDG>#N1C3 _X00B&$J5S!
M2?M9H9:OO$3CL*9SJ$4CALXWQ9*FOL20!=NL?3P*O$C/V>^1%BESOO>K]:%D
M6S#+H+H"1,]Y56D,OTZI_?O1YDCX_8OH5\8$$NBA_>I0UQ_@7L_JUWZU,5LP
M6=^-0. S2*!1TE+UK ^/[<S.11HOA8P^LW7(IIPN<"CZA>H>!_-$+O+,#=37
M9P,_.J[]K]/RV:9=$0%5%MJ5)+O-N/Y$,Q$@K](BMFD+\0GGK_@38]-[T3^E
M2IV /U@Q<]_NAUJKR[&#U[A-=1"W$?IC)WJ/<%3$C[96[!+5:7:AZM:[^ <]
MQ*(/]TZT(A=^%KN7%+O]B;'P:TU^#NV\?NCNW='0^?91%G1#*9CRK$0@@U8S
M"CRT3=?]K[5=YU_=[>(O0T<'?<'"/D+(09\'_X=3$1<\&B6X!-H#G*X#^Y3W
MMP%<AY(2BH:42P<Q6G+B.%HM'=C)I0K$5)F%4%".(:*BO>T74$^1LQ:4#2CC
M?D)YPU^5PDNA[0M$Q'I"6FN%84WCBJ_X+)?C*-C':"7*U6KH /[\Q0XQG&5I
M$6]-43+74%#^1'#:A'$U9=02[(@:^'.3:KTD#_C/P9$'DII<=$Y&D#$! 0S+
M$1=#*;Y6H:B,I6.,WZA&E56:G[6W*Z;HN2'B[V$!WLT<*!+R68]_T%J<@N9Q
M',5O:%18JLY[[B0%ALU[1-&5?T1:\__ZXJW%TRQWU>&4,Q;K\F$]@WA1UM/K
M*5DIJ#_HDFBOLFA@Y 2K&C/Z')6],B_@-"95(3?R(S[SYE;901&W!OK"J'EB
M)>U#31K=<9_:"GT)=7%[J:[['T+)66O#A6:*0!2CCJRS^.UP $2'AM?H_8>;
MKRAI9>  ,#[21L<AH8NU;EV/LTW6J>TT3\%386WF%Z-85 =9;^@XAF54?@<C
M#Q]'!@T=ES@+VSZ2=B>]#<N&)H:!'\#R2J9=">%61XE>7VGN:-><@,P$>D;S
MD2$=484R\"?'L4G_7FZ",*7<0Y'8A)CMV&I'7D\L5=\-0X-05I%2C!FSD5R"
MSTF%5^D^X]9'LMG,BPUWZ'/,O>N(ZU).755S6!<6/JWOB1XN;@-.]6$3K+.9
MV,"UH'CNO;Y54?O1H9=1;=#S,B>@\###M9I6@N=VI2%$4OPX^PLN)L6QFSXH
MUR6@<1-&ROY@'^/=&$6.A3G^,1Z$_*M<^FM*(&>S+)77..5&; DN#22OA*O_
MQ-B0T,:!)R"0"*2HB1%-@%;)@T('64*H>FAX;]9OS')N^8Y'.*1"!\-\7E@Q
M)#E43?+TPM=P\5E0EU^XE2-,#X.T/_WDS9^+Q?=OO_O^YO/VOV\^]:Y%HI;^
MT-%" ?G3^<,)E-E^=_M 9E-U_4$(T3DC^''PAUZQ^'SKG:(DB;W?_)#_$KCS
MXJYNER3UHYP4X/;\UI^;U3J>WR. YMI'%R6=;H>\-2\"+A-P26+.5Q0+J%(5
MU0BN<V^8 C7)@D$EKVW: 5C%\NZ.2@Q &*P,O)#JY5PK]AZ]7.M]2T!H=P32
M?\#KVN:&H.J\Z>Y*BDS\WWE6S+6 9*[\M^'+??R3?MZOPSUFT:BS;16:=/_(
M,]Y15Z#A341O0NFYP)Z?7M+RZAXBD7K=KDP5J.J!J55F!Y__USXZO_$V!T"T
MLCO@MGKQ^NN*JD*HM-U7ZX%./YHZYJ\N2F55Q@7P^++\_I7^QK!3:.'$_4R!
M+-W1;\/@F($(X6/*-MF\3(C$OUPA$E>(Q$N#2 1AA9CUC*9'HA=<DF@""X-X
M+_.N$6Y9O42_"'U?W'^EK,_2(:?/6L^VB@Y*ASSW+>E4.%42:7NI)^M N3C"
MK.N>9U+B:9318%R0'+]7V<J^;A^@LQ"(G1C'(?7><1 T1Q!^AMQ"G./A%ZIZ
M%7(R06)D'&+175?=6<!T^Z-T]A_<W1'3.LBQD;H@6[6+8=KW#X1J0'M\BW%Y
MA>F2W$I7\:IQ6RVN_,.V-8-+*L@7Y$D.C!FF9!?2 2D;D QDXV67*P&1%M$P
MXA&GV0UW*L+ATD*XPI^D]?.U:E]?(O*V/[%G-''@4Q^;+.27YMSV:]G2VB86
M'(&G#)&9RSCF=M!DJP47]%P,WR]I<9_&7V<9ZPQAG2!IXM:R4AMFL1(Z!RD>
MALD$EZR@LNV'&IT4EY4<& 6ZQ5?_]<65E_*C\5+&U6>9T"GLBQ*'>@[89?F=
M1<NJ::8%@M>QP%=F^.<V0S1?9$Q7<ODX"6<(CAF1]AIM[$6UOI]V\,RO<3SS
M28XM<O_;5&/\'3/C-/XZ#=14=R6#6VWT@'_O#^5F<S66EV$L8^/HS3'%@B;4
M/PQ40@Q6Z<$TH%P#'*-D'(:UKB0H\C\J]<Q^6^WW_%LIL163)Y1-#\6*B21%
MO)7/SB33N!K($PV$(6BPD"1"X0I"SXIST(@BT?>V893#TTF78Q"<]H<-!.Y!
M+)4_FK$T9O%@2Z0FK[VFPMBC*!C3@Q4RSX>!$VG90$]V<NU:*1RO3NW";7;-
MI Z<^FR=7[GMJDSP!>4#"1LJ8CTXKXGDS5CQ*KUR2[JF9!O^ 3BB[S-F*0X5
M'1WY!A^.JL2C%S>W<8V[7I[5I0G_9O'.C<7TDD*DBE9GC,7()A<J(3CJTW!#
MBPH&K0PJ=2CXT;0(@V7]R=RQL"]Z>*;F&%5].T-ZPIYP_!#CNY/^$BV)#+M3
M_4CT9M>L>0P0UHJ+DHQ+MG &<[+3C]U!YWGZ2X1INIK\BS)Y6^."#<3R<1L1
M=F&L+5_JR)3# C9R'4LF1*-94S7S:B,7;B,D>\!Q/?,05'O$>UQO$"QT)I03
M<B06T(IQHS>.VF4T718@XT-)/$5/B0U95=*19@-?(&FW$5B-:&)[/9HCA4N[
MI,.>L V)TLRKDY2Y6+O+&QGAJ\O:^IF(M08\EO&"(R.C#I_.H=TYHJ#8;ZOG
M(VVZF#?[D2WL;*I/Y03#>6$[79,N2D!_2T6!QUR/4P:R;#]L1B[;7S*0'47L
M^NV"RPDI'9R$:4GWF)#%0( =XOWI[V]$/?>F;4*;/EP#WBM\MV D-!+H'<:6
M6,(,B$%5F%U) SA@KZA%('H% &-S"PB]H:^^_OKFS<V;3_Z@J;K?+^HUN8/\
ML A9LLY(\:\"$/#WP7MR=H>??O+IIPD7S/3>4OD\)B$D[)O.G 76!O]'0D8Q
M-=2W6X)<O1F[>7^%>/=9>LU E->W=>5O?]A1?1)$4%+7WI;=$L'UXKNWWR]V
M \U@F,^QLC$UNG,/*KS==,?3UTG8=/@<M[[26+Z/;OW80>O8L#II0>5_$#VO
M=/_V8'7-)>Y,R>6WJO\=!:GTAW9/0_N*ATAM'%2 IHLR*2JLB:1B;?CP;=9G
M<K*'BLG:&& 10(O11]TNOO=[#<Q.Q;AMK"R.D<K_9:+[_GA%]UW1?2\-W;?O
M:$Q[#^7"<9\LML<(O873TQ0I*<&E<:2>AY3@??BW70,XKW_.@7%BLRZOF/(M
M!%)ZGMK/XP>2R6O]!J=#>?G%DYF^CER=X*X1C#73TPKJ[//OOI'TKP0,FMRD
MWY E4^:*BG*0E"&$=3P8Z&<UGLB?*(#7\0O<VD(;KTRY$5* E,_17V)'I$4L
MX8?Y=A6EY/K5FF?UGGPV&?YL++01+PG834$/AA.F8+8\.CG,4)O4ZW@\R=#6
M<KR%8;](D\#BJ%9W9*YOUP'YSM7I_J <IK4HB>1:,$TNW$ZJ?11OUY6>5%2Z
M;'TH?E!4*^KL(67+_,85:/B$497($T_!+ T7-:@^CR81Q#$AEK#P5)Y,* 1@
M3/.4,DW )1VD*OJ9?CL<*$#J;8TO(E?5DDV;(P!GC0-AJY2YNG/C._ZUJ@%G
M$1&6A-GBI ID5-T.G,O<L%I6.G(;L;"+8=\V*44_HRI3I+:\'1E4#7:M6R9T
MJ=/2E"2TL<&N>>/\9*#?P6TRL!L=G;3H]8RACM3*G"89FB?_>^I/"=^\K.F0
MPAH,@7-*+EYZ?V/9055W!X1;=.48KL;?\)ZENF?:-M:I".0'\B_TKN_:=IW<
M,OSK$)+A)[O4(KGO!$7)W=V=<R,X"[][_Q/(^$^.VL?GC.(A([[8$Z0I,L?%
MB/(K8OIILB_G#!SP3*^@H<MWS",N0POT0;E&"'-T9T9J>F]YD2*M/OK()%2<
MX\RG?D+]RA+\!30T'FD(UD.G E?%>R2M.CL?U#2HGDES:D+]YM;>K:KF0R10
M2ZCN8L4,$R!<&8L5+2%C+O@%A?G3N&4D/UV5:%J/ZNK6 \Y1_%=_]V&:3GG$
M']9(?21D(F"?-<]?PQ5L@F\_H?-@6)ZVWJC\/=RWE 'X93.,$1I:/#$^,WS$
M 88/*OD$*->552]DW.CO*Z,%ZZ^)4_B\]@O(M<.W&%T'I4.[>L=J92O]N"Q]
M2V"537G?<OCL#97XD=_/]MG%B_7;T61EAG3^E=T[F1KBL\7_*R_X:2/U6\"M
M>8.<Y0@+.T24C )IO5!G6XIP0H[G<E!"F0U;Y?HPYE!AT95I97AE?G#'-NF1
MAK!$(*V'6+OY=&_KIF)]@5F$XW,6Z 8C)39MT"%LFPW/;8Y/]:=[BS&O7I\^
M7KK]I-JM9"5G(N<B<?PA3)8QOH9STR!.(/M, L"1Z/GY4N<1(<'C:)S54Y+5
MVB*S#'Z%\OU,2L(5YD9.;,(M]M?#]SDYM=A/5C7S'["^IS=/"KZD&0N4'\>4
M,=XDISX<C% 06 <UFM5^,&N"/D$'(F(* G]&Y_2'"N6249Q@X'7EG5>W=.Y>
MJ12>H?)/Z4%)# 4E,5?=M043B-Z5.+Q:(@$];1)/M(0H;N6=>E<!<_(/4"-X
MGY2X2ZJ0@>?6!R0# L0'4C;E!L!CAOK$NQJKU_U[^T#C>X6R\\;Y3KX^*"KI
M$TD45+)(T1IC@3V_RIU_Z\\UNG<QW>PGX 24Z)$.2@ZF4=]3I[3RK\LG:!U]
M_,V?/F. ^Q5B=.D0(RGHGK$ML=(B#PIRDV9==FL5?:+(3[,.80Y3V7(MC>F5
M7I5-7*P!S&!]$%M+^N#7R93U2.=KJ#<4M7,E?!(Y7(%:'W7Q,O3R0A$<I [F
MP[]8S)3=B9-NM#.OX*U+ &^QM,#S)@#01#CN$5U1ZAW]>3&)\.^Z]H&L+-$S
MD8%ZX@0]&'63*4G]F1E"6LXB8:P^W"#4_,+=,[=*3]1;:" <@FA@U=#_; Z+
MVD?!M>3/*>.<]L[P"'W?KJHR%!7HN1_:[IV\T42LL.S1.W2]2O\%0FVYK9=7
MCWYI6)8_7;$L5RS+Y6!9<F?:J6K@=_!&WYE*'(%)F$U86&D(T-"M%]\R9]2S
MC]P^4AUY0;60]ZJR!0IQ5"@ZUK 2#5"F 4R*_2SFTZ2\7NE\]EH6\Q#+J%,$
M$T%T"COV'0K><I:&ZO^$9ZC0.D72/\^ /(25NW?IW9*6*=73(??8]S[:IZ9
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MDIO^OYZ+$_<E':M/XUA-#9?#HU1JPD> VCC1F7M][VHLHSE?@>W+9' )]$<
MC8U/Q&8=CC]C8R/AFK(/(Y:OBJ'U]5L4K2W5FOTY@?.E[7BIAXZZH>>=B[-A
M-\(\Y"IT3<O>@[(&02L>=;VAOTY(1GC*D5IHD%58;4N,G52J=Y5QIA$5A1DE
MZZA&\^DEZBO2W=6DD?\A%& )R<JE(5.$%^?+]:F0"E$B(P!/FL;MZ&S6MIH*
M+M PXHKK[D'I:TWMIX/M$+:=@"5[TUU24O57QI#\:]E_5 F<]$T535$UHX08
M6FG<EDZW@NP5@%;WTW^FKRS]!D6!-5OK!)<),Z;B'P%^FA(/*!J#)_7H3%#<
M9+Z,RIVI<!T'&,754%^4H>KH?&"%P*0S_%YA?& F72\BPY2T=IB+>NU-:'5@
MS#DUB^6_PAQCYDRIIA@*:I\R=Y>Y>&4;UIS6(VV3G(*[JDG\'+"J,'^>FDS8
M#)1!B.M7S,ZBE[7*99.VM'^4#^:4?SW&5R:+S$9A^AP-9!R]1UHR&QZ*Y,@^
MPJA%6/TX_+ CTIA3/"4G?F$4Z&CU&,51R\-R/8 OW;2F!S B7IT X5(W23E7
M#?^OM=L@2>\"S1U90AZ+(X8HP>_0!Q:4,$@S'CS*7X=@< @+%P\$RA'8XSTA
M,J@:<#="GLS<C,#C (EST")6+TG._"?7>A>]EK#?7YTGC][WEA':HB8@W'5F
MEN<7W/%U/UWX?J+\:%"IU;(CD=:E.SP0DF5Z6/,X#UNA)%N2KXFR8&?Y313F
MJ #DXA>4Z@)C0?Q90@+Z'9^:9]DMJX-499,4S")[#S!MV0[A&+F:ZH6;ZJBX
M)5B[E F+F<'"GPH%'XG-E-P3W0AO2MH-A=OCTLFH.7G28*><MR/;O1K62S(L
M"T+3\*(FDD(FRWO4''*)C_08B7['A?C5/U,C0M]HIK\ZD:6K=LG__M=/KL"F
M*[#I<H!-3_.+1%&<9O(<G_6+!R&_7#HE&A,@<@[>K(,;W#U8\QE;<4]">A<!
MOC29T#O55IBP.Y+X-770^NV8)?-#=<4_LF/]56)#G@Y2^B951$^$)-I ]%]@
M4L9'ADPS;.;;DZQGEMR^$+(VC.!73O*C>_]#6IIPS1U->OB=L2,Z%B[+QR1:
MB"L2X&]L:34T]NX?HHKR"F:@*I7AM RS5WC2LS'X<(5$ 1D 3424RHLTN-O%
MU_&#/-!G1$L"XRX 34)_W(^9]FD T)#-Q]Z7"@<G)2AY=_Y+J;R0$MV#S@=,
M]\Q8#_;$">M]& #DW9$CO2^L<''G0,\8N0GM+06J$;2+5S6J8(V,+%+SP,!L
M 9$!#PB3OQ+O1,%H_F)4@8[2V"D\#,]O'RZ._W5Q_A&3WCZLZ*E.G27UIR)<
M(RPZ^XY)=?&>R$*6W@!Z24FL/D!A+*-8O*M6[R@&):-R]>9F[>\JG<>FU\WM
M&!'Z57+U["TEHSY,$;+U^_I E5"R"+P'SI*@R%TP3]5 H<'=[SJW!'72^$42
M%W?+D81L('R(1RC0&,"C%D&*FDR62CS<1HH3_D+'EEN7<S8"IBLEWL$BA@TE
M'#>)4:$2[0(KW8H")Y>=L;4D[[%689U]&3!AD&SH*L)L$3A0!TVC;*>WS4-D
MGZ'T0'4X7<+SQ0.RA.+=S3]X88:1:<Y12/(<TZ$B(SZ0L?(JL0DR&QCOF*-%
MWP;Y6J[> 0P(:QN:=PTDXOV+;+A0MQ9$FO\3ZX1RD1L$ZXXY]762+(H/)/Y2
M*>3%C%?A#V2X TWN] >W ^H0ERE/"XG W-MND>J;;*+(@_X";VA_#X<!-:D[
M8K8Z %<G3.U3G#+#OZA/(; ]T4IH>0:].RB:CQL4A>"?]2?9<H2GU0+,YBA:
M4X"?_Y1!R-CO^S/,>ZE17++R"UO[O=91J"T.NUPC[#[(Y*KYWKK<E>!SV#!Q
MO]_O=VW'FPX'I;_:FKH(M)>JOFWX']S/_N?@O[ XAFB;P7)&<8) %?Y%)_HF
M.J:EX)RO@1GM^-S@_ZBH5N@]Z!W43^AR/9C,V:71:8&7'G%R12I9H,\5=QXI
MZOHMF20AX$@2$)] AWT*V*"9$RCR>:I-TQWXST'GV'46+3#K7X<;?I$$)Q^7
M7UNN@*O>YC.F8C^@,:]OFZ?>B4Q!939J]W-0<K# ?_.=$-LJT?6ZHB+J  \C
MAP*$5G#X)83N\U<TM-E@-327+,:<XR&>5?V=R*8ZTZU*(5-1\\4*MM%G(OE$
MI<0:5,684:V@X_42U2LOW&B3S:Y4'N#I$*+Y1F8U_.)&Q9_4/"V-$?GL$/ U
M[;U 20R5QNWB2R*EJ5M5N="EY?J6&@S4SP!,NJ.DJ&7F3D'8P3XX6H-@VZ'S
MR=UA6ZBH34%U-.581+=^=;Q=9)XULOW[?]!I!"5,+1D^)8,&/.2R5A93I_S!
M_F7X'Z/<EX.8OMUO04N+SZC*3B2II\_H7W7J Z" -<\O4P#D*/8I.W_/W]<X
M>-?NO@JX]2/S*VKG)'FJ#('MID(D6?B%)$ 9_2\?^;PK[SA1\$%T*;,X1,:R
MU\1B?(\XD?GUCSN'M)::  =,')$Z^#>(O=WOVZKVOP)RHB;@F0$S*]<N@I2R
MCR)S:LM4<%(=C]4)+:T^*-+6?HOQ#,DR @O/.;9#?H5-QW 2L7M294**[C;!
M3\ICP<_NJE77+BL:([VO1*-.-;1\,+Z+[!:="WS$%!*SIHJQ1G&DUD-+[&8^
M9"=:"=]7HQ3#)AM$DE2+@I[&NQ$!WDA*H)II.[<^AIITN,\T#\O">B7652T_
M)& VLF9^'O$-3,\<MEA7<9'\CL1;4 D@H")22FTODO9"R%PV$DQ:/=R-BVD,
M?;@C+#P18$F BE.G[>6<52,U[U#$K$)"F+P +.IX'?H1,8-(,EH@7G2;<^?>
M#*7<1%..JA1!@:((]O0 -JWS^!-U:B;H2%$.1/LI574,^D$B9L&YZ5EB%L4)
MQ:N[KGU@_4HK=?&2#NF7UF!]<VVP7ANL+ZW!^EYC]UI].#53/\JT3F0G&>GQ
M4VKM+$V5<^_ !/J\:8=">S'CZX7U)L3!&5JW'RC,3#6_[2,J6T8_:KU8+:0Q
M 84YF4XB"SE.;B7&,=^"BJLEP"#08290*$+UL^WDQ)F<5]GW(L?5,^=TSV.5
M%X[N^C'PDA#++,^\!-5"'TMUI=;9!$$M@WV!5)?UQLR.DK[;*6-BL0-GR,/G
M8Y4@17%JX_&_ZV[(EC)T\\<RR-/W?II6R-:6F1E_:5*P+X7S<N>(8RZ\A+:[
M*QO[1)8,)M+U*D]] -<%'D<:PF&(2%<^!)FQDR*ADBHQ<!=U7%;; #5_H?5\
MDENIW0U_*C1-E;-&(2S@:ZT<IZW^D8/:+/4=6/5"BSVGE1#:SGY@GC!2F228
M-KP(E)FC<#A)%(MP%UW(9D%YW(^"Y <G;LD\%LN[%4ITS*E"/_3$2J39A(%M
MTT,C]AXEHU27AN!+)[.&!1YC[\)LK%_L-J-V?%57?8++FO<"YSD! RHXUW!9
MP5I$QX4KRC1@A>XW4)4O;3JH<S:8'PD<J\%LQL*K\_??I@J84X&:$6'EE*O_
M[-\JIE'&3(F8VC*)@B::DB8G?RY*C-=GVHHI/!@=;2DYQ3AO<N+.B<ZL5CX)
M$^4J^DR_VKKU0((J 4Z=5$ZFW0 #RUG<4?WV#F/YG0[C*ZF&K?4GDX),8S-_
M%@2G'-302<J+60,JP_F2/$MD5M7!@FC4.I8SA,[A[CI9\ *L'0R@BC,:C4?9
MD*T+?.4.&@L!Y54LQ+=W9=5+3YCP,ZY7)H[(G]_R],MUYN0E6$9B#)#$ *T*
ML\\EH+$VD5/WQG'*G9'_D^HW)<CH9/5A5-]_TI^DE5*.#[_*\?:+,.M9NUBR
MIH7H*\PMLP1TT[#GE9T+%V N3UR_)+[)+]X(8V;F!PWLSZ*ZKTMZ.4OZ84)6
M[< CYWY5RWN9/O^7G]>[JE=\08+CU;I@*L'%I1QNW.+K#QV)/*R!W 3S)<7T
M+$Z#[P/F(^0SP(E0J:XN5V[9"H16( -,=:&JE1^.M>^3T]:##L\?8X/G$E;Q
MD7L,$[[CI3(O5*)N+G+%#U;(XQH$4@5:]+)Y1[Q<+'4<ZFH\)(?ER_V6DM+(
MK\5BC4YQ5$8_@2>$B]22:IHB!O3]U0T,G]IX44XLK6_G:$YLZH] N2, 3N^(
M;).39\*;WVS;A^<M35Z T_O(ZWKV=)5M&C#N[N!2PN"2V$X95:&G<!9+A>HU
M<#J$.@IC6.!T'+K811U]V1_EC=91QV-WJ[]^_6TRY@)5\.3[U').?+>H0*HJ
MW$8!X18 "+S0*<CKF+;<1(R3>S+B73,AI'_^ PF#Z>O[6P-:YN\/@59]Y@71
M[?A0)IU9J),;#GT;I2C";NSSP4Y OLN@T.S];G14+!346(3M&%N^YO5 _1$8
MK]]A?:0R/2UE:[&\&J]B1$IAPBN*/#V,+73,9"T-P_;D.[3U\H E'F$0BU-P
M2CKLJ7#8M_Y@J%7+65]0:=%_)S3XCOY9Y%22?KQ@KPQ0[&F @A9ZS15#$]8=
M3X;I7(R^])'P[DBCPF^0=2+!-K<R*8[K16*6/KUBEJZ8I<O!+)UW2)NY,$H^
M9+(L'92(E*)S743NZJOJU8P_2:8AF*1?\N]0"C?Y^,DYC^+Q2HL9H8MP[SAQ
MR8$[9N28P7H8(<\;'H_[27G["YZ02X;@I ,?F^X+H<4D9RGU7GE#_F/^!DDP
MB%0(VI5$M+VK_@'P/$K^@CK/L@TIGJE0<*J_2YW)#:=OF-XCJ*H_-W5BFAO%
M%M^4KGL*@"X9-7L&+B: K.@"$]RT$K%-4;4O#T#[$44IH1H@,[A KH6 9(05
M0%M[M#%P6*?A%UKRVJ>D*4:K&L#R4)A3KL-D?Y@O.(B>1XK@[K03&YNJ= MM
MH[_'+=:( 5HZ_^_^Q:F$B.*T*-\6\#]_A<$TR<X4K+M,N,);R8B#MS:W W(^
M# 1^_LU_?_7%S9L_,T.FOYG[TM\!)K/B: ;H0]?C@A^'27K'87BW2'$5$8-F
M TD@-HR(N\Q_,B%AP:2E06BI--QDXLR:H%RM[J^(/YG)(-8 5\2R0ZTP)"O-
M2,Y7Y;U2F@.&+:$FI;J+4^M25\K#4G:<V C:!I5LJY_;A3==AA6/BJ8Q C:W
MP(&Z!7]Q8VVUE3+.NTKF<XQ6CD4UG5&Z#:"7ZN\L?F#+#F)A/JZ^@S^U[T('
MOH.$99@R/%)-HNDWWI*#.G7V5K'LDT5F-[S8^*7#&$<:-_.J0Z=ZE,:HHNJ\
MG]913!K'MX^Y<SYW6(N&2>,H[X':K8R#K 7W6F-1Z#]CJLD)$:D3'0O[1K#@
MF#&:8-4T;<QI;\(\C80IL7GN]H<4"]1 &#D7$R 8&:L[SRE](5+A)U?:"Y5]
M>%!JE"CA9U%%6-'$%@SS/C/LJBI?..X!6YQ^$> J #%;'5N9&L3C9FQU5NT&
M\/=UW]:#STH!2^$!KPRX+($L"N9ZA! D[,+F&"1JL K)HVCVFXPB"L.'#@<&
M(G@]F#0?3AF/V/^) DXFH,,TSE!1<;=Q6G&0^]*7$XRWZA?T&#[ZPN'9\D?C
M/[/D0D633'S?HL0NUNHS]795X2C1%BR_"REXL+#"Y&W #\:?#4L&RVHP"79O
MHJQ\K#W#-SFJ(6NXZ?]E.:SOW.$:5YU[K]\,S-%IMYL(TO26,L3]3&&TTQ&R
MU./8N*J(*,>3!['JHAD+SA0 3;PF)#7CZ#P)M)D#-YRI#TA+_DEPQ@LT@1-]
M!W^:FRD -TI6,P5-]5.C-?'I7G] Y/>J>KPO>#&KIF+I\K:+(.O)U.ILB,13
M$28T>?4O^B(,[FQ">SZ3(<&P]#F$U#]B%9SCA=BN[=S*5=!+G):K)(L[5:9B
M[N;7]*8OP.+>=VLGHC\\GC+=P*(C0*ON<B7*UH1/2R*G?1VKF_F]3(%;;_12
M !V7Z_3F7EYJGGI3]L,/V^K@;OQ?5NY_[3MW\]"5>_^51?;#DROK7!I/^X12
M*8@>Q^+$+=2K?G5GP24YK7//+>']9"*7N<J%Y4SI,GF&^7>J',7!)9]S[Y4\
M9'G,=86A/GF*1.U__H\W?_SDLX](EG:)IT\2[-,!A&K0:.P; WS4LO''R6&U
M/=4H>1U'S2O>II5MLYBV'=>2T=0<#WO/5>2H&II),PTH<.W\PZRGH] Z:HPR
MX.RD\>O&!UZ2\60M)9T"WU2$!J*//?,\] 6\I"<9RTL#[_S^"MZY@G<N![SS
M7(1#GT<]=NW]Y> FH_B3N=Z"H/1(?,THKK4]-_Q1K;FRWWSXQWG;YTH?:*)2
M'^"P9;+1669)*8.&J":ID&3I; H"@#)MZD[5%PE%053U(^!VIJ\;N;I3BU+C
M X@ZFE;!)!#4]R::">*9X1F;$GRNI3(KH<.Y)S2*#\..E:O70N>:@+<I*E_0
MVR9UA(8_S":*1OMJ"XGJ6,N/&-V(6[I=?&\(,DG8H3N.J*I2Y+)>EIO/0<RA
MY33PGCJV;QOEY61F1+XRVCP,FI@I41O8#D$.G"!/F,L332'1Y53 U;ZF-N%T
M^0.^1BL+HW\7W0#;^-0U"9 88?9*:#49X2]5BXD>@B7:#2(FF\6RJ]9W&7Z9
M,![O6#Q<YD,:%/@A\3WYA="W'PWS8-$%KV<*@B?A$E:(-VW1GI<$),S/:%N[
MQD$V!91B@[ORYWP QO?_='?BN+Z+M8_/XZ#'UX0CZ?HK%_PSQA3?,$B&>R_;
M:B\3ZZERP\9!S 7;-.S.C R20#KB'.Z^/,H W8K&(YA5 S\ !!+C[ZP00T2?
M1GD?91:+(CQSND1962)2"2D2O1WY$^!>_CY!M<Q_PE:/,A9@](C*$RG)H)7F
M+FAZE&(M!0$UA/4-@-Z 7,[@D+,"%B.IC41.)2NJD5&\&.E_+ >?L4A;_#PQ
MC&L(^.$?Y]^3Q2,B\<[LFIMDU^QQX)$1[@CNU[5U(%_O',ZQ9ATEY'W4V'N#
MVUMJSU] +/9-?G\F,+U?X"F*W ,CA!6Y*-&7,'O,QQIMN:Z/%EV6DR#C/6AN
M*ZN*A>!OA[BGH3TB+S;X'\J: L]T\M1\)>LQ-7 W*%]ZH=#OJF7#Z8SQ5&_B
MG-7XSLX*,-C!OH53[G!&I@SR<8G;$ISNIJUK<-=?>=3>BT=-UN)M<ZAN_D.D
MW##/Z1=?#Q"58.OSYP9/$_*JN4#C3@<!S4@3@^91\)9US5.??>MMH>(SJJ7D
M O\KHB@8(.W=#0,O=D,C'4IBH/0?"TQ$^E_@[UR5_58TOMY5I.,.H ZHYH'1
M>/ A=B$?Z)SW#PT9M#^]*GD<<E2$IY9IFL9J2^&3RI(Z=#Z3XG&$M>)R$P_'
M \1'?Q*VP#7[I;OW9[,%]'LGLF,-;X0+$'B0K1)697IVGI:C8D@IR%*QR)]\
M9E\>_O3F,W_>]HR\5@^%>0COD"7.5;%&_P!88GH9?EO[+&+Q5A9;Q@J205 =
MPV2 ,4<(9 "U6]^%@>&3]L8:&(R*XVP6X=-]U=:0@#Q,@<R0[CM )4T^YQ_T
MU]B2NHCNROMXGDRDFVK+<0CZ%WSL<_[8VU5DT/;OFH0!&YFL65(84=V3O9"'
M^8=KXH''5WH@W9G:+?VQP7OW[T.U.)0[U<+CL)H_Z[T=#R^$"%AN,:A21A?1
MATVA_B_O+J-3I!C(->(&.]1CA"!DZ?0?'?LQ^\9B>%WH>V,A*'8H/+A%F05>
M&44&%'8,M;22=^4[G-;R[SB!=[+5RON61.W63F<2 &]<.9S69G8+Y2'ON.C]
M'$_='V*N0&FS\)FRU#;B&E-_DG/I0^<H/I"T@N.#1$JPX^<UJT%_,Q;$Y,;R
M0*/)%9!0QV2)_"XK(\H;DRL8RD]_F=YX[]ZPJ @_=' Y@1#A]OO;1YP<(CA(
M._9A$=)%XAO!FK)D4@3K9/?"U=^]('_WN6;9X=!K9$&_5\.5JI/X I.#285)
M?9_?R=1>@>WZJV*&8"[D(COS]U?H?F:/ _:)8>\O$,@WJ*9=X-*(8/3O<@D*
M82BP/U!-OAC9;1\?@!F^V849H"PN*_SVN:LO'KKJ(!'@NET-V*GR2$SW4>Z<
M,EMC].E];U&<-5A_)M4>;C" TXGG7Z-WI5UIPK*E:]P&D3&\16'=Q:]Q6W[
M?0)7][4>P-\&E_^?Y8-N@*"OW>N,KE6A9?H<G#NSI[EJZU*W1Z7.),(N%WNJ
M3)4K-QQ0%["35P4?&@YBZ3P3$RN X0A)$];%;][\EA%P3P\!2G,HA..(HFXI
MRZSICO$1'J14VM9((9T[:&0#/93'SQ:_^51NCJL'*A_81BH:^I/,#-O,**8"
M^J,H!](]Y85W=85?)';C#U?LQA6[\=*P&YD:O-6&S 6ZU6XY=#U>R/)XLB3A
M7<?OQ76$<+@_*]__C'[S-W^0+],@I/@^;F%(&1"%FG(A^N[^2):C^-=XO+[8
MJ)>#6)^0*2'9MWZ!-1>D=7Z[@IBR_NDM]^O?_/G/?\3!^.]???OV;?%8)9('
M:"5^E*E^,2F=K2TA],!!Y-II0?Z8B>E"R2WFS*.,N9?".O^"N<*.X_3;Q?="
MIS?*D&>JK>4OK:[UUSK:"]MA+W9#?[L]]CZJ\ROT+;OC?O']0 VFQF'S!L5H
MT_A)&2' W,.LN4(V1?+-(*U1W5NN >U0W3;$N],BN@\ZRWM_?N!GN(JN!?(B
M5,>U?/_YMJK7G6O""/[4.2F@C&F-="OYN-8I22]859I!QN[W@A/#Y1%#\EUF
MJ_2+[^68A6?[_.OO"\L\2XVODFF^]_IF8Y]0.5_Z4)3'0:Z+X7,,GP=XOU8U
M7 L5C_!;0]PR[C?&QB[$N80C^--//OU4Q*P)9>;_N&W[/;6QR??VBP?T"ON9
M._='M;_@MMHS&1(:JKQ0]&X<P>*V!*2C:FV\=^'TK(@'AA:=G!5;N2K&<8,C
M_4UZ]TS L1^6WM2H]!%L 8.8O0_25EO\]X-;$BVSK"PI2HO8<=2;DE6].K\+
M]T:ES^';.X*&<A-9X)V@+,UUD6-FKY_WA_ [/83Q[6DK8L<@OAI%;E!F1^K!
M"0\0HU_Q;6_R;8U>IMEI\W$V;]:F;6X2[,P4=&";(]KGJ,AO^<WQ&9-8\=/A
M#2@*TOM30PC%3$HRX&?Y0( H2#Y*[=/^T$6V$N7Y.5J&XPE)#C0IW3T5[4<?
MP__P'F<WU'? U8E"R;1W("#;0(;!M,<3-ESQO:E+")"]]_&@65!&=)+)\A/M
M%&EZ$^W0AYR5NCJ-YQJ1??H.R5@8^0+V(7>N60D#U>]:J\X;0 (=2P" ,\I;
MF.@^R&&<4'E+2=$'&0C#]3,U(=UQU :UAHBKDETFQ[Q/..CY MX["Z8)I?/=
MLKH;R'^F$ZAT$V8;MI!"IO8F$[?Y7.3HT*/J<"^WB[]6I*M(]U.3)P4<N^RX
MR2=_?D@/=R%Y$T@'$Y\):%&[L():3(&4>(NHW1YY1_:VU@ ZP 9%^@G"*/<F
M?HV@Z+,WZTG^@"]9<AIY-0X?MII'0;(3-%ZJSXVYAAFFW<<@8O@NG[H4]=VP
MC&S2 R!@_NWB*V0+^[9GWL.1N9/1Q&EVO2,!Q(2'#$^T1UU\Y?JQ7L3T4>,)
M4[ 7 DENN^-M%0/F&"%73!2L;(P)<Y>\Y3:,58@' +8V8?0G3DMZ928D.8%(
M#-,:C[SOP/4?>789<T"E;VE?^/M/^N.E'47!19,AY&01LMC'$(@-":>J<1 I
M7"" EN/:H!%DH,Y,1IP@CRWIL@*<A:+9YPMW;<?+6M@>B'=I7=6W GH8P:$G
M#1#C73<#)G:R(.F34*\"AG('-TN7ZVE#RRJI*S5<NS/ [0P.^SRP=0CTO"62
MQ*VV5,$2/819OK&-W"Z^<!M1>XZM-Z7Y5\_/D!Y6' 0/L+LAT,0 /N!Q6&B7
MW$!@&Z-R$/EPD3\R96B! 7PC!QQU*5AZ_='[#':Y)+T]0A@=PH?1>;:>0CY'
M-,*49@;I<A[>"3O#!J*YO9C$H0%L!)\ 9_)@Y9_7K6'MZY.]20X%C>]4IL1X
M!ADZH'FSZ3[3_:,# K21TUUD9@CB[@L;HQ\/"IS8",^+Z[\8LJ!Q%/$>-)AG
M3="\91= D 8?J1*!U5HY*$]I"J[+ V'[*4KFJ W9YXJ+]Y!-(4_$1I,FW0GG
MJE)M/XUS4O6K1LSNA>KBR*:G03\TW9YY%.3U,9125>VN;I<X&Y*%]DO:K/M5
MN7?D0KIR7Q%BV$DH$=B8:<,B,SX*X;KU%LW@DZ)0J"F2\-Q6;(K4,,8A'GN+
M  MMZUIM<2#03RSFT76 .,20K[5/FE/%J8 Q#Z/VI6=MDN61?Y<P0WXM!Q8:
MCY)*T@,D( =6!+/V 5.2]HSVA>!798Q+@DJ\U;IZYSCJ\>^%\K:AT<Q0%7;H
M'?;.<4 GVCBR+J*Y1!G;VK%8L+-\]G*LG]JW1? 585B'\[ADL0)!N9#7ZM:5
MT5TRF"$,]*\@E!Z?A%/%=,?G*8MY\R.VU+?PDU_:?JW3)LR5]"*A)?]RA99<
MH267 RTY[^00QTC^ D&UEE<7.M_6;Q',9;VN]Z,T@(<*#0;_5^1DF !_PW/W
M;<-'A]4-$5^A&4T(#Z!M&1#F+"< J=0):PAEUMQ+HC^HB(B-A&.6FF;44E(2
MU^T]V]:_+>YR]<97!W: 1+*,Z1B"\% F!*-Z^#")P^3 +*28Q10IL='1=JGK
MII>#,@+4>3!K-27)%SZP\!+-\2HS?U@;SN)RRS<1/%*^>>G# 4QI(OPX5EG%
M:;%XZH7I"^F@H#%@JT,83$3BJMH.,7O-R@XQ5"(BFR7$)%H/G"SC$R<78YX*
M,:^QY5GW^K:?%(K\*PV)J3_2'DPU9QP[4F:)]9(6F;]1))MA1T_CU4QUD+M[
M*Q?VI=_$JXZ@0D>%"B%<Y+0T3VWI4W;,#K(F9V'CO,+[*N]&<GFZ37\I2J-.
M-"Y"$R Q$TX4=V2RE@I&M#/XLJGGY()%>$O99,R^ -MR8WR$(*H(Z+P#;<SM
MXD>.XU%L#%I# OP%(%KQ&@).:JW\E@I8V,M+E6CHPW7-/5>'M/-PN_CW]H%D
M87@S"Q1*:@^J,9;>?FA+6BTR[0K(6*<=&)7Y2LR5WOA[NRF7[J!X,2HQ[:N.
M7J-_G7Z[^W#=WY0_L'M_EW@9A:C!XAOBV.$[>6*L6PT[46R%1;,;@MTEA>AP
MLP&&SE6H" M7:NE88C1JW:8>GOACF4G"F[G1I<K8I-3I)J;("0]-AV*E_$5[
M-)O25YU$_92!&!"%]YQ/N>/;Q=6)GJ]OS&Q5?3N?9X^S\ZQO].?<4+O<C'T(
M*I*,BMV>^[FD])6GZ+X<2$#>O[N_-735OX)LJ%Y\0;_V;?RU[\+5P^3T7[_X
M]CL-"OJ0P<54WM2(3 "2C%;HLX60! ]9+MLA'<84]_SEEV]]U)7!BNKM2) X
M,NP(90*N,E<_H-\MA)[+KR3B!MR+K CS)Z.FS+&+@R+UZ/L!)^>C%?HYOT14
M@5Z6F/IK%.>6/*P4R.4-N;6>,=.'B.A4(<+JA7/6OBG_KZ@=2P_5_! C*7IS
MEVM'U7X256NY1 &QZY0!*_0[M(B3$&I8PZ.*HX5CI+\.?R9KR(] X2!@PEVE
M)/RA*8V)]E#B5FA[T$@VNX#Z1,/XI8ZGCL?*UN-)TL1TK'='JPBOA9)O4#73
M$QMH_&^&O:[('0HAT-'QSN;W?_S#9Y]^LO ^I:X8!?R'_U][* Q+TR*=T'K]
MEG,8W M< XEF@Z(E@(-@F^B^\</[_TN-E(GXJ+M"1Z.<XBK/6+>$+D8J0F6:
M7G4>]P1@ZD<!$A&(N'?>>ZP!&*!ZE5MKY"XQ#5W*-;T<6'1ZR+#O:+1V.DE
M#VFZ)OC4_RW]2_$W\:8@O.*;P@ W6!MQBF_B=P6AZ)[7X&__(6X)6XV0G7<.
MGB+RT7& 1)\<^SB"NG[ZR9M_1<D1LF31.!KZ0J/=-;^Q>;7D]_PR=QWM!T01
M,!H.3Z*?=+=WM_I/YYG,;VB4XO>?O?G3[;_HWWX;[4B,AP8JR /S[01G_CE!
MP$&'@QB@7+<0R"Q5:-S'16NW0G"%PZ*\;[LP]OP?_FY)>"J<.G%?8Z6^_)M
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M?J','%XCY2M[1W[ J#5^&X8D4*"<?2C;NLEC)V$.7WORI72LDNT O^]N(-3
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MHDU>X9PIX07E@W,U^Q]4RA$$H>[2K*6:,12OG1G4V_<!2BWOWT\V&T=1B-[
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MO9B 2J272 (>0(&?724W$8!W5PDK!CEU,)4%8H$:0Y +S,E=,>&S,U$A8G]
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MKY"'<E]!(8O0/ZC\=CP)]7J<\%D%$X CI?7ALY6$>-)FE8-]W\K*,%%!5D2
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ME'1 KX'&=D.ZCLLS2VHP]+ ^O*G00=0'RA0EMQ_(/CB@ROQ4(P0YV:?S=DS
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MS[_[ _G.N>_>XYE-3S4\E4Y/AG9U 1Y/TNB[<\A(N> 5S5F30=UN$9^0I^;
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MNRE6?VOK\&DB(B7P<)&I[6A9B>)RWE"?U]G^+/?,0ZY6%;Y\X(NY9T$A1VQ
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MDX79,'1?I+<"%:H#N%E6D-.!EZJ$H"D$"2(?RT*Q>M3TG&"M<H+@#@I.=R@
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M7VU26C>]C]"MHSR<T^[)$8AK.-/!90.<==D 739 >[(!'B';!.VG_I_'2.S
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MSGVZ+2+@,RVGPQ13RWO+3%)JJ&91@2D&N7+9K,XH$ ?G29Z<:%_G80;.+KO
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M%0[_Z0XW44AGBGY37\0;$@G6$+&D(D+O$T(P.[G,W%Z.==\//[_VO0]!.@[
MTCMY]R522^_5!*.OA-HBR?H)MKREGH^5<\S%^[<JTU?*XC"CP?<TWI5P191I
M;424/O+&VW.)\H/8Y]N8G$PO!&;[^P:'9#6XEW^8T?_* _AC6*-58//'</(C
M=DX$'@LKB(0$(_SC#^&?GW!LE;=;K'=)D*??!+1?MUQ>VSUY#-(SUAX8O+2V
ME3)[M5E*HQ?S7Y+R9'K)(CUQ"@GV%ER2BURZ@5)+N?26#:2GW$)7-[P-LY =
M\2]OPNE4Q1)U[8]LHD%+B(MI7UC;$Y-6Z=TEPJ)62W-$*[?6*>SL/"SFF9C1
MJ?'7D2NZB/,5C.]ZXMH74:RN_I9D$GCA]$_??/IK]/GJ?'0VNKJZ_(;-AS;0
MCW!-U.Y$#WYR_E0= +(#\4RA6REB56=&H2ULE85DPUR" )-0%@[[PP$+;W9#
M:1HT'DYXQQB;&37,51ZD,3Z&Q1R<+V38^4(Z7\C!^$)VV';SZF$C^>.XO!GT
MB-Y9W4.X?VB0AIEMK/A/6.?,^YGP,MZ 088A<;8+1@-?V".H;-BV^X\_C)OD
M[P_.N;"I.B+:BSEZ<_ZC,ATQT%OB6(':/N9^@1FAK!*PZH-1Z7CD>"3E.")A
M3IB@-4NE\Q\4>:*_X,-/WY1X1-_F6,DUJUPX3_7 Y(4#R1PS"5B5W"YFZ/*4
ML\O>U7>NQ*QD:SF'S7D\)FG/8)6U;-&?3S!!["4SU#M8IGL9F9,W9RX-QED2
M%;EZ"@;6[_7/Z@6H<Q^FQSU$G,K_E[/@UFS"VO2ZWOEIMR]MW)=1=UY:N"\7
MO;/S;E_:MR_#WN"BVY?V[0OPL<MN7]JW+QT?:^>^=/I86_>E/^KVI7W[TO&Q
M=NY+Q\?:N2]GO8ONO+1P7P:]BV&W+SO;%ZJ.+->X?HVW<F]K<%GG2-]V47;*
MT+]Z22XWQ>CJUZ@<:RC'%CAJL/K_)FR@EV.21+A&?_KF[)O'^AY@5!<Z@&?2
M>Q9?/#@_X=33H<'#63N,PJP+PJQ9Q8ZHZHGJ]+%$-3CO]0?'1%2O*>VO,<+9
M+"X/ET%WDJIC*O<QE>%CF0H0R]DQ\11,"&B(H]P70&C;U)^6:DZ/C&KZG0*S
M>ZHYNSHFJOFV(YG-)/,U#JGC(9/O=K!&3Z/M/G 1=JO_5IQ=_36^GQ*K&HP,
MKZHL4*=9'X9FW2(Z+!%6_[%"<'2QZZ/;,/MZ02!%29$%\31#Y!-$KL-T57PP
M E5\W_&T9V;3'Q%K:=N<-^=X'N.<[XO7'^.<=^Y::.&<[\O[.\8Y/T?:?IY\
M>W,NV#'.N:/MYS'G^_*#CG'.+0LF[MRR<$O9$<JX7,K^])/?9(^^5[<J+IH+
M&^.);MO\]V1XM&P9OFU,2NUA8HZ?@>IGW9F.-FZX.Y=%JBAS#Z[QAG[_LM^T
M#=*R+=^76=*R9>@HOT+YH\&@:2VN95N^+Z.E9<MPM)2_></74?Z+X6CP?4?Y
M.S%ICH- !G!/HQ2"ED_+*.2[0PZ<;,R 33)"]$IW8-,\KR,M!LS^DD;N71.=
M_]&4>-OS5)O7\@;^X&S4Q5@:,&:Z4W#(IV#8I)7_/&7!OJ,Q#5/Y(:JEPXO&
M[9;G1<5/$W?9P=9?]:X:-T@.V?IHF3&UT2#Y2YID&?>BS;L(RY-$6/:MPCRE
MMM:^V3>OP%T-+[H@S5,%:?9-/MWA:=KZZ8^Z2,^SB/3L_G@<H.X\Z)]VX9XN
MW+,QW--L0+ +]SR==?7.M&/3'=NZB,\!U\H<F)?O_JDT-J'G&WO9_R9V]-CQ
MQRX*TM%CV^AQ_W4DC6_BOB,3S[I(Y/V:!L^=W7S412''[39Z9'[\N7]VVJ#;
MM(LZM+<TI*/_FJC!F=_OGW9^TRYL\$SI?^"?C1J,.G?TW]ZXP>,HY.*\=]5%
M#5H;-?B+BE4:1&3*!--Y&(=9GE)7CL[9\#6FRS/*#CFZ5)!+?W@Q[,I!NG*0
M9WT*1OY@T)6#=(&0MI2#/(Z*S_S!>8.\_#E2\?[+01YIFYZ?]QIE8/L.NAQ9
M.<C') ?#(ZG)3.K<"%WE1Y>\_A!=[=2_'#1>P=Z=GZ[XHXVSWX&J< G&3A?&
MZ<(XSS6,<^Z?7S7JIN_H_[C".%?#7J-F=!?&>;KBC[]A9?TL3>;:V$KBKORC
M*_]HA5=O\WZN+48;C?S+R_,&R]&>;Y"F(^2]5E5>^/W+40=8U,59#IV0S_W+
M?D?(SS/4<G79:]1[<I"1EK6;VL;@RVI[2?V6US"K<1K"4_^JHEN%,\4W!'%V
MLOJ:P:*^%^Z.^A]UBWA\936'MHA[<_L=TR*V/\!T (O8RBJA0UO$[CAWTKDM
MB]C":-FA+6)WG+OCW(Y%W%OP[Y@6L96!PCTMXG$%)=_E-RKUPGB2S)7W0G(_
MO^_"DEU8\@A1E[KH8D>/;:+'Y\D?NR!A1X_MH<<.E:X]FW@,Y51OXURE*LM%
MIWX6;H#G&S7KLMAKLM@O&BSW;'^$ZOG&F#KB7R7^TP;+_SK&W]Z 3$?[-8R_
MR<9G'?$?6^W2\.JLURAW;&%,XI"+ES@4("& SIMPH-[_IY]S^Y&W-B_2^ESZ
M1EM8=\&'YS'G]A^'QXEO7*C!L/'TEN=%'/N/?NSK0#Q[_O\<R;V%A52__?#K
M4019C@R%[G[DA+&:):G2J4IY\*7AYIEM6Y NP+)7_:U='I='2C#$9SAMLAJX
M"\>T-QS3'96O4O8N_/YIO^N]_BRB-]U1^:JCLAN,B6=/(T<4Z[FZ[)T?>:CG
M:;/<]IO2IDTN,,)B-0N;:[%ZD!MXQ$V).G=Y8UC@_0:3(9YO[&C?A-&N-3G6
MP]+%EKK8TH'&EEH@'9XCL7>1I2ZRU$!DZ3>5>U&2=9&D?30\&H'F,DV*<:1:
MH<Y]^W3-6O8P\]U$E\Y&S:-_=\=GNWY'W?$Y[./319R>4<3I\.N%GK2$O2/D
M@X NZ\#''A?]^2$/0'CM0#;]J\CR<+9TEZ8R5O[%. ^'BZW1S[YZL)?WC966
M&8=D+6IV#0Y^]'Y+<F^N@AAV>59$S0R(5F_%*EP_GO?J5L6%:O#E#UJ.CS?*
MFR51E-QAGUXB(2\KYG #/"_S<O@YY1'"OY/D.H:OIW!'2C\M8 #)-//"> J'
M+U?3ES0/>0S/1=2L";PD6&3JI?[#'?8YC.6&EVL>?(%KXUS%^K"<1&J6OPR*
M/-%?D+;$W\@AY6N<4RO7X#=RXOO][Y!N\U0/3%XX8'K>VALQV.@0G8:W-<]/
MX)DS6&-]%O1G4MQ>CE,5?#ZY@W7Z<9%D(3;Q>IFJ*,C#6U5YIAPQ>K&^-!AG
M253DJC+1?8 E\GW;'_\?8&KF_[^6H7?[TLI]V1QE[/9E/_MRT1N==?O2OGT9
M]"Z[?6GEO@PVQH:Z?=D;'^OVI87[TNEC;=V7?B=?6K@O%YV>W,I]Z?A8._<%
MSLO&#/9N7_:S+\/>J#LON]N7AR=/;797[FT1+NN\Y$\5^MGMDE1"$A.%Z,V/
M3R=SXZ#EF&@EO6R21+A&?_KF[)O'+LUE[VJPUUSPAM?NGRI(O9_CJ9IZ;]1$
MS<<JY<4;#?PUJ]@153U1G3Z:J$!4GQX34;V^">)KU1#AW"<OVS;Y.C+IA%+'
M/^[E'\/'\H_+WMGHF-C'L#\<-"9U-@<+VC;UCFJ^AFKZG:ZR>ZH9'I7^^VU'
M,IM)YFN<3\=#)M_M8(V.2+&M.*SZ:_PW)18T&!D>5)EXIS(?D,K<*#F5Z&/P
M6!EUVN\-=EO-V?#)>A'&7GZ3%%D03S/?4U\F"FY<J!0?'%RK[/NC,B>/@_A;
M.>?G!UAR7YK>,<YYYU9M*^>\.;WL&.=\7^K6,<[Y>?+MS2E'QSCG^])YCG'.
MSY&V[TM#.<8Y[]RR;Q-,YJ!]9=\;C2U33MB@WZ]M\]^3Y7'P$!+-H&F@07)H
M2_'(YI)^_[+!MM-LU[0,BKD=I^L8 %H:.ET'N!2//5VCP:!I[;,[7?76UZ&1
MU(Y.UU&(\>V0H(:C0:,P4-WIVA )/J1U68\=!O<T"KPW:A_)K(BJ*C!ILR@Z
MK83,V0K?1^Q(;ZHFJ0HR-?7&2R]8+-+D2S@/<A4MO6_[O:$';X_")/:])/4&
M_>^\/*E>->P-]%4&-V:)>=FJ/B_;PP0Y;Y+,%T$*O]<]<+3- SUY5K_G(<B-
MGH@7Q@;1YB[(O"G\N_J.OO,.*C7AD4Q@J9(Y/#NX3I6:JSA'B)P@]^Y4JFC,
MD<)+X1WX9EB5V2Q3.:T=/M2N1!C;X<2P:_K)B*5SWXP&/6]=:<F0-L][8GJI
M@@H]B@]3D8M3RC.)8 60R]S\6#XL(WS)+FIYUL:\AZ>:JYHI#H:C:H7.?_]7
MJ1+),#Z$/DK2EUJ7<.8E"25#XH37ZH0+G8(9O/IE$-T%RTR+F:N>R69\:=21
M$2U['RURS_F;DDRJJXFP2LZ:E6"3Y+8R<I+^\IZ"*]F:/%F\!+I$'*<Y?)2)
MG8+:<+:CS:I0W\ANS1\#[R95LS]]\X>/[U[7)J[@WR"LTGD0E9)7Y*MO_OR1
M *R2F?<Z(22JS%!JL VUEI>Z;@6?'&;L=9+E.*'VPXTA%TUB8JTPWHF,6[-L
M]66AX@PN?<X09&<;\W^.M\1R?1K:OFK#+[N-:,5&#+J-:,-&7/1&&[N&=!OQ
M=#!BSQ1.I'4;\5QQ75JV$1?/%IBB91L!6M.@VXA6;$2W#VW8AXO>L.-,;=B(
MSIYKR49T)Z(E&W%?X\!N(W8-W[79U?=TL]YKG>=&KKSS<L?[4FX[@*X'+-93
M(G)M5&_WOA)/"\%%6;N'2S:-8FX]=3O<'7+53J!T N6H89+N6ZMFT;1V6[-W
M6'1QV'I&LWA9QZ9)? 5=C Z;7S2(B'4D0N1K7#0'3 B[P+QZ&L7ROEGO5M6L
M^'OZ:[PANP7#ZI38)^$_#^4VNX"[&EWUSG=;8O^UG&3W^%;[)??CH.=V3')S
MGMI13/*^'+"CF.3.;<5V3/)I06SV1:Y/BF:R+^ZZ6Q.V'9,\_CG>%QD_BDD^
M"UW@N>QDRPSBW0=7]HJ6!,_\>;Z(DJ52IFX52ZBRQH[EOJ>W+ZU]W_-N"%[F
MM)TE^0^#*K@:G3:MRK=K4?:H[A\)G;<4>N)A=#[P^Y<735L![5J6_5D*QT'H
MP]81^K;$_6)P-FH6H6@_4KIMQ'W8-''::QBV:C\:^3TF215UJ-W1@ ]Y,OE\
M,B84($1G4'$68"ZV!F/H3/[6NO]U7.Y O/I-ZT_]T:&Y_-LF3?80 VB29I_
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M7E^GH,[F^.K<R/D:Y?-RT#NUE@#.J1F>B;L5%41EURGLS*8Q#$][EYO'D-T
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MC+02_B:-[W</3-^4.-W7K7H4IK:M. 'KZ/Q1GEK&I3NUCVS%?-L?CJV0CK;
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MD34T?F5B&KDHS$T9VP!AAIWGH-/S4R7PGWU *^Y*5^[]&:T[>/#R9X[18XU
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MOK%N6LJDK/NVM^A7NG]0K/&[&"0$"AU7/&K)+XI[H=*N!&:N]?("H*\45_P
MTKUL\$G'R[F%CMR4E#;:5S76#/H2"%M]\;#B!RBG%]&G(S.RNU\.!(OV%SE\
M,O))RIN^S_3CET?8;'.&]S<:NT<Y56AQI3S?F%:OD4W\P*CBPID0TXD]WZ#"
MML^.:W-Z.C9O(9)Z[U'%6Y?09X)6[E H#0HSQT?IM4)/%OU>19Q^3 W=;=\Z
MSP7Z)&. 2"5NBRYVJ$3/F1;-Y7XR:NNS1_QNV.E(:X6^;J5>S90Y9+HAY[S
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M"Z;4&VF+&PH*I<KB(Y7%A1!2JBL^S-[Z#5WA:K*U5<E^3A+TH-K(K>I.P&R
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M>;Y8FKJ6-\+>0V[K3L5#*@N*D;CAH&C4%\4"F=M$<@LZ\K,$AF4I@GJ?B1S
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M_ @^##Y\(C[\(>W@<?OP"9/J 0O-*?,M'97(,;1R#$7>#[W248D<0RO'4&1
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MM:PZ7Q*]K50MKR/[Y?$QK3N%LJRBQT*YTTF/PJI%OO@A<V)28C/G4KD<(W
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M=;><R@WJGCD8CX++]@WO78\K^*X;O,6O],=^^W5:'(B:C(N;BMS4L+=P&WQ
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M.L=ELSS-,]H&&?9H,.$XN$1!Q;WA."E' 9O@>4KM97.:P%,;"JK*4CE!UVG
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M]VO)YH;CG-IZJ"Y'Y]>+ZJ2EJT-_D@<J1)8LM9\TV22;XIN<.<FF^'B&=)!
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M,NY98%;']))0ST T%Z^A HT?"'>"#0BBNY,Z+TQ_*KJ/4.L$4 )J TS!;K8
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M(H:C%>0Z[SK0"F8Q>*TB@&^]JR"I;ZT<*7H@ A0J_MJJ=<(0!=1"Z3QQ/_X
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M5_]>AY*+G'FXG!"(T<2N+QQBQ7%(! E7B\$RBJ.BG%<U%K8,6BF@-(Q!$+E
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MB3,5MK%LGKONWBSXA3BJ^YEBB\K=7O+3YIZP+*8?4V?KFNSSAA3U=D,JN+_
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M/TJO<"*AMJ(&S@,&_GFWN-VZH8^RW\U1I'HU%=%B%"1L;$:_VRG06R?!KC"
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M S[.=8IO2.W&:%:5 +V(I;*9N#E6&B,25\Z+)H(Q,OQTK)^.]=.Q_FUS]S/
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M:*E^:8HL8$#Y4F.+:U3+=#JT9=CP;*;&8]JBW&X@K4Q2D"(CIQEJ[]7*6*1
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M0YU%)Q&-QQJ\MI0:.'.1I(+QR.<=#D1PV$4$$,[\3G_S&GQ6U<R  H")!_
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M(Q2ZM(LL92(.[>33RJG?RDY^54C;M3(N)Z._+4O?^>SJX1C\(SGVC#*7M0T
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MT/ *Z.C^;]=^E=U>:).S7)]VFH(T%,BYN6T.F^,T4O)LG(ZPW,L!<10T."S
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M]->=.GFJ"\S73 =[0QI<^)K0FU#Y(!"@V8@^Q 4UGP,(0\;8U$V/B'QK)N0
MN4'\@1NT2VJ=&J89LLT-LLW?$L&EYZAZNNN.N>2,,W:_A!A"U)\3]7\W-#<4
M@7=@.5P)*F\9]3\4+%]"+#<.@V]-&I\3H5?M8XR&:3W/8UFJK45'%D"W.R#L
M4)-&2W+ V5C@V@>^POQIWUZXZGRFDYQPJ0LI+V2.3I3YJ\9>F;^F+4</6WO
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M4;9:>2T^X=OQHEI89H5^%OCC*6DJ1EZF3"]Q>V+@'X?J[URJ[Z<SQ<=+5&^
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M;DOI%=N)#[3R1$^FMR!*==0FNN;#1E+QXYG2OMA^4J:R#O4>5(L>7UNXM4E
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M,?J*:VOM8=&UF%Z*I\0F)$HF$4ERQS,^KFG*S]$D$3]1MQMUN3^9\5!@06Z
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M.RPTBI.QU_>3BZ<BJ=2;]\9OVQ: 2&#N08/?CCS[TD,&9L:Y)%@HKNY77 V
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M\0?TI:%+"@^#P1-Y\4>W!%O(-N[,]5Q_[(B;LYF+?! _%H!^(S\+.>S+!0\
MB.N\R,4Q\[[$M#Z7>@$&:0[A U>A*!F*8^BZN<+X0W$]B#@;^U06=*HM_+(=
M>)[X*T94=_O") /]_^TNA&-L7N0_Z.OXCCHQ@6_%L8X=BIY",(CH4)@B\)],
M ^YM%[  */;B6O!L7BQ AC)NZ0?Y5.BB#:>>L FB0KN=&@!1-*1D^#3)]_40
M*(,H#<*Q+[B"F"%J[Q8=0KDU0J%-;)I!Z$S4.0[,F#9T6O07239&9/;CF.!
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M+[D/J'7('\J]<JZ0>V:+&S6CJ2+^(?XA_B'^'03_J@2 Z )N!L!RNX (@ B
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MF=.8%U%>UNK :K:]4"[EO BYB2&]74[ZDUBK"O>]1$RRNUVPT [<L5PSG(O
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MD&"S1,IG/)V]4(=,GN<BQ:*6-.DGE25CZ38>HHN$U07#T]X=XMC7*:+Y?'L
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MNB 0L+! ->J9WX7C[; $HKE6BR@+UZH&C+9[P3 YL>J]?;W>3RQ8MR>8-4Z
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MS'[@MLT\'\>_1(XO"*_$(P"W$WC);V!SDK])&0A+*/*1#45X[VNJ8.%4QK$
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M2/7@A_GA/4"6"4]:1Y9OH2LBS)8@77L ]VX3@UU/X 2(N*TUZ)T_![D['(:
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M60%R!NK=.KF/&^42&'I*>#%^>%4][A__!499(<'>@V@;P&$U.'*/"$>_[%P
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M-J$VG\5K@002@K4WM++%[V?V<3.<(+@-:B$UY_3)#P:B_OZ)/:KD/<"QV*&
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MQVQ^UIA?7Q![O69;V:%ZN-8S1F-161+K$.\:NP<\NL:ZJSED;W[T.^-ZSN;
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M%I(*ERL7%O0>3'MY>Y7&ZDD<Q-_&,3KH\XS02IK;WA'J#+2(83H.ULP4.YP
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MM&-O[1#73M4Y-;MR'N>CJ&P&8$T+D#3ZK5<'^]Y:C:N][F1/R<@<FSYY3 ^
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M*W^*D\!?B.E[ -6'$65Z-I+ ^D,)0I, JS<_6IRE#I>E9T!!/&T19!J:?W9
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M_:8XZ;RPR&JCBX9"=_5K=8593$JCJ:<=$/%H<>BM-2:C%Q2\B.I&'EW8M^M
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MI.[!NY5IGB2!V"\<\A5FJGQ:2S9P!OJ?'[4T1UH>./,<\XG;7 $8H[^A%Z\
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M)A:MG/*#(?UM_O.RNS)@_A!;:,LSAI5%*2Y X>6.#P'1ZEP]!WN VL,B$QL
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MOD)!<S_QY565>U_W?'@GUDVMIXQ'>V?Z]?VIRD,@X;GU19B= U=T; X"H(L
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M54Y9\LMYT+(5KF<&7%-08Y+2-9VT3FX?M,_:N(WA/E.+ - WC][N+8^T)K2
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M(^%\4O,ES(WM3<%),5=+W OL"/B4"?R4]K34OO3Q/1\S,;\7=21 [%SYQ97
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M6M#_[_<(_U?^5_X3D4+^_"]02P,$%     @ TC1J5 ?SD6TA>P  7Z0  !@
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MQI+87UQ&1O+='DL!-1<5\[2?>1K,)8 9.COGHM^'G7-_HJ05PL38X';6K42
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MA9?,,#Q@D)JR?.7INV\8]3#L@61HY:F^HW3&PUU-3>JW)OE+[/LFI@'E53
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M&N>>,.!IJ;WBI"Y$"8HQO*G+$-B0::/J^;I?@D-=G6&@O" CC?0A_PD3Z>Z
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M@DM58E:]U'1#C9U+Q$-272BRO-(BB!/+5W7@'%W#1N:P?)$6UN5GDC##LJQ
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M 2X1(0$N/CXQ&?U[XG>TI/CXE.Q4M!\865A8B-YS\G(P\= SLS ],8%"0$!
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M^E1P_\FNA+QV='8)CE/M]%1Z )IDF]\UHM7PXUP:@ZPQ3#WIC[I]-"4[V7Q
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M-KGMB&7ZV;FT%')ME"._)57S #SZ23_YLO,6=YS<#&#-\\;?VF4S,<=RX'N
MB]28/Y*CXNC_P3:@.([D%<B0&W[D.?JHJ) AM!IA6MV>&8Q?/7P_SG(M'?%
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MTK'"TUEP^32H"X8[V")$QR Q2HH^Q91U[VWD;.<%V_)7IH@_Q+K^+1>89D'
MIU=9A%$Y;<:LF4XV10U[ [0@V$DZ2,0BJUL0D)5CZH0K73U=<2-NF3:X'T$_
MDJ+NT91B:DS>'CMQW'Z!AF-(R=@8;G^HG/M?^ID(IG_[F;F6XH]H^Z<H.X0=
M6F@W]3J$.KMH(#:NA&>A6=N=J^+H% 5?=IU?,=7_FDLZX7W-S"F=8Q#8X/P
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M'\18RB74KI2K\R,*8_]'0N^?-G+BU'\ 4$L#!!0    ( -(T:E16$3Y;I<0
M )79   8    :6UR>"TR,#(Q,3(S,7@Q,&LP,3 N:G!GW+L%5%S?DC?:> @6
MW"5((&APMQ!HG !!&PDA:-,0W )-(+A#\. >: CN[N[NKHV[-"__>^=[,W/?
MS/>^[ZTU][UYNU>MTZMKG^KZG:I=M:7.T^S3*N"%HIR"'  )&0! ^O,!/"T
M9 #/T-$QT-&>86!@8&(^>XY-A(.-A85-3D"(1T1-04M#34%%1<?(R4Q'S\Y
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M)\^8@GVNM0=[.M2HLYOBV'&AEJ=?^]BF54*-@X[,;V*E)OC$D;TT%:J4V!8
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MY09E3F,%J0R ,-\/%U!G+YVC,0,V)N@F;$O@Q9#Y]2.W#'_[>@5=UK 38?Y
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M12Q7U>T2XZ083(MSD/R!Q&&N*JFQ>@PMQ#UB00R^[SAQM$IA/+,J^.BUU?L
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M3Y D7H<+TW?+%IC\:YR3?/1C@<FNFI&LM4+F?OU1)NK\_MS"PH(L*Z- #%\
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MXH4<&-YV#+R3<F]%C?$\ U?5!$G;4;$Z,+S//B'+0%_2;_.TN;KF9O]=V\&
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MA)BJ_Z.GG&2<U:6[*\/"N^M^MO;,&_]U2SR1H-AYW?=/ &F0MB3Q)4L0Z;3
M-=8!.7?-)5$:C:5UI1HHJXZ:;5W KP"N8 Y^K7:RB(W]!&@4*BD7)OB@$SXU
M%B#SNI?_1]9&75:,)VY6"*O<_]P9Y.7?*] A328#]-EBIR5>[NIKBBGP&JDV
MVM20 ^YK%#?X\4+J*^_]XV!-OUS,!\,DHQ[9=,?^#J]%#MR:<VH1?$G2.GE,
MEK[F _GKS4/!_E/#'E'G0HEFB/'4BC:PVA#_^$)G9'NG2]N8.T7W.Y<+SZJW
ML_5,#X*IXB/.$^ GQHD:1<T-A43)W9NK@5_B\R%GCX+K \=8OZPZ[-PY4O(?
M4)\ X:[ZDL%.J<Z\)BX1JY\[5]@B;S"WR^.$@4Y6Y%V'X#\#"NV?OEGM2,-R
M6IV^UO7F"= S=$K^@L%KQ46\)=7T9J7'3YG'RD,SH*F;*='AY14-[*$H^&3D
M.S\>L0'_0(.L5<MU#5>?XR*G]^DU;$T!E.Q)KFC[4+986G#@<1UZ_!W;+,7^
MEN,CQL<'T4<5IWK!]H;"]H&B)2PSR;-N*EX$<\8C>*P2@J$Z"OD:BN6L_'@M
MUG ?NUQ9$.=:R2=5Z!P]LK?\_ 213-25+\L8^@3@8'[<H!T)698?9UJ@8.7*
M"GON3!P*.;*, ?U5N6F&M42J-/D!MN5?.7=TZ@N5J.K;7\&J3/D]DC_ \2,P
M:\?#&QA].^,J^\&"Y;#/7LVQC=\8!]Q,7$O*&4.?><L)3X0_]#"<EJ1W0 ES
MP[.K9G0&(S/JI<^Y[OM%'H%;1CF[Y2^![_L[4/&C9-U70B4HNT2:CKZ'$G7$
M5^V6(HXSK_8N8%/R(PI)M4('A*.PHY?UWYA]96.8*>-&-_$/K15/TK'=RO^,
MFAH8=LBQI3$A2!)-S:%N=WGI8($/_G9!JRSD;%B=D2"L"&_3"Z_*3"/%[XR3
M4(/CCT<DF?R'&>[/E)__QG=,+-DHE)-:0:\DX4;-60T*[?_UPM'E7;\BZ^&N
MF-I&DV3'%FR#UKJYY^Z'&/-]3\T$S-T\LP2\S-[X0G1(XOQ,OS7_XQ/ )Z)%
M4^<KQVK*,4$O9YZY;X>PU4)\[(RMQR,TU1,],M-JGK@FVL2FS.\ZO4BR3ES%
M2?"Y/H=>7*ZF%_YV/;"]X3Y.CU\TIU)S)(YL^0D0O"NI?U@L0>/FT(-6/#00
MN5[KL)*O-EZ?S$:N];,^F=5>%N3%TS[ELC 'ZA1G"-:Y?5ZVE<==9K\7XDR<
M.L"FDJ^[&*9F8<=RX1;7DEA,^00(1%"UH#Y^!]4A1%U>WSD]LN5G%2K $G]J
M+IY!C->TX/65R8;S2RQ/@'B-\,@;FL"+$O,!G9D')L_-[!&;?H?I"92REE7F
MVY#KN\Q?N_7>-=:08WB,&8+ S4PBXY*X$MR47YB2._T*(T#,TZ3T1_5/+*7S
MUO#(_IW'V$>1&4,CIO469",WMZJM0G"X&-6MWW$7XDHR\9'-M<WXA2Z?AWD-
M-UW4[R7AO=T2:.G.P;N]5W49^"EJ\<""OV8!UO]QN#* AHM!2 .S!%Q2S"9S
M#'S<=;\A7EU?$*N'QI836K%5*'6FL4\T"J+;4@[5F23"1Q^&CKPPZDH9I[_J
MP&ZR-D%'SL'#!.,K0I(&#MU)6984I6'."I_/R;]!9D@U-K\AF$>AK%<<*.UW
M%H&0]OFW%)_>7./R'-]<T;37B_<;V?0L%VY&"H])D.X+_BK?=\1BB:1_@R(/
M_3,@&R:^8JS!^3^$$M=&00>4_!K3._+W##F(PWX-&ZHPJ+)$L-!_<^D@D&L.
MRL ;S\D*&?S]*\%#.]T[U_80MH.!\)## 66%SN*R?;@QRS+RG?8V"TN_&#Q2
MN]]\ KQE&ZDJ10.G43LZO!A"M:#?GDU/6(PH0KB7NF2$A5',\^=27_+&L53T
M?A4^Y3GKS&W^37&TDO]3<IKE&G%]?C=3I+NBOZ\=[&PAHH(55I396R+898P+
M=^;W;&(RK6K<3.S!'W@"=*9[G ]1&DQ]I2[J3:%VJ5X(51#"06#\64=S:Z]1
MA)PL^K^6G@?1W,M:6-9/Y37E]7B9W\JM_7C<M-T'PBQG1+7'4O*_9(6\_J>\
MD*!#OG%,0OV\4T^O+_SMFAM#L<+C<:G)[55)NM9DQCA?0^A];%#FVQYJM0R:
MS5,C4E0=!.^I-AD"L:\RO/1.7C*#"GIW8/U&Y5P\.E4!)%OGV99&D-(YL^T9
M/I#?.9>L?,[@/(]76@B_+(74U 2,+XMZNDVSF!H6A+P!%#@-"2PH3&265:I$
M==:BU%TR+UX6.?.S"K>\;*<J8/G+KO^XB D[K?'-FH$L7_41\[-TNZTJ8YRD
M0V5N=%!65XC4UL(_+"R1DO TSVV8#$(FOE ''<.--HP,3P4[L/ 1RY7*Z"]M
M?^ ^HCP!_MPA^SK_2+X[!W+,,/%78=F8'P- ZULOPW2JD>M)1Z?Y]EBE4L)@
M]4$SLIKN?>DJ5 9N%*P[S,DY.,ZSK?.<)2LGX]^KUGTJUT ;6"E<"D(WKGM.
MN^XX\:#V.R_6ME=ESF#+^^5-5_&+W7FGVCKGQX<0]W"UD\BKR%V)JA$WRC8,
MD/.D,Q%;_LM;PLR?D8\)M]/  #[12!*W[\5GHL!8_LFE7N:9R33)1ZVC$VGB
M2OR_%TE]D"4#X/K66W"9T<@?F1(/WZ9U9(>_##<-)\8':&G]X;6GRA+WV_[C
MF&?(Z@V+R(P+>,9 %W+Z!*"^^3]X>^NHN+XM7;0("1(@!'<)D$""!0]:$(('
ME\()$JQP*!R*H,&* $&#NQ8AN =WEPKNKH5K\?AUOSY]3O=YW>_>U_?]L<;8
M>XRJY>N;WUQ3-N/-BQ_JXZ; 3Z8W?T+$Y$2[;YA/RXSS%(B=VX[ZPI#U<9^-
MOTGLX!D(U@IG69 P>0RWEY$WM2KBJR9PHX7K:!__AJ*)-<=M\RVA.(Y.FTD1
MXC46I,=T_%/B'OJT26?J46--]FVZUY<A$L%;WSB(+IP+]E9;1LYNP?(C1M2N
M9NJQESH-4L1:&)G_*%6H3[IM[9E.WLEFJQUT_T1G&L$$KG(2RRPWL51^UKVV
M*2%(-]SS"?)0#JG$N0>0@Y7&9#=$9P_@>C$/:F4%;5O69-FAB.E*ZE&F1:TC
M2:/%)5'-97I74YGX*'LC,*?3U(:G)HFIFQOH"MS,A0#GN@<3H82&4J7"2E5C
M):85%4$FP5Q^V2UU9V)GUF&LW_]3>AW6)"0TD+U1SMS@46>!-!#"+W0/^+60
M?052E'K7VSF/G3.9M%2/40-=VO>9TH"(HPSFZPXPH04[^)>(>ET#22\KDLE&
M?]G/*ENKF1BURJ&&9&35,KJ547>OYJ&^Q#Z7W= "E)%\_Z7Q"O"5ZPC<:.U;
M0C73J5U)2Y3J)>+#6"$MI.Z[7F"=SDZEJI0SU?\?[(S6%*FG(U@UFF6'?[C1
MO99]E=Y7V4QN:=(O[:.F>7>W.3>L2KY]E9+>UW@!2E8F<I\RIB(Z+\[$E1EU
MKO0-X#ODGT+.Z';:/]V',6%ECZ!],> 3[6%);%_X$<W^((2Z6O\9M5"9GVGW
ML> K;<,,UF#9\0I05Q6G Z)#E@Y)3V)??K\'*',!KW? B[:;L(T%P17;T9[,
MB6M_;M9^7]9M$]9==E5,HM?!RD7'^<?,Q_ ?R]4Y]HW,U!S3,:,#S A[S;MG
MP*?;Q8>M'[O2&YB)'E"&-?'//ZQPE^\KL(4*HC/0-I%->AQV3-<(1?MRA8!;
M"X3G;R> HB)_?ABCOO@]Z&X1M&?4(?:V6B\J?>#[G)*RP[/5JQ3\KGH6IC+F
MD;[B&98SZ*,M2<FCM?<?9B'.H7EGCT^-?D-UMPNR?L8ZN9F'ZF@_M"?YSS*1
M"=X#*"P9C8Y.CQ@"G)^??!*]>+;X=:5Q?'FHTJ6,D#TGYRNG(Q'Z]#T@\$&L
M7"*J$ &7"&5;LBXR,9D>^,H&H;#9YNDG<%;XAA)N5U:%FDRCJD:E%[+(<LJM
M/VJQ#2Z^)[OFZU%<-309Z?_W6EHM9YC0:,7HRCB#C9R[7"S-!S#BY!U=JEO5
MLJ'8!)TZ,G(FDZUZ3:]+M-OHUCUY)M >*"D$'Q6*"O)\/BM6PWWLC-?L!?5H
MR=\T_*%S39M<+QUB\:GEN(N^]&!>[O9$EX3DY>"KOD /S8=&"UC^F<NIM,J.
MIM\;:2Q1K#)T)&FJ0%"C#H,>H?_KQ^>#J%Y!H_[H2U S(M4;--:1[)-6$+ 9
M=)L W*MA/&8\*RV0'ZMQ?E.TLVF?O:.Z<RV:ETG>-DSN[4F[>B1(XMEX#UA6
MRK(8A5=>V/RP<J._!WR^0GU"0;9(B*+8DCDX=I:EB#6(_T_>%)"DP_7OHB0F
M."1MN?1Z?E_3Y)-DZE_ C/J/M H6RFUO_^#O:I)X,+VVC.*\=+3D\/YL,\!-
M'[D.5'D+U"IS+&.X5$I"/CE9/9A9/7%$D>Q6P5_<;+B ZA_.T$;IBEZ#J ^O
M%QZE[?NEF;O",*7H((-9Z%?8V9?"T5%]5.R*1=-DNMP$;W\D_ZW49HXS=WTO
MK8/\KYAG^*H&& _=4\$2?<TM:HEF6<*,)*H $\Q:C<\IY@U3B^G;\'"L:_6<
M_K9#Q=5]8T&S+$I .,W<)?16QF\.I9I V:+F7P_I;_[LWM7ZA:DNCB-%T6F^
M6U]OZ<G>E8/D[7\VE_4-N__)X5D&WIN_=C5G**G);FL"9T150T[_U1(J$,%U
M%+-6>I!OE4;)^QW?018X ');Z>EH)IS4B+@'9-7=!H,'FDGE*CIC.'SOBJ-N
M/11=)'45R?OE0],&I8A!@C\?M&YTIB60:+'[HL08#E--..\#!6/+N)I%=J,C
M>2?T_BCFUHUJ."N3-)K+Y<JNTNC\ 0")#%6+;C4G.- 4N<>$->\!:3&IAU<N
M=*7.4Z0SFY%5G_T5"O.[N15>OV0PTG>Y1INJUJ I8\>=U_PEZC_;J>N;7>@3
M\I'3B^&$L0/H1G[&YGY;D3Q7,HC_X=<1*B7>%>PGZ ;TE#[CRZWUG%*K.N4%
M[3BE$QP,U@1P:%!3S#/<8O?>H<'UEMD3O?;E+V&FD0SJ*"33/6"+H<J73>X>
M0$C%A!E</R3V=7%5ILVR;0LT9AI?W^4;!NRJUE4U5]8-R5!5=-(D+SJ@-\/7
M73WP-BV9,=2945X6CDM#)GTRJG[O1F+0G8+\?:B_T?U92G7LX)"3';=FQNN/
M8F-9S'%)" U,8S6Y(3K%W(\T[..7A01&BH>SGUMLC9.[=5$?_B+:]I-'V.M6
MVXP4WSC1TM]U%?Y+>%G:D[]%?_&($ZEJ\*7JXA')_5"MU:%EJ5XW!93WHW7Y
M5EXTQD&TV4G'0,&R:=)UCVW>8Z$I>S^(!#\.5;F'EA+H'V"=8I4WB:8 #=R/
M8I_^PI'DB<DDPN:;:'P';AF!?$;PZOG(,5C&V_Z1IH\.9IW=UJ_IU YP-\3F
MZC.  TF,=4==DQGRRC^G![N9K[8BN[I?+5B$'PTMWP,R0::&CD<Q^MLS*1^.
M*K)-=UKNK$]MVZ?B-*U^YAT2FQBX%RN/0SA_[GS>2ZT+DY,Y6*/-#*'[TFDC
M*2) @/TI[F7$J=DGB5LIE:E3/7:HDI=P1U^::O>"]!E&HY%*Y=0M45$EU[PB
MA@=,.S$PSL=Q? =/XP5%*4UB+C/-N>A!V+$HZPH\T[Z*3UC[(+8Q^C;JR@68
MZR:D#'.AT0^$'4ER/:B$(+H7MSRMMW@?"Y6$,XNB+62DZ%_XT?OCL9MK3U-+
M$<EV/\THOV7]W2A(=MX2:>,]HC?4<&(D>J20OFZX# ?&95ASCMM6ACP0-K[5
M13S3Q55A]:@ZW,A[ &SU&B%%\^*5J;H.DU?07T#PK\+TD[7O*]+Z'U:>KNG.
MA3M8_G(F?D4E\I[VKO2/O)Y56C6SP Y6-OH.NE;:U6I"AL$ZYS';=VN?9(W3
MWFV+4YUJ<225R17I;9,16)U\Y<-Q%I;[]H'Z$4G3D)>GUI!,*7\)66VE)I<'
MU^3"P'3?"^W'69N,QB8=-F<]Z,!(O9XA'MDG6=^^"24/-4R.(?3'*]N)> Q+
M2J@)@OZ@;>XF \;^8LPE0/+I\$.L'8?H&'HKLIV6MRC-.LW#;W+&#H%FO!^Q
M;O'>-?!V3$Y&O;C4<UN[+%P:[G>T::?=D:";:DIN]CR"%Y.&K%")OE\VL\S"
M:Y3F[GXC<\+0Q(DBK7Z8)#'$/>!B'WI9M%6FI 22[?H^%IDT!HZOSXF_!UB.
M'@2"''&_YE!E?X>ZP+I'PM9LQ%B8>*K@#?D*8!$;S1G.1/2#_.CKR;)+W1FZ
MVQNC>\!BU3U@I3@&&?551'#E7>=@5=,:91@N-B4?#OVI#5W/6)! Y;=UOD:=
MG6OSAMQ=@L.?3<%03:VKD$EEADK6#0U7F/C6 *PQ6-T?2+G#6_95%Y541;MD
M^![HOV3V4+ED^J:2ML6Y=IS=9IVJ/G\<4E*VL<VH^V5$R.6/3>4!)R"!063N
M6>DM UCA:_X#(A+;D/O&!6:R'$1JQ/Y)^981(XX>HVAQ#["WO ><DOSZR^WY
M'D!9XW8/H'6^!R#X49JK*.RCLX2OG!Q93=Q!87R?C_\\D^O.++%XE:Q0V!G>
MJ9&K15S8*<!ZN.:Y7IUMZMYI:\^^:3PA0V_CJU$C%!3WHTA_OA6GY<TO6>+T
M/'#?K5Z&U#)5/U43Q\YG"S:0\Z,^$/6:*0SLW$DF]'(@6;2KG.1BYF4-2,)&
M@Z47,^5F[#Q*XT*:;H:$,,6".)<*,JX^8EF"!^ZL]PTH:+5PCSV(DPR1>J)!
M*".R665:TS$HRB'.+P U9WYD\TRF@$3)49<?,M%MO-W;Y2R779-5&*G6?\-Y
MH["/?2Z:9O$CC0OE!7K)W-&/]IIK^\))K[ U >#[?6ZEYO-DYTBNG8?NIBU;
M>2N1 FN)8T8_#S5 5*Z <:+D<[57XB'[ A;JMIC^38OZB!9_:>$,F!9K@I-M
M;9%([]VV?SZUOS#E^NW+<]6C&VV!+'7;C9I$AJX]6\.D53X.SVERC:[C297(
M9$<[5$C6K,&LH;1956V8"^:3;(=VL202/L=FZHE36\8V,K=S+L.[,(I02(*5
M4[?E*K5IM&+ZBE)\_&BOO:TS;P2VY1&:^#,QTQ3U3:V)@M5"Z:>:9K'6]X"C
M;BLI$W>WCG-#1G_I&A!,NWQ#ZA4WST@$A"2U^/)">;Q,=V@!N\Q",N3YER#1
M+J]D;V35@272A5%1T^E"9TI5FY8.:9>^0NJ>B8_7AUO)?=9=<%9Z;94'C[32
M#-(^:?W+U/9QY'\Y&"@5.69_I%0@RH!W]99O5,NUQ?9\&-^:_[(W9D8*?=&J
M4\,@)S&WR"+IEMD&?+&=5IV!4@)V-;DV2BY7_:E!1M:7_ZX-7;EUK(5N\>V?
MP5]X;;CX/H<3:49IQJYX1C)XR5J@NJ^2=UY%RU_- ]0$AU@;BHRFM5IFH3,W
M>OM0BQO^_6XJ ;LN4>>%GWK)33 >PY$JELI(9X,I/BP[3B+YY 6L_4PN&<+H
M>)$8N7<T.[#BS_P_\K<<]7+W]ZX[OG+.VU7+.58SK+SM\ M3<B=?,FDB4RD/
M4!^'L]E)6'(P6N8\=9"/#ABV]C^1^CG!6SD.SSAA'^'XK1VLU@()>"9!FY7:
M:>H7;*#>7D,942TD,F-0=FYVXA/O-9'H48 &^H K>X!O%Y=OOSQ(.=L^)321
MG-M9NJUMX:,RQV5%41V#Q6REQ4SEN%"OR-DN9!?+5O$A5M'QC8<]W\0@SW?4
M@78*9Y5&]9%8"!A"/-K*!2,[>5'M%6)I:K-&$I&:C9E/K5ZKO0YIT^KN?BF'
MN7^>$A"U'%P%^E")$/%8(:_"YP=;9E4QS,GW!875#(@S,IE&%<+]-]N%;.=T
MOSMUOS"0UHA?)22(5VQPW+Z0T@_X6%T]<<B'-1G4^2="7H$02_S]DNN.E9'R
M;@_EQ,FNU4M%1KDJ'GGDS&7.[ >#_K>1!FV%S+%?NOFR<RS/#5E_:+=,?1S7
MEX+R5<HSNY#VA#PE?DW.?&BQ4"]U-)1<\)4Q%ML7@G;3CJJ-D;LV2WN#)]DZ
M(YWMQ3X7/2?%='G2V=3?4;%DNOE4W.Y=U@-"S0DTIT]M"GN=L[\7)5)4*)7L
MH->38^@D+@IUR/0/_>P-"_FRX]%ITO-KUMVTBQ\/1T_"WM%V7?<N8^#%_,]O
MY-=ICK-\BXN7"K(M>N+&\=.EC,<97G+)I!]0&QI1"5\ZQ47PLYC<HF5P>VE6
M&(;"A9?[ODE2IS=%]T-XQU]F9V>%O9'GNM5"&06>:0T!1\U0FAMT.*;S*PC[
M ]VZ.PV0&Y)V3_>2>YLGN-8LT)>9^12CSCXPOK.L2KC1(3I'_$Z.^>KI5O#W
M'USQ582B6EEU.C,+4M71C(E1T:EN+&*KC,!4!2GG'[2**Z7XW43Q @+X4-N[
M6<DJF4D,_),R,?<%,JZ>"%B39C#6+>MVT?!$I2(/2+'F7&5X:Z#E[35M5OT+
MPQE>TS>@29Y-H:9\J^NT##,#_H45DT0.^F':I$Y/Z>*CK"GQX5S#1O:9UZC/
MM]V,9W"I4SJBR_=WG*O5W\BCKK>@[H%N>+#NA7H2[5[+,VX'L%/9+:/OZWM
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M7(_/C(6;96?PG$MU93$*2@J\M2_1S$C[W9;=]".X-1#K$CXT7WDCZO3RIR#
MS!]M%X9-]R4[1M9(O51:KG)F76$>[#MSRFJERY^=[:[>P660&*&F=Z!*G7GT
MA_YTN^L-/CZTEQL!7;2_>P(N^744H>L6!#\M]I!(V^$G5.J/*"??WGI3G;2,
M\X,.>T=(V.##F $7*[UZ4 ]Z>E\ZH]8I^Z>BSDZ6K>R736=N(QN5+5=,US5W
MWE ->/CR8"-C6^=M%3O;$'7TA=_OUO-\77>AC=G6FOH7]5_['5\AZ=4KG9I:
MEOA*EWU(#3"E]2@^RVG+#M>AH<<>*A%8%9_SM1E;OZ\25!)BT=MT_G*D+EI=
M7$;E2RDL)X^V0Q46TLILH-GX0[KF5URO*NL<72*$D1J&S_?GTJ(-1$E;[N'%
M-Z"6V\8=I$D?4>TQJ%I[I%28M^.TX&ZOIJ"9<"C%+'6^)4&;1*W!(L<TI/UI
MMXUX;?Q"OU*KN4E5OE\"T1VQ7P4N*,EPIN<N(?P2UX4]FY8#R@$Q/LA5+'V=
MG=(2,)G_\6W$:^J@58K>0QCF1Y"![GAD],X22[U#K%5QP\Y!6QA+Z;.E_]5$
M8QG'+%E^(N@JD;><JSI/"^E,&P@SSCX>T%UNEWGYF]76P-Q_N#BQ0,0R(L).
MZ,)F!'7V(5\1Z\9K'V4*UN7N9)98[9?3:OGP'F\?5UO\$I;V3!R>!X8P'I&,
MJR_Z)T6(3K]+;?I_M)))D=!T(&=F>T6&"%DF&LKW +V\:!MTI!#Z"WY*$UI3
M# \,KS2R:X3DT; 2OR^QSKS#A1-ORQ%=?4O&\*JAL1O?<(2(K@X:H>$ (===
MQQ;P)4695U4U;&B,RE*:,?01RSGZHWKKFV\J7"%-S S6+%EU?[,5X6Z.G*[Z
M)O3:1!N4W5:'KYGN/!.**K4<E1*>8S-W#VZ_46]'G&OW*^ \H=LW93Q[U!BR
MO)##>T@F_HNFT"5OOF+'PVC"%%GF6(:-A,>]"EB9GGEN"@.1O7V['QL;E6UQ
M6KHEG(\YT06/E+VP9N5IOV[TW @!^R9B?+B:@.+ R'TA^=I\%N8VJ6=/6;*^
M_5.[I7MZ1ZFB?:/64;:=PKL.$:A7,?0M\.G9O+U&N/0HO K;X0.+K-&A@#B0
M* S)B;,][A[5^1/[RS?>O)7UJ Q!8-+O6W"6?]7&-?FD6Z7J7AK)^%#2LH_0
M:#"-,>[J7=Y5U [8)(P5X^# .BXN8GWD=+E ]&:6J<;V 89SK_X\^VV1<:T5
M2:PRW_WIWQPY0('N.YVG+10+Q%0?X!RF0$/H*3UX?G>X^?76H'.>WDXYA^'$
M7@+=G-T]X L*4H6MZYL'T5QQ]13+2(9'6?F&A*Z Q+JIHX;Y/!MGEPWK:1=\
M",VOLEY9\LS+784L>=R"QZS?R,0KDF [LP81JZJH_%-GC_1;S8DI/,I91?6;
M_B2!G\-'G/< _:B^AF/QQVF ,@RD83%S:".(40^=P9[TO$_8SP%_18ZO"FL!
MM&>AI14)0RR+I9B,VU>1Z7L<8XVD'Y093:#BMJK2LZQ"L[>JDST_?35]*ON7
MI4\)_#XKIRYG6D5+ZV&%,C+^HR,'G<;14&KQ8KN7:PSOB-_SDL!GSV3H=/]D
MA<DQ?;!J8^]C!=4^]+?_?^JS3BQ@(7VAJ6CG_.&VCXGS\\HJ4/2PHSNAXYO6
MYM?S# 3L#8F;$2[1PE$=GZ+:FE"U1E\-"1_4[?/4"+VR#'TAE@V->P#![''I
MUB"GJQ[/F^CF8N=?Y<TU$R7&C57?Y![W49![:H8A@>B7K8U MW/A+F;%I&9[
M;;V;]MD)7[Y]U9Y8Z5_2.UOM;_J<L,XPLG(%,#1>Y83\4Z\Z0PND0,?N^CW@
MTXQ<_#MPGOH(!/M.>=D ,U+$%#^D9+"I@75'K>Q@O"P>V+@XXE;&>Y0?PN$-
M*JE,P'M1);,($10I%UD5RS^%AZG4M+!'6,NC=H2&@U T7-F[-:S^2]TV^!?0
MT!;: &290L%RL+ [(;FJ&LO$FZ(( *:$FI;ZC^]P*_+CXB?_<?^ &)&8[=UZ
M(Q$CKW8;1'K\GNE 0Z%E$R"#?_5X*"ZFY3O:[&B7FQA*A;R:%:ZFDA-A2D6[
MIDV/\V)W1W308=/0GNYH.:;_U!<8*GH7.FR?N7_E"5)<HJ/DR,;U5,JF)XN&
MOXB.NEZGB;J1/(.'E:OI([D#ZXQ8A:__'G7^O; &(S<CR62_G Z*B=NOZ0L7
MW@/4\N\!YJ)-0I/2'$H]:C%A#8)1H6*O*",OQVS-!DN+S;4P0V+'MUJ&Q>*F
M;@6/D&.\DEX.B?5-[=]D7M,=1>U>(@B6.+%3W51N(&L6-V+SOYP?CK+138O2
MYG&9-3KZH^KBE^0W[Y+4E913_\[0\C=O!3TI+RN^DBW:URK9A0=8K84%&?CI
MA[9EC50KI>7E1+H]M,RB3)+C1XP!EXA:R_JFZKI<2:CUM!PFZSQ5?;JC=K/
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MD,.A!RBC?4$,+RG*PKLGDK0)*_;/>V,Q,MUB+S;8*WW9.[T&M*J/H$7^+/>
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M">;*ZA.ST(E5-&WJ1](>-'A"B&Z0%BW!U!E!L1[XU>2HK7:7:9)""AKW$EK
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M,BI;SI9JJ,;QHP99U-[!K++C-\'"_]CO['B:L/^-P:E%?4VC&QYD[XO2JG8
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M410^$E2_3M1V\^_8,6_XP.]#"$1R(-N:OKK2_!LEINZ]H775AJV*SB23[L'
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MI&4B1DB,U0E]_6:\F9,E<$J-R_DI:<([JK6M.%6^>< MP/%>;5[UE=1B.5X
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MO.;F>6:86:(1HIL$&9$D<%5(;WZKS$K'X@PQ:J#J(T>\"!5>HS) 238N1 W
M@N#H/TRN@IJ1'D^ES!__54U8^^\EP)5#%I;$&^X;3S3_Q=$62IM 0S9B!U]"
MTH[F.&T%_@TY8=^W_V('HYF!_A78^>L?6(DT_(LUG\MQ?UP]4*NC>MI8US(
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MN^[+TJZT3\I[%1L;F..\8B=%VXU($\B\YA244&3(E*]J,6!IPO*;3CW65.3
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M_[$,26Q*!F*IO.HY*OB;*K;',3@1!:9Q0X2\OTQX0)>[8<2SH1OA^<E(=*A
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M)SNOBNX"@[S]=%ZC^M=K4$[$7P"9+;^?$1O(3BLO#>\.B_W6==7Y5OS43N?
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MMS\QPZ;S32X9U0E*8JIG:U_<]5CJ;&YG'[P?_'.&DN6=XY"HD^0L.2&4ZDP
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M9X]?*#XJQ;;L*%K?G!:8_?]- %!+ P04    " #2-&I44 PV2 YL  #8A0
M&    &EM<G@M,C R,3$R,S%X,3!K,#$Q+FIP9^Q\951=R[+N1 *!($&#.\%)
M<(< P8-+T 1W=U](($!@84&#N[M[<'=W@GN  ,'6>BO[[+/WV>=<>W>\=W_=
MR:@QUNQ97=U5L[OJJ^Z>0.>AZ\!364D920 .'@#@8'\ = D0!QXC(2$C/7J,
MC(R,@O(8%0T7'>W)$S1";!Q,7%(B<C)2(A(2"AI6.@HJ9FH2$GH>!N:7;)R<
MG.1T?$*\[(*L')SLOX3 H:"@H#U!(T!')V"G)*%D_[^^H!T UF,X;01*!#@J
M !X+#@$+#MH-D,/Z^0CNMPOX_8*#1T!\A(3\& 7U"8RA]BD #X>  (^(\.@1
M(B+LJ0_L.8"(]0B;DDT4"4?9 )G* 9?=/SKS,;58Y5<\E8GO-!R&C@$HJ/C/
M" B):)_3T3,P<G)Q\_#R\8N_EI"4DI:15553UWBKJ:5M9&QB:F9N8>GD[.+J
MYN[A&?@A*/AC2&A83.SGN/B$Q*3DK.R<W+S\@L*BJNJ:VKKZAL:FSJ[NGMZ^
M_H'!R:GIF=FY^87%C6^;6]L[NWO[!V?G%S\NKZY_WMS^T@L.0(#[^_5OZH4%
MTPL>$1$!$?F77G#P;K\8L! ?4;(A88LJ(QLXX%"Q^S_&%8O.K/R*0LVA\AW/
MT'$"%9^&<X/V[)=JOVGV7U,LX+^EV1^*_:G7(H"&  =[>0A8@ AP?4M?$%%C
M[>@&6C.[-X?79B2OZMF# M=+H ARDT\34."T#@H0 <EA'X\J/44>KM8VI18,
M?X#NCMM[_9YG9=XQOXN$ C[U/R>N-%O)(7=V9QDH!06^0\^RH<":#833)_Z%
M%!1H6X*)MOQ?T?]SHIDPQ=N3#RZ4@L7C KY)3^T1^.M\!I0E</_'25U/P8+E
M1_% EDV5%$)3BADB U6I.HL9Y)7GQP<O&2B0D6SE(!0I  4^-.M!@?33^P_I
M]_+DWQ.LVB\>H$!4+!0(+9%E*H\7 ON:+2_]QVSTVY'Z.SXC[3_E:M=N(%"@
M'R:_&V96%-=F*""R=H,B\C.Y.PNL>87QOZ+^IT45-UECZ<KSRS:'U$='&3^L
MYX#394F,YOG2':_O:1=/[Z$ :(L&"GPS_VM;:LFSM!53>D9&S-O7QP,LP1T=
M]SWRA5V6%!XL!D&(3H@"1*\.'O.^?;OI-NB[W_'U*M?\BG1[.0&"?>P& ;6?
M8X/..$&=>F508.P:(J8(>5YD41>]TN-,XGU06-G>]":LL<\7I?A%EAB-30)X
MXK4I=N5'-#3WT8GFE!/2'OQ(_99F\'^D>R'->*8.38-5L*93Q*'MTA*-S6#\
M_IC=O1=5S*E8&)O+RT8P'O8P9422)R4U8C5";#@:PA)GZ^C74[3_2&IFS>.1
MC@"F7@O$D!C;CW!NE-Z1B;M!@@XCS/QH'#J?HD%5*_V:B\::HPI.J<-(2/R%
M=I/IC?-"&R(;K'.@W3LH0$D'!7"D_F)6JZ?A),J*\4)!PW=?0']I+?L?;,45
M*D%2>40RUCBYGT8_:\NEPVO2LD(2F_7R/,H8'[@JERJGG&C?XLN' G/#H-NG
MY>]*&'.2*TNY%Z=WO+E@[0J]A[330H'Q$>>9X9]6$#'/]@=?.2B0F;Q?3/TJ
M*XP>^).L(ZJXO<W,Z7"!!5/I!L'*O>S"HO%WBE3X\<MB;D^+WCOT%?8IYG,]
M*GQA1S+J)D,5;'I) V),]GM^)P=WS?&#B].1IK@10^J\R 6WRB<I?L.]BQ[D
M0D?RP)$,3&6%A2QWL#YJ3&9C(\1*( ZY[-,&XL/H,^#_("8RJZ4/:1):+Q&>
M"BL?RC.%-A/C:M MG;3OED/X13HCZU= 8^_OG4%!PAK/N/=*%/^X)[=K@@)I
M[3]A;AN53U-W*:M2>,T%"@B!SB8@N#YMAQ!/*+"9?4^_;>!D&]9]YS-W?PD%
M^J1^*E_=E=\<0@%PY/?LN*"1)B9&@8'%63=V[Z%Z9(3PY(_'U^\OYJ  *?F&
M%-.3+\[*$M*=?^GP?X$*K43.$:9%#A<5'Q!G%G-+8!,14PD*E%N(_,"1MZ6K
MW+K2B'G_3L(*2^F\;H;9?:Q5CC7!YUGRFDE2=GB%A08W@Y\T'>_^UWSS>BQM
M*^X$G+K^["@.;I2.>Z9L/2>%B]*!QAM\XCB[Z ;6A7<K/2X#-3_X)N5)'MI"
MO1PL6.;B#8,Y+Q"D2Q BK]QWLF-E6V3R(EAV$L6O%RB]7Q#N4F#]]-?#L>)W
MZG*A:%XTJP'3!AJ9$'J"$_OR-^6*+*^(/D4CY<P&"P12Q!EY-] C20I<[>()
M3K9U;4LQU[V5M[;56#0"#NG#C\DC9>NY@[RL_?/#^Q(%OZ/R;8ZODY"EVB-)
MREN+%NY7[F,2-'5'F-#0TD0DBU/N7SCBN>]A\.VDDE7F]WZB?E-%?E13SX9K
MJ^=PGL86>*B8K!?0OS,2M*Z9N*B .'\>&GY_LP_FNV>H7M1=/+Z3:*DXW?;N
M9FK>3SZ8TIG*:FMHX E6:VH*5FK3,7V:3Y,";FT8DQV>N236:66@"M,[_S1@
MW#LIK$$3V)\ILZ9O0<"I+*$%)X&K]'=ZU,K?<<##9)OPM(?I*9;QR@7.OA](
M5V4@3^$%V>S2 [L:LGN]E$T#KY :^?Z(@$1#V)1634-JG02)?U*% O*&]LNU
M13FD7&M;B<JTK3>QQT:-XF082.ZC4C\*;?)49'OM)U^ TZ_6JMOC=F[$M_E8
MIO+SW&]35$MK= X_;=6X:Z^^U3"YF(FE0$M;G1F7*;5P4ZD>$.@.5,*Q41H<
M3M.4[RA7\#C X%B-<TGE%FCEBIB6T-?QIPS#5X>Y*F>X\#NSB\*=!(/S;'!6
M&)/8KT&'[O+]_F3VC&6FLJ'!3Q&7SV<X5Z;7]1@Y<'I:VS?)R\',H6"Q(<)&
MV' IK))W8 F\[J1C?Q@O;-*"R9@#6AA"7M0@7Q6E1R0AL>VS%>G-KIRM.>9F
MX5Y BRG"]_HH7LL.!1CZF>([;XWJ-U*W]**_X*5"LLWG8@]00ZD]*,M,#7:>
M\ACQ4I.K(%DJ5OP,." P8Y>G"L)^K;V'G1$> &<=Z =B;,ZQQ,=_PE53?S:2
M7U/:MFKE*I#P4TN:U)V$!*2=T4;3&!HECD;%>_4!#857J<,L79+S<H_(!7ON
M]72@ H]/JI$DZYL,XZ*/".5-*3](O30L5Y9S EXWQ.FRV7_MIXQ435==K5GJ
M3E DE*ROI_3'ME]K&43DNVD%]L-Z\\JG%5:>,!6LEJ09KNHB[^Y@UWEL79^&
M2;2WJ,7AG]C'Q!@K4W;%S@DW%OU0UT+=R<&OYYA/E927H(@<0VF2C*ITT0T\
M+]S#1"H5M2CC;A4*>"^;X/YPU.:E7T"(&#WZ4E*XM6#*Q<N*E(C 6'K'P6=G
M "T::=@+H,%^B>%S\5.]T$6(>^%2)^0DKRGYY%6!*EM3W_3]<#[)NO.1"-K*
M'6Z)L7CV$-5J36P7_$*#S)LOD331O>.*R@J1K]I2$>,[&3;L&JD&<;DQ,!#T
M+WFW-%I7:PW'+567^M/-6^1<SXT_N;]5<0._M>CX.M:.E_ LQ/9;*+7F\?>D
M7NJEF:X?B!A%_*@6 T%9^&VD[0W-8.3PU\069J;D]-;KFR)':4+%#)^SJU*,
M24B>2NWPSZ[=T_)D!MYPWUTS/5M<H-0*(?<BN(DP9$,[^BH6X(AKAK"4G.N;
MY;JG]]?P\R_AB,DV@L':29@(%MO2RJ' ^Q@HL&?:9/DOT2FTX!\QJIKC *ZE
MX-QK#0')S?#8Q9PBS]1B/6U#KK?QW-A4]9+4]=_818B PGR<AU1;3%HE!N'-
MR'T-2R8WJ2!9>D4UR/X)9INE-L!8EK47;^95A&2B6]FQ':1=@HD-!2S(JZ2,
M"%S<*"+"NNN5OUZ- "Y*@['=5;U+T1^1*ED%V?#Z0I *;(U)@MG\P:\ZNLS\
M>RSGNVA;XUJ8BU IT -7\X:_>#X_;FLQNZ<'V K'6$9%0JY@J"J"]6O*=M/)
M7=\4>4(MLJ\"_"7!;KTGTGUX4*^"Q_&B'\Z@+ES".M;U&*CO,GM(=:491'@,
M 1&)>-1GV2X=.#3?,XC[GGV^(L0%/(SXAGR.U]QOC<ZO<L[G9II^5;KXJ;J7
M@>1A=; "W/75W]Q;86Q"A$V@@#<4X%\K.C:R/=**I4E)3YQ2Z+3<392RLJ1Q
MX(YP>][T',1^;+/@!J\XLFMD]7SRY9=( KUL ES5-VT!?3)3.[5M,<.:TN(=
M[2T?G5]QF@E]I2D0DAJ*3$C7A8S!4I\TT,^S[#OA)8@'+(CV%NUIF,%M2.,C
MM6)I=2'2&6!BI+.$"7@OD+WY<(ZTW' 8)1+<)+OT;U0$&^.ST9>V']W9W>Q"
M@4@BD>KC]MUTB*#YCJ@1=MB_4X/# ,;*E/X3^:)HIJG.GI$=\4:'D%"HL'WA
M:NUB# J0<3I15 P)Q$>C#I9EZO96R;ZR0(W)63>*K4E#>BE*%K"M*DK8VE ?
MMRAV9Z;F$)4-9]\NUGC%<JJ2$T%<HLJ]:^CZ4A<>V6B)]_Z[!9>/OX"MH@2N
MVF=<90G@[V1H1;0RDU=HD6M1Q^#FXT0\%&IZO@GFZF#NAO>, N SI[P-#-Q,
M!!,\JAMK+QY-(SX[#Q/N[8+K'V5;2XMSTA@WF+&U*>N9&4G=KC !?UOX_%*C
M5^T$\:D]?UA?8&<33:<.L;RD$0U<=JM:$IF,=R^&]W(A10Q'=.!L6L#T0LU<
M22T'C;9W!&U'1"J^>4[H>V1;<?9S'GULCK#A*6]Y#_H95BXY.0$!%NZW 1Y&
MC1XZGD7U@VV:_5V8WE?%BXK!UIQR>0U5%WBK[#&[MC0WGY"L,5O8):5L&SNZ
MWG=>L4NXX0RY;*^L/=E7-UE*@'L%%"#2T^<'IH!KS(E@D[13/L<GD_).U:3;
MFD0,\H[$A/WG(L?2\VPRIDF"7GR=! N/")5!4PLDE.6,Y[+KY(D.IVH&W_$C
M$8H#[4?#VW0$&(Q%&SST-VFY*W5)4N!&)2UYOB.ELW2K#OAXT$33OV:GP8 /
M6H1#)T3W[Y6F\Q\10E"5!>'M<U^_L&-ZQSPX&.3[E6\[%!4))V5]D]3>4OV,
M+-$.>WR(_<T2$DU='/#B6AP[@T'(GV*:*#*HY)*-+I5S(WV QI^0\)/K6MSG
M<@&P)-N//(D- <V3&",/Y_[2)YP$H4:NGS[3,*+IKZ\_Y251&>?BV<L*$T>E
MS_+[@W*+"VWP']2P>U=? 22Q-3.+]*_<U^9MH<#N+.CNROP.?>W^%C;R?$>\
M:/'JZWS"6V,$[8YX0!>'(@]WG#[!IQ ?,RC0;MH:$R94?40V0,9S1=Q^<YD.
M>4@6[G*# L+54&"M^MV !-G"%:9Q)/&?\L@-8(E9NA84.%TH-\Z*M+Y#KI**
M>/A#8&3%"BQ?@N''ZZ.Y*F6I.I_ !>I>R)\BI?[HH]4"??:2\->CZ$W0GR*S
M_]Y'KJ//RL?I^E?29^U_2ISXHY-7LO178Q5>-/^>SKA>9O-"_ZOR_YW*=)/,
M90G:%:9UB?0-X3%&O CVY9I98:%CB0U]G_^S'*T(]2_#$T;LK"R0D5+FLQ3:
M2;QH'ST/Y//^^T=:>9;(#^P]7B=./VU$OC'\ -0<))]/1U=&V^:VA2]C3KGM
M,,K*\QXGGW#?0?1!17$ ^7ADI]^+B=^#K:K'A>)J[\1^Y-D(?Z+('%FZ,^B9
M2!P@_%L:PQB>G-Q'31>O,"GI),_D[QDV!IEY?[,%XA>I?0OQ(!\%:S!EB_UK
MX3/)(+STAZ+VBWZ(,\BR_/Y<))6DA#4"E4GD3AVT&WV_]WL%/DT](EQUFFF\
MC1A%YOO$32&G-[\_8>[<JW3<(;39XO!P.#U?D-UBLWVVYQ0YFN>,34UMAO;2
MWA[$IKR2$Z,M6Q$RO.1$GLB>V<>HN!D6PX>M.2N]HD>"I*$:);HG 4@0MSAZ
MJ$1&/4)AXAW^2!+ NQN6EGR6\ZEVFOV[O:2GF@RUY"'N2&-*7>\3OU>[R&OD
M:?3+.C@PXX3]W>B$'"WVTF>])BXJ&B]?,3MT#*R;MO2^0/U9UR&TA83?/&W@
MTG(G&,R'M1#N_\D.B*/)'P*C>T;@3E4D-_;"/"E/.<A\B>YJIJ,^XDE-ELQ+
MXF%$"E56G>W^H1,2")XL.GG/RZTQEJU*:?'!Z'<5CEFZ528Y CJV+Y4*>M?M
M'?0><)T>@?%7QWIE"B3L,V=G40BI@[TJ1B>:>5B1Q#\C<<0LW!"@+Q5I'@E*
M:LP=?3M?F"'1Y5J92R&]KV+'E>E@F4KC/\9;G)#H[$/(W?>E!:^>O9#,,7-'
M[:-H&<7HV7LSCTS9[N=T+U[J0D82J?1)2OJ2UB75V-LCLC'L1$#F)AV9M)YG
MMK8@LSE 5 )7A> ORXE*RWI?+;8]SJTO<K#H$+<C17OD7SW"5?Y_2B1CP>U;
M=,4P2+G5?DM8EMR8C@[J5WP+RZ,'0#\X]+C^"->X:D[RI"WRS!%![R\B2TU1
M7MC!"X)ME/B$5?2K7^CWU6_<C".5Q- HU\3P9]$/F/("&BKN :L'!J0?5/0P
MOT5+3BL6BDR&<-[)>6AK9B@SD=1\C!<)W2D91WPG8U7M1!,^^E9?][Y Z./V
MC5H-K&OB#B3#>,<Y6*,?&36-L9;)C2!X7+AP":6'/$_WV3UD;6P_':G\I/SH
M6#J57X;^;GQ-V8?J>1NC&35%[ #A*9A?;<6RQC5XNGP^YR6%X0@^>T2Z[5HP
M/<+;W;'OFV[[D;O)HCL.J:V8NXN-Z)+H[^1-!R^WS#?1B@[AS![#;:UC!#<_
M%0=$$<E$<8&U5?V'U<"+4WFJ]R\KSL^BD)Q2W'9OU6J4$/5'HJ/)V)T&]A=C
M>8A]CW3J0.Z;;MN3N5E^U,^M4YC=^WME]M=J#75!?</MI^F[.I=?6)//94]H
ME!M#]]6?&7",MF_031M.'><ECQY)OLB18:U$D:%^ZU #+%4'(9R 4[UF$@7?
M.W G<4V97]#X]6P5:@4,DJ0%9:%)(]!0M2,:"6[6D)&'2$9_\*,222RB)M 8
M$/B8.4 G?"GOC9=#PR'69)I<J2 :]ZCH4118U #L$!M^.]50XOC,E[4E_57R
M3N\(5:KU3K)DO$H>=G@_:C'=J!L#KWZ+D6"*>CG>0<*5DW9/_IL):R2O?#AI
M,,6KU8Y"6BD^5(Z^U7</XC]%WL2O$GMPWB$'DZZJV5CG&HW!<"_A:5CR:1=W
M_3'..YW%94Z6)FI.RD%RY>BOZ\Y9&T9)LUQ,,S9D>BSUI=WAQSC/T?JIS)8N
M] MY-_,P.'JMJ%X0#^W(UEW%6E(,49?'X7XH>>6'BQC19KUE4!=^*9QZ[TL6
M0!-$#5[!Q[RD- *D>H7?*Z"0J'M%(ELDA-;M*E:DNM4DQB]HVMJU+(/S&T]A
M,Y*AY&?\R>KLS?$ZF-[0-)CO?MV$G3%8I(FIO]<3VWV4K7]YT@5IAO.RY65(
MO*1-:#,SP-L5CE[RF**<EYJ0*P>"5QE_(%?(PKSZ36V!IA0^P64SP"&&E\1+
M/:2&ZT/CI\'P_IXU0R,GLIS;-&3.DX NRC\A=5&R5PYV7ZOCSUU2-F60B<C]
MY?O!3YE:"<=EALU^\D]LQ63/'U,$B"*2BSW.TV*2@OO0&QV2&HV'"0=WXYO.
MRDA/\_* YZF,X&OIUU'=S]"RR7GF:-@*\;Q;)<(Z'#B]TI263:0!K,/ N:5Y
M-73V$>H"9V.^+C02$O)AE0GI+%S3B)9&X3V N:2+U0>S55[>?5*-@2I8=1HK
M.=38/$<SSZ97THXE8-VH#+/]?1G#B4)W%9MTZD<EE"+R15@.YR)"#>'RM+O$
M!C6!XISFYK"U-14=\&H2V"6#X@G.FL201=,N[65*I0L6/8E ?Z_ "3*7>YB^
MC_PYZU-3+E3"/H C=N*?3->K%)U"XD;*E#;]O,WGK0;;(8Z6J)$5R> G$GE"
M&FD9GW[-R,_.!KT>I)8W;PUQ<Y>/0#6TD -?J7MSR'C"7>$-^5F9PE@/DCM+
MFI<HSI#].'L2L%2'P&#[ZD<O!EO*3K7A6=#(EA&WHU;+6_RE:1KP.X8G]@B2
M.>F?'\9%-Q$G:Z0\2*^O/K2O*/9#@8@_M>L8^O8E\5Z*NXM:4\82?W75G.@9
M#YV'>A>]08-D5_HK*>W\_ /^AX>^F#G/FEYZZM4KK(6"Y7>OM#YD"QZ3O,C]
M;:4\+>XA\\6UZKG(IM0?+3C(E*PIENKNC]#477W[V?U"L+;S&Z=)D--*J%UB
M@,@'[VZCHKRL#]NTT_7_6E<M"ZS&ZN'& @5^M^3$WWG4Z;/CD 6;XZ' /QNG
MZ+/R8&":W@BQ3GZ:2@DNP-&C4V)NQW)T0G7W^HO@SM.^KP(I/TA\T*UGG2*2
M:OGT8!Y?22OTF\C-!R@P+TM^J./REQM%8]IFCMJ[PI(:XJ4O;@N<#OB2';PB
MXKK':>U%>NB2=,GTK#;6<U1*19^XI5=BY\.QTOC*.LV_)3\#.TN%?APN@U,1
M^EI$Y'VK4$HRAV^%.-@U$-=2@D]PET]-H__ I.T4%MABM^,T\R%765OC_ X*
MK!/4W;8>3>K,<RV/#U_;H4T.X1IL=MH^?CS()H1@]+UXW\,)OSI_ 681VFF[
M*W\FV+PH6\FLO!>GX^V;+%O2V>?1B-7165SBJG&LDGD6 V^G.H:H_V IPUG*
MKVD8)B\\L_E)6)N34<RL#(DWGS&J;?;FQ>$6_51J^8A/4SN+R'I2],J*GNX!
M=EU!G8R%(Z5FTM/,]PD)8R,79@B(KH<ZEVK[=2R<3L1,1LRO'B]W-T=A^)$X
MA-5J*<@<V2BP1YQTAC$$J^.4:/H,Y_H_=MU\.-(GMYXFPOSKPO\O.K^+>.U3
MW!UML4K31L]YDQNC91SSOEJZ*G5I&GUV"UY=C&Y%Y4'-&&&:OIRY/EVGY7M+
M_?<# >8C+AFT%V39G)WFKW01$VP/(U>?*95VX81_9\K[;MOH!G(KM*@_,SR?
ME+_@;6!_9.8V:-,QC[3VV7C;?D4F Z,N+&S#S)Q 1X;$R:%V*[P)[-&/:!;I
MF;UEE?X#:ZK].QP4^'D)6$QHI4DV0@%14@$H )##/)B&V4<;;U6D7._%GNV:
M>!;!X,>=WC^7[47'!AOV4 SY'10Z&Z>4)9R2:YL&OCUA,*ILM/J03#6%2(-[
MTR1""0PP-SQJN)T1$QSM5DNG:@6#PS:9?\Q,E]?BR6G]V-L.S52F;?DPE(!F
M[&J+H0B8\3Y/SWZ>;U"XV&NC+>>!,X3QG3UQ4^7AEDYP?2MJ4$"C+$#FL(A-
M,WBQQ=E'H3.,OLRI@#XK#*#/BIXPEI12ZN]"*V%__(,3J'E+B?G1J'F\;,?\
MT>=Z#L(W8DL"RBBH7Y X^H1SDBLS2!765+V\BE6K-+LC.2C[.PO47XRO._B/
MB@H=NDERV\@9)7-M.^>2CJ:%T9=@1,'>&D+2][G[#Y>@V_L$*"#.-?668Z/\
M!N4 "ES>O( $6^7]L0^!5OSY67)R/$V/N?N[7C&.V!^(1@>6GN6F;J_/75XP
M1Z3;])'G,?8 _[CR\8LX(U/=A6[)&.)I=-8&+'/K9(--$+<8$)$0QAU;?"Q&
M(KDXJ@4WA4"H!C=<Q#R0,W,H )_;GAP&3/_KZ/H+P:>>-Y@_#U\J9CI^\7(+
M"1' ;+8FWU)VVZZH:X*7$2S\7/"I[2ASK( X5$31LE)03I"%F+&".MMYS+(4
M_^98FP'UU86D>RC$V.GZNU2FD(]%S#7KA-*B0CUWY6")#C5B=&#TU_[C?BXN
MJH#HS_QQ?%\)>'EA@(=1@/-EBXIQ1N03IH8ALD1A*#!:7=2;[RPG95XIZ]V+
M*)V!=9[:QW?L'WX;#4M&#WDOGZ <;5O@\XWW]G(S=F"!'^]9N9>R.HWD'<]7
MZIZ4\@3/:89;:K]=?-$KV BJ,DY)<>1N" \$MY QN2XBUM8&K[+W4+T*T_N$
M#?317 I?:A^,REP*/(DS0;$U9D79.M%%4S7.JLMH>I[JO!BW$BZV%82T83T<
MPRT=3F^B(B-0=TRR_J-'LV;"^0M-3UJ"F6W)X):$;>'%"T9[9.78R#=SS*N(
M%T3S TAI&R;8BHT<.^0UR#3;'L*:3&-3N;3Y@2Y,'BY"<UALC<&O<3R*!,]'
M"3S"*HK)X C9^8 4%\[:(_4$I])X%GYY4:IX8K=F$QS6O:_6E "WPWP[N2KX
M\MUIURW:3?*%U%0N??Y.S Q!T-8UV1:$:Z0]\.33 ">1:Z3EI/88$$9(PBPP
M&(57Y\SKO:&&OKMMZZ8W?L]18'&K-EOUGEAO#IVQRVJ;TSH(U]INN0"!,K*_
M^+II-UE8[":AMWACOZ;9*V+VV*10)N0"KGL4V:77D=N%NN*JD.),.,G!AG;P
M2W>]=,LF9QU';Q#O%@<%<L&Z\2QZ>F!YZ7&F_TX=@ZV1.7P\L6/QKAG8\3#*
M9X0E/YA+[?M#;_Q9#\Z R94#SU5K3^<)@!:R)5_ >SR5QR8Q?P1N?$$1?ZXC
MO5PS 1C#R3Q)\ZMC2]'?Y/N*3$"57S+"))\@&V_EOG7!K)ND-$1IH2')IR]S
MUY%2)]-/ T[L355FALUMQ%^SPP0VT<XNLD&_PI)>D,-M^[WWWMH5]L?;.0/9
M^B[R)#5A!N^ 7]X@I_N,_+X3=$2+>5G:](^_\ZNP5SY?6GE]:67<69V8H(M#
M99)60'*G\_,RK3#^#LM.I>/G&(2R;] F=*-X$D.(,69Z)S,P/F;T<\THOT6M
M"JAB+Y3$(]UR$/G^\5TU_)@M]1KU8\,$\T].\*@<DO."1GZ8"&DSKHIH>EQ'
M]<HC:$ZMURG5 =X](9DJ'.!&OC[9 _-B]Z+P$0,&ZLC(SOIBU!>W) ;X>#&(
MK@NNRM?XL=OKT4?331^#:XE;A5=G:::RL)ALEE)Z>ZX!PK@O!#^6;AST?'!]
M3-T:?%122YQPW$W?QD"L=01C5VDV='AC*$39&ON Z+0/]HQ/VI^L+FO32%MO
M])14?)#R*=+J0L-&H4:X1V(JRXKI5A-WU[:%)7=)@R)!)]C':335,<-O8CXQ
MH&@NW^@0I# 0]H^)IUUJ>1,Z2IK&+YHAK6%L5^%QM$J1OGQ%EN$4=DR?5ZG^
M- T[=L_!31AWAG9J<H2HR]B&6K+O]/E[>^ S#9HKL6]^KNMG9:WI8H;%G9J]
MWM0;4#$,9F@E!_W_RT:5WLGJ5S9\=I%>:*=,!D:G&J<R[$Y_'7I(/]0H$G"_
M_V*>!?GVZ#Y(YG?!JGJSG&:NJ&'L,H)PKQ!.YI?8VI%M/4TK.?%GD[5@J,I_
M(;K>'=A-2SR>K"VULRG/9M=Y4T7/2^M%E.9'>#?LK+L.\2E4@"QY@2[W9]#F
MV#HFF%((B6$^6437UQGX]GY8N1>%;SV-[7 I.<R)(F:.V,VCZP(6*DSS^59;
M>'Q%-\\*7BCT:_B"[ \I^S)$>/:3@6EA,_U69-^'?5]O*(#!XYL(\<C50,O\
M'/"XG[J5!>#T2.W\(?)@B?6)5?KKG@3_%X+.M,<WD1ICH(L^2\ %5P.ON^I)
MTJOH#@Q0R.V4[#?;WF.\GL6?::/GQS:9#4T7I"M8::MJ4B:CZV6#>"&+GF1]
MDS7W^Z!=F&G7)-/I=??,R[Q&$R">[0\_+#E\'TWJ$ =?I!*]^@)V#8 3^8+*
M)S'L7/-6:%<."@B]A]QR>DS"C M[#6T1))G#SIS__A,-3I5^ZQ,4U_ZEP+24
M&1#_^QO83+Z>R/[LQD^4$U6CR"YN781W/S]?)XY/TSY^>77C?UE<J[&M(=#L
M%8T+7D^44=S0Z*-Q(U2_=5)!T[$037-O&Z?ETU(S.LG&X#L=K.<R+?0>MV1C
MM=D,FHEBM3]Q-XC,/^6]+JZ!1_7/X1">UT*S[#&EXR-Q)C@=>[<V8,)"S8FR
M\_SM<W4$A+1 H=L'$<;@JU=X!MB";[J?'C02+@/(!XI;F+(%I3*QX]GF1FE6
MH1OQ+OX4\_%'S<K\8.3R0=^DHOHQ%](/IT;8<LX%;Y3[E]2_D,![:8Q4F%4P
MTUG<]]"2!K,__E;T  ;=[-Z&S27I)3DV4Z56OYFMJ!UD5% BQ,(0J^,#K@G+
MK+2:*O5,W5U2M7V$N?RU^Z6<QY'I!!)MJ(?M[;E3YS>W;\!>Y)5C4$ 0"BA+
MS>_^VK0IR#ILB/$!LRYUN\T1%6GV<17$+7?757<..1%@/</I1\#\7(% ++6*
MX.K.6>YMX4.6QOI-3L[9XP,J*S"66'GRV7M2,A_#U<B>3[+#=C7PB@\*[*8?
MT-^10(&+L4M</3?2=*,16V^# AW^E8S7<@TLQBP<3!)PY@LA<-L1CHIWXOGB
MVA/NG]33-$W5J\#S/I]&/B%)VM6\5*V3\&E0<<1X3#W9K/C/7<YU66:^(_-V
M\9&Y?U: 0N:QB[3_[G8AGLUV\ 0^9:"%!X& !+XMJ>3XK<;TFOS:U<(W;HUZ
M_%B\N.PU?H;5+; G(@5L1CJ\R_WGWEHL>UX)SBXI-SQS#<U:7M#3D^%X$4?6
MSG5D=LW^U)B5/9N:%R'%R]B5GZ12/H])BO-\H.$&ECGX3-*T=Y?P,R!7=(*7
M#>M\^T3N+QXDR(W2(1Z0K&2KAF2[S$=X(K_W/?O("3:<1:95=\2V?4+H"R%_
MX08;DY17ZEJ,'SS#WS%UN++0V.!^RCXT)>B\4V\9EX+=PV"FB]YPP'ALPJ<W
M/YMB709S5J*9_VZV]4:LT"@%+@W),JU?SI4%#WEQ$W*T=KT!!3HC:_L>%MI/
MNZ! D/3 7H'P'/FU*11HQX3@^I2)G(Q  5_R>WIX3T;,/_G(K2+OJD%K'Z$
M*I 6%GCL  5<[>Z^0X$-J3_E^M%E9=SI@E:^0.Y%?BI?-4"!9IZ'GZ#O&2C_
MV\C_]T:";+--4?%U8\$&]B)Q\O^U2(>GJ,97:0P;F>#0G_@ )*DX+A5$'W,^
MN^+!V/OV"DZ:O) \#A#.3A/%:XDA"\EMIU11]]I>,V$&78Q[&$$>]5UF/*Z9
M=K=97163Z]Z6$5[G@8R\M7Q.]J[8OC7G=>S9MN(>?FX&?%:C/VMI3L";HVC9
M%)>OA>89:,<O).LFLYQ#JJO3D]++A!BA0'QB[T0XW$^,SP?T<&W:9@*23LUG
M^VJ[-3PQR^($"";5CZ[<K -O\D!$K3)YY]<1RV.1 [A*C\R]"S<#Y$/O^ON0
MR]BFR",4#"5'U4A24JYY>\2?G93EUX_"2VNBMW[9.5R*D=K0,(<7>DZ_$70,
M?%L)R_,\LI6Z) ]Z?V[TE1@)->@>V3+3UM6R&S2FR0$%O'F@@)FV&C!%A*TP
M$>/F*US3GQUIJT:' 06<W9B=?M[>3=?,#S Z:M[WG:*Y92">&RW5Z_>N)%[]
M*!&(_'F3\'!Q?^B;:! 2\T9:YD VS&)>7O=\2/&))9LN.D2%4<;^FVB!/(4#
M1=2C<RU7NC7$N-UMX;S,3U_?<C?EI3L@+\S2:Z!#=')LB%EYXI[C&Q)LI;#;
M#B"76<T*AH!V/X.N^[/[/T(\I&#]#',3-?7@)'LZK7*J%J]68]Q2GTP5*KS&
MECH3R';NU(%^/9SJ,)[<G.ENNBL_;5VV&Z@X_'($ZSP@.)P#2:_94$*D)X7Q
M87,NQH?C#XE_M)'T".P;MO>O37IW;O/=,F6<4\(&CC(LWE-%4I'?;),_G-/O
M8*A2D?\\AZ7[?B#^4KW'P12/L3*0"Q;Y<OYD!NM7:G>*1;!\&F"NTK%!DD%F
M?=PO?.^0MD54Z00TUL;#GY(G!KEE=K%Z!1XJO2O*J;O&?J-"OV2A:XQO")\"
M3A3T- !;#BN,!KH_H;@;Q+"WA'-ET&5KK R[(C;QR.[*DC^/V[(EM<?@.$ZN
M,KT@H4$G7H]\>7*7$7YU BJSK+NX:BY^E#I<]2(E=W.Y,O/&8>R=.(G7K6I-
M0=N8,0MD9(N9IC=,Q\'D'8+9,L:ESI-"$PT!'6]Z*D[$M)S;V -Y5=.HFV"!
MU'!'[D&.*LDG%5[ZKF2-Q3C];;:S%M32K^*6[7.<OHH$@S \IXQDT"J9LY#T
MT6*B^- G''X:FRTF3VG0E874  #P$OD5@T5,#)4C!L:45IMS^L6OX^K9,I*;
MGV_DM9F81F,AGB(//\PO<F!V^W5*G:A,S*?HR')"Z]W?>:52Z>Y_@.[V)OK)
M9ERYS$O*^15O]GX#0W^OO(5IV4Q4H_'V[XR[,C!010X#58[(M7H1_V8K? B+
M9;VE>'%_L'I,@L:D?H-?_L=OC33"!O_D%=P7V?UU5%X2_.JJN+)80J7:S4+:
MS)#[FLLULYA]D]7$/BN, =?0/1)B(/(KMYI=^<??J@LHMIUA](4$_P]/Q\/]
M\RG9?UID^>W,(#P'(X,I!3TAS15>G"5/\7)%U^C26)G(!U\$/.XJK9HY?PRR
M]1"IB4B8SP5O07#77[[D5X)3YK])T*ATO>"IN%).?WAB(R=GW&9<I9OV\=KA
M 6X+0G>#"H"OMZ>/=>XF^MN+HN\CA+.;#%CSL1G&HH+2Y^L1?J#?JOW^P8!Z
M^2EV9Z].OLH0P2BRZBAC6UQQ3Y%6S2%Q7T74H*@0WSJXU1Q!,E;^F]S,CQ3R
MD6>W.U$-B)?K_N/7>5K].*I)PM9O_!.VA=Y2MHO5 /4#V^^7EH$E70)=<%IQ
M>A\UY)&*:CF^0(C8#UJYXJ>..?H!2'R[).KNK(@5-$'2-&AEF(A7]^@ <V:\
M9KYH8Q8=(W]5=(!(]#V3&(.*>;SF//O+P8H3QOCO"GR'X. O>8_J8^2<Q^(H
M+;+[>Y>C&WS-1$)_9* S6ANA.OZ>+OS(5Z5:JCA>B!BYYC>C$XDL;P6$PYA&
MN43(#^H\2[=+7*\D*%,W5?H7*-@01'AJ;20_'')G&+S'0D7ANQ0B"SL__:E%
MU'=_IPD;2/50X%L!++!%EX#&:B,?[D 0QB:1ZD.2M45WW],3(<G_C#GRZ/;K
M0_['$\CFM'DYZS\]^Z>:D+$2\O^&V#*DH=[;N-&@HO>"^ $ZXH_#$6WRO9XZ
M77AIF-TS1QA!?$I ITM0X$R="4&K+D$LS4B49N42"@0+O0H/8!)>-:4T DN?
MO*!DP)O"JM@D'""M3@&W^O#A[WRQ>FQ$/>9"RXZ"0#HJX%P@?4>[*#V9 =;'
M.O=[EN"73^$&@'UP,7WES%V%-#^4MKA.YHZ=/#EV7.-)U-WP.'+#.AZXIXPJ
MC;N<'K(1#!^LXGA!61W$V+9IF.+U8&G5)VT8K>UNB,%&=DD@M14L L:<+9 K
M6-25M^+0E1[".M_2\6Y1X;AO5N#W<U@J)+N4X<-BD+!PDAL2B"$]?*X[0!&U
M=<Q'C3"_>5Y(J6*:K!%"C?V49*L*G%YHF?UHDQE[A#3\O"JB0-W>6&)T58=P
M5.;>LEO86RE':?&1.@&9=0;Y.)&- (H";5+[] !D'Z(>!/(@2S40VAJBED(T
ME<0J-*5 ^XZL7>U5L"Q!]0H?WTR_I#A^$?.=^Y&/D) %8_8SO,*4(DG'JCT)
M&WX][2X' OV8K*:/*CGP[.R8XL>Z>>W?],059TZ.;;:#.8,)DKELV+T"F6/P
MU<7VOJHRXZ)=/F]&[6OEIX]5>V8@QXF5^ZW"J!%C/0S9448?_EP&H8RADNJ3
M>Q7]O192!'-\=/QKL'2R\D[)<&X'@F !@+89<ZA8-7-)-R>1>QJ+*AA#U3'K
M1 D8%VH-L/7+AA\34. \3#**U+L[\N9,$=IYM]=DRY[:.:J;,I?EYE&CBM)[
M&("1"8HU7+5Q^:?W;4]8CT4\QVN[\^C= B\8<2H54.ZR_5;J'3$5NFV^:5&V
M-M=9$9[DZO36!P@H928R,U#2-/NG)S5?D=[6@?!R0BUG\6,'8X7R]A>0$PB2
MIN#:])?JN-T1X245+1/>I(M-NU!S)<M?9?7N:VOF?1H>+#&9<H?K'<]FBF+'
M]#7GN:>R0H\8%ONFN1EG4SH[KBM-NBYH0CWZT"Q\ANP_AQNHT/O%/6W )L:)
MM'<NV$+-AI"*1XVZ7&64[?9;]0MO$]J\8C,;X2\N)HA^23D-$01YI%+?!\+U
M=QU/#G@W_-J-LO9XO@_XV*#%2#G']*X:5VV("^N)L3TL++<"B%B+L+#Q05'B
M0C^NU-B#TO'@7'=P>Z!7+J9O^*[XNCH<;C$M\R0J$E^,<OG6YO9-[PO6E0]>
M6UHRCSM.%^$8I6BPEM'"9J;LIE0J=7+"-*M&(T@RD"0U&#O6H[^J\-*HZ]AA
M6+CZ/5Z/BCIK8->5H233H@68NX-4%)[ETX&MQ!87B:63>7$,.2,I">EV7)G[
MTC4,S:<55E#,L\(,?YT187PGS\RQ#]$-_W*R*;GHT*C@B%GK[#)\(')VE@>:
M^P&:;;)4]R6(1%L3A+R/4I; \Y_]C\/:Z-Q)7M6XG:W-FO%$MQ8QL/Z ;JJS
M=E"G+._@T9AA0-11;QT@Y32-2:M#/:Z?7##I&,G.D6K>JUM*2HLW!$L-]*@7
M>SBU/2N]M&PU.;==0^8#D(<&-A=+>K[9"6VY'ZMI%_,CQ]B7:1EA1GQPQ'#X
M2M?&IO;]$G\O+C3G"I34+N&$T). Q*2A1[L5X^X[3AVT*$;=CY#ELO7=GI?D
M(JR:)R3)Q<@ %VN@01I;E'J=/^^X]%R?7 F%NB%[7NWX@4(S6;'\Q\@!$WA*
M4-EUO.\J<7@..P?UT\ZC\)KP5W0H<?MCJU>EI%+J33883Q));?)CMBE!#)-Z
MC3[YR(CD@RD5%^&-FMFA^?07+U0SLAH+7)J_L'C\*/[((VVJIO-Q,=ROKR6P
M!O#T<LF=NM=8_/AYP#B4_*1E)V:+0?%E!;$C8-=\@,D+3#K3M2M>$'5/V<[-
MO>_8IR\3%L'7TUZ0XYI^^N90T"_'D7M;PKZQ(SS<>)-9$B2[-&E'U]@Z8Y0L
M/_!H+(&@@_BM.>]F^?-0I10<:\J0#XO*7+"7W;W\M]V=?Z:,F*M9IL]U,3NX
M:0HJSZ.0[#(.+')6.VU8!O:*UA:Y!?+>U^F<^)DJ[Y09D1\[]6VJ2+C8L2GC
MGDEK\93U(3,="+7N;?L$)@GGU"A+4/ZQ,(FG9)GLI=/:N;:8^/38 G&H5C&3
MKX/+X'F8E+$,5I)# Q.\I*?9H7Q/Z?CGV(5(&%A"^]6;_^Q86<&O;1@$_N\W
M39^Q,*(RXUI#;][^6%,LFAVF2_YVK.,H^U,<,GC?'DV1WIL?/4N_**5?D!%/
M5Y&!)-<X*$I(N<7;#\%:AF&X+8TPJCZB+* H T V4/LQ;AIY')[K/7%7*R3F
M>J_X?F@R=YK6W)K.F=>G6?5ALQ.2H_2(F%OK_C S<+=?6KA(6/T!$(G0*CC>
MT+$RSU!L)D(D]^OYM2"J0=::O6KIM-1:.]A;>8DF_?62X/05L4(H%3M_L"0!
M8Q=%F/5+"9NG802SG*1XDH\8)0>+T$JZX5$HG&Z5*RND$E> ,?)T6<!'O26Z
MM.5+[3Z:7_O=Q^#[ZO3.$AN^T:O#%(<;Y[P:T?'L2A-]440,T7MZ!-'(TZ=F
M<S^=;J^*L%]$>P]-\@5?7AE<?]S\>K\WE:;SB?[3 (4+.DYT/=SG.+JT73RN
MA^C66O-X-[#\UTU[Y/ZN_(W#2TY@,$#2/4LK2GCOBX/J '7#?75DYR<W1VT^
M+>_IC;D&04A:V@R-YGDO]^9#;/0K(M3! T)I1DE1TI[G4]$7]2I>3L>3A?NG
MVS5U'R%:J3"$WN#EBTR]'];Z"FU^R6&GS763E]3'TZ4<:ZY]RW :"AR>O']
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M06;FIU=.SVQ,LW4=++L8Y;?3\!B@65=ASN@F\R@&A8OFOAT:.*F"M$S861R
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M]" =\G<'$OQ#X1_V@H.9;Y=24@@)7()(&5\#5D4GB>X,Z3J*4KVS&2_!N\)
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MOU+HSVO 3A5_BMA65>\"M2+8R[\6@<V'-9P;T3K&<PTLKOPZ3JEY'^7]]1J
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MB7JAT7_?SL]_-A!?3_\;4$L#!!0    ( -(T:E1]%-HW$$$  -1@   8
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MAUDA?.O!I#Q_84Z19],HCC!>8_9@^%[,NRI*5^:.;&=*[22]G 0"=4+5(Q3
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MSO:DKB*3G4>7#PH@BY,SG<HHP!-\I#P)_X0"UI9^JJVVIB9\ZQ6[, X%2*"
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MV$\U+'(^1FPN1M\YL^Q%7K-8-GM6C\R:]GB'/$DSXR%?RY*7*6.'-M_H4Q!
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M^94?6 34U;AC9/#'MLO]:0UBKUX4_E;>F6U+JC(XX-X?_CJA+2%%H$:L*D4
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M]%4Q! >J'PK9M"HU3N]KE7(A<NEZ(!M=/-QU\_AASS1\,>^$ [6W%7U3/>%
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ML;_?P6GM02H;*W!Z_!&P+5U[QBNQ.@2T_M7(BFY=\LGCGL7X%KMW/SFYF6P
MZH3 Z@W!#B3MG,ZM3]%B4!MWH,3-'VBJ1:UO^*P%LO4$[07^Z>_X/>[/=JW#
MMKAPY^F_;L]?2SWP"/"E*;\2I#/&M& <K$GFW]-LX2E"*ITWZC9_6YB=M/&Q
M.H3BNM\\RZZ@:N+@;(_3SJ'0C(2?0<36MO_M0 LH__G2^],[)=H'BSJ*T O
M(R!XJJU<6V9JWSVN&;-D?=C7;7FJ_>)9^ Q62O*B7.)0SUKF[(C>((*E/Z L
MK\-2J*9Z4RW<K++"]CMLP[*N_LRBR0&O>4G!)\\1_?=XMWOI@)BW+Y/EB 4Y
MNF-,^[J1X\UV^W ])$?!SB8GVI16)<<7/5QU @)5D+1W*\RC>X74;5;* 1R^
MX'5;JE[7!Z7@S@$1"MR1I*PFR>;!XPV%8G83PE(E;VA(VG2&!8,7ZQ,[!$G?
MT2_*H-3(ST"\W?9T:R^J.%'K+.>J1 W0&X9QY]0L7X[XL[KRW0OS/-P\ I@;
M?<16&WX^ BIP],:!O GWB3Y\-TS/.=+!5[ $X-3)+IXQ5[8H#S-8V.16[2+J
M.##"ERF Y9C_@(9-]SQ&]_,AA"9]1*AK6S?B(.ZS!A_1>*==1>UT\NFGL3B>
M-VH L8&F5IG.- ^P$SM]S/AGDW[\)#K?B;SCATSL]+=?G9+"C-M/*8;.><#U
ML0^9F/=?Z\YW79N&*F?O,&SJ=HO;FX'8@EN-A3 V=Z ;QQE$09'H[?,7$8B=
M.)^]MEZTF=!T:5) .B^? &'\ZR^U7F!=5+5WZHWFP)?B 4F<Y4V7C6KY+#OP
MN50/)R:$?TC?QT+68*Q8\'1:JQ< T1V)@OIK]A*2O3_G>/"V_<7'W2R=-XCZ
M'07Z3$?V7(I3IM,UM5+7'ARH0FEZ>Q)((TWKM#$X9^T@[?+>76R@^L!A&7KL
M1Z.OT0AD3S67X3><74[;#5RAG&BO35?!XYH7]<3=0J.E8'3$ 4***$1RZ9><
MG3#(O^QB:4-#C[:5JS/;'@%=F\*R37ESLYD?-D>94CTDD/%NTF#$CX"O)QPW
M9R6/@!7,L;LBZ5AK!F*/[\G&X$*]QN/%=+=1[JI&+P)F?A=LM$H(GQ91?:4$
MLWKKO>"%P*#..2]"J:C.D[=*.?ZA]>5;_])D,-"3O"E]T->1K2/">VPNE]PG
M:W)F5Y1B BHCQQ#YM?@=70RH3A3*%A9I6M1!QWN,51U8SN[Y^B9141LT?7;_
M\?C$Q^W\'KWT NVW;PW5;,!(W.>UZ\W<8R.Q%=(O%'Q\I_D/N$-D0VP;"C\S
MKHU,9[,+[69T)(K@;-#JI$BY-_AIPVIQ+'*'0Z8O3QGH:K4$[GT?I \P[M?N
M[<SU8/:U][S6:9JHN>@%)[TSZNZ*SSMU;> (BFAS#&A?Z=0B[IB]E:X6K+FD
M[Y3\)U6XO$ .S'%4P):!7=_6-?[719I5D!49GT&*P$':+,)@+"J&G:W3U^ Y
M1I:SOEY8*K!4[SYM5V1LBQ8-E<IVY,MOO4_8L;3QZ]*8%.MTB'OF))VZ0K9S
MZK$$)<[9N6/&PJ')Q69_RD1'(&H\;HV!$L9[*A,6,<53OJL(!:?$_HW,\3>_
M&"C*<MJ.ZU(#/::YZ")9[D_)0SW]@2;';2EVK'&HRE2I)#%)!LMQ"/"!J6.#
M4I+TPR-@MQN+"TOOR0L> ;/UW^:"J48V99JY[51M<:_DKVSY.$>8>DBYX8"^
MBK#Q<18RG8,<5.DOZ"^'WAY\%PS-A\\CFP40HX!&X+>7.Z[*EH=Z-W/K+I[X
M6.@GG9H[J!>_!0(744#Y(C65X:]N',^G4Z*8&":$M8&>!;I+.F^3NBQS/IE8
MQ\?YZ$.8QT^F6( JUZK?-%"BS0OURI/:(2_<Z([N;5T%(:%MA6LL0K[?>M[;
M92>!LMKRZMC\F IUYWN=T3_116^XOL>[MBJ$M?"!;6L*IE6;!=E'-?M62[N7
MATA)U#1 AGT=X4?*JC*U2DRN//<^<;,\]-?JTS?;YEA$6-8]>GD&S=>JS]X2
MK#G31M\S'X9[LD>6U'WQZ^I1VM-5=MXQQ&I+M[?W=_8F_9GFA)+@Q;_S">86
M):(B=5'<;Y/NPI5!**:G5)W2=/&3F5WTS+/1I^5PZ4$*R_6A3?FL4E(3GNNB
M]%R@O/OX(2N9C\B,[\2!RN^+=S\/=U%^>[P[L!&^:$FA1KQZS%V5!XAR:""^
MT;*53K1M>_V*T?3"?D8TUZXLJP<C_7EUO%QPBBG@- [RH4DJ31'X3GK))IWF
MN@G3' $F+>%H/Z'72+?;N'I/:P3P2O]@\LZS861%U_$10&G$_!0YL\>;;C,%
MX8>'\$U->GV73Q;D)FE?MY.EA;H8YQRQK:[C&.;&,VR[Z=HAATQJB?:/ 'V=
MLH+6R..,C\0/?]Y<WPNZ9OMLL/$] GX+%!R.I-P7"+<\ CP]KS:;K(ZMHO]P
M$I1FKNG*:MV QK/E:K(P;/38JN8$6^3#D61W%#6_&F7J9#+UVUE:FC/O41UG
MZ@9.USP"!,,_<,81VK&(BL(,"!:FK:%VNS[8V64MCI[XKZ--=75*>E<^P5J$
MP+:Q"<IDK']%@;JG*,!<8&\-[Q9TW6PZ"OS5G9'OM6M<O1;%<"N]F-I+<L^\
M%&*?&]X9/X GV?=G>&;]-&Y#S\<CTK2P@TZKBO TX+9JD \&N] BNO%/@.N7
MX%8XO>S?C(0I"9?U4<N5N(J)]70EG^C+1MMGT:O,T'.]&%E9+"K5<TBQ*^BD
MTP(-),A:V ]ER:+<:,)[M-K"$*W0_TBJ_F+K$:#*< N^UL[PK)3];O6::C_M
M-(S,,#RWVU&F)-0A1%6*L"KB7^;E]2Z5JV&YN$MZ$JZX B^Y37L"PDJD5OR1
M2;1T:@U%Z-23+.O$)2Y6H<5Y?>Q]U%6U=7*O,&SR=>6 R&^0(G>5(69[/CP3
M,QV.!1*F%UYS7+K*Z-=J<4H9 82C8Y+BJ7W;E*2-]5.QA9Y <XM(/!"+/N=)
M]#G=LE6=3)@;-6M"#,V@7U"XXUL7UVFH[9B<%'7C^V^3=V+^%[5$/@%)@45Y
MSV*'=]\:OVW5#'E(\OS]0)DH6]^2<-EG%]7/UT_.$C%JCB1^5@$""6@>D@]/
MO8=P8U'VK,_#@<G?A@,W"IP!@8)0BI@"!:Y>^U>LZ[6Y*ECKYPQ3X+S,4)>2
MB<]Z?;KI_%BE:[@_>CKB')((+R(+=WU%%\!S!I]7_&8Z[6\T;QA_&I3=IYJN
M=^+,+)_DFHPQ)+_[ZO;&@X<N.?ED7L:9#J]V#)DV_CN1P7G'@;JJ."';V2"&
M0BJ[_3YD)<OX/$&&6,NQA,)V@4 %2>J?8<@1*CB/4^BJ.7&E&* 0=HF<!_YM
M*!:Q\Y26;@B&_#]?S/R/ Y6660;JO0#W]G3ER,_>,HHR8&]\G53V28AS05_5
MY\>4'@E,51E/=@$O;E1K$X6Q1*I\JX K<(G^V]P?P:ZU!V2;!IU8D%JT8 F5
MJMS?G^K[>W!?)(JS_QIWOU4AW9R)3L4@^Q5O$&LITUKSMNA[2@M0]7^6N__G
M@MHK0#\WH!8_%HJA>#]VE191Y0#FWE>(%TB5:1^OXHE8]4ZP"M:)CZZS4RHS
MEMJ$_Z20H:D0Y*([C):@-FXH;C\L)FAS:S\=:Q>,!<%[M"DVQ2[G3@M?]0G*
M+F5R@0")(RG-B>>;:=U41YWX@;^<[TIJ54T:>FIK$VOCJ32%PM<#>\KZBP:X
MS"R_!U8[!=)J;8.+:[E(=,DP"Z@^,+$ ,V2;+:7B ^&[HF&E@^#G@_IM@3,!
M[<%'2O?=#CW^!.71T9K?R[!SQM5Q_W7I2^FC-S$SDY5($(21^TNG0=O8?=?Z
M(^"\1.!MP_CG010&9(@4V/ 35Q5N&^37O9T#HVF0&7'24P^!@MYT&8EI0Y/[
M>N&N7")D#[X&Q1<Q"H'"&GN%LY7&/ _E:&=E;AH"_7%)N!ADG./S :S*YV#_
MA.D'_\3S$IO"/[>Q?4&SNEEU>U><5%,_X);I;KKX]]./ #RMXOS42PQ:X>WB
M?51MX<2Q":KB(0_<4IE7TE]-Q9&K#O#=9O=9/A2Y.KHL)\PT2FGIDOAN[:F5
M#_@<V[(;]C\-2?._MQI//-X36SS.W.P_R8!ZSW0^8KM(_ ";.H#B0&O-6)&#
M?,@1AE@:W]6T+*3ZZ]T(MZ:R\2RH"-RIT)?F9 @+'.+U#-D#@*0\_C&)T1D9
M_BRC=@/:G4Y>X*YV7+=K\FX^N+U%?6; &5<$01E.;@GK/L1/1KA-$'8FH$8
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M29MO,Q@_=#Y]/.QB'Y41+\A B5UM2>FJ\PE+6CTP7SE(>P>=AO*SXU,@OU+
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M-714LTSHWY2>6!XO;**K-*$ZBGS;A:7.]4EG[L2D652MO#ZU)G6TV9<.(H^
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M&=&SQ5^!=EC9Q]OQ[;9%]HS"LQRP3.V($4_P1[9V7MX;VU_6#$.PR_RVRUO
M1\/?!3[6J@VPC4Y+TIY.NT5T%+-TP+6T%=I0.#X":HF++AAH:ATZ#[YB]AL5
M2@-J<:W39B\KKEOFXD#<US$]M)X;S9XM;@N"?K_NR(Z9[#W@G>BWS=O,15,
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M-WFA-)]7;DK"]S^*7"ST7-)A(4_/JBGM+!C>: !U(]:4+FN34F5DQ<H\+$E
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MZ@X !G2U(-K].P/I=J^ !@3MMEH=,T/UW OM]CSKC<!IM6Y^:$[P!H31'R]
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MIWTEH*[E:;6."$H%(G=^"2Q9AF1&OMI,DT24YP=QO]V(_<7KV+Y[..F",;>
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M=$8EO;;7RZS?NS@P,C*SA'[6K"WF1,A1>'_ZCJ"@&O2QHMLL\7R=:KX=FC2
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MF FA,/V?-:0*+(^N^2F/?] \KIN\ >CD+508?\AOOK40]5I'J1H4=4%&XVZ
MEV4Y\1%E?5*>PH;G+S;NP#/#N+^^^!\%'DT][MK$GT#R'QH(#-[R.2+=6S('
MI\_]A"LI!I*QV^P&I$!F< .H.MS25%1\/%!R2__^\D3%+=G@"YV\>8L20/0K
M6*E!@EKT#T'X>NN\PS\-%N%ZO?<S10/6#/9!!I!8C$)';H!BBQ)0GK2Z@[-3
M-,"^K'DK:!CJ6G75\_X>TW$@<\+L\Z3_'(&_>D47VG[+  ER(.[V4>=Q!190
M6>KWOG@%O+GV58\.EJ64+958?NMKOI=LR2J"(N/LQ"IFA0UQ\^'+7+CH2H!G
MP9KI3&Y?R#<*DYP_GF[KEVLIJC> WSAEJK_G >1/ $N*&JJ;K]PLQ4)JAW)H
MJ-9#%/6E3(X%,UKUX@8PO %B4&>HGSLW0%;1!L7ESDGQ(COW?/U4>!:N:DKT
ML]S.VW;]WFBQ5OU(C5;EJV/,SXAK=579Y0"R'U<F:$V<=I3HLC-?&<[,2S7Z
MUF6X N#9+V9_[V;5!2T]?)[**=?S0 P?[8J[NX4;UC/E= .8J]T &=6:^U/N
M=ZID/'SQ?I?$4HE]1LS(+C$/F4;H\W_4J4*>?A-:]DM^[?A[,U:EN+ 17K^Q
M )5\MDHX>?5E,Q477###$Y ;B-\ ">[[8&)KYKC0_V_OOH[FW>T>42#M(/T?
M:NVQ*RH;1:8"9JM9P[\(+.I]($G2.=%$[.WATUT-IT6D+G3@EK[*CVG->UW;
MTBD0G$5/!)+!PC?5\V[SM KX3T9Z &J<E/S;K-X^^<M,_XI@C+%A$#GR6[9@
M$TC'S$&AG63?'L"7_T5>[X,3@\>&;_D8?>YMPFINJZC^Q1L'VFVC0,4C!ELF
MCZ]E5XPU#B\N,=]9O9O'50&^I9_I7N@WJN4[E3 WU/KO]V6,E$<$[\B1,_Q#
M<D'<LOQ-ZH3;WH96E97E#REAX[@U+W=7 ^(<D)OR]Q@H;;(,NWKG9H%<%$.%
M),Q<"=P L>[9L+H; $EC2'#0BGK4P'_])N4&>*0ZLA^B[K2@3KA+4]3Q:?9'
MCL&:W&?[! ,:H5I,$DG/T@+NX>A?']@H"GYX[<<<T!AR1\X[/+7)?9.PBWR5
M54CG0L-]].J@UXFU<)B%$\M8(#@6UHHT#/$Z0JF*EMP %@57L<WP:93B- /R
M, VLTN\+*S2^6L3PJ:NS5(,Y_FF,(S,,^,^1G[I$F1M&Q:80:QHZ7(.W\'+!
M\T>&XPO[I%HCK5]A5%GX8H!KD%)&VU4^NO'KM*WI#>C8%.26?>,DGH<ON7K!
MS!I')Y4HT,=*7XI)B5D_=D/X^]OGU$Z($-68M/OFM>&:/F;-'S']0M2'UH:%
M<]9LWRW+!#+,S1)_W1M H<3G>N@J1!B&/ +C-$Q2&9+BHIDQ&YJ!ZU8P*%7M
MF@27Y9C9ILZI27/(4*PP+7]BT\R(CSYSE1IN@DP+VW6+I-%I:ARU$II2(WW%
ML>M2UH1.N)1%Y\_=VP2R6);<CS> F05XE6;/.4D0U+X=\R<G-E>)\:PS--9+
M#\<V)R)8*FN7S/;7H]P9[C>/&?BP-;T:8Y%(/([8'10(!?6@\*SKTGW;"4GU
M'_"0 1A>G^X.S1-?9<K!T=26H.\!Q+#N-5"UF8+Y_K4Z;AEV@7EN@FI^ #K2
M2;LWY>K.N0B]=M:^%)/:)J+8$D.24@^=RC1YN"BSL.R$U%VO)WWU]I(^FJB4
MEC^0J2+PN=0PHS7%$\.]#:-?1H.#^/;V4S#YKF)](<B]&Z!6L8X_5.(&")FT
MZ+80AVU4968GA]DF4]JYEG&HO4Q;\)4V;LF@NS*81/@1WWT1JV?K^#3M#;H\
M%DZ)BP][)UZ)IT[U]YKA3"/'^'A!\Z_X?+LPSPWN?%'JE-F<G>,:7\::+V2,
M1+&FA*!#'DU6/\2TIL[S%%(73Q7SIU[?OP%XHG/T5J&L#5\6-Q[E2,;"K+GI
MJPN]6I:51ZII^DL$A602?FE16M7WU>QGTTTKRI[EV94LMM)LF7-<JDYMU(Q<
M?R[=$SW_&];K_#HX\X%_8J,#V:@\_MEWY;C0<)N7SL<X5"O$:@NM!+"?_$5;
MB;#78N8OWZ@T=58R>%E1R<:?K!T*AF5N5J&X49C4\QVZV<:V1WP)ZW2*HSM2
MZEWS_'G]W_)D? X,JVX \BW)]]'6134Q3G3??HUT=B[:F,'O'$4&TFOX3'[S
MZD?)IQ+? -_!ACK%_?UO@*]I4*V\K<<E=E8/UI;L)>\]LQTWJ;G]OK(UC"AS
MNS;9QS9S^4_%Q8N!B8%UC)KVJ);J4:,MGUV^E^/"'#P+[W$2S*4.!%YI?ZO#
M%>CR+J,^R+N*0G9?^T>O5.\B\ZZ"REJW$1;7 #SD:TI=N1Z3!NE, +Q1W(%H
MR7JNN5 ^SWA#F[6R2+ J*1L@\Z2/N31H*5G&BZ1YW-12/TJ<5].DIHMK:FWB
M\GZVT:GUJ>'G*V$W)YK-MV8JA]8;KN"^1+K/28/8MC<!??K%@.2UC4CY("3:
M\:*@G9C:>6KZ0.0*LARIUO')7";WHV/0$,U5_Y+0)TW*Z.OD<(OS,#?M7 =X
MTY&_+9^&H^CKWJ[Y!M>3I?(64E 21H?"=I)0@2=5*)S1*]UL6T]#3\]/*@1A
M3UIM7@+!P8.KPJ/QZ<DS@R62PN5\@IH)8ENVT!:N,7=>OG9]AP=SW%+UQ-C\
M>)*[#E^Z?A#)GH077.G$J4^65OT^UD_IJ3O$?+_MN/Q)*/(#G;_]8[4:$P@&
MU*#G5R_!DF).PR>^.^MTV_U7"F 23X R\ 582S-XR5B7$CZ\R] H7DGM%?45
MLO<\C1VB0Z5A!IA]K55^42_H.!51T(?OOCW@+)HJD-*%'/QF*4SCGU_QU"IY
M?\<IWOVG.U5I8P?DX P,VW/?UK6$-0L\4!R[5("MS@AR3);IXARKEI\_'%*@
MES(G6H[8EB4<J^;'Z\^;5K*QY[9CWF2Z+Z08>H\/PV'0-6ZTV6#?,:7T_)D]
MN2*\:S51>=6#XFG@*UG@@M#',,N &=9C C+D4F?81F&+WJIKJLBKQ3]ENW,W
M@!"[T4$)ZFNRZ]2YXY&66O^3.E["0Q;>*QP[,4B"<<6!;([GB]RM^YOWVAS\
MA;6M=E[VTI\B!'-P&$^H2J*)8#W-V: T_\J 1)^4;3WDWK X):Z] 4:.X4Q&
M1<]6I!\O.-@1.%Z:*5;X6OF?)CSFQF;LN8.S^D-Z$B86RO]ZK57M6I(2,=>E
MMGKHJ/;ASAN]56S9IO$T4$_T-+O?  !8NR8R4X63NMYS$IN+P6>-GKV\9PT$
MJPJHGO*Y6^MP?_M3W$QH(W<>Y[W$J^)VJ4Z(E; ,=64[Z**@VF1H-CZ@3ROP
MFFR/A&(:3$PF)K\U-/Q<01<8_'XZ;8FN2&L#Z?AER8SWC_"EO8'7.OZ+4$X6
MVX6ED@TZ=Z?+N^K7G":SE31?K41T8JM;;+@7T_"\HMN3-?)>/A_-NW1F%6^P
MGCITV/R^EGG@%'@2Z8+JLN=\_;/M5>(NFX=NO<IFH%>9"L0=QK#^]TZJLX9T
M,[IX<GG!CNY9%/_/)&1"TOLF".8I^?RK&,M:DIQ>'D%"PMG@T8EF$H83SN-2
MC*=@#NG^O %.#G .[?8602J3IEKTK$]-^]C H+6X-V-SR(_'NB&,T=B"=UR5
M8Z]WK:@LC->A/5);(:1P*^B!,PLYUS-\/F]$]K!*H\)+A:5(<E]O]C 4)TLT
ME*=>@N#GSO):+R:^#2LU_Y6\/32#SAAPS)B+R8\,G/FU"*SG4AZE?A9&*U-X
M;N35KM*@9_2*?/2+,7G8(\()HLI$TPCR!=J%L1BO(M5KN*F9 CX\KEK,<=E;
M3@4#(*=<;R5%JU6PL46.Y]8ZL)ZFOOJ]ZO5,^9VRM65>F;G>>)LKGFGU]P3\
MK0S$P_8WNI_NTG_ .4R_:YN?4?=^^=>AM8ITK4#+!(X]83J2.C&0Z9^[D(?<
ML/!#,_O^[+;T:$&U]S5*OK_P@Q0U>W?,&T&^=ZW@5Y8)ZU4":^WWK%O98:*=
MF^=[_*1WBG[9>ZG_FYC:!-^>\.^.9#?B09:P]3>?I 27G;4C'&0B+;WLEQS6
MP_C9JRJ'+2,7(U2[3$:#A*($Z-C#P4Q$6[H!+K$1H,5>^XAS")C\]&#RFX,?
M98S_C#>.^_-J"V+SRQ/%=/Y^CF%$>/I".$,X*4[]_I-:RCM6EG=G:[\N#VMG
MGR,OC893GH4K!$G93L4DE&G< /$1GZ1;?98"V& ].>FPR9,S5(1(UD+T!5L2
M[ 3AM%:5P-'@U_X5H9)EU04A-?F)7!V,HX\[_1#%ZBQ0-]W/I]1?=8R<V UL
MX4E>ZEO7::SQE6">YRJ%=U2L6!&72LA6KS"0MZZD@TQCLHD!"90%P&$KQ'G@
M?U462*"@ (M2H33WPS?H/$7.6'7/<9$_VI/*I\-9S6O8BMX0]FJWI#G^NE%A
M?\O3HZ<1:GE*M*EZAE(A;Y%^G8H0%G.V17I9ILVI&R!M'6Q8VZ--EO+[\Q$/
M8:N(Z8ODAO@L&I.>H6]'AXG20@=<1YUB8N03/J0"5;@5 HG'"T'.72RG!5?R
M![0;U'Q) 4C-KV<#7)3ONC"M"8D&:M-Z#(GV/5&/?<JN?;O!$"<[=5A<D$F+
M@)QI]U9IZG,)Z.OYF+*(KHS,05,A+>-^LNY5(TQ1X\^*.)O94 8(#>FF@&K-
MSC0RI7=^"I[@3EG1E%5B6?$C/!S[=C=!<$AV[D=?Q:K< -O9\TC!>H9PV*%6
M=1IRG0$53IJER)?'\<AA;KWVV?;DZ):HP9F/V[UNC]*> ],O=[A2ZK%PG'R6
MJZ(C2+:IFUM2G-*Y>M]T$J>> <_O#_7NF(FT7KV7ED&MM")9)S^<XT[Q77EF
MM;$HYQ^)/Q#CF'=&$O<41'*TV!_+WY507*^UHQ>H@Q_+6*+VGFJ*:1S"W,D&
M%QD_!<I:9E$BJ?OWASI\Y\G47 E2W^&_FN$6N&5_/90= >/LT<<I9OR+<PT3
M*&?OJV"6?FYE#58M"4M_$)QB-P 3@16JOAT,G CI9I>6R]'=/NU(Y+>TT!96
M.@R5D3V-N/6:S J!"%,'XC^,]!Y?3X[)1).6&W<,'X<;F5'?V:&6I\+>3V(0
M?[K\BHA]HNEL2>PJW!PD)J6>%D@2 Y#GM:[$@]8M,$!53?Y.578H)5_#P;@K
MZ6,+#Q'!>=2>*C5G_:40QU' :*6'GIAZ'MA&\ZLGRU*1E/S"&TPJ&;%Z7J5/
M/ZP "T'!E^.+K?=A*QG;D#UPHS,GFM-0ECXVU]XSL(V[3S85Y%4\:.)TE=>J
MG,)'[8V;J!UJ HMXV[A*V':!'^Q?08!*ED6LCU01:&HWCM[KMQ+6!GE>C__"
M/4\RRNU-<\X%/,^&@ZXD?$]!DTKISXD/<S[TS&*@0U1/^$.3#4]MVIN-D@]]
M"QSY&#UCGP?NZ\NAD>(_]]'6^<HB0K8B,@!C9L [+],^2*PM,/\-%=V_$-U_
MM"FRB#K.OO?(%Y7@:GX0T4HDW$RAF:9A,I7SMC8^S;) 1R@Z?KVL^KD?X0U@
M4N;/>P.<YB@<M*,>43-<.]\*+&._CQ.G_FBLS<L5\"LG_\*-B8:ZD?0HN,W=
MZ!J2[:,+[ZY?](H^$YJA*%XBPO/$,Q5JIKI+UK?2\U5_9A-P<D=!AF?X,^U0
M[7C^+_-^T'0#+$&NXAT\42T4H)S($8>'I_''/$SQ;'6=+1%I7!N+A9]I!MW;
M5^%J,GR@61\1A!MMO%S%$!ZWC<RF=J\)_,BSI5J5U(1/,+,H4Y3G=$%9 MGN
M6[]@\X*UO__B9YU+R8M8TN1[JEA,FC:;NAZFG4,Q$! 4L<IA4? 'F1:9"Y>&
M%&P92AI3%?,Q![;3=>F?[3#N<@E$HKX5)KUO8;8X+Y2*L\EH8YCZ\MB[MOM;
M>PW+:7$9G8E9^P+_/5,S1'4MPJG$7-C&0!Q;9!TS*GW"L&W^1'+HVBW\@II)
M53 XZ;.&2P3_&.(@^IT[)%0TF;PD3Z2DX?I39;?T!RX+>^ .[3+]>$;FN:'Y
MJ!N!F&*J%'IB[;V^HYQV$OU7)+1\@W64VV;L(6#]UAQIW>[CO\8TF+[>^V$@
M"S=M:B:@U9TYV+OOQSM9G48^;Y>81(Z.%_XN@5R%4A0P)R1%&J9O)DIF3+YH
M;@F:H,RLC65D^MKSK%+1-__'!=&Z&;K_P4FV>=%)QEB<P8N^,E>-,.[[1I..
MPBF-RO=5DS<=L^]U;7)QS#VFI4U3D!XC=1AY]KBS04^ J:4A;,)@1E5H%X'Q
MAS7F!Q7E4,G3.?:1B2E'@JT[4U]<JRMPK_]$O 3N@!\R!XIL%)O9=VAO,ECB
MO3Y[\*=E()8K@HN"G4=N0SQ_^>!]M/.K5T&K1@.U" -V*4)1IS;VP$>?E+<X
M,'S".I(ZDZ6Y):L15<.*0ZS*=UGL]KBDR*<')9>JBOE?C!4S-M7RKCY].^F2
M((ZD!GX>D)B9;"=[%#RO.1,C'_Y58L/S\X'7M..:HC1Z-OYZ!'UFDF+-V%[U
ME,B.(IR;S5[; :OA*=LKL^GP2G[ZSQ@RUW9E46[PB>5GJ''[.SL.JT$Z-6FV
M/+$).'A?U]_""[P,.P00<TK9%O9"@],L[^<XCVNK$<Z'D=T%C,['Z82'R3<
MJ-[M)9>04ANE.U77BN*["S? ,ST<@<M[ 2%ZDHYYK*E4HV5\(;']SIC6O[03
M+SX3*M/AM-H!^TZAL$-)>PL]D&C:F[>ZWM8^!E33+N08LXSQ_$-WI'M9(6RC
MNNQY'=78?TKYBKP#Y1.!M!\Y&U[K@:TK;B.0[2*PL]>67G;##OF]4E MQ3=
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M'RK (/98M<_O@J4O4]VKK#WZ@B.9_=H3=DU^L@/*M$.J_;/+VQ_<Q)ES[R_
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MOJ&?Q[M5FB,K).8$&_!-EOW&IN!="R2M]*,#B$[ _FE\JJ_T]=C##^#KF#S
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MX86_OLU'7S#JF:^5)>.A$C[V?TG_;M,(5XCXK4H3JTKG0\/1P5D?-AM.X6?
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M=ND"&V04L0I_^\L:;2ZMI9ML"P[:?6%TM7IR</GN2[7\K'@$(\^$#I[U"AD
MR0;IS!MWK%C)Q*S6E<'S:V]>6:>>M4FI\P,<_SJUXSK[52JBD87X,R >0Y6
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ME XZCE/%.ELWF9&-!KMV5G.)^"ZG$XY3KX&#]^M>>EO>'G >[63,.&C:_<@
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M088H<U^]4JZ%S>C8VJ+\?IVWP2J6#9/3WP;F\SD\'I%JY0[._N;-K,:LL.X
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M-(>3>!QWD5)D&6:WET7I('G&D)U(5Y-J,'L>"2$^Y?]FP"W76 /=A\XN'_5
MLO?PO9+$ZV@P0,YU=7?BMV.4;X#,SYIUA'9AD+)*"0>#AB 4B53\%NDCJJBL
MN$.6S6"%EZ7GU1>%&\  @F?V<9#AJ]58&X9?_Q,P\-C6?JFD_U;/^1'+V]7X
M\0($R>7I1Y__B=:\1YBS[KBVIX;C^XB]^8N5W@YC>.+]_ J:ZU8P0,;$\M@
M>@RBIYZ+'/_NGX,T/453UQYKT U"=Q[1MZ%*>]6D4+6$6$6IFTX'H';/3!G@
M./>/DT=+-:D106VQ8&^PBU"9&@USGP)<[#X7M^$]TXFQAV)TG\:8W^Q.JOOP
ME[5BOY, )B;)P( 2[MW[^Z*+">^&OU.S(O^XR+X(KLHART2&W&^%LJT3!_3/
M$IG:\K<2>>EGB?P6DL)B<OU*85G^CTIDJ,0U^*KJB?):@?ZG0U8V+(-X@6K^
M"^U1\$(E<9,VY!,76$E'DI51FBQK=>9UF2J;-Z%Y"(M7GT?>3D99E9Q0C1S4
M10IH[E*HQL8&U)L#Z&^G2%M07R%M<NI1\]9^VZ@99]UEM1!\,#Y M 7F$Z,=
MN@#N*-Z/J"^RBRRC2JR+PA8W;$J(4&O35]+-(YX^D>[?5;4YR D_Y=VH21U5
MA^EC=(.=[M\(N>"](&GY"K?XQWG7=JC?QNOCY0=O2.&735++P-(-.F6]MGML
MHP8#XZC:B9#2O>"SDC@VU6^G:13LV4FN2,7LFND W9L.BJ=0\(&HGD#@Z.6\
M8OW9 ;76)T95_G-*(B)?+@D0A@4[93ES)9%23=X<MYJ)2@B]U(V_<$KA^9#L
M>V)V6;,Z0].FM <M@\6<:K1%3\,H>*Y1W3?\>8\I!=]\(K-]V+]/>E7]R+@B
M@Y(20I O(+;4<>7?G<C=F,I,/JR;^F'MPJ#W4OK2S='X.;^@=40C/OY3J VU
MIOZ)]<8TC2D7N@/36ND)O)PH91[B@*H^F( AX^,RSS?;1=CX6A"^7_G_6<X\
M\53V5Q#5[8NL^7Y!*,?.2YV)>^?MP2:EPO"V@<AE5XZ,Q]CU.4VJ=!J5F+5H
M)N^>G^"C&O%%>K*&IW/A(,Z<$\7;!2S3]1,N6UKO#W%<*K42L/SQ1 ;,A=W3
M92Y>JT1*H>KS7C>%R<\(9;*^\,!2NO639J@V'G?'/V2^H>%VS.G\0#$WWEN9
MOHJH>YOUPG-63IR!XLUL@K+25TC6:$;V_Z(3456"^ W;_\1GV/Z[S_AGW\ P
MPS#PR.+7+RL+!LI1(7B11BN^>/)IW$WY^L5N8Q5=S>[1T:D<54QIT%WT3=J#
M@<+W#SV/JK<FH#UR,.#@ERC<'.W_MV7/WYV+#:,20N)(2K'?+,L>@X?OSJTZ
M?"08V'@U#=I/OL!N:W?VH=?H'LF[Q[MM'R0?%\>6^$].Y> ,0M<:LKH\(]2K
M2S%;GF)(^ 3(@UKG)X5*$@)'9[:NY-]+'"?.Q+K9.1 ..5\.(.7*^+HP%URE
MA6@0;?-=E;_KO@UN47\KXZ53TGB!M_$R\#MZEB&TDS<88(9;G6W$ENU2U\!5
M3W([<4_6S/PNK6+CAD7_75FU9)7'!$UTNUX;6)A^\B,@*"KYB=)&@MQ&'<+S
MZ%?F0L*U$H-[7AE*.*<2#H3\7TY$-[L/>6UEV2B?1G65<ZA?5' Q4:0B,%.E
M\D$95!\L-,)@ANRQ>F!+2LT+]31E5W59OT,P4Q;++-WWGX]2T'79%2$\R"BP
M -8C9GA"RBMLR^S:EOGE.'DF7^!C&AVH=P F8(!#1TW+^4Y5\F40?<N2%RRE
MZ5G&\H>/* PJ,RX"Q-1,V@R[VK+-C641C%BYLLEJ]&S3KD^<9M-G)7-;APF6
M<O*'G+B&6<5AQ@?88 -\5A-BX'Q70,?TG[V%\FJ')VL+S1)X7<R-LD#+9-)S
MB(<B R4X!*;YJ7%,Q:QG>!S5_1,<:*SLP](KJ-I WPGJ?80P1-$58>WG8C-Y
M3K<_C% )=IR82OT'3]^E#R7:+=0/X@J20/5#W\QLIX*V4Q_-XO,WBRR]B[L3
M5'TA-5RFU4WJTV(X&5KHA8E+1M]I;"XYJU?C9%%Z\I>$4AM&A1/I<!3I:OUY
MTJO21H8G32'JQ B";S6;1E-H0IG0E?=_2$61\,$P4/ T/.LHTP0YV6')A2$]
M5]XP=H7714GPHB:9JA27W(J^V6I/R9>K<M>GB;"Q5UW)3/#"(9E^EKEZ/U8]
M#TSZH8-<V?;\OA1$(DD4CXZ*;*85%=?9BQDCAN,]*CN=L='<3$=S^HUQW8^
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M,746F3:TW4*Y-:BT*2JPX !O[Q!,U-%_%=U.0SJ@T#(?J;]=J)T24)V %'W
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M0.17^JGLL-C0QN7<A/Z()H>-ZOI$T]174%]6.BM-L[+-WSEV'.-  #2>\.E
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MZ':2TJL&4?$7[ C/&@4%.N$00-0PZ3Z43QO(N-DQE^P'^\NRKGM1,&$^RTF
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M?5[F7]8!%'%A,6$ #!P P%X_P,L2\!& @8*"AH*$@8:&AH6%@4/ 0$2 AT?
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M[^SN[1\<GE]<7EW?W/ZZN_^#+C  !/:7YU_2A?I*%S@$! @"^@^ZP, =_D!
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MR./7=4?3*/0Q'G0@VT,MB2:!!R4"%AN^67_"+-DX10\YLI/=&U\IJI\8Z)G
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MV0O^^N.AC.G\"Z#T=\KW J3]R6PF_JX]#G%P"SV9*IH-]Z^T 4/:V6JV 66
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M=^J>3H* -+M5ZNK,U(0 ?FJ1\:4QJEL>=PQ,G,:MCQ_QY;T[9H:*B\N3H/N
MY:8E3]TG2&?"F@8AP/KGH@F2HEO/LDG_O)\ 0-QGH1(C7MNFKD(34K^+$Q2;
M!KX7GN'..OG_B'X96PUD#D;XLK_>IM<9 QHM%#]> "ZW#Y,P.@CM*6F=>2?_
M?JC5[879^2/<#^R@( ?W<^CO UL([>GMN,<TL=/-'VW>A-!=%5M_9M)Q*::7
MOK=&XA\3!P[W2YZT=R\FNR7UHYB#4-@38>_$@'6DQSEFETT"]_:[7#KSMTZZ
M2M'<BFA<!>LZ'C9K4S6 K<I2G#<*CO^!',H[6F220B*'0V-^U$(3[ !NUYVU
M+M1P9[\]S.](V2Z%!X5DP]S>P_5)^+T!41VRW2FV966>''?='6;1@T9HY K8
M841&IN$C(Y)D-_GPJ4L1\;ML*1_$8)O.-*W4Y3' !@:*#Z$VM!6BLDF,Z,!D
MVWTN=8BFY>>^EY9>!>DS^:G=^=(0KK27WE."$M-NI8WR3<AU0ZL8R-$<;/LT
M"@O*\J:'O53$!,/\]43[R1R0Q8\H,R (H#ES_T72^O\"&N_Q=UAM**QX'E6M
M[>K9WR]@H(G>KW*":@76(U3.3((FZ0G/>E%7CSV%;##*O+'4#Z&@2,_2=P0(
M:C!#BHYB#N8L+#!]OJP9,/5^]&JI*SIY ?IZ=//#AI\UHG3#R:$'=>C'Q3/L
M1T5 4_?24*/S?2&HL8*[>&+L9FI\[")A??57I<[=-8T/Y@TFEFV&2JN#PG)Q
MX%[Q@3^M8NYF5W[[4_U#YYOD;,PWMU $0_5$=/,ZAV ]'WB^9N.Q-;$G:RG
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MM8UTFFE;G,W:_3\N7L#]<TN-[@6^NG$&,O3SJ3(\@?4(I)%/;%=%GU@P@J/
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M^:;:?Y(=M3+#%MK$>"?M+$\SM&FURRP$PR&ZB1.M?R7SY)A3,X6[73)G553
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M+I7HRMB;<[TZ", H,.N4WTH[9ENBG+'M<2LB3]OQ]OS5 L./<-_8PQ4QB7$
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MQ(L>&N/!616W%E\]+5GE!B?\4P>^G+0:XV =/B2,_X^TMXRJ:]NRA1>20-!
M< ]L@KN['2P$=]@0".X6W"% <(?@[NX2W-UUX^X$=_DXN?7JGJI[ZE6]^G[,
MUE9;-FW,(7/TU9>E:774^]K>'8Q1)EOAARY[Z(QZM3<BUIU<JT8A4PL_3HJ\
M]UWDH.(Y5RFOMXM&R,A%BH:$=GD\P,KA#&0[Y*U"LC PT,&O^IJ:GH%!UL_@
M<PFZK*?W/_>I32G+P3K^[R?8B/W8I8SU 68D(UZE:L7R4L+7_RTB*2K%TEX
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M$)D=!6-@CS PX$-VW\_8#+W#-;H19J.UA0$U(%H(WD^T;8K\23W4VN*5']I
M0)!\.AFT?]#/S^)T+W_R%:*/Q1YG]Z8](J$S*IMH04VE-G+=V3Z%&[*C%-&^
MG6Y%"J),#CN4D3TK>2^C>",W8:57'RVO2.4SC;>M.T6Q)'N=E'YG?U4*LZ[:
M>>MFAIRTM P&11!'\4C 4,*&;$;QJ*J;N%J.^=7:ZA%F&;0]%%A9HKU_+=I
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MW/:""1+=[)PK F!7[Z>::V&$@[)^KV$.CNOP'3G22TP""B:DJ9C_R'J!K*G
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MQTFU,U_W[(.#61M%K+E[?2.]AXV;I] >;[.(53"+]P;H:-0L6$W^25$^([M
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MI_(%2RF +U!Y;RP9:0Q.IL7H 61DER%;19B.(C[$?:YA'ZA/C]*\#89HMM-
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MY('OQW:[LLR&K TISBGGN/AO/4&SM)$^Y?J>V *#;%A5&Y0EQ;_P>B#[5B2
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M)F?Z"<TUK[NL%K;;K-2;O4U.-4.@F_>[\@\@^MY>^ ^@E@'A;83CWS;XK]\
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MBGR#4:36*U2VE-29R=;X53H:( /'IV_D(5?T0 02$O%"AY&J YQ^C"KWW#=
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MNP["F/;)C8QY&?4F\D.T*C+V?)EAOHUO]/*F5QQ)]O"CS' J?#5EA#C KAV
M%9P $,)0OS&V8.J4,1+:-N@0 ^Y%C\0NT-G.$6A_[P_]/_994(K5UG6<94ZL
ML$Y;@+\J':)J3VADA<RW^N[[F>68>$<J0N8'+H1U]! X8SBU*;.9$1XF$0,
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M1\4TMX67,O]6SP=-%]*> 1 G/2RE;PR6_!K&1];T(8'2/Z >+I3B\@_ \=M
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MX8N-8V.LH:%L/QI<F!: TM>90QS;UB_VIZ]ETM2]YX%E' -#B#-V#(&IU[A
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M%>G!@1E=7])""8L;"[;MQ]'2DTE3RN=Z7;:7<0Z?B$UQI()%TOH%<_@^T1^
MN?4/WVE*"0 YU?CG[3:[%*W),1N0%S-F'W<??Y%/-W 3=ST2:3PN8O]J@ECO
M,'G*H-_..W:B>655@8@VW<FH6'RB@EMWEI<YRA>3^%TS9&E4UN:4E/.US#@
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MSX('O>-X-?2@45WI6:]#5G(WE:R2?'S31.3U?8I#\3MT%-QE;IK&TFYKEG3
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MV2KI$L;C$I?[Q5P%NZ"!%3II/<^TC9S437V6$EH%0\MN7::^,)$%.3</I((
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M:C]9=:I%!@K$TH&O,Q9>=/]5TX\$S8+TV6MR#J+CQ^E2F9@94</) @"^:/J
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M?WI?\RS0,$_.BT^)QT[N\#A4]^'K/[TO_QG47AU[]L0]W_K0B3!5YSGRY[M
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M5YI:ZL"U/3 ,V\T)HQ@%V_^_"0!02P,$%     @ TC1J5#<V ^O3T   R^(
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M D%$\COR!0TA\E@GK>34OBB*U,#A5)I( P[460)B]40&%F <B.OYT/869<2
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M7TMJ/4TR'9\3N 3:OY^!11>A;"!A7: CMR&^^[A>[330CA^SN(9,LV!8TF+
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M:3=PZ*)ZG" N'4ZV&(PY^ 5P\-[_\ 'M%[)6^Q]'JK#M?Q5X?\=#_KAVZ@!
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M]";'J? 2)WX]5851*<K,T9G"MNM]7"+PDG2Z)>Z9V@XX&=;5E'P]L#HX,[A
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ME=IX31M4J2&3UC-T6L._"H.*,YY:V]F<%)W3"'?S\K/7274I_"+4&>,LLQ8
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M>%BUH5+98^W1C&KL2+VN8T'B)X*:>D.3!*(C![-@4>6R9=WN(!)9E\)D.CW
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M9+^E+96GO %*P"E+VIC&-^E)M-LGB^!KG6X57^80L^[WZ#M\PR1-,RV>PCV
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MWTH]@/_7@/L\ _Q5D7WJ%T@C,!+UNFFSRT]#E121ZPF*U5^;1\@/O<Y]XY/
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MWZN:8P#>5F(%>%<:]!"VM$_$5"UHUG:";2OP4XCU,%P9XT,W["GD]@/<C+8
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M2=2P7XU)W"Q]8W/B@T*CZ_!0+1<7AGZ7L&[^VG&[9S+7NNE*[T2+*\3:R%G
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M/&I7-L;5C:><A_:^H';DII\QQ^;8,94[JY;U"Z;/+YYF);V-[;<%UU1[:II
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M-8D*NC $M%4CJ(1*(;I3HR?W&5BAYV#.%HICW7)6HN!9&0#AIW19V%KZ"%S
M,SQ"RH4>X2.%Q?L@7E0=L/=VS8A+(E5Y+V4F:NX73M6R#X9K8]>L!%#".-TS
MJ.V\<\#-N@F0]!1WU,2WJHPBMUCI^L7C<:_\%<4M$/G*;11C5<F<3,^$-1(
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MO.QN)-@Y*XA)WGIH0!0.'/O"1*77*F&J9IP07;LP1C\RXZ5ZY0D_DA%OM)0
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M'?=[Q@^L'!P<9+2\@CQL LSL'&Q_? G4FS=O4)!1\%%1\=DHB"G8_O+QT@'
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MDIN&@*.XD!_$>M^,\]GC\]QK# +H<AM/,7Z/R9S5SIX=TOC= E*Z54Y'^5X
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M*AH_332K1WZ,A\>05*EFO:WVSFK1S%41&>..Z/*^3I=QPOF>\9UK#C?,^A8
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MM^U7[I?:(!RL>N[5QJ>EBY#Q@;J_;A(N,9+81.CW"/\OAV(9,X;5IYSWGW9
M73#D6QE;=581)>,J$BY3GC_69S 'KM(+L/C['*ABVVR*1P$" 7[>J@3C$WJV
M;4*ZNC:-%5>-3,]C?+J/MQ@0*R):HIK 2!>@86]57VVF$/!C%'6CYXZ4EL8H
M7NQG!P-^9;@8''&JI:6F+NO#&JGOB;Y'ES'-^H!]AO1SC=+E3BMG1A#-&T93
M!?J@\YV^E<TFT7%EZ(F_6T#YJP:4^/88Z=W^\-.?YA6>?KX XF)>A]H=?7L:
MJO+/Q$O]6@MN-,GMC<A&GC!%I$QS=+H2PK[U#C;4+I]92K9JT.%4UQ@F:!U
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MA.2J*6OICGZV.Z^ B64^.SBW ?VW+/BJJ7XRLQSU:3O.BQL:'J.W(K+/^72
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M.U_LW7QY^TUP)P7$<@Q+W7I47#!D\K.9+O?!/3%A(24;#3LI'[[97DJF:@U
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MC;;)_S/+XT:>V8IU60O,)(8CEU0*0U0L1$V.?D>?JUM>@9[\5<U5G+^28[$
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M.B;2>R)'M5KH^76L  4GK-]SP.HOFLF7DM7(12EYZ'"730(5';;4W8@=1C*
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MY*KN;E9*5UKO$;1(:1)5])T<,6][^VHLY[9P4?98ANLX K.&4;$_?1Y:;(^
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M?97#]ZTNXL3S$S;>'3>%V#!/HY.2%OWV]%.C("5C3@7R/K_P;>E+6Z+.>I;
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M6]+[EQW0+*6I,'/OF/?)<EHFJ)9/X'6@N2-,940EN:O*;5QP%.MF&X^M5GC
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M&P]G]IJ N"QL-?8\3I:B3?;^A"J[9O([,>%YQ@4-KBR2P Y,A],=A""_\6C
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MFL['[:N-.J)W]TT-4KP"["5>W IC5/Z2K S'<B,WTJ][X]2-M?574:1#B_H
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M6C\OK>CY_G4ED5&OH;'D8U88%&E/@"ZG))]_?8'P+PTB76OKH75O[J&"R']
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M+J]:+-EBBNSMXV4\40.U_\+PS$._)T-ELDRXD4+[W/:!'7"D[,*P%<.X2[$
M 9^Z4(DTJ!7I>?3L_-J&B[U>T$7R^V5=7;6E_[FNPZJ&-G>HA3!F_BKZ8DX-
MR=)>V" F6O.>E2I9RLM%#AI>JSDU;^1A7'M^D[78=#I*P(\"TD][ #"XH@L:
MT4G4_\@PX977M'9PFLM"NR%%^E'81^2;41WD\P65<5A8!J=)W J.D?S#8:M#
MM>NO)N9;S<J&-L0^+P!*T;[P]DRK1H2A@#8K(IQI@J'(?O 9J[ R1E&7)6L,
M-LTLEU<\H]^.^E18]5&@P+AE'Q[',&NV&SI,BHKYO2O5,XS+E7#R3_D?54Q]
M&^<H?JKFZ"*?0NOX-XQP3<Y7LSR9Y0>M"Z5;TCF;+!:S'U\!ZMB*L@.#K+*B
M%J0=C*KO[P+4?LP59%S_NH2PP&#OZ<&&>!- $7JX$D?6=0$:&(ZI"ZZQZMTB
M$ULD,^L918N/L@Q=_5B"^!?B$@S>MXC>+ANX\^-[7N]W3J[<LS-;+1MMP[_+
M7)CQ&H3D+0?8KOTBKF<B8?4_BO;-P\CY\V;!VCN[L]YL5HZX#,T4S*"%J$,J
M0<K@QB(K0CMMQGNEG()9I'.80OT'X(IKTMOJVVJ10-HP)8<#4K 'XZ^JZE!?
MTV9NR?/X0&CRILU 0N&?"7>^LF>?^UG!"0@K%"YU\^B"S06CC]_^'+X*)S$E
M6SLN-9-CU-=NS(J._K4(Y_:+J:W-5H&R[1'GG#$O"!G,#F<>P<S5?,NS4<88
MB+<JOO-WAI&0N^!%98O&G/53&:LKYEJYY$A50NJ$XQ4>LL@:_55A;[\L_#CX
MSP.ILFQK+<;MKX"(BG7JF6N(IB947@=F1"O,'2]<C!:7PQ4T1):<O?D*@%<J
MM+5V_;'<5SM,E1E1OS=&LD/E@P(X?4OAO*DE0, 2J^S<&@[B;HD$EM5\#D/B
M+!K'P],(CV_?OWK;.O+K5)AGBU1E6R-1S5:5T]4*LJ,/_#"8VXI/.JBY$"@8
M@V_8M+"=UH]V/HR* !9(0B0D)/T+A'/5EC_)R%+%8P\_X=W$?QK16%B+HOS
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M/^K[M&.1ZYKQYRUEI#GK_5O2MA<UGP6#NSI3>'P=;RV+HZVQ]34FI9BR4BO
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M5W69CZ'_S<<#"%KW F$-"[>\MQ!+%Q0%_+0/HNK=J^S^WS.F9W\7SE91U$>
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MH6]=Y49/[@E/GY6YZO>*9Q_%GT*IQNIT;6JZA.D-@CY0\,51'$ZC?X.N\#Z
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M.*S[]-6=_+'^PTD;]\E4$I7IK;-[LUKZ?(KT7'$39$.!+YU>A[-:H!: = O
M&JOYAV><[QVDTS<8O;A6W2,IY.F-WGJ_N&QRZRWU>1LVWJ18PFA3G%/EC"C>
MY](AK>*V2P$TYJ W<_ 5W&B([(&<N7WU<%E%XG^% &J%()G'0N(4X8LX$NU<
M^I4*_GW%()J??<Z*=S@86;F/NSVH8S=^76?W,A?+,+]C>/L\XEG2RZ:,>S''
MSX?*>:",.(7M3-4E(3,(?']7(Y\5J3\RYBB!+<H @$0^S"G=9^Q49 G*0WT.
MGJQ@$/V?D5C9*!::),)RU0622QTJWMR,1]5N9LC8AJ$)?\BLB'A!^).O_8T
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MSPV<A1&Y+ABA ,^PT2FZV@>@WQ#0*W8U7@I.X2YFO:TN+R_C2A$CX-G[C(J
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M8.O_P5#Z\<RIW+ 7=Z=<!=F&0!MIK8SR@AOEF3Q.T@GY3J!H/[-6D(,#V9Y
M(OZ:_I1AHV"7B)E7-7M17_#A38N&T.570KY^UZF)G)%O&O>;*@H1</CI^3D-
M1%I*P3,QH='CTS@FN]B[@&U+XW>&-@*^9_:T(+A0)>^_9#,;XKS_)GH1/'R0
MD5>^P?P<E R,^\3!"'@?WPQP6M;:!S>;!11GW"0.OH?4>^V:1H/S@G[;:E38
M]"%G;NI'9#55/(0@/R*)8:_H29E:8!3R7VV+124D!&G,(N(CHI)?H1;]USGC
M_P]Y.V+PA;V\P1U]F2P;PRF;J7L1?@Y:Q&'OCU,=4'!PD.QYKF@LM- :VD=!
MH:2H'5!S,QTK,O,5MI#WG>1EL+DRE@.B&8GC.'^\AL=!1-$#] ;N0[P"S+;&
M5Z#C/YH['K3H/Y5#>@+TCHX@@\1']3JS7X7@;LA:,UI:G;_,S\Z!9$+CNW\!
M.)L=?^A+#?1[R,&XT6R*(Y51E/:4T9!^[MGB&M\E0LVJ\Y_VKO=6-M$-+$7$
M>R!-QNLP@,<N[@E&X5%U&)$*U()_+/4;6%G%02_V"45F^=,3S; )/]J=ZY"?
MM\;'W:/=%S>NR\-U9?MJNX_,P3+)5ASU#WEBHX)O/4MZ=VNPB4CPI:CFC&VN
M%-L2L:75SB@5259ED;%+/&SO-$I6",P28?IIE #*!S,&E+QAG.[OT"?QEB<F
M$1^WA'&B6/M.:Z3@B[^ "&ZTFA^/VA'%'?$++ 354?^<HA[;^PMHC_,/G-?*
MYEO0T(A1JLEP\&!RSDT(KI-]TK"A,D,+]N2GBKSA@C:!EU>I.Q3LQ=^2![)@
M&0EHZ/5-[$=J0X,*HR*6A]ZIY,'%2$$.NX:6_<IS&:I@0<@,4:"I)19%1!&H
MZEA.?&ZQ:-[7J4+'EN?!!ZTX"1=1CY/CRW<V@T_SF")_^$D89_P';=^3-4@F
MXANOQR;Z>+N)9GWERN+^;IVBTOBQ>4/\_=8K?BZFD9__M=HT5UJA2TE4^WG#
MVL2GH#K$UA%^0>>Q@AJ"P7<[)%ID6-9P0+!/Q7AS$_::E8VF'+[H>#2$DBS+
M+<;,>C'''*BCU,2^ESKTRT] XW4"(#LW&FMG?#PT$[I+[.TH^VR-%!@UK-<O
M]P8Z;5,[X?0AC=HR@/DSD&=NBLG]<JZ[2#5CZ+$FR[1"N@A>8AG:%YJ:8LMR
M1-0U_6MEF ^Q?5V_W]N]SB[.X*N::K!0)8LG)<J\L^U$<8*IA15N(5X=ZG?#
MTB+Q'N$ D1N$B2,1YH[N)3LXL4Z&3YX('H\#MU!] 6VFR>'%GTK^VX?MNA^J
M J<A.NF_AU_29S':/> ,GYH0)H'U]1?5*::5317H#G<0 FWFOK=#CJ((VD4S
M-Z-G& -M?A63WB,S] Y3!+F8@OV/,3WMT_*VUQNC 409+51QLI0(+BT!'IE8
M0Y"38;TP:-53QCMLA5$XA:;E^CNP4M[>X5F.G?MAMJ ^B&=H= 7.5+5E^32!
M(U_XXLB IH2BV* [X.Z8X'@E5/D;O]6=29RV=/1(# ?J9WFB-F=O)&F=L&K(
MW2Y?^,!A$IOF-46^2R T[WT[5 "J.L)P<(NR(9F!+_#'-V%S;&1B,CHQP0N:
M]5V;?YH8M^.+X;AD9PG,QQ *,G(PXO*K2SOZE2*%7]PU>Y+[_.CT67^4[4HR
MV)/BI2H=7B>1%BY'VO5SGN5T\C SHZ(G5N=RW__3G/:I17.*@(C]/#NXO=0.
MQ/R\2;.(_[R;QB/]]OK\Y&LR3_W #/1CX'CS%S%*0%#(*B#36Q4E_22;?9%V
MUHW1VKZ*LBUXL$;+YRVM[0/+,O_4E^ 7O_+]PP%F"6:.JS-!(*,7LVFR1W,[
M$[$=*)\SY,_39?P(DC"P8E:(MO#W.%_PFNP26I-T!KJN4TRWLLIB@NY%=D+U
M+XA1G[+(8QZ,ZNA/I[?9T2# 141@OE$?9)$_=YB$[&VF7-X<!<#$WP9O2;H>
M:6Y?#I4SGU<SYP=;,YOR.A,%]JX#C)/$1.G)$R8=@=,LKJMH2S+M]4U9TZ9Z
M.DF1+QST!V/SYQ-0T0[\@/785&\R/< 6J,.L6G:<!(JG1+:*M^36SP^:/$-R
M6G$'"]Z,E.;>_RA?GZRER4$D8]-O=_DSXI E9]I#*>@H1W#0B6$'USY;E1 Q
M62,_%B"K8K-IHG#-U-7_&?>A9I]E'Z4:4WCJ4(S4K?!^RA#R)D9DV(EC9=2#
MJ_ZL]V,A57F@)]7XO=E%T=RS53F)Q-V>G/UB&3KKG6YF&I'K;-G5RP6*P0U2
M%W#F^URE";*4E0,^>=D[;# FAX K'UE<\5^ Q=&KK<(=D0.':,NK^K[_#V)5
M%(2=&#,MZ"5+,:C:4@>$O9+(/)LKMK+^5"_JE>DZ4BQ>8;!YHJVV 6SFT;J4
M\:"RL'@W-M7HC&7 BE\CF:)8V]*JGU8)*LQR^FE$S<0^!^%4RI";JR8Q HDL
M2JO+-_05!BO+[7E/HW"R_G1C]$,1RWC!%*RX%0&N[]$-*+X@$&=U5\GDWR]>
M:[8U>C0U16[L[)YN6JTI_G9_N^$#.BP6,#EL=/L,$P87,1>LKQ9N6CA?%@1^
MPR[R(L%"GA\WLTX1M5'0T?(%77\UX1'F7 QD^N^.HT3GS5>@![-)N;3EA'"U
MPSEV8/AX].;&R8H)T#ONF1D]C2H!Y0MWP@1]?)A'.->$H IXE@]!%:?!_/F7
MX")TQ#S\*_XX/9*HO!].B;H;R<$91G/K#A[9&[<,2=L)/Q/?I+"F=V36\0:?
M3:\\5 %5?HS;FQ%<1S6)*[_1F[$-<-L_NSR4U]L/CS<X>-]&,B![B=U[[?A)
M2H/GOK7,4OHPLP")N)L@TIA7-.NSG'0]PR887S??NXWN@*0-;?EN4\W#X&8Q
M#?9"10@>[$JOG<(^2]5J8J1RHGTQZOH5?M*"[7P.RGF'Z_F"#\Z#+6P$JUD]
M8+YGX SW!(.AW,U=Z$ Q[(Q_K<M+4R@H:+'Q=RZ60/L%39&/%R63GB%D^*!>
MP>Z\;3\C"9MEC0XE&\U94.N7/\E\-=3/QJ%K) 668<\^2"DDBQB&Y*2JHGAS
M;FB!@W"8\HJ0!*HA70=16+9$6EA_.T>-P T$N%&1"BXJA^0>>T]6.3'JP%96
MBCK8.2ED@Z7%EK?CY?B'/'MNN4^X5%$2)K:59/J:5#\TP4+1*$:;-"$2YG2:
M29$%)"'!)<2D[(88L3_.SX40BG1P(F$'O-AM(M_H-O3QAV10BMQO_A4<UOX8
M.3.=L(62A%I!F=:ZPW!1WO4CZ*N)ADJ_G^(@5P 0^G'J4*CNS(XSQ3+Z9:.W
MM48I/Y#OJ0;M.!ENY56R'M7>@E,3[^,X_N&-HWM<8;0?@P\KVIIN;[[,X5>E
M.!?!:G'JWLD-8?U.MW_&?BSWE-'B4.9ZFF_3'W<!":6'PKNX:053WGOX88I
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M(0:3L8T[ULIE]!K=SWQ^"G_+R"*,J(GV"S58XE7=RC96?%!!)(JJ68G<LX^
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MD_;ZZS1C*VV1'Q&PSNP7Y"] ()Y"G=0E"A.JI![Y77X\HG+V>N.VC[3*!V/
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M<0WN<#,SY]P[,^?,=[^YY^UG_:KJ>M[557OMM7?M?EUXW0#>?)22E0*@H $
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M='_WE;ALE;@((*7@[1)K1$;83]Z3?2D?^8A.A5HNBI S7FY5'34E$P<Q<39
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M0H3%8SZ\"#=?O\+J"+M@;(A[*@W?/4%DS% C88M\Z9*>O)$#;M%2_D50 ^;
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MZ=[T#?ZF"O8UEX#(M9I;#&V#FU?9J<Y: X/I':6<XF*1CE)OF@6(Y?D7F<K
M.77^\'B\2N]B.I00N+\)E%E5E652SCR5BHILXQ<V4UG['N2W"#S#3W9L-0F@
M\0_+U6AKHVC89.O%]?A+;]./_OOEWW*_HSQYI&'J*O70$CUGW?:F@C'EZ-O@
MV17\>/^ E?/^_,6_#0E>5F M+LA#\%+>>$C1=0LE)"'V&9PUCURV.=JK%[5[
M E?%@VPEO(,P.>4\/6T<1/KA-:WOWJOA6D >M0="4,L)Z-]>#PP*-5Q#JO4;
MA!,&P9M9PY=&ZA<K_+:$2]TY9$\3"%DL85S.VE8>IX5R&>+N'YQ@8.,DL8=K
MJG!)'?QXL ?AZVN\52X__WX%'L1UQNE7=+2)T^2+=20Y^LA!; UT@@Z#8-7?
M+[%Q.A^:7'[)17K\?&/XRU%$SZ>FWC7)M8FM5H,)4ALE7F:[IF-@-N.<C?B-
MF6W3FY-T_1#_S.7)ZD_B8O#?U.6PA7[.<*C9]H&OW?^;_E2R7)\7N8</*Z12
M,)V^<^6(OR4Q]O,.1;O;JK)N\;6<H_%Z= O^S/@CG.5'F5S-F37DL=M_/)O+
M$LMR?U(E35WFV+S<\A7H_2WV]E&HI:HC5W>>VM?UHY1.$-^@(-1R&P8NXQK+
M-/C4+,#\%*>;>$#?H/M8:03'3 A#QV!C(U4'=,QB(MPO)FE$&TJ9)3?#G%N7
M^=YZBYW %M]"A&9'$+N3//1,4TV82SW99NK#X=P@^W.:P]?CS@\&;]A[XB:>
M'>3%/UDF9$F4YS:6CA,L=1H*3FCIRCD@RYCX48S \=__$'24_O3;D;>TCNQ=
M37LFBCLD;3QVJ"S(=_;>&)YI7*+1WNL4IY':*FP:I%Y9*>G$X0[>F+$Y7IN5
MXSI.NF3G_E;<J2HEO#U(ONO]_NMY!DC2W'8VL1Q'MHDM(9K;L;+:#"'=%8'T
M;C>+*N2X:.' O-QQOO<F7EOL?<!.3YK;((ZFS#"?)-JXH]#SN6K.>8D7;F)-
M<X50.JP2_"+^&"96F2(O8PN)H[2M^8WC,=F0=W15.-0  D%N]LA?XI2!4FN&
M2TADR$N 6"Y43V:+QJHP+%#@.PGB<K38T9U:J\G1*W .^1,+^G/M#T)TT,_5
M.EQ-Q,5;T4ZWH/<HQ0]LJK07N$QF5D2[&3E:SWE*C1J!)%)^>![$C\5Y2<)=
MOWQ&*^XJE=92:IA(HR$VQ!BU*RP&IR*S,"LLH\OO_)@MA1D_M,=_G+0A5ILU
M(F\)IUG&(3S8'0S /ACV^J*FA^W5'.I"CKW*7.)-;!?]IJ&V_L^C9U9"OF:=
M"<%M+K)(XI=,7;*XJ=06;?D>Y3#NZ*W86.H,E8S_%,4C<KV'_Q)\7:+IX#LP
M[?0GC!U\]^VT$O[EK$'J?"TO9,XYX9$YCW:1!;6:DQM;)D>^Y2>BB3@&<UZ
MYR/1?FZL//+'G("F8*B9$N A<$"XSX_]Z0N,^V=5_?<TJU84F(T4/$/N&X'W
MF#KKW6$L@J4#Y3NM<8E&UFME QM/'7Y5E;P;)'X(5$[A2^>UM:WKW\\V4QD\
M3%@KZV7#-P9K3OJVX'T*J]I(E[2UEM>>T_4#1M*B5EQ_*B(4Q?VIS900;/2,
MOWEYEUBFKM:E.4';!*]H2&T:&8P*2(W(;=A2PKZ_5AX<];3YTCAU;(?:MSM%
M^&DR-)_9[U14%GB$EGTRAPFVPSYD3,Z4/SX73D:1I=?)_S0]0$.OE @8P0#E
M&"-";+KHS2Z,4:B^1NT?M$-#?C0+%M[/5_ ],\@]PL@L6F<MSBW;1!N2:=RC
MNSG<13Y[_!2FH7Q&N56J?_C@RS%:F[RGW]1P7PSC\[=*OTHD&;N-HU:V%^ /
MWZ8\+VW+R%.P49+W=OPU2F@4ZF^ ]$<3$UZX<L@C.0?5Q"/X#.N'1+-K[FWR
M#,:=CF+T$J<92=V?LXZ^-A*V2SJY9C+(@G9EP2:*=+\PX>[O8K,1:('S,7>R
M&C!$2$@\SLZ]0W)W0(6UBQI=*:GS6-KZT31YED%O)6=H+#J\>ZZV?YH%?#(_
MJ)I$&]N2$[/*T(&,M"=2P#W?BW>IO23S6S[,**P Q$K$^RG+&3O]^HK$K9<Z
M^.=685(DGVZYG;+.L0]S7=++$G5=@[;%M*/"^8:P+J:&;Y6<B^ 5)+7> QQ:
M$U<B1FB.MVD4[TYQ?,G-@5&DGYVS^;,P7CN$@6N_7 T#7[":T<XZ[C[9Q(AY
M8=46=V$XNI52T"N\FCSBZGY"ILU8AM0M)9E 2LW@B>R'Q'Q<M.277XG)B^A2
MSISJ(J\ TA='SJ_$*%.]><_+'V#8FQI5\H1NW/H$( C8!ZD/AZEIRY)6].),
M()?$\[$M,1V8A0#A[$=3D^!2G&5M! 9N\]SPCMB_2'&95:N<:J!J\!B3\-"'
M=+YHZ1837AT7,N7.O9FY41.]/R'17^ [S_<*@";@L\<F&P"' 01.+( J'6IE
M3KA^RPKM33[&KL[Z< \>]W";A>(O4H1':<!S3FG"11]KH/HN5=G.,+(\QOI>
MZA4HGT+7>06J6-O/E&!.!3^[E,IQ)7\_ =U\,2))_;Z(%UOOT.!$B7%:L26I
M,_6-P<[$,S4SQX&FI#2(\B09\#D3^B WQ7;,=TU3=W*R65,OP[0EDQ-I(S,I
M_C-&%$Y6E%!+Y,G'2N3Z^16HR0-K#?WQAI!+S3_5S=ES :GE_Q[EA?][EUB:
M150F\AN$]RB<]ZOC[?ISEO#J\KCWC_[VC_MT !54_%1+DI#*TF7_$5=YK:%(
MBD]H,,/LUR\\]&]AJ" ,F5F]Z:CJ9=6P*OW9A+R$%9Q3+A':,?A\BVZL#:WK
ML/GKXK@*K$0BC-*=XY\#5R80"M43UBR7KAZ*0K$>=KW)>(('(3SL-N&SJ!>!
MEU(**#_]M*/O*0"KV6)*2H0"P$/\*%D>+>=E,I7!'X=2,8HY9>Y"L99?9KAA
M5Y+NS<8>\N)M>7]/B=/;[X-VMF]EMRZV'YW#]_9T7HYIYAZPK HZ(/[]'_>>
MON /5=/(J0I_<\=:3G:ZK%BQZ;;;-H?)^7/K8;@O-0.&-2JG"Z0O66!P'&[5
M[2KF>8MM6N0*Q]%&IA3J?G<ZSJT9C^ (H!\=BG2E@,U5+)-1!-7?$6*MYD75
M;9<F2Z'=63];ACR]??G 1EUV*)B"(E6N XUJF9Y(L;<SKK?;;(C*$;#KZCO_
M!#T55<ME]TVR<'$85L0B7+/0636,2F7!-BKRZDRE'WPP3J54NXWD0/55#"G1
MS2!J-::(*X3\NUE]E$W._Z+M+:/B;+ITX89.( E.< \>) GNDJ - 8)+XR[!
MW2VX-P$2W-VA<;?&71MW)[C+Q_.\[YR9]SLSL^:<M<Z/6GOUC[JKJ_:NJGU5
M77M78]#!DH<J6@-;JUVZ)C U&7@(>@*\BIA) R;-SNG1BXN8!#<U&7##%).-
MB^;T+*ULJMU3<./S] JL[W W\/E8&ONC.=DF\D8?E5,,UM2LEMXQ5]>,#;R5
M@DCV51=>T"%']>2,.QCDRA#?%+8S94#;- UAC6DP1P.QE3X/7]18#5%LNG"0
M]6O56)M'5CD*Q^ZO[P*;8MW,K&$7+S*MN8+9 ZKN5"_CRF+KTJW9=6O8HDH9
MI-&TAQ][X%L\,6(=&4K&Q/ZL@6\\C]U4^*Z=;O[,*]PIES?9] YLOB7XXNM"
M..R"+!3 )C%*5SVM^['QH,8I1OPU@*GJQZR6N+U/%LGMZ*[>#;'"S.V$=1<S
M,7X9OYR9_FGVF'0+'[3&"&!H]6W^"; (V#[F8/=Z-Q'URZ0N<I:YLRW0!&4+
MMXW&=3>5H?E/X'KS=%Z+F2W)=.!B)NR$).()H)6'^T4.F:<"ZFNEG,IGXF?L
MN<)CO#!T&A.;?.R21["JJ3PO5[;XZ/U+@W8A\2C%BF!Q"3RO+_YY:S#+:2FO
MK"Y?:)5N/)XOBV9!\G+^JD?3NN,**'#G*6;?,.Q;(#P#RNNP0CMG[1A4PO3]
MA051PUI.%;,$K=9 1CNW\VE*"6J6;W9RO+\^QLE&$K$HV"TXA32B]MF^L!=M
MSXH1>4_:GC>ILG,"%B,)D"Y\J=_\&C&G%-EBQ_A_47IZ4CW%/&0LC1.^H:BG
MQ]OE(JI]-YTAKG5><NW^/BW0_@0(A<D] <H]9Q[#_7PX&7)S"M5V+EFU][CD
MP6!Q03/J[QAZ1W)Y;IU-)P::RYR_5QOE"Y;RWLK4E4!K[TZ=A0Y*Y4K?WYK\
M&+/&5YSYD*0RA;  D:H+78;3W])?\1CL"^-Z391=%T2K,\')(ETM?L?BVT==
M8IX07'U/$^:=/HK*,(.C57W.FP^^[UEF"I<&L7F[+IS"%A+',GW8'(2N3Y(>
M6S]XG[M/QQGO>)^L<SUX/2^*.U<E#/\+*?77/B]15?+/2Q>QS@.AK08TZGMM
MZS%$2[-/O\^:H^E;<: 8-_TXQ ;=QCET]E_.Q71=HE3\Q>IKE<?CG1)Y##^\
MZWTIS)_L/OWP=YJ/4A.=$\,&U6!%:=!YD:XNJ'99=D?'GG7U2\%N;?T?85+]
MY'S!S/H'BZZ3W<3IE%P1@D2+D)^:S[X\E>Z\VATD&^' DS%=,0XY4L*\;]*#
M.<-\IGQIV4S%7JMCGW+XN,"C3!A,2 7WX5E=UQ*FR81&M*84!">V(5L6DEX^
MGNVT<I&ZN4_GE 5GM8X!%]-KZ\^,:V->,/,BAXI'5/CV]D/8(M'X7;BDL"J-
M-]9-(#T&2381S:(FUS;>G3E:47)!$F-H.1#-GU^&[G+1&-E8C+_7*H"H8_>%
M48\KD#O@9@3MOFZH7BE%SY#C8]JUV/G"$7*O3O/,R3_OY_NGJE'0#%F7K&_&
M%#>^8P(#UY>I3@LAUR)R9JFF1G5^ZJA)<$[-. \C5V1R!]U(B1*9PJ%+&7O9
M!I</A@'ZO]73?3?ALH.&]-0.'"&.^?NLVK+3N3>TK+4)KZ'63. ;T:+3K.W%
M2+;DD]!I_NFQI'99.)N^]1MU62/QU UP??3-FWY<#3&&+A*3:#G%Z<R$]FGL
MX5.![IX95E*?=/(FA9+AA=0FPY/0=M[<BH?P8J(G *.-4@ML,(VB9V+3BIS3
MA3'\)''\!%7'7(97Z\NPZZ'@ *W^*9$XV*^HO#*?6\@%.)OH!'&/,\N--1&^
M5:[J=@O7L5SX\M[+>A6E-DH6S:3VQR&UFL=^8U_J(JYERIP]TK3*2YMT$_KF
MS[MJUMDZ\!>-]@*+D]/R876?G*)Q@8CBTH9E '0@:(:[I&A1Y%M2Y^A"2=-E
M)7]_57"6<0SE<J"1 M!A^V@#.!&J8F$LDUW2WQ7;$2]#$O-0NDE=C\T\&-I+
MMB*TM'AZA_ZK#9<S+CLGMS9?I_Z'-+=DC,*7+DI41#LD@I-H[AL)C>$QR])2
M:*/%78;=+@X;[$6L1/5/5K0<7R"JQ 3%F_;JB0\&,]H;ZJ!MVBK^-C2.L276
MPQ$X!K&-?>3#^[G&W/XJ9UD) _O5",ZC=854)6^V;R&4<?ZZ^=H!GN@V]GM9
MXQ!K- T0$VJ5IFB%& E313GQ.*N4GVU,'T\[(3)NO\;>[49\+9+.X2M?26HD
M-<,7I"-;'U;Q!^X) 9_(\F)5*":;0!\*S$MP!UFPK#=?8T5>T%WEG)"Q3=HI
MDI#82S E?+MTQ%<X;\%.Y=&MG2CU:.8G2!2>((49!CP>3:36K92U6*@W<1A:
MOJN52'F!\,.JF#6[MW([)JHI3)W3"1X2) W5@6IDT31\/8%!_<)<65]31253
M;&>T_5%R.)3HJM(RT]_]0!4WO3PH$3(E=4AF1C709MT\%8C.?4$4NX<F<S'[
M1P)8^NS-=6W]O3;>G*VG7 4O]ZC$MY W3'W]-M=E$MH!XLS.59U5>]=F$-#C
MNJ+?'-2E<3B(C[73P, $7QS'D^E\;TDNPI3:67[DDH\>A.2?(?+"#L1_NH<W
MOK H/1C;:QSU 7:\.PH [ H3+J-Y\-8\$DU (Y0_''',ASF>Y4T:FM%&/00L
M]V/H7<\X_A--_2OD*EA](.+SM4G42AQ$%_7#74QMMM50^I?+=97'_O[+9<N+
M9"[YO$%LM1_)=X@8'"&KC ^\ESSH:5G=>8PB.(/86(3ZW4$R6=SS,TO0BQ))
MTUN:RVR#LY?%S!\ZYITM"7O</2W8.N"#1%V*371B@FK*3X 0H^-Z@+W/K-C\
M,G!?F!3-EDN0W[9@C[/&R;8_QC.>#Z3Q]?5&HE,0'2F6FN.>C6=13:GC/<IJ
ME:VM+7J<M07[3O"()4&P7U2SFB40K1%9X%B 'LCX^%9+Y(%&+*(B5@8=[G-&
M_((I1\@99I-3?TEVD;>&TA5SF!$I^M**$KWL^X'<<*OC+<9TJ@=Q#JXR[7;*
MDNU9I!7K76_LW3++R.YX]@GA3YIT$;NW(U$VX;0C+:WN_(]*"(U_>:LRNI4]
MXG;%+#&[HOXLY:0V%M&5+:D8J&8J%N@95J/9(*>.<>%>'[URJ5-[WQZ7OI("
M>4?<&<?;",9$LU6T]]2J*)Q*'1(C/?H]2XN7X;=KR:EXU9*B^FOK6'&?2,J.
MG)(CFNP\AUW6*I R2G(.(Y\ M?S?OQ2^4E=/&-*K;_F"T5=+$0?3&#_>7,K@
M&-IPUC&-SO0C4C:2F>/7S6_?'2TO[8_I$O\@ZUQ[SV(I-1_OO8I7]9KB[ @U
M<AXNS@"RW#SS8YE,G<W\^&96C'30&+1\B%G]03W0J0J/NVT_GGV1=UTE00&E
MD*F<I#8!!PLIB.1AEX?ZP>F!0=(2/M(%3YF3#@HX6+6<-7GI+QVGTTE.?W%5
MG,-;N#LR(MN0H77%O&1FN[C8:5?+ULXO7VT^ACL\31%MAW$EIA#6<<FY3_(-
MQ.^TKN<B@E899]E6T6.?*OMJR-Y?JJ[^Q+&3=4'4I.ZW^@]40OU/AVA;ZR_M
MD-Y6P'(T)]::QLHH0HG?EZXL4YO1]BB'XQ-?YB.;TN5*$LAB<%3ET(N)X_)J
M+WOK?+RF=[(PUFX\3O:>JYJ'RU!'3I>8(2X,G K_\.]!LGOUPB05,&1>FF+,
MSCD^\ 3(>B73&#U+88"<"DN>YFQT+A(K&(Q/,T.MZ/H.X0Z38(SGZPHB 0#V
MQ!&&Y.O&2ZF.D7*LXL^:NV8^OA/!,K%>1G?RC3WU\?I9;\(-2W6'7E_<>#FC
M<%E4I4=UWJHG$HX+/"IG5.DD40UP_YGA-Q#<RG@"_% 9A',TQ<KQKKS$K@6\
M- +XAA_#Z HN2IU8/'/#RBK!P^4C_#I-M146WP15>^>@O]#QMX 0X8+S(6E-
M]Q3VQ9+UIN P:FU%B>J(]M^5OZAR75\X#2EFJ=.N*\KM1H[4%V6:XG.JHCD6
M: ;]? 6AP4YX@Z4E02.A\^DD<JZ/>CHB,,(B;\'U\@_=IQM1O!=8];_(4NQ@
M9Z4L8.W6.XKZT"WER#7D. U:/NJ^Q?!,'\ >DO!ZJOF--68[B3WXH>B][0MI
MRXU5_BK$(VZ8\,;9**88;[4YJ,6LJ+51QC=OX3"_U+YCABBBK8YKB 6!:DU9
M5^2L":VW90'5=U^+U'7*K,'>QA,57E4N+X;[RZ]%[:0E;YVX+"0QZE(PHTP
MLL1NPY$\03"*BORZ>L6@CCS"?:LD7^O:7SZA\Y9I_#/.5WR%20/N4P3"TRRA
ML\GGJ=&!+D>MW%L]+T.E,,;$I*=FF1YH)*K=B7([^N(6.8C] 6DVR73QR+A3
M4TMV"Y1KM9E\ZI6"K ?^FVBE2!-!&Y)E^U//#P%&'@ PWGD"G-P4/P%FKA['
M(Z'F$;E1>@9\,I9(?02;D9<\W#VR<G0 Y;U_80DRIDQR1&A@8'4;(/U^7VF
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M8  JQ/T;T#B1ST7;+,4@!*>JD>0EL(#C[+)@U=.ZIQ4O8]HRLTZ0K-DHQF/
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M'L)DR!K&!Z2"D:_ZZVZD_)!<R2Y&73J&._YTP(,GJ51"*)S0];%92<B4R)X
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MB%4UT:@XUR]VB)O'>;9SR0[\,5I0^Y*5$N8<UZ\)+;K4;1V;K6.5JR,)N_&
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M\U;NPDFEWRCE,;B>^XK_&])$929;14=^GZ!?TXK'UU$KQ_G><^+L*0[&.HK
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M7#*WVZV]ZC./S>8**#5D'2*LD^,5TUSC$%U*+WW](M4'&V'O(F!-U DLCKG
M&Q9\>C($Q=_6::HG;J72?)>Z;EC?V(HE2OW816G&QHCBA\]_?V])SNFE8[Y_
M+SITF?39F2SA"4".=8,$$O*^FN'[3.H5Z,.;^"]@H' &'A'_V\JDI=$/CC6U
M%4UQ/P10SZQW/NG.:9O/-(,'5FX?):DY=5_WWJF2?S&CBNIQ^[7(#G<*(7:0
M_-SP"\.)[QMY>P# Z+IS32>0GZ,$O)N8LE&A)4+Y=:^<#Y CBRX,<QN5(YW?
MRV0_GDYS+N[=(QZ,\,BGZAT98EPQF36\4P6N?_1C+K.HV%.\3MT#6:F_,ZX+
MT*KR'WDI3.( #+UXH)+38A2OG)CR#S/%)FVW;30%<E]U W0Y_<OV[9!F./S-
M+)X @D3R],1S6T(\3P"?PY(2QB_CYY)S[/L$EE>>E\HW:8N_3KW?:K!_0\2*
M%I<<L57GA+^NF43[<UF:P12.JV5H"%^U]['QOX/EE5B,_2<;?4S)?I!H\/"M
MY^#E'H*9/F, ]0JZI(#D_2[$XE2<,NR.X6"I'VQ4JN@T%E[!5X[,O0\6#P#1
M4%=[F7H4PS,K9KJP/&.'$\?7"/%6F9?P@795F C#-A(4&RK=H@7]Y-A(B6_>
M5TI&=YU*MLLC&-.5X\:0AQ0;3Q#=TB1*/HY:CBD+FI&0Z(F[WZT%3R1#0U\D
M<9H6"UU+,4ME,N>L+[)'D,_AL6SYI;]-M0W'&G8/=1"DGS!Q449=;F;(_C5,
M9:Q?6.R._1G76[7(XC0J+DE)"2\!Y/HZGD./;*UP4/ 2G56@T*TO-^4W)2:A
M) 6F"\5,G,;LO,3)ZXS*JDB^(O?5&NK:&K!#3=N "9G)[\E(M_5KBZFB\$ Y
M5)WK!E#91^HD56C]I_:7"[^P.)%03;G_=&+*-5/P\18\%.3Y<W/5W/@_./^1
M.'H"+&V'UFJ;T,:Y>^9#SUR\GD?2)I=8+/(3Y NMJIWLGU3QMN\D".'HLI+(
M&4\ TSDK7Z\Y)),MK"V,)>_&?;4EQD\W3EXFLU<W)P=GK=.>%W>I%_W>'4*%
M!^\?XMY9M*5*&[&8A/71WM2OO]J?X"]E+#PAJ(LPH-VSQXGM#H;,LH;S7NAR
MWYL"L_[%LXF.3H<( PLX?!W7+1&7G&I#KPYK&:=1J,V63UZA"Y%\0_XL9A=6
M=%VFXF$&Q]$PJG\")$2HZ"1'F6:-['7$Z[Q:,J\CN@JV/LKZ8VF\;!A\1QKD
M2JZ2CNX-6\9Q\'YUG2!=WN"WMJ;V!!A7FS_4!3+%'.[/\#\PNC'K=,'/WYV7
MO&<O,D-2V5;:^B(@RN!]3BD8EU!R__'8:"DOJ[H!A^+W5VH8=4B]J!WW\#0A
MGP\/_\D,[C(EDVE^UIMT@$ ^,!%Z+!/+NV#AS$6T.<O7-##.#Q4ZZ/H4=O/V
MCQ8#94]H<(:R.&)^&V**&(!43*%F[/R.SU^@N5#B_=XZ#X?3?S@TRO](!X%/
M;8;"I1,T]>F#41?NHAG19[HK1BQLG3F37*TM$!Q==?2()U?R$4+H^%7*LWA*
M33.RY\;&U*;=#F(7J?'=E!=CXJ1%QP_?5?0AFW%S'Y@_)GF2Y>7.+W45%_ B
M*UNEDVLHYG";SUP\4)AE3CV#HN!_?^OPQ\F')&KG4^K(L5G?K3KMUU3I%^S1
M+I!^T0:+X",F^.3[N ]O48$F9BO)VT@UM\TZF]XS][SDC)STQ<8GS*&S&DO?
MZTR/]-GHU4[[_0F-8<*LC%_@E\3UQI)V'91 H>.-\!7WE:CA7*4\7">_P2HQ
M'!7]?\O>N^TE5#UA=$*M:(Y7,\([3U%IQIP1.QCK;J25;*3DT<PR>99X+OV/
M8&_D,"U+C^]5TERQ)/$V^0PUX6HAU'NTNL(;!J9'IL"QMP\:Q\A W_$4R58;
M3T84C?I)RXN'U[IUD7R$>2[;4<;:(IM\&$GI0--GIZQ9N6P1,BP.HHD($@_]
MR!(T9F.O[=2P5($0"5]7_#G@S2^TRR*'4_$99: ZK@,M+S.B.T@PLU3;972G
M%6-SZL*PL:G6;\_"N 'J*!ZCX!1"[L>CB\"]7@)PU,:G_BOK.,0C8"/\[;53
MB=MI%-!#YWCQ*)QI SQ+4QG)_D;/+%7?_NH+HBS+L*>88\5UE<(DOE/"JB5H
M]!QR YGT7F9R?@*L5R-,R6L6AZV#'U].1V3WN&<*3/KO@,0>T%ZO7*9M336!
MBO90W=*3P;!KIL]R>Z; 7]>Q)_A2QT'!Q=\_#)=M-5G8T\U1(Z"*-JS'DW-N
M#EGOIO+(J(*JTT1&+R*$I=]45L?<2+(B=$IN($I\475>UZP-\WIE1D8YE=E4
MG3Q'*4IE"++3>1FBKZYVM&&?ZI_CIA*4!\LR)7**K[0"\YD>=N+UO</YX.[F
M]@V) >XRH&PYDW#)R_P\.^,Y09<A%7^H?-(?<":+5@2PS2">RG33=")QGE**
MW(H'01OD/J4);D\ %R\':YT_&,,^6%2266KK8J+R <H$ #<$V>REUB7R%.*9
MN\ZS]#>\U<X3ZDV<+/,\,>H$(XRTHQ+R 3P/#&",&A3=VHIVDK VS%Y-K L&
MAN&+Q^/[G;^K IAQDOZJG?6/5@#5"G\W%+'_L'HSBC@&:O9N$N+E*KL*VG[&
M"K3_PWI( H<!74M,XV4Q;-;6+SLDYW; QD(QQ:Y,4 MIBT,.IM(<U3J(.S@)
MG(&_3+TF$BW^6K!)OQ'MK[IC?S<(Y8S 5:GF>0#*33*7X;G?5P?)U 2""*_P
MXIRM^_[,E"BUC'+\O@#E!;J\8*;=1#K=E!4,G9=8[79T_P__R5W"/0B:P,62
MM$8,*KL7\K2P:LR-I\QG"T_LG3Z\("X:,Y]65=CU^A*"-S6F8;S-,-B%F>Y$
M:J\E^^^]Q$H)((JD97)ZNW =B/([X[3X^Z%P;5@DC763C5!#.D;7M%/&ZBYE
MJEFUA9B?9$?#)RNM,(]V9\,/F"U\1OM%_ZZ;#)F,PLJO(V-X#^Q31&$L2>YQ
M2Y]UDR)'NVS !,.,XK'_0<4YC8W1BXN#RUC=U$M$DVNA<U;9[F8XPIV47PO6
M@643S?:/P"KIC[5BUB0],U=&M*E3A[,UZ*H&3B3VOC,D:S4>.L0#*X?&W!.#
M3E4_&=9Y^.2LG@"R%Q'']VV6I?<_0VQ4G1-RF=,,)I'X"EX=[&36N3\8=(&\
MURRX:6JPVTG39G%POJ5^C\R.]T+1L_?OL0$(M/&%=IQ05U+"*0<HBS0EZE7F
MDKF&FS5MTB+LBM:TM#+JY_+[(;LVU;'%)Z(R77[ZN:Q*!@0$+VWL.@7CR+N\
M@S5, OY\+[X@X&"/"1TACRV',001]@Z[.S_#:RW<KED/I>/IK%SPXGSSPH1L
M3OSXTM3V+_MP3!\?K]PRNN"+@<W%O&N%7<R'.8[7X\MGW]2#UNB!^9GUJM4G
MI>FVM$4YN_)OQZ?G2JG)YI,#G@ PL[Z5?%K"*8X2 P6K-7 5D?<R2P#![98/
M-ZCEX[733(_=[L22!8A$\2&E$B>SEYHB-M+I$;J8AKNL\_$>Q,^3KV5R-.0D
M.(!U-7#?Y8DS@V!VS, H1-!>*N9:PVT=?_CNK0FQX1+RPFX/[R/'P0U9-4(_
M+/NZ3.$&JN5$_&KDOG'WVZE@91_$^R6N_D3;[4OHVM*0T>7^YJZCU];:Y_./
MR5X$I6%4T^%1&@#ZK'_(WJFW:O%;&!5PM3Y4A== &:>3*IO/!%CEI&Y;4$I6
M@NC!? C6&0.++D8%A<DISGV4!JN *2 S_/]( JFZ+MGV!,GJH34R9SSAA=ND
MI* 'A/P+/O<ZQU^.*.XF]<'ST*:*GE4MN\^H];"\_)*FO^I9F*K82G%.Z/0L
M;RC$17YA_JB2^/I'Q3 55[DTJOW";W4LR44(:#M\#>JXR'KWS04MJRL#87%+
MAL$1=O5J9!VL3E9MZ#;%_W7A)V3^D8 GY4AAO"2O:D+?;S4F1W,CJPH=)* 6
M>S--!#>_)!*;=*JY*Z6=-(K&5/H9\2NEDXX0=E::]_<0_9HQJYDZ.GHC07D)
M_\EYW&FDYX[=1]4\V:,&=^(FZ'SKFZ8]NU8BZ&M)$Y$W=[Y<M>!'A4%EE*D)
M45M938KU'Z'C&#=T&XO95SE1W,U;OMXC.6@?/81*@VLC=^IJ1!D0C!A3EC^T
M\0"M-:]*]IY'J_>BV%S)D69P-*E.-?FAY5:.1*":3:=_(-]GAF6 #4RM1AC<
M@Z_[W3:U:UN@:*QH<*5)BPM6BZDYO_P$R#'W;DCBLNV,!R#XDO]T\W9'KL_'
MVOTIK^U:#'-%6PY>\]18XS9,[>Z:"'S_!I\F86,>^@E 1^7?]T>8+$A-D$["
MPL*N8H$U9'UAK!]7]2KL*M#+>KHNJG:1WVG0,)$QB@%W0H60>IXOK%;5"!6D
MVXL53+TJE\?>BG=OPT]%FT+:$_MR.W5+DN2K"*P\@X?8I6^]S-Q,TTSS0HHQ
M\/@)$.GHC;T3#P],6P7[T<K,;]5'<OM>4A]1+5OJ0#X2ZYQ<-I.#_KH,X$[=
M^WQ=H?Q ;]XV%5E88,[;\SM;9-M<(Z D66>Y[K<!\AE'8"H:VUF12Y#Z),&I
MZB'BJR? R^"/9QQ. ^V/).4)P_X256<--Y7BI&>/9X;C6!O33X"W'@+.)]('
M<.L?EG]RS(CHK0X]*D_K:)JZ^R/E2O_T--/WK<NHGY#P>@5\]PY5L,H3.L:"
MXI^9.V@#QRE/A.ZI7QU]=$Y8(P#T79U>>?&,-#OR/,^_@5K?@[($HLW'C&+T
M7,:"T ZY!_NO[^\_E_KU=XS(0,%@8C5FRXFC;E0]'"_$XK_MX!DH_4,2UMYJ
MUM8ZG>5F";1&SX]1B5(Y32O(;M)E$8T! @#)T;RWXQO_4N&_E'8A&<MIJ$OP
MEV(-7..:'<5>*@]'%\C[H7NG?YE3B=ETG%!0@[?-1$7_C5OS4:.)0XUS3?1[
M:RAUK:OXS2N$;]BOAM%=\HL_6I_S69"RVGX/KZGPW6I!Y"1)3GT"V",V/$][
M@VZ<-$^L*M@@0F&!UC!_#<@[[@DP:*4ZVE9]0EV++YEF)*ZZ(D:\I?P ;Y'D
M7D_V4@KJLB<.#!%+M')2/J.A@%67W_1P#R\Q.C&:OHL'444H;U@.+_:UD8\J
M)A* G7:R^"+!##R"%[YT?.3!?W(C<J6Y\2A*KUW1#^@5W+VAL/',ZA.. ;!P
MV:4X1$QGF= FI!-"'HG1-[$,;T@)&>EONE/T".:,.\V"+\14ZXXBB9VKNAT%
MF#&G2QK&*2A4]E%:OC A_(+A%BL\4<:^8PR&A?R>Q3W=C+E^ OC&1G5 3^F?
M!\JSNCFM:H>O4:W3W5(<_@10;ZH.Y8(H![>1'&^JOG!7(D)*LT>J*M!.,BNQ
M/%(6<N;W74PVH>/A)N &<HS]K2O5BQ"[NGF'A$7K4W+.( ZD'ZW'(6KS2VK%
M5_$UJU@H#M\-7OCW[L8<RE1,.+JCZ=-G.MV]:=FV'*CXF0NF^F/-BFT_@3OQ
M]Y?D]A7-\DK^7%^B_Q5Q9X_]SU=^& .:)RWO)8MKN50O"UJDS?3\)5VG_*0&
M8C[&VT8CBW0[J_Q]LIB&B@66V&S'%D\*L_SL"P'1G5"G]?B0^;SXQN;#/<2Q
M%BDN[J!BR/<S)B6/H/?^==XT9TFQUN[M<*P9[B]WBWI2VCH3H#&5,8*$@NQR
M.@Z"@QFO'8Q?OV.6^@FPKR1:YW5_,J3O,M/)249Q;-03QEXQ!R?]\4F/*'?Z
M!>J*#_=Y<?NZP#<:" <T+Z7P5>( 0DT/F4PV:(1;DXPE%D9JH0'K0GH"B&(X
MH#7/)EJX\A<YIP"[&<6[=!UH[-CVA4GD?%I(-*[=I8@"8XN61!S=<:P.XURN
M1XAM>V]:H#.<>86[X4@Y>I>_^!9F_>8]X6R]]VPJ'MSVJ\W\VSR^KCU\;DXE
M4CD?PJ',3%/]\1HI\9D!)1\,$LA=WF]Z9>7?FR\:+^^H$(6'L<<0'*D>+7SI
MX<%_?,%SCX$K'ZL]\>I3DUM)W1Y$__U/]T\WX!/$,+HJ<B:=CL<SI]"UB[2W
M.V-:<)2^"Y3W2T;J>JXTP3_:-P*X>VQ[2SL ?J^Z9+4%LBSPF&-F-TZ]JC>1
M<9)P"NJREQ6DZ#/3??XO7NI"# KA"';H92[9?H-]WL0'Q_OU[I6:$7X\B4.A
M%Z;?R"'^E=,55A]UBT9#I^YT?J-]5%Q#JAS/>6G,84:B&BWDT_@7:7%8(>23
M[?5;Q6\(RG3C!Q]:QK;GVC_"E14L3_RW&#;RK34-UR<XK.J)1P@6P3K[>/[2
M\S19<YWF- ED[@N28P7<PU,O,#Q,0@$+3X ?WA+S5JUS\8U_91OX=H-N#UL?
MF:X3"M4&5IW(YN0L:VH':Y (OQU\H\86^26.+THP$_H$6.5L?;B-X%SHRPNR
M%'7=!OP5HW-ZUL8\+""P+]+E/'U:C4E=<1/"KQ=WJ!4R4+;HA?A8C2 G-FKM
MP9S=J9>[(.%L_8H[TO$5+/FX\S:JISI]>L482ZLX7C$VZH-M^ -QQCV:F2)-
MX/MUEB$BR8AV54*D:L4P%<A=D..DEQTK&J$@]"=["-.IP_-2[19L^+#A[<,?
MU3;^H80C<UVIVI1EVK35%>MJ1/XZU&L@:<7Y_O'/:1VXHB1V7URNQ#[^\5U%
MP[3*,)H4"(6$H5C7S[YWF%>_@5?YO522E"21A4W?11;=="@C"Y)<":%@M;SP
M_VN)1VLB34@FU%(!:3))5L7-VFW(S>'\76#>H!0YM*G))UC%2-F"L$0!Q\1T
MG1\E.HH]^CBJF/]L26L?.4K,2764*MSSJ12=3= :8>2WOS:-7YQ-!0/+" 4$
MA/G<UKPHKNVE9L13:+->.P?*5*S161'D4]FL>I-+93P!7@M6; Y\G'^+A\#U
M,;ZN86@CFN36HR+<H%%5;(TGST&MN^2T)U;B;M+T/G>@3+[1>5>&,V5TH@)P
MO*#BA'>9*-95\]H*O5N<FF2]U"N.;IZ#SWT5YSA+8_W!NYPD-C+H&!&Z4X*K
M:@'2G%-UVDQL>&SX?=DPB/^IJ9@(5ZYI^+-.NR]EF02#E.^ZS9X;+@^N[+IT
MJ*AU595&[U!=$P4:;,&Y^*:D=#5UB<IJ7)R;BW-DL]Q@,HY$OPB2_(AOO7^[
MIU.5(W\7N:0S<W,?458MTFB=_'LWHB.[[Z+L4\V4AAQQ2<.>V,P( VZ*C]YN
MU-F0&]'>JPJV10F:<@4$UG626ZQNL^ .J2B&I;UM]K<I-_I3*= /AK=CL?LR
M(&PE#.*B]SM*&T2.=J]8/4W[+C)# ?^O9>N_\][R\O\9=2PG_%*UOL+OR,+,
M6&'$\AU$T#:00?5D-4(MT^>3A/^Y+W%> A<??Z7Q]TYH;?ZSFX5.G"H4!Y;A
M16,4NR,-=T9D[T/$0Q(WMART@T% U+%[%GC+L/@9SC,9W/#B%WW6B,4G;')4
M@E,$:'&[R37<2-4&T]\O(E[)03$;^2VM[;E^]N]LDH((=_HE"'>%,5WLA8XC
MS6X6T]YY76FG["M4WG-%78N?'P"0HYN ,1,SS>;_S"P'78U@U(E?TOJR[-XV
MIX+\(NHH3?Y0AHR@PD>_QZ(1DQ?%K%?^"8# HS->DU^X'5=B-P7*L=C1\XSM
M4HE*\A2?OOQXL^WX6@)VMV.;=HW&O\]UN<Z52-,++-(H3_820;M5F<*QUW$@
MN5HDY&RA&3O:/%6YY-[>W1CYE2:8!$:"BB 1OL ZE-?4 &OE#B2YY.J ,+G.
MBNOY/^;YR"1IS@H95_^.)3\F4SW/6M0[$J(R#UWEUS(IF]UYF^2IP+> SG\]
M12=V]*T4@?MR)(_#6;AIIN2<S_Y#S,O!) 1[2X>,$-@)T@JY)AG4:V1QZ^O$
M[%UR7]G^Y'Y^L= UB#\7Q35KK^:QY-*;0V+MQV3%=9Y8-,DR#(^;TD9?Z/H8
MEP1R8'*P/3N36=3I;6*#$+A'R#9AZ+-5J&5!.?W(1V7"-_#!([U2E,N'5?)E
M^\-[^@KZF@.S,4ET86JL W>%<>K_C>Z6ZUH1&\5BOYOH^2\7M=KD#I[OS9 7
MR:4T (R45YUNGO<S55]IL+6*$>9T7GYETN#4^4)8=:/2;&+1T,2+'F%;H$G%
M;Q-P@^.C%O\&21;01U4","%_N6OTY29!A_,/_TW3@I7G!@@FQ"+ LCN>MN84
M+6+^]A",>G)TZO?];O_J;&1362Y"7^U=7/5N_Z^FFV>#H_!CO@-B%XO8O6X;
M!@A)5:QYI_(I!)?BN5QQP=]8WLQ<(Z-=CR+%_1NQOM+%0,Y3_>*E:JBX3%U
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M7>?\N\$;DU . (6XE=,:.Y-$K <9730K7)'K^.)U3)-G][3TFV'<$]87H""
M?6^'H.$%<!GWI5;09M_$<E0F"&>2PVSL[Z*/B8U:3DMM"WY\&+=I?@'2WCN_
M N@]>\57RAN0HYDZ818?OK)\KN*R$S[#XG$ZW[.A5=M6V]Q0$TJK3AH3]H83
M3=^^9N8_35W^-#U]QF%;=O%_!3W["EH%)S9R:!R]2&C-V-Q4Q?;C@I>/G,[]
MP=;@"Y!)PZYJ85<(6YH3/&TAS'</BY[9>D&X3S3"MU/Y JS_1QP;?!>SEZ]S
M-7.H]!!](C5Q\R8-0:1E[E]XJD_CVY1B.O(F"Q2/%:],N1=P57D!!"4F5CRB
M;F\"7ETOK;?\Z4*R]81O_T./ST[EW@O@.3:\!,/G&%X]?44J;]W,X1G\_*,?
MK>V!OH00]79;BW@9UJ"RS6\S^E/D.I -BKUP&.%4,?HOIH/T&_/(W'RIPJ)>
M9CNLF,XB3$@C:<7SX#:= R58D1O31@=_L'UDH"NW6(0%6IA>D;2:D*'Z>VGO
M>K2K,_C1&T<$W2=]X6<;=8;D2?Y2/&D1QAZ%V(,QLX43OIVO/"_ 5N4C7U#<
MQFR:Z37CBMJ4S'TZPC+;DV/:*W?.11";>Q/YW"4@\QWDGOOP6ZCR3(OH!6,3
MGD]>GCPR)_^EY.#_*CG2:.$"T>FQ^.P%8/KJO]%-WHO:^Q2F3X0,JHA&5DFA
MC\4><5@X+<M9O@UTWYV.>#ZZN<V5KD6L([ -WAEAPYUS \7T\$G4O4[\[ 3:
M[@7@B=)YV"Y20MU5W.]1OE&YNF!,5CA[\P(,-;ZVO?>1_92^0$ $DP[7MN:!
M7)IZX_8"*"!R_&W&+X!*"^X?B_S;B%^ @^O";:TVO@OR-+Z!-L(+1A6UJ=<5
MH5-%Z&GA6]3SL#R"^:77"X!D3O(T_?4%.+S*_C>.B#_]RR$R\FU5[JW<FCG0
M=FQ'G3_[;-O-[T2RX',I3Y3J_;:>(O?D',IV3*U(%L<^Z2];Q?.U%?' Z6^J
M:&NJ#_)A%M&S8616D4>OC=LW(,\F["FGTJ8,9/@\NV'WW=_UX,9LN#O74'$+
M(X&RLHQW]UY^@IA67X&XJ)7CW1SHK#U_$AM*<?)PLZW"PS7_O9A$A0-*'[NN
MK5(]T09!ZU<"\R4TB-YR/V?J-9:/"F[UVD=?(8A_)GR ]I;.<3DX4&Z6@FH6
MF1JC!HNF<2<$,_+B>Q\X/SJHS]QOI^9I"D-M]86*VRI:Z0.D%-3\'>'1C+:,
MYL&A7SJ65P; MMR[Y]]\LU^7R!_^HFO\.&B* CNC#!\9^:+JO">3CQF><YDB
MTTP\GRC>F%/B7^P\21CP74S4;8D\A/L4?MEX=G=Y+'B]0S.Q\R3O\LPW6//Q
M[@78"?WC[NGIYD!2:+!7[^.9S,/KM].Y2+QN(0PQ+P -'^\D! TZXG_ZR$]<
MX9/0>NU:WH!OY>A.%K+ZE6W^C!MUM_>GU0JOSQ2YS\9CTU]W=EY=\-/"L[JW
M5\'*J_:X%=H>JU_5+PN98XC<NZ&&[.J]1+?=%$.S:59[YY<!D]&+O:>N<<SW
M-Z0G<[9%@R<)GY71YQI-<PG,+8\(UEJJ5%Q)ZT:KQ/OVMC6IY\[QMEU<<]X8
M".6;T?2K/YOQ/B] J7CK!N&^PA__3WT!*'E*7H#$P#G97<[7Q"P!2_2WP9VB
MU%HI6=O65/##3_9GD6JVU[:?_FSDRSS7X/XSFY7S(J6BTISGTVVOH;&U"&JO
MV6/,/2>Z%P!=R>C4.H$U&VJBI(P$QEZ<JO9$6GP4O5';,^5SJLS9LU8AVZ+/
M*-K1']'=3TFBJEF1WT2E:?7\TC,Q9X J8?"I]U7ZCZ2E7X#SB?,CR4;/%Z!(
M.OOV!>"="K/:[R?+RERQB[KZE.(S^OJ3.-R=T?N<5_[*MQF(1I63/:GOO?_^
MRD;Y/@/?J^_80SC3_Q'W?R67;OX7A)._($Q"L.";$UW<A'#Y$.[,QWKU\$WF
M_7&EUSM =T6MQH5[)45*[]8QZ-8AZ:?L23K?O@+VJ^C^$?_K4C/1MB55>P.2
MXEU_@N),)KRO&<W(EP>*DN)3;8KFDBW2Z3]NV8Z)C356I?ACBQ'Y4[[:_^@+
MT(&=M3UYQ[2^ D-H%HNR-A0PA'WW;*^Q/4HZT2QK_,#2VNF(.B+U+!MELJ+3
MUK3]A^'O\T.L+HM?@*I^*VX_% [R>/HF/36\K-C8V#X>B%5%;<H@,YK2>>8!
MTL*6Y_&]NAV=51#2[64& @XE,EYVZ2_NJ#6TH$^V?.,:^3?"@(RPP);4"\#W
M>GF6$BC6OU),[,1#EB]Y5@:#A PF-=\J<12ES=V]S<.63\>?;\^W>A\]TQ\V
M9?43GKTUGN_0('C0=0:2G[V3G^_471+H'A\)VOY,S>+Y;<5,#5:Y89(J/K\:
MI!<I*,_K0%D*]"7^;::'K,$W/< 9ZS%"@T'R[\%#9?X>QL(EI&0#JX&+)O3K
M%HQK$^-/4W>/Q=)?@<W=/0PD ,-$^'H6+\'/"P)A\);6][(39C#3K@Q+!LDK
M&MB]1^+H[E<$%2^ ;VB<>M;#ES%]RO+J(9];44/_N?$)A::(_D7$$^NX8=-&
MC#:K$N;BQJ56W?&V(=Q'BY;SO!<@_?5J58ZBU?3I[7_])&P#;R76(^?L<BPE
M$5F2S9E4O]^V>G.7>(#86!?N/65^W<OE0C?$OI%Q=9-7[!KX(;K9V8;H%W_.
MXW)6=;C\SC.OJD^[,'D<V^,3V]-Y353M"?H-CI=!L\JB"<MV?:7(REP,4TJP
M'/W&> YG[KY6B4S.\!8KGVL)(M,^W_V5S^#KE&2>SC]Q%_KL[+6=Q$C."Y^@
MOYK_CY9J@E.=J+O$L8.2+\6LR6ZX/;D5J%R5,S"YNE(;_:CJJBA]7F&VRB:D
M$CRN>UH^_XPO*(,T-UA8EDD^;/^N]A!1[+JT8*HS[RF'TX6AG-:P!5Q;].2X
M'])66\J:^<8>SU ?AF_\^P'&LUFXL+T89.PF/8A@4RF=TM*G=\)GA4K\_[$:
M/5?G1Y]5' ?Y9Y77H*R=2>;;V@/S!!Q5!4D[Q,9"?5IG4F;!;?6"&?&657,#
MJ0HEJ4TCS!D!WPA5UE^VE+)1-B:[/-?O9L%,:-8Q\"YZ+ B+IW*Y)E""4C()
M1Z<AJU!XK_^V[6!H_9%FO7@PN:<F:1W;);K3]1<V!_L\'X%%7H"FVK*EEMIA
M.&IZ,DD*_':QJ39:E$"\2FVCSC* BPRX[O5_K(.DA;E_ 1YME>N+)LGD&NTF
MCI_@]^SE\S+IW&[:TI,H$&18NU^ :FH!FD!KNV/.IT_CVJUZ$4Y4+#&^?9]2
MY_:BDDH&]7_F]6MI,:66HL3<AY;3AEBPQ>L8&V!)518=[7#K5RCD3WF+5!9*
M%CVBHML(:;'CQ%5^[C?M. <.1LR*W?-@23E+&S0#$0L A;O)]#E=Z?'2I79J
M<2(^O ?'3.8Y@_",21..7FJTC<OL),*IMCZ./<?SW;:^-4<$<:.S!:+)H>2<
M&"'==4W$/X0M<=EX<432Z7*=1L,V^C:2CU7DPC\\M1.?2\7E3\S(!U-W&KHW
M9"2M1+QZ3W<@E#!+R4GN<;#BH!Q*4<[]3TE#&=F_BUFD_96:,#R*YBV:LSJ7
MFB/G5S>%[I$X=_17-LA[V$HCE5&V!F?PE(&)6YTU@NOK&YSJ$N-D!ZG$JPVP
M>PY-YAO?]9_1'-[[!)<=6^4@2V0*#O 3<U?(SW+;PG+?RT)IH?*'XF.,<SQ/
M@DMT&9.#L?A2U6+Y \N('.L;52><+Q^$'N_P7(Z^G"Y-#9V9O]?2;!FK;G9%
M69L2$LM4W#R"L(=#;L>G,O=E:JNDX6MS> '\Z)Y9$%K]X$T[U(YSR&8#KH.Q
M($\YK]'+A0$]G=TBWL%KYZ97)@N\8+!] 1Q2;HK39^/35UZ#OO:$%P"GYZPV
MN\!LFL]THCR)0S<BS\,1V>@W<@+7KX%RVWIRDJ2]=3M2<:)-1G_V7G5@*%C
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MZ%8-;/+"@Z2]71#M3J<[RQ "W%Y\:(G  +_OJ</>D?P+H+='> E7^<IICB_
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M#W49#0JYJC6F9<"P,:F7.'L>S9=22>W)PXVJ\Z,C[KU,$?HF\(68V&),P2;
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M\K:IMEZ);BL36JH)R]\916#4?*3E-LPJW_Q&T'3> N*AR0 V'!L;C;F\84E
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M.U#+%(_5#;A?H>\L4[<T5S2?'D5,79?D:<"5<SW0DL=L)BJ_+_TJ[WV!9VA
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M>L;^TVK\JF<MS\)\1*1O5ERXC:.07:MX8)GO2&HM?AQCB7]27MA<\,_,[>&
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MN>L[\A"422JN%^ 2I&_"XN>9GJ+@J:K78E&M4];S1'X.7B$'@VL)TLYF&Q]
M&K!1&@O6N0Z7C\6MKBIS*>PJ@@L:)$4D"=P2N;M:&(";3:'ACO#I8@Z_/"&E
M)RD.(WDW=\K]S7O;?%/D/J2,MW'.D:$^54[[YP[*[3T1R_PVR,<=^@SN6OZ<
M\<$3;XC41/CP8?X]/1VSDF>M>S(4%$0H:;LQ2D[1Y*AT3#BXM0"7+2;(T%V
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M<%=#]OOK31G),!7E:,*CK1,8^]^]K:3QG5<L7U,U9[%JAJ;,,JHC#I:QHTI
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MUQR_.R5+V.F<9#)QH-)&<(7-[(N34UN'!?X!,(BLKG?:3HN\B\?.!7&-(%"
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M9O_&=(J^<%/W>(?H%N]OF%"G!6JBDV_-RO"OXJ2J=]I)HKA2'"@T3Q%6U.$
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M=.6?6,[-5RL;_>M'0' 6G@;?='2U]\DV5:00R&2KOU.$_Q0HK2-7SIGUI;*
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M]ES@=_T,?7<*_VLI5W-OZ-W[$ WV>X>XF0+ &5N5D%B)?@2AQ?3]MR%-U2?
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M.HTX5,O$F?U:PN?14)-[JW;"A-:S8,$GT?P]&W7P"9BCOL_-D U[5 *UT%X
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ML_:$Q"]<3P[ UEEC]L?:K1/%I2.7D03SWA(F,A0<+',)=7NZ'NBB8L/TRJ-
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M[;-EW/XL9-'E + -C/$V_]"H6=B@?]S7$JK'%>C"7#.&8J U;').SMSL2H*
MU'6][<=%_E?YYL+*_!<Y-_D_6T+#D5&UWJKV8*!LC%2!#\FD<GF+EHQ2!^-6
M8)_T:97O]&75UZP;B8M%-I>W>R[O]_ N%5=S.N;K,_1>";R ;"[O$WREY^B=
MGV)])8GWPBG1+GGG1:L<M4S]E/,@^SU-MPCR$6SS)?5L*M!46OP%XT-I., +
M(_-O^,OJL*<(9W,5=;LZFKJOW,Q3AX\W-B3@O/,3U(:(+O&V6_='%RZ++U!)
M;#YHF"5+^&'29'Z0$CKT%[[NIX$5ZG+2GLACT[:<YZ3=)EW1'#65KY!F%@IT
M=DG*.: ':\OP?CBE$YPDEJ[^V62 =(>A%0\H1CH]W]3H'V758H6;DDS7)I@V
MTT*NQ'P1+SP8T<YU'/W7?[-_XA]"":/).*O;#S<T=.U1FH4B%H:'@Y&FM2RB
MC.\OJD&Q\^X'M.A6>3$!N_8]X$;5+."DLD ^=[@Y0U6CK;D8SS\_WB>I),_W
MG3Q*>A@LV6>E0[8TN;C@LB2$ON>TIMN!B;VLXB(8<%HNA&1QW<BE[%ZDJW^3
MLEK!N&'K.V W*R[P<O_'R4'H^+3-T@#!IE6MT\8CKQ*C8O #2(<9E85T6;D[
M<H<Z](*@N$3 A&I^D*9XIRD4@IOH@<N]4,92OG+MV7C7?M4@<3/8&QME^$!^
M6< ;RIQ@=8^#;"N3LML:I[-O:,HY[_"8N],2<%;42C*K;9D<K[,Z=!56T1L5
M(Q#O>G=9IC9?!?E(]N4%S<-$\V5)J2H7]9BR/E/8PZ.T"[8ZHP#_7>?9!7))
MX7.'"'T"GAO%'4:A%:0],ZQHQ,.+1C(/?T#->!?122<QK$37??C'TA*;IN5D
M];T,PN-600B?2F0 L;R68ZJR3.7#^P^H71U!?=O53J7+0X6[**VS1TT=Y"Q=
M^V_N)XZ6VJTLM<0J8FR-_7!CQO?,G)(26A,YC*;'5[OG&,&&&CDB@:IX. )*
MD8U>,;26%H=_  ."7@%:#N4HU>HQA*8'A2%Q=$>P&8W[JL\RV\"/![YZ"!;(
M*A!ES&@[)M'H>7\L5>*'#!##?S2:33,=ENI[9Y$;6O,/*PME:WH]11H3'O:2
M0=A,]^*?$+/+<)(V6?-Z/$,L9$>V.(U1U.T'BK=\L6%D1)L;V]HT\WX_7GXY
MRXC=W%!X09R0;+^U%8U.7N_,\8L4[=CVYZFQIIS[],"55#529U,ZU4*8Y1+Y
M:QBU]9\+J^UZ?N]:6AJK&V*W]RW6_5F28L612P6D.#*>@)?ZP=!N9E!#N>"P
MR=G7-0O=@M.,Y@D=)]4'4[NK2E3Y5XR+X6VFT,'L06QN"C_/GR27_6*<>23%
MJ0D/;M=W'YD=X/-KM:.XRWK3:THCN1 5[+G987:5K5O$VE?:RR$9^6YOWK*S
ML \3"+O#H9QGSJ&'"FVIS#T!!^/ZC\!"6D_!/BZOP%62D['C-20"G JIZ=>@
ME?5_!4*;=IH NT(9Z^?2A.=,PI0#&0/S4[Y"CHTXB1Z6!O2?54KUOZ _D0;[
M &QU+M/\+M)0V\&F60TQ(D<RP1R^MT;:0K2.2.L.X>I2SW-4U?K^7HYU7*9U
MZ=OSCY7HQOW"CV$AUMOX%'7K3F'J@87C\*[<$;%)3@!_U&']\:Q=,*B%W*?B
MYD?R12U33$XFP>T"UK@ N?*U"/3T@3Z[9M+Y!-V""]?3IJ6/-/'P:&[K,U$M
MRU;<O@6L_PV.<<G2C>W5CGI#2^2^I?KG),FNE1>G_IZAEU8YN:!!V$]/0*5&
MYP6&^K\JK_^WZ_G:*K%!4=32P=C)^_IKJ;9VMID!#\66'_"S!!RZX4M)W@X.
MCHVD%F6(&6UD[:DKW;%@B784=[C(1BN2<(Y=W-)E]>&O_9673F/DXZM&?@DF
M^-E!I"/GD"._LT*8*/4-TZ=0J@L/,2@FI*+?C\9*:SXI[]MX0;'68H@4QNW9
MUY7(I@DMJP.(Z)J$44M&3FN,&P69Z6H/_B#^3J1URFFJ;.H8>%9IOTJ*N#P,
MKD&1OB0ZYJSJ;::] &*[TY%YJ8XP^]XA-4'O7;R;V;I$(#(,9:,SD7?3=3:Z
M5.V\\]B';6MK@0^03?=/%)&THJP^PGNJ''\/V;_XV:SM(9E)*&I.6D-%BT.H
MH['B'TZHPT%>\PT[#;,;I[BQ"RWA7"Q)WG3:'B;$':T1@ O[G]*\JB>?-SL:
MWH_.T&'%&F9LVMWO(0F! 2F[)X#D] EHH9/>;B-+O,K$JTI?7I%A[$4Z-F^)
M==0F;JP>V A=7G/@6M:G%6I;SAJN45:4IE?3I_>,DV)P8-K#H[DN]MY[1D!E
MDCGH_1,@\BERGMWF*"GN_F3H>>JHJ7_C5RZZ\3$.U;U^<WYJ9VK+)<-R11S<
MO*YH.>(C5/',&XKUZ&WD7AHW-@0>VYGIQI28QZK!O$8KFD2^K=VTK=P4PG)O
M/N9G>ZQUR)/!BUP\VHB6H'T53#M 7GF@-_4FR(491S:I@YFNP:IK?2KW<V]1
M=?(3,")Z-.DUWU'/ 2ZLSO$ $TG6# +< #IM"81];MZON?#0<@_WP#I/4SO_
M V4DG"*>;HY]7KAKX<J^#/::66/XLFX,%.Q)<VG\0X7$9[7H#'+<4'_"AY[2
MN4+<4:][&8'U 6&>]F/<F>Q[6(9RK[A(I\OR%0FA8+&UA\Z)<PZ564%*MZ6'
MYZ<X8Q(IK(L%CV=O6@;3!1Q+7!!/M%OPY5OH+JJJF-02 ?2P1ZOO9B,9RLEF
M-H3.YG\?.UV(00L#?V>TCY2WC*WTE[WE><5G\XW48N'7P[DJ7"X8_APT-Y3F
MZ)9VR[S?4W!J&AY;1V#B9!57TH5;UHQ]W[E"FL$V>$I5!&W91*6#?7@=Q:H#
M:G-'_ V^,0Q=I0S%FZ:9-53$IH']@>RC3P_"(D]A#L1K6,69SHX>XZ>Z6H\T
M;;5CA^*O^^*8?ZSWGY"1M,G5R$.Y4<6#DFMQ*,L] 5$X?]T^02XE1DO/] 1D
M+Z<%M![=)>[FENGOXZ;JYNFNCE9]ST=PW66UIQ<_:DY5G\*UJ/!E)KRQM53C
MOM30_!$((.R#D!M+W),DI\U?ZZU)$/7:+@Z]]8RF\_AIO5PAI3?/85$*JS6C
M+0.=T1Z$C."??QDL&^Z:94TOP4=(M0PI;,0-I>/9>>[SJ1Z8W-&F&>- (9DT
M74)F=>$^!G]#4I5L3'BS!*+=?(I-A:5ZTHM7-A]6-3_9A[REF-[6'1B^)\!6
M=;<#,U'%XMD:QFI [\C]U??I)(M"7<Q"YKJKE22*]VF7&8:>130<SH3[4,7&
MY.K^-"G7X7WFQWOK)5/7: ^QSY>[[B>9]#FEO%--!(P[BQAZ6[VK6E6(#@.?
MW+/12+M\72I#R8(V<5%=BMJ&?VHG7@ $+/4)\8"OX;B/\(E>A)[N[_GAXQ'M
M9 E3$'QUJ%U=^U%E0G/;I!%$$BZCX#PJ'F@_F+7X*Q+^7]PZH6WF1EWI_:J4
M+>:\FD%HD?L/=QY$V#UAPIA_Q>&$I5N"BON(0MLWH'9:]2'$<VTD9+,%B>[3
M[ W?:MD  /X 60ZD=NH]8;GQ&;)7ZCI6+IW.51PHORIT1$(#JZ]W:E,1Q?IC
M290JIW18R,74;H3450#;*W5\YH':HTR/"KQY.WV\\>G 1Y#YYJK^02BB$R+D
M!P8C]O"Z!><86D50]J:/N;#9)2KOCVEC W[PP!]:L-BN\V?W#K29ZXQ#0,3G
M&9S>"%T.=<9D(]]1/_BQG]Q=ACUC#(YOL476&3#3>3#/_ BG^J\X)']GA/J?
M9L^B59K;8/,$[8T/"35LUT$^A&_1843E#%U47#5%A21><WD2B."TC\[O>,1K
MB6X/XZ''P<:%[U"@7&2_ZH!SA0XW?_EIXFZ+CV:7>4AJ?XA(,C>GSKPN>4PV
M*2UCP]'V0G2+XA1I:RGR8-8ILVWA/^BUL57G&?$SZ!_D/0&['+4ZQP5VK#=E
M,AF5%!8IZ0SPZE89[2+](+;_CJR;>$[]QSM,8(@;1V.YKEQIT<UST/>YGQ"D
MR$DXQFM3Q7X,<>,#!/;K_*U_#+\]RQ7J[8F[4:E>HK$YPZ+(!"_MTIF9*B:^
M15>RYL)744L,:[R\PTZ-7$J_]@?S1[VR'-?4]JDS\6XB_W6W\&&TN"#%OQB?
M(AU&)S%M4X"Y!PH_76%W_&$;PA%)TW]+:9.'',I#,8=8/=>FX7_>6^'L@WXB
M45">G*CX8[RG$-0DX%$6;OR)4XM,.W[-5;/M5"VG4F>HT)T7.R'^*$LMP\D&
ML5C_=A?:$Z6LY4D:Y+R&2M$8]^E:ZVO;LM4;FQ0*(?T-?3$BY-1I-=PIB$7B
M2SM+/$A-RZ&PT*)>8>PI^R,=::,UEZ\ULRCS!Q\<1.6CH?(5<^8OWG>@+F@]
MAXJ'+]>95N<-Z7Q@T!Q5\_#>/-3@A+^3P?@NJ[MMIN]-8Z,OXPQFM]"1NA0R
M>[;-MZ&@6P1>@%5JZ(&^2497IC>;8U^JR%*_QP)ML8#T*.9:XIZL?%6KR[QT
M%_=JBD*1HB;P(Q[LM9RF=$!I^[7+H_,3P*:QH*+?5 ]M>0)B4'R).V=?$SNI
MI7Y\"\I9A&YC#+R-.>?:M#8;D*F>(3\[!)-] ?W0P;H4V%_!F<,3(ZI)3U84
MP_D8^%S=UWH?KG$GL&T(:HT1)*\K-UG9;N=LZ.63Y$-BI0SCJ-\.(";=/@QP
MY(C)DSEN[ZOS_?JUBQU>>E ?__Z"G+U.%=/1%S>(O/PF[MJR[_? ,/<MO.KO
M^7.[2KT^2^)M\-4M1EY"-V;VAK@D-UY%Z81L?57FL;4SW;621TUL[Z_JJ)X"
M\]4;M>[C.YE9KS3M$/<$\"_:;1_A<@\"Z56SY;U&$'ED4UND'<I-YJ)ST\6M
M00K*$,Y0"OY2K 2 EE$V26#6.-4[2,X0'41B;*.7,6&H^=M=5+RQNJ4V="61
ML+W#_AQ-(S)8L+Y^:V#KFW10E.U*.2M2$9*4+0[UF\;+ZL&^S94/4C$HGDSX
M?GPN1%G?;< KKDN?VNJ"UI323.1Y;92^OR3D0?81N2B#E9I)^(*+^SU2!(/Y
M1K%DS[6E/4YK)<=B" 4Y%CEFTI^7P(JU5EY))\]Y/AB55X\ZQ 6O @PNWVF>
M@? 9OHIBC">1:20ZXU,%\]W+BS1/E[O0^S!NM)*:1VJSF\9R+G519"4;-X$/
M0"_WJCV.A#+<*$YOY2E[ \<G1/8^5?UNR#)TPQFT#MGZBA,\$=_TC?0X0+/4
ML7U,5Q(RP'DG  UVL*.Z9^;X&+V$A_$U-FE_VKPF/.X"7(EN[6K+>+%K8YL3
M$5V')9N'M?XP^MXS;H*CX>KUD"\S*2-9O[&"/#*Z#KJR*@,_7Y%EH]GV*C6F
M02#J.P._].CLBP>Z62*]M-?[M,Q>3FJA-&#9#TUK(5@WCNCHW:L4[<WU?N-P
MC)\/*Z8-UDT<9@3<*X9K+VW>6[D.^Y]M3DLN><K! BH_F]Z6H1NA AXG/3)I
M4O5+"759GQ(Q;&5-]$*8!I<[/7!2/MQ?C@M8SY8ES#B7V.Z@<H6N0FEN6;20
M-E;&!5WET_#A## F%U2%D49Q9%@ F%AYJYV!B#KJ&8/.H&VI]:98R<VS=Q[X
M#S6BT0 UK.5.@=8I4Y)'^6Z-QN(*9:OT=\GQ_"#9AV%[IX"9/1W!F&SW -'0
MU7UKI.-4PK!+W*OO5)B:^ E^U#E"T>PPBS(_43'IO^5RR4*-)-[%<J?$<CA]
M9?INZ"C2;P7Z^W99@<G\REJ-0'4ULD$<=$3O9<*%_/,S2H!UT,GW+KR*LKY4
MT]Y4A#+>@S>G;^NB;Y'(?M@'1RHT"FD!>\9_PJ:"EQ,_/;31<F[PZ'ZAJ>KW
MUO-<QM#UNB'$?OX(R1Y?-1G+GY57Z1G@7[8^ 15R#R7.$[=PBW_L-GP")L4
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M J*46ELS1%@4+DWR9!"G:-U&_ E0_=U>OW)9YWH?1*XR0<>7/O]KLWCF&!M
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M@2Z,A6ZVF*^ JPUB*FP?49KS=%EFPR'W*/P5^9W_7L!2Z5G".2K@?3U" WD
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MQK*X5%"GEPVZ/\)SU[CCF@$SGWK3.DYL2IGF"4*1;YGU-CMZ+&N>@(-4RR'
MT]&YF249%HH?%P;L0=H>9WH/ /XV!=C*[.!$;E_:V+- =?SE"K\'@''0[H?"
M(ZM<6"M0[CCXSW%]5^NL]22CG=L8EW]-L6"_YQC4Z-SKRGA5PW?,AF>C8[FY
M*>D!(.W(@],96[CW93DX7)[LU!F#B(S[(WI\2[-=F]=XOT5IM_LG7U/@GX:.
M1VS*6@[0FD\9LQ%\"Y<9.2UK'!)%K42U],X_ )69M(8($CRLU?,;_!%QA0]
MV@'AI1\1J*@3_Z/6+.ZQB_*,#R)8>M/:OJRHK+_^$G2 \KCM;U23<R[)>9@(
M;C<L\YV)!](ZCH_7 E7DSNKK-T*89]WEK,L75F-NJZX76^C4UZK0%.??M->M
M.<N?)P1!?'1?7ZV'QZ3UR.!*2G@6];@EOX.]=UW4_/C!<T"T2KL BAROR!_,
M;C\\(8I1NQ"+=7T\;P3@.>3-'[@[F<\=U*VZDB>\1VAKR5P<R;E,&+3JZD]-
MIG\S/XI9H&\#EN7>!CC*K)+4'OJ6YE8NS"!(VNN,K\-S3'_Q7;T]0YZ:TU<N
M/ #BZ8^B=_VV$0I[J$ASW1BB>9ZQ\JLGQW1,LOIH]&N0L7_$9UO1X]JC0RR>
M+%^VF-V.5>(:>I]M#?.BOXT=*^,+E)E5#,AD/1OET<9F*G2G^G6_= CB^_OR
M U?)XX'3\(!DX$*7S&@:\ME>T6W&14&'GO8]ET\,J&(:_@!X3+/?A>R9FCWP
MBSE$8E#1[QI*,Q\==  +55WI*NHV[/ +)*T6T4V+]-N2"NN#JX<X;!BXWQ/#
MP#F<!1F.LV?F&]COUH-8BJX*Y<=Y5LWW=W4*J@UIAQA"5TB;[LO 7;TW3]*F
M*\$ZR/@8V"3E:.XC)=PD2?<?20SHB9R;XHT)#E#1DDMDG(OI1#C*UWTG !Q8
M3O]AC+]_4?%3AG1$!2O6"R=ROKF^%GIIX\J-5(V9*[6#-#2;0LF.E:6895=&
MZ[8*+F/-0'>S<*Z!ZAT7QD;5(U6:<G@<14@*B^7P*@^F[=)].J[S_8XGBCL'
MW%%!?3=_DJ?##[C/U0Y&ES=]N&V",I^#,+QC"!EJ?RE2CH^SHQY]P(0CO4Z$
M[[R!7@46  6X7MBV8=W$N[->-$+I1]Q-LL%)ZURNE,,^LQHF_80"H#&OUQ($
MR'IG%0(U9;.;A9$0>S%]3UAI!3V"GI#M9H2(C/YL=(-^BT.MI8QMY0BQ/<TL
MCZP'36_#5@)0)KAIBR"-0,V=_]4M@DT;M(MYN&%/QS/I>3MX:/D  *>"98KH
M]<IAC$.\_0FEL.)T#\MXT];B0=N%?H*:4DGI4Z7\>4I+@P> 5^/\;:W &6D\
MV&]%OG[BP(SC[AJ;].0CYR+(75^2\@?0R<\6YN[*S%[ZS#>W+70&K,/Y&B14
M:!-2X.ZDEQ 6PRX9I\_^F;FN(6.+*YU1/H/FVD6!*Z>QV)'*.;7\@W,5PK+I
MT[D2^?/&!\ S>W=C^+QBS*6&IK]OK0;O"D6_WW9,S0^C5I%FURAG/MZ",(\Q
MH4@M:TX)3,E9CQZYTL:QP+8&E9"B$U87!R3%^%EE\8!*_<=R%]SH01FS^I"9
MG_-#E#SO%5,66QY3#-,5-^Y9%._2,87AR>@VQG);9<Q['-326_IAUDNR2=;1
MZH^DK#BO8RSV_@G SFCT9V\Z?0D)*'_:_7-GE[W":878P,!4JG5B*4VMB&<N
M:@O#O+HC2JN!G/#I(^(XQ0CU#:<<'4=YR1%[+JG>*:%A'J.I!?/Y/O>G8G//
M-VSC)=[5P)SEP+E.I*V ;6NGT(SMJJWIU6-P)@U4,Y;2L%N.[!4#P=J^X_=A
M8*7YWA?6$N\/0MLGB+70BS(&.YX]4X'NAI3MHJK9MJBAJ7V>"L1^3ZR?%L.^
M:4.<#4A;D=M99_3M,^0#X-Y%WO=BJ[$<IV6%U+P(DA$Q4N%F6!%_8?O;=(R2
M;3+A:]_4N?_9@E=J8 \NT1!I[TQTLY;"TAWG,J;#W)!YU>Y>]7WZ_&\''RH3
M5=J(K)># RR6LGFYW96SM%;EHVLCPDY=CCQI@JV@ZA;ZYI(5FB33 ''EF.-J
M:XO$SHUG)M,[/S,OZUGZ>TH+8CK_*5UC0M_K&RGFI=#H9+!&K-2LTN(IZ722
M4"I^'Q@BO*POO&:H=\13#PE(Z1T7.216;SPQ?"&ZZ/&"'0V)ESQO2ILQX_34
MZI1@Q,KQ_;L'0'/@K)S)83C"FUKUI?>4](S(.R/2EMR1%.UJUF9.0.]L_7 ;
M ZAN5]V;ZNVDJJ#R\P1A6BBAQ_*BWKL0Z1@EIBP'&/C;)$^+:3JFGCPENJT8
MY;K8GIZD;OZ>T?12P;R)X0/ 3NY4U<F]U7\L1X047@@K&_F#>+WE6J?B_:'9
M.DW%GU.^Q,]-&GZQD&./_D;^V&&:;S7,5 IAU1Q?!$GZOK25)SI$<:T.%?;4
M?0 D'H > *;T#X!7%6W4W="&M)D1H.?CF08-X;;:_B>V>C(#.5?K,7^"#(]Q
M>D*>'B_J">QH1>^/6B<381[!!4"C'Z7 -<*'I+O2M,^*$%U.98UA,-(7J@)G
M.C2Y5<KK+I(6X*ND1[N)TB#+GO0-]1>; [?L+\CA#C=J*8'%K<D[-\PCOB(W
M2Z^ONU+5R^G<]P5,)OM>.5 /75,/$(B43_AG$)5$!RF+.!+GXN\Z/P!XC_E%
MM @N,@N"L80#WU&11Q6^;)8JN*X<K@T[40PV.%&ZF=8YVO[L:NR-V*R0/3?/
M4#\B+<3ZI*@*%6\[K?+Z^)D$^43P9L;D=T8FK^YEG9F)I$C0+^^9?!_B7\U^
M'PID^KSYXT(,D?7?FF>^<)&HOM[3##EV&!<D&%$XKUQP?;KSLFJ+-1U]:/;7
M-__XZP8GTV=6&J7Y.EZ ]]BEJ]ZMV2LY'1MLT2J*7$!SP>3 ^%<56U3FD=90
M%OPYL"$Z<$6,3<;():G0W(G,B;726]R(**C%X"@T;?KSGJGNHL>0BQYMR^G=
M.YT0JXRJ[ZAUGN<6P8W["<"@3 !*ISA&%+<8I!D=!0_M[SM_8" T>D4C %J5
MZS,HB-FM3[ ]^,_4./R?*MN$KKGBYQ*.%*%+CO<Y>=@FY66O)H)XTC:M&1(,
M?"MOV-'IE8^6P""O64(SQR^"C*K0@$^3Q2_P7[<0$M &G%?^UUJBL^LBGS:.
M%2)7O7+8(T#I8LNWOA8!^/@!@?I%>FRQE7F-1\6EMM',' Y<O*M9M%%)JA(2
MH;_N)(]T0DB.Y@T7>UQYQC)@_GF8HJ*=HQ@^RH_N)T!%S/^<V:H5:'U0PFF\
MR1"AUU:28XS]MS< [SK<?C%8E84$T (J*W0_%_JJ\>A NCA^8 JF*8OS?^)G
M/S1KD#.97Y"5CIO:IB])FD4>J8#XSW^-A"/BUL!X7(OV+?_63C8"U8B1^5Q(
M4Y9R?KIYT:&VUS:5%BYO*6?IMWO*05\DM]KB6KU+N,#2UQM+%8'S@G/_@EH7
M:#)33UH"N10#>-0LBDDY;FJ9MTO7^]2A,QG ;*9<(67K2:0?#B1G\;*J^_DY
M>0+EFCHR9F[5&Q7Y*I4$TLG9.\^Q:&8V22%.HY(-NS?Q2H5)F6]FSTU?_]S3
M;*R.YK'&9X3BG08DJSKM&+V;UVQ_,0BZB WGW!\#W,RTD6KWCKIO3/#QM;JH
MEE/X(FF<]J"-5,M5KBU(PRY1'?I7D)F$;$NO6TVTEJ;FKK%TC]7<4X!N,R>+
MD0>(*P#[T(I- U;4.G.VL)%$)J'5-[7-QE1OO;Q#U:L_'PT#\\@U?'^CNAVY
M0FWU&"Q^;&I#ZM8[2J92 %T'_G)4I<GT\]2"'5@V3; V\#I'M Y[/,&BI;"L
MAP3S.M/+O]Q[KN+E*R%&H><YMIDQ4Q"]YJ@#XNY8[1JJ^]IT5#\1-J_B[VS=
MJKIEY4EIDY1;=GZC=Y'TWFN$<WZPT9/(F1L3[8X30?+#DA/5*N?CQG*H'(G>
MX[]79S \+J7Q01JS5=XXF4NO2;XQR-5U9."'8[G) V91MJ().VOTRM1VQ;WT
MY)" FIJT(AX P6*L5?]F2JL=A.WD'9^E&7D+TB;*6FP>2?4P6284TGA5>8 ]
MC1I"@]X4F7 KLMJYC6(Q.W^?[L^.G?%9@\$H=- V\\RD(@S^4:O>__^U^O_E
MSX@7DI6&RN!M'=IZ_^[]P4=MB&'#.16WU%.3%[QO-3Z:CN6-8GCX( 6G^,XJ
M>5547S "@^H&+5)-N)V(">45M#OIXWVBDDP2C[S[ZB-S4JD^Q\#'QC2Y^AI?
M*/<FQ9U34MQH8 BL[X(9DF\FU>4G$8R1QOW^3[Q/Q;IQWR-HLLY'7/Q^7$Q(
M"I3WSO)71(Z:,":B7Q(X]C\ /F'DAU94>M/S=J]16+;$%P[+I.7H;,<E$, :
M)'4M;)&4TUN!BE2:=ASX5AB-;Q+L'YW]"X>*^_Z52O*?VN_X'Q_=V_4]?<?D
M^^/S<LA_M%P(6L2:*Z%*GK'Q$%FN\&SFB_[1QJ>$W)@&VRL?N5[N]>N30<>8
M##A@A<UD'JH=EZ&#MUT!SF-T]2U@AS>&DZKI:<._/M_6Y#9W=119FOJ]4"G?
MTIL2*)8:;TE>&+Z.^^BUM)MCCW;#%W/@>EBYWEJKXL?'Z( PM1Z:)SB^H?'4
M=ISUF:5:3JQ>E&-Z2L](0R1M[@A2.,IJ#KXC6C*/_<;SW-[9\N2X_NFV^^&N
M^O2'2I[Z-L8_]9&LO-<"_22Y:?,?A7?^/Y3?WR=CI:R<U SU\;_(^6:+!;^'
MHCB(-86)SX$3O!Z7'15J[ U::X2I8SLN3!B3>20E9=%&?N3^U_DF_,._CCO_
M$W\]]C\_&/^@=QG?"KU1R_]>&5O/C.E?>&MXK!@IN#\/#-$V\-I3)F9E*OO#
M36 TSZ->2!O3Y*9^%"K]/RY7M+Z]$.9I9V$\(^,WC^;L]YYFL+V#W%Y_H%_M
M7J<[#^R;/TAR7FTS6P[6^LF!'. [R/$F^$D3U#2B6G:E/*D]Q=(<F/DM^8\\
M;UY\Y% WD;Z/O(()#9V< _Q"M71GMD&QRV@-*]K@#.,K:$^6XMG5<(^!X@,
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MPI)R(8>NFVHQZ.AV_D'3J>?";'N92:D_U*BDIJ!!H SH0>GV9(]$S=_E%'T
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M+M2Q(>A\1PT+S@ZDOC(3M@T&JF&WU*JBR!A?<&4Q.%!?W97@BS.)PN,"#.9
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MT$8=)NO"5^R *S_K'AH:%?_'JB@!U!CS-K*!E-\>U<Y=BH2%[/(GQ@9!)>+
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MVPMR!;$:K<]J>KN* 66:(QNT@J(^XERQ?[ [N$R^*[OER=NYE)YW\HOY&A6
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MPDPB10YIN-DS_Y+F:)'<L%U*%$<)\>!2J]G32C:SEO0%$OKOKX91P;4!V+:
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M':4$@@#QB9)0_?:Q#(E-8BG.IC427/GUX0)WP.&:-_5I4@KU_>9M(:EEN]P
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M-Y=\]WPV]STSWYEW9LX?=_.L?MA=5=VUI%;]5JVU^V'J80G >2,M)PW P0,
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M7/ZH^"]CLRJ_H]%RJQP1&#D.HQ/2\2S3'_]F[2^<_6N,!?RG./L;8W_G:P;
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MX9HWH;6PFV=EPQ+D"Z%\8$OBFHS7B02;L3.*D/:708[S<(/ I-R_)M/_(])
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MI^O-:$_0%/9!Y>W@^4IC)(?L*$2>OGJ4-1-2JQ_[PU]F[";#28)2=#4Z^ '
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M&K'>#"N8?7>KIJL2_%Y^@1 O3J=K,8 INO?>?*QV _B SJW5G"Y<2MX(V?:
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M/#->>>AS;B<@F$/ET-NB%K2Y\OEYK4=+KZ-AYFU^_:TLR>>VNI[WSV=5IV#
MY1-U]SMHS&[,I^YE%DPOFEK)]PLHZ5CST]3QHFAQ"@WG64WAU&>'5BE:\S%Y
M#[ZI&[/B]+L7W=N9%&G57UYWFRCQP4G!':7\]-4%Y*:))^&S!1^&Y@SF_'6I
MO1#W)J;:YI9A.KH@2-&>=:?QQ^5PGHXLGQ> K'%K@,S)X*I&TC'/(HI&I2O0
M#1&>'R7[FA;@0D$YW6#-O73BH=,4/ :,-&T"3Y'XKD069M:MP\L*1\"W>O\G
M=K_Y_^7_F00[<EJ55F51UZ=M:[EJF P5T$"< ;E8QH\2D^*7"GH1-P%I.R\
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M)M:5N<6[[+AGF8RRNWI23&>\9OJQFN[TG"I)@_ (<8ZC&#UH?(YDC^)*-N_
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M=0KUB4Y]J%_U4\" J$^?B(,A7V&J7$UVM^ ;NPT?F>[0L'A\@U\><79H+9(
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MSDT%TN27]Y;IC/5^[6A,"!Q\PY049X@IL/H\=N2Q<)J;8;EZL8T95\4 WTM
MJHPK9F&M\H7(_:+'7MCE0%E+6V6HZQLD&!M1!?[?OB:GR%8^5!1H\9";K3R5
M]=_=@U!7B*3!2378-F/SHCX0P_HW6+$A=/$"WU:)":CY42"OXS5^-5RME/>K
M-,"UXG%"GAOXVAL9JM@^, WIZO!U(92A3 72Y9?3E7VE^<AIN-3N]'2K*XY^
M+5P^)="*(H51R8G*_P\(Q=4V\"EIX.!K7?F[)5AF\4LZC^3#"/%;D>)78^0_
M*%"H#>])[]1V-YZ'W,T$?:M5Z:PYY!IX]95_$*5?T)BR'>9ZT.._.EMN/+)L
M<4$EF(28,SN4+.3?0?^3D$"=" KJ:#5R&C_S4YZ 9W,#O2=0! /*G^(/W_J5
MF:99AAG'!;HWCH4TC_V!Y<<XT#<WLI89,"TO+TL=%HFA%MV$;<6U\A_!6M4B
M=3A4=# 08JT=A1D08M]E]>B-W+XKC%=$)&E4K?<Z1L=(B,M,!'0^-[04<O^^
MY9T>=Z(&?>^K2>3I@R_CVTI*]()*O,,M+$]LCQ50KP4#MFF:&YLFKU$M;$4;
MO*8R2JO$5]ADEP+Y^4F=XGJ*A!T<*%8/SPR&,60:]W$<A]%:\SRVS>+?'$U#
MW:0^66*IRE=+42?(!PJB ;9+9NEKO0H;.Q(OQNAT>A(IV0[%2"/TV94?CF>D
M?-I*-X##+1JZ^CT.+(&AV RF+7$4&:("QYH$&DRE: ( OB*&2E3S?PB6@-WZ
M!.ZF&Q?H3&4J$9[4.0\/W$,?,?%Z<$$.5%3+*TFS^8+.RLP*E#2B\@:NA.KZ
MAJZ5!5N.'?NK&-E(@B)="4&2X3((?!::1.VI#F?"%6?X9!.;YR8Z7R)K#\1A
M-.+^1DC*]CE<R%F,8-'8DH^DP.H*'VXXH_%!';ATB.WFL"?^,#6THQN-K-+I
M#?"KTSBNVFF:-M:I6C EG'Q#NY'.;LZTQW<L[*UM41K9K*G"E0D'AF= 1 )0
M-./#C4@*W0J =<7+QF[\G>#-S%G6V@8-YO=0R*[W""Q\HL//PJ;K*R^8ADGB
MS]PKDL?)SYB]5#4 Y0!R #F#YY3,(J_*0&=PH:-X+D;%_'M%">D8:K%H9J9
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M!;.+]7%,!?(#LU3-9VBR!>,XF;UTJ*400$_#>+%])6=/C],V>$N#KG1&M#2
ML1_QLOS; !1[9"<#W'P&. V  (!!9Y*C@<!I&@$?;DS6S^^F[%AD8N!F:=<+
M;,F1<.$4Z\6W]=! 'W%-WJUS^E&A$/7LA&D@+(-ZQQA%_9'&3%LB2%%G$ID
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MCWJ@U/<_;WOTO[$@O"S\%U!+ P04    " #2-&I49^5=8!"7  !<L0  &
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MZ%938^^>3?A0JSL]4VP]CJ!1F8_KYP+(1UBK^ 7)6IM15(G!E"4!>H&!"6L
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MT!4.0],[^3#C4]CI/(:CHH=0A*.BSB6D-"%3%7_[ZD"_*FCO%U*=$-@%.XD
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MAT]RU;._ZI)/T=F.=[&[/*H6MGZN_[%<_=X P;XBQ:OM.ZM9Y0(OMW+Z,&^
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M!(73Y2!BOXKLO $JY)XAA47_1.>@)S^[O $H=UO_:)@8G6QDD>V\@[53Q3=
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M@U5!<'*0TX&1"DE%"^MK9(",;;15-97"'RV'K_*)Z$CJZDZO1WCBM959Q&/
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M<O:$"AQ "[=G:-<;@RDJ0Q>$,O ^MWXN-9D:M*[56Z]$ O@VFIYGNJ-4<TC
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M<S^/PJT/W:\.Q7=_:NP>D;:%%01.!*P/"JU-RH RH"V?]D[;'0V4DUT#.BL
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MK=C!&/[D_CEH ZZWH_10%>#-_&_Z.Q_9+3R:J *9++8?V/0[Y"@PN#<2&JR
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ME\H'CML"@CH.5@0-AML/NK2"1@3(PS'-Q!7$=VI0TV&6'FMNB[S^9;Q@>:-
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M2C=J V3X>*5K?)WS,;$I<3[("_&A)&#-V<O"^EC=^RSVYI'&/9Y,!NZMV)D
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MSL%4U?@^KR:6>C5&EW5*F)+R%#U 0K7T6S,)N%?R]H'3*!+XI9V%!' 76Y'
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MGY,GL[S++OV R3O;GS+4-E:6/6BNRXR6G#GP?".\;.W3^%LN&2VNQI9=#L%
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MZ[H_$KYN%@I;LPDP+!Y\F7<6N(%PW1 J)=0UNO-?#]F6YBLB@7NS)9+KX:A
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M76RQ5PN,R/#X]29'NZ2 @\*16]]C:/5&'N5$#GZ@;"I3-)QRSIB$4(;)U..
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M[NXL[DY8W+G\_N_\I=X]Y]5YMTZ=6_7NFZVNFMK^?N<[W3W3\^F>F>?YYS7
M6P49>1D '#P  /?R SPO J0 **]>(;]"0D%&1G[]&N4-&@XZ&BHJ&B'V.TP<
M4B)R,E(B$A(*&C9Z"BH6:A(2!GY&%@Y.'AX><GI!40$N$39N'JZ_&H%[_?HU
M&BH: 3HZ 1<E"277_^ORW [ 0H&[1NA$@*,"P&/!(6#!/7<#R%_ZB03WMP+X
MMP('CX"(] H9Y?4;U)<':MX"X.$0$. 1$9"0$!%?N'XO?  B%A(V):?$JW>J
M)LA43CA<@;%9*-22%1VX:A.G--RFSD&OW^#A$Q 2T=+1,S R\?#R\0L("DE]
MD):1E9-74-?0U-+6T=4S,[?X8FEE;>/BZN;NX>GE_>U[<,B/T+#PN%_Q"8E)
MOY-3LG-R\_+!!85%E575-;5U]0V-G5W=/;U]_0.#DU/3,[-S\PO0]8W-K>V=
MW;W] ]C9^<7EU?7-[=U?<L$!$.#^7OY=N;!>Y()'1$1 1/Y++CAXC[\>P$)$
MHN1\A2VABFSB](Z**Q %1S(VJZ+C-36WVBFNJ?/$&SP:GG5:V%^B_4VR_YQ@
M0?]+DOU#L'_*!06@(<"]& \!"R .N+YCR/[ZYO^G_S5BS.KX"88!7C\$/&H<
M !BRP_^/(*:H43!NWA;?N30'=KET/$#;:4]H]Z)X)BD@7\DOP('1$UO T%!'
MQG<B.I//$SEK,XL'CN@F5<4BMHI!4XK&''RWC5X=?WD;2AYZ"4[W7OJ $K2>
MM](_S@1_H&%1-2J 2-;2RRSJR[3!L 'LJ(52X^:_.XGA-,#;3<-178R<"<PV
MI":.;PPU$JF4.S*C%7/3;"<<@]-N =CH*Y%V9_@J-0I2RJ@?8-@,4*"EY)A8
MU>K4R7[168MZY5?)F++^T]IAVWKG<0A 2=!G!*9Q%!I_%2T+H9,MV*C/G>3%
MF:[N5?2I#6=8,SSC\FW2C3BYK00C.C8@?_56DP(?:#FM-%G'&7954,KI6W'5
MN]-](>X70/1 W,P#N%]HBC*]<\B%=J[8;X5IW,ZO3K6^?G)S_M\_1O^;B-+X
MYN'74T/9N4U*UC^K7T5R#&]ZQ&+*C*V+L_L8:I*SL8F#^,U:^6#:#\0P!0=<
MSW!1QHOX6DSBMM]5B;T34\327IA1SX MK]EGP.&9RJY^&XKX5I;^,V"NN:W_
M$_($CZHT .?_$))L@]W2/[H8[\SP_DL5X%NU&7!+YM9V]_#K=O9/)^8M@]8S
MX/(/^QEN\'_ P(&[4,)1?8_T[Q#*<$%><E#!5IPCDD7,.RM6\;C&E32+43[4
MW&50/C#NIH_VR!\C4B\94<DY>PU\S>%];XG;8>-M&?1N?9B_5GU7ST(BD!N?
MR]P>+;D=8%F7I_:AUJ=F)\L"O(@:L5C/FDD#1S.):)#QC3Y\[!GPO:G+^(+#
MVOB&D/QF3G =$Q/=8;T5!+Y)6=A]WRNW&;N@PZ8\_%-B+X"*.>TF:MT8Y<:X
M2P:HQ"(;X+@A\+H^(?1$'ZG<4?QWGD4YW[6HPIS.%#LDKZ%ZVHZ-XL>C>>S'
MDL)>+PI8CX7UD]#I:&%!!*JH$2&;?&>AUJ>^<6R >&"9<.7IXVSJJ;AJ(N[/
MI56[^ECMLGA"SV= JP3]?,K(=&EUNJSLJ47&CVV^0N+,!)./0AG<3; !\.<=
MR_H5(_W]*^?EY<$*">Q$#_NO&D):$#/(_KX?^..76F?)!IF/F]^Z ,#1!VDW
MI\UG  XX^&)?QYK/EOQ3?4P.QQ/)HR?9,T#AHDE1CL6.JJ8FS#2(%B6T!>>-
M%I$'778X(]H_'6Q#$ZO6E4,H47[B^9=15(&\:-&<[2\B:9OTYYD8<>$[OE+%
M1O,W.5U:[E-'=2TIFO5*X1[!GV1IS-V.PVL*/-ND)D]R:QJ;'80HT")PN!2W
MGP$M-<KB1"S,J?%:IIX_%'[=BP\U:Q&%4<TDR.NB$%(+M(L;:)P=U'XZ^+E?
MJ131D&.MQI'[4#P=]PIP-\ZUC3L60^SINNR79J.8_F2<O-V6U)0O,FPWMFF(
M!,#1AMOX@VO3Z-^LKO#3+T(Q6K"&=A[28-B^&,?%T0P[U']BF;%G$6&#AJ0+
MR*.5(_YD<$C8?N])$2W!<\2<CH0[(+LQ[D\QE-547Z?OB(/J,?"[SKWOH\?^
M'^V39NOU>^$&5O TP#/5/+)"F,9N;Q1.]2:%!9^_H"1=I1LJ]G-VX^I4QEZC
M6E@5Y$F6*G%)KA>]V9-""\FK&9X+5MM[]\:+S=S7T3'0PS^^1#A50\LOI"'?
MQAW;"&HD<P6S''9).(/-.0I0PTKUN\F$J_RXJ+,.!!J !>IT\ A9CL3VEUV8
M3BGNN*,[X<Q?QQ\<>,00:J9K!(FN-1H\HE&HWY-YH+T',)!XIZF5&_S9*\74
M;8&)_3B]5YTI<Z-HS.)L=NI#LV#])I=C=>MO%B1!S^OE"GK7FE+'>=-IS-%-
M@TH;2<P=N?:SH4<8:;0Q?+>9>H.0M^VU5-$J8EB[$S<[ZADV*J8]MPX9%LP(
M4N#Y;6B&_!%9(_B$9X:A2%6SG_DGE_(2F8MTT&ZFJ@$H]-+O@V>$RKCKX3S/
M54/P#K#ADV!GFNU[3];+8^5*,?K)FD-]Q?N88S^Q;7VWP<42._MV<_O%#N0\
M/-1T35PCU'O]U-0(*S;J.!]3Q'XP'9>,C!\74VEQ"5N\W4_=9<,AYVWJ\'FZ
M#<E$<:]X5^06RA0-+=&R4.SUW1 EH2?H 4-D)]3<\(QAD[DF/,/S<*4F)X"+
MQJ\D-9ZTA$.VXCH3654:!Z JS:6+R-%<\EI#K8_4D0'N0@//0][/S,'CK0D)
MK*2(N "-B_O/B,J+3]*BG0L3B5+;Z42G5FV)6U#- [I%6"V])O>:OA(M0+ /
M+\P_T+J#@*&LUU\)<G(C:C9-9G3<J2#C<-)2/#OXP1^X!G9:AS/[E5\/>6-P
M7E(52Q7UN.!P+7:)5 P)2S6H?V>28UDZY:H?J\]$O?C_D",G"X 9=U\3O0IS
ML 82$;K![QE]0,/%03OU'%@2NI\C+WK@BI ]U0->05/]6E=XZ_T#,1P=6[];
MQNA=JN!XJJO OJ35)MU/]RI*LYB_DKJYNBIE\"5+V%34!^$:#8&S^FNQ?B)/
ML;U_*/I%"U&.6.\+/7E07#=Q\86K#U%'E7N%L :/.9=ROHK3OR)\ W;(D=PN
M.38>,&T!D/3+;L>T:Y=:0]%+(S*? 1;6NK7O([%5FCMB8.3J!M=!K:0=Z\2'
MJ?OL(Y?30Q4&7=M'A -/U'&>N]"(3.LC=Z<>DD\E#(%FTF^*D $8G$9^FSZ'
MI A#DP^B^;I]90<!3;)!2+(?1/!HT+:> 6''1B$NWR(M:X$QIW/?2ET?_>^-
M9TNSFZ=/"$*A'.[=Z1S<QWU3A_+H:6K6^"G\H=4@I/D##SQ%)WPHNSTD>H'V
M%^+I\GN"]M)?[42U^2+2I3<>GUH3'UG(.98^.M^,<JCXKT* -Z .QC(;K49(
M1AY?:N$B>J$3$3*27Z]L&43GM.R[W0-7G5IJH8/#R:I?SW0.TECYD2#/GTQ(
MX<2,3^A)AEP*ZO<HC8>#B9,ET6@9IAY<6MSU!B_:1$&[%=*HX"\48<BFF!?%
MN.@S)=H_";X8#CK*8*!09R%77.?6I<C[SL3A1>4XYXB$D$HAW#QY9;[>>UDP
MF$=+FX7S/2,V0B!X>0@*L3J=_0B5:W&R9D81FK]4JF-4DS[)X1@.!@G2DNK*
M2BAQ\GB=Y*S;T7>U\I_F6"<>8Z5L?+J-3160B 8OS:0J:3UM'!J /L3(3K%0
M-KLU-C1[6)/VH6U[P_4!8@U[1M,M/=R ;D[P\J+%>(%C&C2?-PH,;A2[KKW#
MIMEX4G7MPY;,S4=5"DG1\5%)\)*L>7<[A8&'DF2'2HT^\X3:A O,[P)/&C:J
M64[H8#1&C##<_ WTK(J*/@,F>UL_G3DOZ_R%>6A+#:11&J&*6Z;EM5GBP[[K
MH]"80J6B,+%K7=W'XRAD!'KZ2QX#%B](<'S=*OJZO(@F6'__U8)9@KXR8>AF
M OWP??MUK_Q.RYN>G*EF8?OSY;"-NAJU:UKW/YI&!M%./[DUB3M62'PVO:&\
M6?6L]6U)TW>;>38K>A(!UJQYTZ8ZM(:5E'M=DR$=U".NI/P]0AD)A0=XIU8C
MKYK'J/TJMK%1^IF*STHYHV5GLZ*?-HQ#^/64;LGM)QTRJY,RLBR5P/O1XF\N
M!2C"9U<$*"1(5 LTI/< >TR1*^23]G2-B?H$R2>#/+N@%1R*0G%))'S<:'\^
M$YC"HYD%=CJI.[S/GU*/3KZY<T^F#V+4Y=5!XKSLGS/:A66ZTQ?G^[E4"G'W
MDO3HDGT*%@_P\53EO1R>BDS%+!YL(+O?140#O!W8JB-T[5\/N"N#5V<C@J.%
MH*/$#F\]X6?89;+0G R\/(CYP@!1X6G83M'"5X5_<EH<PJM*A-);03R)**QZ
M/@X"0KL[FD-L&%[7I=L7381LQVPI4'&Q<2S[-;,AQ,^!-TZJ-BED29#NB@,M
MCF4FDK+?#<P7HM+XI#'\<]4-V9/-^B)Z1T)16S^[KOI9(<U9!%H'CL/<=>X!
M1+,PR.PO_N^N*E7-+&0'\U D:@%$2[)V<Z)CUV-RY4D[]!=C\IWRLX36HU]>
MEFR=:H?D).0I$4T8E/L-_NY IB9+NU-UTEDI(SH%?=MI/M70.TEW8[]:PB9D
MN>8?#)0?_NS:9;[3DEBT?^>6D?"E-I&#!F]/7F<J<XSN^Q%?J:,_X]PZC+R3
M50:&G,3!*>OT^A G2&,I/[7,4^S8EY5T!51T<$W'D"AO"VZ-S4GG0*7C[B,5
M2UB07T_'LVC1GEIG]M4LE:50D.BG\?."?)".YHUZCY)C1184$=R4X0>QN?)H
MPRAA:1:*[78S3=0:CQ9I?CSU_RTH]G0)VB 5[_&6B<FWX=+?&WH5-$"%RA_?
M\!Z^_#:)@!KBD;B"/\%R8EI?-Y45K9.>&UGJ+^/0_'[TE2.SLB=50UW<BBNV
M-!..JWUD[N=O-R\*V.1M>@9@ AL3HI,@"SU7BDVJ+I8^-$W.?44(O1@<WN<]
MEGTHIW41/';B'V9+V8[_T#**?J_RZN3I]8@YV6B2]Q7-5<GKR5<"=]#&4V-U
M'];33XF$*S%WI?"%CM[9IR-5U7=QL0_+YGM/.,U7V/"L^WC:(14TL;39G-7^
M&14SO-D5V$\9@J&Y#!7O,3HX;2G8TW2G(FQ>L\_/UK2F6UM[N+DAHI)<2^MY
MD!H4M(^MRP?D+1P B58D:;!JMV[#$P1Z)1#=<Y$I(;(>)@6&J$,5WM="FIV]
MG9R$7QD03S%03&7%,C73N96JYMCLM35#E5FS BFBYC=X.+_58W2G+UW> OU7
MN^XTBT:IJB1VP4F,ICJ5=]C*3HH>F?L>K;KU55'#UMN%6Z2@Y?X#T2CAX&AQ
MN8H?!C/'9M.$?UA-*Y/-L#FIS'4'<_BO6U5!LXFD=-"A+G=HKI%U6_03CV)(
M;/(LMS/U_&MQ#Y->(6TGW. 2[-SR]MA&Z:U"U:C"M&.$R1370YEJO'PD#F1L
MQ.-ZOM. /UDI;'@"HA:0K<K6V9(2BQ2=$^5EA0W'$#Y=ON-(M/3,J/KVL4T]
MF+56DG=;*/L)-=>8 ]L\/V=W0(.:'"F7R]R\UG0KX00X1=YB:OU+;$2M2U!?
ML5F^W]W,5E6=E*,6[:NUDZ3'JJ_-3X W+Q\B)=NY8V7<:8LA^DXDFYY'Q6<V
M3[5+$E RRGTD(SS=Z)>PW3(:Y84;%16AQ/2:+4G-FNQ8UWEPT(QX@"3:DZK)
MX6B1@_5]G<J%1*CX/,'BRVS^I&]%I)D^WE!7$49G<&P"^B7J'AT!LF'#XQ1!
MR(-*K ^Q2IBQ>HD(Q'TQU2GU-,YL?RBD,E1MMBQ]!E@J6A*<'=<]9O,YK-N:
MH3&#JZN#>F>%@3J)#-0$'XR^JI+F8ADJN9 H5"GCR&T6VXUR7PQDKYO]4L*@
MG<V<O&04FT/O5/+A,*FA2ZO\=K:;728Q!M&LKV*;2Q&-_SD ?)5%&#*XX8XU
M+)(]AG$B!TB?WT(SPUTPMJ[UCK<FW4)ERK'_>*IQ%R2(BWE%EO28P2+6\[86
MLYF"H,MM.:/A^E"ZLX\=4,<.GD?%KSZKX2:9A;#_#FM$%I!ZG,14%KHH2O%/
MM0":Y;"V5#N]KO&*4XJ(:O=J1[@@T0:^B@%#^["E;$*I?@ZF.Y,CVH^I.<KM
MQ(F^4PYQX!/6T#YO/G7V_ 7ZC7;J)9[^LLA5*KFXH-?]F&/E2V=N&7P&^ N$
M[,D^H%3+GO*FYB_:O+-NM"^IY>-<5H )VS@4<L9)#O,S&K.W*AR-(BO/[%E;
MV)$>U86]8>TN*J3YZMSA\M4_F5>5!YU)>+66-5+2<>?]^S7.)Q;7L59NZ<[>
M!!Q5.1-IG$]P_RER,GY;$U%,# 0*6^NQBSNY2P6][R-\L!:A76^1'/114@8^
M3BAB67YC?9"*,3-\$W3E/ZD\-[_MF7CHP]![M7PE;,-02O<,Z"7*O8N\\J;[
M/7G+HIH>7RMWV+ZO.Y7'%+/,6ZR'$^=\X#ZMG:;O^W[ZF/TA2FN4(ZO\H$@U
M:15Q+KN/:HBH_SN7 %JNQZMT/>X\>_O<B6YUB+_RMX+L!M"[FT96I$0H0?=U
M)'=UQEMW^@<F$V5-VB'2H4(MGIP1_JPI52-/$:6-\[?U3X.OWDV]Y;^9,Q8K
MKS4B5=(ZP5/?RHW"CI9Z*V;D-V*PIX"GOUJ1+J)![U%4YVJC:F0I'E/3@*!B
M9T;BWOZX$_4;L]@5TH;J.7V('V#2$D95__FC+<@--FU6T6-PFF!&]L42S8UP
M1$)TM#=\5T1QPYK'.JNJNAJ8VI#D'-UN2=K .[SL.=8-=0V=F\7Z$#4N\L$2
M-L)@4J1DZ,94RI7 -]6:(9L[H>O]J@ZC)9]U"5@1N$!CO@O4RC-AJ&\2'0U5
M4F9270A^,5UF=C@#X(7@J_FOKO'GM)P:N!?MSF6F NO-75;#JXS<-@DN4AW>
MBDZG1+>1;O8&:4QN0:D^KBNF?843_'/88^^I!X5.J4]#<F8N(X8BG"N&,'*$
MQ2:FA;[-GX_5"+_959?&42-XB;7@WCP#^K9 ER,!J1HS_U*?ACL;^P]3:UKX
M_U59-UP9V$9M<VUCXGJ.D>E"D%0B->%%K]!]2HOF29)3L&]P/#[%"2'J648
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M&FN.J6K0W$1E4PT/X3X4(E0JP_2J2@0$AF+;<738HFO#=]3[O%F23O6S&JW
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M7-['-.8:W:\0WZ*(O+5")5."6._[V.7,2VWH7A;F-T0<_7SX'<[A/+KH)8!
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M][.%Q68L#JM-J_@BK/' 2'A&!Q:62P+?U$,YMNQ1=Q4"M['Q<#8\D4.YQHR
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M$<)"K-74.E6#*D"HU"UO;_KY^U>%M ROTI!G0(\W61)E^#- +63E?5$/#;V
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MD#]=B7"]2QM?,1KD1+22@_J8M37P=DUH[(E96NOR^P1T4)IJ,^V$VS'3/P,
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M?F&4<=6Z8A=-2(BODPM)9):41Y&N3N: DY/3:A<AWT/F[X,N,6%NI1*F7S=
M]Z.-K<OJR2?'1+5L7<+@+9=E<N--K%G6YYE'1_TUW?JIMLY-MIK#7^CIM^45
M[UIR0@V@4GF9XKXA\7<C>JF8OVUX7H69Q_[H? GN41T#[]Q# %?/E&VU? U:
M"&[:<B3-NDJ/(T<;5+.GJ35$%+L1@'P(FGVT@ST]$Y(23K5P:[?0C.:].U:9
MV%\ZVB];I67\-:\F]^.II*1W3.#"S-N?"W]_AM#_KN%%TKXR^<,72/*'[>V>
MX%:D[Y<XR,G0*&=4;H!IH&"9=M>&_['=LC.&>Y<@)^QM42HJ9=.++<$D*TS0
M![E<2U4K[R;2\_BSYP<O&8]^+,J(?L/+K2]4=XJ1*2&8EGUO=H<QJ7&_=EZ*
ML5<]I/QAX#M\:S7):(E7=Q(^ GAK#9:F%>,.O$+=//5E>ZMU[#@HE&\R0%ZU
MYT601%M!WP::S!F5F0$VN%YM<;^FP&+#BO=IH=O.SF3K 9:6^127-_A[13]C
ME.^N=R9M8C=),@F:$2;F]H4ZQ6[I8M6X&^V#ICBEXKBH;N7Q6CE[$.=ZV:8$
M)#@5*E,>AXMC[:S7R1@G%6,IYG4/H$_V*-!Z']]\8[6E^J/V9@$T.!?!&+)G
M<K"6YK#$^O6I7=K.@)&]!J-#(OVLJ0<ZQ8#TR8VF^+A]QMB;FL3NK-RN-]1R
M1D$])WLLL9[-\0[M\1^BY[;+?KF<DWB0A&(KDHOSO)$^GE-\J:3I5D!)>2/5
M-@EQ?(E../-CER[Z+J6G?,R/=1KXJ9S.V(?<-&=[7V&[N_3==;7.&P(;*VE3
M(<IE/HPU)JDD4T[>' ;SP8\EB#3%NW_?&?VOW649;YGLA14"> A=N-H!Q3J;
M@-\-PB WB[Z#:\@$W[\2^^-KN'?'C+V^\L/^NZW>68_YMS!K *^%\"R2AH@"
MWODTGK4M9I+>U4=<=\\@@PGD,XJ&WO,'?7ZM[3,M%38VO+4I3E3*94GD84-T
M>_U)BB)WR45L4)<[*-3W,EBZEON*^!>EAPF(S!B$O(QCF02VQQ)G#OP+J/=*
M?!P<EK";S9DS)+EZ*-@LVU-1E/ \"S<452LS0UAD_Q=/C!/5/FR%10HNW/C+
MP+8]%C%A7UC!5^?QE_=^_!?[@2O&__ #J__3C26NQ(TW-8UA^)$%V7J$ $TU
MBGM(3KXA;T3"XX6H^G'\N:KE:+$M[FV)YH%Y!' "M63__(N5O?.FWQN'F @Y
M-DBNSU(.R][XQ=>Y^F_0U 18N%)2.\E=<VG[1XEJ ?V%T66#SUYC_N(^2<?5
M86ENWJT9XWKIA!/]\'*$BE,QG_K) ^6**#/39HA9Z(TQ80'6Z7H(4"4A%N^H
M@![]G<V%Q?0!Y3LN(5./XI^\H5VUD,8TQ0@A[3/CZ&47W(M.3<M3Z@TT\Y""
MFPQT)>$I57%4MG":M:\F@1'-D1!KUX8/7PBR8_2AG1%<Q4< F?<[11$)0#LS
M/>1LU"N1S#XC6ITRA"&@G*:.Z.<I]I-$]9"CN7ZQ!-1>O&\B7DL!;"-JD@5V
M["O/=/N(EA2^)PJ@_!3#Q*35B5.0[&0>E>%@'V'@E[12PQ#M$AZ^D\B"Q6%'
M%TL7O444=5A#(89MD7M'W O,P.>DHZM;/$5(+Q,<\^8#.JI+X!9_!V"0606N
M37\/[?*]DSTF/?(^ZALY6CX3.?4SOPYM_1<]"1,.[#WA<OR$D5_PL(0/F%$'
MB--$(;E0Z..>YK>97NC&D^KT#%?K$%6E>1NGF:]CS^=-J\BR%IR)I0&JF,"(
MK#":K,D WOQ"FP+=+ANJ*1>H;CP#SF".#"899MAXU8*.SLZUQ/C]_>L6T[<>
M?MR3 4R95?:\15JYC;4RQC9)GN^#!!C5, 66F7(YAZA,U>LY[![5:3UN^, (
M;J241N,;=DO'VB@<R)]F6,)L@FC+V1$DJ'&*?ATRD) J-$0 YM,W63U6Y5LY
M1+]^)9MZWS"C[A(K;1'$51U5,'B\VG6<1:FN];M2<I,#8IXU01P>/GBHK?;E
MZK@#T,TL?)DO[I+KUS 7I]5OUCF)F3Z(17VMCFUGOB?G(U04+LI?4MK47!Q/
M^=.A<S8\:]PC';>0Y4YSC4V6->19TMN>C])\D6TE/-8D"@)O'=C[,VJ_MA?5
MT<I;E"!SGJ7[D8(GRCPL*YD>@\QD ]^[A"3/6N612$>UJDQXQ>662[38]_UD
MVN[A.S,L=\OLS%-^A:R1,RJV4DAC<XR[%XYNG64NW7T81SXO XO'8F;DKDEB
MP#]W"@&&__4. /SVUL,EFT[6:9@T5@5_&>61&0)(=4  OHDGE6OQO+!6U:Z!
M&-^XXQL,9<4CT[^."2> UI,0P )CLZC9[&&]V4\S(@3 J'BYA@#.>[)Z8N!>
MK3='EFOZ;7'ZX6 <Z[@KR<(I/B%8%79>-Y>SMP8W52/![%C37T(B_YI9(,OR
M6G.V=FTIRXY@V$IG(-F -EX^T:?H"<Z\4>JTLYX)F;W4<8$;M8=BC.*8W:[H
MZ-K@K^Y.E[C/%@)#I3Z:O"L]"$!X 7[)X\4%'N)# "T*4E7!O'M6NX7.1]#N
MK<>3U=EING%83RFO94E0#)X]%Q#H=!F;+Q+-R-YJ</NB$S,+G9V1?(1_#Y/P
MX<9=!J-)S!@FV#'X>F7D'X)C^=F_"D[0;"M>\ FRXAK*C)T*06K?>988C*0K
M=+EP$YQ'YOH5IL870*<W&FJR&V'0;/5(-/J'ZXD]_TGPBJ*IK_U1SV*%/#9G
M-W(G3A(&HX0/>KAUOL4=0QMPBS.D9RE%O)U"'">JYX3D6R$5]2UUI,I?HY^,
MHW^DN?$"Q;KXRZ<=#R" _1BI/PT=O^:W<[JV3H(:*G[N?0+_GP]/SO;5![,U
MXF2F_<=(4?75.?>5]YZ4!:4=X38C@-*V2\UD+ZZT2_/;S" 7,@>B**NI5%/;
MA"\$=2;"FHR\>1(ITZXZ[:REZW;(]2_$C^R/VUZ>RQ RI\J0L3QDZ_<&F-$"
M#TD*\JVF9IH:GB=D?]PQ^;2WVA">D!S5B1HUK%$65'::-WF*RZ=-8:OH0"A#
MY:[,%:PQ-!3'-!RF(:S3&@236")%MW9\FH6F8Q]-%W<>6*%Z\XO[G9,^:3#L
M62)Q1T=_XH>)F_[N*"\(.F%%J6,6K8YIEG\(*\G:EK2PMIG#6=O*D-V3Y^OV
M?$_D"3I=CFE.0I[GE]*(^"B3;#)!^40Z&F6>,;=NV*VS.'61:3@TI]6GZ=3?
M9+CVVR6I>OZ269-HO.1:5-;"B8(4\=F[#V/*__,RK(65)H<'CJHL)RNT?9 S
MXK6"Y?"_\^ZB__VF1EJ[8%L=C7O-M[S6Z31H[<V,QMU^O[GSDQ.14U,8U%\-
M/>887S;D[#O;KHJ<9UZ,Z6'W%GFV[9,=+-'FHC<AP*IYD,)+U415,]#G<XUV
MK_+RV:)&)G37JXDY#3[=T&SIQ\:\H5*T\>3&=?;\#'B"AZDUC1* 2V)M$G>H
MM*T1LW\/C[9X !<ID#HM6O/Z:'C.:NSCF_%4Z5U]5#G[B@^#HLKO[[3BA&QO
MI-_5(0H960IZ5G@_H%"DZ$OMN^?E%2'8U.)N9.\]K=Y\D0SCK%MMT3,!C392
M,*,EOGMBQ\OMY60G](VA3GWZ@8"D%1>E)?EWZF]Y/Z=!4*/876UZJ.-($=-5
M>7\=3?MQAZN:$J; G1CHM.6\?I9#N.G3I+O?.2&XFS$A&:OZ@X<$Z-<J@YYG
MV-R$G;*.@<*I4@9I*>[(*;QNV7U.%CE078=:*!JFJ3S@CD<YQE3F;:SM/W;V
MR;@%$KX;1XSL>41'<P(?W:$$#L1_$>A+$*&$YFCYI5Y4M3'UV!#2]Z,8AT^3
MHY%3N1;P&@5Y*@Q\B8'>$3)[JYT=#@\=O'MR4F+-C)8<H-=Q)K,6L9DN!^$,
MEO0BX29'<R0'>:8V8W#+$5=!/=W.IC$2UDWHJB4BA$<]B*EJ,>[2RF[DI^.I
M$ZY^6!FB'@]=AW:3EX20WIO]'& 1YF>]HM0_U<,1P_S2?]3L<]B34'+1Z24(
M<KSU@$ZG1.+6H!>])P4O%K: ZIK PP NKGO'8R%R$W7WZ"(&=MMTWBL3UW]-
M7E^9&Q%;+BNK<1U7PJ1E(Z67:GP_,YOPE"=?&?@0V5\(_7+X?<71>K??C'Y\
MU[0B43>T@*Q]F\#,-H H?J/NO)-3GYH(9: TC6XS<?+:W>;38Z'7/^06'Z![
M'R=.C&=YL9?\H.=\T"Z-QH\2I&"8&2!0U(?=7:8Q.O/\6NB3:9#ZX*,W8??2
MQ*/O7J7).F?IU;QW/U/],3DBV&M &(#ZP?V=).7:P\.H#E=7)0RS#"MAP8J/
MJ]HDT#[FP\K:7W7TZ!8E9C-653J;,R)M2?6O9.['31]!L92X2/-9?#05)0#G
MVDFN6$C-ERV090CXV1*#UG=,H::!Y,#-1J8<>B*M:AOSRD2!7PUB>X?$2EX]
MN".57LN\$^.JNAU.JY<%C7U.=,Z29*X\*$,Z7CTVN3\IY:+8FP?-3 CNII.L
M\+T0H'[2()G&-^,A8W]8-S9!L/+B.23A49?()>91*;+S6V4O-HO#MG$3#)G5
M[6Q;_T3(_[. UL=H%DODTRGO,VSVP7 J';MV13M&!O> PL[GS^C=GXGSKSA=
M3LG]_3>8XBZV\4]J.B4LTO!G'IS?L9DB+_#L[!(;A\F)C%D_D,KM,A]M.R(;
MEM5#(_NU'E8KL\$I1@D^B-0!.RHC@+NG>>=W-,>:E)Z>9H_:GS3.B:YI42RA
M.)5_4I;&#2]VE%SM%LV,-SB4UZ')R[-:,&IL:AP7'J(3<LQ[## )T%-1K>=A
M!# A@/?>8]?O(B^D2D!UK"*^#E9GY"L^V.,M0;NV\VUO$GPGR96_0]\)S"6_
M24_J.HMSO_K>.N; ;E_=:-88-WW&+2POC9.C%=A-7P+8(( ?(E8WWZ5@])-I
ML\2*KP^]#:PG$_T&XWW>G%?PU$8Z/GAPAYQ^]8WX]T$\_A)V%YW:8=?]FMGB
MR :)$.9,O:9*SA^%D:IB]_\N)Q$N4%LCUS[.T_QB]&B:'ESY!>_H$Z6U+8NT
M@+W@H:(BN60\GP;D2G\UO)_$P;NB5[GIY]B^'4N[J=/W+AV@]<] T?X.FX9Z
M9,2OQKI1#3\FI:K:B0BH4,(/NZC:N'MB;]0^XW$)Y"C2Z,C[C^&E^#'&GJ55
M@2TS"SZV[":@"87L+;MSBE&D_2WX9HK+4&F)U=Y-R-&FABK94[>[$_*6O8Y=
MY+/JBBJ89**QUB#2QT.?]ESE1+CV5DO>L_/V$A&P=#<&FM8JTKP+8/^[G[0?
M?15H@]?'C)[S\<5L/2![%+%@[W&'?7 )H'(K5%SF<C"KK!D^I6PLLHR6ZUZ\
MZS^H9?KH<8!YE]D 8/EW21(P.S.NS>WL&;VM&$/=I/PER$S.&TS*KQ6 2Z?@
MNFAL+&U$<4W<Z,HG-UTNM]HQ>3&ZN"@3ME<!ZRM71BMXXR@C?Q>7DG,QP1OH
M(!(7F=^7.RMO''%)K(V%7KJ4OJ?>+1REE>@0N;=S,J=QKC7&0<-_&FAV-[*/
M:<VH, !C)0)>OR]&;7EP4YC\GC@/AQ7=F,B1E5;Q\&'C1))<X]@>V],/93/O
M!KO%%5856:2[OS%-?] >YLUO>IDM5:#[G4U)=H_N6.S.A%:^4T07.4V[$D;*
M7U]XFGN&:\-X"PJ?6#RO!(A,8ZHG4XA05CWF62K3Q(?MZ"K&F[;)=[-C;K"^
MH6!08A+/6:8R54ZMQ;%J.=!;?N&F#'4/H[JR*+%3?KU4KD:HK=/G""'4?7',
M-!>5=2=^PWO\1(6< OHM]T5Y)TZ:[P=:OJG)1-O=,&P42'"O:FRDT8SHN]S?
MW?7U_UN[Z_^'MJ:A#E&BR5/*(;(>*[.UIUDTR;5Y ^)K9 G]*8IDW=MA9P/>
M9D0H@PN;\3&>"$!R?#GXN?LDG[(<X^)18[6$)'=,2LFP>[$AZ=S\M*_807(<
M"=V9*O7,5_2WY/%O8JHAY,OUQ/.W^1CPN#->>RC23OE>I1)U9(],2%$Y:C)
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M9HD%,J'8BZ K4M<A&(;A03JNG4"Q0C1C\D%-I6_12KD9S30Q7D$NU-KFGMX
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M4XR8MW$;F6?DZM1<?^Q]'(8 ")=I+G^?ANQ2G&8]Q/P"P(1TR_JR1OQ>9 [
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M>,D!"Z<+UI$4[< $'0V 8Q56(W5"ND!&D+FI/L-5#68TWF5:Z,$Q G@ZA"Q
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MZJ>C36F_P\1\EGE0*JA,>E^#WZLV56RKGU2X-ZBGMUC.[+QJ<0HSEC-)5F\
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MT@N(\',*LW)Q<_ZQ"!PJ*BH&.@81)B81YW.RYYS_Z0/6!CQ%@1>#/T& >P'
M/X5#> H'ZP(H?UWG$[A_.X"_'W#P"(A/D)!14-'0?TVHP0'@X1 0X!$1GCQ!
M1/SUK?>O[P'$IT^>/>>00,)5_(#\PAZ/\V/T-Q3J5Q7M^$IC)S1<A@[^J&@$
MA$3$)+1T] PO&;EY>/GX!00E7TM)R\B"WBBKJ*JI:VAJ&1F;F)J96U@Z.CF[
MN+JY>P1\"@SZ_"4X)"8V+CXA\6M2<E;V]YS<O/R"PLJJZIK:NOJ&QH[.KNZ>
MWK[^@?&)R:EIR,SLW.K:^L;FUO;.[A[T].S\XO+J^N;V#UQP  +<_SS^75Q/
M?^&"1T1$0$3^ Q<<O.L?$YXB/GG.@?1,0A'Y@SWN"\Z/*'BOHK]5M*-2<RF=
MX!LZC*$1T'"OTD+_@/9OR/XU8/[_)63_"]C_QC4'8"# _5(>PE- #+BZ9<CR
M0_LG@\'R=CHC<S:T17Y# L[N8TB5280\.YQ(Y*;\^(45N66[K=--U^6!+!9>
M&=7*B?B+>C&2C&M9+\]OUV"[D]=>=_$4:;)B)_@PH'?GVI7)/)UZ^IZ)BTSJ
M93)F;_X*Y= ;RK:IT[LZNMNTB*JU-,+.TVZ" @\J=Y5*MH3C*+%%9+Q#PJY&
MF2]>,."@J+7:G=1K9+$1O)CJO<(U"GFR+B*F,^E#U<Z3$/CP[4DQ'+7VES.;
M;<34&'%^E@F1(OVVI>=5\<YR5B4O1F1^5)$>!3:_X#'1.9713TQOV._5(E-G
MZ;A-DZ]:(V?JA$JQ%KBP3*LQ9E!S& J>9"9G*$]9<WM*.N?KRMBB\"]L%YPC
M%(AV-(OUN*JG/Y=< [G*&%Y1FE2$74DA)MS# )V(J9E[9201N4X(7S1WHXIR
M1C4#&642"'DO<QV:UU_>4"<$INQ*%OU!><=Y*Q1 R5S/V.9Q:( ELO_&0@F%
M)EEMGLQ2,X++#^F=VV9"R7?*4!*O1[(P*3-VG+[\="T!JH# MK:[EL8P2*4@
M\Y>^/6*B#_%!$A1!N8H5H(7-UE43-YE'_^4;%C88@*NEQ1=2K8^C0".H>SQ'
M$^S*?YK&SA6Y!E\O%B(HG90WOTLW*%]=RZF#LT6$SX>!A87, W'[,G<MUJD^
M5QN9LWNBTX/C5;LJ";]7+V2GH*]EPSBP*.4ZN;M3RJ<,!3]D=#;9XO1B5C3%
M&YE*JYT^&@5\3'VL4>X2Y9^L]L;M3!S5FI>CRWG6/!9OD_-^E=WMKK?44TG1
MVJOOV+Q,J!6:&,(-]H&\;1VOWOW>HGAI4A<=1!P!F(I^)E[QMGR,7&LQ>L2E
M/]EJL#*NXO8Q=IA-F)]PP5K?S9"/<RC?DK&2LN=RJ]*:\I)R_WYM.C#4':&V
MM@5-,3WZ"N>^AW*/_29%$AIW&_ZCQ,+3/&&NYVO$^&NL#2^SZ,/H_07'$60F
M].SR_"/ZD.DY[> 4:\7GKM:X@0@T4!V^3\(*:Y%X/8ERX!Q)$[(EW<[R6$<G
M&JK^#7C!](MIMX!'J1;EQQ9:&#"*25=\T"Z4]2-\K06W"[<?*=&#/H9G:7!3
MT,",^,8OO^S>;/6!2T709"N3NEDILW>CR: <T0$OXI-K&<.U-]^EPA?NT&EP
MU'+UM(WCI-]WG^+XE *.29XO/&OR;!<@5;B#+T;4,$"R=U7+D\?SZ<\#;VPI
M!U$JJ,EA;2MX]1!KF"E-WF3I4.@IF1PDU7'4K"Q/R2)9)I0'#RIV3YW^O+K.
M_U)J&7'Z^XU2&.Z]3L3GTUW%@0/=L9EI<%!KKF7B50*OJRAX* 4O3;A6]],S
MP2BX#8KX08FU0T\]2-FAL)")P;0+O76L;A,V^T9DHNW;E?6 "7K\@!6P*HOS
M,>%>705/XS>+S5"A$/*#-]L-(W@WW),ZO<73-F5EN\EH'7/Q(U'TX.C'PQ1[
M&. 7H*-_3_>#0? IE&J\^I?W@F' 7ECD]L%BG< N)"(CB#&C:W#'602WLVYZ
MXZM9XD^=BW:$@.-70;4&F]_V5%2)?6M\:ZE.?_0^)&YF"/D<"_GRS]_S[T*6
MRE3PE"><Y40,?^K.O-L6U\@'Y[@C(_O#Y1M J@>+YIOX6;UF2Y#,9DGQ(V=J
M>;?G!59NU6-W'QG3!SOL=WGI-/ 6RG^TJM!H9?>)]]Z]-H8!K!X>@1&Q'[*N
M3>5T!62B-ZK<D_KCXN\VKNA*>KKR'$+N7Y]4Y9M,IGT\8C$5NZ.UVB6Y3"SM
M.K5(#+:CYK>#4]//IWJJ0QG0K$L1O&+%DR$]31L$]]SJ*TNG5"1'A"L!&<;*
M78#6$I[_NAI4Y#BD.VMV5G<>Y4.D1]6[/CKI^1X?'8_1M?AVKMQIGB$^B5JY
M</D=[:[CS0+&H81V$3S<N6K\  83J@)B1-=24I4J!4*W)6_!5^\2$HUWMHDI
MG 8_7@=NSX2,GU!DLRQ_5AO>#UWDE:Y*4]#) QXU[L/IJLDOF/=$>4^V8EVF
MZY*_@P13.1FY#D4_F_/S%.7MJ6F59"UJZ/3:(Y A2Z9[8W^[+,66;6HX$=2=
MW4O&7(#V"_4YD\IV9:D:]3RN0\4"+79<;NF^Y5E!?$@:'&[]G](V/%<CYBTG
MTH%OH+DCLQ]/"7EFV@#E5L!(5&NT^>9J0DRU*!Y<OE[P_B>QWX4JU7K8U&"X
MX[N:L=::S:8PC:]=H:P^)]14< L9\C7QV;H))\ZAFGJ:LZ3\:DQE-:]U7O5E
M"I8OI<B*YIUL957$B)BU<2PM:FHQAX*9NBHZX&7\VO"0A=P0OAV_Z7/E,88<
M*LM43+Y6KO]QVMV,EOW3Q3Y>KQZ9F)X> 3E9UDO2U+#5LSJY^P!/Y*<K8((7
M%C1 @$A&\>D495_EO$5I7O:$+M+902>R0ON[?4]3NCK#-T7")MQ1WS<E#VD8
M@FH5A=<9UF;OI0@Y9!()3B*>PBG&2!\DD!G?8HP9$W+'=KVAJY$;XGWL9DV5
MP:A#IQC?SHHJ?1/[.$J19F5:OZVKWEEI4:EM!2[8K</MM*Z]DBVA@XAYF^@0
M4#GZ<X3=JK6&VAXYC:#M$=8ZN+OB=#=0FO,+D$?B\<RP@A7UG LMEYC&JN4H
M<88*) 3EH<<3/WX6?M,QQH0!GJ(ME=X-H^EG71Y8#=DPP'RO7%_;DNLA759I
MU@BG@@QL\]W;6V1G$\NH)K>IV'SX !_/)"D"H,@M=PI_<[3?0T%=G@R>GO8U
M/<4U)^7KD7- DE<H,2S-+K0<7!>B]C'4YD6WZ< 3PL70]'",XHA--8UXWS [
MJS>_1V"_./>&UE\BS@Z+R.E8&8*PZ@PY]*'0^I'$J+<PC*?=R\C(4FD<1+-!
MV*OG?GO^O76J)@/+4M"B'DI;6D#>/2XA4N#/OXA 9J.;)^QYISA8$E7J>JY.
MZ.J]AGY,IK?3Z)--GE/L OUI8DX@29G_WB-&=L^.0\G\JG&S^[)N=7_H'>9A
M9OC*Y+-%!]4>=X6FZ+;[=V39#9,:RUI[:L&N)IQ#-IO^?2U8J,J1720!:M/5
M#VAS0N%O-K0[:?QI'8H[[1$_MO&O4'BH<YTTHN??DX*YZX*TW5W=V=TM?\C3
MV"VS;U:Z;^>(K=$6JT]KD:>N?#6;!J]%(?BK!@2,C(Z9#!G\2!3"-]@CEF64
MED#V9XQ/K\I;WF4JG%]\7F'PD\[N_0<08MI,+]5%J6/[U96@\V+OIPL0GZXF
MYG1,W7U=W2.99T3&8[;&G'2T<ZD706UYI<G9LB<C1YMW5<6<@O5:A-Y:PW@O
M%*&C4N<&O?@U)?\@=2$,6'YM=%$:ZW&P7 _N<34+\X# B84X!>3  */K4/'F
M\0].IR?3*QU)1 /LY%63:/KX*,5>3[[O)IL<Q,SJZ4B:TK,2)]/U[W$\C(JF
M*F^BI\1<7W7B#(_^*"%FG)>CL>G/N&ICNIVNZ2GY ,[A+: =(,5_MV4\6+JL
M6"=PSRCG+3@\WFYM4!O,HNJ"XA]>?T4. RAJ!MP^2]:,BI);\;J\8XMJ_ZX2
M757%S*\O =*,5*X(4DE'V0JNDWD1I!QF_#1:<4EO;O>RS-%=V$X\@/F4%\AW
MBKR!G_&%-/O>HI1J:X?S^ 9KR<>[9<DQ>?(VGVJ8Z+W[F4W]@UU,7PMD2<@#
M%G9<+9K_7OM9)7(H:A4QNOG#CT _Y+/2H*J+<))!G?&-B6/#1?0P^'J,SQ7*
M,R%U8*"F)FA1=]%0_&/JYA<$8OJ&;_.9EG)2>$I$BE)XP']EO'<CS@H!3M\Q
MM3M<#^I-.[_S(9?NIGAOH)2NS2[0NZS<]CXKX:H#]YJI6U TYUM[_K*V[8L5
M1O?B[&SO*3)\HTA[O1HI?2'Z>#+>UL+KUE=0:AUM#5"1^3A;/R)'>)\=5TRA
M!EE ?U_[Q6YLEIN8"N0#Y )3A9S36P,Q'.V9HFL03:G$(XZ P+Y>AA2K%0M"
M'-06_QI9:_R\2+;D@D52,]!XKK:B;?,#D; ?<<7NJ+KV&CE75[+^)^L2:QNL
MRI,F[V(=<5JK3RSU7F7UJ=Y+6/:WKG'*V[9VFS*)UXY2D\ZMQ//[KAY$8]5W
M1)>=5ILW[C;V'S\N!@\C6UZ@,13$UH]7;,, O.K]PU?S( (U5T(Z(?_AY\$9
MYFT;*_:ZV.%.@VE&[;>!X5FVZ5)J4B-+C'LS#TP^(5[S[D\BJ29-IX\?R=LS
MNU=+%,UJ4>BB5ZAP2GK:IX+7^<DPID;P+ 3C>SZNY*].'&W&+#%T[455$7W1
M.*N'ZY6$C+?(AWBM;0K#@.XYYXN1+C9,G78S>Y9FUA_6%5T_"\ZV8Y"0UU\G
M.^]>#V&>5-7?$=6UUS_E2\Q@#K/I$81D*LI]=1&>ZUE6.1$+<78/BG3/WVT,
MO<F_!&T)XFCXR=RC!&24U8!6%]&5W>]EUDCW^6H2%8-4_4?#ZI5'J"%^') R
M^!:"$('  7M]] .;<QB !L(\++X<3\D#QTHK5M2XMQ_J\C:0#F5:*O:$G8H4
M%Q9FTP9+^B&7Z&?%NKJ2:&E -87Y"NLZA422G??V".8"^+^\ZA /$PSL\0C<
MRIMLYLJ76(U$D<1*<::!@FBJ/@4&1WHR>;5A\;=MC[=$A+2:=P^X/_XJW3S$
M(@V@[\(_-086]6XN2 (_0T\/^\BOV^]1UDLX>SJ5H&)=Z+Y/=7;K2)P#X_1T
M0$Y-M%'A,S>>#EVW]GJ?I138#]S3(RD*5FQQK'!J@[WS-9?%DFQY4CVA_G:D
M$\<&V[E"4VQ8;JX:DZ90:\'XN&EE2Y0WU5]>N0<FE9,249$Y#7D,X=UT#[B%
MMWY.QGSI=".,[6I?$LSKG2L=IUVY7<"XXK0>$'%SJ(L<(2SFD4Y^<A@>D4%3
M8@T#FB.&^:+?KY@1]_<X3D+R%&6$6CKCLEES-JUP+)8-FWUY.6& A6P5FI$P
MEUE KX*]>GY69G;$B7P8MO]F^62QEEBU''O"2R.&G^AV\M(>1LB[[]WL>73)
MG2DQEN87%6P1K:W9$-\JKE,?$2  D0KYYR/V4NKLQ8X40%7Z1%NC=\EF<]1
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M/ZO:"24[I2M91RFKV=;U625_GX$./(I(T43;6)D/E9Z;:C-?;DY2V.,M/_P
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MA7>&3S-Q^ZRQLDL9M^^9] E]1^EA )WAKRQ6-'HA-#79#%K1WD1D::^/ESA
M*\!7T&X]F?0H.1U:U\?1UF4N)5DB_OZT9_:NZ$M?F^AYPP99_NGTZ 7>V'#Q
M]$S%LQLZW?VK!X[4Q[B;>Y%"K9W1O2N"'ZIA72C?W?$(1]Z^%(I\>[X[\N;<
M%\W7Z%>Q4P6ZN((!KX+N!P8D;#GJ.U8<W$5$&M9Y1KP4(Q4I7D18!7]J]*I
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MJB;%>/,$3I])^X.GB8^((A9S9<%L*=U:$<$F]H46TX(J=M(EN19(T.^N[V
MQ\Q>(5X^NA]HA#\36^)_1?88U]EG37[&UKB!R 5M] CEW'6$[)KS($=';CN)
M9PDQFAJ,F>0@>C^FG[8UF*ZZ%2?&L3VW-H7.[L\MS*J-5PWCW+/XVHD5OB+T
M*-BK\:0I:TQ4+Q/O$D)V"T)%7MH<;M?7A+H.TSPAAS^PCWL\EAPV1QB/_Y__
M&)"_M+<D]+7D>SI-_5<N*5Q^C%7[^OP]^^A4I[Y2B3*>-,<N!_,YEURG(FUT
M(OIT-X,($$V,[KP*\A-5\5<*Q+>J3 T\+&+=/@2).@E+:T=+@\H6M+5*12_*
MXE16S@TSC9V&[>S%_WA0FKPNW LD&FM5)O%0XRS<32?X5@LC:/:;*;'*5[JU
M=M#S*QS9W0"]R#6KV?-EU'W"RR[T4"OBK;!U?I/P+P_BF<B+;I]?5S9K"[48
M*=0U&GU$K&.(\%VAV:K^V-=7JM#A0S:._;'ZFJXR:$-?BP;B(/]Q;G7C_<_A
MWA@0??*PQ;*"/N:U3*=@ X<.S<8>J]+J>A"95U'/^*Q!-I4?W#HWW-*8GFV)
M6Z3^R6)B</7-<??B5$0:Q3<3+P,IA^*#'%WQ.5E&.W%BY!R+I'NI;+>\5]4_
MI@//!>LR\,8>DOF[GC%+BQM1&4?&A7&(R'##S<IP.QR?;LC,=)-:(=1\-MJQ
MN-@0=+I="EA]9[HWJ!FCG0AEFF?+0)1RL+D4PBG$'DF7L5V=U^6NLNKMJEW"
M"^C"127HKT%/DSK\P(7/:2T[Y7) =D03+XS=XR<DE%+DR8!QI=R-2%681&M7
MB$H%%[LGB[ 0DM!<UT62GL,6Y"65M5?%,M63F&_1SCK-GN[D\ Z]=),,B2P@
M#"$"*%/ZA\?3T-EA0"%EY%G>Q',8H")&N:V0"5\T\EAU4H2/.+/<+R*$!H2$
MZ"=.M;(]ME"R%?GH/W@ ;U[ZZ*O=M]Z>>_THN?&]V$&(:CUQ/D@4S!^_V)XX
M<#9E<[=A^11&EJ_NEF$WHP&7&K0='3(;"4H>.O_"/;]<:5&+8ICP\U79=NY0
M/A^%N@6PX;QCI;UY83L( \ID!O>6$V& GA\'3SC"G;;F& ]V]8W^K"LV7^+F
MT9GK\[=FU.2.2R7[6EZ-M;$BG]3?66W[Q;P)33CM)^TX97^S@3 OL(W_[?2V
M;A,&0++_OJ@XV8^J58+61)<T'^Z-F+;=JAZ6+K_YV#:%K]8?8N!N/@L7E 9-
MSS$Q\;,8Z)9WDO2$[F0:8/>IP("_ 1;]&UJX3HM';*AHK/$TB6_HBO_(4,)K
M!)!:M'"O&;_1<^)!"ME[QH4?"#44)!5C8)N-,.UE*6_:KJ(MD' HW25+WV:$
M^^&NKNO?X47^C5' D=U-E,'+52PX<#X^@0Q=)(/QIZIBSK!'G)2.$62Z"OR#
M/%0!VX)7[;:YW-+C[<2017XWVJ87Q-2$H<O_.R_*"#]RR)'HGY417WE2FDU7
M95:P?PN=W*A@GB[O-J^%4E?&LXJ;,L_08*1BG!^_><3_43%IRWHO5((IP&;,
MI:.M8,[Z@C-Z,'\A!]0K'.7-5'#CK7WZJ\P=^SN5F1COD#LKS,<7%P>=62[S
M/ 8@ZK$,:M[9:-_4 ]\+PNTOU1;\V2C@&')^7P(QCT^_S9=1X6_8!6JW"W:$
M/-\C_#L3LQ)_-X=GY?=BJUNC!E/9<B,\91?HH2M+:LO, XYUQ *]9<3G^$W_
MH/*AXR#;LO,AAJ$2OLNMY$=CK:C:]\0A\09C".'%>8CP@AA/%:56OK(R\^1?
M%/6T-DV_EW$6E'Z!%L(>2K)QB#YIG"XO;U7T^Y5AZ2N<U%Q/,SN3VVH+INSV
M[9L663Y'^\F;1(GA*KK$R?LQ]N.04OT)V:F$9XYD23,%94M23G(WN#W*%CS^
M0JYI4UI@W8*:'GFBYO>%D5XPF^>'X*L8P(VB.;/]9B6T>*U_LD0@;OT*>1(&
MO/D[E2_GRQT\TI?? .!_F*AT_S=U_/U\H_"*<K\S193._,?O.V@I2!O&12<N
M;076;/D&E\-CF,[[]NO(/:<6I:=O-XL?N_.]PZ0<*G6P:8W/UH M49\C$"7[
MAM%2F=>?SX#\W'=E?Y;563%G?R1O9N^GWNF"-BJ1P/M2J.AJ>3F" .8(-;[A
M68>HSIS)=( '=U.+X,QLSQ"0S%>WON$T$.N?Z8\B,*(#4?@'A69=4\PV"[CF
MCG@*)R:JZ]LDW#-HBHX3<?9E9Z*IBNM])2HB4?_,NCK=4U6\5Y2_+&,#SN28
M=W_:]<F_BW7K)AB!7@0 U&5^7Q95ZJ_9_@<2,^I%\VZ5+6  :WO_GJ>RSW^"
M[;\^']S KA[:9SEHX&,C&XG&]M+T99 PNEFL15* 6=HFW ['2(G@50<D= V]
MQ$IR"B+?T!),W00"OX8.*'_RLE$B0PC;"#,*V?LM*B0IH/*_0Y0K6M25RUD4
MF1AR/FOIY!2,3@W/M%W!\ .(CA7W1;$>(1GZB8>/ZI>UR0E$IZ[NVG+WL/_!
MW5L&U95MX:*;H,'=+0%"@@8-+B&XN[NS@[L[!-M8@.#N[NX.P36X:Y"-.Y>T
MI-/G=)];]5Z]/^_'JIK46FNLH=\8<\S)W  GB]M[MMWIAM*_)X$M>BY:!Q:#
MJ2ISQ8_T805S"WCF35=;@INBF@,"B$E$B\A4!"B0ZK.+N_+NY=O8IDZ4IYG0
M)2D;A9SE4-";T@#BEJGI_U 6+([I2K)8SS#2R^5N'%F3"!%\-C(_BCZ^;VC7
MJY6UM8O#;$,.C$)1/>"^]+')0FI$'Q0H?,__T*5US0/JM-T@R?=BLFY&M5T!
M:DP;U:+*MM0%D%RG]VQ%.7&3PND5_C02KW#@AT9WQFWAY0OVB^=.UD%0P2(+
M!/D;A"=P):7_B3ULA:T0HOFF+GMF^/6I"E,KZL[T/"/5+\(\]K)<Z_#(D\K)
M4ZJ;\TU2YSBV0O+=,P<?OL:J<C7'G[[K&EMG7R>H'#WK!OZGK+@/,,EIK57X
M#?>@;45-.;:A$C7*4[^2QEJWMDCO-K*EJO-2Y 5MLXN&GKA\3V,S!S SC)"7
M)&$Y U1F#C\;*2H_E*TF['\*/WZ%,3)F3PT,D]V:M*?.HRLI34$[Q4W&DY4A
MB>$+!QBLL_>7=/PWM/[?\OL_0?E_(S2-P$.>!^]PJD0(L4HWCQ=\*>_-2$>1
MHO,C8-H#$X+HC^U+N U'P6>62.) [$)[<CG-P+?D#B<2VD;OK(*MPSJ+F43
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ME6CDZB@YKP(J@D1+L@><8T+L34DK3GVTDV35%)"M0U7K#CODYQ8! "#(H_@
MB#,XQ;V&N7L."0+[6F3U*@?Q,U(3&RGB/N*I2X.,-0>M'>F?"(F;ZR6EQ,.,
M5[,'EC7W)#YRO:^)B-^F?A=+R8<MEXNX1X!'OA)ZGH:B7]X<*%L!.EP>.LF"
M*DU$Z%H@M"F!1$[N5BFE:XQ3: $[%&?R6ZXA#/$*!R_!Q4E/H<,N@(_HJ9N"
M#Z7X""-/DD[,5%.[3DR7,";.@8V+'!?N<NK.62"#4T,OP3>:W<\UN_ENWO:U
M=P-<B#/SU';5['O27>EC@.9XL:JLL7-I!DD T3LJ-A8@0;*0)@_>I:8@O!3X
MNZZ?S?ND2)!#"@=8R[%PQ#.M?=V==49IDMQG7AAT,K5=[TSA/2M"\-'OL+</
MA1(T6RB:65,+?GDEGF^&/?8JS$3SXZ$:=F2(N(^FAP7[.E?T\-.,(US0EABF
MM:EIG-Z\M$1MSYQ3MJX<ASYL@L;2WZ@7KQUP&[R[\Z-Q!_B](#%G;WB O):!
M-/EC@IF;OQ?+P>(7-Q<VH#XO[#7\;4\* + 1Y0*PLZ@+@U_%E/1S*>'03/"'
ML^+I.AGPN:"#TLO<K8,U'8C(OD=J[PN1UTX8X9C2E"CJV4/![/=?@R!&*&>P
MO%=G#\\? =C2:]?%6L.#W[5URT"*\S1C<<B&UJ%YY$B9$Y2$H["2!7L7^!21
M39,6<DM([1"D45]=J/+ZC;B]H*;443!VYF*3[3TMW7R61LOJ36/2WZ(R.A9Z
M*8.<G]67XG/O.YVVEZET0U74SFOQ5F%L"NT%!>JPLRFY0?A&3]KCSDUE)7PF
MIA^K?C7QL;K>W-R"?%)VB1KX*68DED@3U!GSVID=Z4H&UC'+J?;##)W'B*Z+
MEEZ*'GE$/UHD;Y/WI*66,'6DK/2Z-HKZGJ0N7094_VOOA0];Y!%)'TW??U<:
MAD& '+*9ZWZH=EY+A2%H1C2U2/ MF:D'"7]LN[WX2+D!L)%ZOA[,99P#N<+9
MN;I;1-*YO[5HAMJSF57_[/TI5"(-YL;;'2DA"$R(74P%;&79917UQ2Y<82YQ
MJ@!<-AVXOAO\E-_/=?C;_)\/Z8\F[(\+$D,);!&4OABB?MLC>M?*DAG\G.)U
M?,_V;*[>;0TT4%VCW=D<:ZBJGQD]S6DCS)?Z:0J,-JG,G;][(GU?2NEO:;=O
M;N$@<F24A%>SQH@F%G"-#!\9(<1H99M@W!E_L'6,_#FV3/29>L_T$&8)4<RZ
M7M@I .+Z<Q*(_6#<B]4^V5;R^#QPOEJ]NJ9VJ3R M-Q(WPL B/+P+>?.;^AI
MS3&A?CYI(6'.B15,'K89]9[CX ,TB'/%6DL C*!:,WW6K'4D$_#PAI8R&(EU
M3OQYQ\N@]=-7QM\J;;W>GW: ISZ5RG[>O:F>Q ](9FD >NK;&EF,=9)+#-:'
MDA?JDR*N$'_;\F*N:E;K52M7'^)8-?:*:O0B+83T*7J280$5+FNB.IE3*?:$
M$Z&J#L@>UG3+^%X$0&$[&AF99 P+2IO!6T6 =#9>:T7>JQ!C(:F-IS\T-WA-
MP9A1466 $KT!7[<1:K^5?669.V>JW$)35NZM4^VK] T3.*8@2 1P_"PK",#\
MX_I;JRMG%)I67;%B]*S^G%9('RD+@$<.-Q(: 0O_G"MR5(FBM4L:86&Q_2/+
M<[TH1[3>BQ#V527],4<.B-2/D]H8(?2=Q2IIB&V"7E*,;I-%RZ@J3K4]:O([
MC@W$R=G?-$3Q4C;V8!P5E!$=7H>Z+5B)KGEQWE"/5-^& $<PM.=:<M?$^_5$
MIFBJ&,C?3Y 5]OE1,V$DL:_H@\YC<O<X2C_9\0*$K0NU/MR$UJ(M#EF^"=I2
M68\X43CGA"5+9X?E&H4ME-6R+T0@GZ$83U0&<]^JS0OBJYK2L][:\'-NQ4M_
M/6@GZ&O;AF4O.D!1F6H2S''B%6V8/'J!TW-]>*CO2>>LM/3^4^+DL12_7BZ7
M_987-QV1U/"Z?.-$1J+]8H;0:6]5F/>E.7L/LD.MM%BMEJBKL^LJP0C)@IK6
MH"UW<TY2[,D""</:TOCK)>FE^;JD%"L8V\FC/6QE+=1)-UYK\V(S1Z!SGK"^
M,]+YA%CE<ZP6>Z3D4+AA'$C"I_2D2%O-R3FX/__ZU;*UP5[<\ZHP_\\<H9&^
M,:3@A%/.P@,Q7N+^%<,9(VQE1VH7BZ'.^PS</CISK%[2J'A84C_*N>)]_*5\
MT[RKG.GI!Q$M376ILMJ8>:MJU8Q/3*_9(0M)\H< +H98?40,7"Q<)_0AASI!
MWPUYI'+9ZZD&8(]F7(T14N.%!VPXE"F)<R[4P@-*[ :/,"4O"J_,2^CLZ1G,
M2R+;AV<WR$S)+0B4 ?" <P0DJ1'Y6^G9S5.>0:N+"3=_A[ZZA2;O) ,;MH+4
MXVB31\!QU".@@_.B_;YXTWG9F*'VS7XC@2?B5H4;TB. B?X^L*3U0FW=32)G
M8HVU<@UN,MY.I(ANWF2CPZWKB^=RK?XCX >J<-1^.DM&/I6JFK2$PMAC@J/%
MT&>([(<DA 2IV%BQ9T\W"69=.=-J*S:I&S8DFZ_2%#FR[[#!0H)R 2XSB4ZM
M%J7K2+Q*4%S8^!?).?-O=U1:$YE0M-18'@%>^%R:!28)VV'GDDPJ"?85$V<S
ME7[=IC1M&L.,1U^FRA3?(Q)OC,+F[N-W@WRSA_+-Y''-7U 1=7W<P-;)](=*
MBH7T7BHO]GCAI'=X@< \20$"!IZLX6#;\I4L?F9*P[L8LI[1>IG8Q0N)#O[<
MG]?.G=W\U8;(;X3H*U_ ^B:E[T38(C50K0QL'$K[8MRRRIQ7K/P=FCAW6^L[
M=&AAI$]M85:]N/U<STP@RZNGBBSMJ>\YELPOE6!8ZB5#N2KVZYW)8,E2GN>=
M#3E*3K]J"I&NN^6OC.N/GV:=)6D() .B+4.M-SL;51JO:0IW/_!6CSJ0DWX;
MM*UY7ZD!\>QAC9%G5[=QZP9YJYFZ0SE!\-*_B([Y=101>\:SUS+Z@[W0(@_'
M[+!+7O1[+LDI83D+9AQ^'0CB]LOD?AA5[C"B-_ .J9[ @MWIRPOYY\46^JIZ
M$<_>O<&#A8T\XYI! I.H5X0K'C_X.I,7 KG[FIM/TIVEHY\C%BA"?&1.%+*>
M/2OR1'*J("+IU&*LF$#@,%D#+C)+(W1_,8">_*A# '_K??<:<KJ0]DXP*[O*
M\158@G$Q!-->2<>8OHP2\G;!..V\Q*67+VJ ^^6-)8X9L?LP^J:%18B@TW#@
M9MCS9ZPC7QO9 ?JPQ38--.@F#]C5"<,W]VKKW::6K_;K<7&[U]_@4H:U)2\O
M'24 SF^HOYX3Z<N/%W')KFXT)I^+6I*%B\=LZJUQMJ 6VG>9;]T_@Z\N)E"8
MGI&(4P$3[<]]^Q"BG^7<(3+"VYR@0$;3AOB$.ES;S!"+FLMSLXG6MHQ=%J]0
MWZ,H1_B\#W=[Y@DI437Y_:C$DO8@9YGV<P:!_YQ0+Q4!(<A)QVE$[<1 ]4YP
M=016/%_;3)+#R4>=E^F %M,?9P10&VN]!?"R(#S?CDXV%U"?HD7Y9$Y;>HBV
M/7/ /&OLN&2N'\OFRQC01Z0._OCDH+(:PI'6JYYX.]A*<\7W4[&%VYU<.)>2
M[$HB7T->5AJ$-_ #UK<(E>EU6,0M ]3H0PBZ\*OFTESEUM1S3 R$X_5?CVV;
M7JO'\C)P;8]"SOSHV5>BW*1?/0(XW!E)S@7 #W8W@#\63\ME),.9HEQ<9* 4
MY,M:<D\R$?8\J0#FF-_I\^_R.FY2![S8EU&OI%!0]_#-KR>K"1"*N<1>Q Y\
MD+]M2Z^L)Z@(GXZ6.JZJP4$B;R&?/HK,-/GZSJ:KOZ_'JMPW\KPD_ >UMT]D
MTY!=']"H4:Z$F.\AA^MO*4+XQG@VE]QBE31[+=BIF+QXX</ECLVS']+MG9'3
M\TV/7-+IL0<,!>L Y@056;Z@=V_D0?<,XZONTIM".),/"A!#FD[T4C%%665U
M3>,6-,7^6?(J(@5+(KL$,$I*&J=]^T,T6@CC:>55U:$+*)5[D'*F$HE9*=9)
M5:'\BTFG$VD]#)JO?M!)_2$E9.IDTQOHA\K[8ICLO-W+,/AV:M6!-'%<<J_V
MF$"H%"$4;K,D3Y2J3U748<3L1_Y%EX,>XA)$7=XQY?7>Y.CQ[/T;IYI&/ZC5
M:<M?R\!RYCN)S=TJN2O-/0)D)N@W/@DP3S,6Q$>@*[PU-"0W6/&".\^8;Y_3
M3&X)AVY-Q3=51K)%.7J'1VYHU?.>GS;YNZNM)O8/:KI/PO(17N2N4B,IF6N)
M;M4K3='$]KB'9IK1W6$-)+T;=MFP6RM<NGHUO:]BKH:DK%C>#%2H.J5])7@_
M%^7"B"HZ(L>)J)^P9_73JB-C9R'<"!(ATN5A47 G'D8T7[NBOGYU)H\2Y3EW
M2?8_YXW!_2$!I$FN[I^*!OR^(OG;^TKS*;EI!P=\B!G__"S$R%5A1^P2;45M
M56-S<PWH^?2*>TR$A>%N'6,9J7T/Q\29)8IDUA+7B9.ORJ2 D/Q <RPK?Q^G
MEX)\"L-,??'"7Q[7S_4"R!.DFSN29V8SHO-@V))),6P1>7T=L@X;0.T#1Q8J
M:[DRQ,A)*[<$/JS&F<(8;*IKBL CYX-#B(''1$PRAX3:+K9S>N)/]@>C -L$
M;3]:NP,I6B'7>V&YAMJ@]!K7ZY@[OX\6<%@*!BO/>FFLIPN&CA\!$C$E+]07
MQ6A9M_2Y;@QLO2W),&+[YNO><,4@0FR#@,4_N O]P29$<,&GW[J$@+> [%^U
M]6;VYU?_*(Q_N]'Z6W]*!O+UOST;[/"7R9<R5Q'4#Y36Y6HF[6D9M_980+M%
M1@JW[_,Z#A=RH9 AZ9 YI_+N6(S-<TU=/%)9IE.!N1*5PD19C5!UPW)2C3$A
MZ&WG7%LU?T7S !C9'[BFB6Y.=2*:Z6,4%I].^G9V;QW*AR/O0&:?AZ!ZVN+
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MU?B[KX2(-S9>IT^QJ..>0S:<+$W;JVQQOH^RR<HG!3A$)MCW^A1)SFGLUMZ
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M5= :MZ(>J,JU*1NGE:63PGX4/%_*=B7ZD-GUT#K/Y/EBJ9DXX<=:*%JU[B.
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MD<!/;?>VB$L2R*^'L^ 3_B*QAGHQ_-!-&75]. R=,*SXWG"H9<:1;!H2^#&
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MYW34B4$9&N7^O[!A0VPUD6-:SJ)-6M-\[M"89L@G$59?,:A8S)I!=AO>9?C
M^AL2C5'<LT#\'Z_,#]G;/SA^K8&SHS3A,O\O-.%,;$QYS5H8@P3>;CYZ2WJT
M6#NSNW-'D)?'&+_:EMRVIE*4:Y+MD8_9DM.'B#;-&Q,LV^EC]FV!Z2D40![\
M-_;:V[_X[8+WFR_O%.7Y8Y+7VL_X,:M1O"M:+7[>[NW=(%P(8TF(LPTV++31
MC/3L+-V5'3N(:V@B8H>8V]LB[L/#4W_SQ0*LPT=^R;SS9]HB>>:?[:>$]G"<
MDQNJ_"K7<=)I+7&*T!YSK6/.6"4VX,(_0YM.S^V10)J2%@LA1E'F=,$S$KB4
MF]/^D-N)\+\)(TU_^[KL?\L9Q_+2-_CU;]I*IKKO\5C7)^CZARZ7\'*U+&;4
M9%6<6DI1?DZJ,6=NDD;(&OQK\V#/N3!7':TT2!9B9Z2K@GT=QB<.B'AY/!WB
MFQI8M$\W^FA7VP'R(<5P6.F)UH!<E\!FIX^FB!B>71/1FU*!"5OQ%I=+2O9_
M92@IF1E@*P.LIDJ>WL(2H[@)\NGM4)<\RX.J3*K2.W$9@E:)G R<,96:YV82
M'9PJ6S\5C><_$X^70BN1P.W1323P+R++$B_YHQSCA@)#2>'.5A[:6$P4,K"!
MZ+>\FJJ-6.J;$R=(3OJ?":^7/<B^?S<P\U*MWR=P&7N&87W?E*I5Q K"VAG$
MOENYX>+&4=G63&AI7HXILDZZC FU@6U=*$[->9>K0,Q!WI=OH=?AF?\B:A=Y
M7$BIDFUM4KE"I["-[7;[RZF-:F"+:C,>]CMGP_VH,*&XF@>*FK7\1OFN\UG$
MJP^^XIPW5F3%[A<TV?\N^$3ZXN^Z])*?3CXU[C(/X:%M7)#KX-QB=/7%]\5;
M"MGR=DN>< SB8QE" @T=XAJ:)=7:.W&-Q>GLI*$*NYL;M;N#VTW_,E0S(?Y*
M80FI?]M>UAS\Q37M-BKBW@S)HB)N1&,(*N)"S0_RD<!OONLX!8.#99& <=S\
M%1VSV'<2)AS&:@1+S?+A/27&_T8"RO\K25C\[]SY_U3N_-]HY7]=XNY$Q"9V
M(Y"BL[?'2_)NZ\+N@&/*C6U+P8P+]26Q"^SJ!"5^"<*6\-:1;(*%0B]!MV<0
M:WE-]^LP%':M'QG_A6!%ZI9DX:':O][Z-UV13U ;??PG5&V,P(*37%$SAR$!
MC]1<-6G"8:= PNR,-_%>N^>3$ G@P;#<O"OFY:[1_0L,18J,5KW*NIK/^\\!
MDC-:SLXE9M(EQI:C[BU[E0?:69X9%0(]C -A%&'D>3KJ4HQ;=[^/?W_R7[='
M!UUXM\Y/S]LB 84CL0%_)#"V-SLQ8Y[]8IU$-M& ^*Y"5HUY3; T@58D87HF
MN/,D]733&0ED&)=O2\D@@8A-\>WA=23PHD%:Q3]1XV(B+]78WUP, EJXCU7A
MD;#^J-HL"HN$;6V#PWNI'E'U\=/>TT%6GFE[OCE%3U+$$$&[(GH*!R:EK[>V
M;HB=#2/SEFU0 9F=4IWUR!AE&Z<4=1O_T9)TU,G1<89[)%0\G-,0 G_H^]Z>
MO24^+I3XZ6)VP@>_%;R(@9J+XJ*%&N^O13GA[@.;ZL])R[N[MYPUY"$VY3)#
MW7ES(G;WRBIV)#%+20O3@[Z069_M59WPI3 ]^JSDZOMH?N)$Z- Q6VKQ 6 S
M+K.&:44>)Z-!W>?D('3#6#L,(_[L(WXORUQ)_@F1C$BDAM,Z[:FH.+8._KD.
M?@L%O@IS*Y6;S(!"\:!;'DZZESH!?_SMQT\R3'A+22GO'7<N*KU*=&\"MZD0
M)7F"I@_VO*1/^XLJW0L\; BN:=?/@Q^_]1S&,7 3"@]H0I^J)N<?V]%1@U:$
M6QJ%42X5&ISE=@F'X\S!#S41DZYG394WW^TKUL7<CIO$:K:5$8,-\]PW9<LN
MRV\[^]]V";VJ63_,S_[H,A(R9MWD9+.DI9UU8G/M1C]81%LY46@97%62H".
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MQ@8J;A5B_8(SE36I//;UO5OOG9XG>:4(13+EP&G/=!*5(8[?NSJV58(3Y=A
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M)NY]V2 5[UQ1WR*Q<[Z"4&\AZ.U040EN_I7J^NMX.1VP-_?M)5@GYD[G[@F
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M4P'G9,]&(Y=Z$$V,;]VV)$61.0J(F-=8A!^P^]U7&[?V?":]+J'(FD-;LLH
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MW_M+!>"_0?+B1J5R\K!MJM! %R(6VV;774*T=49(_=2TJ2X=+86+W@U%^H"
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M0B^%6+H@_1FSO7X8D%RRYPTS:)^WN]5S6)X;P.&O="0X 9_LN9S,Y4Z(D@0
M.>_L+]6G%A6"S>MNA+K9Y:R9N@N/WEA:?,*JQ"#V2$1QY.7%'=/R?*VC@+5-
M',6+$GYLRR^+D,CN>XZ-$"/0Y#LPII@&[2N<$"73++TRZ7Z6?16B$"G!'YK2
MVIHC(9*)H45$-Z'#L_1EBQU/]7,0RX"!@IL!W\0YJ<:4;*H"1S(CR^3N9CT;
MLOZKJML,2[8CU8[P(V$#)%ZN&151,J_/5[HJ=;-G<M<'1Z_Z/ KU%1UH@[Y&
MY:L_[18OCM!%E5;X8L]GDA(B,<Z5#BO$?F2'IB#>]];%C";MS>LVRM-DG-LC
MC!)FF([^SF.OOKQ'@G9>Z^EO>XL*7L1@E14Y63B13G/0QAM1:G5)#6@*"-;1
MU[)ZH#>/,LE]MG%?(9O-J:U$V-XQO#$N?D\F&3+ZRD"$@^T#;!%#^V>X-H;V
M[$#!,;GCT;88XF4=/3QA6GWIUN[CF@RQ.B3MNK<>"&O%0+@IJI1(J6/_>AL_
M*SL/LKR76DO+2S1]$";5!6"PZ-,P):'DT+226([XAC6+Z4>PT38?FS>L8$\R
MOIT*; CIG//V[:_J97.B[*GE:$:DT<V0*MHN7?)TT$UTP-C=?"W I3LD8SSM
M^ZVNN[(/R=Q(UU\MQPY DG9&DJF4'<CG0+Q+E)%G9L4=W=@6+@5<#\Y\J06A
MY:/V6QYZ(7#M^5UO9B>HUB8*OUM#13SN"5M''H5;UR*XH^$E1VQSO9?66Z D
M.ZO7V1X=W/#F<5NYFSO+=LUTBC97)/&'@)J"6G:"=41VVZ!7S.R(*^8"4G"P
M44J=WL,KU#-OAJ8+JJ:YB&UF$E<V9NG4)*D> %JC4:RF;*;P_11!)U]+?F[N
M=NFNXRDOL?2NS8M?+4OG!-.4VD<<D+$'3?F\_"IS) 6_F8'.$_!Y[\AA.[*+
M#6>F)MZXSDD);1%_E<I</H%8=UC#@9$-M>"[HU+.(^XL"J\8WJ0J0FF*JN7J
M6NZ'Q#U,'P#26H+MK.E]65TD/ 9.:3/-#P!4ZR1AEI0S;<0:._?1,S;7OB32
M(DE?[+1W$"%/>,VL1T(>=NL*BIAF50-O7:'J*Y\9<K(H$;'#8M=.8Z% MU[>
M3: ?1X?W+;^>CM],6PYUDW^JEPT.2 _"U!)%:4>F)7ZJQ==%SEF&!)_XZX59
MZ'?Q15::_+@_+,>*:,J KM>,ZR :S[1K"ZIALU<%;]^$9'R"MR $?2.CK$N\
MWQB3T35+5:U)-J[DGA14SLON79%*@X4M@PWN\%=VY,/==55&C)59:\>2R1ZR
MGT6;(N"J)3ZBI$Z-1=6F"$KD0PR$0>0E "_ZD9VPD"]H'8@5<+)9U[]$9W A
M,0>@SUW:(GW'W#<(4WYM8N7@XN3RI!13R5EM[*4D;AZ%$1Y5XI<U\T!><@RF
M+E^I]NA%\?MI4  :$NR[*'>'1+%3!ZHMD1Y@!N+@<K4;.?)5Q)CDK*N/'=_Y
MBVG.9@;+HTG/./C8SU*KK2&F:YB!8LN/!NX=6UN/;WX@A@^1-^;@[FC)H@Y;
MGB.DWES)RT)#^-[Y(_>'9H0*TYN1IMGL]F!NMYYIE4AGY31H0^]^>)^!(YIU
MURXDO&2C%5_= >T9/['/0%YZ7B)>\JFMB:9C*'#G*>NP(X+39+,U'=S0QO'.
M!SO.$>9)8GH3<?X(Z=DHF^V^'3T\(/Y'[OD(YQ4#W:!>R9?PQWWO[3B9V(GM
M7NYR/<_561@4OZB"]$,M4%Q(D@740*_%Y3#Z/L,)ETL O#[>8\TJO?].%<=%
M6'I4^[X6-Q'YT"3HU0%%HZG5);T\H!'>R,S9B9J,;#:[8>)L9V(XLF!_RAK+
MVMRR;@0GBL'TV>+E/?0U+.+R6ES$60H=+(.5@8\K2,Z+:3E<7C6!L5T_-Z8_
M)?%_^,? _[_' )3T/B]_ETDXP9C%?@A>J\UDK@VPD^;VD@TDW0.P4='+FN-J
MU7P3(S]%5565P<!;]MV\*5P[D>/%6ERQ_^Z':V2:NLV@>NKU.@.>^KH(73M?
MO]0W]2W<Z*2E[/*T\8-8X5'J<F]CCYXZ2\G'#P#V+4M?0*/#&9E8\+:ML(ZD
M(I V:E)DTN.?]WTLUK.#N"1LMJOH*.\EXA/)[E7J=]H2D0OJ)<$(ME@XT6;U
M"9YEH;AJ$H-]Q:8.;YD*]W1TY9A&JIYK%52FRUYG.D'8BU>T=[;72##0;-S.
MW[N.H*W<J#<2QE(>1<]*0Z0<FDJ0ERE,,AN'E!' N'%6&WYDYZ6)*P?5*T.,
M&#GB>RNF1DF2JC"2R@7/*SP+L7MU2*H@$KC3DP/NDZ7TN+FCND/Q0\ZB;P++
M.VCAVA4MX;PCOLRTR*!%@J\]YMPK=J&[4P;RJ,Z<72:]S4& LB\D6WX'<=$<
M<@Z;0D^_1C!-]V]8&C%PY4ZP6LE@.GY#FZ4(7'7-X! EGM9@FHLXL^%.H&E,
MR(W>.<CG!><E0/2#!K.+05OT Q TOE%6:^(88D]_R.3*[G?]M0R$1HUPB+:[
M> M'/Z8,$*Z#!8@A]LT19EQ%SVPL^K6-1XI^C=-BJL ^@XO0]!N<9',S5)QB
M(QY>51G$HFLOL"DT.O1'J;?U"E]CXCHX^P$@E60**J1),%VLC#BD6#N61$/'
M@6F6<+XD$Y[ Z_WA(T/;"(),ZC:,ZPR7.'X(E+=_@];(<,J\!C,F&RD/!;<.
M+J^LC#QK_>CNGH2"'L^322RO9V>DYK"D!O^4W6LSH1]15\+E<%,?AO%M,P_H
M(.4K&(O-ABUU3%FKUWBQ5?>IXM-@SSZ5I = Y]ML4F'(.3-MHD"R 4%.Q*C5
M"^;0=P@TKS:MWJ05]A$^QACWB.VS[]AEX U/.\8,PIKF*!HN)'-UHP.=5SE%
M:R8DF+$!+PM*]LCH:J"*J?DZ>T2\(2H<-7;,J0R<#$3A@#A>5$6G-);)0(&G
M# DS+6_M+)Z-Y-5NT;ZIR5A!24H9W>R7]'B/H:T6J&U*++DY0,C[+")%*7JC
M(5Z]<9J&%?+:W]:.:4JAX70YW#]?DI?6.NLE(B<,9$++^:I=/*)S]%A?CM$C
MK!OY24W5X")'^Z5T7N\DZP*<U=I:FH9?9LQ9"5A)(_2[' .*%G/BF105]0 %
MM=TUJ]+R4QB: 0&QCBRTJHC12;>A9_9\D%X9F?KXP12^+! AE=WGB@'*$C0"
MLK3MQCN&7HZAC0 L+6L;NV>)Z8V'ID",X;CBY,BMM,-3JF^(*UEHO1$G^P'O
M=:93)..$<[@C<Q2\BO1TE+B6;(WKM38ME,42A(U%WYR:T.;9M4=:U$V=W=3,
M<3+IH$1I"/"5V>;0XT@K5YM>C_*@PH$<8797 @6L&5"Z?I1]+I,1_KS5@P"\
MU4*0Q%9L/YT_#9.\Q^V5[J"VP GI]8:9296_L?'+8WY2\@#(&?B:VY?-F>J.
M(!0DF :3 EC);H1NZC\![Z3;VQ/1F=_PF55]^I[DI!^W+N*Y@/B<79+=<SLW
M -\RL@"R IZNZG.CDD!U7)1C'-Y/'_KZ,NF)>UIPBTF:,L)7W#'(U5S7Y:16
M7OI!$I-?P^(UWN1 Z^M/0VGTD*!P%!*ZM1UXHN?0]G<[^$]83!>>U"292]8F
MJ$J;W'PGQNTN9N=[M2S)/XXH)N$\!L7N0JKB,%B"(7GE_@ 0;>@/W<$VL6!S
MNJ_P;>7;TLBH+18*];;I$,IFFCECQ>9O1M2D#5VXE:H480'_](E;9-P3++DV
M/L1%U.F)*LB@6;4(*2#68!5[F#&K,\P8XF2E;1OEZX#_4\N=A;.A8'$ 1V(O
M&C6MM:Y*PJW@4K&KJJJH08NVEMJO)27:<&VE7$8M*2F*J*(&N:B=( B:A :5
M5$M006T5Q+Y+.^YEGF;>YF7.]_U?S\OYOO.=\_*;B5OC1:-0U>EJ:ZNMNDTU
M1*6;BQ[9. MOWG$G#,]&0*TAC7:OM$>VZ]5;1,9SUS[43)91U"UO1*GO#ICL
M")E\-GE?GP9][3^?=I@T;$E,UY!=6>$JH0//D)6<P!-O62_Y.[2 JLHF0GV"
M_A:A0X?SU";6M"UN]1*A12_D"FL@OEAFL.&;97[!TX5)@XNE/ZM@=80P43B]
MR]("X'$&,&#PKAMC\)*DN$Q].3#A6K$XYC]%T_]CQ,._6S-1QN;0YI*:@K4P
M/M>I";?!H:H@V!TF4SY!KUZM%0CJHQF$3XN/W'<<AKM6545IQC4KWNF><%*=
M"AJJ1J.SI()D@OR!6X7-K).#_?$QS\A\M#5Q(2DP15-SDI*?MN\U1\0-"M)3
M(Y+<JG+(#B^7Q!Z5)]ZS2[:/=+'$C']$@C7V65] 7\&9BUI^<GE[06^"MD9.
M/1S\K$*$.X&I,B+^&A47ZB.6IN4ZL'V#SVKQ2E.VO;8MW[-Y!=O(96/KL@<K
M&<@=9QW3P.$-^VU5MG?#@*-VCA]/SD"'Y\Q)G;HGY+K$YJKH*AL_Q=6C,#A3
MI3N?R?XM4=AK.QP6+_HK3SG$P&#&L4MZ,[:\=,7%C;FP_V+?"2[T;=NY#;E^
M8\ 1-*1*[I_A[M5.8WCF2,A9,?.>^WHASO2@!-3Y>3L/@SQO*W!JO+[@-XI\
M4:<^7+=N5J[0P6%+C/9&RJH"N;_IJJ\2X]#SV;!-^CU &]2_%%A7\KN^T0;0
M@^Y5PLCJA>+]83M3E]SI 2^-CY"Z]+/3Q5I'D::J9$"S\P_12EJ9,]4750Z9
M,S,D;#Z,R/U,!M<^R,F[$(53@7C(^$Z]#W]Q\[1?MP#GW,-&1G"-BE6=#JM-
M)1-C!&_2?+7-_U.P"()=20/DLW>/%$@6LQOBX^[( RTDMW.J?_O5,5-R[0TT
M ",!$\C0L%+:+O.4W1LX>2-68P!U\ &;RFDS6+EU>WU^>#>1&.5R.R];6."L
MKZV/NZ#W$U'0H9R3YYA]OR<.;?&'#JBZ=HO0DJZDE%>LY*1/YLF((K_[6'(R
M2^.K("9D5#WL>1MLOAWE\_WZHE"9'V+(54>DHM<L-+TL2RKDJ4&"AR#GT_L&
M<ICHM8G"O<G1Y3B3BDQH!N%7DCGZLO# T^$BDLC&4K&X"GE:8L38),P+,C):
MFSN!J+]JK0>#^@/Y!.40W(L&'-?\W!?HJ+E""8?TN;-.ZN]RG II@W<!CZ37
M&(B:MZH S(BQ8H4;=0Z,#;P=IF[/V%<8_'KYAN>DW+>9X^6&-*RE[</"C7BX
M3&BH_%!GCPN=_@.MOCI*0>#M._[>D+Y$-9@YB_Y'1N2NK"H@<?B'\MNEK.6)
MW#<"A9!=ZS %>C4N-&7<EJ/D=255H4#[3%9I^%RL>W9KD<R63B/G'#7:5V$4
MC_2K,SYGS2M)66C7 &@KEX)(6KZ[M2O_QJZ!]&!N Q.<J]/9AIV#-S)K6_\)
M@OFZ/ZCJGF)8L4T$^.V978H>#R6TL"M30&Z'C<:BG[93OQ3Z TB?L;A-YF %
M;)XH2/%2^F?=@D>/&<=]R -)5N"%B&/',0E)0NC-)8%9.:^D'T5"\S4N8SIB
M#KTM]\ZW,PKQ%F(M>+'!##QK$MR@BGJW"&:#'YL!_:&G0'G1YG%RQ"R'TZ$6
M'D^Z^B=/%R&E0=*ES53G%I'\_#"^3RV+J P,:0_/J>3@II6',UR@V=/*SNR"
MONDG>8G:*$<685VU%.WUNYT@9K==%9"<3)'%_Y%9?J0]856QS.U\7RKU2!EF
M7UVGV4<GY!A!5J1FL//Y],[&EY0(0_>FZ#B\>9SZVD*C9801.2!F4]C,-#>\
M,66,/_L1==/HR5TI7K:'Q&\FYJM<VU:CG@INV$BD4%\OOGTGDP*BY+"![$S'
MV<.XN9_-._>FJL?4R]R1&\;MSWH6G2%W61H*:.F!@I(T\9[=BZ46/.@+Q^(C
MP27,3]!F@1VJ59EEV^O4Y-<[BKCUV*THSAAFE$F0J_J7T?56#,)\W)WUX)8;
M5L;G._FQP=57M%DW,2E>JO/AE3NMC9N[FB:U:[KK^U$I?E38!WTW4HAE?AO#
M4-Z_*^R .N7"H1K>R\>=OQYH)V&'[W/^BLP9_4DZICOBP%]%9IE6?LJ!\8\E
MPK^LPS_\PGW\>2^:"(TBL<]14C+5>#I^Z261)/)0G(_7EDB@"LBN-JF%#B(Q
M96\W-M8GK1WP=6MJ%)_!"JKD;P042^@3-W7;*@*2*"LVNM#&(?9GF(N,?&H:
MYODB0D0"QBL94]6]<3&2;=[C_C?FGFB>WW!L/__ EQI"Q-:T'<JD3=! B=<U
M43#C!0%0%.N#/5E_"9.3BQ9$Q'XEGYZS,%+@4Q8U0"2TB-?8DUT@O/3?1O?_
M$M,_O_P%4$L#!!0    ( -(T:E3"]V@JKJ(  &BR   8    :6UR>"TR,#(Q
M,3(S,7@Q,&LP,C4N:G!G[+EE5%S;M@:X">[N'B X!'<+P8.[)P&"!0NNA22X
M$R! @CL4!"=H< ONA4O0 %6X%LUY][Z^[YSW;L[K'OVC1X_>->:OO6JN->W[
MYMSK?NY^%<!3EE>2!Q > 0#"PP^X7P!D 304%%049#145%1T=#0,+")L+$Q,
M+'("0EPB:@I:&FH**BHZ1BYFNL<<#%14+$*L'$]Y^/GY:9E%)(1YQ;GX^'G_
M4(* CHZ.A8E%AHU-QDM/1<_[?_FY_P[@HR$(/)I"1'@,/,)'0,1'N.\&:!_.
MB8SP'P_PSP?A$2(2,@HJ&CH&YL.".CS@$0(BXB,D1&1D)*2'M_X/[P$D?&0"
M>AX9%$+-5ZB/78AX@Q)RT!B>5740:XU#&?E>OPM&QR A)2.G8'K"S,+*QB\@
M*"0L(BK[7$Y>05%)65M'5T_?P-#(PM+JC;6-K9VKF[N'IY>W3\C[#Z%AX1&1
MB4D?DU-2/Z6EY^;E%Q06%9>45M?4UM4W-'YKZNSJ[NGMZQ\8G)B<FIZ9G9N'
MK*UO;/[<VM[9W8,=GYR>G5]<7EW_81<"@(CPG\__:!?^@UV/D) 0D5#_L OA
MD><?"_"1D.EY4 AD-%%?N1 ^Y@U"(WJ6D%/5@<[ IP4E?OUN'(.$D7^-"?:'
M:?]AV?_.L.#_6Y;]GX;]RRX(@(6(\! \1'Q "KB0T-<*4YRT:FLTI&"I:I1'
M<%2DLHPSVFI?L]RY!TX._.^!@,E[(!),2P7JSP+= V_O@=/7L[&S1<&=DV#5
M0=-1!MKHLF>ET8(-5YEY]P FL\(]D&5_='.>=:M+"ZUV UV=M]T#[;;W0(]^
MJJ8I:/Y4C?;@A8+[!<W?KU8X]\>#3W5[FKOL2?WYI>9?_NMB1!+C5+*;WOIC
ME*WU(XWE*S3@,\\V0Q'B1)+<^,$9)[-!4]I/0XX< GF\0'3ZIDU?7.6!M:>#
M%VTIMZIY,3V#,_4-MS@+<!*UN'M <G;EXD#JLE3J+RZH()CM$AT^B&AI^)JP
MVD%?C?!2@NASUG=7S=TFG)*R".R8/&4&X7<&+*B3C+%V;44?9DU;!J[/^>0<
MSL>.[H&_*,O[\UZ;IU*8 C/M@FEEC.<'5"@F#%B9\B(=2.]\M-K?.Y)VNNSM
M46]9;/'[?F23#?9TWSR]O=81ER06$UJH=)6+[&T\85HILBB[!SXD/3AUM.[B
M[D8=SA9W:2@J=7MC#EJIO0?6R[[,B&-[$Z\7)CA)=-,H-[=4A&PQ0D6M Z5$
MMZTGG,#E#&WIBP4MB633$>2+O&@,(J@A4QY%6%PD=KMPQJE>"];Z_';$\;_Z
MY"]FG&0L\9ZH&6 O2NIG!BMVO%0RUT+HO[7W[;K&B?/-7MSSJ9O^@=\AE&+$
M88'$)0Q1URL2?T+!LS5=21<J1"KRSB8K,^ROD?UK5O"478(43)'K'$C@MFN1
MYFR:O!N,&T6#HI8>1P>&%Y*$LQRKWMM5K!1XZ"=XQXH @*/.B,-F$=HYX'$V
MYMJS\?B@W91X?.$>Z!P8OP>V(3?PNZ)[@%CAEN,++=R_LOT( H+I=BU=ZAM7
MU=B71:$H:EA]$JU"G ITU5J\](=PTG,X.,8,G\K!^!,.W@%23W 1DRZ^^FA?
M5Y#FW<J=_7C38![6_^OOHKU6X<<)GI\?\)0(R>?9]G74DL?A"W2- ZGYZ$F8
M.!MXVU,'6*H_[9%58O>+T_Q]5(>*2^&CN0KGA0Q--W$663T0/PKB^HJQQ0S?
M""R;''TONJ^;CGW0S+.,O[C5M2GU-HF:%MZ6=35@\L%* 5G9=B7/9KGME1$.
MJ[O2W<[9$GLOQ+&R1,[""1DRQ.61AO\,BKZ-Y<]>4$D#E;J-):$]?S!,KLX7
MVWG#IC=&CNQ< @O9>S;_I\017$:.2)]^47O:G<4M1M!X_T-";A3E^Y<DFT&]
MBF<5]G]VQ3BL[S;BXAXX'[T'Y#F]#GR\.#A%IQ8+%H]Y+@=KV8J[[$%I?U?\
MWN[$LW=9S]?^=U#A[4X$LA['_7\>@_Z_KEAO^\.IL'O9[H?%..+/^.1,"6A(
M/EB?;[(Z"[TXQ!]O'IJ*=Q%J*?/4S4-^7UW==A1XD[<Z33K16Z1IQ+3?Y!E0
M]T<D<RO,+R6A^ZDS1L\)3&3?:I D/L<2HG-TC?.)*WOEUKQD[JH.WA"HGE]P
M;)\0;?]3$13_I42^?:'M2!H <Z;4$-4/0FLC?BJ^_XPG9CU3S>TG5K9[SN[M
M:<&H(2CY6H9!@A=A$"Y\FO/J:X5)"9R>PTR09\L>NC!U!/J; E8(%<@KNFN_
MD32O.5CZ'#-WMO!EI4C-1_L>J'K>1EO='+R\L[BX>(7Q W;U0FT5(%]\P(D^
M(Y!.Y\7Q8G),K\>N?^S*W[ -FSGJ/K3[N"V#7F>_+CEN%6'@EJTB;^U.7PF?
M<D$H6MDC!XN2>?(G<Y8="2'&4M+M,X/%M[J+#L=B]\!OO=.H4HFU+ZCW^'R]
M\WD(D-+/)',&; 8P1+[STC?RI??BN ?&H\T\/UE)"UJ(;%YKGKW@K 1U2S;'
MM'X#(7[[/1C%3;6(QY4:&=F\]LUQL:N!GP#12:,R08&BUS<S'D4Y>T:2HPV0
M6GKXOB,6;KT, [\">FAR<UOJ%'-,3^\!F-38]B(SY&^RD'A-E6+%=!HRL?M3
ML?O%57C@.[0SU)EZ"^AHF(!-893L=%'B&:%/?A="ZS?=VS[EB#7H6"K[BXE,
M=E(M\7%[\]:,K-^7A/.Q+8:XB+TO==W:M_2-@45ELH4CYU*<NT6</&K_$FYQ
M3K#M>8R[Z\L!C+LM''!<,5*"WM=/II67:2V.O+,JHQ9_XZ'W-="1&I"EXT$Y
MHY=(E^6CN5.D33@QR9?LO?2JCX9&XIF:78G/ OUYNUT/U/>\3-T7?IB;]8K9
MMD%H@O[&,8CW !H<?%=REW'.*CG;X/$CVN%LQ"7.[T;;G1I59\*(Q]<&=E6$
M)H.%?CJ8-%I'J]TE9 ^G@UUV9]C+;?J@_M<*U0']N7Q-F&9#W3/8\7U=7CV6
M"52Q),B^#GPGA=]C.1F+BLMI4?E#ZX>+AD=*%L/4WY3-\1Y;>\U.PEU)^&';
MQM\O9GE@-EK(I]C]0PF%WQ=+)5=NW*]K^O_/* 9SVO=  D)\ZE,U%EMBR.+)
MDA4[&#U?[9J)F(*ZG:[(']\#E;KWP%AZ=0I&8@G9J><=]MHG/;<"H::&#=?<
MOZ1@[:DZR9S];*6]/?:@J+SE$UV-IVC4GZXC84V_ BA!_3TN]X!9S#V04\!V
MR:91N-D@$_J#7:>,3.6-3PR1IIG($=4]$"NUJ=Y^#]2#KGGL^^P76A0*A\MV
MA 0%#RB&N)8*GSV#?C\)]&</?MC8H1PT.AQW=PN"/VE]B^SCMEO'[ #JA_%Q
M2!C5:;]W!%_7Q.8VTU[J0?IN;^?N@96^AZJP^?/_F@,:%*[BI/8,XC:MJ>4\
MI*#@NKBKJZJ'1'_P9_=#8F(L&#S400;MS>4]<*M*:YQWVW'&H7#, T=N\N44
M,V^*9DVD=$^0=6-$%9^)28UP$I==&_8R[7GD3;+"_3'?FK[F<]*N(>AOU+X;
M7BMB%F+R=$J.';0G1F-A$6._/7(M^)#;$J4X];9VQY&AH>%[H^\&Q@)>2QD+
MZN[8#<SPV@_?CL(QS]O*"?MGUPI?AB%71G\<\U&R,);P*)W+9"$[.YRX_F%'
M*4&I"]@#3*=+K1G;TYZ<6-P#(-I[(*)8.1)2M T')<=0=@N!N8?JF@,\11-&
MNY%=@F,*K Q]:+/JWFU!'&37/F+:Y<K:OSO^@8A0)?U.:73*939=_;=.+97L
M%:R3*VC'O ?2^,Y/6G=;G69;V_LA4YN@2X-K-B>',D<T\E7K )!H92&'Z$A.
MY67 SZ^A5Q4,U^B2+R7$ M[4@/Y\5O P9>=U9I2U4 +*Y]EC=KIF(0*_4I=;
M,1Y(KN/'5S8CAP,!0M^<8VS53CXD.;0UEQEL^!D6QZAT>VHQ7Q?')='>E/7M
MO0-1[-VBGZ]<RE6":N"CYY6UMUDV(R-1GS<RT\HK?VM/?8DH07Y)"9CCE7+F
M$^(O^BA'H.X%V.O%A@_,HON&407)JL5U;X!,A+6FSR2W[%(]ST3:Z&QABXO\
M3S_$702='UQ%K)YOM^K\66G<G[>T8[TA PWUS,*J"G3#O]P#'M<!I"M'HKYE
M2IRU1WARY\*OY!M<":\*#8L0U PC&#?B 0F14KU[ ':S6GE]GO30'H-?/[1"
M]3-2VUM]<+C4/4"H<,ON8 $/> LZVGA8)\"J65]'>@I>+&([V%6Z!]3NHM+]
MXIA&8Z)JA ZW]EPGO6CC*S#^IER:6&=R4%9$9U:"JX;T0A_GJB3L@GH6-XHK
M^GZ?;. _RBPZH" <+B^D=0\D6CQ QNP#^(BPQU>J-4-C<Z1"ROD_I,^9&/^8
M$"-Q>$^P'=(@U2VF1_IG$V*P5%F*O-U!:6T,Z$9J@G%R5^1PU'L@H;,+#@'M
MU%>^JL#LRD2?JHWQ@5RO^\I'<BZ\=^SYIB4\&&=T9#_:-Q6C'-&SHGXB\:+^
MXZZ6G=W(/9"+P9+;&">]??L 3(\?$/&NYJ$EB3(3,YM>+Z/\HM+EZ9&2<)4T
M4&-WB"CLSIS4)VT_W+Z&"B.]0VP_%@?=ZOJ2^QL\2])*-'HXQ=J;CW9JU<Y1
M/FYF;[>+*\+@>"!\T-A#B\30]P_R1Y,*;]^A?EBY\0<]-^\3M:?Y[YP$@,VO
M:!='?")W0/]5,RTTY#(*'K1R12/UP.SE6G"KB^SK.M FR%5DCSWG'GA/VVU^
MBG,/]#_X^P\6Q5WGOD8%;7H]>+]4LDKE*G4Y9&_Z8:^['W]_EN+K'NXM<Q_<
M,GVXP@5?9FX3[:7,K=P]('UT&T?['STU'?R!!K(]X0IQ?U#1/TXN^?^Z@U=<
M*/GS=<%Q]:=S4M0/%!C[2+$TW+898N] D5\?YN1_=\CJ,E%= C5;;FT?O$JE
M;VP.S1[6"F5W&2:FA&9?]=&))XS[*U!6A:*MDU;N@6?$EC;H)9<G6NV-JE C
MLLANM+N-*SOI:]R %M]9YK\>[R_6ZH8Q\8,IRMZTJ:Y\&Q_5;1Z,\BF\6&+W
M$#U@=0^##9G:S<"E4R R2 &OO^I@M3BK5^X;^'#TJB/N)RZ^T7#$7Q02B_W)
M#"M?^6UT"O-4KF;5N[:811]8_M#4\\0LS%N\Y"Y?H,R>TION1HKB?>I/0B<W
M%@2XJ?\^RGSR+?O:Q?,Y<'D)^N<#RI7(CM]'Z--D;G)K[LV=W^U@LMVQY[GZ
MX9$3-_<ELX4M?SLTW2OJ(N;8F&O9YY4\SU762'6Y=>A"QS)MYC:-CD\VA[H<
M>0 (IR[L;[RD,RTJYBLWV2#GN.YN?_1KQ>S.R+\E=DC;JLK4[!ZXX5TT7I2M
M71PH%N22,7M4B#;Z:G)N_5LE23/HI9<MK\==/)7O@7+!W^VQVQM-$3!NN_W3
M\9>NM5F^B7^&_O%)NZ72&F79^6RFP9/ZE'7%2%XSQ94VD^C2S !'%#[]6]TB
M.=OL!<4!KB^L'P\F56>_T(@,%?_ROG8US/I3SO\Y/$9"2E/:VBK79W=8N65L
M:AF%*T-PU#V32_>'G&9_@,'F>T  [$#8I76I=JAJKMM29_ Z(CA\+K'[?!.W
M7U_L[U)*0.+S)J0XT?< ;C5Q_C5:.W\ARL$)+C_P932XUO=](IDE?/J$^"?S
MZ\_]\BX+ GDE<^+G%,G+>6B3C$^#9U-2W_=X>,0CJ,MF;C#/SB;_/O:I%/I-
MQ0UW_LK:8'M1U9W4-<>5Y%:UB;D>7_O<%4/;<1-P+>!]X//*^ T&+[FTR&U<
M.[&L>B2GVI!N<TU#Z/'/2A5*^28G>E&_GUXX..@#5!O49>F_WS%9+1&2>W-[
MM')<I0:VMI\ >2;_T:;</3/.AX%KZ[DM>TTE=!A_/7O1/,#V_A'?]QZMMKK:
MB=X$3[?$W04GHB\B%2T[4Y9)=-15\?[L7WZ_EQU1<KM7>^6G JV:YG/UZX;4
M/0^C#,[(O8M[8#YE?7F=NG!+5:;J'0:4^*F\+TYF'_'/Y+$'QOVO*J3^*\38
MRTSD9[5EC<(Q>;K9SM(#ABM308E_#X$K_P#7K?\?Z_\&Z]O7A6ZC$T"SI??
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M<N;$'CDW^+Z;?X;P5E!I1%H\6C]WWXSLTQZJ"?1TUZ(\VCLGZ-A)!X14*J5
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M7R3&B)(:@AW4^_^+%/Y?@\N'+$'X9P_Q?>5N@GD*E">];@T41;N/LX__EYH
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MMUR3Z#7BC?8:K_MI1:\@&Z4V;]+9)"OA6U<^0=7-6MFI*T>#%)CS <EQY@=
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MR8/288<F+5]E (E(V?U(L&K]GR2*3:ZG+N"A)QI;"J[B7_'3E]T^F\6- ->
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MF^5RX*6&T/1%RW[F&U<VF 8Z2;OHA=67Z1K^K%9Y![V'"=LMWDMR+^_UD%Z
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M\2P.PX[^9QH%0<H;BB".=3;_PVMXY&)>(-<?0"WW+ N27CE+P5O0FUIF EX
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M/OTE3N>=<0+,M6,G@80N#^)?<AXBP[^CW4958V8&'C7:=AM(4L'T:TBM>3U
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M.>=/[INY<^^\F7O?S/>]><VJM4YW[UV[JG;5KZJZ&^@4= G DI>6DP9@8 $
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MQX"J(<'V6\S((#4#$[:#8R4L\C4_T:8 S[ 'NX>?E.M]]47CI\A>PB!J^J2
MC=7>53/':N'S_5!@Q^+O@["P4;E=\&T\YZSLH<AN6)>Y39#<%Z] <J3:[Y?Y
ME*:3YTWVYH(\T5 @T5H&W6'UOM:+?I@3-).&Y!'<CCTSI[-UP?>-KLB;LSUM
M>09?@.Y9L[AC*DJ'C.?7N>V+5P93UH(A#8%H ?N:B%I9WP<F)+\CC8L_*0:C
M;C-EB:;8VUY83+<WF=#CA,!TQWK^8,84$+CLUTB4&&=+MU94T+?<TWHCNURE
ME1GO7<!/'[!HH0-,CMH3JCRDQ_A'+'T,[!H[<$_YQ5)TLM.9+7)#\?&,U-
MAC% 10KO]Z1>LEQ;4Q;#)-1<IC0URY= ,]L]V.,A0$P9_@8*&'LD0H*:[W)D
M(-PPP\-ZFQ=\(: M:RC0XP):E?GMB3@Y.?X Z#?#?_L;9DB16^.H8;0[^GD
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MWG(RBOIWT6#$PDF.Y5D/6Q_U%8^BY8BG[55K-%9XH#SR0)<S0(/NZPKF'A3
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MW$_"7D>I.XB^<1SP*/J0J ;N([2V1#-[\LXH&NR<NA9/!#>:VC2>(:7[V51
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MD^2@<.CM(^J\.XDR\G1'U)9-ANT6"8Y\L\S&P^NI"J,6E8IW8E6OS1@&N*#
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MCC6\$N3P<5;GS:'//(RYDG%O*@Q6;^\ 2Y?KQ\%&IM\OU?>4(_V 'H%=9P2
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M:*C:YNJ$D(E9$ GHE%0-:299I-AO1T"KR&2H(/KB%(M]4S6S# &8K8OO?48
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MF:V)@)Q&]HY+(-U>E-T%Z8;@ 77Y/+-\E!XT?A\\_;D+K(F&)Q'NGPBJSF;
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MG4;ZP3HC%&#_*U*D!^]B!*4VS9FA &V+8VC9Z8S/TUJ/\Z,>Y7E'*DB3U<)
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M:"XE3@"DA 9N.Z, #\?S_;D%Q<DEY-;<R0JTZ1E;1MJY$60F"8FHA&L<5Z&
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M7\KB,8<:?',:,X\&C//*N8?(\LDQRGFF:K\CM4WC0I=A>$*9!WH&:6E_X:0
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MX]\V#%WSX'*:(\7ATS59>?SJ588Z[4Q[XF@X)3@^1P9>ALRC\\#BIM=PJ(Z
ML_V[+,H1-$6O;T"[; L3_!($7J, AWCEZ9<G.:4]B;'U0@'M&_4%\AV].J%S
M0XB;-2427Y&LGZKU>L?X#>,:-T"1@^^3/I]4A+@Z>Q9,--L0. H*5\\#*E<.
M]G 8!UF6K<3D'46"S U]Q:9:*C"Y1A]60$K?W>\62/?W=^'<17!-[9X1-J*
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M]\[,.6?.O'=FOOM[WYU?_;%9N]>JJE7UU+,DL&G8,H C)R4K!2 \   $^#\
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M!"_B/E>TH]%RJQX1&CN-/"*BXUFA/_YEVE\L^]<,"_B/+/N;87^W:Q; 0$2
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MY*^=1+HMY^:E7>TICKY:K"OW2SM8Y94WAT9G[-%GAS/+_TND(. 2*LP.VDL
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M'>V9&4,W8[-Y(BB%*LCC,+K:>\AP5;2^-C17MYMBC)L# >?E1U&XCPPZP=#
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M]2W35P-7+G% 7<OU)A,*T>ZT"[^]L:AC^F97HKP&"J4)JGKH\@\[/[_$Q-J
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M$5Z)4D]WSZA^%RF2H/?]WA&R\I(6LIFY,*"X&<Z<O[>=,?\LN6>\U]^Z?Z<
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M&9J0LS,ID^+AHI,SB>"E:,TVCXH8:C\)CACUD?BAPDG.$ZGN#J."7J4\T7#
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MJ6>X9Q>E]E=:E>"?@N##0QB@T[QI>$W"!MZ;-;Q'8[ZG#\Z;ML=_K:#X?QP
MK)XWG5DR<>"M^-'#%9-K<?]+)]?#N?354CA2MZWKPJ=\+[14Y^1+*4/<;OOB
MTR "==)S[^>6J4]-F??&;1GB(Y)#Z9FZ#12[=UGX;[V58$!&*0SP(0/55<.
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M=1\^\R=)OI4^OS'XHU%M0J @!Q&*+X(/]5H$+[>NP4TIG<[5SI9]_5Q? B,
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MR)Y.ZG>\@NP2;V".N^RHO^X02LY.'9"VM#2]Q+/"+1W@+AD+HS,*7S/'C:;
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M. B=A0S4EH#:P@[[YK] IC+W+GI!:8&LJ\HQ.$QI[S&(5<3_E+0'H\"J%1I
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M3: 355)F/!_-Z?]/(H2_HD?#"&!A '2V30;W8[G\_HHYQ>2,*>WM']ZM,E(
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M7+,&NKN29_.]6J64IOF<1Y$/[JV!QQ& 9:C)Y/,VG[(D'H-, XE=XY:8,X*
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M4E)T4Y?FJABQE797&LL+:?I3TR$F;Y[@BD^]J!'E-'@X"3H=!/$&O%_4IF!
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M9EK_N3].O;68>9^V5*!:=&\_M5-J3*_)<A#?!_8@XH[Q"PJ6+('+Z'U&;;&
M)N,'9 7>B<&%3<60PG0/OLY=IB(G&NW#9\8S*^_>K$X^F+QH*7#!_MA45H$-
MX]I]\5!3GXH6"\2_'$.]?Z<VX":0"FUS\8W=[<EM?4^\4HPA"\*:XK^O[5A2
MH1#8K"0%=AI5U0?\>9X]+>5?$BP+<0W8RDW%DG9Z<6F^)8$(=QY_*=+=,?U)
M1Q^#U\;Z.U6XVX,B)DG(XEYLG/%SN70I_C:L#SH&>WWVHPIH=#DG7%,,WM;W
MZ/<^&_A[F^OLRNAO3.-9B@UE?AFU)_FFSYXY?+5([;V24RE@<*"+B0OJ:9OO
M,2$7_,SN7BL8$V?,;NLCE$<QGBL^#YDL[NM!K(/3>*@)241='>0'0M\#C%7I
M'OSN=*W4+\<^C(X\9V#DS-8W1_1-1$Q>?()@XL.%I;8J=[CKRBVBJ-S .6.^
M+L/I'FRLA^@%12\TTQM"!$VGR$WBR7J_2J*2"&&AF=T$*[[;V]OP9XT!?,8J
MVK&]@H$H5^L#%$5V7 IHPMDG-HL3:B''B'VB9W?W6LNT_?K'J7=($Y-1[+C^
MBZZK*(YS+128*D^6,_C'F#+5^:[<S'58KDJ[ RGZEN8YLB@1DE-V&E81UB$2
M4:)%AIWS,N]&&ONK!F%>SZVV'F&\E5["NKNQ<3H!>0[8J(E@0(056<BWGRQB
M?6&+H&71H=?Q;C)9$_4I_'X"5:BM:^0Y"U+0ULO5Q&W5'-5'0Z.NL/NL@$;B
M.F\4OY)5V2AM6R;.CM.=S]Z"P7^V[*H:)_3$$8P#OP;,6*>JXM[-6J#[8SOP
MG_JNZ,KA@KIXO?06XA<1EW++5>A,7[[B-W>AW@<E?P0EFP;/*Q[7Q<CZ(7-P
M<B"A$T@T8V%MZH>^V+SIF!G9_7FG,E891F,,D+3EJ2D]H1IY+')H1U*^D\B
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MT='0'V-@/&9]2O*4]?_X@GX%8#^ SX"/0(![!H#'AD/ AH.V \AA.)'@[B_
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MMOP@[6&D,[DTS8Y@-"S=_.'A#Y2G>>24U0$/$8+-OJ_NQD2HO)N&23?2WQ,
MDT<K8.N#4%8JXI^*@X=/4S$EEC"V6S)$S7&M/&KA36<:W\Y,4X4%C,^S^,N
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M] SG":($9,)CA>VUG0,\#O& \?3XXL*T:)^<--CKKSU<^/S1W!;GH+0[920
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M*IE?QP2FG1>\FJA@R]>2IO"'.WJ9^+A[.WYU]?P+6C_MB".IJ'Q%R >/3P%
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M!]'(BD)!(#D:K[M1'==JQ-P:?X1>)J(@S&]*5H'9%5+45W*-.NU?2K7]<E*
M@&/K'59Y5?6^20(Z7;+2C$\[YN.(GD)&A!;<L$ '5Q=U9:G,2'%DSGE<:A\,
M(XU)3_$A]N6T:5%]@3KX\-GZ'_[LJ&V>>CGF@F3[@A7QZ!<$2C2URN&<WQL,
M*YD#*N7PU,^M.S'XVE3WS R0M$&77]U++\>_!^V?TH-0=,V)_.:MQBX6^#,2
MN=YZT5/+59U_7$Q@W@FBU^+K->KV<;86.CN^5(+7 YA=SH4%<VCU;K.75]4K
MKM',/B*GJ'3WLFMZL%_T\X,-!X;N9C$'7Q?S<Y*RG)+B[UG!-/_FUQY/@9^
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M4"@;WAJ_U75;<Z(,:RS>)7BNO3VX8CN0II2M=\ETQ2!E1[\HE)'=8DX9PIG
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M@U:1SR,3M\HBGXW_IZU'2T]& (OLGUL6&52+Q'2Q35-!]-S.FP\*W:9PXBG
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M8&X&.0OJE%L$'[T@$G*'K8,O0,88Q-\),X;[O(BEPKXO"JBL8R:I[A%LQ?F
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M-GVW;DA_O/]1)=?4Y'D'#5-J38-]Z_S 1&'9O*R.O2]I[4I2AMG&^,B9MG]
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MI>Y;:'=]^>>YM7$G0X>%+;,F+#>7*HA)DEZ:U>+X8L@QU<0N9+:G?[,6K:Z
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M_O#%"IG8U6.2%<(5>8\7PN*:&@3&VZ=>N4U65N!G+V28,C4$^Y-9?+*:P^\
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M_&+G%8!0.88_@9!,O0>"<7:VEF0G@B=.J5"\J]W8?_<&+[_^'U!+ P04
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MLQF_A@VHCV.\FL<>IZC=K5L]GQFE\O;9!?Z'7N0=^]=5'0:BFWUEZ4O'S[T
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M,3LSZU]=W/0YASVGU\*9A,0=DYS-U>KK.M15GB_<JNJ(?*@BFOKB:8;4"M_
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MLQ7;F,*^.6>\P<R_O6Z# 6^ZM+)\F>^")J ^+V' %^/HWPDT(L;$\:$=5C!
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M9,K,4,. M,*?C;.T;UK\C7^([>% 1K1@P$]<FGO<2ACP#VR#_YGM+X)N=,$
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M,H]W^_85)TX2XV3BX$T"4KZI )ZZV]$[VZS0#X[/T)3*$.5DC7YN ?YW1>,
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MIX+[MAK66.GSV*T\%U#/*MVC2+ UE <*I71G1!CO_^$^BHI]9AH>VY(>2TL
M:B(O%%D13)41N:1TOGU.:"8<]WT\/ODI_!ZZ)8[W$5>*:9M8R43]2V7-XH+Y
M\),%WHNEX^_#;VJK*[Q4=^_9#H4-+Z#F)#'B4.C9FQ$-,UDWUGBI5/HPPN7B
MV_\NE\:G[/'(\"UQS)_?P\9!40DU?]EUH.$- ZZ0Y^YGCT=0Z9*_//FBBUV>
M16_=V:0WC=F;3M2&C#)\<'Q=S^Z_Z,'6X>]M884_^NM(&7U23)2!A;73H?/I
M;':^JN<AZEKJ4]->AV?>*I^B.M+;$S8GM@F;^J7Y)(@[.0YF0\F*Y;DF(K-G
M4S7=PYZ#OJDUE#CP&9!.Y4^ 9_OJ9ZM<#<1-62-SSL_6;(HF3M]E!BUHQ]_1
MT^K?KMJW(D 3"_VV%,(T?VZA (7_T*>QM5&,FD$UD9&;4ENWL &E)ZRDG?7,
M;U5=OCG"'"I]FV:;.P!/<!L9AFKXH7+39KP8O9."'+IPC/(I:?*''.U<&*E3
M RA83!Y8VQ.F]/8VLQ(D%_UNV)_ ;6"^"@2U;I!7&H1DP^-CYMYGK!UV.8FA
M<'!>2QCJIZ#WY09*1ME*SJ] L6X1L3$9%8B5NZAB@8Y3T\GYRDV\]8]=F?6^
M)'.\0-52C\" XF^:PJ'04DVH$F4#=+(9+B#Q+@XR^I'06FW:, \W"5O^.-F/
MK61L@%K\8OR.VD")#::-I_-YB/'Q6AA]1#F\4R$=QT&<8QIS^3M=.LEAK;?6
M'@M(H+S0W8VY<#HV8G?.5;)H-7$RX;3'D_K4Q^^5413L$Y]>E1'Y"Q[S[^WH
M(]47S,WFAJ&.CPMT$%N8S>$%]AKV7&M<V;_"WUVAT MG":1AS/2/0;WEQS<K
M8UD+_)X3^$/R!%<"N!F'#YIP553%Q,^)6L'1T6F]>>XYIW7;F2[.- >E:TQ9
M7S9N"2/5B#W7(SKF+,AY\D/NMK@<V[8FT=)WABO"Q&KK$BQ\N"4XV705,4JG
MQBUIX^GYTD%:$*>+G6N?1ZCY &.VID(>PQ^9#]VW1*',03"L-T"])4 O2,J0
M#5D_7A9$P[%>0>:=BG%>=HY=];38C#C"4QZN*S4&^043Y!$-RO$$<GD_(SI9
MDE_9MOMU58_CVEN?FQ^]\P38Y *W.Y5Y+"K9U276Q$T59"D^U.\,V(*L;D4X
MVS#B9>DBSZ4;C>']'43][X.GVAP&J$1*/13NDUN-,C(V;P-52)](5#Z9).CC
MWCM0?)0B+Z.A_I3M3.>[E<IXSH7R<H_D:9$;M!U7$5%RS1=IW2ON\9Q[/J4!
MT:5R9F;V^3-2-C:X/1@VM?@R$N($H!^--P=XL[HBG<P80YS2>Q1J<$^SZ= V
MA30Y%S!K[^=!Q<'.QGC 5W:!74)$J1:.T>H-:W.*M,WE6QSJ-@J5@=<?HD28
MGU^F+6@%/(OKODE>3>)$+T2(\'%4LD?32:0=3DYBJ+_@A3 EW@J\.LX)TN;T
M(R1SKGD@]E$$R+3_L8G9-*=?+/F9QRS :DX[%("_U$B_5*CY+IR@PE73B AG
M6H:%!2$);2&WHJ,18*-W$\_B-4,V'Y==R=QYMH!=GS;#J+.M]YB^(OS$.35*
M5&V?$5/.U=:V9DAZ&$0Q:QZ9FZ3?.).= 3^= KFEYWTO"QUQ8J.0(/+M=C_F
MQ!+A #^I$?(^3K.1>QO2"8A$"8R4PQ7/>M@QVOUH3MJVVE>Y>$\)[P /O'2#
M\WU\&6[0-.'*;&-)092D%1&8&YJZP=]-4%W[A&!!6]_ST7XW3=T.U8D)9*%R
M5X0Y:Y);SO[ N+G^JT55"C?'.KU:P\.T'X&'MRP,?$Z?)I30NFCY@50781=N
MT+"A1X=*?0/\0!"9)%DD7DAGW+RT#/Q1?M^/G<G)!= YA-Y<]K:J- YEY\O^
M5,("+F<EY<RT#5DLBQH5^LTD.:?CU@M[E&Z+U]:$S.:[95,9;.,R+QS3OH)8
M\_(+R2&[FBJS[^:)VSL[:\1=YF=3IG\)OS?N;)CE#T]3]&_K:5733-^'"]N%
M]XG>>92"*8\X?H*M,'Z>F4'\/28O^O4[ ,^OP3E";DFDKDIS==K4PC#*6LIR
M"(7)'CR\:"+VS.O[7%B40.SR >0R)9><33*MCL^RY$F-1SST-0ODD H&'''[
M9'>FGRR;W.?,R# @-#M^4. V<D:^XT8F5&RCO0<&P&'#@(=2:?D%'_59[/=>
M1@]&--6H)FUZ'\DP.F>[A3$6LORG=.-?IB%_75BY^&-=!;$<;>NNQ^C2@O9J
M8O\1P?GX8&LL"0&5*S]QP>P%G\07?\,$&- B^":1.Z2JLW?1-:'PF@2P;6G_
ML2"0O-_K%^2#,J2@-6KE%5F#BJ!3@-.=J<[3P "?+U#XIJ,(!HQJ0PZ)($?J
MH$(I,Y]@#1B0T00#EMAAP(]_AM_] J_Z#5YP@U4, R3,8$"K$0SH4D;*Q4\^
M)]>$^@_  -\.&!"6\RN"ZQ\(I;\A[/R&D+TK6'Z'. T#0,$P %^<)$%3R.7Z
M4UVFA67]D> \ 9(D$IHM\9)%ZN1!Q?:74P+#6R3*6PW@46->72%F"37.N%!"
MXN0U/O&0L](R>J9U96N%Y",[^*94,WT_J94Z)(Y9G@F?OTA<*/H7C8;3,1:'
M][?(>&FDKXQ#JVCOQA3GW.FB$O'+ Y]D1GO6RS >)=5[2FC7!:3Y@KY2^##G
M_U4AU;_:HW .+# 0C6V=1:R*;F-&2'#4V1OWH&+/:<ZB'/FTP%Z8OD#QL7,H
M?D2&-!UZO7,<:8RWEW.7*Z71)&23[<LEAMAET:_BZ?\JGAZ+\7</K^N13I7Y
MHIXUNT=RQ!U)I(X]I'XCGYG+2\I_6H3P5XL\^59K>(W^! J/#66*&9(OMW&K
M5V17EDFDCMAHQ%?ZQ<;)O]D8S'U#:P)/J[#>NZ^_:,>I5 OH_:?/Z3S:HM[?
ML<V4:[FC:*7=-A%E7@4:SRWZ#*^(/_SE#,7*6H/_B^],$))J%27*#^B,.U]]
M+/T-.:GFKW$.Q'%_HH06W@>+$%D8X*5TAU2@CVDQU))$F&@RIP&B):^L,:'=
MMCZO88A6F2A;KDU:IG9?H %B8Z-.#_8:OVQB%D 6X6]MM!;ZNW'EZIT?Z&T7
MLK:X/QS^H!W@O,^..CNR!<YH^LJ7_L@F--1^@;FGG>P0U)-K!;$=@0'BMI+0
M2\H5F?/5^9K[V[OHHR+;SV\+NERYP@V4K,22O;T>Z1'<C>I'IHGW%DMAO'E<
M^71W5:=A;EZ))A\Z]P'J.Q-\=T.YHE&ZVOCYB(Q/T<C1'L.!D^ =*$[V(K>T
MEB(9+,C$F%4I^$^;-/_;4CR??FIA<'#\YK5&6,G&4),&60F$B_*\&7OG2AEA
MO+M*6B5(HL X,?$M9WIZ)?3PK)B'K)*NL+9;QM#!$DZ>J<XB.,*S;R?UWO=(
M5#RQ'(8JKOEG;S?ANO )9U["@+2QGZ>XHVLZ?CM@7 "GP_3DEZ=?SD7G85_M
M_3Q"#:<3M+4>]7UA@8,EXW6!H27#SDSR'CMDQ/+G<7!9.RJQXQFQFTUE),SZ
M<&H"93UK#G1)!Z6$,*C1##^+ S\Q#_\13T)<#QFZ\.P^XN>UB!7^^V0]0'EH
M>?Z192DM5XRMA+IMOYRJDT2O6#[WYBDF+W-/DT*C\%2BZ?#9"O%*OHB2@<]6
M2)KNCB?%^K:6P[7+9YU*NV;_56@M8GXX"QOUTW;3Q%2J\ %C.;JE* $R"I_"
M$RN"N+FY7E=B,'/2/!UHVLH.R<NBXN!Y[2CW@#98PITEB.O8,RXZUF&1\?PJ
M]"P#.1I_R_:+:3Q7\94WP2.6%ZA;4>^0CTN96>5G8 #D>P[;0](H+ $@>G1*
M*CJX9DC0+(TTW^K!OO)^PZ8X,OSHG?5"L!52HM%JS1$Q^8S,S)QIZI)%Q:9H
M0M K%94_K'CSG/+G&?9M7_JLK-_OHVO:?C,VB/6O7?*S/OOG&6I 04KJ_)W8
M1@WDYQEL]E\/X1<!26'A?W2!S"^$?3_/F_]-_2\,_]KHSQZ._Q>-_JOZ/_WC
M#]$HK0*@W@R_.,@_5E,W^4(&?A% _*&: L#Y@@F[-@@&J$<S-!!1OL]X>D(V
M+"VVD7)ZZV,) '/\QF(N^1$P .>LF-L7>/SK.E_1.+,D=2*(Z<UU] ;8"F4(
MH&FJ\L^GNLC7, ^,#6]MD]L.WD\_S-#'AP&ZI/E?5*["@&J_+:FG;!F_^J+J
MW9^^^U>)?_N-!66$&N-?##+SRZ\*O(-L5$'^M-+W7P[Q&_WV,P?J_Q,S_:OZ
MO_1E%>3?5'?\[Q[Q2\>*3B#?GD?_7_?-OZN6^1<.]%\YUF]V_-5/,U M"S#G
MJ);X33:_\!WG):?9X0CG0D]<;Y$O1^'S$@+6>DYDYY'S&_.['H2)9*RF*5!L
M3,4QJM(+.<G=#'H^ROUU[/,';7/=I\\CCYY<K:=?]&;WA4,]\^^.'Y\JPPN_
M^[*1 EFDB;Z'K=[#\L?$,8Z-[V6ZC]Y>A_T.39<"N'XC8OP3ZO.W+)&DJXMT
M-^M^>'+?A*Y '_E3S;YIN?E:YWY>K])M,#>KP";?YH!O2N7>;3G-LO:5V_N#
M%N]5%8"TXO>5<DMO[R"PW.((?MY4#B].ALJ9=Y'9DI*-=_5T5\; \J$@::2"
M0DW@6HJ-0\@.Z0.)F<XE^"VP@0+_/&ULAF;\/O,#=!\1FXC@=J\$!8=P>VN:
M?L[N?4IOYOWENE4,BZ"^]9K:(;3S"XWZEMJ@!VTJ"LW^A)CI[^53HY\V".0A
MBYM5S=,<!'#<'<4>W_D\QO4F=)&*FW_?O:H\D$21/=4H?5A[,J,W0ZK[L(']
M1HYA,)T3Z>H3$F@GA4V8UL4U/XD%A7QL7"J!(09NQ5*Y4?0;E=<HLN;&MX^7
M<7-7%MC]M_F+X^FD.D-$<4\>CYZ:M5&^*WN$C6108HM7V=WF]MCB XTR&8?0
MTPB7?;G2AAK4"?DIEFS+)4*G9LGJ_0(J-W*1(W%:<X$2<Z#S?!^5"H]J-:H&
MM23"G_T<:H+9YL0I4S[>R+7\45HK-XW(EH5-]%D4_RP3@*A?!:P&;'U34PK8
MSYSD>P;?UB(;1URW"W*LMYM+'\$#3>6<X]H?K];;IGO;/)X]*_C17.TQ]M'D
M;6^7AND,.L[6D'/A,K$J.2=_YX- "?)#I2O+C'VBE?AT@TEY>V1KC*-4NC!-
M\\EW5.$;#&(N:<%U6);PM8M6$?O!1 P%FTQ&>"R<M$^Q!6:80S^TU>^Y:=.'
M/*4_'K43N!$B'Q9MO&-ND$()"V/'>ZE*E/;<\*1/["!6)I[P]D3I9E5M,P/)
MDP,R0G?_4DE1W .'[H%*6;[$JUTP0#@>>H7W!U0T#+"XISJ^IU+Y WK-"/J=
MI7@HWBI-P.Z]:_[=,A/\<\L>>KP[*8;?6/QW#7/_;<,3?VU8P]XT:GAR@\!>
MP/#* @VN9Y-ICZ?-]*5@K#A1BEVS24'K1&WJE$- H'?!)'SJ"GS*:)PW46IV
M"]JR^RZ]<_TT?K_!I:9RRG K9M4'"+<PC;+O@;&D:2&9S^.'[<F'U@1[&&[+
M3QGC9.('$4#^[ /-(GX(V"K/=3X^)YQQ[?(WI(OQ2>P&2[=2ECXWK<8*T0&.
M,;)6S8+K2YTU#2B:/W2 P89FX<.UK_?DGEY'!-24+TE)V2\/R1,;<^E:76!L
M$7&Q]WP_?]A>0'XR2W:>@94Z;[6L0%SJBUD3-^#K(UIS'C=F_B#)5UYZ*=6.
M=AJ_>^Y2]& WZ2ECEGF(/'TH'0I1,RXI_8L7_%LI#]LNQK;1%%#5&-O51'EM
M]6R[YWORR:):QC+T=HWCAMV,T"6H#3+14L'J!E1U*?NRQN/E%/RKEC..<%<O
MHUHV^ NX*;$5<_5G!M;:2$HS_]>ZXG7^/K_#O]SVY_+,?^)-][Q/GUS[V/S2
M6>4E"_OOYK&Y>S%<V[IKT^XM?<\,&E4"#E@P]'PYL;SS3;'"9]W/XO>EIS_Y
M]2M<8Y_,U<6MN4':97WQF[=,FNFAD6S38'A^X]E@?Y;[/X.=E8X=S_0W?'9B
MACC+4Z>>PE?^MAK,VS^_85$*5MT_Q>_"[^DLO]+F[[HRI^ZUZK;'?7L+OZZ+
M>WXXW+/:Y-JWL. #:6G>D7Q7#BO$WCC&R%*W;.[2ES[[=*9^5XZ^[;+NU"JG
MM0=CETO^9T@)8'?(6_-X6LK,Y!8WA_MJ5WDGSM-\EJWPHO7!G1]:1D8WOWQ=
MP[V>]VSI([;=TZPK=7L/G0K]J<)QLY*E:F+$Q8JJ#_>\$[]9IQ7F"M4NG?&,
M?^X)S>,6$B_[KK MSRRO7AYQR[.TX,,:PY5I>59\6[-4M\]2F6;2._% JJ*[
MPG7)XH>]88_,MF:\K9EQ[8E*ZZ<4HY1U;A;'*M<=.REG+2'X*&)N<D"@G].<
M$K8)0C]AJ5T.FJK]%S7VH-80DY!J"'5L-<03U!J"B4$D@8%]JRZ!^5]:8C?0
MP@40-D0:7@YVO[>HBZ'PI0^0K$5>_(&&Y?_?! !02P,$%     @ TC1J5)R/
MR4;L30  Y5L  !@   !I;7)X+3(P,C$Q,C,Q>#$P:S S-"YJ<&><N@585%OW
M!WR0E!0D)4;I1J1#!D1*1+I+ND&Z&5!!01H!Z>[N!D%"NKND04*ZF?D&]7KU
MOO=]O__WS3QGGCE[K[WV;\5>>ZUS-FP"]@6X]41<2AQ N $ "/ O )L&1 $T
M%!14%&0T5%34FS?1T#'QL3 Q,#!)\&[CX)/? 5&0WR$CNTO-2G>7DIF*C(R>
MAX'Y/CLG)R>(CN\A[P-!5@[.!]=,$&[>O(F)@4F,A47\X![9O0?_GS^PCP N
M&M!WHP01@1*X@8N B(L :P5 <)S("-\_P,\/P@U$)&045+2;Z!AP@HI;P T$
M1,0;2(C(R$A(\%Y/>#^ A(N,=X]=!.6VO!XJI2W^ Y^P%#2J1R7-! J#N]0<
M^G8O;Z(3$A&3W*&AI:-G8.3DXN;AY>,7?2PF+B$I]41125E%54U=P\#0R-C$
MU,S<WL'1R=G%U>W5:U^_-V_] \(CWD=&17^(B4U-2\_(S,K.R2TM*Z^HK*JN
MJ6WYU-K6WO&YLVMH>&1T;'QB<FIA<6EY975M?>/KWO[!X='QR>G9^;5<"  B
MPE^??Y4+%R[7#20D1"34:[D0;CA?$^ B(=]C1\$3D4?5L[U-^< '#?]16$I)
M\TTJ#H5= GV[071":LX%FKUKT;Y+]G\3[.7_+\E^"?:W7%, )B("W'B(N  8
M.#D/,!M"1N[L7%"R4SM'>#STUH!9_-F+7/Z2+8;0%N7 TH1A'L5)B>3C9!2K
MFJ1O3:%)LT\)+V5ENP^R,$B]"D ?/ UIFA+44[V9(":3B951:]!)='#95M-:
MWSSTBN5G.Z0_H>GJ'/_7/XTR,4 %VE\* Y($(!>'Y;\Z='?S..602=]9\8^-
M:?I;W<5M]9UYZ_,%,W'4GZ(AM3&&-G5*K,?I*R6C87%S=,]SHN=05LG+37ME
M/^D@BF/B:(=P$4K&\_!T]"7*(3:Z7;>-=T9Y;2\*3)JV>1!**H8A4<X)U4#B
M;(Y_F5[%-H*ET/ Q*LMQF/G88L]9-P,)NB+)1B].H>FCH;E%@9NT'#V[S+CJ
MQLIA(LSY'SY3F>5+]R+*5Y6'#UH568>3ZS,U58C1W^[%U7FV^&E5MV[:FY$]
MY:NMAEITZ0BTGS"+\VMQ7^JVOLL'HYG[W41T-;Q4G.A;ZW1CA_0.$UQHAV?6
M+!DJ=@-JT?NC+OJ7'M5\2T4HA7,S9MQN3%_G#?TLE .?8,HS,&<14QT4FEE5
MU($Q-=;39.HN!+_11RZ83IE:=9/=._-^<)^793JBLV#6K47S&Z*VVL0DO\#4
MV\4*:@:=#T_7$(/Y!S@>F1Z>1G$3LC^ED"?:25&9DFJ732;_JF>6%3W!4B!M
MP(M6TV8KO^XL"SE^]Y#D\(+#W7#>F :AQZB^\T46.7K@D8"Y-!OFK"97Y CW
M(XP#3[=A+4-KW.IH/8-$55J.X!DY(IZ=;PYYTC"@Y,K'.&YK7TN?F*!:7)D)
M>M+#6P J-;N(E*DH-EYOU%BMWX3BUHV5AUEY@&GBT\2BAHR98Q(]!Q-[#TPP
MG2DJJEP7.C-'CC3WGM_9^JH2/M5C6RW>J+*?)8@-$BI78^W+VIHR>]^QK''V
MZM2)%<*H4CX<.7IG;D+ <Y2^!OSD  9@Q*E[*%HXVN*Y#G6ZL!@%W2I__5D]
M,*@.@EY-HKP9,+0G'I.K:U&W7=[VW&_V2VTP?7="Z8V+=..9. GAM/A89B).
MZXI9BLDBV\R;"F.&E3/^A-0Q 0M$=.#6!\]0=5P*-(U*JH,E//D%("P!Q;$T
MY #UJX%@MPM5-OL%=F;GF,'MB>Y""3![5B^*HNVY)U2H_&AW^>1.>,9<(G49
M=#IV(?(SH_Y]*Q4JP: )XC3A.G[IK*'\;L[C,.:;B,\.SIA6<@LY(C9[99'X
MM7L8..]/U5NF?&*V"*0X:FM;B#MCH2YSOTL)[1MAT5='8ZS+PD*_XO:6R&3$
M:.!V21ZT*F">:C[2A&S5==M7J"M[.84B\_+>D$\Z;B/$2-B<,OM<-S<WJDK2
M*8:(3RK#)]S;D-U)W,7&MZ'5_R[5VX*"-$"&=UZXM!<:X//L"R6XI16E(T-U
M%P;XF;R3'S8:<=BEJBB+[E1]OC@;:_>YP6L_!?%A21N"?1&AF[L Y;0FH6X]
MDD784?Y8PY!X&E>X&O.0&)G";7ST3W@"=R\#XL=!%@N>ZI8VE/L[2Z-"'8(R
M]&KA?)/]>T^P5_OE9&?[S<L(?5^,GZ@24H \^<=$L[9?OU=XJAAE7Z'FX]LQ
MCJ_&ZN3,E#[9S#F..R5!AAM#0T.T(C\38$DE4YU %=!%)_&N5_TU4W'@$LG1
M<:&*S WI.!GS=D^,GA%KL4EM<1E?,J&G!D[.$ >KCN[*&%;_[!GU^\7#B9^Y
M@UDN4U7 \=(UPRN"UB1K5[DWUDRC:AW>U;!LJ]L'OE;@D+0J'[P5^LF4RCJH
MY 7DSF+F[F'5,%_%($6'3-1JMV<$DLPT60PU8Q9@Q=BT;94Y[^*TBL:J,/TD
MK(?_]="$<(D$38W*XS-M$K]1EKJPKH-3'_OZOT->TX+$L6?TY=DT#)C/R-&?
M7:8]4O9,8\06YJ*Y%]GT*WZ")H]U#]9L8(!7]"5C+SZ"YH50-]1C&P9\&QJ\
M2C*" 4).,.!D73F6_D;5W_S2?E$-7(=3FZT+MK.#*AC0]"CDUU]I*(%Q %#P
M&Q/YO_]OF/]?YTKY6XP4%=-D]/E?@'W_QAZ5/RA,\&]"^?[?]@>&(@/]MSU6
M++MI="?2*E\91AKJ<].H4P O?(2>CD4L/)D'5I(;/.Q3$G>Z:,(_F8:I>=?Q
MGOE_SH(!UJ:4719^Q6$Z).$W66*[;Z-Z6)*RSU.A%!<<NJ_N<IX_V3@OU2$U
ME?=M78BP*YY=N5RSL9].SK&I!V=K3INKY""O3%5<%0QI,W_:QA,G<69=E.B)
M>\;_0J)!@-*Z-WJ<\][S:.FLSRL[7MW++-'?5+0(IQ1)R#"'D]0&Q>,(#ODM
MQ]GK'KQ_V5K6+K?PJ5!(.ROPSEK2XQ'?E_K]"A?W1]N&Z!*;+''/GN;W7-3N
M"'I,3JO<?:4][,%SE623-8=44QM]XI/FNOW%(+ZJUR_2W]K.-CY^T;N.7SUK
MB'(@?<R@TL]"K(J'<; UO=9JMF-!H7HX:M)$FGA%Q4B[Y%&^4@EB4J9KKO.8
M+-BGT)*9>=DGMBWYY=0C1+;.<H;ED+&:S^5,E:Z&I8.ZSUY9O;=!H!><I/K
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MIC))R%%ABC^Z),EQ$5]IXCD.(6V":T[?XZHD4PM(^30#<O0]8K8^X<-O(4^
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M';FA;O)^K@W)DN!)#O&4$4N4CJ:UVP"JE>LB/7/%Z^'>^B%[O%[^)4,6)H)
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M=60G#/9/K#L$;8/YOCP/\VD#E'1OG4UC529Q=MZ;)CW+CHOKQC- S>J>'TN
M 3<Q[[H66#!.!7GWJ;NP$'U(L]&)][1XK*Z)@LDR<&NZ'55\N@Q\TD^@04[8
M@I%5H^GXX+ZR]J=[^'>%X2F/@_,1YR%A&N48SRQ-_IB=J #6M'2>1R;W"[N'
M[P.=LA5;Y4O]=8:4*J=JHMWB.<16?:J*9I>$*BQ-ITRK]H7:0)%-7G->Q^SC
M?!OM#WES(F3+@A[1E.N)8*+P?M9^!0/(ES;$?7(4VL]W=JQ$C*KV-6@"VW"?
M=ZS*S(2-T^%?,:XNNN@(M.NY4LQS<[_J8M_1\@GJH"KBR]DNWY2F7PZ>FJ24
M$CHE.:ON +_!W]1D<J>?9$G!S2/O#0SOF$DT)7F([X6O'XHL373]YA&:FGK)
MJ-8TVCN^ ]EJ\:9,#6D):?%&I[^D;X/OEB$%(%_ <-,M:"X!%'?#:X/25;V'
MY:ZQECY'U<ZRR:I0)+.]#G?-,82?CZ55R#XKLB)MYL6[.L%$TBKS"ELC&X?!
MBE9*6>85D3XP*PP(8IH2N1LOR.@U"*VZ:F3O7WB*7BSM,K4<52!HIYFN.8/F
M]-[8)LS9>LV[=6]#R63<VK#$N;QL?X=$5/.LAUA2<)YYE]_^<M.:5X$N;$FX
MB,K&CK_D(\FE=[:O;^KK&[- H![O19K3MRN,6*"_8DSC0LV/_H:G__;D.]P#
M5V\F@O[BYS@-EDJXZAH?NP:FVWVE2R.)F^VC+GME0PKN7@M\"<^!0EH"/4V!
M D^,;_!*"P%:$7:JTNA[ J]RO&& !C )SY&(_UKN@2_2SU7C-+YR3[T)6/!C
M6H=V<RW.DAHV5MJO^6[[S8=$[_A,#P<<YAZHLVZCMMYD%NP<8_?$7YP0=$^/
M\V4)JFM!\&MW!8X7O;FY,D?&VXK+I;WD2 VLG\\NO\:& :8'[!VST^.)<18"
M2A':U2-%1L,1BIHQB((@)N9'$].[][WDZ>(F+B>/BT33\!'6&CW;JH=-@AQ3
M+&N;=@B&C"%EQ!]MV-VVY^-M+AE7O6NGS<=311W)YI1:G.M43#V^<9[1LH>B
MGT%FMZL$QZW$Z1'#=H?FL]Y=/JX-'#O0<E5)XJJ7N;.$Y\0\=[596&@#+UG"
MOK4F';7WPP"1\-HGOX+^KRM7PSK-)D^=93:'EM983K)C5C_KB,#)+W^K-=9\
M'4Z!0A!DU!]P)'HU[>YX9<A5IE;K+$0[%C<@W'2Z ;[@4G(RE':PDO]Y+)?X
M?/P2LEZPX0X#RM,+ CK&L5D=[&& ;#<\?#VT5'X8ACL+)U-0NXYM_7!(-.B?
M8<#(?YR-@*=^Y]R,ZS^.P[R\_BD?;EHFM8"G>XIP.0@(EG#O-U.MY/P1!G^^
M?;OUS>;;'9ZJDR#N ,#I&+J7Y@YQ&3;G2W<9P??-H/[B>_>YVP'4-?EF%9R$
M=/JB/?FE.HW* \UZ:ESOK2Q!Q.F9L%.E<F![^VI)'#XZ<U 8CZJJ]P!4:Q8'
M)TX [<& 6K/WO_=CS\W/<=K )[7"_[MYF-8YF,C!/\.1!#<'J*H2E$.J@P\/
M@G<K+\:J4QNYJU/*89/'2(+9R4.24?=RLA&F?_:?#9LFH]K\D"%D32;5F[RA
MJ=ZL:TL9:G "*9!X)EL+ W:N?9KGIP!Q8H  7,;!:[)R.<2J_]H<LG8-[?)K
M>A5'&J_TS72,^ >U6#.([;(UH-W;VRJFOR#\G-3T6K I^A_-W[XW$\$YCM9Q
M4S=*/61,T"RYZ#^50^[Z[?3,C1=,?1X\>:P%BSD[BHI55>KJUO>J(O6BI"@M
M"T=?3(>NV"E66@SF!KJ)Q^"WF)9O/H[4?!&F)_?Q? T?X=E)J].Q6ZN;NXC@
MZP]1Z@-8H3%J^7HU_3U*AZAD)@6J#7N>P4F>]EBM1)08GI]/[HG(<DJLNAK$
M[TSV/W7J56O<7:DXSHU])6-+ZK55;UM\DTI<6ES-X%3Z=H<.1[RR>CVY@2-G
MB*.M\X,G63W^\<BNF%[RT3XGQWL=Y'O"N%)+%J8BZN47$ZNO2^I>OZ:=)++6
M+IZ@6E/<7UX2BK21WA/+S*%-O<^R5!(6+A&K1/;7NYN5DC#E]%WE]]T7F]V3
M-*'%-9$)SEII5EU"1*1>8B!6?O?8P:J!E'>*U4W5U;$[9@;[PG'6$XNS=<\!
MS,#SY3UA$AU00WG37O3;K++OKVX&/3X;8M>TQANJJFHUOD'BAG+MD;UX'';7
MKW\EZ%%PN)OJ;T??KR\1)ZAV?/_5Q 0T\J'\Z+1UD,=<U#[HTF%8,X(E4!>@
MBUS@O7>=%DN"]Q8A!8X$?2X//1H>+()W9HIA0(=*+6-NX8%E +\(!CRKN>.=
M[\F$E;]I#5Y;Y+I,E=TKL%4[!_'$=AXU4L& >QU*E?"E;OG7"7SBVK/66GAX
MR3J$+SZ-RCH5NK=>Q^&0K_= ^^;3VTK'C]G\?RUU'WAY1PJ^0(:O^#3]@O./
M<= G6$E7+]>NW[ZH7/U[<9<[/R-*\%$= [&*"B.VXCGWQMBG(6KHH]**HM,K
MV1/4 TZ@R;(2>IATT@$#=$(J-2%>LA?P.%*DGA1DG+$]\LX+75/XN-2W)["G
MCAME9J*#EQ-MPVO2ZFH#_"T$V@""C[W\,;;&9)15;\"J*-./,]98^".*D7"'
MWY20\1*(?BW)W&T3,*OD4=#\O*_-UDU&;.T4)1@NP)#,ZC /9W ! ^9!5VY"
M<*XG,* 1?'[4E>#$=P\'4X$*MYIY(ZA+WXR@6M#$QLW2;76FXK-RD B=?O@+
MRJ#3M4)=4.3]FC'/RNF+?<A?/,Z^([/;WRQN4=<9VGH2UQ-FJ3#HJVQ,M]K.
M72QX9P2) (GLY0.LNUQ+=54"N_TMMT\8DOZ6(_NOU$P)(>NXV^9;)PSP@!RM
M7QA5G2S_0-<+,7MR9V<AG*:XPBE8G";P=?:R-^]7VP##J<-;-NI6UF-J)R3Z
M$QEARJ*$8&[VBK+F9%9'T)]*=ONA9*WF\7L?;PSMI7?CT-^=]16^:#QFK_"Y
MXA^8NHIM-[XIH/EE\442U7V9"PF^OGE+)[B^8,"?C#QAP+6T]LYW1@CW.;W$
M6@OK2JF$793P;G="-Q7!%:VU004-]<\&NJG$#R+/[*CF?=?X-D;<!HCX(7_#
MD)AF:6J@NX+'Y/%"CUDM<N6M,?I1KQZC@$>M45;-KN1ON) ;4QPLV7:,@V>A
M/3LE'S[D=I9[S%3)QC&=ROW@]!/'[_Z@*6-E.&32E/ @M+/LA''2IBXDLO&Y
MW43S^2!MPYT.GG/!W4Z*O8MEXIE Q"*L/AX<<R>,!%4XDD88\$_Q[,SRGUH_
M?1KFT_2<EPZJ>2;:E+6I$.0TDQMFX^#1FXE;['6F7NFGXRFY&9P\^+QF^*IT
M^F+HNT/8:4]'1F!>LLIV[C#AC:VP;BLX8.9.GFD]ST%% K4J5T-&>Z%KT!X&
M!/?MJ/EYR"]U_ 6BC#X9"_RG?#_=M2?5FQ/ZRV4//7]-V9/YI">T[JYV5WK0
M6<=2L"FBYC7K".@I#-@<_-NC-H.TW58U%7:;K??%R(:EHHQ4)*=MNOA?3D)9
M(YTNY&+GI%7$@EB,9/9E'P@@K;S GHN9<16T?=9LGW'MBNE_S_K#\Y=6QDW>
MON$>_)#I2EE)VK?=M2#D-4&]%O*D.C9.PHICYE-,<LT%$TOU#+F_=H;]9K7C
MAK#6QM]+[O!Z!1S\D&R%2%<T>[IUT-4I_%'/?N>GQU][N,.&3TGW\O@?7M9&
MQO5RWB!23^!&3'KO.7/Q)8"9B!_\KQY01I^.DC1MU=3TP[72X&J8^Z&&,2/\
MWQ?7UYT$3D42)*-@]OA"IJ0"3YQOLH>ZF\*]L?\\5,H4-!8!SUQ>EY)02>\'
M6/76"6MVH9$W#M9C\VDWN&Y4EE7(;D\>"70>+H\2K@KW(MS[\P1:-N+ >M&#
M1')=,\(PBT<]G$V3 >VR[+0]FD]K^":A5:2G[9YYNB(A6G<*-B#E^:LD]2=U
MV ,D]<,K^"07C;HG[@:" RB)D3" :OPM7 C?I/WP6L8%!T^P8MV>5R,7UM/F
M%R4:.] ^4EP_$,E\]=I>X9L+%*^FZ=K,;]IP!;!\R S?D;8I*9.92P\EQA-0
M07=1Q^6&6&QBQO0-.TD\=/-)S SS(,\4I4NR/GFA]:KZ632FIK/36>E-O<!E
M>Q]ETQ.Z6,]@OX!VZ*?:[2)S2+SNI1AHPEGW$#0" _:)8 #ND^[JLXR)R=22
M9[YVK3;C%:+!XG>XH%+25V\<^"W./YQ_"(%VBD6_6(TV,*Y)PK-@C\%Y4W#Y
M*7NNE0#GO;H\2649WD,462[G"[Q-Z*OS).@C&+#(Z F6TKRY5FT1]R[._V6>
M-!_2MM873 !8'@YA=IR)L9?2&&-:I[];/5I0U^$<[TX\$#"5_R[A5C>$9;8Q
MQ=F$^N/-Q\CWEU_@]&3%VYXI0HH+!2RFLJZ.0-<G[\O&%DC;--I["=[! :*@
M-.4L57JDP8!2!1B@-^L(G1\YV/S0=!J@HMT%1ZRP:%A9&>6*C<?)VC&!.<;V
MNFUSHTS'_!;S[3DMKHZH@FKDNPCGZ Z-%%&+A"_7-$:,?=HGJ6COD[N_?(3X
M2M,\11@ 4 %T4BGUF[0K3D(!]#F<UQ[%+OA82)N]#NL1:%7BJ*"P0E6NY)U\
MF;O9.U_J^X:\1G>7;[G?$N82O<"&:V3JIT;*+51,<JW2K>35FB:<$^I%<B#+
M;%#*D"V!_G-B+K8N^/]WK$MPQ.8!;=#6>GC&#LV  :%P08(LN3;5M33-!V9:
M)JBVBU=&3IIETD"^9'G5]D(M,O L'J4?V@Q/\]<G\KQJ!(Q&)$(*(.74%4[0
M[CB3R<%HJ$9;_'*2^2:C1HG4S'5%\4))\;(,OMMS2]PB#E'[D/4%!Y3)1*<)
MWOA^VCD;SNC$R^:R+!H=VCL!+QZZLES2[*."U,XC>P$[UUQ$J?(;6^P);?/G
M7P[^GW*N-1RJM0TO"46(QDX9C5"*24)RRHB<0G;**6QAA\:I4HSCHAPR#I-3
M)>40D6(8##F4E&U$#..0\VD8I1%2!L/,M^J[[*UV/[[K^G[LZ[N^'^O?6NM^
MGONYW^>]G[76M4JY5S$CSO$#5E<7,*C)6)#Q(IL^"Y)%H24=IATO2VL8>O\*
M,E0/3RA?+H')W5,<F0UQ;N%S1"<<$R:%5PPXB^&XPC8R)R]]^&!?U/OU^>$A
MJ)-LP)76L0%-9ZB_<'$X1[&:2J@,AZLB/*TA4]D2D&NRB:(:7DGC-B\4F)#(
MY\+I8*.@R=]BY4DE4Q,QWX!BCIQ:"R83>?%U3J]D<0_=QMY^/"7UCBI'2?WX
M;&:@$_X1;Y:!GJA(=W"ZX!(5L3J[;^WB7WD.<; !VX[5TV=L&/B*QG"P61J*
M1$_FK_C"[FE6621W&$LG$.9+:22:@H%JPUAE ]TO%Y_@))2<$V__#:U',<*#
MH*8)'"78O_UI<AL(=7;ONF^?UJ=3).S[PR\KWFK:."5@T/24%  N:&70E)80
M<OL=#@;Z!^$I.I/ -/7PX-_#_475^DJ,*$=?XJ%S=:D3+C*7(SP2P2I@9;\3
MQ2.KROA&>WAT$^YP^?6*"QH^L2G4PP.K/]QB'+I%4?&KU0<'&2V3X3VHH'[?
M9<_W,U]R[ZNT%&27'DKRW D3FE&5B(7/DZG#=Z=99)Z5.1QK$?9G+'QPPPY/
MO;)BA81N5T$I(SFEZBWG;LEH>B)2I*O.WV/6-,Y7YCC/I^./>;]YA!]>$TB"
MP9^D2(82ZD$7FZ6TE=HT7_K,4;^EC.7MRHUE,:*BBOK#<G+[%)4V]O6'VF6D
M^+3RB/R,!+5-N[%]NV&ZZ VV.\C2XZS<@N,A1O_^/!RR/J[761AH8PGBU2(+
MHJI.@KVP+>/S,_KN!4Q-U#<*_E*,P&FMSZF[B'_3Q?BO/#)W/1Z5U+<3SA4H
MG""<7A1JQ%?_*?:_<MD0JJK2KLR(E<J):][NK.25Y'N$QV,B[$6C5O*2<K5_
M5_@G4]FR6'JZNRP\H^H,7$04;N7SD\53<+$PNT?#I$7(6\-WY'</^;$=V-B5
MG)L"!I?,28Z>XE4O1;#1Q^NK;[D$?1QXXR]SN._'LGY5AM$53W5,3KPU9\Z=
M ;[T$!\95KC1DP1=&+<#TKDEX6%( &'*O6@MP34.&C.1E_VS#_^$ :4D\K,=
M^-*?)JVFV=T0P<B;9-9V$[76%#(>+=5:;T'._ /06O_&$#HXUSYY\[D=(OX\
MV.N#><>77OI.FBK%NGM(C:.WFH<&#Z8:+"!N@.^\GK*!%Z*HQ;OOWF4*^#"W
MU:,^'[$#1[8@5DP1/2'0>)55!;DOX!S48]VS"U BZKE1^U7\_&)M='0]*/N1
M9ERQH,*ISM5]G!(]F!Q,&-(@VLOTR=FR!BI3"\XCD"GO2\V2F2T4I)MMA2:I
MP4ML(%0!G#O</'!V,5K,\UY?SO*U5T1Y.\7CLZMWXN,^16O2=X5X,*U.CTJG
M:[BW.3^+;Y[>46H\..2&<_)JG4D38U!1S3 @HR?]N\C<6/5S@JO\;Q&+G#QL
M8)N]N$7GKFEE9A0A>D^U4$5BHDJ7"PFX"TP0Q01A?69YTKOV5*9ZR8>?%LI[
M&536,UT=04TY12YT QT7K[,BF;@5CNML(!JO+^:]3?K2GC?JQ:E[T^@MM-NK
MC/2\*Q&8WN+R(T%/!^.[:D=5B;]WX>.FAF+KA]%'N,J56>[G2.DJ=-(@52RP
MC8L-T%'KTU:& *+6 <3?_)PI<.1L\=S)C)R6JZYCMD]2V_ ]D1E\7LT AB\]
M/.-E&:IX11ND>:\5B9H9Y; UN3.K:T_$P^&@A0^R)\[W2FRZXYW*Z>^Z/ZR1
MO*%<>=_5B3G^TBFY("]P8N(URE5AB:],<'20-IG7PJAV"E4!BU=TV8#N51(+
M@'IE??MJU!AB60R/FN469.VM4M_'F9JD/\=[G/X<68F$W>2*A;,!*M'*L*/&
M+#B[UWX0<Y<V-.8F;.2HLA5WH/&UG0B9N_B+'+@5(8PVXT6[# Y$6QZE,L3&
MF(7W"TXLI>D KV2D.\N+W766V\H"\'5(L)>9.@='N06/A00L:6BQ =0LLHW'
M:#5Z712X']32WN;&>>_[$MOTF>*PWJ.5@1G"@[9E5J=UL!Z[Q1+L(KRLGM+R
M!PI?V4W=1*HW6X-H ^E12T_RYAC^B8HA.1K'RUWI73JJFE8$/GX#ID,CAS0R
MJ$B.3I(=?D7S[V&T:OS*8_,=(;@?*OA\FU$VL89?G.X;257)#[!MX2/XN?JU
MQ#&7V0#22D\;/KD@LWY5M9:6S)DV$/+[C,>,[XR4'_)7"KXF1/MH5Z%Q\2)F
M+"/?:!R3?4;1%CW?]SIW_Y4*&VP-EC01&\\Y31J4))CWVVU]7RV0VQ+7G174
M4GS"E2M1IP?Y9'O3CD4)%37)4/46#>V:\N[(/+#0%)3L)U;)U<$=+5*M,Y)]
M&'K>;Q&C^[XH=^+C^GY[+&HUS3U>WETYQ(SU9XE7A\PTQSV;MX\ 1/@[(^4N
MP(-'M!R*O+MS'Q>EQ3P\QI#42%O]^&J9=8;#C"F,.BMW%@NX/VB,@)^W/G?=
MXI9EN2/\C8EK>#(;V,M@S%B^?ZB;;PE<4^,.%=<[\PM%[[JG?!?4N;R;6.)_
M6*59VNKW7Q+B8:7>'R9#XX6>$QMX:7H>VJ3QJ!G(M.]$C<J40&?[(1A-;" .
M^.K?9I-Z0;(&CCD!-N 6C>BUD_=)JY]JJ=IB9RP/KD@O.,RW4EE+#G/9+.'
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MSN85.7900A61*X&'2BI2IX4-:YY2]"]<:Z*4[;JX>P/5197\-I9W:)96>ZF
M^,;*,J&?S*LK+W7[C7EB[L0D9T*CI@4X?6!3:Q)XON@N84D6<N4FCZ_T"6 <
MT.D'0)/P6UB*83/7Q@+T9LY0]85,@6O8/[Z3$/B=>H"^!P3P.P4AUDD@5.51
M@<,Z!1FLTVTF_V.Y[>NUV_Z];CG1V*8H6^SX]#69 U__<&S25;O7/WYO&CIC
M) ;74L6RSN1*=/%3J&N&MGA?,U8MT1AF#'.$(?*GS K552G2FW=&G&KCO?K-
MW(+LWG\!4$L#!!0    ( -(T:E18:*2N1P(  &<%   8    :6UR>"TR,#(Q
M,3(S,7AE>#(Q9#$N:'1MS51M;YLP$/XK'E673:HQD'3*@"(U-%,KM5NU$DW[
M:/ %K!@;&2>T^_4SD&QIM7VKIB%A['MY[KG#=_$;C)>RHK( AJZSNUO$5+&M
M01I4:*#&2CMN*I2IIJ$2W8'67 BTT)R5@-!'U_==SYV?8YS$%BK=^R@9HBGQ
M/1)X08#\()QZH3]#EW?HW2I+WP_65U_2[/O]<HQZOUK<WJ3(P81\FZ:$7&57
MHV+F>C[*-)4M-UQ)*@A9?G:04QG3A(1T7>=V4U?IDF1?265J,2-"J19<9IB3
MQ+W$KD!9$M=@*"HJJELP%\XJ^X3GUL)P(R")R>$[VN:*/24QXSO4FB<!%TY-
M=<DE-JJQN30FLI[$JE_8/.*.,U.%ON>=1@UEC,L2"UB;\-R=SW^+-"^K7S(U
MIA9J$-3P'?381ZB% *K#7)DJ>AG@3Y[-P6^MI,%K6G/Q%$Y2*GBN^>1L<@UB
M!X87U.Y;6U;<@N;K2328M_P'6&R;GX%'@ZU3:=%[LM%8@-#J4/_ZP;CI0^;/
M0HX8OE4-QPZ&7',EF+5=/E8\Y^;MB?_!BP+?]6.2VTHVK\;[=6@^;/.6,TXU
MAQ:I-;JIZZT$&U"6*%6Z49KVA?^'Y'O+O_!WDF-Z#U!LM;T6EO@SIKW3?T%V
MP=6EWMC;>H9N9.$>,QL[:EPK?4#(:;$IM=I*A@LEE Y/O.&)CCKCN:(:?Z9E
M% DN >_/WI[S<4?N)<<-^;+5&UH"SNUDVV"Z-J!#NE.<16,CSN=N,#N-<J49
MZ'US>L-T&$?(,).2GU!+ P04    " #2-&I4>SQIE"T#  "B"   &    &EM
M<G@M,C R,3$R,S%X97@R,V0Q+FAT;<U646_;-A#^*S</15K %"4[*3S)-9 X
M"5HLS@+'0;%'2CQ)1"E2(.DXWJ_?27(V-RCRL'5#!8B6[H[WW7<ZWGG^$V-7
MIA:F0 D?-ZL;D+;8-F@"% Y%(.E.A1HVMFV%@14ZI[2&"Z=DA0"_1$D2Q='L
MC+'%G%PM#WNL26'*DYA/XLD$DDDZC=/D/9ROX.W#9OFNM[[\;;GY_>YJ0+U[
MN+CYM(01X_SS=,GYY>9R4)Q&<0(;)XQ705DC-.=7MR,8U2&T*>>[W2[:32/K
M*KY9\SHT^I1K:SU&,LC18MY):$4A%_,&@X"B%LYC^#!ZV%RS&5D$%30NYOSY
M=[#-K=POYE(]@@][C1]&C7"5,BS8EKBT(:.=G-0O;)[83LE0ITD<O\E:(:4R
M%=-8AO0LFLW^%CE5U7_)[$ M=:A%4(_8^3[R6F@4+LUMJ+.7 -_:V3[O*ZT)
MK!2-TOOTY-PIH4_&)Q]1/V)0A:!G3TEE'ITJ3[+>V*L_D#P3NX!/@0FM*O+=
MA9H-]%/207<GD^&A \R_";A1#7JXQ1VL;2,,P?62#O8(<8=](G*K);FZ>JI5
MK@),IE$RYSEEN/W^? JJ;73_#Z&E-;X[2K:$3T9BB[30ZQHKY2D(.BAWVURK
M LZ+PFY-H-* :^6:[TO^%:J=Y3]C.UI\1B@._(*%4",H4UC76B>ZHH1\#PY+
M8DF]A52]Q<#\8' ?J%?TK>;MK8U@.IVRR=GL-'G_COH'7%O7P#V;]<EKFJU!
M J;\+(\@2&6WCF!($D#VK6<E7%%#$H^AZSUC&,X&;3P$V<5LM1J,2V6H]5$V
M*0F'8/QK@,)(\-O<*ZF$4^C'(-J6CF=GUU-4'LZ-V9+#]1#4,Y,D9K^^YKFT
MK@]O3]Z@JQ,)EUA@DZ.#:=*32:(Y[S[2CU\:W'-8WZ_@X1YN;N[^PZC_;: 7
MU@=KQE0TWHNBWM)D"/X'CO?KXCX.=!A&PUJ[9_^Y*+Y4CEJ+9(75UJ4_Q_V5
M'0V5KQ7UT,"H$#*M#++#>WP@<3S,#I+C6?9R2K:B0I;3GX(O3)34\5+Q:)7,
MAADVFT63TS=9;IU$=YAK<3]8A^G;C_/%GU!+ P04    " #2-&I4KS *PIT(
M  #A.   &    &EM<G@M,C R,3$R,S%X97@S,60Q+FAT;>U;;7/;N!'^*ZAN
MKK%G1%&2[8LM.9Y)9&?J]O(R'F4Z[3>07(FH08('@)+57]]=@)0HV8Z=^"47
M5YF);8$+8 $\S^X#$#K^2Q"<Y2G/8TC8W\8??F>)BLL,<LMB#=QBZ5S8E(U5
M4?"<?0"MA93LG1;)%!@[ZO1ZG6[G\" (3HZQJ5%51^4#MA?VNF&_V^^S7G^P
MUQWTCMC;#VSGRWBTZZQ//XW&__I\YGO]_.7=[^<CU@K"\)][HS \'9_Z!_N=
M;H^--<^-L$+E7(;AV<<6:Z76%H,PG,_GG?E>1^EI.+X(4YO)_5 J9:"3V*1U
M<DPE^!-X<G*<@>4L3KDV8-^TOHS?!X=H8865<'(<UK^];:22Q<EQ(F;,V(6$
M-ZV,ZZG( ZL*'$MAAU@SQ,<;-E?!7"0V'?2ZW5^'!4\2D4\#"1.+)9W^T:I,
MBVFZ*E1^< ,-DELQ VJ]T6XL@>M!I&PZW.SBIII%76^B<AM,>";D8O!J+#(P
M["/,V87*>/ZJ[4OPMP$M)J^&SMJ(_P(VC0.4(H<@!>]GIW<TM'!E R[%%'NC
MTJ&?DD$U&]%:KW-?,5(RP8=G5ZF(A&5[V! [#B.<N^(Y_(P1QZ!K1WO]PK+N
MZO]=7H_.+L;G[\]';\?GGSX^M=>W^WC>9N\@_P]VE+._=]B_P5R*/&FS&+05
MDP6S*;<#YGRS/)+ (J43T&]:W1;:2%E!;OG9%#RN/F,-C?^3>D@S:C+FLIH^
M-Y.(^.$\%18"J@B#7,TUQR('PKW?T,6J@QH(#Y^@_NT3%" +K,I<7PU*_N:[
MIC;6>E]->.NDUSD.J= O8VB3YLA_DC&<LY3/@&F8"9ACG+6I,.QMGI=<L@LH
ME+88>ME[I3/6ZP;_8&K"SK.LS ']RZ=LI#3:<(H80W9M-D("0^@PM(725Y>A
M_P*@](X;EZA9MF"7N!(2,*.W/:*TAU*BT,=<H13 RAS##\\7K,RM+@&;Q43O
M= )BC+,,/VF!*)SP&(LT4QG&>ZN\W36#'&(PANL%F63\$K#?1IL&RQ)T!KN4
M-&3J@PQBH5&<H!G*%8.>(#89 BI.F2GIQZK^'#14C=  ,F$PA]*R>#FCP100
M.P>IW0)=4PD.$U&+DQ(MFM.P9<H#4+;WDID";")RQ"+!>H6]-M($S?&Q;CP7
M^02CL@N]^'<LRP3;1'PW@-9&;@@M%ZQ >!*SB'$HMI?4J5!K-KI&=B9.!;;)
MHI1H@'Q1"&K7G7'^Q-RD;"+5W-1DTC 5QJ*RMHQ3H?<;O6PW.&%J9ZYYNZ7%
M R"U_P)H,5[#T%]_.>SW7@]-!?Q*G%+ 59.)P(\.7>>,:W X1EP* @CBC8$A
ML B3DCF999AL*.'0YT286"I38CU*0UI)#^A"*]RS8K%A.XC?!) 0'J1G5[C)
MRW%[^A8C_$4IT:*WQX/>P0[LNJJ]@\1_VG7=;Y(!+4AE#9X8X+>C=@,/+YH)
M.WSWYZ?"*1A<&42?DR%W([9-"BGFI;E_%9(J$2#,JYZ\^%&EQ@8P5,^$<0D
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M?[:L"X5Y75)6)DJKZ!EH8WRFTUK"]:67W^ZCK$Q"/^8N82!'7Z-/!=Y6@7=
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M8>->7/'Q4Q$=8TE$)VI[+)7#15/7SQ6'0Z4BXXO?E)^):K+(FKEM<T4/4WQ
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M?\]S="C];";ZAA,_LS\H>'13K\/QOQSH0RDRU95S"%-A9LYETU2*;SR-8D)
ML4L"A#@QXYGD[3G $,9RL$EG>Y$#EX'>#9B:59GY=H0J*FZ3J\;O$1M,-=(^
M:$)MT7)/ W[A48! G<:SM@>?(SK\F:6,_CD2;,@^7_CACQMZU7^MZWV3K:EG
M((17!WAK#V\(N,9?&>C\F+N\$E$%W'&7:8V,(/\VP$2]?7OQ)[]6"OUN-SE\
M0@ARR^R^W>G.M_E:1[W )E2&QQJ (S_:,::2R+I^=_//0\E<_:%EG_]KC6=5
MVO2^$L\1_XL^]$\$O?I?4$L! A0#%     @ TC1J5$'ZM+Z-$@  E<X  !$
M             ( !     &EM<G@M,C R,3$R,S$N>'-D4$L! A0#%     @
MTC1J5+6Q;1[,$@  C"4! !4              ( !O!(  &EM<G@M,C R,3$R
M,S%?8V%L+GAM;%!+ 0(4 Q0    ( -(T:E2 YG*/Y#@  '<)!  5
M      "  ;LE  !I;7)X+3(P,C$Q,C,Q7V1E9BYX;6Q02P$"% ,4    " #2
M-&I42\E'_-5[  "(/P@ %0              @ '27@  :6UR>"TR,#(Q,3(S
M,5]L86(N>&UL4$L! A0#%     @ TC1J5 >D&C(.50  C-,& !4
M     ( !VMH  &EM<G@M,C R,3$R,S%?<')E+GAM;%!+ 0(4 Q0    ( -(T
M:E3TN%*6ZXP$ ,5;*P 5              "  1LP 0!I;7)X+3(P,C$Q,C,Q
M>#$P:RYH=&U02P$"% ,4    " #2-&I46_ DH8UR  #/@0  &
M    @ $YO04 :6UR>"TR,#(Q,3(S,7@Q,&LP,#8N:G!G4$L! A0#%     @
MTC1J5(MPS/LO:@   W<  !@              ( !_"\& &EM<G@M,C R,3$R
M,S%X,3!K,# W+FIP9U!+ 0(4 Q0    ( -(T:E0'\Y%M(7L  %^D   8
M          "  6&:!@!I;7)X+3(P,C$Q,C,Q>#$P:S P."YJ<&=02P$"% ,4
M    " #2-&I4G9!T_AE.   .60  &               @ &X%0< :6UR>"TR
M,#(Q,3(S,7@Q,&LP,#DN:G!G4$L! A0#%     @ TC1J5%81/ENEQ   E=D
M !@              ( !!V0' &EM<G@M,C R,3$R,S%X,3!K,#$P+FIP9U!+
M 0(4 Q0    ( -(T:E10##9(#FP  -B%   8              "  >(H" !I
M;7)X+3(P,C$Q,C,Q>#$P:S Q,2YJ<&=02P$"% ,4    " #2-&I4?13:-Q!!
M  #48   &               @ $FE0@ :6UR>"TR,#(Q,3(S,7@Q,&LP,3(N
M:G!G4$L! A0#%     @ TC1J5 'I#BQ/8   ]&\  !@              ( !
M;-8( &EM<G@M,C R,3$R,S%X,3!K,#$S+FIP9U!+ 0(4 Q0    ( -(T:E3D
M^1^8:XT  *J6   8              "  ?$V"0!I;7)X+3(P,C$Q,C,Q>#$P
M:S Q-"YJ<&=02P$"% ,4    " #2-&I4SU!R 1%?  !R<   &
M    @ &2Q D :6UR>"TR,#(Q,3(S,7@Q,&LP,34N:G!G4$L! A0#%     @
MTC1J5-@<#A3@R   ,MT  !@              ( !V2,* &EM<G@M,C R,3$R
M,S%X,3!K,#$V+FIP9U!+ 0(4 Q0    ( -(T:E0W-@/KT]   ,OB   8
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M;7)X+3(P,C$Q,C,Q>#$P:S R,"YJ<&=02P$"% ,4    " #2-&I4P;L\#8^
M  "2E0  &               @ %$60X :6UR>"TR,#(Q,3(S,7@Q,&LP,C$N
M:G!G4$L! A0#%     @ TC1J5&?E76 0EP  7+$  !@              ( !
M"=H. &EM<G@M,C R,3$R,S%X,3!K,#(R+FIP9U!+ 0(4 Q0    ( -(T:E0A
M9W+KN9    .K   8              "  4]Q#P!I;7)X+3(P,C$Q,C,Q>#$P
M:S R,RYJ<&=02P$"% ,4    " #2-&I4ZO%6BM@/ 0#^. $ &
M    @ $^ A  :6UR>"TR,#(Q,3(S,7@Q,&LP,C0N:G!G4$L! A0#%     @
MTC1J5,+W:"JNH@  :+(  !@              ( !3!(1 &EM<G@M,C R,3$R
M,S%X,3!K,#(U+FIP9U!+ 0(4 Q0    ( -(T:E39C.<#+$@   Q9   8
M          "  3"U$0!I;7)X+3(P,C$Q,C,Q>#$P:S R-BYJ<&=02P$"% ,4
M    " #2-&I4P:%E;/0G   "0   &               @ &2_1$ :6UR>"TR
M,#(Q,3(S,7@Q,&LP,C<N:G!G4$L! A0#%     @ TC1J5/0&T0L9-   A$0
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M:S S,BYJ<&=02P$"% ,4    " #2-&I434I,HTE$   S3P  &
M    @ $SQQ, :6UR>"TR,#(Q,3(S,7@Q,&LP,S,N:G!G4$L! A0#%     @
MTC1J5)R/R4;L30  Y5L  !@              ( !L@L4 &EM<G@M,C R,3$R
M,S%X,3!K,#,T+FIP9U!+ 0(4 Q0    ( -(T:E18:*2N1P(  &<%   8
M          "  =19% !I;7)X+3(P,C$Q,C,Q>&5X,C%D,2YH=&U02P$"% ,4
M    " #2-&I4>SQIE"T#  "B"   &               @ %17!0 :6UR>"TR
M,#(Q,3(S,7AE>#(S9#$N:'1M4$L! A0#%     @ TC1J5*\P"L*="   X3@
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=-&0S+FAT;5!+!08     *@ J &4+  "]EQ0    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
